PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	GELMAN, MS; CHANG, WS; THOMAS, DY; BERGERON, JJM; PRIVES, JM				GELMAN, MS; CHANG, WS; THOMAS, DY; BERGERON, JJM; PRIVES, JM			ROLE OF THE ENDOPLASMIC-RETICULUM CHAPERONE CALNEXIN IN SUBUNIT FOLDING AND ASSEMBLY OF NICOTINIC ACETYLCHOLINE-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; TRANSFECTED COS CELLS; MUSCLE-CELLS; BREFELDIN-A; MEMBRANE; OLIGOMERIZATION; ER; PHOSPHORYLATION; TRANSPORT; SURFACE	The nicotinic acetylcholine receptor (AChR) is a pentameric complex assembled from four different gene products by mechanisms that are inadequately understood. In this study we investigated the role of the endoplasmic reticulum (ER)-resident molecular chaperone calnexin in AChR subunit folding and assembly. We have shown that calnexin interacts with nascent AChR alpha-subunits (AChR-alpha) in muscle cell cultures and in COS cells transfected with mouse AChR-alpha. In chick muscle cells maximal association of labeled alpha-subunits with calnexin was observed immediately after a 15-min pulse with [S-35]methionine/cysteine and subsequently declined with a t(1/2) of approximately 20 min. The decrease in association with calnexin was concomitant with the folding of the alpha-subunit to achieve conformational maturation shortly before assembly. Brefeldin A did not inhibit AChR subunit assembly or the dissociation of calnexin from the assembling subunits, confirming that the ER is the site of AChR assembly and that calnexin dissociation is not affected under conditions in which the exit of assembled AChR from the ER is blocked. These results indicate that calnexin participates directly in the molecular events that lead to AChR assembly.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PHARMACOL SCI, STONY BROOK, NY 11794 USA; MCGILL UNIV, DEPT ANAT & CELL BIOL, MONTREAL, PQ H4P 2R2, CANADA; NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, EUKARYOT GENET GRP, MONTREAL, PQ H4P 2R2, CANADA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; McGill University; National Research Council Canada			Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025945] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07518] Funding Source: Medline; NINDS NIH HHS [NS25945] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GU Y, 1989, J BIOL CHEM, V264, P11952; GU Y, 1989, J CELL BIOL, V10, P729; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JASCUR T, 1991, BIOCHEMISTRY-US, V30, P1908, DOI 10.1021/bi00221a025; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE AQ, 1994, J BIOL CHEM, V269, P7514; LENTER M, 1994, J BIOL CHEM, V269, P12263; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MERLIE JP, 1986, J MEMBRANE BIOL, V91, P1, DOI 10.1007/BF01870209; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; MILES K, 1988, MOL NEUROBIOL, V2, P91, DOI 10.1007/BF02935341; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; ONEILL MC, 1972, J CELL BIOL, V52, P52, DOI 10.1083/jcb.52.1.52; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PRIVES J, 1982, J CELL BIOL, V92, P231, DOI 10.1083/jcb.92.1.231; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; ROSS AF, 1987, J BIOL CHEM, V262, P14640; Sambrook J, 1989, MOL CLONING LABORATO; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WADA I, 1994, J BIOL CHEM, V269, P7464; WADA I, 1991, J BIOL CHEM, V266, P19599	50	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15085	15092		10.1074/jbc.270.25.15085	http://dx.doi.org/10.1074/jbc.270.25.15085			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797492	hybrid			2022-12-25	WOS:A1995RE66600038
J	ODA, H; STOCKERT, RJ; COLLINS, C; WANG, H; NOVIKOFF, PM; SATIR, P; WOLKOFF, AW				ODA, H; STOCKERT, RJ; COLLINS, C; WANG, H; NOVIKOFF, PM; SATIR, P; WOLKOFF, AW			INTERACTION OF THE MICROTUBULE CYTOSKELETON WITH ENDOCYTIC VESICLES AND CYTOPLASMIC DYNEIN IN CULTURED RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URCHIN EGG KINESIN; ORGANELLE MOVEMENT; AXONAL-TRANSPORT; BINDING-PROTEIN; GTP HYDROLYSIS; RECEPTOR; MOTOR; MOTILITY; INVITRO; LIVER	In a recent study (Goltz, J. S., Wolkoff, A. W., Novikoff, P. M., Stockert, R. J., and Satir, P. (1992) Proc. Natl. Acad. Sci. U.S. R 89, 7026-7030), we found that ligand- and receptor containing endocytic vesicles bind to endogenous microtubules in vitro after 60 min of receptor-mediated endocytosis of asialo-orosomucoid. In the presence of ATP, ligand-containing endocytic vesicles are released from microtubules, while those containing receptor are not. We hypothesized that cytoplasmic dynein may associate with ligand-containing, but not receptor-containing, domains of endocytic vesicles and might be involved in the movement of ligand-containing vesicles along microtubules during sorting of ligand from receptor. Direct evidence in support of this hypothesis has been obtained in the present study. Binding of ligand-containing vesicles to microtubules correlates highly (p < 0.001) with binding of dynein, but not kinesin, under a variety of conditions. Binding of receptor-containing vesicles to microtubules is independent of both cytoplasmic dynein and kinesin binding. Tight association of cytoplasmic dynein with a population of ligand-containing vesicles is seen directly by immunoprecipitation. These results support the view that in receptor-mediated endocytosis, ligand-containing vesicles become bound to microtubules by cytoplasmic dynein. While receptor domains of endosomes remain attached to microtubules in an ATP-independent manner, ligand-containing domains might be moved away toward pericentrosomal lysosomes by this motor molecule.	ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,BRONX,NY 10461; NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,CHICAGO,IL 60611	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Northwestern University					NCI NIH HHS [CA-06576] Funding Source: Medline; NIDDK NIH HHS [DK-41296, DK-41918] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041918, P30DK041296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; CLARKE BL, 1989, BIOCHEM J, V262, P277, DOI 10.1042/bj2620277; COHN SA, 1989, J BIOL CHEM, V264, P4290; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; DABORA SL, 1988, CELL MOTIL CYTOSKEL, V10, P482, DOI 10.1002/cm.970100405; EUTENEUER U, 1981, P NATL ACAD SCI-BIOL, V78, P372, DOI 10.1073/pnas.78.1.372; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; HARFORD J, 1983, J CELL BIOL, V96, P1824, DOI 10.1083/jcb.96.6.1824; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; JELICKS LA, 1992, AM J PHYSIOL, V263, pH903, DOI 10.1152/ajpheart.1992.263.3.H903; KAISER J, 1988, EXP CELL RES, V174, P472, DOI 10.1016/0014-4827(88)90316-3; KAUFMAN SS, 1990, AM J PHYSIOL, V258, pG129, DOI 10.1152/ajpgi.1990.258.1.G129; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KOLSET SO, 1979, EXP CELL RES, V122, P159, DOI 10.1016/0014-4827(79)90570-6; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; LIN SXH, 1992, J CELL SCI, V101, P125; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYE RJ, 1987, CELL, V51, P309, DOI 10.1016/0092-8674(87)90157-7; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; NOVIKOFF PM, 1992, MOL BIOL CELL, V3, P48; OBRIEN ET, 1987, BIOCHEMISTRY-US, V26, P4148, DOI 10.1021/bi00387a061; OKA JA, 1983, BIOCHIM BIOPHYS ACTA, V763, P368, DOI 10.1016/0167-4889(83)90098-8; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PORTER ME, 1987, J BIOL CHEM, V262, P2794; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; SAMUELSON AC, 1988, AM J PHYSIOL, V254, pC829, DOI 10.1152/ajpcell.1988.254.6.C829; SATIR P, 1990, CANCER INVEST, V8, P685, DOI 10.3109/07357909009018945; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SCHLIWA M, 1991, J CELL BIOL, V112, P1199, DOI 10.1083/jcb.112.6.1199; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; STEWART RJ, 1990, BIOCHEMISTRY-US, V29, P6489, DOI 10.1021/bi00479a022; STOCKERT RJ, 1983, HEPATOLOGY, V3, P750; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; VALE RD, 1992, J CELL BIOL, V119, P1589, DOI 10.1083/jcb.119.6.1589; Vallee R, 1991, Trends Cell Biol, V1, P25, DOI 10.1016/0962-8924(91)90066-I; WOLKOFF AW, 1985, J CLIN INVEST, V76, P454, DOI 10.1172/JCI111993; WOLKOFF AW, 1984, J CELL BIOL, V98, P357	49	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15242	15249		10.1074/jbc.270.25.15242	http://dx.doi.org/10.1074/jbc.270.25.15242			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797509	hybrid			2022-12-25	WOS:A1995RE66600060
J	PRENDERGAST, GC; KHOSRAVIFAR, R; SOLSKI, PA; KURZAWA, H; LEBOWITZ, PF; DER, CJ				PRENDERGAST, GC; KHOSRAVIFAR, R; SOLSKI, PA; KURZAWA, H; LEBOWITZ, PF; DER, CJ			CRITICAL ROLE OF RHO IN CELL-TRANSFORMATION BY ONCOGENIC RAS	ONCOGENE			English	Article						RHO; RAS; CELL TRANSFORMATION; SIGNAL TRANSDUCTION	MAMMALIAN-CELLS; GROWTH-FACTOR; GENE-PRODUCT; PROTEIN; EXPRESSION; GAP; IDENTIFICATION; FARNESYLATION; LOCALIZATION; FIBROBLASTS	We demonstrate that Rho, a regulator of cytoskeletal actin, is necessary for Ras transformation. A dominant inhibitory Rho gene (RhoB(N19)) specifically suppressed Rat1 cell focus formation induced by oncogenic Ras but not by Raf. An activated Rho gene (Rho(V14)) lacked focus formation activity but augmented the focus formation activity of both oncogenes. NIH3T3 cell lines expressing Rho(V14) grew to higher saturation density and displayed reduced serum and anchorage requirements for growth. We concluded that Rho played a role in cell growth regulation and was required for transformation by oncogenic Ras but not Raf. A model for Ras signal transduction proposing separate Rho-dependent and Raf-dependent pathways is discussed.	UNIV PENN,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,MOLEC BIOL GRAD GRP,PHILADELPHIA,PA 19104; UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC; LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC	University of Pennsylvania; University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill	PRENDERGAST, GC (corresponding author), WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Khosravi-Far, Roya/C-3789-2008	Der, Channing/0000-0002-7751-2747				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOS JL, 1990, MOL GENETICS CANCER, P273; BURRIDGE K, 1988, ANN REV CELL BIOL, V7, P337; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8232; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COX AD, 1994, METHOD ENZYMOL, V238, P277; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; DARTSCH PC, 1994, EUR J CELL BIOL, V63, P316; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUJITA H, 1990, EXP CELL RES, V186, P115, DOI 10.1016/0014-4827(90)90217-X; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1993, LIPID MODIFICATIONS, P335; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HARLOW E, 1988, ANTIBODIES LABORATOR; INGBER DE, 1994, INT REV CYTOL, V150, P173; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, UNPUB; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MULLAUER L, 1993, ONCOGENE, V8, P2531; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PERONA R, 1993, ONCOGENE, V8, P1285; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SELF AJ, 1993, ONCOGENE, V8, P665; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	58	273	277	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2289	2296						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784077				2022-12-25	WOS:A1995RE54300003
J	HIMANEN, JP; SCHNEIDER, K; CHAIT, B; MANNING, JM				HIMANEN, JP; SCHNEIDER, K; CHAIT, B; MANNING, JM			PARTICIPATION AND STRENGTH OF INTERACTION OF LYSINE 95(BETA) IN THE POLYMERIZATION OF HEMOGLOBIN-S AS DETERMINED BY ITS SITE-DIRECTED SUBSTITUTION BY ISOLEUCINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; DEOXYHEMOGLOBIN-S; MASS-SPECTROMETRY; SICKLE; RESOLUTION; MECHANISM; KINETICS; GELATION; YEAST	The role of Lys-95(beta), which is on the exterior of the hemoglobin (HbS) tetramer, in the aggregation process has been addressed because there is a lack of agreement on its importance, The early studies on the aggregation of HbS in the presence of other mutant hemoglobins are consistent with the subsequent electron microscopic studies in demonstrating the participation of Lys-95(beta) in gelation; the results of the crystal structure do not agree with these conclusions, Therefore, with the objective of clarifying its role we have carried out site directed substitution of Lys-95(beta) to an isoleucine residue, The mutation was introduced by polymerase chain reaction recombination methodology, and the absence of other mutations in the beta-globin gene was established by sequencing the gene in its entirety, The recombinant mutant hemoglobin was expressed in yeast and characterized by peptide mapping and sequencing, which demonstrated that the only different tryptic peptide had the Ile substitution at position 95(beta). The recombinant hemoglobin had the correct amino acid composition and molecular weight by mass spectrometric analysis. It was also pure as judged by isoelectric focusing, It was fully functional because it had an average Hill coefficient of 3.1 and responded normally to the allosteric regulators, chloride, 2,3-diphosphoglycerate, and inositol hexaphosphate, Of particular interest was the finding that this hemoglobin mutant aggregated at a concentration of about 40 g/dl, nearly twice that at which HbS itself aggregated (24 g/dl). Therefore, Lys-95(beta) has a very important role in the aggregation process and is a good candidate site for the design of a therapeutic agent for sickle cell anemia.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Rockefeller University			Schneider, Klaus/N-6604-2014	Schneider, Klaus/0000-0002-3068-8681	NHLBI NIH HHS [HL-18819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018819, R37HL018819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1994, J BIOL CHEM, V269, P17477; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P245; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BENESCH RE, 1978, ANAL BIOCHEM, V89, P162, DOI 10.1016/0003-2697(78)90737-6; BOOKCHIN RM, 1971, J MOL BIOL, V60, P263, DOI 10.1016/0022-2836(71)90292-0; CERAMI A, 1971, P NATL ACAD SCI USA, V68, P1180, DOI 10.1073/pnas.68.6.1180; CREPEAU RH, 1978, NATURE, V274, P616, DOI 10.1038/274616a0; DEAN J, 1978, NEW ENGL J MED, V299, P863, DOI 10.1056/NEJM197810192991605; DELLANO JJM, 1993, J BIOL CHEM, V268, P27004; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; DELLANO JJM, 1994, PROTEIN SCI, V3, P1206, DOI 10.1002/pro.5560030806; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P135; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; EDELSTEIN SJ, 1979, J MOL BIOL, V134, P851, DOI 10.1016/0022-2836(79)90491-1; FERRONE FA, 1985, J MOL BIOL, V183, P611, DOI 10.1016/0022-2836(85)90175-5; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HOFMANN OM, 1994, PROTEIN ENG, V7, P281; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; HOFRICHTER J, 1973, P NATL ACAD SCI USA, V70, P3604, DOI 10.1073/pnas.70.12.3604; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; LOWRY OH, 1954, J BIOL CHEM, V207, P1; Manning J M, 1981, Methods Enzymol, V76, P159; MANNING JM, 1974, ADV ENZYMOL RAMB, V40, P1; MANNING JM, 1991, ADV ENZYMOL RAMB, V64, P55; OGDEN JE, 1994, METHOD ENZYMOL, V231, P374; PADLAN EA, 1985, J BIOL CHEM, V260, P8272; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WATOWICH SJ, 1989, J MOL BIOL, V209, P821, DOI 10.1016/0022-2836(89)90610-4; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; YANASE H, 1995, PROTEIN SCI, V4, P21; YANASE H, 1994, PROTEIN SCI, V3, P1213, DOI 10.1002/pro.5560030807	34	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13885	13891		10.1074/jbc.270.23.13885	http://dx.doi.org/10.1074/jbc.270.23.13885			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775447	hybrid			2022-12-25	WOS:A1995RC44800046
J	PANG, L; SAWADA, T; DECKER, SJ; SALTIEL, AR				PANG, L; SAWADA, T; DECKER, SJ; SALTIEL, AR			INHIBITION OF MAP KINASE KINASE BLOCKS THE DIFFERENTIATION OF PC-12 CELLS INDUCED BY NERVE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRK PROTOONCOGENE PRODUCT; TYROSINE KINASE; PROTEIN-KINASE; CELLULAR ACTIONS; FACTOR RECEPTOR; PHOSPHORYLATION; RAS; RAF-1; ASSOCIATION; MEK	The mitogen-activated protein kinase (MAP kinase) pathway is thought to play an important role in the actions of neurotrophins. A small molecule inhibitor of the upstream kinase activator of MAP kinase, MAP kinase kinase (MER) was examined for its effect on the cellular action of nerve growth factor (NGF) in PC-12 pheochromocytoma cells. PD98059 selectively blocks the activity of MEK, inhibiting both the phosphorylation and activation of MAP kinases in vitro, Pretreatment of PC-12 cells with the compound completely blocked the 4-fold increase in MAP kinase activity produced by NGF. Half-maximal inhibition was observed at 2 mu m PD98059, with maximal effects at 10-100 mu M The tyrosine phosphorylation of immunoprecipitated MAP kinase was also completely blocked by the compound. In contrast, the compound was without effect on NGF-dependent tyrosine phosphorylation of the pp140(trk) receptor or its substrate She and did not block NGF-dependent activation of phosphatidylinositol 3'-kinase. However, PD98059 completely blocked NGF-induced neurite formation in these cells without altering cell viability. These data indicate that the MAP kinase pathway is absolutely required for NGF-induced neuronal differentiation in PC-12 cells.	WARNER LAMBERT PARKE DAVIS,DIV PHARMACEUT RES,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT MICROBIOL,ANN ARBOR,MI 48109	Pfizer; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P552; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OHMICHI M, 1992, NEURON, V9, P767; PANG L, 1995, IN PRESS BIOCH J; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SALTIEL AR, 1994, BIOESSAYS, V16, P405, DOI 10.1002/bies.950160608; SALTOFF SP, 1992, J BIOL CHEM, V267, P17472; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V238, P351; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	33	892	900	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13585	13588		10.1074/jbc.270.23.13585	http://dx.doi.org/10.1074/jbc.270.23.13585			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775407	hybrid			2022-12-25	WOS:A1995RC44800002
J	PENG, HB; LIBBY, P; LIAO, JK				PENG, HB; LIBBY, P; LIAO, JK			INDUCTION AND STABILIZATION OF I-KAPPA-B-ALPHA BY NITRIC-OXIDE MEDIATES INHIBITION OF NF-KAPPA-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ACTIVATION; ENDOTHELIUM; ADHESION; PROTEINS; INVITRO; FAMILY; CELLS; PHOSPHORYLATION; PROSTACYCLIN	To determine the mechanism(s) by which the endogenous mediator nitric oxide (NO) inhibits the activation of transcription factor NF-kappa B, we stimulated human vascular endothelial cells with tumor necrosis factor-alpha in the presence of two NO donors, sodium nitroprusside and S-nitrosoglutathione. Electrophoretic mobility shift assays demonstrated that both NO donors inhibited NF-kappa B activation by tumor necrosis factor-alpha. This effect was not mediated by guanylyl cyclase activation since the cGMP analogue 8-bromo-cGMP had no similar effect. Inhibition of endogenous constitutive NO production by L-N-monomethylarginine, however, activated NF-kappa B, suggesting tonic inhibition of NF-kappa B under basal conditions. NO had little or no effects on other nuclear binding proteins such as AP-1 and GATA. Immunoprecipitation studies showed that NO stabilized the NF-kappa B inhibitor, I kappa B alpha, by preventing its degradation from NF-kappa B. NO also increased the mRNA expression of I kappa B alpha, but not NF-kappa B subunits, p65 or p50, and transfection experiments with a chloramphenicol acetyltransferase reporter gene linked to the I kappa B alpha promoter suggested transcriptional induction of I kappa B alpha by NO. me propose that the induction and stabilization of I kappa B alpha by NO are important mechanisms by which NO inhibits NF-kappa B and attenuate atherogenesis.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X	NHLBI NIH HHS [HL34636, HL02508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034636, R01HL034636] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKALAY R, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; COLLINS T, 1993, LAB INVEST, V68, P499; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; DECATERINA R, 1995, IN PRESS J CLIN INVE; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KOWALUK EA, 1990, J PHARMACOL EXP THER, V255, P1256; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LANDER HM, 1993, J IMMUNOL, V150, P1509; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIAO JK, 1995, J BIOL CHEM, V270, P3219; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; XIE QW, 1994, J BIOL CHEM, V269, P4705	44	589	621	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14214	14219		10.1074/jbc.270.23.14214	http://dx.doi.org/10.1074/jbc.270.23.14214			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775482	hybrid			2022-12-25	WOS:A1995RC44800090
J	CHALFANT, CE; MISCHAK, H; WATSON, JE; WINKLER, BC; GOODNIGHT, J; FARESE, RV; COOPER, DR				CHALFANT, CE; MISCHAK, H; WATSON, JE; WINKLER, BC; GOODNIGHT, J; FARESE, RV; COOPER, DR			REGULATION OF ALTERNATIVE SPLICING OF PROTEIN-KINASE C-BETA BY INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED 2-DEOXYGLUCOSE UPTAKE; PHORBOL ESTER TREATMENT; SMOOTH-MUSCLE CELLS; PRE-MESSENGER-RNA; BC3H-1 MYOCYTES; RAT ADIPOCYTES; GLUCOSE-TRANSPORT; PREMESSENGER RNA; DOWN-REGULATION; GROWTH	Insulin regulates a diverse array of cellular signaling processes involved in the control of growth, differentiation, and cellular metabolism. Insulin increases glucose transport via a protein kinase C (PKC) dependent pathway in BC3H-1 myocytes, but the function of specific PKC isozymes in insulin action has not been elucidated. Two isoforms of PKC beta result via alternative splicing of precursor mRNA. As now shown, both isoforms are present in BC3H-1 myocytes, and insulin induces alternative splicing of the PKC beta mRNA thereby switching expression from PKC beta I to PRC beta II mRNA. This effect occurs rapidly (15 min after insulin treatment) and is dose-dependent. The switch in mRNA is reflected by increases in the protein levels of PKC beta II. High levels of 1a-0-tetradecanoylphorbol-13-acetate, which are commonly used to deplete or down-regulate PKC in cells, also induce the switch to PKC beta II mRNA following overnight treatment, and protein levels of PKC beta II reflected mRNA increases. To investigate the functional importance of the shift in PKC beta isoform expression, stable transfectants of NIH-3T3 fibroblasts overexpressing PKC beta I and PKC beta II were established. The overexpression of PKC beta II but not PKC beta I in NIH-3T3 cells significantly enhanced insulin effects on glucose transport. This suggests that PKC beta II may be more selective than PKC beta I for enhancing the glucose transport effects of insulin in at least certain cells and, furthermore, that insulin can regulate the expression of PKC beta II by alternative mRNA splicing.	JAMES A HALEY VET HOSP,RES SERV 151,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT INTERNAL MED,TAMPA,FL 33612; UNIV TAMPA,DEPT CHEM,TAMPA,FL 33606; NCI,BETHESDA,MD 20892	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Tampa; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Mischak, Harald/E-8685-2011; Farese, Robert/B-3605-2015	Mischak, Harald/0000-0003-0323-0306	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038079] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38079] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACEVEDODUNCAN M, 1989, FEBS LETT, V244, P174, DOI 10.1016/0014-5793(89)81186-X; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; CASCIERI MA, 1986, CIRC RES, V59, P171, DOI 10.1161/01.RES.59.2.171; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER DR, 1993, ARCH BIOCHEM BIOPHYS, V302, P490, DOI 10.1006/abbi.1993.1244; COOPER DR, 1987, FEBS LETT, V214, P122, DOI 10.1016/0014-5793(87)80025-X; COOPER DR, 1992, BIOCHEM BIOPH RES CO, V188, P142, DOI 10.1016/0006-291X(92)92361-Z; COOPER DR, 1989, BIOCHEM BIOPH RES CO, V161, P327, DOI 10.1016/0006-291X(89)91600-8; COOPER DR, 1987, J BIOL CHEM, V262, P3633; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; FARESE RV, 1991, ANTISENSE RES DEV, V1, P35, DOI 10.1089/ard.1991.1.35; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GOODE N, 1992, J BIOL CHEM, V267, P16878; HOUSEY GM, 1988, CELL, V52, P853; ISHIZUKA T, 1991, DIABETES, V40, P1274, DOI 10.2337/diabetes.40.10.1274; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; MAGNUSON VL, 1991, J BIOL CHEM, V266, P14654; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MIRANDA PV, 1993, ANAL BIOCHEM, V209, P376, DOI 10.1006/abio.1993.1138; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NORGREN S, 1994, P NATL ACAD SCI USA, V91, P1465, DOI 10.1073/pnas.91.4.1465; OBEID LM, 1992, J BIOL CHEM, V267, P20804; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; SELL SM, 1994, J BIOL CHEM, V269, P30769; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STANDAERT ML, 1993, ENDOCRINOLOGY, V132, P689, DOI 10.1210/en.132.2.689; STANDAERT ML, 1988, J BIOL CHEM, V263, P8696; STANDAERT ML, 1990, METABOLISM, V11, P1170; STUMPO DJ, 1994, J BIOL CHEM, V269, P21184; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; YU BZ, 1992, ENDOCRINOLOGY, V130, P3345, DOI 10.1210/en.130.6.3345	41	83	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13326	13332		10.1074/jbc.270.22.13326	http://dx.doi.org/10.1074/jbc.270.22.13326			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768933	hybrid			2022-12-25	WOS:A1995RB43900058
J	CHEN, CS; ROSENWALD, AG; PAGANO, RE				CHEN, CS; ROSENWALD, AG; PAGANO, RE			CERAMIDE AS A MODULATOR OF ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CELL-FREE SYSTEM; CULTURED HUMAN-FIBROBLASTS; ACTIVATED PROTEIN-KINASE; LOW-DENSITY LIPOPROTEIN; GOLGI-APPARATUS; SECRETORY PATHWAY; PLASMA-MEMBRANE; LIVING CELLS; SPHINGOMYELIN	The effects of ceramide analogs on the uptake of markers for fluid-phase (horseradish peroxidase, HRP) and receptor-mediated (low density lipoprotein, LDL) endocytosis were studied in Chinese hamster fibroblasts. N-Hexanoyl-D-erythro-sphingosine (C-6-Cer) decreased the uptake of HRP in a dose-dependent manner. Internalization was inhibited >40% with 25 mu M C-6-Cer, relative to controls, and was apparent within 5 min. Internalization of HRP was also inhibited by other Cer analogs and by treatment with agents that raise levels of endogenous Cer (sphingomyelinase or the glycosphingolipid synthesis inhibitor, 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP)), but not by N-hexanoyl-D-erythro-sphinganine (C-6-dihydro-Cer) or sphingosine. Internal of LDL was also inhibited by C-6-Cer in a concentration dependent manner, but was less pronounced than the effect on HRP internalization (10% versus 40% inhibition with 25 mu M C-6-Cer), suggesting that ceramide might affect fluid-phase and receptor-mediated endocytosis to different extents. C-6-Cer also slowed HRP and LDL transport from endosomes to lysosomes as studied by analysis of endocytic vesicles on Percoll density gradients and induced a redistribution of endocytic organelles as determined by fluorescence microscopy of intact cells using appropriate markers. This resulted in decreased degradation of I-125-Iabeled LDL in the presence of C-6-Cer. These results suggest that endogenous ceramide may modulate endocytosis.	CARNEGIE INST WASHINGTON, BALTIMORE, MD 21210 USA	Carnegie Institution for Science					NIGMS NIH HHS [R37 GM22942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BARAK LS, 1981, J CELL BIOL, V90, P595, DOI 10.1083/jcb.90.3.595; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BETTS JC, 1994, J BIOL CHEM, V269, P8455; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FALLON RJ, 1992, EXP CELL RES, V203, P420, DOI 10.1016/0014-4827(92)90016-2; GLUCK S, 1982, J BIOL CHEM, V257, P9230; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; KREIENBUHL P, 1992, BLOOD, V80, P2911; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MERRILL AH, 1993, ADV LIPID RES, V25, P1; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P4439, DOI 10.1021/bi00412a034; RADIN NS, 1993, ADV LIPID RES, V26, P183; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; ROSENWALD AG, 1993, J BIOL CHEM, V268, P4577; ROSENWALD AG, 1993, ADV LIPID RES, V26, P101; SPENCE MW, 1993, ADV LIPID RES, V26, P3; STEINMAN RM, 1974, J CELL BIOL, V63, P949, DOI 10.1083/jcb.63.3.949; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731; WILSON RB, 1993, J BIOL CHEM, V268, P25357	45	82	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13291	13297		10.1074/jbc.270.22.13291	http://dx.doi.org/10.1074/jbc.270.22.13291			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768929	hybrid			2022-12-25	WOS:A1995RB43900053
J	COLOMBATTI, A; MUCIGNAT, MT; BONALDO, P				COLOMBATTI, A; MUCIGNAT, MT; BONALDO, P			SECRETION AND MATRIX ASSEMBLY OF RECOMBINANT TYPE-VI COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOV-13 MOUSE CELLS; ALPHA-3 CHAIN; MESSENGER-RNA; VONWILLEBRAND-FACTOR; GLOBULAR DOMAINS; MOSAIC STRUCTURE; MAMMALIAN-CELLS; MULTIPLE FORMS; I COLLAGEN; EXPRESSION	A monomer of type VI collagen is composed of three different chains of 140 (alpha 1), 130 (alpha 2), and 250-350 kDa (alpha 3). Monomers assemble into dimers (6 chains) and tetramers (12 chains) that are stabilized by disulfide bonds and, once associated one to another, give rise to a microfilamentous network in close apposition with cell surfaces and banded collagen fibers. We have derived murine NIH/3T3 cell lines that were transfected with the cDNAs for the three chains and that constitutively expressed chicken type VI collagen. Cotransfection was efficient because, in three out of six isolated cell lines, all chicken chains were expressed. Southern blotting demonstrated that several copies of each cDNA were integrated approximately in equal number. Expression of the three polypeptide chains was consistent with the levels of the respective mRNAs. The three chicken chains assembled by disulfide bonding to form correctly folded triple helical aggregated composites with sizes corresponding to type VI collagen monomers, dimers, and tetramers. These functional recombinant assemblies were secreted and became incorporated into the extracellular matrix, where they formed an extensive fibrillar network.	UNIV UDINE,DIPARTIMENTO SCI & TECHNOL BIOMED,I-35100 UDINE,ITALY; UNIV PADUA,IST ISTOL & EMBRIOL,I-35100 PADUA,ITALY	University of Udine; University of Padua	COLOMBATTI, A (corresponding author), CTR RIFERIMENTO ONCOL,DIV ONCOL SPERIMENTALE 2,VIA PEDEMONTANA OCCIDENTALE 12,I-33081 AVIANO,ITALY.		Mucignat, Maria Teresa/AAY-3908-2020	Mucignat, Maria Teresa/0000-0002-9601-054X; Bonaldo, Paolo/0000-0002-9571-8140; colombatti, alfonso/0000-0002-3676-2379				AYAD S, 1989, BIOCHEM J, V262, P753, DOI 10.1042/bj2620753; BONALDO P, 1989, J BIOL CHEM, V264, P5575; BONALDO P, 1989, J BIOL CHEM, V264, P20235; BONALDO P, 1990, MATRIX, V10, P139, DOI 10.1016/S0934-8832(11)80162-9; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BRUNS R, 1986, J CELL BIOL, V103, P394; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1989, EMBO J, P1937; COLOMBATTI A, 1988, COLLAGEN REL RES, V8, P331; COLOMBATTI A, 1987, J BIOL CHEM, V262, P14454; COLOMBATTI A, 1989, MATRIX, V9, P177, DOI 10.1016/S0934-8832(89)80048-4; COLOMBATTI A, 1992, EUR J BIOCHEM, V209, P785, DOI 10.1111/j.1432-1033.1992.tb17349.x; DEMARS M, 1990, J VIROL, V64, P5260, DOI 10.1128/JVI.64.11.5260-5269.1990; DOLIANA R, 1990, J CELL BIOL, V111, P2197, DOI 10.1083/jcb.111.5.2197; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURTH JJ, 1991, EXP CELL RES, V192, P118, DOI 10.1016/0014-4827(91)90165-Q; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; HUYLEBROECK D, 1983, GENE AMST, V66, P163; JANDER R, 1983, EUR J BIOCHEM, V133, P39, DOI 10.1111/j.1432-1033.1983.tb07427.x; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; KIELTY CM, 1991, J CELL SCI, V99, P797; KOLLER E, 1989, EMBO J, V8, P1037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE ST, 1992, J BIOL CHEM, V267, P24126; LEE ST, 1988, J BIOL CHEM, V263, P13414; MAZZORANA M, 1992, J BIOL CHEM, V268, P3029; NELSON KK, 1990, P NATL ACAD SCI USA, V87, P6253, DOI 10.1073/pnas.87.16.6253; PERRIS R, 1993, EXP CELL RES, V209, P103, DOI 10.1006/excr.1993.1290; SAMBROOK J, 1989, MOL CLINING LABORATO; SCHNIEKE A, 1987, P NATL ACAD SCI USA, V84, P764, DOI 10.1073/pnas.84.3.764; SEGAT D, 1994, BLOOD, V83, P1586; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; TRUEB B, 1987, EUR J BIOCHEM, V166, P699, DOI 10.1111/j.1432-1033.1987.tb13568.x; TRUEB B, 1986, EMBO J, V5, P2815, DOI 10.1002/j.1460-2075.1986.tb04573.x; VANDERMARK K, 1984, EUR J BIOCHEM, V142, P493; WISE RJ, 1989, NUCLEIC ACIDS RES, V17, P3591; WU JJ, 1987, BIOCHEM J, V248, P373, DOI 10.1042/bj2480373; ZANUSSI S, 1992, J BIOL CHEM, V267, P24082	42	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13105	13111		10.1074/jbc.270.22.13105	http://dx.doi.org/10.1074/jbc.270.22.13105			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768905	hybrid			2022-12-25	WOS:A1995RB43900027
J	GOROVITS, BM; HOROWITZ, PM				GOROVITS, BM; HOROWITZ, PM			THE MOLECULAR CHAPERONIN CPN60 DISPLAYS LOCAL FLEXIBILITY THAT IS REDUCED AFTER BINDING WITH AN UNFOLDED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLASMA FIBRONECTIN; BOVINE LIVER RHODANESE; FLUORESCENCE POLARIZATION; ESCHERICHIA-COLI; STEADY-STATE; GROEL; RECONSTITUTION; SPECTROSCOPY; HYDROLYSIS; INVITRO	Steady-state fluorescence polarization was used to examine the chaperonin cpn60 that was covalently labeled with pyrene. Two compounds, 1-pyrenesulfonyl chloride or N-(1-pyrene)maleimide, were used to incorporate up to 8 mol of pyrene per mol of cpn80 14-mer. The fluorescence lifetime of the cpn60-pyrenesulfonyl chloride conjugate exhibited a double exponential decay: 5.36 ns, with a fractional contribution to the intensity of 7%, and 48.77 ns, with a fractional contribution to the intensity of 93%. These yield a second-order average lifetime of 45.58 ns at 20 degrees C. Analysis of the fluorescence polarization data for the pyrene probe by the Perrin-Weber treatment revealed the existence of two components that account for the depolarization. The fast component accounted for 24% of the depolarization at 20 degrees C. The rotational relaxation time for the cpn80 14-mer derived from the low viscosity part of the Perrin-Weber plot which accentuates the slow motion gave rho(h) = 1113 +/- 55 ns. When this value of rho(h) is compared with the rho(h) calculated based on the Stokes radius of cpn80 from ultracentrifugation, rho(Stokes), it leads to rho(h)/rho(Stokes) = 0.4 which is considerably smaller than the value expected (rho(h)/rho(Stokes) = 1) or actually found in the cpn60-rhodanese complex (rho(h)/rho(Stokes) = 0.93). These considerations and the observed presence of the fast motion suggest that cpn60 is not a rigid protein. Analysis of the polarization data as a function of temperature, which is weighted more toward the fast motion, showed that the rotational relaxation time assessed by temperature variation is greatly increased (from 552.5 to 2591 ns) for the complex of cpn80 with partially folded rhodanese (34-kDa monomeric protein). No change in rho(h) was observed upon formation of the cpn60 . ATP complex (rho(h) = 556.9 ns). These data indicate that there is local motion in the cpn80 14-mer molecule that can be frozen by formation of a binary complex with partially folded proteins. This conclusion is in keeping with results showing that the structure of cpn80 is generally stabilized when it forms complexes with passenger proteins (Mendoza, J. A., and Horowitz, P. M. (1994) J. Biol. Chem. 269, 25963-25965).	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ESO5729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACUNA AU, 1987, BIOPHYS CHEM, V26, P63, DOI 10.1016/0301-4622(87)80008-X; AZUMI T, 1962, J CHEM PHYS, V37, P2413, DOI 10.1063/1.1733019; BENECKY MJ, 1990, BIOCHEMISTRY-US, V29, P3082, DOI 10.1021/bi00464a027; BENECKY MJ, 1991, BIOCHEMISTRY-US, V30, P4298, DOI 10.1021/bi00231a028; BERMAN HA, 1985, BIOCHEMISTRY-US, V24, P7140, DOI 10.1021/bi00346a018; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; Brent R. P., 1973, ALGORITHMS MINIMIZAT; BROCHON JC, 1972, EUR J BIOCHEM, V25, P20, DOI 10.1111/j.1432-1033.1972.tb01662.x; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V334, P44; HANTGAN RR, 1982, BIOCHEMISTRY-US, V21, P1821, DOI 10.1021/bi00537a018; HARTL FU, 1994, TRENDS BIOCHEM SCI, V217, P20; HAUGLAND RP, 1989, HDB FLUORESCENT PROB, P23; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KIM DS, 1983, J BIOL CHEM, V258, P1768; KOPP JA, 1969, J BIOL CHEM, V244, P6309; Lakowicz J, 1983, PRINC FLUORESC SPECT, P51, DOI 10.1007/978-1-4615-7658-7; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P128; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; OHYASHIKI T, 1982, J BIOCHEM, V91, P1575, DOI 10.1093/oxfordjournals.jbchem.a133848; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SOGAMI M, 1975, BIOCHIM BIOPHYS ACTA, V393, P446, DOI 10.1016/0005-2795(75)90073-2; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; WAHL P, 1967, J MOL BIOL, V30, P371, DOI 10.1016/S0022-2836(67)80045-7; WEBER G, 1953, ADV PROTEIN CHEM, V8, P415, DOI 10.1016/S0065-3233(08)60096-0; WEBER G, 1952, BIOCHEM J, V51, P145, DOI 10.1042/bj0510145; WEBER G, 1966, BIOCHEMISTRY-US, V5, P1900, DOI 10.1021/bi00870a017; WELTMAN JK, 1967, BIOCHEMISTRY-US, V6, P1437, DOI 10.1021/bi00857a028; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	44	25	25	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13057	13062		10.1074/jbc.270.22.13057	http://dx.doi.org/10.1074/jbc.270.22.13057			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768899	hybrid			2022-12-25	WOS:A1995RB43900020
J	MU, FT; CALLAGHAN, JM; STEELEMORTIMER, O; STENMARK, H; PARTON, RG; CAMPBELL, PL; MCCLUSKEY, J; YEO, JP; TOCK, EPC; TOH, BH				MU, FT; CALLAGHAN, JM; STEELEMORTIMER, O; STENMARK, H; PARTON, RG; CAMPBELL, PL; MCCLUSKEY, J; YEO, JP; TOCK, EPC; TOH, BH			EEA1, AN EARLY ENDOSOME-ASSOCIATED PROTEIN - EEA1 IS A CONSERVED ALPHA-HELICAL PERIPHERAL MEMBRANE-PROTEIN FLANKED BY CYSTEINE FINGERS AND CONTAINS A CALMODULIN-BINDING IQ MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; AMINO-ACID-SEQUENCE; SECONDARY-STRUCTURE; GLOBULAR PROTEINS; ZINC FINGERS; CONFORMATION; PREDICTION; RECOGNITION; PATTERNS; DOMAINS	Early endosomes are cellular compartments receiving endocytosed material and sorting them for vesicular transport to late endosomes and lysosomes or for recycling to the plasma membrane. We have cloned a human cDNA encoding an evolutionarily conserved 180-kDa protein on early endosomes named EEA1 (Early Endosome Antigen1). EEA1 is associated with early endosomes since it co-localizes by immunofluorescence with the transferrin receptor and with Rab5 but not with Rab7. Immunoelectron microscopy shows that it is associated with tubulovesicular early endosomes containing internalized bovine serum albumin-gold. EEA1 is a hydrophilic peripheral membrane protein present in cytosol and membrane fractions. It partitions in the aqueous phase after Triton X-114 solubilization and is extracted from membranes by 0.3 M NaCl. It is a predominantly cu-helical protein sharing 17-20% sequence identity with the myosins and contains a calmodulin-binding IQ motif. It is flanked by metal-binding, cysteine ''finger'' motifs. The COOH-terminal fingers, Cys-X(2)-Cys-X(12)-Cys-X(2)-Cys and Cys-X(2)-Cys-X(16)-Cys-X(2)-Cys, are present within a region that is strikingly homologous with Saccharomyces cerevisiae FAB1 protein required for endocytosis and with Caenarhabditis elegans ZK632. These fingers also show limited conservation with S. cerevisiae VAC1, Vps11, and Vps18p proteins implicated in vacuolar transport. We propose that EEA1 is required for vesicular transport of proteins through early endosomes and that its finger motifs are required for this activity.	MONASH UNIV SCH MED,DEPT PATHOL & IMMUNOL,PRAHRAN,VIC 3181,AUSTRALIA; NATL UNIV SINGAPORE,DEPT PATHOL,SINGAPORE 0511,SINGAPORE; EUROPEAN MOLEC BIOL LAB,D-69021 HEIDELBERG,GERMANY; FLINDERS MED CTR,CTR TRANSFUS MED & IMMUNOL,ADELAIDE,SA 5042,AUSTRALIA	Monash University; National University of Singapore; European Molecular Biology Laboratory (EMBL); Flinders Medical Centre			Parton, Robert G/C-5673-2009; McCluskey, James/A-1291-2007; Stenmark, Harald/B-8868-2008	Parton, Robert G/0000-0002-7494-5248; McCluskey, James/0000-0002-8597-815X; 				AIZAWA H, 1990, J BIOL CHEM, V265, P13849; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COURTOY PJ, 1991, INTRACELLULAR TRAFFI, P102; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOULD B, 1992, SEMIN CELL BIOL, V3, P301; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOOY J, 1992, J BIOL CHEM, V267, P20255; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MELLMAN I, 1993, J EXP BIOL, V172, P39; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MU FT, 1988, CLIN EXP IMMUNOL, V71, P100; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PAYRE F, 1988, FEBS LETT, V234, P245, DOI 10.1016/0014-5793(88)80091-7; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PITT A, 1991, EXP CELL RES, V194, P128, DOI 10.1016/0014-4827(91)90141-G; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; RECHID R, 1989, COMPUT APPL BIOSCI, V5, P107; ROBINSON JS, 1991, MOL CELL BIOL, V12, P5813; ROBSON B, 1976, J MOL BIOL, V107, P327, DOI 10.1016/S0022-2836(76)80008-3; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SHEPHERD VL, 1989, TRENDS PHARMACOL SCI, V10, P458, DOI 10.1016/S0165-6147(89)80011-2; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; YEO JP, 1994, NATURE, V386, P488	52	603	613	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13503	13511		10.1074/jbc.270.22.13503	http://dx.doi.org/10.1074/jbc.270.22.13503			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768953	hybrid			2022-12-25	WOS:A1995RB43900081
J	RAYMOND, WW; TAM, EK; BLOUNT, JL; CAUGHEY, GH				RAYMOND, WW; TAM, EK; BLOUNT, JL; CAUGHEY, GH			PURIFICATION AND CHARACTERIZATION OF DOG MAST-CELL PROTEASE-3, AN OLIGOMERIC RELATIVE OF TRYPTASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LUNG TRYPTASE; GENE-RELATED PEPTIDE; HUMAN-SKIN TRYPTASE; SERINE PROTEASE; VASODILATOR ACTIVITY; COMPLEMENTARY-DNA; SUBSTANCE-P; CLONING; CHYMASE; TRYPSIN	The existence of a protein similar to 48% identical with mast cell tryptases was predicted previously from a dog mastocytoma cDNA Antibodies raised against a peptide based on the deduced sequence suggested that the protein (dog mast cell protease-3, dMCP-3) is expressed in mast cells. In this report, characterization of the protein purified from mastocytomas reveals an N-glycosylated, high molecular weight, tryptic serine protease, which appears to be a tetramer of catalytic subunits, approximately half of which are Linked by disulfide bonds. The oligomeric complex yields a single NH2-terminal sequence, which is identical with that predicted by dMCP-3 cDNA. This finding, and the lack of closely related genes on blots of genomic DNA, predict that each subunit is the product of one gene. Although dLMCP-3 binds to heparin, it is active and stable at low ionic strength in heparin's absence. It resists inactivation by inhibitors in plasma but is sensitive to small inhibitors, e.g. leupeptin and bis(5-amidino-2-benzimidazolyl)methane (BABIM). dMCP-3 hydrolyzes extended peptidyl p-nitroanilides ending in basic residues, with P1 arginine preferred to lysine; it hydrolyzes the Arg(18)-Ser(19) bond of calcitonin gene-related peptide but cleaves neither vasoactive intestinal peptide nor casein. These data suggest that dMCP-3 is a unique serine protease whose stability, formation of intersubunit disulfide bonds, inhibitor susceptibilities and substrate preferences differ from those of its closest relatives, the mast cell tryptases.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV HAWAII,JOHN A BURNS SCH MED,DEPT MED,HONOLULU,HI 96813; UNIV HAWAII,JOHN A BURNS SCH MED,DEPT PHARMACOL,HONOLULU,HI 96813	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Hawaii System; University of Hawaii System					NHLBI NIH HHS [HL-24136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTER SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P26, DOI 10.1016/0003-9861(90)90005-J; ALTER SC, 1989, IMMUNOL RES, V8, P130; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BRAIN SD, 1988, NATURE, V335, P73, DOI 10.1038/335073a0; CAUGHEY GH, 1988, IMMUNOLOGY, V63, P339; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; CAUGHEY GH, 1987, ARCH BIOCHEM BIOPHYS, V258, P555, DOI 10.1016/0003-9861(87)90377-8; CAUGHEY GH, 1991, AM J RESP CELL MOL, V4, P387, DOI 10.1165/ajrcmb/4.5.387; CAUGHEY GH, 1993, J PHARMACOL EXP THER, V264, P676; CAUGHEY GH, 1994, AM J RESP CRIT CARE, V150, pS138, DOI 10.1164/ajrccm/150.6_Pt_2.S138; CAUGHEY GH, 1988, J HISTOCHEM CYTOCHEM, V251, pC935; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; HARTMANN T, 1992, AM J PHYSIOL, V262, pL528, DOI 10.1152/ajplung.1992.262.5.L528; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; ORTIZ C, 1991, BIOCHEMISTRY-US, V30, P10026, DOI 10.1021/bi00105a030; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; SALI A, 1993, J BIOL CHEM, V268, P9023; SAYAMA S, 1987, J BIOL CHEM, V263, P6808; SCHECHTER NM, 1993, BIOCHEMISTRY-US, V32, P2617, DOI 10.1021/bi00061a020; SCHWARTZ LB, 1981, J IMMUNOL, V126, P1290; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1990, NEUTRAL PROTEASES MA, V27, P90; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; SMYTH MJ, 1992, J BIOL CHEM, V267, P24418; SOMMERHOFF CP, 1992, J IMMUNOL, V148, P2859; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; TANAKA T, 1983, J BIOL CHEM, V258, P3552; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; WALLS AF, 1992, BIOCHEM PHARMACOL, V43, P1243, DOI 10.1016/0006-2952(92)90498-8; YEZZI MJ, 1994, J IMMUNOL, V152, P3064	39	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13164	13170		10.1074/jbc.270.22.13164	http://dx.doi.org/10.1074/jbc.270.22.13164			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768912	hybrid			2022-12-25	WOS:A1995RB43900035
J	WEBER, J; SENIOR, AE				WEBER, J; SENIOR, AE			LOCATION AND PROPERTIES OF PYROPHOSPHATE-BINDING SITES IN ESCHERICHIA-COLI F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING; NONCATALYTIC SITES; ADENOSINE-TRIPHOSPHATASE; MITOCHONDRIAL F1-ATPASE; BETA-SUBUNIT; DIRECTED MUTAGENESIS; CATALYTIC SITES; ATP; ADENINE; F(1)-ATPASE	Binding of pyrophosphate (PPi) to the three catalytic (''C'') and three noncatalytic (''NC'') nucleotide sites of Escherichia coli F-1-ATPase was determined by fluorescence spectroscopy using mutant enzymes with tryptophan inserted specifically in either C sites (beta Y331W) or NC sites (alpha R365W). Fluorescence of the tryptophan is quenched on binding of nucleotide; PPi binding parameters were determined by competition with ATP or adenyl-5'-yl imidodiphosphate. It was found that MgPPi binds to each NC site with K-d = 20 mu M. In contrast, even at millimolar concentration, neither MgPPi nor free PPi showed significant binding to C sites. We confirmed that free PPi displaces nucleotide from C sites, but this was shown to be due to complexation of Mg2+ ions rather than to occupancy of the sites. MgPPi bound at NC sites was found not to affect ATP hydrolysis rates. From the data we propose a two-phase model for nucleotide binding at NC sites. In phase one, NC sites recognize the pyrophosphate ''end'' of the nucleotide, which binds initially with K-d similar to MgPPi; in phase two, a slow conformational change occurs which tightly sequesters adenine nucleotide. Phase two does not occur with guanine nucleotide. This model explains the preference of NC sites for adenine nucleotides. P-i (5 mM) did not bind to either C or NC sites.			WEBER, J (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DAWSON RMC, 1984, DATA BIOCH RES, P399; DOWNIE JA, 1981, J BACTERIOL, V145, P200, DOI 10.1128/JB.145.1.200-210.1981; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; ISSARTEL JP, 1986, J BIOL CHEM, V261, P895; ISSARTEL JP, 1987, J BIOL CHEM, V262, P13538; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KIRONDE FAS, 1986, J BIOL CHEM, V261, P2544; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; O'Sullivan W J, 1979, Methods Enzymol, V63, P294; PAGAN J, 1990, FEBS LETT, V273, P147, DOI 10.1016/0014-5793(90)81071-U; PEINNEQUIN A, 1992, BIOCHEMISTRY-US, V31, P2088, DOI 10.1021/bi00122a028; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; RAO R, 1988, J BIOL CHEM, V263, P5569; RAO R, 1988, J BIOL CHEM, V263, P15957; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1994, J BIOL CHEM, V269, P11261; WEBER J, 1993, J BIOL CHEM, V268, P20126; WEBER J, 1993, J BIOL CHEM, V268, P6241; WILKEMOUNTS S, 1994, ARCH BIOCHEM BIOPHYS, V309, P363, DOI 10.1006/abbi.1994.1125; WISE JG, 1981, J BIOL CHEM, V256, P383; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343	28	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12653	12658		10.1074/jbc.270.21.12653	http://dx.doi.org/10.1074/jbc.270.21.12653			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759515	hybrid			2022-12-25	WOS:A1995QZ71100051
J	CHEN, RH; MOSES, HL; MARUOKA, EM; DERYNCK, R; KAWABATA, M				CHEN, RH; MOSES, HL; MARUOKA, EM; DERYNCK, R; KAWABATA, M			PHOSPHORYLATION-DEPENDENT INTERACTION OF THE CYTOPLASMIC DOMAINS OF THE TYPE-I AND TYPE-II TRANSFORMING GROWTH-FACTOR-BETA RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; SIGNAL TRANSDUCTION; PROTEIN PHOSPHATASE; EXPRESSION CLONING; XENOPUS EMBRYOS; KINASE; CELLS; ACTIVIN; LIGAND; BETAGLYCAN	Transforming growth factor-beta (TGF-beta) transduces signals through its type I and type II receptors. Both receptor types have previously been shown to interact in a heteromeric complex in the presence of TGF-beta. We have now characterized these interactions between both receptor types using a combination of yeast two-hybrid interaction assays and coimmunoprecipitation analyses. Our results indicate a direct association between the cytoplasmic domains of the two receptor types. Mutation analysis of these cytoplasmic domains reveals that this direct interaction requires kinase activity and, thus, depends on phosphorylation, probably via a transphosphorylation mechanism. Furthermore, the two receptor types already have an inherent affinity for each other in the absence of TGF-beta, and the heteromeric complex can be detected in coimmunoprecipitation under these conditions. Taken together, our results reveal a novel mechanism of receptor complex formation, whereby two different cytoplasmic domains directly associate with each other. This interaction may play a major role in activation of serine/threonine kinase receptors.	UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA; VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Vanderbilt University	CHEN, RH (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT GROWTH & DEV, SAN FRANCISCO, CA 94143 USA.		Chen, Ruey-Hwa/G-6121-2019	Chen, Ruey-Hwa/0000-0001-8124-5832				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BRAND T, 1993, J BIOL CHEM, V268, P11500; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1994, CYTOKINE HDB, P319; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARPER JW, 1993, CELL, V75, P805; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LUCAS C, 1991, METHOD ENZYMOL, V198, P303; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	46	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12235	12241		10.1074/jbc.270.20.12235	http://dx.doi.org/10.1074/jbc.270.20.12235			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744874	hybrid			2022-12-25	WOS:A1995QY73600079
J	HEYMACH, JV; SHOOTER, EM				HEYMACH, JV; SHOOTER, EM			THE BIOSYNTHESIS OF NEUROTROPHIN HETERODIMERS BY TRANSFECTED MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CRYSTAL-STRUCTURE; TRANSFORMING GROWTH-FACTOR-BETA-2; MONOCLONAL-ANTIBODIES; RECEPTOR-BINDING; SYSTEM; NGF; EXPRESSION; NEURONS; SUPERFAMILY	Prompted by the recent discovery that neurotrophins, which are known to be biologically active as noncovalently linked homodimers, can also be induced to form biologically active heterodimers in vitro, we have investigated the biosynthesis of neurotrophin heterodimers by transfected mammalian cells. When COS cells were cotransfected with expression plasmids for nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), or neurotrophin-3 (NT-3), the appropriate heterodimers were detected in the conditioned medium by immunoprecipitation and, in the case of NGF . NT-3, using a two-site enzyme-linked immunosorbent assay. Heterodimer formation occurred predominantly intracellularly and did not require precursor cleavage, because heterodimers containing pro-NGF and pro-BDNF were detected in the conditioned medium. When rat C6 glioma cells or mouse AtT-20 neuroendocrine cells were cotransfected with expression plasmids for NGF and NT-3, NGF . NT-3 heterodimer was detected at levels comparable with those of homodimeric NGF and NT-3, indicating that heterodimer formation can occur at significant levels in a variety of cell types. These data provide evidence that NGF, BDNF, and NT-3 are capable of forming heterodimers when coexpressed in mammalian cells and suggest that such heterodimers are likely to be formed in vivo when a single cell expresses multiple neurotrophins.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Heymach, John/AAG-2361-2019	Heymach, John/0000-0001-9068-8942	NICHD NIH HHS [HD-07249] Funding Source: Medline; NINDS NIH HHS [NS 04270] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON M, 1994, J BIOL CHEM, V269, P926; ARAKAWA T, 1994, J BIOL CHEM, V269, P27833; BOTHWELL MA, 1977, J BIOL CHEM, V252, P8532; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; EBENDAL T, 1989, J NEUROSCI RES, V22, P223, DOI 10.1002/jnr.490220302; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; HAMEL W, 1993, J NEUROSCI RES, V34, P147, DOI 10.1002/jnr.490340202; HARLOW E, 1988, ANTIBODIES LABORATOR, P490; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1991, J NEUROCHEM, V57, P1033, DOI 10.1111/j.1471-4159.1991.tb08254.x; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JUNGBLUTH S, 1994, EUR J BIOCHEM, V221, P677, DOI 10.1111/j.1432-1033.1994.tb18780.x; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIRANDA RC, 1993, P NATL ACAD SCI USA, V90, P6439, DOI 10.1073/pnas.90.14.6439; MURPHY RA, 1977, J CELL BIOL, V72, P769, DOI 10.1083/jcb.72.3.769; NARHI LO, 1993, J BIOL CHEM, V268, P13309; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; PHILO J, 1994, J BIOL CHEM, V269, P27840; RADZIEJEWSKI C, 1992, BIOCHEMISTRY-US, V31, P4431, DOI 10.1021/bi00133a007; RADZIEWJEWSKI C, 1993, BIOCHEMISTRY-US, V32, P13350, DOI 10.1021/bi00211a049; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; SUTER U, 1992, J NEUROSCI, V2, P306; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; ZIMMERMANN A, 1981, P NATL ACAD SCI-BIOL, V78, P4611, DOI 10.1073/pnas.78.7.4611	39	52	58	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12297	12304		10.1074/jbc.270.20.12297	http://dx.doi.org/10.1074/jbc.270.20.12297			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744882	hybrid			2022-12-25	WOS:A1995QY73600087
J	WELHAM, MJ; LEARMONTH, L; BONE, H; SCHRADER, JW				WELHAM, MJ; LEARMONTH, L; BONE, H; SCHRADER, JW			INTERLEUKIN-13 SIGNAL-TRANSDUCTION IN LYMPHOHEMATOPOIETIC CELLS - SIMILARITIES AND DIFFERENCES IN SIGNAL-TRANSDUCTION WITH INTERLEUKIN-4 AND INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GAMMA-CHAIN; TYROSINE PHOSPHORYLATION; GROWTH-FACTORS; IGE SYNTHESIS; B-CELLS; PROTEIN; ACTIVATION; KINASE; IL-4; GRB2	Interleukin-13 (IL-13) and interleukin-4 (IL-4) are related in structure and function and are thought to share a common receptor component. We have investigated the signal transduction pathways activated by these two growth factors, as well as insulin, in cell-lines and primary cells of lymphohemopoietic origin. All three factors induced the tyrosine phosphorylation of a protein of 170 kDa (p170), which coimmunoprecipitated with the p85 subunit of PI3'-kinase, via high affinity interactions mediated by the SH2 domains of p85. Antibodies raised against the entire insulin-receptor substrate-1 (IRS-1) protein immunoprecipitated p170 much less efficiently than they did IRS-1 from 3T3 cells. However, antibodies directed against the conserved pleckstrin homology domain of IRS-1 immunoprecipitated both p170 and IRS-1 with similar efficiency, suggesting they share structural similarities in this region. In lymphohemopoietic cells, IL-13, IL-4, and insulin failed to induce increased tyrosine phosphorylation of Shc, or its association with grb2, modification of Sos1, or activation of erk-1 and erk-2 mitogen-activated protein kinases, suggesting that p170 mediates downstream pathways distinct from those mediated by IRS-1. Both IL-13 and IL-4 induced low levels of tyrosine phosphorylation of Tyk-2 and Jak-1. IL-4 also activated the Jak-3-kinase, but, despite other similarities, IL-13 did not. Insulin failed to activate any of the known members of the Janus family of kinases. In that Jak-3 is reported to associate with the IL-2 gamma c chain, these data suggest that the IL-13 receptor does not utilize this subunit. However, both IL-13 and IL-4 induced tyrosine phosphorylation of the IL-4-140 kDa receptor chain, suggesting that this is a component of both receptors in these cells and accounts for the similarities in signaling pathways shared by IL-13 and IL-4.	UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia; University of British Columbia								ANDERSSON J, 1972, EUR J IMMUNOL, V2, P349, DOI 10.1002/eji.1830020410; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BECKMANN MP, 1992, CHEM IMMUNOL, V51, P107; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BROWN KD, 1989, J IMMUNOL, V142, P679; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; DEVRIES JE, 1991, CURR OPIN IMMUNOL, V3, P851, DOI 10.1016/S0952-7915(05)80003-2; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HARADA N, 1992, J BIOL CHEM, V267, P22752; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JUSTEMENT L, 1986, J IMMUNOL, V137, P3664; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOETTNITZ K, 1993, EUR J IMMUNOL, V23, P988, DOI 10.1002/eji.1830230437; KOHLER I, 1994, FEBS LETT, V345, P187, DOI 10.1016/0014-5793(94)00438-2; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSDORP PM, 1986, CURR TOP MICROBIOL I, V132, P105; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MIZUGUCHI J, 1986, J IMMUNOL, V137, P2215; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SELDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140, DOI 10.1073/pnas.91.6.2140; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LW, 1983, P NATL ACAD SCI USA, V90, P4032; WATTS JD, 1993, J IMMUNOL, V151, P6862; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YIN TG, 1994, J BIOL CHEM, V269, P26614; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	65	144	155	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12286	12296		10.1074/jbc.270.20.12286	http://dx.doi.org/10.1074/jbc.270.20.12286			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744881	hybrid			2022-12-25	WOS:A1995QY73600086
J	MORISHITA, K; SUZUKAWA, K; TAKI, T; IHLE, JN; YOKOTA, J				MORISHITA, K; SUZUKAWA, K; TAKI, T; IHLE, JN; YOKOTA, J			EVI-1 ZINC-FINGER PROTEIN WORKS AS A TRANSCRIPTIONAL ACTIVATOR VIA BINDING TO A CONSENSUS SEQUENCE OF GACAAGATAAGATAAN(1-28) CTCATCTTC	ONCOGENE			English	Article						ZINC FINGER PROTEIN; EVI-1; DNA-BINDING; CONSENSUS SEQUENCE; TRANSCRIPTIONAL REGULATION	MYELOID-TRANSFORMING GENE; CYCLIC AMPLIFICATION; CELL-LINES; EXPRESSION; IDENTIFICATION; TRANSLOCATIONS; KILOBASES; SELECTION; COMPLEXES; LEUKEMIAS	Previously, the DNA-binding consensus sequences for domains 1 (GACAAGATAAGATAA) and 2 (GAAGATGAG) of the EVI-1 protein were identified using GST fusion proteins of each domain in binding and amplification reactions, We have utilized full-length EVI-1 protein to confirm these consensus sequences and determine the spacial and orientation requirements for binding, Our data demonstrate that full-length EVI-1 can independently bind the consensus sequences in gel mobility shift assays. In binding and amplification reactions only the domain I consensus sequence (D1-CONS) was obtained with full-length EVI-1 protein. However, by using constructs in which D1-CONS was anchored, products were obtained in which the domain 2 consensus sequence (D2-CONS) was observed with the spacing and orientation of GACAAGATAATATAAN(1-28) CTCATCTTC. Using this consensus sequence we show that EVI-1 can activate transcription from reporter constructs. No transcriptional activation was seen with the reporter construct containing DT-CONS atone while activation was seen with the construct-containing D2-CONS alone. These results indicate that the EVI-1 protein works as a transcriptional activator and the binding of the domain 2 with D2-CONS is essential for its activation.	NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	National Cancer Center - Japan; St Jude Children's Research Hospital				Suzukawa, Kazumi/0000-0001-9904-3905				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T, 1989, MOL CLONING; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SUZUKAWA K, 1994, BLOOD, V84, P2681; WRIGHT WE, 1993, TRENDS BIOCHEM SCI, V18, P77, DOI 10.1016/0968-0004(93)90156-H; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0	26	46	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					1961	1967						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761097				2022-12-25	WOS:A1995QZ92600010
J	BORYCKI, AG; FOUCRIER, J; SAFFAR, L; LEIBOVITCH, SA				BORYCKI, AG; FOUCRIER, J; SAFFAR, L; LEIBOVITCH, SA			REPRESSION OF THE CSF-1 RECEPTOR (C-FMS PROTOONCOGENE PRODUCT) BY ANTISENSE TRANSFECTION INDUCES G1-GROWTH ARREST IN L6-ALPHA-1 RAT MYOBLASTS	ONCOGENE			English	Article						D-TYPE CYCLINS; C-FMS; MYOGENESIS	CYCLIN MESSENGER-RNA; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASE; DNA-REPLICATION; GROWTH-FACTOR; G1 PHASE; S-PHASE	Colony Stimulating Factor (CSF-1) and the CSF-1 receptor (the c-fms product) are expressed during the proliferation of L6 alpha 1 rat myogenic cell line and both are down regulated during the formation of myotubes. In this study, we demonstrated that the expression of c-fms antisense RNA in stably transfected myoblasts repressed the CSF-1 receptor (c-fms protein) and induced a G1-growth arrest. Expression of the cyclin genes, that control passage through the G1 phase and in particular the cyclins identified as genes induced late in G1 by CSF-1 in mouse macrophages was studied in comparative Northern blot analyses of RNAs of subpopulations prepared by centrifugal elutriation of L6 alpha 1 myoblasts and induced Antifms D5 cells expressing c-fms antisense RNA. Repression of the CSF-1 receptor (c-fms product) did not affect cyclins A, B and G expression during the cell cycle. However, D-type cyclins and, at a lesser extend, cyclin E expression were dramatically altered specifically during the late G1 and early S phases, in Antifms D5 cells. These results suggest a role for the CSF-1/c-fms autocrine loop in the control of the proliferation of L6 alpha 1 rat myogenic cell line at the G1/S boundary via the D-type and E cyclins expression.	INST GUSTAVE ROUSSY, EXPTL CANCEROL LAB, CNRS, UA1158, URA126, F-94800 VILLEJUIF, FRANCE; UNIV PARIS 13, BIOL DEV & DIFFERENCIAT LAB, F-93012 BOBIGNY, FRANCE; UNIV PARIS 13, BIOL CELLULAIRE LAB, UFR BIOMED, F-93012 BOBIGNY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Universite Paris 13; Universite Paris 13								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BORYCKI, 1995, IN PRESS EYPT CELL R; BORYCKI AG, 1993, BIOCHIM BIOPHYS ACTA, V1174, P143, DOI 10.1016/0167-4781(93)90108-P; Borycki AG, 1992, GROWTH FACTORS, V6, P209, DOI 10.3109/08977199209021534; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUILLIER M, 1991, NUCLEIC ACIDS RES, V19, P1339, DOI 10.1093/nar/19.6.1339; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HILLION J, 1984, CANCER RES, V44, P2959; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1993, ONCOGENE, V8, P3447; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LU XP, 1992, J BIOL CHEM, V267, P2841; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NEVINS JR, 1992, SCIENCE, V258, P424; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; RUTSGI AK, 1991, NATURE, V352, P541; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; SURMACZ E, 1992, CANCER RES, V52, P4522; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TAMURA K, 1993, ONCOGENE, V8, P2113; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YEN A, 1993, J CELL PHYSIOL, V157, P379, DOI 10.1002/jcp.1041570222; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	67	7	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1799	1811						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753556				2022-12-25	WOS:A1995QX46900013
J	FORNEROD, M; BOER, J; VANBAAL, S; JAEGLE, M; VONLINDERN, M; MURTI, KG; DAVIS, D; BONTEN, J; BUIJS, A; GROSVELD, G				FORNEROD, M; BOER, J; VANBAAL, S; JAEGLE, M; VONLINDERN, M; MURTI, KG; DAVIS, D; BONTEN, J; BUIJS, A; GROSVELD, G			RELOCATION OF THE CARBOXYTERMINAL PART OF CAN FROM THE NUCLEAR-ENVELOPE TO THE NUCLEUS AS A RESULT OF LEUKEMIA-SPECIFIC CHROMOSOME REARRANGEMENTS	ONCOGENE			English	Article						LEUKEMIA; FUSION PROTEINS; NUCLEOPORINS; TRANSLOCATIONS; CAN PROTOONCOGENE	ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; MAMMALIAN-CELLS; TRANSLOCATION 6-9; CDNA CLONING; PORE COMPLEX; EXPRESSION; GENE; PROTEIN; FUSION	Fusion genes encoding the 3' part of the can gene are implicated in two types of leukemia, The dek-can fusion gene is present in t(6;9) acute myeloid leukemia and the set-can fusion gene is present in one case of acute undifferentiated leukemia. In order to obtain leads towards the molecular basis of these diseases, we have studied the cellular localization of the DEK-CAN and SET-CAN fusion proteins and their normal counterparts. DEK-CAN and SET-CAN were localized exclusively in the nucleus, and also DEK and SET were found to be nuclear proteins. However, CAN was mainly located at the nuclear and cytoplasmic face of the nuclear envelope. This observation is in accordance with the presence of an amino acid repeat in the C-terminal part of CAN, common to the family of nucleoporins. The C-terminal part also contains a nuclear location domain as shown by deletion analysis. This domain may be important for the presence of CAN at the nucleoplasmic side of the nuclear envelope. The relocation of the carboxyterminal part of CAN due to DEK-CAN and SET-CAN may reinforce a nuclear function of the CAN protein.	ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38105 USA; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS; RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Erasmus University Rotterdam; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Boer, Judith/A-7546-2010; Fornerod, Maarten/A-7503-2010; von Lindern, Marieke/AAH-2350-2020	Fornerod, Maarten/0000-0002-6166-3030	NCI NIH HHS [CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1994, J BIOL CHEM, V269, P2258; ADRIAANSEN HJ, 1988, LEUKEMIA, V2, P136; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HURT EC, 1989, J CELL SCI, P243; HURT EC, 1990, J CELL BIOL, V111, P2829, DOI 10.1083/jcb.111.6.2829; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MEIJER D, 1990, NUCLEIC ACIDS RES, V18, P7357, DOI 10.1093/nar/18.24.7357; MEYN MS, 1993, AM J HUM GENET, V53, P1206; MOGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068; MURTI KG, 1985, J ELECTRON MICR TECH, V2, P139, DOI 10.1002/jemt.1060020205; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; ROWLEY JD, 1976, BLOOD, V47, P705; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SIERAKOWSKA H, 1993, CLIN EXP IMMUNOL, V94, P435; SMITH GE, 1993, MOL CELL BIOL, V2, P2156; SOEKARMAN D, 1992, LEUKEMIA, V6, P489; SOEKARMAN D, 1992, BLOOD, V79, P2990; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; VONLINDERN M, 1990, MOL CELL BIOL, V10, P4016, DOI 10.1128/MCB.10.8.4016; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WEBSTER RE, 1978, EXP CELL RES, V117, P47, DOI 10.1016/0014-4827(78)90426-3; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; YARMUSH ML, 1981, J IMMUNOL, V126, P2240; YOUNG BD, 1992, BAILLIERE CLIN HAEM, V5, P791	40	140	144	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1739	1748						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753551				2022-12-25	WOS:A1995QX46900007
J	TONG, Q; LI, YS; SMANIK, PA; FITHIAN, LJ; XING, SH; MAZZAFERRI, EL; JHIANG, SM				TONG, Q; LI, YS; SMANIK, PA; FITHIAN, LJ; XING, SH; MAZZAFERRI, EL; JHIANG, SM			CHARACTERIZATION OF THE PROMOTER REGION AND OLIGOMERIZATION DOMAIN OF H4 (D10S170), A GENE FREQUENTLY REARRANGED WITH THE RET PROTOONCOGENE	ONCOGENE			English	Article						H4 (D10S170); VET; PROMOTER; OLIGOMERIZATION	THYROID PAPILLARY CARCINOMAS; TYROSINE KINASE; TRANSGENIC MICE; CELL-LINE; PROTOONCOGENE; ACTIVATION; SEQUENCE; CLONING; FUSION; EXPRESSION	PTC-1, the predominant form of PTC oncogene in human papillary thyroid carcinoma, encodes a fusion protein containing the N-terminus of H4 (D10S170) fused 5' to the ret tyrosine kinase domain. Accordingly, the PTC-1 expression is driven by the H4 gene promoter. Our study showed that H4 is expressed in various human tissues, including thyroid. Furthermore, we have localized the transcriptional start sites of H4 to a region 100 to 190 bp upstream of the translation initiation site (ATG) by primer extension assay, and the 114 promoter to a region within 259 bp upstream of the ATG site by luciferase assay. Interestingly, protein sequence analysis indicated a potential coiled-coil domain in the N-terminal region of H4. Indeed, oligomerization was demonstrated by an in vitro assay with recombinant proteins containing this region. As dimerization is considered to be a crucial step for receptor tyrosine kinase activation, we hypothesize that both unscheduled expression of ret tyrosine kinase and constitutive oligomerization of PTC-1 proteins are responsible for PTC-1 transforming activity in thyroid.	OHIO STATE UNIV,DEPT PHYSIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT INTERNAL MED,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NCI NIH HHS [R29 CA60074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V4, P1519; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P259; IWAMOTO T, 1991, EUR J IMMUNOL, V21, P1809, DOI 10.1002/eji.1830210805; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JHIANG SM, 1992, ONCOGENE, V7, P1331; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RENOLDS GA, 1984, CELL, V38, P275; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1994, ONCOGENE, V9, P509; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13449; WEINER DB, 1989, NATURE, V239, P230	41	29	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1781	1787						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753554				2022-12-25	WOS:A1995QX46900011
J	TRAUTWEIN, C; WALKER, DL; PLUMPE, J; MANNS, MP				TRAUTWEIN, C; WALKER, DL; PLUMPE, J; MANNS, MP			TRANSACTIVATION OF LAP/NF-IL6 IS MEDIATED BY AN ACIDIC DOMAIN IN THE N-TERMINAL PART OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTIONAL ACTIVATOR; LEUCINE ZIPPER; C/EBP FAMILY; FACTOR-TFIIB; NUCLEAR FACTOR; PHOSPHORYLATION; EXPRESSION; ELEMENTS; BINDING; CELLS	LAP/NF-IL6 is a member of the C/EBP family of transcriptional activators and has been shown to be involved in the regulation of the acute-phase response. We have previously shown that phosphorylation of the liver-enriched transcriptional activator protein (LAP) Ser-105 enhances the activation of LAP-dependent genes. To identify the region which is important for gene activation, a series of LAP mutants were constructed, and domain swapping experiments with the DNA-binding domain of GAL4 were performed. These experiments point to an acidic region located between amino acids 21 and 105 of LAP/NF-IL6 which activates genes independent of the DNA-binding domain and the leucine zipper of LAP/NF-IL6. Computer-assisted predictions reveal two regions, a helical and a hydrophobic region in the transactivation domain, which could be important in mediating the direct interaction with the basal machinery. Site-directed mutagenesis of acidic residues in both regions demonstrates that the hydrophobic region located between amino acids 85 and 95 is the likely motif for the interaction with the basal machinery. Our results demonstrate that a hydrophobic region in the acidic transactivation domain of LAP/NF-IL6 seems to be relevant in mediating gene activation of LAP dependent genes.	HANNOVER MED SCH,ZENTRUM INNERE MED & DERMATOL,GASTROENTEROL & HEPATOL ABT,D-30625 HANNOVER,GERMANY	Hannover Medical School								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DELEAGE G, 1987, ANAL BIOCHEM, V163, P292, DOI 10.1016/0003-2697(87)90226-0; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; NISHIZAWA M, 1990, J BIOL CHEM, V265, P5897; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; Sambrook J, 1989, MOL CLONING LABORATO; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	41	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15130	15136		10.1074/jbc.270.25.15130	http://dx.doi.org/10.1074/jbc.270.25.15130			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797496	hybrid			2022-12-25	WOS:A1995RE66600044
J	LAMA, J; SANZ, MA; RODRIGUEZ, PL				LAMA, J; SANZ, MA; RODRIGUEZ, PL			A ROLE FOR 3AB PROTEIN IN POLIOVIRUS GENOME REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-RNA AMPLIFICATION; LINKED PROTEIN; NONSTRUCTURAL PROTEINS; ESCHERICHIA-COLI; POLYMERASE; VPG; INITIATION; POLYPEPTIDE; PRECURSOR; SEQUENCE	The poliovirus polypeptide 3AB, the precursor of the genome-bound VPg protein, stimulates in vitro the synthesis of poly(U) directed by the viral polymerase 3D(pol) (Lama, J., Paul, A., Harris, K., and Wimmer, E. (1994) J. Biol. Chem. 269, 66-70), suggesting that 3AB could be modulating the activity of the viral polymerase in poliovirus-infected cells. To address the exact function of 3AB in the viral replication cycle, a biochemical and molecular genetic analysis of 3AB has been carried out, 3AB protein bound RNA probes in two different assays, and amino acid positions implicated in the RNA binding activity of 3AB were determined, Mutant proteins with reduced RNA binding activity were unable to stimulate 3D(pol) polymerase activity. Purified protein 3A showed no RNA binding or 3D(pol) stimulatory activity, but 3A and VPg mutations conferred a synergistic effect on the 3AB functions. Polioviruses encoding for these mutant SABs were constructed. These mutant viruses translated their RNA genomes in vitro and processed their polyproteins as wild type virus did. Cells infected with 3AB mutant viruses showed over 90% inhibition in the accumulation of plus and minus viral RNA strands and more than 100-fold reduction of virus yield at 4 h postinfection. Our results suggest that 3AB protein functions in vivo as a co-factor of the viral polymerase and that the activity of 3AB maybe regulated by proteoIytic processing.			LAMA, J (corresponding author), UNIV AUTONOMA MADRID, CTR BIOL MOLEC SEVERO OCHOA, E-28049 MADRID, SPAIN.		Rodriguez, Pedro L./K-4605-2014; Sanz, Miguel A/H-1914-2015; sanz-gomez, miguel/Y-6244-2019	Rodriguez, Pedro L./0000-0002-5886-9425; Sanz, Miguel A/0000-0001-6573-883X; sanz-gomez, miguel/0000-0002-5761-9010				ANDINO R, 1990, J VIROL, V64, P607, DOI 10.1128/JVI.64.2.607-612.1990; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; BERNSTEIN HD, 1988, J VIROL, V62, P2922, DOI 10.1128/JVI.62.8.2922-2928.1988; BERNSTEIN HD, 1986, J VIROL, V60, P1040, DOI 10.1128/JVI.60.3.1040-1049.1986; BIENZ K, 1983, VIROLOGY, V131, P39, DOI 10.1016/0042-6822(83)90531-7; BURNS CC, 1989, J VIROL, V63, P4866, DOI 10.1128/JVI.63.11.4866-4874.1989; Favaloro J, 1980, Methods Enzymol, V65, P718; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P961, DOI 10.1073/pnas.74.3.961; FLANEGAN JB, 1979, J VIROL, V29, P352, DOI 10.1128/JVI.29.1.352-360.1979; FLANEGAN JB, 1979, J VIROL, V32, P155, DOI 10.1128/JVI.32.1.155-161.1979; GIACHETTI C, 1991, J VIROL, V65, P2647, DOI 10.1128/JVI.65.5.2647-2654.1991; GIACHETTI C, 1992, J VIROL, V66, P6045, DOI 10.1128/JVI.66.10.6045-6057.1992; JACOBSON SJ, 1993, J VIROL, V67, P2961, DOI 10.1128/JVI.67.6.2961-2971.1993; JOHNSON KL, 1991, J VIROL, V65, P4341, DOI 10.1128/JVI.65.8.4341-4349.1991; Kirkegaard K, 1992, CURR OPIN GENET DEV, V2, P64, DOI 10.1016/S0959-437X(05)80324-7; Kuhn R. J., 1987, The molecular biology of the positive strand RNA viruses, P17; KUHN RJ, 1988, J VIROL, V62, P4207, DOI 10.1128/JVI.62.11.4207-4215.1988; LAMA J, 1994, J BIOL CHEM, V269, P66; LAMA J, 1992, J BIOL CHEM, V267, P15932; LARSEN GR, 1982, J VIROL, V41, P340, DOI 10.1128/JVI.41.1.340-344.1982; LEE YF, 1977, P NATL ACAD SCI USA, V74, P59, DOI 10.1073/pnas.74.1.59; MOLLA A, 1994, J BIOL CHEM, V269, P27015; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; MOLLA A, 1993, VIROLOGY, V196, P739, DOI 10.1006/viro.1993.1531; PAUL AV, 1994, J BIOL CHEM, V269, P29173; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PORTER AG, 1993, J VIROL, V67, P6917, DOI 10.1128/JVI.67.12.6917-6921.1993; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; RODRIGUEZ PL, 1994, BIOTECHNIQUES, V17, P702; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; SEMLER BL, 1988, RNA GENETICS, V1, P23; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TSUNG K, 1990, P NATL ACAD SCI USA, V87, P5940, DOI 10.1073/pnas.87.15.5940; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; WIMMER E, 1987, J CELL SCI, P251; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033	38	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14430	14438		10.1074/jbc.270.24.14430	http://dx.doi.org/10.1074/jbc.270.24.14430			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782305	hybrid			2022-12-25	WOS:A1995RD45500032
J	BRACEY, TS; MILLER, JC; PREECE, A; PARASKEVA, C				BRACEY, TS; MILLER, JC; PREECE, A; PARASKEVA, C			GAMMA-RADIATION-INDUCED APOPTOSIS IN HUMAN COLORECTAL ADENOMA AND CARCINOMA CELL-LINES CAN OCCUR IN THE ABSENCE OF WILD-TYPE P53	ONCOGENE			English	Note						APOPTOSIS; CELL CYCLE; COLORECTAL; GAMMA RADIATION; G2 ARREST; P53	TUMOR-SUPPRESSOR GENE; THYMOCYTE APOPTOSIS; IONIZING-RADIATION; DNA-DAMAGE; DEATH; IRRADIATION; ACTIVATION; CHECKPOINT; MUTATIONS; CANCER	The tumour suppressor gene p53 codes for a transcription factor which is thought to play a critical role in the induction of G1 cell cycle arrest and programmed cell death (apoptosis) following DNA damage by ionizing radiation, The aim of this investigation was to determine whether a p53 independent radiation-induced apoptosis pathway exists in human colon epithelial cell lines. This report describes the induction, by gamma-radiation, of apoptosis in the colorectal adenoma cell line S/RG/C2, and in the colorectal carcinoma cell line PC/JW, both of which lack wild type p53, In addition, flow cytometry revealed that both cell lines failed to arrest in G1 after radiation. Thus, although loss of wild type p53 may abrogate GI arrest, radiation-induced apoptosis can still occur in human colonic tumour cell lines through a p53 independent mechanism.	UNIV BRISTOL, SCH MED SCI,DEPT PATHOL & MICROBIOL,CRC, COLORECTAL TUMOUR BIOL RES GRP, BRISTOL BS8 1TD, AVON, ENGLAND; BRISTOL ONCOL CTR, BIOPHYS GRP, BRISTOL BS2 8ED, AVON, ENGLAND	University of Bristol; Bristol Haematology & Oncology Centre								ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BAKER SJ, 1990, CANCER RES, V50, P7717; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BRACHMAN DG, 1993, CANCER RES, V53, P3667; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HEERDT BG, 1994, CANCER RES, V54, P3288; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWENTHAL JW, 1985, J IMMUNOL, V135, P1119; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MERRITT AJ, 1994, CANCER RES, V54, P614; OCONNOR PM, 1993, CANCER RES, V53, P4776; Okada S, 1970, RAD BIOCH, P247; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PARASKEVA C, 1989, CANCER RES, V49, P1282; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P229, DOI 10.1080/09553009414550261; SEKI H, 1994, EUR J IMMUNOL, V24, P2914, DOI 10.1002/eji.1830241150; SHINOHARA K, 1993, RADIAT RES, V135, P197, DOI 10.2307/3578295; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	38	106	107	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2391	2396						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784088				2022-12-25	WOS:A1995RE54300015
J	YOUN, HD; YIM, YI; KIM, K; HAH, YC; KANG, SO				YOUN, HD; YIM, YI; KIM, K; HAH, YC; KANG, SO			SPECTRAL CHARACTERIZATION AND CHEMICAL MODIFICATION OF CATALASE-PEROXIDASE FROM STREPTOMYCES SP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL HISTIDINE RESIDUE; RESONANCE RAMAN-SPECTRA; ELECTRON-PARAMAGNETIC RESONANCE; LIGNIN-DEGRADING BASIDIOMYCETE; PHANEROCHAETE-CHRYSOSPORIUM; DIARYLPROPANE OXYGENASE; BACTERIAL CATALASES; HEME ENZYME; PURIFICATION; PROTEINS	Catalase-peroxidase was purified to near homogeneity from Streptomyces sp. The enzyme was composed of two subunits with a molecular mass of 78 kDa and contained 1.05 mol of protoporphyrin IX/mol of dimeric protein. The absorption and resonance Raman spectra of the native and its cyano-enzyme were closely similar to those of other heme proteins with a histidine as the fifth ligand. However, the peak from tyrosine ring at similar to 1612 cm(-1), which is unique in catalases, was not found in resonance Raman spectra of catalase-peroxidase. The electron paramagnetic resonance spectrum of the native enzyme revealed uniquely two sets of rhombic signals, which were converted to a single high spin, hexacoordinate species after the addition of sodium formate. Cyanide bound to the sixth coordination position of the heme iron, thereby converting the enzyme to a low spin, hexacoordinate species. The time-dependent inactivation of the enzyme with diethyl pyrocarbonate and its kinetic analysis strongly suggested the occurrence of histidine residue. From the above-mentioned spectroscopic results and chemical modification, it was deduced that the native enzyme is predominantly in the high spin, ferric form and has a histidine as the fifth ligand.	SEOUL NATL UNIV, COLL NAT SCI, DEPT MICROBIOL, SEOUL 151742, SOUTH KOREA; SEOUL NATL UNIV, COLL NAT SCI, DEPT CHEM, SEOUL 151742, SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)			Youn, Hong-Duk/J-2774-2012					ANDERSSON LA, 1985, J BIOL CHEM, V260, P6080; ANDERSSON LA, 1987, BIOCHEMISTRY-US, V26, P2258, DOI 10.1021/bi00382a028; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; APPLEBY CA, 1959, BIOCHEM J, V73, P539, DOI 10.1042/bj0730539; BEERS RF, 1952, J BIOL CHEM, V195, P133; BLANKE SR, 1990, J BIOL CHEM, V265, P12454; BROWNPETERSON NJ, 1993, J BACTERIOL, V175, P4197, DOI 10.1128/JB.175.13.4197-4202.1993; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; CHUANG WJ, 1988, J INORG BIOCHEM, V34, P201, DOI 10.1016/0162-0134(88)85030-X; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; CLAYTON RK, 1959, BIOCHIM BIOPHYS ACTA, V36, P40, DOI 10.1016/0006-3002(59)90067-8; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EHRENBERG A, 1962, ARK KEMI, V19, P119; ESAKA M, 1982, PLANT CELL PHYSIOL, V23, P315; FELTON RH, 1978, PORPHYRINS, V3, P347; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; GOLD MH, 1984, ARCH BIOCHEM BIOPHYS, V234, P353, DOI 10.1016/0003-9861(84)90280-7; HERBERT D, 1948, BIOCHEM J, V43, P193, DOI 10.1042/bj0430193; HOCHMAN A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P299, DOI 10.1016/0167-4838(91)90544-A; HOCHMAN A, 1987, J BIOL CHEM, V262, P6871; HOLBROOK JJ, 1973, BIOCHEM J, V131, P729, DOI 10.1042/bj1310729; JACOB GS, 1979, BIOCHEMISTRY-US, V18, P2975, DOI 10.1021/bi00581a010; KANG SO, 1993, BIOCHIM BIOPHYS ACTA, V1163, P158, DOI 10.1016/0167-4838(93)90177-S; Kim H. P., 1992, KOREAN J MICROBIOL, V30, P291; KITAGAWA T, 1975, CHEM LETT, P849, DOI 10.1246/cl.1975.849; Kitagawa T, 1978, Adv Biophys, V11, P153; LAMBIN P, 1978, ANAL BIOCHEM, V85, P114, DOI 10.1016/0003-2697(78)90281-6; LANIR A, 1979, BIOCHEMISTRY-US, V18, P1656, DOI 10.1021/bi00576a004; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; LOEWEN PC, 1990, MOL GEN GENET, V224, P147, DOI 10.1007/BF00259461; LUNDBALD RL, 1984, CHEM REAGENTS PROTEI, V1; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MINO Y, 1988, J BIOL CHEM, V263, P7029; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MULRAD A, 1967, BIOCHIM BIOPHYS ACTA, V2, P19; NADLER V, 1986, BIOCHIM BIOPHYS ACTA, V882, P234, DOI 10.1016/0304-4165(86)90160-1; OZOLS J, 1964, J BIOL CHEM, V239, P1018; RAKSHIT G, 1974, BIOCHEMISTRY-US, V13, P5317, DOI 10.1021/bi00723a010; SATO R, 1978, CYTOCHROME P450; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; SHARMA KD, 1989, J BIOL CHEM, V264, P12772; SIEVERS G, 1979, BIOCHIM BIOPHYS ACTA, V581, P1, DOI 10.1016/0005-2795(79)90215-0; SPAULDING LD, 1975, J AM CHEM SOC, V97, P2517, DOI 10.1021/ja00842a032; Spiro T.G., 1983, IRON PORPHYRINS P2, P89; SPIRO TG, 1976, J AM CHEM SOC, V98, P5482, DOI 10.1021/ja00434a013; TORII K, 1968, J BIOCHEM-TOKYO, V64, P171, DOI 10.1093/oxfordjournals.jbchem.a128877; WAYNE LG, 1986, ANAL BIOCHEM, V157, P89, DOI 10.1016/0003-2697(86)90200-9	53	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13740	13747		10.1074/jbc.270.23.13740	http://dx.doi.org/10.1074/jbc.270.23.13740			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775429	hybrid			2022-12-25	WOS:A1995RC44800026
J	FUH, G; WELLS, JA				FUH, G; WELLS, JA			PROLACTIN RECEPTOR ANTAGONISTS THAT INHIBIT THE GROWTH OF BREAST-CANCER CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERM TISSUE-CULTURE; HORMONE RECEPTOR; BINDING-PROTEIN; RATIONAL DESIGN; LACTOGEN; SERUM	We investigated the mechanism of action of the human prolactin (hPRL) receptor on four different breast cancer cell lines, T-47D, MCF-7, BT-474, and SK-BR3, that express elevated levels of the receptor compared with normal cells. Cells treated with human growth hormone (hGH), which binds and activates the hPRL receptor, exhibited bell-shaped dose-response growth curves consistent with the sequential dimerization mechanism proposed for the hPRL receptor (Fuh, G., Colosi, P., Wood, W.I., and Wells, J.A. (1995) J. Biol. Chem. 268, 5376-5381). Growth stimulation was enhanced by Zn2+ which preferentially increases the affinity of hGH for the hPRL receptor. Furthermore, receptor-selective variants of hGH that bind the hPRL receptor but not the hGH receptor were agonistic, providing additional support that specific binding to the hPRL receptor can stimulate these breast cancer cells to grow. On this basis we produced variants of hGH and human placental lactogen (hPL) that were potential antagonists because they bind but do not dimerize the hPRL receptor. The hPL-based antagonist was less potent than the hGH-based antagonist toward the growth of MCF-7 cells, consistent with the lower affinity of hPL for hPRL receptor than for hGH. However, the hPL-based antagonist was more potent than the hGH antagonist for BT-474 cells. Antibodies to the hPRL receptor inhibited growth of FDC-P1 cells transfected with the hPRL receptor; these also inhibited MCF-7 cells and T47D cells but not BT-474 cells. A unique feature of BT-474 cells was found when screening its cDNA revealed the presence of a novel alternative splice of the hPRL receptor that codes for the soluble extracellular domain; this may explain these differential inhibitory effects. These studies provide further molecular insight into the potential role of the hPRL receptor in breast cancer and demonstrate that hPRL receptor antagonists can inhibit the growth of breast cancer cells.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	Roche Holding; Genentech; University of California System; University of California San Francisco			Wells, Jim A/O-9854-2016					ASHKENAZI A, 1987, FEBS LETT, V210, P51, DOI 10.1016/0014-5793(87)81296-6; BAUMANN G, 1986, J CLIN ENDOCR METAB, V62, P134, DOI 10.1210/jcem-62-1-134; BISWAS R, 1987, CANCER RES, V47, P3509; BONNETERRE J, 1987, CANCER RES, V47, P4724; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DJIANE J, 1985, J BIOL CHEM, V260, P1430; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; HUFF KK, 1988, MOL ENDOCRINOL, V2, P200, DOI 10.1210/mend-2-3-200; KELSEY JL, 1991, CA-CANCER J CLIN, V41, P146, DOI 10.3322/canjclin.41.3.146; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOVE RR, 1991, CANCER, V68, P1401, DOI 10.1002/1097-0142(19910915)68:6<1401::AID-CNCR2820680637>3.0.CO;2-K; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; LOWMAN HB, 1991, J BIOL CHEM, V266, P10982; MADDOX PR, 1992, BRIT J CANCER, V65, P456, DOI 10.1038/bjc.1992.92; MANNI A, 1986, CANCER RES, V46, P1669; MURPHY LJ, 1984, CANCER RES, V44, P1963; PHARES CK, 1986, ANTICANCER RES, V6, P845; PLATICA M, 1991, INT J CANCER, V48, P109, DOI 10.1002/ijc.2910480120; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SHIU RPC, 1979, CANCER RES, V39, P4381; SHIU RPC, 1985, J BIOL CHEM, V260, P1307; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; TORNELL J, 1991, INT J CANCER, V49, P114, DOI 10.1002/ijc.2910490121; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553	29	106	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13133	13137		10.1074/jbc.270.22.13133	http://dx.doi.org/10.1074/jbc.270.22.13133			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768908	hybrid			2022-12-25	WOS:A1995RB43900031
J	HERTZ, R; BISHARASHIEBAN, J; BARTANA, J				HERTZ, R; BISHARASHIEBAN, J; BARTANA, J			MODE OF ACTION OF PEROXISOME PROLIFERATORS AS HYPOLIPIDEMIC DRUGS - SUPPRESSION OF APOLIPOPROTEIN C-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; BETA,BETA'-METHYL-SUBSTITUTED HEXADECANEDIOIC ACID; HORMONE RECEPTOR SUPERFAMILY; TRIGLYCERIDE-RICH LIPOPROTEINS; CIII GENE-EXPRESSION; ACTIVATED RECEPTOR; RAT-LIVER; TRANSCRIPTIONAL REGULATION; CLOFIBRIC ACID; HEPATIC-UPTAKE	The hypolipidemic effect exerted by beta,beta'-tetramethyl-hexadecanedioic acid (Medica 16) is accounted for by enhanced catabolism of plasma triglyceride-rich lipoproteins due to a decrease in plasma apolipoprotein C-III (Frenkel, B., Mayorek, N., Hertz, R., and Bar-Tana, J. (1988) J. Biol. Chem. 263, 8491-8497; Frenkel, B., Bishara-Shieban, J., and Bar-Tana, J. (1994) Biochem. J. 298, 409-414). Decrease in apolipoprotein C-III exerted by peroxisome proliferators/hypolipidemic amphipathic carboxylates (e.g. Medica 16, fibrate drugs) is shown here to result from suppression of apolipoprotein C-III gene expression. Transcriptional suppression of apolipoprotein C-III is due to transcriptional suppression of hepatic nuclear factor (HNF)-4 as well as displacement of HNF-4 from the apolipoprotein C-III promoter. HNF-4 displacement exerted by peroxisome proliferators/hypolipidemic amphipathic carboxylates is mediated by the peroxisome proliferators activated receptor (PPAR). Transcriptional suppression of HNF-4-enhanced genes (e.g. apolipoprotein C-III) along with transcriptional activation of peroxisomal and other genes by hypolipidemic drugs may account for their broad spectrum pharmacological effect.	HEBREW UNIV JERUSALEM,FAC MED,DEPT HUMAN NUTR & METAB,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BARTANA J, 1988, J LIPID RES, V29, P431; BARTANA J, 1985, J BIOL CHEM, V260, P8404; BARTANA J, 1989, J MED CHEM, V32, P2072, DOI 10.1021/jm00129a010; CHEN M, 1994, J LIPID RES, V35, P1918; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FRENKEL B, 1994, BIOCHEM J, V298, P409, DOI 10.1042/bj2980409; FRENKEL B, 1988, J BIOL CHEM, V263, P8491; GIBSON G, 1993, PEROXISOMES BIOL IMP; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; GOLDBERG AP, 1977, NEW ENGL J MED, V301, P1073; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRETEN H, 1980, LIPOPROTEINS CORONAR; GRUBER PJ, 1994, NUCLEIC ACIDS RES, V22, P2417, DOI 10.1093/nar/22.12.2417; HERTZ R, 1994, EUR J BIOCHEM, V221, P611, DOI 10.1111/j.1432-1033.1994.tb18773.x; HERTZ R, 1991, BIOCHEM J, V274, P745, DOI 10.1042/bj2740745; HERTZ R, 1987, CANCER LETT, V34, P263, DOI 10.1016/0304-3835(87)90176-5; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KALDERON B, 1992, ENDOCRINOLOGY, V131, P1629, DOI 10.1210/en.131.4.1629; KASHYAP ML, 1981, J LIPID RES, V22, P800; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAZAROW PB, 1977, SCIENCE, V197, P580, DOI 10.1126/science.195342; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAEDA N, 1994, J BIOL CHEM, V269, P23610; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T, 1989, DECONTAMINATION DILU; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; METZGER S, 1993, J BIOL CHEM, V268, P16831; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MOTOJIMA K, 1992, BIOCHEM BIOPH RES CO, V188, P799, DOI 10.1016/0006-291X(92)91127-C; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; OGAMI K, 1990, J BIOL CHEM, V265, P9808; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; REDDY JK, 1982, ANN NY ACAD SCI, V386, P81, DOI 10.1111/j.1749-6632.1982.tb21409.x; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REUE K, 1988, J BIOL CHEM, V263, P6857; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; SIRTORI CR, 1988, PHARMACOL THERAPEUT, V37, P167, DOI 10.1016/0163-7258(88)90024-1; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, TRANSCRIPTINAL REGUL; THORP JM, 1962, NATURE, V194, P948, DOI 10.1038/194948a0; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VESSBY B, 1980, ATHEROSCLEROSIS, V37, P257, DOI 10.1016/0021-9150(80)90011-8; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; WINDLER E, 1980, J BIOL CHEM, V255, P5475; WINDLER E, 1985, J LIPID RES, V25, P556; YASHUSHI I, 1990, SCIENCE, V249, P790; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	57	303	325	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13470	13475		10.1074/jbc.270.22.13470	http://dx.doi.org/10.1074/jbc.270.22.13470			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768950	hybrid			2022-12-25	WOS:A1995RB43900076
J	KRIEG, J; OELGESCHLAGER, M; JANKNECHT, R; LUSCHER, B				KRIEG, J; OELGESCHLAGER, M; JANKNECHT, R; LUSCHER, B			HIGH-AFFINITY DNA-BINDING OF NATIVE FULL-LENGTH C-MYB AND DIFFERENTIAL PROTEOLYTIC SENSITIVITY OF ITS N-TERMINAL AND C-TERMINAL DOMAINS	ONCOGENE			English	Article						LEUCINE ZIPPER; PHOSPHORYLATION; PROTEIN EXPRESSION; TRANSCRIPTION; VACCINIA VIRUS	HELIX-RELATED MOTIF; V-MYB; TRANSCRIPTIONAL ACTIVATION; ONCOGENE PRODUCT; LEUCINE-ZIPPER; PROTEIN; GENE; EXPRESSION; SITES; PHOSPHORYLATION	c-Myb is the prototype of a family of transcription factors characterised by a unique DNA binding domain. Previous analyses have concentrated on truncated versions of c-Myb as it has been very difficult to produce full length c-Myb. To overcome these difficulties we expressed full length c-Myb in HeLa cells using a recombinant vaccinia virus. Partially purified native full length c-Myb bound efficiently and specifically to DNA ,vith a dissociation constant similar to that obtained with bacterially expressed DNA binding domains. No evidence was found for a negative effect of the leucine zipper on DNA binding. Furthermore the DNA binding domain was protease resistant in contrast to the transactivation and negative regulatory domains. Phosphorylation had no apparent effect on this differential protease sensitivity. The increased sensitivity of the C-terminal domain suggests a mote open conformation, which may be relevant in the integration of signals and/or in protein-protein interactions.	HANNOVER MED SCH,INST MOLEK BIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School			Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709; Janknecht, Ralf/0000-0003-1741-1562				ANTON IA, 1988, NATURE, V236, P719; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUSSET K, 1993, ONCOGENE, V8, P3211; DUDENDORFF JW, 1992, GENE DEV, V6, P2524; EBNETH A, 1994, FEBS LETT, V337, P265, DOI 10.1016/0014-5793(94)80205-X; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KANEIISHII C, 1995, J BIOL CHEM, V265, P19990; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KU DH, 1993, J BIOL CHEM, V268, P2255; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MADAN A, 1994, BIOCHEMISTRY-US, V33, P7120, DOI 10.1021/bi00189a015; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NOMURA T, 1993, J BIOL CHEM, V268, P21914; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; ORDING E, 1994, EUR J BIOCHEM, V222, P113, DOI 10.1111/j.1432-1033.1994.tb18848.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; VORBRUEGGEN G, 1994, NUCLEIC ACIDS RES, V22, P2466, DOI 10.1093/nar/22.13.2466; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; ZOBEL A, 1991, ONCOGENE, V6, P1397	46	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2221	2228						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784067				2022-12-25	WOS:A1995RB70300018
J	AMROLIA, PJ; CUNNINGHAM, JM; NEY, P; NIENHUIS, AW; JANE, SM				AMROLIA, PJ; CUNNINGHAM, JM; NEY, P; NIENHUIS, AW; JANE, SM			IDENTIFICATION OF 2 NOVEL REGULATORY ELEMENTS WITHIN THE 5'-UNTRANSLATED REGION OF THE HUMAN (A)GAMMA-GLOBIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; HUMAN GAMMA-GLOBIN; DOMINANT CONTROL REGION; STAGE SELECTOR ELEMENT; TRANSGENIC MICE; DEVELOPMENTAL EXPRESSION; DNA-SEQUENCES; MESSENGER-RNA; TRANSCRIPTION; PROMOTER	Interaction between the stage selector element (SSE) in the proximal gamma-globin promoter and hypersensitivity site 2 in the locus control region partly mediates the competitive silencing of the beta-globin promoter in the fetal developmental stage. We have now demonstrated that a second SSE-like element in the 5'-untranslated region of the gamma-gene also contributes to this competitive silencing of the beta-gene. Utilizing transient transfection assays in the fetal erythroid cell line, K562, we have shown that the core enhancer of hypersensitivity site 2 can preferentially interact with the proximal gamma-promoter in the absence of the SSE, completely silencing a linked beta-promoter. Mutation of a 20-base pair sequence of the gamma-gene 5'-untranslated region (UTR) led to derepression of beta-promoter activity. A marked activation of gamma-promoter activity was also observed with this mutation, suggesting the presence of a repressor. Fine mutagenesis dissected these activities to different regions of the 5'-UTR. The stage selector activity was localized to a region centered on nucleotides +13 to +15. Electromobility shift assays utilizing this sequence demonstrated binding of a fetal and erythroid-specific protein. The repressor activity of the 5'-UTR was localized to tandem GATA-like sites, which appear to bind a complex of two proteins, one of which is the erythroid transcription factor GATA-1. These results indicate that the 5'-UTR of the gamma-gene contains sequences that may be important for its transcriptional and developmental regulation.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN 38101 USA; ROYAL MELBOURNE HOSP, BONE MARROW RES LAB, PARKVILLE, VIC 3050, AUSTRALIA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Royal Melbourne Hospital	AMROLIA, PJ (corresponding author), ST JUDE CHILDRENS RES HOSP, DIV EXPTL HEMATOL, 332 N LAUDERDALE, MEMPHIS, TN 38101 USA.		Jane, Stephen/D-6659-2011	Jane, Stephen Marsden/0000-0002-1045-0481	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CHADA K, 1986, NATURE, V319, P685, DOI 10.1038/319685a0; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; DIX DJ, 1992, BIOCHEMISTRY-US, V31, P2818, DOI 10.1021/bi00125a024; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALLARDA JL, 1989, GENE DEV, V3, P1845, DOI 10.1101/gad.3.12a.1845; GEBALLE AP, 1986, CELL, V46, P865, DOI 10.1016/0092-8674(86)90068-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROSVELD GC, 1981, CELL, V25, P215, DOI 10.1016/0092-8674(81)90246-4; GROSVELD GC, 1982, NATURE, V295, P120, DOI 10.1038/295120a0; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; GUSTIN KE, 1993, BIOTECHNIQUES, V14, P22; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; MANSOUR SL, 1986, MOL CELL BIOL, V6, P2684, DOI 10.1128/MCB.6.7.2684; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SORRENTINO B, 1990, NUCLEIC ACIDS RES, V18, P2721, DOI 10.1093/nar/18.9.2721; Stamatoyannopolous G., 1994, MOL BASIS BLOOD DIS, P107; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; THEILL LE, 1987, MOL CELL BIOL, V7, P4329, DOI 10.1128/MCB.7.12.4329; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x	39	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12892	12898		10.1074/jbc.270.21.12892	http://dx.doi.org/10.1074/jbc.270.21.12892			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759548	hybrid			2022-12-25	WOS:A1995QZ71100085
J	MONLAUZEUR, L; RAJASEKARAN, A; CHAO, M; RODRIGUEZBOULAN, E; LEBIVIC, A				MONLAUZEUR, L; RAJASEKARAN, A; CHAO, M; RODRIGUEZBOULAN, E; LEBIVIC, A			A CYTOPLASMIC TYROSINE IS ESSENTIAL FOR THE BASOLATERAL LOCALIZATION OF MUTANTS OF THE HUMAN NERVE GROWTH-FACTOR RECEPTOR IN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; INFLUENZA-VIRUS HEMAGGLUTININ; PLASMA-MEMBRANE GLYCOPROTEIN; POLARIZED EPITHELIAL-CELLS; HUMAN NGF RECEPTOR; MDCK CELLS; VIRAL GLYCOPROTEINS; INTRACELLULAR-TRANSPORT; TRANSFERRIN RECEPTOR; GOLGI-APPARATUS	Deletion of 58 internal amino acids from the C-terminal cytoplasmic domain of p75 human nerve growth factor receptor (hNGFR) changes its localization from apical to basolateral in transfected Madin-Darby Canine Kidney (MDCK) cells (Le Bivic, A., Sambuy, Y., Patzak, A., Patil, N., Chao, M., and Rodriguez-Boulan, E. (1991) J. Cell Biol. 115, 607-618). The mutant protein, PS-NGFR, also shows a dramatic increase in its ability to endocytose NGF and to recycle through basolateral endosomes. We report here the site-directed mutagenesis analysis of PS-NGFR to localize and characterize its basolateral and endocytic sorting signals. Both signals reside in the proximal part of the PS cytoplasmic tail, between positions 306 and 314. Transferring the cytoplasmic tail (19 residues) and transmembrane domain of a truncated PS mutant to the ectodomain of the placental alkaline phosphatase, an apical glypiated ectoenzyme, redirected it to the basolateral membrane and the endocytic compartments. A tyrosine at position 308, present in this short cytoplasmic segment, was mutated into phenylalanine or alanine. The resulting mutants were expressed predominantly on the apical membrane of MDCK cells. Their ability to endocytose NGF was reduced with the alanine mutant showing the stronger diminution. The PS mutant contains a short cytoplasmic sequence necessary both for basolateral targeting and endocytosis, and the requirement for tyrosine at position 308 is crucial for basolateral targeting.	FAC SCI LUMINY, GENET & PHYSIOL DEV LAB, UMR 9943, F-13288 MARSEILLE 09, FRANCE; CORNELL UNIV, COLL MED, DEPT CELL BIOL & ANAT, NEW YORK, NY 10021 USA	UDICE-French Research Universities; Aix-Marseille Universite; Cornell University				Chao, Moses/0000-0002-6969-3744	NIGMS NIH HHS [R01 GM034107] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034107] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BERGER J, 1988, J BIOL CHEM, V263, P10016; BERND P, 1986, DEV BIOL, V115, P415, DOI 10.1016/0012-1606(86)90261-7; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; GOTTARDI C, 1993, J TISSUE CULTURE MET, V14, P173; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; Riezman Howard, 1993, Trends in Cell Biology, V3, P273, DOI 10.1016/0962-8924(93)90056-7; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; RINDLER MJ, 1985, J CELL BIOL, V100, P136, DOI 10.1083/jcb.100.1.136; RODRIGUEZBOULAN E, 1984, J CELL BIOL, V98, P308, DOI 10.1083/jcb.98.1.308; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; RODRIGUEZBOULAN E, 1983, METHOD ENZYMOL, V98, P486; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; STEPHENS EB, 1986, EMBO J, V5, P237, DOI 10.1002/j.1460-2075.1986.tb04204.x; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987	42	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12219	12225		10.1074/jbc.270.20.12219	http://dx.doi.org/10.1074/jbc.270.20.12219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744872	hybrid			2022-12-25	WOS:A1995QY73600077
J	SHOU, CC; WURMSER, A; LING, K; BARBACID, M; FEIG, LA				SHOU, CC; WURMSER, A; LING, K; BARBACID, M; FEIG, LA			DIFFERENTIAL RESPONSE OF THE RAS EXCHANGE FACTOR, RAS-GRF TO TYROSINE KINASE AND G-PROTEIN MEDIATED SIGNALS	ONCOGENE			English	Article						RAS; EXCHANGE FACTORS; GRF	EPIDERMAL GROWTH-FACTOR; SACCHAROMYCES-CEREVISIAE CDC25; GRB2 ADAPTER PROTEIN; T-CELL ACTIVATION; MOLECULAR-CLONING; GUANINE-NUCLEOTIDES; HEMATOPOIETIC-CELLS; MAP KINASE; RECEPTOR; PHOSPHORYLATION	Ras-GRF, a guanine-nucleotide exchange factor that activates Ras p21, was tested for its ability to couple to either tyrosine kinase or heterotrimeric G protein signal transduction pathways. Ras-GRF failed to bind the SH2 and SH3 containing adaptor protein Grb2, either in vitro or in vivo. Furthermore, Ras-GRF did not form a stable complex with activated EGF receptor. However, as has been shown previously (Cen et al., 1994), the presence of Ras-GRF in NIH3T3 cells enhanced the activation of Ras induced by serum stimulation. A similar effect was not observed with PDGF stimulation. Moreover, serum stimulation lead to the hyperphosphorylation of Ras-GRF. Both the serum induced super-activation of Ras, and the hyperphosphorylation of Ras-GRF were blocked by pretreatment of cells with the G(i,o) inhibitor pertussis toxin, but not by pretreatment with the tyrosine kinase inhibitor genistein. These results suggest that Ras-GRF has the capacity to mediate Ras activation initiated by signals using heterotrimeric G proteins.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; BRISTOL MYERS SQUIBB CO,DEPT MOLEC BIOL,PRINCETON,NJ	Tufts University; Bristol-Myers Squibb								ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BUSTELLO, 1994, ONCOGENE, V9, P2405; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1994, MOL CELL BIOL, V13, P7718; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LAMORTE VJ, 1993, J BIOL CHEM, V26, P19411; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SWANSON ME, 1986, J CELL BIOL, V103, P485, DOI 10.1083/jcb.103.2.485; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEI W, 1993, MOL BRAIN RES, V19, P124; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	45	55	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1887	1893						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761090				2022-12-25	WOS:A1995QZ92600002
J	VAIRO, G; VADIVELOO, PK; ROYSTON, AK; ROCKMAN, SP; ROCK, CO; JACKOWSKI, S; HAMILTON, JA				VAIRO, G; VADIVELOO, PK; ROYSTON, AK; ROCKMAN, SP; ROCK, CO; JACKOWSKI, S; HAMILTON, JA			DEREGULATED C-MYC EXPRESSION OVERRIDES IFN-GAMMA-INDUCED MACROPHAGE GROWTH ARREST	ONCOGENE			English	Article						C-MYC; IFN-GAMMA; CAMP; CELL CYCLE; CSF-1; GROWTH ARREST	COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; CELL-CYCLE ARREST; GENE-EXPRESSION; MITOGENIC RESPONSE; SIGNALING PATHWAYS; FACTOR-BETA; FACTOR-I; S-PHASE; INHIBITION	Induction of c-myc gene expression is an essential response to growth promoting agents, including colony-stimulating factor 1 (CSF-1), Down regulation of c-myc expression occurs in response to a variety of negative growth regulators in many cell types, However, for many of these systems the causal link between c-myc down regulation and growth arrest remains to be established. Here we show for CSF-l-dependent BAC1.2F5 mouse macrophages that interferon-gamma (IFN gamma) results in a midlate GI phase decrease of CSF-l-dependent c-myc mRNA and subsequent cell cycle arrest. Introduction of a deregulated c-myc gene into these cells, which prevents the IFN gamma-mediated decrease in c-myc expression, overrides the cell cycle arrest and restores CSF-l-dependent growth in the presence of the cytokine, This result contrasts with the macrophage growth arrest induced by cAMP elevation, which also suppresses c-myc expression, but is not overcome by a deregulated c-myc gene, These results show that inhibition of c-myc expression is an essential component in IFN gamma-mediated cell cycle arrest and demonstrates that distinct mechanisms contribute to IFN gamma- and cAMP-mediated growth arrest in macrophages.	UNIV MELBOURNE, ROYAL MELBOURNE HOSP, DEPT MED, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, DEPT DIAGNOST HAEMATOL, PARKVILLE, VIC 3050, AUSTRALIA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; St Jude Children's Research Hospital			Jackowski, Suzanne/N-8168-2018; rockman, steve/AAT-5105-2021	Jackowski, Suzanne/0000-0002-6855-1429; Hamilton, John A/0000-0002-9493-9224				ANDERSSON KB, 1993, J CELL PHYSIOL, V157, P61, DOI 10.1002/jcp.1041570108; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEAN M, 1987, ONCOGENE RES, V1, P279; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HAMILTON JA, 1989, J CELL PHYSL, V141, P619; HAMILTON JA, 1991, J IMMUNOL, V148, P4028; HARELBELLAN A, 1988, J IMMUNOL, V141, P1012; HARELBELLAN AH, 1987, J IMMUNOL, V140, P2431; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERTZOG PJ, 1988, CLIN IMMUNOL IMMUNOP, V48, P192, DOI 10.1016/0090-1229(88)90083-9; HOANG T, 1989, J EXP MED, V170, P15, DOI 10.1084/jem.170.1.15; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; JACKOWSKI S, 1990, J BIOL CHEM, V265, P6611; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KNIGHT KR, 1992, J LEUKOCYTE BIOL, V51, P350, DOI 10.1002/jlb.51.4.350; KREK W, 1995, IN PRESS METHODS ENZ; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LONGSTREET M, 1992, ONCOGENE, V7, P1549; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; METCALF D, 1984, HEMOPOIETIC COLONIES; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STAEHLI P, 1990, ADV VIRUS RES, V42, P147; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VAIRO G, 1991, J IMMUNOL, V146, P3469; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VAIRO G, 1992, J CELL PHYSIOL, V151, P630, DOI 10.1002/jcp.1041510324; VAIRO G, 1991, IMMUNOL TODAY, V12, P362, DOI 10.1016/0167-5699(91)90067-4; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	57	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1969	1976						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761098				2022-12-25	WOS:A1995QZ92600011
J	SINGER, WD; BROWN, HA; BOKOCH, GM; STERNWEIS, PC				SINGER, WD; BROWN, HA; BOKOCH, GM; STERNWEIS, PC			RESOLVED PHOSPHOLIPASE-D ACTIVITY IS MODULATED BY CYTOSOLIC FACTORS OTHER THAN ARF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ADP-RIBOSYLATION FACTOR; REGULATORY PROTEIN; BOVINE BRAIN; RHO; DISSOCIATION; PURIFICATION; HYDROLYSIS; GDP	Phospholipase D, which has been extracted from porcine brain membranes and chromatographically enriched 100-fold, was activated better by impure preparations of Arf than by purified or recombinant Arf. Examination of brain cytosol with this enriched preparation of PLD activity revealed at least three stimulatory components. One of these is Arf or the first cytoplasmic factor. A second peak of PLD-stimulating activity (cytoplasmic factor II, CFII) was resolved from Arf by anion exchange and gel filtration. This CFII can be further separated into multiple activities by chromatography with heparin-agarose. The activities were differentiated by their stimulatory properties as measured in the absence or presence of guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) alone and in the presence of added Arf and GTP gamma S. While all of the CFII pools stimulated PLD activity to some degree and showed synergistic activation when administered in conjunction with Arf, they could be classified into two groups with distinct behavior. When used together, pools from the two respective groups showed synergistic activation of PLD. The first set of pools contained the RhoA monomeric G protein. Recombinant RhoA was used to show that it could indeed activate this enriched PLD activity and act synergistically with Arf proteins. A related monomeric G protein, Cdc42, was also effective. The second set of CFII pools were devoid of RhoA and, in contrast to the first group, demonstrated significant stimulating activity in the absence of guanine nucleotides. These data indicate that the PLD activity from brain can be modulated by several cytosolic factors and that Arf-sensitive PLD may represent a complex activity that can be regulated in an interactive fashion by a variety of cellular signaling events.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; Scripps Res Inst, DEPT IMMUNOL & CELL BIOL, LA JOLLA, CA 92037 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954, R01GM044428, F32GM015359] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31954, GM44428, GM15359] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD M, 1906, ANAL BIOCHEM, V72, P248; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CHUANG TH, 1993, J BIOL CHEM, V268, P775; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COCKCROFT S, 1994, SIGNAL ACTIVATED PHO, P65; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; DRUBIN DG, 1991, CELL, V65, P1039; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; Heller M, 1978, Adv Lipid Res, V16, P267; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SIMMONDS AC, 1985, BIOCHIM BIOPHYS ACTA, V813, P331, DOI 10.1016/0005-2736(85)90249-4; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TERUI T, 1994, J BIOL CHEM, V269, P28130; UEDA T, 1990, J BIOL CHEM, V265, P9373; WANG XM, 1994, J BIOL CHEM, V269, P20312; XU XM, 1994, J BIOL CHEM, V269, P23569; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	36	129	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14944	14950		10.1074/jbc.270.25.14944	http://dx.doi.org/10.1074/jbc.270.25.14944			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797474	hybrid			2022-12-25	WOS:A1995RE66600018
J	SWEE, MH; PARKS, WC; PIERCE, RA				SWEE, MH; PARKS, WC; PIERCE, RA			DEVELOPMENTAL REGULATION OF ELASTIN PRODUCTION - EXPRESSION OF TROPOELASTIN PRE-MESSENGER-RNA PERSISTS AFTER DOWN-REGULATION OF STEADY-STATE MESSENGER-RNA LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MESSENGER-RNA; 5'-FLANKING REGION; POSTTRANSCRIPTIONAL MECHANISM; EXTRACELLULAR-MATRIX; FUNCTIONAL PROMOTER; FIBROBLAST-CULTURES; SKIN FIBROBLASTS; COLLAGEN GENES; RAT LUNG	To assess the mechanisms controlling the developmental regulation of tropoelastin expression in vivo, we developed a reverse-transcription-polymerase chain reaction (RT-PCR) assay to detect tropoelastin pre-mRNA as an indicator of ongoing transcription in intact tissue. RNA was isolated from mid-fetal (early-elastogenic), neonatal (peak tropoelastin expression), and adult (very low tropoelastin expression) rat lungs and reverse transcribed, and the cDNA was amplified with intron specific primers. A weak hybridization signal for tropoelastin pre-mRNA was seen in mid-fetal samples, and paralleling the increase in steady-state mRNA levels, a strong signal for pre-mRNA was detected in neonatal samples, indicating transcriptional regulation. Stimulation of fetal lung tropoelastin expression by maternal administration of dexamethasone also led to an increase in pre-mRNA levels. However, signal for tropoelastin pre-mRNA in adult samples was equal to that detected in neonatal samples, even though mRNA levels had dropped about 80-fold. Persistence of tropoelastin transcription in adult tissue was also seen in cell culture models and was verified by nuclear runoff assay. In addition, an RT-PCR assay for alpha 1 (I) procollagen pre-mRNA accurately revealed the known transcriptional regulation of this gene. Our results demonstrate that the induction and maintenance of elastogenesis is controlled by a transcriptional mechanism, whereas, the cessation of tropoelastin expression is controlled by a post-transcriptional mechanism.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED DERMATOL,DIV DERMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Parks, William C./AAH-6786-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, R01HL048762] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29594, HL-48762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; Belasco J.G., 2012, CONTROL MESSENGER RN; BERNSTEIN EF, 1994, J INVEST DERMATOL, V103, P182, DOI 10.1111/1523-1747.ep12392693; BOTNEY MD, 1992, AM J PATHOL, V140, P357; BOYD CD, 1991, MATRIX, V11, P235, DOI 10.1016/S0934-8832(11)80230-1; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BRUCE MC, 1991, AM J RESP CELL MOL, V5, P344, DOI 10.1165/ajrcmb/5.4.344; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON JM, 1990, EUR RESPIR J, V3, P1048; DAVIDSON JM, 1986, REGULATION MATRIX AC, P177; DSOUZA RN, 1993, J BONE MINER RES, V8, P1127; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; GOLDSTEIN RH, 1991, AM J PHYSIOL, V261, pL29, DOI 10.1152/ajplung.1991.261.2.L29; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HARPOLD MM, 1981, MOL CELL BIOL, V1, P188, DOI 10.1128/MCB.1.2.188; HEIM RA, 1991, MATRIX, V11, P359, DOI 10.1016/S0934-8832(11)80207-6; HSUWONG S, 1994, J BIOL CHEM, V269, P18072; INDIK Z, 1990, EXTRACELLULAR MATRIX, P221; JAKUBOWSKI M, 1994, J BIOL CHEM, V269, P4078; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KAHARI VM, 1992, LAB INVEST, V66, P580; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; Krug RM, 1993, CURR OPIN CELL BIOL, V5, P944, DOI 10.1016/0955-0674(93)90074-Z; LIU RG, 1993, AM J PHYSIOL, V265, pL430, DOI 10.1152/ajplung.1993.265.5.L430; MAUVIEL A, 1993, J BIOL CHEM, V268, P6520; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; MECHAM RP, 1981, J CELL BIOL, V90, P332, DOI 10.1083/jcb.90.2.332; NOGUCHI A, 1992, PEDIATR RES, V31, P280, DOI 10.1203/00006450-199203000-00018; PARKER A, 1993, PUBLIC CULTURE, V6, P133, DOI 10.1215/08992363-6-1-133; PARKS WC, 1988, J BIOL CHEM, V263, P4416; PARKS WC, 1992, BIOCHEMISTRY-US, V31, P6639, DOI 10.1021/bi00144a003; PARKS WC, 1992, MATRIX, V12, P156, DOI 10.1016/S0934-8832(11)80057-0; PARKS WC, 1988, DEV BIOL, V129, P555, DOI 10.1016/0012-1606(88)90400-9; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; PIECE RA, 1990, BIOCHEMISTRY-US, V29, P9677; PIECE RA, 1991, GENOMICS, V12, P651; PIERCE RA, 1992, J BIOL CHEM, V267, P11593; PIERCE RA, 1995, AM J PHYSIOL-LUNG C, V268, pL491, DOI 10.1152/ajplung.1995.268.3.L491; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; RUCKER RB, 1984, ENV HLTH PERSPECT, V53, P179; SACHS A, 1991, CURR OPIN CELL BIOL, V2, P1092; SAGE H, 1981, COMP BIOCHEM PHYS B, V68, P473, DOI 10.1016/0305-0491(81)90158-9; SAGE H, 1979, COMP BIOCHEM PHYS B, V64, P313, DOI 10.1016/0305-0491(79)90277-3; SEHGAL PB, 1976, SCIENCE, V1194, P431; SEPHEL GC, 1986, J INVEST DERMATOL, V86, P279, DOI 10.1111/1523-1747.ep12285424; SEPHEL GC, 1987, J INVEST DERMATOL, V88, P732, DOI 10.1111/1523-1747.ep12470403; SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; STENMARK KR, 1994, J CLIN INVEST, V93, P1234, DOI 10.1172/JCI117077; WOLFE BL, 1993, J BIOL CHEM, V268, P12418	53	119	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14899	14906		10.1074/jbc.270.25.14899	http://dx.doi.org/10.1074/jbc.270.25.14899			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797468	hybrid			2022-12-25	WOS:A1995RE66600012
J	KASTURI, L; ESHLEMAN, JR; WUNNER, WH; SHAKINESHLEMAN, SH				KASTURI, L; ESHLEMAN, JR; WUNNER, WH; SHAKINESHLEMAN, SH			THE HYDROXY AMINO-ACID IN AN ASN-X-SER/THR SEQUON CAN INFLUENCE N-LINKED CORE GLYCOSYLATION EFFICIENCY AND THE LEVEL OF EXPRESSION OF A CELL-SURFACE GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABIES VIRUS GLYCOPROTEIN; PLASMINOGEN-ACTIVATOR; ANIMAL-CELLS; SITES; PROTEIN; SEQUENCE; OLIGOSACCHARIDES; MEMBRANE; BIOSYNTHESIS; SECRETION	N-Linked glycosylation usually occurs at the sequon, Asn-X-Ser/Thr. In this sequon, the side chain of the hydroxy amino acid (Ser or Thr) may play a direct catalytic role in the enzymatic transfer of core oligosaccharides to the Asn residue. Using recombinant variants of rabies virus glycoprotein (RGP), we examined the influence of the hydroxy amino acid on core glycosylation efficiency. A variant of RGP containing a single Asn-X-Ser sequon at Asn(37) was modified by site directed mutagenesis to change the sequon to either Asn-X-Cys or Asn-X-Thr. The impact of these changes on core glycosylation efficiency was assessed by expressing the variants in a cell-free transcription/translation/glycosylation system and in transfected tissue culture cells. Substitution of Cys at position 39 blocks glycosylation, whereas substitution of Thr dramatically increases core glycosylation efficiency of Asn(37) in both membrane-anchored and secreted forms of RGP. The substitution of Thr for Ser also dramatically enhances the level of expression and cell surface delivery of RGP when the sequon at Asn(37) is the only sequon in the protein. Novel forms of membrane-anchored and secreted RGP which are fully glycosylated at all three sequons were also generated by substitution of Thr at position 39.	CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19106	Case Western Reserve University; The Wistar Institute								ANILIONIS A, 1981, NATURE, V294, P275, DOI 10.1038/294275a0; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; BAUSE E, 1989, 10TH INT S GLYC JER; BENMANSOUR A, 1992, VIROLOGY, V187, P33, DOI 10.1016/0042-6822(92)90292-W; BRUGER SR, 1991, J GEN VIROL, V72, P359; BULLEID NJ, 1992, BIOCHEM J, V286, P275, DOI 10.1042/bj2860275; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CURLING EMA, 1990, BIOCHEM J, V272, P333, DOI 10.1042/bj2720333; DIETZSCHOLD B, 1977, J VIROL, V23, P286, DOI 10.1128/JVI.23.2.286-293.1977; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FODOR I, 1994, ARCH VIROL, V135, P451, DOI 10.1007/BF01310030; GALLAGHER P, 1988, J CELL BIOL, V107, P2059, DOI 10.1083/jcb.107.6.2059; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; HASEGAWA M, 1992, EUR J BIOCHEM, V210, P9, DOI 10.1111/j.1432-1033.1992.tb17384.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KANE SE, 1993, J BIOL CHEM, V268, P11456; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LADENHEIM RG, 1991, EUR J BIOCHEM, V198, P535, DOI 10.1111/j.1432-1033.1991.tb16047.x; LIVI GP, 1991, J BIOL CHEM, V266, P15348; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; Marshall R D, 1974, Biochem Soc Symp, P17; MONONEN I, 1984, BIOCHIM BIOPHYS ACTA, V788, P364, DOI 10.1016/0167-4838(84)90050-5; MORIMOTO K, 1992, J GEN VIROL, V73, P335, DOI 10.1099/0022-1317-73-2-335; NAKAMURA S, 1993, J BIOL CHEM, V268, P12706; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; OMURA F, 1992, EUR J BIOCHEM, V210, P591, DOI 10.1111/j.1432-1033.1992.tb17459.x; OPDENAKKER G, 1993, FASEB J, V7, P1330, DOI 10.1096/fasebj.7.14.8224606; OTVOS L, 1994, BBA-MOL CELL RES, V1224, P68, DOI 10.1016/0167-4889(94)90114-7; PLUMMER TH, 1964, J BIOL CHEM, V239, P2530; POHL G, 1984, BIOCHEMISTRY-US, V23, P3701, DOI 10.1021/bi00311a020; RAU S, 1993, J GEN VIROL, V74, P699, DOI 10.1099/0022-1317-74-4-699; ROBERTS PC, 1993, J VIROL, V67, P3048, DOI 10.1128/JVI.67.6.3048-3060.1993; Sambrook J, 1989, MOL CLONING LABORATO; Shakin-Eshleman W. H., 1993, TRENDS GLYCOSCI GLYC, V5, P355; SHAKINESHLEMAN SH, 1992, J BIOL CHEM, V267, P10690; SHAKINESHLEMAN SH, 1993, BIOCHEMISTRY-US, V32, P9465, DOI 10.1021/bi00087a026; SHEARES BT, 1988, J BIOL CHEM, V263, P12778; SMITH JS, 1984, J CLIN MICROBIOL, V19, P267, DOI 10.1128/JCM.19.2.267-272.1984; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WRIGHT A, 1991, EMBO J, V10, P2717, DOI 10.1002/j.1460-2075.1991.tb07819.x; WUNNER WH, 1983, J GEN VIROL, V64, P1649, DOI 10.1099/0022-1317-64-8-1649; WUNNER WH, 1988, REV INFECT DIS, V10, pS771; WUNNER WH, 1985, VIROLOGY, V140, P1, DOI 10.1016/0042-6822(85)90440-4; YELVERTON E, 1983, SCIENCE, V219, P614, DOI 10.1126/science.6297004	53	123	134	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14756	14761		10.1074/jbc.270.24.14756	http://dx.doi.org/10.1074/jbc.270.24.14756			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782341	hybrid			2022-12-25	WOS:A1995RD45500078
J	CORCORAN, ML; STETLERSTEVENSON, WG				CORCORAN, ML; STETLERSTEVENSON, WG			TISSUE INHIBITOR OF METALLOPROTEINASE-2 STIMULATES FIBROBLAST PROLIFERATION VIA A CAMP-DEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-POTENTIATING ACTIVITY; SWISS 3T3 CELLS; PROTEIN-KINASE; PERTUSSIS TOXIN; DNA-SYNTHESIS; CYCLIC-AMP; TIMP-2; ACCUMULATION; ENHANCEMENT; COLLAGENASE	In addition to inhibiting the proteolytic activity of the matrix metalloproteinases, tissue inhibitors of metalloproteinases (TIMPs) promote the growth of cells in the absence of other exogenous growth factors. TIMP-2 stimulates the proliferation of fibrosarcoma (HT-1080) cells and normal dermal fibroblasts (Hs68) in a dose-dependent manner. This response is evident as early as 2 h and persists up to 48 h after treatment with recombinant TIMP-2 (rTIMP-2). The specificity of this response is demonstrated by the ability of affinity-purified polyclonal anti-TIMP-2 antibodies to ablate TIMP-2 mitogenesis and by the lack of response to TIMP-1. This response is also blocked by the presence of an adenylate cyclase inhibitor, 9-(tetrahydro-2-furyl) adenine (SQ22536). Although SQ22536 did not affect untreated fibroblasts or fibrosarcoma cells, this inhibitor completely abrogates the proliferative response induced by rTIMP-2. Treatment of these cells with rTIMP-2 also stimulates the production of cAMP in a time-dependent manner that differs for the two cell lines. Moreover, treatment of purified cell membranes with rTIMP-2 suppresses cholera toxin-mediated ADP-ribosylation of the GTP-binding protein, Gs alpha subunit. These results indicate that the alpha beta gamma heterotrimer is dissociated by treatment with rTIMP-2, which may facilitate the Gs alpha-mediated activation of adenylate cyclase and subsequent production of cAMP. Since cAMP binds to the regulatory subunit of cAMP-dependent protein kinase and activates kinase activity, we evaluated how treatment with rTIMP-2 affected both these parameters. We demonstrate in this report that the cAMP produced in response to treatment with rTIMP-2 binds to the type I regulatory subunit of cAMP-dependent protein kinase and stimulates kinase activity. These results are the first demonstration that TIMP-2 directly activates adenylate cyclase to produce cAMP, which increases cAMP-dependent protein kinase activity, resulting in stimulation of fibroblast mitogenesis.	NCI,PATHOL LAB,EXTRACELLULAR MATRIX PATHOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808				ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BENYA RV, 1994, MOL PHARMACOL, V46, P235; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BRASS LF, 1988, J BIOL CHEM, V263, P5348; BURCH RM, 1989, J CELL PHYSIOL, V139, P29, DOI 10.1002/jcp.1041390106; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EMMERTBUCK M, 1995, IN PRESS FEBS LETT; Fabbri E, 1991, J Enzyme Inhib, V5, P87, DOI 10.3109/14756369109069062; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; GRAZIANO MP, 1987, J BIOL CHEM, V264, P409; HALENDA SP, 1986, FEBS LETT, V204, P341, DOI 10.1016/0014-5793(86)80840-7; HARRIS DN, 1979, J CYCLIC NUCL PROT, V5, P125; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HUANG N, 1989, P NATL ACAD SCI USA, V86, P7909; LALLI E, 1994, J BIOL CHEM, V269, P17359; LECO KJ, 1994, J BIOL CHEM, V269, P9352; MANNING DR, 1990, ADP RIBOSYLATING TOX, P349; MATSUMOTO H, 1993, BIOCHEM BIOPH RES CO, V194, P909, DOI 10.1006/bbrc.1993.1907; MILLAR JBA, 1988, J CELL PHYSIOL, V137, P214, DOI 10.1002/jcp.1041370203; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; NEMETH JA, 1993, EXP CELL RES, V207, P376, DOI 10.1006/excr.1993.1204; OKUYAMA K, 1994, CANCER J - FRANCE, V7, P150; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; ROHLFF C, 1993, J BIOL CHEM, V268, P5774; ROSENBERG N, 1982, FEBS LETT, V137, P105, DOI 10.1016/0014-5793(82)80324-4; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; ROZENGURT E, 1982, EXP CELL RES, V139, P71, DOI 10.1016/0014-4827(82)90319-6; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1989, CELL, V34, P265; SHI WX, 1992, J NEUROSCI, V12, P2433; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPAULDING SW, 1993, ENDOCR REV, V14, P632, DOI 10.1210/er.14.5.632; STETLERSTEVENSO.WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSO.WG, 1992, FEBS LETT, V296, P231; STRICKLIN G, 1991, J INVEST DERMATOL, V103, P488; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TOYOSHIGE M, 1994, BIOCHEMISTRY-US, V33, P4865, DOI 10.1021/bi00182a014; WANG D, 1990, BIOCHEM BIOPH RES CO, V166, P251, DOI 10.1016/0006-291X(90)91938-O; WELGUS HG, 1982, J BIOL CHEM, V257, P1534; ZURIER RB, 1981, P NATL ACAD SCI USA, V86, P251	47	163	167	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13453	13459		10.1074/jbc.270.22.13453	http://dx.doi.org/10.1074/jbc.270.22.13453			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768948	hybrid			2022-12-25	WOS:A1995RB43900074
J	LAGROST, L; DENGREMONT, C; ATHIAS, A; DEGEITERE, C; FRUCHART, JC; LALLEMANT, C; GAMBERT, P; CASTRO, G				LAGROST, L; DENGREMONT, C; ATHIAS, A; DEGEITERE, C; FRUCHART, JC; LALLEMANT, C; GAMBERT, P; CASTRO, G			MODULATION OF CHOLESTEROL EFFLUX FROM FU5AH HEPATOMA-CELLS BY THE APOLIPOPROTEIN CONTENT OF HIGH-DENSITY-LIPOPROTEIN PARTICLES - PARTICLES CONTAINING VARIOUS PROPORTIONS OF APOLIPOPROTEINS A-I AND A-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CELLULAR LIPID EFFLUX; HUMAN-PLASMA; ADIPOSE-CELLS; HUMAN-FIBROBLASTS; LPA-I; MONOCLONAL-ANTIBODIES; BINDING DOMAIN; HEPG2 CELLS; RAT-LIVER	The influence of apolipoproteins (ape) A-I and A-II on the ability of high density lipoproteins (HDL) to remove cholesterol from cultured Fu5AH rat hepatoma cells was studied independently on alterations in the overall structure and lipid composition of the lipoprotein particles. To this end, apoA-I was progressively replaced by apoA-II in ultracentrifugally isolated HDL(3) without inducing changes in other remaining Lipoprotein components. As apoA-II was progressively substituted for apoA-I in HDL(3) (A-II:A-I+A-II percentage mass: 29.5, 47.6, 71.5, 97.4, and 98.9%), the rate of cholesterol efflux from Fu5AH hepatoma gradually and significantly decreased after 2 or 4 h of incubation at 37 degrees C (cholesterol efflux: 30.4 +/- 0.8, 24.1 +/- 1.0, 19.8 +/- 1.2, 15.7 +/- 1.4, and 13.4 +/- 1.3%/2 h, respectively; 38.4 +/- 1.5, 29.2 +/- 0.9, 27.0 +/- 0.2, 20.4 +/- 0.4, and 17.5 +/- 1.0%/4 h, respectively) (p < 0.01 with all A-II-enriched HDL(3) fractions as compared with non-enriched homologues). In agreement with data obtained with total HDL(3), increasing the A-II:A-I+A-II percentage mass in HDL(3) particles containing initially only apoA-I (HDL(3)-A-I) progressively reduced cellular cholesterol efflux. After 2 h of incubation, cholesterol efflux correlated negatively with A-II:A-I+A-II percentage mass (r = -0.86; p < 0.0001; n = 20), but not with either free cholesterol:phospholipid ratio, A-I+A-II:total lipid ratio or mean size of HDL(3). As determined by using Spearman rank correlation analysis, the A-II:A-I+A-II% mass ratio correlated negatively with the apparent maximal efflux (V-max(efflux)) (rho = -0.68; p < 0.05, n = 10), but not with the HDL(3) concentration required to obtain 50% of maximal efflux (K-m(efflux)) (rho = -0.08; not significant, n = 10). It was concluded that the apoA-I and apoA-II content of HDL(3) is one determinant of its ability to promote cholesterol efflux from Fu5AH rat hepatoma cells.	FAC MED DIJON,INSERM,BIOCHIM LIPOPROT LAB,CJF 9310,F-21033 DIJON,FRANCE; INST PASTEUR,INSERM,SERV ETUDE RECH LIPOPROT & ATHEROSCLEROSE,U325,F-59019 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille								AGNANI G, 1993, BIOCHEMISTRY-US, V32, P2643, DOI 10.1021/bi00061a024; ALLAN CM, 1993, BIOCHEM J, V290, P449, DOI 10.1042/bj2900449; ALLAN CM, 1992, J BIOL CHEM, V267, P13257; BARBARAS R, 1986, BIOCHIM BIOPHYS ACTA, V888, P143, DOI 10.1016/0167-4889(86)90015-7; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BARKIA A, 1991, ATHEROSCLEROSIS, V87, P135, DOI 10.1016/0021-9150(91)90016-V; BEKAERT ED, 1991, J LIPID RES, V32, P1587; BEKAERT ED, 1992, BIOCHIM BIOPHYS ACTA, V1126, P105, DOI 10.1016/0005-2760(92)90223-I; BIESBROECK R, 1983, J CLIN INVEST, V71, P525, DOI 10.1172/JCI110797; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V1085, P209; BRINTON EA, 1987, BIOCHIM BIOPHYS ACTA, V920, P68, DOI 10.1016/0005-2760(87)90312-2; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CASTRO GR, 1994, CIRCULATION, V90, P240; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1993, J CLIN INVEST, V91, P522, DOI 10.1172/JCI116231; CHUNG J, 1979, J BIOL CHEM, V254, P7456; COLLET X, 1991, J BIOL CHEM, V266, P9145; CURTISS LK, 1985, J BIOL CHEM, V260, P2982; DAVIDSON WS, 1994, J BIOL CHEM, V269, P8959; DELAMATRE J, 1986, BIOCHIM BIOPHYS ACTA, V875, P419, DOI 10.1016/0005-2760(86)90061-5; DUVERGER N, 1993, BIOCHEMISTRY-US, V32, P12372, DOI 10.1021/bi00097a014; FIDGE NH, 1985, J BIOL CHEM, V260, P3570; FIELDING C J, 1981, Proceedings of the National Academy of Sciences of the United States of America, V78, P3911, DOI 10.1073/pnas.78.6.3911; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FIELDING PE, 1994, BIOCHEMISTRY-US, V33, P6981, DOI 10.1021/bi00188a030; FRUCHART JC, 1992, CLIN CHEM, V38, P793; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HARA H, 1991, J BIOL CHEM, V266, P3080; JACKSON RL, 1975, J BIOL CHEM, V250, P7204; JAMES RW, 1988, J LIPID RES, V29, P1557; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JOHNSON WJ, 1993, J LIPID RES, V32, P1993; JONAS A, 1994, J LIPID RES, V35, P860; KILSDONK EPC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P205, DOI 10.1016/0005-2760(90)90121-D; LAGOCKI PA, 1980, J BIOL CHEM, V255, P3701; LAGROST L, 1994, J BIOL CHEM, V269, P3189; LEBLOND L, 1991, J BIOL CHEM, V266, P6058; LETIZIA JY, 1991, BIOCHEMISTRY-US, V30, P866, DOI 10.1021/bi00217a041; LI QQ, 1993, BIOCHEMISTRY-US, V32, P4597, DOI 10.1021/bi00068a016; LUCHOOMUN J, 1994, BBA-LIPID LIPID MET, V1212, P319, DOI 10.1016/0005-2760(94)90206-2; MAHLBERG FH, 1991, J BIOL CHEM, V266, P19930; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MARZ W, 1988, BIOCHIM BIOPHYS ACTA, V962, P155, DOI 10.1016/0005-2760(88)90107-5; MILLER GJ, 1975, LANCET, V1, P16; MORRISON JR, 1992, J BIOL CHEM, V267, P13205; MOYA MD, 1994, ARTERIOSCLER THROMB, V14, P1056; NAKAMURA R, 1993, ARTERIOSCLER THROMB, V13, P1307, DOI 10.1161/01.ATV.13.9.1307; OHTA T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P119, DOI 10.1016/0005-2760(92)90083-8; OIKAWA S, 1993, BIOCHIM BIOPHYS ACTA, V1165, P327, DOI 10.1016/0005-2760(93)90144-X; ORAM JF, 1983, ARTERIOSCLEROSIS, V3, P420, DOI 10.1161/01.ATV.3.5.420; ORAM JF, 1981, J BIOL CHEM, V256, P8348; PHILLIPS MC, 1980, ATHEROSCLEROSIS, V36, P409, DOI 10.1016/0021-9150(80)90220-8; PIETERS MN, 1993, BIOCHEM J, V292, P819, DOI 10.1042/bj2920819; RADER DJ, 1991, J LIPID RES, V32, P1849; RIFAI N, 1986, CLIN CHEM, V32, P957; ROSSENEU M, 1981, EUR J BIOCHEM, V117, P347, DOI 10.1111/j.1432-1033.1981.tb06344.x; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; SEGREST JP, 1992, J LIPID RES, V33, P141; SOLA R, 1993, ARTERIOSCLER THROMB, V13, P958, DOI 10.1161/01.ATV.13.7.958; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; VADIVELOO PK, 1990, BIOCHIM BIOPHYS ACTA, V1045, P135, DOI 10.1016/0005-2760(90)90142-K; VADIVELOO PK, 1992, BIOCHEM J, V284, P145, DOI 10.1042/bj2840145; VANTORNOUT P, 1983, BIOCHIM BIOPHYS ACTA, V751, P175; VONECKARDSTEIN A, 1993, J BIOL CHEM, V268, P2616; VONHODENBERG E, 1991, BIOCHIM BIOPHYS ACTA, V1086, P173, DOI 10.1016/0005-2760(91)90005-3	69	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13004	13009		10.1074/jbc.270.22.13004	http://dx.doi.org/10.1074/jbc.270.22.13004			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768892	hybrid			2022-12-25	WOS:A1995RB43900013
J	REVERT, F; PENADES, JR; PLANA, M; BERNAL, D; JOHANSSON, C; ITARTE, E; CERVERA, J; WIESLANDER, J; QUINONES, S; SAUS, J				REVERT, F; PENADES, JR; PLANA, M; BERNAL, D; JOHANSSON, C; ITARTE, E; CERVERA, J; WIESLANDER, J; QUINONES, S; SAUS, J			PHOSPHORYLATION OF THE GOODPASTURE ANTIGEN BY TYPE-A PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-POLYACRYLAMIDE GELS; GLOMERULAR-BASEMENT-MEMBRANE; COLLAGEN TYPE-VI; IV COLLAGEN; ALPHA-3 CHAIN; IDENTIFICATION; SEQUENCE; BINDING; ACTIVATION; POLYMERASE	Collagen IV is the major component of basement membranes. The human alpha 3 chain of collagen IV contains an antigenic domain called the Goodpasture antigen that is the target for the circulating immunopathogenic antibodies present in patients with Goodpasture syndrome. Characteristically, the gene region encoding the Goodpasture antigen generates multiple alternative products that retain the antigen amino-terminal region with a five-residue motif (KRGDS). The serine therein appears to be the major in vitro cAMP-dependent protein kinase phosphorylation site in the isolated antigen and can be phosphorylated in vitro by two protein kinases of approximately 50 and 41 kDa associated with human kidney plasma membrane, suggesting that it can also be phosphorylated in vivo. Consistent with this, the Goodpasture antigen is isolated from human kidney in phosphorylated and non-phosphorylated forms and only the non-phosphorylated form is susceptible to phosphorylation in vitro. Since this motif is exclusive to the human alpha 3(TV) chain and includes the RGD cell adhesion motif, its phosphorylation might play a role in pathogenesis and influence cell attachment to basement membrane.	FDN VALENCIA INVEST BIOMED, INST INVEST CITOL, E-46010 VALENCIA, SPAIN; UNIV AUTONOMA BARCELONA, FAC CIENCIAS, DEPT BIOQUIM & BIOL MOLEC, E-08193 BARCELONA, SPAIN; UNIV VALENCIA, FAC FARM, DEPT BIOQUIM & BIOL MOLEC, E-46100 BURJASSOT, SPAIN; UNIV LUND HOSP, DEPT NEPHROL, S-22185 LUND, SWEDEN; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT ENVIRONM & COMMUNITY MED, PISCATAWAY, NJ 08854 USA	Autonomous University of Barcelona; University of Barcelona; University of Valencia; Lund University; Skane University Hospital			Itarte, Emilio/K-5275-2014; REVERT, FERNANDO/ABF-8171-2021; Bernal, Dolores/K-7769-2014; Penadés, José R/W-9685-2019; Plana Coll, Maria/L-3414-2014; Itarte, Emilio/Q-6246-2019	Itarte, Emilio/0000-0002-9366-5807; REVERT, FERNANDO/0000-0002-7304-5846; Bernal, Dolores/0000-0003-4627-8393; Penadés, José R/0000-0002-6439-5262; Plana Coll, Maria/0000-0001-5808-9229; Saus, Juan/0000-0003-2082-1597	NIDDK NIH HHS [DK-42514] Funding Source: Medline; NIEHS NIH HHS [ESO 5022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042514] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BERNAL D, 1993, J BIOL CHEM, V268, P12090; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; FENG LL, 1994, J BIOL CHEM, V269, P2342; FERRERMONTIEL AV, 1991, P NATL ACAD SCI USA, V88, P10213, DOI 10.1073/pnas.88.22.10213; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GUASCH MD, 1986, ARCH BIOCHEM BIOPHYS, V250, P294, DOI 10.1016/0003-9861(86)90730-7; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HELLMARK T, 1994, KIDNEY INT, V46, P823, DOI 10.1038/ki.1994.338; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUTCHCROFT JE, 1991, METHOD ENZYMOL, V200, P417; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KUBLER D, 1989, J BIOL CHEM, V264, P14549; KUBLER D, 1982, J BIOL CHEM, V257, P322; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; MORRISON KE, 1991, AM J HUM GENET, V49, P545; PENADES JR, 1995, EUR J BIOCHEM, V229, P754, DOI 10.1111/j.1432-1033.1995.tb20524.x; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; QUINONES S, 1992, J BIOL CHEM, V267, P19780; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1988, J BIOL CHEM, V263, P13374; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; STETLER DA, 1992, AUTOIMMUNITY, V12, P29, DOI 10.3109/08916939209146127; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; VONDERMARK K, 1987, METHOD ENZYMOL, V144, P490; WALKER JM, 1988, J BIOL CHEM, V263, P4537; ZETTERQVIST O, 1982, FEBS LETT, V139, P287, DOI 10.1016/0014-5793(82)80872-7	38	15	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13254	13261		10.1074/jbc.270.22.13254	http://dx.doi.org/10.1074/jbc.270.22.13254			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768924	hybrid			2022-12-25	WOS:A1995RB43900048
J	FALASCA, M; SILLETTA, MG; CARVELLI, A; DIFRANCESCO, AL; FUSCO, A; RAMAKRISHNA, V; CORDA, D				FALASCA, M; SILLETTA, MG; CARVELLI, A; DIFRANCESCO, AL; FUSCO, A; RAMAKRISHNA, V; CORDA, D			SIGNALING PATHWAYS INVOLVED IN THE MITOGENIC ACTION OF LYSOPHOSPHATIDYLINOSITOL	ONCOGENE			English	Article						PHOSPHOLIPASE A(2); LYSOLIPIDS; LYSOPHOSPHATIDIC ACID; GLYCEROPHOSPHOINOSITOLS; THYROID; FRTL5 CELLS	FRTL-5 THYROID-CELLS; GROWTH FACTOR-I; LYMPHOCYTE-T ACTIVATION; GTP-BINDING PROTEINS; MURINE SARCOMA-VIRUS; EPITHELIAL-CELLS; IODIDE EFFLUX; ARACHIDONIC-ACID; PHOSPHOLIPASE-C; PERTUSSIS TOXIN	Lysophosphatidylinositol has been previously shown to stimulate cell proliferation in differentiated and in K-ras transformed thyroid cells. Increased levels of lysophosphatidylinositol, but not lysophosphatidylcholine or lysophosphatidylethanolamine, are present in thyroid as well as in other ras-transformed cell lines. We have now investigated the mechanism of action of this lysolipid by analysing its effects in a differentiated thyroid cell line. Lysophosphatidylinositol did not increase the levels of cAMP, the main stimulator of cell proliferation in the thyroid, whereas it stimulated phosphoinositide breakdown, mobilization of cytosolic Ca2+ and arachidonic acid release, suggesting that it activates both phospholipases C and A(2). None of the effects of lysophosphatidylinositol were prevented by pretreatment of cells with pertussis toxin. Instead, the tyrosine kinase inhibitors, tyrphostins AG18 and AG561, completely blocked its mitogenic action. The effects of lysophosphatidylinositol were distinguishable from those of the well known mitogen lysophosphatidic acid, which affected differently the signalling pathways analysed and was not mitogenic in ras-transformed cells. These results suggest that the mitogenic activity of lysophosphatidylinositol is associated with the activation of phospholipase C and phospholipase A(2) and is relatively specific for ras-transformed cells.	IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,CELLULAR & MOLEC ENDOCRINOL LAB,I-66030 SANTA MARIA IMBAR,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CHIM,I-88100 CALABRIA,ITALY	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Universita Mediterranea di Reggio Calabria			Corda, Daniela/K-6385-2016; Falasca, Marco/S-4020-2016	Corda, Daniela/0000-0002-3614-751X; Falasca, Marco/0000-0002-9801-7235; Fusco, Alfredo/0000-0003-3332-5197				ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; ALONSO T, 1990, BIOCHEM BIOPH RES CO, V171, P14, DOI 10.1016/0006-291X(90)91349-W; AMBESIIMPIOMBAT.FS, 1989, FRTL5 TODAY; AMBESIIMPIOMBAT.FS, 1980, P NATL ACAD SCI USA, V77, P3455; ASAOKA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1378, DOI 10.1016/0006-291X(91)91046-F; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BARAN DT, 1987, ENDOCRINOLOGY, V122, P930; BENTON AM, 1982, BLOOD, V60, P642; BERMAN MI, 1987, ARCH BIOCHEM BIOPHYS, V253, P249, DOI 10.1016/0003-9861(87)90658-8; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIZZARRI C, 1990, P NATL ACAD SCI USA, V87, P4889, DOI 10.1073/pnas.87.12.4889; BIZZARRI C, 1994, EUR J BIOCHEM, V219, P837, DOI 10.1111/j.1432-1033.1994.tb18565.x; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BONE EA, 1986, ENDOCRINOLOGY, V119, P2193, DOI 10.1210/endo-119-5-2193; BURCH RM, 1986, J BIOL CHEM, V261, P1236; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CHIARIOTTI L, 1992, ONCOGENE, V7, P2507; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; CONDORELLI G, 1992, ENDOCRINOLOGY, V130, P1615, DOI 10.1210/en.130.3.1615; CORDA D, 1985, J BIOL CHEM, V260, P9230; CORDA D, 1989, ADV EXP MED BIOL, V261, P245; CORDA D, 1985, EXP EYE RES, V40, P575, DOI 10.1016/0014-4835(85)90079-X; CORDA D, 1987, ENDOCRINOLOGY, V120, P1152, DOI 10.1210/endo-120-3-1152; Cucchi P., 1992, Acta Medica Romana, V30, P176; DIGIROLAMO M, 1991, ACTA ENDOCRINOL-COP, V125, P192, DOI 10.1530/acta.0.1250192; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; FIELD JB, 1987, BIOCHEM J, V247, P519, DOI 10.1042/bj2470519; FUJIMOTO J, 1992, ENDOCRINOLOGY, V130, P1587, DOI 10.1210/en.130.3.1587; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gennis R. B., 1989, BIOMEMBRANE, P235; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; JALINK K, 1990, J BIOL CHEM, V265, P12232; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LOMBARDI A, 1988, ENDOCRINOLOGY, V123, P1544, DOI 10.1210/endo-123-3-1544; LORENZET R, 1992, THROMB HAEMOSTASIS, V68, P357; MALAGODI MH, 1974, EUR J PHARMACOL, V27, P25, DOI 10.1016/0014-2999(74)90198-8; MARCOCCI C, 1987, ENDOCRINOLOGY, V120, P1127, DOI 10.1210/endo-120-3-1127; MARSH D, 1993, BIOMEMBRANE, V1, P1; MARTIN SC, 1992, J MEMBRANE BIOL, V125, P243; MCHOWAT J, 1993, J BIOL CHEM, V268, P15605; METZ SA, 1988, AM J MED, V85, P9, DOI 10.1016/0002-9343(88)90393-2; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATO K, 1992, BIOCHEM J, V283, P281, DOI 10.1042/bj2830281; SCHUMACHER KA, 1979, THROMB HAEMOSTASIS, V42, P631; SHINITZKY M, 1976, BIOCHIM BIOPHYS ACTA, V433, P133, DOI 10.1016/0005-2736(76)90183-8; SMALLRIDGE RC, 1991, ENDOCRINOLOGY, V129, P542, DOI 10.1210/endo-129-1-542; TAHARA K, 1991, J BIOL CHEM, V266, P440; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; TAKAHASHI SI, 1991, J BIOL CHEM, V266, P7834; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TORNQUIST K, 1991, MOL CELL ENDOCRINOL, V79, P147, DOI 10.1016/0303-7207(91)90105-2; TORNQUIST K, 1992, J CELL PHYSIOL, V150, P90, DOI 10.1002/jcp.1041500113; TRAMONTANO D, 1986, ENDOCRINOLOGY, V119, P940, DOI 10.1210/endo-119-2-940; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VITTI P, 1983, J CLIN ENDOCR METAB, V57, P782, DOI 10.1210/jcem-57-4-782; VOGT W, 1963, BIOCHEM PHARMACOL, V12, P415, DOI 10.1016/0006-2952(63)90074-1; WANG WQ, 1992, J CHROMATOGR-BIOMED, V581, P139, DOI 10.1016/0378-4347(92)80457-2; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1108, DOI 10.1210/endo-114-4-1108; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346	76	47	49	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2113	2124						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784056				2022-12-25	WOS:A1995RB70300006
J	JAMAL, S; ZIFF, EB				JAMAL, S; ZIFF, EB			RAF PHOSPHORYLATES P53 IN-VITRO AND POTENTIATES P53-DEPENDENT TRANSCRIPTIONAL TRANSACTIVATION IN-VIVO	ONCOGENE			English	Article						RAF; P53; TRANSCRIPTION; PHOSPHORYLATION; KINASE; BACULOVIRUS	CASEIN KINASE-II; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; SERUM RESPONSE ELEMENT; MAP-KINASE; V-RAF; GENE-EXPRESSION; MOUSE P53; C-FOS; ACTIVATION	Using recombinant baculovirus expressed p53 and Raf proteins, we show that activated Raf-1 kinase can phosphorylate mouse p53 in vitro. We also show that co-expression of vRaf and p53 in NIH3T3 fibroblasts, potentiates the ability of p53 to transactivate a minimal promoter with a p53 cognate DNA binding site. A dominant negative mutant of Raf inhibits the transactivation function of p53 in NIH3T3 fibroblasts. Incubation of Raf-1 kinase with a series of p53 derived synthetic peptides maps the Raf-1 phosphorylation sites to the 27 amino terminal residue region of p53 which coincides with the transactivation domain. Phosphorylation occurs on serines which are phosphorylated in vivo. Our results suggest that the transactivation function of p53 can be regulated by a signaling cascade involving Raf.	NYU,MED CTR,DEPT BIOCHEM,HOWARD HUGHES MED INST,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	Howard Hughes Medical Institute; New York University; New York University				Ziff, Edward/0000-0001-7389-8649				BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BUSCHER D, 1993, ONCOGENE, V8, P3323; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1993, ONCOGENE, V8, P1519; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRAISS S, 1990, ONCOGENE, V5, P845; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LISSOOS TW, 1993, J BIOL CHEM, V268, P25132; LOWE PN, 1991, J BIOL CHEM, V266, P1672; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; METZ R, 1991, ONCOGENE, V6, P2165; MIHALY A, 1991, BRAIN RES, V547, P309, DOI 10.1016/0006-8993(91)90976-3; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; OLAH Z, 1991, EXP BRAIN RES, V84, P403; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEGAWA K, 1993, FEBS LETT, V329, P283, DOI 10.1016/0014-5793(93)80238-P; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	49	75	77	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2095	2101						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784054				2022-12-25	WOS:A1995RB70300004
J	DENNIG, J; HAGEN, G; BEATO, M; SUSKE, G				DENNIG, J; HAGEN, G; BEATO, M; SUSKE, G			MEMBERS OF THE SP TRANSCRIPTION FACTOR FAMILY CONTROL TRANSCRIPTION FROM THE UTEROGLOBIN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENT ACTIVATION DOMAINS; BETA-GLOBIN PROMOTER; BOX-BINDING-PROTEINS; GLUCOCORTICOID RECEPTOR; GEL-ELECTROPHORESIS; MAMMALIAN-CELLS; SV40 ENHANCER; CC10 GENE; EXPRESSION; ELEMENTS	Previous analyses of the uteroglobin promoter revealed seven distinct regions, which contribute to its overall activity in epithelial cells from endometrium and lung, Most significantly, a mutation of the promoter sequence around 65 base pairs upstream of the transcriptional start site severely impairs promoter activity. The transcription factor acting through this sequence has not been identified yet, Here, we report that members of the Sp transcription factor family specifically recognize this non-classical GC box, in addition to another functional motif located 230 base pairs upstream of the transcriptional start site. We have characterized in detail the interaction of recombinant Sp3 with both motifs by DNase I footprinting and methylation protection using the wild-type uteroglobin promoter and various linker scanning mutants as templates, Electrophoretic mobility shift analyses show that Sp1 and Sp3 both bind with similar affinity to these elements, We demonstrate that the DNA-binding proteins in the endometrial cell line Ishikawa which recognize these motifs are also Sp1 and Sp3. Gene transfer experiments into Drosophila Schneider cells that do not contain endogenous Sp factors revealed that both DNA motifs respond to transiently expressed Sp1 and Sp3. Our results show thus that the level of transcription from the uteroglobin promoter is controlled by members of the Sp transcription factor family through unusual Sp binding sites.			DENNIG, J (corresponding author), UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,D-35037 MARBURG,GERMANY.		Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222; Suske, Guntram/0000-0002-4807-0513				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEATO M, 1983, REGULATION GENE EXPR, P151; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1986, TRENDS BIOCHEM SCI, V11, P395, DOI 10.1016/0968-0004(86)90149-0; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; JANTZEN K, 1987, NUCLEIC ACIDS RES, V15, P4535, DOI 10.1093/nar/15.11.4535; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLUG J, 1994, MOL CELL BIOL, V14, P6208, DOI 10.1128/MCB.14.9.6208; Maniatis T, 1989, DECONTAMINATION DILU; Maxam A M, 1980, Methods Enzymol, V65, P499; MISSEYANNI A, 1991, NUCLEIC ACIDS RES, V19, P2849, DOI 10.1093/nar/19.11.2849; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PITLUK ZW, 1991, J VIROL, V65, P6661, DOI 10.1128/JVI.65.12.6661-6670.1991; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SANDMOLLER A, 1991, MECH DEVELOP, V34, P57, DOI 10.1016/0925-4773(91)90091-J; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; Suske Guntram, 1992, Gene Expression, V2, P339; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	43	107	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12737	12744		10.1074/jbc.270.21.12737	http://dx.doi.org/10.1074/jbc.270.21.12737			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759528	hybrid			2022-12-25	WOS:A1995QZ71100064
J	LIU, WC; YOON, J; BURG, M; CHEN, L; PAK, WL				LIU, WC; YOON, J; BURG, M; CHEN, L; PAK, WL			MOLECULAR CHARACTERIZATION OF 2 DROSOPHILA GUANYLATE CYCLASES EXPRESSED IN THE NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC PEPTIDE RECEPTOR; LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; PHOSPHOLIPASE-C GENE; NITRIC-OXIDE; CYCLIC-GMP; ACTIVITY REQUIRES; ENZYME SUBUNITS; CARBON-MONOXIDE; MEMBRANE FORM	We have isolated, by interspecies hybridization, two classes of Drosophila cDNA each encoding a different guanylate cyclase (GC). One of them encodes an alpha subunit homolog of soluble GC, designated DGC alpha 1, and the other encodes a receptor-type GC, designated DrGC. The dgc alpha 1 cDNA encodes a protein of 676 amino acids and maps to 99B. In situ hybridization to adult tissue sections showed that dgc alpha 1 mRNA is found mainly in the cell bodies of the optic lobe, central brain, and thoracic ganglia. The DGC alpha 1 protein was also localized primarily to the nervous system by immunocytochemical staining, consistent with results of in situ hybridization. However, no detectable expression of this protein was found in the retina. The other class of cDNA, drgc, maps to 76C and encodes a 1525-amino acid protein displaying structural features similar to other known receptor-type guanylate cyclases. However, it has a C-terminal 430 amino acid region that has no homology 60 any known proteins. drgc RNA is expressed at low levels throughout development and in adult heads and bodies. In situ hybridizations to adult tissue sections showed that drgc mRNA is expressed in a wide range of tissues, including the optic lobe, central brain, thoracic ganglia, digestive tract, and the oocyte.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; KYUNG HEE UNIV,DEPT GENET ENGN,KYONGGI DO,SOUTH KOREA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Kyung Hee University					NATIONAL EYE INSTITUTE [R37EY000033, R56EY000033, R01EY000033] Funding Source: NIH RePORTER; NEI NIH HHS [EY00033] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGERER LM, 1987, IN SITU HYBRIDIZATIO, P42; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BACIGALUPO J, 1991, P NATL ACAD SCI USA, V88, P7938, DOI 10.1073/pnas.88.18.7938; BAUMANN A, 1994, EMBO J, V13, P5040, DOI 10.1002/j.1460-2075.1994.tb06833.x; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; BURG MG, 1993, EMBO J, V12, P911, DOI 10.1002/j.1460-2075.1993.tb05732.x; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CRAVEN PA, 1978, J BIOL CHEM, V253, P8433; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; DEVEREUX J, 1992, GCG SEQUENCE ANAL SO; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; ENGELS WR, 1986, FOCUS, V8, P6; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FESENKO EE, 1985, NATURE, V313, P311; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIGLIOTTI S, 1993, DEV BIOL, V159, P450, DOI 10.1006/dbio.1993.1255; GOY MF, 1991, TRENDS NEUROSCI, V14, P293, DOI 10.1016/0166-2236(91)90140-P; GUAN KL, 1988, ANAL BIOCHEM, V192, P262; HAFEN E, 1986, DROSOPHILA PRACTICAL, P139; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; ITOH N, 1985, DROS INF SERVICE, V61, P89; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; KOESLING D, 1988, FEBS LETT, V239, P29, DOI 10.1016/0014-5793(88)80539-8; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MAHMOUDI M, 1989, BIOTECHNIQUES, V7, P331; MCNEIL L, 1995, J BIOL CHEM, V270, P7189, DOI 10.1074/jbc.270.13.7189; MILLER K, 1987, BRL FOCUS, V9, P14; MINKE B, 1991, PROG RETIN RES, V11, P99, DOI 10.1016/0278-4327(91)90026-X; MONTELL C, 1985, SCIENCE, V230, P1040, DOI 10.1126/science.3933112; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V156, P1000; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PALMER RMJ, 1987, NATURE, V333, P664; PAUPARDINTRITSC.D, 1986, NATURE, V323, P812; PAUPARDINTRITSC.D, 1986, J NEUROSCI, V6, P2715; PAYNE R, 1986, PHOTOBIOCH PHOTOBIOP, V13, P373; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REGULSKI M, 1993, ABSTRACT NEUROBIOLOG, P126; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; THORPE DS, 1989, J BIOL CHEM, V264, P6545; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VINCENT SR, 1992, TRENDS NEUROSCI, V15, P108, DOI 10.1016/0166-2236(92)90021-Y; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WILCOX JN, 1991, MOL CELL BIOL, V11, P3454, DOI 10.1128/MCB.11.7.3454; YOON JS, 1989, J BIOL CHEM, V264, P18536; YOSHIKAWA S, 1993, J NEUROCHEM, V60, P1570, DOI 10.1111/j.1471-4159.1993.tb03324.x; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	76	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12418	12427		10.1074/jbc.270.21.12418	http://dx.doi.org/10.1074/jbc.270.21.12418			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759483	hybrid			2022-12-25	WOS:A1995QZ71100016
J	MARSHALL, NF; PRICE, DH				MARSHALL, NF; PRICE, DH			PURIFICATION OF P-TEFB, A TRANSCRIPTION FACTOR REQUIRED FOR THE TRANSITION INTO PRODUCTIVE ELONGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RNA POLYMERASE-II; ADENOSINE-DEAMINASE GENE; C-FOS GENE; MESSENGER-RNA; SEQUENCE REQUIREMENTS; MAMMALIAN-CELLS; FACTOR-SIII; HELA-CELLS; 5,6-DICHLORO-1-BETA-D-RIBOFURANOSYLBENZIMIDAZOLE; TERMINATION	Production of full-length runoff transcripts in vitro and functional mRNA in vivo is sensitive to the drug 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB). We previously proposed the existence of an activity, P-TEF (positive transcription elongation factor) that functions in a DRB-sensitive manner to allow RNA polymerase II elongation complexes to efficiently synthesize long transcripts (Marshall, N. F. and Price, D. H. (1992) Mol. Cell. Biol. 12, 2078-2090). We have fractionated nuclear extracts of Drosophila melanogaster K-c cells and identified three activities, P-TEFa, factor 2, and P-TEFb, that are directly involved in reconstructing DRB-sensitive transcription. P-TEFb is essential for the production of DRB-sensitive long transcripts in vitro, while P-TEFa and factor 2 are stimulatory. P-TEFb activity is associated with a protein comprising two polypeptide subunits with apparent molecular masses of 124 and 43 kDa. Using a P-TEFb-dependent transcription system, we show that P-TEFb acts after initiation and is the limiting factor in the production of long run-off transcripts.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa			Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CHEN Z, 1991, MOL CELL BIOL, V11, P6248, DOI 10.1128/MCB.11.12.6248; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; FLORES O, 1992, J BIOL CHEM, V267, P2786; FRASER NW, 1979, P NATL ACAD SCI USA, V76, P2571, DOI 10.1073/pnas.76.6.2571; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KESSLER M, 1989, J BIOL CHEM, V264, P9785; KESSLER M, 1991, J BIOL CHEM, V266, P13019; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAUB O, 1980, P NATL ACAD SCI-BIOL, V77, P3297, DOI 10.1073/pnas.77.6.3297; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MEULIA T, 1993, MOL CELL BIOL, V13, P5647, DOI 10.1128/MCB.13.9.5647; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; SCHNEIDERSCHAUL.J, 1987, EUR J IMMUNOL, V17, P713; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; SPENCER CA, 1990, ONCOGENE, V5, P777; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAMM I, 1980, BIOCHEMISTRY-US, V19, P2743, DOI 10.1021/bi00553a032; TAMM I, 1979, P NATL ACAD SCI USA, V76, P5750, DOI 10.1073/pnas.76.11.5750; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	31	417	430	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12335	12338		10.1074/jbc.270.21.12335	http://dx.doi.org/10.1074/jbc.270.21.12335			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759473	hybrid			2022-12-25	WOS:A1995QZ71100003
J	ZHAO, H; BANERJEE, AK				ZHAO, H; BANERJEE, AK			INTERACTION BETWEEN THE NUCLEOCAPSID PROTEIN AND THE PHOSPHOPROTEIN OF HUMAN PARAINFLUENZA VIRUS-3 - MAPPING OF THE INTERACTING DOMAINS USING A 2-HYBRID SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; REGULATES TRANSCRIPTION INVITRO; PARA-INFLUENZA VIRUS-3; P-PROTEIN; SEPARATE DOMAINS; GENE-EXPRESSION; VIRAL-PROTEINS; MESSENGER-RNA; ACIDIC DOMAIN; GENOME RNA	A two-hybrid system was used to study interaction in vivo between the nucleocapsid protein (NP) and the phosphoprotein (P) of human parainfluenza virus type 3 (HPIV-3). Two plasmids, one containing the amino terminus of P fused to the DNA-binding domain of the yeast transactivator, GAL4, and the other containing the amino terminus of NP fused to the herpesvirus transactivator, VP16, were transfected in COS-1 cells along with a chloramphenicol acetyltransferase (CAT) reporter plasmid containing GAL4 DNA-binding sites. A specific and high-affinity interaction between NP and P was observed as measured by the activation of the CAT gene. Mapping of the domains in P (603 amino acids) involved in the association with NP revealed that NH2-terminal 40 and COOH-terminal 20 amino acids are important for such association. Interestingly, a stretch of NH2-terminal amino acids as short as 63-403 interacted with NP more than the wild type, reaching greater than 2.5-fold as measured by the CAT assay. These results suggest that a domain is present in P that negatively regulates its interaction with NP. Deletion of NH2-terminal 40 and COOH-terminal 160 amino acids of NP reduced the CAT activity by more than 95%. These results underscore the important differences between negative strand RNA viruses with respect to interactions between these two viral proteins involved in gene expression.	CLEVELAND CLIN FDN, RES INST, DEPT MOLEC BIOL, CLEVELAND, OH 44195 USA; CASE WESTERN RESERVE UNIV, DEPT BIOL, CLEVELAND, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032027] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-32027] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE AK, 1991, PHARMACOL THERAPEUT, V51, P47, DOI 10.1016/0163-7258(91)90041-J; BANERJEE AK, 1992, VIROLOGY, V188, P417, DOI 10.1016/0042-6822(92)90495-B; BARIK S, 1992, J VIROL, V66, P1109, DOI 10.1128/JVI.66.2.1109-1118.1992; BARIK S, 1992, P NATL ACAD SCI USA, V89, P6570, DOI 10.1073/pnas.89.14.6570; CHATTOPADHYAY D, 1987, P NATL ACAD SCI USA, V84, P8932, DOI 10.1073/pnas.84.24.8932; CHATTOPADHYAY D, 1987, CELL, V49, P407, DOI 10.1016/0092-8674(87)90293-5; CURRAN J, 1993, J VIROL, V67, P4358, DOI 10.1128/JVI.67.7.4358-4364.1993; CURRAN J, 1995, J VIROL, V69, P849, DOI 10.1128/JVI.69.2.849-855.1995; CURRAN J, 1994, VIROLOGY, V202, P875, DOI 10.1006/viro.1994.1409; DE BP, 1990, J VIROL, V64, P1135, DOI 10.1128/JVI.64.3.1135-1142.1990; EMERSON SU, 1987, P NATL ACAD SCI USA, V84, P5655, DOI 10.1073/pnas.84.16.5655; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FU ZF, 1994, VIROLOGY, V200, P590, DOI 10.1006/viro.1994.1222; GALINSKI MS, 1991, ADV VIRUS RES, V39, P129; GALINSKI MS, 1992, VIROLOGY, V186, P543, DOI 10.1016/0042-6822(92)90020-P; HOMANN HE, 1991, J VIROL, V65, P1304, DOI 10.1128/JVI.65.3.1304-1309.1991; HORIKAMI SM, 1992, J VIROL, V66, P4901, DOI 10.1128/JVI.66.8.4901-4908.1992; LUK D, 1986, VIROLOGY, V153, P318, DOI 10.1016/0042-6822(86)90036-X; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; PATTNAIK AK, 1990, J VIROL, V64, P2948, DOI 10.1128/JVI.64.6.2948-2957.1990; PELUSO RW, 1988, VIROLOGY, V162, P369, DOI 10.1016/0042-6822(88)90477-1; RYAN KW, 1990, VIROLOGY, V174, P515, DOI 10.1016/0042-6822(90)90105-Z; RYAN KW, 1991, VIROLOGY, V180, P126, DOI 10.1016/0042-6822(91)90016-5; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ A, 1985, VIROLOGY, V143, P45, DOI 10.1016/0042-6822(85)90095-9; SMALLWOOD S, 1994, VIROLOGY, V202, P154, DOI 10.1006/viro.1994.1331; TAKACS AM, 1993, P NATL ACAD SCI USA, V90, P10375, DOI 10.1073/pnas.90.21.10375; TAKACS AM, 1992, J VIROL, V66, P5842, DOI 10.1128/JVI.66.10.5842-5848.1992; TAKACS AM, 1991, NEW BIOL, V3, P581; VASAVADA HA, 1991, P NATL ACAD SCI USA, V88, P10686, DOI 10.1073/pnas.88.23.10686	32	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12485	12490		10.1074/jbc.270.21.12485	http://dx.doi.org/10.1074/jbc.270.21.12485			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759493	hybrid			2022-12-25	WOS:A1995QZ71100026
J	COLEMAN, ME; DEMAYO, F; YIN, KC; LEE, HM; GESKE, R; MONTGOMERY, C; SCHWARTZ, RJ				COLEMAN, ME; DEMAYO, F; YIN, KC; LEE, HM; GESKE, R; MONTGOMERY, C; SCHWARTZ, RJ			MYOGENIC VECTOR EXPRESSION OF INSULIN-LIKE GROWTH-FACTOR-I STIMULATES MUSCLE-CELL DIFFERENTIATION AND MYOFIBER HYPERTROPHY IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN GENE; SKELETAL-MUSCLE; IGF-I; MYOBLAST DIFFERENTIATION; TISSUE CONCENTRATIONS; REGULATED EXPRESSION; BINDING-PROTEIN; SEQUENCE; ACID; RAT	The avian skeletal alpha-actin gene was used as a template for construction of a myogenic expression vector that was utilized to direct expression of a human IGF-I cDNA in cultured muscle cells and in striated muscle of transgenic mice. The proximal promoter region, together with the first intron and 1.8 kilobases of 3'-noncoding flanking sequence of the avian skeletal alpha-actin gene directed high level expression of human insulin-like growth factor I (IGF-I) in stably transfected C2C12 myoblasts and transgenic mice. Expression of the actin/IGF-I hybrid gene in C2C12 muscle cells increased levels of myogenic basic helix-loop-helix factor and contractile protein mRNAs and enhanced myotube formation, Expression of the actin/IGF-I hybrid gene in mice elevated IGF-I concentrations in skeletal muscle 47-fold resulting in myofiber hypertrophy, IGF-I concentrations in serum and body weight were not increased by transgene expression, suggesting that the effects of transgene expression were localized, These results indicate that sustained overexpression of IGF-I in skeletal muscle elicits myofiber hypertrophy and provides the basis for manipulation of muscle physiology utilizing skeletal alpha-actin-based vectors.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT COMPARAT PATHOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine			DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336	NATIONAL INSTITUTE ON AGING [T32AG000183] Funding Source: NIH RePORTER; NIA NIH HHS [T32AG00183] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASANTE EA, 1994, TRANSGENIC RES, V3, P59, DOI 10.1007/BF01976028; AYLING CM, 1989, J ENDOCRINOL, V123, P429, DOI 10.1677/joe.0.1230429; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BEHRINGER RR, 1990, ENDOCRINOLOGY, V127, P1033, DOI 10.1210/endo-127-3-1033; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BISCHOFF R, 1990, J CELL BIOL, V111, P201, DOI 10.1083/jcb.111.1.201; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; CARSON JA, 1995, IN PRESS AM J PHYSL; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; DEVOL DL, 1990, AM J PHYSIOL, V259, pE89, DOI 10.1152/ajpendo.1990.259.1.E89; DUNWOODIE SL, 1994, J BIOL CHEM, V269, P12212; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FLORINI JR, 1987, MUSCLE NERVE, V10, P577, DOI 10.1002/mus.880100702; FLORINI JR, 1989, AM J PHYSIOL, V256, pC701, DOI 10.1152/ajpcell.1989.256.4.C701; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; FORNWALD JA, 1982, NUCLEIC ACIDS RES, V10, P3861, DOI 10.1093/nar/10.13.3861; FRENCH BA, 1990, GENE, V88, P173, DOI 10.1016/0378-1119(90)90029-Q; GRICHNIK JM, 1986, NUCLEIC ACIDS RES, V14, P1682; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HAN VKM, 1987, SCIENCE, V236, P193, DOI 10.1126/science.3563497; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; HOGAN B, 1986, MANIPULATING MOUSE E; HU MCT, 1986, MOL CELL BIOL, V6, P15, DOI 10.1128/MCB.6.1.15; JAMES PL, 1993, J BIOL CHEM, V268, P22305; JANSEN M, 1983, NATURE, V306, P609, DOI 10.1038/306609a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVINOVITZ A, 1992, MOL ENDOCRINOL, V6, P1227, DOI 10.1210/me.6.8.1227; LI H, 1994, J CELL BIOL, V124, P827, DOI 10.1083/jcb.124.5.827; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PEARSE AGE, 1972, HISTOCHEMISTRY THEOR, V1; PETROPOULOS CJ, 1989, MOL CELL BIOL, V9, P3785, DOI 10.1128/MCB.9.9.3785; POWELL DR, 1986, J CLIN ENDOCR METAB, V63, P1186; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SCHWARTZ RJ, 1973, J BIOL CHEM, V248, P6426; SHANI M, 1986, MOL CELL BIOL, V6, P2624, DOI 10.1128/MCB.6.7.2624; SOUTHERN EM, 1979, J MOL BIOL, V98, P503; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; VANDEKERCKHOVE J, 1984, J MOL BIOL, V179, P391, DOI 10.1016/0022-2836(84)90072-X; VANDENBURGH HH, 1991, AM J PHYSIOL, V260, pC475, DOI 10.1152/ajpcell.1991.260.3.C475; WADE R, 1989, ANNU REV PHYSIOL, V51, P179, DOI 10.1146/annurev.physiol.51.1.179; ZHU YY, 1991, J CELL BIOL, V115, P745, DOI 10.1083/jcb.115.3.745	54	497	522	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12109	12116		10.1074/jbc.270.20.12109	http://dx.doi.org/10.1074/jbc.270.20.12109			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744859	hybrid			2022-12-25	WOS:A1995QY73600062
J	MERRILL, JE; JONAKAIT, GM				MERRILL, JE; JONAKAIT, GM			INTERACTIONS OF THE NERVOUS AND IMMUNE-SYSTEMS IN DEVELOPMENT, NORMAL BRAIN HOMEOSTASIS, AND DISEASE	FASEB JOURNAL			English	Article						CYTOKINES; GLIA IMMUNE CELLS; LIGANDS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NEURONS; TIDES; NEUROTRANSMITTERS; NEUROTROPHINS; RECEPTORS	SUBSTANCE-P; NEURONAL CELLS; GROWTH-FACTOR; NITRIC-OXIDE; GLIAL-CELLS; RECEPTOR; INTERLEUKIN-1; CYTOKINES; INDUCTION; ASTROCYTES	Neurotransmitters, neuropeptides, neurotrophins, and neuroendocrine hormones have traditionally been assigned functions in normal development and homeostasis of neuronal networks; cytokines and adhesion molecules have been assigned functions within the peripheral immune system. Molecular dissection of the presence and function of these receptors and ligands during development of the immune and nervous systems, in normal healthy adult central and peripheral nervous tissue, and in the pathological response of immune elements in the brain and neuroelements in the immune system has forced us to alter these long-held concepts. Examples of how glia and neurons function in relationship to these paracrine and autocrine stimuli in health and disease are provided in this short review.	UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024; RUTGERS STATE UNIV,DEPT BIOL SCI,NEWARK,NJ 07102	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Rutgers State University Newark; Rutgers State University New Brunswick					NINDS NIH HHS [R0-1 NS30768] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030768] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANATI RB, IN PRESS DEV NEUROSC; BANNER LR, 1994, IN PRESS P NATL ACAD; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BHARUCHA VA, 1994, NEURON, V12, P627, DOI 10.1016/0896-6273(94)90218-6; BREDESEN DE, 1994, APOPTOSIS, V2, P397; BRENNEMAN D, 1994, SOC NEUR ABSTR, V20; BROSNAN CF, 1994, IN PRESS DEV NEUROSC; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CONSTAM DB, 1992, J IMMUNOL, V148, P1404; DACUNHA A, 1993, J NEUROIMMUNOL, V42, P71, DOI 10.1016/0165-5728(93)90214-J; DAWSON MT, 1994, IN PRESS NEUROSCIENT; DAWSON TM, 1994, IN PRESS ADV NEUROIM; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; FANSLOW WC, 1990, SCIENCE, V248, P793; FILBIN MT, 1994, IN PRESS DEV NEUROSC; GEARING DP, 1993, ADV IMMUNOL, V53, P31, DOI 10.1016/S0065-2776(08)60497-6; GRAU GE, 1993, EUR CYTOKINE NETW, V4, P415; HART RP, 1993, J NEUROIMMUNOL, V49, P56; HILL JM, 1993, BRAIN RES, V605, P222; HUANG K, 1991, J CLIN INVEST, V88, P1778, DOI 10.1172/JCI115498; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JONAKAIT GM, 1994, TINS, V16, P419; KALARIA RN, 1993, CLIN NEUROSCI, V1, P204; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; LIPTON SA, 1994, IN PRESS DEV NEUROSC; LUBERNAROD J, 1994, J IMMUNOL, V152, P819; MARTIN FC, 1992, BRAIN RES, V599, P13, DOI 10.1016/0006-8993(92)90846-2; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MEHLER MF, 1994, IN PRESS DEV NEUROSC; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642; MINCGOLOMB D, 1994, BRIT J PHARMACOL, V112, P720, DOI 10.1111/j.1476-5381.1994.tb13136.x; MITROVIC B, 1994, IN PRESS NEUROSCIENC; MITSUO K, 1993, J MOL NEUROSCI, V4, P21, DOI 10.1007/BF02736687; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NOGUCHI M, 1993, SCIENCE, V262, P1977; OEHM A, 1992, J BIOL CHEM, V267; OLSSON T, 1994, EUR J IMMUNOL, V24, P308, DOI 10.1002/eji.1830240205; OTERO GC, 1994, GLIA, V11, P117, DOI 10.1002/glia.440110207; PARK SK, 1994, BIOCHEM BIOPH RES CO, V201, P762, DOI 10.1006/bbrc.1994.1766; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAMESHWAR P, 1993, BLOOD, V81, P391; RAMESHWAR P, 1994, J IMMUNOL, V152, P4044; RELTON JK, 1992, BRAIN RES B, V585, P135; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SHADIACK AM, 1993, J NEUROSCI, V13, P2601, DOI 10.1523/JNEUROSCI.13-06-02601.1993; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SMITHSEINTOSKY VL, 1994, IN PRESS J NEUROCHEM; SUN L, 1993, J NEUROIMMUNOL, V48, P59, DOI 10.1016/0165-5728(93)90059-8; SUN Y, 1993, J NEUROBIOL, V25, P415; SUNDAR SK, 1991, P NATL ACAD SCI USA, V88, P11246, DOI 10.1073/pnas.88.24.11246; Togni PD, 1994, SCIENCE, V264, P703; WELLER M, 1994, EUR J IMMUNOL, V24, P1293, DOI 10.1002/eji.1830240608; WELLER M, 1994, IN PRESS J CLIN INVE, V94; WONG MH, 1994, IN PRESS J CELL BIOL, V126	62	106	111	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					611	618		10.1096/fasebj.9.8.7768352	http://dx.doi.org/10.1096/fasebj.9.8.7768352			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768352				2022-12-25	WOS:A1995RC10600006
J	CONNOR, H; NORNES, H; NEUMAN, T				CONNOR, H; NORNES, H; NEUMAN, T			EXPRESSION SCREENING REVEALS AN ORPHAN RECEPTOR CHICK OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR-I AS A REGULATOR OF NEURITE SUBSTRATE-CELL CONTACTS AND CELL-AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE; GROWTH CONES; ADHESION MOLECULE; GENE-REGULATION; SUPERFAMILY; MEMBER; COLLAPSE; PROTEIN; FAMILY	A rat homologue of chick ovalbumin upstream promoter transcription factor I (COUP-TF I) was isolated using an expression cloning method developed to isolate neurite outgrowth inhibitors. Overexpression of COUP-TF I in 3T3 fibroblasts resulted in reduction of stable contact formation between neurites and transfected cells. Additionally, COUP-TF I enhanced retinoic acid response element-dependent reporter gene expression in 3T3 fibroblasts, indicating that COUP-TF I can modulate transcriptional activation in these cells. Our data suggest that COUP-TF transcription factors are involved in the regulation of cell surface molecules during neurogenesis.	COLORADO STATE UNIV,DEPT ANAT & NEUROBIOL,FT COLLINS,CO 80523	Colorado State University								BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; CHAN SM, 1992, P NATL ACAD SCI USA, V89, P10568, DOI 10.1073/pnas.89.22.10568; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1989, NEURON, V2, P1105, DOI 10.1016/0896-6273(89)90177-3; FJOSE A, 1993, EMBO J, V12, P1403, DOI 10.1002/j.1460-2075.1993.tb05784.x; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; JONES FS, 1993, P NATL ACAD SCI USA, V90, P6557, DOI 10.1073/pnas.90.14.6557; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; LU XP, 1994, MOL ENDOCRINOL, V8, P1774, DOI 10.1210/me.8.12.1774; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MATHARU PJ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P331, DOI 10.1016/0167-4781(92)90512-X; MCEWEN BS, 1991, J STEROID BIOCHEM, V40, P1, DOI 10.1016/0960-0760(91)90160-7; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NEUMAN K, 1995, J NEUROSCI RES, V41, P39, DOI 10.1002/jnr.490410106; QIU YH, 1994, P NATL ACAD SCI USA, V91, P4451, DOI 10.1073/pnas.91.10.4451; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; RICHIE HH, 1990, NUCLEIC ACIDS RES, V18, P6857; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; TOSNEY KW, 1984, J NEUROSCI, V4, P2518; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	43	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15066	15070		10.1074/jbc.270.25.15066	http://dx.doi.org/10.1074/jbc.270.25.15066			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797489	hybrid			2022-12-25	WOS:A1995RE66600035
J	PERILLO, B; TEDESCO, I; LAEZZA, C; SANTILLO, M; ROMANO, A; ALOJ, SM; BIFULCO, M				PERILLO, B; TEDESCO, I; LAEZZA, C; SANTILLO, M; ROMANO, A; ALOJ, SM; BIFULCO, M			REGULATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE GENE-EXPRESSION IN FRTL-5 CELLS .2. DOWN-REGULATION BY V-K-RAS ONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID EPITHELIAL-CELLS; MURINE SARCOMA-VIRUS; MAMMALIAN-CELLS; A REDUCTASE; THYROTROPIN; PROTEIN; TRANSFORMATION; INHIBITION; PATHWAY; ADENOSINE-3',5'-MONOPHOSPHATE	3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity and mRNA levels were significantly reduced in FRTL-5 cells transformed with the Kirsten-Moloney sarcoma virus (KiMol); these cells have lost thyrotropin dependence and express high levels of p21(ras). FRTL-5 cells, transformed with a temperature-sensitive mutant of the v-K-ras oncogene (Ats cells: 33 degrees C, permissive; 39 degrees C, nonpermissive), showed significant reduction of HMG-CoA reductase expression when exposed to 33 degrees C. In KiMol cells, as well. as in Ats cells at 33 degrees C, the transcription driven by cAMP-responsive element was probed by measuring chloramphenicol acetyl transferase (CAT) levels after transfection with a chimeric plasmid containing the reporter gene linked to the rat reductase promoter, Basal CAT activity in KiMol cells transfected with wild-type promoter was lower than in FRTL-5 cells but was increased by forskolin to the levels attained in thyrotropin-stimulated FRTL-5 cells, Forskolin failed to increase CAT activity in KiMol cells transfected with the plasmid harboring a reductase promoter in which the cAMP-responsive element octamer was mutated to a nonpalindromic sequence. The effect of v-K-ras could be mimicked in FRTL-B cells by tetradecanoyl phorbol acetate and reverted in RiMol and Ats cells, expressing active Ras protein, by increasing intracellular cAMP and/or by protein kinase C inhibition. The data are consistent with the contention that v-K-ras, through protein kinase C and depletion of intracellular cAMP, is inhibitory for the protein kinase A pathway. This is the first demonstration that active v-K-ras down-regulates HMG-CoA reductase expression.	UNIV NAPLES FEDERICO II,CTR ENDOCRINOL & ONCOL SPERIMENTALE,CNR,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria			laez, chi/AAW-4437-2020	Bifulco, Maurizio/0000-0002-1771-4531; Aloj, Salvatore, M./0000-0003-1703-7523; Perillo, Bruno/0000-0001-8935-0370				ALOJ SM, 1990, MOL ENDOCRINOL, V4, P611, DOI 10.1210/mend-4-4-611; Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; AMBESIIMPIOMBAT.FS, 1980, P NATL ACAD SCI USA, V77, P3455; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; BIFULCO M, 1990, J BIOL CHEM, V265, P19336; BIFULCO M, 1995, J BIOL CHEM, V270, P15231, DOI 10.1074/jbc.270.25.15231; BUNCE CM, 1988, ANAL BIOCHEM, V75, P67; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLETTA G, 1988, FEBS LETT, V228, P37, DOI 10.1016/0014-5793(88)80579-9; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIECO D, 1990, J BIOL CHEM, V265, P19343; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4853; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KOHN LD, 1975, J BIOL CHEM, V250, P6503; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; PERILLO B, 1993, J ENDOCRINOL INVEST, V16, P72; Sambrook J, 1989, MOL CLONING LABORATO; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SPINA A, 1988, BIOCHEM BIOPH RES CO, V157, P1093, DOI 10.1016/S0006-291X(88)80986-0; SUAREZ HG, 1988, ONCOGENE, V2, P403; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	43	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15237	15241		10.1074/jbc.270.25.15237	http://dx.doi.org/10.1074/jbc.270.25.15237			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797508	hybrid			2022-12-25	WOS:A1995RE66600059
J	VENISSE, A; RIVIERE, M; VERCAUTEREN, J; PUZO, G				VENISSE, A; RIVIERE, M; VERCAUTEREN, J; PUZO, G			STRUCTURAL-ANALYSIS OF THE MANNAN REGION OF LIPOARABINOMANNAN FROM MYCOBACTERIUM-BOVIS BCG - HETEROGENEITY IN PHOSPHORYLATION STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MULTIPLE QUANTUM NMR; MYOINOSITOL PHOSPHATES; MASS-SPECTROMETRY; TUBERCULOSIS; SPECTROSCOPY; STRAINS; OLIGOSACCHARIDES; GLYCOPROTEIN; MACROPHAGES	Lipoarabinomannan (LAM) is a major antigen of mycobacterial cell walls, involved in host-Mycobacterium interactions. In a previous work, LAM from the vaccine strain, Mycobacterium bovis BCG, was found to exhibit mannooligosaccharides at its arabinan nonreducing ends (ManLAM). The present report concerns the mannan core structure of this ManLAM. After partial hydrolysis of ManLAM, two populations of mannans (Ma1 and Ma2) were obtained by gel filtration chromatography. Their structural features were defined by means of two dimensional homo- and heteronuclear (H-1-C-13) NMR se sequences and methylation analysis. They were both found to be composed of an alpha-(1 --> 6) linked mannan backbone with alpha-(1 --> 2)-Manp-linked side chains. They are highly branched, and Ma2 presents a higher fre frequency of branching than Ma1. Moreover, chemical analysis indicates that only Ma1 is phosphorylated. By a two-dimensional heteronuclear H-1-P-31 total correlation experiment, the phosphate was found to be involved in a phosphodiester bond between inositol C-1 and glycerol C-3. Then, the molecular mass of mannan was established by mass spectrometry, which revealed a molecular mass of 3517 Da for the major molecular species of Ma1. Likewise, analysis of unfractionated mannans showed the occurrence of other, quantitatively minor molecular species, endowed with two phosphates. This study clearly indicates that the mannan region of M. bovis BCG ManLAM exists as a heterogeneous population of molecules whose structures differ in their degree of glycosylation, level of branching, and phosphorylation state. The hypothesis that the relative abundance of these different molecules modulates the biological functions of LAM is discussed.	CNRS,PHARMACOL & TOXICOL FONDAMENTALES LAB,DEPT 3,F-31062 TOULOUSE,FRANCE; LAB PHARMACOGNOSIE,F-33076 BORDEAUX,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Vercauteren, Joseph/AAF-7151-2019	Vercauteren, Joseph/0000-0002-0201-1235				ADAMS LB, 1993, INFECT IMMUN, V61, P4173, DOI 10.1128/IAI.61.10.4173-4181.1993; ALLERHAND A, 1984, J AM CHEM SOC, V106, P2400, DOI 10.1021/ja00320a030; BARNES PF, 1992, J IMMUNOL, V149, P541; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRADBURY MG, 1993, CLIN EXP IMMUNOL, V94, P57; CERDAN S, 1986, J BIOL CHEM, V261, P4676; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; CHATTERJEE D, 1992, INFECT IMMUN, V60, P1249, DOI 10.1128/IAI.60.3.1249-1253.1992; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COHEN RE, 1980, BIOCHEMISTRY-US, V19, P4345, DOI 10.1021/bi00559a031; DANIEL TM, 1984, MYCOBACTERIA SOURCE, P417; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; GLUSHKA J, 1992, BIOCHEMISTRY-US, V31, P10741, DOI 10.1021/bi00159a014; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; JOHANSSON C, 1990, CARBOHYD RES, V207, P177, DOI 10.1016/0008-6215(90)84047-X; JOSELEAU JP, 1977, CARBOHYD RES, V58, P165, DOI 10.1016/S0008-6215(00)83412-6; KOGAN G, 1988, CARBOHYD RES, V172, P242; LEMASSU A, 1994, BIOCHEM J, V297, P351, DOI 10.1042/bj2970351; LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MISAKI A, 1977, J BIOCHEM-TOKYO, V82, P1759, DOI 10.1093/oxfordjournals.jbchem.a131874; MORENO C, 1988, CLIN EXP IMMUNOL, V74, P206; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; ROACH TIA, 1993, J IMMUNOL, V150, P1886; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; SWEET DP, 1975, CARBOHYD RES, V40, P967; VENISSE A, 1993, J BIOL CHEM, V268, P12401; WEBER PL, 1979, CARBOHYD RES, V74, P259, DOI 10.1016/S0008-6215(00)84781-3	40	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15012	15021		10.1074/jbc.270.25.15012	http://dx.doi.org/10.1074/jbc.270.25.15012			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797482	hybrid			2022-12-25	WOS:A1995RE66600028
J	LEVIN, G; KEREN, T; PERETZ, T; CHIKVASHVILI, D; THORNHILL, WB; LOTAN, I				LEVIN, G; KEREN, T; PERETZ, T; CHIKVASHVILI, D; THORNHILL, WB; LOTAN, I			REGULATION OF RCK1 CURRENTS WITH A CAMP ANALOG VIA ENHANCED PROTEIN-SYNTHESIS AND DIRECT CHANNEL PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; K+-CHANNEL; POTASSIUM CHANNEL; XENOPUS OOCYTES; MESSENGER-RNA; MODULATION; ACTIVATION; APLYSIA; SUBUNIT; BRAIN	We have recently shown that the rat brain Kv1.1 (RCK1) voltage-gated K+ channel is partially phosphorylated in its basal state in Xenopus oocytes and can be further phosphorylated upon treatment for a short time with a cAMP analog (Ivanina, T., Perts, T., Thornhill, W, B., Levin, G., Dascal, N., and Lotan, I. (1994) Biochemistry 33, 8786-8792), In this study, we show, by two-electrode voltage clamp analysis, that whereas treatments for a short time with various cAMP analogs do not affect the channel function, prolonged treatment with 8-bromoadenosine 3',5'-cyclic monophosphorothioate ((S-p)-8-Br-cAMPS), a membrane-permeant cAMP analog, enhances the current amplitude, It also enhances the current amplitude through a mutant channel that cannot be phosphorylated by protein kinase A activation. The enhancement is inhibited in the presence of (R(p))-8-Br-cAMPS, a membrane-permeant protein kinase A inhibitor. Concomitant SDS-polyacrylamide gel electrophoresis analysis reveals that this treatment not only brings about phosphorylation of the wild-type channel, but also increases the amounts of both wild-type and mutant channel proteins; the latter effect can be inhibited by cycloheximide, a protein synthesis inhibitor. In the presence of cycloheximide, the (Sp)-8-Br-cAMPS treatment enhances only the wild-type current amplitudes and induces accumulation of wild-type channels in the plasma membrane of the oocyte, In summary, prolonged treatment with (S-p)-8-Br-cAMPS regulates RCK1 function via two pathways, a pathway leading to enhanced channel synthesis and a pathway involving channel phosphorylation that directs channels to the plasma membrane.	TEL AVIV UNIV, SACKLER SCH MED, DEPT PHYSIOL & PHARMACOL, IL-69978 TEL AVIV, ISRAEL; MT SINAI HOSP, MT SINAI SCH MED, DEPT PHYSIOL & BIOPHYS, NEW YORK, NY 10029 USA	Tel Aviv University; Sackler Faculty of Medicine; Icahn School of Medicine at Mount Sinai					NINDS NIH HHS [NS-29633] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029633] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER GK, 1992, MOL ENDOCRINOL, V6, P476, DOI 10.1210/me.6.3.476; AZHDERIAN EM, 1994, NEURON, V12, P1223, DOI 10.1016/0896-6273(94)90439-1; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BENSON JA, 1983, P NATL ACAD SCI-BIOL, V80, P3522, DOI 10.1073/pnas.80.11.3522; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; BOSMA MM, 1993, J NEUROSCI, V13, P5242, DOI 10.1523/JNEUROSCI.13-12-05242.1993; CAI YC, 1993, J BIOL CHEM, V268, P23720; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DASCAL N, 1991, NEURON, V6, P165, DOI 10.1016/0896-6273(91)90131-I; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; DOSTMANN WRG, 1991, BIOCHEMISTRY-US, V30, P8710, DOI 10.1021/bi00099a032; DRAIN P, 1994, NEURON, V12, P1097, DOI 10.1016/0896-6273(94)90317-4; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; GILES W, 1989, J PHYSIOL-LONDON, V415, P233, DOI 10.1113/jphysiol.1989.sp017720; GREEN WN, 1991, P NATL ACAD SCI USA, V88, P854, DOI 10.1073/pnas.88.3.854; GREEN WN, 1991, NEURON, V7, P659, DOI 10.1016/0896-6273(91)90378-D; HOSODA K, 1994, J NEUROCHEM, V63, P1635; HUA JL, 1992, MOL ENDOCRINOL, V6, P1418, DOI 10.1210/me.6.9.1418; HUANG XY, 1994, P NATL ACAD SCI USA, V91, P624, DOI 10.1073/pnas.91.2.624; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LOTAN I, 1988, NEURON, V1, P963, DOI 10.1016/0896-6273(88)90153-5; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; PAYET MD, 1992, J BIOL CHEM, V267, P18270; PEDARZANI P, 1993, NEURON, V11, P1023, DOI 10.1016/0896-6273(93)90216-E; PROUD CG, 1994, NATURE, V371, P747, DOI 10.1038/371747a0; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; REINHART PH, 1991, J NEUROSCI, V11, P1627; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SCHREIBMAYER W, 1993, PFLUEGERS ARCH, V426, P453; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; SHUSTER MJ, 1985, NATURE, V313, P392, DOI 10.1038/313392a0; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STRONG JA, 1986, J NEUROSCI, V6, P814; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; THORNHILL WB, 1987, BIOCHEMISTRY-US, V26, P4381, DOI 10.1021/bi00388a029; WALSH KB, 1991, AM J PHYSIOL, V261, pC1081, DOI 10.1152/ajpcell.1991.261.6.C1081; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; YAZAWA K, 1990, J PHYSIOL-LONDON, V421, P135, DOI 10.1113/jphysiol.1990.sp017937	43	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14611	14618		10.1074/jbc.270.24.14611	http://dx.doi.org/10.1074/jbc.270.24.14611			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782324	hybrid			2022-12-25	WOS:A1995RD45500058
J	RANDAZZO, PA; TERUI, T; STURCH, S; FALES, HM; FERRIGE, AG; KAHN, RA				RANDAZZO, PA; TERUI, T; STURCH, S; FALES, HM; FERRIGE, AG; KAHN, RA			THE MYRISTOYLATED AMINO-TERMINUS OF ADP-RIBOSYLATION FACTOR-1 IS A PHOSPHOLIPID-SENSITIVE AND GTP-SENSITIVE SWITCH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLTRANSFERASE; ADENYLATE-CYCLASE; BINDING PROTEINS; GOLGI MEMBRANES; SACCHAROMYCES-CEREVISIAE; REGULATORY COMPONENT; NUCLEOTIDE-BINDING; RNA-POLYMERASE; CHOLERA-TOXIN; CLONED GENES	ADP-ribosylation factor 1 (Arf1) is an essential N-myristoylated 21-kDa GTP-binding protein with activities that include the regulation of membrane traffic and phospholipase D activity. Both the N terminus of the protein and the N-myristate bound to glycine 2 have previously been shown to be essential to the function of Arf in cells. We show that the bound nucleotide affects the conformation of either the N terminus or residues of Arf1 that are in direct contact with the N terminus. This was demonstrated by examining the effects of mutations in this N-terminal domain on guanosine 5'-O-(3-thio)triphosphate (GTP gamma S) and GDP binding and dissociation kinetics. Arf1 mutants, lacking 13 or 17 residues from the N terminus or mutated at residues 3-7, had a greater affinity for GTP gamma S and a lower affinity for GDP than did the wild-type protein. As the N terminus is required for interactions with target proteins, we conclude that the N terminus of Arf1 is a GTP-sensitive effector domain. When Arf1 was acylated, the GTP-dependent conformational changes were codependent on added phospholipids. In the absence of phospholipids, myristoylated Arf1 has a lower affinity for GTP gamma S than for GDP, and in the presence of phospholipids, the myristoylated protein has a greater affinity for GTP gamma S than for GDP. Thus, N-myristoylation is a critical component in the construction of this phospholipid- and GTP-dependent switch.	MAXENT SOLUT LTD, CAMBRIDGE CB75 QS1, ENGLAND		RANDAZZO, PA (corresponding author), NCI, DIV CANC TREATMENT,DEV THERAPEUT PROGRAM, BIOL CHEM LAB,BLDG 37, RM 5D-02, BETHESDA, MD 20892 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BROWN HA, 1973, CELL, V75, P113; CHA S, 1970, J BIOL CHEM, V245, P4814; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FERRIGE AG, 1991, MAXIMUM ENTROPY BAYE, P327; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HAMEL E, 1984, J BIOL CHEM, V259, P1060; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HAYAKAWA T, 1992, GENE, V119, P273, DOI 10.1016/0378-1119(92)90282-T; HONG JX, 1994, J BIOL CHEM, V269, P9743; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; KHAN R, 1992, J BIOL CHEM, V267, P13039; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LODGE JK, 1994, J BIOL CHEM, V269, P2996; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; RANDAZZO PA, 1992, J BIOL CHEM, V267, P18182; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; RANDAZZO PA, 1995, IN PRESS METHODS ENZ; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; ROSENWALD AG, 1994, CHALL MOD MED, V6, P143; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; WEISS O, 1989, J BIOL CHEM, V264, P21066; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	49	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14809	14815		10.1074/jbc.270.24.14809	http://dx.doi.org/10.1074/jbc.270.24.14809			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782347	hybrid			2022-12-25	WOS:A1995RD45500085
J	SAITO, T; KAWABATA, SI; HIRATA, M; IWANAGA, S				SAITO, T; KAWABATA, SI; HIRATA, M; IWANAGA, S			A NOVEL TYPE OF LIMULUS LECTIN-L6 - PURIFICATION, PRIMARY STRUCTURE, AND ANTIBACTERIAL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; CRAB TACHYPLEUS-TRIDENTATUS; ENDOTOXIN-BINDING PROTEIN; C-REACTIVE PROTEIN; HORSESHOE-CRAB; FLUOROGENIC REAGENT; AMEBOCYTE LYSATE; POLYPHEMUS; HEMOCYTES; PEPTIDES	Lipopolysaccharide (LPS)-binding protein(s) was first screened in the detergent extract of horseshoe crab (limulus) hemocytes, using LPS-immobilized agarose. A protein, designated L6 (M(r) = 27,000), was found to bind to LPS-agarose and was eluted with EDTA or o-phenanthroline. The L6 protein, however, did not inhibit the LPS-mediated activation of a limulus serine protease zymogen factor C. L6 had an affinity to the matrix: of Sepharose CL-6B itself, and it could be eluted with high concentrations of monosaccharides (0.5-1.0 M), such as glucose, mannose, and galactose, suggesting a lectin-like nature. The entire amino acid sequence of L6 was determined by sequencing peptides derived from CNBr sind enzymatic cleavages. L6 contained 7 half-cystines, and 1 cysteine residue at position 201 had a free SH-group. In addition, positions of the remaining three intrachain disulfide bonds were assigned by amino acid and sequence analyses of three cystinyl peptides produced by lysyl endopeptidase digestion. These results indicated that the entire sequence of L6 consisted of 221 residues with no N-linked sugar and was composed of six tandem repeats, each consisting of 33-38 amino acid residues. Inductively coupled plasma spectrometry of L6 indicated the presence of 0.75 mol zinc/mol of protein. No significant sequence homology was observed between L6 and other proteins, including various animal lectins and LPS-binding proteins. However, L6 showed agglutinating activity on LPS-coated sheep erythrocytes;md Gram-negative and Gram-positive bacteria, it inhibited the growth of Gram-negative bacteria, and thus it presumably recognizes carbohydrate components in the cell wall of bacteria.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,HIGASHI KU,FUKUOKA 81281,JAPAN; KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT MOLEC BIOL,HIGASHI KU,FUKUOKA 81281,JAPAN; IWATE MED UNIV,SCH MED,DEPT BACTERIOL,MORIOKA,IWATE 020,JAPAN	Kyushu University; Kyushu University; Iwate Medical University				Saito, Tetsu/0000-0002-9045-6743				AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ARMSTRONG PB, 1991, IMMUNOLOGY INSECTS O, P4; BRANDIN ER, 1983, BIOCHEM BIOPH RES CO, V113, P611, DOI 10.1016/0006-291X(83)91770-9; Brehelin M., 1986, IMMUNITY INVERTEBRAT; FUJII N, 1992, J BIOL CHEM, V267, P22452; HARLOW E, 1989, ANTIBODIES LABORATOR, P471; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HIRATA M, 1990, ADV EXP MED BIOL, V256, P287; IWANAGA S, 1992, THROMB RES, V68, P1, DOI 10.1016/0049-3848(92)90124-S; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRICK JW, 1993, ANTIMICROB AGENTS CH, V37, P2534, DOI 10.1128/AAC.37.12.2534; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; LIANG SM, 1980, J BIOL CHEM, V255, P5586; MARCHALONIS JJ, 1968, J MOL BIOL, V32, P467; MEGA T, 1991, J BIOCHEM-TOKYO, V109, P600, DOI 10.1093/oxfordjournals.jbchem.a123426; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; MIURA Y, 1994, J BIOL CHEM, V269, P542; MIYATA T, 1989, J BIOCHEM, V106, P663, DOI 10.1093/oxfordjournals.jbchem.a122913; MORITA T, 1985, J BIOCHEM, V97, P1611, DOI 10.1093/oxfordjournals.jbchem.a135218; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NGUYEN NY, 1986, J BIOL CHEM, V261, P456; OPPENHEIM JD, 1974, BIOCHEM BIOPH RES CO, V58, P1127, DOI 10.1016/S0006-291X(74)80260-3; Ornberg R.L., 1979, Progress in Clinical and Biological Research, V29, P125; PENKE B, 1974, ANAL BIOCHEM, V60, P45, DOI 10.1016/0003-2697(74)90129-8; ROBEY FA, 1981, J BIOL CHEM, V256, P969; ROCHE AC, 1974, BIOCHIM BIOPHYS ACTA, V371, P242, DOI 10.1016/0005-2795(74)90174-3; ROTH RI, 1993, INFECT IMMUN, V61, P1033, DOI 10.1128/IAI.61.3.1033-1039.1993; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; SHIMIZU S, 1977, BIOCHIM BIOPHYS ACTA, V500, P71, DOI 10.1016/0304-4165(77)90047-2; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; SRIMAL S, 1985, BIOCHEM J, V230, P321, DOI 10.1042/bj2300321; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; SUEYOSHI T, 1985, J BIOCHEM-TOKYO, V97, P1811, DOI 10.1093/oxfordjournals.jbchem.a135241; TOYOOKA T, 1985, ANAL CHEM, V57, P1931, DOI 10.1021/ac00286a032; TOYOOKA T, 1984, ANAL CHEM, V56, P2461, DOI 10.1021/ac00277a044; YAMAMOTO A, 1989, J BIOCHEM-TOKYO, V106, P552, DOI 10.1093/oxfordjournals.jbchem.a122892	39	77	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14493	14499		10.1074/jbc.270.24.14493	http://dx.doi.org/10.1074/jbc.270.24.14493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782311	hybrid			2022-12-25	WOS:A1995RD45500041
J	ZONDAG, GCM; KONINGSTEIN, GM; JIANG, YP; SAP, J; MOOLENAAR, WH; GEBBINK, MFBG				ZONDAG, GCM; KONINGSTEIN, GM; JIANG, YP; SAP, J; MOOLENAAR, WH; GEBBINK, MFBG			HOMOPHILIC INTERACTIONS MEDIATED BY RECEPTOR TYROSINE PHOSPHATASE-MU AND PHOSPHATASE-KAPPA - A CRITICAL ROLE FOR THE NOVEL EXTRACELLULAR MAM DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEURONAL RECOGNITION MOLECULE; FAMILY; PROTEINS; CLONING; REGION	The receptor-like protein tyrosine phosphatases (RPTP) mu and RPTP kappa have a modular ectodomain consisting of four fibronectin type III-like repeats, a single Ig-like domain, and a newly identified N-terminal MAM domain, The function of the latter module, which comprises about 160 amino acids and is found in diverse transmembrane proteins, is not known, We previously reported that both RPTP mu, and RPTP kappa can mediate homophilic cell interactions when expressed in insect cells, Here we show that despite their striking structural similarity, RPTP mu and RPTP kappa fail to interact in a heterophilic manner, To examine the role of the MAM domain in homophilic binding, we expressed a mutant RPTP mu lacking the MAM domain in insect Sf9 cells, Truncated RPTP mu is properly expressed at the cell surface but fails to promote cell-cell adhesion, Homophilic cell adhesion is fully restored in a chimeric RPTP mu molecule containing the MAM domain of RPTP kappa. However, this chimeric RPTP mu does not interact with either RPTP mu or RPTP kappa, These results indicate that the MAM domain of RPTP mu and RPTP kappa is essential for homophilic cell cell interaction and helps determine the specificity of these interactions.	NETHERLANDS CANC INST, DIV CELLULAR BIOCHEM, 1066 CX AMSTERDAM, NETHERLANDS; NYU, CTR MED, DEPT PHARMACOL, NEW YORK, NY 10016 USA	Netherlands Cancer Institute; New York University								BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CRAIG SS, 1987, AM J PHYSIOL, V253, pC535, DOI 10.1152/ajpcell.1987.253.4.C535; DEVEREUX J, 1989, NUCLEIC ACIDS RES, V12, P387; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; HIRATA T, 1993, NEUROSCI RES, V17, P159, DOI 10.1016/0168-0102(93)90092-5; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; SAP J, 1994, MOL CELL BIOL, V14, P1; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	19	144	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14247	14250		10.1074/jbc.270.24.14247	http://dx.doi.org/10.1074/jbc.270.24.14247			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782276	hybrid			2022-12-25	WOS:A1995RD45500002
J	GOUBIN, F; DUCOMMUN, B				GOUBIN, F; DUCOMMUN, B			IDENTIFICATION OF BINDING DOMAINS ON THE P21(CIP1) CYCLIN-DEPENDENT KINASE INHIBITOR	ONCOGENE			English	Article						CYCLIN-DEPENDENT KINASE INHIBITORS; P21CIP1; CDK2; PCNA	CELL NUCLEAR ANTIGEN; CONTROL GENE CDC2; SCANNING MUTAGENESIS; PROTEIN; SEQUENCE; SUC1; P21	Members of the recently discovered family of cyclin-dependent kinases inhibitors (CKIs) appear to play an essential regulatory role in the control of cell proliferation. To investigate the molecular basis of the interaction between these proteins and the cyclin-dependent kinases (CDKs), we performed a systematic mutagenesis of the CKI family member p21Cip1 using the alanine-scanning strategy. We have examined the interaction between in vitro translated human cdk2, cyclins A and D1, purified proliferating cell nuclear antigen (PCNA) and a set of human p21Cip1 mutants fused to glutathione S-transferase. Independent domains that are required for the interaction with cdk2 and with PCNA have been identified. The cdk2 binding domain is located in the N-terminal part of the protein, between residues 45 and 60, a region that is fully conserved in the p27Kip1 inhibitor. A PCNA binding region was localised to the C-terminus of the protein, between residues 142 and 163. These findings define protein motifs that are highly conserved between members of the CKI family and that are likely to play an essential function in the regulation of the G1/S transition.	UNIV TOULOUSE 3, PHARMACOL & TOXICOL FONDAMENTALES LAB, CNRS, F-31077 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier			DUCOMMUN, Bernard/B-3208-2008	DUCOMMUN, Bernard/0000-0002-7126-8368				BRAMBILLA P, 1992, SPR COLD HARB S QUAN, V56, P515; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DOWNES CS, 1994, BIOESSAYS, V16, P75, DOI 10.1002/bies.950160112; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WETZEL R, 1988, PROTEIN ENG, V2, P1, DOI 10.1093/protein/2.1.1; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	40	136	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2281	2287						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784076				2022-12-25	WOS:A1995RE54300002
J	WEINBERG, WC; AZZOLI, CG; CHAPMAN, K; LEVINE, AJ; YUSPA, SH				WEINBERG, WC; AZZOLI, CG; CHAPMAN, K; LEVINE, AJ; YUSPA, SH			P53-MEDIATED TRANSCRIPTIONAL ACTIVITY INCREASES IN DIFFERENTIATING EPIDERMAL-KERATINOCYTES IN ASSOCIATION WITH DECREASED P53 PROTEIN	ONCOGENE			English	Article						P53; EPIDERMIS; DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; WAF1; MDM-2	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; LARGE T-ANTIGEN; DNA-BINDING; MONOCLONAL-ANTIBODIES; MALIGNANT PROGRESSION; ACTIVATING MUTATIONS; CELL-DIFFERENTIATION; EPITHELIAL-CELLS; GROWTH-FACTOR	The regulation of p53 protein synthesis and p53-mediated gene transactivation mere evaluated in cultured mouse keratinocytes maintained as basal cells or induced to differentiate by Ca2+>0.1 mM. p53 protein half-life, p53 protein synthesis and the level of p53 mRNA decreased during terminal differentiation, as detected by immunoprecipitation ,vith a panel of p53-specific antibodies and Northern blotting. Thus differentiating keratinocytes have lower levels of p53 protein. This decline is not observed following growth arrest alone, or in papilloma cell lines which do not terminally differentiate in response to Ca2+. In contrast, the ability of endogenous p53 to transactivate transcription from the PGI, CAT plasmid increased during differentiation in vitro. This change in activity cannot be explained by changes in p53 conformation or nuclear localization. Consistent with these findings, mRNA for the p53-mediated genes WAF1 and mdm-2 increased with Ca2+-induced differentiation in a time dependent manner, suggesting activation of p53 contributes to the differentiated phenotype. However, p53-null mice exhibit histologically normal skin and epidermal keratinocytes from these mice express the appropriate markers of differentiation and suppression of DNA synthesis in vitro when the [Ca2+] is >0.1 mM. The observation that proliferating cells have higher levels of p53 protein which is less active for its function than differentiated cell types could have a consequence for the selection of p53 gene mutations during carcinogenesis, depending upon the stage of differentiation of the tumor cell type.	PRINCETON UNIV,DEPT MOLEC BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544	Princeton University	WEINBERG, WC (corresponding author), NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BLDG 37,BETHESDA,MD 20892, USA.		Weinberg, Wendy/A-8920-2009					ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOND JA, 1994, ONCOGENE, V9, P1885; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; BURNS PA, 1991, ONCOGENE, V6, P2363; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOTTO GP, 1988, MOL CARCINOGEN, V1, P171, DOI 10.1002/mc.2940010305; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GINSBERG D, P NATL ACAD SCI US; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HAINAUT P, 1993, CANCER RES, V53, P4469; HALEVY O, 1993, BIOCHEM BIOPH RES CO, V192, P714, DOI 10.1006/bbrc.1993.1473; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTLEY JA, 1985, CANCER RES, V45, P4864; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUFF CA, 1993, J BIOL CHEM, V268, P377; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KINJILAL S, 1993, CANCER RES, V53, P2961; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAGANO T, 1993, ARCH DERMATOL, V129, P1157, DOI 10.1001/archderm.129.9.1157; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REISS M, 1993, CANCER RES, V53, P899; RUGGERI B, 1991, CANCER RES, V51, P6615; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SPANDAU DF, 1994, ONCOGENE, V9, P1861; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STRICKLAND JE, 1988, CANCER RES, V48, P165; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAGUCHI M, 1994, J INVEST DERMATOL, V103, P500, DOI 10.1111/1523-1747.ep12395643; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINBERG WC, 1994, CANCER RES, V54, P5584; WEINBERG WC, 1990, DIFFERENTIATION, V45, P168, DOI 10.1111/j.1432-0436.1990.tb00470.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; YUSPA SH, 1985, METHODS SKIN RES, P213; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1994, CANCER RES, V54, P4448	90	102	103	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2271	2279						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784075				2022-12-25	WOS:A1995RE54300001
J	CRERAR, MM; KARLSSON, O; FLETTERICK, RJ; HWANG, PK				CRERAR, MM; KARLSSON, O; FLETTERICK, RJ; HWANG, PK			CHIMERIC MUSCLE AND BRAIN GLYCOGEN PHOSPHORYLASES DEFINE PROTEIN DOMAINS GOVERNING ISOZYME-SPECIFIC RESPONSES TO ALLOSTERIC ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-TISSUES; RABBIT MUSCLE; HUMAN-LIVER; BINDING; EXPRESSION; AMP; QUANTITATION; EVOLUTION; MECHANISM; FAMILY	Muscle and brain glycogen phosphorylases differ in their responses to activation by phosphorylation and AMP. The muscle isozyme is potently activated by either phosphorylation or AMP. In contrast, the brain isozyme is poorly activated by phosphorylation and its phosphorylated a form is more sensitive to AMP activation when enzyme activity is measured in substrate concentrations and temperatures encountered in the brain. The nonphosphorylated b form of the brain isozyme also differs from the muscle isozyme b form in its stronger affinity and lack: of cooperativity for AMP. To identify the structural determinants involved, six enzyme forms, including four chimeric enzymes containing exchanges in amino acid residues 1-88, 89-499, and 500-842 (C terminus), were constructed from rabbit muscle and human brain phosphorylase cDNAs, expressed in Escherichia coli, and purified. Kinetic analysis of the b forms indicated that the brain isozyme amino acid 1-88 and 89-499 regions each contribute in an additive fashion to the formation of an AMP site with higher intrinsic affinity but weakened cooperativity, while the same regions of the muscle isozyme each contribute to greater allosteric coupling but weaker AMP affinity. Kinetic analysis of the a forms indicated that the amino acid 89-499 region correlated with the reduced response of the brain isozyme to activation by phosphorylation and the resultant increased sensitivity of the a form to activation by saturating levels of AMP. This isozyme specific response also correlated with the glycogen affinity of the a forms. Enzymes containing the brain isozyme amino acid 89-499 region exhibited markedly reduced glycogen affinities in the absence of AMP compared to enzymes containing the corresponding muscle isozyme region. Additionally, AMP led to greater increases in glycogen affinity of the former set of enzymes. In contrast, phosphate affinities of all a forms were similar in the absence of AMP and increased approximately the same extent in AMP. The potential importance of a number of isozyme-specific substitutions in these sequence regions is discussed.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	CRERAR, MM (corresponding author), YORK UNIV, DEPT BIOL, 4700 KEELE ST, N YORK, ON M3J 1P3, CANADA.				NIDDK NIH HHS [DK32822] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032822] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acharya K.R., 1991, GLYCOGEN PHOSPHORYLA, V2nd; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BARFORD D, 1992, PROTEIN SCI, V1, P472; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1992, BIOCHEMISTRY-US, V31, P11297, DOI 10.1021/bi00161a006; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; BROWNER MF, 1992, BIOCHEMISTRY-US, V31, P11291, DOI 10.1021/bi00161a005; BUCHBINDER JL, 1995, IN PRESS BIOCHEMISTR; CARNEY IT, 1978, ANAL BIOCHEM, V85, P321, DOI 10.1016/0003-2697(78)90309-3; COATS WS, 1991, J BIOL CHEM, V266, P16113; CRERAR MM, 1988, GENOME, V30, P582, DOI 10.1139/g88-098; DAVID ES, 1986, BIOCHIM BIOPHYS ACTA, V880, P78, DOI 10.1016/0304-4165(86)90122-4; GELINAS RP, 1989, MOL BRAIN RES, V6, P177, DOI 10.1016/0169-328X(89)90052-1; GEVERS G, 1981, BIOCHEM J, V193, P793, DOI 10.1042/bj1930793; GLASER T, 1989, GENOMICS, V5, P510, DOI 10.1016/0888-7543(89)90017-7; GOLDSMITH EJ, 1989, SCIENCE, V245, P528, DOI 10.1126/science.2756432; GOLDSMITH EJ, 1989, T AM CHEM ASS, V25, P87; GUENARD D, 1977, EUR J BIOCHEM, V76, P447, DOI 10.1111/j.1432-1033.1977.tb11614.x; HUDSON JW, 1993, BIOCHIM BIOPHYS ACTA, V1164, P197, DOI 10.1016/0167-4838(93)90248-P; HUDSON JW, 1993, J MOL BIOL, V234, P700, DOI 10.1006/jmbi.1993.1621; JOHNSON LN, 1993, J MOL BIOL, V232, P253, DOI 10.1006/jmbi.1993.1380; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; JOHNSON LN, 1990, J MOL BIOL, V211, P645, DOI 10.1016/0022-2836(90)90271-M; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P1290; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1967, J BIOL CHEM, V242, P271; LUONG CBH, 1992, J CHROMATOGR-BIOMED, V584, P77, DOI 10.1016/0378-4347(92)80011-E; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NEWGARD CB, 1988, J BIOL CHEM, V263, P3850; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; PICKETTGIES CA, 1985, J BIOL CHEM, V260, P2046; RATH VL, 1987, PROTEINS, V2, P225, DOI 10.1002/prot.340020307; RICHTER F, 1983, BIOMED BIOCHIM ACTA, V42, P1229; RISMAN CA, 1991, BIOCHEM CELL BIOL, V69, P251, DOI 10.1139/o91-038; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Sambrook J, 1989, MOL CLONING LABORATO; SATO K, 1976, CANCER RES, V36, P487; Segel I.H., 1975, ENZYME KINETICS; SPRANG S, 1987, SCIENCE, V237, P1012, DOI 10.1126/science.3616621; SPRANG SR, 1991, SCIENCE, V254, P1367, DOI 10.1126/science.1962195; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0	43	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13748	13756		10.1074/jbc.270.23.13748	http://dx.doi.org/10.1074/jbc.270.23.13748			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775430	hybrid			2022-12-25	WOS:A1995RC44800027
J	LYNCH, JW; RAJENDRA, S; BARRY, PH; SCHOFIELD, PR				LYNCH, JW; RAJENDRA, S; BARRY, PH; SCHOFIELD, PR			MUTATIONS AFFECTING THE GLYCINE RECEPTOR AGONIST TRANSDUCTION MECHANISM CONVERT THE COMPETITIVE ANTAGONIST, PICROTOXIN, INTO AN ALLOSTERIC POTENTIATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; AMINOBUTYRIC-ACID; MULTIPLE MECHANISMS; CHLORIDE CURRENT; GABA RESPONSES; BETA-SUBUNIT; NEURONS; CHANNELS; RAT	Contrary to its effects on the gamma-aminobutyric acid type A receptor, picrotoxin antagonism of the alpha 1 subunit of the human glycine receptor is shown to be competitive, not use-dependent, and nonselective between the picrotoxin components, picrotin, and picrotoxinin. Competitive antagonism and non-use dependence are consistent with picrotoxin binding to a site in the extracellular domain. The mutations Arg --> Leu or Arg --> Gln at residue 271 of the glycine receptor alpha 1 subunit, which are both associated with human startle disease, have previously been demonstrated to disrupt the transduction process between agonist binding and channel activation, We show here that these mutations also transform picrotoxin from an allosterically acting competitive antagonist to an allosteric potentiator at low (0.01-3 mu M) concentrations and to a noncompetitive antagonist at higher (greater than or equal to 3 mu M) concentrations. This demonstrates that arginine 271 is involved in the transduction process between picrotoxin binding and its mechanism of action, Thus, the allosteric transduction pathways of both agonists and antagonists converge at a common residue prior to the activation gate of the channel, suggesting that this residue may act as an integration point for information from various extracellular ligand binding sites.	UNIV NEW S WALES, SCH PHYSIOL & PHARMACOL, SYDNEY, NSW 2052, AUSTRALIA	University of New South Wales Sydney	LYNCH, JW (corresponding author), ST VINCENTS HOSP, GARVAN INST MED RES, 384 VICTORIA ST, DARLINGHURST, NSW 2010, AUSTRALIA.		Lynch, Joseph/C-8636-2009; Schofield, Peter/C-9669-2011	Schofield, Peter/0000-0003-2967-9662				AKAIKE N, 1985, EXPERIENTIA, V41, P70; AKAIKE N, 1986, J PHYSIOL-LONDON, V379, P171, DOI 10.1113/jphysiol.1986.sp016246; AKAIKE N, 1987, CELL MOL NEUROBIOL, V7, P97, DOI 10.1007/BF00734993; AKAIKE N, 1989, J NEUROPHYSIOL, V62, P1400, DOI 10.1152/jn.1989.62.6.1400; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; BETZ H, 1988, NEUROCHEM INT, V13, P137, DOI 10.1016/0197-0186(88)90048-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONSTANTI A, 1976, BRIT J PHARMACOL, V57, P347, DOI 10.1111/j.1476-5381.1976.tb07673.x; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Curtis D.R., 1974, NEUROPOISONS THEIR P, P207; DEVILLERSTHIERY A, 1992, NEUROREPORT, V3, P1001, DOI 10.1097/00001756-199211000-00014; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; GALLAGHER JP, 1978, J PHYSIOL-LONDON, V275, P263, DOI 10.1113/jphysiol.1978.sp012189; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERZ JM, 1989, J BIOL CHEM, V264, P12439; HILLE B, 1992, IONIC CHANNELS EXCIT, P390; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLAND KD, 1990, J NEUROSCI, V10, P1719; INOUE M, 1988, NEUROSCI RES, V5, P380, DOI 10.1016/0168-0102(88)90024-7; LANGOSCH D, 1994, EMBO J, V13, P4223, DOI 10.1002/j.1460-2075.1994.tb06742.x; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; PORTER NM, 1992, MOL PHARMACOL, V42, P872; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; RAJENDRA S, 1995, TRENDS NEUROSCI, V18, P80; RAJENDRA S, 1994, J BIOL CHEM, V269, P18739; RAJENDRA S, 1995, NEURON, V14, P169, DOI 10.1016/0896-6273(95)90251-1; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; SIMMONDS MA, 1982, EUR J PHARMACOL, V80, P347; SMART TG, 1986, PROC R SOC SER B-BIO, V227, P191, DOI 10.1098/rspb.1986.0019; TAKEUCHI A, 1969, J PHYSIOL-LONDON, V205, P377, DOI 10.1113/jphysiol.1969.sp008972; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VALENZUELA CF, 1994, BIOPHYS J, V66, P674, DOI 10.1016/S0006-3495(94)80841-0; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; YAKUSHIJI T, 1987, NEUROSCIENCE, V22, P1123, DOI 10.1016/0306-4522(87)92987-3; YOON KW, 1993, J PHYSIOL-LONDON, V464, P423, DOI 10.1113/jphysiol.1993.sp019643; ZHANG HG, 1994, J PHYSIOL-LONDON, V479, P65, DOI 10.1113/jphysiol.1994.sp020278	45	105	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13799	13806		10.1074/jbc.270.23.13799	http://dx.doi.org/10.1074/jbc.270.23.13799			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775436	hybrid			2022-12-25	WOS:A1995RC44800035
J	SUPEKOVA, L; SUPEK, F; NELSON, N				SUPEKOVA, L; SUPEK, F; NELSON, N			THE SACCHAROMYCES-CEREVISIAE VMA10 IS AN INTRON-CONTAINING GENE ENCODING A NOVEL 13-KDA SUBUNIT OF VACUOLAR H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; MUTATIONAL ANALYSIS; YEAST; MEMBRANE; TRIPHOSPHATASE; ACIDIFICATION; POLYPEPTIDE; EVOLUTION; PROTEINS; COMPLEX	The vacuolar H+-ATPase (V-ATPase) functions as a primary proton pump that generates an electrochemical gradient of protons across the membranes of several internal organelles. It is composed of distinct catalytic and membrane sectors, each containing several subunits. We identified a protein (M16) that copurifies with the V-ATPase complex from Saccharomyces cerevisiae and appears to be present at multiple copies/enzyme. Amino acid sequencing of its proteolytic products yielded three nonoverlapping peptide sequences matching an unidentified reading frame located on chromosome VIII. Sequence analysis of cDNA encoding M16 revealed that the gene encoding this protein (VMA10) is interrupted by a 162-nucleotide intron that begins after the ATG codon of the initiator methionine. The cDNA encodes an hydrophilic protein of 12,713 Da with a basic isoelectric point of pH 9. A Delta vma10::URA3 null mutant exhibited growth characteristics typical of other vma disruptant mutants in genes encoding subunits of V-ATPase. The null mutant does not grow on medium buffered at pH 7.5. It fails to accumulate quinacrine into its vacuole, and subunits of the catalytic sector are not assembled onto the vacuolar membrane in the absence of M16. A cold inactivation experiment demonstrated that M16 is a subunit of the membrane sector of V-ATPase. M16 exhibits a significant sequence homology with subunit b of F-ATPase membrane sector.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA	Roche Holding								ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; FANGER BO, 1987, ANAL BIOCHEM, V162, P11, DOI 10.1016/0003-2697(87)90004-2; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; GRAF R, 1994, J BIOL CHEM, V269, P3767; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; HO MN, 1993, J BIOL CHEM, V268, P18286; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NELSON N, 1995, ORGANELLAR PROTON AT; NELSON N, 1988, METHOD ENZYMOL, V157, P619; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Sambrook J, 1989, MOL CLONING LABORATO; Sherman F., 1983, METHODS YEAST GENETI; SUPEK F, 1994, J BIOL CHEM, V269, P26479; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; TAKASE K, 1994, J BIOL CHEM, V269, P11037; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WANG SY, 1988, J BIOL CHEM, V263, P17638; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	44	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13726	13732						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775427				2022-12-25	WOS:A1995RC44800024
J	RIIKONEN, T; WESTERMARCK, J; KOIVISTO, L; BROBERG, A; KAHARI, VM; HEINO, J				RIIKONEN, T; WESTERMARCK, J; KOIVISTO, L; BROBERG, A; KAHARI, VM; HEINO, J			INTEGRIN ALPHA-2-BETA-1 IS A POSITIVE REGULATOR OF COLLAGENASE (MMP-1) AND COLLAGEN ALPHA-1(I) GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; FIBRONECTIN RECEPTOR; CELL-ADHESION; MESSENGER-RNA; VLA-2; ANTIGEN; IDENTIFICATION; REORGANIZATION; HOMOLOGY; LAMININ	A classical model for studying the effects of extracellular matrix is to culture cells inside a three-dimensional collagen gel. When surrounded by fibrillar collagen, many cell types decrease the production of type I collagen, and the expression of interstitial collagenase (matrix metalloproteinase-l; MMP-1) is simultaneously induced. To study the role of the collagen-binding integrins (alpha 1 beta 1 and alpha 2 beta 1 in this process, we used three different osteogenic cell lines with distinct patterns of putative collagen receptors: HOS cells, which express only alpha 1 beta 1 integrin, MG-63 cells, which express only alpha 2 beta 1 integrin, and KHOS-240 cells, which express both. Inside collagen gels, alpha 1(I) collagen mRNA levels were decreased in HOS and KHOS-240 cells but not in MG-63 cells. In contrast, MMP-1 expression was induced in KHOS-240 and MG-63 cells but not in HOS cells. Transfection of MG-63 cells with alpha 2 integrin cDNA produced cell clones overexpressing alpha 2 beta 1 integrin. Transfection of MG-63 cells with alpha 2 integrin cDNA in an antisense orientation reduced the expression level of alpha 2 integrin. These cell clones showed induction and reduction of mRNA levels for MMP-1, respectively. HOS cells normally lacking alpha 2 beta 1 integrin mere forced to express it, and this prevented the down-regulation in the levels of (alpha 1(I) collagen mRNA when cells were grown inside collagen gels. The data indicate that the level of MMP-1 expression is regulated by the collagen receptor alpha 2 beta 1 integrin. The down-regulation of collagen alpha 1(I) is mediated by another receptor. Integrin alpha 2 beta 1 may compete with it and thus be a positive regulator of collagen synthesis.	UNIV TURKU,MEDICITY RES LAB,SF-20520 TURKU,FINLAND; UNIV TURKU,DEPT MED BIOCHEM,SF-20520 TURKU,FINLAND; UNIV TURKU,DEPT DERMATOL,SF-20520 TURKU,FINLAND	University of Turku; University of Turku; University of Turku			Kähäri, Veli-Matti/E-5144-2011; Westermarck, Jukka/AAL-6464-2020; Kahari, Veli-Matti/T-4925-2019	Kähäri, Veli-Matti/0000-0003-2421-9368; Westermarck, Jukka/0000-0001-7478-3018; Kahari, Veli-Matti/0000-0003-2421-9368				AKIYAMA SK, 1990, CANCER RES, V50, P1601; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHIRGMAN JM, 1979, BIOCHEMISTRY-US, V10, P5294; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; ECKES B, 1993, FEBS LETT, V318, P128; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HEINO J, 1989, J BIOL CHEM, V264, P21806; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IVARSSON M, 1993, J INVEST DERMATOL, V101, P216, DOI 10.1111/1523-1747.ep12364810; KATAMA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1994, J BIOL CHEM, V269, P22811; KLEIN CE, 1991, J INVEST DERMATOL, V96, P281, DOI 10.1111/1523-1747.ep12464485; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; MAKELA JK, 1988, NUCLEIC ACIDS RES, V16, P349, DOI 10.1093/nar/16.1.349; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RIIKONEN T, 1995, J BIOL CHEM, V270, P376, DOI 10.1074/jbc.270.1.376; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SANTALA P, 1994, J BIOL CHEM, V269, P1276; SANTALA P, 1991, J BIOL CHEM, V266, P23505; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAKADA Y, 1987, NATURE, V326, P607, DOI 10.1038/326607a0; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	37	265	269	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13548	13552		10.1074/jbc.270.22.13548	http://dx.doi.org/10.1074/jbc.270.22.13548			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768957	hybrid			2022-12-25	WOS:A1995RB43900087
J	WANG, WY; POLAND, BW; HONZATKO, RB; FROMM, HJ				WANG, WY; POLAND, BW; HONZATKO, RB; FROMM, HJ			IDENTIFICATION OF ARGININE RESIDUES IN THE PUTATIVE L-ASPARTATE BINDING-SITE OF ESCHERICHIA-COLI ADENYLOSUCCINATE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLONING; SEQUENCE; PURA	Three arginine residues in the putative aspartate binding site of Escherichia coli adenylosuccinate synthetase were changed to leucines by site-directed mutagenesis. The mutant enzymes R303L, R304L, and R305L were purified to homogeneity on the basis of sodium dodecyl sulfate polyacrylamide gel electrophoresis and characterized by CD spectrometry and initial rate kinetics. CD spectral analysis indicated no differences in secondary structure between the mutants and the wild-type enzyme in the absence of substrates. The K-m values for GTP and IMP for the mutants and the mild-type enzyme were comparable. However, the mutant enzymes exhibited 50-200-fold increases in their values of K-m for the substrate aspartate relative to the wild-type enzyme. Although the K-m values for the mutant enzymes decreased, the changes were not as dramatic as those observed for the K-m of aspartate. The modeling of aspartate in the crystal structure of the complex of adenylosuccinate synthetase with IMP and MgGDP(-1) is consistent with the results of mutagenesis, placing the alpha- and beta- carboxylates of aspartate near the side chains of Arg-131, -303, and -305.	IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA	Iowa State University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; HAMPTON A, 1970, BIOCHIM BIOPHYS ACTA, V198, P594, DOI 10.1016/0005-2744(70)90136-1; KANG C, 1994, J BIOL CHEM, V269, P24046; KANG CH, 1994, ARCH BIOCHEM BIOPHYS, V310, P475, DOI 10.1006/abbi.1994.1195; KUSANO T, 1992, J BIOL CHEM, V267, P11242; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; MANTSALA P, 1992, J BACTERIOL, V174, P1883; POLAND BW, 1993, J BIOL CHEM, V268, P25334; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; RUDOLPH FB, 1971, THESIS IOWA STATE U; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPEISER DM, 1992, MOL CELL BIOL, V12, P5301, DOI 10.1128/MCB.12.12.5301; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; STAYTON MM, 1976, 172ND ANN M AM CHEM, P155; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WOLFE SA, 1988, J BIOL CHEM, V263, P19147	24	17	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13160	13163		10.1074/jbc.270.22.13160	http://dx.doi.org/10.1074/jbc.270.22.13160			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768911	hybrid			2022-12-25	WOS:A1995RB43900034
J	DESAINTES, C; HALLEZ, S; DETREMMERIE, O; BURNY, A				DESAINTES, C; HALLEZ, S; DETREMMERIE, O; BURNY, A			WILD-TYPE P53 DOWN-REGULATES TRANSCRIPTION FROM ONCOGENIC HUMAN PAPILLOMAVIRUS PROMOTERS THROUGH THE EPITHELIAL SPECIFIC ENHANCER	ONCOGENE			English	Article						HPV; P53; TBP; TRANSCRIPTION; EPITHELIAL ENHANCER	CARCINOMA CELL-LINES; OPEN READING FRAMES; NUCLEAR FACTOR-I; HUMAN KERATINOCYTES; GENE-EXPRESSION; SV40-TRANSFORMED CELLS; RESPONSIVE ELEMENT; BINDING PROTEIN; E6 ONCOPROTEIN; TUMOR-ANTIGEN	High-risk Human Papillomavirus (HPV) E6 and E7 immortalizing oncoproteins are expressed from promoter tightly regulated by an epithelial specific enhancer. To determine if the p53 tumour suppressor protein can modulate the transcription of these genes, we performed co-transfection experiments with plasmids containing the HPV type 16 or 18 long control regions linked to the chloramphenicol acetyl transferase gene, along with p53 expression vectors. Wild-type, but not mutant, murine or human p53 expression vectors reduced the activity of reporter constructs when co-transfected into HeLa or C33 cell lines. Mutations within the HPV TATA boxes did not significantly alter the levels of p53 repression, suggesting a TATA-independent mechanism. Deletion analyses mapped the p53-responsive domain to the constitutive 230 base pair epithelial specific enhancer. In addition, the enhancer could confer p53-mediated repression when placed upstream of a heterologous promoter.	FREE UNIV BRUSSELS,CHIM BIOL LAB,B-1640 RHODE ST GENESE,BELGIUM									AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BLANTON RA, 1992, CELL GROWTH DIFFER, V3, P791; CHONG T, 1990, NUCLEIC ACIDS RES, V18, P465, DOI 10.1093/nar/18.3.465; CRIPE T P, 1990, New Biologist, V2, P450; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CRUM CP, 1988, J VIROL, V62, P84, DOI 10.1128/JVI.62.1.84-90.1988; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GARCIACARRANCA A, 1988, J VIROL, V62, P4321, DOI 10.1128/JVI.62.11.4321-4330.1988; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GLOSS B, 1989, NUCLEIC ACIDS RES, V17, P3519, DOI 10.1093/nar/17.9.3519; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOPPESEYLER F, 1991, J VIROL, V65, P5613, DOI 10.1128/JVI.65.10.5613-5618.1991; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MAY M, 1994, EMBO J, V13, P1460, DOI 10.1002/j.1460-2075.1994.tb06400.x; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MOMMAND J, 1992, CELL, V69, P1237; MUNGER K, 1989, J VIROL, V63, P4417; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PEACOCK JW, 1994, EMBO J, V13, P1084, DOI 10.1002/j.1460-2075.1994.tb06357.x; PFISTER H, 1984, REV PHYSIOL BIOCH P, V99, P111, DOI 10.1007/BFb0027716; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICK.A, 1986, EMBO J, V5, P2285; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; THIERRY F, 1991, NEW BIOL, V3, P90; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; THIERRY F, 1987, CANCER CELL, V5, P23; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	64	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2155	2161						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784059				2022-12-25	WOS:A1995RB70300010
J	CIPPITELLI, M; SICA, A; VIGGIANO, V; YE, JP; GHOSH, P; BIRRER, MJ; YOUNG, HA				CIPPITELLI, M; SICA, A; VIGGIANO, V; YE, JP; GHOSH, P; BIRRER, MJ; YOUNG, HA			NEGATIVE TRANSCRIPTIONAL REGULATION OF THE INTERFERON-GAMMA PROMOTER BY GLUCOCORTICOIDS AND DOMINANT-NEGATIVE MUTANTS OF C-JUN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; DNA-BINDING; GENE-EXPRESSION; NUCLEAR FACTOR; LYMPHOCYTE-T; HUMAN INTERLEUKIN-2; SIGNALING PATHWAY; MAMMALIAN-CELLS; FAMILY MEMBERS; TATA BOX	Interferon-gamma (IFN-gamma) is an immunoregulatory cytokine expressed in large granular lymphocytes and T cells. However, the molecular mechanisms underlying IFN-gamma gene transcription have not been fully defined. Here, we analyze the mechanisms responsible for the inhibition of IFN-gamma promoter activity by the glucocorticoid hormone dexamethasone. Cotransfection assays performed in Jurkat T cells demonstrated that the activity of the initial 108 base pairs of the IFN-gamma promoter was down-regulated in the presence of dexamethasone. Furthermore, utilizing electrophoretic mobility shift analysis, we identified activator protein 1 AP-1-cAMP response element binding protein-activating transcription factor (CREB-ATF) binding elements situated in positions of the IFN-gamma promoter previously identified as essential for promoter activity. Moreover, dominant negative mutants of the c-Jun proto-oncogene were able to mimic the same down-regulatory effect exerted by dexamethasone, and mutations that abolished the binding of the AP-1 . CREB-ATF factors were able to block the glucocorticoid effect. These results suggest a model involving the inhibition of IFN-gamma AP-1 CREB-ATF DNA binding complexes as one of the mechanisms involved in the negative regulatory action of glucocorticoids on IFN-gamma gene expression and support the relevance of AP-1 . CREB-ATF binding factors during the transcriptional activation of the IFN-gamma promoter in T cells.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,EXPTL IMMUNOL LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; NCI,DIV CANC PREVENT & CONTROL,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD 20850	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Sica, Antonio/AAB-9546-2020; Ye, Jianping/N-1998-2017; Young, Howard/A-6350-2008	Ye, Jianping/0000-0003-3875-365X; CIPPITELLI, Marco/0000-0002-9620-538X; Young, Howard/0000-0002-3118-5111				ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARYA SK, 1984, J IMMUNOL, V133, P273; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOUMPAS DT, 1991, J CLIN INVEST, V87, P1739, DOI 10.1172/JCI115192; BOUMPAS DT, 1991, CLIN EXP RHEUMATOL, V9, P413; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BROWN DA, 1992, EUR J IMMUNOL, V22, P2419, DOI 10.1002/eji.1830220935; BROWN DA, 1991, EUR J IMMUNOL, V21, P1879, DOI 10.1002/eji.1830210815; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CHRIVIA JC, 1990, J EXP MED, V172, P661, DOI 10.1084/jem.172.2.661; CICCARONE VC, 1990, J IMMUNOL, V144, P725; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CULPEPPER J, 1987, LYMPHOKINES, V13, P275; DEGRAZIA U, 1994, J EXP MED, V180, P1485, DOI 10.1084/jem.180.4.1485; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HADMAN M, 1993, ONCOGENE, V8, P1895; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MARINE J, 1991, P NATL ACAD SCI USA, V88, P7284, DOI 10.1073/pnas.88.16.7284; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MUKAIDA N, 1992, IMMUNOLOGY, V75, P674; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NORTHROP JP, 1992, J EXP MED, V175, P1235, DOI 10.1084/jem.175.5.1235; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; PALIOGIANNI F, 1993, J CLIN INVEST, V91, P1481, DOI 10.1172/JCI116353; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; PETRAK D, 1994, J IMMUNOL, V153, P2046; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STAUBER C, 1992, NEW BIOL, V4, P527; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; VACCA A, 1990, J BIOL CHEM, V265, P8075; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YE JP, 1994, J BIOL CHEM, V269, P25728; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q; YOUNG HA, 1994, J IMMUNOL, V153, P3603; ZHANG XK, 1991, J BIOL CHEM, V266, P8248	65	114	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12548	12556		10.1074/jbc.270.21.12548	http://dx.doi.org/10.1074/jbc.270.21.12548			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759501	hybrid			2022-12-25	WOS:A1995QZ71100036
J	KONRAD, RJ; YOUNG, RA; RECORD, RD; SMITH, RM; BUTKERAIT, P; MANNING, D; JARETT, L; WOLF, BA				KONRAD, RJ; YOUNG, RA; RECORD, RD; SMITH, RM; BUTKERAIT, P; MANNING, D; JARETT, L; WOLF, BA			THE HETEROTRIMERIC G-PROTEIN G(I) IS LOCALIZED TO THE INSULIN SECRETORY GRANULES OF BETA-CELLS AND IS INVOLVED IN INSULIN EXOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; PERMEABILIZED RINM5F CELLS; ACYL-COA ESTERS; PANCREATIC-ISLETS; KINASE-C; HUMAN PLATELETS; GLUCOSE SENSOR; COMPOUND 48/80; ION CHANNELS; MALONYL-COA	Mastoparan, a tetradecapeptide found in wasp venom that stimulates G-proteins, increases insulin secretion from beta-cells. In this study, we have examined the role of heterotrimeric G-proteins in mastoparan-induced insulin secretion from the insulin-secreting beta-cell line beta-TC3. Mastoparan stimulated insulin secretion in a dose-dependent manner from digitonin-permeabilized beta-TC3 cells, Active mastoparan analogues mastoparan 7, mastoparan 8, and mastoparan X also stimulated secretion, Mastoparan 17, an inactive analogue of mastoparan, did not increase insulin secretion from permeabilized beta-TC3 cells, Mastoparan-induced insulin secretion from permeabilized beta-TC3 cells was inhibited by pretreatment of the cells with pertussis toxin, suggesting that mastoparan-induced insulin secretion is mediated through a pertussis toxin sensitive G-protein present distally in exocytosis. Enriched insulin secretory granules (ISG) were prepared by sucrose/nycodenz ultracentrifugation, Western immunoblotting performed on beta-TC3 ho mogenate and ISG demonstrated that G alpha(i) was dramatically enriched in ISG. Levels of G alpha(o) and G alpha(q) were comparable in homogenate and ISG. Mastoparan stimulated ISG GTPase activity in a pertussis toxin sensitive manner. Mastoparan 7 and mastoparan 8 also stimulated GTPase activity in the ISG, while the inactive analogue mastoparan 17 had no effect. Selective localization of G alpha(1) to ISG was confirmed with electron microscopic immunocytochemistry in beta-TC3 cells and beta-cells from rat pancreas, In contrast to G alpha(o) and G alpha(q), G alpha(i) was clearly localized to the ISG, Together, these data suggest that mastoparan may act through the heterotrimeric G-protein G alpha(i) located in the ISG of beta-cells to stimulate insulin secretion.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Ritchie, Rae/0000-0002-0693-0693	NIDDK NIH HHS [R01 DK28143, R01 DK43354] Funding Source: Medline; NIGMS NIH HHS [R01 GM34781] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028143, R01DK043354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM034781] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; BAFFY G, 1993, DIABETES, V42, P1878, DOI 10.2337/diabetes.42.12.1878; COLCA JR, 1985, BIOCHEM J, V228, P529, DOI 10.1042/bj2280529; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DANILENKO M, 1993, BIOCHEM BIOPH RES CO, V196, P1296, DOI 10.1006/bbrc.1993.2393; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; EASOM RA, 1990, J BIOL CHEM, V265, P14938; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HILLAIREBUYS D, 1992, MOL CELL BIOCHEM, V109, P133; HORISBERGER M, 1994, HISTOCHEMISTRY, V82, P219; HSU WH, 1991, J BIOL CHEM, V266, P837; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; JONES PM, 1993, MOL CELL ENDOCRINOL, V94, P97, DOI 10.1016/0303-7207(93)90056-P; JOYCEBRADY M, 1991, J BIOL CHEM, V266, P6859; KOMATSU M, 1993, J BIOL CHEM, V268, P23297; KONRAD RJ, 1992, BIOCHEM J, V287, P283, DOI 10.1042/bj2870283; KOWLURU A, 1994, BBA-MOL CELL RES, V1222, P360, DOI 10.1016/0167-4889(94)90041-8; KOWLURU A, 1994, BBA-MOL CELL RES, V1222, P348, DOI 10.1016/0167-4889(94)90040-X; LAW SF, 1992, MOL PHARMACOL, V42, P398; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MALAISSE WJ, 1979, METABOLISM, V28, P373, DOI 10.1016/0026-0495(79)90111-2; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; MONTMAYEUR JP, 1994, SCIENCE, V263, P95, DOI 10.1126/science.8272874; MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; NILSSON T, 1989, J BIOL CHEM, V264, P973; NORGAUER J, 1992, BIOCHEM J, V282, P393, DOI 10.1042/bj2820393; OLSZEWSKI S, 1994, J BIOL CHEM, V269, P27987; OZAKI Y, 1990, BIOCHEM BIOPH RES CO, V170, P779, DOI 10.1016/0006-291X(90)92159-W; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; ROBERTSON RP, 1991, DIABETES, V40, P1, DOI 10.2337/diabetes.40.1.1; ROSS EM, 1994, METHOD ENZYMOL, V297, P26; SEAQUIST ER, 1992, DIABETES, V41, P1390, DOI 10.2337/diabetes.41.11.1390; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOLER AP, 1989, P NATL ACAD SCI USA, V86, P6640, DOI 10.1073/pnas.86.17.6640; SUKUMAR M, 1992, J BIOL CHEM, V267, P21421; TANIMURA A, 1991, BIOCHEM BIOPH RES CO, V177, P802, DOI 10.1016/0006-291X(91)91860-F; TOMITA U, 1991, J BIOCHEM-TOKYO, V109, P184, DOI 10.1093/oxfordjournals.jbchem.a123342; TRAN D, 1993, CELL SIGNAL, V5, P565, DOI 10.1016/0898-6568(93)90052-N; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; ULLRICH S, 1988, J BIOL CHEM, V263, P8615; ULLRICH S, 1990, BIOCHEM J, V270, P273, DOI 10.1042/bj2700273; VALLAR L, 1987, J BIOL CHEM, V262, P5049; VITALE N, 1993, J BIOL CHEM, V268, P14715; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; WHEELERJONES CPD, 1991, BIOCHEM SOC T, V19, pS114, DOI 10.1042/bst019114s; WHEELERJONES CPD, 1992, BIOCHEM J, V281, P465, DOI 10.1042/bj2810465; WILLIAMS AG, 1990, BLOOD, V76, P721; WOLF BA, 1988, J BIOL CHEM, V263, P3565; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914	66	97	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12869	12876		10.1074/jbc.270.21.12869	http://dx.doi.org/10.1074/jbc.270.21.12869			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759545	hybrid			2022-12-25	WOS:A1995QZ71100082
J	LEE, SH; KIM, DK				LEE, SH; KIM, DK			THE ROLE OF THE 34-KDA SUBUNIT OF HUMAN REPLICATION PROTEIN-A IN SIMIAN-VIRUS-40 DNA-REPLICATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; POLYMERASE-ALPHA-PRIMASE; SV40 T-ANTIGEN; CELL-CYCLE; INVITRO REPLICATION; BINDING-PROTEIN; FACTOR-A; SACCHAROMYCES-CEREVISIAE; CDC2 KINASE; ORIGIN	Human replication protein A (RPA) is a three subunit protein complex involved in DNA replication, repair, and recombination. We investigated the role of the 34-kDa subunit (p34) of RPA in DNA replication by generating a series of p34 mutants. While deletion of the N-terminal domain of p34 prevented its phosphorylation by both cyclin dependent kinase (Cdk) and DNA-dependent kinase, a double point mutant that lacks the major phosphorylation sites for Cdk could be phosphorylated by DNA-dependent kinase. In simian virus 40 (SV40) DNA replication, RPA containing either of these mutants functioned as efficiently as wild-type RPA. However, mutant RPA containing C-terminally deleted p34 was only marginally active. This indicates that the C-terminal region, but not the phosphorylation domain of p34, is necessary for RPA function in DNA replication. Furthermore, RPA containing the C-terminally deleted p34 mutant could stimulate DNA polymerase alpha, and bind to single-stranded DNAs but was limited in its ability to unwind DNA or interact with SV40 large T antigen (T Ag). These results suggest that RPA p34 interacts with SV40 T Ag during the initiation of SV40 DNA replication and may be necessary for DNA unwinding.	UNIV TENNESSEE, COLL MED, DEPT PATHOL, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	LEE, SH (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38101 USA.				NCI NIH HHS [5P30 CA 21765-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BROWN GW, 1993, MOL BIOCHEM PARASIT, V59, P323, DOI 10.1016/0166-6851(93)90230-U; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1991, COLD SH Q B, V56, P315; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; PAN ZQ, 1993, J BIOL CHEM, V268, P20443; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PAN ZQ, 1993, J BIOL CHEM, V268, P20438; ROBERTS JM, 1988, SCIENCE, V241, P1486, DOI 10.1126/science.2843984; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; UMBRICHT CB, 1993, J BIOL CHEM, V268, P6131; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	53	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12801	12807		10.1074/jbc.270.21.12801	http://dx.doi.org/10.1074/jbc.270.21.12801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759535	hybrid			2022-12-25	WOS:A1995QZ71100072
J	TAN, JC; BRAUN, S; RONG, H; DIGIACOMO, R; DOLPHIN, E; BALDWIN, S; NARULA, SK; ZAVODNY, PJ; CHOU, CC				TAN, JC; BRAUN, S; RONG, H; DIGIACOMO, R; DOLPHIN, E; BALDWIN, S; NARULA, SK; ZAVODNY, PJ; CHOU, CC			CHARACTERIZATION OF RECOMBINANT EXTRACELLULAR DOMAIN OF HUMAN INTERLEUKIN-10 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; BIOLOGICAL PROPERTIES; MOLECULAR-CLONING; LYMPHOCYTES-B; CELLS; GROWTH; IL-10; DIMERIZATION; BINDING; STOICHIOMETRY	The extracellular region of the human interleukin-10 (hIL-10) receptor was expressed using a myeloma cell line and was purified to homogeneity by Ligand-affinity chromatography. SDS-polyacrylamide gel electrophoresis analysis indicated that the soluble receptor is glycosylated and has an apparent molecular mass of 35,000-45,000. Under native conditions, soluble hIL-10 receptor was determined by gel filtration to be a monomeric protein. Soluble hIL-10 receptor was able to inhibit the binding of I-125-hTL-10 to the full-length receptor and was able to antagonize the effect of human IL-10 in cell proliferation and cytokine synthesis inhibition. The apparent dissociation constant (K-d) of soluble hIL-10 receptor was determined to be 563 +/- 59 pM, approximately 2- to 10-fold higher than that found on intact cells (Tan, J. C., Idelicato, S. R., Narula, S. IL, Zavodny, P. J., and Chou, C.-C. (1993) J. Biol. Chem. 268, 21053-21059; Liu, Y., Wei, S. H.-Y., Ho, A S.-Y., de Waal Malefyt, R., and Moore, IL m. (1994) J. Immunol. 152, 1821-1829). When hIL-10 binds soluble hIL-10 receptor in solution, a single complex was detected by gel filtration, and the complex was found to consist of two hIL-10 dimers and four soluble receptor monomers, suggesting that hIL-10 may induce a novel mode of oligomerization of the receptor upon binding.	SCHERING PLOUGH CORP,RES INST,DEPT IMMUNOL,KENILWORTH,NJ 07033	Merck & Company; Schering Plough Corporation								ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BAIOCCHI RA, 1995, BLOOD, V84, P1063; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BURDIN N, 1993, J EXP MED, V177, P295, DOI 10.1084/jem.177.2.295; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; DEVOS R, 1993, J BIOL CHEM, V268, P6581; DING L, 1993, J IMMUNOL, V151, P1224; FERNANDEZBOTRAN R, 1991, J EXP MED, V174, P673, DOI 10.1084/jem.174.3.673; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; Galfre G, 1981, Methods Enzymol, V73, P3; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HOWARD M, 1992, J CLIN IMMUNOL, V12, P239, DOI 10.1007/BF00918147; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; LEV S, 1992, J BIOL CHEM, V267, P15970; LIU Y, 1994, J IMMUNOL, V152, P1821; MACNEIL IA, 1990, J IMMUNOL, V145, P4167; MALEFYT RD, 1991, J EXP MED, V174, P1209; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSMANN TR, 1991, IMMUNOL TODAY, V12, pA49; OGARRA A, 1992, EUR J IMMUNOL, V22, P711, DOI 10.1002/eji.1830220314; OZMEN L, 1993, J IMMUNOL, V150, P2698; PENG B, 1995, IN PRESS LEUKEMIA RE, V19; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SUDA T, 1990, CELL IMMUNOL, V129, P228, DOI 10.1016/0008-8749(90)90200-B; TAN JC, 1993, J BIOL CHEM, V268, P21053; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; WANG P, 1994, BLOOD, V83, P2678, DOI 10.1182/blood.V83.9.2678.bloodjournal8392678; WARD LD, 1994, J BIOL CHEM, V269, P23286; YET MG, 1993, BLOOD, V82, P1713, DOI 10.1182/blood.V82.6.1713.bloodjournal8261713	41	53	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12906	12911		10.1074/jbc.270.21.12906	http://dx.doi.org/10.1074/jbc.270.21.12906			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759550	hybrid			2022-12-25	WOS:A1995QZ71100087
J	MARSTON, NJ; JENKINS, JR; VOUSDEN, KH				MARSTON, NJ; JENKINS, JR; VOUSDEN, KH			OLIGOMERIZATION OF FULL-LENGTH P53 CONTRIBUTES TO THE INTERACTION WITH MDM2 BUT NOT HPV E6	ONCOGENE			English	Article						P53; HPV E6; MDM2	HUMAN PAPILLOMAVIRUS TYPE-16; CYCLIN-DEPENDENT KINASES; WILD-TYPE; DNA-BINDING; MUTANT P53; PROTEIN; CONFORMATION; DEGRADATION; ONCOPROTEIN; EXPRESSION	The tumour suppressor protein p53 normally functions as a tetramer in a defined conformational state. Mutations within p53 which contribute to cancer development frequently induce a conformational shift in the protein which correlates with loss of wild type growth suppressor functions. Both the cell encoded mdm2 protein and the human papillomavirus oncoprotein E6 can regulate p53 function and we have examined the interaction of these proteins with p53. The E6/p53 association is sensitive to conformational alterations in the p53 protein, although oligomerisation is not necessary for this interaction to occur. Analysis of C-terminal p53 truncations has indicated that the region between residues 327 and 347 may play a role in E6 binding. Since monomeric forms of p53 retain transcriptional and transformation suppressor activities, our results indicate that E6 targets p53 proteins which retain these wild type functions. Conversely, the interaction of p53 with mdm2 is not dependent on the conformation of the p53 protein but is significantly impaired by loss of quaternary structure. It is possible that mdm2 plays a role in mediating activities of p53 which, unlike transcriptional activation, depend on oligomerisation.	ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; MARIE CURIE RES INST, CELL PROLIFERAT LAB, SURREY RH8 0TL, ENGLAND	Imperial College London; Ludwig Institute for Cancer Research								BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, LANCET, V79, P817; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Farthing Alan J., 1994, Trends in Microbiology, V2, P170, DOI 10.1016/0966-842X(94)90667-X; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1994, ONCOGENE, V9, P299; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TARUNINA M, 1993, ONCOGENE, V8, P3165; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	54	54	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1709	1715						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753547				2022-12-25	WOS:A1995QX46900003
J	BIFULCO, M; PERILLO, B; SAJI, M; LAEZZA, C; TEDESCO, I; KOHN, LD; ALOJ, SM				BIFULCO, M; PERILLO, B; SAJI, M; LAEZZA, C; TEDESCO, I; KOHN, LD; ALOJ, SM			REGULATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE GENE-EXPRESSION IN FRTL-5 CELLS .1. IDENTIFICATION AND CHARACTERIZATION OF A CYCLIC AMP-RESPONSIVE ELEMENT IN THE RAT REDUCTASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG COA REDUCTASE; A REDUCTASE; RECEPTOR PROMOTER; MAMMALIAN-CELLS; THYROID-CELLS; TRANSCRIPTION; THYROTROPIN; BINDING; PROTEIN; INVITRO	Thyrotropin (TSH) increases 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase gene transcription in FRTL-5 rat thyroid cells, and the effect of TSH can be mimicked by cAMP. Sequence analysis of the rat reductase promoter has revealed a hitherto unnoticed cAMP-responsive element (CRE)-like octamer. This octamer is located between 53 and 60 nucleotides downstream of the sterol regulatory element 1; its first 6 nucleotides are identical to the consensus somatostatin CRE, and the entire octamer is identical to the fos CRE. A synthetic oligonucleotide containing the HMG-CoA reductase CRE-like octamer (RED CRE) formed protein-DNA complexes with nuclear extracts from FRTL-5 cells, which could be prevented by unlabeled CRE-containing oligonucleotides whose flanking sequences were otherwise nonidentical. The complexes were specifically supershifted by anti-CREE antibodies. FRTL-5 cells transfected with a fusion plasmid carrying the bacterial chloramphenicol acetyl transferase (CAT) under the control of the HMG-CoA reductase promoter displayed CAT activity, which was specifically stimulated by TSH. In contrast, CAT activity in FRTL-5 cells transfected with similar constructs carrying mutations in the reductase CRE was significantly lower and did not increase after TSH challenge. We suggest that the HMG-CoA reductase gene contains a functional CRE, important for TSH regulation of transcription. The data presented provide the molecular basis for a novel regulatory mechanism for HMG-CoA reductase gene expression in rat thyroid cells, which involves the direct effect of cAMP.	UNIV NAPLES FEDERICO II,CTR ENDOCRINO & ONCOL SPERIMENTALE,CNR,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; NIDDK,BIOCHEM & METAB LAB,CELL REGULAT SECT,BETHESDA,MD 20892	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			laez, chi/AAW-4437-2020; Saji, Motoyasu/E-4007-2011	Perillo, Bruno/0000-0001-8935-0370; Bifulco, Maurizio/0000-0002-1771-4531; Aloj, Salvatore, M./0000-0003-1703-7523				ALBERTS AW, 1988, AM J CARDIOL, V62, pJ10, DOI 10.1016/0002-9149(88)90002-1; Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; AMBESIIMPIOMBAT.FS, 1980, P NATL ACAD SCI USA, V77, P3455; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIFULCO M, 1990, J BIOL CHEM, V265, P19336; BUNCE CM, 1988, ANAL BIOCHEM, V75, P67; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIECO D, 1990, J BIOL CHEM, V265, P19343; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KOHN LD, 1975, J BIOL CHEM, V250, P6503; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SAJI M, 1992, P NATL ACAD SCI USA, V89, P1944, DOI 10.1073/pnas.89.5.1944; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMURA H, 1993, J BIOL CHEM, V268, P24125; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; VALENTE WA, 1983, NEW ENGL J MED, V309, P1028, DOI 10.1056/NEJM198310273091705	31	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15231	15236		10.1074/jbc.270.25.15231	http://dx.doi.org/10.1074/jbc.270.25.15231			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797507	hybrid			2022-12-25	WOS:A1995RE66600058
J	HO, WH; ARMANINI, MP; NUIJENS, A; PHILLIPS, HS; OSHEROFF, PL				HO, WH; ARMANINI, MP; NUIJENS, A; PHILLIPS, HS; OSHEROFF, PL			SENSORY AND MOTOR NEURON-DERIVED FACTOR - A NOVEL HEREGULIN VARIANT HIGHLY EXPRESSED IN SENSORY AND MOTOR-NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION FACTOR; RNA; PROTEIN; MEMBRANES; HER4/P180(ERBB4); HYBRIDIZATION; INHIBITORS; MECHANISMS; SEQUENCES; PLASMIDS	The heregulin family of polypeptides arise as splice variants from a single gene and share a conserved epidermal growth factor (EGF)-like domain thought to be the major determinant of their biological activities, We report here the cloning of a novel member of this family, termed sensory and motor neuron-derived factor or SMDF, which is highly expressed in sensory and motor neurons in human and rodent species, It contains a C-terminal beta-type EGF-like domain and an unique N-terminal sequence which lacks an Ig-like domain and is distinct from all known heregulin variants. Mammalian cell-expressed SMDF activates tyrosine phosphorylation of a 185-kDa protein in cell lines expressing p185(erbB2), indicating that it is biologically active. Analyses of expression patterns suggest that, unlike other heregulin variants, SMDF is expressed mainly in the nervous system. In situ hybridization signals with the unique SMDF sequence probe and with a probe to the conserved EGF-like domain are comparable, suggesting that SMDF is the predominant isoform expressed in sensory and motor neurons, Expression of SMDF is maintained in both adult motor neurons and dorsal root ganglion neurons. These findings suggest that SMDF may mediate biological responses such as Schwann cell proliferation and acetylcholine receptor induction in the peripheral nervous system.	GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOANALYT TECHNOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech								BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORFAS G, 1993, J NEUROSCI, V13, P2118; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HALL ZW, 1993, NEURON S, V10, P99; HAYES C, 1992, J NEUROSCI RES, V31, P175, DOI 10.1002/jnr.490310123; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KING IC, 1993, LIFE SCI, V53, P1465, DOI 10.1016/0024-3205(93)90619-E; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KROCZEK RA, 1990, ANAL BIOCHEM, V184, P90, DOI 10.1016/0003-2697(90)90017-4; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEEK RL, 1982, J BIOL CHEM, V257, P2245; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PERIN MS, 1991, J BIOL CHEM, V266, P623; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VARTANIAN T, 1994, P NATL ACAD SCI USA, V91, P11626, DOI 10.1073/pnas.91.24.11626; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	41	151	156	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14523	14532		10.1074/jbc.270.24.14523	http://dx.doi.org/10.1074/jbc.270.24.14523			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782315	hybrid			2022-12-25	WOS:A1995RD45500046
J	HOLLENBERG, AN; MONDEN, T; WONDISFORD, FE				HOLLENBERG, AN; MONDEN, T; WONDISFORD, FE			LIGAND-INDEPENDENT AND LIGAND-DEPENDENT FUNCTIONS OF THYROID-HORMONE RECEPTOR ISOFORMS DEPEND UPON THEIR DISTINCT AMINO TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; RESPONSE ELEMENTS; AUXILIARY PROTEIN; X-RECEPTORS; RXR-BETA; GENE; BINDING; DNA; ACTIVATION; EXPRESSION	Isoform specificity likely plays a large role in the ability of the thyroid hormone receptor (TR) to specifically regulate gene expression in both the presence and absence of its cognate ligand, triiodothyronine. To investigate further the mechanism of isoform specificity of human TRs (TR alpha 1 and TR beta 1), we have examined their functional effects on positive thyroid hormone response elements (TREs) both in the presence and absence of ligand. TR alpha 1 was greater than 2-fold more potent than TR beta 1 on both TREs studied, in terms of both ligand-independent repression and ligand-dependent stimulation. By creating a number of chimeric and mutant receptors, we have established that the increased functional potency of TR alpha 1 is due to its unique amino terminus. Deletion or substitution of the TR alpha 1 amino terminus leads to a loss of both its ligand-independent and -dependent functions on positive TREs. Furthermore, the TR alpha 1 amino terminus antagonizes homodimer formation on the positive TREs studied, TR constructs, which contain the TR alpha 1 amino terminus, are unable to form homodimers and form exclusively heterodimers with RXR alpha on direct repeat and palindromic TREs. Deletion of the amino terminus from either TR isoform leads to preferential homodimer formation, which suggests that the TR amino terminus is important for relative heterodimerization capability. From these data, we conclude that TR alpha 1 isoform specificity on positive TREs resides predominantly in its amino terminus through its ability to favor heterodimerization with the retinoid X receptor or other nuclear proteins.	BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP, THORNDIKE LAB, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	HOLLENBERG, AN (corresponding author), BETH ISRAEL HOSP, THYROID UNIT, RES N 330B, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043653] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43653] Funding Source: Medline; PHS HHS [K08D4-02354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BRADLEY DJ, 1994, P NATL ACAD SCI USA, V91, P439, DOI 10.1073/pnas.91.2.439; BREATHNACH R, 1983, NUCLEIC ACIDS RES, V11, P7119, DOI 10.1093/nar/11.20.7119; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FLYNN TR, 1994, J BIOL CHEM, V269, P32713; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P702; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; ROSEN ED, 1992, J BIOL CHEM, V267, P22010; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WONDISFORD FE, 1993, J BIOL CHEM, V268, P2749; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1994, ENDOCRINOLOGY, V134, P1075, DOI 10.1210/en.134.3.1075; YEN PM, 1993, ENDOCR J, V1, P461; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZAVACKI AM, 1993, MOL ENDOCRINOL, V7, P1319, DOI 10.1210/me.7.10.1319; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	41	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14274	14280		10.1074/jbc.270.24.14274	http://dx.doi.org/10.1074/jbc.270.24.14274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782283	hybrid			2022-12-25	WOS:A1995RD45500009
J	JOSHI, B; CAI, AL; KEIPER, BD; MINICH, WB; MENDEZ, R; BEACH, CM; STEPINSKI, J; STOLARSKI, R; DARZYNKIEWICZ, E; RHOADS, RE				JOSHI, B; CAI, AL; KEIPER, BD; MINICH, WB; MENDEZ, R; BEACH, CM; STEPINSKI, J; STOLARSKI, R; DARZYNKIEWICZ, E; RHOADS, RE			PHOSPHORYLATION OF EUKARYOTIC PROTEIN-SYNTHESIS INITIATION-FACTOR 4E AT SER-209	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; KINASE-C; TRANSLATIONAL INITIATION; NUCLEOTIDE-SEQUENCE; PHORBOL ESTERS; FACTOR EIF-4E; GROWTH-FACTOR; COMPLEX; CELLS; OVEREXPRESSION	Initiation factor 4E (eIF-4E) binds to the m(7)GTP-containing cap of eukaryotic mRNA and facilitates the entry of mRNA into the initiation cycle of protein synthesis. eIF-4E is a phosphoprotein, and the phosphorylated form binds to mRNA caps 3-4-fold more tightly than the nonphosphorylated form. A previous study indicated that the major phosphorylation site was Ser-53 (Rychlik, W., Russ, M. A., and Rhoads, R. E. (1987) J. Biol. Chem. 262, 10434-10437). In the present study, we synthesized the phosphopeptide expected to result from tryptic digestion of eIF-4E, O-phosphoseryllysine. Surprisingly, the tryptic and synthetic phosphopeptides did not comigrate electrophoretically. Accordingly, we redetermined the phosphorylation site by isolating a chymotryptic phosphopeptide on reverse phase high performance liquid chromatography. The peptide was sequenced by Edman degradation and corresponded to (198)QSHADTATKSGSTTKNRF(215). The site of phosphorylation was determined to be Ser-209 by four methods: the increase in the ratio of dehydroalanine to serine derivatives during Edman degradation, the release of P-32, the further digestion of the chymotryptic phosphopeptide with trypsin, Glu-C, and Asp-N, and site-directed mutagenesis of eIF-4E cDNA The S209A variant was not phosphorylated in a rabbit reticulocyte lysate system, whereas the wild-type, S53A, and S207A variants were. This site falls within the consensus sequence for phosphorylation by protein kinase C.	LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,SHREVEPORT,LA 71130; UNIV KENTUCKY,MED CTR,MACROMOLEC STRUCT ANAL FACIL,LEXINGTON,KY 40536; UNIV WARSAW,DEPT BIOPHYS,PL-02089 WARSAW,POLAND; UNIV WARSAW,DEPT CHEM,PL-02089 WARSAW,POLAND	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Kentucky; University of Warsaw; University of Warsaw				Keiper, Brett/0000-0002-8621-9825; Stolarski, Ryszard/0000-0002-3272-5140; Mendez, Raul/0000-0002-1952-6905	NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMICK GD, 1992, BIOCHEM BIOPH RES CO, V183, P431, DOI 10.1016/0006-291X(92)90499-B; ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; BODANSZKY M, 1984, PRACTICE PEPTIDE SYN, P145; BU X, 1993, J BIOL CHEM, V268, P4975; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEDNER N, 1988, FEBS LETT, V236, P77, DOI 10.1016/0014-5793(88)80288-6; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; HAAS DW, 1991, ARCH BIOCHEM BIOPHYS, V284, P84, DOI 10.1016/0003-9861(91)90267-M; HAAS DW, 1992, SEC MESS PHOSPHOPROT, V14, P55; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; HUG H, 1993, BIOCHEM J, V291, P115; IKEBE M, 1990, J BIOL CHEM, V265, P8975; JAGUS R, 1993, DEV GENET, V14, P412, DOI 10.1002/dvg.1020140603; JOSHI B, 1994, J BIOL CHEM, V269, P2048; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KAUFMAN RJ, 1993, J BIOL CHEM, V268, P11902; KEIPER BD, 1990, J BIOL CHEM, V265, P19397; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; RYCHLIK W, 1992, NUCLEIC ACIDS RES, V20, P6415, DOI 10.1093/nar/20.23.6415; RYCHLIK W, 1986, J BIOL CHEM, V261, P71; RYCHLIK W, 1990, J BIOL CHEM, V265, P19467; SMITH M R, 1990, New Biologist, V2, P648; SMITH MR, 1991, NEW BIOL, V3, P601; TRACHSEL H, 1991, TRANSLATION EUKARYOT, P415; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; TUAZON PT, 1990, J BIOL CHEM, V265, P10617	49	184	187	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14597	14603		10.1074/jbc.270.24.14597	http://dx.doi.org/10.1074/jbc.270.24.14597			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782323	hybrid			2022-12-25	WOS:A1995RD45500056
J	SCHNITZER, JE; LIU, J; OH, P				SCHNITZER, JE; LIU, J; OH, P			ENDOTHELIAL CAVEOLAE HAVE THE MOLECULAR-TRANSPORT MACHINERY FOR VESICLE BUDDING, DOCKING, AND FUSION INCLUDING VAMP, NSF, SNAP, ANNEXINS, AND GTPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; INTEGRAL MEMBRANE-PROTEIN; VESICULAR TRANSPORT; SECRETORY PATHWAY; FAMILY; CELLS; YEAST; SYNAPTOBREVIN; COMPONENTS; RECEPTORS	Transport by discrete vesicular carriers is well established at least in part because of recent discoveries identifying key protein mediators of vesicle formation, docking, and fusion. A general mechanism sensitive to N-ethylmaleimide (NEM) is required for the transport of a divergent group of vesicular carriers in all eukaryotes. Many endothelia have an abundant population of noncoated plasmalemmal vesicles or caveolae, which have been reported with considerable controversy to function in transport. We recently have shown that like other vesicular transport systems, caveolae-mediated endocytosis and transcytosis are inhibited by MEM (Schnitzer, J. E., Allard, J., and Oh, P. (1995) Am. J. Physiol. 268, H48-H55). Here, we continue this work by utilizing our recently developed method for purifying endothelial caveolae from rat lung tissue (Schnitzer, J. E., Oh, P., Jacobson, B. S., and Dvorak, A. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1759-1763) to show that these caveolae contain key proteins known to mediate different aspects of vesicle formation, docking, and/or fusion including the vSNARE VAMP-2, monomeric and trimeric GTPases, annexins II and VI, and the NEM-sensitive fusion factor NSF along with its attachment protein SNAP. Like neuronal VAMPs, this endothelial VAMP is sensitive to cleavage by botulinum B and tetanus neurotoxins. Caveolae in endothelium are indeed like other carrier vesicles and contain similar NEM-sensitive molecular machinery for transport.			SCHNITZER, JE (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,RES N BATH ISRAEL,99 BROOKLINE AVE,BOSTON,MA 02215, USA.				NHLBI NIH HHS [HL43278, HL52766] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043278, R01HL052766] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BRAUN JEA, 1994, J BIOL CHEM, V269, P5328; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUNDGAARD M, 1983, FED PROC, V42, P2425; BURGOYNE RD, 1994, TRENDS BIOCHEM SCI, V19, P231, DOI 10.1016/0968-0004(94)90143-0; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DUNPHY WG, 1986, P NATL ACAD SCI USA, V83, P1622, DOI 10.1073/pnas.83.6.1622; FROKJAERJENSEN J, 1980, J ULTRA MOL STRUCT R, V73, P9, DOI 10.1016/0022-5320(80)90111-2; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PALADE GE, 1958, ANAT REC, V130, P467; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PREDESCU D, 1994, P NATL ACAD SCI USA, V91, P3014, DOI 10.1073/pnas.91.8.3014; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; RALSTON E, 1994, J BIOL CHEM, V269, P15403; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P124, DOI 10.1016/1050-1738(93)90012-U; SCHNITZER JE, 1995, AM J PHYSIOL-HEART C, V268, pH48, DOI 10.1152/ajpheart.1995.268.1.H48; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; Simionescu M, 1984, HDB PHYSL 2, P41; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1993, J PHYSIOLOGY-PARIS, V87, P107, DOI 10.1016/0928-4257(93)90004-D; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WITEHEART SW, 1994, J CELL BIOL, V126, P945	50	306	314	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14399	14404		10.1074/jbc.270.24.14399	http://dx.doi.org/10.1074/jbc.270.24.14399			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782301	hybrid			2022-12-25	WOS:A1995RD45500028
J	SHEPS, JA; CHEUNG, I; LING, V				SHEPS, JA; CHEUNG, I; LING, V			HEMOLYSIN TRANSPORT IN ESCHERICHIA-COLI - POINT MUTANTS IN HLYB COMPENSATE FOR A DELETION IN THE PREDICTED AMPHIPHILIC HELIX REGION OF THE HLYA SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN; TRANSMEMBRANE DOMAIN; ALPHA-HEMOLYSIN; FUNCTIONAL CONSEQUENCES; SECRETION; MUTATIONS; PROTEIN; IDENTIFICATION; SUBSTITUTION; RESISTANCE	The alpha-hemolysin transporter of Escherichia coli, a member of the ATP-binding cassette transporter superfamily, is responsible for secretion of the 107-kDa protein toxin HlyA across both membranes of the Gram-negative envelope in a single step. Secretion of HlyA is dependent on a signal sequence, which occupies the C-terminal 50-60 amino acids of HlyA. Previously, it was shown that point mutants in the transmembrane domain of the transporter HlyB could partially correct the transport defect caused by a deletion of the C-terminal 29 amino acids of HlyA. These suppressor mutations demonstrated a direct interaction between HlyA and HlyB. They also displayed suppressor effects on a broad spectrum of HlyA signal mutants. In the present study, we selected HlyB alleles that complemented an internal deletion of 29 amino acids in HlyA containing a predicted amphiphilic helix region immediately upstream from the previous deletion. This set of HlyB mutants identifies further sites in HlyB that modulate substrate specificity but display allele-specific effects on a range of HlyA signal mutants. The inability to isolate mutations with effects restricted to either half of the signal sequence suggests that the signal is not recognized in a modular fashion by the transporter but rather functions as an integrated whole. We also report the isolation of the first substrate specificity mutation, which lies within the ATP-binding domain of HlyB. This could support a model in which the region of the ATP-binding cassette between the two Walker consensus motifs involved in ATP binding interacts with either the substrate or the transmembrane domains.	UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; CHU CT, 1979, VIROLOGY, V98, P168, DOI 10.1016/0042-6822(79)90535-X; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; GENTSCHEV I, 1992, MOL GEN GENET, V232, P40, DOI 10.1007/BF00299135; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HACKER J, 1985, CURR TOP MICROBIOL I, V118, P139; HESS J, 1990, MOL GEN GENET, V224, P201, DOI 10.1007/BF00271553; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HIGHLANDER SK, 1989, DNA-J MOLEC CELL BIO, V8, P15, DOI 10.1089/dna.1.1989.8.15; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; JURANKA P, 1992, J BIOL CHEM, V267, P3764; KENNY B, 1994, MOL MICROBIOL, V11, P99, DOI 10.1111/j.1365-2958.1994.tb00293.x; KENNY B, 1992, MOL MICROBIOL, V6, P1477, DOI 10.1111/j.1365-2958.1992.tb00868.x; KORONAKIS V, 1987, J BACTERIOL, V169, P1509, DOI 10.1128/jb.169.4.1509-1515.1987; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; LETOFFE S, 1993, J BACTERIOL, V175, P7321; LETOFFE S, 1990, EMBO J, V9, P1375, DOI 10.1002/j.1460-2075.1990.tb08252.x; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1993, J BIOL CHEM, V268, P19965; MACKMAN N, 1985, MOL GEN GENET, V201, P282, DOI 10.1007/BF00425672; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; STANLEY P, 1991, MOL MICROBIOL, V5, P2391, DOI 10.1111/j.1365-2958.1991.tb02085.x; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; ZHANG F, 1995, BIOCHEMISTRY-US, V34, P4193, DOI 10.1021/bi00013a007; ZHANG F, 1993, P NATL ACAD SCI USA, V90, P4211, DOI 10.1073/pnas.90.9.4211; ZHANG F, 1993, J BIOL CHEM, V268, P19889	33	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14829	14834		10.1074/jbc.270.24.14829	http://dx.doi.org/10.1074/jbc.270.24.14829			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782350	hybrid			2022-12-25	WOS:A1995RD45500088
J	SHYNG, SL; MOULDER, KL; LESKO, A; HARRIS, DA				SHYNG, SL; MOULDER, KL; LESKO, A; HARRIS, DA			THE N-TERMINAL DOMAIN OF A GLYCOLIPID-ANCHORED PRION PROTEIN IS ESSENTIAL FOR ITS ENDOCYTOSIS VIA CLATHRIN-COATED PITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; MEMBRANE-PROTEIN; PATHWAY; CONVERSION; SIGNAL; SITES; CELLS; FORM	The cellular prion protein (PrPC) is a glycolipid-anchored protein that is involved in the pathogenesis of fatal spongiform encephalopathies. We have shown previously that, in contrast to several other glycolipid-anchored proteins, chPrP, the chicken homologue of mammalian PrPC, is endocytosed via clathrin-coated pits in cultured neuroblastoma cells, as well as in embryonic neurons and glia (Shyng, S.-L., Heuser, J. E., and Harris, D. A. (1994) J. Cell Biol. 125, 1239-1250). In this study, we have determined that the N-terminal half of the chPrP polypeptide chain is essential for its endocytosis. Deletions within this region reduce the amount of chPrP internalized, as measured by surface iodination or biotinylation, and decrease its concentration in clathrin-coated pits, as determined by quantitative electron microscopic immunogold labeling. Mouse PrP, as well as two mouse PrP/chPrP chimeras, are internalized as efficiently as chPrP, suggesting that conserved feature!s of secondary and tertiary structure are involved in interaction with the endocytic machinery. Our results indicate that the ectodomain of a protein can contain endocytic targeting information, and they strongly support a model in which the polypeptide chain of PrPC binds to the extracellular domain of a transmembrane protein that contains a coated pit localization signal in its cytoplasmic tail.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Harris, David/0000-0002-6985-5790	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007071, R29NS030137] Funding Source: NIH RePORTER; NINDS NIH HHS [T32 NS07071, NS30137] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BAZAN JF, 1987, PROTEIN ENG, V1, P125, DOI 10.1093/protein/1.2.125; BLASI F, 1994, FIBRINOLYSIS, V8, P182, DOI 10.1016/0268-9499(94)90716-1; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; COYNE KE, 1992, J IMMUNOL, V149, P2906; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; Curtis Rory, 1994, Trends in Cell Biology, V4, P383, DOI 10.1016/0962-8924(94)90045-0; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; EBERLE W, 1961, CELL, V67, P1203; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Harris D. A., 1993, Molecular Biology of the Cell, V4, p436A; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; Higuchi R., 1989, PCR TECHNOLOGY, P61; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; LEHMANN S, 1994, NEUROBIOL AGING, V15, pS87; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; Low M.G., 1992, LIPID MODIFICATION P, P117; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; ULRICH MJ, 1990, BLOOD, V75, P990; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6	37	144	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14793	14800		10.1074/jbc.270.24.14793	http://dx.doi.org/10.1074/jbc.270.24.14793			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782345	hybrid			2022-12-25	WOS:A1995RD45500083
J	COHEN, O; FLYNN, TR; WONDISFORD, FE				COHEN, O; FLYNN, TR; WONDISFORD, FE			LIGAND-DEPENDENT ANTAGONISM BY RETINOID-X RECEPTORS OF INHIBITORY THYROID-HORMONE RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT GENE; AUXILIARY PROTEIN; DNA-BINDING; RXR-BETA; ENHANCES BINDING; T3 RECEPTOR; ACID; EXPRESSION; H-2RIIBP; HETERODIMERIZATION	The role of retinoid X receptors (RXRs) on negative thyroid hormone response elements (nTREs) is not well understood, In this report, we demonstrate that an orientation-specific monomeric thyroid hormone receptor (T(3)R) DNA-binding site mediates thyroid hormone inhibition in the thyrotropin beta subunit gene (TSH-beta) from human and murine species. Unlike positive TREs, addition of the ligand 9-cis retinoic acid (9-cis RA) to cells transfected with a T(3)R beta 1 expression vector significantly reduces thyroid hormone inhibition of the TSH-beta gene, indicating that endogenous retinoid receptors antagonize T(3)R function. Cotransfection of an RXR-alpha but not a retinoic acid receptor-alpha expression vector further antagonizes thyroid hormone inhibition, but only in the presence of 9-cis RA. Antagonism by RXR requires both an intact DNA- and ligand-binding domain, Removal of monomeric T(3)R binding to the TSH-beta nTRE also requires both RXR domains. A model is proposed whereby monomeric T(3)R is removed from a nTRE by RXR occupied by its ligand 9-cis RA. This is the first report of 9-cis RA-dependent antagonism of thyroid hormone inhibition via negative TREs.	BETH ISRAEL HOSP,THYROID UNIT,BOSTON,MA 02215; BETH ISRAEL HOSP,CHARLES A DANA RES INST,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,THORNDIKE LAB,DEPT MED,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043653] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43653] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CARR FE, 1992, J BIOL CHEM, V267, P18689; CARR FE, 1994, J BIOL CHEM, V269, P4175; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HSU JH, 1995, ENDOCRINOLOGY, V136, P421, DOI 10.1210/en.136.2.421; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; WONDISFORD FE, 1993, J BIOL CHEM, V268, P2749; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	33	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13899	13905		10.1074/jbc.270.23.13899	http://dx.doi.org/10.1074/jbc.270.23.13899			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775449	hybrid			2022-12-25	WOS:A1995RC44800048
J	HONG, J; SALO, WL; ANDERSON, PM				HONG, J; SALO, WL; ANDERSON, PM			NUCLEOTIDE-SEQUENCE AND TISSUE-SPECIFIC EXPRESSION OF THE MULTIFUNCTIONAL PROTEIN CARBAMOYL-PHOSPHATE SYNTHETASE-ASPARTATE TRANSCARBAMOYLASE-DIHYDROOROTASE (CAD) MESSENGER-RNA IN SQUALUS-ACANTHIAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIMIDINE BIOSYNTHESIS; UREA SYNTHESIS; HAMSTER-CELLS; GENE; PHOSPHORYLATION; DOMAIN; ENZYME; ELASMOBRANCHS; POLYPEPTIDE; EVOLUTION	Carbamoyl-phosphate synthetase II (CPSase II), aspartate transcarbamoylase (ATCase), and dihydroorotase (DHOase) catalyze the first three steps of de novo pyrimidine nucleotide biosynthesis, respectively. In mammalian species, these three enzyme activities exist in the cytosol in liver and other tissues as a multifunctional complex on a single polypeptide called carbamoyl-phosphate synthetase-aspartate transcarbamoylase-dihydroorotase (CAD) in the order of NH2-CPSase II-DHOase-ATCase-COOH. Previous studies provided evidence that in Squalus acanthias (spiny dogfish) these enzymes are not expressed in liver and that they exist as separate entities in the cytosol of extra-hepatic tissues such as testes and spleen (Anderson, P. M. (1989) Biochem. J. 261, 528-529). Here we report that the genes for these three enzymes are expressed in testes as a single transcript analogous to CAD in mammalian species and that these genes are not expressed in liver at levels that can be detected by Northern blots or by the polymerase chain reaction. The absence of the pyrimidine pathway in the liver may be related to the exclusive localization of glutamine synthetase in the mitochondrial matrix which provides for efficient assimilation of ammonia as glutamine for urea synthesis in these ureoosmotic species; thus glutamine may not be available for CPSase II or other amidotransferase activities in the cytosol. The amino acid sequence deduced from the nucleotide sequence of the shark CAD cDNA reported here is very similar to CAD from other species; alignment with the hamster CAD sequence shows 77% identical residues.	UNIV MINNESOTA, DEPT BIOCHEM & MOLEC BIOL, DULUTH, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth								ANDERSON PM, 1980, SCIENCE, V208, P291, DOI 10.1126/science.6245445; ANDERSON PM, 1991, BIOCHEM CELL BIOL, V69, P317, DOI 10.1139/o91-049; ANDERSON PM, 1981, J BIOL CHEM, V256, P2228; ANDERSON PM, 1989, BIOCHEM J, V261, P523, DOI 10.1042/bj2610523; ANDERSON PM, 1995, J EXP BIOL, V198, P755; ANDERSON PM, 1995, ANIMAL PHYSL EVOLUTI; ANDERSON PM, 1995, FISH PHYSL, V14; AOKI T, 1987, COMP BIOCHEM PHYS B, V87, P143, DOI 10.1016/0305-0491(87)90481-0; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BEIN K, 1991, J BIOL CHEM, V266, P3791; BERGER SL, 1987, ANAL BIOCHEM, V161, P272, DOI 10.1016/0003-2697(87)90451-9; Borson N D, 1992, PCR Methods Appl, V2, P144; Campbell J.W., 1991, Biochemistry and Molecular Biology of Fishes, V1, P43; CAO XY, 1991, J EXP ZOOL, V258, P24, DOI 10.1002/jez.1402580104; CARREY EA, 1992, BIOCHEM J, V287, P791, DOI 10.1042/bj2870791; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CARREY EA, 1993, BIOCHEM SOC T, V21, P191, DOI 10.1042/bst0210191; CARREY EA, 1988, EUR J BIOCHEM, V171, P583, DOI 10.1111/j.1432-1033.1988.tb13828.x; CHRISTOPHERSON RI, 1980, J BIOL CHEM, V255, P1381; COHEN P, 1985, EUR J BIOCHEM, V151, P439, DOI 10.1111/j.1432-1033.1985.tb09121.x; DAVIDSON JN, 1993, BIOESSAYS, V15, P157, DOI 10.1002/bies.950150303; DENISDUPHIL M, 1981, J BACTERIOL, V148, P659, DOI 10.1128/JB.148.2.659-669.1981; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Evans D.R., 1986, MULTIDOMAIN PROTEINS, P283; EVANS DR, 1993, BIOCHEM SOC T, V21, P186, DOI 10.1042/bst0210186; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; KELLY RE, 1986, J BIOL CHEM, V261, P6073; KENT RJ, 1975, P NATL ACAD SCI USA, V72, P1712, DOI 10.1073/pnas.72.5.1712; KIM HS, 1992, J BIOL CHEM, V267, P7177; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MOMMSEN TP, 1989, SCIENCE, V243, P72, DOI 10.1126/science.2563172; MUKHERJEE T, 1988, J BIOL CHEM, V263, P708; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; OTSUKI T, 1982, J BIOCHEM-TOKYO, V92, P1431, DOI 10.1093/oxfordjournals.jbchem.a134067; QUINN CL, 1991, J BIOL CHEM, V266, P9113; Sambrook J, 1989, MOL CLONING LABORATO; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SIMMER JP, 1989, P NATL ACAD SCI USA, V86, P4382, DOI 10.1073/pnas.86.12.4382; TAMPITAG S, 1986, MOL BIOCHEM PARASIT, V19, P125, DOI 10.1016/0166-6851(86)90117-9; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203	43	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14130	14139		10.1074/jbc.270.23.14130	http://dx.doi.org/10.1074/jbc.270.23.14130			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775474	hybrid			2022-12-25	WOS:A1995RC44800079
J	JACQUIERSARLIN, MR; JORNOT, L; POLLA, BS				JACQUIERSARLIN, MR; JORNOT, L; POLLA, BS			DIFFERENTIAL EXPRESSION AND REGULATION OF HSP70 AND HSP90 BY PHORBOL ESTERS AND HEAT-SHOCK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA; PROTEIN-SYNTHESIS; 3'-UNTRANSLATED REGION; NUCLEOTIDE-SEQUENCE; GENE-TRANSCRIPTION; NADPH-OXIDASE; HUMAN-CELLS; ACTIVATION; DISTINCT	Human peripheral blood monocytes (PBM) produce superoxide anions (O-2-radical-anion) by a process involving electron transfer from NADPH to O-2-radical-anion, catalyzed by the respiratory burst enzyme NADPH oxidase. We have previously shown that phagocytosis, while activating NADPH oxidase, induced in PBM the synthesis of heat shock (HS) proteins (HSP). The present study was undertaken to establish whether this increase in HSP expression was related to O-2-radical-anion and/or to classical second messengers such as protein kinase C (PKC). Thus, the effects of the PKC activator phorbol 12-myristate 13-acetate (PMA) were compared with those of heat shock on the expression, in PBM, of the major HSP, hsp70 and hsp90, using biometabolic labeling, Western and Northern blotting, and gel mobility shift assays. PMA induced the accumulation of mRNA and an increased expression of hsp90 and, to a lesser extent, hsp/hsc70 (hsc is the cognate, constitutive form). This induction was also observed in PBM from patients with chronic granulomatous disease, a genetic defect in NADPH oxidase, and was abolished by the PKC inhibitors staurosporine and H-7. PMA did not cause activation of the HS factor, and the PMA-induced overexpression of HSP was not blocked by the transcriptional inhibitor actinomycin D. HSP-specific mRNA stability was increased after PMA exposure as compared with heat shock. These results suggest that O-2-radical-anion is not involved in the PMA-mediated induction of hsp70 and hsp90 and that, in contrast to HS, PMA increases the expression of HSP as a result of PKC-induced mRNA stabilization rather than of transcriptional activation of HS genes.	CHU COCHIN PORT ROYAL,PHYSIOL RESP LAB,F-75014 PARIS,FRANCE; UNIV HOSP GENEVA,DIV NUCL MED,HLTH & ENVIRONM PROGRAM,CH-1211 GENEVA 14,SWITZERLAND; UNIV HOSP GENEVA,DIV PULM,CH-1211 GENEVA 14,SWITZERLAND	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Geneva; University of Geneva			Jacquier-Sarlin, Muriel/ABF-4923-2021	Jacquier-Sarlin, Muriel/0000-0001-8501-7511				ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BENSAUDE O, 1983, NATURE, V305, P331, DOI 10.1038/305331a0; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CLERGET M, 1990, P NATL ACAD SCI USA, V87, P1081, DOI 10.1073/pnas.87.3.1081; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HANSEN LK, 1991, EXP CELL RES, V192, P587, DOI 10.1016/0014-4827(91)90080-E; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; JOHNSTON RB, 1984, METHOD ENZYMOL, V105, P365; JORNOT L, 1991, AM J RESP CELL MOL, V5, P265, DOI 10.1165/ajrcmb/5.3.265; KANTENGWA S, 1995, IMMUNOL CELL BIOL, V73, P73, DOI 10.1038/icb.1995.12; KANTENGWA S, 1991, BIOCHEM BIOPH RES CO, V180, P308, DOI 10.1016/S0006-291X(05)81293-8; KANTENGWA S, 1991, INFECT IMMUN, V61, P1281; KAO HT, 1985, MOL CELL BIOL, V5, P628, DOI 10.1128/MCB.5.4.628; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGAGNEUX V, 1989, DIFFERENTIATION, V41, P42, DOI 10.1111/j.1432-0436.1989.tb00730.x; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LINDSTEN T, 1989, SCIENCE, V246, P339; MALTER JS, 1991, J BIOL CHEM, V266, P31657; MANIATIS T, 1990, MOL CLONING; MARIDONNEAUPARI.I, 1986, J IMMUNOL, V137, P2925; MARIDONNEAUPARI.I, 1993, J CELL PHYSIOL, V156, P204; MOSELEY PL, 1993, AM J PHYSIOL, V264, pL533, DOI 10.1152/ajplung.1993.264.6.L533; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; PETERSEN RB, 1990, STRESS PROTEINS BIOL, P379; POLLA BS, 1991, CURR TOP MICROBIOL, V167, P93; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; REBBE NF, 1989, J BIOL CHEM, V264, P15006; RICHARDS FM, 1988, CANCER RES, V48, P6715; RITZ MF, 1993, RECEPTOR, V3, P311; Schlesinger M. J., 1982, HEAT SHOCK BACTERIA; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; TWOMEY BM, 1993, CLIN EXP IMMUNOL, V93, P178; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WU B, 1986, MOL CELL BIOL, V7, P4357; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	40	87	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14094	14099		10.1074/jbc.270.23.14094	http://dx.doi.org/10.1074/jbc.270.23.14094			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775471	hybrid			2022-12-25	WOS:A1995RC44800074
J	OLSON, DC; OETIKER, JH; YANG, SF				OLSON, DC; OETIKER, JH; YANG, SF			ANALYSIS OF LE-ACS3, A 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID SYNTHASE GENE EXPRESSED DURING FLOODING IN THE ROOTS OF TOMATO PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING FACTOR; ETHYLENE BIOSYNTHESIS; DIFFERENTIAL ACCUMULATION; LYCOPERSICON-ESCULENTUM; MAIZE ADH1; SEQUENCES; FRUIT; TRANSCRIPTS; EPINASTY; ELEMENTS	The plant hormone ethylene is produced in response to a variety of environmental stresses. Previous work has shown that flooding or anaerobic stress in the roots of tomato plants caused an increase in the production of the ethylene precursor 1-aminocyclopropane-1-carboxylate (ACC) in the roots, due to flooding-induced activity of ACC synthase (EC 4.4.1.14). RNA was extracted from roots and leaves of tomato plants flooded over a period of 48 h. Blot analysis of these RNAs hybridized with probes for four different ACC synthases revealed that the ACC synthase gene LE-ACS3 is rapidly induced in roots. LE-ACS2 is also induced, but at later times. The genomic clone for LE-ACS3 was isolated and sequenced. At all time points, the probe from the LE-ACS3 coding region hybridized to two bands in the RNA blots. Hybridization using the first and third introns of LE-ACS3 separately as probes indicate that flooding may inhibit processing of the LE-ACS3 transcript. Sequence homology analysis identified three putative cis-acting response elements in the promoter region, corresponding to the anaerobic response element from the maize adh1 promoter, the root-specific expression element from the cauliflower mosaic virus 35S promoter and a recognition element for chloroplast DNA binding factor I from the maize chloroplast ATP synthase promoter.			OLSON, DC (corresponding author), UNIV CALIF DAVIS,DEPT VEGETABLE CROPS,MANN LAB,DAVIS,CA 95616, USA.							Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRADFORD K J, 1980, Plant Physiology (Rockville), V65, P40; BRADFORD KJ, 1980, PLANT PHYSIOL, V65, P322, DOI 10.1104/pp.65.2.322; BRADFORD KJ, 1978, PLANT PHYSIOL, V61, P506, DOI 10.1104/pp.61.4.506; BROWN WS, 1986, NUCLEIC ACIDS RES, V14, P954; CZARNECKA E, 1988, MOL CELL BIOL, V8, P1113, DOI 10.1128/MCB.8.3.1113; DEIKMAN J, 1988, EMBO J, V7, P3315, DOI 10.1002/j.1460-2075.1988.tb03202.x; GOSWH D, 1990, NUCLEIC ACIDS RES, V18, P1749; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Hoagland D.R., 1950, WATER CULTURE METHOD, V347, P1, DOI DOI 10.1007/S12374-010-9112-0; JACKSON MB, 1976, PLANTA, V129, P273, DOI 10.1007/BF00398271; JACKSON MB, 1976, NEW PHYTOL, V76, P21, DOI 10.1111/j.1469-8137.1976.tb01434.x; JACKSON WT, 1956, AM J BOT, V43, P557; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KAWASE M, 1972, J AM SOC HORTIC SCI, V97, P584; KAWASE M, 1974, PHYSIOL PLANTARUM, V31, P29, DOI 10.1111/j.1399-3054.1974.tb03673.x; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KRAMER PJ, 1951, PLANT PHYSIOL, V26, P722, DOI 10.1104/pp.26.4.722; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; LAM E, 1988, J BIOL CHEM, V263, P8288; LINCOLN JE, 1993, J BIOL CHEM, V268, P19422; NASH J, 1992, PLANT PHYSIOL, V100, P464, DOI 10.1104/pp.100.1.464; OLIVE MR, 1990, PLANT MOL BIOL, V15, P593, DOI 10.1007/BF00017834; OLSON DC, 1991, P NATL ACAD SCI USA, V88, P5430; ORTIZ DF, 1990, MOL CELL BIOL, V10, P2090, DOI 10.1128/MCB.10.5.2090; PAUL AL, 1991, PLANT CELL, V3, P159, DOI 10.1105/tpc.3.2.159; POULSEN C, 1988, MOL GEN GENET, V214, P16, DOI 10.1007/BF00340173; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; ROTTMANN WH, 1991, J MOL BIOL, V222, P937, DOI 10.1016/0022-2836(91)90587-V; Sambrook J, 1989, MOL CLONING LABORATO; SPANU P, 1993, J PLANT PHYSIOL, V141, P557, DOI 10.1016/S0176-1617(11)80456-6; TURKOVA NS, 1944, AKAD NAUK USSR LEN C, V42, P87; VAN DER STRAETEN D, 1990, P NATL ACAD SCI USA, V87, P4859, DOI 10.1073/pnas.87.12.4859; WALKER JC, 1987, P NATL ACAD SCI USA, V84, P6624, DOI 10.1073/pnas.84.19.6624; WANG TW, 1992, PLANT PHYSIOL, V98, P97, DOI 10.1104/pp.98.1.97; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865; WINTER J, 1988, MOL GEN GENET, V211, P615; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YIP WK, 1992, P NATL ACAD SCI USA, V89, P2475, DOI 10.1073/pnas.89.6.2475	39	99	107	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14056	14061		10.1074/jbc.270.23.14056	http://dx.doi.org/10.1074/jbc.270.23.14056			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775465	hybrid			2022-12-25	WOS:A1995RC44800068
J	PANG, JHS; HUNG, RY; WU, CJ; FANG, YY; CHAU, LY				PANG, JHS; HUNG, RY; WU, CJ; FANG, YY; CHAU, LY			FUNCTIONAL-CHARACTERIZATION OF THE PROMOTER REGION OF THE PLATELET-ACTIVATING-FACTOR RECEPTOR GENE - IDENTIFICATION OF AN INITIATOR ELEMENT ESSENTIAL FOR GENE-EXPRESSION IN MYELOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; HIP1 BINDING; PROTEIN; SITE; DIFFERENTIATION; INVITRO; CDNA; TATA	To understand the molecular mechanisms that direct the expression of the gene encoding the platelet-activating factor (PAF) receptor, the 5'-flanking region of the human PAF receptor gene was cloned, and its promoter activity in myeloid cell lines was characterized By the 5'-rapid amplification of cDNA ends method and primer extension, the transcription initiation site was mapped to an adenosine residue 137 bases upstream of the ATG translation initiation codon, The promoter region lacks a typical TATA or CCAAT box. However, the sequence encompassing the transcription initiation site shows high homology to the initiator (Inr) sequence. Transfection of promonocytic U937 cells with recombinant plasmids containing a series of truncated segments of the 5'-flanking region linked to the luciferase reporter gene revealed that the sequence from nucleotides -44 to +27 relative to the transcription initiation site was sufficient to promote a high level of gene expression, The promoter activity was much lower in nonexpressing HeLa cells and promyeIocytic HL-60 cells, which express relatively low levels of the PAF receptor, Gel mobility shift analysis demonstrated the binding of nuclear factors extracted from myelocytic cells to the -16/+18 sequence containing the Inr element, No binding activity was detected using the nuclear extracts from the non-myelocytic HeLa cells, The DNA-protein complexes were sequence-specific since the binding was not significantly affected by the mutated Inr sequences or the Inr sequence of the terminal deoxynucleotidyltransferase gene, Furthermore, point mutations in the Inr element significantly reduced promoter activity in both U937 and THP-1 cell lines. When Me(2)SO or retinoic acid was used to induce granulocytic differentiation of HL-60 cells, a distinct Inr-protein complex was induced concurrently, but the complex was not observed in 12-O-tetradecanoylphorbol-13-acetate-induced monocytic differentiated HL-60 cells or Me(2)SO-induced differentiated U937 cells, indicating that the inducible Inr binding activity is granulocyte-specific. These results suggest that distinct nuclear factors interact with the unique Inr element and play a role in the transcriptional regulation of the PAF receptor in various myeloid cells.	ACAD SINICA, INST BIOMED SCI, DIV CARDIOVASC RES, TAIPEI 11529, TAIWAN	Academia Sinica - Taiwan			Chau, Lee-Young/N-7659-2018	Chau, Lee-Young/0000-0002-6316-2328				BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; DIMARTINO JF, 1994, INT IMMUNOL, V6, P1279, DOI 10.1093/intimm/6.8.1279; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; FARAONIO R, 1994, NUCLEIC ACIDS RES, V22, P4876, DOI 10.1093/nar/22.23.4876; GOMOLIN HI, 1993, BLOOD, V82, P1868; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LENORMAND JL, 1993, NUCLEIC ACIDS RES, V21, P695, DOI 10.1093/nar/21.3.695; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MULLER E, 1991, BIOCHEM BIOPH RES CO, V181, P1580, DOI 10.1016/0006-291X(91)92119-5; MURPHY PM, 1990, J IMMUNOL, V145, P2227; MUTOH H, 1993, FEBS LETT, V322, P129, DOI 10.1016/0014-5793(93)81552-B; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PAHL HL, 1991, EXP HEMATOL, V19, P1038; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; SUGIMOTO T, 1992, BIOCHEM BIOPH RES CO, V189, P617, DOI 10.1016/0006-291X(92)92245-S; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TSAIMORRIS CH, 1993, J BIOL CHEM, V268, P4447; VALLARI DS, 1990, J BIOL CHEM, V265, P4261; VENABLE ME, 1993, J LIPID RES, V34, P691; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	33	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14123	14129		10.1074/jbc.270.23.14123	http://dx.doi.org/10.1074/jbc.270.23.14123			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775473	hybrid			2022-12-25	WOS:A1995RC44800078
J	SAENKO, EL; SCANDELLA, D				SAENKO, EL; SCANDELLA, D			A MECHANISM FOR INHIBITION OF FACTOR-VIII BINDING TO PHOSPHOLIPID BY VON-WILLEBRAND-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN VONWILLEBRAND-FACTOR; COAGULATION FACTOR-VIII; AMINO-ACID-SEQUENCES; ACTIVATED PROTEIN-C; LIGHT CHAIN; MONOCLONAL-ANTIBODY; MEMBRANE-BINDING; FACTOR-V; DOMAIN; PHOSPHATIDYLSERINE	von Willebrand factor (vWf) acts as a carrier for blood coagulation factor VIII (fVIII) in the circulation, The amino-terminal 272 residues of mature vWf contain a high affinity fVIII binding site, Upon thrombin activation, fVIII is released from vWf, thereby allowing its binding to phospholipid which is required for its procoagulant activity. Although phospholipid and vWf compete for fVIII binding, it was previously suggested that their binding sites are not closely juxtaposed within the fVIII protein because only amino-terminal vWf proteolytic fragments larger than SPIII-T4 (1-272) were able to block the binding of fVIII to phospholipid. We have demonstrated, however, that SPIII-T4 is able to inhibit fVIII binding to phosphatidylserine (PS) in a dose-dependent fashion, but only at concentrations higher than those used in previous experiments. Our demonstration that the K-d values for vWf and SPIII-T4 for fVIII are 0.52 nM and 48 nn, respectively, explain this discrepancy. Inhibition (>95%) of SPIII-T4 binding to fVIII by a purified recombinant fVIII C2 domain polypeptide demonstrated that SPIII-T4 binds directly to C2, as we had previously shown for vWf, The similarity of the C2 binding sites for vWf and SPIII-T4 was further confirmed by the identical inhibitory effects of synthetic peptides and monoclonal antibodies (mAbs) on vWf-fVIII or SPIII-T4-fVIII binding, In both cases, binding was inhibited by synthetic peptide 2303-2332, containing a PS binding site, and by mAb NMC-VIII/5 Fab' (epitope within C2 residues 2170-2327), We propose that vWf, via residues 1-272, and PS compete for fVIII binding because they recognize overlapping sites within fVIII C2 domain residues 2303-2332.	AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD 20855	American Red Cross					NHLBI NIH HHS [R01-HL36094, P50-HL44336] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BAHOU WF, 1989, J CLIN INVEST, V84, P56, DOI 10.1172/JCI114169; BARDELLE C, 1993, J BIOL CHEM, V268, P8815; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOPEK MW, 1986, BIOCHEMISTRY-US, V25, P3146, DOI 10.1021/bi00359a012; FAY PJ, 1990, J BIOL CHEM, V265, P6197; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GINSBURG D, 1993, THROMB HAEMOSTASIS, V669, P177; GIRMA JP, 1986, BIOCHEMISTRY-US, V25, P3156, DOI 10.1021/bi00359a013; HAMER RJ, 1987, EUR J BIOCHEM, V166, P37, DOI 10.1111/j.1432-1033.1987.tb13480.x; HOYER LW, 1982, METHOD ENZYMOL, V84, P51; JORIEUX S, 1994, BRIT J HAEMATOL, V87, P113, DOI 10.1111/j.1365-2141.1994.tb04879.x; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; KAMISUE S, 1994, BRIT J HAEMATOL, V86, P106, DOI 10.1111/j.1365-2141.1994.tb03259.x; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LANGONE JJ, 1980, METHOD ENZYMOL, V7, P221; LAYET S, 1992, BIOCHEM J, V282, P129, DOI 10.1042/bj2820129; LECOMPTE MF, 1994, J BIOL CHEM, V269, P1905; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LEYTE A, 1991, J BIOL CHEM, V266, P740; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1988, BLOOD, V71, P137; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MERRIL CR, 1986, ANAL BIOCHEM, V156, P96, DOI 10.1016/0003-2697(86)90160-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; SCANDELLA D, 1992, THROMB HAEMOSTASIS, V67, P665; SCANDELLA D, 1993, BLOOD, V82, P1767; SHIMA M, 1991, INT J HEMATOL, V54, P515; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1990, J BIOL CHEM, V265, P1484	46	89	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13826	13833		10.1074/jbc.270.23.13826	http://dx.doi.org/10.1074/jbc.270.23.13826			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775440	hybrid			2022-12-25	WOS:A1995RC44800039
J	RUSINOL, AE; VANCE, JE				RUSINOL, AE; VANCE, JE			INHIBITION OF SECRETION OF TRUNCATED APOLIPOPROTEINS-B BY MONOMETHYLETHANOLAMINE IS INDEPENDENT OF THE LENGTH OF THE APOLIPOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEP G2 CELLS; LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; PAUSE TRANSFER; OLEIC-ACID; TRANSLOCATION; CHOLESTEROL; HEPATOCYTES; RECEPTOR	Translocation of apolipoprotein (ape) B across the endoplasmic reticulum membrane is a likely site for regulation of secretion of very low density lipoproteins from the liver. When primary rat hepatocytes are enriched with the phospholipid phosphatidylmonomethylethanolamine, the secretion of apoB, but not other proteins such as apoprotein Al and albumin, is disrupted (Vance, J. E. (1991) J. Lipid Res. 32, 1971-1982). Moreover, less apoB enters the microsomal lumen and the intracellular degradation of apoB is increased (Rusinol, A E., Chan, E. Y. W., and Vance, J. E. (1993a) J. Biol. Chem. 268, 25168-25175). In the present study we have used McArdle 7777 rat hepatoma cells stably transfected with carboxyl-terminal-truncated variants of human apoB100 and have demonstrated that the reduction in apoB secretion induced by phosphatidylmonomethylethanolamine is not a function of assembly of the apoB into a buoyant Lipoprotein particle. In addition, inhibition of the intracellular degradation of the apoproteins B does not restore apoB secretion, suggesting that the effect of phosphatidylmonomethylethanolamine enrichment on apoB degradation is secondary to the effect on translocation of the protein into the endoplasmic reticulum lumen. Furthermore, supplementation of the culture medium with oleic acid does not increase apoB secretion, reduce the intracellular degradation of apoB or reverse the effects of phosphatidylmonomethylethanolamine enrichment on these processes. Our data support the hypothesis that translocation of apoB protein across the endoplasmic reticulum membrane, regardless of the association of the apoB with neutral lipids, may be a key regulatory step in very low density lipoprotein secretion.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,DEPT MED,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta								ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1992, J BIOL CHEM, V267, P9858; BROWN MS, 1976, SCIENCE, V191, P150, DOI 10.1126/science.174194; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DASHTI N, 1990, J LIPID RES, V31, P113; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; LOWRY OH, 1951, J BIOL CHEM, V192, P265; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; NAKAHARA DH, 1994, J BIOL CHEM, V269, P7617; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SATO R, 1990, J BIOL CHEM, V265, P11880; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VANCE JE, 1991, J LIPID RES, V32, P1971; WHITE AL, 1992, J BIOL CHEM, V267, P15657; YAO ZM, 1991, J BIOL CHEM, V266, P3300	28	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13318	13325		10.1074/jbc.270.22.13318	http://dx.doi.org/10.1074/jbc.270.22.13318			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768932	hybrid			2022-12-25	WOS:A1995RB43900057
J	STRUM, JC; SWENSON, KI; TURNER, JE; BELL, RM				STRUM, JC; SWENSON, KI; TURNER, JE; BELL, RM			CERAMIDE TRIGGERS MEIOTIC CELL-CYCLE PROGRESSION IN XENOPUS OOCYTES - A POTENTIAL MEDIATOR OF PROGESTERONE-INDUCED MATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOMYELIN TURNOVER; PLASMA-MEMBRANE; LAEVIS OOCYTES; INDUCTION; PROTEIN; DIFFERENTIATION; SPHINGOSINE; RELEASE; KINASE	The role of sphingomyelin-derived second messengers in progesterone-induced reinitiation of the meiotic cell cycle of Xenopus laevis oocytes was investigated. A brief treatment of defolliculated oocytes with sphingomyelinase (Staphylococcus aureus) was sufficient to induce maturation as measured by H1 kinase activity and germinal vesicle breakdown (GVBD). Pretreatment with cycloheximide inhibited sphingomyelinase-induced GVBD demonstrating a requirement for protein synthesis. Microinjection of ceramide or sphingosine, potential products of sphingomyelin hydrolysis, were capable of inducing GVBD in the absence of hormone. Metabolic labeling studies suggested the conversion of sphingosine to ceramide was necessary for sphingosine-induced GVBD. Additionally, fumonisin b(1), an inhibitor of sphingosine N-acyltransferase, blocked sphingosine-induced GVBD demonstrating that ceramide is the more proximal biologically active metabolite. Treatment of oocytes with progesterone, the physiological inducer of oocyte maturation, resulted in a time- and concentration-dependent increase in the mass of ceramide and decrease in the mass of sphingomyelin through activation of a Mg2+-dependent neutral sphingomyelinase. These observations suggest that the generation of ceramide from sphingomyelin is part of the signal transduction pathway activated in response to progesterone and that the increase in ceramide is likely to be functionally important in resumption of the meiotic cell cycle.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710	Duke University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020205, R37DK020205] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20205] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; CHIEN EJ, 1991, MOL CELL ENDOCRINOL, V81, P53, DOI 10.1016/0303-7207(91)90204-6; CHRISTIANSEN K, 1975, ANAL BIOCHEM, V66, P93, DOI 10.1016/0003-2697(75)90728-9; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; GODEAU JF, 1978, P NATL ACAD SCI USA, V75, P2353, DOI 10.1073/pnas.75.5.2353; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KIM MY, 1991, J BIOL CHEM, V266, P484; KOSTELLOW AB, 1993, MOL CELL ENDOCRINOL, V92, P33, DOI 10.1016/0303-7207(93)90072-R; LIU ZM, 1993, BIOL REPROD, V49, P980, DOI 10.1095/biolreprod49.5.980; LOOMIS CR, 1985, J BIOL CHEM, V260, P4091; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P1009; MATTEN WT, 1994, DEV BIOL, V5, P173; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; RAMACHANDRAN CK, 1990, BIOCHEM BIOPH RES CO, V167, P607, DOI 10.1016/0006-291X(90)92068-B; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SADLER SE, 1981, J BIOL CHEM, V256, P6368; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; SMITH LD, 1989, DEVELOPMENT, V107, P685; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SPEAKER MG, 1977, NATURE, V267, P848, DOI 10.1038/267848a0; STITH BJ, 1987, EXP CELL RES, V169, P514, DOI 10.1016/0014-4827(87)90211-4; STRUM JC, 1994, J BIOL CHEM, V269, P15493; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; VARNOLD RL, 1990, DEVELOPMENT, V109, P597; VARNOLD RL, 1990, UCLA S MOL CELL BIOL, V125, P1; WANG E, 1991, J BIOL CHEM, V266, P14486; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	39	50	50	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13541	13547		10.1074/jbc.270.22.13541	http://dx.doi.org/10.1074/jbc.270.22.13541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768956	hybrid			2022-12-25	WOS:A1995RB43900086
J	MONTANER, S; RAMOS, A; PERONA, R; ESTEVE, P; CARNERO, A; LACAL, JC				MONTANER, S; RAMOS, A; PERONA, R; ESTEVE, P; CARNERO, A; LACAL, JC			OVEREXPRESSION OF PKC-XI IN NIH3T3 CELLS DOES NOT INDUCE CELL-TRANSFORMATION NOR TUMORIGENICITY AND DOES NOT ALTER NF-KAPPA-B ACTIVITY	ONCOGENE			English	Article						PKC-XI; CELL TRANSFORMATION; NF-KAPPA-B	PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; RAT FIBROBLASTS; ZETA-ISOFORM; ACTIVATION; GROWTH; ONCOGENE; BINDING; EPSILON	Signal transduction is the major mechanism by which cells communicate among themselves through extracellular stimuli. Among the different Structural components involved in signal transduction, protein kinases are one of the key elements in the process. Protein kinase C is a multimember family of kinases which has been involved in the regulation of diverse cellular functions. Regulation of cell growth in fibroblasts has been reported to be one of such functions, In particular the PKC zeta isoenzyme has been postulated to be transforming to NIH3T3 cells (Berra et al., 1993) and to serve as an effector for Ras proteins through the regulation of the NF kappa B transcription factor (Dominguez et al., 1993) and direct interaction (Diaz-Meco et al., 1994). We have investigated the effects of overexpressing the mouse wild-type PKC zeta in NIH3T3 cells. When compared to the parental NIH3T3 cells, we have found (1) no significant effect on cell morphology; (2) no difference in growth properties in the absence of serum or in the presence of individual growth factors such as insulin, phorbol esters or PDGF; (3) no growth in soft agar nor tumorigenic activity in nude mice. In addition cells stably overexpressing the PKC zeta kinase did not interfere or amplify the induction of NF kappa B activity by tumor necrosis factor alfa (TNF-alpha) nor altered NF kappa B activity in transient expression of cells treated with TNF-alpha. Thus, mammalian PKC zeta is most likely not directly involved in the regulation of cell proliferation in fibroblasts nor affects directly or indirectly the activation of NF kappa B.	CSIC,INST INVEST BIOMED,MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Lacal, Juan Carlos/AAL-2235-2020; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777; Carnero, Amancio/0000-0003-4357-3979				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CACACE AM, 1993, ONCOGENE, V8, P2095; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARNERO A, 1994, ONCOGENE, V9, P1387; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; EXTON JH, 1990, J BIOL CHEM, V265, P1; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LACAL JC, 1994, ONCOL REP, V1, P667; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; SINGHAL RL, 1994, CANCER RES, V54, P5574; TOKER A, 1994, J BIOL CHEM, V269, P32358; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159	36	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2213	2220						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784066				2022-12-25	WOS:A1995RB70300017
J	JUNG, LJ; CHAN, CF; GLAZER, AN				JUNG, LJ; CHAN, CF; GLAZER, AN			CANDIDATE GENES FOR THE PHYCOERYTHROCYANIN ALPHA-SUBUNIT LYASE - BIOCHEMICAL-ANALYSIS OF PECE AND PECF INTERPOSON MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM MASTIGOCLADUS-LAMINOSUS; CRYSTAL-STRUCTURE ANALYSIS; INVITRO ATTACHMENT; SYNECHOCOCCUS-SPP; ENERGY-TRANSFER; C-PHYCOCYANIN; ANABAENA; PHYCOBILIPROTEINS; PHYCOBILISOMES; CRYSTALLIZATION	The rod substructures of the Anabaena sp, PCC 7120 phycobilisome contain the light harvesting proteins C-phycocyanin and phycoerythrocyanin (PEG), Even at low light intensities, PEC represents no more than 5% of the phycobilisome protein, The beta subunits of both proteins carry thioether-linked phycocyanobilin (PCB) at beta-Cys-82 and beta-Cys-155; however, C-phycocyanin has PCB at alpha-Cys-84 whereas PEC alpha subunit carries phycobiliviolin at this position. The Anabaena sp, PCC 7120 pec operon is made up of five genes, PecB and pecA encode the beta and alpha subunits of PEC, pecC encodes a linker polypeptide associated with PEC in the rod substructure, and pecE and pecF are genes of unknown function that show a high degree of homology to cpcE and cpcF, that encode a C-phycocyanin alpha subunit PCB lyase (Fairchild, C, D., Zhao, J., Zhou, J., Colson, S, E., Bryant, D. A., and Glazer, A. N. (1992) Proc. Natl. Acad. Sci. U.S. A. 89, 7017-7021), Insertional mutants in pecE and pecF, and an interposon mutant in which a portion of both pecE and pecF was deleted, were constructed. All three types of mutants grew 1.3 times slower than wild-type under limiting light conditions and showed a 20% reduction in the PCB content of whole cells relative to chlorophyll alpha. Holo-PEC was missing from the phycobilisomes of all three types of mutants and the level of the PEC linker polypeptide was reduced relative to the wild-type. However, similar to 30% of the wild-type level of the PEC beta subunit was present in all of these phycobilisomes, In contrast, the PEC alpha subunit was barely detectable in the pecE and pecF mutants, but was present in the pecEF deletion mutant as a PCB-adduct in a 1:1 ratio with the PEC beta subunit. The identity of this ''unnatural'' adduct was confirmed by isolation of the subunit and amino-terminal sequencing, These biochemical results support the inference that pecE and pecF encode a PEC a subunit phycobiliviolin lyase, and, in conjunction with earlier findings, demonstrate that phycobiliprotein bilin lyases show high selectivity (rather than absolute specificity) for both the bilin and the polypeptide substrate.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NIGMS NIH HHS [GM28994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; ARCIERO DM, 1988, J BIOL CHEM, V263, P18350; BANCROFT I, 1989, J BACTERIOL, V171, P5949, DOI 10.1128/jb.171.11.5949-5954.1989; BELKNAP WR, 1987, EMBO J, V6, P871, DOI 10.1002/j.1460-2075.1987.tb04833.x; BLACK TA, 1993, MOL MICROBIOL, V9, P77, DOI 10.1111/j.1365-2958.1993.tb01670.x; BRYANT DA, 1976, ARCH MICROBIOL, V9, P77; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; CORNEJO J, 1992, J BIOL CHEM, V267, P14790; DELORIMIER R, 1993, PLANT MOL BIOL, V21, P225, DOI 10.1007/BF00019939; DEMARSAC NT, 1988, METHOD ENZYMOL, V167, P318; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; DUERRING M, 1990, J MOL BIOL, V211, P633, DOI 10.1016/0022-2836(90)90270-V; EBERLEIN M, 1990, GENE, V94, P133, DOI 10.1016/0378-1119(90)90480-F; ELHAI J, 1988, METHOD ENZYMOL, V167, P747; FAIRCHILD CD, 1994, J BIOL CHEM, V269, P8686; FAIRCHILD CD, 1992, P NATL ACAD SCI USA, V89, P7017, DOI 10.1073/pnas.89.15.7017; FAIRCHILD CD, 1994, J BIOL CHEM, V269, P28988; FICNER R, 1992, J MOL BIOL, V228, P935, DOI 10.1016/0022-2836(92)90876-L; FUGLISTALLER P, 1986, BIOL CHEM H-S, V367, P601, DOI 10.1515/bchm3.1986.367.2.601; GLAZER AN, 1985, ANNU REV BIOPHYS BIO, V14, P47, DOI 10.1146/annurev.biophys.14.1.47; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GLAZER AN, 1973, J BIOL CHEM, V248, P663; GLAZER AN, 1973, J BIOL CHEM, V248, P659; GROSSMAN AR, 1993, MICROBIOL REV, V57, P725, DOI 10.1128/MMBR.57.3.725-749.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI LM, 1992, J BIOL CHEM, V267, P19204; MATHIES RA, 1994, REV SCI INSTRUM, V65, P807, DOI 10.1063/1.1144905; ONG LJ, 1991, J BIOL CHEM, V266, P9515; Sambrook J, 1989, MOL CLONING LABORATO; SWANSON RV, 1992, J BIOL CHEM, V267, P16146; SWANSON RV, 1992, J BACTERIOL, V174, P2640, DOI 10.1128/jb.174.8.2640-2647.1992; SWANSON RV, 1990, ANAL BIOCHEM, V188, P295, DOI 10.1016/0003-2697(90)90609-D; SWANSON RV, 1992, J BACTERIOL, V174, P5488; YAMANAKA G, 1978, J BIOL CHEM, V253, P8303; YU MH, 1981, J BIOL CHEM, V256, P3130; ZHAO JD, 1989, ARCH MICROBIOL, V152, P447, DOI 10.1007/BF00446927; ZHOU JH, 1992, J BIOL CHEM, V267, P16138	38	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12877	12884		10.1074/jbc.270.21.12877	http://dx.doi.org/10.1074/jbc.270.21.12877			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759546	hybrid			2022-12-25	WOS:A1995QZ71100083
J	LOPEZ, LA; SHEETZ, MP				LOPEZ, LA; SHEETZ, MP			A MICROTUBULE-ASSOCIATED PROTEIN (MAP2) KINASE RESTORES MICROTUBULE MOTILITY IN EMBRYONIC BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL-NEURONS; SOLUBLE FACTORS; CELL-DIVISION; PHOSPHORYLATION; TUBULIN; LOCALIZATION; SEPARATION; BINDING; AXON; IDENTIFICATION	Motility driven by the microtubule motors, kinesin and cytoplasmic dynein, is inhibited by MAP2 (Lopez, L. A., and Sheetz, M. P. (1993) Cell Motil. Cytoskeleton 24, 1-16). The MAP2 inhibition is reversed by a kinase that is co-purified with chicken embryonic MAP2, completely releasing MAP2 from the microtubules. We have identified this activity with a kinase, embryonic MAP2 kinase (M(r) = 100,000), which phosphorylates MAP2 at serine amino acid residues. This kinase is c-AMP independent and inhibited by potassium fluoride and glycerol 2-phosphate. Only the phosphorylation produced by embryonic MAP2 kinase can change the affinity of MAP2 by microtubules. Bovine MAPS kinase, Cdc2 kinase, mitogenic activated protein kinase, and the NIMA kinase are able to phosphorylate MAP2 but do not change the affinity for microtubules. In vivo, embryonic MAP2 kinase could play a major role in the regulation of motility and positioning of membranous organelles within the cells even at substoichiometric levels.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University					NIGMS NIH HHS [GM-34775] Funding Source: Medline; NINDS NIH HHS [NS-23345] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; BERKOWITZ SA, 1977, BIOCHEMISTRY-US, V16, P5610, DOI 10.1021/bi00644a035; BORISY GG, 1975, ANN NY ACAD SCI, V253, P107, DOI 10.1111/j.1749-6632.1975.tb19196.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; BURNS RG, 1984, EUR J BIOCHEM, V141, P609, DOI 10.1111/j.1432-1033.1984.tb08236.x; CACERES A, 1984, DEV BRAIN RES, V13, P314, DOI 10.1016/0165-3806(84)90167-6; CACERES A, 1984, J NEUROSCI, V4, P394; CACERES A, 1986, J NEUROSCI, V6, P714; CHENG HC, 1986, J BIOL CHEM, V261, P989; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GRIFFITH LM, 1982, J BIOL CHEM, V257, P9143; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HOSHI M, 1992, EUR J BIOCHEM, V203, P43, DOI 10.1111/j.1432-1033.1992.tb19825.x; HUTCHCROFT JE, 1991, METHOD ENZYMOL, V200, P417; JAMESON L, 1981, P NATL ACAD SCI-BIOL, V78, P3413, DOI 10.1073/pnas.78.6.3413; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KOSIK KS, 1987, J NEUROSCI, V7, P3142; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; LOCKWOOD AH, 1978, CELL, V13, P613, DOI 10.1016/0092-8674(78)90212-X; LOPEZ LA, 1993, CELL MOTIL CYTOSKEL, V24, P1, DOI 10.1002/cm.970240102; LOPEZ LA, 1991, J CELL BIOL, V115; LU KP, 1993, J BIOL CHEM, V268, P8769; MABUCHI I, 1990, DEV GROWTH DIFFER, V32, P549; MURTHY ASN, 1983, EUR J BIOCHEM, V137, P37, DOI 10.1111/j.1432-1033.1983.tb07792.x; OKABE S, 1989, P NATL ACAD SCI USA, V86, P4127, DOI 10.1073/pnas.86.11.4127; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; RAPPAPORT L, 1976, EUR J BIOCHEM, V62, P539, DOI 10.1111/j.1432-1033.1976.tb10188.x; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1988, J BIOL CHEM, V263, P12721; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SEVERIN FF, 1991, FEBS LETT, V282, P65, DOI 10.1016/0014-5793(91)80445-9; SHERLINE P, 1977, J CELL BIOL, V72, P380, DOI 10.1083/jcb.72.2.380; SILLIMAN CC, 1989, BIOCHEM BIOPH RES CO, V160, P993, DOI 10.1016/S0006-291X(89)80099-3; SLOBODA RD, 1982, METHOD ENZYMOL, V85, P409; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; VALE RD, 1985, CELL, V40, P559, DOI 10.1016/0092-8674(85)90204-1; VALLANO ML, 1986, ANN NY ACAD SCI, V466, P453, DOI 10.1111/j.1749-6632.1986.tb38422.x; VALLEE RB, 1981, J CELL BIOL, V90, P568, DOI 10.1083/jcb.90.3.568; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376	53	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12511	12517		10.1074/jbc.270.21.12511	http://dx.doi.org/10.1074/jbc.270.21.12511			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759496	hybrid			2022-12-25	WOS:A1995QZ71100030
J	RAUSSENS, V; NARAYANASWAMI, V; GOORMAGHTIGH, E; RYAN, RO; RUYSSCHAERT, JM				RAUSSENS, V; NARAYANASWAMI, V; GOORMAGHTIGH, E; RYAN, RO; RUYSSCHAERT, JM			ALIGNMENT OF THE APOLIPOPHORIN-III ALPHA-HELICES IN COMPLEX WITH DIMYRISTOYLPHOSPHATIDYLCHOLINE - A UNIQUE SPATIAL ORIENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; HIGH-DENSITY-LIPOPROTEINS; SECONDARY STRUCTURE; MANDUCA-SEXTA; APOLIPOPROTEIN; PROTEINS; PEPTIDES	Apolipophorin-III (apoLp-III) from Manduca sexta can exist in two alternate states: as a globular, lipid-free helix bundle or a Lipid surface-associated apolipoprotein. Previous papers (Ryan R. O., Oikawa K., and Kay C. M. (1993) J. Biol. Chem. 268, 1525-1530; Wientzek M., Hay C. M., Oikawa H., and Ryan R. O. (1994) J. Biol. Chem. 269, 4605-4612) have investigated the structures and properties of apolipophorin-III from M. sexta in the lipid-free state and associated to lipids. Association of apoLp-III with dimyristoylphosphatidylcholine vesicles leads to the formation of uniform lipid discs with an average diameter and thickness of 18.5 +/- 2.0 and 4.8 +/- 0.8 nm, respectively. These discs contain six molecules of apoLp-III. Geometrical calculations based on these data, together with x-ray crystallographic data from the homologous L. migratoria apoLp-III (Breiter D. R., Kanost M. R., Benning M. M., Wesenberg G., Law J. H., Wells M. A., Rayment I., and Holden H. M, (1991) Biochemistry 30, 603-608), have allowed the presentation of a model of lipid-protein interaction, in which the alpha-helices of the apoLp-III orient perpendicular to the phospholipid chains and surround the lipid disc. Here, using polarized Fourier transform-attenuated total reflection infrared spectroscopy, we provide the first experimental evidence of a unique perpendicular orientation of the alpha-helices with respect to the fatty acyl chains of the phospholipids in the disc.	UNIV ALBERTA, DEPT BIOCHEM, LIPID & LIPOPROT RES GRP, EDMONTON, AB T6G 2S2, CANADA	University of Alberta	RAUSSENS, V (corresponding author), FREE UNIV BRUSSELS, CHIM PHYS MACROMOLEC INTERFACES LAB, CP206-2, CAMPUS PLAINE, B-1050 BRUSSELS, BELGIUM.			Narayanaswami, Vasanthy/0000-0001-7088-4057; Goormaghtigh, Erik/0000-0002-2071-2262				BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; COLE KD, 1987, J BIOL CHEM, V262, P11794; FRINGELI UP, 1981, MEMBRANE SPECTROSCOP, P270; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GOORMAGHTIGH E, 1991, EUR J BIOCHEM, V202, P1299, DOI 10.1111/j.1432-1033.1991.tb16503.x; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOORMAGHTIGH E, 1991, EUR J BIOCHEM, V195, P421, DOI 10.1111/j.1432-1033.1991.tb15721.x; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; HOLDEN HM, 1988, J BIOL CHEM, V263, P3960; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; RIFICI VA, 1985, BIOCHIM BIOPHYS ACTA, V834, P205, DOI 10.1016/0005-2760(85)90157-2; ROTHSCHILD KJ, 1979, BIOPHYS J, V25, P473, DOI 10.1016/S0006-3495(79)85317-5; RYAN RO, 1993, J BIOL CHEM, V268, P1525; SHAPIRO JP, 1983, BIOCHEM BIOPH RES CO, V115, P924, DOI 10.1016/S0006-291X(83)80023-0; SONVEAUX N, 1994, J BIOL CHEM, V269, P25687; SWANEY JB, 1980, J BIOL CHEM, V255, P877; TSUBOI M, 1962, J POLYM SCI, V59, P139, DOI 10.1002/pol.1962.1205916712; VANDENBUSSCHE G, 1992, BIOCHEMISTRY-US, V31, P9169, DOI 10.1021/bi00153a008; VANDERHORST DJ, 1988, J BIOL CHEM, V263, P2027; WALD JH, 1990, J BIOL CHEM, V265, P20044; WELLS MA, 1985, INSECT BIOCHEM, V15, P565, DOI 10.1016/0020-1790(85)90116-7; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; ZHOU NE, 1992, J AM CHEM SOC, V114, P4320, DOI 10.1021/ja00037a042	27	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12542	12547		10.1074/jbc.270.21.12542	http://dx.doi.org/10.1074/jbc.270.21.12542			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759500	hybrid			2022-12-25	WOS:A1995QZ71100035
J	SKURAT, AV; ROACH, PJ				SKURAT, AV; ROACH, PJ			PHOSPHORYLATION OF SITES 3A AND 3B (SER(640) ANS SER(644)) IN THE CONTROL OF RABBIT MUSCLE GLYCOGEN-SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SKELETAL-MUSCLE; MULTISITE PHOSPHORYLATION; MOLECULAR MECHANISM; HORMONAL-CONTROL; IDENTIFICATION; INACTIVATION; SEPARATION; INSULIN; CLONING	Glycogen synthase kinase-3 inactivates rabbit muscle glycogen synthase by sequential phosphorylation of four COOH-terminal residues Ser(652) (site 4), Ser(648) (site 3c), Ser(644) (site 3b), and Ser(640) (site 3a). Effective recognition of glycogen synthase by glycogen synthase kinase-3 occurs only after the phosphorylation of Ser(656) (site 5) catalyzed by casein kinase II. The present study addresses specifically the role of sites 3a and 3b in the regulation of glycogen synthase expressed in COS cells, Simultaneous Ser --> Ala substitutions at sites 3 a, b and c, 4, and 5 in the same protein molecule eliminated P-32 labeling in the proteolytic fragment Arg(634)-Lys(682), which contains these sites, This mutant enzyme (which also had a Ser --> Ala substitution at site 2 in the NH2 terminus) had a -/+ glucose-6-P activity ratio of similar to 0.8, similar to that of totally dephosphorylated enzyme, Reinstating serine residues at either site 3a or site 3b restored labeling in the Arg(634)-Lys(682) peptide and caused a decrease in the activity ratio to 0.4-0.6, When both sites 3a and 3b were reintroduced, there was complete inactivation of the enzyme. Thus, sites 3a and 3b are sufficient for the inactivation of glycogen synthase and act synergistically to control activity. This investigation demonstrates the existence of an alternate mechanism for the phosphorylation of sites 3a and 3b that does not depend on prior phosphorylation of site 5.			SKURAT, AV (corresponding author), INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R56DK027221, R01DK027221] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27221] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAI G, 1990, J BIOL CHEM, V265, P7843; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; COHEN P, 1982, EUR J BIOCHEM, V124, P21, DOI 10.1111/j.1432-1033.1982.tb05902.x; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; Cohen P., 1986, ENZYMES, VXVII, P461; DEPAOLIROACH AA, 1983, J BIOL CHEM, V258, P702; DEPAOLIROACH AA, 1981, J BIOL CHEM, V256, P8955; EMBI N, 1981, EUR J BIOCHEM, V115, P405, DOI 10.1111/j.1432-1033.1981.tb05252.x; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; KASLOW HR, 1984, FEBS LETT, V172, P294, DOI 10.1016/0014-5793(84)81144-8; KURET J, 1985, EUR J BIOCHEM, V151, P39, DOI 10.1111/j.1432-1033.1985.tb09066.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LAWRENCE JC, 1983, J BIOL CHEM, V258, P710; Maniatis T., 1982, MOL CLONING; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; NUTTALL FQ, 1994, ARCH BIOCHEM BIOPHYS, V311, P443, DOI 10.1006/abbi.1994.1260; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; PICTON C, 1982, EUR J BIOCHEM, V124, P37, DOI 10.1111/j.1432-1033.1982.tb05903.x; POULTER L, 1988, EUR J BIOCHEM, V175, P497, DOI 10.1111/j.1432-1033.1988.tb14222.x; ROACH PJ, 1976, J BIOL CHEM, V251, P1913; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; SKURAT AV, 1993, J BIOL CHEM, V268, P14701; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; WANG YH, 1993, J BIOL CHEM, V268, P23876; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275; ZHANG WM, 1993, ARCH BIOCHEM BIOPHYS, V304, P219, DOI 10.1006/abbi.1993.1342	33	82	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12491	12497		10.1074/jbc.270.21.12491	http://dx.doi.org/10.1074/jbc.270.21.12491			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759494	hybrid			2022-12-25	WOS:A1995QZ71100027
J	LEI, KJ; PAN, CJ; LIU, JL; SHELLY, LL; CHOU, JY				LEI, KJ; PAN, CJ; LIU, JL; SHELLY, LL; CHOU, JY			STRUCTURE-FUNCTION ANALYSIS OF HUMAN GLUCOSE-6-PHOSPHATASE, THE ENZYME-DEFICIENT IN GLYCOGEN-STORAGE-DISEASE TYPE 1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL GLUCOSE-6-PHOSPHATASE; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; ALKALINE-PHOSPHATASE; PROTEINS; SYSTEM; MUTAGENESIS; MUTATIONS; MECHANISM; CATALYSIS; GENE	Glucose-6-phosphatase (G6Pase) is the enzyme deficient in glycogen storage disease type 1a, an autosomal recessive disorder. We have previously identified six mutations in the G6Pase gene of glycogen storage disease type 1a patients and demonstrated that these mutations abolished or greatly reduced enzymatic activity of G6Pase, a hydrophobic protein of 357 amino acids. Of these, four mutations (R83C, R295C, G222R, and Q347X) are missense and one (Q347X) generates a truncated G6Pase of 346 residues. To further understand the roles and structural requirements of amino acids 83, 222, 295, and those at the carboxyl terminus in G6Pase catalysis, we characterized mutant G6Pases generated by near-saturation mutagenesis of the aforementioned amino acids. Substitution of Arg-83 with amino acids of diverse structures including Lys, a conservative change, yielded mutant G6Pase with no enzymatic activity. On the other hand, substitution of Arg-295 with Lys (R295K) retained high activity, and R295N, R295S, and R295Q exhibited moderate activity. All other substitutions of Arg-295 had no G6Pase activity, suggesting that the role of Arg-295 is to stabilize the protein either by salt bridge or hydrogen-bond formation. Substitution of Gly-222, however, remained functional unless a basic (Arg or Lys), acidic (Asp), or large polar (Gin) residue was introduced, consistent with the hydrophobic requirement of codon 222, which is predicted to be in the fourth membrane-spanning domain. It is possible that Arg-83 is involved in stabilizing the enzyme (His)-phosphate intermediate formed during G6Pase catalysis. There exist 9 conserved His residues in human G6Pase. His-9, His-119, His-252, and His-353 reside on the same side of the endoplasmic reticulum membrane as Arg-83. Whereas H119A mutant G6Pase had no enzymatic activity, H9A, H252A, and H353A mutant G6Pases retained significant activity. Substitution of His-119 with amino acids of diverse structures also yielded mutant G6Pase with no activity, suggesting that His-119 is the phosphate acceptor in G6Pase catalysis. We also present data demonstrating that the carboxyl-terminal 8 residues in human G6Pase are not essential for G6Pase catalysis.	NICHHD, HUMAN GENET BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ARION WJ, 1980, J BIOL CHEM, V255, P396; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BEAUDET AL, 1991, HARRISONS PRINCIPLES, P1854; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUNTAWAY JL, 1988, J BIOL CHEM, V263, P2673; FELDMAN F, 1972, BIOCHIM BIOPHYS ACTA, V268, P698, DOI 10.1016/0005-2744(72)90274-4; Hers HG, 1989, METABOLIC BASIS INHE, P425; HOYLAERTS MF, 1992, BIOCHEM J, V286, P23, DOI 10.1042/bj2860023; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LEI KJ, 1994, J CLIN INVEST, V93, P1994, DOI 10.1172/JCI117192; LEI KJ, 1995, J CLIN INVEST, V95, P234, DOI 10.1172/JCI117645; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; NANDI CL, 1993, PROTEIN ENG, V6, P247, DOI 10.1093/protein/6.3.247; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, P349; ROBERTS VA, 1994, J MOL BIOL, V235, P1098, DOI 10.1006/jmbi.1994.1060; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SUKALSKI KA, 1989, ADV ENZYMOL RAMB, V62, P93; TAULER A, 1990, J BIOL CHEM, V265, P15617; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4	25	62	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11882	11886		10.1074/jbc.270.20.11882	http://dx.doi.org/10.1074/jbc.270.20.11882			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744838	hybrid			2022-12-25	WOS:A1995QY73600034
J	SILLMAN, AL; MONROE, JG				SILLMAN, AL; MONROE, JG			ASSOCIATION OF P72(SYK) WITH THE SRC HOMOLOGY-G (SH2) DOMAINS OF PLC-GAMMA-1 IN B-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; PHOSPHOLIPASE-C; PHOSPHORYLATION SITES; ACTIVATION; BINDING; IG; C-GAMMA-1; EXPRESSION	Phospholipase C gamma-catalyzed inositol phospholipid hydrolysis, a critical step in B cell antigen receptor signaling leading to second messenger generation and proliferation, depends upon tyrosine kinase activation. The B cell antigen receptor-associated tyrosine kinases p53/ 56(lyn), p59(fyn), p55(blk), and p72(syk) are assumed to participate in receptor-initiated signaling. It is unknown, however, which of these kinases is involved in the tyrosine phosphorylation and resulting activation of phospholipase C gamma in response to antigen receptor cross-linking. We have used a fusion protein containing the tandem src homology-2 (SH2) domains of phospholipase C gamma 1 (PLC gamma 1) to identify B cell kinases which associate with PLC gamma 1. Using an in vitro kinase assay, we demonstrate SH2-dependent association of tyrosine kinase activity from anti-mu-stimulated B cells. The PLC gamma 1 SH2 domains associate with a prominent 70-72-kDa tyrosine phosphoprotein from anti-mu-stimulated, but not resting, B cells. Immunoblotting and secondary immunoprecipitation studies definitively identify this protein as p72(syk). These results imply a physical interaction between PLC gamma 1 and p72(syk) in antigen receptor-stimulated B cells. This conclusion is confirmed by our ability to co-immunoprecipitate p72(syk) and PLC gamma 1 from lysates of anti-mu-stimulated B cells. These results implicate p72(syk) in the activation of phospholipase C gamma 1 during B cell antigen receptor signaling.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania				Sillman, Amy/0000-0001-6970-3765	NIAID NIH HHS [AI23568, AI23592] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R23AI023568, R01AI023592, R01AI023568] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V888, P7410; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; COGGESHALL KM, 1984, J IMMUNOL, V133, P3382; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; GOLDSCHMIDTCLER.PJ, 1991, SCIENCE, V251, P1231; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HEMPEL WM, 1991, J IMMUNOL, V146, P3713; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LANE PJL, 1991, J IMMUNOL, V146, P715; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MONROE JG, 1985, J IMMUNOL, V135, P1674; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; RANSOM JT, 1986, J IMMUNOL, V137, P708; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROIFMAN CM, 1992, BIOCHEM BIOPH RES CO, V183, P411, DOI 10.1016/0006-291X(92)90496-8; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	29	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11806	11811		10.1074/jbc.270.20.11806	http://dx.doi.org/10.1074/jbc.270.20.11806			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744830	hybrid			2022-12-25	WOS:A1995QY73600024
J	LANDGREN, E; BLUMEJENSEN, P; COURTNEIDGE, SA; CLAESSONWELSH, L				LANDGREN, E; BLUMEJENSEN, P; COURTNEIDGE, SA; CLAESSONWELSH, L			FIBROBLAST GROWTH-FACTOR RECEPTOR-1 REGULATION OF SRC FAMILY KINASES	ONCOGENE			English	Article						FGF RECEPTOR; SRC FAMILY KINASES; REGULATION	PROTEIN-TYROSINE KINASE; B-TYPE RECEPTOR; SIGNAL-TRANSDUCTION; C-SRC; PDGF RECEPTOR; SH2 DOMAIN; PHOSPHOLIPASE C-GAMMA-1; BETA-RECEPTOR; CDNA CLONING; PHOSPHORYLATION	Fibroblast growth factors (FGFs) induce proliferation and differentiation of a wide variety of cells by stimulation of cell surface expressed high affinity-binding receptor tyrosine kinases. Members of the Src family of cytoplasmic tyrosine kinases are substrates for certain growth factor receptors, We have examined interactions between FGF receptor-1 (FGFR-1) and Src, Fyn and Yes. In lung capillary endothelial cells and murine fibroblasts, bFGF stimulation led to increased autophosphorylation of Src family members, In contrast, in porcine aortic endothelial cells (FGFR-1/PAE) and lung fibroblasts from chinese hamster (CCL 39), activation of FGFR caused reduced autophosphorylation of Src and Fyn. In neither case could complex-formation between Src members and FGFR be seen, Analysis of a panel of mutated FGFR-1 expressed in PAE cells showed that FGFR-1/Y766F mediated an increased autophosphorylation of Src members and upregulation of their kinase activities, Y766 in FGFR-1 has been shown to serve as a binding site for phospholipase C-gamma, which regulates Ca2+ fluxes and protein kinase C (PKC) activity. The negative effect on Src kinase activity upon FGFR stimulation was mimicked by activation of PKC in FGFR-1/PAE or CCL 39 cells using phorbol 12-myristate 13-acetate (PMA) and Src was phosphorylated in vitro by purified recombinant PKC alpha. Moreover, inhibition of PBC attenuated the bFGF induced decrease in autophosphorylation of Src family members, These data indicate a negative regulatory role for PRC on Src kinase activity in certain cell types.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)	LANDGREN, E (corresponding author), BIOMED CTR, LUDWIG INST CANC RES, UPPSALA BRANCH, BOX 595, S-75124 UPPSALA, SWEDEN.			Claesson-Welsh, Lena/0000-0003-4275-2000				ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CASSEL D, 1983, P NATL ACAD SCI-BIOL, V80, P6224, DOI 10.1073/pnas.80.20.6224; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHINKERS M, 1986, J BIOL CHEM, V261, P8295; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COCHET C, 1984, J BIOL CHEM, V259, P2553; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FARESE RV, 1992, CELL SIGNAL, V4, P133, DOI 10.1016/0898-6568(92)90077-L; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GANDINO L, 1990, ONCOGENE, V5, P721; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HOU JZ, 1993, PROTEIN SCI, V2, P86; IWASHITA S, 1992, CELL SIGNAL, V4, P123, DOI 10.1016/0898-6568(92)90076-K; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKADA M, 1991, J BIOL CHEM, V266, P24249; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; STABEL S, 1991, METHOD ENZYMOL, V200, P670; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; ZHAN X, 1994, J BIOL CHEM, V269, P20221	51	84	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					2027	2035						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761103				2022-12-25	WOS:A1995QZ92600017
J	SU, ZZ; YEMUL, S; STEIN, CA; FISHER, PB				SU, ZZ; YEMUL, S; STEIN, CA; FISHER, PB			C-FOS IS A POSITIVE REGULATOR OF CARCINOGEN ENHANCEMENT OF ADENOVIRUS TRANSFORMATION	ONCOGENE			English	Article						IMMEDIATE-EARLY RESPONSE GENES; INDUCIBLE EXPRESSION VECTORS; C-FOS ANTISENSE RNA; VIRAL TRANSFORMATION; AP-1 BINDING; NUCLEAR RUN-ON	EMBRYO FIBROBLAST CELLS; DNA-DAMAGING AGENTS; HOST-RANGE MUTANT; TYPE-5 ADENOVIRUS; METHYL METHANESULFONATE; GROWTH-ARREST; JUN-B; IONIZING-RADIATION; GENOTOXIC-STRESS; GENE-EXPRESSION	The early gene expression changes mediating carcinogen enhancement of viral transformation (GET) remain to be elucidated. A model cell culture system has been developed that is now permitting a molecular analysis of GET. Pretreatment of cloned rat embryo fibroblast (CREF) cells with methyl methanesulfonate (MMS) prior to infection with the cold-sensitive host-range type 5 adenovirus mutant, H5hr1, results in a dose-dependent increase in viral transformation, The present study investigates the role of immediate-early response genes, specifically c-fos, in the CET process, MMS pretreatment, alone or in combination with infection with H5hr1 temporally and differentially increases c-fos, c-jun, jun-B, jun-D and c-myc steady-state mRNA levels, Maximum induction occurs with c-fos and c-jun 8 to 12 h posttreatment and the magnitude of response is generally greatest in CREF cells pretreated with MMS and then infected with H5hr1. Enhancement in RNA levels is observed in the presence of cycloheximide indicating that ongoing protein synthesis is not required for induction of c-fos, c-jun, jun-B or c-myc expression, Nuclear run-on analysis indicates an enhancement in transcriptional rates for c-fos, c-jun, jun-B and c-myc in CREF cells treated with MMS or MMS plus infection with H5hr1. A requirement for elevated c-fos in the early stages of CET is indicated by the ability of c-fos antisense oligonucleotides to prevent the CET process, Direct evidence implicating early increases in c-fos as a mediator of the CET process is demonstrated by stably expressing mouse mammary tumor virus promoter-regulated human sense and antisense c-fos genes in CREF cells, Induction of c-fos sense expression by dexamethasone (DEX) in the absence of MMS treatment results in enhanced c-fos mRNA, Fos protein, AP-1 DNA-binding activity and H5hr1-induced transformation and GET. Induction of c-fos expression by DEX in stable c-fos-sense CREF constructs also results in elevated levels of c-jun, jun-B and c-myc mRNA and protein. Conversely, induction of c-fos antisense expression prevents the increase in c-fos mRNA, Fos protein and AP-I DNA-binding activity and eliminates GET. In the antisense-c-fos constructs, increases in c-jun, jun-B and c-myc mRNA and protein normally induced by MMS also are not apparent, Thus, induction or inhibition in c-fos expression affects the level of expression of additional immediate-early response genes, including c-jun, jun-B and c-myc. These results demonstrate a pivotal role for the early induction of c-fos and possibly c-fos responsive genes, in the CET process.	COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES, CTR COMPREHENS CANC,DEPT UROL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES, CTR COMPREHENS CANC,DEPT SURG, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES, CTR COMPREHENS CANC,DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES, CTR COMPREHENS CANC,DEPT PATHOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University					NATIONAL CANCER INSTITUTE [R01CA043208, R01CA035675, R29CA060639] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA43208, R29 CA60639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1983, P NATL ACAD SCI-BIOL, V80, P1352, DOI 10.1073/pnas.80.5.1352; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P2167, DOI 10.1073/pnas.83.7.2167; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN PH, 1993, ONCOGENE, V8, P877; Casto B C, 1973, Prog Med Virol, V16, P1; CATLING AD, 1993, ONCOGENE, V8, P1875; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CURRAN T, 1987, ONCOGENE, V2, P79; Curran T, 1988, ONCOGENE HDB, P307; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER PB, 1983, CANCER INVEST, V1, P495, DOI 10.3109/07357908309020275; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FISHER PB, 1984, MECHANISMS TUMOR PRO, V3, P57; FISHER PB, 1981, CARCINOGENS IND ENV, P113; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRITSCHE M, 1993, ONCOGENE, V8, P307; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HAUGEN A, 1990, HDB EXPT PHARM, V94, P249; HERMO H, 1987, CARCINOGENESIS, V8, P967, DOI 10.1093/carcin/8.7.967; HERMO H, 1988, CANCER RES, V48, P3050; HERMO H, 1985, MOL BASIS CANCER A, P489; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1989, CANCER RES, V49, P1687; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P197; JIANG HP, 1992, INT J ONCOL, V1, P227; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PRICE BD, 1994, CANCER RES, V54, P896; REDDY PG, 1993, METHODS MOL GENETICS, V1, P68; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHEN R, 1995, IN PRESS P NATL ACAD; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SU ZZ, 1989, MOL CARCINOGEN, V2, P252, DOI 10.1002/mc.2940020505; SU ZZ, 1993, ONCOGENE, V8, P1211; SU ZZ, 1990, MOL CARCINOGEN, V3, P141, DOI 10.1002/mc.2940030307; SU ZZ, 1994, ONCOGENE, V9, P1123; SU ZZ, 1991, MOL CARCINOGEN, V4, P328, DOI 10.1002/mc.2940040412; SU ZZ, 1991, MOL CARCINOGEN, V4, P231, DOI 10.1002/mc.2940040310; SU ZZ, 1993, MOL CARCINOGEN, V8, P155, DOI 10.1002/mc.2940080306; SU ZZ, 1993, CANCER RES, V53, P1929; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TISHLER RB, 1993, CANCER RES, V53, P2212; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WICK M, 1992, ONCOGENE, V7, P859; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; zur Hausen H, 1987, Appl Pathol, V5, P19; [No title captured]	86	3	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					2037	2049						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761104				2022-12-25	WOS:A1995QZ92600018
J	BROWN, AD; LOPEZTERRADA, D; DENNY, C; LEE, KAW				BROWN, AD; LOPEZTERRADA, D; DENNY, C; LEE, KAW			PROMOTERS CONTAINING ATF-BINDING SITES ARE DE-REGULATED IN CELLS THAT EXPRESS THE EWS/ATF1 ONCOGENE	ONCOGENE			English	Article						ONCOGENES; TRANSCRIPTION, CAMP	TRANSCRIPTION FACTOR CREB; MULTIPLE SEQUENCE ELEMENTS; C-FOS PROMOTER; CYCLIC-AMP; MALIGNANT-MELANOMA; RESPONSE ELEMENT; SOMATOSTATIN GENE; PROTEIN-KINASE; FRTL5 CELLS; SOFT PARTS	Chromosomal translocations that fuse the N-terminal region of the Ewings sarcoma oncogene (EWS) to the C-terminal region (including the DNA-binding domain) of the cellular transcription factor ATF1 are associated with a tumour type termed malignant melanoma of soft parts (MMSP). It is envisioned that transformation by the EWS/ATF1 fusion protein results from aberrant transcriptional regulation of genes that are normally regulated by ATF1. To examine this hypothesis we have expressed exogenous EWS-ATF1 in JEG3 cells and tested its ability to activate several promoters that contain binding sites for ATF1. We show that EWS-ATF1 is a strong constitutive activator of some promoters tested but represses others. Significantly, the ability of particular promoters to be activated by EWS/ATF1 in JEG3 cells correlates with promoter activity in two MMSP-derived cell lines (SU-CCS-1 and DTC1). Our results therefore provide evidence that endogenous EWS/ATF1 can de-regulate transcription and that this capacity may contribute to transformation in MMSP.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; UNIV SO CALIF,CHILDRENS HOSP,DEPT PATHOL,LOS ANGELES,CA 90027; UNIV CALIF LOS ANGELES,MED CTR,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024	Children's Hospital Los Angeles; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHUNG EB, 1983, AM J SURG PATHOL, V7, P405, DOI 10.1097/00000478-198307000-00003; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPSTEIN AL, 1984, CANCER RES, V44, P1265; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRIGNANI F, 1994, BLOOD, V83, P10; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERBER B, 1994, ONCOGENE, V9, P1295; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; JIN S, 1986, ENDOCRINOLOGY, V119, P802, DOI 10.1210/endo-119-2-802; JONES C, 1991, MOL CELL BIOL, V11, P4297, DOI 10.1128/MCB.11.9.4297; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; LADANYI M, 1994, CANCER RES, V54, P2837; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEE KAW, 1989, MOL CELL BIOL, V9, P4390, DOI 10.1128/MCB.9.10.4390; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LIU F, 1993, J BIOL CHEM, V268, P6714; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MACARTHUR H, 1984, J VIROL, V483, P84; MAO XH, 1994, J BIOL CHEM, V269, P18216; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P4166, DOI 10.1093/nar/21.18.4166; MASSON N, 1993, NUCLEIC ACIDS RES, V5, P1163; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; OHNO T, 1993, CANCER RES, V53, P5859; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	58	77	77	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1749	1756						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753552				2022-12-25	WOS:A1995QX46900008
J	LEDENT, C; MARCOTTE, A; DUMONT, JE; VASSART, G; PARMENTIER, M				LEDENT, C; MARCOTTE, A; DUMONT, JE; VASSART, G; PARMENTIER, M			DIFFERENTIATED CARCINOMAS DEVELOP AS A CONSEQUENCE OF THE THYROID-SPECIFIC EXPRESSION OF A THYROGLOBULIN-HUMAN PAPILLOMAVIRUS TYPE-16 E7 TRANSGENE	ONCOGENE			English	Article						RETINOBLASTOMA SUSCEPTIBILITY; GENE PRODUCT; THYROID TUMORS; TRANSGENIC MODEL	TISSUE-SPECIFIC EXPRESSION; MICE; GENE; PROTEIN; TUMORIGENESIS; ONCOGENES; CLONING; COEXPRESSION; THYROTROPIN; FRAGMENTS	The oncogenic properties of the high risk human papillomaviruses (HPV) E7 protein are attributed to its interaction with the retinoblastoma susceptibility gene product RB1 and other related proteins, We report here the generation of a transgenic model expressing the E7 oncogene of HPV16 in thyroid follicular cells, under control of the bovine thyroglobulin gene promoter. Transgenics develop differentiated and functionally regulated thyroid goitres, due to thyroid cell proliferation and accumulation of colloid, On the background of this colloid goitre, the mice develop foci of more actively proliferating cells that become invasive and ultimately tend to loose their differentiation, Old mice display secondary tumour nodules that mimic the various histological aspects of the human differentiated thyroid cancers: the follicular and papillary carcinomas, The development of totally undifferentiated carcinoma is in contrast exceptional, We conclude that RB1, and/or related proteins, are responsible for the strict negative control of proliferation that characterizes the thyroid cell of the adult, Inactivation of these proteins results in a continuous growth of the thyroid, without affecting its differentiation, function and regulation, Given the high frequency of progression to highly malignant phenotypes, the retinoblastoma susceptibility and related genes are good candidates as targets for mutations or deletions in early steps of human thyroid carcinogenesis. The search for such mutations in human thyroid cancers will test if this hypothesis holds true.	FREE UNIV BRUSSELS,SERV GENET MED,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	LEDENT, C (corresponding author), FREE UNIV BRUSSELS,IRIBHN,CAMPUS ERASME,808 ROUTE LENNIK,B-1070 BRUSSELS,BELGIUM.			Parmentier, Marc/0000-0001-8081-4685				AASLAND R, 1988, BRIT J CANCER, V57, P358, DOI 10.1038/bjc.1988.82; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; CHRISTOPHE D, 1990, TRENDS ENDOCRIN MET, V1, P351, DOI 10.1016/1043-2760(90)90083-F; COCLET J, 1989, CLIN ENDOCRINOL, V31, P655, DOI 10.1111/j.1365-2265.1989.tb01290.x; CORDONCARDO C, 1994, AM J PATHOL, V144, P500; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIGGE J, 1991, AM J PATHOL, V139, P1213; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; HEDINGER C, 1988, INT HISTOLOGICAL CLA; HOGAN B, 1986, MANIPULATING MOUSE E; HOLM R, 1994, J PATHOL, V172, P267, DOI 10.1002/path.1711720307; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; LEDENT C, 1994, EUR J ENDOCRINOL, V130, P8, DOI 10.1530/eje.0.1300008; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; LEMOINE NR, 1989, ONCOGENE, V4, P159; LOWY DR, 1994, P NATL ACAD SCI USA, V91, P2436, DOI 10.1073/pnas.91.7.2436; MACMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MAYOL X, 1993, ONCOGENE, V8, P2561; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NEVINS JR, 1992, SCIENCE, V258, P424; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PONTA H, 1994, BBA-REV CANCER, V1198, P1, DOI 10.1016/0304-419X(94)90002-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH P, 1989, THYROID TUMORS MOL B; STUDER H, 1986, SIMPLE NODULAR SPORA; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WILLIAMS DW, 1989, THYROID TUMORS MOL B; WYLLIE FS, 1989, BRIT J CANCER, V60, P561, DOI 10.1038/bjc.1989.313; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	47	46	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1789	1797						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753555				2022-12-25	WOS:A1995QX46900012
J	SZEKELY, L; POKROVSKAJA, K; JIANG, WQ; SELIVANOVA, G; LOWBEER, M; RINGERTZ, N; WIMAN, KG; KLEIN, G				SZEKELY, L; POKROVSKAJA, K; JIANG, WQ; SELIVANOVA, G; LOWBEER, M; RINGERTZ, N; WIMAN, KG; KLEIN, G			RESTING B-CELLS, EBV-INFECTED B-BLASTS AND ESTABLISHED LYMPHOBLASTOID CELL-LINES DIFFER IN THEIR RB, P53 AND EBNA-5 EXPRESSION PATTERNS	ONCOGENE			English	Note						EBV; RB; P53; B-CELL; EBNA	EPSTEIN-BARR-VIRUS; ENCODED NUCLEAR ANTIGEN; TUMOR-SUPPRESSOR GENES; RETINOBLASTOMA PROTEIN; TRANSFORMATION INVITRO; GROWTH TRANSFORMATION; BURKITTS-LYMPHOMA; LYMPHOCYTES-B; ANTIBODIES; DIFFERENTIATION	Using immunofluorescence technique we have analysed the Rb, p53, EBNA-2 and EBNA-5 expression pattern in EBV infected human B-cells and established lymphoblastoid cell lines (LCL-s). Resting B-cells showed only a faint Rb and no p53 immunostaining. The expression of both Rb and p53 increased after EBV infection. The change was first detectable 6 h after infection. The frequency of brilliantly Rb positive cells increased more than p53 positives. EBNA-2 and EBNA-5 first detectable 12 h after infection. The frequency of EBNA positive cells in the freshly infected cultures was concordant with the proportion of CD23 and PCNA positives, but remained consistently below the frequency of Rb and p53 positive cells. Double immunofluorescence staining showed that all EBNA-5 positive cells were strongly Rb and p53 positive. LCL-s did not stain for p53, whereas the Rb staining was maintained at a high level. The EBNA-5 staining pattern changed from brilliant almost homogeneous nuclear staining in the freshly infected B-cells, to a nonhomogeneous pattern with a small number of strongly fluorescent nuclear bodies in established LCL-s. There was no change in the EBNA-2 staining pattern. Our findings indicate that the immortalization of B-cells by EBV may initially involve a high expression of EBNA-5, p53 and Rb, but only cells with low p53 and focal expression of EBNA-5 in nuclear bodies have the selective advantage required to grow into immortalized lines.	KAROLINSKA INST, DEPT CELL & MOLEC BIOL, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet	SZEKELY, L (corresponding author), KAROLINSKA INST, CTR MICROBIOL & TUMOR BIOL, S-17177 STOCKHOLM, SWEDEN.		Szekely, Laszlo/B-1268-2009; Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Selivanova, Galina/0000-0002-8698-4332; Pokrovskaja Tamm, Katja/0000-0001-6359-1256; Szekely, Laszlo/0000-0001-6144-6573	NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [2 R01 CA14054-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; COHEN JI, 1991, J VIROL, V65, P2545, DOI 10.1128/JVI.65.5.2545-2554.1991; COHEN JI, 1991, J VIROL, V65, P5880, DOI 10.1128/JVI.65.11.5880-5885.1991; COHEN JI, 1992, J VIROL, V66, P7555, DOI 10.1128/JVI.66.12.7555-7559.1992; DILLNER J, 1988, INT J CANCER, V42, P721, DOI 10.1002/ijc.2910420516; DILLNER J, 1988, ADV CANCER RES, V50, P95, DOI 10.1016/S0065-230X(08)60436-4; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; JIANG WQ, 1991, EXP CELL RES, V197, P314, DOI 10.1016/0014-4827(91)90438-Z; JIANG WQ, 1991, J CELL SCI, V99, P497; KNUTSON JC, 1990, J VIROL, V64, P2530, DOI 10.1128/JVI.64.6.2530-2536.1990; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LING PD, 1994, J VIROL, V68, P5375, DOI 10.1128/JVI.68.9.5375-5383.1994; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MIDDLETON T, 1991, ADV VIRUS RES, V40, P19; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; RING CJA, 1994, J GEN VIROL, V75, P1, DOI 10.1099/0022-1317-75-1-1; SAMPLE J, 1990, J VIROL, V64, P1667, DOI 10.1128/JVI.64.4.1667-1674.1990; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TOMKINSON B, 1992, J VIROL, V66, P2893, DOI 10.1128/JVI.66.5.2893-2903.1992; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; WANG F, 1991, J VIROL, V65, P4101, DOI 10.1128/JVI.65.8.4101-4106.1991; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817	32	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1869	1874						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753563				2022-12-25	WOS:A1995QX46900021
J	IYER, M; NORTON, JC; COREY, DR				IYER, M; NORTON, JC; COREY, DR			ACCELERATED HYBRIDIZATION OF OLIGONUCLEOTIDES TO DUPLEX DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST REPLICATION ORIGIN; TRIPLE-HELIX FORMATION; SUPERCOILED DNA; CRUCIFORM STRUCTURES; NUCLEASE; TRANSCRIPTION; POLYMERASE; GENERATION; SEQUENCES; CLEAVAGE	We report two strategies for accelerating the hybridization of oligonucleotides to DNA. We demonstrate that oligodeoxyribonucleotides and peptide nucleic acid oligomers hybridize to inverted repeats within duplex DNA by D-loop formation. Oligonucleotides and duplex template form an active complex, which can be recognized by T7 DNA polymerase to prime polymerization. Quantitation of polymerization products allowed the rate of hybridization to be estimated, and peptide nucleic acid oligomers and oligonucleotide-protein adducts anneal with association constants 500- and 12,000-fold greater, respectively, than the analogous unmodified oligonucleotides. Together, these results indicate that sequences within duplex DNA can be targeted by Watson-Crick base pairing and that chemical modifications can dramatically enhance the rate of strand association. These findings should facilitate targeting of oligomers for priming DNA polymerization, the detection of diagnostic sequences, and the disruption of gene expression. The observed acceleration of hybridization may offer a new perspective on the ability of RecA or other proteins to accelerate strand invasion.			IYER, M (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, HOWARD HUGHES MED INST, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.							BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; BENHAM CJ, 1993, P NATL ACAD SCI USA, V90, P2999, DOI 10.1073/pnas.90.7.2999; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; CONNOLLY BA, 1985, NUCLEIC ACIDS RES, V13, P4485, DOI 10.1093/nar/13.12.4485; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; COREY DR, 1989, BIOCHEMISTRY-US, V28, P8277, DOI 10.1021/bi00447a004; COREY DR, 1995, BIOCONJUGATE CHEM, V6, P93, DOI 10.1021/bc00031a011; COREY DR, 1989, J AM CHEM SOC, V111, P8523, DOI 10.1021/ja00204a038; COREY DR, 1987, SCIENCE, V238, P1401, DOI 10.1126/science.3685986; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DILLER JD, 1994, TRENDS BIOCHEM SCI, V19, P320, DOI 10.1016/0968-0004(94)90070-1; DUEHOLM KL, 1994, J ORG CHEM, V59, P5767, DOI 10.1021/jo00098a042; FRANKKAMENETSKII MD, 1992, METHOD ENZYMOL, V211, P180; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JOHNSON NP, 1994, P NATL ACAD SCI USA, V91, P4840, DOI 10.1073/pnas.91.11.4840; KMIEC EB, 1994, J BIOL CHEM, V269, P10163; LANDGRAF R, 1994, BIOCHEMISTRY-US, V33, P10607, DOI 10.1021/bi00201a006; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; LUKOMSKI S, 1994, P NATL ACAD SCI USA, V91, P9980, DOI 10.1073/pnas.91.21.9980; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MURCHIE AIH, 1992, METHOD ENZYMOL, V211, P158; NATALE DA, 1992, P NATL ACAD SCI USA, V89, P2654, DOI 10.1073/pnas.89.7.2654; NIELSEN PE, 1994, BIOCONJUGATE CHEM, V5, P3, DOI 10.1021/bc00025a001; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NORTON JC, 1995, BIOORGAN MED CHEM, V3, P437, DOI 10.1016/0968-0896(95)00033-D; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P285, DOI 10.1021/bi00001a035; PEI DH, 1990, P NATL ACAD SCI USA, V87, P9858, DOI 10.1073/pnas.87.24.9858; PERRIN DM, 1994, BIOCHEMISTRY-US, V33, P3848, DOI 10.1021/bi00179a008; PONTIUS BW, 1991, P NATL ACAD SCI USA, V88, P8237, DOI 10.1073/pnas.88.18.8237; REEVES R, 1990, J BIOL CHEM, V265, P8573; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; UMEK RM, 1990, NUCLEIC ACIDS RES, V18, P6601, DOI 10.1093/nar/18.22.6601; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	34	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14712	14717		10.1074/jbc.270.24.14712	http://dx.doi.org/10.1074/jbc.270.24.14712			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782335	hybrid			2022-12-25	WOS:A1995RD45500072
J	LITHGOW, T; SCHATZ, G				LITHGOW, T; SCHATZ, G			IMPORT OF THE CYTOCHROME-OXIDASE SUBUNIT VA PRECURSOR INTO YEAST MITOCHONDRIA IS MEDIATED BY THE OUTER-MEMBRANE RECEPTOR MAS20P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN IMPORT; INTERMEMBRANE SPACE; MACHINERY; BINDING; PATHWAY	Post-translational import of precursor proteins into yeast mitochondria is mediated by at least four protease-sensitive outer membrane proteins: Mas20p, Mas22p, Mas37p, and Mas70p, These ''import receptors'' recognize either the N-terminal targeting signal or some other feature of mitochondrial precursor proteins. The only exception to this general rule appeared to be the precursor to subunit Va of cytochrome c oxidase (COXVa). Although this precursor carries a typical N-terminal mitochondrial targeting sequence, its import into mitochondria has been suggested to be independent of the known import receptors. Here we show that if import into isolated yeast mitochondria is assayed under conditions in which binding of the COXVa precursor to mitochondria is rate-limiting, import is strongly inhibited by protease pretreatment of the mitochondria or by antibodies against Mas20p. Post-translational import of the COXVa precursor can thus proceed by the general, receptor-mediated pathway.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel			Lithgow, Trevor J/H-5925-2017	Lithgow, Trevor J/0000-0002-0102-7884				CUMSKY MG, 1987, MOL CELL BIOL, V7, P3511, DOI 10.1128/MCB.7.10.3511; GARTNER F, 1995, J BIOL CHEM, V270, P3788; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GLICK BS, 1995, IN PRESS METHODS ENZ; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1994, J MEMBRANE BIOL, V135, P191; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; LITHGOW T, 1994, J BIOL CHEM, V269, P15325; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MILLER BR, 1991, J CELL BIOL, V112, P833, DOI 10.1083/jcb.112.5.833; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHATZ G, 1993, PROTEIN SCI, V2, P141; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353	22	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14267	14269		10.1074/jbc.270.24.14267	http://dx.doi.org/10.1074/jbc.270.24.14267			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782281	hybrid			2022-12-25	WOS:A1995RD45500007
J	GREENFEDER, SA; NUNES, P; KWEE, L; LABOW, M; CHIZZONITE, PA; JU, G				GREENFEDER, SA; NUNES, P; KWEE, L; LABOW, M; CHIZZONITE, PA; JU, G			MOLECULAR-CLONING AND CHARACTERIZATION OF A 2ND SUBUNIT OF THE INTERLEUKIN-1 RECEPTOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; T-CELLS; MAMMALIAN EXPRESSION; IL-1 RECEPTOR; II RECEPTOR; CDNA; BINDING; GENE; PROTEIN; TARGET	A monoclonal antibody (mAb) was isolated that blocked the binding and bioactivity of both human and murine interleukin 1 beta (LI-1 beta) on murine IL-1 receptor-bearing cells. This mAb recognized a protein that was distinct from the Type I and Type II IL-1 receptors, suggesting that an additional protein exists that is involved in IL-1 biological responses. By expression cloning in COS-7 cells, we have isolated a cDNA from mouse 3T3-LI cells encoding this putative auxiliary molecule, which we term the IL-1 receptor accessory protein (IL-1R AcP), Sequence analysis of the cDNA predicts an open reading frame that encodes a 570-amino acid protein with a molecular mass of similar to 66 kDa. The IL-1R AcP is a member of the Ig superfamily by analysis of its putative extracellular domain and also bears limited homology throughout the protein to both Type I and Type II IL-1 receptors, Northern analysis reveals that murine IL-1R AcP mRNA is expressed in many tissues and appears to be regulated by IL-1, In mammalian cells expressing natural or recombinant Type I IL-1R and IL-1R AcP, the accessory protein forms a complex with the Type I IL-1R and either IL-1 alpha or IL-1 beta but not IL-1ra, The recombinant accessory protein also increases the binding affinity of the recombinant Type I HL-1R for IL-1 beta when the two receptor proteins are coexpressed. Therefore, the functional IL-1 receptor appears to be a complex composed of at least two subunits.	HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT INFLAMMAT AUTOIMMUNE DIS,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT BIOTECHNOL,NUTLEY,NJ 07110	Roche Holding; Roche Holding								ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CHIZZONITE R, 1991, J IMMUNOL, V147, P1548; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DINARELLO CA, 1989, IMMUNOL TODAY, V10, P49, DOI 10.1016/0167-5699(89)90304-6; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER S K, 1990, P137; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORUK R, 1987, J BIOL CHEM, V262, P16275; HORUK R, 1989, BIOCHEM J, V260, P657, DOI 10.1042/bj2600657; KILIAN PL, 1986, J IMMUNOL, V136, P4509; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOHIRA T, 1993, J BIOCHEM-TOKYO, V114, P658, DOI 10.1093/oxfordjournals.jbchem.a124233; KUNO K, 1993, J BIOL CHEM, V268, P13510; KUPPER TS, 1988, J CLIN INVEST, V82, P1787, DOI 10.1172/JCI113792; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANCILLA J, 1992, LYMPHOKINE CYTOK RES, V11, P197; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MIZEL SB, 1987, J IMMUNOL, V138, P2906; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SLACK J, 1993, J BIOL CHEM, V268, P2513; SOLARI R, 1990, Cytokine, V2, P21, DOI 10.1016/1043-4666(90)90039-V; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854	43	534	574	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13757	13765		10.1074/jbc.270.23.13757	http://dx.doi.org/10.1074/jbc.270.23.13757			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775431	hybrid			2022-12-25	WOS:A1995RC44800028
J	JUST, I; WILM, M; SELZER, J; REX, G; VONEICHELSTREIBER, C; MANN, M; AKTORIES, K				JUST, I; WILM, M; SELZER, J; REX, G; VONEICHELSTREIBER, C; MANN, M; AKTORIES, K			THE ENTEROTOXIN FROM CLOSTRIDIUM-DIFFICILE (TOXA) MONOGLUCOSYLATES THE RHO-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; TRIPHOSPHATE CONFORMATION; GENE-PRODUCT; PURIFICATION; TOXINS; CELLS; C-3; MECHANISM; P21	The enterotoxin from Clostridium difficile (ToxA) is one of the causative agents of the antibiotic-associated pseudomembranous colitis. In cultured monolayer cells ToxA exhibits cytotoxic activity to induce disassembly of the actin cytoskeleton, which is accompanied by morphological changes. ToxA-induced depolymerization of actin filaments is correlated with a decrease in the ADP-ribosylation of the low molecular mass GTP-binding Rho proteins (Just, I., Selzer, J., von Eichel-Streiber, C., and Aktories, R. (1995) J. Clin. Invest. 95, 1026-1031). Here we report on the identification of the ToxA-induced modification of Rho. Applying electrospray mass spectrometry, the mass of the modification was determined as 162 Da, which is consistent with the incorporation of a hexose into Rho. From several hexoses tested UDP-glucose selectively served as cosubstrate for ToxA-catalyzed modification. The acceptor amino acid of glucosylation was identified from a Lys-C-generated peptide by tandem mass spectrometry as Thr-37. Mutation of Thr-37 to Ala completely abolished glucosylation. The members of the Rho family (RhoA, Rac1, and Cdc42Hs) were substrates for ToxA, whereas H-Ras, Rab5, and Arf1 were not glucosylated. ToxA-catalyzed glucosylation of lysates from ToxA-pretreated rat basophilic leukemia (RBL) cells resulted in a decreased incorporation of [C-14]glucose, indicating previous glucosylation in the intact cell. Glucosylation of the Rho subtype proteins appears to be the molecular mechanism by which C. difficile ToxA mediates its cytotoxic effects on cells.	INST PHARMAKOL & TOXIKOL,D-79104 FREIBURG,GERMANY; EUROPEAN MOLEC BIOL LABS,D-69012 HEIDELBERG,GERMANY; UNIV MAINZ,INST MED MIKROBIOL,D-55101 MAINZ,GERMANY	European Molecular Biology Laboratory (EMBL); Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf	JUST, I (corresponding author), UNIV SAARLAND,INST PHARMAKOL & TOXIKOL,D-66421 HOMBURG,GERMANY.		Aktories, Klaus/CAJ-5682-2022; Mann, Matthias/A-3454-2013	Aktories, Klaus/0000-0002-5397-0436; Mann, Matthias/0000-0003-1292-4799; Wilm, Matthias/0000-0002-5461-6834				AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; FIORENTINI C, 1991, TOXICON, V29, P543, DOI 10.1016/0041-0101(91)90050-2; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1994, J CELL SCI, V107, P1653; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KNOOP FC, 1993, CLIN MICROBIOL REV, V6, P251, DOI 10.1128/CMR.6.3.251-265.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; LYERLY DM, 1985, INFECT IMMUN, V47, P349, DOI 10.1128/IAI.47.2.349-352.1985; MADSHUS IH, 1992, CURR TOP MICROBIOL I, V175, P2; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SELF AJ, 1993, ONCOGENE, V8, P655; VONEICHELSTREIB.C, 1987, MICROB PATHOGENESIS, V2, P307; VONEICHELSTREIB.C, 1991, BIOCHEM SOC T, V19, P1154; VONEICHELSTREIB.C, 1992, MOL GEN GENET, V233, P260; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	25	393	400	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13932	13936		10.1074/jbc.270.23.13932	http://dx.doi.org/10.1074/jbc.270.23.13932			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775453	hybrid			2022-12-25	WOS:A1995RC44800052
J	KIM, J; CHUBATSU, LS; ADMON, A; STAHL, J; FELLOUS, R; LINN, S				KIM, J; CHUBATSU, LS; ADMON, A; STAHL, J; FELLOUS, R; LINN, S			IMPLICATION OF MAMMALIAN RIBOSOMAL-PROTEIN S3 IN THE PROCESSING OF DNA-DAMAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA PIGMENTOSUM FIBROBLASTS; NUCLEOTIDE EXCISION REPAIR; COLONY-FORMING ABILITY; ESCHERICHIA-COLI; ENDONUCLEASE-V; RAT-LIVER; CELLS; GENE; PURIFICATION; INITIATION	A human apurinic/apyrimidinic endonuclease activity, called AP endonuclease I, is missing from or altered specifically in cells cultured from Xeroderma pigmentosum group-D individuals (XP-D cells) (Kuhnlein, U., Lee, B., Penhoet, E. E., and Linn, S. (1978) Nucleic Acids Res. 5, 951-960). We have now observed that another nuclease activity, UV endonuclease III, is similarly not detected in XP-D cells and is inseparable from the AP endonuclease I activity. This activity preferentially cleaves the phosphodiester backbone of heavily ultraviolet-irradiated DNA at unknown lesions as well as at one of the phosphodiester bonds within a cyclobutane pyrimidine dimer. The nuclease activities have been purified from mouse cells to yield a peptide of M(r) = 32,000, whose sequence indicates identity with ribosomal protein S3. The nuclease activities all cross-react with immunopurified antibody directed against authentic rat ribosomal protein S3, and, upon expression in Escherichia coli of a cloned rat cDNA for ribosomal protein S3, each of the activities was recovered and was indistinguishable from those of the mammalian UV endonuclease III. Moreover, the protein expressed in E. coli and its activities crossreact with the rat protein antibody. Ribosomal protein S3 contains a potential nuclear localization signal, and the protein isolated as a nuclease also has a glycosylation pattern consistent with a nuclear localization as determined by lectin binding. The unexpected role of a ribosomal protein in DNA damage processing and the unexplained inability to detect the nuclease activities in extracts from XP-D cells are discussed.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; MAX DELBRUCK CENTRUM MOLEK MED,D-13125 BERLIN,GERMANY	University of California System; University of California Berkeley; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Chubatsu, Leda S./H-2603-2012	Chubatsu, Leda S./0000-0002-8687-2816; Admon, Arie/0000-0003-0504-3950	NIEHS NIH HHS [P30ES011896] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R43ES011896] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMACHER DE, 1977, P NATL ACAD SCI USA, V74, P1553, DOI 10.1073/pnas.74.4.1553; ANDERSON CTM, 1980, NUCLEIC ACIDS RES, V8, P875; ANDERSSON S, 1994, GENETICS, V137, P513; ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; BOMMER UA, 1991, BIOCHIMIE, V73, P1007, DOI 10.1016/0300-9084(91)90142-N; BOYCE RP, 1964, P NATL ACAD SCI USA, V51, P293, DOI 10.1073/pnas.51.2.293; BRUCKNER RC, 1989, NUCLEIC ACIDS RES, V17, P3145, DOI 10.1093/nar/17.8.3145; CHAN YL, 1990, ARCH BIOCHEM BIOPHYS, V283, P546, DOI 10.1016/0003-9861(90)90682-O; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; DEMPLE B, 1982, NUCLEIC ACIDS RES, V10, P3781, DOI 10.1093/nar/10.12.3781; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DEWEERDKASTELEI, 1972, NATURE NEW BIOL, V238, P80; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; FRIEDBERG EC, 1971, J BACTERIOL, V106, P500, DOI 10.1128/JB.106.2.500-507.1971; GALLOWAY AM, 1994, J BIOL CHEM, V269, P974; GATES FT, 1977, J BIOL CHEM, V252, P1647; HADJINOLOV AA, 1985, CELL BIOL MONOGR, V12; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; KANE CM, 1981, J BIOL CHEM, V256, P3405; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KIM J, 1989, J BIOL CHEM, V264, P2739; KRAEMER KH, 1976, BIOCHIM BIOPHYS ACTA, V442, P147, DOI 10.1016/0005-2787(76)90485-8; KRAEMER KH, 1984, CARCINOGENESIS, V5, P511, DOI 10.1093/carcin/5.4.511; KUDRNA RD, 1979, MUTAT RES, V62, P173, DOI 10.1016/0027-5107(79)90230-6; KUHNLEIN U, 1976, P NATL ACAD SCI USA, V73, P1169, DOI 10.1073/pnas.73.4.1169; KUHNLEIN U, 1978, NUCLEIC ACIDS RES, V5, P951, DOI 10.1093/nar/5.3.951; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; LINN SM, 1993, NUCLEASES, P455; LOEBER G, 1977, Photochemistry and Photobiology, V25, P215; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUSBAUGH D, 1980, J BIOL CHEM, V255, P11743; NAKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; POGUEGEILE K, 1991, MOL CELL BIOL, V11, P3842, DOI 10.1128/MCB.11.8.3842; ROBSON CN, 1992, NUCLEIC ACIDS RES, V20, P4417, DOI 10.1093/nar/20.17.4417; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SNAPKA RM, 1981, BIOCHEMISTRY-US, V20, P68, DOI 10.1021/bi00504a012; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOLAN DR, 1983, BIOCHIMIE, V65, P427, DOI 10.1016/S0300-9084(83)80062-5; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEINFELD M, 1986, BIOCHEMISTRY-US, V25, P2656, DOI 10.1021/bi00357a055; WESTERMANN P, 1979, FEBS LETT, V97, P101, DOI 10.1016/0014-5793(79)80061-7; WILSON DM, 1994, J BIOL CHEM, V269, P25359; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	48	167	178	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13620	13629		10.1074/jbc.270.23.13620	http://dx.doi.org/10.1074/jbc.270.23.13620			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775413	hybrid			2022-12-25	WOS:A1995RC44800009
J	NAISMITH, JH; DEVINE, TQ; BRANDHUBER, BJ; SPRANG, SR				NAISMITH, JH; DEVINE, TQ; BRANDHUBER, BJ; SPRANG, SR			CRYSTALLOGRAPHIC EVIDENCE FOR DIMERIZATION OF UNLIGANDED TUMOR-NECROSIS-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN STRUCTURES; MOLECULAR-CLONING; TNF RECEPTOR; ANTIBODIES; ACTIVATION; EXPRESSION; INTERFACES; BINDING; SURFACE	Activation of the cell surface receptors for tumor necrosis factor (TNF) is effected by the aggregation of cytoplasmic domains that occurs when the extracellular domains of two or three receptors bind to trimeric TNF alpha or TNF beta. The structure of the type I TNF receptor extracellular domain (sTNF-R1), crystallized in the absence of TNF, has now been determined at 2.25-Angstrom resolution. The receptor itself is an elongated molecule comprising four disulfide-rich domains in a nearly linear array. Contrary to expectations, the unliganded domains are found to associate into dimers of two distinct types, in which monomers are related by local two-fold axes of symmetry. In one case, the receptors are antiparallel to each other and associate through an interface that overlaps the TNF binding site. If intact receptors were capable of such an association, their cytoplasmic domains would be separated by over 100 Angstrom. This interaction could inhibit signaling in the absence of TNF. Parallel dimers are also observed in which the dimer interface is well separated from the TNF binding site. Associations among TNF-bound parallel dimers could cause receptor clustering. Both dimers bury substantial areas of protein surface and are formed by polar and non-polar interactions.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; SYNERGEN INC,BOULDER,CO 80301	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Naismith, James Henderson/H-3408-2012; Naismith, James Henderson/AAB-8614-2020	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAJZER Z, 1989, J BIOL CHEM, V264, P13623; BALKWILL F, 1993, IMMUNOL TODAY, V14, P149, DOI 10.1016/0167-5699(93)90228-D; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAZAN JF, 1993, CURR BIOL, V3, P603, DOI 10.1016/0960-9822(93)90009-D; BAZZONI F, 1995, IN PRESS P NATL ACAD; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; Brunger A.T., 1992, X PLOR VERSION 3 1 M; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; HAMLIN R, 1981, J APPL CRYSTALLOGR, V14, P85, DOI 10.1107/S0021889881008856; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1990, O VERSION 5 6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; OTWINOWSKI Z, 1993 P CCP4 STUD WEE, P56; RODSETH LE, 1994, J MOL BIOL, V238, P332; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SONG HY, 1994, J BIOL CHEM, V269, P22492; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	29	149	158	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13303	13307		10.1074/jbc.270.22.13303	http://dx.doi.org/10.1074/jbc.270.22.13303			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768931	hybrid			2022-12-25	WOS:A1995RB43900055
J	REINHOLD, BB; HAUER, CR; PLUMMER, TH; REINHOLD, VN				REINHOLD, BB; HAUER, CR; PLUMMER, TH; REINHOLD, VN			DETAILED STRUCTURAL-ANALYSIS OF A NOVEL, SPECIFIC O-LINKED GLYCAN FROM THE PROKARYOTE FLAVOBACTERIUM-MENINGOSEPTICUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY GAS-CHROMATOGRAPHY; MASS-SPECTROMETRY; GLYCOPROTEIN OLIGOSACCHARIDES; METHYLATION ANALYSIS	In the preceding paper, preliminary analysis revealed a new type of O-linked oligosaccharide of 1244 Da at each of two proposed glycosylation sites on several proteins secreted by the Gram-negative bacterium Flavobacterium meningosepticum (Plummer, T. H., Jr., Tarentino, A. L., and Hauer, C. R. (1995) J. Biol. Chem. 270, 13192-13196). In this report we detail the linkage, sequence, and branching this unusual heptasaccharide by electrospray (ES) ionization mass spectrometry (MS), and collision induced dissociation (CID). The proposed structure was supported by a combination of isotopic labeling, composition and methylation analysis, and the preparation of several chemical analogs and derivatives with each product evaluated by MS and CID. The singly branched structure contained seven residues, including three different uronyl analogs: a methylated rhamnose and mannose, a glucose, and a reducing terminal mannose. Only pyranose ring forms were detected ((2-OMe)Man1-4GlcNAcU1-4GlcU1-4GIc1-4(2-OMe)GlcU-4[(2-OMe)Rham1-2]Man).	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,DIV MOLEC MED,ALBANY,NY 12201	Harvard University; Harvard T.H. Chan School of Public Health; State University of New York (SUNY) System; Wadsworth Center				Hauer, Christoph/0000-0001-8704-2198	NIGMS NIH HHS [GM45781, GM30471] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045781, R01GM030471] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL AS, 1990, METHOD ENZYMOL, V193, P587, DOI 10.1016/0076-6879(90)93440-V; ASPINALL G. O., 1965, METHOD CARBOHYD CHEM, V5, P397; BJORNDAL H, 1967, ACTA CHEM SCAND, V21, P1801, DOI 10.3891/acta.chem.scand.21-1801; BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DANISHEFSKY I, 1958, INTRO POLYSACCHARI A, V2, P375; GERWIG GJ, 1993, J BIOL CHEM, V268, P26956; GEYER R, 1982, ANAL BIOCHEM, V121, P263, DOI 10.1016/0003-2697(82)90478-X; GEYER R, 1983, ANAL BIOCHEM, V133, P197, DOI 10.1016/0003-2697(83)90243-9; HERSCOVICS A, 1993, FASEB J, V1, P540; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; KRUSIUS T, 1987, BIOCHEM J, V245, P229, DOI 10.1042/bj2450229; Lindberg B, 1972, METHODS ENZYMOL, V28, P178; LINSLEY KB, 1994, ANAL BIOCHEM, V219, P207, DOI 10.1006/abio.1994.1259; PLUMMER TH, 1995, J BIOL CHEM, V270, P13192, DOI 10.1074/jbc.270.22.13192; REINHOLD BB, 1994, J BACTERIOL, V176, P1997, DOI 10.1128/jb.176.7.1997-2002.1994; Reinhold V N, 1972, Methods Enzymol, V25, P244, DOI 10.1016/S0076-6879(72)25021-2; REINHOLD VN, 1994, BIOLOGICAL MASS SPECTROMETRY: PRESENT AND FUTURE, P403; REINHOLD VN, 1995, IN PRESS METHODS ENZ; SPIRO RG, 1980, J BIOL CHEM, V255, P5347; VELARDO MA, 1993, J BIOL CHEM, V268, P17902; WHISTLER RL, 1958, ADV CARBOHYD CHEM, V13, P289	23	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13197	13203		10.1074/jbc.270.22.13197	http://dx.doi.org/10.1074/jbc.270.22.13197			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768917	hybrid			2022-12-25	WOS:A1995RB43900040
J	TAYLOR, GA; THOMPSON, MJ; LAI, WS; BLACKSHEAR, PJ				TAYLOR, GA; THOMPSON, MJ; LAI, WS; BLACKSHEAR, PJ			PHOSPHORYLATION OF TRISTETRAPROLIN, A POTENTIAL ZINC-FINGER TRANSCRIPTION FACTOR, BY MITOGEN STIMULATION IN INTACT-CELLS AND BY MITOGEN-ACTIVATED PROTEIN-KINASE IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; GENE-EXPRESSION; KAPPA-B; SEQUENCE; IDENTIFICATION; ACCUMULATION; PROMOTER; ENCODES; FAMILY; DOMAIN	Tristetraprolin (TTP) is a potential transcription factor that contains three PPPPG repeats and two putative CCCH zinc fingers. TTP is encoded by the early response gene Zfp-36, which is highly expressed in response to growth factors and in several hematopoietic cell lines. In the present studies, we investigated the possibility that TTP is phosphorylated in intact cells. In NIH/3T3 cells that were made to overexpress TTP constitutively, we found that the protein was phosphorylated on serine residues, and that this phosphorylation was rapidly (within 10 min) stimulated by several mitogens. In cell-free assays, recombinant mouse TTP was a substrate for the mitogen-activated protein (MAP) kinase. By a combination of protease digestion experiments and site-directed mutagenesis strategies, we found that serine 220 was phosphorylated by p42 MAP kinase in vitro. Expression of mutant TTP in fibroblasts confirmed that serine 220 was one of the major, mitogen-stimulated phosphorylation sites on the protein in intact cells. These results suggest that TTP may be phosphorylated by MAP kinases in vivo and that this phosphorylation may regulate its function.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710	Duke University; Duke University	TAYLOR, GA (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV METAB ENDOCRINOL & NUTR,DIABET & METAB SECT,POB 3897,DURHAM,NC 27710, USA.		Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NIDDK NIH HHS [K11-DK02227-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002227] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; AGUILERA G, 1981, NATURE, V292, P262, DOI 10.1038/292262a0; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CONTOR L, 1987, ANAL BIOCHEM, V160, P414, DOI 10.1016/0003-2697(87)90069-8; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1994, BIOCHEM J, V303, P105, DOI 10.1042/bj3030105; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMPERTS M, 1990, ONCOGENE, V5, P1081; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KURTZ S, 1984, P NATL ACAD SCI-BIOL, V81, P7323, DOI 10.1073/pnas.81.23.7323; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LAI WS, 1990, J BIOL CHEM, V265, P16556; MA QF, 1994, ONCOGENE, V9, P3329; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOHLER J, 1992, GENETICS, V131, P377; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; Robertson E, 1987, TERATOCARCINOMAS EMB; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SMITH DB, 1991, CURRENT PROTOCOLS MO; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; TAYLOR GA, 1995, J CELL PHYSIOL, V162, P378, DOI 10.1002/jcp.1041620310; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754	35	113	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13341	13347		10.1074/jbc.270.22.13341	http://dx.doi.org/10.1074/jbc.270.22.13341			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768935	hybrid			2022-12-25	WOS:A1995RB43900060
J	WOLF, DA; HERMEKING, H; ALBERT, T; HERZINGER, T; KIND, P; EICK, D				WOLF, DA; HERMEKING, H; ALBERT, T; HERZINGER, T; KIND, P; EICK, D			A COMPLEX BETWEEN E2F AND THE PRB-RELATED PROTEIN P130 IS SPECIFICALLY TARGETED BY THE SIMIAN-VIRUS-40 LARGE T-ANTIGEN DURING CELL-TRANSFORMATION	ONCOGENE			English	Article						TRANSFORMATION; E2F; P130; SV40 LARGE T ANTIGEN; CELL CYCLE	RETINOBLASTOMA SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR E2F; CYCLIN-A; VIRAL ONCOPROTEINS; BINDING PROTEIN; PRODUCT; RB; INHIBITION; EXPRESSION; KINASE	The p130 protein is a recently cloned member of the retinoblastoma protein family. We show here that transformation of NIH3T3-L1 fibroblasts (L1 cells) by the simian virus 40 large T antigen (LTAg) depends on the disruption of DNA binding complexes between transcription factor E2F and p130. LTAg binds to the pocket region of p130 in vivo and disrupts the E2F-p130 complexes. E2F-p130 complexes are present only in quiescent L1 cells and disappear at the G1/S phase boundary concomitantly to induction of DNA synthesis and expression of the E2F-regulated cdc2 gene. p130 is a substrate of cyclin-dependent kinase 2 (Cdk2) in vitro and associates with a Cdk in vivo which is activated upon serum stimulation in late G1. Overexpression of p130 inhibits cdc2 promoter activity and entry of quiescent L1 cells into S phase. The results demonstrate that p130 is a negative regulator of cell cycle progression which is specifically targeted by LTAg during cell transformation.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,MOLEK PATHOL ABT,D-80337 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich			Wolf, Dieter/AAE-5890-2021	Wolf, Dieter/0000-0002-3761-1070; Albert, Thomas Karl/0000-0002-2488-0706				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEW J, 1992, J BIOL CHEM, V267, P25922; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MAYOL X, 1993, ONCOGENE, V8, P2561; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NEVINS JR, 1992, SCIENCE, V258, P424; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER JW, 1994, SCIENCE, V246, P1467; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLF DA, 1991, BRIT J CANCER, V64, P47, DOI 10.1038/bjc.1991.237; WOLF DA, 1993, MOL ENDOCRINOL, V7, P924, DOI 10.1210/me.7.7.924; YEUNG RS, 1993, ONCOGENE, V8, P3465; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	59	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2067	2078						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784051				2022-12-25	WOS:A1995RB70300001
J	IWAMI, G; KAWABE, J; EBINA, T; CANNON, PJ; HOMCY, CJ; ISHIKAWA, Y				IWAMI, G; KAWABE, J; EBINA, T; CANNON, PJ; HOMCY, CJ; ISHIKAWA, Y			REGULATION OF ADENYLYL-CYCLASE BY PROTEIN-KINASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HETEROLOGOUS DESENSITIZATION; PHOSPHORYLATION SITES; PHOSPHOLIPASE-C; IDENTIFICATION; ATTENUATION; CELLS	The changing relationship between stimuli and responses after prolonged receptor stimulation is a general feature of hormonal signaling systems, termed desensitization. This phenomenon has been best exemplified in the covalent modification of the G protein-linked catecholamine receptors. However, other components within this signaling pathway can be involved in desensitization. Here we present evidence that desensitization occurs at the level of the effector enzyme itself through phosphorylation. Type V adenylyl cyclase (AC) is the major isoform expressed in the heart. Using purified enzymes, we demonstrate that protein kinase A (PKA) directly phosphorylates and thereby inhibits type V AC catalytic activity, This inhibition was negated in the presence of PKA inhibitor. Analysis of enzyme kinetics revealed that this inhibition was due to a decrease in the catalytic rate, not to a decrease in the affinity for the substrate ATP. Our results indicate that AC catalytic activity can be regulated through PKA-mediated phosphorylation, suggesting another mechanism of desensitization for receptor pathways which signal via increases in intracellular cAMP.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,PEARL RIVER,NY 10965	Columbia University; Columbia University					NHLBI NIH HHS [HL-21006, HL-38070] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038070, P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BREDT DS, 1992, J BIOL CHEM, V267, P10976; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CLARK RB, 1989, MOL PHARMACOL, V36, P343; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HOMCY CJ, 1991, ANNU REV PHYSIOL, V53, P137, DOI 10.1146/annurev.physiol.53.1.137; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KASSIS S, 1982, J BIOL CHEM, V257, P5312; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KIRCHICK HJ, 1983, ENDOCRINOLOGY, V113, P1638, DOI 10.1210/endo-113-5-1638; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; OZAWA K, 1993, J BIOL CHEM, V268, P2280; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; PREMONT RT, 1989, ENDOCRINOLOGY, V125, P1151, DOI 10.1210/endo-125-3-1151; RYU SH, 1990, J BIOL CHEM, V265, P17941; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIBLEY DR, 1984, J BIOL CHEM, V259, P9742; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TOBISE K, 1994, CIRC RES, V74, P596, DOI 10.1161/01.RES.74.4.596; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302	24	175	178	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12481	12484		10.1074/jbc.270.21.12481	http://dx.doi.org/10.1074/jbc.270.21.12481			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759492	hybrid			2022-12-25	WOS:A1995QZ71100025
J	ZHANG, L; ESKO, JD				ZHANG, L; ESKO, JD			ACCUMULATION OF A PENTASACCHARIDE TERMINATING IN ALPHA-N-ACETYLGLUCOSALMINE IN AN ANIMAL-CELL MUTANT DEFECTIVE IN HEPARAN-SULFATE BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-LINKAGE REGION; SWARM RAT CHONDROSARCOMA; CHONDROITIN SULFATE; FLAVOBACTERIUM-HEPARINUM; GALACTOSYLTRANSFERASE-I; CARTILAGE PROTEOGLYCAN; STRUCTURAL-ANALYSIS; LYSOSOMAL-ENZYMES; DERMATAN SULFATE; OLIGOSACCHARIDES	Heparan sulfate biosynthesis initiates by the transfer of alpha-D-GlcNAc from UDP-GlcNAc to the D-GlcA moiety of the linkage tetrasaccharide, GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-core protein. The enzyme catalyzing this reaction differs from the alpha-GlcNAc transferase involved in chain polymerization based on genetic and enzymatic studies of an animal cell mutant defective in chain polymerization (Fritz, T. A., Gabb, M. M., Wei, G., and Esko, J. D. (1994) J. Biol. Chem. 269, 28809-28814), In this report we show that this mutant also accumulates a pentasaccharide intermediate containing alpha-GlcNAc, A fusion protein was made from the IgG-binding domain of protein A and a segment of the proteoglycan, betaglycan. This segment contained one glycosaminoglycan attachment site that primes only chondroitin sulfate and another that primes both heparan sulfate and chondroitin sulfate (Zhang, L., and Esko, J. D. (1994) J. Biol. Chem. 264, 19295-19299). Expression of the chimera in the mutant resulted in the accumulation of an oligosaccharide that labeled with [6-H-3]GlcN. The oligosaccharide comigrated with a pentasaccharide standard derived from chondroitin sulfate, but acid hydrolysis gave 98% [H-3]GlcN, Heparin lyase III digestion yielded [H-3]GlcNAc, suggesting that the GlcNAc residue was alpha-linked to the nonreducing terminus, Enzymatic treatment of [6-H-3]Gal-labeled material yielded the tetrasaccharide, Delta GlcA-[H-3]Gal-[H-3]Gal-xylitol. These findings suggest that pentasaccharide had the structure, GlcNAc alpha 1-4GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl. Its accumulation in a Chinese hamster ovary cell mutant defective in the polymerizing alpha-GlcNAc transferase provides in vivo evidence that two alpha-GlcNAc transferases catalyze the formation of heparan sulfate.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham								DEWAARD P, 1992, J BIOL CHEM, V267, P6036; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FRANSSON LA, 1990, BIOCHEM J, V269, P381, DOI 10.1042/bj2690381; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HASCALL VC, 1972, J BIOL CHEM, V247, P4521; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KINGSLEY DM, 1986, CELL, V67, P785; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; NADER HB, 1990, J BIOL CHEM, V265, P16807; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; QUENTIN E, 1990, P NATL ACAD SCI USA, V87, P1342, DOI 10.1073/pnas.87.4.1342; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; SALIMATH PV, 1995, J BIOL CHEM, V270, P9164, DOI 10.1074/jbc.270.16.9164; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; SU K, 1993, J BIOL CHEM, V268, P14301; SUGAHARA K, 1992, EUR J BIOCHEM, V204, P401, DOI 10.1111/j.1432-1033.1992.tb16649.x; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; VARKI A, 1980, J BIOL CHEM, V255, P8398; VERTEL BM, 1994, BIOCHEM J, V301, P211, DOI 10.1042/bj3010211; VILLERS C, 1994, BIOCHEM J, V298, P135, DOI 10.1042/bj2980135; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295	39	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12557	12562		10.1074/jbc.270.21.12557	http://dx.doi.org/10.1074/jbc.270.21.12557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759502	hybrid			2022-12-25	WOS:A1995QZ71100037
J	LEE, SF; COTE, GP				LEE, SF; COTE, GP			PURIFICATION AND CHARACTERIZATION OF A DICTYOSTELIUM PROTEIN-KINASE REQUIRED FOR ACTIN ACTIVATION OF THE MG2+ ATPASE ACTIVITY OF DICTYOSTELIUM MYOSIN ID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; ACANTHAMOEBA MYOSIN; SENSITIVE METHOD; CASTELLANII; ISOFORM; BINDING; LOCALIZATION; DISCOIDEUM; AUTOPHOSPHORYLATION; PHOSPHORYLATION	We have isolated a protein from Dictyostelium with a molecular mass of 110 kDa as judged by SDS-gel electrophoresis that can stimulate the actin-activated MgATPase activity of Dictyostelium myosin ID (MyoD). In the presence of MgATP the 110-kDa protein incorporated phosphate into itself and into the heavy chain, but not the light chain, of MyoD. Phosphorylation to 0.5 mol of P-i/mol increased the MyoD actin-activated MgATPase rate from 0.2 to 3 mu mol/min/mg. Renaturation following SDS-gel electrophoresis demonstrated that the 110-kDa protein contained intrinsic protein kinase and autophosphorylation activity. Autophosphorylation to 1 mol of P-i/mol enhanced the rate at which the 110-kDa protein kinase phosphorylated MyoD by 40-fold. The rate of autophosphorylation was strongly dependent on the 110-kDa protein kinase concentration, indicating an intermolecular reaction. Synthetic peptides of 9-11 residues corresponding to the heavy chain phosphorylation site of Acanthamoeba myosin IC and the homologous sites in Dictyostelium myosin IB (MyoB) and MyoD were poor substrates for the 110-kDa protein kinase. The 110-kDa protein kinase was unable to phosphorylate the MyoB isozyme suggesting that it may be specific for MyoD.	QUEENS UNIV, DEPT BIOCHEM, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada								ALBANESI JP, 1985, J BIOL CHEM, V260, P8649; ALBANESI JP, 1985, J BIOL CHEM, V260, P1174; BEMENT WM, 1993, NATURE, V365, P785, DOI 10.1038/365785a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; COTE GP, 1985, J BIOL CHEM, V260, P4543; COTE GP, 1987, J BIOL CHEM, V262, P1065; COUDRIER E, 1992, FEBS LETT, V307, P87, DOI 10.1016/0014-5793(92)80907-X; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; DOBERSTEIN SK, 1993, NATURE, V365, P841, DOI 10.1038/365841a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; FATH KR, 1994, CURR OPIN CELL BIOL, V6, P131, DOI 10.1016/0955-0674(94)90126-0; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; Hammer J A, 1991, Trends Cell Biol, V1, P50, DOI 10.1016/0962-8924(91)90089-R; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HAMMER JA, 1983, J BIOL CHEM, V258, P168; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; JUNG G, 1989, P NATL ACAD SCI USA, V86, P6186, DOI 10.1073/pnas.86.16.6186; JUNG G, 1994, FEBS LETT, V342, P197, DOI 10.1016/0014-5793(94)80500-8; JUNG G, 1993, J BIOL CHEM, V268, P14981; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KING MM, 1983, J BIOL CHEM, V258, P9925; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SF, 1993, J BIOL CHEM, V268, P20923; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; MARUTA H, 1977, J BIOL CHEM, V252, P8329; MEDLEY QG, 1991, METHOD ENZYMOL, V196, P23; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; ROSENFELD SS, 1994, BIOCHEMISTRY-US, V33, P2322, DOI 10.1021/bi00174a045; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TITUS MA, 1989, CELL REGUL, V1, P55, DOI 10.1091/mbc.1.1.55; TITUS MA, 1994, P NATL ACAD SCI USA, V91, P9446, DOI 10.1073/pnas.91.20.9446; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TODHUNTER JA, 1977, BIOCHIM BIOPHYS ACTA, V485, P87, DOI 10.1016/0005-2744(77)90195-4; URRUTIA RA, 1993, BIOCHIM BIOPHYS ACTA, V1173, P225, DOI 10.1016/0167-4781(93)90185-G; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	45	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11776	11782		10.1074/jbc.270.20.11776	http://dx.doi.org/10.1074/jbc.270.20.11776			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744826	hybrid			2022-12-25	WOS:A1995QY73600019
J	DARNAY, BG; SINGH, S; CHATURVEDI, MM; AGGARWAL, BB				DARNAY, BG; SINGH, S; CHATURVEDI, MM; AGGARWAL, BB			THE P60 TUMOR-NECROSIS-FACTOR (TNF) RECEPTOR-ASSOCIATED KINASE (TRAK) BINDS RESIDUES 344-397 WITHIN THE CYTOPLASMIC DOMAIN INVOLVED IN TNF SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; EXPRESSION; ACTIVATION	The p60 form of the tumor necrosis factor (TNF) receptor lacks motifs characteristic of tyrosine or serine/threonine protein kinases, Our recent observations have indicated that a p60 TNF receptor-associated kinase (p60-TRAK) from U-937 cells physically interacts with and causes the phosphorylation of the cytoplasmic domain of the TNF receptor. To define which region of the cytoplasmic domain is necessary for physical interaction with p60-TRAK, we constructed a series of deletions (grouped into three sets Delta 1-Delta 5, Delta 6-Delta 12, and Delta 13-Delta 16) of the p60 cytoplasmic domain, expressed them as glutathione S-transferase (GST) fusion proteins, and used them in affinity precipitations, followed by in vitro kinase assays. Our detailed analysis indicated that a serine-, threonine-, and proline-rich region (residues 243-274, Delta 2) and the N-terminal half of the cytoplasmic domain (residues 243-323, Delta 3) neither associated with p60-TRAK nor underwent phosphorylation. We found that out of 222 residues (205-426) in the cytoplasmic domain, only 54 (344-397, Delta 12) were sufficient for binding p60-TRAK and for phosphorylation of the cytoplasmic domain. A region of approximately 30 residues (397-426) at the C-terminal end was found to interfere with optimal binding of the p60-TRAK activity. Thus, our results indicate that the minimal region of the cytoplasmic domain necessary for interacting with p60-TRAK and for phosphorylation resides within the domain previously reported to be needed for signaling the cytotoxic effect of TNF.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC ONCOL,CYTOKINE RES LAB,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; ENGLEMANN H, 1990, J BIOL CHEM, V265, P14497; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; ITOH N, 1993, J BIOL CHEM, V268, P10932; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, P1019; SONG RY, 1994, J BIOL CHEM, V269, P22492; SONG RY, 1995, J BIOL CHEM, V270, P3574; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043	20	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14867	14870		10.1074/jbc.270.25.14867	http://dx.doi.org/10.1074/jbc.270.25.14867			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797464	hybrid			2022-12-25	WOS:A1995RE66600007
J	KADRIHASSANI, N; LEGER, CL; DESCOMPS, B				KADRIHASSANI, N; LEGER, CL; DESCOMPS, B			THE FATTY-ACID BIMODAL ACTION ON SUPEROXIDE ANION PRODUCTION BY HUMAN ADHERENT MONOCYTES UNDER PHORBOL 12-MYRISTATE 13-ACETATE OR DIACYLGLYCEROL ACTIVATION CAN BE EXPLAINED BY THE MODULATION OF PROTEIN-KINASE-C AND P47(PHOX) TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; ARACHIDONIC-ACID; NADPH OXIDASE; CHEMI-LUMINESCENCE; ESTER BINDING; OLEIC-ACID; PHOSPHORYLATION; PHOSPHOLIPIDS; INHIBITION; MEMBRANES	We studied the translocation of protein kinase C (PKC), the endogenous phosphorylation and presence in the membrane fraction of p47(phox) (the 47-kDa cytosolic component of the phagocyte NADPH oxidase), and the O-2-radical-anion production in human adherent monocytes (HAMs). This was performed under phorbol myristate acetate (PMA) or diacylglycerol stimulation after cell preincubation in the presence of either 13-methyltetradecanoate or arachidonate. At 3 nM and 30 mu M, both fatty acids had enhancing and depressing effects, respectively, on PKC translocation and O-2-radical-anion production strictly depending on the PMA- or diacylglycerol-stimulated state of the cell. Endogenous phosphorylation and membrane presence of p47(phox) were markedly reinforced in PMA-stimulated HAMs in the presence as compared to the absence of 13-methyltetradecanoate. These results emphasize the fact that in intact cells the capacity of both FAs to potentiate or depress the HAM O-2-radical-anion production is mediated by a direct action on the PKC membrane translocation leading to a simultaneous endogenous phosphorylation and membrane translocation of p47(phox). They confirm the recent findings (Kadri-Hassani, N., Leger, C. L., and Descomps, B. (1995) J. Lipid Med. Cell Signal. 11, 159-173) on the PKC-mediated, adherent monocyte-specific capacity of these fatty acids and others (with the exception of linear saturated fatty acids) to enhance the PMA-stimulated O-2-radical-anion production at nanomolar concentrations and to depress it at micromolar concentrations.	INSERM, CTR RECH, F-34090 MONTPELLIER, FRANCE; UNIV MONTPELLIER 1, INST BIOL, UNITE FORMAT RECH MED, BIOL & BIOCHIM LIPIDES LAB, F-34000 MONTPELLIER, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier								ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; BADWEY JA, 1984, J BIOL CHEM, V259, P7870; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P971, DOI 10.1021/bi00218a013; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CHANG ZL, 1993, IMMUNOLOGY, V80, P360; CURNUTTE JT, 1984, J BIOL CHEM, V259, P1851; DANA R, 1994, BIOCHEM J, V297, P217, DOI 10.1042/bj2970217; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; FOLCH J, 1957, J BIOL CHEM, V226, P497; GYLLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209, DOI 10.1016/0022-1759(87)90461-3; HENDERSON LM, 1993, EUR J BIOCHEM, V211, P157, DOI 10.1111/j.1432-1033.1993.tb19882.x; HUANG XP, 1993, BIOCHIM BIOPHYS ACTA, V1175, P351, DOI 10.1016/0167-4889(93)90228-H; KADRIHASSANI N, 1995, J LIPID MEDIAT CELL, V11, P159, DOI 10.1016/0929-7855(94)00035-B; KHAN W, 1991, FEBS LETT, V292, P98, DOI 10.1016/0014-5793(91)80843-R; KHAN WA, 1992, J BIOL CHEM, V267, P3605; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGER CL, 1993, PROSTAG LEUKOTR ESS, V48, P17, DOI 10.1016/0952-3278(93)90004-G; LESTER DS, 1991, BIOCHEM BIOPH RES CO, V179, P1522, DOI 10.1016/0006-291X(91)91745-X; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PARK JW, 1992, J BIOL CHEM, V267, P19901; PONTREMOLI S, 1986, BIOCHEM BIOPH RES CO, V136, P228, DOI 10.1016/0006-291X(86)90898-3; RUBINEK T, 1993, BIOCHIM BIOPHYS ACTA, V1176, P51, DOI 10.1016/0167-4889(93)90176-P; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; VACHIER I, 1992, AM REV RESPIR DIS, V146, P1161, DOI 10.1164/ajrccm/146.5_Pt_1.1161; WILSON E, 1986, J BIOL CHEM, V261, P2616; WOLFSON M, 1985, J IMMUNOL, V135, P2057; YOSHIDA K, 1992, P NATL ACAD SCI USA, V89, P6443, DOI 10.1073/pnas.89.14.6443; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E	39	36	36	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15111	15118		10.1074/jbc.270.25.15111	http://dx.doi.org/10.1074/jbc.270.25.15111			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797495	hybrid, Green Submitted			2022-12-25	WOS:A1995RE66600041
J	ALEXANDER, C; BILGIN, N; LINDSCHAU, C; MESTERS, JR; KRAAL, B; HILGENFELD, R; ERDMANN, VA; LIPPMANN, C				ALEXANDER, C; BILGIN, N; LINDSCHAU, C; MESTERS, JR; KRAAL, B; HILGENFELD, R; ERDMANN, VA; LIPPMANN, C			PHOSPHORYLATION OF ELONGATION-FACTOR TU PREVENTS TERNARY COMPLEX-FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; FACTOR-EF-TU; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; FACTOR-TS; FACTOR-I; KIRROMYCIN; DOMAIN; ACID; MUTAGENESIS	The elongation factor Tu (EF-Tu) is a member of the GTP/GDP-binding proteins and interacts with various partners during the elongation cycle of protein biosynthesis thereby mediating the correct binding of amino-acylated transfer RNA (aa-tRNA) to the acceptor site (A-site) of the ribosome. After GTP hydrolysis EF-Tu is released in its GDP-bound state. lit vivo, EF-Tu is posttranslationally modified by phosphorylation. Here we report that the phosphorylation of EF-Tu by a ribosome associated kinase activity is drastically enhanced by EF-Ts. The antibiotic kirromycin, known to block EF-Tu function, inhibits the modification. This effect is specific, since kirromycin-resistant mutants do become phosphorylated in the presence of the antibiotic. On the other hand, phosphorylated wild-type EF-Tu does not bind kirromycin. Most interestingly, the phosphorylation of EF-Tu abolishes its ability to bind aa-tRNA. In the GTP conformation the site of modification is located at the interface between domains 1 and 3 and is involved in a strong interdomain hydrogen bond. Introduction of a charged phosphate group at this position will change the interaction between the domains, leading to an opening of the molecule reminiscent of the GDP conformation. A model for the function of EF-Tu phosphorylation in protein biosynthesis is presented.	FREE UNIV BERLIN,INST BIOCHEM,D-14195 BERLIN,GERMANY; UPPSALA UNIV,INST MOLEK BIOL,BMC,S-75124 UPPSALA,SWEDEN; HUMBOLDT UNIV BERLIN,MAX DELBRUCK CENTRUM MOLEK MED,FRANZ VOLHARD KLIN,D-13122 BERLIN,GERMANY; GORLAEUS LABS,2300 RA LEIDEN,NETHERLANDS; INST MOLEC BIOTECHNOL,DEPT STRUCT BIOL & CRYSTALLOG,D-07708 JENA,GERMANY	Free University of Berlin; Uppsala University; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin			Lindschau, Carsten/AAE-6721-2020; Hilgenfeld, Rolf/C-9675-2011; Lindschau, Carsten/G-1798-2011	Lindschau, Carsten/0000-0003-1960-099X; Mesters, Jeroen/0000-0001-8532-6699				ABRAHAMS JP, 1991, BIOCHEMISTRY-US, V30, P6705, DOI 10.1021/bi00241a010; ABRAHAMS JP, 1988, NUCLEIC ACIDS RES, V16, P10099, DOI 10.1093/nar/16.21.10099; ARAI K, 1980, P NATL ACAD SCI-BIOL, V77, P1326, DOI 10.1073/pnas.77.3.1326; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERTRAM S, 1983, NUCLEIC ACIDS RES, V11, P575, DOI 10.1093/nar/11.3.575; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUBUNENKO MG, 1992, BIOCHIMIE, V74, P419, DOI 10.1016/0300-9084(92)90081-O; EHRENBERG M, 1990, J MOL BIOL, V211, P739, DOI 10.1016/0022-2836(90)90074-V; FORSTER C, 1993, BIOCHIMIE, V75, P1159, DOI 10.1016/0300-9084(93)90015-K; HWANG YW, 1989, J BIOL CHEM, V264, P8304; HWANG YW, 1992, J BIOL CHEM, V267, P22198; JONES MD, 1980, EUR J BIOCHEM, V108, P507, DOI 10.1111/j.1432-1033.1980.tb04748.x; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LEBERMAN R, 1980, ANAL BIOCHEM, V104, P29, DOI 10.1016/0003-2697(80)90272-9; LIMMER S, 1992, BIOCHEMISTRY-US, V31, P2970, DOI 10.1021/bi00126a018; LIPPMANN C, 1988, FEBS LETT, V240, P139, DOI 10.1016/0014-5793(88)80355-7; LIPPMANN C, 1993, J BIOL CHEM, V268, P601; LIPPMANN C, 1991, NATO ASI H, V56, P441; LITALIEN JJ, 1979, FEBS LETT, V107, P359, DOI 10.1016/0014-5793(79)80407-X; MESTERS JR, 1994, EMBO J, V13, P4877, DOI 10.1002/j.1460-2075.1994.tb06815.x; NIERHAUS KH, 1982, CURR TOP MICROBIOL I, V97, P82; PETER ME, 1990, NUCLEIC ACIDS RES, V18, P6889, DOI 10.1093/nar/18.23.6889; RODNINA MV, 1993, TRANSLATIONAL APPARATUS, P317; SCHWARTZBACH CJ, 1991, J BIOL CHEM, V266, P16324; SCOBLE J, 1994, BIOCHIMIE, V76, P59, DOI 10.1016/0300-9084(94)90063-9; VANDERMEIDE PH, 1982, FEBS LETT, V139, P325, DOI 10.1016/0014-5793(82)80881-8; VENEMA RC, 1991, J BIOL CHEM, V266, P12574; VENEMA RC, 1991, J BIOL CHEM, V266, P11993; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WOLF H, 1977, EUR J BIOCHEM, V75, P67, DOI 10.1111/j.1432-1033.1977.tb11504.x; WOLF H, 1974, P NATL ACAD SCI USA, V71, P4910, DOI 10.1073/pnas.71.12.4910; ZEEF LAH, 1993, MOL GEN GENET, V238, P252, DOI 10.1007/BF00279554	33	64	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14541	14547		10.1074/jbc.270.24.14541	http://dx.doi.org/10.1074/jbc.270.24.14541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782317	hybrid			2022-12-25	WOS:A1995RD45500048
J	ITOH, K; ADELSTEIN, RS				ITOH, K; ADELSTEIN, RS			NEURONAL CELL EXPRESSION OF INSERTED ISOFORMS OF VERTEBRATE NONMUSCLE MYOSIN HEAVY-CHAIN II-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RETINOBLASTOMA CELLS; SMOOTH-MUSCLE MYOSIN; DIFFERENTIAL EXPRESSION; SODIUM-BUTYRATE; MESSENGER-RNAS; NERVOUS-SYSTEM; CYCLIC-AMP; CDNA; CLONING; ACID	Previous work has demonstrated that unique isoforms of nonmuscle myosin heavy chain II-B (MHC-B) are expressed in chicken and human neuronal cells (Takahashi, M., Kawamoto, S., and Adelstein, R. S. (1992) J. Biol. Chem. 267, 17864-17871). These isoforms, which appear to be generated by alternative splicing of pre-mRNA, differ from the MHC-B isoform present in a large number of nonmuscle cells in that they contain inserted cassettes of amino acids near the ATP binding region and/or near the actin binding region. The insert near the ATP binding region begins after amino acid 211 and consists of either 10 or 16 amino acids. The insert nc ar the actin binding region begins after amino acid 621 and consists of 21 amino acids. Using a variety of techniques, we have studied the distribution and expression of the inserted MHC-B isoforms. In the developing chick;en brain, mRNA encoding the 10-amino acid insert gradually increases after embryonic day 4, peaks in the 10-14-day embryo, and then declines. In contrast, the mRNA encoding the 21-amino acid insert appears just before birth and is abundantly expressed in the adult chicken cerebellum. There is a marked species difference between the distribution of the inserted isoforms in adult tissues. The mRNA encoding MHC-B containing the 10-amino acid insert near the ATP binding region is expressed at low levels in the adult chicken brain, but makes up most of the MHC-B mRNA expressed in the human cerebrum and approximately 90% of MHC-B in the human retina. It is also expressed in neuronal cell lines. The mRNA encoding MHC-B containing the 21-amino acid insert is abundantly expressed in the chicken cerebellum and human cerebrum, but is absent from the retina and cell lines, Employing human retinoblastoma (Y-79) and neuroblastoma (SK-N-SH) cell lines, an increase in expression of mRNA encoding the 10-amino acid inserted isoform was seen following treatment by a number of agonists or by serum deprivation. In each case, expression of the inserted MHC-B isoform correlated with cell differentiation (neuronal phenotype) and inhibition of cell division. Using a rat pheochromocytoma cell line (PC12), we found that prior to treatment with nerve growth factor (NGF), there was no evidence for either inserted isoform, although noninserted MHC-B was present. NGF treatment resulted in the appearance of mRNA encoding MHC-B containing the 10-amino acid insert, concomitant with neurite outgrowth. Both the inserted isoform and neurites disappeared following withdrawal of NGF, showing that the appearance and disappearance of the neurites is coupled to the inclusion and exclusion of this MHC-B insert.	NHLBI, MOLEC CARDIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Itoh, Kazuyuki/0000-0002-0761-0499; Adelstein, Robert/0000-0002-8683-2144				BABIJ P, 1993, NUCLEIC ACIDS RES, V21, P1467, DOI 10.1093/nar/21.6.1467; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BHATIADEY N, 1993, P NATL ACAD SCI USA, V90, P2856, DOI 10.1073/pnas.90.7.2856; CAMPBELL M, 1988, OPHTHALMIC PAED GEN, V9, P171, DOI 10.3109/13816818809031495; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; CHOI OH, 1994, J BIOL CHEM, V269, P536; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENG MH, 1991, BRAIN RES, V561, P274, DOI 10.1016/0006-8993(91)91604-Y; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; Itoh K., 1994, Molecular Biology of the Cell, V5, p403A; Itoh K., 1993, Molecular Biology of the Cell, V4, p41A; ITOH K, 1994, FASEB J, V8, pA1303; KAPOOR CL, 1985, NEUROCHEM INT, V7, P285, DOI 10.1016/0197-0186(85)90117-2; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KELLEY CA, 1995, J BIOL CHEM, V270, P1395, DOI 10.1074/jbc.270.3.1395; KELLEY CA, 1992, J BIOL CHEM, V267, P2127; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; KYRITSIS AP, 1984, NATURE, V307, P471, DOI 10.1038/307471a0; KYRITSIS AP, 1986, ANTICANCER RES, V6, P465; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MURAKAMI N, 1992, CELL MOTIL CYTOSKEL, V22, P281, DOI 10.1002/cm.970220408; MURAKAMI N, 1991, FEBS LETT, V278, P23, DOI 10.1016/0014-5793(91)80074-D; NAKAGAWA Y, 1987, OPHTHALMIC RES, V19, P205, DOI 10.1159/000265495; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; PEARSON R, 1972, AVIAN BRAIN, P74; PHILLIPS CL, 1995, IN PRESS J MUSCLE RE; PIERCE ME, 1989, J NEUROCHEM, V53, P307, DOI 10.1111/j.1471-4159.1989.tb07330.x; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SCHROEDER TE, 1976, CELL MOTILITY, P265; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SUN WD, 1992, J MOL BIOL, V224, P1185, DOI 10.1016/0022-2836(92)90482-Y; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; WIECHELMAN KJ, 1988, ANAL BIOCHEM, V175, P231, DOI 10.1016/0003-2697(88)90383-1; WIECHMANN AF, 1990, J NEUROCHEM, V55, P208, DOI 10.1111/j.1471-4159.1990.tb08840.x	47	70	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14533	14540		10.1074/jbc.270.24.14533	http://dx.doi.org/10.1074/jbc.270.24.14533			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782316	hybrid			2022-12-25	WOS:A1995RD45500047
J	JEOHN, GH; SERIZAWA, S; IWAMATSU, A; TAKAHASHI, K				JEOHN, GH; SERIZAWA, S; IWAMATSU, A; TAKAHASHI, K			ISOLATION AND CHARACTERIZATION OF GASTRIC TRYPSIN FROM THE MICROSOMAL FRACTION OF PORCINE GASTRIC ANTRAL MUCOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; 4 TANDEM REPEATS; SERINE PROTEASE; PLASMA PREKALLIKREIN; NUCLEOTIDE-SEQUENCE; CDNA; SPECIFICITY; EXPRESSION; INHIBITOR; PANCREAS	A gastric serine protease(s) was found in porcine gastric antral mucosa and was shown to be distributed in the endoplasmic reticulum (ER)-microsome fraction and also in the vesicle fraction. Two forms of the protease were purified over 6,000-fold from the ER-microsome fraction. Analyses of various molecular and enzymatic characteristics including the N-terminal and partial internal amino acid sequences of both forms revealed that they share the same properties and are indistinguishable from porcine pancreatic trypsin. This is the first time that trypsin or a protease almost identical with trypsin has been found to be present intracellularly in normal tissues. The gastric trypsin activities from the ER-microsome and the vesicle fractions were located in distinct density regions upon density gradient centrifugation, which indicates association of the protease with different organelle membranes. Taken together, these results suggest that there may be a novel function of trypsin in the gastric mucosa; it might function as a specific degrading or processing enzyme as an intracellular protease.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN	University of Tokyo; Kirin Brewery Company Limited								ATHAUDA SBP, 1991, FEBS LETT, V292, P53, DOI 10.1016/0014-5793(91)80832-N; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DAVIS BP, 1992, J BIOL CHEM, V267, P26070; FREEMAN TC, 1990, GUT, V31, P1318, DOI 10.1136/gut.31.11.1318; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; Fujita T, 1988, PARANEURON, P165, DOI [10.1007/978-4-431-68066-6_16, DOI 10.1007/978-4-431-68066-6_16]; HARTLEY BS, 1964, NATURE, V201, P1284, DOI 10.1038/2011284a0; HARTLEY BS, 1966, BIOCHEM J, V101, P229, DOI 10.1042/bj1010229; HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3146, DOI 10.1021/bi00741a002; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; JENSEN S, 1989, GASTROENTEROLOGY, V96, P1063, DOI 10.1016/0016-5085(89)91624-7; JOHN GH, 1995, J BIOL CHEM, V270, P7809; KAWASHIMA I, 1987, DNA-J MOLEC CELL BIO, V6, P163, DOI 10.1089/dna.1987.6.163; Keil B., 1971, ENZYMES, V3, P249, DOI [10.1016/S1874-6047(08)60399-6., 10.1021/bi00843a047, DOI 10.1021/BI00843A047]; LAVALLIE ER, 1993, J BIOL CHEM, V268, P23311; LEHUEROU I, 1990, EUR J BIOCHEM, V193, P767; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; LOH YP, 1984, J BIOL CHEM, V259, P8238; LOWRY OH, 1957, METHOD ENZYMOL, V4, P371; MACDONALD RJ, 1982, J BIOL CHEM, V257, P9724; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MATSUSHIMA M, 1994, J BIOL CHEM, V269, P19976; MELOUN B, 1966, BIOCHIM BIOPHYS ACTA, V130, P543, DOI 10.1016/0304-4165(66)90258-3; PLAYFORD RJ, 1994, GASTROENTEROLOGY, V106, P735, DOI 10.1016/0016-5085(94)90709-9; SHIBATA T, 1986, CLIN CHIM ACTA, V159, P27, DOI 10.1016/0009-8981(86)90163-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STORRIE B, 1990, METHOD ENZYMOL, V182, P215; SWANSON MA, 1955, METHOD ENZYMOL, V2, P541, DOI 10.1016/S0076-6879(55)02247-7; TANI T, 1990, NUCLEIC ACIDS RES, V18, P1631, DOI 10.1093/nar/18.6.1631; TAYLOR IL, 1991, TXB GASTROENTEROLOGY, V1, P24; UCHINO T, 1993, J BIOL CHEM, V268, P527; USUI Y, 1982, BIOCHIM BIOPHYS ACTA, V719, P539, DOI 10.1016/0304-4165(82)90244-6; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; Walsh K. A., 1970, METHODS ENZYMOL, V19, P41; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K	37	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14748	14755		10.1074/jbc.270.24.14748	http://dx.doi.org/10.1074/jbc.270.24.14748			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782340	hybrid			2022-12-25	WOS:A1995RD45500077
J	BERBERICH, SJ; POSTEL, EH				BERBERICH, SJ; POSTEL, EH			PUF/NM23-H2/NDPK-B TRANSACTIVATES A HUMAN C-MYC PROMOTER-CAT GENE VIA A FUNCTIONAL NUCLEASE HYPERSENSITIVE ELEMENT	ONCOGENE			English	Article						PUF; NM23; NDPK; C-MYC; NUCLEASE HYPERSENSITIVE METASTASIS	NUCLEOSIDE DIPHOSPHATE KINASE; REGULATORY ELEMENTS; CHROMATIN STRUCTURE; TUMOR-METASTASIS; LEUKEMIA-CELLS; RNA LEVELS; TRANSCRIPTION; BINDING; RIBONUCLEOPROTEIN; DIFFERENTIATION	We have isolated the transacting factor PuF that, through its interaction with a nuclease hypersensitive element (NHE) located upstream of the c-myc gene, transactivates the human c-myc gene in vitro (Postel et al., 1989). PuF was recently identified as being encoded by the nonmetastatic 23-H2 (nm23-H2)/nucleoside diphosphate kinase-B (NDPK-B) gene (Postel ct al., 1993). In addition to its ability to transactivate the c-myc gene in vitro, PuF/NDPK-B catalyzes the shuttling of gamma-phosphates between nucleoside triphosphates and diphosphates (Gilles et al., 1991; Postel and Ferrone, 1994) and has been postulated to suppress tumor metastasis (Stahl et al., 1991). Here we have extended our studies of PuF and c-myc transcription by testing whether PuF affects c-myc transcription using a transient transfection assay. A plasmid containing the human c-myc promoter-NHE region was cloned upstream of the bacterial chloramphenicol acetyltransferase (CAT) gene. When cotransfected with a PuF expression vector, CAT activity was elevated 3-4 fold relative to transfections containing the myc-CAT plasmid. In contrast, a myc-CAT reporter plasmid in which the NHE element was deleted showed no increase in CAT activity when cotransfected with the PuF expression vector. From these results we conclude that PuF transactivates the c-myc gene via the nuclease hypersensitive element.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University	BERBERICH, SJ (corresponding author), WRIGHT STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, DAYTON, OH 45435 USA.				NCI NIH HHS [R01CA5584] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCINAS M, 1994, ONCOGENE, V9, P2699; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSSO LE, 1985, CANCER RES, V45, P5035; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1992, ANN NY ACAD SCI, V660, P57, DOI 10.1111/j.1749-6632.1992.tb21057.x; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STAHL JA, 1991, CANCER RES, V51, P445; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; YAMASHIRO S, 1994, ONCOGENE, V9, P2461	31	133	133	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2343	2347						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784082				2022-12-25	WOS:A1995RE54300009
J	CHUN, PW				CHUN, PW			NEW THERMODYNAMIC STUDIES ON RIBONUCLEASE-A AT LOW PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN STABILIZATION; ALPHA-CHYMOTRYPSIN; DIMERIZATION; DEPENDENCE; MECHANISM; GLYCEROL	The Planck-Benzinger thermal work function, Delta W-0(T), represents the heat-flux term which is responsible for breaking or forming the noncovalent bonds in macromolecular interactions, while the temperature-invariant chemical bond energy, Delta H-0(T-0), gives molecules the cohesiveness to form macromolecular structures. A method is described for evaluating Delta H-0(T-0) at different temperatures for ribonuclease A at low pH in the standard state, in order to determine the effect of pH on the thermodynamic stability of this protein. Ribonuclease A at pH 1.13 has a Delta H-0(T-0) value of 58 kcal mol(-1); at pH 2.50, Delta H-0(T-0) is 58, at pH 2.77, 59, and at pH 3.15, 60 kcal mol(-1). In the conformational thermal transition of ribonuclease A at pH 2.8, the compensatory temperature ranges from 50 to 320 K, and Delta H-0(T-0) is approximately 5 similar to 6 kcal mol(-1). This widening temperature range is typical of the unfolding process. Such differences in the magnitude of the temperature-invariant chemical bond energy can be attributed to specific changes in the solvent ordering in the immediate domain of ribonuclease A.			CHUN, PW (corresponding author), UNIV FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610, USA.							ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AUNE KC, 1971, BIOCHEMISTRY-US, V10, P1609; AUNE KC, 1971, BIOCHEMISTRY-US, V10, P1617; BARR AJ, 1979, SAS GLM 27 GLM 131 S; BENZINGER TH, 1971, NATURE, V29, P100; BRANDTS JF, 1965, J AM CHEM SOC, V87, P2759, DOI 10.1021/ja01090a043; CHUN PW, 1982, BIOPHYS J, V37, pA398; CHUN PW, 1994, J PHYS CHEM-US, V98, P6851, DOI 10.1021/j100078a030; CHUN PW, 1988, INT J QUANTUM CHEM Q, V15, P247; CHUN PW, 1993, MANUAL COMPUTER AIDE; CHUN PW, 1995, BIOPHYS J, V68; CHUN PW, 1995, ANN M FLORIDA SECTIO, V28, P61; CHUN PW, 1994, BIOPHYS J, V66; CRESTFIELD A M, 1962, Arch Biochem Biophys, VSuppl 1, P217; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V27, P439; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; Gibbs J.W., 1878, AM J SCI, Vs3-16, P441, DOI [DOI 10.2475/AJS.S3-16.96.441, 10.2475/ajs.s3-16.96.441]; GIBBS JW, 1878, T CONN ACAD SCI, V3, P228; HAGERMAN PJ, 1979, BIOCHEMISTRY-US, V18, P293, DOI 10.1021/bi00569a009; HAGERMAN PJ, 1976, BIOCHEMISTRY-US, V15, P1462, DOI 10.1021/bi00652a017; HEARN RP, 1971, BIOCHEMISTRY-US, V10, P806; INOUE H, 1973, BIOPOLYMERS, V11, P737; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KIM PS, 1980, BIOCHEMISTRY-US, V19, P6124, DOI 10.1021/bi00567a027; Kupke D. W., 1973, PHYS PRINCIPLES TECH, P1; LEE JC, 1977, BIOCHEMISTRY-US, V16, P1754, DOI 10.1021/bi00627a037; LEWIS GN, 1961, THERMODYNAMICS, P164; MOELWYNHUGHES EA, 1957, PHYSICAL CHEM, P90; NEUMANN NP, 1962, BIOCHEMISTRY-US, V1, P68, DOI 10.1021/bi00907a011; PLANCK M, 1927, TREATISE THERMODYNAM, P179; REISLER E, 1977, BIOCHEMISTRY-US, V16, P197, DOI 10.1021/bi00621a006; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; STEIN WH, 1960, CHEM MODIFICATIONS R, P104; Utiyama H, 1986, Methods Enzymol, V131, P51	36	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13925	13931						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775452				2022-12-25	WOS:A1995RC44800051
J	LEVINE, SA; NATH, SK; YUN, CHC; YIP, JW; MONTROSE, M; DONOWITZ, M; TSE, CM				LEVINE, SA; NATH, SK; YUN, CHC; YIP, JW; MONTROSE, M; DONOWITZ, M; TSE, CM			SEPARATE C-TERMINAL DOMAINS OF THE EPITHELIAL SPECIFIC BRUSH-BORDER NA+/H+ EXCHANGER ISOFORM NHE3 ARE INVOLVED IN STIMULATION AND INHIBITION BY PROTEIN KINASES GROWTH FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; FUNCTIONAL-PROPERTIES; CYTOPLASMIC DOMAIN; MOLECULAR-CLONING; CELL-LINE; EXPRESSION; CALMODULIN; KINETICS; ANTIPORTER	NHE3, a cloned intestinal and renal brush border Na+/H+ exchanger, has previously been shown to be both stimulated and inhibited by different protein kinases/growth factors. For instance, NHE3 is stimulated by serum and fibroblast growth factor (FGF) and inhibited by protein kinase C. In the present study, we used a series of NHE3 C terminus truncation mutants to identify separate regions of the C-terminal cytoplasmic tail responsible for stimulation and inhibition by protein kinases/growth factors. Five NHE3 C terminus truncation mutant stable cell Lines were generated by stably transfecting NHE3 deletion cDNAs into PS120 fibroblasts, which lack any endogenous Na+/H+ exchanger. Using fluorometric techniques, the effects of the calcium/calmodulin (CaM) inhibitor W13, calcium/CaM kinase inhibitor KN-62, phorbol myristate acetate, okadaic acid, FGF, and fetal bovine serum on Na+/H+ exchange were studied in these transfected cells. Inhibition of basal activity of full-length NHE3 is mediated by CaM at a site C-terminal to amino acid 756; this CaM effect occurs through both kinase dependent and independent mechanisms. There is another independent inhibitory domain for protein kinase C between amino acids 585 and 689. In addition, there are at least three stimulatory regions in the C-terminal domain of NHE3, corresponding to amino acids 509-543 for okadaic acid, 475-509 for FGF, and a region N-terminal to amino acid 475 for fetal bovine serum. We conclude that separate regions of the C terminus of NHE3 are involved with stimulation or inhibition of Na+/H+ exchange activity, with both stimulatory and inhibitory domains having several discrete subdomains. A conservative model to explain the way these multiple domains in the C terminus of NHE3 regulate Na+/H+ exchange is via an effect on associated regulatory proteins.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV GASTROINTESTINAL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,GASTROINTESTINAL UNIT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NIDDK NIH HHS [F32DK08820, P01DK44484, R01DK26523] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026523, P01DK044484, F32DK008820] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; CHAKRABORTY M, 1994, P NATL ACAD SCI USA, V91, P2115, DOI 10.1073/pnas.91.6.2115; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; DEGRADO WF, 1987, METHOD ENZYMOL, V139, P455; DONOWITZ M, 1989, J CLIN INVEST, V83, P1953, DOI 10.1172/JCI114104; EMMER E, 1987, J MEMBRANE BIOL, V108, P207; FALCHETTO R, 1991, PROTEIN SCI, V1, P1613; HIDAKA H, 1983, METHOD ENZYMOL, V102, P185; JAMES P, 1988, J BIOL CHEM, V263, P2905; KRAYERPAWLOWSKA D, 1991, J MEMBRANE BIOL, V120, P173, DOI 10.1007/BF01872400; LEATHERBARROW RJ, 1987, ENZFITTER MANUAL; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; LI PM, 1993, ANTICANCER RES, V132, P1957; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SEGEL IH, 1957, ENZYME KINETICS BEHA, P957; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; TSE CM, 1993, P NATL ACAD SCI US; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WATSON AJM, 1991, AM J PHYSIOL, V261, pG229, DOI 10.1152/ajpgi.1991.261.2.G229; WINKEL GK, 1993, J BIOL CHEM, V268, P3396; YU FH, 1993, J BIOL CHEM, V268, P25536; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; 1991, PC GENE USER REFEREN	33	107	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13716	13725		10.1074/jbc.270.23.13716	http://dx.doi.org/10.1074/jbc.270.23.13716			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775426	hybrid			2022-12-25	WOS:A1995RC44800023
J	MERRILL, AH; LINGRELL, S; WANG, E; NIKOLOVAKARAKASHIAN, M; VALES, TR; VANCE, DE				MERRILL, AH; LINGRELL, S; WANG, E; NIKOLOVAKARAKASHIAN, M; VALES, TR; VANCE, DE			SPHINGOLIPID BIOSYNTHESIS DE-NOVO BY RAT HEPATOCYTES IN CULTURE - CERAMIDE AND SPHINGOMYELIN ARE ASSOCIATED WITH, BUT NOT REQUIRED FOR, VERY-LOW-DENSITY LIPOPROTEIN SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTESTINAL-CELLS; NECROSIS-FACTOR-ALPHA; LONG-CHAIN BASES; FATTY-ACIDS; LM CELLS; CHOLESTEROL; LIVER; METABOLISM; FIBROBLASTS; MEMBRANES	Sphingolipids are constituents of liver and lipoproteins, but relatively little is known about their synthesis and secretion. Incubation of rat hepatocytes with [C-14]- or [H-3]serine labeled the long-chain base backbones of mainly ceramide and sphingomyelin. Most of the labeled sphingolipids were associated with the cells; however, 1-5% (the majority of which was ceramide) was released into the medium as part of very low density Lipoproteins (VLDL). Since this is the first report that Lipoproteins contain ceramide, lipoproteins were isolated from rat plasma, and the ceramide contents were (per mg of protein): 6.5 nmol for VLDL (d < 1.018), 0.6 nmol for low density lipoproteins (1.018 < d < 1.063), 0.2 nmol for high density lipoproteins (1.063 < d < 1.18), and 0.1 nmol for the albumin fraction; the lipoproteins also contained 0.1-0.4 nmol of free sphingosine/mg of protein. A number of factors affected the secretion of radiolabeled sphingolipids: 1) addition of palmitic acid, but not stearic or oleic acid, enhanced secretion due to an increase in long-chain base synthesis de novo. 2) Choline deficiency caused a 42% reduction in the secretion of radiolabeled sphingomyelin, but this was due to an effect on VLDL secretion rather than a decrease in sphingolipid synthesis. Removal of choline was examined because previous studies (Yao, Z, M., and Vance, D. E. (1988) J. Biol. Chem. 263, 2998-3004) have shown that choline deficiencies depress phosphatidylcholine synthesis and lipoprotein secretion. 3) Incubation of the cells with fumonisin B-1, a mycotoxin inhibitor of sphinganine (sphingosine) N-acyltransferase, reduced overall sphingolipid synthesis and secretion by 90%, but had no effect on the secretion of apoB, phosphatidylcholine, or cholesterol. Ah together, these findings demonstrate that rat hepatocytes synthesize ceramide and sphingomyelin de novo and incorporate them into both cellular membranes and secreted VLDL, but normal sphingolipid synthesis is not required for lipoprotein secretion.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta	MERRILL, AH (corresponding author), EMORY UNIV,SCH MED,DEPT BIOCHEM,4113 ROLLINS RES CTR,ATLANTA,GA 30322, USA.			Merrill, Alfred/0000-0002-6673-968X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046368] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46368] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BARENHOLZ Y, 1982, PHOSPHOLIPIDS, P129; BELL RM, 1993, ADV LIPID RES, V26; BELL RM, 1993, ADV LIPID RES, V25, P339; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; CHAPMAN MJ, 1986, METHOD ENZYMOL, V128, P70; CHATTERJEE S, 1986, J BIOL CHEM, V261, P3474; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CHEN H, 1993, J LIPID RES, V34, P2159; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FEX G, 1971, BIOCHIM BIOPHYS ACTA, V231, P161, DOI 10.1016/0005-2760(71)90264-5; FIELD FJ, 1993, J CLIN INVEST, V92, P2609, DOI 10.1172/JCI116876; FUGLER L, 1985, J BIOL CHEM, V260, P4098; GATT S, 1980, J BIOL CHEM, V255, P3371; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HATCH GM, 1992, J BIOL CHEM, V267, P12443; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KIM MY, 1991, J BIOL CHEM, V266, P484; KIVATINITZ SC, 1992, BIOCHEM INT, V26, P821; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KUDCHODKAR BJ, 1983, ATHEROSCLEROSIS, V46, P353, DOI 10.1016/0021-9150(83)90184-3; LANGE Y, 1979, BIOCHIM BIOPHYS ACTA, V556, P388, DOI 10.1016/0005-2736(79)90127-5; MALGAT M, 1986, J LIPID RES, V27, P251; MAZIERE JC, 1984, FEBS LETT, V173, P159, DOI 10.1016/0014-5793(84)81038-8; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; MERRILL AH, 1988, BIOCHEMISTRY-US, V27, P340, DOI 10.1021/bi00401a051; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MESSMER TO, 1989, J NUTR, V119, P534, DOI 10.1093/jn/119.4.534; MUEHLENBERG BA, 1972, CAN J BIOCHEM CELL B, V50, P166, DOI 10.1139/o72-022; PATTON S, 1970, J THEOR BIOL, V29, P489, DOI 10.1016/0022-5193(70)90111-6; PHILLIPS J, 1985, BIOL CHEM H-S, V366, P1131, DOI 10.1515/bchm3.1985.366.2.1131; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SHIAO YJ, 1993, J BIOL CHEM, V268, P26085; SIUTAMANGANO P, 1982, J BIOL CHEM, V257, P1463; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1025, P152; STEIN O, 1988, BIOCHIM BIOPHYS ACTA, V960, P322, DOI 10.1016/0005-2760(88)90040-9; STEVENS VL, 1986, BIOCHEMISTRY-US, V25, P4287, DOI 10.1021/bi00363a017; SWEELEY CC, 1991, BIOCH LIPIDS LIPOPRO, P327; ULLMAN MD, 1974, J BIOL CHEM, V249, P1506; VALENTINO LA, 1992, CANCER RES, V52, P810; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE DE, 1975, J BIOL CHEM, V250, P8119; VANDENHEUVEL FA, 1965, ANN NY ACAD SCI, V122, P57; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VERDERY RB, 1982, J BIOL CHEM, V257, P1412; WANG E, 1991, J BIOL CHEM, V266, P14486; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; YAO Z, 1990, BIOCHEM CELL BIOL, V68, P552, DOI 10.1139/o90-079; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YEAGLE PL, 1986, J BIOL CHEM, V261, P8175	57	110	113	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13834	13841		10.1074/jbc.270.23.13834	http://dx.doi.org/10.1074/jbc.270.23.13834			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775441	hybrid			2022-12-25	WOS:A1995RC44800040
J	JI, L; ARCINAS, M; BOXER, LM				JI, L; ARCINAS, M; BOXER, LM			THE TRANSCRIPTION FACTOR, NM23H2, BINDS TO AND ACTIVATES THE TRANSLOCATED C-MYC ALLELE IN BURKITTS-LYMPHOMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; LIGATION-MEDIATED PCR; NM23-H2 MESSENGER-RNA; CHROMATIN STRUCTURE; TUMOR-METASTASIS; DIFFERENTIAL EXPRESSION; PROTEIN-BINDING; TRANSGENIC MICE; LEUKEMIA-CELLS; GENE	We have identified an in vivo footprint over the PuF site on the translocated c-myc allele in Burkitt's lymphoma cells. The PuF site on the silent normal c-myc allele was unoccupied. We demonstrated by electrophoretic mobility shift assay, electrophoretic mobility shift assay with antibody, UV cross-linking followed by SDS-gel electrophoresis, and Western analysis that Nm23H2 in B cell nuclear extracts bound to the c-myc PuF site. Transfection experiments with c-myc promoter constructs in both DHL-9 and Raji cells revealed that the PuF site functioned as a positive regulatory element in B cells with a drop in activity with mutation of this site. Access to this site is blocked in the normal silent c-myc allele; these data suggest that the Nm23H2 protein is involved in deregulation of the translocated c-myc allele in Burkitt's lymphoma cells.	STANFORD UNIV, SCH MED, DEPT MED, DIV HEMATOL, STANFORD, CA 94305 USA; VET ADM MED CTR, CTR MOLEC BIOL MED, PALO ALTO, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764, P01CA034233] Funding Source: NIH RePORTER; NCI NIH HHS [CA34233, CA56764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ARCINAS M, 1994, ONCOGENE, V9, P2699; ARCINAS M, 1994, J BIOL CHEM, V269, P21919; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DYSON PJ, 1985, P NATL ACAD SCI USA, V82, P1984, DOI 10.1073/pnas.82.7.1984; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1988, ONCOGENE, V3, P397; ENGEL M, 1993, INT J CANCER, V55, P375, DOI 10.1002/ijc.2910550306; FLORENES VA, 1992, CANCER RES, V52, P6088; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LEONE A, 1993, ONCOGENE, V8, P2325; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MYEROFF LL, 1993, J NATL CANCER I, V85, P147, DOI 10.1093/jnci/85.2.147; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; OKABEKADO J, 1988, J BIOL CHEM, V263, P10994; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1992, ANN NY ACAD SCI, V660, P57, DOI 10.1111/j.1749-6632.1992.tb21057.x; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; YU BW, 1993, J BIOL CHEM, V268, P19586; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	56	80	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13392	13398		10.1074/jbc.270.22.13392	http://dx.doi.org/10.1074/jbc.270.22.13392			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768941	hybrid			2022-12-25	WOS:A1995RB43900066
J	MORIGUCHI, T; KAWASAKI, H; MATSUDA, S; GOTOH, Y; NISHIDA, E				MORIGUCHI, T; KAWASAKI, H; MATSUDA, S; GOTOH, Y; NISHIDA, E			EVIDENCE FOR MULTIPLE ACTIVATORS FOR STRESS-ACTIVATED PROTEIN-KINASES C-JUN AMINO-TERMINAL KINASES - EXISTENCE OF NOVEL ACTIVATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MAP KINASE; PHOSPHORYLATION; PATHWAYS; IDENTIFICATION; CASCADE	Stress-activated protein kinases (SAPRs) or c-Jun amino-terminal kinases (JNKs), which belong to a subgroup of the mitogen-activated protein kinase (MAPK) superfamily, are activated in response to a variety of stresses in mammalian cells. An activity to activate a recombinant rat SAPK alpha was detected in extracts obtained from rat fibroblastic 3Y1 cells exposed to hyperosmolar media and was resolved into unadsorbed and adsorbed fractions on Q Sepharose chromatography. The adsorbed activity was identified as XMEK2/SEK1/MKK4 by using several anti-XMEK2 antibodies. Thus, a 45-kDa protein that was recognized specifically by these anti-XMEK2 antibodies co-eluted with the SAPK alpha activating activity during chromatography on Q-Sepharose and Superose 6, and the activity could be immunoprecipitated by the antibodies from these fractions. The unadsorbed activity, whose level was much greater than that of the adsorbed activity, did not contain XMEK2/SEK1/MKK4 and was also activated in a time-dependent manner by osmotic shock. This activity was further resolved into several peaks during chromatography on heparin-Sepharose and hydroxylapatite. Most of these peaks eluted separately from major peaks of a kinase activity toward p38/MPK2, another subgroup of the MAPK superfamily, whereas the activated XMEK2/SEK1/MKK4 could phosphorylate p38/MPK2 efficiently. These results indicate the existence of multiple activators for SAPR/JNK; one is XMEK2/SEK1/MKK4, and the others are previously undescribed factors.	KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University			Kawasaki, Hiroshi/C-4404-2015; Moriguchi, Tetsuo/D-7061-2012	Moriguchi, Tetsuo/0000-0002-9598-4991; Kawasaki, Hiroshi/0000-0002-2514-1497				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1994, J BIOL CHEM, V269, P25699; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738	28	119	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					12969	12972		10.1074/jbc.270.22.12969	http://dx.doi.org/10.1074/jbc.270.22.12969			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768885	hybrid			2022-12-25	WOS:A1995RB43900006
J	SKIBA, NP; ARTEMYEV, NO; HAMM, HE				SKIBA, NP; ARTEMYEV, NO; HAMM, HE			THE CARBOXYL-TERMINUS OF THE GAMMA-SUBUNIT OF ROD CGMP PHOSPHODIESTERASE CONTAINS DISTINCT SITES OF INTERACTION WITH THE ENZYME CATALYTIC SUBUNITS AND THE ALPHA-SUBUNIT OF TRANSDUCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; INHIBITORY SUBUNIT; OUTER SEGMENTS; RETINAL RODS; ACTIVATION MECHANISM; VISUAL EXCITATION; PROTEIN; BOVINE; BINDING; IDENTIFICATION	The interaction between the GTP-bound form of the transducin alpha-subunit (G alpha(t)) and the gamma-subunit (P gamma) of cGMP phosphodiesterase (PDE) is a key event in effector activation during photon signal transduction. The carboxyl-terminal half of P gamma is involved in interaction with G alpha(t), as well as in inhibition of PDE activity. Here we have utilized a combination of synthetic peptide and mutagenesis approaches to localize specific regions of the carboxyl-terminal region of P gamma interacting with G alpha(t) and P alpha beta and have determined residues involved in inhibition of PDE activity. We found that synthetic peptide corresponding to residues 68-87 of P gamma completely inhibit trypsin-activated PDE. The peptide P gamma-63-87 bound to G alpha(t)GTP gamma S with a K-d Of 2.5 mu m, whereas the binding of P gamma-68-87 60 G alpha(t)GTP gamma S was approximately 15-fold less (K-d = 40 mu M) suggesting that carboxyl-terminal P gamma region 68-87 contains a site for interaction with P alpha beta and also a part of the alpha(t) binding site. To map G alpha(t) and P alpha beta sites more precisely within the carboxyl-terminal region, a set of carboxyl-terminal mutants was generated by site-directed mutagenesis. Deletion of residues 63-69 and 70-76 diminished the binding of mutants to alpha(t) while binding to carboxyl-terminally truncated mutants lacking up to 11 amino acid residues was unchanged. In contrast, carboxyl-terminal truncations of P gamma from Delta 1 to Delta 11 resulted in a gradual decrease of its inhibitory activity. Thus, the extreme carboxyl-terminal hydrophobic sequence -Ile(86)-Ile(87) together with 9 adjacent residues provides inhibitory interaction of P gamma with P alpha beta. The carboxyl-terminal G alpha(t)GTP gamma S binding site of P gamma is different from but adjacent to its PDE inhibitory site. During the visual transduction process, G alpha(t)GTP Likely binds to this region of P gamma inducing a displacement of the extreme carboxyl terminus from the inhibitory site on P alpha beta, leading to PDE activation.	UNIV ILLINOIS,COLL MED,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60680	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Artemyev, Nikolai/0000-0002-5266-6854	PHS HHS [06062] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Artemyev Nikolai O., 1993, Methods (Orlando), V5, P220, DOI 10.1006/meth.1993.1027; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CATTY P, 1992, J BIOL CHEM, V267, P19489; CLERC A, 1992, J BIOL CHEM, V267, P6620; COLEMAN DE, 1994, NATURE, V265, P1405; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; EIBL H, 1969, ANAL BIOCHEM, V30, P51, DOI 10.1016/0003-2697(69)90372-8; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; Lipkin V M, 1990, Biomed Sci, V1, P305; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; LIPKIN VM, 1993, BIOCHIM BIOPHYS ACTA, V1176, P250, DOI 10.1016/0167-4889(93)90052-Q; Maniatis T, 1989, DECONTAMINATION DILU; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OPPERT B, 1991, J BIOL CHEM, V266, P16607; OPPERT B, 1991, BIOCHEM BIOPH RES CO, V175, P474; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V204, P288; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRYER L, 1991, J BIOL CHEM, V266, P10711; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539	47	60	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13210	13215		10.1074/jbc.270.22.13210	http://dx.doi.org/10.1074/jbc.270.22.13210			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768919	hybrid			2022-12-25	WOS:A1995RB43900042
J	WANG, SP; MILLER, WA				WANG, SP; MILLER, WA			A SEQUENCE LOCATED 4.5 TO 5 KILOBASES FROM THE 5' END OF THE BARLEY YELLOW DWARF VIRUS (PAV) GENOME STRONGLY STIMULATES TRANSLATION OF UNCAPPED MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; EUKARYOTIC MESSENGER-RNAS; POLY(A) TAIL; NUCLEOTIDE-SEQUENCE; PLANT; INITIATION; CAP; INVITRO; PROTEIN; EFFICIENCY	An infectious, in vitro transcript from a full-length cDNA clone of the barley yellow dwarf virus (PAV serotype) genome translated efficiently in a wheat germ translation extract. Deletions in a region that Re call the 3' translational enhancer, located between bases 4,513 and 5,009 in the 5,677-base genome, reduced translation of the 5'-proximal open reading frames from uncapped RNA by at least 30-fold. Deletions elsewhere in all but the 5' end of the genome had no effect on translation. Presence of a m(7)G(5')ppp(5')G cap on the 5' end fully restored translational efficiency of transcripts lacking the 3' translational enhancer. The translation enhancer reduced inhibition of translation by free cap analog, did not affect RNA stability, and did not function in reticulocyte lysates. When placed in the 3'-untranslated region of uncapped mRNA encoding the beta-glucuronidase gene, the translation enhancer stimulated translation more than 80-fold, in the presence of the viral, but not a plasmid-derived, 5' leader. A polyadenylate tail could not substitute for the 3' translation enhancer. These observations provide an extreme example, in terms of distance from the 5' end and level of stimulation, of an mRNA in which a sequence near the 3' end stimulates translation.	IOWA STATE UNIV SCI & TECHNOL,DEPT PLANT PATHOL,AMES,IA 50011; IOWA STATE UNIV SCI & TECHNOL,MOLEC CELLULAR & DEV BIOL PROGRAM,AMES,IA 50011	Iowa State University; Iowa State University								BRAULT V, 1992, P NATL ACAD SCI USA, V89, P2262, DOI 10.1073/pnas.89.6.2262; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; CHALHOUB BA, 1994, ARCH VIROL, V139, P403, DOI 10.1007/BF01310801; DANTHINNE X, 1993, MOL CELL BIOL, V13, P3340, DOI 10.1128/MCB.13.6.3340; DARCY CJ, 1986, MICROBIOL SCI, V3, P309; DAUBERT SD, 1983, METHOD VIROL, P347; DI R, 1993, MOL PLANT MICROBE IN, V6, P444, DOI 10.1094/MPMI-6-444; DINESHKUMAR SP, 1993, PLANT CELL, V5, P679, DOI 10.1105/tpc.5.6.679; DINESHKUMAR SP, 1992, VIROLOGY, V187, P711, DOI 10.1016/0042-6822(92)90474-4; DINESHKUMAR SP, 1993, THESIS IOWA STATE U; DOEL MT, 1976, CELL, V8, P51, DOI 10.1016/0092-8674(76)90184-7; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; GALLIE DR, 1990, GENE DEV, V4, P1149, DOI 10.1101/gad.4.7.1149; GALLIE DR, 1991, MOL GEN GENET, V228, P258, DOI 10.1007/BF00282474; GALLIE DR, 1994, GENE, V142, P159, DOI 10.1016/0378-1119(94)90256-9; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; KELLY L, 1994, VIROLOGY, V202, P565, DOI 10.1006/viro.1994.1378; KEMPER B, 1977, BIOCHEMISTRY-US, V16, P5676, DOI 10.1021/bi00645a004; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMMEL SA, 1989, NUCLEIC ACIDS RES, V17, P8587; MAYO MA, 1982, J GEN VIROL, V59, P163, DOI 10.1099/0022-1317-59-1-163; MAYO MA, 1991, CLASSIFICATION NOMEN, P400; McBratney S, 1993, CURR OPIN CELL BIOL, V5, P961, DOI 10.1016/0955-0674(93)90077-4; MILLER JS, 1991, J GEN VIROL, V72, P2633, DOI 10.1099/0022-1317-72-11-2633; Miller W. A., 1994, ENCY VIROLOGY, P792; MILLER WA, 1988, NUCLEIC ACIDS RES, V16, P6097, DOI 10.1093/nar/16.13.6097; MILLER WA, 1995, IN PRESS CRIT REV PL; MOSS B, 1977, BIOCHEM BIOPH RES CO, V74, P374, DOI 10.1016/0006-291X(77)90314-X; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; MURPHY JF, 1989, J GEN VIROL, V70, P2253, DOI 10.1099/0022-1317-70-8-2253; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; RATHJEN JP, 1994, VIROLOGY, V198, P571; Sambrook J, 1989, MOL CLONING LABORATO; SCHNARE MN, 1982, NUCLEIC ACIDS RES, V10, P3921, DOI 10.1093/nar/10.13.3921; SEELEY KA, 1992, PLANT CELL, V4, P29, DOI 10.1105/tpc.4.1.29; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SILVER SL, 1994, VIROLOGY, V198, P331, DOI 10.1006/viro.1994.1036; SKUZESKI JM, 1990, PLANT MOL BIOL, V15, P65, DOI 10.1007/BF00017725; SLEAT DE, 1992, GENETIC ENG PLANT VI, P55; TIMMER RT, 1993, J BIOL CHEM, V268, P9504; TOMASHEVSKAYA OL, 1993, J GEN VIROL, V74, P2717, DOI 10.1099/0022-1317-74-12-2717; TURNER R, 1994, ARCH VIROL, V134, P321, DOI 10.1007/BF01310570; UENG PP, 1992, J GEN VIROL, V73, P487, DOI 10.1099/0022-1317-73-2-487; WADSWORTH GJ, 1988, ANAL BIOCHEM, V172, P279, DOI 10.1016/0003-2697(88)90443-5; YOUNG MJ, 1991, VIROLOGY, V180, P372, DOI 10.1016/0042-6822(91)90042-A; YSEBAERT M, 1980, J MOL BIOL, V143, P273, DOI 10.1016/0022-2836(80)90190-4	55	59	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13446	13452		10.1074/jbc.270.22.13446	http://dx.doi.org/10.1074/jbc.270.22.13446			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768947	hybrid			2022-12-25	WOS:A1995RB43900073
J	RASHEED, BKA; MCLENDON, RE; FRIEDMAN, HS; FRIEDMAN, AH; FUCHS, HE; BIGNER, DD; BIGNER, SH				RASHEED, BKA; MCLENDON, RE; FRIEDMAN, HS; FRIEDMAN, AH; FUCHS, HE; BIGNER, DD; BIGNER, SH			CHROMOSOME-10 DELETION MAPPING IN HUMAN GLIOMAS - A COMMON DELETION REGION IN 10Q25	ONCOGENE			English	Note						GLIOBLASTOMA; CHROMOSOME 10; LOSS OF HETEROZYGOSITY	FACTOR RECEPTOR GENE; MALIGNANT GLIOMAS; GLIOBLASTOMA-MULTIFORME; HUMAN ASTROCYTOMAS; GLIAL ORIGIN; HETEROZYGOSITY; AMPLIFICATION; MUTATIONS; TUMOR; OLIGODENDROGLIOMAS	The high incidence of loss of chromosome 10 alleles in glioblastoma multiforme suggests the presence on this chromosome of a tumor suppressor gene that is important in glioma tumorigenesis and progression. Our initial deletion mapping studies using restriction fragment length polymorphism markers indicated a common deletion region in 10q24-qter. In an attempt to localize the deleted region further, we screened a panel of 117 gliomas for loss of heterozygosity for chromosome 10 loci using 10 microsatellite markers. Seventeen tumors showed partial loss of a copy of chromosome 10 and;were further analysed using 28 additional microsatellite markers. Of these, 10 had terminal deletion in the q arm, three had deletions in both p and q arms, two contained interstitial deletion in 10q and two carried deletions in 10p. In the 15 tumors with deletions in 10q, the minimal overlapping deletion region was in distal 10q between markers D10S587 and D10S216. Loci D10S587 and D10S216 are approximately mapped to a 5 cM region in 10q25.1.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,PREUSS LAB BRAIN TUMOR RES,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Duke University; Duke University; Duke University; Duke University					NATIONAL CANCER INSTITUTE [R37CA043722, R01CA043722] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43722] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIGNER SH, 1988, CANCER RES, V48, P405; BURGER PC, 1991, SURGICAL PATHOLOGY N; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1989, CANCER RES, V49, P6572; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HE J, 1994, CANCER RES, V54, P5804; JAMES CD, 1988, CANCER RES, V48, P5546; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KUMABE T, 1992, ONCOGENE, V7, P627; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MIYAKOSHI J, 1990, CANCER RES, V50, P278; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P348, DOI 10.1002/gcc.2870050411; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; REIFENBERGER G, 1993, CANCER RES, V53, P2736; REY JA, 1992, INT J CANCER, V51, P703, DOI 10.1002/ijc.2910510507; VONDEIMLING A, 1992, CANCER RES, V52, P4277; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899	24	197	205	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2243	2246						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784070				2022-12-25	WOS:A1995RB70300021
J	NIEDERGANG, F; HEMAR, A; HEWITT, CRA; OWEN, MJ; DAUTRYVARSAT, A; ALCOVER, A				NIEDERGANG, F; HEMAR, A; HEWITT, CRA; OWEN, MJ; DAUTRYVARSAT, A; ALCOVER, A			THE STAPHYLOCOCCUS-AUREUS ENTEROTOXIN-B SUPERANTIGEN INDUCES SPECIFIC T-CELL RECEPTOR DOWN-REGULATION BY INCREASING ITS INTERNALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR VIRUS SUPERANTIGENS; CYTOTOXIC LYMPHOCYTES-T; CLASS-II MOLECULES; ANTIGEN RECEPTOR; HLA-DR; TRANSGENIC MICE; CLONAL ANERGY; BINDING; MODULATION; COMPLEX	Superantigens are able to stimulate T lymphocyte populations expressing T cell antigen receptors (TCR) belonging to particular V beta families. Moreover, the presence of these superantigens may induce long term unresponsiveness (anergy) of these sensitive cells, Some bacterial toxins are potent superantigens, We have analyzed in vitro the capacity of some Staphylococcus aureus enterotoxin superantigens to modulate T cell antigen receptor expression and the cellular mechanisms involved, Staphylococcus enterotoxin B (SEB) induced rapid down regulation of surface T cell antigen receptors in V beta 3-expressing T lymphocytes, as assessed by flow cytometry, This phenomenon was a consequence of the direct interaction between the toxin and the TCR since it was observed in the absence of cells expressing major histocompatibility complex class II molecules. The cellular mechanism involved in SEE-induced downregulation of TCR was further investigated, Immunofluorescence and confocal microscopy experiments showed that toxin B induced intracellular accumulation of TCR . CD3 in endocytic vesicles, Moreover, SEE induced an increase in T cell receptor endocytosis as measured using radiolabeled Fab fragments of an anti-CD3 monoclonal antibody. Taken together, our observations indicate that Staphylococcus enterotoxin B superantigen induced changes in the dynamics of surface T cell receptors, which resulted in the fast reduction of membrane receptor numbers,	INST PASTEUR,UNITE BIOL INTERACT CELLULAIRES,CNRS,URA 1960,F-75724 PARIS 15,FRANCE; IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Cancer Research UK			Hewitt, Colin/GXH-7289-2022	Hewitt, Colin/0000-0001-5826-8577; Niedergang, Florence/0000-0002-7064-830X; Alcover, Andres/0000-0002-9507-3450				ACHAORBEA H, 1993, IMMUNOL REV, V131, P5, DOI 10.1111/j.1600-065X.1993.tb01527.x; ACRES RB, 1986, J BIOL CHEM, V261, P6210; ARNOLD B, 1993, IMMUNOL TODAY, V14, P12, DOI 10.1016/0167-5699(93)90317-E; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BORST J, 1993, IMMUNOL REV, V132, P49, DOI 10.1111/j.1600-065X.1993.tb00837.x; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; DISANTO JP, 1989, IMMUNOGENETICS, V30, P494, DOI 10.1007/BF02421181; DUPREZ V, 1991, J BIOL CHEM, V266, P1497; FISCHER H, 1989, J IMMUNOL, V142, P3151; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HEWITT CRA, 1992, J EXP MED, V175, P1493, DOI 10.1084/jem.175.6.1493; HOMMELBERREY GA, 1991, J IMMUNOL, V147, P3237; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1993, IMMUNOL REV, V131, P79, DOI 10.1111/j.1600-065X.1993.tb01531.x; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; MOLLICK JA, 1988, SCIENCE, V244, P817; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; OHEHIR RE, 1990, P NATL ACAD SCI USA, V87, P8884, DOI 10.1073/pnas.87.22.8884; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; ROBBINS PA, 1991, J EXP MED, V173, P221, DOI 10.1084/jem.173.1.221; RUSSELL JK, 1990, BIOCHEM BIOPH RES CO, V168, P696, DOI 10.1016/0006-291X(90)92377-C; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; TAKADA S, 1987, J IMMUNOL, V139, P3231; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; UCHIYAMA T, 1989, J IMMUNOL, V143, P3175; VINEY JL, 1992, HYBRIDOMA, V11, P701, DOI 10.1089/hyb.1992.11.701; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEYAND CM, 1987, J IMMUNOL, V138, P1351; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; ZANDERS ED, 1983, NATURE, V303, P625, DOI 10.1038/303625a0; ZUMLA A, 1992, CLIN INFECT DIS, V15, P313, DOI 10.1093/clinids/15.2.313	43	63	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12839	12845		10.1074/jbc.270.21.12839	http://dx.doi.org/10.1074/jbc.270.21.12839			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759540	hybrid			2022-12-25	WOS:A1995QZ71100077
J	BENKIRANE, N; GUICHARD, G; VANREGENMORTEL, MHV; BRIAND, JP; MULLER, S				BENKIRANE, N; GUICHARD, G; VANREGENMORTEL, MHV; BRIAND, JP; MULLER, S			CROSS-REACTIVITY OF ANTIBODIES TO RETRO-INVERSO PEPTIDOMIMETICS WITH THE PARENT PROTEIN HISTONE H3 AND CHROMATIN CORE PARTICLE - SPECIFICITY AND KINETIC RATE-CONSTANT MEASUREMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; HEXAPEPTIDE; PEPTIDES; ANALOGS; BOND	A series of monoclonal antibodies has been generated against an hexapeptide of sequence IRGERA corresponding to the C-terminal residues 130-135 of histone H3 and three analogues of this model peptide. The analogues correspond to the D-enantiomer, containing only D-residues, and two retro-peptides containing NH-CO bonds instead of natural amide peptide bonds. The chirality of each residue was maintained in the retropeptide and inverted in the retro-inverso-peptide. Monoclonal antibodies were generated from mice immunized with the analogues coupled to neutral small unilamellar liposomes containing monophosphoryl lipid A as adjuvant. The reactivity of antibodies with the four analogues and with the parent protein H3 was studied in enzyme-linked immunosorbent assay and in a biosensor system. The equilibrium affinity constant (K(a)lpha) toward the retro-inverso-peptide of two out of three antibodies of IgG1 isotype induced against the L-hexapeptide was 7-75-fold higher than toward the homologous L-peptide. The range of K-alpha, values of four antibodies of IgG1 and IgG2a isotypes generated against the retro inverso-peptide was 0.6-1.9 x 10(9) M(-1) for both the retro-inverso- and L-peptides. Furthermore, antibodies to the L- and retroinverso-peptides cross reacted strongly (in some cases better than with the homologous peptide) with the parent histone H3 and with chromatin subunits containing H3. The results are thus promising in respect to the potential use of retro inverso-analogues, which are particularly stable, in the design of much more potent synthetic vaccines or to generate antibody probes.	INST BIOL MOLEC & CELLULAIRE, CNRS, UPR 9021, F-67084 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			GUICHARD, Gilles/I-3858-2016; Muller, Sylviane/J-5319-2014; Benkirane-Jessel, Nadia/H-6438-2016	GUICHARD, Gilles/0000-0002-2584-7502; Benkirane-Jessel, Nadia/0000-0003-3059-3559				ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; BRIAND J-P, 1989, Peptide Research, V2, P381; CHOREV M, 1983, J MED CHEM, V26, P129, DOI 10.1021/jm00356a003; FAUCHERE JL, 1992, ADV DRUG RES, V23, P128; FRIEDE M, 1993, MOL IMMUNOL, V30, P539, DOI 10.1016/0161-5890(93)90028-A; GOODMAN M, 1979, ACCOUNTS CHEM RES, V12, P1, DOI 10.1021/ar50133a001; GUICHARD G, 1994, PEPTIDE RES, V7, P308; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON R, 1992, STRUCTURE ANTIGENS, V1, P127; KAZMIERSKI WM, 1992, INT J PEPT PROT RES, V39, P401; LEBAN JJ, 1993, P NATL ACAD SCI USA, V90, P1922, DOI 10.1073/pnas.90.5.1922; MARRAUD M, 1993, BIOPOLYMERS, V33, P1135, DOI 10.1002/bip.360330715; Miggiano V., 1982, RES DISCL, V217, P155; MULLER S, 1982, EMBO J, V1, P421, DOI 10.1002/j.1460-2075.1982.tb01185.x; MULLER S, 1987, MOL IMMUNOL, V24, P779, DOI 10.1016/0161-5890(87)90062-9; MULLER S, 1989, METHOD ENZYMOL, V170, P251; MULLER S, 1988, SYNTHETIC POLYPEPTID, P95; NEIMARK J, 1993, PEPTIDE RES, V6, P219; SHEMYAKIN MM, 1969, ANGEW CHEM INT EDIT, V8, P492, DOI 10.1002/anie.196904921; Zeder Lutz Gabrielle, 1993, Journal of Molecular Recognition, V6, P71, DOI 10.1002/jmr.300060205	23	52	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11921	11926		10.1074/jbc.270.20.11921	http://dx.doi.org/10.1074/jbc.270.20.11921			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744843	hybrid			2022-12-25	WOS:A1995QY73600039
J	LIU, M; PELLING, JC				LIU, M; PELLING, JC			UV-B/A IRRADIATION OF MOUSE KERATINOCYTES RESULTS IN P53-MEDIATED WAF1/CIP1 EXPRESSION	ONCOGENE			English	Article						UV IRRADIATION; P53; WAF1/CIP1; KERATINOCYTE; SKIN CANCER	P53 MUTATIONS; ATAXIA-TELANGIECTASIA; SKIN-CANCER; DNA-DAMAGE; WILD-TYPE; CELL; RADIATION; PROTEIN; INDUCTION; ULTRAVIOLET	The tumor suppressor gene p53 is involved in controlling cell cycle checkpoint or triggering apoptosis. p53 may accomplish these roles by acting as a sequence-specific transcription factor, One of the downstream targets of p53 transcription control is the WAF1/CIP1 gene, whose gene product p21 interacts with several cyclins and cyclin-dependent kinases, resulting in inhibition of these kinases. Tn our previous studies, we have shown that the p53 protein level in mouse keratinocytes was elevated following UV-B/A irradiation. In this paper we further investigated the consequences of increased p53 protein level by characterizing p53 DNA-binding level and WAF1/CIP1 gene expression in UV-B/A-irradiated mouse keratinocytes. Consistent with the increased level of p53 protein, both p53 DNA-binding level and steady-state level of WAFI/CIP1 mRNA were elevated. We have demonstrated that the induction of WAF1/CIP1 mRNA was mediated by p53, since no WAF1/CIP1 induction was observed in p53-deficient cells upon W-B exposure. These observations suggest an important role for the tumor suppressor gene p53 in the response of keratinocytes to the biologically relevant W-BIA irradiation and in suppressing UV-induced skin cancer.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NATIONAL CANCER INSTITUTE [R01CA040847, P30CA036727] Funding Source: NIH RePORTER; NCI NIH HHS [CA36727-07, CA40847] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOL MOL; BEER JZ, 1993, PHOTOCHEM PHOTOBIOL, V58, P676, DOI 10.1111/j.1751-1097.1993.tb04951.x; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAMPBELL C, 1993, CANCER RES, V53, P2697; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CRUTZEN PJ, 1992, NATURE, V356, P104, DOI 10.1038/356104a0; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINALY CA, 1989, CELL, V57, P1083; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HARPER JW, 1993, CELL, V75, P805; HERRLICH P, 1984, ADV ENZYME REGUL, V25, P485; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSON BE, 1984, PHYSL PATHOPHYSIOLOG, V8, P2414; KANJILAL S, 1993, CANCER RES, V53, P2961; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; KOONE MD, 1986, J INVEST DERMATOL, V87, P343, DOI 10.1111/1523-1747.ep12524440; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LOGANZO JF, 1994, MOL CELL DIFF, V2, P23; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MICHIELI P, 1994, CANCER RES, V54, P3391; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRICE BD, 1993, ONCOGENE, V8, P3055; Romerdahl C A, 1989, Cancer Commun, V1, P209; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; URBACH F, 1984, TOPICS PHOTOMEDICINE, P67; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG W, 1994, CANCER RES, V54, P4448; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; [No title captured]	48	77	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1955	1960						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761096				2022-12-25	WOS:A1995QZ92600009
J	BLYTH, K; TERRY, A; OHARA, M; BAXTER, EW; CAMPBELL, M; STEWART, M; DONEHOWER, LA; ONIONS, DE; NEIL, JC; CAMERON, ER				BLYTH, K; TERRY, A; OHARA, M; BAXTER, EW; CAMPBELL, M; STEWART, M; DONEHOWER, LA; ONIONS, DE; NEIL, JC; CAMERON, ER			SYNERGY BETWEEN A HUMAN C-MYC TRANSGENE AND P53 NULL GENOTYPE IN MURINE THYMIC LYMPHOMAS - CONTRASTING EFFECTS OF HOMOZYGOUS AND HETEROZYGOUS P53 LOSS	ONCOGENE			English	Article						MYC; P53; LYMPHOMA	WILD-TYPE; P53-DEFICIENT MICE; CELL-LINE; APOPTOSIS; MUTATIONS; COOPERATION; EXPRESSION; ONCOGENE; LEUKEMIA; TUMORS	Activation of the c-myc oncogene and functional loss of the p53 tumour suppressor gene are among the most frequently recorded genetic lesions in neoplasia but their combined effect has not previously been investigated. By breeding together mice transgenic for human c-myc (CD2-myc) and mice carrying an inactive p53 allele (p53(-/-)) we found that these genetic lesions act synergistically in vivo, Offspring carrying the CD2-myc transgene and the homozygous p53 null mutation (p53(-/-)/CD2-myc) were viable but developed thymic lymphomas with dramatically increased frequency and reduced latency compared to both parental groups. The tumour phenotype was similar to that previously recorded for CD2-myc mice (predominantly CD3+, CD4+8+) but tumour clonal complexity and metastasis was significantly greater in the p53(-/-)/CD2-myc mice, In contrast, no significant increase in tumour incidence was seen in p53(+/-)/CD2-myc vs p53(+/+)/CD2-myc mice over a 6 month observation period, However, the loss of wild type p53 in a proportion of tumour cells in p53(+/-)/CD2-myc lymphomas suggests that wild type allele loss can occur as a late progression step rather than an initiating step in these tumours, We suggest that p53 loss of function may collaborate with the CD2-myc transgene at more than one stage in thymic lymphoma development.	UNIV GLASGOW, SCH VET, DEPT VET PATHOL, GLASGOW G61 1QH, LANARK, SCOTLAND; UNIV GLASGOW, SCH VET, DEPT VET ANIM HUSBANDRY, GLASGOW G61 1QH, LANARK, SCOTLAND; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA	University of Glasgow; University of Glasgow; Baylor College of Medicine				Blyth, Karen/0000-0002-9304-439X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1992, CANCER SURV, V15, P119; ASKEW DS, 1991, ONCOGENE, V6, P1915; BARTEK J, 1991, ONCOGENE, V6, P1699; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BORN W, 1988, J IMMUNOL, V140, P3228; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EISENMAN RN, 1989, ONCOGENES MOL ORIGIN, P175; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FARRUGIA MM, 1994, BLOOD, V83, P191; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HAUPT Y, 1993, ONCOGENE, V8, P3161; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; NEIL JC, 1984, NATURE, V308, P814, DOI 10.1038/308814a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PURDIE CA, 1994, ONCOGENE, V9, P603; RAGIMOV N, 1993, ONCOGENE, V8, P1183; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SMITH ML, 1993, CARCINOGENESIS, V14, P503, DOI 10.1093/carcin/14.3.503; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEWART M, 1993, INT J CANCER, V53, P1023; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176	41	94	95	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1717	1723						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753548				2022-12-25	WOS:A1995QX46900004
J	INAGAKI, N; KUROMI, H; GONOI, T; OKAMOTO, Y; ISHIDA, H; SEINO, Y; KANEKO, T; IWANAGA, T; SEINO, S				INAGAKI, N; KUROMI, H; GONOI, T; OKAMOTO, Y; ISHIDA, H; SEINO, Y; KANEKO, T; IWANAGA, T; SEINO, S			EXPRESSION AND ROLE OF IONOTROPIC GLUTAMATE RECEPTORS IN PANCREATIC-ISLET CELLS	FASEB JOURNAL			English	Article						GABA; INSULIN; GLUCAGON; PARACRINE; NEUROTRANSMITTERS	GAMMA-AMINOBUTYRIC-ACID; SYNAPTIC-LIKE MICROVESICLES; BETA-CELLS; MOLECULAR DIVERSITY; GLUCAGON-SECRETION; INSULIN RELEASE; AMPA SUBTYPE; GABA; CHANNELS; GLUCOSE	Although the excitatory amino acid glutamate and its receptors play crucial roles in many functions of the central nervous system (CNS), their presence in the peripheral tissues has remained unclear. In the present study, we have identified kainate, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), and N-methyl-D-aspartate (NMDA) receptor subtype mRNAs in pancreatic islets, using reverse transcriptase polymerase chain reaction (RT-PCR). Intracellular calcium ([Ca2+](i)) measurements and electrophysiological recordings indicate that kainate, AMPA, and NMDA. all elicit increases of [Ca2+](i) in single pancreatic beta-cells and depolarize them. In addition, kainate and AMPA stimulate insulin secretion from isolated pancreatic islets, whereas NMDA does not. Also, immunocytochemical study shows the presence of intense glutaminase immunoreactivity in pancreatic alpha-cells and intrapancreatic ganglia, a finding compatible with the possibility that glutamate is released from alpha-cells as well as from neurons. Because the inhibitory amino acid gamma-amino butyric acid (GABA) is present in beta-cells as well as in neurons and inhibits glucagon secretion from alpha-cells, the present study suggests that glutamate and GABA are coordinated in the regulation of hormone secretion in pancreatic islets.	CHIBA UNIV, SCH MED, CTR BIOMED SCI, DIV MOLEC MED, CHUO KU, CHIBA 260, JAPAN; CHIBA UNIV, PATHOGEN FUNGI & MICROBIAL TOXICOSES RES CTR, CHUO KU, CHIBA 260, JAPAN; KYOTO UNIV, FAC MED, DEPT METAB & CLIN NUTR, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT MORPHOL BRAIN SCI, SAKYO KU, KYOTO 606, JAPAN; NIIGATA UNIV, SCH MED, DEPT ANAT, NIIGATA 951, JAPAN	Chiba University; Chiba University; Kyoto University; Kyoto University; Niigata University			, gonoi/GRS-0648-2022; gonoi, tohru/AAC-5181-2021	, gonoi/0000-0003-3655-7911; gonoi, tohru/0000-0003-3655-7911; Inagaki, Nobuya/0000-0001-8261-2593				AKIYAMA H, 1990, J COMP NEUROL, V297, P239, DOI 10.1002/cne.902970207; BERTRAND G, 1993, EUR J PHARMACOL, V237, P45, DOI 10.1016/0014-2999(93)90091-U; BERTRAND G, 1992, BRIT J PHARMACOL, V106, P354, DOI 10.1111/j.1476-5381.1992.tb14340.x; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; Gasic G P, 1991, Curr Opin Neurobiol, V1, P20, DOI 10.1016/0959-4388(91)90006-S; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GILON P, 1991, ENDOCRINOLOGY, V129, P2521, DOI 10.1210/endo-129-5-2521; GONOI T, 1994, J BIOL CHEM, V269, P16989; GONOI T, 1988, J PHYSIOL-LONDON, V401, P617, DOI 10.1113/jphysiol.1988.sp017183; HIRIART M, 1988, J GEN PHYSIOL, V91, P617, DOI 10.1085/jgp.91.5.617; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KATAOKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P3218, DOI 10.1073/pnas.81.10.3218; KITAYAMA S, 1984, N-S ARCH PHARMACOL, V326, P106, DOI 10.1007/BF00517305; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LINDSTROM P, 1992, ENDOCRINOLOGY, V131, P1903, DOI 10.1210/en.131.4.1903; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OKADA Y, 1976, SCIENCE, V194, P620, DOI 10.1126/science.185693; OKAMOTO Y, 1992, DIABETES, V41, P1555, DOI 10.2337/diabetes.41.12.1555; RACAGNI G, 1979, NATURE, V281, P575, DOI 10.1038/281575a0; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SHANNON HE, 1989, J PHARMACOL EXP THER, V251, P518; SORENSON RL, 1991, DIABETES, V40, P1365, DOI 10.2337/diabetes.40.11.1365; THOMASREETZ A, 1993, P NATL ACAD SCI USA, V90, P5317, DOI 10.1073/pnas.90.11.5317; TOMIKO SA, 1983, NATURE, V301, P706, DOI 10.1038/301706a0; UNGER RH, 1978, ANNU REV PHYSIOL, V40, P307, DOI 10.1146/annurev.ph.40.030178.001515; VINCENT SR, 1983, NEUROENDOCRINOLOGY, V36, P197, DOI 10.1159/000123456; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; YONEDA Y, 1986, BRAIN RES, V383, P387, DOI 10.1016/0006-8993(86)90046-6; YONEDA Y, 1986, Neuroscience Research, V3, P430, DOI 10.1016/0168-0102(86)90034-9	35	166	176	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					686	691		10.1096/fasebj.9.8.7768362	http://dx.doi.org/10.1096/fasebj.9.8.7768362			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768362				2022-12-25	WOS:A1995RC10600016
J	ROSSIER, MF; APTEL, HBC; PYTHON, CP; BURNAY, MM; VALLOTTON, MB; CAPPONI, AM				ROSSIER, MF; APTEL, HBC; PYTHON, CP; BURNAY, MM; VALLOTTON, MB; CAPPONI, AM			INHIBITION OF LOW-THRESHOLD CALCIUM CHANNELS BY ANGIOTENSIN-II IN ADRENAL GLOMERULOSA CELLS THROUGH ACTIVATION OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE; RAT; K+; CURRENTS; STEROIDOGENESIS; MODULATION; GENERATION; RESPONSES	In adrenal glomerulosa cells, low threshold voltage-activated (T-type) calcium channels play a crucial role in coupling physiological variations of extracellular potassium to aldosterone biosynthesis. Angiotensin II markedly reduced the activity of these channels by shifting their activation curve toward positive voltage values. This inhibition of the channels resulted in a marked decrease of the cytosolic free calcium concentration maintained by potassium. This effect was abolished by losartan, a specific antagonist of the angiotensin II AT(1) receptor. Hormone action on T-type channels appeared to be mediated by protein kinase C because 1) it was mimicked by phorbol ester and diacylglycerol, and 2) it was significantly reduced by decreasing protein kinase C activity with specific inhibitors such as chelerythrine chloride or a pseudosubstrate of the enzyme, as well as by protein kinase C down-regulation. Similarly, protein kinase C activation reduced the cytosolic calcium response to potassium and the steroidogenic action of this agonist. Low threshold T-type calcium channels therefore appear as potential sites for the modulation of steroidogenesis by protein kinase C in adrenal glomerulosa cells.			ROSSIER, MF (corresponding author), UNIV HOSP GENEVA, DIV ENDOCRINOL, CH-1211 GENEVA 14, SWITZERLAND.		Rossier, Michel/AAW-2895-2021					BALLA T, 1991, MOL PHARMACOL, V40, P401; BALLA T, 1991, BIOCHEM J, V273, P399, DOI 10.1042/bj2730399; BARRETT PQ, 1991, AM J PHYSIOL, V261, pF706, DOI 10.1152/ajprenal.1991.261.4.F706; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUNEIS U, 1991, AM J PHYSIOL, V260, pE772, DOI 10.1152/ajpendo.1991.260.5.E772; BUISSON B, 1992, FEBS LETT, V309, P161, DOI 10.1016/0014-5793(92)81086-2; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; CAPPONI AM, 1987, BIOCHEM J, V247, P335, DOI 10.1042/bj2470335; CAPPONI AM, 1988, J BIOL CHEM, V263, P16113; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HESCHELER J, 1988, EMBO J, V7, P619, DOI 10.1002/j.1460-2075.1988.tb02855.x; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KANAZIRSKA MV, 1992, AM J PHYSIOL, V263, pE760, DOI 10.1152/ajpendo.1992.263.4.E760; LANG U, 1991, METH SURV I, V21, P115; LOBO MV, 1991, J STEROID BIOCHEM, V39, P323, DOI 10.1016/0960-0760(91)90042-4; LU HK, 1994, AM J PHYSIOL, V267, pF183, DOI 10.1152/ajprenal.1994.267.1.F183; MATSUNAGA H, 1987, BIOCHEM BIOPH RES CO, V149, P1049, DOI 10.1016/0006-291X(87)90514-6; MCCARTHY RT, 1993, P NATL ACAD SCI USA, V90, P3260, DOI 10.1073/pnas.90.8.3260; PYTHON CP, 1995, BIOCHEM J, V305, P569, DOI 10.1042/bj3050569; QUINN SJ, 1987, ENDOCRINOLOGY, V120, P903, DOI 10.1210/endo-120-3-903; QUINN SJ, 1987, ENDOCRINOLOGY, V120, P1581, DOI 10.1210/endo-120-4-1581; ROSSIER MF, 1993, ENDOCRINOLOGY, V132, P1035, DOI 10.1210/en.132.3.1035; ROSSIER MF, 1993, BIOCHEM J, V296, P309, DOI 10.1042/bj2960309; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353	25	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15137	15142		10.1074/jbc.270.25.15137	http://dx.doi.org/10.1074/jbc.270.25.15137			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797497	hybrid			2022-12-25	WOS:A1995RE66600045
J	KRAMER, RM; ROBERTS, EF; HYSLOP, PA; UTTERBACK, BG; HUI, KY; JAKUBOWSKI, JA				KRAMER, RM; ROBERTS, EF; HYSLOP, PA; UTTERBACK, BG; HUI, KY; JAKUBOWSKI, JA			DIFFERENTIAL ACTIVATION OF CYTOSOLIC PHOSPHOLIPASE A(2) (CPLA(2)) BY THROMBIN AND THROMBIN RECEPTOR AGONIST PEPTIDE IN HUMAN PLATELETS - EVIDENCE FOR ACTIVATION OF CPLA(2) INDEPENDENT OF THE MITOGEN-ACTIVATED PROTEIN-KINASES ERK1/2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; PROTEOLYTIC MECHANISM; ARACHIDONIC-ACID; PHOSPHORYLATION; HYDROLYSIS; DESENSITIZATION; IDENTIFICATION; TRANSLOCATION; MOBILIZATION; EXPRESSION	The thrombin receptor agonist peptide SFLLRN was less effective than thrombin in eliciting the liberation of arachidonic acid and the generation of thromboxane A(2) by human platelets, We found that while SFLLRN evokes an initial transient increase in cytosolic free calcium concentration ([Ca2+](i)) of similar magnitude as that caused by thrombin, the SFLLRN-induced elevation of [Ca2+](i) declines more rapidly to near resting levels than that evoked by thrombin, suggesting that disparate levels of [Ca2+](i) may contribute to the attenuated arachidonic acid release. Furthermore, we observed that SFLLRN is less effective than thrombin in mediating the ''activating'' phosphorylation of cytosolic phospholipase A(2) (cPLA(2)). Both thrombin and SFLLRN rapidly and transiently activated kinases that phosphorylate the 21-residue synthetic peptide Thr(669) derived from the epidermal growth factor receptor, but the maximal activation of proline-directed kinases by SFLLRN was less pronounced than that by thrombin. MonoQ chromatography and immunoblot analysis of extracts from stimulated platelets revealed that while thrombin induced a prominent activation of the mitogen-activated protein kinases ERK1 and ERK2, SFLLRN completely failed to do so. On the other hand, SFLLRN, like thrombin, stimulated the activity of a proline-directed kinase distinct from ERK1/2, but the activation of this kinase was less pronounced following stimulation of platelets with SFLLRN compared with thrombin. We conclude 1) that the partial activation of cPLA(2) and the subsequent attenuated mobilization of arachidonic acid in response to SFLLRN may be the consequence of a less prolonged elevation of [Ca2+](i) and insufficient activation of proline-directed kinase(s) by SFLLRN and 2) that the ability of SFLLRN to mediate the activating phosphorylation of cPLA(2) in the absence of ERK1/2 stimulation suggests that, at least in human platelets, proline-directed kinases other than ERK1/2 may phosphorylate and activate cPLA(2).			KRAMER, RM (corresponding author), LILLY RES LABS, CARDIOVASC RES, INDIANAPOLIS, IN 46285 USA.							AHN NG, 1990, J BIOL CHEM, V265, P11487; BARTHA K, 1993, J BIOL CHEM, V268, P421; BRASS LF, 1992, J BIOL CHEM, V267, P6044; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; GARCIA JGN, 1993, J CELL PHYSIOL, V156, P541, DOI 10.1002/jcp.1041560313; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; JAKUBOWSKI JA, 1994, PROSTAGLANDINS, V47, P189, DOI 10.1016/0090-6980(94)90060-4; JAKUBOWSKI JA, 1985, BRIT J HAEMATOL, V60, P635, DOI 10.1111/j.1365-2141.1985.tb07467.x; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KINLOUGHRATHBONE RL, 1993, THROMB HAEMOSTASIS, V70, P1019; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1988, BIOCHIM BIOPHYS ACTA, V959, P269, DOI 10.1016/0005-2760(88)90200-7; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KROLL MH, 1989, BLOOD, V74, P1181; LAU LF, 1994, BIOCHEM J, V303, P391, DOI 10.1042/bj3030391; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LUM H, 1993, J CELL BIOL, V120, P1491, DOI 10.1083/jcb.120.6.1491; MCHOWAT J, 1993, J BIOL CHEM, V268, P15605; NAKASHIMA S, 1994, BIOCHEM BIOPH RES CO, V198, P497, DOI 10.1006/bbrc.1994.1073; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; POLLOCK WK, 1986, BIOCHEM BIOPH RES CO, V139, P308, DOI 10.1016/S0006-291X(86)80114-0; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; RITTENHOUSESIMMONS S, 1977, BIOCHIM BIOPHYS ACTA, V488, P370, DOI 10.1016/0005-2760(77)90196-5; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SCHRAMEK H, 1994, KIDNEY INT, V46, P1644, DOI 10.1038/ki.1994.464; SEILER SM, 1992, BIOCHEM BIOPH RES CO, V182, P1296, DOI 10.1016/0006-291X(92)91873-O; SHANKAR R, 1994, J BIOL CHEM, V269, P13936; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; THOMPSON CB, 1983, J LAB CLIN MED, V101, P205; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; XU XX, 1994, J BIOL CHEM, V269, P31693	44	115	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14816	14823		10.1074/jbc.270.24.14816	http://dx.doi.org/10.1074/jbc.270.24.14816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782348	hybrid			2022-12-25	WOS:A1995RD45500086
J	MAKKINJE, A; XIONG, HS; LI, M; DAMUNI, Z				MAKKINJE, A; XIONG, HS; LI, M; DAMUNI, Z			PHOSPHORYLATION OF EUKARYOTIC PROTEIN-SYNTHESIS INITIATION-FACTOR 4E BY INSULIN-STIMULATED PROTAMINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; TUMOR-NECROSIS-FACTOR; BOVINE KIDNEY CORTEX; MESSENGER-RNA; TRANSLATIONAL CONTROL; PHORBOL ESTERS; EIF-4F; SERINE; CELLS; PHOSPHATASE-2A	Insulin-stimulated protamine kinase (cPK) and protein kinase C (PKC) phosphorylated eukaryotic protein synthesis initiation factor 4E (eIF-4E) on serine and threonine residues located on an identical tryptic fragment as judged by two-dimensional phosphopeptide mapping. With cPK and PKC, the apparent K-m for eIF-4E was about 1.2 and 50 mu M, respectively. Relative to recombinant human eIF-4E, cPK exhibited about 100% and less than or equal to 5% activity with eIF-4E(S209A), and eIF-4E(T210A) respectively, and eIF-4E(S209A) was phosphorylated exclusively on threonines. Bovine kidney eIF 4E enhanced up to 1.8-fold globin synthesis in m(7)GTP-Sepharose-treated reticulocyte lysates. In contrast, following incubation with cPK, these eIF-4E preparations stimulated globin synthesis up to 6-fold. Compared to the dephosphorylation of the cPK-modified serine on elF-4E, reticulocyte lysates and highly purified protein phosphatase 2A exhibited marked preference for the cPK-modified threonine. The results indicate that cPK phosphorylates eIF-4E on Ser(209) and Thr(210), that the hydroxyl group or phosphorylation of Thr(210) is necessary for cPK to act on Ser(209), and that Ser(209) phosphorylation activates reticulocyte globin synthesis. The results suggest that cPK could contribute to the insulin-stimulated phosphorylation of eIF-4E, but that protein phosphatase 2A may confer the site specificity of this response.	PENN STATE UNIV,COLL MED,MILTON S HERSHEY MED CTR,DEPT CELLULAR & MOLEC PHYSIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								AMICK GD, 1992, BIOCHEM BIOPH RES CO, V183, P431, DOI 10.1016/0006-291X(92)90499-B; AMICK GD, 1992, BIOCHEM J, V297, P1019; AMICK GD, 1993, THESIS U S CAROLINA; BRADFORD M, 1976, ANAL BIOCHEM, V72, P579; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; BU X, 1993, J BIOL CHEM, V268, P4975; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DAMUNI Z, 1989, J BIOL CHEM, V264, P6412; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; FREDRICKSON RM, 1991, MOL CELL BIOL, V12, P1239; GUO H, 1993, J BIOL CHEM, V268, P11193; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; HAAS DW, 1992, SEC MESS PHOSPHOPROT, V14, P55; HAAS DW, 1993, FEBS LETT, V283, P219; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MARINO MW, 1991, J BIOL CHEM, V266, P2685; MAROTO FG, 1988, J BIOL CHEM, V263, P15720; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1993, BIOCHIMIE, V75, P985, DOI 10.1016/0300-9084(93)90149-M; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; MORLEY SJ, 1993, EUR J BIOCHEM, V218, P39, DOI 10.1111/j.1432-1033.1993.tb18349.x; OCHMAN H, 1988, GENETICS, V120, P621; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; REDDY SAG, 1990, J BIOL CHEM, V265, P7748; REDDY SAG, 1993, J BIOL CHEM, V268, P15298; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RUAZON PT, 1988, J BIOL CHEM, V264, P2773; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; RYCHLIK W, 1990, J BIOL CHEM, V265, P19467; Sambrook J, 1989, MOL CLONING LABORATO; STERN BD, 1993, PROTEIN EXPRES PURIF, V4, P320, DOI 10.1006/prep.1993.1041; TUAZON PT, 1990, J BIOL CHEM, V265, P10617; WEBB NR, 1984, BIOCHEMISTRY-US, V17, P177; XU B, 1991, FEBS LETT, V283, P219	45	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14824	14828		10.1074/jbc.270.24.14824	http://dx.doi.org/10.1074/jbc.270.24.14824			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782349	hybrid			2022-12-25	WOS:A1995RD45500087
J	RICHARDS, SA; LOUNSBURY, KM; MACARA, IG				RICHARDS, SA; LOUNSBURY, KM; MACARA, IG			THE C-TERMINUS OF THE NUCLEAR RAN/TC4 GTPASE STABILIZES THE GDP-BOUND STATE AND MEDIATES INTERACTIONS WITH RCC1, RAN-GAP, AND HTF9A/RANBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREMATURE CHROMOSOME CONDENSATION; BINDING PROTEIN; MUTANT; MAINTENANCE; MITOSIS; GENES; PRP20	Ran/TC4 is a member of the Ras superfamily of GTPases. It is unusual in being predominantly nuclear and because it possesses an acidic -DEDDDL sequence instead of a consensus prenylation domain at the C terminus. Ran is required for nuclear protein import rind cell cycle progression, and has been implicated in mRNA processing and export and DNA replication. The inhibition of cell cycle progression by a dominant gain-of-function mutant of Ran has been shown to be abrogated by removal of the -DEDDDL sequence, suggesting that this domain is essential for Ran function. We demonstrate here that the -DEDDDL sequence stabilizes GDP ; binding to Ran, and that the domain is required for high affinity interaction with a Ran-binding protein, HTF9A/RanBP1. RTFSA functions as a co-stimulator of Ran-GAP (GTPase activating protein) activity on wild-type Ran, but in the absence of the acidic C terminus of Ran, HTF9A behaves as a Ran-GAP inhibitor. An antibody directed against the C-terminal region preferentially recognizes the GTP;bound form of Ran, suggesting that this domain undergoes a nucleotide-dependent conformational change. The results suggest that the acidic C-terminal domain is important in modulating the interaction of Ran with regulatory factors, and implicate Iran-binding proteins in mediating the effects of Ran on cell cycle progression.			RICHARDS, SA (corresponding author), UNIV VERMONT, COLL MED, DEPT PATHOL, MED ALUMNI BLDG, BURLINGTON, VT 05405 USA.				NIEHS NIH HHS [EST3207122] Funding Source: Medline; NIGMS NIH HHS [GM50526] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050526] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACH RA, 1994, P NATL ACAD SCI USA, V91, P5863, DOI 10.1073/pnas.91.13.5863; AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESSAN A, 1991, GENE, V103, P201, DOI 10.1016/0378-1119(91)90274-F; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FLEISCHMANN M, 1991, MOL GEN GENET, V227, P417, DOI 10.1007/BF00273932; Harlow E., 1988, ANTIBODIES LABORATOR, P79; JOHN J, 1989, J BIOL CHEM, V264, P13086; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577	30	99	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14405	14411		10.1074/jbc.270.24.14405	http://dx.doi.org/10.1074/jbc.270.24.14405			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782302	hybrid			2022-12-25	WOS:A1995RD45500029
J	SEKIYA, F; YAMASHITA, T; ATODA, H; KOMIYAMA, Y; MORITA, T				SEKIYA, F; YAMASHITA, T; ATODA, H; KOMIYAMA, Y; MORITA, T			REGULATION OF THE TERTIARY STRUCTURE AND FUNCTION OF COAGULATION-FACTOR-IX BY MAGNESIUM(II) IONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA THROMBOPLASTIN ANTECEDENT; GAMMA-CARBOXYGLUTAMIC ACID; PHOSPHOLIPID-BINDING SITE; BOVINE FACTOR-IX; BLOOD-COAGULATION; FACTOR-XIA; FACTOR-X; CONFORMATIONAL TRANSITIONS; PROTHROMBIN FRAGMENT-1; CHRISTMAS FACTOR	The indispensable role of Ca2+ ions in the maintenance of the functional tertiary structures of vitamin K-dependent coagulation factors has been definitively established but the participation of Mg2+ ions, another alkaline earth metal that is present abundantly in blood plasma, in such a process is not yet understood. We show here that the Ca2+-stabilized conformation of coagulation factor IX undergoes a further conformational change upon binding of Mg2+ ions using three independent structural probes, The probes we used were (i) IX/X-bp, a snake venom anticoagulant that recognizes the Gla domains in coagulation factors IX and X, (ii) conformation-specific polyclonal antibodies against bovine factor IX, and (iii) monoclonal antibodies against the Gla domain of human factor IX The binding of all these probes had an absolute requirement for Ca2+ ions, and Mg2+ ions alone were ineffective. However, when added together with Ca2+ ions, Mg2+ ions at physiological concentrations greatly augmented the binding of these probes to factor IX; the required concentration of Ca2+ ions was much reduced, and the affinity of each probe for factor IX was increased even in the presence of an excess of Ca2+ ions, These results suggest the presence of a Mg2+-specific binding site that does not interact with with Ca2+ ions in factor IX, Furthermore, Mg2+ ions potentiated the susceptibility of factor IX to activation by factor XIa, concomitant with their effect on the conformation. Similarly, the required Ca2+ concentration was reduced by Mg2+ ions, and the rate of conversion to factor IXa was increased by Mg2+ ions in the presence of an excess of Ca2+ ions. At a saturating concentration of Ca2+ ions (5 mM), addition of 1 mM Mg2+ reduced the apparent K-m value for factor IX from 0.31 to 0.18 mu M, and in the presence of a physiological concentration of Ca2+ ions (1 mM), the reduction in K-m by Mg2+ ions was far more striking (from 0.91 to 0.24 mu M). The apparent V-max values were hardly affected by Mg2+ ions, Our present data reveal a hitherto novel physiological role of the Mg2+ ions in plasma. Not only Ca2+ ions but also Mg2+ ions are important regulators of the stabilization of the native conformation of factor IX as well as of its efficient activation.	MEIJI COLL PHARM,DEPT BIOCHEM,TANASHI,TOKYO 188,JAPAN; KANSAI MED UNIV,DEPT CLIN SCI,MORIGUCHI,OSAKA 570,JAPAN; KANSAI MED UNIV,MED LAB,MORIGUCHI,OSAKA 570,JAPAN	Meiji Pharmaceutical University; Kansai Medical University; Kansai Medical University								AMPHLETT GW, 1978, J BIOL CHEM, V253, P6774; AMPHLETT GW, 1982, BIOCHEMISTRY-US, V21, P125, DOI 10.1021/bi00530a022; ASAKAI R, 1989, P NATL ACAD SCI USA, V86, P7667, DOI 10.1073/pnas.86.20.7667; ATODA H, 1994, EUR J BIOCHEM, V224, P703, DOI 10.1111/j.1432-1033.1994.t01-1-00703.x; ATODA H, 1989, J BIOCHEM, V106, P808, DOI 10.1093/oxfordjournals.jbchem.a122935; BAJAJ SP, 1982, J BIOL CHEM, V257, P4127; BLOOM JW, 1978, BIOCHEMISTRY-US, V17, P4430, DOI 10.1021/bi00614a012; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; BUTENAS S, 1994, BIOCHEMISTRY-US, V33, P3449, DOI 10.1021/bi00177a039; BYRNE R, 1980, J BIOL CHEM, V255, P1430; CHURCH WR, 1989, J BIOL CHEM, V264, P17882; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HOAK JC, 1966, LANCET, V2, P884; KOMIYAMA Y, 1988, THROMB RES, V50, P329, DOI 10.1016/0049-3848(88)90234-4; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KOMIYAMA Y, 1989, THROMB RES, V55, P527, DOI 10.1016/0049-3848(89)90385-X; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LIEBMAN HA, 1987, J BIOL CHEM, V262, P7605; LIEBMAN HA, 1985, P NATL ACAD SCI USA, V82, P3879, DOI 10.1073/pnas.82.11.3879; LIEBMAN HA, 1993, EUR J BIOCHEM, V212, P339, DOI 10.1111/j.1432-1033.1993.tb17667.x; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; MANN KG, 1990, BLOOD, V76, P1; MILETICH JP, 1980, ANAL BIOCHEM, V105, P340; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; NAITO K, 1991, J BIOL CHEM, V266, P7353; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PATERSON CR, 1983, ESSENTIALS HUMAN BIO, P237; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; ROSENTHAL RL, 1953, P SOC EXP BIOL MED, V82, P171; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; SPERLING R, 1978, J BIOL CHEM, V253, P3898; THOMPSON AR, 1986, BLOOD, V67, P565; VALCARCE C, 1993, METHOD ENZYMOL, V222, P416; WALSH PN, 1984, J CLIN INVEST, V73, P1392, DOI 10.1172/JCI111343; WUEPPER KD, 1975, J CLIN INVEST, V56, P1663, DOI 10.1172/JCI108248; ZUR M, 1987, HAEMOSTASIS THROMBOS, P148	39	43	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14325	14331		10.1074/jbc.270.24.14325	http://dx.doi.org/10.1074/jbc.270.24.14325			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782291	hybrid			2022-12-25	WOS:A1995RD45500017
J	SLEPAK, VZ; ARTEMYEV, NO; ZHU, Y; DUMKE, CL; SABACAN, L; SONDEK, J; HAMM, HE; BOWNDS, MD; ARSHAVSKY, VY				SLEPAK, VZ; ARTEMYEV, NO; ZHU, Y; DUMKE, CL; SABACAN, L; SONDEK, J; HAMM, HE; BOWNDS, MD; ARSHAVSKY, VY			AN EFFECTOR SITE THAT STIMULATES G-PROTEIN GTPASE IN PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; PHOSPHODIESTERASE GAMMA-SUBUNIT; CYCLIC-GMP PHOSPHODIESTERASE; SURFACE-PLASMON RESONANCE; BOVINE RETINAL RODS; CGMP-PHOSPHODIESTERASE; INHIBITORY SUBUNIT; SYNTHETIC PEPTIDES; TRANSDUCIN GTPASE; ALPHA-SUBUNIT	Heterotrimeric G-proteins mediate between receptors and effecters, acting as molecular clocks. G-protein interactions with activated receptors catalyze the replacement of GDP bound to the alpha-subunit with GTP. alpha-Subunits then modulate the activity of downstream effecters until the bound GTP is hydrolyzed. In several signal transduction pathways, including the cGMP cascade of photorecepter cells, the relatively slow GTPase activity of heterotrimeric G-proteins can be significantly accelerated when they are complexed with correspending effecters. In the phototransduction cascade the GTPase activity of photoreceptor G-protein, transducin, is substantially accelerated in a complex with its effector, cGMP phosphodiesterase. Here we characterize the stimulation of transducin GTPase by a set of 23 mutant phosphodiesterase gamma-subunits (PDE(gamma)) containing single alanine substitutions within a stretch of the 25 C-terminal amino acid residues known to be primarily responsible for the GTPase regulation. The substitution of tryptophan at position 70 completely abolished the acceleration of GTP hydrolysis by transducin in a complex with this mutant. This mutation also resulted in a reduction of PDE(gamma) affinity for transducin, but did not affect PDE(gamma) interactions with the phosphodiesterase catalytic subunits. Single substitutions of 7 other hydrophobic amino acids resulted in a 50-70% reduction in the ability of PDE(gamma) to stimulate transducin GTPase, while substitutions of charged and polar amino acids had little or no effect. These observations suggest that the role of PDE(gamma) in activation of the transducin GTPase rate may be based on multiple hydrophobic interactions between these molecules.	CALTECH,DEPT BIOL,PASADENA,CA 91125; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60680; UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706; UNIV WISCONSIN,NEUROSCI TRAINING PROGRAM,MADISON,WI 53706; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	California Institute of Technology; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Yale University			Hamm, Heidi E/G-2374-2014	Artemyev, Nikolai/0000-0002-5266-6854; Sondek, John/0000-0002-1127-8310	NATIONAL EYE INSTITUTE [R01EY010336, R01EY006062] Funding Source: NIH RePORTER; NEI NIH HHS [EY-00463, EY-10336, EY-06062] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1994, NAT STRUCT BIOL, V1, P752, DOI 10.1038/nsb1194-752; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; Gibbs C.S., 1991, METHODS COMPANION ME, V3, P165; GODCHAUX W, 1979, J BIOL CHEM, V54, P7874; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; OTTOBRUC A, 1994, BIOCHEMISTRY-US, V33, P15215, DOI 10.1021/bi00255a001; PAGES F, 1992, J BIOL CHEM, V267, P22018; PAGES F, 1993, J BIOL CHEM, V268, P26358; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; WAGNER R, 1988, FEBS LETT, V234, P44, DOI 10.1016/0014-5793(88)81299-7	39	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14319	14324		10.1074/jbc.270.24.14319	http://dx.doi.org/10.1074/jbc.270.24.14319			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782290	hybrid			2022-12-25	WOS:A1995RD45500016
J	GRAHAM, DK; BOWMAN, GW; DAWSON, TL; STANFORD, WL; EARP, HS; SNODGRASS, HR				GRAHAM, DK; BOWMAN, GW; DAWSON, TL; STANFORD, WL; EARP, HS; SNODGRASS, HR			CLONING AND DEVELOPMENTAL EXPRESSION ANALYSIS OF THE MURINE C-MER TYROSINE KINASE	ONCOGENE			English	Article						TYROSINE; KINASE; RECEPTOR; EXPRESSION; ONCOGENE; DEVELOPMENT	EMBRYONIC STEM-CELLS; YOLK-SAC; RECEPTOR; INVITRO; ONCOGENE; CLEAVAGE; CULTURE	We have cloned the putative mouse homologue of the human c-mer receptor tyrosine kinase proto-oncogene. Comparison of the mouse and human c-mer amino acid sequences reveals an overall identity of 88%, Similar to the human, the extracellular region of the murine c-mev protein possesses two amino terminal immunoglobulinlike domains and two membrane proximal fibronectin type III domains, which places it in the Axl family of tyrosine kinases, Our analysis of the Axl family identifies eight different regions of amino acid consensus that have residues characteristic of this and no other tyrosine kinase family; six of the eight are within tyrosine kinase subdomains. The homology within the Axl family is highest between c-mer and c-eyk, the chicken proto-oncogene of the tumor virus gene product v-eyk, Northern analysis of adult tissues suggests that the mouse c-mev, although expressed in many tissues, has an expression pattern unique among Axl family members. In normal adult hematopoietic cells c-mer seems to be expressed predominantly if not exclusively in the monocytic lineage, Mouse c-mer is expressed during most, if not all, stages of embryological development beginning in the morula and blastocyst and progressing through the yolk sac and fetal liver stages. This early and consistent expression of c-mer was confirmed during in vitro differentiation of embryonic stem cells, The embryonic expression profile of c-mer suggests that this tyrosine kinase may play an important function in the developing mouse.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT IMMUNOL & MICROBIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Stanford, William/0000-0002-5813-8016; Dawson, Thomas/0000-0003-3878-1722	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007040] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK4351701] Funding Source: Medline; NIGMS NIH HHS [GM07040] Funding Source: Medline; PHS HHS [A107273] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BISHOP JM, 1988, LEUKEMIA, V2, P199; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAI W, 1994, ONCOGENE, V9, P975; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FAUST M, 1992, ONCOGENE, V7, P1287; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; JIA R, 1994, J BIOL CHEM, V269, P1839; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KOZAK M, 1986, CELL, V144, P283; KUNG HJ, 1990, DEV BIOLOGICALS, V72, P139; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; MARK MR, 1994, J BIOL CHEM, V269, P10720; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; NEUBAUER A, 1994, BLOOD, V84, P1931; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; POLVI A, 1993, GENE, V134, P289, DOI 10.1016/0378-1119(93)90109-G; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SNODGRASS HR, 1992, J CELL BIOCHEM, V49, P225, DOI 10.1002/jcb.240490304; SNODGRASS HR, 1993, PERIPHERAL BLOOD STE, P65; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; TYAN ML, 1968, J IMMUNOL, V101, P446; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILES MV, 1991, DEVELOPMENT, V111, P259; 1991, GCG SOFTWARE PACKAGE	38	113	127	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2349	2359						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784083				2022-12-25	WOS:A1995RE54300010
J	ZORNIG, M; GRZESCHICZEK, A; KOWALSKI, MB; HARTMANN, KU; MOROY, T				ZORNIG, M; GRZESCHICZEK, A; KOWALSKI, MB; HARTMANN, KU; MOROY, T			LOSS OF FAS/APO-1 RECEPTOR ACCELERATES LYMPHOMAGENESIS IN E-MU L-MYC TRANSGENIC MICE BUT NOT IN ANIMALS INFECTED WITH MOMULV	ONCOGENE			English	Note						HOMEOSTASIS; FAS/APO-1; APOPTOSIS; TRANSGENIC MICE; TUMOR PROGRESSION	TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; C-MYC; N-MYC; LEUKEMIA-VIRUS; FAS ANTIGEN; LPR MICE; SYSTEMIC AUTOIMMUNITY; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING	The Fas/Apo-1 receptor is an integral membrane protein that transduces apoptotic signals upon binding to its natural ligand or to specific antibodies. Loss of Fas/Apo-1 receptor leads in (lpr;lpr) mice to a nonmalignant accumulation of abnormal T-cells very probably due to the lack of induction of apoptosis in peripheral T-cells. It has been reported that soluble forms of Fas/Apo-1 receptor that may interfere with apoptotic signaling occur in patients suffering from various forms of lymphoid neoplasms. Therefore, we wished to investigate whether the loss of proper homeostatic regulation through Fas/Apo-1 receptor mediated apoptosis could influence the process of lymphomagenesis, To this end, we performed two experiments (i) we infected (lpr,lpr) animals with Moloney Murine Leukemia Virus (MoMuLV) that causes T-cell lymphoma in mice and (ii) we crossed (lpr,lpr) animals with E mu L-myc transgenic mice that are prone to develop T- and B-cell lymphoma due to deregulated expression of the L-myc transgene by the immunoglobulin enhancer E mu. We find that infection with MoMuLV did not accelerate the formation of lymphoid neoplasms in (lpr,lpr) mice when compared to infected normal animals. However, E mu L-myc/(lpr,lpr) animals that constitutively express the L-myc transgene in the lymphoid lineage clearly show accelerated formation of T- and B-cell lymphoma when compared to normal E mu L-myc transgenics. These data demonstrate that in cooperation with particular oncogenes impairment of Fas/Apo-1 receptor function can indeed affect and modulate the process of tumor formation.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; UNIV MARBURG,INST EXPTL IMMUNOL,D-35037 MARBURG,GERMANY	Philipps University Marburg; Philipps University Marburg			Moroy, Tarik/D-9923-2011					ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHU JL, 1993, J EXP MED, V178, P723, DOI 10.1084/jem.178.2.723; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; CUYPERS HT, 1984, CELL, V37, P141; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; KNIPPING E, 1995, IN PRESS BLOOD; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MOLLER P, 1993, BLOOD, V81, P2067; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MOROY T, 1991, ONCOGENE, V6, P1941; MOROY T, 1991, MOL F ONCOLOGY, P455; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nagata S, 1994, Semin Immunol, V6, P3, DOI 10.1006/smim.1994.1002; OEHM A, 1992, J BIOL CHEM, V267, P10709; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	33	81	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2397	2401						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784089				2022-12-25	WOS:A1995RE54300016
J	COLEMAN, RA; PUGH, BF				COLEMAN, RA; PUGH, BF			EVIDENCE FOR FUNCTIONAL BINDING AND STABLE SLIDING OF THE TATA-BINDING PROTEIN ON NONSPECIFIC DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; MINOR-GROOVE; ESCHERICHIA-COLI; TFIID BINDS; BOX COMPLEX; ACTIVATION; YEAST; MECHANISM	The TATA binding protein (TBP) is required at RNA polymerase I, II, and III promoters that either contain or lack a TATA box, In an effort to understand how TBP might function at such a wide variety of promoters, we have investigated the specific and nonspecific DNA binding properties of human TBP, We show that TBP has less than a 10(3)-fold preference for binding a TATA box (TATAAAAG) than for an average nonspecific site, In contrast to TBP, which binds to the minor groove of DNA, major groove binding proteins typically display binding specificities in the range of 10(6). Once TBP is bound to DNA, whether it be a TATA box or nonspecific DNA, binding is quite stable with a t(1/2) of dissociation in the range of 20-60 min for a 300-base pair DNA fragment, In this binding state, TBP appears to be capable of stable one-dimensional sliding along the DNA. Sequence-specific binding can be accounted for, in part, by different rates of sliding, Additional findings demonstrate that specific and nonspecific DNA impart upon TBP an enormous and equivalent degree of thermal stability, suggesting that the TBP . DNA interface on nonspecific DNA is not radically different from that on TATA. Consistent with this notion, we find that nonspecifically bound TBP is competent in establishing pol II transcription complexes on DNA. Together, these finding provide a plausible mechanistic explanation for the ability of TBP to function at TATA-containing and TATA-less promoters.	PENN STATE UNIV,CTR GENE REGULAT,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIGMS NIH HHS [GM47855] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMOUZNI G, 1994, DEV BIOL, V165, P654, DOI 10.1006/dbio.1994.1283; ARMALEO D, 1985, J BIOL CHEM, V260, P6169; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3833, DOI 10.1021/bi00516a026; BURLEY SK, 1994, 1994 FASEB SUMM RES; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PUGH BF, 1959, IN VITRO TRANSCRIPTI, V37, P359; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SHINDO H, 1993, BIOL PHARM BULL, V16, P437; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; Weinmann Roberto, 1992, Gene Expression, V2, P81; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	45	113	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13850	13859		10.1074/jbc.270.23.13850	http://dx.doi.org/10.1074/jbc.270.23.13850			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775443	hybrid			2022-12-25	WOS:A1995RC44800042
J	JUNG, HI; KIM, SI; HA, KS; JOE, CO; KANG, KW				JUNG, HI; KIM, SI; HA, KS; JOE, CO; KANG, KW			ISOLATION AND CHARACTERIZATION OF GUAMERIN, A NEW HUMAN-LEUKOCYTE ELASTASE INHIBITOR FROM HIRUDO-NIPPONIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE SITE; FACTOR-XA; NEUTRAL PROTEINASES; CATHEPSIN-G; ANTISTASIN; DEGRADATION; EMPHYSEMA	A new human leukocyte elastase inhibitor was extracted and purified from a Korean native leech Hirudo nipponia. The inhibitor, called guamerin, has a molecular weight of 6,110 and shows inhibition constant (K-i) of 8.1 x 10(-14) M. It is stable at a wide range of pH from 1 to 11 and heat-stable up to 90 degrees C. The complete amino acid sequence of guamerin reveals a cysteine-rich polypeptide of 57 amino acid residues that shows no similarity to any known elastase inhibitors but has 51% sequence homology with hirustasin, Guamerin has identical spacing of 10 cysteine residues as antistasin-type serine proteinase inhibitors, but the P1 reactive site residue is Met(36) instead of Arg, The neighboring sequence of the reactive site consists primarily of hydrophobic amino acid residues, Based on examinations of the target proteinases and the reactive site specificity, guamerin is a new low molecular weight protein that inhibits elastases.	KOREA ADV INST SCI & TECHNOL,DEPT SCI BIOL,TAEJON 305701,SOUTH KOREA; KOREA BASIC SCI CTR,BIOMOLEC ANAL GRP,TAEJON 305701,SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST); Korea Basic Science Institute (KBSI)				Ha, Kwon-Soo/0000-0002-4219-1787				BEYNON RJ, 1989, PROTEOLYTIC ENZYMES, P28; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DUNWIDDIE C, 1989, J BIOL CHEM, V264, P16694; DUNWIDDIE CT, 1992, ARCH BIOCHEM BIOPHYS, V294, P647, DOI 10.1016/0003-9861(92)90737-H; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; FRITZ H, 1978, AGENTS ACTIONS, V8, P57, DOI 10.1007/BF01972403; GLINSKI W, 1980, J INVEST DERMATOL, V75, P481, DOI 10.1111/1523-1747.ep12524244; HERMANN S, 1987, ANAL BIOCHEM, V166, P368; HOCHSTRASSER K, 1981, H-S Z PHYSIOL CHEM, V362, P1369, DOI 10.1515/bchm2.1981.362.2.1369; HOFMANN KJ, 1992, BIOCHEM J, V287, P943, DOI 10.1042/bj2870943; HONG SJ, 1993, KOREAN J ZOOL, V36, P588; JANOFF A, 1980, AM REV RESPIR DIS, V121, P1025; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LASZLO L, 1981, METHOD ENZYMOL, V80, P756; LUI TY, 1971, J BIOL CHEM, V246, P2842; MAINARDI CL, 1980, J BIOL CHEM, V255, P5435; MICHAEL K, 1991, MASS SPECTROM REV, V10, P335; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NEURATH H, 1983, SCIENCE, V224, P350; ODANI S, 1978, J BIOCHEM-TOKYO, V83, P737, DOI 10.1093/oxfordjournals.jbchem.a131967; REILLY CF, 1980, BIOCHIM BIOPHYS ACTA, V621, P147, DOI 10.1016/0005-2795(80)90070-7; RHODES MB, 1960, J BIOL CHEM, V235, P1686; ROBERT CT, 1986, P NATL ACAD SCI USA, V83, P6692; SCHALWIJK J, 1986, BRIT J DERMATOL, V1512, P181; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEEMULLER U, 1980, H-S Z PHYSIOL CHEM, V361, P1841; SNIDER GL, 1981, MED CLIN N AM, V65, P647, DOI 10.1016/S0025-7125(16)31517-6; SOLLER C, 1944, EUR J BIOCHEM, V219, P937; TARR GE, 1986, MICROCHARACTERIZATIO, P155; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27; WIEDOW O, 1990, J BIOL CHEM, V265, P14791	33	64	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13879	13884		10.1074/jbc.270.23.13879	http://dx.doi.org/10.1074/jbc.270.23.13879			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775446	hybrid, Green Accepted			2022-12-25	WOS:A1995RC44800045
J	MAO, F; RECHTIN, TM; JONES, R; CANTU, AA; ANDERSON, LS; RADOMINSKA, A; MOYER, MP; DRAKE, RR				MAO, F; RECHTIN, TM; JONES, R; CANTU, AA; ANDERSON, LS; RADOMINSKA, A; MOYER, MP; DRAKE, RR			SYNTHESIS OF A PHOTOAFFINITY ANALOG OF 3'-AZIDOTHYMIDINE, 5-AZIDO-3'-AZIDO-2',3'-DIDEOXYURIDINE - INTERACTIONS WITH HERPESVIRUS THYMIDLNE KINASE AND CELLULAR ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; THERAPY; HIV; AZT; 3'-AZIDO-3'-DEOXYTHYMIDINE; 5'-TRIPHOSPHATE; REPLICATION; 3'-AZIDO; SITE	Long term administration of 3'-azidothymidine (AZT) for the treatment of AIDS has led to detrimental clinical side effects in some patients, the biochemical causes of which are still being delineated. Base-substituted, azido-nucleotide photoaffinity analogs have routinely proven to be effective tools for identifying and characterizing nucleotide-utilizing enzymes. Therefore, we have synthesized 5-azido-3'-azido-2',3'-dideoxyuridine, which is a potential photoaffinity analog of two human immunodeficiency virus drugs, AZT and 3'azido-2',3'-dideoxyuridine. A partially purified herpes simplex virus type 1 thymidine kinase and [gamma-P-32]ATP were used to make an AZT monophosphate analog, [P-32]5-azido-3'-azido-2',3'-dideoxyuridine monophosphate. The photoaffinity properties of this analog were initially tested with herpes simplex virus type 1 thymidine kinase. Photoaffinity labeling of this enzyme was saturable (half-maximal, 30 mu M) and could be specifically inhibited by AZT, AZT monophosphate, thymidine, and thymidine monophosphate. Photolabeling of rat Liver microsomal membranes was also done, and several membrane proteins that interact with AZT monophosphate were identified. The antiviral and cytotoxic activities of 5-azido-3'-azido-2',3'-dideoxyuridine were determined using human immunodeficiency virus, type 1 strain IIIB and an AZT drug-resistant strain in human T lymphocyte H9 cells.	UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOLEC BIOL, LITTLE ROCK, AR 72205 USA; UNIV ARKANSAS MED SCI HOSP, DEPT MED, LITTLE ROCK, AR 72205 USA; UNIV TEXAS, HLTH SCI CTR, DEPT SURG, SAN ANTONIO, TX 78284 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Texas System; University of Texas Health San Antonio			Mao, Feng/B-8280-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048497] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48497] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACK ME, 1993, BIOCHEMISTRY-US, V32, P11618, DOI 10.1021/bi00094a019; BOSSUYT X, 1995, BIOCHEM J, V305, P321, DOI 10.1042/bj3050321; CARUSO M, 1992, P NATL ACAD SCI USA, V89, P182, DOI 10.1073/pnas.89.1.182; CHEN MS, 1979, J BIOL CHEM, V254, P747; COEN DM, 1991, ANTIVIR RES, V15, P287, DOI 10.1016/0166-3542(91)90010-O; CULVER KW, 1994, TRENDS GENET, V10, P174, DOI 10.1016/0168-9525(94)90095-7; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DOSHI KJ, 1989, DRUG METAB DISPOS, V17, P590; DRAKE RR, 1992, J BIOL CHEM, V267, P11360; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GINGERAS TR, 1991, J INFECT DIS, V164, P1066, DOI 10.1093/infdis/164.6.1066; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HALL ET, 1994, J BIOL CHEM, V269, P14355; HERDEWIJN PAMM, 1992, ANTIVIR RES, V19, P1, DOI 10.1016/0166-3542(92)90052-7; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LEWIS W, 1992, J CLIN INVEST, V89, P1354, DOI 10.1172/JCI115722; LIN TS, 1988, J MED CHEM, V31, P336, DOI 10.1021/jm00397a011; LIN TS, 1983, J MED CHEM, V26, P544, DOI 10.1021/jm00358a016; MAZUMDER A, 1994, P NATL ACAD SCI USA, V91, P5771, DOI 10.1073/pnas.91.13.5771; MOYER MP, 1991, J LEUKOCYTE BIOL, V49, P499, DOI 10.1002/jlb.49.5.499; RADOMINSKA A, 1994, METHOD ENZYMOL, V230, P330; RAM Z, 1993, CANCER RES, V53, P83; RECHTIN TM, 1995, J BIOL CHEM, V270, P7055, DOI 10.1074/jbc.270.13.7055; ZHU Z, 1990, MOL PHARMACOL, V38, P929	26	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13660	13664		10.1074/jbc.270.23.13660	http://dx.doi.org/10.1074/jbc.270.23.13660			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775417	hybrid			2022-12-25	WOS:A1995RC44800014
J	NAKAMOTO, RK; ALSHAWI, MK; FUTAI, M				NAKAMOTO, RK; ALSHAWI, MK; FUTAI, M			THE ATP SYNTHASE GAMMA-SUBUNIT - SUPPRESSOR MUTAGENESIS REVEALS 3 HELICAL REGIONS INVOLVED IN ENERGY COUPLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL REGION; ESCHERICHIA-COLI; H+-ATPASE; ADENOSINE-TRIPHOSPHATASE; DIRECTED MUTAGENESIS; CROSS-LINKING; PHOTOPHOSPHORYLATION; F0F1-ATPASE; CATALYSIS; MUTATIONS	A role in coupling proton transport to catalysis of ATP synthesis has been demonstrated for the Escherichia coli F0F1 ATP synthase gamma subunit. Previously, functional interactions between the terminal regions that were important for coupling were shown by finding several mutations in the carboxyl-terminal region of the gamma subunit (involving residues at positions 242 and 269-280) that restored efficient coupling to the mutation, gamma Met-23 --> Lys (Nakamoto, R. K., Maeda, M., and Futai, M. (1993) J. Biol. Chem. 268, 867-872). In this study, we used suppressor mutagenesis to establish that the terminal regions can be separated into three interacting segments. Second-site mutations that cause pseudo reversion of the primary mutations, gamma GLn-269 --> Glu or gamma Thr-273 --> Val, map to an amino-terminal segment with changes at residues 18, 34, and 35, and to a segment near the carboxyl terminus with changes at residues 236, 238, 242, and 246. Each second-site mutation suppressed the effects of both gamma Gln-269 --> Glu and gamma Thr-273 --> Val, and restored efficient coupling to enzyme complexes containing either of the primary mutations. Mapping of these residues in the recently reported x-ray crystallographic structure of the F-1 complex (Abrahams, J. P., Leslie, A. G., Lutter, R., and Walker, J. E. (1994) Nature 370, 621-628), reveals that the second-site mutations do not directly interact with gamma Gln-269 and gamma Thr-273 and that the effect of suppression occurs at a distance. We propose that the three gamma subunit segments defined by suppressor mutagenesis, residues gamma 18-35, gamma 236-246, and gamma 269-280, constitute a domain that is critical for both catalytic function and energy coupling.	OSAKA UNIV, INST SCI & IND RES, IBARAKI, OSAKA 567, JAPAN	Osaka University	NAKAMOTO, RK (corresponding author), UNIV VIRGINIA, DEPT MOLEC PHYSIOL & BIOL PHYS, JORDAN HALL, BOX 449, CHARLOTTESVILLE, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050957] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50957] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1993, J BIOL CHEM, V268, P20831; AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1993, J BIOLC EHM, V268, P14563; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIKI J, 1986, ARCH BIOCHEM BIOPHYS, V251, P458, DOI 10.1016/0003-9861(86)90352-8; MORONEY JV, 1980, J BIOL CHEM, V255, P6670; MORONEY JV, 1982, J BIOL CHEM, V257, P5915; MORONEY JV, 1979, J BIOL CHEM, V254, P8951; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NAKAMOTO RK, 1992, ANN NY ACAD SCI, V671, P335, DOI 10.1111/j.1749-6632.1992.tb43807.x; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHIN K, 1992, J BIOL CHEM, V267, P20835; SUGINO Y, 1964, J BIOL CHEM, V239, P2360; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURINA P, 1994, J BIOL CHEM, V269, P13465; WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8; WEISS MA, 1977, J BIOL CHEM, V252, P8007; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; [No title captured]	32	54	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14042	14046		10.1074/jbc.270.23.14042	http://dx.doi.org/10.1074/jbc.270.23.14042			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775464	hybrid			2022-12-25	WOS:A1995RC44800066
J	DIEUAIDENOUBHANI, M; RAFFARD, G; CANIONI, P; PRADET, A; RAYMOND, P				DIEUAIDENOUBHANI, M; RAFFARD, G; CANIONI, P; PRADET, A; RAYMOND, P			QUANTIFICATION OF COMPARTMENTED METABOLIC FLUXES IN MAIZE ROOT-TIPS USING ISOTOPE DISTRIBUTION FROM C-13-LABELED OR C-14-LABELED GLUCOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; ACID BETA-OXIDATION; PISUM-SATIVUM-L; CARBOHYDRATE-METABOLISM; STARCH BIOSYNTHESIS; HYPOXIC ACCLIMATION; TRIOSE PHOSPHATES; NITRITE REDUCTION; SOLUBLE SUGARS; POTATO-TUBERS	Metabolic pathways of the intermediate metabolism of maize root tips were identified and quantified after labeling to isotopic and metabolic steady state using glucose labeled on carbon-1, -2, or 6 with C-14 or C-13. The specific radioactivity of amino acids and the C-13-specific enrichment of specific carbons of free glucose, sucrose, alanine and glutamate were measured and used to calculate metabolic fluxes. The non-triose pathways, including synthesis of polysaccharides, accumulation of free hexoses, and to a lesser extent starch synthesis, were found to consume 75% of the glucose entering the root tips. The cycle of synthesis and hydrolysis of sucrose was found to consume about 70% of the ATP produced by respiration. The comparison of the specific radioactivities of amino acids and phospholipid glycerol phosphate after labeling with [1-C-14] or [6-C-14]glucose revealed the operation of the pentose phosphate pathway. The transfer of label from [2-C-14]glucose to carbon-1 of starch glucosyl units confirmed the operation of this pathway and indicated that it is located in plastids. It was found to consume 32% of the hexose phosphates entering the triose pathways. The remaining 68% were consumed by glycolysis. The determination of the specific enrichment of carbohydrate carbons -1 and -6 after labeling with [1-C-13]glucose indicated that both the conversion of triose phosphates back to hexose phosphates and the transaldolase exchange contributed to this randomization. Of the triose phosphates produced by glycolysis and the pentose phosphate pathway, about 60% were found to be recycled to hexose phosphates, and 28% were directed to the tricarboxylic acid cycle. Of this 28%, two-thirds were found to be directed through the pyruvate kinase branch and one-third through the phosphoenolpyruvate branch. The latter essentially has an anaplerotic function since little malate was found to be converted to pyruvate (malic enzyme reaction).	INRA, CTR RECH BORDEAUX, PHYSIOL VEGETALE STN, F-33883 VILLENAVE DORNON, FRANCE; UNIV BORDEAUX 2, CNRS, UMR 9551, F-33076 BORDEAUX, FRANCE	INRAE; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux								BORCHERT S, 1993, PLANT PHYSIOL, V101, P303, DOI 10.1104/pp.101.1.303; BOWSHER CG, 1989, PLANTA, V177, P359, DOI 10.1007/BF00403594; BRETHARTE MS, 1994, PLANT PHYSIOL, V105, P19, DOI 10.1104/pp.105.1.19; BROUQUISSE R, 1992, PLANTA, V188, P384, DOI 10.1007/BF00192806; BROUQUISSE R, 1991, PLANT PHYSIOL, V96, P619, DOI 10.1104/pp.96.2.619; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; COHEN SM, 1981, P NATL ACAD SCI-BIOL, V78, P60, DOI 10.1073/pnas.78.1.60; DAVIES KM, 1993, PLANT PHYSIOL, V102, P1337, DOI 10.1104/pp.102.4.1337; DAWSON RMC, 1974, BIOCHEM J, V144, P169, DOI 10.1042/bj1440169; DIEUAIDE M, 1993, BIOCHEM J, V296, P199, DOI 10.1042/bj2960199; DIEUAIDE M, 1992, PLANT PHYSIOL, V99, P595, DOI 10.1104/pp.99.2.595; DOUCE R, 1989, ANNU REV PLANT PHYS, V40, P371, DOI 10.1146/annurev.pp.40.060189.002103; EMES MJ, 1983, PLANTA, V158, P97, DOI 10.1007/BF00397700; ENTWISTLE G, 1990, BIOCHEM J, V271, P467, DOI 10.1042/bj2710467; FREHNER M, 1990, PLANT PHYSIOL, V94, P538, DOI 10.1104/pp.94.2.538; GEIGENBERGER P, 1993, PLANTA, V189, P329, DOI 10.1007/BF00194429; GIAQUINTA RT, 1983, PLANT PHYSIOL, V72, P362, DOI 10.1104/pp.72.2.362; GIBBS M, 1955, PLANT PHYSIOL, V30, P343, DOI 10.1104/pp.30.4.343; GRAHAM IA, 1994, PLANT CELL, V6, P761, DOI 10.1105/tpc.6.5.761; HARGREAVES JA, 1988, PHYTOCHEMISTRY, V27, P1627, DOI 10.1016/0031-9422(88)80416-3; HATZFELD WD, 1990, PLANTA, V180, P198, DOI 10.1007/BF00193996; HILL SA, 1994, PLANTA, V192, P52, DOI 10.1007/BF00198692; HOLE DJ, 1992, PLANT PHYSIOL, V99, P213, DOI 10.1104/pp.99.1.213; JAMES F, 1993, PLANT PHYSIOL BIOCH, V31, P845; JOURNET EP, 1986, J BIOL CHEM, V261, P3193; JOURNET EP, 1985, PLANT PHYSIOL, V79, P458, DOI 10.1104/pp.79.2.458; KATZ J, 1967, BIOCHEMISTRY-US, V6, P2227, DOI 10.1021/bi00859a046; KATZ J, 1979, TECHNIQUES METABOL B, V208, P1; KEELING PL, 1988, PLANT PHYSIOL, V87, P311, DOI 10.1104/pp.87.2.311; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; LJUNGDAHL L, 1961, J BIOL CHEM, V236, P1622; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MCDERMITT DK, 1981, ANN BOT-LONDON, V48, P275, DOI 10.1093/oxfordjournals.aob.a086125; MOING A, 1992, PLANT PHYSIOL, V100, P1878, DOI 10.1104/pp.100.4.1878; MORRIS GA, 1982, CAN J CHEM, V60, P2431, DOI 10.1139/v82-352; NEUHAUS HE, 1993, BIOCHEM J, V296, P395, DOI 10.1042/bj2960395; PORTAIS JC, 1993, EUR J BIOCHEM, V149, P1; REES T, 1988, BIOCH PLANTS, P1; Rees T.A.P., 1990, PLANT PHYSIOL, P106; REES TA, 1980, BIOCH PLANTS, V2, P1; ROBERTS JKM, 1992, PLANT PHYSIOL, V98, P480, DOI 10.1104/pp.98.2.480; SAGLIO PH, 1980, PLANT PHYSIOL, V66, P516, DOI 10.1104/pp.66.3.516; SAGLIO PH, 1980, PLANT PHYSIOL, V66, P1053, DOI 10.1104/pp.66.6.1053; SALON C, 1988, J BIOL CHEM, V263, P12278; STITT M, 1980, PHYTOCHEMISTRY, V19, P1583, DOI 10.1016/S0031-9422(00)83774-7; SUMEGI B, 1993, BIOCHEMISTRY-US, V32, P12725, DOI 10.1021/bi00210a022; VIOLA R, 1991, PLANTA, V183, P202, DOI 10.1007/BF00197789; WENDLER R, 1991, PLANTA, V183, P31, DOI 10.1007/BF00197564; XIA JH, 1988, PLANT PHYSIOL, V88, P1015, DOI 10.1104/pp.88.4.1015; XIA JH, 1992, PLANT PHYSIOL, V100, P40, DOI 10.1104/pp.100.1.40	50	140	141	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13147	13159		10.1074/jbc.270.22.13147	http://dx.doi.org/10.1074/jbc.270.22.13147			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768910	Green Submitted, hybrid			2022-12-25	WOS:A1995RB43900033
J	MICHAEL, MD; KILGORE, MW; MOROHASHI, K; SIMPSON, ER				MICHAEL, MD; KILGORE, MW; MOROHASHI, K; SIMPSON, ER			AD4BP/SF-1 REGULATES CYCLIC AMP-INDUCED TRANSCRIPTION FROM THE PROXIMAL PROMOTER (PII) OF THE HUMAN AROMATASE P450 (CYP19) GENE IN THE OVARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL MICROSOMES; STEROIDOGENIC FACTOR-I; GRANULOSA-CELLS; ESTROGEN BIOSYNTHESIS; PRIMARY CULTURE; BOVINE LUTEAL; GROWTH-FACTOR; EXPRESSION; CYTOCHROME-P-450; PURIFICATION	Aromatase P450, which is responsible for the metabolism of C-19 steroids to estrogens, is expressed in the pre-ovulatory follicles and corpora lutea of ovulatory women by means of a promoter proximal to the start of translation (PII). To understand how this transcription is controlled by cAMP, we constructed chimeric constructs containing deletion mutations of the proximal promoter 5'-flanking DNA fused to the rabbit beta-globin reporter gene. Assay of reporter gene transcription in transfected bovine granulosa and luteal cells revealed that cAMP-stimulated transcription was lost upon deletion from -278 to -100 base pairs, indicating the presence of a functional cAMP-responsive element in this region; however, no classical cAMP-responsive element was found. Mutation of an AGGTCA motif located at -130 base pairs revealed that this element is crucial for cAMP-stimulated reporter gene transcription. When a single copy of this element was placed upstream of a heterologous promoter, it could act as a weak cAMP-response element. Supershift electrophoretic mobility shift assay and UV cross-linking established that Ad4BP/SF-1 binds to this hexameric element. Ad4BP/SF-1 mRNA and protein levels and DNA binding activity are increased in forskolin-treated luteal cells. We conclude that cAMP-stimulated transcription of human aromatase P450 in the ovary is due, at least in part, to increased levels and DNA binding activity of Ad4BP/SF-1.	UNIV TEXAS,SW MED CTR,CECIL H & IDA GREEN CTR REPROD BIOL SCI,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OBSTET GYNECOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,HIGASHI KU,FUKUOKA 812,JAPAN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Kyushu University				Michael, Mervyn/0000-0002-0224-1065	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013234, T32HD007190] Funding Source: NIH RePORTER; NICHD NIH HHS [HD13234, 5-T32-HD07190] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKHTAR M, 1982, BIOCHEM J, V201, P569, DOI 10.1042/bj2010569; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; BEGEOT M, 1993, J BIOL CHEM, V268, P17317; CARR BR, 1992, WILLIAMS TXB ENDOCRI, P733; CASPI E, 1984, J AM CHEM SOC, V106, P7282, DOI 10.1021/ja00335a090; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE PA, 1988, J AM CHEM SOC, V110, P1284, DOI 10.1021/ja00212a043; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FITZPATRICK SL, 1994, MOL ENDOCRINOL, V8, P1309, DOI 10.1210/me.8.10.1309; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; GOTO J, 1977, SCIENCE, V195, P80, DOI 10.1126/science.831259; HARADA N, 1990, BIOCHEM BIOPH RES CO, V166, P365, DOI 10.1016/0006-291X(90)91954-Q; JENKINS C, 1993, MOL CELL ENDOCRINOL, V97, pR1, DOI 10.1016/0303-7207(93)90227-B; KELLIS JT, 1987, J BIOL CHEM, V262, P4413; KILGORE MW, 1992, MOL CELL ENDOCRINOL, V83, pR9, DOI 10.1016/0303-7207(92)90202-H; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LAUBER ME, 1993, MOL CELL ENDOCRINOL, V93, P227, DOI 10.1016/0303-7207(93)90128-7; LYNCH JP, 1994, MOL ENDOCRINOL, V7, P776; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MCALLISTER JM, 1994, J CLIN ENDOCR METAB, V79, P106, DOI 10.1210/jc.79.1.106; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MEANS GD, 1989, J BIOL CHEM, V264, P19385; MENDELSON CR, 1985, ARCH BIOCHEM BIOPHYS, V243, P480, DOI 10.1016/0003-9861(85)90525-9; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; NAKAJIN S, 1986, BIOCHEM BIOPH RES CO, V134, P704, DOI 10.1016/S0006-291X(86)80477-6; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OSAWA Y, 1987, Steroids, V50, P11, DOI 10.1016/0039-128X(83)90058-2; Sambrook J, 1989, MOL CLONING LABORATO; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Simpson E.R., 1994, ENDOCR REV, V15, P342, DOI DOI 10.1210/ER.15.3.342.PUBMED:8076586; STEINKAMPF MP, 1988, MOL CELL ENDOCRINOL, V59, P93, DOI 10.1016/0303-7207(88)90199-2; STEINKAMPF MP, 1987, MOL ENDOCRINOL, V1, P465, DOI 10.1210/mend-1-7-465; STIRLING D, 1990, J BIOL CHEM, V265, P5; TAKAYAMA K, 1994, 9TH INT C HORM STER, P120; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; TODA K, 1990, EUR J BIOCHEM, V193, P559, DOI 10.1111/j.1432-1033.1990.tb19372.x; WEHRENBERG U, 1994, P NATL ACAD SCI USA, V91, P1440, DOI 10.1073/pnas.91.4.1440; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794	41	203	208	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13561	13566		10.1074/jbc.270.22.13561	http://dx.doi.org/10.1074/jbc.270.22.13561			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768959	hybrid			2022-12-25	WOS:A1995RB43900089
J	TRONCHERE, H; PLANAT, V; RECORD, M; TERCE, F; RIBBES, G; CHAP, H				TRONCHERE, H; PLANAT, V; RECORD, M; TERCE, F; RIBBES, G; CHAP, H			PHOSPHATIDYLCHOLINE TURNOVER IN ACTIVATED HUMAN NEUTROPHILS - AGONIST-INDUCED CYTIDYLYLTRANSFERASE TRANSLOCATION IS SUBSEQUENT TO PHOSPHOLIPASE-D ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHORBOL 12-MYRISTATE 13-ACETATE; STIMULATED HUMAN-NEUTROPHILS; II ASCITE CELLS; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; PHOSPHATIDATE PHOSPHOHYDROLASE; POLYMORPHONUCLEAR LEUKOCYTES; DIACYLGLYCEROL FORMATION; SIGNAL TRANSDUCTION	Phosphatidylcholine synthesis and degradation are tightly regulated to assure a constant amount of the phospholipid in cellular membranes. The chemotactic peptide fMLP and the phorbol ester, phorbol 12-myristate 13-acetate, are known to stimulate phosphatidylcholine degradation by phospholipase D in human neutrophils. fMLP alone triggered phosphatidylcholine breakdown into phosphatidic acid, but did not stimulate phosphatidylcholine synthesis or activation of the rate-limiting enzyme CTP:phosphocholine cytidylyltransferase. Adding cytochalasin B to fMLP led to some conversion of phosphatidic acid into diglyceride, and fMLP was then able to trigger choline incorporation into phosphatidylcholine, and cytidylyltransferase translocation from cytosol to membranes. Inhibition of phosphatidylcholine-phospholipase D activation with tyrphostin led to inhibition of choline incorporation. Therefore, phosphatidic acid-derived diglyceride but not phosphatidic acid alone was effective to promote cytidylyltransferase translocation. With phorbol 12-myristate 13-acetate as agonist, and by selective labeling of phosphatidylinositol and phosphatidylcholine, we demonstrated that only phosphatidylcholine-derived diglyceride participated in cytidylyltransferase translocation. Oleic acid stimulated phosphatidylcholine synthesis, but induced a weak increase in diglyceride and a slight cytidylyltransferase translocation, and did not stimulate phospholipase D activity. Our data established that only diglyceride derived from phosphatidylcholine degradation by the phospholipase D/phosphatidate phosphatase pathway are required for agonist-induced cytidylyltransferase translocation and subsequent choline incorporation into phosphatidylcholine.	HOP PURPAN, INSERM, U326, F-31059 TOULOUSE, FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)			RECORD, Michel/G-3493-2017; TRONCHERE, Helene/M-5631-2014; Tercé, François/M-5863-2018	RECORD, Michel/0000-0003-1893-0022; Tercé, François/0000-0003-4488-2167; Planat-Benard, Valerie/0000-0002-0712-4220				AGWU DE, 1989, J BIOL CHEM, V264, P1405; BENTLEY JK, 1981, BIOCHIM BIOPHYS ACTA, V678, P238; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOMALASKI JS, 1990, J LEUKOCYTE BIOL, V47, P1; CABOT MC, 1988, BIOCHIM BIOPHYS ACTA, V959, P46, DOI 10.1016/0005-2760(88)90148-8; CHALIFOUR R, 1982, J NEUROCHEM, V39, P299, DOI 10.1111/j.1471-4159.1982.tb03946.x; COOK HW, 1989, J BIOL CHEM, V264, P2746; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P37, DOI 10.1016/0005-2760(87)90215-3; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; Garcia Gil M, 1982, Biochem J, V206, P67; GELAS P, 1992, BIOCHEM J, V287, P67, DOI 10.1042/bj2870067; GELAS P, 1989, FEBS LETT, V251, P213, DOI 10.1016/0014-5793(89)81457-7; GEORGE TP, 1991, J BIOL CHEM, V266, P12419; GIL MG, 1981, BIOCHEM BIOPH RES CO, V101, P740, DOI 10.1016/0006-291X(81)91813-1; GUY GR, 1982, CANCER RES, V42, P1980; HONEYCUTT PJ, 1986, J BIOL CHEM, V261, P5900; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; JAMIL H, 1992, J BIOL CHEM, V267, P1752; KISS Z, 1992, ARCH BIOCHEM BIOPHYS, V296, P457, DOI 10.1016/0003-9861(92)90597-P; KOLESNICK RN, 1987, J BIOL CHEM, V262, P14525; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MATO JM, 1983, P NATL ACAD SCI-BIOL, V80, P1929, DOI 10.1073/pnas.80.7.1929; OHTA H, 1985, J BIOL CHEM, V260, P5771; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P447, DOI 10.1016/0005-2760(84)90171-1; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PIKE MC, 1980, CELL, V20, P373, DOI 10.1016/0092-8674(80)90623-6; PREISS J, 1986, J BIOL CHEM, V261, P8597; RECORD M, 1985, BIOCHIM BIOPHYS ACTA, V819, P1, DOI 10.1016/0005-2736(85)90188-9; RECORD M, 1982, BIOCHIM BIOPHYS ACTA, V688, P57, DOI 10.1016/0005-2736(82)90578-8; REINHOLD SL, 1989, J BIOL CHEM, V264, P21652; SIDDIQUI RA, 1992, EUR J BIOCHEM, V210, P601, DOI 10.1111/j.1432-1033.1992.tb17460.x; STRUM JC, 1993, BIOCHIM BIOPHYS ACTA, V1169, P25, DOI 10.1016/0005-2760(93)90077-M; TERCE F, 1988, J BIOL CHEM, V263, P3142; TERCE F, 1991, BIOCHIM BIOPHYS ACTA, V1084, P69, DOI 10.1016/0005-2760(91)90057-O; THOMPSON NT, 1991, TRENDS PHARMACOL SCI, V12, P404, DOI 10.1016/0165-6147(91)90617-2; TORRES M, 1993, J IMMUNOL, V150, P1563; TREVES S, 1987, EXP CELL RES, V168, P285, DOI 10.1016/0014-4827(87)90001-2; TRONCHERE H, 1993, BIOCHEM J, V293, P739, DOI 10.1042/bj2930739; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; TRONCHERE H, 1991, BIOCHEM BIOPH RES CO, V176, P157, DOI 10.1016/0006-291X(91)90903-K; TYAGI SR, 1988, J BIOL CHEM, V263, P13191; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; VANCE DE, 1981, METHOD ENZYMOL, V71, P579; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210	52	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13138	13146		10.1074/jbc.270.22.13138	http://dx.doi.org/10.1074/jbc.270.22.13138			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768909	hybrid			2022-12-25	WOS:A1995RB43900032
J	JUANG, HH; COSTELLO, LC; FRANKLIN, RB				JUANG, HH; COSTELLO, LC; FRANKLIN, RB			ANDROGEN MODULATION OF MULTIPLE TRANSCRIPTION START SITES OF THE MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE GENE IN RAT PROSTATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; CITRATE PRODUCTION; RESPONSE ELEMENT; VENTRAL PROSTATE; TESTOSTERONE; EXPRESSION; PROMOTER; RECEPTOR; INTRON	Mitochondrial aspartate aminotransferase (mAAT) is one of two key enzymes in the pathway of citrate production in prostate. Expression of mAAT is modulated by testosterone and prolactin in prostate. We cloned the promoter and 5'-flanking region of the rat mAAT gene and sequenced 2.0 kilobases of the DNA. This fragment contains the 5'-regulatory promoter region that lacks a TATA and a CCAAT box but is G+C rich. The 5'-upstream flanking region contains sequences that have high homology with the consensus glucocorticoid response element/androgen response element (ARE) and a reported ARE sequence that is different from the consensus sequence. Functional transcription studies showed that a 481-base region containing the two ARE sequences was sufficient for androgen-regulated gene expression. There are multiple transcription start sites that are regulated by testosterone in prostate. In liver, on the other hand, castration did not affect transcription from any of the start sites. Therefore, these data provide evidence that transcriptional regulation of the rat pmAAT gene occurs through an ARE located in the 5'-region. In addition, not only is gene expression modulated by testosterone, but the effect of testosterone on transcription is cell specific.	UNIV MARYLAND,SCH DENT,DEPT PHYSIOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore			Juang, Horng-Heng/AAG-7683-2020; Juang, Horng-Heng/G-2313-2012	Juang, Horng-Heng/0000-0002-8524-8253	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028015, R01DK042839] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42839, DK28015] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALDER AJ, 1991, MOL ENDOCRINOL, V5, P1587; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; COSTELLO LC, 1991, PROSTATE, V19, P181, DOI 10.1002/pros.2990190302; DENISON SH, 1989, ENDOCRINOLOGY, V124, P1091, DOI 10.1210/endo-124-2-1091; FRANKLIN RB, 1990, J STEROID BIOCHEM, V35, P569, DOI 10.1016/0022-4731(90)90200-C; FRANKLIN RB, 1987, J STEROID BIOCHEM, V28, P247, DOI 10.1016/0022-4731(87)91015-6; FRANKLIN RB, 1982, J UROLOGY, V127, P798, DOI 10.1016/S0022-5347(17)54052-5; FRANKLIN RB, 1992, MOL CELL ENDOCRINOL, V90, P27, DOI 10.1016/0303-7207(92)90097-P; FRANKLIN RB, 1986, HORM METAB RES, V18, P177, DOI 10.1055/s-2007-1012264; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; Maniatis T., 1982, MOL CLONING; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MODARESSI S, 1993, BIOL CHEM H-S, V374, P327, DOI 10.1515/bchm3.1993.374.1-6.327; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; PAVEPREUX M, 1990, J BIOL CHEM, V265, P4444; QIAN K, 1993, J STEROID BIOCHEM, V44, P13, DOI 10.1016/0960-0760(93)90146-N; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SETOYAMA C, 1990, J BIOL CHEM, V265, P1293; TAN JA, 1992, J BIOL CHEM, V267, P4456; TOUSSAINT C, 1994, J BIOL CHEM, V269, P13318; TSUZUKI T, 1987, J MOL BIOL, V198, P21, DOI 10.1016/0022-2836(87)90454-2; WEISINGER G, 1992, J BIOL CHEM, V267, P4508	29	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12629	12634		10.1074/jbc.270.21.12629	http://dx.doi.org/10.1074/jbc.270.21.12629			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759512	hybrid			2022-12-25	WOS:A1995QZ71100047
J	HIRANO, Y; YAMATO, K; TSUCHIDA, N				HIRANO, Y; YAMATO, K; TSUCHIDA, N			A TEMPERATURE-SENSITIVE MUTANT OF THE HUMAN P53, VAL138, ARRESTS RAT-CELL GROWTH WITHOUT INDUCED EXPRESSION OF CIP1/WAF1/SDI1 AFTER TEMPERATURE SHIFT-DOWN	ONCOGENE			English	Article						TEMPERATURE-SENSITIVE MUTANTS; P53; TUMOR SUPPRESSOR GENE; CIP1/WAF1/SDI1	WILD-TYPE P53; MAMMALIAN-CELLS; GENE; PROTEIN; TRANSFORMATION; SUPPRESSOR; DNA; CARCINOMA; ONCOGENE; SEQUENCE	To investigate functions of wild type p53 in human cells, we introduced a (Ala-->Val) mutation at the 138th codon of the human p53 (Val138), which corresponds to the Val135 mutation of the temperature sensitive mouse p53, The human Val138 mutant showed temperature-sensitive transformation of rat embryo fibroblasts (REFs) in collaboration assay with activated vas, and arrested cell proliferation of transformed clones in G1 at 32.5 degrees C. Transient CAT assay for transcriptional activation in human Saos2 cells revealed activity equivalent to that of wild type at 32.5 degrees C but undetectable at 37.5 degrees C. These results suggest that the human Val138 mutant also exhibited the wild type phenotype at the permissive temperature as is for the mouse Val135 mutant, although we observed differences between the two mutants such as in transactivational activities in CV-1 and HeLa cells, Further, the role of cip1/waf1/sdi1 in the cell growth arrest of the Val138/ras-transformed REFs and Val138-introduced Saos2 cells was studied by northern hybridization analysis, Although rapid induction of cip1/waf1/sdi1 mRNA was observed in the Saos2 cells, no detectable induction of mRNAs for cip1/waf1/sdi1 and gadd45 was observed in the transformed REFs upon temperature shift-down, while mdm2 mRNA was enhanced, suggesting that the p53 gene could arrest cell growth by a mechanism other than that,vith induced expression of the gene for p21 cdk-cyclin inhibitor.	TOKYO MED & DENT UNIV,FAC DENT,DEPT MOLEC CELLULAR ONCOL & MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,DEPT ORAL & MAXILLOFACIAL SURG 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1994, CANCER RES, V54, P3391; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GEY G, 1952, CANCER RES, V12, P246; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARPER JW, 1993, CELL, V75, P805; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HIRANO Y, IN PRES ORAL ONCOL E; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IKEDA M, 1989, RECENT PROGR LIFE SC, P119; JENSEN FC, 1964, P NATL ACAD SCI USA, V52, P52; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEDCALF EA, 1992, ONCOGENE, V7, P71; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MOMAND J, 1992, CELL, V69, P1233; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OTTO A, 1993, ONCOGENE, V8, P2591; RIDGWAY PJ, 1994, J VIROL, V68, P7178, DOI 10.1128/JVI.68.11.7178-7187.1994; SAKAI E, 1992, ONCOGENE, V7, P927; Sambrook J, 1989, MOL CLONING LABORATO; SEHGAL PB, 1993, ONCOGENE, V8, P3417; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; VOGELSTEIN B, 1994, NATURE, V370, P174, DOI 10.1038/370174a0; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	50	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1879	1885						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761089				2022-12-25	WOS:A1995QZ92600001
J	SUZUKITAKAHASHI, I; KITAGAWA, M; SAIJO, M; HIGASHI, H; OGINO, H; MATSUMOTO, H; TAYA, Y; NISHIMURA, S; OKUYAMA, A				SUZUKITAKAHASHI, I; KITAGAWA, M; SAIJO, M; HIGASHI, H; OGINO, H; MATSUMOTO, H; TAYA, Y; NISHIMURA, S; OKUYAMA, A			THE INTERACTIONS OF E2F WITH PRB AND WITH P107 ARE REGULATED VIA THE PHOSPHORYLATION OF QRB AND P107 BY A CYCLIN-DEPENDENT KINASE	ONCOGENE			English	Article						PRB; P107; E2F; CDK; PHOSPHORYLATION	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; MAMMALIAN FIBROBLASTS; CELL-PROLIFERATION; CDC2 KINASE; PROTEIN; RB; CDK2; COMPLEX; IDENTIFICATION	It has been postulated that the product (pRB) of the retinoblastoma gene dissociates from the E2F-pRB complex upon phosphorylation by cyclin-dependent kinase(s) (cdk). However, there is no direct evidence for the regulation of formation of the E2F-pRB complex via phosphorylation by purified cdk, Therefore,we investigated the regulation of formation of this complex by phosphorylation using pRB and purified cyclin A-cdk2, cyclin E-cdk2 or cyclin D1-cdk4. Purified pRB was incubated with nuclear extracts prepared from pRB-defective cells and then subjected to gel mobility shift assays, We confirmed that unphosphorylated pRB associated with various types of E2F but pRB has been phosphorylated by cyclin A-cdk2 did not. We found that E2F-pRB complexes were disrupted as a consequence of phosphorylation by cyclin A-cdk2, and the levels of the free forms of E2Fs increased. We also found that not only the E2F-pRB complexes but also the E2F-p107 complexes were disrupted upon phosphorylation by cyclin A-cdk2. Furthermore, E2F-pRB complexes were disrupted through phosphorylation by cyclin D1-cdk4 and cyclin E-cdk2, as web as by cyclin A-cdk2. These results clearly demonstrate that the phosphorylation of pRB and p107 by cdks regulates the formation of complexes between E2F and pRB or p107.	BANYU TSUKUBA RES INST,MERCK RES LABS,TSUKUBA,IBARAKI 30033,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN	Merck & Company; National Cancer Center - Japan			Higashi, Hideaki/F-6872-2012					AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; KITAGAWA M, 1994, ONCOGENE, V9, P2549; KITAGAWA M, 1995, ONCOGENE, V10, P229; KITAGAWA M, 1993, ONCOGENE, V8, P2425; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MORI N, 1990, ONCOGENE, V5, P1713; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAN ZQ, 1993, J BIOL CHEM, V268, P20443; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SAVOYSKY E, 1992, BIOCHEM BIOPH RES CO, V187, P697, DOI 10.1016/0006-291X(92)91251-K; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	39	56	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1691	1698						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753545				2022-12-25	WOS:A1995QX46900001
J	BELAAOUAJ, A; SHIPLEY, JM; KOBAYASHI, DK; ZIMONJIC, DB; POPESCU, N; SILVERMAN, GA; SHAPIRO, SD				BELAAOUAJ, A; SHIPLEY, JM; KOBAYASHI, DK; ZIMONJIC, DB; POPESCU, N; SILVERMAN, GA; SHAPIRO, SD			HUMAN MACROPHAGE METALLOELASTASE - GENOMIC ORGANIZATION, CHROMOSOMAL LOCATION, GENE LINKAGE, AND TISSUE-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEINASE INHIBITOR; MATRIX METALLOPROTEINASES; INSITU HYBRIDIZATION; COLLAGENASE GENE; DNA-MOLECULES; LOCALIZATION; RNA; ELASTASE; CLONING	Human macrophage metalloelastase (HME) is a recent addition to the matrix metalloproteinase (MMP) family that was initially found to be expressed in alveolar macrophages of cigarette smokers. To understand more about HME expression, analysis of the structure and location of the gene was performed. The gene for HME is composed of 10 exons and 9 introns, similar to the stromelysins and collagenases, and HME shares the highly conserved exon size and intron-exon borders with other MMPs. The 13-kilobase (kb) HME gene has been localized by fluorescence in situ hybridization to chromosome 11q22.2-22.3, the same location of the interstitial collagenase and stromelysin genes. We determined that HME and stromelysin 1 genes are physically linked within 62 kb utilizing pulse field gel electrophoresis. The promoter region of the HME gene contains several features common to other MMP genes including a TATA box 29 bp upstream to the transcription initiation site, an AP-1 motif, and a PEA3 element. HME mRNA is not detectable in normal adult tissues but is induced in rapidly remodeling tissues such as the term placenta. In situ hybridization and immunohistochemistry of placental tissue demonstrated HME mRNA and protein expression in macrophages and stromal cells. Cell-specific expression and response to inflammatory stimuli such as endotoxin is conferred within 2.8 kb of the HME 5'-flanking sequence as demonstrated by HME promoter-CAT expression constructs. Knowledge of the genomic organization and chromosomal location of HME may allow us to further define mechanisms responsible for cell- and tissue-specific expression of HME.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV RESP & CRIT CARE,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; NCI,DIV CANC ETIOL,BIOL LAB,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,JOINT PROGRAM NEONATOL,BOSTON,MA 02115	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School			A, Bentaher/F-6531-2018; Silverman, Gary/AAJ-1269-2020; Zimonjic, Drazen/AAX-7513-2020; Bentaher, Abderrazzaq/M-4424-2017	A, Bentaher/0000-0001-6001-5456; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NHLBI NIH HHS [P0-1 HL29594, HL2401] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BANDA MJ, 1981, BIOCHEM J, V193, P589, DOI 10.1042/bj1930589; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brophy C M, 1991, Ann Vasc Surg, V5, P229, DOI 10.1007/BF02329378; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; FORMSTONE CJ, 1992, GENOMICS, V16, P289; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; POPESCU N, 1994, GENOMICS, V20, P333, DOI 10.1006/geno.1994.1182; PROSSER IW, 1989, AM J PATHOL, V135, P1073; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, P5160; SMITH GE, 1980, ANAL BIOCHEM, V109, P123, DOI 10.1016/0003-2697(80)90019-6; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; Southern E, 1979, Methods Enzymol, V68, P152; VOLLRATH D, 1987, NUCLEIC ACIDS RES, V15, P7865, DOI 10.1093/nar/15.19.7865; WERB Z, 1975, J EXP MED, V142, P361, DOI 10.1084/jem.142.2.361; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628	36	130	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14568	14575		10.1074/jbc.270.24.14568	http://dx.doi.org/10.1074/jbc.270.24.14568			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782320	hybrid			2022-12-25	WOS:A1995RD45500052
J	JANOUEIXLEROSEY, I; JOLLIVET, F; CAMONIS, J; MARCHE, PN; GOUD, B				JANOUEIXLEROSEY, I; JOLLIVET, F; CAMONIS, J; MARCHE, PN; GOUD, B			2-HYBRID SYSTEM SCREEN WITH THE SMALL GTP-BINDING PROTEIN RAB6 - IDENTIFICATION OF A NOVEL MOUSE GDP DISSOCIATION INHIBITOR ISOFORM AND 2 OTHER POTENTIAL PARTNERS OF RAB6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMG P25A; ACTIVATING PROTEIN; VESICULAR TRANSPORT; REGULATORY PROTEIN; EXCHANGE PROTEIN; RAS PROTEIN; MUTANTS; FAMILY; MEMBRANES; CYTOSOL	Rab6 is a small GTP-binding protein that belongs to the Ras superfamily and is involved in intra-Golgi transport. Using a two-hybrid system screen of a mouse brain cDNA library, we have isolated several clones encoding proteins that interact with Rab6. Approximately 60% of the clones identified encoded anew mouse Rab GDP dissociation inhibitor (GDI) isoform. This GDI isoform is distinct from mouse mGDI-1 and mGDI-2, which have been characterized previously, and most likely represents the mouse counterpart of the rat Rab GDI beta isoform. In the two-hybrid system, GDI beta interacts with wild-type Rab6 and Rab5, but not with a GTP-bound Rab6 mutant, or a Rab6 mutant that cannot be post-translationally processed. We further examined whether mouse GDI beta is functional; we show that recombinant mouse GDI beta is able to remove several Rab proteins, including Rab1, Rab2, Rab4, and Rab6, from membranes. The identification of a third GDI isoform in mouse raised the question whether GDI genes belong to a larger multigenic family. We have shown, by Southern blot analysis of genomic DNA, that at least five GDI gene copies exist in both the mouse and rat genomes. In our two-hybrid screen, we have also characterized another clone that specifically interacts with Rab6. This clone was partially sequenced but shows no homology to known sequences. Finally, a third clone, interacting with both Rab5 and Rab6. also appears to encode a novel protein.	INST PASTEUR,DEPT IMMUNOL,CNRS,URA 361,UNITE GENET SOMAT,F-75724 PARIS 15,FRANCE; INST PASTEUR,DEPT IMMUNOL,CNRS,URA 359,UNITE IMMUNOCHIM ANALYT,F-75724 PARIS 15,FRANCE; FAC MED LARIBOISIERE,INSERM,U248,F-75010 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Marche, Patrice N/K-5060-2013; Janoueix-Lerosey, Isabelle/G-1758-2018; Goud, Bruno/GWC-4807-2022	Marche, Patrice N/0000-0002-8930-9340; Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; 				ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; JOUVINMARCHE E, 1990, EMBO J, V9, P2141, DOI 10.1002/j.1460-2075.1990.tb07383.x; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; ROSE MD, 1990, LABORATORY COURSE MA; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; YANG CZ, 1994, J BIOL CHEM, V269, P31891; ZAHNER JE, 1993, MOL CELL BIOL, V13, P217, DOI 10.1128/MCB.13.1.217; 1991, PROGRAM MANUAL GCG P	43	96	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14801	14808		10.1074/jbc.270.24.14801	http://dx.doi.org/10.1074/jbc.270.24.14801			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782346	hybrid			2022-12-25	WOS:A1995RD45500084
J	KOUMENIS, C; NUNEZREGUEIRO, M; RAJU, U; COOK, R; ESKIN, A				KOUMENIS, C; NUNEZREGUEIRO, M; RAJU, U; COOK, R; ESKIN, A			IDENTIFICATION OF 3 PROTEINS IN THE EYE OF APLYSIA, WHOSE SYNTHESIS IS ALTERED BY SEROTONIN (5-HT) - POSSIBLE INVOLVEMENT OF THESE PROTEINS IN THE OCULAR CIRCADIAN SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; DEPENDENT ANION CHANNEL; OUTER MITOCHONDRIAL-MEMBRANE; GLUCOSE-REGULATED PROTEIN; CHAIN BINDING-PROTEIN; BIOCHEMICAL-CHARACTERIZATION; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; STRESS PROTEINS; MAMMALIAN-CELLS	Previous results using translation inhibitors in the ocular circadian system of Aplysia suggest that protein synthesis may be involved in the light and serotonin (5-HT) entrainment pathways or perhaps in the circadian oscillator. Proteins have been previously identified whose synthesis was altered by treatments of light capable of perturbing the phase of the circadian rhythm in the eye of Aplysia. We extended these studies by investigating the effects of other treatments that perturb the ocular circadian rhythm on protein synthesis. 5-HT altered the synthesis of nine proteins. Interestingly, five of the proteins affected by treatments with 5-HT were previously shown to be affected by treatments with light. Four of the proteins affected by treatments with 5-HT were also affected by treatments with analogs of cAMP, a treatment which mimics the effects of 5-HT on the ocular circadian rhythm. To identify the cellular function of some of these proteins, we obtained their partial amino acid sequences, Based on these sequences and additional characterizations, a 78-kDa, pI 5.6 Aplysia protein appears to be glucose-regulated protein 78/binding protein, and a 36-kDa, pI 5.7 Aplysia protein appears to be porin/voltage-dependent anion channel. Heat shock experiments on Aplysia eyes revealed that yet another one of the Aplysia proteins (70 kDa) affected by 5-HT appears to be a heat-inducible member (heat shock protein 70) of the family of heat shock proteins. These findings suggest that these three identified proteins, together or individually, maybe involved in some way in the regulation of the timing of the circadian oscillator in the eye of Aplysia.	UNIV HOUSTON,DEPT BIOCHEM & BIOPHYS SCI,HOUSTON,TX 77204; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030	University of Houston System; University of Houston; Baylor College of Medicine; Baylor College of Medicine			Koumenis, Constantinos/B-2002-2008	Koumenis, Costas/0000-0001-5945-4726	NIMH NIH HHS [MH41979] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH041979, R37MH041979] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; BENZ R, 1985, CRC CR REV BIOCH MOL, V19, P145, DOI 10.3109/10409238509082542; BENZ R, 1990, EXPERIENTIA, V46, P131, DOI 10.1007/BF02027308; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; CERVERA J, 1985, CELL BIOL INT REP, V9, P131, DOI 10.1016/0309-1651(85)90087-6; CHAO CCK, 1992, NUCLEIC ACIDS RES, V20, P6481, DOI 10.1093/nar/20.24.6481; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; CORRENT G, 1982, AM J PHYSIOL, V242, pR326, DOI 10.1152/ajpregu.1982.242.3.R326; COURGEON AM, 1984, EXP CELL RES, V153, P515, DOI 10.1016/0014-4827(84)90618-9; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DERMIETZEL R, 1994, P NATL ACAD SCI USA, V91, P499, DOI 10.1073/pnas.91.2.499; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; ESKIN A, 1984, P NATL ACAD SCI-BIOL, V81, P7637, DOI 10.1073/pnas.81.23.7637; ESKIN A, 1982, P NATL ACAD SCI-BIOL, V79, P660, DOI 10.1073/pnas.79.2.660; ESKIN A, 1982, J NEUROBIOL, V13, P241, DOI 10.1002/neu.480130305; FELDMAN JF, 1989, SCI PHOTOBIOLOGY, P193; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREENBERG SG, 1985, J NEUROSCI, V5, P1239; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDINPE, 1993, MOL GENETICS BIOL RH, P155; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLDEN MJ, 1988, FEBS LETT, V241, P105, DOI 10.1016/0014-5793(88)81040-8; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; JACKLET JW, 1980, J EXP BIOL, V84, P1; JACKLET JW, 1977, SCIENCE, V198, P69, DOI 10.1126/science.897685; KENNEDY TE, 1988, P NATL ACAD SCI USA, V85, P7008, DOI 10.1073/pnas.85.18.7008; KHALSA S B S, 1990, Society for Neuroscience Abstracts, V16, P640; KHALSA SBS, 1990, BRAIN RES, V520, P166, DOI 10.1016/0006-8993(90)91702-I; KHALSA SBS, 1992, P NATL ACAD SCI USA, V89, P10862, DOI 10.1073/pnas.89.22.10862; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KOUMENIS C, 1992, CHRONOBIOL INT, V3, P201; KUHL D, 1992, J CELL BIOL, V119, P1069, DOI 10.1083/jcb.119.5.1069; LANGER T, 1994, BIOL HEAT SHOCK PROT, P53; LEE AS, 1984, J BIOL CHEM, V259, P4616; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEEE AS, 1992, CURR OPIN CELL BIOL, V4, P267; LIU MY, 1992, J BIOENERG BIOMEMBR, V24, P41, DOI 10.1007/BF00769529; LOOMIS WF, 1982, MOL CELL BIOL, V3, P1540; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; NOVER L, 1984, EUR J BIOCHEM, V139, P302; NOVER L, 1991, HEAT SHOCK RESPONSE, P5; OHI K, 1991, Society for Neuroscience Abstracts, V17, P675; PAGE TL, 1994, SCIENCE, V263, P1570, DOI 10.1126/science.8128243; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; RAJU U, 1990, AM J PHYSIOL, V258, pR256, DOI 10.1152/ajpregu.1990.258.1.R256; RAJU U, 1994, J NEUROCHEM, V61, P1236; RENSING L, 1987, CHRONOBIOL INT, V4, P543, DOI 10.3109/07420528709078546; RENSING L, 1990, CHRONOBIOL INT, V7, P353, DOI 10.3109/07420529009059146; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; ROTHMAN BS, 1976, J GEN PHYSIOL, V68, P359, DOI 10.1085/jgp.68.4.359; TAKAGI N, 1989, B SOC SEA WATER SCI, V42, P279; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275; UEUNG SJ, 1987, P NATL ACAD SCI USA, V84, P279; VONGROMOFF ED, 1989, MOL CELL BIOL, V9, P3911, DOI 10.1128/MCB.9.9.3911; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; YEUNG SJ, 1988, J BIOL RHYTHM, V3, P225, DOI 10.1177/074873048800300301; ZIZI M, 1994, J BIOL CHEM, V269, P1614; [No title captured]	70	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14619	14627		10.1074/jbc.270.24.14619	http://dx.doi.org/10.1074/jbc.270.24.14619			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782325	hybrid			2022-12-25	WOS:A1995RD45500059
J	PERNIS, A; GUPTA, S; YOPP, J; GARFEIN, E; KASHLEVA, H; SCHINDLER, C; ROTHMAN, P				PERNIS, A; GUPTA, S; YOPP, J; GARFEIN, E; KASHLEVA, H; SCHINDLER, C; ROTHMAN, P			GAMMA-CHAIN-ASSOCIATED CYTOKINE RECEPTORS SIGNAL THROUGH DISTINCT TRANSDUCING FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; INTERLEUKIN-7 RECEPTOR; FUNCTIONAL COMPONENT; TRANSCRIPTION FACTOR; PHOSPHORYLATION; CELLS; BINDING; ACTIVATION; PATHWAY; JAK2	The IL-2, IL-4, and IL-7 signaling pathways have been shown to utilize shared components. The receptors for these cytokines are composed of ligand-specific binding chains that associate with a shared signaling subunit, the common gamma (gamma(c)) chain. In addition, IL-2, IL-4, and IL-7 induce activation of a common set of nonreceptor tyrosine kinases, Jak-1 and Jak-3. We have further investigated the signaling events induced by these cytokines and find that the gamma(c)-associated receptors activate distinct signal transducing factors (STFs). In addition, we show that a 94-kDa STAT-related protein (p94) is activated in response to IL-2 and IL-7, but not IL-4. These data indicate that IL-2, IL-4, and IL-7 activate distinct signaling molecules which might be differentially recruited to the receptor complex by the ligand-specific units of the IL-2, IL-4, and IL-7 receptors.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University					NATIONAL CANCER INSTITUTE [T32CA009503] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033450, R01AI033450] Funding Source: NIH RePORTER; NCI NIH HHS [T 32CA09503] Funding Source: Medline; NHLBI NIH HHS [HL 21006-17] Funding Source: Medline; NIAID NIH HHS [AI 33450-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1994, CELL, V77, P68; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EILERS A, 1993, MOL CELL BIOL, V13, P3245, DOI 10.1128/MCB.13.6.3245; FOURCIN M, 1994, EUR J IMMUNOL, V24, P277, DOI 10.1002/eji.1830240143; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITAMURA T, 1994, TRENDS ENDOCRIN MET, V5, P8, DOI 10.1016/1043-2760(94)90115-5; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOHLER I, 1994, FEBS LETT, V345, P187, DOI 10.1016/0014-5793(94)00438-2; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NISHIMOTO N, 1994, J EXP MED, V179, P1343, DOI 10.1084/jem.179.4.1343; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SATO N, 1994, CURR OPIN CELL BIOL, V6, P174, DOI 10.1016/0955-0674(94)90133-3; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SMITH RK, 1992, MOL CELL BIOL, V12, P1578, DOI 10.1128/MCB.12.4.1578; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P6323, DOI 10.1073/pnas.88.14.6323; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	53	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14517	14522		10.1074/jbc.270.24.14517	http://dx.doi.org/10.1074/jbc.270.24.14517			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782314	hybrid			2022-12-25	WOS:A1995RD45500045
J	KOUHARA, H; KUREBAYASHI, S; HASHIMOTO, K; KASAYAMA, S; KOGA, M; KISHIMOTO, T; SATO, B				KOUHARA, H; KUREBAYASHI, S; HASHIMOTO, K; KASAYAMA, S; KOGA, M; KISHIMOTO, T; SATO, B			LIGAND-INDEPENDENT ACTIVATION OF TYROSINE KINASE IN FIBROBLAST GROWTH-FACTOR RECEPTOR-1 BY FUSION WITH BETA-GALACTOSIDASE	ONCOGENE			English	Article						FIBROBLAST GROWTH FACTOR RECEPTOR 1; TETRAMERIZATION; TYROSINE KINASE; TRANSFORMATION	FGF RECEPTOR; POINT MUTATION; MITOGENIC ACTIVITY; CODING SEQUENCE; CELLS; EXPRESSION; GENE; IDENTIFICATION; BINDING; CANCER	To examine the biological role of fibroblast growth factor receptor 1 (FGFR1) oligomerization far its signal transduction, we construct an expression vector encoding a FGFR1-beta-galactosidase fusion protein, This vector is designed to fuse the 3'-portion of FGPR1 to beta-galactosidase. Transfection of this vector into FGFR-negative rat L6 myoblast cells results in ligand-indpendent inhibition of differentiation into myocytes, suggesting that FGFR1 within this fusion protein is constitutively activated, This can be confirmed by demonstrating that this fusion protein exhibits the tyrosine kinase activity and phaspholipase C-gamma I is tyrosine-phosphorylated even in the absence of ligand stimuli, Since the transfected cells also exhibit the enzyme activity of beta-galactosidase which is known to be active only in a tetramer form, this constitutive activation can be elicited by tetramerization of FGFR1, Furthermore, deletion of a region corresponding to C terminal 10 amino acids important for tetramerization of beta-galactosidase from this expression vector abolishes the constitutively active nature of FGFR1 with simultaneous loss of P-galactosidase activity, Transfection of non-deleted expression vector into NIH3T3 cells results in acquisition of focus-forming activity while a deleted form of expression vector fails to show this activity even in the presence of basic FGF, These results would suggest that tetramerization of FGFR1 can produce a constitutively active form responsible for transformation of NIH3T3 cells.	OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN	Osaka University			Kishimoto, Tadamitsu/C-8470-2009					AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; FOWLER AV, 1966, SCIENCE, V25, P1027; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAHN CR, 1978, P NATL ACAD SCI USA, V75, P4209, DOI 10.1073/pnas.75.9.4209; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KOUHARA H, 1994, ONCOGENE, V9, P455; KOUHARA H, 1991, BIOCHEM BIOPH RES CO, V176, P31, DOI 10.1016/0006-291X(91)90885-B; LI YH, 1992, J CLIN ENDOCR METAB, V75, P1436, DOI 10.1210/jc.75.6.1436; MARICS I, 1989, ONCOGENE, V4, P335; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; NONOMURA N, 1990, CANCER RES, V50, P2316; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; POON B, 1991, P NATL ACAD SCI USA, V88, P877, DOI 10.1073/pnas.88.3.877; RODRIGUES CA, 1994, CURR OPIN GENE DEV, V4, P15; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SAMBROOK L, 1989, MOL CLONING, V16, P66; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	35	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2315	2322						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784079				2022-12-25	WOS:A1995RE54300006
J	XIE, YM; LI, KY; HUNG, MC				XIE, YM; LI, KY; HUNG, MC			TYROSINE PHOSPHORYLATION OF SHC PROTEINS AND FORMATION OF SHC/GRB2 COMPLEX CORRELATE TO THE TRANSFORMATION OF NIH3T3 CELLS MEDIATED BY THE POINT-MUTATION ACTIVATED NEU	ONCOGENE			English	Note						SHC; GRB2; P185(NEU); TYROSINE PHOSPHORYLATION; TRANSFORMATION	GROWTH-FACTOR RECEPTOR; ONCOGENIC ACTIVATION; SIGNAL TRANSDUCTION; 3T3 CELLS; GENE; KINASE; DOMAIN	PLC-gamma, ras-GAP and She have been proposed to be in vivo substrates for the nea-encoded p185(neu) receptor tyrosine kinases. We compared the tyrosine phosphorylation levels of PLC-gamma, ras-GAP and She in two NIH3T3 derived cell lines, transformed B104-1-1 and non-transformed DHFR/G8 cells in which point-mutation activated and normal rat nea genes were transfected and expressed, respectively. We found that tyrosine phosphorylation of She and formation of Shc/ Grb2 complex were more significant in B104-1-1 cells than in DHFR/G8 cells, while no obvious difference could be detected for the tyrosine phosphorylation levels of ras-GAP and PLC-gamma between these two cell lines. Furthermore, we observed that association with She was severely impaired by deletion of most of the major autophosphorylation sites of the point-mutated neu. The truncated nea product, however, fully retained its ability to transform NIH3T3 cells, induce She tyrosine phosphorylation and Shc/Grb2 complex formation. Our results suggest that tyrosine phosphorylation of She which allows formation of Shc/Grb2 complex may play an important role for cell transformation induced by the point mutation-activated neu, and that stable binding to mutant p185(neu) may not be necessary for She to mediate this signaling pathway.	UNIV TEXAS, MD ANDERSON CANCER CTR, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JANES PW, 1994, ONCOGENE, V9, P3601; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SEGATTO O, 1993, ONCOGENE, V8, P2105; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1993, MOL CARCINOGEN, V7, P44, DOI 10.1002/mc.2940070108; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	24	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2409	2413						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784091				2022-12-25	WOS:A1995RE54300018
J	EAKLE, KA; LYU, RM; FARLEY, RA				EAKLE, KA; LYU, RM; FARLEY, RA			THE INFLUENCE OF BETA-SUBUNIT STRUCTURE ON THE INTERACTION OF NA+/K+-ATPASE COMPLEXES WITH NA+ - A CHIMERIC BETA-SUBUNIT REDUCES THE NA+ DEPENDENCE OF PHOSPHOENZYME FORMATION FROM ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; CONFERS OUABAIN RESISTANCE; TISSUE-SPECIFIC EXPRESSION; (NA++K+)-ACTIVATED ATPASE; CATION OCCLUSION; NA,K PUMP; NA+,K+-ATPASE; (NA++K+)-ATPASE; H,K-ATPASE; SODIUM	High-affinity ouabain binding to Na+/K+-ATPase (sodium- and potassium-transport adenosine triphosphatase (EC 3.6.1.37)) requires phosphorylation of the alpha subunit of the enzyme either by ATP or by inorganic phosphate, For the native enzyme (alpha/beta 1), the ATP-dependent reaction proceeds about 4-fold more slowly in the absence of Na+ than when saturating concentrations of Na+ are present, Hybrid pumps were formed from either the alpha 1 or the alpha 3 subunit isoforms of Na+/K+-ATPase and a chimeric beta subunit containing the transmembrane segment of the Na+/K+-ATPase beta 1 isoform and the external domain of the gastric H+/R(+)-ATPase beta subunit (alpha/NH beta 1 complexes), In the absence of Na+, these complexes show a rate of ATP-dependent ouabain binding from similar to 75-100% of the rate seen in the presence of Na+ depending on buffer conditions, Nonhydrolyzable nucleotides or treatment of ATP with apyrase abolishes ouabain binding, demonstrating that ouabain binding to alpha/NH beta 1 complexes requires phosphorylation of the protein, Buffer ions inhibit ouabain binding by alpha/NH beta 1 in the absence of Na+ rather than promote ouabain binding, indicating that they are not substituting for sodium ions in the phosphorylation reaction, The pH dependence of ATP-dependent ouabain binding in the presence or absence of Na+ is similar, suggesting that protons are probably not substituting for Na+, Hybrid alpha/NH beta 1 pumps also show slightly higher apparent affinities (2-3-fold) for ATP, Na+, and ouabain; however, these are not sufficient to account for the increase in ouabain binding in the absence of Na+. In contrast to phosphoenzyme formation and ouabain binding by alpha/NH beta 1 complexes in the absence of Na+. ATPase activity, measured as release of phosphate from ATP, requires Na+. These data suggest that the transition from E(1)P to E(2)P during the catalytic cycle does not occur when the sodium binding sites are not occupied, Thus, the chimeric beta subunit reduces or eliminates the role of Na+ in phosphoenzyme formation from ATP, but Na+ binding or release by the enzyme is still required for ATP hydrolysis and release of phosphate.	UNIV SO CALIF, SCH MED, DEPT BIOCHEM, LOS ANGELES, CA 90033 USA	University of Southern California	EAKLE, KA (corresponding author), UNIV SO CALIF, SCH MED, DEPT PHYSIOL & BIOPHYS, 2025 ZONAL AVE, LOS ANGELES, CA 90033 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028673] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28673] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS RW, 1968, MOL PHARMACOL, V4, P325; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CANTLEY LC, 1981, CURR TOP BIOENERG, V11, P201; CHARNOCK JS, 1963, NATURE, V199, P910, DOI 10.1038/199910a0; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P834; EAKLEKA, 1991, SODIUM PUMP RECENT D, P125; FALLOWS D, 1987, MOL CELL BIOL, V7, P2985, DOI 10.1128/MCB.7.8.2985; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; FORBUSH B, 1991, SOC GEN PHY, V46, P211; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GEERING K, 1987, J CELL BIOL, V105, P2613, DOI 10.1083/jcb.105.6.2613; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; HARA Y, 1986, J BIOL CHEM, V261, P2655; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; HOOTMAN SR, 1988, METHOD ENZYMOL, V156, P213; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; NOGUCHI S, 1988, BIOCHEM BIOPH RES CO, V155, P1237, DOI 10.1016/S0006-291X(88)81272-5; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; NORBY JG, 1983, J GEN PHYSIOL, V82, P725, DOI 10.1085/jgp.82.6.725; POLVANI C, 1988, J BIOL CHEM, V263, P16757; POST RL, 1965, J BIOL CHEM, V240, P1437; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; Sherman F, 1979, METHODS YEAST GENETI; SHULL GE, 1990, J BIOL CHEM, V265, P12123; STEKHOVEN FMAHS, 1986, BIOCHIM BIOPHYS ACTA, V854, P21; STEKHOVEN FMAHS, 1985, BIOCHIM BIOPHYS ACTA, V815, P16, DOI 10.1016/0005-2736(85)90468-7; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; YODA S, 1987, J BIOL CHEM, V262, P103	49	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13937	13947		10.1074/jbc.270.23.13937	http://dx.doi.org/10.1074/jbc.270.23.13937			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775454	hybrid			2022-12-25	WOS:A1995RC44800053
J	LARSSON, N; MELANDER, H; MARKLUND, U; OSTERMAN, O; GULLBERG, M				LARSSON, N; MELANDER, H; MARKLUND, U; OSTERMAN, O; GULLBERG, M			G2/M TRANSITION REQUIRES MULTISITE PHOSPHORYLATION OF ONCOPROTEIN-18 BY 2 DISTINCT PROTEIN-KINASE SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING PHOSPHOPROTEIN P19; LEUKEMIA-ASSOCIATED GENE; MASS-SPECTROMETRY; EXPRESSION; CELLS; IDENTIFICATION; ACTIVATION; LYMPHOCYTES; STATHMIN; SITES	Oncoprotein 18 (Op18) is a conserved cytosolic protein that is a target for both cell cycle and cell surface receptor-regulated phosphorylation events, The four residues Ser(16), Ser(25), Ser(38), and Ser(63) are all subject to cell cycle-regulated phosphorylation, Ser(25) and Ser(38) are targets for cyclin dependent kinases (CDKs), while Ser(16) and Ser(63) are phosphorylated by an unidentified protein kinase, We have recently shown that induced expression of a CDK target site deficient mutant, Op18-S25A,S38A, blocks human cell lines during G2/M transition, In the present report we show that mitosis is associated with complete phosphorylation of the two Op18 CDK target sites Ser(25) and Ser(38) and that Ser(16) and Ser(63) are also phosphorylated to a high stoichiometry, To evaluate the function of multisite phosphorylation of Op18, we expressed and analyzed the cell cycle phenotype of different kinase target site-deficient mutants. The data showed that induced expression of the S16A,S63A, S25A,S38A, and S16A,S25A,S38A,S63A mutants all resulted in an indistinguishable phenotype, i.e. immediate G2/M block and subsequent endoreduplication, a given fraction of G2 versus M-phase blocked cells, and a characteristic nuclear morphology of M-blocked cells, This result was unexpected; however, a likely explanation was provided by analysis of Op18 phosphoisomers, which revealed that mutations of the CDK sites interfere with phosphorylation of Ser(16) and Ser(63). The simplest interpretation of our results is that phosphorylation of Ser(16) and Ser(63) is essential during G2/M transition and that the phenotype of the S25A,S38A mutant is mediated by the observed block of Ser(16)/Ser(63) phosphorylation.	UMEA UNIV,DEPT CELL & MOLEC BIOL,S-90187 UMEA,SWEDEN	Umea University				Gullberg, Martin/0000-0002-3984-4572				BERETTA L, 1993, J BIOL CHEM, V268, P20076; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; COOPER HL, 1991, J IMMUNOL, V146, P3689; DOYE V, 1989, J BIOL CHEM, V264, P12134; DOYE V, 1990, J BIOL CHEM, V265, P11650; DRAETTA DF, 1994, CURR OPIN CELL BIOL, V6, P842; FRIEDRICH B, 1995, IN PRESS PROSTATE; GHOSH PK, 1993, ONCOGENE, V8, P2869; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; Hunt T, 1991, Semin Cell Biol, V2, P213; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LUO KX, 1991, METHOD ENZYMOL, V201, P149; LUO XN, 1994, J BIOL CHEM, V269, P10312; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; MELHEM RF, 1991, J BIOL CHEM, V266, P17747; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OKAZAKI T, 1993, FEBS LETT, V336, P8, DOI 10.1016/0014-5793(93)81598-T; RASMUSSEN C, 1994, MOL BIOL CELL, V5, P785, DOI 10.1091/mbc.5.7.785; ROOS G, 1993, LEUKEMIA, V7, P1538; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; WANG YK, 1993, J BIOL CHEM, V268, P14269; ZHU XX, 1989, J BIOL CHEM, V264, P14556	38	101	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14175	14183		10.1074/jbc.270.23.14175	http://dx.doi.org/10.1074/jbc.270.23.14175			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775478	hybrid			2022-12-25	WOS:A1995RC44800085
J	CASTUMA, CE; HUANG, RP; KORNBERG, A; REUSCH, RN				CASTUMA, CE; HUANG, RP; KORNBERG, A; REUSCH, RN			INORGANIC POLYPHOSPHATES IN THE ACQUISITION OF COMPETENCE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY-BETA-HYDROXYBUTYRATE; MEMBRANE-STRUCTURE; PLASMA-MEMBRANES; TRANSFORMATION; COMPLEXES; PROTEIN; KINASE; GENE	A complex of polyhydroxybutyrate (PHB), Ca2+, and inorganic polysulphate (polyP) was proposed as the membrane component responsible for competence for DNA entry in Escherichia coli (Reusch, R.N., ans Sadoff, H.L. (1988) Proc. Natl. Acad. Sci. USA 85, 4176-4180). While chemical and immunological assays and 1H NMR have unequivocally established the identity and content of PHB in the complex, comparable methods were not available for polyP. With specific enzyme assays developed for polyP, we have identified, in chloroform extracts of competent cell membranes, a novel form of polyP of about 60 to 70 residues in a stoichiometric ratio of PHB to polyP of 2:1. In E-coli mutants, incapable of synthesizing the predominant, thousand-long polyP chains, appearance of this short polyP and its inclusion in membranes can account for their capacity to develop competence and indicates an auxiliary pathway for polyP synthesis. A variety of fluorescent lipid probes demonstrate the appearance of extensive rigid domains in membranes of competent cell. We propose that the PHB.Ca2+.polyP complex perturbs the conformation of the lipid matrix, making it more permeable to charged molecules and thus allowing the entry of DNA.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824	Stanford University; Michigan State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033375, R01GM007581, R37GM007581] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33375, GM-07581] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1993, J BIOL CHEM, V268, P633; AKIYAMA M, 1992, J BIOL CHEM, V267, P22556; CALVIN NM, 1988, J BACTERIOL, V170, P2796, DOI 10.1128/jb.170.6.2796-2801.1988; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; CLARK JE, 1987, ANAL BIOCHEM, V161, P280, DOI 10.1016/0003-2697(87)90452-0; CORNIBERT J, 1971, MACROMOLECULES, V3, P741; CROOKE E, 1994, J BIOL CHEM, V269, P6290; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; KORNBERG A, 1994, PHOSPHATE IN MICROORGANISMS, P204; KULAEV IS, 1983, ADV MICROB PHYSIOL, V24, P83, DOI 10.1016/S0065-2911(08)60385-9; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; REUSCH R, 1987, CAN J MICROBIOL, V33, P435, DOI 10.1139/m87-073; REUSCH RN, 1992, BIOCHIM BIOPHYS ACTA, V1123, P33, DOI 10.1016/0005-2760(92)90168-U; REUSCH RN, 1989, P SOC EXP BIOL MED, V191, P377; REUSCH RN, 1983, J BACTERIOL, V156, P778, DOI 10.1128/JB.156.2.778-788.1983; REUSCH RN, 1988, P NATL ACAD SCI USA, V85, P4176, DOI 10.1073/pnas.85.12.4176; REUSCH RN, 1986, J BACTERIOL, V168, P553, DOI 10.1128/jb.168.2.553-562.1986; REUSCH RN, 1992, FEMS MICROBIOL LETT, V103, P119, DOI 10.1016/0378-1097(92)90301-4; SEEBACH D, 1994, EUR J BIOCHEM, V224, P317, DOI 10.1111/j.1432-1033.1994.00317.x; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; SKLAR LA, 1980, MOL CELL BIOCHEM, V32, P169; SMITH M, 1990, FOCUS, V12, P38; WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235, DOI 10.1146/annurev.bi.57.070188.001315; WURST H, 1994, J BIOL CHEM, V269, P10996	26	82	93	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					12980	12983		10.1074/jbc.270.22.12980	http://dx.doi.org/10.1074/jbc.270.22.12980			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768888	hybrid			2022-12-25	WOS:A1995RB43900009
J	DIECI, G; DUIMIO, L; PERACCHIA, G; OTTONELLO, S				DIECI, G; DUIMIO, L; PERACCHIA, G; OTTONELLO, S			SELECTIVE INACTIVATION OF 2 COMPONENTS OF THE MULTIPROTEIN TRANSCRIPTION FACTOR TFIIIB IN CYCLOHEXIMIDE GROWTH-ARRESTED YEAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-III; TATA-BINDING PROTEIN; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; GENES; SEQUENCES; LOOP; 5S	Following protein synthesis inhibition in cycloheximide growth-arrested yeast cells, the rates of tRNA and 5 S RNA synthesis decrease with apparent half-times of about 20 and 10 min, respectively. This effect is mimicked by extracts of treated cells, and the impairment of tRNA gene transcription activity that is observed in vitro parallels the in vivo inactivation of RNA polymerase III transcription. As revealed by experiments in which partially purified class III transcription factors were singly added to extracts of treated cells, only the activity of the multiprotein transcription factor TFIIIB is severely impaired after 3 h of cycloheximide treatment. Similar assays carried out in an in vitro transcription system in which TFIIIB activity was reconstituted by a combination of the TATA box-binding protein (TBP), the 70-kDa component TFIIIB70, plus a partially purified fraction known as B '' have shown that the latter two components are both necessary and sufficient to restore control levels of transcription. Their activity, but not TBP activity, is considerably reduced in extracts of treated cells. TFIIIB70 and a component of fraction B '' thus appear to be the selective targets of the down-regulation of polymerase ill transcription that is brought about by cycloheximide. A substantial depletion of the TFIIIB70 polypeptide was detected by Western immunoblot analysis of extracts derived from cycloheximide growth-arrested cells, indicating that the inactivation of this TFIIIB component results primarily from its enhanced destabilization under conditions of protein synthesis inhibition.	UNIV PARMA, INST BIOCHEM SCI, I-43100 PARMA, ITALY	University of Parma			Dieci, Giorgio/B-3434-2012	Dieci, Giorgio/0000-0002-8792-3961				ABELSON HT, 1974, CELL, V1, P161, DOI 10.1016/0092-8674(74)90107-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROW DA, 1987, J BIOL CHEM, V262, P13953; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; Burton N, 1991, Protein Expr Purif, V2, P432, DOI 10.1016/1046-5928(91)90105-R; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DEKLOET SR, 1966, BIOCHEM J, V99, P566, DOI 10.1042/bj0990566; DELEON AL, 1992, CELL, V71, P211; DIECI G, 1993, J BIOL CHEM, V268, P11199; GARBER ME, 1994, MOL CELL BIOL, V14, P339, DOI 10.1128/MCB.14.1.339; GOKAL PK, 1986, J BIOL CHEM, V261, P2536; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; GROSS KJ, 1974, J BIOL CHEM, V249, P568; HARLOW E, 1988, ANTIBODIES LABORATOR; HUET J, 1994, NUCLEIC ACIDS RES, V22, P2282, DOI 10.1093/nar/22.12.2282; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEIGEBORN L, 1990, NUCLEIC ACIDS RES, V18, P4179, DOI 10.1093/nar/18.14.4179; OTTONELLO S, 1994, BIOCHEM BIOPH RES CO, V203, P1217, DOI 10.1006/bbrc.1994.2312; PHILIPPSEN P, 1978, J MOL BIOL, V123, P387, DOI 10.1016/0022-2836(78)90086-4; POON D, 1993, J BIOL CHEM, V268, P15325; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHULMAN RW, 1977, J BIOL CHEM, V252, P1344; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; SULLIVAN HS, 1994, MOL CELL BIOL, V14, P1806, DOI 10.1128/MCB.14.3.1806; TOWER J, 1988, MOL CELL BIOL, V8, P1001, DOI 10.1128/MCB.8.2.1001; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1994, RNA POLYMERASE 3 TRA, P1; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; WISE JA, 1991, METHOD ENZYMOL, V194, P405	40	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13476	13482		10.1074/jbc.270.22.13476	http://dx.doi.org/10.1074/jbc.270.22.13476			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768951	hybrid			2022-12-25	WOS:A1995RB43900077
J	GRAY, DA; INAZAWA, J; GUPTA, K; WONG, A; UEDA, R; TAKAHASHI, T				GRAY, DA; INAZAWA, J; GUPTA, K; WONG, A; UEDA, R; TAKAHASHI, T			ELEVATED EXPRESSION OF UNPH, A PROTOONCOGENE AT 3P21.3, IN HUMAN LUNG-TUMORS	ONCOGENE			English	Article						UBIQUITIN PROTEASE; 3P21; LUNG CANCER	CANCER CELL-LINES; TRE ONCOGENE; GENE FAMILY; DELETION; REGION; HETEROZYGOSITY; CHROMOSOME-17; HYBRIDIZATION; CLONING; MARKERS	The murine Unp proto-oncogene encodes a nuclear ubiquitin protease whose overexpression leads to oncogenic transformation of NIH3T3 cells. We have cloned cDNAs originating from the human homolog of this gene, designated herein as Unph (Unp, human), and have used these cDNAs to map the gene to 3p21.3, a region frequently rearranged in human tumor cells. Unph mRNA levels are consistently elevated in small cell tumors and adenocarcinomas of the lung, suggesting a possible causative role for the gene in the neoplastic process.	UNIV OTTAWA,DEPT MED,OTTAWA,ON K1H 8M5,CANADA; UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1H 8M5,CANADA; KYOTO PREFECTURAL UNIV MED,DEPT HYG,KAMIGYO KU,KYOTO 602,JAPAN; AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	University of Ottawa; University of Ottawa; Kyoto Prefectural University of Medicine; Aichi Cancer Center	GRAY, DA (corresponding author), OTTAWA REG CANC CTR,501 SMYTH RD,OTTAWA,ON K1H 8L6,CANADA.		Takahashi, Takashi/I-7262-2014; /U-3554-2018	Takahashi, Takashi/0000-0003-0615-7001; /0000-0002-8634-4984				ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; BAKER RT, 1992, J BIOL CHEM, V267, P23364; CHEN LC, 1994, CANCER RES, V54, P3021; DALY MC, 1993, ONCOGENE, V8, P1721; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V553, P205; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1994, ONCOGENE, V9, P611; HIDA T, 1993, JPN J CLIN ONCOL, V23, P14; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PINES J, 1994, NATURE, V371, P742, DOI 10.1038/371742a0; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; SHKEDY D, 1994, FEBS LETT, V348, P126, DOI 10.1016/0014-5793(94)00582-6; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YUN K, 1993, CANCER RES, V53, P5166	27	94	100	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2179	2183						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784062				2022-12-25	WOS:A1995RB70300013
J	MARINCS, F; WHITE, DWR				MARINCS, F; WHITE, DWR			DIVERGENT TRANSCRIPTION AND A REMOTE OPERATOR PLAY A ROLE IN CONTROL OF EXPRESSION OF A NOPALINE CATABOLISM PROMOTER IN AGROBACTERIUM-TUMEFACIENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; DNA-TEMPLATE; TI PLASMIDS; GENE; PROTEIN; OPERON; INVIVO; FUSION	The nocP-nocR divergent gene arrangement of the nopaline catabolism (noc) operon of the Agrobacterium tumefaciens Ti plasmid pTiT37 was examined with respect to the expression of the nocP promoter. Under repressive conditions, i.e. in the absence of nopaline, four distinct levels of P-nocP expression were observed. The lowest level of expression, i.e. full repression, was detected in the presence of the NocR repressor, together with the remote noc operator and productive transcription from the divergent nocR promoter. The next level was observed in the absence of either the NocR protein or of the operator or of both. The third level was detected when abortive transcription from the nocR promoter occurred, irrespective of the presence or absence of the NocR protein. The highest level of P-nocP expression was observed in the absence of both productive transcription from P-nocR and the operator sequence, whether or not the NocR protein was present. Under inductive conditions, i.e. in the presence of nopaline, expression of P-nocP was activated if both the NocR protein and the operator were present. Absence of either NocR or the operator resulted in lack of inducibility of the nocP promoter. Transcription from the divergent nocR promoter had no influence on the activation of P-nocP. It was also found that the absence of the operator affected plasmid supercoiling in vivo. The results suggest that DNA topology has a role in the regulation of the nocP promoter.			MARINCS, F (corresponding author), AGRES,GRASSLANDS RES CTR,PLANT MOLEC GENET LAB,TENNENT DR,PRIVATE BAG 11008,PALMERSTON NORTH 5320,NEW ZEALAND.		Marincs, Ferenc/A-8562-2011	Marincs, Ferenc/0000-0002-5388-8344				AMOUYAL M, 1989, CELL, V58, P545, DOI 10.1016/0092-8674(89)90435-2; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BOWATER RP, 1994, EMBO J, V13, P5647, DOI 10.1002/j.1460-2075.1994.tb06903.x; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; CHEN DR, 1992, P NATL ACAD SCI USA, V89, P8784, DOI 10.1073/pnas.89.18.8784; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CONDEE CW, 1992, J BACTERIOL, V174, P8094, DOI 10.1128/JB.174.24.8094-8101.1992; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; FIGUEROA N, 1988, P NATL ACAD SCI USA, V85, P9416, DOI 10.1073/pnas.85.24.9416; GIAEVER GN, 1988, BIOPHYS CHEM, V29, P7, DOI 10.1016/0301-4622(88)87020-0; GOODRICH JA, 1991, TRENDS BIOCHEM SCI, V16, P394, DOI 10.1016/0968-0004(91)90162-O; IRANI MH, 1983, CELL, V32, P783, DOI 10.1016/0092-8674(83)90064-8; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; LEWIN B, 1990, GENES, V4, P257; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MARINCS F, 1993, MOL GEN GENET, V241, P65, DOI 10.1007/BF00280202; MARINCS F, 1994, MOL GEN GENET, V244, P367, DOI 10.1007/BF00286688; NORDHEIM A, 1982, COLD SPRING HARB SYM, V47, P93; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; ROSENBERG M, 1983, SCIENCE, V222, P734, DOI 10.1126/science.6356355; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS SE, 1990, NUCLEIC ACIDS RES, V18, P4948, DOI 10.1093/nar/18.16.4948; SCIAKY D, 1978, PLASMID, V1, P238, DOI 10.1016/0147-619X(78)90042-2; TAN JY, 1994, J BACTERIOL, V176, P1077, DOI 10.1128/JB.176.4.1077-1086.1994; THOMPSON RJ, 1990, BACTERIAL CHROMOSOME, P227; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; VANLAREBEKE N, 1977, MOL GEN GENET, V152, P119, DOI 10.1007/BF00268807; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259	31	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12339	12342		10.1074/jbc.270.21.12339	http://dx.doi.org/10.1074/jbc.270.21.12339			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759474	hybrid			2022-12-25	WOS:A1995QZ71100004
J	RAMAMOORTHY, R; SWIHART, KG; MCCOY, JJ; WILSON, ME; DONELSON, JE				RAMAMOORTHY, R; SWIHART, KG; MCCOY, JJ; WILSON, ME; DONELSON, JE			INTERGENIC REGIONS BETWEEN TANDEM GP63 GENES INFLUENCE THE DIFFERENTIAL EXPRESSION OF GP63 RNAS IN LEISHMANIA-CHAGASI PROMASTIGOTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA; TRYPANOSOMA-BRUCEI; DONOVANI-CHAGASI; SURFACE GLYCOPROTEIN; MAJOR PROMASTIGOTES; DNA TRANSFECTION; SITE SELECTION; PARP PROMOTER; HEAT-SHOCK	The major surface protease, gp63, of Leishmania chagasi is encoded by 18 or more tandem msp genes that can be grouped into three classes on the basis of their unique 3'-untranslated sequences (3'-UTRs) and their differential expression, RNAs from the mspLs occur predominantly during the logarithmic phase of promastigote growth in vitro, RNAs from the mspSs are present mainly in stationary phase, and RNAs from mspCs occur throughout growth in culture, All three classes of gp63 genes are constitutively transcribed during all growth phases, indicating that their expression is post-transcriptionally regulated, Chimeric plasmids containing the three different 3'-UTRs and downstream intergenic regions (IRs) fused downstream of the beta-galactosidase (beta-gal) coding region were transfected into L. chagasi, and their effects on beta-gal RNA processing and enzymatic activity were examined, The presence of the 3'-UTRs by themselves had no substantive effect on beta-gal expression, However, the 3'-UTR from a mspS plus its IR resulted in about 20-fold more beta-gal activity and RNA in stationary phase relative to logarithmic phase cells, In contrast, the 3'-UTRs plus IRs of mspL and mspC had either no or little effect, respectively, on beta-gal expression, Thus, differential expression of the mspLs and mspSs is post-transcriptionally controlled by different mechanisms.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,DEPT MICROBIOL,IOWA CITY,IA 52242; VET ADM MED CTR,IOWA CITY,IA; HOWARD HUGHES MED INST,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute			Donelson, John E/F-5795-2010	Wilson, Mary/0000-0001-8680-7275	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032135, R01AI032135, R29AI030126] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30126, AI32135] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORDIER C, 1986, P NATL ACAD SCI USA, V83, P5988, DOI 10.1073/pnas.83.16.5988; BORDIER C, 1987, PARASITOL TODAY, V3, P151, DOI 10.1016/0169-4758(87)90199-2; BRODIN TN, 1992, MOL BIOCHEM PARASIT, V52, P241, DOI 10.1016/0166-6851(92)90056-P; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; CHUNG SH, 1990, NUCLEIC ACIDS RES, V18, P4561, DOI 10.1093/nar/18.15.4561; Cleveland DW, 1989, CURR OPIN CELL BIOL, V1, P1148, DOI 10.1016/S0955-0674(89)80065-1; COBURN CM, 1991, MOL BIOCHEM PARASIT, V46, P169, DOI 10.1016/0166-6851(91)90210-W; COULSON RMR, 1990, MOL BIOCHEM PARASIT, V40, P63, DOI 10.1016/0166-6851(90)90080-6; DASILVA R, 1987, INFECT IMMUN, V55, P2802, DOI 10.1128/IAI.55.11.2802-2806.1987; ERONDU NE, 1991, MOL BIOCHEM PARASIT, V49, P303, DOI 10.1016/0166-6851(91)90074-G; FRANKE ED, 1985, J IMMUNOL, V134, P2713; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GONZALEZ A, 1985, NUCLEIC ACIDS RES, V13, P5789, DOI 10.1093/nar/13.16.5789; GOTTLIEB E, 1992, P NATL ACAD SCI USA, V89, P7164, DOI 10.1073/pnas.89.15.7164; HUANG J, 1991, MOL CELL BIOL, V11, P3180, DOI 10.1128/MCB.11.6.3180; HUANG J, 1991, EMBO J, V10, P3877, DOI 10.1002/j.1460-2075.1991.tb04957.x; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KAPOTAS N, 1993, NUCLEIC ACIDS RES, V21, P4067, DOI 10.1093/nar/21.17.4067; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LAYDEN RE, 1988, MOL CELL BIOL, V8, P1352, DOI 10.1128/MCB.8.3.1352; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; MALLINSON DJ, 1989, PARASITOLOGY, V98, P7, DOI 10.1017/S0031182000059631; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; PEARSON RD, 1980, J IMMUNOL, V125, P2195; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; ROBERTS SC, 1993, MOL BIOCHEM PARASIT, V62, P157, DOI 10.1016/0166-6851(93)90106-8; RUDENKO G, 1990, MOL CELL BIOL, V10, P3492, DOI 10.1128/MCB.10.7.3492; RUSSELL DG, 1989, IMMUNOL TODAY, V10, P328, DOI 10.1016/0167-5699(89)90188-6; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; WALDER JA, 1986, SCIENCE, V233, P569, DOI 10.1126/science.3523758; WILSON ME, 1988, J IMMUNOL, V141, P265; WILSON ME, 1989, J IMMUNOL, V143, P678; WILSON ME, 1993, J BIOL CHEM, V268, P15731; WONG S, 1993, MOL CELL BIOL, V13, P207, DOI 10.1128/MCB.13.1.207; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	41	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12133	12139		10.1074/jbc.270.20.12133	http://dx.doi.org/10.1074/jbc.270.20.12133			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744862	hybrid			2022-12-25	WOS:A1995QY73600065
J	CHAMBERS, RS; WANG, BQ; BURTON, ZF; DAHMUS, ME				CHAMBERS, RS; WANG, BQ; BURTON, ZF; DAHMUS, ME			THE ACTIVITY OF COOH-TERMINAL DOMAIN PHOSPHATASE IS REGULATED BY A DOCKING SITE ON RNA-POLYMERASE-II AND BY THE GENERAL TRANSCRIPTION FACTORS IIF AND IIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR; SUBUNIT-IIA; CALF THYMUS; PHOSPHORYLATION; PURIFICATION; PROTEIN; IDENTIFICATION; PROMOTER; KINASES; CLONING	Each cycle of transcription appears to be associated with the reversible phosphorylation of the repetitive COOH-terminal domain (CTD) of the largest RNA polymerase (RNAP) II subunit. The dephosphorylation of RNAP II by CTD phosphatase, therefore, plays an important role in the transcription cycle. The following studies characterize the activity of HeLa cell CTD phosphatase with a special emphasis on the regulation of CTD phosphatase activity. Results presented here suggest that RNAP II contains a docking site for CTD phosphatase that is essential in the dephosphorylation reaction and is distinct from the CTD. This is supported by the observations that (a) phosphorylated recombinant CTD is not a substrate for CTD phosphatase, (b) RNAP IIB, which lacks the CTD, and RNAP IIA are competitive inhibitors of CTD phosphatase and (c) CTD phosphatase can form a stable complex with RNAP II. To test the possibility that the general transcription factors may be involved in the regulation of CTD phosphatase, CTD phosphatase activity was examined in the presence of recombinant or highly purified general transcription factors. TFIIF stimulates CTD phosphatase activity 5-fold. The RAP74 subunit of TFIIF alone contained the stimulatory activity and the minimal region sufficient for stimulation corresponds to COOH-terminal residues 358-517. TFIIB inhibits the stimulatory activity of TFIIF but has no effect on CTD phosphatase activity in the absence of TFIIF. The potential importance of the docking site on RNAP II and the effect of TFIIF and TFIIB in regulating the dephosphorylation of RNAP II at specific times in the transcription cycle are discussed.	UNIV CALIF DAVIS,DIV BIOL SCI,SECT MOLEC & CELLULAR BIOL,DAVIS,CA 95616; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	University of California System; University of California Davis; Michigan State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300, R01GM040708] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33300, GM40708] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DAHMUS ME, 1981, J BIOL CHEM, V256, P1239; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FINKELSTEIN A, 1972, NATURE, V355, P464; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KANG ME, 1993, J BIOL CHEM, V68, P25033; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LU H, 1991, P NATL ACAD SCI USA, V8, P10004; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PETERSON MG, 1991, NATURE, V354, P369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1994, TRANSCRIPTION MECHAN, P27; SERIZAWA H, 1992, P NATL ACAD SCI USA, V9, P7476; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TAN SY, 1994, J BIOL CHEM, V269, P25684; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	39	107	108	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14962	14969		10.1074/jbc.270.25.14962	http://dx.doi.org/10.1074/jbc.270.25.14962			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797476	hybrid			2022-12-25	WOS:A1995RE66600021
J	ABRAMS, CS; WU, H; ZHAO, W; BELMONTE, E; WHITE, D; BRASS, LF				ABRAMS, CS; WU, H; ZHAO, W; BELMONTE, E; WHITE, D; BRASS, LF			PLECKSTRIN INHIBITS PHOSPHOINOSITIDE HYDROLYSIS INITIATED BY G-PROTEIN-COUPLED AND GROWTH-FACTOR RECEPTORS - A ROLE FOR PLECKSTRINS PH DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; POLYMERASE CHAIN-REACTION; HUMAN-PLATELETS; SIGNALING PROTEINS; PHORBOL ESTER; FEEDBACK-REGULATION; MOLECULAR-CLONING; THROMBIN RECEPTOR; KINASE-C; PHOSPHORYLATION	Pleckstrin is a 40-kDa protein present in platelets and leukocytes that contains two PH domains separated by a 150-residue intervening sequence. Pleckstrin is a major substrate for protein kinase C, but its function is unknown. The present studies examine the effects of pleckstrin on second messenger generation. When expressed in cos-1 or HEK-293 cells, pleckstrin inhibited 1) the G(alpha)-mediated activation of phospholipase C-beta initiated by thrombin, M1-muscarinic acetylcholine, and angiotensin II receptors, 2) the stimulation of phospholipase C-beta by constitutively active G(q alpha), 3) the G(beta gamma)-mediated activation of phospholipase C-beta caused by alpha(2A)-adrenergic receptors, and 4) the tyrosine phosphorylation-media ted activation of phospholipase C-gamma caused by Trk A. However, pleckstrin had no effect on either the stimulation or inhibition of adenylyl cyclase, The inhibition of phosphoinositide hydrolysis caused by pleckstrin was similar in magnitude to that caused by activating protein kinase C with phorbol 12-myristate 13-acetate (PMA). When combined, pleckstrin and PMA had an additive effect, inhibiting phosphoinositide hydrolysis by as much as 90%, Structure-function analysis highlighted the role of pleckstrin's N-terminal PH domain in these events. Although deleting the C-terminal PH domain had no effect, deleting the N-terminal PH domain abolished activity (but not expression) and mutating a highly conserved tryptophan residue within the N-terminal PH domain decreased activity by one-third, Notably, however, a pleckstrin variant in which the N-terminal PH domain was replaced with a second copy of the C-terminal PH domain was nearly as active as native pleckstrin, These results show that: 1) pleckstrin can inhibit pathways leading to both phospholipase C-beta- and phospholipase C-gamma-mediated phosphoinositide hydrolysis, 2) this inhibition affects activation of phospholipase C-beta mediated by either G(alpha) or G(beta gamma) but does not affect the regulation of adenylyl cyclase activity by G(alpha) or G(beta gamma), 3) although pleckstrin is a substrate for protein kinase C, the effects of pleckstrin and PMA are at least partially independent, 4) the inhibition caused by pleckstrin appears to be mediated by the PH domain at the N terminus, rather than the C terminus of the molecule, and 5) location of the two PH domains within the molecule clearly contributes to their individual activity, These results do not appear to be readily attributable to an interaction between pleckstrin and G(beta gamma), but they are consistent with a recent report showing an association between PH domains and phosphatidylinositol 4,5-bisphosphate in vitro.	UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; VET ADM MED CTR,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, K11HL002464] Funding Source: NIH RePORTER; NHLBI NIH HHS [5K11 HL02464, P01 HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CONTRERAS ML, 1993, J NEUROCHEM, V61, P1035, DOI 10.1111/j.1471-4159.1993.tb03617.x; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GOLDSCHMIDTCLER.PJ, 1991, SCIENCE, V251, P1231; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1979, BIOCHEM J, V178, P397, DOI 10.1042/bj1780397; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HAWES BE, 1994, J BIOL CHEM, V269, P29825; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IMAOKA T, 1983, J BIOL CHEM, V258, P1404; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JENKINS AL, 1994, J BIOL CHEM, V269, P17104; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LIANG M, 1991, J BIOL CHEM, V266, P13342; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MORRIS JF, 1991, ONCOGENE, V6, P2339; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RITTENHOUSE SE, 1985, J BIOL CHEM, V260, P8657; RYU SH, 1990, J BIOL CHEM, V265, P17941; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; SHIMIZU H, 1969, J NEUROCHEM, V16, P1609, DOI 10.1111/j.1471-4159.1969.tb10360.x; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WANG DS, 1994, BIOCHEM BIOPH RES CO, V203, P29, DOI 10.1006/bbrc.1994.2144; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; YANG LJ, 1993, J BIOL CHEM, V268, P3739; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859	47	46	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14485	14492		10.1074/jbc.270.24.14485	http://dx.doi.org/10.1074/jbc.270.24.14485			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782310	hybrid			2022-12-25	WOS:A1995RD45500040
J	CABISCOL, E; LEVINE, RL				CABISCOL, E; LEVINE, RL			CARBONIC ANHYDRASE-III - OXIDATIVE MODIFICATION IN-VIVO AND LOSS OF PHOSPHATASE-ACTIVITY DURING AGING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID OXIDATION; S-THIOLATION; GLUTAMINE-SYNTHETASE; PROTEIN OXIDATION; HYDROGEN-PEROXIDE; RAT-LIVER; ISCHEMIA-REPERFUSION; CATALYZED OXIDATION; OXIDIZED PROTEINS; CREATINE-KINASE	Oxidative modification of DNA, lipids, and proteins occurs as a consequence of reaction with free radicals and activated oxygen. Oxidative modification of total cellular proteins has been described under many pathologic and experimental conditions, but no specific proteins have been identified as in vivo targets for oxidative modification. Utilizing an immunochemical method for detection of oxidatively modified proteins, we identified a protein in rat Liver that was highly oxidized. It was purified to homogeneity and identified as carbonic anhydrase, isozyme III. Its characteristics match those previously described for a protein that was lost during aging of the rat, senescence marker protein-1. Carbonic anhydrase III was purified from rats aged 2, 10, and 18 months, and the proteins were characterized. All three preparations were highly oxidatively modified as assessed by their carbonyl content. The enzyme has three known catalytic activities, and the specific activities for carbon dioxide hydration and for ester hydrolysis decreased during aging by similar to 30%. However, the third activity, that of a phosphatase, was virtually lost during aging. While the physiologic role of carbonic anhydrase III is unknown, we suggest that it functions in an oxidizing environment, which leads to its own oxidative modification.	NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Levine, Rodney L/D-9885-2011; Cabiscol, Elisa/A-4584-2009	Cabiscol, Elisa/0000-0003-2795-7999				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AYENE IS, 1993, ARCH BIOCHEM BIOPHYS, V303, P307, DOI 10.1006/abbi.1993.1288; BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BERLETT BS, 1984, P NATL ACAD SCI USA, V87, P398; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CHAI YC, 1991, ARCH BIOCHEM BIOPHYS, V284, P270, DOI 10.1016/0003-9861(91)90295-T; CHATTERJEE B, 1981, J BIOL CHEM, V256, P939; CLIMENT I, 1991, ARCH BIOCHEM BIOPHYS, V289, P371, DOI 10.1016/0003-9861(91)90425-I; COLLISON MW, 1987, BIOCHIM BIOPHYS ACTA, V928, P121, DOI 10.1016/0167-4889(87)90112-1; COLLISON MW, 1986, BIOCHIM BIOPHYS ACTA, V885, P58, DOI 10.1016/0167-4889(86)90038-8; ENGBERG P, 1985, ARCH BIOCHEM BIOPHYS, V241, P628, DOI 10.1016/0003-9861(85)90589-2; ERIKSSON AE, 1993, PROTEINS, V16, P29, DOI 10.1002/prot.340160104; GARLAND D, 1990, EXP EYE RES, V50, P677, DOI 10.1016/0014-4835(90)90113-9; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Jeffery S, 1991, CARBONIC ANHYDRASES, P289; KARSEKSTAPLES JA, 1993, FREE RADICAL BIO MED, V14, P115; KELLER RJ, 1993, CHEM RES TOXICOL, V6, P430, DOI 10.1021/tx00034a007; KELLY CD, 1988, BIOSCIENCE REP, V8, P401, DOI 10.1007/BF01121636; KIM KW, 1988, J BIOL CHEM, V263, P4704; KOESTER MK, 1981, ARCH BIOCHEM BIOPHYS, V211, P632, DOI 10.1016/0003-9861(81)90499-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LEVINE RL, 1982, BIOCHEMISTRY-US, V21, P2600, DOI 10.1021/bi00540a004; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; LII CK, 1994, ARCH BIOCHEM BIOPHYS, V308, P231, DOI 10.1006/abbi.1994.1033; LYNCH CJ, 1993, AM J PHYSIOL, V264, pE621, DOI 10.1152/ajpendo.1993.264.4.E621; MILLER RM, 1989, ARCH BIOCHEM BIOPHYS, V276, P355; OLIVER CN, 1987, ARCH BIOCHEM BIOPHYS, V253, P62, DOI 10.1016/0003-9861(87)90637-0; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; PARK EM, 1988, BIOCHIM BIOPHYS ACTA, V964, P151, DOI 10.1016/0304-4165(88)90161-4; PARK Y, 1991, FREE RADICAL RES COM, V14, P179, DOI 10.3109/10715769109088947; POSTON JM, 1992, ARCH BIOCHEM BIOPHYS, V295, P35, DOI 10.1016/0003-9861(92)90484-E; REDDY VY, 1994, J BIOL CHEM, V269, P4683; ROKUTAN K, 1989, EUR J BIOCHEM, V179, P233, DOI 10.1111/j.1432-1033.1989.tb14546.x; Rothstein M., 1984, P209; SHACTER E, 1994, FREE RADICAL BIO MED, V17, P429, DOI 10.1016/0891-5849(94)90169-4; SHIELS A, 1983, BIOCHIM BIOPHYS ACTA, V760, P335, DOI 10.1016/0304-4165(83)90370-7; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; SPICER SS, 1990, AM J ANAT, V187, P55, DOI 10.1002/aja.1001870107; STADTMAN ER, 1990, P NATL ACAD SCI USA, V87, P384, DOI 10.1073/pnas.87.1.384; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; Stadtman ER, 1994, OXIDATIVE PROCESSES, P117; STARKE PE, 1987, FASEB J, V1, P36, DOI 10.1096/fasebj.1.1.2886388; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Tashian RE, 1991, CARBONIC ANHYDRASES, P247, DOI DOI 10.1007/978-1-4899-0750-9_21; TASHIAN RE, 1990, BIOESSAYS, V10, P186; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERPOORTE JA, 1967, J BIOL CHEM, V242, P4221; WILBUR KM, 1948, J BIOL CHEM, V176, P147; YIM MB, 1990, P NATL ACAD SCI USA, V87, P394, DOI 10.1073/pnas.87.1.394; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; ZSNAGY I, 1984, BIOCHIM BIOPHYS ACTA, V790, P238, DOI 10.1016/0167-4838(84)90028-1; 1994, PROTEIN IDENTIFICATI	63	133	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14742	14747		10.1074/jbc.270.24.14742	http://dx.doi.org/10.1074/jbc.270.24.14742			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782339	Green Published, hybrid			2022-12-25	WOS:A1995RD45500076
J	GUERINI, D; SCHRODER, S; FOLETTI, D; CARAFOLI, E				GUERINI, D; SCHRODER, S; FOLETTI, D; CARAFOLI, E			ISOLATION AND CHARACTERIZATION OF A STABLE CHINESE-HAMSTER OVARY CELL-LINE OVEREXPRESSING THE PLASMA-MEMBRANE CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ PUMP; CALCIUM-PUMP; MOLECULAR CHARACTERIZATION; LIMITED PROTEOLYSIS; MESSENGER-RNAS; MUSCLE-CELLS; RAT-BRAIN; EXPRESSION; ATPASE; ISOFORMS	Stable Chinese hamster ovary (CHO) cell lines overexpressing the human plasma membrane Ca2+-ATPase (PMCA) were generated, and three independent cell clones were characterized in details. They ovel expressed high amounts of active PMCA pump (15-20 times over the amount of endogenous PMCA) as indicated by experiments in which the formation of the phosphoenzyme intermediate and the uptake of Ca2+ by microsomes were measured. Immunocytochemistry experiments coupled to the biotinylation of the pump in the intact cells indicated the correct delivery of the expressed pump to the plasma membrane. The expressed pump was purified by affinity chromatography on calmodulin sepharose. The PMCA of transfected CHO cells promoted an increase of Ca2+ into the medium, after induction of Ca2+ release from the internal stores by activation of a purinergic receptor. An evident decrease of the activity of the endogenous sarcoplasmic reticulum Ca2+-ATPase pump was observed, probably related to the down-regulation of its expression. The cells overexpressing the PMCA pump had delayed recovery after trypsinization and plating. Their doubling time was, however, the same as CHO cells.	ETH ZENTRUM,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND	ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; BLAUSTEIN MP, 1991, SODIUM CALCIUM EXCHA; BOBE R, 1994, J BIOL CHEM, V269, P1417; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BRANDT P, 1992, J BIOL CHEM, V267, P4376; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FESCHENKO MS, 1992, J BIOL CHEM, V267, P4097; GUTHEIL JC, 1994, J BIOL CHEM, V269, P7976; HEIM R, 1992, J BIOL CHEM, V267, P24476; HUSSAIN A, 1992, ARCH BIOCHEM BIOPHYS, V296, P539, DOI 10.1016/0003-9861(92)90608-Y; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; KEETON TP, 1993, J BIOL CHEM, V268, P2740; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRYL CR, 1981, ANAL BIOCHEM, V110, P680; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; Sambrook J, 1989, MOL CLONING LABORATO; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHATZMANN HJ, 1982, MEMBRANE TRANSPORT C, P41; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STOSSEL TP, 1993, SCIENCE, V250, P1086; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WRZOSEK A, 1992, CELL CALCIUM, V13, P281, DOI 10.1016/0143-4160(92)90063-X; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; ZVARITCH E, 1992, 8TH INT S CALC BIND	41	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14643	14650		10.1074/jbc.270.24.14643	http://dx.doi.org/10.1074/jbc.270.24.14643			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782327	hybrid			2022-12-25	WOS:A1995RD45500062
J	JAKOB, U; MEYER, I; BUGL, H; ANDRE, S; BARDWELL, JCA; BUCHNER, J				JAKOB, U; MEYER, I; BUGL, H; ANDRE, S; BARDWELL, JCA; BUCHNER, J			STRUCTURAL ORGANIZATION OF PROKARYOTIC AND EUKARYOTIC HSP90 - INFLUENCE OF DIVALENT-CATIONS ON STRUCTURE AND FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CONFORMATIONAL CHANGE; ESCHERICHIA-COLI; BINDING; QUANTITATION; PURIFICATION; RECEPTOR; KINASE; CELL	Hsp90 is a very abundant molecular chaperone that apparently helps to protect cellular proteins from denaturation upon temperature upshift. The unusual ability of Hsp90 to function under conditions where other proteins unfold prompted us to investigate the stability and structural organization of Hsp90 itself. Both procaryotic and eucaryotic members of the Hsp90 family were found to have very similar physicochemical properties: (i) they are stable against thermal unfolding up to at least 50 degrees C, (ii) they show biphasic, reversible unfolding transitions in guanidinium chloride, and (iii) their oligomerization state is strongly and rapidly affected by millimolar concentrations of divalent cations. In the presence of MnCl2 and MgCl2 defined changes in the quaternary structure of Hsp90 could be observed which resulted in a decrease in thermostability and an increased tendency to form larger aggregates. The addition of divalent cations also almost completely abolished the chaperone function of Hsp90 and induced release of folding intermediates of citrate synthase bound to Hsp90. These modulating effects of divalent cations on structure and function of Hsp90 in vitro represent a potential mechanism for regulation of Hsp90 chaperone action in vivo.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY	University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; KAWAHARA J, 1992, ANAL BIOCHEM, V201, P94, DOI 10.1016/0003-2697(92)90178-A; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LANKS KW, 1992, BIOCHEM BIOPH RES CO, V184, P394, DOI 10.1016/0006-291X(92)91206-6; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PAYOT P, 1975, EUR J BIOCHEM, V63, P263; PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515; RADANYI C, 1989, J BIOL CHEM, V264, P2568; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SPENCE J, 1989, J BIOL CHEM, V264, P4398; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WEST SM, 1990, BIOCHIM BIOPHYS ACTA, V1037, P332, DOI 10.1016/0167-4838(90)90034-D; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WIECH H, 1993, J BIOL CHEM, V268, P7414; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	35	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14412	14419		10.1074/jbc.270.24.14412	http://dx.doi.org/10.1074/jbc.270.24.14412			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782303	hybrid			2022-12-25	WOS:A1995RD45500030
J	MEYER, SC; FOX, JEB				MEYER, SC; FOX, JEB			INTERACTION OF PLATELET GLYCOPROTEIN-V WITH GLYCOPROTEIN-IB-IX REGULATES EXPRESSION OF THE GLYCOPROTEINS AND BINDING OF VON-WILLEBRAND-FACTOR TO GLYCOPROTEIN-IB-IX IN TRANSFECTED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; LEUCINE-RICH GLYCOPROTEINS; AMINO-ACID-SEQUENCE; PLASMA-MEMBRANE GLYCOPROTEINS; BERNARD-SOULIER PLATELETS; GEL-ELECTROPHORESIS; ALPHA-CHAIN; SHEAR RATE; GP-IB; COMPLEX	The goal of the present study was to determine whether platelet glycoprotein (GP) V interacts directly with the von Willebrand factor receptor GP Ib-IX and, if so, whether it affects the expression and function of this receptor. A melanoma cell line that does not contain actin-binding protein was transfected with the cDNAs coding for GP V and for each of the three subunits of GP Ib-IX. GP V co-immunoprecipitated and co-localized with GP Ib-IX. Although GP V could be expressed in the absence of GP Ib-IX, the amount incorporated in the membrane was markedly increased when GP Ib-IX was present. Similarly, there was an enhanced expression of GP Ib-IX on the cell surface in the presence of GP V. The binding affinity of botrocetin-induced von Willebrand factor to GP Ib-IX was unaffected by the presence or absence of GP V. However, the binding capacity was increased by the presence of GP V. We conclude that GP V interacts directly with GP Ib-IX, that GP V must associate with GP Ib-IX to be efficiently expressed in the membrane, and that GP V increases the binding capacity of the cells for von Willebrand factor by enhancing the surface expression of the GP Ib-IX complex.	CHILDRENS HOSP OAKLAND,RES INST,OAKLAND,CA 94609; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030657, R23HL030657, R01HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNDT MC, 1981, J BIOL CHEM, V256, P59; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BERNDT MC, 1984, PROG HEMOST THROMB, V7, P111; BERNDT MC, 1983, BLOOD, V62, P8500; Booth W J, 1990, Platelets, V1, P169, DOI 10.3109/09537109009005485; CHOW TW, 1992, BLOOD, V80, P113; CLEMETSON JM, 1994, BLOOD, V84, P1124; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; COLLER BS, 1983, BLOOD, V61, P99; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DU XP, 1987, BLOOD, V69, P1524; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FOX JEB, 1994, BLOOD COAGUL FIBRIN, V5, P291, DOI 10.1097/00001721-199404000-00020; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1988, J BIOL CHEM, V263, P4882; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANDA M, 1986, J BIOL CHEM, V261, P2579; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HICKEY MJ, 1993, P NATL ACAD SCI USA, V90, P8327, DOI 10.1073/pnas.90.18.8327; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZA F, 1993, J BIOL CHEM, V268, P20801; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1994, J BIOL CHEM, V269, P23716; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MEYER S, 1993, J BIOL CHEM, V268, P20555; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; MOSHER DF, 1979, BLOOD, V53, P437; NURDEN AT, 1981, J CLIN INVEST, V67, P1431, DOI 10.1172/JCI110172; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; PHILLIPS DR, 1977, BIOCHEM BIOPH RES CO, V75, P940, DOI 10.1016/0006-291X(77)91473-5; ROTH GJ, 1990, BIOCHEM BIOPH RES CO, V170, P153, DOI 10.1016/0006-291X(90)91253-O; ROTH GJ, 1991, BLOOD, V77, P5; SHIMOMURA T, 1990, BLOOD, V75, P2349; SIMSEK S, 1994, THROMB HAEMOSTASIS, V72, P444; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURITTO VT, 1977, ANN NY ACAD SCI, V283, P284, DOI 10.1111/j.1749-6632.1977.tb41775.x; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VICENTE V, 1990, J BIOL CHEM, V265, P274; VONDEMBORNE AEG, 1989, LEUCOCYTE TYPING, V4, P951; WEISS HJ, 1974, AM J MED, V57, P920, DOI 10.1016/0002-9343(74)90170-3; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x; WICKI AN, 1987, EUR J BIOCHEM, V163, P43, DOI 10.1111/j.1432-1033.1987.tb10734.x	56	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14693	14699		10.1074/jbc.270.24.14693	http://dx.doi.org/10.1074/jbc.270.24.14693			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782333	hybrid			2022-12-25	WOS:A1995RD45500069
J	OGASAWARA, Y; VOELKER, DR				OGASAWARA, Y; VOELKER, DR			ALTERED CARBOHYDRATE-RECOGNITION SPECIFICITY ENGINEERED INTO SURFACTANT PROTEIN-D REVEALS DIFFERENT BINDING MECHANISMS FOR PHOSPHATIDYLINOSITOL AND GLUCOSYLCERAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A SP-A; II CELLS; PHOSPHOLIPID SECRETION; PURIFICATION; CP4	Pulmonary surfactant protein D (SP-D) is a member of the collectin subgroup of the C-type lectin superfamily that binds glycosylated lipids such as phosphatidylinositol (PI) and glucosylceramide (GlcCer). We have previously reported that the carbohydrate recognition domain of SP-D plays an essential role in lipid binding. However, it is unclear how the carbohydrate binding property of SP-D contributes to the lipid binding. To clarify the relationship between the lectin property and the lipid binding activity of rat SP-D, we expressed wild-type recombinant rat SP-D (rSP-D) and a mutant form of the protein with substitutions Glu-321 --> Gln and Asn-323 --> Asp (SP-D-E321Q,D-N323D) in CHO-K1 cells. The indicated mutations have previously been shown to change the carbohydrate binding specificity of surfactant protein A and mannose-binding protein from mannose > galactose to the converse. rSP-D expressed in mammalian cells was essentially identical to native rat SP-D in its lipid and carbohydrate binding properties. In contrast, SP-D-E321Q,D-N323D was unable to bind GlcCer, but retained binding activity toward PI liposomes and solid-phase PI. The efficiency of SP-D-E321Q,D-N323D binding to PI liposome was similar to 50% of that of rSP-D in the presence of 5 mM Ca2+, but equivalent at 20 mM Ca2+. Carbohydrats competed for SP-D binding to PI such that maltose > galactose for rSP-D, and the order was reversed for SPDE321Q,N323D. Furthermore, SP-D-E321Q,D-N323D could bind to digalactosyldiacylglycerol more effectively than rSP-D. These results suggest the following. 1) The carbohydrate binding specificity of Sp-D-E321Q,D-N323D was changed from a mannose-glucose type to a galactose type; 2) the GlcCer binding property of SP-D is closely related to its sugar binding activity; and 3) the PI binding activity is not completely dependent on its carbohydrate binding specificity.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,ANNA PERAHIA ADATTO CLIN LABS,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV PULM SCI & CRIT CARE MED,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NHLBI NIH HHS [HL29891, HL45286] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029891, R37HL029891, R01HL045286] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSBEL FM, 1992, CURRENT PROTOCOLS MO; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; CROUCH E, 1994, J BIOL CHEM, V269, P17311; CROUCH E, 1994, J BIOL CHEM, V269, P15808; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUAN SF, 1994, AM J RESP CELL MOL, V10, P430, DOI 10.1165/ajrcmb.10.4.8136158; KUROKI Y, 1991, BIOCHEM J, V279, P115, DOI 10.1042/bj2790115; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1992, ARCH BIOCHEM BIOPHYS, V299, P261, DOI 10.1016/0003-9861(92)90273-Y; KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V187, P963, DOI 10.1016/0006-291X(92)91291-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; MIYAMURA K, 1994, BIOCHEM J, V300, P237, DOI 10.1042/bj3000237; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1990, J BIOL CHEM, V265, P5755; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANIWAARDEN JF, 1992, BIOCHEM J, V286, P5, DOI 10.1042/bj2860005; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888	33	48	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14725	14732		10.1074/jbc.270.24.14725	http://dx.doi.org/10.1074/jbc.270.24.14725			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782337	hybrid			2022-12-25	WOS:A1995RD45500074
J	RATHOUZ, MM; VIJAYARAGHAVAN, S; BERG, DK				RATHOUZ, MM; VIJAYARAGHAVAN, S; BERG, DK			ACETYLCHOLINE DIFFERENTIALLY AFFECTS INTRACELLULAR CALCIUM VIA NICOTINIC AND MUSCARINIC RECEPTORS ON THE SAME POPULATION OF NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK CILIARY GANGLION; PANCREATIC ACINAR-CELLS; INOSITOL TRISPHOSPHATE; ALPHA-BUNGAROTOXIN; CYTOSOLIC CALCIUM; CA2+ OSCILLATIONS; ENDOPLASMIC-RETICULUM; CA-2+ OSCILLATIONS; SIGNALING PATHWAYS; RELEASE	Multiple receptor subtypes activated by the same ligand but coupled to different second messengers can produce divergent signaling in a cell, while receptors activated by different ligands but sharing the same second messenger can produce convergent signaling, We show here that chick ciliary ganglion neurons have three classes of receptors activated by the same neurotransmitter, acetylcholine, and that all three regulate the same second messenger, intracellular free calcium, Activation of muscarinic receptors on the neurons stimulates phosphatidylinositol turnover and induces calcium oscillations that are initiated and maintained by calcium release from caffeine/ryanodine-insensitive intracellular stores, Extracellular calcium is required to sustain the oscillations, while cadmium abolishes them, Activation of either of two classes of nicotinic receptors, distinguished both by location on the neurons and by subunit composition, induces a single, rapid elevation in intracellular calcium without inducing phosphatidylinositol turnover, The nicotinic responses are entirely dependent on extracellular calcium, show no dependence on release from internal stores, and do not display oscillations, Low concentrations of the native agonist, acetylcholine, induce repetitive calcium spikes in the neurons characteristic of muscarinic receptors, while higher concentrations induce nonoscillating increases in intracellular calcium that include contributions from nicotinic receptors, The three classes of receptors also differ in the acetylcholine concentration required to elicit a response. These differences, together with differences in receptor location and sources of calcium mobilized, may enable the receptor subtypes to target different sets of calcium-dependent processes for regulation.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012601, P01NS025916] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS12601, P01 NS25916] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BERRIDGE MJ, 1990, CELL REGUL, V1, P675, DOI 10.1091/mbc.1.9.675; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOWERS CW, 1992, DEV BIOL, V154, P410, DOI 10.1016/0012-1606(92)90079-V; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CHIAPPINELLI VA, 1981, BRAIN RES, V211, P107, DOI 10.1016/0006-8993(81)90070-6; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DEXTER F, 1994, AM J PHYSIOL, V266, pH298, DOI 10.1152/ajpheart.1994.266.1.H298; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P215, DOI 10.1113/jphysiol.1991.sp018466; FRIEL DD, 1992, J PHYSIOL-LONDON, V450, P217, DOI 10.1113/jphysiol.1992.sp019125; FURUKAWA K, 1994, BRAIN RES, V657, P185, DOI 10.1016/0006-8993(94)90966-0; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GRAY DB, 1990, J NEUROSCI, V10, P2687; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HAROOTUNIAN AT, 1988, COLD SPRING HARB SYM, V53, P935, DOI 10.1101/SQB.1988.053.01.108; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUANG CF, 1994, NEURON, V13, P167, DOI 10.1016/0896-6273(94)90467-7; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JACOB MH, 1984, P NATL ACAD SCI-BIOL, V81, P3223, DOI 10.1073/pnas.81.10.3223; JACOB MH, 1983, J NEUROSCI, V3, P260; LANDMESSER L, 1972, J PHYSIOL-LONDON, V222, P691, DOI 10.1113/jphysiol.1972.sp009822; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; MACNICOL M, 1992, FEBS LETT, V304, P237, DOI 10.1016/0014-5793(92)80627-S; MARGIOTTA JF, 1989, DEV BIOL, V135, P326, DOI 10.1016/0012-1606(89)90183-8; MINTA A, 1989, J BIOL CHEM, V264, P8171; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MULLE C, 1992, NEURON, V8, P135, DOI 10.1016/0896-6273(92)90115-T; NEERING IR, 1984, NATURE, V309, P158, DOI 10.1038/309158a0; NISHI R, 1981, J NEUROSCI, V1, P505; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; PUGH PC, 1994, J NEUROSCI, V14, P889; RATHOUZ MM, 1994, J NEUROSCI, V14, P6935; RAVDIN PM, 1981, J NEUROSCI, V1, P849; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHMID HA, 1992, NEUROPHARMACOLOGY, V31, P1001, DOI 10.1016/0028-3908(92)90101-T; SEGUELA P, 1993, J NEUROSCI, V13, P596; SORIMACHI M, 1993, BRAIN RES, V627, P34, DOI 10.1016/0006-8993(93)90745-9; SORIMACHI M, 1995, BRAIN RES, V669, P26, DOI 10.1016/0006-8993(94)01218-7; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOESCU EC, 1993, J BIOL CHEM, V268, P18654; TROUSLARD J, 1993, J PHYSIOL-LONDON, V468, P53, DOI 10.1113/jphysiol.1993.sp019759; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; VIJAYARAGHAVAN S, 1992, NEURON, V8, P353, DOI 10.1016/0896-6273(92)90301-S; VIJAYARAGHAVAN S, 1995, IN PRESS J NEUROSCI; WAKUI M, 1990, FEBS LETT, V263, P206, DOI 10.1016/0014-5793(90)81374-W; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WISGIRDA ME, 1994, P NATL ACAD SCI USA, V91, P2858, DOI 10.1073/pnas.91.7.2858; YAWO H, 1993, J PHYSIOL-LONDON, V460, P153, DOI 10.1113/jphysiol.1993.sp019464; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHANG ZW, 1994, NEURON, V12, P167, DOI 10.1016/0896-6273(94)90161-9; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	68	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14366	14375		10.1074/jbc.270.24.14366	http://dx.doi.org/10.1074/jbc.270.24.14366			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782297	hybrid			2022-12-25	WOS:A1995RD45500023
J	SCHIFFER, SG; HEMLER, ME; LOBB, RR; TIZARD, R; OSBORN, L				SCHIFFER, SG; HEMLER, ME; LOBB, RR; TIZARD, R; OSBORN, L			MOLECULAR MAPPING OF FUNCTIONAL ANTIBODY-BINDING SITES OF ALPHA-4 INTEGRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-ADHESION MOLECULE-1; PLATELET INTEGRIN; OVERLAP EXTENSION; I-DOMAIN; VLA-4; RECEPTOR; FIBRONECTIN; MURINE; IDENTIFICATION; DISTINCT	Integrin (alpha 4 beta 1 is a leukocyte receptor for fibronectin and vascular cell adhesion molecule-1 (VCAM-1). It is important in inflammatory recruitment of leukocytes, lymphopoiesis, and a number of developmental events. Here we have mapped a panel of functional monoclonal antibodies (mAbs) recognizing the integrin alpha 4 chain, using murine/human chimeric constructs expressed in COS7 cells. We find that: 1) mAbs that induce homotypic aggregation (epitope A mAbs) map to the most N-terminal 100 amino acids of the human alpha 4 chain; 2) mAbs that block adhesion of alpha 4 beta 1 to VCAM-1 and fibronectin (epitope B mAbs) map to a 52-amino-acid region between residues 152 and 203 of human alpha 4; 3) epitope B mAbs that do or do not induce aggregation (epitope B2 and B1 mAbs, respectively) map to the same regions and are therefore indistinguishable by this analysis; 4) mAbs that neither induce homotypic aggregation nor block adhesion (epitope C mAbs) map to a distinct region of the molecule comprising amino acids 422-606. The N-terminal region of the alpha 4 chain identified by functional A and B epitope mAbs does not correspond to ligand binding sites identified in other alpha subunits, such as cation binding sites or the ''I-domain,'' which alpha 4 lacks, and thus represents a novel site for epitope functionality among the integrins.	BIOGEN INC,CAMBRIDGE,MA 02142; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Biogen; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38903] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CLAYBERGER C, 1987, J IMMUNOL, V138, P1510; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HESSION C, 1992, BIOCHEM BIOPH RES CO, V183, P163, DOI 10.1016/0006-291X(92)91623-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JAKUBOWSKI A, 1995, IN PRESS CELL ADH CO, V3; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1994, J BIOL CHEM, V269, P22811; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MOY P, 1993, J BIOL CHEM, V268, P8835; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PULIDO R, 1991, J BIOL CHEM, V266, P10241; PULIDO R, 1991, FEBS LETT, V294, P121, DOI 10.1016/0014-5793(91)81356-D; RANDI AM, 1994, J BIOL CHEM, V269, P12395; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SMITH JW, 1990, J BIOL CHEM, V265, P2168; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; WANG JH, 1994, PROTEINS, V20, P287, DOI 10.1002/prot.340200310; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YANG JT, 1995, DEVELOPMENT, V121, P549; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	43	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14270	14273		10.1074/jbc.270.24.14270	http://dx.doi.org/10.1074/jbc.270.24.14270			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782282	hybrid			2022-12-25	WOS:A1995RD45500008
J	YOSHIDA, Y; KOJIMA, N; KUROSAWA, N; HAMAMOTO, T; TSUJI, S				YOSHIDA, Y; KOJIMA, N; KUROSAWA, N; HAMAMOTO, T; TSUJI, S			MOLECULAR-CLONING OF SIA-ALPHA-2,3GAL-BETA-1,4GLCNAC ALPHA-2,8-SIALYLTRANSFERASE FROM MOUSE-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; SIALYLTRANSFERASE GENE FAMILY; ALPHA-2,3-SIALYLTRANSFERASE; EXPRESSION; ADULT	A cDNA encoding a new alpha 2,8-sialyltransferase (ST8Sia III), which exhibits activity toward the Sia alpha 2,3Gal beta 1, 4GlcNAc sequences of N-linked oligosaccharides, was cloned from mouse brain by means of the polymerase chain reaction based approach. The predicted amino acid sequence of ST8Sia III showed 27.6 and 34.4% identity with those of so far cloned mouse alpha 2,8-sialyltransferases, i.e. G(D3) synthase (ST8Sia I) and STX (ST8Sia II), respectively. Transfection of the protein A-fused ST8Sia III gene into COS-7 cells led to alpha 2,8-sialyltransferase activity toward sialylated glycoproteins and alpha 2,3-sialylated glycosphingolipids, such as alpha 2,3-sialylparagloboside and G(M3). However, the kinetic properties of ST8Sia III revealed that it is much more specific to N-linked oligosaccharides of glycoproteins than glycosphingolipids. The expression pattern of the ST8Sia III gene was clearly different from those of other alpha 2,8-sialyltransferase genes. The expression of the ST8Sia III gene was tissue and stage specific. The ST8Sia III gene was expressed only in brain and testis, and it appeared first in 20 postcoitum embryonal brain and then decreased. Therefore, the new alpha 2,8-sialyltransferase is closely involved in brain development.	RIKEN,INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN	RIKEN				Kurosawa, Nobuyuki/0000-0002-1548-4541				CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; KITAGAWA H, 1994, J BIOL CHEM, V268, P17872; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; LEE YC, 1994, J BIOL CHEM, V269, P10028; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; ROTHBARD JB, 1982, J BIOL CHEM, V257, P1064; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SASAKI K, 1993, J BIOL CHEM, V268, P22782; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; ZUBER C, 1992, J BIOL CHEM, V267, P9965	18	102	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14628	14633		10.1074/jbc.270.24.14628	http://dx.doi.org/10.1074/jbc.270.24.14628			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782326	hybrid			2022-12-25	WOS:A1995RD45500060
J	MUKHERJI, S; SODERLING, TR				MUKHERJI, S; SODERLING, TR			MUTATIONAL ANALYSIS OF CA2+-INDEPENDENT AUTOPHOSPHORYLATION OF CALCIUM/CALMODULIN-DEPENDENT PROTEIN-KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; CALMODULIN-BINDING; INTRASTERIC REGULATION; BASIC RESIDUES; SITE; ACTIVATION; DOMAIN	Previous studies with synthetic peptides indicate that residues 290-309, corresponding to the calmodulin (CaM)-binding domain of Ca2+/CaM-dependent protein kinase II interact with the catalytic core of the enzyme as a pseudosubstrate (Colbran, R. J., Smith, M. K., Schworer, C. M., Fong, Y. L., and Soderling, T. R. (1989) J. Biol. Chem. 264, 4800-4804). In the present study, we attempted to locate the pseudosubstrate motif by generation or removal of potential substrate recognition sequences (RXXS/T) at selected positions using site-directed mutagenesis. Based on previous results, Arg(297), Thr(305/306), and Ser(314) were selected as key residues. Single mutations such as N294S, K300S, A302R, A309R, and R311A were expressed, purified, and characterized. Several of the mutants exhibited decreased binding of and activation by CaM, not surprising since the mutations were within the CaM-binding domain. None of the mutants exhibited enhanced Ca2+-independent kinase activity toward exogenous substrate, but the K300S and N294S mutants showed a significant enhancement in the rate and stoichiometry of P-32 incorporation during Ca2+-independent autophosphorylation. Using two-dimensional peptide mapping and phosphoamino acid analyses, enhanced phosphorylation of the introduced Ser residue was demonstrated in the K300S mutant but not in the N294S mutant. This specific Ca2+-independent autophosphorylation of Ser(300) is consistent with the hypothesis that Arg(297) may occupy the P (-3) position in a pseudosubstrate autoinhibitory interaction with the catalytic core in the nonactivated state of the kinase.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41292] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BAGCHI IC, 1992, MOL ENDOCRINOL, V6, P621, DOI 10.1210/me.6.4.621; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; GAO ZH, 1993, J BIOL CHEM, V268, P20096; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HERRING BP, 1991, J BIOL CHEM, V266, P11838; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JARRETT HW, 1991, J BIOL CHEM, V266, P362; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MUKHERJI S, 1994, J BIOL CHEM, V269, P20733; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; O'Reilly DR, 1992, BACULOVIRUS EXPRESSI, P130; ORR JW, 1994, J BIOL CHEM, V269, P8383; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SMITH MK, 1992, J BIOL CHEM, V267, P1761; SODERLING TR, 1990, J BIOL CHEM, V265, P1823	27	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14062	14067		10.1074/jbc.270.23.14062	http://dx.doi.org/10.1074/jbc.270.23.14062			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775466	hybrid			2022-12-25	WOS:A1995RC44800069
J	RAMAKERS, GMJ; DEGRAAN, PNE; URBAN, IJA; KRAAY, D; TANG, T; PASINELLI, P; OESTREICHER, AB; GISPEN, WH				RAMAKERS, GMJ; DEGRAAN, PNE; URBAN, IJA; KRAAY, D; TANG, T; PASINELLI, P; OESTREICHER, AB; GISPEN, WH			TEMPORAL DIFFERENCES IN THE PHOSPHORYLATION STATE OF PRESYNAPTIC AND POSTSYNAPTIC PROTEIN-KINASE-C SUBSTRATES B-50/GAP-43 AND NEUROGRANIN DURING LONG-TERM POTENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC TRANSMISSION; NEUROTRANSMITTER RELEASE; HIPPOCAMPAL SLICES; CALMODULIN-BINDING; B-50 GAP-43; RAT-BRAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; TRANSMITTER RELEASE; AMINO-ACIDS; INDUCTION	The phosphorylation state of two identified neural-specific protein kinase C substrates (the presynaptic protein B-50 and the postsynaptic protein neurogranin) was monitored after the induction of long term potentiation in the CA1 field of rat hippocampus slices by quantitative immunoprecipitation following P-92(i) labeling in the recording chamber. B-50 phosphorylation was increased from 10 to 60 min, but no longer at 90 min after long term potentiation had been induced, neurogranin phosphorylation only at 60 min. increased phosphorylation was not found when long term potentiation was blocked with the N-methyl-D-aspartate receptor antagonist D-2-amino-5-phosphonovalerate, when only low frequency stimulation was applied or tetanic stimulation failed to induce long term potentiation. Our data show that both B-50 and neurogranin phosphorylation are increased following the induction of long term potentiation, thus providing strong evidence for pre- and postsynaptic protein kinase C activation during narrow, partially overlapping, time windows after the induction of long term potentiation.	UNIV UTRECHT, RUDOLF MAGNUS INST NEUROSCI, DEPT MED PHARMACOL, 3508 TA UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center				Ramakers, Geert/0000-0001-7499-6996; Pasinelli, Piera/0000-0002-3385-2707				ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BEHNISCH T, 1994, SOC NEUR ABSTR, V20; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPAGNE MV, 1989, J NEUROCYTOL, V18, P479, DOI 10.1007/BF01474544; COGGINS PJ, 1989, J NEUROCHEM, V53, P1895, DOI 10.1111/j.1471-4159.1989.tb09259.x; COGGINS PJ, 1991, NEUROSCI RES COMMUN, V8, P49; COHEN RW, 1993, BRAIN RES, V627, P147, DOI 10.1016/0006-8993(93)90758-F; COLLEY PA, 1993, BRAIN RES REV, V18, P115, DOI 10.1016/0165-0173(93)90009-O; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DEGRAAN PNE, 1988, NEUROSCI RES COMMUN, V3, P175; DEGRAAN PNE, 1990, J NEUROCHEM, V55, P2139; DEGRAAN PNE, 1993, BIOCHEM SOC T, V21, P406, DOI 10.1042/bst0210406; DEGRAAN PNE, 1989, J NEUROCHEM, V52, P17; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DEKKER LV, 1991, PROG BRAIN RES, V89, P209; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GHIJSEN WEJM, 1992, J NEUROCHEM, V59, P482, DOI 10.1111/j.1471-4159.1992.tb09395.x; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; GISPEN WH, 1985, BRAIN RES, V328, P381, DOI 10.1016/0006-8993(85)91054-6; HENS JJH, 1993, J NEUROCHEM, V61, P1530, DOI 10.1111/j.1471-4159.1993.tb13649.x; HENS JJH, 1995, J NEUROCHEM, V64, P1127; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; HUANG YY, 1992, NEUROSCIENCE, V49, P819, DOI 10.1016/0306-4522(92)90359-A; IVINS KJ, 1993, J NEUROCHEM, V60, P626, DOI 10.1111/j.1471-4159.1993.tb03194.x; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; LEAHY JC, 1993, NEUROSCIENCE, V52, P563, DOI 10.1016/0306-4522(93)90406-6; LEE KS, 1983, J NEUROSCI, V3, P1369; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOVINGER DM, 1986, BRAIN RES, V399, P205, DOI 10.1016/0006-8993(86)91510-6; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MCMAHON HT, 1991, BIOCHIM BIOPHYS ACTA, V1059, P243, DOI 10.1016/S0005-2728(05)80210-5; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORDEN JJ, 1991, ANN NY ACAD SCI, V627, P75; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; REYMANN KG, 1988, BRAIN RES, V440, P305, DOI 10.1016/0006-8993(88)91000-1; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SCHAECHTER JD, 1993, J NEUROSCI, V13, P4361; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; VORONIN LL, 1991, NEUROSCI RES COMMUN, V8, P87; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WAXHAM MN, 1993, BRAIN RES, V609, P1; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0	61	100	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13892	13898		10.1074/jbc.270.23.13892	http://dx.doi.org/10.1074/jbc.270.23.13892			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775448	Green Submitted, hybrid			2022-12-25	WOS:A1995RC44800047
J	ROUSSELLE, P; GOLBIK, R; VANDERREST, M; AUMAILLEY, M				ROUSSELLE, P; GOLBIK, R; VANDERREST, M; AUMAILLEY, M			STRUCTURAL REQUIREMENT FOR CELL-ADHESION TO KALININ (LAMININ-5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMOLYSIS-BULLOSA; MULTIDOMAIN PROTEIN; BASEMENT-MEMBRANES; GLOBULAR DOMAIN; COLLAGEN-IV; B2 CHAIN; LONG ARM; BINDING; ATTACHMENT; SITES	Laminin-5 (kalinin) was purified from spent cell culture media (SCC25 cells) by affinity chromatography on monoclonal antibody BM165. The protein was recovered as a mixture of the typical polypeptides of 165-155, 140, and 105 kDa as judged by SDS-polyacrylamide gel electrophoresis analysis under reducing conditions. The amino acid composition of purified laminin-5 was in agreement with that compiled from the recently published cDNA sequences of the alpha(3)-, beta(3)-, and gamma(2)-laminin chains. Moreover, the content of half-cystine residues in laminin-5 was about two-thirds that in laminin-1, which confirms the prediction of a smaller number of epidermal growth factor-like repeats in the amino-terminal portion of the three chains. The content of coiled-coil alpha-helices (27%) determined by CD spectroscopy was comparable to that reported for laminin-1, which indicates that the long arm portion of laminin-5 is equivalent to that of other laminin isoforms. The melting temperature was recorded at 72 degrees C by CD monitoring of unfolding and refolding of the coiled-coil structures during thermal denaturation and renaturation, respectively. The thermal stability of laminin-5 is therefore significantly higher than that of laminin-1 or alpha(2)-chain-containing laminins, which suggests higher ionic interactions between the three polypeptide chains of laminin-5. Cell adhesion-promoting activity of laminin 5 was found to be strictly and entirely dependent on the presence of coiled-coil structures, It decreased gradually after heat denaturation of the protein above 65 degrees C and was totally abrogated at 75 degrees C. This is in contrast to laminin-1, which contains both conformation-dependent and -independent cell-binding sites on the long and short arm domains, respectively.	INST BIOL & CHIM PROT,CNRS,UPR 412,F-69367 LYON 07,FRANCE; MRC CTR,CTR PROT ENGN,CAMBRIDGE CB2 2QH,ENGLAND	Centre National de la Recherche Scientifique (CNRS); MRC Laboratory Molecular Biology; University of Cambridge			Rousselle, Patricia/CAF-3915-2022; Rousselle, Patricia/J-5290-2019	Rousselle, Patricia/0000-0003-0275-4562; Rousselle, Patricia/0000-0003-0275-4562				ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; AUMAILLEY M, 1987, J BIOL CHEM, V262, P11532; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BROWN JC, 1994, J CELL SCI, V107, P329; BURGESON RE, 1994, MATRIX BIOL, V5, P209; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GOODMAN SL, 1991, J CELL BIOL, V113, P931, DOI 10.1083/jcb.113.4.931; GOODMAN SL, 1987, J CELL BIOL, V105, P589, DOI 10.1083/jcb.105.1.589; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HABER RM, 1985, J AM ACAD DERMATOL, V13, P252, DOI 10.1016/S0190-9622(85)70168-5; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HOOGERHEIDE JG, 1992, ANAL BIOCHEM, V201, P146, DOI 10.1016/0003-2697(92)90187-C; HUNTER I, 1992, J BIOL CHEM, V267, P6006; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBLOM A, 1994, EUR J BIOCHEM, V219, P383, DOI 10.1111/j.1432-1033.1994.tb19950.x; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAULSSON M, 1985, EMBO J, V4, P309, DOI 10.1002/j.1460-2075.1985.tb03630.x; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; UTANI A, 1994, J BIOL CHEM, V269, P19167; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; VERRANDO P, 1991, LAB INVEST, V64, P85	42	45	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13766	13770		10.1074/jbc.270.23.13766	http://dx.doi.org/10.1074/jbc.270.23.13766			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775432	hybrid			2022-12-25	WOS:A1995RC44800029
J	LEVY, AP; LEVY, NS; WEGNER, S; GOLDBERG, MA				LEVY, AP; LEVY, NS; WEGNER, S; GOLDBERG, MA			TRANSCRIPTIONAL REGULATION OF THE RAT VASCULAR ENDOTHELIAL GROWTH-FACTOR GENE BY HYPOXIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; PERMEABILITY FACTOR; MAMMALIAN-CELLS; PHORBOL ESTER; PROTEIN; ENHANCER; MITOGEN; INVITRO; ANGIOGENESIS; EXPRESSION	Vascular endothelial growth factor (VEGF), a potent angiogenic factor and endothelial cell-specific mitogen, is up-regulated by hypoxia. However, the mechanism(s) responsible for hypoxic induction of VEGF has not been clearly delineated. We report that the steady state VEGF mRNA levels are increased 12 +/- 0.6-fold, but the transcriptional rate for VEGF is increased only 3.1 +/- O.6-fold by hypoxia in PC12 cells. In order to investigate cis-regulatory sequences which mediate this response to hypoxia, we cloned the rat genomic sequences encoding VEGF and identified a 28-base pair element in the 5' promoter that mediates hypoxia-inducible transcription in transient expression assays. This element has sequence and protein binding similarities to the hypoxia-inducible factor 1 binding site within the erythropoietin 3' enhancer. Post-transcriptional mechanisms have also been suggested to play a role in the hypoxic induction of VEGF. Evidence is provided that a frequently used polyadenylation site is 1.9 kilobases downstream from the translation termination codon for rat VEGF. This site is 1.5 kilobases further downstream from the polyadenylation site previously reported for VEGF. This new finding reveals sequence motifs in the 3'-untranslated region that may mediate VEGF mRNA stability.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [T32HL07604, 1F32HL08838-02] Funding Source: Medline; NIDDK NIH HHS [DK45098] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008838, T32HL007604] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045098] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADAIR TH, 1990, AM J PHYSIOL, V259, pR393, DOI 10.1152/ajpregu.1990.259.3.R393; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; AKASHI M, 1994, BLOOD, V83, P3182; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARROLL SM, 1994, CIRCULATION, V90, P521; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GILMAN M, 1994, CURRENT PROTOCOLS MO; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDWASSER E, 1989, CONTRIBUTIONS NEPHRO, P2; GONFURNINO M, 1991, P NATL ACAD SCI USA, V88, P2927; GOROSPE M, 1994, J BIOL CHEM, V269, P11845; GREENBERG ME, 1994, CURRENT PROTOCOLS MO; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1989, GROWTH FACTORS, V2, P9, DOI 10.3109/08977198909069077; LEVY AP, 1995, IN PRESS CIRC RES; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; SABRI MN, 1991, AM HEART J, V121, P876, DOI 10.1016/0002-8703(91)90202-S; SCHUSTER SJ, 1989, BLOOD, V73, P13; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SHARMA H, 1992, J MOL CELL CARDIO S5, V24; Sharma H S, 1992, EXS, V61, P255; SHARMA HS, 1992, J CARDIOVASC PHARM, V20, pS23, DOI 10.1097/00005344-199206201-00006; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TRIEZENBERG SJ, 1989, CURRENT PROTOCOLS MO; WANG GL, 1993, J BIOL CHEM, V268, P21513; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WU X, 1994, CIRCULATION, V90, pA1343	56	822	863	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13333	13340		10.1074/jbc.270.22.13333	http://dx.doi.org/10.1074/jbc.270.22.13333			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768934	hybrid			2022-12-25	WOS:A1995RB43900059
J	MCKAY, RR; CHEN, DM; MILLER, K; KIM, SK; STARK, WS; SHORTRIDGE, RD				MCKAY, RR; CHEN, DM; MILLER, K; KIM, SK; STARK, WS; SHORTRIDGE, RD			PHOSPHOLIPASE-C RESCUES VISUAL DEFECT IN NORPA MUTANT OF DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTIAL-PURIFICATION; NERVOUS-SYSTEM; RAT-LIVER; GENE; PHOTOTRANSDUCTION; PHOTORECEPTORS; EXPRESSION; PLATELETS; CASCADE; RETINA	Mutations in the norpA gene of Drosophila melanogaster severely affect the light evoked photoreceptor potential with strong mutations rendering the fly blind. The norpA gene has been proposed to encode phosphatidylinositol-specific phospholipase C (PLC), which enzymes play a pivotal role in one of the largest classes of signaling pathways known. A chimeric norpA minigene was constructed by placing the norpA cDNA behind an R1-6 photoreceptor cell-specific rhodopsin promoter. This minigene was transferred into norpA(P24) mutant by P-element-mediated germline transformation to determine whether it could rescue the phototransduction defect concomitant with restoring PLC activity. Western blots of head homogenates stained with norpA antiserum show that norpA protein is restored in heads of transformed mutants. Moreover, transformants exhibit a large amount of measurable PLC activity in heads, whereas heads of norpA(P24) mutant exhibit very little to none. Immunohistochemical staining of tissue sections using norpA antiserum confirm that expression of norpA protein in transformants localizes in the retina, more specifically in rhabdomeres of R1-6 photoreceptor cells, but not R7 or R8 photoreceptor cells. Furthermore, electrophysiological analyses reveal that transformants exhibit a restoration of Light-evoked photoreceptor responses in R1-6 photoreceptor cells, but not in R7 or RS photoreceptor cells. This is the strongest evidence thus far supporting the hypothesis that the norpA gene encodes phospholipase C that is utilized in phototransduction.	SUNY BUFFALO, DEPT BIOL SCI, BUFFALO, NY 14260 USA; ST LOUIS UNIV, DEPT BIOL, ST LOUIS, MO 63103 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Saint Louis University					NEI NIH HHS [EY07192] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007192] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BANNO Y, 1986, BIOCHEM BIOPH RES CO, V136, P713, DOI 10.1016/0006-291X(86)90498-5; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; CHEN DM, 1992, VISUAL NEUROSCI, V9, P125, DOI 10.1017/S0952523800009585; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; FERREIRA PA, 1994, J BIOL CHEM, V269, P3129; Gall JG, 1971, METHOD ENZYMOL, V21, P470; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HAKATA H, 1982, J BIOCHEM-TOKYO, V92, P929, DOI 10.1093/oxfordjournals.jbchem.a134008; HARLOW E, 1988, ANTIBODIES LABORATOR; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; HOTTA Y, 1970, P NATL ACAD SCI USA, V67, P1156, DOI 10.1073/pnas.67.3.1156; INOUE H, 1988, J BIOCHEM-TOKYO, V103, P91, DOI 10.1093/oxfordjournals.jbchem.a122246; KAUPP UB, 1986, TRENDS BIOCHEM SCI, V11, P43, DOI 10.1016/0968-0004(86)90232-X; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE RD, 1994, THESIS ST LOUIS U; LONG JJ, 1994, J BIOL CHEM, V269, P2827; MANNE V, 1987, BIOCHEM J, V243, P763, DOI 10.1042/bj2430763; MCKAY RR, 1994, NEUROSCIENCE, V61, P141, DOI 10.1016/0306-4522(94)90067-1; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MELDRUM E, 1989, EUR J BIOCHEM, V182, P673, DOI 10.1111/j.1432-1033.1989.tb14878.x; NAKANISHI O, 1988, BIOCHEM J, V256, P453, DOI 10.1042/bj2560453; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; PAK WL, 1991, PHOTOCHEM PHOTOBIOL, V53, P871, DOI 10.1111/j.1751-1097.1991.tb09901.x; PAYNE R, 1986, PHOTOBIOCH PHOTOBIOP, V13, P373; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Roberts D.B., 1986, P1; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEUWLY S, 1991, J BIOL CHEM, V266, P24314; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STARK WS, 1976, J COMP PHYSIOL, V105, P15, DOI 10.1007/BF01380050; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKENAWA T, 1981, J BIOL CHEM, V256, P6769; THUMMEL CS, 1991, DROS INFORMATION NEW, V2; WANG P, 1986, J BIOCHEM-TOKYO, V100, P1015, DOI 10.1093/oxfordjournals.jbchem.a121780; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V97, P1251, DOI 10.1093/oxfordjournals.jbchem.a135171; ZHU LQ, 1993, J BIOL CHEM, V268, P15994; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	45	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13271	13276		10.1074/jbc.270.22.13271	http://dx.doi.org/10.1074/jbc.270.22.13271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768926	hybrid			2022-12-25	WOS:A1995RB43900050
J	PARK, NH; GUJULUVA, CN; BAEK, JH; CHERRICK, HM; SHIN, KH; MIN, BM				PARK, NH; GUJULUVA, CN; BAEK, JH; CHERRICK, HM; SHIN, KH; MIN, BM			COMBINED ORAL CARCINOGENICITY OF HPV-16 AND BENZO(A)PYRENE - AN IN-VITRO MULTISTEP CARCINOGENESIS MODEL	ONCOGENE			English	Article						ORAL CANCER; HPV; BENZO(A)PYRENE; MULTISTEP CARCINOGENESIS; TUMOR SUPPRESSOR	PRIMARY HUMAN KERATINOCYTES; HUMAN PAPILLOMAVIRUS; INSITU HYBRIDIZATION; CERVICAL-CARCINOMA; CELLULAR-RESPONSE; ACTIVATED RAS; DNA DAMAGE; CELLS; TRANSFORMATION; EXPRESSION	We previously immortalized normal human oral keratinocytes by transfection with recombinant HPV-16 DNA and subsequently exposed the cells to benzo(a)pyrene for 7 days. The exposure to benzo(a)pyrene modified the immortalized cells: the modified cells (HOK-16B-BaP) proliferated in an ordinary culture medium containing physiological calcium level (1.5 mM), but demonstrated only enhanced proliferation capacity without tumor formation in nude mice and failed to show in vitro anchorage-independency. In this study, we further modified the HOK-16B-BaP cells by subculturing the cells in a medium containing benzo(a)pyrene for 6 months. The cells were further modified with a chronic benzo(a)pyrene exposure and were termed HOK-16B-BaP-T cells (1) demonstrated a malignant phenotype in organotypic 'raft' culture, (2) showed in vitro anchorage-independency, (3) developed tumors in nude mice when injected subcutaneously, (4) contained a significantly higher copy number of intact and integrated HPV-16 DNA; (5) contained higher level of HPV-16 E6/E7 messages and E7 protein, (6) were more resistant to transforming growth factor-beta 1 and (7) secreted higher level of vascular endothelial growth factor with molecular weight of 56 kd than parental HOK-16B-BaP cells. However, the levels of p53 and ras proteins and the levels of p53, c-myc and c-fos transcripts in the HOK-16B-BaP-T cells were not different from those in the HOK-16B-BaP cells. The highly conserved coding regions of the p53, c-Ha-ras1, and c-Ki-ras2 genes of the tumor cells were not mutated. These data indicate that the HPV-immortalized human oral keratinocytes can convert to tumorigenic cells by chronic exposure to benzo(a)pyrene. The tumorigenic conversion seems to be associated with (1) the overexpression of viral oncogenes such as E6 and E7 genes, (2) the higher resistance of cells to transforming growth factor-beta(1) and (3) the high secretion of 56 kd vascular endothelial growth factor from the cells.	UNIV CALIF LOS ANGELES, SCH DENT, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	PARK, NH (corresponding author), UNIV CALIF LOS ANGELES, DENT RES INST, LOS ANGELES, CA 90024 USA.		Min, Byung-Moo/F-2854-2012		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010049] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE 10049] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAEK JH, 1994, INT J ONCOL, V5, P1023; BIREK C, 1993, AM J PATHOL, V142, P917; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; CLINE MJ, 1994, NEW ENGL J MED, V330, P328; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CURRAN T, 1984, CELL, V36, P259; DILUCA D, 1990, J DENT RES, V69, P51; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; FIELD JK, 1990, ANTICANCER RES, V10, P1; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HIRNING U, 1991, MECH DEVELOP, V33, P119, DOI 10.1016/0925-4773(91)90078-K; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; JOHNSON MA, 1990, J GEN VIROL, V71, P1473, DOI 10.1099/0022-1317-71-7-1473; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIM MS, 1993, CANCER RES, V53, P4811; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LI SL, 1992, CARCINOGENESIS, V13, P1981, DOI 10.1093/carcin/13.11.1981; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MEANWELL CA, 1988, CANCER SURV, V7, P481; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; MIN BM, 1991, IN VITRO CELL DEV B, V27, P128; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SCULLY C, 1988, ORAL SURG ORAL MED O, V65, P526, DOI 10.1016/0030-4220(88)90134-X; SHAH KV, 1990, PAPILLOMAVIRUSES HUM, P73; SHIN KH, 1994, MOL CARCINOGEN, V9, P76, DOI 10.1002/mc.2940090205; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SYRJANEN S, 1992, SCAND J DENT RES, V100, P17; WEINBERG WC, 1994, CANCER RES, V54, P5584; WOODS KV, 1993, J ORAL PATHOL MED, V22, P101, DOI 10.1111/j.1600-0714.1993.tb01038.x; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; ZURHANSEN H, 1986, LANCET, V3, P489	43	79	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2145	2153						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784058				2022-12-25	WOS:A1995RB70300009
J	FRANK, S; HUBNER, G; BREIER, G; LONGAKER, MT; GREENHALGH, DG; WERNER, S				FRANK, S; HUBNER, G; BREIER, G; LONGAKER, MT; GREENHALGH, DG; WERNER, S			REGULATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR EXPRESSION IN CULTURED KERATINOCYTES - IMPLICATIONS FOR NORMAL AND IMPAIRED WOUND-HEALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; FACTOR-ALPHA; PERMEABILITY FACTOR; CELL GROWTH; FACTOR-BETA; PROLIFERATION; ANGIOGENESIS; DIFFERENTIATION; INHIBITION; INDUCTION	Recent in situ hybridization studies had demonstrated a strong increase in vascular endothelial growth factor (VEGF) mRNA expression in the hyperproliferative epithelium during wound healing. To determine potential mediators of VEGF induction during this process, we analyzed the regulation of VEGF expression in cultured human keratinocytes, We found a large induction of VEGF expression upon treatment of quiescent cells with serum, epidermal growth factor, transforming growth factor-beta 1, keratinocyte growth factor, or the proinflammatory cytokine tumor necrosis factor alpha, respectively, Since all these factors are present at the wound site during the early phase of wound healing, they might also be responsible for VEGF induction after cutaneous injury. To determine the importance of increased VEGF production for wound repair, we compared the time course of VEGF mRNA expression during wound healing of healthy control mice with the kinetics of VEGF expression during skin repair of genetically diabetic db/db mice which are characterized by impaired wound healing, In normal mice we found elevated VEGF mRNA levels during the period when granulation tissue formation occurs. In contrast, VEGF mRNA levels even declined during this period in db/db mice, suggesting that a defect in VEGF regulation might be associated with wound healing disorders.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST PHYSIOL & CLIN RES,D-61231 BAD NAUHEIM,GERMANY; NYU,SCH MED,INST RECONSTRUCT PLAST SURG,NEW YORK,NY 10016; SHRINERS BURNS INST,DEPT SURG,CINCINNATI,OH 45229; UNIV CINCINNATI,CINCINNATI,OH 45229	Max Planck Society; Max Planck Society; New York University; University System of Ohio; University of Cincinnati			Breier, Georg/E-3580-2016	Breier, Georg/0000-0002-9467-780X; Werner, Sabine/0000-0001-7397-8710				BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRAUCHLE M, 1994, ONCOGENE, V9, P3199; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1988, AM J PATHOL, V130, P455; CHEDID M, 1994, J BIOL CHEM, V269, P10753; CICCO NA, 1990, BLOOD, V75, P2049; Clark RAF, 1991, PHYSL BIOCH MOL BIOL, P576; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; COLEMAN DL, 1982, DIABETES, V31, P1; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DINARELLO CA, 1991, CYTOKINE HDB, P47; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GREENHALGH DG, 1990, AM J PATHOL, V136, P1235; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LINDEMANN A, 1989, J CLIN INVEST, V83, P1313; LORD PCW, 1991, J CLIN INVEST, V87, P1312, DOI 10.1172/JCI115134; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; RAPPOLEE DA, 1988, SCIENCE, V241, P7087; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAUDER DN, 1988, ARCH DERMATOL RES, V80, P71; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SYMINGTON FW, 1989, J INVEST DERMATOL, V92, P798, DOI 10.1111/1523-1747.ep12696816; TOSATO G, 1988, SCIENCE, V239, P502, DOI 10.1126/science.2829354; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Wong H. L., 1989, HUMAN MONOCYTES, P383	49	621	654	1	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12607	12613		10.1074/jbc.270.21.12607	http://dx.doi.org/10.1074/jbc.270.21.12607			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759509	hybrid			2022-12-25	WOS:A1995QZ71100044
J	LINSEMAN, DA; BENJAMIN, CW; JONES, DA				LINSEMAN, DA; BENJAMIN, CW; JONES, DA			CONVERGENCE OF ANGIOTENSIN-II AND PLATELET-DERIVED GROWTH-FACTOR RECEPTOR SIGNALING CASCADES IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; NUCLEOTIDE EXCHANGE; MESSENGER-RNA; GRB2; KINASES; RAS; ACTIVATION; PDGF; SH2; DIACYLGLYCEROL	Signaling cascades elicited by ansotensin II resemble those characteristic of growth factor stimulation. In this report, we demonstrate that angiotensin II converges with platelet-derived growth factor (PDGF) beta-receptor signaling cascades, independent of PDGF. Stimulation of smooth muscle cells with angiotensin II resulted in tyrosine phosphorylation on She proteins and subsequent complex formation between She and growth factor receptor binding protein a (GRB2). A 180-kDa protein co-precipitating with Shc . GRB2 complexes also demonstrated increased phosphorylation in response to ansotensin II. Immunoblot analyses and proteolytic digests failed to distinguish this 180-kDa protein from authentic PDGF beta-receptors. Corresponding with Shc and PDGF receptor phosphorylation induced by angiotensin II was the recruitment and phosphorylation of c-Src. Autocrine release of platelet-derived growth factor failed to account for Shc complex formation at the PDGF receptor following angiotensin II treatment, and a specific ansotensin II type I receptor antagonist, losartan, abolished the response. These results support a novel model for cross-talk between the G-protein-linked ansotensin II receptor and the PDGF receptor tyrosine kinase in vascular smooth muscle cells, Communication with the PDGF receptor may account for the ability of angiotensin II to elicit responses typical of growth factor signal transduction.	UPJOHN CO,KALAMAZOO,MI 49001	Pfizer			Linseman, Daniel/L-3846-2019					BENJAMIN CW, 1994, J BIOL CHEM, V269, P30911; BERK BC, 1993, J CELL PHYSIOL, V154, P368, DOI 10.1002/jcp.1041540221; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSEGUE B, 1993, BIOCHEM J, V292, P509, DOI 10.1042/bj2920509; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OWENS GK, 1986, J CELL BIOL, V105, P343; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALEINI AE, 1994, ONCOGENE, V9, P2827; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SJOLUND M, 1988, J CELL BIOL, V106, P403, DOI 10.1083/jcb.106.2.403; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	36	270	275	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12563	12568		10.1074/jbc.270.21.12563	http://dx.doi.org/10.1074/jbc.270.21.12563			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759503	hybrid			2022-12-25	WOS:A1995QZ71100038
J	SU, W; LIU, W; SCHAFFHAUSEN, BS; ROBERTS, TM				SU, W; LIU, W; SCHAFFHAUSEN, BS; ROBERTS, TM			ASSOCIATION OF POLYOMAVIRUS MIDDLE TUMOR-ANTIGEN WITH PHOSPHOLIPASE-C-GAMMA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE-C; T-ANTIGEN; TYROSINE PHOSPHORYLATION; VIRUS; TRANSFORMATION; PP60C-SRC; ACTIVATION; COMPLEX; INVITRO; SITES	Middle tumor antigen (MT) is the primary transforming protein of murine Polyomavirus. MT transforms by associating with and modulating the activities of cellular proteins involved in control of cell proliferation. MT binds to and is phosphorylated by cellular tyrosine kinases. The phosphorylated tyrosines become docking sites for SH2 (Src homology 2) domain-containing molecules. Tyrosine 322 of MT is known to be phosphorylated but has no known binding protein. We have found that phospholipase C-gamma 1 (PLC-gamma 1), a SH2 domain containing protein, coimmunoprecipitates with MT. Tyrosine phosphorylation of PLC-gamma 1 is elevated in cells expressing MT, suggesting activation of this enzyme by MT. A Tyr-322 --> Phe mutation in MT renders it defective in MT-PLC-gamma 1 interaction and in transformation. From the correlation between transformation and MT-PLC-gamma 1 interaction, we suggest that PLC-gamma 1 may play a role in transformation.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Harvard University; Harvard Medical School; Tufts University	SU, W (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,M857,44 BINNEY ST,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R01CA030002, R37CA030002, R01CA034722] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA034722, CA30002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHENG SH, 1990, MOL CELL BIOL, V10, P5569, DOI 10.1128/MCB.10.10.5569; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DELAGE S, 1993, CANCER RES, V53, P2762; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; GOLDSCHMIDTCLER.PJ, 1991, SCIENCE, V251, P1231; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; HARVEY R, 1984, MOL CELL BIOL, V4, P1334, DOI 10.1128/MCB.4.7.1334; HUNTER T, 1984, EMBO J, V3, P73, DOI 10.1002/j.1460-2075.1984.tb01763.x; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KINGSTON RE, 1994, CURRENT PROTOCALS MO; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; MARCELLUS R, 1991, ONCOGENE, V6, P1037; MARKLAND W, 1986, J VIROL, V59, P384, DOI 10.1128/JVI.59.2.384-391.1986; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SHMUELI E, 1993, J INTERN MED, V234, P397, DOI 10.1111/j.1365-2796.1993.tb00761.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	33	77	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12331	12334		10.1074/jbc.270.21.12331	http://dx.doi.org/10.1074/jbc.270.21.12331			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759472				2022-12-25	WOS:A1995QZ71100002
J	XU, XL; WILLIAMS, JW; BREMER, EG; FINNEGAN, A; CHONG, ASF				XU, XL; WILLIAMS, JW; BREMER, EG; FINNEGAN, A; CHONG, ASF			INHIBITION OF PROTEIN-TYROSINE PHOSPHORYLATION IN T-CELLS BY A NOVEL IMMUNOSUPPRESSIVE AGENT, LEFLUNOMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; KINASE-ACTIVITY; CROSS-LINKING; GENE-PRODUCT; ACTIVATION; STIMULATION; EVENTS	Leflunomide, a novel immunosuppressive drug, is able to prevent and reverse allograft and xenograft rejection in rodents, dogs, and monkeys. It is also effective in the treatment of several rodent models of arthritis and autoimmune disease. In vitro studies indicate that leflunomide is capable of inhibiting anti-CD3- and interleukin-2 (IL-2)-stimulated T cell proliferation. However, the biochemical mechanism for the inhibitory activity of leflunomide has not been elucidated. In this study, we characterized the inhibitory effects of leflunomide on Src family (p56(lck) and p59(fyn))-mediated protein tyrosine phosphorylation. Leflunomide was able to inhibit p59(fyn) and p56(lck) activity in in vitro tyrosine kinase assays. The IC50 values for p59(fyn) (immunoprecipitated from either Jurkat or CTLL-4 cell lysate) autophosphorylation and phosphorylation of the exogenous substrate, histone 2B, mere 125-175 and 22-40 mu M respectively, while the IC50 no values for p56(lck) (immunoprecipitated from Jurkat cell lysates) autophosphorylation and phosphorylation of histone 2B were 160 and 65 mu M respectively. We also demonstrated the ability of leflunomide to inhibit protein tyrosine phosphorylation induced by anti-CD3 monoclonal antibody in Jurkat cells. The IC50 values for total intracellular tyrosine phosphorylation ranged from 5 to 45 mu M, with the IC50 values for the zeta chain and phospholipase C isoform gamma 1 being 35 and 44 mu M respectively. Leflunomide also inhibited Ca2+ mobilization in Jurkat cells stimulated by anti-CD3 antibody but not in those stimulated by ionomycin. Distal events of anti-CD3 monoclonal antibody stimulation, namely, IL-2 production and IL-2 receptor expression on human T lymphocytes, were also inhibited by leflunomide. Finally, tyrosine phosphorylation in CTLL-4 cells stimulated by IL-2 was also inhibited by leflunomide. These data collectively demonstrate the ability of leflunomide to inhibit tyrosine kinase activity in vitro, and suggest that inhibition of tyrosine phosphorylation events may be the mechanism by which leflunomide functions as an immunosuppressive agent.	RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60612 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT INTERNAL MED, RHEUMATOL SECT, CHICAGO, IL 60612 USA; CHICAGO INST NEUROSURG & NEURORES, CHICAGO, IL 60614 USA	Rush University; Rush University	XU, XL (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT GEN SURG, CHICAGO, IL 60612 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI034061, R01AI034061] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34061] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM RT, 1992, TRENDS BIOCHEM SCI, V17, P434, DOI 10.1016/0968-0004(92)90015-2; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BARTLETT RR, 1991, AGENTS ACTIONS, V32, P10, DOI 10.1007/BF01983301; CASSATELLA MA, 1989, J EXP MED, V169, P549, DOI 10.1084/jem.169.2.549; CHONG ASF, 1993, TRANSPLANTATION, V55, P1361, DOI 10.1097/00007890-199306000-00028; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; GRABER M, 1992, INT IMMUNOL, V4, P1201, DOI 10.1093/intimm/4.11.1201; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HSI ED, 1989, J BIOL CHEM, V264, P10836; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; LIAO F, 1993, J IMMUNOL, V150, P2668; MATTAR T, 1993, FEBS LETT, V334, P161, DOI 10.1016/0014-5793(93)81704-4; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAIR R, 1995, J HEART LUNG TRANS S, P554; NEL AE, 1991, J IMMUNOL, V147, P1933; NEL AE, 1990, J IMMUNOL, V144, P2683; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TREVILLYAN JM, 1990, J IMMUNOL, V145, P3223; TSGANKOV AY, 1994, J BIOL CHEM, V269, P7792; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WILLIAMS JW, 1993, TRANSPLANTATION, V57, P1233; XIAO F, 1994, TRANSPLANTATION, V58, P828; ZIELINSKI T, 1994, AGENTS ACTIONS, V38, P80; ZIELINSKI T, 1995, IN PRESS INFLAMMATIO	32	189	201	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12398	12403		10.1074/jbc.270.21.12398	http://dx.doi.org/10.1074/jbc.270.21.12398			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759480	hybrid			2022-12-25	WOS:A1995QZ71100013
J	WONG, YH; CHAN, JSC; YUNG, LY; BOURNE, HR				WONG, YH; CHAN, JSC; YUNG, LY; BOURNE, HR			MUTANT ALPHA-SUBUNIT OF G(Z) TRANSFORMS SWISS 3T3 CELLS	ONCOGENE			English	Article						G PROTEINS; NEOPLASTIC TRANSFORMATION; CYCLIC AMP	NUCLEOTIDE-BINDING PROTEIN; CYCLIC-AMP ACCUMULATION; PHOSPHOLIPASE-C; PERTUSSIS TOXIN; ADENYLYL-CYCLASE; INHIBITION; ONCOGENES; RECEPTOR; MITOGENESIS; ACTIVATION	Many hormones and neurotransmitters induce cell proliferation by regulating signaling pathways controlled by heterotimeric G proteins. Mutations that activate the alpha subunits of G(s) and G(i2) produce the gsp and gip2 oncogenes that are found in certain human endocrine tumors. Similar mutations have conferred on other G alpha subunits the ability to promote neoplastic transformation in cultured mammalian cells, G(z), a G protein whose normal signaling function is poorly understood, shares with G(i2) the ability to inhibit adenylyl cyclase. We asked whether mutationally activated alpha(z) can stimulate cell proliferation in a cell line in which stimulation adenylyl cyclase is mitogenic, Swiss 3T3 cells, Stable expression of alpha(z)-Q205L in Swiss 3T3 cells induced focus formation, a faster growth rate with a higher saturation density, anchorage-independent growth in soft agar, and increased [H-3]thymidine incorporation in the absence of growth factors. alpha(z)-Q205L produced a similar but less extensively transformed phenotype in NIH3T3 cells-increased saturation density in culture, a smaller number of foci and few colonies in soft agar. Stimulation of thymidine incorporation by alpha(z)-Q205L in Swiss 3T3 cells was increased by co-treatment with cholera toxin, a stimulator of adenylyl cyclase. Taken together, our results indicate that a(z) stimulates one or more mitogenic pathways in Swiss 3T3 cells, and that effectiveness of these mitogenic pathways does not require reducing the concentration of cellular cAMP.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; HONG KONG UNIV SCI & TECHNOL,DEPT BIOL,KOWLOON,HONG KONG	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Hong Kong University of Science & Technology								ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BLOCH DB, 1989, MOL CELL BIOL, V9, P5434, DOI 10.1128/MCB.9.12.5434; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUI Z, 1991, J BIOL CHEM, V266, P20276; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; FAURE M, 1994, J BIOL CHEM, V269, P7852; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KROLL SD, 1992, J BIOL CHEM, V267, P23183; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; VOYNOYASENETSKA.TA, 1994, ONCOGENE, V9, P2559; WANG HY, 1993, J PHARMACOL EXP THER, V267, P1002; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1994, METHOD ENZYMOL, V238, P81; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; ZACHARY I, 1987, BIOCHEM BIOPH RES CO, V146, P456, DOI 10.1016/0006-291X(87)90551-1; ZIGMAN JM, 1994, ENDOCRINOLOGY, V135, P31, DOI 10.1210/en.135.1.31	31	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1927	1933						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761094				2022-12-25	WOS:A1995QZ92600006
J	RENZING, J; LANE, DP				RENZING, J; LANE, DP			P53-DEPENDENT GROWTH ARREST FOLLOWING CALCIUM PHOSPHATE-MEDIATED TRANSFECTION OF MURINE FIBROBLASTS	ONCOGENE			English	Note						P53; GROWTH ARREST; CALCIUM PHOSPHATE TRANSFECTION	P53 PROTEIN; DNA; INDUCTION; UV	A variety of genotoxic agents can induce an accumulation of p53 protein in the nuclei of mammalian cells and lead to either growth arrest or apoptosis in a p53-dependent manner. Recently, the induction of the p53 pathway has also been reported for non-genotoxic agents such as heat shock and hypoxia, rendering it likely that p53 activity might be triggered by a wider range of cellular stress factors. Here we report the effect of calcium phosphate-mediated transfection, a technique commonly used in studies of transient gene expression in mammalian cells, on fibroblasts containing wild-type p53. Incubation with a calcium phosphate precipitate results in a transient growth arrest in the presence or absence of plasmid DNA. The effect is accompanied by a rise in p53 protein levels and increased transcription of a p53-dependent reporter construct and is not observed in fibroblasts derived from p53 knockout mice.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DOVER R, 1994, J CELL SCI, V107, P1181; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HALL PA, 1993, ONCOGENE, V8, P203; HARVEY M, 1993, ONCOGENE, V8, P2457; KASTAN MB, 1991, CANCER RES, V51, P6304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MANIATIS T, 1990, MOL CLONING; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	16	84	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1865	1868						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753562				2022-12-25	WOS:A1995QX46900020
J	SINGER, TP; RAMSAY, RR				SINGER, TP; RAMSAY, RR			FLAVOPROTEIN STRUCTURE AND MECHANISM .2. MONOAMINE OXIDASES - OLD FRIENDS HOLD MANY SURPRISES	FASEB JOURNAL			English	Review						AGING; INHIBITORS; PARKINSONS DISEASE	SUICIDE INACTIVATION; OXIDATION; FLAVIN; BOVINE; ANALOGS; AMINE; MPTP; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; IDENTIFICATION	The two forms of monoamine oxidase (MAO), A and B, continue to be of major interest to biochemists, pharmacologists, neurologists, and gerontologists. Despite intensive study for more than half a century, unexpected and unique properties of these enzymes continue to come to light. Recent studies have centered on their kinetic mechanism, their unique predilection for substrates related to the neurotoxic tertiary amine MPTP, and their putative role in aging and in the etiology of neurodegenerative diseases. New and potent inhibitors of MAO A and MAO B continue to be developed because of their potential use in clinical medicine. Some are effective in the picomolar range but MAO B from different mammalian species shows remarkable differences in sensitivity to these agents.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DIV TOXICOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SINGER, TP (corresponding author), DEPT VET AFFAIRS MED CTR, DIV MOLEC BIOL, 151-S, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA.		Ramsay, Rona/A-4065-2009; Ramsay, Rona R./A-6681-2008	Ramsay, Rona R./0000-0003-1535-4904				BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BENEDETTI MS, 1987, J NEURAL TRANSM, P103; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; EFANGE SMN, 1993, J MED CHEM, V36, P1278, DOI 10.1021/jm00061a020; ERWIN VG, 1967, J BIOL CHEM, V242, P4230; HOUSLAY MD, 1973, BIOCHEM J, V135, P173, DOI 10.1042/bj1350173; HUSAIN M, 1982, BIOCHEMISTRY-US, V21, P595, DOI 10.1021/bi00532a028; KNOLL J, 1992, PHARMACOL TOXICOL, V70, P317, DOI 10.1111/j.1600-0773.1992.tb00480.x; KNOLL J, 1993, J NEURAL TRANSM-GEN, P69; LANGSTON JW, 1984, SCIENCE, V225, P1480, DOI 10.1126/science.6332378; MANTLE TJ, 1975, BIOCHEM PHARMACOL, V24, P2031, DOI 10.1016/0006-2952(75)90099-4; MAZOUZ F, 1993, J MED CHEM, V36, P1157, DOI 10.1021/jm00061a006; NAGY J, 1981, ARCH BIOCHEM BIOPHYS, V208, P388, DOI 10.1016/0003-9861(81)90523-3; PAECH C, 1980, J BIOL CHEM, V255, P2700; RAMSAY RR, 1987, BIOCHEMISTRY-US, V26, P3045, DOI 10.1021/bi00385a015; Ramsay RR, 1994, FLAVINS AND FLAVOPROTEINS 1993, P99; RAMSAY RR, 1991, BIOCHEMISTRY-US, V30, P4624, DOI 10.1021/bi00232a038; SABLIN SO, 1994, J MED CHEM, V37, P151, DOI 10.1021/jm00027a019; SALACH JI, 1984, BIOCHEM BIOPH RES CO, V125, P831, DOI 10.1016/0006-291X(84)90614-4; SALACH JI, 1979, ARCH BIOCHEM BIOPHYS, V192, P128, DOI 10.1016/0003-9861(79)90078-X; SAYRE LM, 1989, TOXICOL LETT, V48, P121, DOI 10.1016/0378-4274(89)90168-9; SHOULSON I, 1989, NEW ENGL J MED, V321, P1364; Silverman R. B., 1992, ADV ELECTRON TRANSFE, P177; SILVERMAN RB, 1986, BIOCHEM BIOPH RES CO, V135, P154, DOI 10.1016/0006-291X(86)90955-1; SILVERMAN RB, 1987, J AM CHEM SOC, V109, P2219, DOI 10.1021/ja00241a070; Singer T. P, 1991, CHEM BIOCH FLAVOENZY, V2, P437; SINGER TP, IN PRESS PROG BRAIN; SZELENYI I, 1993, INHIBITION MONOAMINE; TAN AK, 1993, BIOCHEMISTRY-US, V32, P2137, DOI 10.1021/bi00060a003; TIPTON KF, 1968, BIOCHIM BIOPHYS ACTA, V159, P451, DOI 10.1016/0005-2744(68)90129-0; URBAN P, 1991, FEBS LETT, V286, P142, DOI 10.1016/0014-5793(91)80960-B; WALKER MC, 1994, BIOCHEMISTRY-US, V33, P7088, DOI 10.1021/bi00189a011; WALKER WH, 1971, EUR J BIOCHEM, V24, P328, DOI 10.1111/j.1432-1033.1971.tb19690.x; WEYLER W, 1985, J BIOL CHEM, V260, P3199; WEYLER W, 1990, BIOCHEM BIOPH RES CO, V173, P1205, DOI 10.1016/S0006-291X(05)80914-3; WEYLER W, 1981, ARCH BIOCHEM BIOPHYS, V212, P147, DOI 10.1016/0003-9861(81)90353-2; WU HF, 1993, MOL PHARMACOL, V43, P888; YAGI K, 1982, BIOCHEM INT, V4, P457; YOUNGSTER SK, 1989, J NEUROCHEM, V53, P1837, DOI 10.1111/j.1471-4159.1989.tb09250.x; YUE KT, 1993, ARCH BIOCHEM BIOPHYS, V300, P178, DOI 10.1006/abbi.1993.1025	40	65	65	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1995	9	8					605	610		10.1096/fasebj.9.8.7768351	http://dx.doi.org/10.1096/fasebj.9.8.7768351			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768351				2022-12-25	WOS:A1995RC10600005
J	DAGOSTARO, GAF; ZINGONI, A; MORITZ, RL; SIMPSON, RJ; SCHACHTER, H; BENDIAK, B				DAGOSTARO, GAF; ZINGONI, A; MORITZ, RL; SIMPSON, RJ; SCHACHTER, H; BENDIAK, B			MOLECULAR-CLONING AND EXPRESSION OF CDNA-ENCODING THE RAT UDP-N-ACETYLGLUCOSAMINE-ALPHA-6-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; ASPARAGINE-LINKED OLIGOSACCHARIDES; EUKARYOTIC MESSENGER-RNAS; 3' UNTRANSLATED REGION; ALPHA-MANNOSIDASE-II; SEQUENCE-ANALYSIS; GLYCOPROTEIN-SYNTHESIS; MEMBRANE-PROTEINS; GOLGI-APPARATUS; GLYCOSYLATION	UDP-N-acetyl-D-glucosamine:alpha-6-D-mannoside beta-1,2-N-acetylglucosaminyltransferase II (EC 2.4.1.143) (GnT II) is a Golgi resident enzyme that catalyzes an essential step in the biosynthetic pathway leading from high mannose to complex N-linked oligosaccharides. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the enzyme purified from rat liver revealed a polypeptide of 42 kDa. Amino acid sequences were obtained from the N terminus and a tryptic peptide. Overlapping cDNA clones coding for the full-length rat GnT II were obtained. The complete nucleotide sequence revealed a 1326-base pair open reading frame that codes for a polypeptide of 442 amino acids, including a presumptive N-terminal membrane-anchoring domain. The region of cDNA coding for the C-terminal 389 amino acids of rat GnT II was linked in frame to a cDNA segment encoding the cleavable signal sequence of the human interleukin-2 receptor and transiently expressed in COS-7 cells. A 77-fold enhancement of GnT II activity over a control carrying the GnT II cDNA out-of-frame was detected in the culture medium at 72 h after transfection. H-1-NMR spectroscopy confirmed that the oligosaccharide synthesized in vitro by the recombinant enzyme was the product of GnT II activity. These data verify the identity of the cloned GnT II cDNA and demonstrate that the C-terminal region of the protein includes the catalytic domain.	BIOMEMBRANE INST,SEATTLE,WA 98119; UNIV WASHINGTON,SEATTLE,WA 98119; ENEA,BIOPHYS LAB,I-00060 CASACCIA,ITALY; ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,JOINT PROT STRUCT LAB,MELBOURNE,VIC 3050,AUSTRALIA; WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; HOSP SICK CHILDREN,DEPT BIOCHEM,TORONTO,ON M5G 1X8,CANADA	University of Washington; University of Washington Seattle; Italian National Agency New Technical Energy & Sustainable Economics Development; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Zingoni, Alessandra/AAC-5481-2022; Moritz, Robert L/B-9222-2011	Simpson, Richard/0000-0002-9834-0796				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BENDIAK B, 1987, J BIOL CHEM, V262, P5784; BENDIAK B, 1985, CARBOHYD RES, V144, P1, DOI 10.1016/0008-6215(85)85001-1; BENDIAK B, 1988, ANAL BIOCHEM, V175, P96, DOI 10.1016/0003-2697(88)90366-1; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BINDER R, 1989, J BIOL CHEM, V264, P16910; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FILBIN MT, 1993, J CELL BIOL, V122, P451, DOI 10.1083/jcb.122.2.451; FUKUDA M N, 1990, Glycobiology, V1, P9, DOI 10.1093/glycob/1.1.9; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; GREGO B, 1985, EUR J BIOCHEM, V148, P485, DOI 10.1111/j.1432-1033.1985.tb08865.x; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JAEKEN J, 1994, ARCH DIS CHILD, V71, P123, DOI 10.1136/adc.71.2.123; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOMEDICO P, 1979, CELL, V18, P545, DOI 10.1016/0092-8674(79)90071-0; MANLEY JL, 1994, GENE DEV, V8, P259, DOI 10.1101/gad.8.3.259; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; POWNALL S, 1992, GENOMICS, V12, P699, DOI 10.1016/0888-7543(92)90297-6; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; SACHS A, 1993, J BIOL CHEM, V268, P22955; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHACHTER H, 1983, CAN J BIOCHEM CELL B, V61, P1049, DOI 10.1139/o83-134; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SIMPSON RJ, 1989, ANAL BIOCHEM, V177, P221, DOI 10.1016/0003-2697(89)90044-4; VANHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WARD LD, 1990, J CHROMATOGR, V519, P199, DOI 10.1016/0021-9673(90)85148-O	56	46	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15211	15221		10.1074/jbc.270.25.15211	http://dx.doi.org/10.1074/jbc.270.25.15211			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797505	hybrid			2022-12-25	WOS:A1995RE66600056
J	KALMAN, VK; ERDMAN, RA; MALTESE, WA; ROBISHAW, JD				KALMAN, VK; ERDMAN, RA; MALTESE, WA; ROBISHAW, JD			REGIONS OUTSIDE OF THE CAAX MOTIF INFLUENCE THE SPECIFICITY OF PRENYLATION OF G-PROTEIN GAMMA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; BETA-GAMMA; RAS PROTEINS; POSTTRANSLATIONAL MODIFICATION; BACULOVIRUS SYSTEM; TERMINAL CYSTEINE; ALPHA-SUBUNITS; AMINO-ACID; FARNESYLTRANSFERASE; CELLS	A family of GTP-binding regulatory proteins (G proteins) transduces signals across the plasma membrane from a large number of receptors to a smaller number of effecters. Recent studies indicate that a series of post-translational modifications are required for their association with the plasma membrane and for their function. In the case of the G protein gamma subunits, the post-translational modifications include the prenylation of a cysteine residue within a carboxyl-terminal CAAX motif. Although prenylation has been shown to involve the addition of either a C-15 farnesyl or a C-20 geranylgeranyl group to proteins, the structural requirements and functional consequences of adding different types of prenyl groups to various members of the gamma subunit family have not been examined. In the present study, we have employed the baculovirus expression system to study the structural requirements for attaching different types of prenyl groups to various members of the gamma subunit family. We show that the gamma(2) subunit is modified by a C-20 geranylgeranyl group, consistent with the presence of a geranylgeranylation target sequence in this protein. However, we found that the gamma(1) and mutant gamma(2(ser-71)) subunits are modified by both C-15 farnesyl and C-20 geranylgeranyl groups, despite the presence of an accepted farnesylation target sequence in both of these proteins. Using chimeras of the gamma(1) and gamma(2) subunits, we provide evidence indicating that structural elements upstream of the carboxyl-terminal CAAX motif play a role in the recognition of members of the gamma subunit family by the appropriate insect and mammalian prenyltransferases.	GEISINGER MED CLIN,WEIS CTR RES,DANVILLE,PA 17822	Geisinger Medical Center					NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039867, R29GM039867] Funding Source: NIH RePORTER; NCI NIH HHS [CA34569] Funding Source: Medline; NIGMS NIH HHS [GM39867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CALDWELL GA, 1994, P NATL ACAD SCI USA, V91, P1275, DOI 10.1073/pnas.91.4.1275; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HIGGINS JB, 1991, J BIOL CHEM, V269, P9067; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LOWE PN, 1990, ONCOGENE, V5, P1045; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; RAHMATULLAH M, 1994, J BIOL CHEM, V269, P3574; RAHMATULLAH M, 1995, J BIOL CHEM, V270, P2946, DOI 10.1074/jbc.270.7.2946; REISS Y, 1991, J BIOL CHEM, V266, P10672; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; UEDA N, 1994, J BIOL CHEM, V269, P4388; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794	43	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14835	14841		10.1074/jbc.270.24.14835	http://dx.doi.org/10.1074/jbc.270.24.14835			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782351	hybrid			2022-12-25	WOS:A1995RD45500089
J	KAZANIETZ, MG; BARCHI, JJ; OMICHINSKI, JG; BLUMBERG, PM				KAZANIETZ, MG; BARCHI, JJ; OMICHINSKI, JG; BLUMBERG, PM			LOW-AFFINITY FINDING OF PHORBOL ESTERS TO PROTEIN-KINASE-C AND ITS RECOMBINANT CYSTEINE-RICH REGION IN THE ABSENCE OF PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							12,13-DIBUTYRATE BINDING; CAENORHABDITIS-ELEGANS; REGULATORY DOMAIN; UNC-13 GENE; ACTIVATION; RECEPTOR; BRAIN; PHOSPHATIDYLSERINE; SEQUENCE; PRODUCT	Binding of phorbol esters to protein kinase C (PKC) has been regarded as dependent on phospholipids, with phosphatidylserine being the most effective for reconstituting binding. By using a purified single cysteine-rich region from PKC delta expressed in Escherichia coli we were able to demonstrate that specific binding of [H-3]phorbol 12,13-dibutyrate to the receptor still takes place in the absence of the phospholipid cofactor. However, [H-3]phorbol 12,13-dibutyrate bound to the cysteine rich region with 80-fold lower affinity in the absence than in the presence of 100 mu g/ml phosphatidlylserine. Similar results were observed with the intact recombinant PRC delta isolated from insect cells. When different phorbol derivatives were examined, distinct structure-activity relations for the cysteine-rich region were found in the presence and absence of phospholipid. Our results have potential implications for PKC translocation, for inhibitor design, and for PKC structural determination.	NCI,MED CHEM LAB,BETHESDA,MD 20892; NIDDK,CHEM PHYS LAB,BETHESDA,MD 20892; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,MOLEC MECHANISMS TUMOR PROMOT SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Barchi, Joseph J/N-3784-2014	Barchi, Joseph/0000-0001-9906-0799				AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; ARECESLB, 1994, J BIOL CHEM, V269, P19553; BLUMBERG PM, 1988, CANCER RES, V48, P1; BLUMBERG PM, 1984, MECHANISMS TUMOR PRO, V3, P143; DASILVA C, 1990, CANCER RES, V50, P2081; DUNPHY WG, 1981, CANCER RES, V41, P2640; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KONIG B, 1985, J CELL BIOCHEM, V27, P255, DOI 10.1002/jcb.240270307; LUO JH, 1993, J BIOL CHEM, V268, P3715; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; NAKADATE T, 1987, CANCER RES, V47, P6537; Nakakuma H, 1989, Cancer Commun, V1, P127; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; SHARKEY NA, 1985, CANCER RES, V45, P19; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZALLASI Z, 1995, MOL PHARMACOL, V47, P258; TURNER JT, 1987, J PHARMACOL EXP THER, V242, P873; WENDER PA, 1995, P NATL ACAD SCI USA, V92, P239, DOI 10.1073/pnas.92.1.239	27	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14679	14684		10.1074/jbc.270.24.14679	http://dx.doi.org/10.1074/jbc.270.24.14679			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782331	hybrid			2022-12-25	WOS:A1995RD45500067
J	KOSTER, JC; BLANCO, G; MERCER, RW				KOSTER, JC; BLANCO, G; MERCER, RW			A CYTOPLASMIC REGION OF THE NA,K-ATPASE ALPHA-SUBUNIT IS NECESSARY FOR SPECIFIC ALPHA/ALPHA ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ADENOSINE-TRIPHOSPHATASE; PERFORMANCE GEL CHROMATOGRAPHY; LASER-LIGHT SCATTERING; INFECTED INSECT CELLS; (NA+ + K+)-ATPASE; BETA-UNITS; MOLECULAR-CLONING; ATPASE ACTIVITY; RAT-BRAIN; K+-ATPASE	While most structural studies of the Na,K-ATPase support a subunit stoichiometry of one alpha subunit to one beta-subunit, the exact quaternary structure of the Na,K-ATPase and its relevance to enzyme function is the subject of much debate. Formation of a higher order enzyme complex is supported by our previous study demonstrating specific alpha/alpha interactions among the rat Na,K-ATPase isoforms (alpha 1, alpha 2, alpha 3), expressed in virally infected Sf-9 insect cells and among native alpha isoforms in rat brain (1). This detergent-resistant association was not observed in insect cells coexpressing the homologous gastric H,B-ATPase alpha-subunit, nor was it dependent on the coexpression of the beta-subunit. To delineate domains necessary for alpha/alpha assembly, a series of H,K-ATPase-Na,K-ATPase chimeras were constructed by combining the N-terminal, cytoplasmic midregion and C-terminal segments derived hom the Na,K-ATPase (N) and the H,K-ATPase (H) alpha-polypeptides (HNN, HNH, NHH, NHN, and HHN), The alpha-subunit chimeras were coexpressed with the Na,R-ATPase alpha 1-subunit in Sf-9 cells using the baculovirus expression system. Specific and detergent-stable association is observed between the Na,R-ATPase alpha-subunit and the HNN and HNH chimeras, but not with the NHH, NHN, or HHN chimeras. Consistent with the Na,K-ATPase cytoplasmic domain as being necessary for alpha/alpha interactions, the full-length alpha-subunit stably associates with an alpha N-terminal deletion mutant (Delta Gly(2)-Leu(273)), but not with an alpha cytoplasmic deletion mutant (Delta Arg(350)-Pro(785)). In addition, the naturally occurring C-terminal truncated alpha 1 isoform, alpha 1T (Delta Gly(554) to, C terminus), does not associate with the alpha 1-subunit in Sf-9 cells coexpressing both polypeptides. Thus, a cytoplasmic region in the alpha-subunit (Gly(554)-Pro(785)) is necessary for specific alpha/alpha association. The same cytoplasmic region contains a strongly hydrophobic segment that, by analogy with oligomerization of water-soluble proteins, may form the interface of the extramembranous alpha/alpha contact site.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Mercer, Robert/F-5918-2012		NIGMS NIH HHS [GM 39746] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039746, R29GM039746] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKARI A, 1980, BIOCHEMISTRY-US, V19, P1132, DOI 10.1021/bi00547a015; Blanco G, 1988, Prog Clin Biol Res, V268A, P271; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; BLANCO G, 1994, SODIUM PUMP, P82; BLANCO G, 1993, P NATL ACAD SCI USA, V90, P1824, DOI 10.1073/pnas.90.5.1824; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; CANTLEY LC, 1981, CURR TOP BIOENERG, V11, P201; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; CRAIG WS, 1982, BIOCHEMISTRY-US, V21, P5707, DOI 10.1021/bi00265a049; CRAIG WS, 1980, J BIOL CHEM, V255, P6262; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; ELLORY JC, 1979, J PHYSIOL-LONDON, V295, P10; ESMANN M, 1980, BIOCHIM BIOPHYS ACTA, V603, P1, DOI 10.1016/0005-2736(80)90386-7; GANJEIZADEH M, 1992, BIOPHYS J, V61, P122; GANJEIZADEH M, 1991, BIOPHYS J, V59, P343; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; HAYASHI Y, 1983, BIOCHIM BIOPHYS ACTA, V748, P153, DOI 10.1016/0167-4838(83)90291-1; HEBERT H, 1982, BIOCHIM BIOPHYS ACTA, V689, P571, DOI 10.1016/0005-2736(82)90316-9; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HUANG WH, 1981, BIOCHIM BIOPHYS ACTA, V645, P54, DOI 10.1016/0005-2736(81)90511-3; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; KASHGARIAN M, 1985, KIDNEY INT, V28, P899, DOI 10.1038/ki.1985.216; KLASSEN CHW, 1993, FEBS LETT, V329, P277; KOSTER JC, 1994, SODIUM PUMP, P90; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MEDFORD RM, 1991, J BIOL CHEM, V266, P18308; Mercer Robert W., 1993, V137C, P139; MILLER S, 1989, PROTEIN ENG, V3, P77, DOI 10.1093/protein/3.2.77; MODYANOV N, 1991, SOC GEN PHY, V46, P99; NICHOLAS RA, 1984, BIOCHEMISTRY-US, V23, P888, DOI 10.1021/bi00300a015; NORBY JG, 1991, SOC GEN PHY, V46, P173; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; PRESSLEY TA, 1992, AM J PHYSIOL, V262, pC743, DOI 10.1152/ajpcell.1992.262.3.C743; Reynolds J A, 1988, Prog Clin Biol Res, V268A, P137; SACHS JR, 1994, BBA-BIOMEMBRANES, V1193, P199, DOI 10.1016/0005-2736(94)90349-2; SCHONER W, 1994, SODIUM PUMP, P332; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SKRIVER E, 1981, FEBS LETT, V131, P219, DOI 10.1016/0014-5793(81)80371-7; SMOLKA A, 1991, BIOCHEM BIOPH RES CO, V180, P1356, DOI 10.1016/S0006-291X(05)81345-2; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; VILSEN B, 1987, J BIOL CHEM, V262, P10511; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332	49	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14332	14339		10.1074/jbc.270.24.14332	http://dx.doi.org/10.1074/jbc.270.24.14332			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782292	hybrid			2022-12-25	WOS:A1995RD45500018
J	NAIDOO, N; COOPERMAN, BS; WANG, ZM; LIU, XZ; RUBIN, H				NAIDOO, N; COOPERMAN, BS; WANG, ZM; LIU, XZ; RUBIN, H			IDENTIFICATION OF LYSINES WITHIN ALPHA-1-ANTICHYMOTRYPSIN IMPORTANT FOR DNA-BINDING - AN UNUSUAL COMBINATION OF DNA-BINDING ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC ENDONUCLEASE; GEL-ELECTROPHORESIS; ELASTASE INHIBITOR; CDNA CLONES; PROTEIN; ALPHA-1-ANTITRYPSIN; SEQUENCE; PLASMA; TRANSCRIPTION; PURIFICATION	The human serum serine protease inhibitor (serpin) alpha 1-antichymotrypsin (ACT) appears to be unique among serpins in its ability to bind to double-stranded DNA. Using site-directed mutagenesis and chemical modification, a tri-lysine sequence (residues 210-212) falling within a solvent exposed loop and the C-terminal peptide containing two lysines (residues 391 and 396) were shown to be important for DNA binding. Mutation of residues 210-212 from lysines to either glutamates or threonines abolished DNA binding. The Lys(210)-Thr(211)-Lys(212) and Thr(210)-Th4(211)-Lys(212) variants displayed reduced affinity for DNA, especially at higher ionic strength. Limited acetylation of rACT with acetic anhydride led to loss of DNA binding and, conversely, DNA protected rACT from acetylation. A combination of CNBr digestion, peptide separation, and peptide sequencing identified Lys(396), two residues from the C terminus, as the most reactive lysine in rACT. Acetylation of Lys(396) is strongly decreased in the presence of DNA. The double mutant K391T/K396T-rACT had very little affinity for DNA. The epsilon-amines of lysines 210-212 are 8-15 Angstrom across a cleft from the epsilon-amines in Lys(391) adn Lys(396), and together these two elements may form an unusual DNA binding domain. Attempts to isolate a DNA sequence to which ACT binds specifically have been unsuccessful to date, raising the possibility that nonspecific binding of ACT to DNA suffices to account for the ACT found in certain cell nuclei. ACT variants not binding to double stranded DNA retain ACT protease inhibitory activity, a potentially important result for the use of ACT variants as therapeutic agents.	UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Naidoo, Nirinjini/0000-0002-7463-2559	NATIONAL INSTITUTE ON AGING [R01AG010599] Funding Source: NIH RePORTER; NIA NIH HHS [AG-10599] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ABRAHAM CR, 1992, RES IMMUNOL, V143, P631, DOI 10.1016/0923-2494(92)80047-O; ADDISON C, 1990, ONCOGENE, V5, P423; BAO JJ, 1987, BIOCHEMISTRY-US, V26, P7755, DOI 10.1021/bi00398a033; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23626; DANG CV, 1989, J BIOL CHEM, V264, P18019; DUBIN A, 1992, J BIOL CHEM, V267, P6576; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GROSS E, 1962, J BIOL CHEM, V237, P1856; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAMILTON WDO, 1987, J GEN VIROL, V68, P2563, DOI 10.1099/0022-1317-68-10-2563; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HILL RE, 1984, NATURE, V311, P175, DOI 10.1038/311175a0; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JANZON L, 1990, EMBO J, V5, P1391; JOHNSON JL, 1990, THESIS U PENNSYLVANI; KATSUNUMA T, 1980, BIOCHEM BIOPH RES CO, V93, P552, DOI 10.1016/0006-291X(80)91112-2; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; LINDMARK BE, 1985, CLIN CHIM ACTA, V152, P261, DOI 10.1016/0009-8981(85)90101-9; Maniatis T., 1982, MOL CLONING; NAIDOO N, 1994, THESIS U PENNSYULVAN; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; POTEMPA J, 1991, BIOCHEM J, V274, P465, DOI 10.1042/bj2740465; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; ROBSON CN, 1991, NUCLEIC ACIDS RES, V20, P4417; ROWLAND SJ, 1989, EMBO J, V8, P2761, DOI 10.1002/j.1460-2075.1989.tb08418.x; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; STRAUSS HS, 1980, BIOCHEMISTRY-US, V19, P3496, DOI 10.1021/bi00556a014; STRUCK JCR, 1990, BIOCHIM BIOPHYS ACTA, V1050, P80, DOI 10.1016/0167-4781(90)90145-R; SUZUKI Y, 1990, J BIOCHEM, V108, P344, DOI 10.1093/oxfordjournals.jbchem.a123204; TAHARA E, 1984, HUM PATHOL, V15, P957, DOI 10.1016/S0046-8177(84)80125-2; TAKADA S, 1982, GANN, V73, P742; TAKADA S, 1986, CANCER RES, V46, P3688; TAKADA S, 1988, BIOCHEM INT, V16, P949; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TSUDA M, 1987, BIOCHEM BIOPH RES CO, V144, P409, DOI 10.1016/S0006-291X(87)80525-9; TSUDA M, 1986, CANCER RES, V46, P6139; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEI A, 1994, NAT STRUCT BIOL, V1, P250; YARUS M, 1970, ANAL BIOCHEM, V35, P450, DOI 10.1016/0003-2697(70)90207-1	56	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14548	14555		10.1074/jbc.270.24.14548	http://dx.doi.org/10.1074/jbc.270.24.14548			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782318	hybrid			2022-12-25	WOS:A1995RD45500049
J	BOLINO, A; SCHUFFENECKER, I; LUO, Y; SERI, M; SILENGO, M; TOCCO, T; CHABRIER, G; HOUDENT, C; MURAT, A; SCHLUMBERGER, M; TOURNIAIRE, J; LENOIR, GM; ROMEO, G				BOLINO, A; SCHUFFENECKER, I; LUO, Y; SERI, M; SILENGO, M; TOCCO, T; CHABRIER, G; HOUDENT, C; MURAT, A; SCHLUMBERGER, M; TOURNIAIRE, J; LENOIR, GM; ROMEO, G			RET MUTATIONS IN EXON-13 AND EXON-14 OF FMTC PATIENTS	ONCOGENE			English	Note						FAMILIAL MEDULLARY THYROID CARCINOMA; RET PROTOONCOGENE; MUTATIONS; SINGLE STRAND CONFORMATION POLYMORPHISM	ENDOCRINE NEOPLASIA TYPE-2A; CHROMOSOME 10Q11.2; PROTOONCOGENE; GENE; LINKAGE; REGION; MEN2A; LOCUS; MAP; 2A	RET is a receptor tyrosine kinase gene which is responsible for three different inherited cancer syndromes namely multiple endocrine neoplasia type 2A (MEN 2A), type 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC) as web as for Hirschsprung disease (HSCR), a congenital disorder affecting the intestinal motility. Germ-line mutations in the RET exons 10 and 11 were demonstrated in the majority of the MEN 2A and FMTC patients, On the other hand, one codon of RET exon 16 is preferentially changed in MEN 2B patients, Recently, a germ-line mutation in the exon 13 was described in one FMTC family as well as in four sporadic MTCs. In the present study, we observed the same exon 13 mutation in two FMTC families. In addition, we identified a previously unreported substitution of RET exon 14 in two unrelated FMTC families. Both mutations segregate with the disease in these four FMTC families and involve the tyrosine kinase domain of RET. Haplotype analysis using polymorphic markers tightly Linked to the RET gene indicates that in each pedigree the mutation arose as an independent event.	IST GIANNINA GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY; HOP EDOUARD HERRIOT,GENET LAB,LYON 03,FRANCE; UNIV TURIN,IST SCI PEDIAT,I-10100 TURIN,ITALY; HOP HAUTE PIERRE,SERV MED INTERNE,STRASBOURG,FRANCE; HOP BOIS GUILLAUME,SERV ENDOCRINOL,ROUEN,FRANCE; HOP HOTEL DIEU,SERV ENDOCRINOL,NANTES,FRANCE; INST GUSTAVE ROUSSY,NUCL MED SERV,PARIS,FRANCE; HOP ANTIQUAILLE,SERV ENDOCRINOL,LYON,FRANCE	University of Genoa; IRCCS Istituto Giannina Gaslini; CHU Lyon; University of Turin; CHU Strasbourg; CHU de Rouen; Nantes Universite; CHU de Nantes; UNICANCER; Gustave Roussy; CHU Lyon			Bolino, Alessandra/O-2933-2013; Seri, Marco/A-4339-2014	Silengo, Margherita/0000-0002-6255-1532; Seri, Marco/0000-0003-2425-2176; Bolino, Alessandra/0000-0002-8980-4878				BROOKSWILSON AR, 1990, NUCLEIC ACIDS RES, V18, P16; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, J ENDOCRINOL INVEST, V17, P201; CECCHERINI I, 1994, ONCOGENE, V9, P1; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1994, IN PRESS ONCOGENE; GARDNER E, 1993, HUM MOL GENET, V2, P241, DOI 10.1093/hmg/2.3.241; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; LAIRMORE TC, 1993, P NATL ACAD SCI USA, V90, P492, DOI 10.1073/pnas.90.2.492; LAIRMORE TC, 1991, GENOMICS, V9, P181, DOI 10.1016/0888-7543(91)90237-9; LOVE DR, 1993, HUM MOL GENET, V2, P491, DOI 10.1093/hmg/2.4.491-a; MCMAHON R, 1994, HUM MOL GENET, V3, P643, DOI 10.1093/hmg/3.4.643; MOLE SE, 1993, HUM MOL GENET, V2, P247, DOI 10.1093/hmg/2.3.247; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NAKAMURA Y, 1989, GENOMICS, V5, P199, DOI 10.1016/0888-7543(89)90046-3; NORUM RA, 1990, GENOMICS, V8, P313, DOI 10.1016/0888-7543(90)90287-5; PASINI B, 1995, IN PRESS NATURE GENE; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, NUCLEIC ACIDS RES, V18, P7472, DOI 10.1093/nar/18.24.7472-a	23	227	234	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2415	2419						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784092				2022-12-25	WOS:A1995RE54300019
J	SPITKOVSKY, D; STEINER, P; GOPALKRISHNAN, RV; EILERS, M; JANSENDURR, P				SPITKOVSKY, D; STEINER, P; GOPALKRISHNAN, RV; EILERS, M; JANSENDURR, P			THE ROLE OF P53 IN COORDINATED REGULATION OF CYCLIN D1 AND P21 GENE-EXPRESSION BY THE ADENOVIRUS E1A AND E1B ONCOGENES	ONCOGENE			English	Note						ADENOVIRUS E1A; ADENOVIRUS EIB; CYCLIN D1; P53; P2L(WAF-1); CIP-1	CELL-CYCLE; PROTEIN; TRANSFORMATION; MUTANT; PHOSPHORYLATION; LOCALIZATION; FIBROBLASTS; INHIBITION; PRODUCTS; G(1)	Expression of the cyclin D1 gene is induced when quiescent fibroblasts are stimulated to reenter the cell cycle by addition of growth factors. Moderate ectopic expression of cyclin D1 in early G1 facilitates progression through G1, When transiently overexpressed at the G1/S boundary, cyclin D1 prevents S phase entry, suggesting a dual role for this protein in cellular growth control. It was shown that the retinoblastoma protein (pRB) can activate cyclin D1 gene expression; furthermore, there is evidence that expression of the cyclin D1 gene is down-regulated by the SV40 large T and adenovirus E1A genes, both of which were shown to target pRB, We now report that in diploid human fibroblasts functional inactivation of pRB by adenovirus E1A is not sufficient for efficient repression Of cyclin D1 gene expression, since the E1B gene product, in addition to E1A, is required for repression of the cyclin D1 gene. Since E1B was shown to target p53, we investigated the role of p53 for expression of the cyclin D1 gene. In a cell line with temperature-sensitive p53, cyclin D1 is moderately expressed at the restrictive temperature. Induction of p53 function by temperature shift leads to an increase of cyclin D1 mRNA and protein, parallel to the activation of p21(WAF-1/CIP1) gene expression in this system, When the capability of adenovirus gene products to affect expression of either gene was analysed, we found that infection of Ad5 drastically reduced cyclin D1 and p21(WAF-1/CIP1) gene expression in cells where p53 function is limiting. Under these conditions E1A and E1B cooperate to reduce the cyclin D1 level, while p21(WAF-1)/(CIP1) expression was found insensitive to E1A expression. In cells containing elevated p53 function, modulation of gene expression by E1B was severely compromised; under these conditions, expression of E1A reduced expression of cyclin D1 without affecting p21(WAF-1/CIP1). The data suggest that E1A and E1B cooperate to inhibit expression of cyclin D1 and identify the cyclin D1 gene as a new downstream target for p53.	DEUTSCH KREBSFORSCHUNGSZENTRUM,ABT 620,D-69120 HEIDELBERG,GERMANY; ZENTRUM MOLEK BIOL HEIDELBERG,D-69120 HEIDELBERG,GERMANY; INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Institut National de la Sante et de la Recherche Medicale (Inserm)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Eilers, Martin/0000-0002-0376-6533				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUPPI K, 1994, ONCOGENE, V9, P3017; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P2547; KATO J, 1993, GENE DEV, V7, P331; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHULZE A, 1994, ONCOGENE, V9, P3475; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; TAM SW, 1994, ONCOGENE, V9, P2663; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	30	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2421	2425						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784093				2022-12-25	WOS:A1995RE54300020
J	DRACHEVA, S; KOONIN, EV; CRUTE, JJ				DRACHEVA, S; KOONIN, EV; CRUTE, JJ			IDENTIFICATION OF THE PRIMASE ACTIVE-SITE OF THE HERPES-SIMPLEX VIRUS TYPE-1 HELICASE-PRIMASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ALPHA; PROTEIN; ALIGNMENT; REGION; EXPRESSION; SEQUENCE	Herpes simplex virus type 1 (HSV-1) encodes a heterotrimeric helicase-primase composed of the products of the three DNA replication-specific genes UL5, UL8, and UL52 (Crute, J. J., and Lehman, I. R. (1991) J. Biol. Chem. 266, 4484-4488). The UL5 and UL52 products constitute a heterodimeric subassembly of the holoenzyme that contains both helicase and primase activities (Calder, J. M., and Stow, N. D. (1990) Nucleic Acids Res. 18, 3573-3578; Dodson, M. S., and Lehman, I. R. (1991) Proc. Natl. Bead. Sci. U.S.A. 88, 1105-1109). The role of the UL52 product in the active HSV-1 helicase-primase was examined. A sequence located between residues 610 and 636 on the UL52 protein was found to be conserved among the UL52 homologues of eight herpesviruses. The carboxyl-terminal portion of this conserved sequence consisted of two Asp residues separated by a variable hydrophobic amino acid residue and is analogous to the divalent metal-binding site of DNA polymerases and several DNA primases. This motif has been designated the herpesvirus primase DXD motif. To study the role of the HSV-1 primase DXD motif in primase action, three site-directed changes were introduced into the UL52 gene. The helicase activity of the recombinant holoenzymes was unaffected by any of the introduced changes. Changing either of the two Asp residues that constitute the divalent metal-binding site (Asp(628) or, Asp(630)) to Ala dramatically reduced the primase activity of the HSV-1 helicase-primase holoenzyme in vitro, whereas alteration of the nearby conserved residue Asn(624) to Gly had minimal effect. Therefore, in the three-subunit HSV-1 helicase-primase, the UL52 product provides at least a part of the primase catalytic site.	BOEHRINGER INGELHEIM PHARMACEUT INC, DEPT IMMUNOL DIS, RIDGEFIELD, CT 06877 USA; NIH, NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20894 USA	Boehringer Ingelheim; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baker T. A., 1992, DNA REPLICATION; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CHALLBERG MD, 1991, SEMIN VIROL, V2, P247; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; DODSON MS, 1993, J BIOL CHEM, V268, P1213; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Sambrook J, 1989, MOL CLONING LABORATO; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; TENNEY DJ, 1994, J BIOL CHEM, V269, P5030; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	27	82	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14148	14153		10.1074/jbc.270.23.14148	http://dx.doi.org/10.1074/jbc.270.23.14148			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775476	hybrid			2022-12-25	WOS:A1995RC44800081
J	PANJWANI, N; ZHAO, Z; AHMAD, S; YANG, ZT; JUNGALWALA, F; BAUM, J				PANJWANI, N; ZHAO, Z; AHMAD, S; YANG, ZT; JUNGALWALA, F; BAUM, J			NEOLACTOGLYCOSPHINGOLIPIDS, POTENTIAL MEDIATORS OF CORNEAL EPITHELIAL-CELL MIGRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC ANTIGEN; WOUND CLOSURE; A-BINDING; GLYCOLIPIDS; EXPRESSION; CULTURE; CHAIN; NEOLACTOGLYCOLIPIDS; GLYCOSPHINGOLIPIDS; SULFOGLUCURONYL	Cell migration is a fundamental process of wound repair in biological systems. In an attempt to identify plasma membrane glycoconjugates which mediate cell migration, migrating and nonmigrating rabbit corneal epithelia were analyzed for reactivity with monoclonal antibodies (mAbs) specific for unsubstituted N-acetyl-lactosamine (mAb 1B2), Le(x) (mAbs 7A and MMA), and sialyl Le(x) (mAb CSLEX1) carbohydrate chains of neolactoglycoconjugates. Immunohistochemical analyses indicated that regardless of whether the epithelia analyzed were from corneas of animals in vivo, corneas in organ culture, or cells in tissue culture, migrating cells stained intensely with mAb 1B2, whereas nonmigrating cells either did not stain or stained only weakly. mAbs MMA and 7A stained migrating epithelium as well as basal and middle cell layers of normal, nonmigrating epithelium. mAb CSLEX1 did not stain wounded corneas but stained the superficial cell layer of normal corneal epithelium. Biochemical analyses by TLC immunostaining revealed the presence of three mAb 1B2-reactive glycosphingolipids (GSL), neolactotetraosyl-(nLc(4), paragloboside), neolactohexaosyl- (nLc(6)), and neolacto-octaosylceramide (nLc(8)) in migrating epithelia. In contrast, nonmigrating epithelia contained only trace amounts of these glycolipids. Exogenous addition of nLc(4), but not various other GSLs including a Le(x)-GSL (SSEA-1), stimulated re-epithelialization of wounds in an experimental model of corneal epithelial wound healing. More-over, re-epithelialization of wounds was significantly inhibited by mAb 1B2 but not by mAb MMA. The data suggest that neolacto-GSLs of corneal epithelium may be among the molecules which mediate healing of corneal epithelial wounds by influencing cell migration.	TUFTS UNIV, SCH MED, NEW ENGLAND EYE CTR, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA; EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC, WALTHAM, MA 02254 USA	Tufts University; Tufts University	PANJWANI, N (corresponding author), TUFTS UNIV, SCH MED, DEPT OPHTHALMOL, 136 HARRISON AVE, BOSTON, MA 02111 USA.				NATIONAL EYE INSTITUTE [R01EY009349] Funding Source: NIH RePORTER; NEI NIH HHS [EY07088, EY09349] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHMAD S, 1992, INVEST OPHTH VIS SCI, V33, P892; BASU M, 1972, J BIOL CHEM, V247, P1489; CAVANAGH HD, 1976, T AM ACAD OPHTHALMOL, V81, P754; CAVANAGH HD, 1979, OCULAR SURFACE INT O, V19, P197; CHOU DKH, 1993, J BIOL CHEM, V268, P21727; CHOU DKH, 1990, J NEUROCHEM, V54, P1589, DOI 10.1111/j.1471-4159.1990.tb01209.x; CUMMINGS RD, 1992, BIOESSAYS, V14, P849, DOI 10.1002/bies.950141210; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUKUSHI Y, 1984, J BIOL CHEM, V259, P4681; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GIPSON IK, 1980, INVEST OPHTH VIS SCI, V19, P341; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HAKOMORI SI, 1981, SEMIN HEMATOL, V18, P39; HAKOMORI SI, 1938, HDB LIPID RES, V3, P353; HANNA C, 1966, AM J OPHTHALMOL, V61, P55, DOI 10.1016/0002-9394(66)90747-1; HOLMES EH, 1987, J BIOL CHEM, V262, P11331; JORNA A, 1993, INVEST OPHTH VIS SCI, V34, P1553; JUMBLATT MM, 1983, INVEST OPHTH VIS SCI, V24, P1139; JUMBLATT MM, 1986, INVEST OPHTH VIS SCI, V27, P8; KOJIMA N, 1994, GLYCOCONJUGATE J, V11, P238, DOI 10.1007/BF00731224; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; MACHER BA, 1981, J BIOL CHEM, V256, P1968; MARANI E, 1992, HISTOCHEM J, V24, P852, DOI 10.1007/BF01046357; MATSUSHITA Y, 1990, LAB INVEST, V63, P780; MCLAUGHLIN BJ, 1986, CURR EYE RES, V5, P601, DOI 10.3109/02713688609015125; MOHAN PS, 1990, J NEUROCHEM, V54, P2024, DOI 10.1111/j.1471-4159.1990.tb04907.x; MYOGA A, 1988, CANCER RES, V48, P1512; PANJWANI N, 1986, INVEST OPHTH VIS SCI, V27, P1280; PANJWANI N, 1990, INVEST OPHTH VIS SCI, V31, P689; PANJWANI N, 1995, INVEST OPHTH VIS SCI, V36, P365; PFISTER RR, 1975, INVEST OPHTH VISUAL, V14, P648; RICHARDSON KC, 1960, STAIN TECHNOL, V35, P313, DOI 10.3109/10520296009114754; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOONG HK, 1989, ARCH OPHTHALMOL-CHIC, V107, P1052, DOI 10.1001/archopht.1989.01070020114042; STULTS C, 1993, ARCH BIOCHEM BIOPHYS, V303, P25; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; SUNDSMO JS, 1976, BIOCHEM BIOPH RES CO, V68, P799, DOI 10.1016/0006-291X(76)91216-X; TAKI T, 1985, J BIOCHEM-TOKYO, V98, P887, DOI 10.1093/oxfordjournals.jbchem.a135368; TRINKAUSRANDALL V, 1988, CELL TISSUE RES, V251, P315, DOI 10.1007/BF00215839; WATANABE H, 1995, INVEST OPHTH VIS SCI, V36, P337; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WILLIAMS MA, 1988, J LIPID RES, V29, P1613; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3045, DOI 10.1073/pnas.82.9.3045; YOUNG WW, 1981, J BIOL CHEM, V256, P967; ZHAO Z, 1992, INVEST OPHTH VIS SCI, V33, P891; ZIESKE JD, 1986, INVEST OPHTH VIS SCI, V27, P1205	48	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14015	14023		10.1074/jbc.270.23.14015	http://dx.doi.org/10.1074/jbc.270.23.14015			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775461	hybrid			2022-12-25	WOS:A1995RC44800063
J	JOLY, M; KAZLAUSKAS, A; CORVERA, S				JOLY, M; KAZLAUSKAS, A; CORVERA, S			PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY IS REQUIRED AT A POSTENDOCYTIC STEP IN PLATELET-DERIVED GROWTH-FACTOR RECEPTOR TRAFFICKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDGF BETA-RECEPTOR; MEDIATED ENDOCYTOSIS; TYROSINE KINASES; BINDING-SITE; SRC FAMILY; INTERNALIZATION; SUBUNIT; EGF; IDENTIFICATION; MOLECULES	We have previously reported that platelet-derived growth factor (PDGF) receptor mutants that lack high affinity binding sites for phosphatidylinositol 3-kinase (PI 3-kinase) fail to concentrate in juxtanuclear vesicular structures after activation with PDGF. We have now identified the point in the endocytic pathway at which PI S-kinase binding sites are required. Receptor internalization from the plasma membrane, measured as the acquisition of acid resistance of prebound I-125-PDGF, was only slightly decreased in cells expressing a PDGF receptor mutant (F5) lacking PI 3-kinase, GTPase-activating protein (GAP), phospholipase C gamma, and Syp binding sites but not expressing mutants where any of these individual sites were restored nor expressing a mutant lacking exclusively PI 3-kinase binding sites. In contrast, the extent of down-regulation of PDGF binding sites from the cell surface after prolonged incubation with PDGF as well as the degradation of [S-35]methionine-labeled receptor were markedly reduced in cells expressing the F5 mutant, mutants restored in GAP, phospholipase C gamma, or Syp binding sites or expressing the mutant exclusively lacking PI 3-kinase binding sites but not in cells expressing the mutant where PI 3-kinase binding sites were restored. Inhibition of PI 8-kinase activity with wortmannin caused a dramatic decrease in the rates of down-regulation and degradation of wildtype receptors. These results suggest that PI 3-kinase binding sites are not required for internalization of PDGF receptor but are required to divert the PDGF receptor to a degradative pathway. Furthermore, the requirement for PI 3-kinase binding sites on the receptor appears to be due to a requirement for PI 8-kinase catalytic activity.	UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,WORCESTER,MA 01605; NATL JEWISH HOSP IMMUNOL & RESP MED,DENVER,CO 80206	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; National Jewish Health					NIDDK NIH HHS [DK-40330] Funding Source: Medline; NIGMS NIH HHS [GM48339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKER JM, 1990, J BIOL CHEM, V265, P16450; BACKER JM, 1991, J CELL BIOL, V115, P1525; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; DUNN WA, 1986, J CELL BIOL, V102, P24, DOI 10.1083/jcb.102.1.24; ESCOBEDO J, 1991, CELL, V33, P75; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; JOLY M, 1994, SCIENCE, V263, P581; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KOCH CA, 1991, SCIENCE, V252, P669; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MARSHALL S, 1981, J BIOL CHEM, V256, P1464; MASUI H, 1993, J CELL BIOL, V120, P85, DOI 10.1083/jcb.120.1.85; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORI S, 1994, J BIOL CHEM, V269, P4917; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OKADA T, 1994, J BIOL CHEM, V269, P3568; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; YANO H, 1993, J BIOL CHEM, V268, P25846	36	167	167	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13225	13230		10.1074/jbc.270.22.13225	http://dx.doi.org/10.1074/jbc.270.22.13225			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768921	hybrid			2022-12-25	WOS:A1995RB43900044
J	LAN, Y; LU, TF; LOVETT, PS; CREIGHTON, DJ				LAN, Y; LU, TF; LOVETT, PS; CREIGHTON, DJ			EVIDENCE FOR A (TRIOSEPHOSPHATE ISOMERASE-LIKE) CATALYTIC-LOOP NEAR THE ACTIVE-SITE OF GLYOXALASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRIOSE-PHOSPHATE ISOMERASE; LIMITED PROTEOLYSIS; PSEUDOMONAS-PUTIDA; CLONING; INHIBITION; SEPARATION; PROTEINS; RESIDUE; GENE	The conformational mobility of glyoxalase I (Glx I) during catalysis has been probed using stable analogs of the enediol intermediate that forms along the reaction pathway: GSC(O)N(OH)R, where GS = glutathionyl and R = CH3 (1), C6H5 (2), C6H4Cl (3), or C6H4Br (4). For human erythrocyte Glx I, catalysis is unlikely to be coupled to major changes in protein secondary structure, as the circular dichroism spectrum of the enzyme (190-260 nm) is insensitive to saturating concentrations of either enediol analog or S-D-lactoylglutathione, the product of the Glx I reaction. However, a small conformational change is indicated by the fact that binding of enediol analog to the active site decreases intrinsic protein fluorescence by 11%, and protects the enzyme from proteolytic cleavage by Pronase E at the C-side of Ala-92 and Leu-93. In contrast, binding of S-D-lactoylglutathione does not affect protein fluorescence, and increases the rate of proteolytic cleavage by 1.5-fold. These observations are consistent with a model of catalysis in which a flexible peptide loop folds over and stabilizes the enediol intermediate bound to the active site. Indeed, a highly conserved sequence of amino acid residues is found near the proteolytic cleavage sites, for human Glx I (100-111) and Pseudomonas putida Glx I (93-105), that shows significant sequence homology to the ''catalytic loop'' of chicken muscle triosephosphate isomerase (TIM) (165-176). The active site base (Glu-165) of TIM, which catalyzes the proton transfer reaction during isomerization, corresponds in position to Glu-93 of P. putida Glx I, Consistent with a functional role for Glu-93, a mutant enzyme in which Glu-93 is replaced by Asp shows no detectable catalytic activity.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,CHEM DYNAM LAB,BALTIMORE,MD 21228; UNIV MARYLAND,DEPT SCI BIOL,CHEM DYNAM LAB,BALTIMORE,MD 21228	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore								ARONSSON AC, 1979, ANAL BIOCHEM, V92, P390, DOI 10.1016/0003-2697(79)90676-6; CLARKE AR, 1986, NATURE, V324, P699, DOI 10.1038/324699a0; CREIGHTON DJ, 1988, MOL STRUCTURE ENERGE, V9, P353; DELAMARE S, 1972, BIOCHEM J, V129, P321, DOI 10.1042/bj1290321; DOOLITTLE RF, 1985, SCI AM, V253, P88, DOI 10.1038/scientificamerican1085-88; DUVALL EJ, 1987, J BACTERIOL, V169, P4235, DOI 10.1128/jb.169.9.4235-4241.1987; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; HAMILTON DS, 1992, J BIOL CHEM, V267, P24933; HARTMAN FC, 1971, BIOCHEMISTRY-US, V10, P146, DOI 10.1021/bi00777a021; KIM NS, 1993, J BIOL CHEM, V268, P11217; LO TWC, 1992, BIOCHEM PHARMACOL, V44, P2357, DOI 10.1016/0006-2952(92)90680-H; LU TF, 1994, GENE, V150, P93, DOI 10.1016/0378-1119(94)90864-8; Maniatis T., 1982, MOL CLONING; MILLER JC, 1971, BIOCHEM J, V123, P163, DOI 10.1042/bj1230163; MURTHY NSRK, 1994, J MED CHEM, V37, P2161, DOI 10.1021/jm00040a007; OTTESEN M, 1967, ANNU REV BIOCHEM, V36, P55, DOI 10.1146/annurev.bi.36.070167.000415; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RAINES RT, 1986, BIOCHEMISTRY-US, V25, P7142, DOI 10.1021/bi00370a057; RANGANATHAN S, 1993, J BIOL CHEM, V268, P5661; RHEE H, 1987, BIOCHEM BIOPH RES CO, V147, P831, DOI 10.1016/0006-291X(87)91005-9; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; ROSE IA, 1961, J BIOL CHEM, V236, P3086; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELLIN S, 1982, BIOCHEMISTRY-US, V21, P4850, DOI 10.1021/bi00263a004; SUN AQ, 1993, J BIOL CHEM, V268, P26872; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; Vander Jagt D.L., 1989, GLUTATHIONE CHEM, P597; WINN SI, 1981, PHILOS T ROY SOC B, V293, P121, DOI 10.1098/rstb.1981.0066	28	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					12957	12960		10.1074/jbc.270.22.12957	http://dx.doi.org/10.1074/jbc.270.22.12957			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768882	hybrid			2022-12-25	WOS:A1995RB43900003
J	ONRUST, R; FINKELSTEIN, J; NAKTINIS, V; TURNER, J; FANG, LH; ODONNELL, M				ONRUST, R; FINKELSTEIN, J; NAKTINIS, V; TURNER, J; FANG, LH; ODONNELL, M			ASSEMBLY OF A CHROMOSOMAL REPLICATION MACHINE - 2 DNA-POLYMERASES, A CLAMP LOADER, AND SLIDING CLAMPS IN ONE HOLOENZYME PARTICLE .1. ORGANIZATION OF THE CLAMP LOADER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III ACCESSORY PROTEINS; ESCHERICHIA-COLI; GAMMA-SUBUNIT; SIZE CLASSES; IDENTIFICATION; PURIFICATION; CHI; PSI; OVEREXPRESSION; MECHANISM	The gamma complex of DNA polymerase III holoenzyme, the replicase of Escherichia coli, couples ATP hydrolysis to the loading of beta sliding clamps onto primed DNA. The beta sliding clamp tethers the holoenzyme replicase to DNA for rapid and processive synthesis. In this report, the gamma complex has been constituted hom its five different subunits. Size measurements and subunit stoichiometry studies show a composition of gamma(2) delta(1) delta'(1) chi(1) psi(1). Strong intersubunit contacts have been identified by gel filtration, and weaker contacts were identified by surface plasmon resonance measurements. An analogous tau complex has also been constituted and characterized; it is nearly as active as the gamma complex in clamp loading activity, but as shown in the fourth report of this series, it is at a disadvantage in binding the delta, delta', chi, and psi subunits when core is present (Xiao, Il., Naktinis, V., and O'Donnell, M. (1995) J. Biol. Chem. 270, 13378-13383). The single copy subunits within the gamma complex provide the basis for the structural asymmetry inherent within DNA polymerase III holoenzyme.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HEARST RES FDN,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute; Cornell University; Cornell University					NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI N, 1981, J BIOL CHEM, V256, P5294; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; CARTER JR, 1993, NUCLEIC ACIDS RES, V21, P3281, DOI 10.1093/nar/21.14.3281; CARTER JR, 1993, J BACTERIOL, V175, P5604, DOI 10.1128/JB.175.17.5604-5610.1993; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; CARTER JR, 1993, MOL GEN GENET, V241, P399, DOI 10.1007/BF00284693; CARTER JR, 1993, J BACTERIOL, V174, P7013; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DONG A, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KELMAN Z, 1995, IN PRESS METHODS ENZ, V262; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1992, BIOESSAYS, V14, P105, DOI 10.1002/bies.950140206; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1993, THESIS CORNELL U; ROWEN L, 1978, J BIOL CHEM, V253, P758; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SINHA NK, 1980, J BIOL CHEM, V255, P4290; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; TURNER J, 1995, IN PRESS METHODS ENZ, V262; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; XIAO H, 1993, J BIOL CHEM, V268, P11779; XIAO H, 1993, J BIOL CHEM, V268, P11773	44	112	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13348	13357		10.1074/jbc.270.22.13348	http://dx.doi.org/10.1074/jbc.270.22.13348			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768936	hybrid			2022-12-25	WOS:A1995RB43900061
J	BIESECKER, LG; GIANNOLA, DM; EMERSON, SG				BIESECKER, LG; GIANNOLA, DM; EMERSON, SG			IDENTIFICATION OF ALTERNATIVE EXONS, INCLUDING A NOVEL EXON, IN THE TYROSINE KINASE RECEPTOR GENE ETK2/TYRO3 THAT EXPLAIN DIFFERENCES IN 5' CDNA SEQUENCES	ONCOGENE			English	Note						RECEPTOR; PROTEIN TYROSINE KINASE; BRAIN	CELLS	Protein tyrosine kinase transmembrane receptors trigger signal transduction cascades upon ligand binding, resulting in cellular proliferation, differentiation, differentiation inhibition or apoptosis depending upon the cell target. The ETK2/TYRO3 receptor is a tyrosine kinase expressed in embryonic stem cells, brain and testis that has recently been cloned by several groups. Analysis of cDNA clones isolated from several tissues shows 2 isoforms of the Etk2/tyro3 gene product that result from usage of alternative exons near the 5' end of the gene. In addition, our data suggest that a third alternative exon is positioned between these two alternative exons. This novel exon encodes yet another isoform that predicts a unique amino-terminal protein sequence, The alternative exons (exons 2A, 2B and 2C), predict three isoforms with different initiation codons, signal sequences and lengths. The existence of these multiple isoforms may be important for protein processing, translocation, or function.	UNIV PENN,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,PHILADELPHIA,PA 19104	University of Pennsylvania	BIESECKER, LG (corresponding author), NIH,NATL CTR HUMAN GENOME RES,GENET DIS RES LAB,BETHESDA,MD 20892, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008414] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00042] Funding Source: Medline; NICHD NIH HHS [HD28820] Funding Source: Medline; NIDDK NIH HHS [DK08414] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BIESECKER LG, 1993, P NATL ACAD SCI USA, V90, P7044, DOI 10.1073/pnas.90.15.7044; DAI W, 1994, ONCOGENE, V9, P975; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GRIBSKOV M, 1992, SEQUENCE ANAL PRIMER; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; LAI C, 1994, ONCOGENE, V9, P2567; MARK MR, 1994, J BIOL CHEM, V269, P10720; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; POLVI A, 1993, GENE, V134, P289, DOI 10.1016/0378-1119(93)90109-G; SCHLESSINGER J, 1991, NEURON, V9, P383; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TAYLOR ICA, 1995, IN PRESS J BIOL CHEM; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	17	19	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2239	2242						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784069				2022-12-25	WOS:A1995RB70300020
J	SU, LC; MUKHERJEE, AB; MUKHERJEE, BB				SU, LC; MUKHERJEE, AB; MUKHERJEE, BB			EXPRESSION OF ANTISENSE OSTEOPONTIN RNA INHIBITS TUMOR PROMOTER-INDUCED NEOPLASTIC TRANSFORMATION OF MOUSE JB6 EPIDERMAL-CELLS	ONCOGENE			English	Article						OSTEOPONTIN; ANTISENSE OPN; TUMOR PROMOTION	RAT-KIDNEY CELLS; SECRETED PHOSPHOPROTEIN; BONE SIALOPROTEIN; MESSENGER-RNA; PHYSIOLOGICAL-PROPERTIES; NONPHOSPHORYLATED FORMS; BINDING-PROPERTIES; MAMMALIAN-CELLS; PROTEINS; TUMORIGENICITY	Elevated expression of osteopontin (OPN), a secreted adhesive phosphoglycoprotein, is frequently associated with many transformed cell lines of epithelial and stromal origin. Moreover, several clonal lines of preneoplastic JB6 cells derived from Balb/c mouse epidermal cultures (Colburn et al., 1978, 1979), upon treatment with 12-O-tetradecanoyl phorbol-13-acetate (TPA), become irreversibly oncogenic and concomitantly synthesize OPN at elevated levels (Smith and Denhardt, 1989). In the present study we sought to determine whether OPN expression facilitates transformation of such preneoplastic (initiated) cells. We transfected TPA-promotable JB6 c141.5a cells with an expression vector containing mouse OPN cDNA in antisense orientation under transcriptional control of dexamethasone-inducible MMTV-LTR promoter. Four stably transfected clones, which expressed drastically reduced levels of OPN in the presence of both dexamethasone and TPA, were characterized. We found that (a) more than 20 copies of OPN antisense cDNA were stably incorporated into the genome of cells from two of these clones that were examined by Southern blot analysis; (b) dexamethasone-induced expression of antisense OPN RNA prevented augmented OPN expression at both mRNA and protein levels following TPA treatment; and (c) cells from all four clones failed to form colonies in soft agar medium containing both dexamethasone and TPA. Taken together, these data demonstrate that inhibition of elevated OPN expression blocks TPA-induced anchorage-independent growth of JB6 c141.5a cells, suggesting the possibility that OPN overproduction is causally related to transformation of preneoplastic cells.	MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1B1,CANADA; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ H3A 1B1,CANADA; NICHHD,HUMAN GENET BRANCH,DEV GENET SECT,BETHESDA,MD 20892	McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BEHREND EI, 1993, J BIOL CHEM, V268, P11172; BEHREND EI, 1994, CANCER RES, V54, P832; BENINATI S, 1994, J BIOCHEM-TOKYO, V115, P675, DOI 10.1093/oxfordjournals.jbchem.a124395; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CASTAGNOLA P, 1991, J BIOL CHEM, V266, P9944; CHACKALAPARAMPI.I, 1985, J VIROL, V53, P841; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CHAMBERS AF, 1993, CANCER RES, V53, P701; CHEN Y, 1992, J BIOL CHEM, V267, P24871; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLBURN NH, 1978, CANCER RES, V38, P624; COLBURN NH, 1979, NATURE, V282, P589; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GARDNER HAR, 1994, ONCOGENE, V9, P2321; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; NEMIR M, 1989, J BIOL CHEM, V264, P18202; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; NOSE K, 1990, CELL GROWTH DIFFER, V1, P511; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; REINHOLT FP, 1990, P NATL ACAD SCI USA, V77, P4473; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SENGER DR, 1979, CELL, V16, P885, DOI 10.1016/0092-8674(79)90103-X; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; SENGER DR, 1980, NATURE, V286, P619, DOI 10.1038/286619a0; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1988, CANCER RES, V48, P5770; SINGH K, 1990, J BIOL CHEM, V265, P18696; SINGH K, 1993, J BIOCHEM-TOKYO, V114, P702, DOI 10.1093/oxfordjournals.jbchem.a124240; SINGH K, 1992, J BIOL CHEM, V267, P23847; SMITH BM, 1986, CANCER RES, V46, P701; SMITH JH, 1987, J CELL BIOCHEM, V34, P13, DOI 10.1002/jcb.240340103; SMITH JH, 1989, J CELL PHYSIOL, V139, P189, DOI 10.1002/jcp.1041390126	39	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2163	2169						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784060				2022-12-25	WOS:A1995RB70300011
J	TOLLET, P; HAMBERG, M; GUSTAFSSON, JA; MODE, A				TOLLET, P; HAMBERG, M; GUSTAFSSON, JA; MODE, A			GROWTH-HORMONE SIGNALING LEADING TO CYP2C12 GENE-EXPRESSION IN RAT HEPATOCYTES INVOLVES PHOSPHOLIPASE A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; ARACHIDONIC-ACID METABOLISM; MESSENGER-RNA EXPRESSION; TYROSINE KINASE-ACTIVITY; DNA-BINDING PROTEINS; MESANGIAL CELLS; NONCYCLOOXYGENASE METABOLITES; 3T3-F442A FIBROBLASTS; PRIMARY CULTURES; MAP KINASE	The expression of CYP2C12 is liver-specific and regulated at the transcriptional level by growth hormone (GH). In attempts to elucidate the nature of signaling molecules mediating the GH regulation of this gene in rat hepatocytes, a role for phospholipase A(2) (PLA(2)) as a transducer of GH-induced levels of P4502C12 mRNA was investigated. GH was shown to induce tyrosyl-phosphorylation of p42 and p44 microtubule-associated protein (MAP) kinases and to reduce the electrophoretic mobility of a 100-kDa protein, immunologically related to cPLA(2). These events were observed in parallel with GH-stimulated release of [H-3]arachidonic acid ([H-3]AA) from cellular phospholipids of rat hepatocytes labeled with [H-3]AA. These rapid effects of GH action, as well as the GH-induced expression of CYP2C12, were inhibited in cells treated with the tyrosine kinase inhibitor herbimycin A. Similarly, when the GH-induced liberation of [H-3]AA was blocked by the PLA(2) inhibitor mepacrine or the Ca2+ channel blocker verapamil, GH-induced accumulation of P4502C12 mRNA was absent. These results suggest a correlation between PLA(2) activity and GH regulation of the CYP2C12 gene. The inhibitory effect of mepacrine on GH induction of P4502C12 mRNA was reversed by AA addition, further supporting a role for eicosanoids in the regulation of CYP2C12. Finally, inhibitors of P45O-mediated AA metabolism, SKF-525A and ketoconazole as well as eicosatetraynoic acid, blocked the GH-mediated induction of P4502C12 mRNA, whereas more specific inhibitors of cyclooxygenase or lipoxygenase metabolism did not. Based on these results, we suggest that GH signaling in rat hepatocytes, leading to increased expression of CYP2C12, involves PLA(2) activation and subsequent P450-catalyzed formation of an active AA metabolite.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,DIV PHYSIOL CHEM 2,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet	TOLLET, P (corresponding author), HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT MED NUTR,F 60 NOVUM,S-14186 HUDDINGE,SWEDEN.			Hamberg, Mats/0000-0002-8910-7810				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BLACKWELL GJ, 1983, BRIT MED BULL, V39, P260, DOI 10.1093/oxfordjournals.bmb.a071830; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BURCH RM, 1983, J PHARMACOL EXP THER, V227, P84; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FITZPATRICK FA, 1989, PHARMACOL REV, V40, P229; FORCE T, 1991, J BIOL CHEM, V266, P4295; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GRASDALEN H, 1975, FEBS LETT, V60, P294, DOI 10.1016/0014-5793(75)80734-4; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HAMMARSTROM S, 1977, BIOCHIM BIOPHYS ACTA, V487, P517, DOI 10.1016/0005-2760(77)90221-1; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; KAST R, 1993, J BIOL CHEM, V268, P16795; KOCAREK TA, 1993, MOL PHARMACOL, V43, P328; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MCGIFF JC, 1981, ANNU REV PHARMACOL, V21, P479, DOI 10.1146/annurev.pa.21.040181.002403; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MODE A, 1989, J ENDOCRINOL, V120, P311, DOI 10.1677/joe.0.1200311; MOLLER C, 1992, J BIOL CHEM, V267, P23403; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NEBERT DW, 1991, MOL ENDOCRINOL, V5, P1203, DOI 10.1210/mend-5-9-1203; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NORSTEDT G, 1987, J ENDOCRINOL, V115, P135, DOI 10.1677/joe.0.1150135; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAO GN, 1993, ONCOGENE, V8, P2759; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUI H, 1994, J BIOL CHEM, V269, P5364; SALARI H, 1984, PROSTA LEUKOTR MED, V13, P53, DOI 10.1016/0262-1746(84)90102-1; SATO N, 1994, CURR OPIN CELL BIOL, V6, P174, DOI 10.1016/0955-0674(94)90133-3; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302; SCHWARTZ Y, 1992, ENDOCRINOLOGY, V131, P772, DOI 10.1210/en.131.2.772; SCHWARTZ Y, 1990, ENDOCRINOLOGY, V127, P170, DOI 10.1210/endo-127-1-170; SCHWARTZ Y, 1991, P NATL ACAD SCI USA, V88, P6790, DOI 10.1073/pnas.88.15.6790; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; STRED SE, 1992, ENDOCRINOLOGY, V130, P1626, DOI 10.1210/en.130.3.1626; TEBBEY PW, 1992, BIOCHIM BIOPHYS ACTA, V1171, P27, DOI 10.1016/0167-4781(92)90136-N; TOLLET P, 1991, MOL ENDOCRINOL, V5, P1351; TOLLET P, 1990, MOL ENDOCRINOL, V4, P1934, DOI 10.1210/mend-4-12-1934; TOLLET P, 1994, J LIPID RES, V35, P248; VANSCHAIK RHN, 1993, BIOCHIM BIOPHYS ACTA, V1169, P1, DOI 10.1016/0005-2760(93)90075-K; WANG XY, 1993, J BIOL CHEM, V268, P3573; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIDA S, 1990, ARCH BIOCHEM BIOPHYS, V280, P346, DOI 10.1016/0003-9861(90)90340-5	80	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12569	12577		10.1074/jbc.270.21.12569	http://dx.doi.org/10.1074/jbc.270.21.12569			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759504	hybrid			2022-12-25	WOS:A1995QZ71100039
J	DESOUZA, AT; HANKINS, GR; WASHINGTON, MK; FINE, RL; ORTON, TC; JIRTLE, RL				DESOUZA, AT; HANKINS, GR; WASHINGTON, MK; FINE, RL; ORTON, TC; JIRTLE, RL			FREQUENT LOSS OF HETEROZYGOSITY ON 6Q AT THE MANNOSE 6-PHOSPHATE/INSULIN-LIKE GROWTH-FACTOR-II RECEPTOR LOCUS IN HUMAN HEPATOCELLULAR TUMORS	ONCOGENE			English	Article						LOSS OF HETEROZYGOSITY; MGP/IGFII RECEPTOR; HEPATOCELLULAR CARCINOMA	FACTOR TYPE-2 RECEPTOR; HUMAN BREAST-CANCER; P53 GENE-MUTATIONS; FACTOR-BETA-1 PRECURSOR; 6-PHOSPHATE RECEPTORS; COLORECTAL CANCERS; SUPPRESSOR GENES; WILMS TUMOR; FACTOR-BETA; CARCINOMA	The mannose 6-phosphate/insulin-like growth factor III receptor (M6P/IGFIIr) is required for the activation of transforming growth factor beta, and previously we have found its expression to be significantly reduced in both rat and human hepatocellular carcinomas (HCCs). Therefore, we have postulated that loss of the M6P/IGFIIr gene may be mechanistically involved in liver carcinogenesis. Using the polymerase chain reaction, we utilized two polymorphisms in the 3' untranslated region of the M6P/IGFIIr gene to screen non-cirrhotic, hepatitis virus negative patients with hepatocellular tumors for LOH. Twenty-two of 36 (61%) patients were informative (heterozygous), and 14/22 (64%) liver tumors had LOH; 11/16 (69%) carcinomas, 1/3 (33%) fibrolamellar tumors and 2/3 (67%) adenomas. This is the first report of LOH at the M6P/IGFIIr locus in human hepatocellular tumors, and the presence of LOH in adenomas suggests that allelic loss may be an early event in the etiology of HCCs. These results support the hypothesis that the M6P/IGFIIr gene may function as a tumor suppressor gene in the liver.	DUKE UNIV,MED CTR,DEPT RADIAT ONCOL,DURHAM,NC 27710; ZENECA PHARMACEUT,DEPT SAFETY MED,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Duke University; Duke University					NCI NIH HHS [CA25951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DEVILEE P, 1991, ONCOGENE, V6, P1705; DRAGAN YP, 1992, CARCINOGENESIS, V5, P739; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJIMORI M, 1991, CANCER RES, V51, P89; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; HEDRUM A, 1994, BIO-TECHNOL, V7, P118; Hol F. A., 1992, Human Molecular Genetics, V1, P347, DOI 10.1093/hmg/1.5.347; JIRTLE RL, 1993, CANCER RES, V53, P3849; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LAUREYS G, 1988, GENOMICS, V3, P224, DOI 10.1016/0888-7543(88)90083-3; LEE JH, 1990, CANCER RES, V50, P2724; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LOUIS DN, 1992, AM J PATHOL, V141, P777; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MARS WM, 1990, CANCER METAST REV, V9, P35, DOI 10.1007/BF00047587; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MILLIKIN D, 1991, CANCER RES, V51, P5449; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MORITA R, 1991, CANCER RES, V51, P5817; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NOSE H, 1993, CANCER, V72, P355, DOI 10.1002/1097-0142(19930715)72:2<355::AID-CNCR2820720208>3.0.CO;2-W; OGAWA O, 1993, HUM MOL GENET, V2, P2163, DOI 10.1093/hmg/2.12.2163; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SAITO S, 1992, CANCER RES, V52, P5812; SANGER F, 1987, P NATL ACAD SCI USA, V74, P5463; SIMON D, 1990, CANCER GENET CYTOGEN, V45, P255, DOI 10.1016/0165-4608(90)90091-N; SLAGLE BL, 1991, CANCER RES, V51, P49; SMITH M, 1986, AM J HUM GENET, V39, P654; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SUE SR, 1994, IN PRESS ANN SURGERY; TAKAHASHI K, 1993, HEPATOLOGY, V17, P794, DOI 10.1002/hep.1840170508; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1993, TRENDS GENET, V4, P138; WALKER GJ, 1991, CANCER RES, V51, P4367; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542; ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x	64	192	194	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1725	1729						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753549				2022-12-25	WOS:A1995QX46900005
J	OFFERMANNS, S; SIMON, MI				OFFERMANNS, S; SIMON, MI			G-ALPHA(15) AND G-ALPHA(16) COUPLE A WIDE VARIETY OF RECEPTORS TO PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; SIGNAL-TRANSDUCTION; HL-60 CELLS; MOLECULAR-CLONING; ESCHERICHIA-COLI; SF9 CELLS; GQ-ALPHA; EXPRESSION; ACTIVATION; ISOZYMES	The murine G-protein alpha-subunit G alpha(15) and its human counterpart G alpha(16) are expressed in a subset of hematopoietic cells, and they have been shown to regulate beta-isoforms of inositide-specific phospholipase C. We studied the ability of a variety of receptors to interact with G alpha(15) and G alpha(16) by cotransfecting receptors and G-protein alpha-subunits in COS-7 cells. Activation of beta(2) adrenergic and muscarinic M(2) receptors in cells expressing the receptors alone or together with G alpha(q), G alpha(11), or G alpha(14) led to a very small stimulation of endogenous phospholipase C. However, when the receptors were coexpressed with G alpha(15) and G alpha(16), addition of appropriate ligands caused a severalfold increase in inositol phosphate production which was time- and dose-dependent. A similar activation of phospholipase C was observed when several other receptors which were previously shown to couple to members of the G(i) and G(s) family were coexpressed with G alpha(15/16). In addition, stimulation of inositol phosphate formation via receptors naturally coupled to phospholipase C was enhanced by cotransfection of G alpha(15) and G alpha(16). These data demonstrate that G alpha(15) and G alpha(16) are unique in that they can be activated by a wide variety of G-protein-coupled receptors. The ability of G alpha(15) and G alpha(16) to bypass the selectivity of receptor G-protein interaction can be a useful tool to understand the mechanism of receptor-induced G-protein activation. In addition, the promiscuous behavior of G alpha(15) and G alpha(16) toward receptors may be helpful in finding ligands corresponding to orphan receptors whose signaling properties are unknown.	CALTECH,DIV BIOL 14775,PASADENA,CA 91125	California Institute of Technology			Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034236, R01GM034236] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34236] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BERTIN B, 1992, J BIOL CHEM, V267, P8200; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BIRNBAUMER M, 1992, NATURE, V357, P383; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BUHL AM, 1993, FEBS LETT, V323, P132, DOI 10.1016/0014-5793(93)81464-B; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FARNDALE RW, 1992, SIGNAL TRANSDUCTION, P75; FREISSMUTH M, 1991, P NATL ACAD SCI USA, V88, P8548, DOI 10.1073/pnas.88.19.8548; FURLONG TJ, 1992, MOL BRAIN RES, V15, P62, DOI 10.1016/0169-328X(92)90152-2; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; Gilman A G, 1974, Methods Enzymol, V38, P49; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; LEE CH, 1995, MOL PHARMACOL, V47, P218; LEE CH, 1992, J BIOL CHEM, V267, P16044; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MAPARA MY, 1994, BLOOD, V84, pA572; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PARKER EM, 1991, J BIOL CHEM, V266, P519; PEREZ HD, 1992, J BIOL CHEM, V267, P358; PROSSNITZ ER, 1993, J IMMUNOL, V151, P5704; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SCHNABEL P, 1992, BIOCHEM BIOPH RES CO, V188, P1018, DOI 10.1016/0006-291X(92)91333-L; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; VANEK M, 1994, MOL PHARMACOL, V46, P832; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811; YU L, 1991, MOL BRAIN RES, V11, P143, DOI 10.1016/0169-328X(91)90116-F	51	435	497	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15175	15180		10.1074/jbc.270.25.15175	http://dx.doi.org/10.1074/jbc.270.25.15175			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797501	hybrid, Green Accepted			2022-12-25	WOS:A1995RE66600051
J	GALDEMARD, C; BRISON, O; LAVIALLE, C				GALDEMARD, C; BRISON, O; LAVIALLE, C			THE PROTOONCOGENE FGF-3 IS CONSTITUTIVELY EXPRESSED IN TUMORIGENIC, BUT NOT IN NONTUMORIGENIC, CLONES OF A HUMAN COLON-CARCINOMA CELL-LINE	ONCOGENE			English	Article						FGF-3/INT-2; DIFFERENTIAL TRANSCRIPTION; COLON CARCINOMA; MYC AMPLIFICATION	GROWTH-FACTOR FAMILY; C-MYC AMPLIFICATION; HUMAN-BREAST TUMORS; INT-2 GENE; MESSENGER-RNA; HUMAN CANCER; MOUSE; PHENOTYPE; MEMBER; ACID	The human colon carcinoma cell line, SW613-S, is composed of cells with a high-level amplification of the MYC proto-oncogene that are tumorigenic in nude mice and of cells with a low-level amplification of MYC that are not tumorigenic. Transcripts from FGF-3, a member of the fibroblast growth factor gene family, accumulate in cells from tumorigenic clones, but are undetectable in those from non-tumorigenic clones. Nuclear run-on analyses indicate that this differential FGF-3 expression is regulated at the level of transcription initiation. Determination of the structure of the FGF-3 transcripts indicates that they are generated by splicing of the three exons and termination at the single polyadenylation site predicted from the genomic sequence. Their size heterogeneity is due to multiple initiation sites spanning a 700 base-pair long promoter region. FGF-3 is activated in tumors induced in nude mice by MYC-transfected cells from non-tumorigenic clones. However, in most of the cell lines established from these tumors, FGF-3 expression tends to be lost upon in vitro propagation. Thus, in these transfectant cell lines, the presence of exogenous MYC gene copies is not sufficient to activate FGF-3 expression and in vivo growth is also required.	INST GUSTAVE ROUSSY,GENET ONCOL LAB,CNRS,URA 1967,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Lavialle, Christian/O-2329-2019; Lavialle, Christian/B-3775-2009					ADNANE J, 1989, ONCOGENE, V4, P1389; ALI IU, 1989, ONCOGENE, V4, P89; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BROOKES S, 1989, ONCOGENE, V4, P429; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHERIF D, 1989, CHROMOSOMA, V97, P327, DOI 10.1007/BF00371974; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DRON M, 1986, MOL CELL BIOL, V6, P1374, DOI 10.1128/MCB.6.5.1374; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GOLDFARB M, 1991, ONCOGENE, V6, P65; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMONERIE T, 1995, EXP CELL RES, V216, P342, DOI 10.1006/excr.1995.1043; LAVIALLE C, 1988, ONCOGENE, V3, P335; LAVIALLE C, 1990, ONCOGENE, V5, P245; LAVIALLE C, 1989, ANTICANCER RES, V9, P1265; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LISCIA DS, 1989, ONCOGENE, V4, P1219; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MODJTAHEDI N, 1992, INT J CANCER, V52, P483, DOI 10.1002/ijc.2910520325; MODJTAHEDI N, 1985, CANCER RES, V45, P4372; MODJTAHEDI N, 1992, EXP CELL RES, V201, P74, DOI 10.1016/0014-4827(92)90349-D; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURAKAMI A, 1993, NUCLEIC ACIDS RES, V21, P5351, DOI 10.1093/nar/21.23.5351; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; ORNITZ DM, 1992, JNCI-J NATL CANCER I, V84, P887, DOI 10.1093/jnci/84.11.887; Sambrook J, 1989, MOL CLONING LABORATO; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; SUAREZ HG, 1987, ONCOGENE RES, V1, P201; THEILLET C, 1989, ONCOGENE, V4, P915; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; ZHANG GH, 1994, CELL GROWTH DIFFER, V5, P349	46	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2331	2342						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784081				2022-12-25	WOS:A1995RE54300008
J	FESCHENKO, MS; SWEADNER, KJ				FESCHENKO, MS; SWEADNER, KJ			STRUCTURAL BASIS FOR SPECIES-SPECIFIC DIFFERENCES IN THE PHOSPHORYLATION OF NA,K-ATPASE BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; CATALYTIC SUBUNIT; NA+/K+-ATPASE; MAMMALIAN KIDNEY; ALPHA-SUBUNIT; NA+,K+-ATPASE; ISOZYME; ENZYME; PURIFICATION; STIMULATION	There is considerable evidence that protein kinases play a role in regulation of the activity of the Na,K-ATPase, but the characteristics of direct kinase phosphorylation of Na,K-ATPase subunits are still not well understood. There are 36 sites that could qualify as protein kinase C motifs in rat alpha 1. Here we have used protein fragmentation with trypsin to localize the site of phosphorylation of the rat Na,K-ATPase alpha 1 subunit to within the first 32 amino acids of the N terminus and then used direct sequencing of the phosphorylated protein to determine which of two candidate serine residues was modified. The result was that at most 25% of the P-32 was found on Ser-11, a site that is well conserved in Na,K-ATPase alpha 1 subunits. The remaining 75% or more of the P-32 was found on Ser-18, a site that is absent in many Na,K-ATPase alpha subunit sequences. This accounts for the observation that dog and pig alpha 1 subunits can be phosphorylated by protein kinase C only to much lower levels than can rat alpha 1. It is also likely to be relevant to other known species specific effects of protein kinase C on Na,K-ATPase.	MASSACHUSETTS GEN HOSP, CTR NEUROSCI, MEMBRANE BIOL LAB, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital					NINDS NIH HHS [NS 27653] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027653] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BORGHINI I, 1994, P NATL ACAD SCI USA, V91, P6211, DOI 10.1073/pnas.91.13.6211; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; CHIBALIN AV, 1993, J BIOENERG BIOMEMBR, V25, P61, DOI 10.1007/BF00768069; DALY SE, 1994, J BIOL CHEM, V269, P23944; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FISONE G, 1994, J BIOL CHEM, V269, P9368; FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; JORGENSEN PL, 1979, BIOCHIM BIOPHYS ACTA, V555, P485, DOI 10.1016/0005-2736(79)90401-2; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1978, BIOCHIM BIOPHYS ACTA, V507, P8, DOI 10.1016/0005-2736(78)90369-3; JORGENSEN PL, 1980, BIOCHIM BIOPHYS ACTA, V597, P305, DOI 10.1016/0005-2736(80)90108-X; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KAIRUZ PB, 1991, FEBS LETT, V290, P83; LOPINA OD, 1995, BIOPHYS J, V68, P308; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIDDLETON JP, 1993, J BIOL CHEM, V268, P18958; OHTA T, 1991, BIOCHIM BIOPHYS ACTA, V1059, P157, DOI 10.1016/S0005-2728(05)80200-2; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SHANBAKY NM, 1994, AM J PHYSIOL, V267, pC590, DOI 10.1152/ajpcell.1994.267.2.C590; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; SWEADNER KJ, 1991, ANAL BIOCHEM, V194, P130, DOI 10.1016/0003-2697(91)90159-Q; SWEADNER KJ, 1988, METHOD ENZYMOL, V156, P65; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; URAYAMA O, 1988, BIOCHEM BIOPH RES CO, V156, P796, DOI 10.1016/S0006-291X(88)80914-8; VASILETS LA, 1991, J BIOL CHEM, V266, P16285; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70; XIE ZJ, 1994, SODIUM PUMP, P49	37	122	123	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14072	14077		10.1074/jbc.270.23.14072	http://dx.doi.org/10.1074/jbc.270.23.14072			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775468	hybrid			2022-12-25	WOS:A1995RC44800071
J	MEDVED, LV; ORTHNER, CL; LUBON, H; LEE, TK; DROHAN, WN; INGHAM, KC				MEDVED, LV; ORTHNER, CL; LUBON, H; LEE, TK; DROHAN, WN; INGHAM, KC			THERMAL-STABILITY AND DOMAIN-DOMAIN INTERACTIONS IN NATURAL AND RECOMBINANT PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; DISSEMINATED INTRAVASCULAR COAGULATION; INVITRO ANTICOAGULANT ACTIVITY; PROTEOLYTIC FORMATION; PURPURA FULMINANS; CALCIUM-BINDING; CA2+ BINDING; FACTOR-XA; CONCENTRATE; EXPRESSION	Scanning microcalorimetry and spectrofluorimetry were applied to a study of the thermal stability and interaction of the modules within natural human protein C (PC) and recombinant protein C (rPC), a potential therapeutic anticoagulant expressed in transgenic pigs. Upon heating in the presence of 2 mM EDTA, pH 8.5, each protein exhibited a similar heat absorption peak with a T-m of similar to 62 degrees C corresponding to the melting of the serine protease (SP) module. Deconvolution of this peak indicated that the SP module consists of two domains that unfold independently. At pH below 3.8, a second peak appeared at extremely high temperature corresponding to the unfolding of the two interacting epidermal growth factor-like (EGF) domains. This second peak occurred at a temperature about 20 degrees C lower in rPC than in PC indicating that the EGF domains in the recombinant protein are less stable. The isolated 6-kDa gamma-carboxyglutamic acid-rich (Gla) fragment as well as a 25-kDa Gla-(EGF)(2) fragment both exhibited a sigmoidal fluorescence-detected denaturation transition in the same temperature region as the SP domains, but only in the presence of Ca2+. In 2 mM Ca2+, the first heat absorption peak in both intact proteins became biphasic, indicating Ca2+-induced structural changes. By contrast, Ca2+ had very little effect on the melting of Gla-domainless protein C. This indicates that not Ca2+ itself but the Ca2+-loaded Gla domain is responsible for conformational changes in the SP domain of the parent protein. Detailed analysis of the shape of the endotherms obtained in Ca2+ and EDTA suggests that Ca2+ induces compact structure in the Gla domain which appears to interact strongly with the SP domain(s) of protein C.			MEDVED, LV (corresponding author), AMER RED CROSS,HOLLAND LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855, USA.			Medved, Leonid/0000-0002-3665-9849				ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; ALTSCHUH D, 1994, PROTEIN ENG, V7, P769, DOI 10.1093/protein/7.6.769; ASTERMARK J, 1994, J BIOL CHEM, V269, P3682; BANGALORE N, 1994, THROMB HAEMOSTASIS, V72, P465; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; DREYFUS M, 1991, NEW ENGL J MED, V325, P1565, DOI 10.1056/NEJM199111283252207; DROHAN WN, 1994, ADVANCES IN BIOPROCESS ENGINEERING, P501; EHRLICH HJ, 1989, J BIOL CHEM, V264, P14298; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON NL, 1983, J BIOL CHEM, V258, P5548; Filimonov V V, 1982, Mol Biol (Mosk), V16, P551; FISHER CL, 1994, PROTEIN SCI, V3, P588; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GERSON WT, 1993, PEDIATRICS, V91, P418; GRINNELL BW, 1987, BIO-TECHNOL, V5, P1189, DOI 10.1038/nbt1187-1189; HOGG PJ, 1992, J BIOL CHEM, V267, P703; HOYER LW, 1994, VOX SANG, V67, P217, DOI 10.1111/j.1423-0410.1994.tb04579.x; INGHAM KC, 1995, ARCH BIOCHEM BIOPHYS, V316, P235, DOI 10.1006/abbi.1995.1033; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; MANCOJOHNSON M, 1992, AM J HEMATOL, V40, P69, DOI 10.1002/ajh.2830400116; MEDVED LV, 1994, BIOCHEMISTRY-US, V33, P478, DOI 10.1021/bi00168a012; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; NOVOKHATNY V, 1992, J BIOL CHEM, V67, P3878; NOVOKHATNY VV, 1994, J MOL BIOL, V238, P833, DOI 10.1006/jmbi.1994.1337; NOVOKHATNY VV, 1993, J BIOL CHEM, V268, P17211; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12194; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; OKAJIMA K, 1990, AM J HEMATOL, V33, P277, DOI 10.1002/ajh.2830330413; ORTHNER CL, 1988, BIOCHEMISTRY-US, V27, P2558, DOI 10.1021/bi00407a043; ORTHNER CL, 1989, J BIOL CHEM, V24, P18781; ORTHNER CL, 1995, IN PRESS VOX SANG; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1993, J BIOL CHEM, V268, P22531; Privalov P L, 1986, Methods Enzymol, V131, P4; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; VELANDER WH, 1992, P NATL ACAD SCI USA, V89, P12003, DOI 10.1073/pnas.89.24.12003; VYSOTCHIN A, 1993, J BIOL CHEM, V268, P8436; WALLS JD, 1989, GENE, V81, P139, DOI 10.1016/0378-1119(89)90344-2; YAN SCB, 1989, TRENDS BIOCHEM SCI, V14, P264, DOI 10.1016/0968-0004(89)90060-1; ZHANG L, 1993, J BIOL CHEM, V268, P12040; ZHANG L, 1992, BLOOD, V80, P942; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	45	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13652	13659		10.1074/jbc.270.23.13652	http://dx.doi.org/10.1074/jbc.270.23.13652			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775416	hybrid			2022-12-25	WOS:A1995RC44800013
J	NAGAHASHI, S; SUDOH, M; ONO, N; SAWADA, R; YAMAGUCHI, E; UCHIDA, Y; MIO, T; TAKAGI, M; ARISAWA, M; YAMADAOKABE, H				NAGAHASHI, S; SUDOH, M; ONO, N; SAWADA, R; YAMAGUCHI, E; UCHIDA, Y; MIO, T; TAKAGI, M; ARISAWA, M; YAMADAOKABE, H			CHARACTERIZATION OF CHITIN SYNTHASE-2 OF SACCHAROMYCES-CEREVISIAE - IMPLICATION OF 2 HIGHLY CONSERVED DOMAINS AS POSSIBLE CATALYTIC SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDA-ALBICANS; PHENOTYPIC SELECTION; NUCLEOTIDE-SEQUENCE; SYNTHESIS INVIVO; GENE; YEAST; RHIZOBIUM; EXPRESSION; NODC; CLONING	Chitin synthase 2 of Saccharomyces cerevisiae was characterized by means of site-directed mutagenesis and subsequent expression of the mutant enzymes in yeast cells. Chitin synthase 2 shares a region whose sequence is highly conserved in all chitin synthases. Substitutions of conserved amino acids in this region with alanine (alanine scanning) identified two domains in which any conserved amino acid could not be replaced by alanine to retain enzyme activity. These two domains contained unique sequences, Glu(561)-Asp(562)-Arg(563) and Gln(601)-Arg(602)-Arg-(603)-Arg(604)-Trp(605), that were conserved in all types of chitin synthases. Glu(561) or arginine at 563, 602, and 603 could be substituted by glutamic acid and lysine, respectively, without significant loss of enzyme activity. However, even conservative substitutions of Asp(562) with glutamic acid, Gln(601) with asparagine, Arg(604) with lysine, or Trp(605) with tyrosine drastically decreased the activity, but did not affect apparent K-m values for the substrate significantly. In addition to these amino acids, Asp(441) Was also found in all chitin synthase. The mutant harboring a glutamic acid substitution for Asp(441) severely lost activity, but it showed a similar apparent K-m value for the substrate, Amounts of the mutant enzymes in total membranes were more or less the same as found in the wild type. Furthermore, Asp(441), Asp(562), Gln(601), Arg(604), and Trp(605) are completely conserved in other proteins possessing N-acetylglucosaminyltransferase activity such as NodC proteins of Rhizobium bacterias. These results suggest that Asp(441), Asp(562), Gln(601), Arg(604),,and Trp(605) are located in the active pocket and that they function as the catalytic residues of the enzyme.	NIPPON ROCHE RES CTR, DEPT MYCOL, KAMAKURA, KANAGAWA 247, JAPAN; UNIV TOKYO, DEPT AGR CHEM, BUNKYO KU, TOKYO 113, JAPAN	Roche Holding; University of Tokyo								ATKINSON EM, 1992, MOL PLANT MICROBE IN, V5, P439, DOI 10.1094/MPMI-5-439; AUYOUNG J, 1990, MOL MICROBIOL, V4, P197, DOI 10.1111/j.1365-2958.1990.tb00587.x; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BGOW NAR, 1994, P NATL ACAD SCI USA, V91, P6216; BULAWA CE, 1990, P NATL ACAD SCI USA, V87, P7424, DOI 10.1073/pnas.87.19.7424; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505; CABIB E, 1989, J CELL BIOL, V108, P1665, DOI 10.1083/jcb.108.5.1665; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CHENWU JL, 1992, MOL MICROBIOL, V6, P497, DOI 10.1111/j.1365-2958.1992.tb01494.x; CHOI WJ, 1994, P NATL ACAD SCI USA, V91, P4727, DOI 10.1073/pnas.91.11.4727; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; DEBELLE F, 1992, MOL PLANT MICROBE IN, V5, P443, DOI 10.1094/MPMI-5-443; DIN AB, 1994, MICROBIOL-UK, V140, P2189, DOI 10.1099/13500872-140-9-2189; DURAN A, 1978, J BIOL CHEM, V253, P4419; FUKUDA R, 1994, J BIOL CHEM, V269, P9556; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; GOETHALS K, 1989, MOL GEN GENET, V219, P289, DOI 10.1007/BF00261190; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; JACOBS TW, 1985, J BACTERIOL, V162, P469, DOI 10.1128/JB.162.2.469-476.1985; KANG MS, 1984, J BIOL CHEM, V259, P4966; KRISHNAN HB, 1991, MOL PLANT MICROBE IN, V4, P512, DOI 10.1094/MPMI-4-512; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Luckow V. A, 1991, Recombinant DNA technology and applications., P97; MOOSER G, 1991, J BIOL CHEM, V266, P8916; MOTOYAMA T, 1994, BIOSCI BIOTECH BIOCH, V58, P1685, DOI 10.1271/bbb.58.1685; ORLEAN P, 1987, J BIOL CHEM, V262, P5732; PIWNICAWERMS H, 1990, CURRENT PROTOCOLS MO; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; ROSSEN L, 1984, NUCLEIC ACIDS RES, V12, P9497, DOI 10.1093/nar/12.24.9497; Sambrook J, 1989, MOL CLONING LABORATO; SAXENA IM, 1990, PLANT MOL BIOL, V15, P673, DOI 10.1007/BF00016118; SBURLATI A, 1986, J BIOL CHEM, V261, P5147; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; SILVERMAN SJ, 1988, P NATL ACAD SCI USA, V85, P4735, DOI 10.1073/pnas.85.13.4735; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; SUDOH M, 1993, MOL GEN GENET, V241, P351, DOI 10.1007/BF00284688; Szaniszlo P. J., 1993, Molecular biology and its application to medical mycology., P229; VALDIVIESO MH, 1991, J CELL BIOL, V114, P101, DOI 10.1083/jcb.114.1.101	43	142	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13961	13967		10.1074/jbc.270.23.13961	http://dx.doi.org/10.1074/jbc.270.23.13961			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775457	hybrid			2022-12-25	WOS:A1995RC44800056
J	KOUNNAS, MZ; LOUKINOVA, EB; STEFANSSON, S; HARMONY, JAK; BREWER, BH; STRICKLAND, DK; ARGRAVES, WS				KOUNNAS, MZ; LOUKINOVA, EB; STEFANSSON, S; HARMONY, JAK; BREWER, BH; STRICKLAND, DK; ARGRAVES, WS			IDENTIFICATION OF GLYCOPROTEIN-330 AS AN ENDOCYTIC RECEPTOR FOR APOLIPOPROTEIN-J/CLUSTERIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-ATTACK-COMPLEX; ALPHA-2-MACROGLOBULIN RECEPTOR; SULFATED GLYCOPROTEIN-2; HEYMANN NEPHRITIS; DENSITY LIPOPROTEINS; MOLECULAR-CLONING; GENE-EXPRESSION; LDL RECEPTOR; TESTIS FLUID; PROTEIN	Glycoprotein 330 (gp330) is a member of a family of endocytic receptors related to the low density lipoprotein receptor. gp330 has previously been shown to bind a number of ligands in common with its family member, the low density Lipoprotein receptor-related protein (LRP). To identify ligands specific for gp330 and relevant to its localization on epithelia such as in the mammary gland, gp330-Sepharose affinity chromatography was performed. As a result, a 70-kDa protein was selected from human milk and identified by protein sequencing to be apolipoprotein J/clusterin (apoJ). Solid-phase binding assays confirmed that gp330 bound to aporJ with high affinity (K-d = 14.2 nM). Similarly, gp330 bound to apoJ transferred to nitrocellulose after SDS-polyacrylamide gel electrophoresis. LRP, however, showed no binding to apoJ in either type of assay. The binding of gp330 to apoJ could be competitively inhibited with excess apoJ as well as with the gp330 ligands apolipoprotein E, lipoprotein Lipase, and the receptor-associated protein, a 39-kDa protein that acts to antagonize binding of all known ligands for gp330 and LRP. Several cultured cell Lines that express gp330 and ones that do not express the receptor were examined for their ability to bind and internalize I-125-apoJ. Only cells that expressed gp330 endocytosed and degraded radiolabeled apoJ. Furthermore, F9 cells treated with retinoic acid and dibutyryl cyclic AMP to increase expression levels of gp330 displayed an increased capacity to internalize and degrade apoJ. Cellular internalization and degradation of radiolabeled apoJ could be inhibited with unlabeled apoJ, receptor-associated protein, and gp330 antibodies. The results indicate that gp330 but not LRP can bind to apoJ in vitro and that gp330 expressed by cells can mediate apoJ endocytosis leading to lysosomal degradation.	AMER RED CROSS,DEPT BIOCHEM,JH HOLLAND LAB,ROCKVILLE,MD 20855; UNIV CINCINNATI,COLL MED,DEPT PHARMACOL & CELL BIOPHYS,CINCINNATI,OH 45267; NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892	American Red Cross; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41496] Funding Source: Medline; NIDDK NIH HHS [DK45598] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; DESILVA HV, 1990, J BIOL CHEM, V265, P14292; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; FRENCH LE, 1993, J CELL BIOL, V122, P1119, DOI 10.1083/jcb.122.5.1119; FRENCH LE, 1992, J CLIN INVEST, V90, P1919, DOI 10.1172/JCI116069; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; JAMES RW, 1991, ARTERIOSCLER THROMB, V11, P645, DOI 10.1161/01.ATV.11.3.645; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; JOMARY C, 1993, MOL BRAIN RES, V20, P279, DOI 10.1016/0169-328X(93)90053-R; JONES SE, 1992, FEBS LETT, V6, P279; KELLY ME, 1994, CELL IMMUNOL, V159, P124, DOI 10.1006/cimm.1994.1302; KERJASCHKI D, 1987, J EXP MED, V166, P109, DOI 10.1084/jem.166.1.109; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; KORENBERG JR, 1994, GENOMICS, V22, P88, DOI 10.1006/geno.1994.1348; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; LASLOP A, 1993, J NEUROCHEM, V61, P1498, DOI 10.1111/j.1471-4159.1993.tb13645.x; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murphy B F, 1989, Int Immunol, V1, P551, DOI 10.1093/intimm/1.5.551; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SENSIBAR JA, 1993, BIOL REPROD, V49, P233, DOI 10.1095/biolreprod49.2.233; SITO A, 1994, P NATL ACAD SCI USA, V91, P9725; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STUART WD, 1992, BIOCHEMISTRY-US, V31, P8553; SYLVESTER SR, 1991, BIOL REPROD, V45, P195, DOI 10.1095/biolreprod45.1.195; VAKEVA A, 1993, IMMUNOLOGY, V80, P177; WATTS MJ, 1990, BIOCHEM J, V265, P471, DOI 10.1042/bj2650471; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	48	201	205	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13070	13075		10.1074/jbc.270.22.13070	http://dx.doi.org/10.1074/jbc.270.22.13070			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768901	hybrid			2022-12-25	WOS:A1995RB43900022
J	LINDSEY, LA; CROW, AJ; GARCIABLANCO, MA				LINDSEY, LA; CROW, AJ; GARCIABLANCO, MA			A MAMMALIAN ACTIVITY REQUIRED FOR THE 2ND STEP OF PREMESSENGER RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; 2ND STEP; SACCHAROMYCES-CEREVISIAE; DEPENDENT ATPASE; SPLICEOSOME; INVITRO; PROTEIN; YEAST; U5; PRP16	Splicing of precursors to messenger RNAs occurs via a two-step mechanism. In the first step, the 5'-exon is released concomitant with the production of a lariat intermediate, and in the second step, the exons are joined, releasing the intron in the form of a lariat product. Several gene products of the yeast Saccharomyces cerevisiae have been shown to be required exclusively for the second step. Although mammalian proteins have been implicated in the second step of splicing, none have been shown to act only at this step. We identify here the first mammalian activity shown to be exclusively required far the second step. The activity was shown to increase by 5-fold the rate for this splicing step, whereas it had no effect on the rate of the first step. The activity was not affected by treatment with micrococcal nuclease, whereas it is sensitive to heating to 55 degrees C, suggesting that it is not dependent on an RNA, but more likely is a protein. The second step activity was separated from other factors required for the first step and from PSF, a splicing factor thought to have a second step activity. The activity does not require ATP hydrolysis, suggesting that it acts at a late stage of the second step of splicing.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Duke University; Duke University			Lindsey-Boltz, Laura/A-3121-2010	Lindsey-Boltz, Laura/0000-0001-6493-8194	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049639] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49639] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; BURGESS SM, 1993, CELL, V73, P1377, DOI 10.1016/0092-8674(93)90363-U; CECH TR, 1993, RNA WORLD, P239; COUTO JR, 1987, GENE DEV, V1, P445, DOI 10.1101/gad.1.5.445; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; FRANK D, 1992, GENE DEV, V6, P2112, DOI 10.1101/gad.6.11.2112; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; HOROWITZ DS, 1993, GENE DEV, V7, P320, DOI 10.1101/gad.7.2.320; HOROWITZ DS, 1993, MOL CELL BIOL, V13, P2959, DOI 10.1128/MCB.13.5.2959; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1988, P NATL ACAD SCI USA, V85, P5459, DOI 10.1073/pnas.85.15.5459; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; RANDERATH K, 1964, J CHROMATOGR, V16, P111, DOI 10.1016/S0021-9673(01)82445-6; SAWA H, 1988, NUCLEIC ACIDS RES, V16, P3157; SCHWER B, 1992, MOL CELL BIOL, V12, P3540, DOI 10.1128/MCB.12.8.3540; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VIJAYRAGHAVAN U, 1990, MOL CELL BIOL, V10, P324, DOI 10.1128/MCB.10.1.324; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	37	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13415	13421		10.1074/jbc.270.22.13415	http://dx.doi.org/10.1074/jbc.270.22.13415			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768943	hybrid			2022-12-25	WOS:A1995RB43900069
J	CULOUSCOU, JM; CARLTON, GW; ARUFFO, A				CULOUSCOU, JM; CARLTON, GW; ARUFFO, A			HER4 RECEPTOR ACTIVATION AND PHOSPHORYLATION OF SHC PROTEINS BY RECOMBINANT HEREGULIN-FC FUSION PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; DIFFERENTIATION FACTOR; MAMMARY-TUMORS; EGF RECEPTOR; GRB2; RAS; MEMBER; ASSOCIATION	Heregulins (HRGs) are mosaic glycoproteins that bind to and induce the tyrosine phosphorylation of the HER4/p180(erbB4) receptor. This work was aimed at studying the biological effects induced by recombinant epidermal growth factor (EGF)-like domains of KRGs as well as identifying intracellular molecules involved in HERA signaling. To this end, we cloned the EGF-like domains of HRG-alpha, -beta 2, and -beta 3 into a eukaryotic expression vector in frame with sequences encoding a thrombin cleavage site followed by the Fc portion of a human IgG1. These chimeric genes directed the expression of recombinant fusion proteins, rHRGs-T-Fc, which specifically stimulated the phosphorylation of HER4/p180(erbB4). We also show that rHRG-alpha-T-Fc bound to human breast cancer cells that express HER4 receptors and induced the expression of intercellular adhesion molecule-1. After thrombin protease cleavage of rHRGs-T-Fc, their EGF-like domains were purified and shown to stimulate protein phosphorylation in HER4-expressing cells. Moreover, the rHRG-beta 2 EGF-like domain markedly induced the phosphorylation of She proteins on tyrosine, suggesting a role for these adaptor molecules in HRG-mediated signaling.			CULOUSCOU, JM (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, 3005 1ST AVE, SEATTLE, WA 98121 USA.							BACUS SS, 1993, CANCER RES, V53, P5251; BLOMQUIST MC, 1984, P NATL ACAD SCI-BIOL, V81, P7363, DOI 10.1073/pnas.81.23.7363; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DUMONT DJ, 1993, ONCOGENE, V8, P1293; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEGATTO O, 1993, ONCOGENE, V8, P2105; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WHITE MF, 1994, J BIOL CHEM, V269, P1; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	27	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12857	12863		10.1074/jbc.270.21.12857	http://dx.doi.org/10.1074/jbc.270.21.12857			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759543	hybrid			2022-12-25	WOS:A1995QZ71100080
J	FENG, YH; NODA, K; SAAD, Y; LIU, XP; HUSAIN, A; KARNIK, SS				FENG, YH; NODA, K; SAAD, Y; LIU, XP; HUSAIN, A; KARNIK, SS			THE DOCKING OF ARG(2) OF ANGIOTENSIN-II WITH ASP(2) RECEPTOR IS ESSENTIAL FOR FULL AGONISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLONING; EXPRESSION; INHIBITION	The structural model of AT(1) angiotensin receptor contains seven-transmembrane alpha-helices with three interhelical loops on either side of the membrane. The angiotensin II binding pocket within the receptor is not clearly defined. We showed earlier that Lys(199) in transmembrane-helix-5 of the AT(1) receptor binds the COOH-terminal alpha-carboxyl group of angiotensin II (Node, Y., Saad, Y., Kinoshita, A., Boyle, T. P., Graham, R. M., Husain, A., and Karnik, S. S. (1995) J. Biol. Chem. 270, 2284-2289), We now show that His(183) Asp(281), both located in the extracellular domain of the AT(1) receptor, are involved in binding the NH2-terminal Asp(1) and Arg(2) residues of angiotensin II, respectively. The Asp(1)/His(183) interaction appears to be weak and is unlikely to be important for agonism, But the loss of Arg(2)/Asp(281) interaction leads to partial agonism of the receptor, The action of non-peptide agonists is not affected by Asp(281) mutations. These results suggest that several independent interactions between angiotensin II and AT(1) receptor are necessary for full agonism. Since L-162,313 the non-peptide agonist of the AT(1) receptor is a partial agonist that does not make contact with Asp(281), we speculate that the degree of agonism may be increased if it is redesigned to make contacts with Asp(281).			FENG, YH (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT MOLEC CARDIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.		Husain, Ahsan/J-6861-2012; Karnik, Sadashiva/Y-2477-2019	Husain, Ahsan/0000-0003-3426-3469; Karnik, Sadashiva/0000-0003-0746-2753	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033713] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33713, R01 HL057470] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIHAREAU C, 1993, P NATL ACAD SCI USA, V90, P5133; BORDERS CL, 1994, PROTEIN SCI, V3, P541; BUMPUS FM, 1977, HYPERTENSION PHYSIOP, P183; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUCKLE WR, 1989, J BIOL CHEM, V264, P8619; HUSAIN A, 1986, J PHARMACOL EXP THER, V2339, P71; JO H, 1994, J BIOL CHEM, V269, P16533; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KIVLIGHN SD, 1995, IN PRESS AM J PHARM; MARIE J, 1994, J BIOL CHEM, V269, P20815; MARSHALL GR, 1974, RECENT ADV RENAL PHY, P215; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NODA K, 1995, J BIOL CHEM, V270, P2284, DOI 10.1074/jbc.270.5.2284; NODA K, 1994, J BIOL CHEM, V269, P6743; PERELMAN S, 1995, J BIOL CHEM, V270, P1493; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Underwood D J, 1994, Chem Biol, V1, P211, DOI 10.1016/1074-5521(94)90013-2; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	24	131	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12846	12850		10.1074/jbc.270.21.12846	http://dx.doi.org/10.1074/jbc.270.21.12846			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759541	hybrid			2022-12-25	WOS:A1995QZ71100078
J	JUZUMIENE, DI; SHAPKINA, TG; WOLLENZIEN, P				JUZUMIENE, DI; SHAPKINA, TG; WOLLENZIEN, P			DISTRIBUTION OF CROSS-LINKS BETWEEN MESSENGER-RNA ANALOGS AND 16-S RIBOSOMAL-RNA IN ESCHERICHIA-COLI 70-S RIBOSOMES MADE UNDER EQUILIBRIUM CONDITIONS AND THEIR RESPONSE TO TRANSFER-RNA BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA ANALOGS; DECODING SITE; CONSERVED LOOP; IDENTIFICATION; SUBUNIT; POSITIONS; COMPLEX; CROSSLINKING; STREPTOMYCIN; DERIVATIVES	The interaction between mRNA and Escherichia coli ribosomes has been studied by photochemical crosslinking using mRNA analogues that contain 4-thiouridine (s(4)U) or s(4)U modified with azidophenylacyl bromide (APAB), either two nucleotides upstream or eight nucleotides downstream from the nucleotide sequence ACC, the codon for tRNA(Thr). The sequences of the mRNA analogues were described earlier (Stade, K, Rinke-Appel, J., and Brimacombe, R (1989) Nucleic Acids Res. 17, 9889-9908; Rinke-Appel, J., Stade, K., and Brimacombe, R. (1991) EMBO J, 10, 2195-2202), Under equilibrium conditions, both of these mRNA analogues bind and cross-link to 70 S ribosomes without the presence of tRNA(Thr); however, there are significant increases both in binding and particularly in cross-linking in the presence of the tRNA(Thr). Four regions contain cross-linking sites that increase in the presence of tRNA, C-1395, A(532) A(1196) (and minor sites around these three positions), and C-1539/U-1532. Three other cross-linking sites, U-723, A(845), and U-1381, show very little change in extent of crosslinking when tRNA is present. A conformational change in the 30 S subunit allowing additional accessibility to the 16 S rRNA by the mRNA analogues upon tRNA binding best explains the behavior of the tRNA-dependent and tRNA-independent mRNA-16 S rRNA cross-linking sites.	N CAROLINA STATE UNIV, DEPT BIOCHEM, RALEIGH, NC 27695 USA	University of North Carolina; North Carolina State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043237] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER RW, 1994, BIOCHEMISTRY-US, V33, P12109, DOI 10.1021/bi00206a014; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BHANGU R, 1992, BIOCHEMISTRY-US, V31, P5937, DOI 10.1021/bi00140a033; BHANGU R, 1994, BIOCHEMISTRY-US, V33, P3063, DOI 10.1021/bi00176a040; CAPEL MS, 1988, J MOL BIOL, V200, P65, DOI 10.1016/0022-2836(88)90334-8; COOPERMAN BS, 1980, RIBOSOMES STRUCTURE, P531; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; DONTSOVA O, 1991, EMBO J, V10, P2613, DOI 10.1002/j.1460-2075.1991.tb07803.x; DRAGON F, 1993, NUCLEIC ACIDS RES, V21, P1199, DOI 10.1093/nar/21.5.1199; England T E, 1980, Methods Enzymol, V65, P65; GAUTHIER A, 1988, MOL GEN GENET, V214, P192, DOI 10.1007/BF00337710; GORNICKI P, 1984, J BIOL CHEM, V259, P493; GREUER B, 1987, NUCLEIC ACIDS RES, V15, P3241, DOI 10.1093/nar/15.8.3241; GUTELL RR, 1993, NUCLEIC ACIDS RES, V21, P3051, DOI 10.1093/nar/21.13.3051; HUTTENHOFER A, 1994, EMBO J, V13, P3892, DOI 10.1002/j.1460-2075.1994.tb06700.x; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; ISAACS ST, 1977, BIOCHEMISTRY-US, V16, P1058, DOI 10.1021/bi00625a005; KATUNIN VI, 1980, NUCLEIC ACIDS RES, V8, P403, DOI 10.1093/nar/8.2.403; KRZYZOSIAK W, 1987, BIOCHEMISTRY-US, V26, P2353, DOI 10.1021/bi00382a042; LAEMAIGREDUBREU.Y, 1991, NUCLEIC ACIDS RES, V19, P3653; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; LIN FL, 1984, J MOL BIOL, V172, P77, DOI 10.1016/0022-2836(84)90415-7; MELANCON P, 1988, NUCLEIC ACIDS RES, V16, P9631, DOI 10.1093/nar/16.20.9631; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; Ofengand J, 1977, Methods Enzymol, V46, P683; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; POWERS T, 1993, P NATL ACAD SCI USA, V90, P1364, DOI 10.1073/pnas.90.4.1364; POWERS T, 1990, P NATL ACAD SCI USA, V87, P1042, DOI 10.1073/pnas.87.3.1042; POWERS T, 1994, J MOL BIOL, V235, P156, DOI 10.1016/S0022-2836(05)80023-3; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; RAMAKRISHNAN V, 1992, NATURE, V358, P768, DOI 10.1038/358768a0; RINKEAPPEL J, 1993, NUCLEIC ACIDS RES, V21, P2853, DOI 10.1093/nar/21.12.2853; RINKEAPPEL J, 1991, EMBO J, V10, P2195, DOI 10.1002/j.1460-2075.1991.tb07755.x; SANTER M, 1993, BIOCHEMISTRY-US, V32, P5539, DOI 10.1021/bi00072a007; SHATSKY IN, 1991, BIOCHIMIE, V73, P937, DOI 10.1016/0300-9084(91)90135-N; STADE K, 1989, NUCLEIC ACIDS RES, V17, P9889, DOI 10.1093/nar/17.23.9889; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; STOEFFLER G, 1984, STRUCTURE FUNCTION G, P28; SYLVERS LA, 1992, BIOCHIMIE, V74, P381, DOI 10.1016/0300-9084(92)90116-V; TANNER NK, 1988, BIOCHEMISTRY-US, V27, P8852, DOI 10.1021/bi00424a025; VARTIKAR JV, 1989, J MOL BIOL, V209, P221, DOI 10.1016/0022-2836(89)90274-X; VLADIMIROV SN, 1990, BIOCHIM BIOPHYS ACTA, V1048, P245, DOI 10.1016/0167-4781(90)90063-8; WELLER J, 1994, J BIOL CHEM, V269, P19369; WOLLENZIEN PL, 1988, METHOD ENZYMOL, V164, P319; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232	48	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12794	12800		10.1074/jbc.270.21.12794	http://dx.doi.org/10.1074/jbc.270.21.12794			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759534	hybrid			2022-12-25	WOS:A1995QZ71100071
J	VATER, CA; BARTLE, LM; LESZYK, JD; LAMBERT, JM; GOLDMACHER, VS				VATER, CA; BARTLE, LM; LESZYK, JD; LAMBERT, JM; GOLDMACHER, VS			RICIN-A CHAIN CAN BE CHEMICALLY CROSS-LINKED TO THE MAMMALIAN RIBOSOMAL-PROTEINS L9 AND L10E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-GLYCOSIDASE ACTIVITY; ESCHERICHIA-COLI RIBOSOME; RNA IDENTITY ELEMENTS; A-CHAIN; EUKARYOTIC RIBOSOMES; TOXIC LECTINS; RAT-LIVER; MECHANISM; SEQUENCE; SITE	Indirect immunofluorescence studies revealed that when fixed, permeabilized cultured human cells were incubated with ricin A chain, the toxin molecule localized in a staining pattern indicative of binding to the endoplasmic reticulum and to nucleoli. Chemical crosslinking experiments were performed to identify the cellular components that mediated the binding of ricin A chain. Conjugates were formed between I-125-labeled ricin A chain and two proteins present in preparations of total cell membranes and in samples of purified mammalian ribosomes, Specificity of the ricin A chain-ribosome interaction was demonstrated by inhibition of formation of the complexes by excess unlabeled ricin A chain, but not by excess unlabeled gelonin, another ribosome-inactivating protein. Complexes of ricin A chain cross-linked to the ribosomal proteins were purified and subjected to proteolytic digestion with trypsin. Amino acid sequencing of internal tryptic peptides enabled identification of the ricin A chain-binding proteins as L9 and L10e of the mammalian large ribosomal subunit.	WORCESTER FDN EXPTL BIOL INC, CORE LAB PROT CHEM, SHREWSBURY, MA 01545 USA	Worcester Foundation for Biomedical Research	VATER, CA (corresponding author), IMMUNOGEN INC, CAMBRIDGE, MA 02139 USA.							BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; CAWLEY DB, 1979, BIOCHEMISTRY-US, V18, P2648, DOI 10.1021/bi00579a034; ENDO Y, 1988, BIOCHEM BIOPH RES CO, V150, P1032, DOI 10.1016/0006-291X(88)90733-4; ENDO Y, 1988, J BIOL CHEM, V263, P8735; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1987, J BIOL CHEM, V262, P5908; ENDO Y, 1991, J MOL BIOL, V221, P193, DOI 10.1016/0022-2836(91)90814-M; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FERNANDEZPUENTES C, 1976, EUR J BIOCHEM, V64, P437, DOI 10.1111/j.1432-1033.1976.tb10320.x; FOXWELL BMJ, 1985, BIOCHIM BIOPHYS ACTA, V840, P193, DOI 10.1016/0304-4165(85)90119-9; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUKUI Y, 1987, METHOD CELL BIOL, V28, P347; GLUCK A, 1992, J MOL BIOL, V226, P411, DOI 10.1016/0022-2836(92)90956-K; GOLDEN BL, 1993, EMBO J, V12, P4901, DOI 10.1002/j.1460-2075.1993.tb06184.x; HAMEL E, 1972, J BIOL CHEM, V247, P805; HARDESTY B, 1971, METHOD ENZYMOL, V20, P316; HEDBLOM ML, 1978, J SUPRAMOL STR CELL, V9, P253, DOI 10.1002/jss.400090210; HOLMBERG L, 1994, BIOCHEMISTRY-US, V33, P15159, DOI 10.1021/bi00254a027; HORI N, 1993, NUCLEIC ACIDS RES, V21, P4395, DOI 10.1093/nar/21.18.4395; IPPOLITI R, 1992, FEBS LETT, V298, P145, DOI 10.1016/0014-5793(92)80042-F; JOHNSON VG, 1991, INTRACELLULAR TRAFFI, P183; JONES DGL, 1991, NUCLEIC ACIDS RES, V19, P5785, DOI 10.1093/nar/19.20.5785; KAETZEL CS, 1987, BIOCHEM J, V241, P39, DOI 10.1042/bj2410039; KISCHA K, 1971, NATURE-NEW BIOL, V233, P62, DOI 10.1038/newbio233062a0; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; LAMBERT JM, 1981, J MOL BIOL, V149, P451, DOI 10.1016/0022-2836(81)90481-2; LARSON DE, 1991, BIOCHEM CELL BIOL, V69, P5, DOI 10.1139/o91-002; MARTIN TE, 1969, J MOL BIOL, V43, P135, DOI 10.1016/0022-2836(69)90084-9; MARTIN TE, 1971, METHOD ENZYMOL, V20, P417; MITSUI K, 1988, NUCLEIC ACIDS RES, V16, P3573, DOI 10.1093/nar/16.8.3573; MONTANARO L, 1975, BIOCHEM J, V146, P127, DOI 10.1042/bj1460127; MONTANARO L, 1973, BIOCHEM J, V136, P677, DOI 10.1042/bj1360677; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; NEWTON CH, 1990, J BACTERIOL, V172, P579, DOI 10.1128/jb.172.2.579-588.1990; NOLAN PA, 1993, GENE, V134, P223, DOI 10.1016/0378-1119(93)90097-M; NOLAN RD, 1976, EUR J BIOCHEM, V64, P69, DOI 10.1111/j.1432-1033.1976.tb10275.x; OLSNES S, 1973, MOL BIOL REP, V1, P15, DOI 10.1007/BF00357400; OLSNES S, 1974, NATURE, V249, P627, DOI 10.1038/249627a0; READY MP, 1991, PROTEINS, V10, P270, DOI 10.1002/prot.340100311; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SANTOS C, 1994, J BIOL CHEM, V269, P15689; SCHRIER PI, 1973, BIOCHEM BIOPH RES CO, V53, P90, DOI 10.1016/0006-291X(73)91405-8; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; SKOLD SE, 1982, EUR J BIOCHEM, V127, P225, DOI 10.1111/j.1432-1033.1982.tb06859.x; SMITH A, 1989, BRIT J CANCER, V59, P174, DOI 10.1038/bjc.1989.36; Spedding G., 1990, RIBOSOMES PROTEIN SY; STOFFLER G, 1986, STRUCTURE FUNCTION G, P28; SUZUKI K, 1990, GENE, V93, P297, DOI 10.1016/0378-1119(90)90239-N; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; TRAUT RR, 1983, J BIOL CHEM, V258, P4592; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; UCHIUMI T, 1992, J BIOL CHEM, V267, P19179; WALLECZEK J, 1988, EMBO J, V7, P3571, DOI 10.1002/j.1460-2075.1988.tb03234.x; WITTMANNLIEBOLD B, 1984, ADV PROTEIN CHEM, V36, P56; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M	57	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12933	12940		10.1074/jbc.270.21.12933	http://dx.doi.org/10.1074/jbc.270.21.12933			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759553				2022-12-25	WOS:A1995QZ71100091
J	WANG, J; AUGER, KR; JARVIS, L; SHI, Y; ROBERTS, TM				WANG, J; AUGER, KR; JARVIS, L; SHI, Y; ROBERTS, TM			DIRECT ASSOCIATION OF GRB2 WITH THE P85 SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; MIDDLE T-ANTIGEN; PHOSPHOINOSITIDE 3-KINASE; SIGNAL TRANSDUCTION; INTACT-CELLS; PROTEIN; TRANSFORMATION; POLYOMAVIRUS; ACTIVATION; BIND	Phosphatidylinositol 3-kinase (PI 3-kinase) has been shown to play a key role in growth factor signaling pathways, although its signaling mechanism has not been fully elucidated. Using the yeast interaction trap system, we have identified Grb2 as a PI 3-kinase interacting protein. Our experiments demonstrate that p85, the regulatory subunit of PI 3-kinase, interacts with Grb2 in vivo, and this interaction is independent of growth factor stimulation. The direct association between Grb2 and p85 was reconstituted in vitro with glutathione S-transferase fusion proteins. Domain analyses and peptide competition indicate that the association is mediated by the SH3 domains of Grb2 and the proline-rich motifs of p85 and that only one SH3 domain is required for minimal binding. The interaction does not displace the catalytic subunit of PI 3-kinase but is exclusive of Sos. Signaling through PI 3-kinase, therefore, may involve the ubiquitous adapter Grb2, which serves as a convergence point for multiple pathways.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PATHOL,DIV CELL & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [CA30002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA030002, R01CA030002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; EBERLE M, 1990, J BIOL CHEM, V265, P16725; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1991, ONCOGENE, V6, P407; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZ VP, 1994, NATURE, V370, P527; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHLAEPFER DD, 1994, NATURE, V372, P786; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VEMURI GS, 1994, BIOCHEM BIOPH RES CO, V202, P1619, DOI 10.1006/bbrc.1994.2118; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	48	100	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12774	12780		10.1074/jbc.270.21.12774	http://dx.doi.org/10.1074/jbc.270.21.12774			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759531	hybrid			2022-12-25	WOS:A1995QZ71100068
J	ZHAO, ZZ; TAN, Z; WRIGHT, JH; DILTZ, CD; SHEN, SH; KREBS, EG; FISCHER, EH				ZHAO, ZZ; TAN, Z; WRIGHT, JH; DILTZ, CD; SHEN, SH; KREBS, EG; FISCHER, EH			ALTERED EXPRESSION OF PROTEIN-TYROSINE-PHOSPHATASE 2C IN 293 CELLS AFFECTS PROTEIN-TYROSINE PHOSPHORYLATION AND MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; CORKSCREW; SIGNAL; SYP	PTP2C, an SH2 domain-containing protein-tyrosine phosphatase, is recruited to the growth factor receptors upon stimulation of cells. To investigate its role in growth factor signaling, we have overexpressed by approximately 6-fold the native PTP2C and a catalytically inactive mutant of the enzyme in 293 human embryonic kidney cells. The native PTP2C was located entirely in the cytosol, while the inactive mutant was nearly equally distributed in cytosolic and membrane fractions. Expression of the latter caused hyperphosphorylation on tyrosine of a 43-kDa protein, which was coimmunoprecipitated and co-partitioned in the plasma membrane fraction with the inactive PTP2C mutant. This protein may represent a physiological substrate of PTP2C. Overexpression of the native PTP2C enhanced epidermal growth factor (EGF)-stimulated mitogen-activated protein (MAP) kinase kinase activity by 30%, whereas expression of the inactive mutant reduced the stimulated activity by 50%. Similar effects were observed for the activation of MAP kinase as determined by activity assay, gel mobility shift, and tyrosine phosphorylation. The data suggest that the phosphatase activity of PTP2C is partly required for MAP kinase activation by EGF and that PTP2C may function by dephosphorylating the 43-kDa membrane protein.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL,PQ H4P 2R2,CANADA	University of Washington; University of Washington Seattle; National Research Council Canada	ZHAO, ZZ (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07902] Funding Source: Medline; NIGMS NIH HHS [GM42508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; CASE RD, 1994, J BIOL CHEM, V269, P10467; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; SEGER R, 1994, J BIOL CHEM, V269, P25699; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780	28	83	85	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11765	11769		10.1074/jbc.270.20.11765	http://dx.doi.org/10.1074/jbc.270.20.11765			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744825	hybrid			2022-12-25	WOS:A1995QY73600017
J	BOGENMANN, E; TORRES, M; MATSUSHIMA, H				BOGENMANN, E; TORRES, M; MATSUSHIMA, H			CONSTITUTIVE N-MYC GENE-EXPRESSION INHIBITS TRKA MEDIATED NEURONAL DIFFERENTIATION	ONCOGENE			English	Article						N-MYC; TRKA; DIFFERENTIATION; NEURONAL CELLS; CELL CYCLE	NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; NEUROBLASTOMA CELL-LINE; AFFINITY NGF RECEPTOR; CLASS-I GENE; PC12 CELLS; NEUROTROPHIC FACTOR; C-MYC; MONOCLONAL-ANTIBODIES; MESSENGER-RNA	The effect of constitutively expressed N-myc gene on nerve growth factor (NGF) induced neuronal differentiation was investigated, B104, a rat central nervous system-derived cell line and its N-myc gene expressing derivative lines (C6, C7) (Bernards et al., 1986), were stably transfected with the trkA proto-oncogene and independent clones for each cell line were analysed. NGF induced phosphorylation of the trkA receptor, activated a cascade of cellular intermediaries such as phospholipase C gamma 1 and ERK proteins, and stimulated c-fos gene transcription in all trk-A-expressing clones. NGF-mediated neuronal differentiation was observed solely in trkA-expressing B104-derived clones and was characterized by reduced cell growth, activation of NGF-regulated genes, and downregulation of the endogenous low-affinity NGF receptor gene (gp75(NGFR)). NO such phenotypical changes occurred in trkA-expressing C6 or C7-derived clones following NGF treatment. These results are consistent with the hypothesis that constitutive expression of N-myc inhibits exit from cell cycle and blocks neuronal cell differentiation.	UNIV SO CALIF,SCH PHARM,LOS ANGELES,CA 90089; CALTECH,DIV BIOL 14775,PASADENA,CA 91125; JIKEI UNIV,SCH MED,DEPT PEDIAT,MINATO KU,TOKYO 105,JAPAN	University of Southern California; California Institute of Technology; Jikei University	BOGENMANN, E (corresponding author), CHILDRENS HOSP LOS ANGELES,RES INST,DIV HEMATOL ONCOL,4650 SUNSET BLVD,LOS ANGELES,CA 90027, USA.				NINDS NIH HHS [NS25795] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025795] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARDO CC, 1991, CELL, V66, P173; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOHERTY P, 1988, NEUROSCI LETT, V92, P222, DOI 10.1016/0304-3940(88)90065-1; EAGER KB, 1991, ONCOGENE, V6, P819; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; FELTNER DE, 1989, J IMMUNOL, V143, P4292; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROSS N, 1990, CANCER RES, V50, P7532; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IKENAKA K, 1990, J BIOL CHEM, V265, P19782; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LO LC, 1991, DEV BIOL, V145, P139, DOI 10.1016/0012-1606(91)90220-W; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1993, J NEUROSCI, V13, P2919; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MACLEOD AR, 1981, EUR J BIOCHEM, V119, P353, DOI 10.1111/j.1432-1033.1981.tb05615.x; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUSHIMA H, 1992, INT J CANCER, V51, P250, DOI 10.1002/ijc.2910510214; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MILLER FD, 1991, J CELL BIOL, V112, P303, DOI 10.1083/jcb.112.2.303; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1982, ANN INTERN MED, V97, P873, DOI 10.7326/0003-4819-97-6-873; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUGIO K, 1991, CANCER, V67, P1384, DOI 10.1002/1097-0142(19910301)67:5<1384::AID-CNCR2820670518>3.0.CO;2-7; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TORRES M, 1993, J IMMUNOL, V150, P1563; VANDERGEER P, 1994, ANN REV CELL BIOL, V100, P251; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WHITESELL L, 1991, MOL CELL BIOL, V11, P1360, DOI 10.1128/MCB.11.3.1360; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZANCA DM, 1989, MOL CELL BIOL, V9, P24; ZANCA DM, 1986, NATURE, V319, P743	82	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1915	1925						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761093				2022-12-25	WOS:A1995QZ92600005
J	NIXON, PJ; KOMENDA, J; BARBER, J; DEAK, Z; VASS, I; DINER, BA				NIXON, PJ; KOMENDA, J; BARBER, J; DEAK, Z; VASS, I; DINER, BA			DELETION OF THE PEST-LIKE REGION OF PHOTOSYSTEM-2 MODIFIES THE Q(B)-BINDING POCKET BUT DOES NOT PREVENT RAPID TURNOVER OF D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; HERBICIDE-RESISTANT MUTANTS; II REACTION CENTER; THERMO-LUMINESCENCE; ORNITHINE DECARBOXYLASE; MANGANESE CLUSTER; DEGRADATION; PROTEIN; CHLOROPLASTS; POLYPEPTIDE-D1	The rapid turn-over of the D1 polypeptide of the photosystem two complex has been suggested to be due to the presence of a ''PEST''-like sequence located between putative transmembrane helices IV and V of D1 (Greenberg, B. M., Gaba, V., Mattoo, A. K. and Edelman, M. (1987) EMBO J. 6, 2865-2869). We have tested this hypothesis by constructing a deletion mutant (Delta 226-233) of the cyanobacterium Synechocystis sp. PCC 6803 in which residues 226-233 of the D1 polypeptide, containing the PEST-like sequence, have been removed. The resulting mutant, Delta PEST, is able to grow photoautotrophically and give light-saturated rates of oxygen at wild type levels. However electron transfer on the acceptor side of the complex is perturbed. Analysis of cells by thermoluminescence and by monitoring the decay in quantum yield of variable fluorescence following saturating flash excitation indicates that Q(B)(-), but not Q(A)(-), is destabilized in this mutant. Electron transfer on the donor side of photosystem two remains largely unchanged in the mutant. Turnover of the D1 polypeptide as examined by pulse-chase experiments using [S-35]methionine was enhanced in the Delta PEST mutant compared to strain TC31 which is the wild type control. We conclude that the PEST sequence is not absolutely required for turnover of the D1 polypeptide in vivo although deletion of residues 226-233 does have an effect on the redox equilibrium between Q(A) and Q(B).	HUNGARIAN ACAD SCI, BIOL RES CTR, H-6701 SZEGED, HUNGARY; DUPONT CO INC, DEPT CENT RES & DEV, EXPTL STN, WILMINGTON, DE 19880 USA	Hungarian Academy of Sciences; Hungarian Biological Research Center; DuPont	NIXON, PJ (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, WOLFSON LABS, PHOTOSYNTHESIS RES GRP, LONDON SW7 2AY, ENGLAND.		Komenda, Josef/H-4083-2014; Vass, Imre/AAS-6171-2021	Komenda, Josef/0000-0003-4588-0382; Vass, Imre/0000-0003-4987-7842; Nixon, Peter/0000-0003-1952-6937				BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BOICHENKO VA, 1993, Z NATURFORSCH C, V48, P224; CANOVAS PM, 1993, FEBS LETT, V324, P341, DOI 10.1016/0014-5793(93)80147-M; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6137, DOI 10.1021/bi00186a013; DALLACHIESA M, 1994, THESIS U LONDON; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEME, 1993, LJU, V336, P852; DEMETER S, 1982, PHOTOBIOCH PHOTOBIOP, V4, P163; DEMETER S, 1984, BIOCHIM BIOPHYS ACTA, V764, P24, DOI 10.1016/0005-2728(84)90136-1; DEMETER S, 1985, BIOCHIM BIOPHYS ACTA, V806, P16, DOI 10.1016/0005-2728(85)90077-5; Edelman M., 1978, CHLOROPLAST DEV, P641; ERICKSON JM, 1992, PHOTOSYSTEMS STRUCTU, P101; ETIENNE AL, 1990, BIOCHIM BIOPHYS ACTA, V1015, P435, DOI 10.1016/0005-2728(90)90076-G; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GLEITER HM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P135, DOI 10.1016/0005-2728(92)90002-J; GRAAN T, 1986, BIOCHIM BIOPHYS ACTA, V852, P320, DOI 10.1016/0005-2728(86)90238-0; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; JOHNSON BM, 1994, EMBO J, V1184, P85; JOHNSON GN, 1994, BBA-BIOENERGETICS, V1184, P85, DOI 10.1016/0005-2728(94)90157-0; KIM J, 1994, J BIOL CHEM, V269, P17918; KIM JM, 1991, J BIOL CHEM, V266, P14931; KLESS H, 1992, BIOCHEMISTRY-US, V31, P11065, DOI 10.1021/bi00160a016; KLESS H, 1994, BIOCHEMISTRY-US, V33, P10501, DOI 10.1021/bi00200a035; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; MAYES SR, 1993, BIOCHEMISTRY-US, V32, P1454, DOI 10.1021/bi00057a008; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MIYAZAKI Y, 1993, EUR J BIOCHEM, V214, P837, DOI 10.1111/j.1432-1033.1993.tb17987.x; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; OHAD N, 1992, PLANT CELL, V4, P273, DOI 10.1105/tpc.4.3.273; PACKHAM NK, 1988, FEBS LETT, V231, P284, DOI 10.1016/0014-5793(88)80835-4; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V196, P647, DOI 10.1111/j.1432-1033.1991.tb15861.x; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; SHIPTON CA, 1991, P NATL ACAD SCI USA, V88, P6691, DOI 10.1073/pnas.88.15.6691; TANG XS, 1990, FEBS LETT, V273, P257, DOI 10.1016/0014-5793(90)81098-9; TANIGUCHI M, 1993, FEBS LETT, V317, P57, DOI 10.1016/0014-5793(93)81491-H; TELFER A, 1994, J BIOL CHEM, V269, P13244; TYYSTJARVI T, 1994, PLANT MOL BIOL, V25, P517, DOI 10.1007/BF00043879; VASS I, 1981, BIOCHIM BIOPHYS ACTA, V634, P140, DOI 10.1016/0005-2728(81)90134-1; VASS I, 1992, BIOCHIM BIOPHYS ACTA, V764, P24; VASS I, 1992, PHOTOSYSTEMS STRUCTU, V11, P269; WETTERN M, 1983, METHOD ENZYMOL, V97, P554; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	47	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14919	14927		10.1074/jbc.270.25.14919	http://dx.doi.org/10.1074/jbc.270.25.14919			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797471	hybrid			2022-12-25	WOS:A1995RE66600015
J	YANG, WL; CARMAN, GM				YANG, WL; CARMAN, GM			PHOSPHORYLATION OF CTP SYNTHETASE FROM SACCHAROMYCES-CEREVISIAE BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; MUTANTS; GENE; IDENTIFICATION; PURIFICATION; ACTIVATION; ENZYME	Phosphorylation of CTP synthetase (EC 6.3.4.2, UTP:ammonia ligase (ADP-forming)) from Saccharomyces cerevisiae by protein kinase C was examined. Using pure CTP synthetase as a substrate, protein kinase C activity was dose- and time-dependent and required calcium, diacyl-glycerol, and phosphatidylserine for full activation. Protein kinase C activity was also dependent on the concentration of CTP synthetase. Protein kinase C phosphorylated CTP synthetase on serine and threonine residues in vitro whereas the enzyme was primarily phosphorylated on serine residues in vivo. Phosphopeptide mapping analysis of CTP synthetase phosphorylated in vitro and in vivo indicated that the enzyme was phosphorylated on more than one site. Most of the phosphopeptides derived from CTP synthetase phosphorylated in vivo were the same as those derived from CTP synthetase phosphorylated by protein kinase C in vitro. The stoichiometry of the phosphorylation of native CTP synthetase was 0.4 mol of phosphate/mol of enzyme whereas the stoichiometry of the phosphorylation of alkaline phosphatase-treated CTP synthetase was 2.2 mol of phosphate/mol of enzyme. This indicated that CTP synthetase was purified in a phosphorylated state. Phosphorylation of CTP synthetase resulted in a 3-fold activation in enzyme activity whereas alkaline phosphatase treatment of CTP synthetase resulted in a 5-fold decrease in enzyme activity. Overall, the results reported here were consistent with the conclusion that CTP synthetase was regulated by protein kinase C phosphorylation.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick					NIGMS NIH HHS [GM-50679, R01 GM050679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679, R01GM063109] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; ARONOW B, 1987, J BIOL CHEM, V262, P5106; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CULBERTSON MR, 1975, GENETICS, V80, P23; DESAINTVINCENT BR, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; EXTON JH, 1990, J BIOL CHEM, V265, P1; HAID A, 1983, METHOD ENZYMOL, V96, P192; Harlow E., 1988, ANTIBODIES LABORATOR, P1; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LIEBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; MCPARTLAND RP, 1979, J BIOL CHEM, V254, P1394; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PIKULA S, 1994, J BIOL CHEM, V269, P27566; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; SIMON AJ, 1991, P ROY SOC B-BIOL SCI, V243, P165, DOI 10.1098/rspb.1991.0027; THOMAS PE, 1988, BIOCHIM BIOPHYS ACTA, V953, P334, DOI 10.1016/0167-4838(88)90042-8; TRAUT TW, 1988, CRC CR REV BIOCH MOL, V23, P121, DOI 10.3109/10409238809088318; TRUDEL M, 1984, J BIOL CHEM, V259, P2355; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028	40	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14983	14988		10.1074/jbc.270.25.14983	http://dx.doi.org/10.1074/jbc.270.25.14983			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797479	Green Accepted, hybrid			2022-12-25	WOS:A1995RE66600024
J	STARLING, AP; EAST, JM; LEE, AG				STARLING, AP; EAST, JM; LEE, AG			PHOSPHATIDYLINOSITOL 4-PHOSPHATE INCREASES THE RATE OF DEPHOSPHORYLATION OF THE PHOSPHORYLATED CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; ADENOSINE-TRIPHOSPHATASE; ATPASE; CALCIUM; (CA2+-MG2+)-ATPASE; MECHANISM; PHOSPHOLIPIDS; PHOSPHOLAMBAN; HYDROLYSIS; MICROSCOPY	Incubation of the Ca2+-ATPase of skeletal muscle sarcoplasmic reticulum with ATP in the absence of Ca2+ leads to phosphorylation of phosphatidylinositol (PtdIns) to phosphatidylinositol 4-phosphate (PtdIns-4P) and to a doubling of ATPase activity. Similarly, reconstitution of the ATPase with mixtures of dioleoylphosphatidylcholine and PtdIns-4P also led to a doubling of activity; ATPase activity increased with increasing PtdIns-4P content, up to 10% beyond which no further increase was observed. Reconstitution with PtdIns had a much smaller effect on activity. Changes in the Ca2+ affinity of the ATPase following incubation with ATP or reconstitution with PtdIns-4P were small. The rates of phosphorylation of the ATPase by ATP rind of the Ca2+ transport step were unaffected, but the rate of dephosphorylation of the phosphorylated ATPase increased by a factor of 2 either following incubation with ATP or following reconstitution with PtdIns-4P. Activation of the ATPase led to a decrease in the level of phosphorylation of the ATPase by P-i corresponding to a 10-fold decrease in the equilibrium constant E2PMg/E2P(i)Mg.			STARLING, AP (corresponding author), UNIV SOUTHAMPTON,DEPT BIOCHEM,BASSETT CRESCENT E,SOUTHAMPTON SO9 3TU,HANTS,ENGLAND.							BAKER KJ, 1994, BBA-BIOMEMBRANES, V1192, P53, DOI 10.1016/0005-2736(94)90142-2; Bird I M, 1994, Methods Mol Biol, V27, P227; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; DEMEIS L, 1981, SARCOPLASMIC RETICUL; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; GODT RE, 1974, J GEN PHYSIOL, V63, P722, DOI 10.1085/jgp.63.6.722; GOULD GW, 1986, BIOCHEM J, V237, P217, DOI 10.1042/bj2370217; HARDWICKE PM, 1974, EUR J BIOCHEM, V42, P183; HENDERSON IMJ, 1994, BIOCHEM J, V297, P615, DOI 10.1042/bj2970615; HUGHES G, 1994, BIOCHEM J, V303, P511, DOI 10.1042/bj3030511; LEE AG, 1993, PROTEIN LIPID INTERA, P259; MICHELANGELI F, 1991, BIOCHEMISTRY-US, V30, P342, DOI 10.1021/bi00216a006; MICHELANGELI F, 1990, BIOCHEMISTRY-US, V29, P8307, DOI 10.1021/bi00488a015; MILTING H, 1994, FEBS LETT, V345, P211, DOI 10.1016/0014-5793(94)00440-4; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; ORLOWSKI S, 1988, J BIOL CHEM, V263, P17576; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P11331, DOI 10.1021/bi00111a020; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SCHAFER M, 1987, BIOCHEM J, V247, P579, DOI 10.1042/bj2470579; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; STARLING AP, 1994, BIOCHEMISTRY-US, V33, P3023, DOI 10.1021/bi00176a035; STARLING AP, 1993, BIOCHEMISTRY-US, V32, P1593, DOI 10.1021/bi00057a025; STARLING AP, 1995, BIOCHEMISTRY-US, V34, P3084, DOI 10.1021/bi00009a040; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VARSANYI M, 1989, EUR J BIOCHEM, V179, P473, DOI 10.1111/j.1432-1033.1989.tb14577.x; VARSANYI M, 1983, EMBO J, V2, P1543, DOI 10.1002/j.1460-2075.1983.tb01621.x; WARREN GB, 1974, BIOCHEMISTRY-US, V13, P5501, DOI 10.1021/bi00724a008	29	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14467	14470		10.1074/jbc.270.24.14467	http://dx.doi.org/10.1074/jbc.270.24.14467			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782308	hybrid			2022-12-25	WOS:A1995RD45500037
J	TIMMERMANSHEREIJGERS, JLPM; SNOEK, GT; WIRTZ, KWA				TIMMERMANSHEREIJGERS, JLPM; SNOEK, GT; WIRTZ, KWA			A SPHINGOMYELIN-TRANSFERRING PROTEIN FROM CHICKEN LIVER - USE OF PYRENE-LABELED PHOSPHOLIPID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; BOVINE BRAIN; EXCHANGE PROTEINS; BINDING-SITES; BEEF-LIVER; PURIFICATION; PHOSPHATIDYLCHOLINE; FRACTIONS; SN-1	A phospholipid transfer protein was purified from chicken liver which, in addition to phosphatidylinositol (PI) and phosphatidylcholine (PC), carries sphingomyelin (SM) between membranes. For comparison, the PI-transfer protein from chicken liver only carries PI and PC. Specificity was established by use of phospholipids that carry a pyrene-labeled acyl chain. Based on the N-terminal sequence and Western blot analysis we conclude that this protein is an isoform of the PI-transfer protein. At increasing length of the pyrene-labeled acyl chain, the isoform expresses a high activity toward SM, a low activity toward PI, and virtually no activity toward PC.	UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,3508 TB UTRECHT,NETHERLANDS; HELSINKI UNIV,DEPT BASIC CHEM,SF-00014 HELSINKI,FINLAND	Utrecht University; University of Helsinki								AITKEN JF, 1990, J BIOL CHEM, V265, P4711; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BLOJ B, 1977, J BIOL CHEM, V252, P1613; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CRAIN RC, 1980, BIOCHEMISTRY-US, V19, P1433, DOI 10.1021/bi00548a026; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; DICKESON SK, 1994, GENE, V142, P301, DOI 10.1016/0378-1119(94)90279-8; DICORLETO PE, 1979, J BIOL CHEM, V254, P7795; DYATLOVITSKAYA EV, 1978, EUR J BIOCHEM, V82, P463, DOI 10.1111/j.1432-1033.1978.tb12040.x; GEIJTENBEEK TBH, 1994, BBA-LIPID LIPID MET, V1213, P309, DOI 10.1016/0005-2760(94)00063-8; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; KADER JC, 1975, BIOCHIM BIOPHYS ACTA, V380, P31, DOI 10.1016/0005-2760(75)90042-9; KAMP HH, 1973, BIOCHIM BIOPHYS ACTA, V318, P313, DOI 10.1016/0005-2736(73)90196-X; KASURINEN J, 1990, BIOCHEMISTRY-US, V29, P8548, DOI 10.1021/bi00489a007; KASURINEN J, 1992, J BIOL CHEM, V267, P6563; KOUMANOV K, 1982, BIOCHIM BIOPHYS ACTA, V713, P23, DOI 10.1016/0005-2760(82)90162-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; POORTHUIS BJH, 1983, METHOD ENZYMOL, V54, P592; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; SNOEK GT, 1992, J CELL BIOCHEM, V49, P339, DOI 10.1002/jcb.240490404; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; VANAMERONGEN A, 1987, BIOCHIM BIOPHYS ACTA, V919, P149, DOI 10.1016/0005-2760(87)90201-3; VANPARIDON PA, 1988, BIOCHEMISTRY-US, V27, P6208, DOI 10.1021/bi00417a003; VANPARIDON PA, 1987, BIOCHIM BIOPHYS ACTA, V898, P172, DOI 10.1016/0005-2736(87)90035-6; VENUTI SE, 1988, BIOCHIM BIOPHYS ACTA, V946, P119, DOI 10.1016/0005-2736(88)90464-6; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73	31	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14263	14266		10.1074/jbc.270.24.14263	http://dx.doi.org/10.1074/jbc.270.24.14263			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782280	hybrid			2022-12-25	WOS:A1995RD45500006
J	TSANG, NM; NAGASAWA, H; LI, CY; LITTLE, JB				TSANG, NM; NAGASAWA, H; LI, CY; LITTLE, JB			ABROGATION OF P53 FUNCTION BY TRANSFECTION OF HPV16 E6 GENE ENHANCES THE RESISTANCE OF HUMAN-DIPLOID FIBROBLASTS TO IONIZING-RADIATION	ONCOGENE			English	Note						TUMOR SUPPRESSOR GENES; RADIOSENSITIVITY; HUMAN PAPILLOMAVIRUS 16; P5A; RETINOBLASTOMA	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR GENE; SV40 T-ANTIGEN; ATAXIA-TELANGIECTASIA; SKIN FIBROBLASTS; HUMAN KERATINOCYTES; NORMAL INDIVIDUALS; TRANSFORMED-CELLS; CELLULAR PROTEIN; DNA-DAMAGE	In order to examine the role of p53 expression on the sensitivity of cells to radiation-induced reproductive failure, we examined the radiosensitivity of a human diploid fibroblast cell strain (AG1521) before and after transfection with the E6 or E6/E7 genes of human papillomavirus 16 (HPV16)(3). HPV E6 binds to p53, promoting its degradation and abrogating wild-type p53 function. AG1521 cells transfected with either E6 or E6/E7 showed no radiation induction of either p53 or WAF1/Cip1. The radioresistance of these cells were significantly increased; the D-0 of the survival curves rose from 130 +/- 4 cGy for wild type (neo-transfected) cells to 178-192 cGy for three subclones transfected with E6 alone, and 151-218 cGy for eight subclones transfected with E6/E7. The change in radiosensitivity took place before the process of cellular immortalization and transformation produced by transfection with these genes. Thus, the effect on radiosensitivity appears to be an early effect of the loss of p53 function in nontransformed cells, perhaps related to the loss of the G(1) checkpoint and of the capacity for programmed death amongst radiation damaged cells.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health			Li, Chuan-Yuan/H-4148-2013		NCI NIH HHS [CA-47542] Funding Source: Medline; NIEHS NIH HHS [ES-00002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; BARBOSA MS, 1989, ONCOGENE, V4, P1529; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FERTIL B, 1984, RADIAT RES, V99, P73, DOI 10.2307/3576448; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1980, PROC R SOC SER B-BIO, V210, P451, DOI 10.1098/rspb.1980.0146; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEONARDO AD, 1994, GENE DEV, V8, P2540; LI CY, 1995, INT J ONCOL, V6, P233; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LITTLE JB, 1988, INT J RADIAT BIOL, V54, P899, DOI 10.1080/09553008814552311; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; MUNGER K, 1992, CANCER SURV, V12, P197; MUNGER K, 1989, J VIROL, V63, P4417; NAGASAWA H, 1987, J INVEST DERMATOL, V88, P149, DOI 10.1111/1523-1747.ep12525294; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; OCONNOR PM, 1993, CANCER RES, V53, P4776; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARRIS CN, 1990, CANCER LETT, V55, P171, DOI 10.1016/0304-3835(90)90029-W; Sambrook J, 1989, MOL CLONING LABORATO; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SU LN, 1992, INT J RADIAT BIOL, V62, P201, DOI 10.1080/09553009214552021; SU LN, 1992, INT J RADIAT BIOL, V62, P461, DOI 10.1080/09553009214552341; TSANG NM, 1994, RADIAT RES, V140, P172, DOI 10.2307/3578900; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	44	109	112	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2403	2408						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784090				2022-12-25	WOS:A1995RE54300017
J	EMIG, S; SCHMALZ, D; SHAKIBAEI, M; BUCHNER, K				EMIG, S; SCHMALZ, D; SHAKIBAEI, M; BUCHNER, K			THE NUCLEAR-PORE COMPLEX PROTEIN P62 IS ONE OF SEVERAL SIALIC ACID-CONTAINING PROTEINS OF THE NUCLEAR-ENVELOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM AGGLUTININ; N-ACETYLGLUCOSAMINE; SUGAR CHAINS; GLYCOPROTEINS; CELLS; IMPORT; IDENTIFICATION; GLYCOSYLATION; INHIBITION; TRANSPORT	While investigating the glycosylation of nuclear envelope proteins of neuroblastoma cells, we found several proteins that bound the sialic acid-specific Sambucus nigra agglutinin, The strongest signals were obtained for proteins with apparent molecular masses of 66 and 180 kDa, The specificity of the lectin binding was checked by acylneuraminyl hydrolase treatment of nuclear envelope proteins, which prohibited S. nigra agglutinin binding, Digestion of nuclear envelope proteins with the N-glycosidase F revealed that sialic acid was N-glycosidically linked to the 180-kDa protein and very probably O-glycosidically linked to the 66-kDa protein, Upon extraction, the latter behaved like the nucleoporin p62 in that it was partly extracted by high ionic strength buffers, could not be solubilized by nonionic detergent, and was completely removed from the nuclear envelope with urea, Two-dimensional gel electrophoretic comparison showed that the S. nigra agglutinin-binding protein and p62 have an identical isoelectric point of about 5.0 and an identical apparent molecular mass of 66 kDa, This, together with the binding of the anti-nucleoporin antibody, demonstrated the identity of the 66-kDa sialoprotein and p62, S. nigra agglutinin inhibits nuclear protein transport in neuroblastoma cells, strongly suggesting a functional significance of sialylation of p62.	FREE UNIV BERLIN,INST BIOCHEM,ARBEITSGRP NEUROCHEM,D-14195 BERLIN,GERMANY; FREE UNIV BERLIN,INST ANAT,D-14195 BERLIN,GERMANY	Free University of Berlin; Free University of Berlin			Prof. Dr. Shakibaei, Mehdi/AAA-7004-2020	Prof. Dr. Shakibaei, Mehdi/0000-0002-6304-7506				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BECKMANN R, 1992, EUR J BIOCHEM, V210, P45, DOI 10.1111/j.1432-1033.1992.tb17388.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAROLL SM, 1981, J BIOL CHEM, V256, P8357; CORDES V, 1991, EUR J CELL BIOL, V55, P31; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; HALLBERG E, 1993, J CELL BIOL, V122, P513, DOI 10.1083/jcb.122.3.513; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HART GW, 1988, TRENDS BIOCHEM SCI, V13, P380, DOI 10.1016/0968-0004(88)90179-X; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOLT GD, 1986, J BIOL CHEM, V261, P8049; HOLT GD, 1987, J CELL BIOL, V107, P1157; JUNGBLUT PR, 1990, J BIOCHEM BIOPH METH, V21, P47, DOI 10.1016/0165-022X(90)90044-D; KLJAJIC Z, 1987, EUR J BIOCHEM, V169, P97, DOI 10.1111/j.1432-1033.1987.tb13585.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGOLIS RK, 1976, BIOCHIM BIOPHYS ACTA, V451, P465, DOI 10.1016/0304-4165(76)90141-0; MILLER MW, 1994, J BIOL CHEM, V269, P9289; MIZUOCHI T, 1979, J BIOL CHEM, V254, P6419; NEWMEYER DD, 1993, CURR OPIN CELL BIOL, V4, P335; OTTO H, 1992, NEUROCHEM INT, V21, P409, DOI 10.1016/0197-0186(92)90192-T; PANTE N, 1994, CURR OPIN STRUC BIOL, V4, P187, DOI 10.1016/S0959-440X(94)90307-7; RODRIGUEZAPARIC.LB, 1992, J BIOL CHEM, V267, P9257; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SADLER JE, 1979, J BIOL CHEM, V254, P2112; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STERNEMARR R, 1992, J CELL BIOL, V116, P271, DOI 10.1083/jcb.116.2.271; STODDART RW, 1979, BIOL REV, V54, P199, DOI 10.1111/j.1469-185X.1979.tb01010.x; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; TAKASAKI S, 1979, J BIOL CHEM, V254, P8548; WOLFF B, 1988, EXP CELL RES, V178, P318, DOI 10.1016/0014-4827(88)90402-8; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	39	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13787	13793		10.1074/jbc.270.23.13787	http://dx.doi.org/10.1074/jbc.270.23.13787			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775435	hybrid			2022-12-25	WOS:A1995RC44800033
J	HOWE, JR; SKRYABIN, BV; BELCHER, SM; ZERILLO, CA; SCHMAUSS, C				HOWE, JR; SKRYABIN, BV; BELCHER, SM; ZERILLO, CA; SCHMAUSS, C			THE RESPONSIVENESS OF A TETRACYCLINE-SENSITIVE EXPRESSION SYSTEM DIFFERS IN DIFFERENT CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR; GLUTAMATE RECEPTORS; MESSENGER-RNA; GENE; PHOSPHORYLATION; ACTIVATION; MODULATION; CLONING; SUBUNIT	A tetracycline-sensitive inducible expression system was used to regulate the expression of neurotransmitter receptor genes in two mammalian cell lines. The dopamine D-3-receptor was stably expressed in GH3 cells, and GluR6 (a glutamate receptor subunit) was stably expressed in human embryonic kidney (HEK 293) cells. Three striking differences were found. 1) In the inactive state, virtually no D-3-receptor expression was found in GH3 cells, whereas substantial levels of GluR6 expression were found in HER 293 cells. 2) The induction of expression obtained upon removal of tetracycline was robust in GH3 cells but only modest in HEK 293 cells. 3) Whereas in each clonal cell line, the expression of a co-transfected hybrid transactivator is clearly regulated in a tetracycline-responsive manner, in the induced state, its mRNA levels were found to be very low in GH3 cells and very high in HEK 293 cells. The results indicate that, in contrast to GH3 cells, HEK 293 cells do not provide a cellular environment in which the expression of a heterologous gene can be tightly controlled in a tetracycline-responsive manner.	MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA; MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06520 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Yale University			Skryabin, Boris/AAL-3100-2020	Skryabin, Boris/0000-0002-4392-185X; Belcher, Scott/0000-0002-1196-3705	NINDS NIH HHS [NS 30996] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030996] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIU K, 1994, J BIOL CHEM, V269, P29220; MARSHALL J, 1994, BIOPHYS J, V66, pA436; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; NOUER L, 1991, HEAT SHOCK RESPONSE, P167; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; RUETHER JE, 1986, MOL CELL BIOL, V6, P123, DOI 10.1128/MCB.6.1.123; SCHMAUSS C, 1993, P NATL ACAD SCI USA, V90, P8942, DOI 10.1073/pnas.90.19.8942; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SOKOLOFF P, 1992, EUR J PHARM-MOLEC PH, V225, P331, DOI 10.1016/0922-4106(92)90107-7; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; VANDENELSEN P, 1982, GENE, V18, P175, DOI 10.1016/0378-1119(82)90115-9; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377	29	104	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14168	14174		10.1074/jbc.270.23.14168	http://dx.doi.org/10.1074/jbc.270.23.14168			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775477	hybrid			2022-12-25	WOS:A1995RC44800084
J	KIM, JH; WESS, J; VANRHEE, AM; SCHONEBERG, T; JACOBSON, KA				KIM, JH; WESS, J; VANRHEE, AM; SCHONEBERG, T; JACOBSON, KA			SITE-DIRECTED MUTAGENESIS IDENTIFIES RESIDUES INVOLVED IN LIGAND RECOGNITION IN THE HUMAN A(2A) ADENOSINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; RADIOLIGAND BINDING; ADENYLATE-CYCLASE; RAT-BRAIN; EXPRESSION; CLONING; AGONIST; ACTIVATION; INHIBITION; CELLS	The A(2a) adenosine receptor is a member of the G-protein coupled receptor family, and its activation stimulates cyclic AMP production. To determine the residues which are involved in ligand binding, several residues in transmembrane domains 5-7 were individually replaced with alanine and other amino acids, The binding properties of the resultant mutant receptors were determined in transfected COS-7 cells. To study the expression levels in COS-7 cells, mutant receptors were tagged at their amino terminus with a hemagglutinin epitope, which allowed their immunological detection in the plasma membrane by the monoclonal antibody 12CA5. The functional properties of mutant receptors were determined by measuring stimulation of adenylate cyclase. Specific binding of [H-3]CGS 21680 (15 nM) and [H-3]XAC (4 nM), an A(2a) agonist and antagonist, respectively, was absent in the following Ala mutants: F182A, H250A, N253A, I274A, H278A, and S281A, although they were well expressed in the plasma membrane. The hydroxy group of Ser-277 is required for high affinity binding of agonists, but not antagonists. An N181S mutant lost affinity for adenosine agonists substituted at N-6 or C-2, but not at C-5 '. The mutant receptors I274A, S277A, and H278A showed full stimulation of adenylate cyclase at high concentrations of CGS 21680. The functional agonist potencies at mutant receptors that lacked radioligand binding were >30-fold less than those at the wild type receptor. His-250 appears to be a required component of a hydrophobic pocket, and H-bonding to this residue is not essential. On the other hand, replacement of His-278 with other aromatic residues was not tolerated in ligand binding. Thus, some of the residues targeted in this study may be involved in the direct interaction with ligands in the human A(2a) adenosine receptor. A molecular model based on the structure of rhodopsin, in which the 5 '-NH in NECA is hydrogen bonded to Ser-277 and His-278, was developed in order to visualize the environment of the ligand binding site.	NIDDK, MOLEC RECOGNIT SECT, BETHESDA, MD 20892 USA; NIDDK, BIOORGAN CHEM LAB, DRUG RECEPTOR INTERACT SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	Intramural NIH HHS [Z01 DK031117-20, Z99 DK999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ASKALAN R, 1994, J NEUROCHEM, V63, P1477; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BARRACO RA, 1994, PROG NEURO-PSYCHOPH, V18, P545, DOI 10.1016/0278-5846(94)90011-6; BARRINGTON WW, 1989, P NATL ACAD SCI USA, V86, P6572, DOI 10.1073/pnas.86.17.6572; CBLUML K, 1994, J BIOL CHEM, V269, P18870; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; ENJALBERT A, 1983, MOL PHARMACOL, V23, P576; FERRE S, 1994, NEUROSCIENCE, V63, P765, DOI 10.1016/0306-4522(94)90521-5; FONG TM, 1994, J BIOL CHEM, V269, P2728; GALLORODRIGUEZ C, 1994, J MED CHEM, V37, P636, DOI 10.1021/jm00031a014; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HIDE I, 1992, MOL PHARMACOL, V41, P352; Higuchi R., 1989, PCR TECHNOLOGY, P61; IJzerman A P, 1992, Drug Des Discov, V9, P49; IJZERMAN AP, 1994, EUR J PHARM-MOLEC PH, V268, P95, DOI 10.1016/0922-4106(94)90124-4; JACOBSON KA, 1992, MOL PHARMACOL, V42, P123; JACOBSON KA, 1992, J MED CHEM, V35, P407, DOI 10.1021/jm00081a001; JACOBSON M, 1995, ADENOSINE ADENINE NU; JARVIS MF, 1989, J PHARMACOL EXP THER, V251, P888; JI XD, 1992, J RECEPTOR RES, V12, P149, DOI 10.3109/10799899209074789; KANDA T, 1994, EUR J PHARMACOL, V256, P263, DOI 10.1016/0014-2999(94)90551-7; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; MARTIN GE, 1993, PHARMACOL BIOCHEM BE, V45, P951, DOI 10.1016/0091-3057(93)90146-K; NIKODIJEVIC O, 1993, DRUG DEVELOP RES, V30, P121, DOI 10.1002/ddr.430300304; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OLAH ME, 1992, J BIOL CHEM, V267, P10764; OLAH ME, 1994, J BIOL CHEM, V269, P18016; OLSSON RA, 1990, PHARMACOL REV, V3, P761; PIERSEN CE, 1994, MOL PHARMACOL, V45, P871; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; STRADER CD, 1989, J BIOL CHEM, V264, P13572; TOWNSENDNICHOLSON A, 1994, J BIOL CHEM, V269, P2373; TUCKER AL, 1994, J BIOL CHEM, V269, P27900; VANGALEN PJM, 1994, MOL PHARMACOL, V45, P1101; VANRHEE AM, 1994, 208TH NAT M WASH; WEISS S, 1985, MOL PHARMACOL, V27, P595; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	42	204	206	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13987	13997		10.1074/jbc.270.23.13987	http://dx.doi.org/10.1074/jbc.270.23.13987			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775460	hybrid, Green Accepted			2022-12-25	WOS:A1995RC44800060
J	SMULDERS, RHPH; VANGEEL, IG; GERARDS, WLH; BLOEMENDAL, H; DEJONG, WW				SMULDERS, RHPH; VANGEEL, IG; GERARDS, WLH; BLOEMENDAL, H; DEJONG, WW			REDUCED CHAPERONE-LIKE ACTIVITY OF ALPHA-A(INS)-CRYSTALLIN, AN ALTERNATIVE SPLICING PRODUCT CONTAINING A LARGE INSERT PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-A-CRYSTALLIN; HEAT-SHOCK PROTEINS; B-CRYSTALLIN; QUATERNARY STRUCTURE; NONLENTICULAR TISSUES; MOLECULAR CHAPERONE; AINS-CRYSTALLIN; EXPRESSION; MODEL; GENE	alpha-Crystallin is a multimeric protein complex which is constitutively expressed at high levels in the vertebrate eye lens, where it serves a structural role, and at low levels in several non-lenticular tissues. Like other members of the small heat shock protein family, alpha-crystallin has a chaperone-like activity in suppressing nonspecific aggregation of denaturing proteins in vitro. Apart from the major alpha A- and alpha B-subunits, alpha-crystallin of rodents contains an additional minor subunit resulting from alternative splicing, alpha A(ins)-crystallin. This polypeptide is identical to normal alpha A-crystallin except for an insert peptide of 23 residues. To explore the structural and functional consequences of this insertion, we have expressed rat alpha A- and alpha A(ins)-crystallin in Escherichia coli. The multimeric particles formed by alpha A(ins) are larger and more disperse than those of alpha A, but they are native-like and display a similar thermostability and morphology, as revealed by gel permeation chromatography, tryptophan fluorescence measurements, and electron microscopy, However, as compared with alpha A, the alpha A(ins)-particles display a diminished chaperone-like activity in the protection of heat-induced aggregation of beta(low)-crystallin. Our experiments indicate that alpha A(ins)-multimers have a 3-4-fold reduced substrate binding capacity, which might be correlated to their increased particle size and to a shielding of binding sites by the insert peptides. The structure-function relationship of the natural mutant alpha A(ins)-crystallin may shed light on the mechanism of chaperone-like activity displayed by all small heat shock proteins.	UNIV NIJMEGEN, DEPT BIOCHEM, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen					NATIONAL EYE INSTITUTE [R01EY009683] Funding Source: NIH RePORTER; NEI NIH HHS [EY09683] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AUGUSTEYN RC, 1989, BIOCHIM BIOPHYS ACTA, V999, P293, DOI 10.1016/0167-4838(89)90012-5; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; BINDELS JG, 1979, OPHTHALMIC RES, V11, P441, DOI 10.1159/000265048; Bloemendal H., 1981, MOL CELLULAR BIOL EY; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BURNSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263; CARVER JA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P22, DOI 10.1016/0167-4838(93)90107-3; CARVER JA, 1994, EXP EYE RES, V59, P231, DOI 10.1006/exer.1994.1101; COHEN LH, 1978, EUR J BIOCHEM, V89, P259, DOI 10.1111/j.1432-1033.1978.tb20921.x; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DEJONG WW, 1980, BIOCHEM BIOPH RES CO, V96, P648, DOI 10.1016/0006-291X(80)91404-7; DEJONG WW, 1984, EUR J BIOCHEM, V39, P207; DERETIC D, 1994, J BIOL CHEM, V269, P16853; DURO G, 1991, ANAL BIOCHEM, V195, P111, DOI 10.1016/0003-2697(91)90304-C; GROENEN PJTA, 1992, EUR J BIOCHEM, V205, P671, DOI 10.1111/j.1432-1033.1992.tb16827.x; HENDRIKS W, 1990, BIOCHIM BIOPHYS ACTA, V1037, P58, DOI 10.1016/0167-4838(90)90101-K; HENDRIKS W, 1988, EUR J BIOCHEM, V174, P133, DOI 10.1111/j.1432-1033.1988.tb14072.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1986, ADV AGE RES EUROPE, P227; IWAKI T, 1993, AM J PATHOL, V143, P487; JAENICKE R, 1993, CURR BIOL, V3, P234, DOI 10.1016/0960-9822(93)90342-L; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAWORSKI C J, 1990, Investigative Ophthalmology and Visual Science, V31, P507; JAWORSKI CJ, 1989, NATURE, V337, P752, DOI 10.1038/337752a0; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KATO S, 1993, NEUROPATH APPL NEURO, V19, P436, DOI 10.1111/j.1365-2990.1993.tb00466.x; KING CR, 1983, CELL, V32, P707, DOI 10.1016/0092-8674(83)90056-9; KING CR, 1984, J BIOL CHEM, V259, P1822; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KOENIG SH, 1993, BIOPHYS J, V64, P1178, DOI 10.1016/S0006-3495(93)81483-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P121, DOI 10.1007/BF00221053; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; OHNO S, 1985, TRENDS GENET, V1, P160, DOI 10.1016/0168-9525(85)90070-8; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; Sambrook J, 1989, MOL CLONING LABORATO; SIEZEN RJ, 1978, EUR J BIOCHEM, V91, P387, DOI 10.1111/j.1432-1033.1978.tb12691.x; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; STUDIER RW, 1990, METHOD ENZYMOL, V185, P60; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; VANDENHEUVEL R, 1985, J MOL BIOL, V185, P273, DOI 10.1016/0022-2836(85)90403-6; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; VANDENOETELAAR PJM, 1989, BIOCHIM BIOPHYS ACTA, V995, P91, DOI 10.1016/0167-4838(89)90238-0; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; VANDENOETELAAR PJM, 1985, J BIOL CHEM, V260, P4030; VERETOUT F, 1989, J MOL BIOL, V205, P713, DOI 10.1016/0022-2836(89)90316-1; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WANG KY, 1994, J BIOL CHEM, V269, P13601; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; WISTOW G, 1993, EXP EYE RES, V56, P729, DOI 10.1006/exer.1993.1090; XIA JZ, 1994, BIOPHYS J, V66, P861, DOI 10.1016/S0006-3495(94)80862-8	56	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13916	13924		10.1074/jbc.270.23.13916	http://dx.doi.org/10.1074/jbc.270.23.13916			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775451	hybrid			2022-12-25	WOS:A1995RC44800050
J	LUTTRELL, LM; HAWES, BE; TOUHARA, K; VANBIESEN, T; KOCH, WJ; LEFKOWITZ, RJ				LUTTRELL, LM; HAWES, BE; TOUHARA, K; VANBIESEN, T; KOCH, WJ; LEFKOWITZ, RJ			EFFECT OF CELLULAR EXPRESSION OF PLECKSTRIN HOMOLOGY DOMAINS ON G(I)-COUPLED RECEPTOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; BETA-GAMMA-SUBUNITS; PH DOMAIN; IDENTIFICATION; TRANSDUCTION; FIBROBLASTS; SEQUENCE; P21(RAS); PATHWAY; DIMERS	Pleckstrin homology (PH) domains are 90-110 amino acid regions of protein sequence homology that are found in a variety of proteins involved in signal transduction and growth control. We have previously reported that the PH domains of several proteins, including beta ARK1, PLC gamma, IRS-1, Ras-GRF, and Ras-GAP, expressed as glutathione S-transferase fusion proteins, can reversibly bind purified bovine brain GP gamma subunits in vitro with varying affinity. To determine whether PH domain peptides would behave as antagonists of GP gamma subunit-mediated signal transduction in intact cells, plasmid minigene constructs encoding these PH domains were prepared, which permit transient cellular expression of the peptides. Pertussis toxin-sensitive, GP gamma subunit-mediated inositol phosphate (IF) product ion was significantly inhibited in COS-7 cells transiently coexpressing the alpha 2-C10 adrenergic receptor (AR) and each of the PH domain peptides. Pertussis toxin-insensitive, G(q) alpha subunit-mediated IP production via coexpressed M1 muscarinic acetylcholine receptor (Mi AChR) was attenuated only by the PLC gamma PH domain peptide, suggesting that the inhibitory effect of most of the PH domain peptides was G beta gamma subunit-specific. Stimulation of the mitogen-activated protein (MAP) kinase pathway by G(i)-coupled receptors in COS-7 cells has been reported to require activation of p21(ras) and to be independent of protein kinase C. Since several proteins involved in activation contain PH domains, the effect of PH domain peptide expression on alpha 2-C10 AR-mediated p21(ras)-GTP exchange and MAP kinase activation as well as direct G beta gamma subunit-mediated activation of MAP kinase was determined. In each assay, coexpression of the PH domain peptides resulted in significant inhibition. Increasing G beta gamma subunit expression surmounted PH domain peptide-mediated inhibition of MAP kinase activation. These data suggest that the PH domain peptides behave as specific antagonists of G beta gamma-mediated signaling in intact cells and that interactions between PH domains and G beta gamma subunits or structurally related proteins may play a role in the activation of mitogenic signaling pathways by G protein-coupled receptors.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FAURE M, 1994, J BIOL CHEM, V269, P7851; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HALSMA RJ, 1993, NATURE, V363, P310; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1994, PROTEIN SCI, V3, P3; PEITSCH MC, 1993, TRENDS BIOCHEM SCI, V18, P292, DOI 10.1016/0968-0004(93)90038-O; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WINITZ S, 1994, J BIOL CHEM, V269, P1889; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WU DQ, 1992, J BIOL CHEM, V267, P1811; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0	44	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					12984	12989		10.1074/jbc.270.22.12984	http://dx.doi.org/10.1074/jbc.270.22.12984			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768889	hybrid			2022-12-25	WOS:A1995RB43900010
J	ZHOU, MJ; LUBLIN, DM; LINK, DC; BROWN, EJ				ZHOU, MJ; LUBLIN, DM; LINK, DC; BROWN, EJ			DISTINCT TYROSINE KINASE ACTIVATION AND TRITON-X-100 INSOLUBILITY UPON FC-GAMMA-RII OR FC-GAMMA-RIIIB LIGATION IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES - IMPLICATIONS FOR IMMUNE-COMPLEX ACTIVATION OF THE RESPIRATORY BURST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; HUMAN-NEUTROPHILS; MONOCLONAL-ANTIBODIES; HUMAN-MONOCYTES; RECEPTOR-III; PHAGOCYTOSIS; PROTEIN; IDENTIFICATION; EXPRESSION; CELLS	Two tyrosine kinase dependent pathways exist for activation of the respiratory burst by polymorphonuclear leukocyte (PMN) immunoglobulin G Fc receptors. Direct ligation of Fc gamma RII activates the respiratory burst, but ligation of the glycan phosphoinositol-linked Fc gamma RIIIB does not. Instead, this receptor and the integrin complement receptor CR3 synergize in activation of the respiratory burst (Zhou, M.-J., and Brown, E. J. (1994) J, Cell Biol. 125, 1407-1416). Here we show that direct ligation of Fc gamma RIII leads to activation and Triton X-100 insolubility of the Src family kinase Fgr, without effect on the related myeloid Src family member Hck. In contrast, adhesion of PMN via Fc gamma RIIIB leads to activation and Triton X-100 insolubility of Hck but not Fgr. The exclusive association of Fc gamma RIIIB with Hck activation and Triton insolubility is not solely a result of its glycan phosphoinositol anchor, since decay accelerating factor (CD55), another prominent glycan phosphoinositol-anchored PMN protein, is associated with Fgr insolubility to a greater extent than Hck. Ligation of decay accelerating factor, with or without coligation of CR3, does not activate the PMN respiratory burst. Coligation of Fc gamma RIIIB with Fc gamma RII overcomes the pertussis toxin inhibition of H2O2 production in response to direct ligation of Fc gamma RII. These data support the hypothesis that activation of Hck upon Fc gamma RIIIB ligation has a role in generation of the synergistic respiratory burst.	WASHINGTON UNIV,SCH MED,DIV INFECT DIS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV HEMATOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NIAID NIH HHS [AI24674, AI35811] Funding Source: Medline; NIGMS NIH HHS [GM38330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035811, R01AI024674, R37AI024674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBAS AK, 1994, CELLULAR MOL IMMUNOL, P393; AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERGER M, 1984, J CLIN INVEST, V74, P1566, DOI 10.1172/JCI111572; BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BLACKBURN WD, 1989, BIOCHEM BIOPH RES CO, V164, P983, DOI 10.1016/0006-291X(89)91766-X; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; CONNOR J, 1992, J BIOL CHEM, V267, P26050; COYNE KE, 1992, J IMMUNOL, V149, P2906; CROCKETTTORABI E, 1990, J IMMUNOL, V145, P3026; DELAHARPE J, 1985, J IMMUNOL METHODS, V78, P323, DOI 10.1016/0022-1759(85)90089-4; DUSI S, 1994, BIOCHEM BIOPH RES CO, V201, P30, DOI 10.1006/bbrc.1994.1665; EDBERG JC, 1994, J IMMUNOL, V152, P5826; EHLENBERGER AG, 1977, J EXP MED, V145, P357, DOI 10.1084/jem.145.2.357; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GRAHAM IL, 1989, J IMMUNOL, V142, P2352; GRAHAM IL, 1993, J CELL BIOL, V120, P1509, DOI 10.1083/jcb.120.6.1509; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2365; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; LIEBL EC, 1992, ONCOGENE, V7, P2417; LINK DC, 1995, IN PRESS BLOOD; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOONEY RJ, 1986, J EXP MED, V163, P826, DOI 10.1084/jem.163.4.826; MICHL J, 1979, J EXP MED, V150, P607, DOI 10.1084/jem.150.3.607; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; ROSALES C, 1993, NEUTROPHIL, P23; SALMON JE, 1991, J IMMUNOL, V146, P997; SEHGAL G, 1993, J IMMUNOL, V150, P4571; SHEN ZH, 1994, J IMMUNOL, V152, P3017; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407; ZHOU MJ, 1993, J IMMUNOL, V150, P3030	45	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13553	13560		10.1074/jbc.270.22.13553	http://dx.doi.org/10.1074/jbc.270.22.13553			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768958	hybrid			2022-12-25	WOS:A1995RB43900088
J	BAZAR, L; HARRIS, V; SUNITHA, I; HARTMANN, D; AVIGAN, M				BAZAR, L; HARRIS, V; SUNITHA, I; HARTMANN, D; AVIGAN, M			A TRANSACTIVATOR OF C-MYC IS COORDINATELY REGULATED WITH THE PROTOONCOGENE DURING CELLULAR GROWTH	ONCOGENE			English	Article						C-MYC REGULATOR; FUSE BINDING PROTEIN; GROWTH RESPONSE GENE	HEMATOPOIETIC-CELLS; LEUKEMIA-CELLS; HL60 CELLS; 3T3 CELLS; EXPRESSION; TRANSCRIPTION; DIFFERENTIATION; ACTIVATION; RNA; GENES	A recently cloned nuclear protein, which binds a far upstream element (FUSE) of the human c-myc protooncogene, stimulates promoter driven expression in undifferentiated cells. In concert with a loss of c-myc expression, both FUSE binding protein (FBP) mRNA and protein levels disappeared in HL60 cells after PMA-induced differentiation, due to a drop in the rate of transcription that was measured by nuclear runoff. During the differentiation of these cells, the brief half-lives of FBP mRNA (3 h) and protein (1.5 h) did not change, allowing for the rapid down-regulation of nuclear protein levels, as detected by immunohistochemical staining. Like c-myc, FBP is expressed in proliferating cells from a variety of lineages, but not in quiescent cells. When T cells and fibroblasts were stimulated to transit from G0 into the cell cycle, there was a dramatic rise of both FBP mRNA and DNA sequence specific nuclear FBP binding activity, which correlated with the appearance of c-myc mRNA. In contrast to the transient expression of many other immediate early growth response genes, both FBP and c-myc expression were sustained for more than 24 h. In fibroblasts, the coordinate expression of FBP and c-myc throughout all phases of the cell cycle is consistent with FBP's role as a growth-dependent regulator of c-myc expression.	GEORGETOWN UNIV, SCH MED, DEPT PATHOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, SCH MED, DEPT MED, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University					NCI NIH HHS [CA54818] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA054818] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BAZAR L, 1995, J BIOL CHEM, V270, P8241, DOI 10.1074/jbc.270.14.8241; BECKER B, 1994, BIOTECHNIQUES, V17, P630; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DANOVA M, 1993, ANN NY ACAD SCI, V698, P174, DOI 10.1111/j.1749-6632.1993.tb17206.x; DIAMOND LW, 1980, CANCER RES, V40, P703; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1988, J BIOL CHEM, V263, P4828; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANDBERG G, 1991, ACTA ONCOL, V30, P917, DOI 10.3109/02841869109088244; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; MARCUKB, 1992, ANNU REV BIOCHEM, V61, P809; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUNITHA I, 1994, CLIN EXP METASTAS, V12, P143, DOI 10.1007/BF01753981; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	47	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2229	2238						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784068				2022-12-25	WOS:A1995RB70300019
J	FINCHAM, VJ; WYKE, JA; FRAME, MC				FINCHAM, VJ; WYKE, JA; FRAME, MC			V-SRC-INDUCED DEGRADATION OF FOCAL ADHESION KINASE DURING MORPHOLOGICAL TRANSFORMATION OF CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Note						V-SRC; MORPHOLOGICAL TRANSFORMATION; FOCAL ADHESION KINASE	PROTEIN-TYROSINE KINASE; EXTRACELLULAR-MATRIX; CELL-ADHESION; PHOSPHORYLATION; PAXILLIN; PP125FAK	Morphological transformation of cells by the v-Src tyrosine kinase is incompletely understood, However, it is independent of nuclear functions and probably involves phosphorylation of targets associated with the cytoskeleton and focal adhesions, structures which tether the cytoskeleton to the points of cell attachment. v-Src activity both stimulates tyrosine phosphorylation of a tyrosine kinase present in focal adhesions (focal adhesion kinase or pp125(FAK)) and disrupts focal adhesions, leading to cell rounding and detachment. However, pp125(FAK) is also phosphorylated on tyrosine as a result of integrin stimulation which induces quite different biological consequences including the organisation of focal adhesions when cells spread on fibronectin (reviewed in Schaller and Parsons, 1993). To address this paradox, we examined changes in pp125(FAK) during activation and shut-off of temperature sensitive mutant v-Src proteins that induce varying degrees of transformation in chick embryo fibroblasts. An efficiently transforming v-Src mutant initially stimulated pp125(FAK) tyrosine phosphorylation, but induced subsequent pp125(FAK) degradation prior to the onset of cell rounding and detachment. v-Src mutants which are impaired in their ability to induce morphological transformation were much less efficient at inducing degradation of pp125(FAK). Moreover, cell spreading during restitution of normal morphology did not require detectable tyrosine phosphorylation of pp125(FAK), or its potential substrate paxillin, suggesting that pp125(FAK) may function more in the turnover of focal adhesions than in their assembly.			FINCHAM, VJ (corresponding author), BEATSON INST CANC RES,CRC,BEATSON LABS,GARSCUBE ESTATE,SWITCHBACK RD,BEARSDEN G61 1BD,SCOTLAND.							BADER JP, 1972, J VIROL, V10, P267, DOI 10.1128/JVI.10.2.267-276.1972; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CATLING AD, 1994, J VIROL, V68, P4392, DOI 10.1128/JVI.68.7.4392-4399.1994; CATLING AD, 1993, ONCOGENE, V8, P1875; FRAME MC, 1994, MOL BIOL CELL, V5, P1177, DOI 10.1091/mbc.5.11.1177; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GATES RE, 1994, CELL GROWTH DIFFER, V5, P891; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCOTTBURDEN T, 1989, J CELL PHYSIOL, V141, P267, DOI 10.1002/jcp.1041410206; TURNER CE, 1993, J CELL SCI, V105, P637; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	25	80	82	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2247	2252						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784071				2022-12-25	WOS:A1995RB70300022
J	BARR, DP; MASON, RP				BARR, DP; MASON, RP			MECHANISM OF RADICAL PRODUCTION FROM THE REACTION OF CYTOCHROME-C WITH ORGANIC HYDROPEROXIDES - AN ESR SPIN-TRAPPING INVESTIGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; OXIDATION; RESONANCE; PEROXYL; ALKOXYL; PROTEINS; CATALASE; HEMATIN; HEART	The mechanism for the reaction of cytochrome c with t-butyl hydroperoxide and cumene hydroperoxide was investigated, ESR spin trapping studies using 5,5-dimethyl-1-pyrroline N-oxide were performed to demonstrate the presence of hydroperoxide-derived peroxyl, alkoxyl, and methyl radicals. Computer simulation of the experimental data obtained at various 5,5-dimethyl-1-pyrroline N-oxide concentrations was used to determine the relative contributions of each radical adduct to each composite ESR spectrum, From these analyses, it was concluded that the alkoxyl radical of the hydroperoxide was the initial radical produced, presumably by homolytic scission of the O-O bond by ferric cytochrome c. This was in contrast to a previous ESR study that proposed a heterolytic peroxidase-type mechanism for the reaction of cytochrome c with organic hydroperoxides, Methyl radicals were produced from the beta-scission of the alkoxyl radical, The peroxyl radicals are shown to be secondary products formed from the reaction of oxygen with the methyl radical to produce the methyl peroxyl radical, In separate experiments, visible absorption spectroscopy revealed that the heme center was destroyed during the reaction, Both the heme destruction and production of radical adducts were inhibited by cyanide, presumably due to the formation of a cyanoheme complex.			BARR, DP (corresponding author), NIEHS, MOLEC BIOPHYS LAB, RES TRIANGLE PK, NC 27709 USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				BARTOLI GM, 1994, ARCH BIOCHEM BIOPHYS, V312, P81, DOI 10.1006/abbi.1994.1283; BLUMENTHAL DC, 1980, J BIOL CHEM, V255, P5859; CADENAS E, 1980, BIOCHEM J, V187, P131, DOI 10.1042/bj1870131; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P7889; CHOO KY, 1981, INT J CHEM KINET, V13, P833, DOI 10.1002/kin.550130907; DAVIES MJ, 1988, BIOCHIM BIOPHYS ACTA, V964, P28, DOI 10.1016/0304-4165(88)90063-3; DICKERSON RE, 1971, J BIOL CHEM, V246, P1511; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; DYER C, 1979, BIOCHIM BIOPHYS ACTA, V579, P253, DOI 10.1016/0005-2795(79)90053-9; HANNA PM, 1992, ARCH BIOCHEM BIOPHYS, V296, P640, DOI 10.1016/0003-9861(92)90620-C; HAREL S, 1988, FREE RADICAL RES COM, V5, P11, DOI 10.3109/10715768809068554; HAREL S, 1988, FREE RADICAL RES COM, V5, P21, DOI 10.3109/10715768809068555; INGOLD KU, 1969, ACCOUNTS CHEM RES, V2, P1, DOI 10.1021/ar50013a001; KALYANARAMAN B, 1983, J BIOL CHEM, V258, P3855; KOPPENOL WH, 1984, ISR J CHEM, V24, P11; LEDWITH A, 1973, PROC R SOC LON SER-A, V332, P151, DOI 10.1098/rspa.1973.0018; MAIR RD, 1971, ORGANIC PEROXIDES, V2, P542; MARGOLIASH E., 1966, ADVANCE PROTEIN CHEM, V21, P113, DOI 10.1016/S0065-3233(08)60128-X; MASON RP, 1984, METHOD ENZYMOL, V105, P416; MOREHOUSE KM, 1987, FEBS LETT, V222, P246, DOI 10.1016/0014-5793(87)80379-4; ODONNELL V, 1994, BIOCHEM J, V304, P707, DOI 10.1042/bj3040707; OSHEROFF N, 1980, J BIOL CHEM, V255, P1689; RADI R, 1993, FREE RADICAL BIO MED, V15, P653, DOI 10.1016/0891-5849(93)90169-U; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P112, DOI 10.1016/0003-9861(91)90171-E; RADI R, 1993, ARCH BIOCHEM BIOPHYS, V300, P409, DOI 10.1006/abbi.1993.1055; ROSEN GM, 1980, MOL PHARMACOL, V17, P233; ROUBAL WT, 1966, ARCH BIOCHEM BIOPHYS, V113, P150, DOI 10.1016/0003-9861(66)90168-8; RUSSELL GA, 1957, J AM CHEM SOC, V79, P3871, DOI 10.1021/ja01571a068; SMALL RD, 1979, PHOTOCHEM PHOTOBIOL, V29, P49, DOI 10.1111/j.1751-1097.1979.tb09258.x; TAPPEL AL, 1953, ARCH BIOCHEM BIOPHYS, V44, P378, DOI 10.1016/0003-9861(53)90056-3; TAPPEL AL, 1961, AUTOXIDAT ANTITOX, V1, P325; TERAO J, 1990, MEMBRANE LIPID OXIDA, V1, P219; THORNALLEY PJ, 1983, BIOCHIM BIOPHYS ACTA, V759, P16, DOI 10.1016/0304-4165(83)90183-6; VANDERZEE J, 1989, BIOCHIM BIOPHYS ACTA, V980, P175, DOI 10.1016/0005-2736(89)90397-0; WUTHRICH K, 1971, BIOCHIM BIOPHYS ACTA, V253, P98, DOI 10.1016/0005-2728(71)90237-4	35	92	95	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12709	12716		10.1074/jbc.270.21.12709	http://dx.doi.org/10.1074/jbc.270.21.12709			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759524	hybrid			2022-12-25	WOS:A1995QZ71100060
J	MAYER, A; NEUPERT, W; LILL, R				MAYER, A; NEUPERT, W; LILL, R			TRANSLOCATION OF APOCYTOCHROME-C ACROSS THE OUTER-MEMBRANE OF MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; HEME LYASE; PRECURSOR PROTEINS; YEAST APOISO-1-CYTOCHROME-C; NEUROSPORA-CRASSA; RECEPTOR-SITES; IMPORT; TRANSPORT; REQUIREMENTS; BIOGENESIS	Apocytochrome c follows a unique pathway into mitochondria, Import does not require the general protein translocation machinery, protease-sensitive components of the outer membrane, or a membrane potential across the inner membrane. We investigated the membrane binding and translocation steps of the import reaction using purified outer membrane vesicles (OMV) from Neurospora crassa mitochondria, OMV specifically bound, but did not import apocytochrome c. If, however, specific antibodies were enclosed inside OMV, apocytochrome c was accumulated in soluble form in the lumen. Import was reversible, since apocytochrome c became accessible to external protease after release from the antibodies. Thus, OMV are competent of translocating apocytochrome c into their lumen, but lack a binding partner which traps the apoprotein. In intact mitochondria, cytochrome c heme lyase (CCHL), a peripheral protein of the inner membrane, serves such a function by stably associating with apocytochrome c in a complex which is detectable by co-immunoprecipitation. We suggest a model for the import mechanism of apocytochrome c in which the apoprotein specifically associates with and reversibly passes across the outer membrane. Translocation is rendered unidirectional by stable association with CCHL which serves as a ''trans side receptor.'' Finally, heme is attached by CCHL and the holoprotein folds into its native structure.	UNIV MUNICH, INST PHYSIOL CHEM PHYS BIOCHEM & ZELLBIOL, D-80336 MUNICH, GERMANY	University of Munich				Lill, Roland/0000-0002-8345-6518				BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; DEKRUIJFF B, 1992, MEMBRANE BIOGENESIS, P85; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; DUMONT ME, 1993, MOL CELL BIOL, V13, P6442, DOI 10.1128/MCB.13.10.6442; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; DUMONT ME, 1995, IN PRESS ADV MOL CEL, V43; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; HAKVOORT TBM, 1990, P NATL ACAD SCI USA, V87, P4996, DOI 10.1073/pnas.87.13.4996; HALLERMAYER G, 1974, H-S Z PHYSIOL CHEM, V355, P279, DOI 10.1515/bchm2.1974.355.1.279; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HENNIG B, 1983, METHOD ENZYMOL, V97, P261; HENNIG B, 1983, P NATL ACAD SCI-BIOL, V80, P4963, DOI 10.1073/pnas.80.16.4963; JORDI W, 1989, J BIOL CHEM, V264, P2292; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MAYER A, 1995, IN PRESS METHODS ENZ; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; NYE SH, 1990, MOL CELL BIOL, V10, P5763, DOI 10.1128/MCB.10.11.5763; NYE SH, 1990, MOL CELL BIOL, V10, P5753, DOI 10.1128/MCB.10.11.5753; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; RIETVELD A, 1984, J BIOL CHEM, V259, P6704; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; SPRINKLE JR, 1990, P NATL ACAD SCI USA, V87, P5729, DOI 10.1073/pnas.87.15.5729; STUART RA, 1990, BIOCHIMIE, V72, P115, DOI 10.1016/0300-9084(90)90136-5; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; ZIMMERMANN R, 1981, EUR J BIOCHEM, V116, P455, DOI 10.1111/j.1432-1033.1981.tb05357.x	38	100	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12390	12397		10.1074/jbc.270.21.12390	http://dx.doi.org/10.1074/jbc.270.21.12390			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759479	hybrid			2022-12-25	WOS:A1995QZ71100012
J	REYMOND, CD; BEGHDADIRAIS, C; ROGGERO, M; DUARTE, EA; DESPONDS, C; BERNARD, M; GROUX, D; MATILE, H; BRON, C; CORRADIN, G; FASEL, NJ				REYMOND, CD; BEGHDADIRAIS, C; ROGGERO, M; DUARTE, EA; DESPONDS, C; BERNARD, M; GROUX, D; MATILE, H; BRON, C; CORRADIN, G; FASEL, NJ			ANCHORING OF AN IMMUNOGENIC PLASMODIUM-FALCIPARUM CIRCUMSPOROZOITE PROTEIN ON THE SURFACE OF DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ALKALINE-PHOSPHATASE; HUMAN MALARIA PARASITE; T-CELL EPITOPES; MEMBRANE ANCHOR; ORAL SALMONELLA; VACCINE; EXPRESSION; GENE; SPOROZOITE; SEQUENCE	The circumsporozoite protein (CSP), a major antigen of Plasmodium falciparum, was expressed in the slime mold Dictyostelium discoideum. Fusion of the parasite protein to a leader peptide derived from Dictyostelium contact site A was essential for expression. The natural parasite surface antigen, however, was not detected at the slime mold cell surface as expected but retained intracellularly. Removal of the last 23 amino acids re suited in secretion of CSP, suggesting that the C-terminal segment of the CSP, rather than an ectoplasmic domain, was responsible for retention, Cell surface expression was obtained when the CSP C-terminal segment was replaced by the D. discoideum contact site A glycosyl phosphatidylinositol anchor signal sequence. Mice were immunized with Dictyostelium cells harboring CSP at their surface, The raised antibodies recognized two different regions of the CSP, Anti-sporozoite titers of these sera were equivalent to anti-peptide titers detected by enzyme-linked immunosorbent assay, Thus, cell surface targeting of antigens can be obtained in Dictyostelium, generating sporozoite-like cells having potentials for vaccination, diagnostic tests, or basic studies involving parasite cell surface proteins.	UNIV LAUSANNE, INST BIOCHEM, CH-1066 EPALINGES, SWITZERLAND; UNIV LAUSANNE, INST HISTOL & EMBRYOL, CH-1005 LAUSANNE, SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD, PHARMA RES DEPT, CH-4002 BASEL, SWITZERLAND	University of Lausanne; University of Lausanne; Roche Holding			Fasel, Nicolas/O-4253-2016	Fasel, Nicolas/0000-0003-0136-7245				AGGARWAL A, 1990, J EXP MED, V172, P1083, DOI 10.1084/jem.172.4.1083; BALLOU WR, 1987, LANCET, V1, P1277; BARTH A, 1994, J CELL BIOL, V124, P205, DOI 10.1083/jcb.124.1.205; BEGHDADIRAIS C, 1993, J CELL SCI, V105, P831; BLUMTIROUVANZIAM U, 1994, J IMMUNOL, V153, P4134; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BORDIER C, 1986, P NATL ACAD SCI USA, V83, P5988, DOI 10.1073/pnas.83.16.5988; BOULANGER N, 1988, ACTA TROP, V45, P55; CALVOCALLE JM, 1993, J IMMUNOL, V150, P1403; CARAS IW, 1994, BRAZ J MED BIOL RES, V27, P185; CARDELLI JA, 1989, J BIOL CHEM, V264, P3454; CASPERS P, 1989, MOL BIOCHEM PARASIT, V35, P185, DOI 10.1016/0166-6851(89)90121-7; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; CORRADIN G, 1994, CLIN IMMUNOTHER, V1, P191, DOI 10.1007/BF03258505; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; DONTFRAID F, 1988, MOL BIOL MED, V5, P185; ENEA V, 1984, SCIENCE, V225, P628, DOI 10.1126/science.6204384; ETLINGER HM, 1988, J IMMUNOL, V140, P626; FASEL N, 1991, CELL BIOL INT REP, V15, P1051; FASEL N, 1992, GENE, V111, P157, DOI 10.1016/0378-1119(92)90683-G; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Glenn D., 1988, Australian Journal of Biotechnology, V1, P48; GOOD MF, 1987, SCIENCE, V235, P1059, DOI 10.1126/science.2434994; HAYNES PA, 1993, EUR J BIOCHEM, V216, P729, DOI 10.1111/j.1432-1033.1993.tb18192.x; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HOFFMAN SL, 1991, SCIENCE, V252, P520, DOI 10.1126/science.2020852; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KHUSMITH S, 1991, SCIENCE, V252, P715, DOI 10.1126/science.1827210; LEW AM, 1989, J IMMUNOL, V142, P4012; Loomis W., 2012, DEV DICTYOSTELIUM DI; LOUVION JF, 1991, NUCLEIC ACIDS RES, V19, P6133, DOI 10.1093/nar/19.22.6133; LOWE ME, 1992, J CELL BIOL, V116, P799, DOI 10.1083/jcb.116.3.799; LUNA EJ, 1984, J CELL BIOL, V99, P58, DOI 10.1083/jcb.99.1.58; MANIAK M, 1990, NUCLEIC ACIDS RES, V18, P3211, DOI 10.1093/nar/18.11.3211; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MORAN P, 1991, J CELL BIOL, V115, P329, DOI 10.1083/jcb.115.2.329; NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351; NELLEN W, 1985, GENE, V39, P155, DOI 10.1016/0378-1119(85)90309-9; NOEGEL A, 1986, EMBO J, V5, P1473, DOI 10.1002/j.1460-2075.1986.tb04384.x; NUSSENZWEIG RS, 1994, SCIENCE, V265, P1381, DOI 10.1126/science.8073276; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; REYMOND CD, 1984, CELL, V39, P141, DOI 10.1016/0092-8674(84)90199-5; ROMERO PJ, 1988, EUR J IMMUNOL, V18, P1951, DOI 10.1002/eji.1830181213; SADOFF JC, 1988, SCIENCE, V240, P336, DOI 10.1126/science.3281260; Sambrook J, 1989, MOL CLONING LABORATO; SHARMA S, 1985, SCIENCE, V228, P879, DOI 10.1126/science.3890178; SIU CH, 1988, BIOCHEM CELL BIOL, V66, P1089, DOI 10.1139/o88-126; STADLER J, 1989, EMBO J, V8, P371, DOI 10.1002/j.1460-2075.1989.tb03387.x; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; VAUTI F, 1990, MOL CELL BIOL, V10, P4080, DOI 10.1128/MCB.10.8.4080; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WARRICK HM, 1988, NUCLEIC ACIDS RES, V16, P6617, DOI 10.1093/nar/16.14.6617; YOUNG JF, 1985, SCIENCE, V228, P958, DOI 10.1126/science.2988125	59	31	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12941	12947		10.1074/jbc.270.21.12941	http://dx.doi.org/10.1074/jbc.270.21.12941			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759554	hybrid			2022-12-25	WOS:A1995QZ71100092
J	WELTER, JF; CRISH, JF; AGARWAL, C; ECKERT, RL				WELTER, JF; CRISH, JF; AGARWAL, C; ECKERT, RL			FOS-RELATED ANTIGEN (FRA-1), JUNB, AND JUND ACTIVATE HUMAN INVOLUCRIN PROMOTER TRANSCRIPTION BY BINDING TO PROXIMAL AND DISTAL AP1 SITES TO MEDIATE PHORBOL ESTER EFFECTS OIL PROMOTER ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL KERATINOCYTES; CROSS-LINKED ENVELOPE; HUMAN KERATIN-1 GENE; C-FOS; MESSENGER-RNA; ULTRASTRUCTURAL-LOCALIZATION; TERMINAL DIFFERENTIATION; CORNIFIED ENVELOPE; PROTEIN COMPLEXES; TRANSGENIC MICE	Human involucrin (hINV) is a cornified envelope precursor that is specifically expressed in the suprabasal epidermal layers. We previously demonstrated that 2500 base pairs of the hINV gene upstream regulatory region confers differentiation appropriate regulation in transgenic mice. An analysis of the hINV gene sequence upstream of the transcription start site reveals five potential AP1 binding sites (AP1-1 to 5). Using reporter gene constructs in human keratinocytes, we show that the most distal (AP1-5) and most proximal (AP1-1) AP1 sites are essential for high level transcriptional activity. Simultaneous mutation of these sites reduces transcription by 80%. Gel supershift experiments indicate the interaction of these sites with Fra-1, junB, and junD. Involucrin mRNA levels increase 10-fold and promoter activity 5-11-fold when differentiation is induced by phorbol ester. Functional studies implicate AP1-1 and AP1-5 in mediating the phorbol ester-dependent increase in promoter activity. No involucrin promoter activity or involucrin mRNA was detected in 3T3 fibroblasts. We conclude that (i) two AP1 sites in the hINV promoter are important elements required for keratinocyte specific expression, (ii) these AP1-1 sites mediate the phorbol ester-dependent increase in promoter activity, and (iii) Fra-1, junB, and junD may be important regulators of hINV expression in epidermis.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL BIOPHYS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT DERMATOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT REPROD BIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT ONCOL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007678] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07678] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; CANDELIERE GA, 1991, MOL ENDOCRINOL, V5, P1780, DOI 10.1210/mend-5-12-1780; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DJIAN P, 1993, MOL BIOL EVOL, V10, P1136; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; ECKERT RL, 1986, CELL, V46, P83; FISHER C, 1991, DEVELOPMENT, V111, P253; GILFIX BM, 1985, J BIOL CHEM, V260, P1406; HANNAN RD, 1993, J MOL CELL CARDIOL, V25, P1137, DOI 10.1006/jmcc.1993.1127; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUFF CA, 1993, J BIOL CHEM, V268, P377; KAY R, 1987, NUCLEIC ACIDS RES, V15, P2778, DOI 10.1093/nar/15.6.2778; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LEE E, 1991, CARCINOGENESIS, V12, P1651, DOI 10.1093/carcin/12.9.1651; LEE SC, 1993, J BIOL CHEM, V268, P12164; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LONGLEY J, 1991, J INVEST DERMATOL, V97, P974, DOI 10.1111/1523-1747.ep12491890; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MIANO JM, 1993, AM J PATHOL, V142, P715; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; MURTHY S, 1993, J STRUCT BIOL, V111, P68, DOI 10.1006/jsbi.1993.1037; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PARK K, 1992, J BIOL CHEM, V267, P10810; PERSICO AM, 1993, MOL BRAIN RES, V20, P91, DOI 10.1016/0169-328X(93)90113-4; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; REDNER RL, 1992, ONCOGENE, V7, P43; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STEPHENS JM, 1993, MOL CELL BIOCHEM, V123, P63, DOI 10.1007/BF01076476; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; WANG ZQ, 1993, J BONE MINER RES, V8, P839; WARHOL MJ, 1982, HUM PATHOL, V13, P1095, DOI 10.1016/S0046-8177(82)80245-1; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; WIRTH PJ, 1987, CANCER RES, V47, P2831; YAFFE MB, 1993, J INVEST DERMATOL, V100, P3, DOI 10.1111/1523-1747.ep12349857; YAFFE MB, 1992, J BIOL CHEM, V267, P12233; Yoneda Kozo, 1992, Journal of Dermatology (Tokyo), V19, P761; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	63	179	183	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12614	12622		10.1074/jbc.270.21.12614	http://dx.doi.org/10.1074/jbc.270.21.12614			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759510	hybrid			2022-12-25	WOS:A1995QZ71100045
J	LORENZI, MV; LONG, JE; MIKI, T; AARONSON, SA				LORENZI, MV; LONG, JE; MIKI, T; AARONSON, SA			EXPRESSION CLONING, DEVELOPMENTAL EXPRESSION AND CHROMOSOMAL LOCALIZATION OF FIBROBLAST GROWTH FACTOR-VIII	ONCOGENE			English	Note						GROWTH FACTORS; FGF-8; AIGF; EXPRESSION CLONING	CDNA CLONING; FACTOR-I; FAMILY; GENE; PROTEIN; TRANSFORMATION; RECEPTORS; SEQUENCE; MEMBER; CELLS	A mouse testis cDNA library in lambda pCEV27 eukaryotic expression vector was transfected in NIH3T3 fibroblasts and several transformed foci were identified. A plasmid with high-titered focus forming activity was rescued from one of these transformants. Structural analysis of this cDNA predicted a protein identical to androgen induced growth factor (AIGF), recently identified as the eighth member of the fibroblast growth factor (FGF) family, A 1.6 kiIobasepair transcript of the FGF-8 gene was detected in testis but not in other adult tissues analysed. During development, expression of FGF-8 was restricted to embryonic days 9 through 13 suggesting that the growth factor plays a role during a discrete stage of mouse embryogenesis, An exon-containing genomic clone of human FGF-8 was isolated and structural comparisons indicated that the gene structure of this region is highly conserved among the FGF genes. Using a panel of human-rodent somatic cell hybrids, the FGF-8 gene was localized to human chromosome 10.	MT SINAI SCH MED,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BROOKES S, 1989, ONCOGENE, V24, P429; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; HAN IS, 1993, MOL ENDOCRINOL, V7, P889, DOI 10.1210/me.7.7.889; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; KELLEY MJ, 1992, P NATL ACAD SCI USA, V89, P9287, DOI 10.1073/pnas.89.19.9287; KOUHARA H, 1994, ONCOGENE, V9, P455; MARICS I, 1989, ONCOGENE, V4, P335; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERGIA A, 1989, BIOCHEM BIOPH RES CO, V164, P1121, DOI 10.1016/0006-291X(89)91785-3; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MULLANEY BP, 1992, ENDOCRINOLOGY, V131, P2928, DOI 10.1210/en.131.6.2928; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YU YL, 1992, J EXP MED, V175, P1073, DOI 10.1084/jem.175.4.1073; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	29	46	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					2051	2055						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761105				2022-12-25	WOS:A1995QZ92600019
J	AXELSON, M; LARSSON, O				AXELSON, M; LARSSON, O			LOW-DENSITY-LIPOPROTEIN (LDL) CHOLESTEROL IS CONVERTED TO 27-HYDROXYCHOLESTEROL IN HUMAN FIBROBLASTS - EVIDENCE THAT 27-HYDROXYCHOLESTEROL CAN BE AN IMPORTANT INTRACELLULAR MEDIATOR BETWEEN LDL AND THE SUPPRESSION OF CHOLESTEROL PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; OXYSTEROL-BINDING-PROTEIN; STEROL CARRIER PROTEIN-2; BILE-ACID BIOSYNTHESIS; HUMAN LIVER-MICROSOMES; CULTURED MOUSE CELLS; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; CEREBROTENDINOUS XANTHOMATOSIS; OXYGENATED STEROLS; FAMILIAL HYPERCHOLESTEROLEMIA	The formation of oxysterols in cultured human fibroblasts and their physiological roles as intracellular regulators of cholesterol production have been investigated, In the presence of low density lipoproteins (LDL) normal fibroblasts converted LDL cholesterol to the oxysterol 27-hydroxycholesterol in quantities apparently sufficient to down-regulate 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. The production of 27-hydroxycholesterol started 5-8 h after the addition of LDL to the incubation medium, and during this time the activity of HMG-CoA reductase decreased by 73%. For formation of other biologically active oxysterols such as 7 alpha-hydroxycholesterol, 24-hydroxycholesterol, and 25-hydroxycholesterol was not observed, When 27-hydroxylation of LDL cholesterol in mitochondria was selectively prevented by treating normal fibroblasts with cyclosporin A or by using fibroblasts genetically lacking sterol 27-hydroxylase, the suppressive effect of LDL on HMG-CoA reductase was reduced by a factor of about 10. In the absence of LDL or when the fibroblasts lacked LDL-receptors, the cells did not produce detectable amounts of 27-hydroxycholesterol, and HMG-CoA reductase was up-regulated. The results provide strong evidence that 27-hydroxycholesterol is an important intracellular mediator between LDL and the suppression of HMG-CoA reductase in human fibroblasts. The mitochondrial uptake/metabolism of LDL cholesterol seems to be a biologically important extension of the LDL pathway in human cells, since the mitochondrial products of LDL cholesterol may regulate cholesterol homeostasis or be precursors of steroid hormones or bile acids. This pathway, which has now been demonstrated in fibroblasts, may link together the two 22-year-old observations that LDL as well as oxysterols can down-regulate HMG-CoA reductase in cells.	KAROLINSKA HOSP,DEPT TUMOUR PATHOL,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital	AXELSON, M (corresponding author), KAROLINSKA HOSP,DEPT CLIN CHEM,S-17176 STOCKHOLM,SWEDEN.							AXELSON M, 1995, J LIPID RES, V36, P290; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; AXELSON M, 1991, J BIOL CHEM, V266, P17770; AXELSON M, 1981, ANAL LETT PT B, V14, P771, DOI 10.1080/00032718108055481; AXELSON M, 1992, J BIOL CHEM, V267, P1701; BELL JJ, 1976, J BIOL CHEM, V251, P1745; BJORKHEM I, 1992, BIOCHIM BIOPHYS ACTA, V1128, P73, DOI 10.1016/0005-2760(92)90259-X; BJORKHEM I, 1992, J LIPID RES, V32, P455; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1974, J BIOL CHEM, V249, P789; BROWN MS, 1973, P NATL ACAD SCI USA, V70, P2162, DOI 10.1073/pnas.70.7.2162; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1976, SCIENCE, V191, P150, DOI 10.1126/science.174194; BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8; BROWN MS, 1974, J BIOL CHEM, V249, P7306; CALI JJ, 1991, J BIOL CHEM, V266, P7779; CAVENEE WK, 1981, J BIOL CHEM, V256, P2675; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CHANDLER HN, 1983, J LEARN DISABIL, V16, P491, DOI 10.1177/002221948301600813; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHANG TY, 1981, J BIOL CHEM, V256, P6174; Dahl K. D., 1988, Hormones and their actions. Part II. Specific actions of protein hormones., P181; DAHLBACKSJOBERG H, 1993, BIOCHEM J, V293, P203, DOI 10.1042/bj2930203; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DAWSON PA, 1989, J BIOL CHEM, V264, P9046; EDWARDS PA, 1979, J LIPID RES, V20, P40; ESTERMAN AL, 1983, J LIPID RES, V24, P1304; GIBBONS GF, 1983, BIOCHEM SOC T, V11, P649, DOI 10.1042/bst0110649; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; GOWR DB, 1988, HORMONES THEIR ACT 1, P3; GUPTA A, 1986, J BIOL CHEM, V261, P8348; Hornsby P.J., 1988, HORMONES THEIR ACT 2, P193; HWANG PL, 1991, BIOESSAYS, V13, P583, DOI 10.1002/bies.950131108; JANNE O, 1969, CLIN CHIM ACTA, V23, P405, DOI 10.1016/0009-8981(69)90340-4; JAVITT NB, 1990, J LIPID RES, V31, P1527; KANDUTSCH AA, 1980, J BIOL CHEM, V255, P813; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; KESAV S, 1992, BIOCHEM SOC T, V20, P818, DOI 10.1042/bst0200818; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LORENZO JL, 1987, FEBS LETT, V218, P77, DOI 10.1016/0014-5793(87)81022-0; LUND E, 1993, BIOCHIM BIOPHYS ACTA, V1166, P177, DOI 10.1016/0005-2760(93)90094-P; MYANT NB, 1990, CHOLESTEROL METABOLI, P33; NICOLAU G, 1974, J LIPID RES, V15, P94; ORAM JF, 1992, HIGH DENSITY LIPOPRO, V3, P125; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PHILLIPS MC, 1992, HIGH DENSITY LIPOPRO, V3, P117; PRINCEN HMG, 1991, BIOCHEM J, V275, P501, DOI 10.1042/bj2750501; RODGWAY ND, 1992, J CELL BIOL, V116, P307; ROMMERTS FFG, 1988, HORMONES THEIR ACT 2, P163; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SHODA J, 1993, HEPATOLOGY, V17, P395; SHODA J, 1993, STEROIDS, V58, P119, DOI 10.1016/0039-128X(93)90048-R; SINENSKY M, 1981, ARCH BIOCHEM BIOPHYS, V209, P321, DOI 10.1016/0003-9861(81)90287-3; SKREDE S, 1986, J CLIN INVEST, V78, P729, DOI 10.1172/JCI112633; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; TINT GS, 1989, J LIPID RES, V30, P633; TORNVALL P, 1990, ATHEROSCLEROSIS, V84, P219, DOI 10.1016/0021-9150(90)90094-Y; VAHOUNY GV, 1983, J BIOL CHEM, V258, P1731; Warnick G.R., 1983, SELECTED METHODS CLI, V10, P91; WEINSTEIN DB, 1979, CIRCULATION S2, V54, P59	65	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15102	15110		10.1074/jbc.270.25.15102	http://dx.doi.org/10.1074/jbc.270.25.15102			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797494	hybrid			2022-12-25	WOS:A1995RE66600040
J	KANG, D; NISHIDA, J; IYAMA, A; NAKABEPPU, Y; FURUICHI, M; FUJIWARA, T; SEKIGUCHI, M; TAKESHIGE, K				KANG, D; NISHIDA, J; IYAMA, A; NAKABEPPU, Y; FURUICHI, M; FUJIWARA, T; SEKIGUCHI, M; TAKESHIGE, K			INTRACELLULAR-LOCALIZATION OF 8-OXO-DGTPASE IN HUMAN-CELLS, WITH SPECIAL REFERENCE TO THE ROLE OF THE ENZYME IN MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT LIPID-PEROXIDATION; DNA-SYNTHESIS; DEGENERATIVE DISEASES; MUTAGENIC SUBSTRATE; OXIDATIVE DAMAGE; MUTT PROTEIN; PARTICLES; HYDROLYZES; EXPRESSION; UBIQUINONE	We examined the intracellular distribution of 8-oxo-dGTPase (8-oxo-7,8-dihydrodeoxyguanosine triphosphatase) encoded by the MTH1 gene, a human mutator homologue. The activity of 8-oxo-dGTPase mainly located in cytosolic and mitochondrial soluble fractions of Jurkat cells, a human T-cell leukemia line. Electron microscopic immunocytochemistry, using a specific antibody against MTH1 protein, showed localization of MTH1 protein in the mitochondrial matrix. Activity in the mitochondria accounted for about 4% of the total activity. The specific activity in the mitochondrial soluble fraction (8093 units/mg protein) was as high as that in the cytosolic fraction (8111 unit/mg protein). The 8-oxo-dGTPase activities in cytosolic and mitochondrial soluble fractions co-eluted with MTH1 protein by anion-exchange chromatography, and the molecular mass of the mitochondrial MTH1 protein was much the same as that of the cytosolic MTH1 protein (about 18 kDa). HeLa cells expressing MTH1 cDNA showed an increased cytoplasmic signal together with a weak signal in the nucleus in in situ immunostaining of MTH1 protein, and the overexpressed MTH1 protein was recovered from both cytosolic and mitochondrial fractions. Thus, the 8-oxo-dGTPase encoded by MTH1 gene is localized. in mitochondria and cytosol.	KYUSHU UNIV,MED INST BIOREGULAT,FUKUOKA 812,JAPAN; FUKUOKA UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 81401,JAPAN	Kyushu University; Fukuoka University	KANG, D (corresponding author), KYUSHU UNIV,SCH MED,DEPT BIOCHEM,3-1-1 MAIDASHI,FUKUOKA 812,JAPAN.		Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bergmeyer H.U., 1965, METHODS ENZYMATIC AN, P736, DOI [10.1016/b978-0-12-395630-9.50134-1, DOI 10.1016/B978-0-12-395630-9.50134-1]; BESTWICK RK, 1982, J BIOL CHEM, V257, P9305; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; CHEN C, 1987, MOL CELL BIOL, V7, P751; DEMAY J, 1981, CELL BIOL INT REP, V5, P889; DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; ETO Y, 1992, ARCH BIOCHEM BIOPHYS, V295, P101, DOI 10.1016/0003-9861(92)90493-G; Fleischer S, 1974, Methods Enzymol, V31, P6; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; GELLERA C, 1990, NEUROLOGY, V40, P495, DOI 10.1212/WNL.40.3_Part_1.495; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; HRUSZKEWYCZ AM, 1990, MUTAT RES, V244, P123, DOI 10.1016/0165-7992(90)90060-W; ISHIBASHI T, 1994, J BIOL CHEM, V269, P7645; ISHIBASHI T, 1994, MUTAT RES-DNA REPAIR, V315, P199, DOI 10.1016/0921-8777(94)90032-9; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KASAI H, 1984, JPN J CANCER RES, V75, P1037; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI T, 1989, J BIOL CHEM, V264, P2581; TAJIRI T, 1995, IN PRESS MUTAT RES; TAKAYANAGI R, 1980, BIOCHEM J, V192, P853, DOI 10.1042/bj1920853; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TREFFERS HP, 1954, P NATL ACAD SCI USA, V32, P1064; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; YOUNG P, 1994, BIOCHEM BIOPH RES CO, V203, P46, DOI 10.1006/bbrc.1994.2146	45	156	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14659	14665		10.1074/jbc.270.24.14659	http://dx.doi.org/10.1074/jbc.270.24.14659			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782328	hybrid			2022-12-25	WOS:A1995RD45500064
J	YANG, AJ; KNAUER, M; BURDICK, DA; GLABE, C				YANG, AJ; KNAUER, M; BURDICK, DA; GLABE, C			INTRACELLULAR A-BETA-1-42 AGGREGATES STIMULATE THE ACCUMULATION OF STABLE, INSOLUBLE AMYLOIDOGENIC FRAGMENTS OF THE AMYLOID PRECURSOR PROTEIN IN TRANSFECTED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; BETA-PROTEIN; SENILE PLAQUES; PEPTIDE; BRAIN; IMMUNOREACTIVITY; IDENTIFICATION; NEUROTOXICITY; DERIVATIVES; LYSOSOMES	We have analyzed the effect of internalized amyloid beta-protein (A beta) 1-42 aggregates on the metabolism of the amyloid precursor protein (APP) in stably transfected 293 cells. The amount of potentially amyloidogenic fragments of APP immunoprecipitatedby anti-carboxyl-terminal APP and anti-A beta antibodies is dramatically enhanced by the treatment of the cells with A beta 1-42, which is resistant to degradation, but not A beta 1-28, which does not accumulate in cells. This accumulation of amyloidogenic carboxyl-terminal fragments is specific, since there is relatively little effect of A beta 1-42 on the amount of the nonamyloidogenic alpha-secretase carboxyl-terminal fragment. The amyloidogenic fragments accumulate in the same nonionic detergent-insoluble fraction of the cell that contains the internalized A beta 1-42. Western analysis indicates that a subset of the amyloidogenic fragments react with antibodies that recognize a conformation of A beta that is specifically associated with aggregated forms of A beta, suggesting that the adoption of this aggregation-related conformation may be an early event which precedes the final processing that produces A beta. Pulse-chase analysis of the [S-35]Met-labeled 16-kDa amyloidogenic fragment indicates that it is relatively stable in A beta 1-42-treated cells, with a half-life of approximately 50 h. This fragment is degraded with a half-life of 30 min in control cells treated with A beta 1-28. In contrast, the turnover of the nonamyloidogenic alpha-secretase product is not significantly altered by the presence of A beta 1-42, The continuous uptake of A beta 1-42 from the medium is not required for the stimulation of amyloidogenic fragment accumulation, suggesting that the presence of intracellular A beta 1-42 aggregates establishes a new pathway for APP catabolism in cells which leads to the long term stability of the fragments. If these amyloidogenic fragments of APP ultimately give rise to A beta, then the production of A beta may be an autocatalytic, ''runaway'' process in cells containing A beta 1-42 nuclei. It is conceivable that the accumulation of insoluble APP and amyloidogenic fragments of APP in response to A beta 1-42 aggregates may mimic the pathophysiology of dystrophic neurites, where the accumulation of intracellular APP and APP fragments has been documented by immunohistochemistry.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT CELL & DEV BIOL,IRVINE,CA 92717	University of California System; University of California Irvine; University of California System; University of California Irvine					NATIONAL INSTITUTE ON AGING [P01AG000538] Funding Source: NIH RePORTER; NIA NIH HHS [AG00538] Funding Source: Medline; NINDS NIH HHS [NS31230] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANCHER C, 1989, NEUROBIOL AGING, V10, P125, DOI 10.1016/0197-4580(89)90021-3; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; CHEUNG TT, 1994, AMYLOID, V1, P30, DOI 10.3109/13506129409148622; COLE G, 1989, NEUROSCI LETT, V100, P340, DOI 10.1016/0304-3940(89)90710-6; COLE GM, 1991, NEUROBIOL AGING, V12, P85, DOI 10.1016/0197-4580(91)90046-M; COLE GM, 1989, NEUROCHEM RES, V10, P933; CRAS P, 1991, P NATL ACAD SCI USA, V88, P7552, DOI 10.1073/pnas.88.17.7552; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FRACKOWIAK J, 1994, J NEUROPATH EXP NEUR, V53, P637, DOI 10.1097/00005072-199411000-00011; FUKUCHI K, 1992, BIOCHEM BIOPH RES CO, V182, P165, DOI 10.1016/S0006-291X(05)80126-3; FUKUCHI KI, 1993, ANN NY ACAD SCI, V695, P217, DOI 10.1111/j.1749-6632.1993.tb23055.x; FUKUCHI KI, 1994, EXP NEUROL, V127, P253, DOI 10.1006/exnr.1994.1101; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; GEARING M, 1993, J NEUROPATH EXP NEUR, V52, P22, DOI 10.1097/00005072-199301000-00004; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; ISHII T, 1989, NEUROPATH APPL NEURO, V15, P135, DOI 10.1111/j.1365-2990.1989.tb01216.x; IVERFELDT K, 1993, P NATL ACAD SCI USA, V90, P4146, DOI 10.1073/pnas.90.9.4146; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMOTO A, 1994, BBA-MOL BASIS DIS, V1225, P304, DOI 10.1016/0925-4439(94)90011-6; MATSUMOTO A, 1991, BIOCHEM BIOPH RES CO, V175, P361, DOI 10.1016/0006-291X(91)91572-T; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; SCHAEFER PW, 1987, ENVIRON ENTOMOL, V16, P368, DOI 10.1093/ee/16.2.368; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SHOJI M, 1990, BRAIN RES, V512, P164, DOI 10.1016/0006-8993(90)91187-L; SIMAN R, 1993, J BIOL CHEM, V268, P16602; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; SUZUKI N, 1994, SCIENCE, V264, P336; WISNIEWSKI HM, 1995, NEUROSCI LETT, V183, P120, DOI 10.1016/0304-3940(94)11129-7; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YASUHARA O, 1994, NEUROSCI LETT, V171, P73, DOI 10.1016/0304-3940(94)90608-4	46	111	114	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14786	14792		10.1074/jbc.270.24.14786	http://dx.doi.org/10.1074/jbc.270.24.14786			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782344	hybrid			2022-12-25	WOS:A1995RD45500082
J	JONES, DE; CUI, DM; MILLER, DM				JONES, DE; CUI, DM; MILLER, DM			EXPRESSION OF BETA-GALACTOSIDASE UNDER THE CONTROL OF THE HUMAN C-MYC PROMOTER IN TRANSGENIC MICE IS INHIBITED BY MITHRAMYCIN	ONCOGENE			English	Article						C-MYC; TRANSCRIPTION; TRANSGENIC; MITHRAMYCIN	RNA STABILITY INVITRO; TRANSCRIPTIONAL ACTIVITY; GENE; BINDING; CELLS; ONCOGENE; PROTEIN; INVIVO; MAX	In order to assess the functional contribution of the human c-myc promoter region in the expression of the c-myc gene, transgenic mouse lines containing a bacterial lac Z gene encoding beta-galactosidase under the control of the human c-myc protooncogene promoter were generated. Transgenic mouse embryos heterozygous for the human c-myc Z transgene demonstrate high amounts of beta-galactosidase activity as early as day 11 of embryogenesis by histochemical staining of whole embryos using 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal) as substrate, localizing specifically to early spinal cord tissue. beta-galactosidase activity can be demonstrated by histochemical staining in brain tissue of day 14 embryos, localizing mainly to the prefrontal cortex region, while relative amounts of beta-galactosidase in spinal cord tissue are reduced. Determination of specific activity of beta-galactosidase using resorufin-beta galactopyranoside as substrate in homogenates of whole embryos heterozygous for the human c-myc/lac Z transgene demonstrates significantly elevated beta-galactosidase activity over control embryos in day 11 and day 14 embryos. Surprisingly, cell homogenates of brain tissue from adult G(1) generation mice heterozygous for the human c-myc/lac Z transgene demonstrate greater than 10-foId higher specific activity of beta-galactosidase over normal control brain tissue. Specific inhibition of the c-myc/lac Z transgene was also demonstrated in developing embryos using mithramycin given at a dose of 150 mu g kg(-1) d(-1) intraperitoneal to pregnant females on days 7-13 of gestation. Both histochemical staining of beta-galactosidase and specific activity assays of day 14 embryos demonstrated significantly lower levels of beta-galactosidase than untreated controls. These results are unique since we are able to detect expression of beta-galactosidase in developing embryonic central nervous system tissue along with adult brain tissue of animals carrying the human c-myc Z transgene and we are able to specifically inhibit expression of the transgene using mithramycin administered in utero.	UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT BIOCHEM & MOLEC GENET, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, BOLDEN LAB, BIRMINGHAM, AL 35294 USA; VET AFFAIRS MED CTR, BIRMINGHAM, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [CA-42664, CA-42337] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042664, R01CA042337] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAMPBELL VW, 1994, AM J MED SCI, V307, P167, DOI 10.1097/00000441-199403000-00002; CHANG Y, 1991, ONCOGENE, V6, P1979; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LAVENU A, 1994, ONCOGENE, V9, P527; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015; MORELLO D, 1993, ONCOGENE, V8, P1921; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; RAY R, 1990, AM J MED SCI, V300, P203, DOI 10.1097/00000441-199010000-00001; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; Sambrook J, 1989, MOL CLONING LABORATO; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; SNYDER RC, 1991, BIOCHEMISTRY-US, V30, P4290, DOI 10.1021/bi00231a027; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7	28	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2323	2330						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784080				2022-12-25	WOS:A1995RE54300007
J	JIANG, SW; EBERHARDT, NL				JIANG, SW; EBERHARDT, NL			INVOLVEMENT OF A PROTEIN DISTINCT FROM TRANSCRIPTION ENHANCER FACTOR-I (TEF-1) IN MEDIATING HUMAN CHORIONIC SOMATOMAMMOTROPIN GENE ENHANCER FUNCTION THROUGH THE GT-IIC ENHANSON IN CHORIOCARCINOMA AND COS CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL-LACTOGEN; FACTOR-I TEF-1; SV40 ENHANCER; COLLAGEN PROMOTER; BINDING; EVOLUTION; SEQUENCE; SPECIFICITY; ACTIVATION; EXPRESSION	Previous studies suggested that transcription enhancer factor-1 (TEF-1) was involved in mediating the human chorionic somatomammotropin (hCS) gene enhancer (CSEn) function (Jiang, S.-W., and Eberhardt, N. L. (1994) J. Biol. Chem. 269, 10384-10392). We now show that an unrelated protein (CSEF-1) found in BeWo and COS-1 cells binds to the GT-IIC enhanson in CSEn and is correlated with CSEn activity in these cells. TEF-1 and CSEF-1 were distinguished by differential migration as GT-IIC complexes, thermal stability, molecular mass, and cross-reactivity with chicken TEF-1 antibodies. TEF-1 and CSEF-1 bound to the GT-IIC and Sph-I/Sph-II enhansons with identical binding properties, and in vitro generated TEF-1 competed with CSEF-1 binding to the GT-IIC motif, suggesting that their actions might be mutually exclusive. Up- and down-regulation of TEF-1 levels by expression systems and antisense oligonucleotides demonstrated that TEF-1 inhibited the hCS promoter in a manner independent of the enhancer or a known TEF-1 DNA binding site. The data suggest that TEF-1 may provide a counter-regulatory stimulus to the actions of CSEF-1, which may be involved in mediating enhancer stimulatory activity.	MAYO CLIN & MAYO FDN,DEPT MED,ENDOCRINE RES UNIT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NIDDK NIH HHS [DK41206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CATALA F, 1989, NUCLEIC ACIDS RES, V17, P3811, DOI 10.1093/nar/17.10.3811; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FORSBERG M, 1991, EMBO J, V10, P2543, DOI 10.1002/j.1460-2075.1991.tb07794.x; HATAMOCHI A, 1993, FEBS LETT, V327, P325, DOI 10.1016/0014-5793(93)81014-Q; HIRT H, 1987, DNA-J MOLEC CELL BIO, V6, P59, DOI 10.1089/dna.1987.6.59; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JIANG SW, 1995, J BIOL CHEM, V270, P3683, DOI 10.1074/jbc.270.8.3683; JIANG SW, 1994, J BIOL CHEM, V269, P10384; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1994, J BIOL CHEM, V269, P3775; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LYTRAS A, 1994, MOL ENDOCRINOL, V8, P478, DOI 10.1210/me.8.4.478; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MIRABITO PM, 1989, CELL, V57, P859, DOI 10.1016/0092-8674(89)90800-3; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; RISTINIEMI J, 1989, J BIOL CHEM, V264, P2164; ROGERS BL, 1986, NUCLEIC ACIDS RES, V14, P7647, DOI 10.1093/nar/14.19.7647; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SNEDECOR GW, 1994, STATISTICAL METHODS, P116; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALKER WH, 1991, ENDOCR REV, V12, P316, DOI 10.1210/edrv-12-4-316; WALKER WH, 1990, J BIOL CHEM, V265, P12940; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	36	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13906	13915		10.1074/jbc.270.23.13906	http://dx.doi.org/10.1074/jbc.270.23.13906			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775450	hybrid			2022-12-25	WOS:A1995RC44800049
J	TAM, SSC; LEE, DHS; WANG, EY; MUNROE, DG; LAU, CY				TAM, SSC; LEE, DHS; WANG, EY; MUNROE, DG; LAU, CY			TEPOXALIN, A NOVEL DUAL INHIBITOR OF THE PROSTAGLANDIN-H SYNTHASE CYCLOOXYGENASE AND PEROXIDASE-ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR GLAND MICROSOMES; HIGHER OXIDATION-STATES; PERFUSED-RAT-LIVER; ENDOPEROXIDE SYNTHASE; BIOSYNTHESIS; SYNTHETASE; HYDROPEROXIDE; MECHANISM; ASSAY; ACID	Prostaglandin-H synthase-1, the rate-limiting enzyme in prostaglandin synthesis, has both cyclooxygenase (CO) and peroxidase (PO) activities. While most nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit only the CO activity, we describe an inhibitor, tepoxalin, that inhibits both the CO (IC50 = 0.1 mu M) and the PO (IC50 = 4 mu M) activities. Unlike many NSAIDs which are competitive inhibitors of CO, tepoxalin is a noncompetitive inhibitor of CO and its inhibitory effect on PO but not CO is reversed by excess heme. Moreover, inhibition of the PO activity by tepoxalin is not dependent on the enzymatic turnover of the CO activity. The hydroxamic acid of tepoxalin is responsible for the PO inhibition since a carboxylic acid derivative of tepoxalin retains full CO but not PO inhibition. We postulated that the hydroxamic group might confer the ability to inhibit PO on conventional CO inhibitors. This idea was supported by the observation that naproxen hydroxamic acid, but not naproxen showed PO inhibition. Furthermore, tepoxalin's carboxylic acid analogue and naproxen each competitively relieved PO inhibition by their respective hydroxamic acids. The intracellular activity of PO as monitored by the release of reactive oxygen species was also inhibited by both tepoxalin and naproxen hydroxamic acid. These observations suggest a strategy for design of novel compounds to inhibit prostaglandin synthase PO. The therapeutic implications of these novel PO inhibitors are discussed.	RW JOHNSON PHARMACEUT RES INST,DISCOVERY RES,DON MILLS,ON M3C 1L9,CANADA									AKERBOOM TPM, 1982, J BIOL CHEM, V257, P4248; ARGENTIERI DC, 1994, J PHARMACOL EXP THER, V271, P1399; BASS DA, 1983, J IMMUNOL, V130, P1910; BOISSY RE, 1989, CYTOMETRY, V10, P779, DOI 10.1002/cyto.990100616; BURK RF, 1978, J BIOL CHEM, V253, P43; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CHARKRABORTI S, 1993, BIOCHEM J, V292, P585; DARGEL R, 1992, EXP TOXICOL PATHOL, V44, P169, DOI 10.1016/S0940-2993(11)80202-2; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1981, J BIOL CHEM, V256, P375; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; Egan R W, 1980, Adv Prostaglandin Thromboxane Res, V6, P153; FERRO MP, 1992, Patent No. 5164381; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Harlow E., 1988, ANTIBODIES LAB MANUA, P553; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HEMLER ME, 1989, ARCH BIOCHEM BIOPHYS, V193, P340; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOLMSEN H, 1977, J BIOL CHEM, V252, P1752; KASMI SMI, 1995, J CELLBIOCH, V57, P299; KUEHL FA, 1977, NATURE, V265, P170, DOI 10.1038/265170a0; KULMACZ RJ, 1985, BIOCHEM BIOPH RES CO, V130, P918, DOI 10.1016/0006-291X(85)90504-2; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1987, PROSTAGLANDINS, V34, P225, DOI 10.1016/0090-6980(87)90246-2; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LANDS WEM, 1976, ADV PROSTAG THROMB R, V1, P7; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MARNETT LJ, 1982, J BIOL CHEM, V257, P6957; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; OHKI S, 1979, J BIOL CHEM, V254, P829; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PLE P, 1989, J BIOL CHEM, V264, P13983; RAZ A, 1990, BIOCHEM J, V269, P603, DOI 10.1042/bj2690603; ROBAK J, 1978, BIOCHEM PHARMACOL, V27, P393, DOI 10.1016/0006-2952(78)90367-2; ROBISON TW, 1990, PROSTAGLANDINS, V40, P13, DOI 10.1016/0090-6980(90)90053-X; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SMITH RC, 1987, FREE RADICAL BIO MED, V3, P251, DOI 10.1016/S0891-5849(87)80032-1; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; WAN CP, 1993, J IMMUNOL METHODS, V159, P131, DOI 10.1016/0022-1759(93)90150-6	52	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13948	13955		10.1074/jbc.270.23.13948	http://dx.doi.org/10.1074/jbc.270.23.13948			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775455	hybrid			2022-12-25	WOS:A1995RC44800054
J	WENG, HQ; CHOI, SY; FALLER, DV				WENG, HQ; CHOI, SY; FALLER, DV			THE MOLONEY LEUKEMIA RETROVIRAL LONG TERMINAL REPEAT TRANS-ACTIVATES AP-1-INDUCIBLE GENES AND AP-1 TRANSCRIPTION FACTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; JUN DNA-BINDING; MURINE RETROVIRUS; DISEASE SPECIFICITY; SIGNAL TRANSDUCTION; ENHANCER ELEMENT; MAMMALIAN-CELLS; PHOSPHORYLATION; VIRUS; FOS	Moloney murine leukemia virus (Mo-MuLV) is a thymotropic and leukemogenic retrovirus which causes T lymphomas. The long terminal repeat (LTR) of Mo-MuLV affects the regulation of a number of cellular genes, including collagenase IV, monocyte chemoattractant protein-1, and c-jun genes, all of which contain 12-O-tetradecanoylphorbol-13-acetate-responsive element consensus sites within their promoters. We report here that Mo-MuLV stimulates the collagenase IV gene through transcription factor AP-1, and that the expression of a subgenomic portion of Mo-MuLV LTR alone is sufficient for this effect. Transient or stable expression of the viral LTR increases cellular AP-1 DNA binding activity. The collagenase IV 12-O-tetradecanoylphorbol-13-acetate-responsive element consensus sequence was shown to be required for this trans-activation. Deletions or mutations of this consensus site which abolished AP-1 binding also abolished trans activation by the LTR. Transient or stable transfection of the viral LTR into cells stimulated c-jun gene expression, suggesting one mechanism whereby the viral LTR may induce cellular AP-1 activity. Thus, the Mo-MuLV LTR, through activation of the transcription factor AP-1, is capable of regulating cellular gene expression, including the induction of proto-oncogenes. This activity may be relevant to the mechanisms whereby retroviruses which do not contain oncogenes induce neoplasia.	BOSTON UNIV,SCH MED,CTR CANC RES,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,MED LAB,BOSTON,MA 02118	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University					NCI NIH HHS [R01-CA50459, R01-CA65420] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050459, R01CA065420] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, ONCOGENE, V6, P2179; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRIGHTMAN BK, 1991, P NATL ACAD SCI USA, V88, P2264, DOI 10.1073/pnas.88.6.2264; CHOI SY, 1994, J BIOL CHEM, V269, P19691; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLYER DC, 1985, J IMMUNOL, V135, P2287; FLYER DC, 1983, NATURE, V305, P315; FRAME MC, 1991, ONCOGENE, V6, P205; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKAFLIPOT I, 1992, J VIROL, V66, P7201, DOI 10.1128/JVI.66.12.7201-7210.1992; HANECAK R, 1991, J VIROL, V65, P5357, DOI 10.1128/JVI.65.10.5357-5363.1991; HOLLAND CA, 1985, J VIROL, V53, P158, DOI 10.1128/JVI.53.1.158-165.1985; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOKA P, 1991, J IMMUNOL, V146, P2417; LENZ J, 1984, NATURE, V308, P467, DOI 10.1038/308467a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MUNDSCHAU LJ, 1991, MOL CELL BIOL, V11, P3148, DOI 10.1128/MCB.11.6.3148; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PAPAVASSILIOU AG, 1992, P NATL ACAD SCI USA, V89, P11562, DOI 10.1073/pnas.89.23.11562; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SPECK NA, 1990, J VIROL, V64, P543, DOI 10.1128/JVI.64.2.543-550.1990; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TIMMERS HT, 1990, NUCLEIC ACIDS RES, V18, P23, DOI 10.1093/nar/18.1.23; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WILSON LD, 1987, MOL CELL BIOL, V7, P2406, DOI 10.1128/MCB.7.7.2406; YAMITHEZI A, 1994, ONCOGENE, V9, P1065	48	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13637	13644		10.1074/jbc.270.23.13637	http://dx.doi.org/10.1074/jbc.270.23.13637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775415	hybrid			2022-12-25	WOS:A1995RC44800011
J	YAMANO, Y; OHYAMA, K; KIKYO, M; SANO, T; NAKAGOMI, Y; INOUE, Y; NAKAMURA, N; MORISHIMA, I; GUO, DF; HAMAKUBO, T; INAGAMI, T				YAMANO, Y; OHYAMA, K; KIKYO, M; SANO, T; NAKAGOMI, Y; INOUE, Y; NAKAMURA, N; MORISHIMA, I; GUO, DF; HAMAKUBO, T; INAGAMI, T			MUTAGENESIS AND THE MOLECULAR MODELING OF THE RAT ANGIOTENSIN-II RECEPTOR (AT(1))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; TYPE-1 RECEPTOR; EXPRESSION CLONING; LIGAND-BINDING; SMOOTH-MUSCLE; CDNA; PROTEIN; IDENTIFICATION; DISTINCT; SUBTYPE	The molecular interaction involved in the ligand binding of the rat angiotensin II receptor (AT(1A)) was studied by site-directed mutagenesis and receptor model building. The three-dimensional structure of AT(1A) was constructed on the basis of a multiple amino acid sequence alignment of seven transmembrane domain receptors and angiotensin II receptors and after the beta 2 adrenergic receptor model built on the template of the bacteriorhodopsin structure. These data indicated that there are conserved residues that are actively involved in the receptor-ligand interaction. Eleven conserved residues in AT(1), His(166), Arg(167), Glu(173), His(183), Glu(185), Lys(199), Trp(253), His(256), Phe(259), Thr(260), and Asp(263), were targeted individually for site-directed mutation to Ala. Using COS-7 cells transiently expressing these mutated receptors, we found that the binding of angiotensin II was not affected in three of the mutations in the second extracellular loop, whereas the Ligand binding affinity was greatly reduced in mutants Lys(199) --> Ala, Trp(253) --> Ala, Phe(259) --> Ala, Asp(263), Ala, and Arg(167), Ala. These amino acid residues appeared to provide binding sites for Ang II. The molecular modeling provided useful structural information for the peptide hormone receptor AT(1A). Binding of EXP985, a nonpeptide angiotensin II antagonist, was found to be involved with Arg(167) but not Lys(199).	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; TOTTORI UNIV,FAC AGR,METAB BIOCHEM LA,TOTTORI 680,JAPAN; YAMANASKI MED COLL,DEPT PEDIAT,YAMANASHI 40938,JAPAN; GREEN CROSS CO,HIRAKATA,OSAKA 573,JAPAN	Vanderbilt University; Tottori University; University of Yamanashi; Green Cross Corporation					NHLBI NIH HHS [HL-14192, HL-35323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035323, P50HL014192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTWOOD TK, 1991, GENE, V98, P153, DOI 10.1016/0378-1119(91)90168-B; BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BERGSMA DJ, 1993, MOL PHARMACOL, V44, P277; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BUMPUS FM, 1991, HYPERTENSION, V17, P720, DOI 10.1161/01.HYP.17.5.720; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; BURNS KD, 1993, AM J PHYSIOL, V269, pF645; BURNS L, 1994, FEBS LETT, V343, P146, DOI 10.1016/0014-5793(94)80307-2; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; CRONET P, 1993, PROTEIN ENG, V6, P59, DOI 10.1093/protein/6.1.59; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; ELTON TS, 1992, BIOCHEM BIOPH RES CO, V184, P1067, DOI 10.1016/0006-291X(92)90700-U; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; HAHN AWA, 1993, BIOCHEM BIOPH RES CO, V192, P1260, DOI 10.1006/bbrc.1993.1552; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HUMBLET C, 1992, ANNU REP MED CHEM, V27, P291; HUSS KM, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; INAGAMI T, 1993, ARZNEIMITTEL-FORSCH, V43-1, P226; ITAZAKI K, 1993, EUR J PHARM-MOLEC PH, V245, P147, DOI 10.1016/0922-4106(93)90122-P; IWAI N, 1991, BIOCHEM BIOPH RES CO, V177, P299, DOI 10.1016/0006-291X(91)91982-I; IWAI N, 1992, FEBS LETT, V298, P257, DOI 10.1016/0014-5793(92)80071-N; JI H, 1993, BIOCHEM BIOPH RES CO, V194, P756, DOI 10.1006/bbrc.1993.1886; JI H, 1994, J BIOL CHEM, V269, P16533; JOESTEN MD, 1974, HYDROGEN BONDING; JULIUS D, 1990, P NATL ACAD SCI USA, V87, P928, DOI 10.1073/pnas.87.3.928; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V183, P1090, DOI 10.1016/S0006-291X(05)80302-X; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KHOLA MC, 1993, J MED CHEM, V16, P829; KHOSLA MC, 1992, J MED CHEM, V15, P792; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARIE J, 1994, J BIOL CHEM, V299, P20815; MARSHALL GR, 1970, P NATL ACAD SCI USA, V67, P1624, DOI 10.1073/pnas.67.3.1624; MAUZY CA, 1992, BIOCHEM BIOPH RES CO, V186, P277, DOI 10.1016/S0006-291X(05)80804-6; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; MOORE GJ, 1991, COMPR MED CHEM, V3, P961; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1993, MOL PHARMACOL, V44, P1; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NIKIFOROVICH GV, 1993, BIOCHEM BIOPH RES CO, V195, P222, DOI 10.1006/bbrc.1993.2033; NIKIFOROVICH GV, 1994, BIOCHEMISTRY-US, V33, P3591, DOI 10.1021/bi00178a016; NORDVALL G, 1993, J MED CHEM, V36, P967, DOI 10.1021/jm00060a003; OLIVEIRA L, 1994, TRENDS PHARMACOL SCI, V15, P170, DOI 10.1016/0165-6147(94)90137-6; OLIVEIRA L, 1993, J COMPUT AID MOL DES, V7, P649, DOI 10.1007/BF00125323; PANDEY KN, 1988, J BIOL CHEM, V263, P13406; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PIERSON ME, 1992, PEPTIDE RES, V5, P102; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SCHIFFER M, 1992, PROTEIN ENG, V5, P213, DOI 10.1093/protein/5.3.213; SPEAR KL, 1990, J MED CHEM, V33, P1935, DOI 10.1021/jm00169a019; STEINBERG MI, 1993, CARDIOVASC DRUG REV, V11, P312, DOI 10.1111/j.1527-3466.1993.tb00194.x; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STROSBERG AD, 1993, PROTEIN SCI, V2, P1198, DOI 10.1002/pro.5560020802; SUGG EE, 1990, PEPTIDES CHEM STRUCT, P305; TAKAYANAGI R, 1992, BIOCHEM BIOPH RES CO, V183, P910, DOI 10.1016/0006-291X(92)90570-B; TEETER MM, 1994, J MED CHEM, V37, P2874, DOI 10.1021/jm00044a008; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WHITE BA, 1982, J BIOL CHEM, V257, P8569; YAMAMOTO Y, 1993, J MED CHEM, V36, P820, DOI 10.1021/jm00059a005; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515; YOSHIDA H, 1992, BIOCHEM BIOPH RES CO, V86, P1942	72	106	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14024	14030		10.1074/jbc.270.23.14024	http://dx.doi.org/10.1074/jbc.270.23.14024			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775462	hybrid			2022-12-25	WOS:A1995RC44800064
J	HENSON, JW; SCHNITKER, BL; LEE, TS; MCALLISTER, J				HENSON, JW; SCHNITKER, BL; LEE, TS; MCALLISTER, J			CELL-SPECIFIC ACTIVATION OF THE GLIAL-SPECIFIC JC VIRUS EARLY PROMOTER BY LARGE T-ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BRAIN; TRANSCRIPTIONAL ACTIVATION; TATA; EXPRESSION; ENHANCER; MULTIPLE; ELEMENTS; BINDS	JC virus causes the human demyelinating disease progressive multifocal leukoencephalopathy by selective infection of glial cells. This cell specificity results from glial-specific expression of viral early genes (large and small T antigens). Analysis of transcriptional regulation by the MH1 JC virus early promoter demonstrates that glial specificity is directed by the basal promoter. Because T antigen regulates the basal region of several viral and cellular promoters, we investigated whether it controls the JC virus basal promoter in a glial-specific manner. A JC virus T antigen expression plasmid generated a 95-kDa protein which exhibited nuclear localization and physical association with p53. T antigen repressed the JC virus and SV40 early promoters 4- to 5-fold in glioma cells. Conversely, T antigen induced 100- to 200-fold activation of the JC virus early promoter in nonglial cells, whereas the SV40 promoter was repressed. Activation required the JC virus TATA box sequence and a pentanucleotide repeat immediately upstream of the TATA box, but was independent of the upstream enhancer region. These data demonstrate that the JC virus basal promoter is responsible for glial-specific gene expression and suggest a mechanism for this regulation.			HENSON, JW (corresponding author), MASSACHUSETTS GEN HOSP EAST,MOLEC NEUROONCOL LAB,149 13TH ST,BOSTON,MA 02129, USA.			, Taek Seung/0000-0002-3943-1145	NINDS NIH HHS [NS 01605] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001605] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACELLAR H, 1994, NEUROLOGY, V44, P1892, DOI 10.1212/WNL.44.10.1892; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEGGS AH, 1988, P NATL ACAD SCI USA, V85, P7632, DOI 10.1073/pnas.85.20.7632; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; GILINGER G, 1993, J VIROL, V67, P6682, DOI 10.1128/JVI.67.11.6682-6688.1993; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; HENSON J, 1992, ANN NEUROL, V32, P72, DOI 10.1002/ana.410320112; HENSON JW, 1994, J BIOL CHEM, V269, P1046; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITOYAMA Y, 1981, ANN NEUROL, V11, P396; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; KUMAR G, 1994, VIROLOGY, V203, P116, DOI 10.1006/viro.1994.1461; PADGETT BL, 1971, LANCET, V1, P1257; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; RICE PW, 1993, J VIROL, V76, P6689; RIO DC, 1983, CELL, V32, P1227, DOI 10.1016/0092-8674(83)90305-7; SHARMA AK, 1991, FEBS LETT, V281, P272, DOI 10.1016/0014-5793(91)80409-V; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; TADA H, 1989, J VIROL, V63, P463, DOI 10.1128/JVI.63.1.463-466.1989; TAYLOR ICA, 1989, J BIOL CHEM, V264, P16160; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097	24	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13240	13245		10.1074/jbc.270.22.13240	http://dx.doi.org/10.1074/jbc.270.22.13240			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768922	hybrid			2022-12-25	WOS:A1995RB43900046
J	DALLERY, E; GALIEGUEZOUITINA, S; COLLYNDHOOGHE, M; QUIEF, S; DENIS, C; HILDEBRAND, MP; LANTOINE, D; DEWEINDT, C; TILLY, H; BASTARD, C; KERCKAERT, JP				DALLERY, E; GALIEGUEZOUITINA, S; COLLYNDHOOGHE, M; QUIEF, S; DENIS, C; HILDEBRAND, MP; LANTOINE, D; DEWEINDT, C; TILLY, H; BASTARD, C; KERCKAERT, JP			TTF, A GENE ENCODING A NOVEL SMALL G-PROTEIN, FUSES TO THE LYMPHOMA-ASSOCIATED LAZ3 GENE BY T(3-4) CHROMOSOMAL TRANSLOCATION	ONCOGENE			English	Article						LAZ3 BCL6 GENE; LYMPHOMA; TRANSLOCATION (3-4); SMALL G PROTEIN; LAZ3 FUSION GENE	GTP-BINDING-PROTEIN; NON-HODGKINS-LYMPHOMA; RAS GENE; BURKITTS-LYMPHOMA; FAMILY; EXPRESSION; CLONING; CDNAS; PURIFICATION; BREAKPOINT	We have previously shown that the LAZ3/BCL6 gene encoding a potential transcription factor, is disrupted in B-diffuse large cell non-Hodgkin's lymphomas (NHL) with 3q27 chromosomal abnormalities involving the immunoglobulin (IG) genes. However, LAZ3 rearrangement also occurs in NHL bearing 3q27 translocations without involvement of the IG genes: for example the VAL cell line exhibits t(3;4)(q27;p11). In the present work we have used a RT-PCR method to detect and to sequence the LAZ3 mRNA products from the VAL cell line. We report that the consequence of the t(3;4) is the expression of a chimeric transcript of LAZ3 with a new gene encoding a small G-like protein, termed TTF (Translocation Three Four). Nucleotide sequence analysis of a 1.4 kb cDNA predicts that the TTF gene encodes a protein of 191 amino-acids similar to members of the RAS superfamily including HRAS (27% identical), RAB1A (30% identical) and RHO proteins: the human RAC1, RHOB and CDC42Hs proteins (respectively 43, 44 and 45% identical) and the yeast RHO2 protein (44% identical). Unlike most other small G proteins which are expressed ubiquitously, TTF was transcribed only in hemopoietic cells as a 2.2 kb transcript. TTF may define a new subgroup of RHO-like proteins.	INST RECH CANC LILLE, INSERM, U124, F-59045 LILLE, FRANCE; CTR HENRI BECQUEREL, F-76038 ROUEN, FRANCE; CTR REG TRANSFUS SANGUINE, DEPT CYTOGENET, F-76232 BOIS GUILLAUME, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Henri Becquerel								BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASTARD C, 1992, BLOOD, V79, P2527; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHARDIN P, 1993, HDB EXPT PHARM, V108, P159; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEWEINDT C, 1993, GENE CHROMOSOME CANC, V8, P149, DOI 10.1002/gcc.2870080303; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FUKUHARA S, 1979, CANCER RES, V39, P3119; HEIN J, 1990, METHOD ENZYMOL, V183, P626; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MANOLOVA Y, 1979, HEREDITAS, V90, P5; MIKI T, 1994, BLOOD, V83, P26; OLOFSSON B, 1988, ONCOGENE, V3, P231; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; TERRYN N, 1993, PLANT MOL BIOL, V22, P143, DOI 10.1007/BF00039002; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	42	114	116	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2171	2178						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784061				2022-12-25	WOS:A1995RB70300012
J	BAKER, RT; VARSHAVSKY, A				BAKER, RT; VARSHAVSKY, A			YEAST N-TERMINAL AMIDASE - A NEW ENZYME AND COMPONENT OF THE N-END RULE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-PROTEIN TRANSFERASE; SHORT-LIVED PROTEIN; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; ESCHERICHIA-COLI; DEGRADATION SIGNAL; HIGH-TEMPERATURES; SHUTTLE VECTORS; UBIQUITIN; GENE	The N-end rule relates the in vivo half-life of a protein to the identity of its N-terminal residue. Tertiary destabilizing N-terminal residues asparagine and glutamine function through their conversion, by enzymatic deamidation, into the secondary destabilizing residues aspartate and glutamate, whose activity requires their enzymatic conjugation to arginine, one of the primary destabilizing residues. We isolated a Saccharomyces cerevisiae gene, termed NTA1, that encodes an amidase (Nt-amidase) specific for N-terminal asparagine and glutamine. Alterations at the putative active-site cysteine of the 52-kDa Nt-amidase inactivate the enzyme. Null nta1 mutants are viable but unable to degrade N-end rule substrates that bear N-terminal asparagine or glutamine. The effects of overexpressing Nt-amidase and other components of the N-end rule pathway suggest interactions between these components and the existence of a multienzyme targeting complex.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology					NIDDK NIH HHS [DK39520] Funding Source: Medline; NIGMS NIH HHS [GM31530] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039520, R01DK039520, R56DK039520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALAGRAMAM K, 1995, MOL MICROBIOL, V15, P225, DOI 10.1111/j.1365-2958.1995.tb02237.x; AMBLER RP, 1987, FEBS LETT, V215, P285, DOI 10.1016/0014-5793(87)80163-1; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER R, 1991, NUCLEIC ACIDS RES, V19, P1945, DOI 10.1093/nar/19.8.1945; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BALZI E, 1990, J BIOL CHEM, V265, P7464; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1988, J BIOL CHEM, V263, P11155; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; Guthrie C, 1991, GUIDE YEAST GENETICS; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, V1, P627; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; KNIGHTON DR, 1994, NAT STRUCT BIOL, V1, P186, DOI 10.1038/nsb0394-186; KNOWLES JR, 1991, J THEOR BIOL, V152, P53, DOI 10.1016/S0022-5193(05)80509-0; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MADURA K, 1993, J BIOL CHEM, V268, P12046; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; NYUNOYA H, 1984, J BIOL CHEM, V259, P9790; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; REISS Y, 1988, J BIOL CHEM, V263, P2693; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SHARON G, 1991, J BIOL CHEM, V266, P15890; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Sherman F., 1986, METHODS YEAST GENETI; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; SIKORSKI RS, 1989, GENETICS, V122, P19; SPENCER J, 1995, IN PRESS MOL CELL BI; SPRAGUE GF, 1983, CELL, V32, P409, DOI 10.1016/0092-8674(83)90460-9; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STEWART AE, 1994, J BIOL CHEM, V269, P23509; STEWART AE, 1995, IN PRESS J BIOL CHEM; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0	65	79	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12065	12074		10.1074/jbc.270.20.12065	http://dx.doi.org/10.1074/jbc.270.20.12065			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744855	Green Accepted, hybrid			2022-12-25	WOS:A1995QY73600057
J	FLASPOHLER, JA; BOCZKOWSKI, D; HALL, BL; MILCAREK, C				FLASPOHLER, JA; BOCZKOWSKI, D; HALL, BL; MILCAREK, C			THE 3'-UNTRANSLATED REGION OF MEMBRANE EXON-2 FROM THE GAMMA-2A IMMUNOGLOBULIN GENE CONTRIBUTES TO EFFICIENT TRANSCRIPTION TERMINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; H-CHAIN GENE; 3' UNTRANSLATED REGION; POLY(A) SITE; MESSENGER-RNA; POLYADENYLATION SIGNAL; GLOBIN GENE; LYMPHOCYTES-B; EXPRESSION; SEQUENCES	Elements of the mouse Immunoglobulin gamma 2a gene, near the membrane specific poly(A) addition site, were inserted into a heterologous location in either a synthetic mouse gamma 2b gene or a gpt/SV40 chimeric gene and then assayed for their ability to terminate RNA polymerase II transcription in isolated nuclei of transfected myeloma cells, The intact gamma 2a membrane specific 3'-untranslated region, with its potential stem loop forming sequences and poly(A) site, is able to efficiently terminate transcription in the absence of the downstream region in which transcription normally terminates (term). Termination efficiency in the presence of the termination fragment decreases either when sequences specifying a potential stem/loop, upstream of the poly(A) region, are interrupted or when the stronger membrane poly(A) site is substituted with a weaker, secretory specific poly(A) site. We therefore conclude that the gamma 2a membrane-specific untranslated region plays a major role in specifying downstream termination. We further conclude that the immunoglobulin gamma 2a, membrane-specific, 3'-untranslated region can function in the context of the gpt gene, driven by an SV40 promoter, to terminate transcription in a poly(A) site dependent fashion.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050145] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50145] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CITRON B, 1984, NUCLEIC ACIDS RES, V12, P8723, DOI 10.1093/nar/12.22.8723; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; EDWALDSGILBERT G, 1993, MOL CELL BIOL, V13, P3472, DOI 10.1128/MCB.13.6.3472; FALCKPEDERSEN E, 1985, CELL, V40, P897, DOI 10.1016/0092-8674(85)90349-6; FLASPOHLER JA, 1990, J IMMUNOL, V144, P2802; FLASPOHLER JA, 1992, BIOTECHNIQUES, V13, P68; FRAYNE EG, 1984, MOL CELL BIOL, V4, P2921, DOI 10.1128/MCB.4.12.2921; GALLI G, 1987, GENE DEV, V1, P471, DOI 10.1101/gad.1.5.471; GILMARTIN GM, 1992, EMBO J, V11, P4419, DOI 10.1002/j.1460-2075.1992.tb05542.x; GUISE JW, 1988, J IMMUNOL, V140, P3988; HAGENBUCHLE O, 1984, CELL, V38, P737, DOI 10.1016/0092-8674(84)90269-1; HALL B, 1989, MOL IMMUNOL, V26, P819, DOI 10.1016/0161-5890(89)90137-5; HALL BL, 1989, THESIS U PITTSBURGH; KOBRIN BJ, 1986, MOL CELL BIOL, V6, P1687, DOI 10.1128/MCB.6.5.1687; LANG RB, 1982, NUCLEIC ACIDS RES, V10, P611, DOI 10.1093/nar/10.2.611; LANOIX J, 1988, EMBO J, V7, P2515, DOI 10.1002/j.1460-2075.1988.tb03099.x; LASSMAN CR, 1992, J IMMUNOL, V148, P2578; LASSMAN CR, 1992, J IMMUNOL, V148, P1251; LAW A, 1987, P NATL ACAD SCI USA, V4, P9160; LEMEUR MA, 1984, EMBO J, V3, P2779, DOI 10.1002/j.1460-2075.1984.tb02209.x; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MAA MC, 1990, J BIOL CHEM, V265, P12513; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MIRALLES VJ, 1991, NUCLEIC ACIDS RES, V19, P3593, DOI 10.1093/nar/19.13.3593; MORRISON SL, 1984, ANNU REV IMMUNOL, V2, P239, DOI 10.1146/annurev.immunol.2.1.239; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; NATSUUMESAKAI S, 1977, IMMUNOLOGY, V32, P861; PETERSON ML, 1989, MOL CELL BIOL, V9, P726, DOI 10.1128/MCB.9.2.726; PRIBYL TM, 1988, MOL CELL BIOL, V8, P5369, DOI 10.1128/MCB.8.12.5369; RICHARDS JE, 1983, NATURE, V306, P483, DOI 10.1038/306483a0; ROHRBAUGH ML, 1985, MOL CELL BIOL, V8, P5369; RUSSNAK R, 1990, GENE DEV, V4, P764, DOI 10.1101/gad.4.5.764; TISCH R, 1990, MOL CELL BIOL, V10, P5340, DOI 10.1128/MCB.10.10.5340; WARD SB, 1992, MOL IMMUNOL, V29, P279, DOI 10.1016/0161-5890(92)90110-J; WEISS EA, 1989, J IMMUNOL, V143, P1046; WELS JA, 1984, EMBO J, V3, P2041, DOI 10.1002/j.1460-2075.1984.tb02089.x; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; YUAN D, 1990, J IMMUNOL, V145, P3491; YUAN D, 1984, J EXP MED, V160, P564, DOI 10.1084/jem.160.2.564	41	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11903	11911		10.1074/jbc.270.20.11903	http://dx.doi.org/10.1074/jbc.270.20.11903			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744841	hybrid			2022-12-25	WOS:A1995QY73600037
J	RUSSELL, M; LANGECARTER, C; JOHNSON, GL				RUSSELL, M; LANGECARTER, C; JOHNSON, GL			DIRECT INTERACTION BETWEEN RAS AND THE KINASE DOMAIN OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE KINASE (MEKK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							P21(RAS); GTPASE	Mitogen-activated protein kinase kinase kinase (MEKK1) is a serine-threonine kinase that regulates sequential protein kinase pathways involving stress-activated protein kinases and mitogen-activated protein kinases. MEKK1 is activated in response to growth factor stimulation of cells and by expression of activated Ras. We demonstrate that the kinase domain of MEKK1 (MEKK(COOH)) binds to GST-Ras(V12) in a GTP-dependent manner. Purified bacterially expressed MEKK(COOH) binds to GST Ras(V12)(GTP gamma S) (GTP gamma S is guanosine 5'-3-O-(thio)triphosphate), demonstrating a direct interaction of the two proteins. A Ras effector domain peptide blocks the binding of MEKK(COOH) to GST-Ras(V12)(GTP gamma S). MEKK(COOH) complexed with GST-Ras(V12)(GTP gamma S) is capable of phosphorylating MEK1. These findings indicate that MEKK1 directly binds Ras . GTP. Thus, Ras interacts with protein kinases of both the Raf and MEKK families.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Lange, Carol/0000-0003-2751-3976	NCI NIH HHS [CA09313] Funding Source: Medline; NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSEBEL FM, 1987, CURRENT PROTOCOLS MO; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOWNWARD J, 1991, J CURR BIOL, V1, P353; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER C, 1994, SCIENCE, V260, P315; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1995, METHOD ENZYMOL, V255, P290; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VICIANA PR, 1994, NATURE, V370, P527; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; YAN MH, 1994, NATURE, V372, P798; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	26	171	173	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11757	11760		10.1074/jbc.270.20.11757	http://dx.doi.org/10.1074/jbc.270.20.11757			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744823	hybrid			2022-12-25	WOS:A1995QY73600015
J	SZEDLACSEK, SE; WASOWICZ, E; HULEA, SA; NISHIDA, HI; KUMMEROW, FA; NISHIDA, T				SZEDLACSEK, SE; WASOWICZ, E; HULEA, SA; NISHIDA, HI; KUMMEROW, FA; NISHIDA, T			ESTERIFICATION OF OXYSTEROLS BY HUMAN PLASMA LECITHIN-CHOLESTEROL ACYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL-METABOLISM; HUMAN-SERUM; PHOSPHOLIPASE-ACTIVITY; SUBSTRATE-SPECIFICITY; MASS-SPECTROMETRY; HUMAN ATHEROMA; HUMAN AORTA; ESTERS; 26-HYDROXYCHOLESTEROL; PHOSPHATIDYLCHOLINE	In the present study, lecithin-cholesterol acyltransferase (LCAT) catalyzed esterification of oxysterols was investigated by using discoidal bilayer particles (DBP) containing various oxysterols, phosphatidylcholines, and apolipoprotein A-I. The esterified oxysterols were analyzed by high pressure liquid chromatography, gas chromatography, and mass spectrometry. LCAT esterified all oxysterols tested that are known to be present in human plasma. The esterification yields in almost all cases were relatively high, often as high as the yield of cholesterol esterification. When DBP preparations containing 27-hydroxycholesterol and various phosphatidylcholines were used for the LCAT reaction, both monoesters and diesters were produced. The mass spectrometry analysis showed that the monoester was produced by the esterification of the 3 beta-hydroxyl group and not the 27-hydroxyl group. The diesters were apparently produced by the esterification of the 27-hydroxyl group only after the esterification of the 3 beta-hydroxyl group. Phosphatidylcholine containing a saturated acyl group at sn-1 position and an unsaturated acyl group at sn-2 position gave generally high esterification yield. The esterification of various oxysterols was compared by using DBP containing dioleoyl-phosphatidylcholine and individual oxysterols. All oxysterols produced 3 beta-oleoyl monoesters, Unlike 27-hydroxycholesterol, 25-hydroxycholesterol, 7 alpha-hydroxycholesterol, 7 beta-hydroxycholesterol, or cholestanetriol did not produce diesters. Various factors influencing the formation of the monoesters and diesters from 27-hydroxycholesterol were investigated. When dioleoyl-phosphatidylcholine was used as the acyl donor, prolonged dialysis of DBP preparations and increase in the ratio of the enzyme concentration to substrate particle concentration increased the diester formation. Significant amounts of diesters were also produced by using 1-palmitoyl-2-oleoyl-phosphatidylcholine and other phosphatidylcholines as the acyl donors. By analyzing the conditions of monoester and diester formation, a scheme for the LCAT reaction pathway was proposed.	UNIV ILLINOIS, BURNSIDES RES LAB, DEPT FOOD SCI, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign			Szedlacsek, Stefan Eugen/F-1830-2010	Szedlacsek, Stefan Eugen/0000-0002-3416-5036	NHLBI NIH HHS [HL-17597] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017597, F31HL117597, R37HL017597] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARON L, 1978, J BIOL CHEM, V253, P7220; ASSMANN G, 1978, SCAND J CLIN LAB INV, V38, P16, DOI 10.3109/00365517809104894; BJORKHEM I, 1986, ANAL BIOCHEM, V154, P497, DOI 10.1016/0003-2697(86)90021-7; BROOKS CJW, 1966, BIOCHIM BIOPHYS ACTA, V125, P620, DOI 10.1016/0005-2760(66)90055-5; BROOKS CJW, 1971, ATHEROSCLEROSIS, V13, P223, DOI 10.1016/0021-9150(71)90025-6; BROOKS CJW, 1972, PROTIDES BIOL FLUIDS, V19, P101; CARPENTER KLH, 1993, BIOCHIM BIOPHYS ACTA, V1167, P121, DOI 10.1016/0005-2760(93)90151-X; Doi Y, 1981, Methods Enzymol, V71 Pt C, P753; DOLPHIN PJ, 1992, STRUCTURE FUNCTION A, P295; FIELDING CJ, 1991, METHOD ENZYMOL, V197, P426; FIELDING CJ, 1990, ADV CHOLESTEROL RES, P271; FUMAGALLI R, 1971, LIFE SCI 2-BIOCH GEN, V10, P25, DOI 10.1016/0024-3205(71)90221-9; GLOMSET JA, 1968, J LIPID RES, V9, P155; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; JAVITT NB, 1981, J BIOL CHEM, V256, P2644; JONAS A, 1987, J BIOL CHEM, V262, P3969; KATO H, 1989, J BIOL CHEM, V264, P4082; KITABATAKE K, 1979, BIOCHIM BIOPHYS ACTA, V573, P145, DOI 10.1016/0005-2760(79)90181-4; KNIGHTS BA, 1967, J GAS CHROMATOGR, V5, P273, DOI 10.1093/chromsci/5.6.273; LUSBY WR, 1984, LIPIDS, V19, P888, DOI 10.1007/BF02534520; MAERKER G, 1986, J AM OIL CHEM SOC, V63, P767, DOI 10.1007/BF02541961; MORRISON WR, 1961, J LIPID RES, V2, P600; NAQVI SHM, 1973, STEROIDS, V22, P285, DOI 10.1016/0039-128X(73)90092-5; NICHOLS AV, 1971, BIOCHIM BIOPHYS ACTA, V231, P175, DOI 10.1016/0005-2760(71)90266-9; NISHIDA HI, 1986, J BIOL CHEM, V261, P2028; ODA H, 1990, J LIPID RES, V31, P2209; PENG SK, 1992, BIOL EFFECTS CHOLEST; PIRAN U, 1979, LIPIDS, V14, P478, DOI 10.1007/BF02533465; POWNALL HJ, 1985, J BIOL CHEM, V260, P2146; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SMITH LL, 1970, ATHEROSCLEROSIS, V12, P1; SMITH LL, 1981, J STEROID BIOCHEM, V14, P889, DOI 10.1016/0022-4731(81)90238-7; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; SMITH LL, 1987, CHEM PHYS LIPIDS, V44, P87, DOI 10.1016/0009-3084(87)90046-6; SUBBAIAH PV, 1994, BIOCHEMISTRY-US, V33, P13259, DOI 10.1021/bi00249a012; SUBBAIAH PV, 1988, BIOCHIM BIOPHYS ACTA, V963, P445, DOI 10.1016/0005-2760(88)90313-X; SZEDLACSEK SE, 1991, BIOCHEM J, V279, P855, DOI 10.1042/bj2790855; TENG JI, 1981, J STEROID BIOCHEM, V14, P569, DOI 10.1016/0022-4731(81)90032-7; VANLIER JE, 1967, BIOCHEMISTRY-US, V6, P3269, DOI 10.1021/bi00862a037	39	46	46	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11812	11819		10.1074/jbc.270.20.11812	http://dx.doi.org/10.1074/jbc.270.20.11812			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744831	hybrid			2022-12-25	WOS:A1995QY73600025
J	WANG, CI; YANG, Q; CRAIK, CS				WANG, CI; YANG, Q; CRAIK, CS			ISOLATION OF A HIGH-AFFINITY INHIBITOR OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR BY PHAGE DISPLAY OF ECOTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BOUND UROKINASE; AMINO-ACID-SEQUENCE; MOLECULAR MASS UROKINASE; PROTEIN INHIBITORS; ESCHERICHIA-COLI; HUMAN-MONOCYTES; POOR PROGNOSIS; REACTIVE SITE; BREAST-CANCER; FUSION PHAGE	Ecotin, a serine protease inhibitor found in the periplasm of Escherichia coli, is unique in its ability and mechanism of inhibiting serine proteases of a broad range of substrate specificity. However, although the catalytic domain of human urokinase-type plasminogen activator (uPA) has 40% identity to bovine trypsin and the substrate specificities of these two proteases are virtually identical, ecotin inhibits uPA almost 10,000-fold less efficiently than trypsin. Ecotin was expressed on the surface of filamentous bacteriophage (ecotin phage) to allow the isolation of more potent inhibitors of uPA from a library of ecotin variants. The 142-amino acid inhibitor was fused to the C-terminal domain of the M13 minor coat protein, pIII, through a Gly-Gly-Gly linker and assembled into phage particles. The ecotin phage were shown to react with anti-ecotin antibodies, revealing a stoichiometry of approximately one ecotin per bacteriophage. The ecotin displayed on the surface of phage inhibited trypsin with an equilibrium dissociation constant of 6.7 nM, in close approximation to that of free ecotin, indicating that phage-associated ecotin is correctly folded and functionally active. Reactive-site amino acids 84 and 85 of ecotin were then randomized and a library of 400 unique ecotin phage was created. Three hundred thousand members of the library were screened with immobilized uPA and subjected to three rounds of binding and in vitro selection. DNA sequence analysis of the selected ecotin phage showed that ecotin M84R/M85R predominated while ecotin M84R, M84K, and M84R/M85K were present at a lower frequency. The four ecotin variants were overexpressed and purified and their affinities toward uPA were determined. Each of the selected ecotin variants exhibited increased affinity for uPA when compared to wild-type ecotin with ecotin M84R/M85R showing a 2800-fold increase in binding affinity.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NIGMS NIH HHS [GM07175] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG CH, 1983, J BIOL CHEM, V258, P1032; COREY DR, 1993, GENE, V128, P129; CRISSMAN JW, 1984, VIROLOGY, V132, P445, DOI 10.1016/0042-6822(84)90049-7; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1990, J BIOL CHEM, V265, P9904; FOEKENS JA, 1994, J CLIN ONCOL, V12, P1648, DOI 10.1200/JCO.1994.12.8.1648; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; GUNZLER WA, 1982, H-S Z PHYSIOL CHEM, V363, P1155, DOI 10.1515/bchm2.1982.363.2.1155; HABER E, 1989, SCIENCE, V243, P51, DOI 10.1126/science.2492113; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JANICKE F, 1993, BREAST CANCER RES TR, V24, P195, DOI 10.1007/BF01833260; KESKIOJA J, 1982, BIOCHIM BIOPHYS ACTA, V720, P141, DOI 10.1016/0167-4889(82)90005-2; KIRCHHEIMER JC, 1987, FASEB J, V1, P125, DOI 10.1096/fasebj.1.2.3038646; KIRCHHEIMER JC, 1988, J IMMUNOL, V141, P4229; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; MASUCCI MT, 1991, J BIOL CHEM, V266, P8655; MAYER M, 1990, CLIN BIOCHEM, V23, P197, DOI 10.1016/0009-9120(90)90601-P; MCGRATH ME, 1991, J BIOL CHEM, V266, P6620; MCGRATH ME, 1994, EMBO J, V13, P1502, DOI 10.1002/j.1460-2075.1994.tb06411.x; MCGRATH ME, 1991, J MOL BIOL, V222, P139, DOI 10.1016/0022-2836(91)90199-G; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; PANNEKOEK H, 1993, GENE, V128, P135, DOI 10.1016/0378-1119(93)90164-X; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PEDERSEN H, 1994, CANCER RES, V54, P120; PERONA JJ, 1993, J MOL BIOL, V230, P919, DOI 10.1006/jmbi.1993.1210; POLLANEN J, 1990, P NATL ACAD SCI USA, V87, P2230, DOI 10.1073/pnas.87.6.2230; QUIGLEY JP, 1987, P NATL ACAD SCI USA, V84, P2776, DOI 10.1073/pnas.84.9.2776; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; ROBERTS BL, 1992, P NATL ACAD SCI USA, V89, P2429, DOI 10.1073/pnas.89.6.2429; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; SEYMOUR JL, 1994, BIOCHEMISTRY-US, V33, P3949, DOI 10.1021/bi00179a022; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; STEFFENS GJ, 1982, H-S Z PHYSIOL CHEM, V363, P1043, DOI 10.1515/bchm2.1982.363.2.1043; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; THORPE SM, 1989, CANCER RES, V49, P6008; TOWLE MJ, 1993, CANCER RES, V53, P2553; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; Williams J W, 1979, Methods Enzymol, V63, P437; YORK JD, 1991, J BIOL CHEM, V266, P8495	60	74	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12250	12256		10.1074/jbc.270.20.12250	http://dx.doi.org/10.1074/jbc.270.20.12250			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744876	hybrid			2022-12-25	WOS:A1995QY73600081
J	MONKAWA, T; MIYAWAKI, A; SUGIYAMA, T; YONESHIMA, H; YAMAMOTOHINO, M; FURUICHI, T; SARUTA, T; HASEGAWA, M; MIKOSHIBA, K				MONKAWA, T; MIYAWAKI, A; SUGIYAMA, T; YONESHIMA, H; YAMAMOTOHINO, M; FURUICHI, T; SARUTA, T; HASEGAWA, M; MIKOSHIBA, K			HETEROTETRAMERIC COMPLEX-FORMATION OF INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMULTIMERIC K+ CHANNELS; DEPENDENT PROTEIN-KINASE; TRISPHOSPHATE RECEPTOR; FUNCTIONAL-CHARACTERIZATION; PERIPHERAL-TISSUES; MOLECULAR-CLONING; MOUSE CEREBELLUM; CALCIUM-RELEASE; INSP3 RECEPTOR; PURKINJE-CELL	The inositol 1,4,5-trisphosphate receptor (IP(3)R) exists as a tetrameric complex to form a functional inositol 1,4,5-trisphosphate-gated Ca2+ channel. Molecular cloning studies have shown that there are at least three types of IP(3)R subunits, designated type 1, type 2, and type 3. The levels of expression of IP(3)R subunits in various cell lines were investigated by Western blot analysis using type-specific antibodies against 15 C-terminal amino acids of each IP(3)R subunit. We found that all the three types of IP(3)R subunits were expressed in each cell line examined, but their levels of expression varied. To determine whether IP(3)Rs form heterotetramers, we employed immunoprecipitation experiments using Chinese hamster ovary cells (CHO-K1 cells), in which all three types are abundantly expressed. Each type-specific antibody immunoprecipitated not only the respective cognate type but also the other two types. This result suggests that distinct types of IP(3)R subunits assemble to form heterotetramers in CHO-K1 cells. We also detected heterotetramers in rat liver, in which IP(3)R type 1 and type 2 are expressed abundantly. Previous studies have shown some functional differences among IP(3)R types, suggesting the possibility that various compositions of subunits show distinct channel properties. The diversity of IP(3)R channels may be further increased by the co-assembly of different IP(3)R subunits to form home- or heterotetramers.	UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; KEIO UNIV,SCH MED,DEPT INTERNAL MED,TOKYO 160,JAPAN; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,TOKYO 194,JAPAN; RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC NEUROBIOL LAB,IBARAKI 305,OSAKA,JAPAN	University of Tokyo; Keio University; Kyowa Kirin Ltd; RIKEN			Miyawaki, Atsushi/K-3569-2014; Mikoshiba, Katsuhiko/N-7943-2015; Furuichi, Teiichi/B-5086-2014; Monkawa, Toshiaki/F-2361-2010	Miyawaki, Atsushi/0000-0002-2329-3235; Furuichi, Teiichi/0000-0002-9676-1888; Monkawa, Toshiaki/0000-0002-7876-7661				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FUJINO I, 1995, CELL TISSUE RES, V280, P201, DOI 10.1007/s004410050345; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1990, FEBS LETT, V267, P85, DOI 10.1016/0014-5793(90)80294-S; KHODAKHAH K, 1993, P NATL ACAD SCI USA, V90, P4976, DOI 10.1073/pnas.90.11.4976; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NHAKADE S, 1994, J BIOL CHEM, V269, P6735; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUGIYAMA T, 1994, FEBS LETT, V349, P191, DOI 10.1016/0014-5793(94)00662-8; SUGIYAMA T, 1994, FEBS LETT, V354, P149, DOI 10.1016/0014-5793(94)01099-4; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; YAMADA M, 1995, IN PRESS BIOCH J; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; YAMAMOTO H, 1989, J NEUROCHEM, V53, P917, DOI 10.1111/j.1471-4159.1989.tb11792.x; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613	40	193	195	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14700	14704		10.1074/jbc.270.24.14700	http://dx.doi.org/10.1074/jbc.270.24.14700			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782334	hybrid			2022-12-25	WOS:A1995RD45500070
J	BOLLINGER, JM; KWON, DS; HUISMAN, GW; KOLTER, R; WALSH, CT				BOLLINGER, JM; KWON, DS; HUISMAN, GW; KOLTER, R; WALSH, CT			GLUTATHIONYLSPERMIDINE METABOLISM IN ESCHERICHIA-COLI - PURIFICATION, CLONING, OVERPRODUCTION, AND CHARACTERIZATION OF A BIFUNCTIONAL GLUTATHIONYLSPERMIDINE SYNTHETASE/AMIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; TRYPANOTHIONE REDUCTASE; CRITHIDIA-FASCICULATA; GLUTATHIONE SYNTHETASE; TRYPANOSOMA-CRUZI; PHYSICAL MAP; D-ALANINE; INHIBITION; SPERMIDINE; DEFICIENT	Glutathionylspermidine (GSP) synthetases of Trypanosomatidae and Escherichia coli couple hydrolysis of ATP (to ADP and P-i) with formation of an amide bond between spermidine (N-(3-aminopropyl)-1,4-diamino-butane) and the glycine carboxylate of glutathione (gamma-Glu-Cys-Gly). In the pathogenic trypanosomatids, this reaction is the penultimate step in the biosynthesis of the antioxidant metabolite, trypanothione (N-1,N-8-bis-(glutathionyl)spermidine), and is a target for drug design. In this study, GSP synthetase was purified to near homogeneity from E. coli B, the gene encoding it was isolated and sequenced, the enzyme was overexpressed and purified in quantity, and the recombinant enzyme was characterized. The 70-kDa protein was found to have an unexpected second catalytic activity, glutathionylspermidine amide bond hydrolysis. Thus, the bifunctional GSP synthetase/amidase catalyzes opposing amide bond-forming and -cleaving reactions, with net hydrolysis of ATP. The synthetase activity is selectively abrogated by proteolytic cleavage 81 residues from the C terminus, suggesting that the two activities reside in distinct domains (N-terminal amidase and C-terminal synthetase). Proteolysis at this site is facile in the absence of substrates, but is inhibited in the presence of ATP, glutathione, and Mg2+. A series of analogs was used to probe the spermidine-binding site of the synthetase activity. The activity of diaminopropane as a substrate, inactivity of the C-4-C-8 diaminoalkanes, and greater loss of specificity for analogs modified in the 3-aminopropyl moiety than for those modified in the 4-aminobutyl moiety indicate that the enzyme recognizes predominantly the diaminopropane portion of spermidine and corroborate N-1 (the aminopropyl N) as the site of glutathione linkage (Tabor, H. and Tabor, C. W. (1975) J. Biol. Chem. 250, 2648-2654). Trends in K-m and k(cat) for a set of difluoro-substituted spermidine derivatives suggest that the enzyme may bind the minor, deprotonated form of the amine nucleophile.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Bollinger, Joseph/C-1425-2016	Huisman, Gjalt/0000-0003-1955-1120	NIGMS NIH HHS [GM20011] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020011, R37GM020011] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APONTOWEIL P, 1975, BIOCHIM BIOPHYS ACTA, V399, P10, DOI 10.1016/0304-4165(75)90206-8; BAILLON JG, 1988, EUR J BIOCHEM, V176, P237, DOI 10.1111/j.1432-1033.1988.tb14274.x; BERG CM, 1992, GENE, V113, P9, DOI 10.1016/0378-1119(92)90664-B; BOVERIS A, 1980, BIOCHEM J, V188, P643, DOI 10.1042/bj1880643; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CENAS NK, 1994, BIOCHEMISTRY-US, V33, P2509, DOI 10.1021/bi00175a021; COLANDUONI J, 1987, J BIOL CHEM, V262, P3037; CONNELL N, 1987, MOL MICROBIOL, V1, P195, DOI 10.1111/j.1365-2958.1987.tb00512.x; DUBIN DT, 1959, BIOCHEM BIOPH RES CO, V1, P262, DOI 10.1016/0006-291X(59)90034-8; DUNCAN K, 1988, BIOCHEMISTRY-US, V27, P3709, DOI 10.1021/bi00410a028; ELVIN CM, 1986, MOL GEN GENET, V204, P477, DOI 10.1007/BF00331028; FAIRLAMB AH, 1985, MOL BIOCHEM PARASIT, V14, P187, DOI 10.1016/0166-6851(85)90037-4; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FAIRLAMB AH, 1986, MOL BIOCHEM PARASIT, V21, P247, DOI 10.1016/0166-6851(86)90130-1; FAIRLAMB AH, 1989, P NATL ACAD SCI USA, V86, P2607, DOI 10.1073/pnas.86.8.2607; FAIRLAMB AH, 1987, HOST PARASITE CELLUL, P29; FAN C, 1995, P NATL ACAD SCI USA, V92, P1172, DOI 10.1073/pnas.92.4.1172; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; FUCHS JA, 1975, J BACTERIOL, V124, P140, DOI 10.1128/JB.124.1.140-148.1975; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HENDERSON GB, 1990, BIOCHEMISTRY-US, V29, P3924, DOI 10.1021/bi00468a019; HENDERSON GB, 1988, P NATL ACAD SCI USA, V85, P5374, DOI 10.1073/pnas.85.15.5374; HENDERSON GB, 1987, MOL BIOCHEM PARASIT, V24, P39, DOI 10.1016/0166-6851(87)90113-7; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JOCKERSSCHERUBL MC, 1989, EUR J BIOCHEM, V180, P267, DOI 10.1111/j.1432-1033.1989.tb14643.x; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KURLAND IJ, 1992, J BIOL CHEM, V267, P4416; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1974, ENZYMES, V10, P699; Meister A., 1974, ENZYMES, V10, P671; PENKETH PG, 1987, FEBS LETT, V221, P427, DOI 10.1016/0014-5793(87)80968-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAMES SL, 1986, BIOCHEMISTRY-US, V25, P3519, DOI 10.1021/bi00360a007; SHAMES SL, 1988, BIOCHEMISTRY-US, V27, P5014, DOI 10.1021/bi00414a010; SHI Y, 1995, BIOCHEMISTRY-US, V34, P2768, DOI 10.1021/bi00009a005; SHIM H, 1988, J GEN MICROBIOL, V134, P807; SMITH K, 1992, PROTEIN SCI, V1, P874, DOI 10.1002/pro.5560010705; Stadtman E.R., 1974, ENZYMES, V10, P755; SULLIVAN FX, 1991, BIOCHEMISTRY-US, V30, P2761, DOI 10.1021/bi00225a004; SULLIVAN FX, 1989, BIOCHEMISTRY-US, V28, P4986, DOI 10.1021/bi00438a013; SULLIVAN FX, 1991, MOL BIOCHEM PARASIT, V44, P145, DOI 10.1016/0166-6851(91)90231-T; TABOR CW, 1970, BIOCHEM BIOPH RES CO, V41, P232, DOI 10.1016/0006-291X(70)90493-6; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1978, J BIOL CHEM, V253, P3671; TABOR CW, 1966, FED PROC, V25, P709; TABOR H, 1975, J BIOL CHEM, V250, P2648; TABOR H, 1966, FED PROC, V25, P879; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TANAKA T, 1992, BIOCHEMISTRY-US, V31, P2259, DOI 10.1021/bi00123a007; TANAKA T, 1993, BIOCHEMISTRY-US, V32, P12398, DOI 10.1021/bi00097a018; WALSH C, 1991, TRENDS BIOCHEM SCI, V16, P305, DOI 10.1016/0968-0004(91)90124-E; WRIGHT GD, 1993, PROTEIN SCI, V2, P1765, DOI 10.1002/pro.5560021020; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106; YANG TP, 1992, J BACTERIOL, V174, P1700, DOI 10.1128/jb.174.5.1700-1701.1992	56	81	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14031	14041		10.1074/jbc.270.23.14031	http://dx.doi.org/10.1074/jbc.270.23.14031			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775463	hybrid			2022-12-25	WOS:A1995RC44800065
J	GONZALEZFLECHA, B; DEMPLE, B				GONZALEZFLECHA, B; DEMPLE, B			METABOLIC SOURCES OF HYDROGEN-PEROXIDE IN AEROBICALLY GROWING ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN; OXIDATIVE STRESS; DEHYDROGENASE; MITOCHONDRIA; GENERATION; OXIDASE; DISEASE; PROTEIN; OXYGEN; DAMAGE	Exposure of cells to hydrogen peroxide (H2O2) mediates adaptive responses or oxidative damage, depending on the magnitude of the challenge. Determining the threshold for peroxide-mediated oxidative stress thus requires quantitation of the changes in endogenous H2O2 production. The intracellular steady-state concentrations of H2O2 were measured in intact Escherichia coli under different conditions. Compounds that block electron transport at NADH dehydrogenase (rotenone) or between ubiquinone and cytochrome b (antimycin) showed that univalent reduction of O-2 can occur at these sites in vivo to form superoxide anion (O-2(-)), in agreement with reports for mammalian mitochondria. Mutational inactivation of different components of the respiratory chain showed that H2O2 production also depended on the energy status of the cell and on the arrangement of respiratory chain components corresponding to particular growth conditions. Production rates for O-2(-) and H2O2 were linearly related to the number of active respiratory chains that reached maximal values during exponential growth. In the strains defective in respiratory chain components, catalase activity was regulated to compensate for changes in the H2O2 production rates, which maintained intracellular H2O2 at 0.1-0.2 mu M during aerobic growth over a wide range of cell densities. The expression of a katG'::lacZ fusion (reporting transcriptional control of the catalase-hydroperoxidase I gene) was increased by H2O2 given either as a pulse or as a steady production. This response not only depended on the type and severity of the stimulus but was also strongly influenced by the growth phase of the cells.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL CANCER INSTITUTE [R01CA037831] Funding Source: NIH RePORTER; NCI NIH HHS [CA37831] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; AMSTAD P, 1994, J BIOL CHEM, V269, P1606; BABIOR BM, 1991, AM J HEMATOL, V37, P263, DOI 10.1002/ajh.2830370410; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; CALHOUN MW, 1993, J BACTERIOL, V175, P3013, DOI 10.1128/JB.175.10.3013-3019.1993; CALHOUN MW, 1993, J BACTERIOL, V175, P3020, DOI 10.1128/JB.175.10.3020-3025.1993; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DEMPLE B, 1983, NATURE, V304, P466, DOI 10.1038/304466a0; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; GERSCHMAN R, 1954, SCIENCE, V119, P623, DOI 10.1126/science.119.3097.623; GONZALEZFLECHA B, 1994, J BACTERIOL, V176, P2293; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; GREEN GN, 1988, J BIOL CHEM, V263, P13138; HARMAN D, 1991, P NATL ACAD SCI USA, V88, P5360, DOI 10.1073/pnas.88.12.5360; HASSAN HM, 1978, J BIOL CHEM, V253, P6445; HAYASHI M, 1989, BIOCHIM BIOPHYS ACTA, V977, P62, DOI 10.1016/S0005-2728(89)80009-X; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; HIDALGO E, 1995, REGULATION GENE EXPR; HOLMBERG K, 1973, ARCH ORAL BIOL, V18, P423, DOI 10.1016/0003-9969(73)90167-2; IMLAY JA, 1991, FREE RADICAL RES COM, V12-3, P59, DOI 10.3109/10715769109145768; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; IVANOVA A, 1994, MOL MICROBIOL, V12, P571, DOI 10.1111/j.1365-2958.1994.tb01043.x; JAMIESON DJ, 1994, MICROBIOLOGY, V150, P3277; JENKINS DE, 1988, J BACTERIOL, V170, P3910, DOI 10.1128/jb.170.9.3910-3914.1988; KAPPUS H, 1981, EXPERIENTIA, V37, P1233, DOI 10.1007/BF01948335; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; MEINHARDT SW, 1989, BIOCHEMISTRY-US, V28, P2153, DOI 10.1021/bi00431a029; Miller JH., 1992, EXPT MOL GENETICS; ODEN KL, 1990, GENE, V96, P29, DOI 10.1016/0378-1119(90)90337-Q; SCHULTZEOSTHOFF K, 1995, IN PRESS ADV MOL CEL; Sies H., 1991, OXIDATIVE STRESS OXI, pxv; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; TARTAGLIA LA, 1989, J MOL BIOL, V210, P709, DOI 10.1016/0022-2836(89)90104-6; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P4608; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787	45	247	263	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13681	13687		10.1074/jbc.270.23.13681	http://dx.doi.org/10.1074/jbc.270.23.13681			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775420	hybrid			2022-12-25	WOS:A1995RC44800017
J	BUSHKINHARAV, I; GARTY, NB; LITTAUER, UZ				BUSHKINHARAV, I; GARTY, NB; LITTAUER, UZ			DOWN-REGULATION OF A 67-KDA YIGSR-BINDING PROTEIN UPON DIFFERENTIATION OF HUMAN NEUROBLASTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; LAMININ-A-CHAIN; AMINO-ACID-SEQUENCE; RETINOIC ACID; SYNTHETIC PEPTIDE; MESSENGER-RNA; NEUROMUSCULAR-JUNCTION; CARCINOMA-CELLS; MELANOMA-CELLS; CYCLIC-AMP	Differentiated human neuroblastoma LA-N1 cells that were exposed to dibutyryl adenosine 3',5'-cyclic monophosphate for 5 days (primed cells) showed increased adhesion to laminin-, fibronectin-, and collagen type I-coated plates as compared to unprimed cells. Moreover, primed cells seemed to adhere best to laminin. The binding site in laminin, mediating cell attachment, was identified as containing the YIGSR sequence, a known cell binding motif, located in the short arm of the B1 chain of laminin. The synthetic peptide amide, C(YIGSR)(3)-NH2, containing a repeat of this binding motif, inhibited the attachment of neuroblastoma cells to laminin in a competitive manner, and its inhibitory activity was inversely dependent on laminin concentrations. Affinity chromatography of membrane-extracted proteins over an Affi-Gel 10 column conjugated to C(YIGSR)(3)-NH2, revealed a major YIGSR-binding protein with an apparent molecular mass of 67 kDa. The 67-kDa surface membrane protein was specifically eluted from the column with the soluble C(YIGSR)(3)-NH2 peptide, but not with an unrelated peptide. Furthermore, no 67-kDa laminin-binding protein was recovered from an unrelated peptide matrix with the free C(YIGSR)(3)-NH2 peptide. Ligand blot overlay assays with biotin-labeled C(YIGSR)(3)-NH2 peptide demonstrated that the 67-kDa receptor is indeed a YIGSR-binding protein. This 67-kDa laminin-binding protein appeared to be down-regulated upon differentiation of LA-N1 cells, as indicated by the level of this protein and its mRNA.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BUSHKINHARAV I, 1994, 8TH INT C INT SOC DI, P177; CASTRONOVO V, 1991, J BIOL CHEM, V266, P20440; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENT B, 1990, J CELL BIOL, V110, P185, DOI 10.1083/jcb.110.1.185; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; DOUVILLE PJ, 1988, J BIOL CHEM, V263, P14964; EDGAR D, 1989, TRENDS NEUROSCI, V12, P248, DOI 10.1016/0166-2236(89)90020-9; GARTY NB, 1991, 15TH INT C BIOCH JER, P229; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GINZBURG I, 1990, REGULATION GENE EXPR, P305; GLICK MC, 1980, ADV NEUROBLASTOMA RE, P171; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GROSS N, 1987, INT J CANCER, V39, P521, DOI 10.1002/ijc.2910390420; HADLEY MA, 1990, DEV BIOL, V140, P318, DOI 10.1016/0012-1606(90)90082-T; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; KIRSCH J, 1990, J NEUROCHEM, V55, P1031, DOI 10.1111/j.1471-4159.1990.tb04593.x; KIRSCH J, 1991, ADV NEUROBLASTOMA RE, V3, P327; KLEINMAN HK, 1991, ARCH BIOCHEM BIOPHYS, V290, P320, DOI 10.1016/0003-9861(91)90547-V; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; KLEINMAN HK, 1988, P NATL ACAD SCI USA, V85, P1282, DOI 10.1073/pnas.85.4.1282; KRAMER RH, 1989, CANCER RES, V49, P393; LAURIE GW, 1991, DIFFERENTIATION, V46, P173, DOI 10.1111/j.1432-0436.1991.tb00879.x; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; LITTAUER UZ, 1979, BIOCHEM BIOPH RES CO, V88, P933, DOI 10.1016/0006-291X(79)91498-0; LITTAUER UZ, 1980, J BIOL CHEM, V255, P5448; LITTAUER UZ, 1990, BASIC CLIN THERAPEUT, V1, P117; LOPRESTI P, 1992, CELL GROWTH DIFFER, V3, P627; MAFUNE K, 1990, CANCER RES, V50, P3888; MARCHETTI D, 1987, J NEUROCHEM, V49, P475, DOI 10.1111/j.1471-4159.1987.tb02889.x; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; NOMIZU M, 1993, CANCER RES, V53, P3459; PONZONI M, 1992, CANCER RES, V52, P931; PRASAD KN, 1975, CANCER, V36, P1338, DOI 10.1002/1097-0142(197510)36:4<1338::AID-CNCR2820360422>3.0.CO;2-1; RAMOS DM, 1990, CANCER RES, V50, P728; RAO NC, 1983, BIOCHEM BIOPH RES CO, V111, P804, DOI 10.1016/0006-291X(83)91370-0; REICHARDT LF, 1989, DEV NEUROSCI-BASEL, V11, P332, DOI 10.1159/000111910; RESCAN PY, 1991, HEPATOLOGY, V13, P289, DOI 10.1016/0270-9139(91)92442-B; ROSS RA, 1988, ADV NEUROBLASTOMA RE, V2, P277; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; RUPNIAK HT, 1984, CANCER RES, V44, P2600; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SEPHEL GC, 1989, BIOCHEM BIOPH RES CO, V162, P821, DOI 10.1016/0006-291X(89)92384-X; Shur BD, 1989, CURR OPIN CELL BIOL, V1, P905, DOI 10.1016/0955-0674(89)90057-4; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SIDELL N, 1982, J NATL CANCER I, V68, P589; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; SOREQ H, 1983, DEV BRAIN RES, V7, P257, DOI 10.1016/0165-3806(83)90182-7; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TERRANOVA VP, 1983, P NATL ACAD SCI-BIOL, V80, P444, DOI 10.1073/pnas.80.2.444; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; TSOKOS M, 1987, AM J PATHOL, V128, P484; VONDERMARK K, 1985, BIOCHIM BIOPHYS ACTA, V823, P147; WEEKS BS, 1991, AM J PHYSIOL, V261, pF688, DOI 10.1152/ajprenal.1991.261.4.F688; WEWER UM, 1986, P NATL ACAD SCI USA, V83, P7137, DOI 10.1073/pnas.83.19.7137; WOO HJ, 1990, J BIOL CHEM, V265, P7097; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L; YAMAMURA K, 1993, CANCER RES, V53, P423; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394	67	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13422	13428		10.1074/jbc.270.22.13422	http://dx.doi.org/10.1074/jbc.270.22.13422			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768944	hybrid			2022-12-25	WOS:A1995RB43900070
J	NAKTINIS, V; ONRUST, R; FANG, LH; ODONNELL, M				NAKTINIS, V; ONRUST, R; FANG, LH; ODONNELL, M			ASSEMBLY OF A CHROMOSOMAL REPLICATION MACHINE - 2 DNA-POLYMERASES, A CLAMP LOADER, AND SLIDING CLAMPS IN ONE HOLOENZYME PARTICLE .2. INTERMEDIATE COMPLEX BETWEEN THE CLAMP LOADER AND ITS CLAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III ACCESSORY PROTEINS; ESCHERICHIA-COLI; PRIMED DNA; SUBUNIT; CHI; PSI; ATP	The Escherichia coli replicase, DNA polymerase III holoenzyme, derives its processivity from the beta subunit sliding clamp that encircles DNA and tethers the replicase to the template. The beta dimer is assembled around DNA by the gamma complex clamp loader in an ATP-dependent reaction. In this report, the essential contact between the clamp loader and beta is identified as mediated through the delta subunit of the gamma complex. The delta subunit appears to contact the face of the beta dimer ring that contains the two C termini. Surprisingly, ATP is required for the gamma complex to bind beta, but not for delta to bind p. This indicates that delta is buried in the gamma complex and suggests a role for ATP in exposing delta for interaction with p. A protease protection assay has been developed to specifically probe the delta subunit within the gamma complex. The results of the assay are consistent with an ATP-induced conformational change in the gamma complex that alters the state of the delta subunit within it. The implication of these key features to the clamp loading mechanism of the gamma complex is discussed.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HEARST RES FDN,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute; Cornell University; Cornell University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRUTE JJ, 1983, J BIOL CHEM, V258, P1344; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15721; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KELMAN Z, 1995, IN PRESS METHODS ENZ, V262; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; KWONSHIN O, 1987, J BIOL CHEM, V262, P2121; LEE SH, 1991, J BIOL CHEM, V266, P594; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, BIOL CHEM, V270, P13348; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; SLICE LW, 1989, J BIOL CHEM, V264, P20940; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; XIAO H, 1993, J BIOL CHEM, V268, P11779; XIAO H, 1993, J BIOL CHEM, V268, P11773; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	24	113	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13358	13365		10.1074/jbc.270.22.13358	http://dx.doi.org/10.1074/jbc.270.22.13358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768937	hybrid			2022-12-25	WOS:A1995RB43900062
J	SHARF, R; AZRIEL, A; LEJBKOWICZ, F; WINOGRAD, SS; EHRLICH, R; LEVI, BZ				SHARF, R; AZRIEL, A; LEJBKOWICZ, F; WINOGRAD, SS; EHRLICH, R; LEVI, BZ			FUNCTIONAL DOMAIN ANALYSIS OF INTERFERON CONSENSUS SEQUENCE BINDING-PROTEIN (ICSBP) AND ITS ASSOCIATION WITH INTERFERON REGULATORY FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR; HUMAN ADENOVIRUSES; INDUCIBLE GENES; FACTOR-I; ELEMENTS; ALPHA; IRF-1; SYSTEM; FAMILY; ISGF-3	Interferon consensus sequence binding protein (ICSBP) is a member of the interferon regulatory factor (IRF) family of proteins that include IRF-1, IRF-2, and ISGF3 gamma which share sequence similarity at the putative DNA binding domain (DBD). ICSBP is expressed exclusively in cells of the immune system and acts as a repressor of interferon consensus sequence (ICS) containing promoters that can be alleviated by interferons. In this communication, we have searched for functional domains of ICSBP by dissecting the DBD from the repression activity. The putative DBD of ICSBP (amino acids 1-121) when fused in frame to the transcriptional activation domain of the herpes simplex VP16 (ICSEP-VP16) is a very strong activator of ICS-containing promoters. In addition, ICSBP-VP16 fusion construct transfected into adenovirus (Ad) 12 transformed cells enabled cell surface expression of major histocompatibility complex class I antigens as did treatment with interferon. On the other hand, the DBD of the yeast transcriptional activator GAL4 was fused in frame to a truncated ICSBP in which the DBD was impaired resulting in a chimeric construct GAIA-ICSBP. This construct is capable of repressing promoters containing GAL4 binding sites. Thus, ICSBP contains at least two independent domains: a DBD and a transcriptional repressor domain. Furthermore, we have tested possible interactions between ICSBP and IRFs. The chimeric construct GAL4-ICSBP inhibited the stimulated effect of IRF I on a reporter gene, implying for a possible interaction between IRF-1 and ICSBP. Electromobility shift assays, demonstrated that ICSBP can associate with IRF-2 or IRF-1 in vitro as well as in vivo. Thus, ICSBP contains a third functional domain that enables the association with IRFs. These associations are probably important for the fine balance between positive and negative regulators involved in the interferon-mediated signal transduction pathways in cells of the immune system.	TECHNION ISRAEL INST TECHNOL,DEPT FOOD ENGN & BIOTECHNOL,IL-32000 HAIFA,ISRAEL; TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT CELL RES & IMMUNOL,TEL AVIV,ISRAEL	Technion Israel Institute of Technology; Tel Aviv University								BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; HAHN S, 1993, NATURE, V363, P672, DOI 10.1038/363672a0; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN RT, 1994, J BIOL CHEM, V269, P17542; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROTEMYEHUDAR R, 1994, GENE, V144, P265, DOI 10.1016/0378-1119(94)90388-3; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V18, P7539; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHEMESH J, 1993, J BIOL CHEM, V268, P15704; SHEMESH J, 1991, J VIROL, V65, P5544, DOI 10.1128/JVI.65.10.5544-5548.1991; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WEISZ A, 1994, INT IMMUNOL, V6, P1125; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x	29	96	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13063	13069		10.1074/jbc.270.22.13063	http://dx.doi.org/10.1074/jbc.270.22.13063			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768900	hybrid			2022-12-25	WOS:A1995RB43900021
J	ZHANG, YH; CHELLAPPAN, SP				ZHANG, YH; CHELLAPPAN, SP			CLONING AND CHARACTERIZATION OF HUMAN DP2, A NOVEL DIMERIZATION PARTNER OF E2F	ONCOGENE			English	Article						E2F; RB; DP1; CELL CYCLE	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; BINDING PROTEIN; DNA-BINDING; GROWTH SUPPRESSION; COMPLEX-FORMATION; S-PHASE; RB; TRANSACTIVATION	The transcription factor E2F consists of a family of proteins that bind to the sequence TTTCGCGC and regulate the expression of various cellular and viral promoters. E2F binds to DNA as homodimers or as heterodimers in association with a protein, DP1 (for dimerization partner 1). E2F-DP1 heterodimers bind more efficiently than homodimers to DNA, retinoblastoma gene product as well as the adenovirus E4 protein and DP1 can stimulate transcription from E2F sites in a synergistic fashion. Here we describe the cloning and characterization of a novel human DP gene, DP2, whose product dimerizes efficiently with E2F. Unlike DP1, there appear to be multiple transcripts for DP2 and their distribution appears to vary in different tissues and cell lines. DP2 binds to E2F as detected by in vitro reconstitution assays and an E2F-DP2 heterodimer can bind to DNA in gel-retardation assays. We believe that DP2 also plays a major role in modulating the function of E2F in cell cycle regulation and oncogenesis.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Columbia University					NCI NIH HHS [CA 63136] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN AA, 1994, J BIOL CHEM, V269, P7735; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BANDARA LR, 1994, EMBO J, V12, P4317; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chellappan Srikumar P., 1994, Molecular and Cellular Differentiation, V2, P201; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JORDAN KL, 1994, ONCOGENE, V9, P1177; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; NEVINS JR, 1992, SCIENCE, V258, P424; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; SAMBROOK J, 1989, LABORATORY MANUAL; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITHIES O, 1981, CELL, V26, P345, DOI 10.1016/0092-8674(81)90203-8; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	62	93	95	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2085	2093						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784053				2022-12-25	WOS:A1995RB70300003
J	HUGUET, EL; SMITH, K; BICKNELL, R; HARRIS, AL				HUGUET, EL; SMITH, K; BICKNELL, R; HARRIS, AL			REGULATION OF WNT5A MESSENGER-RNA EXPRESSION IN HUMAN MAMMARY EPITHELIAL-CELLS BY CELL-SHAPE, CONFLUENCE, AND HEPATOCYTE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; XENOPUS EMBRYOS; GENE FAMILY; ECTOPIC EXPRESSION; MET PROTOONCOGENE; ONCOGENE INT-1; DIFFERENTIATION; INVOLVEMENT; INDUCTION; INVITRO	The Wnts are a family of genes with a role in cell fate and morphological development in numerous embryonic and adult tissues, In mouse mammary tissue a subset of the Wnts have a function in the normal development of the gland, and abberant expression of Wnts normally silent in this tissue causes mammary carcinomas. We have previously shown that Wnt5a expression is elevated in the epithelial component of proliferative lesions of human breast and have therefore examined the regulation of Wnt5a mRNA expression in the human mammary epithelial cell line HB2, which has a luminal phenotype and thus represents the most commonly transformed cell type in human breast cancer, Wnt5a was up-regulated 30-fold at confluence, This up-regulation was induced specifically by confluence and not by the growth arrest that accompanied it, In addition, Wnt5a was down-regulated 3-fold by changes in cell shape associated with the transition from growth on a two-dimensional surface (flat cell morphology) to growth in three-dimensional gels (spherical cell morphology), Cytoskeletal disruption with non-toxic doses of colchicine also induced a spherical morphology and brought about a dose dependent down-regulation of Wnt5a. Wnt5a was also down-regulated 10-fold during the hepatocyte growth factor-induced branching of HB2 cell aggregates in collagen gels, The down-regulation of Wnt5a preceded the branching process, A similar result was obtained with primary human breast epithelial populations and the breast cancer cell line MDA468. We conclude that regulation of Wnt5a expression is a downstream effect of signaling by hepatocyte growth factor, These results are consistent with a role for Wnt5a in mammary epithelial cell motility and are in accord with Xwnt5a's function in embryonal cell migration, If Wnt5a's function in human mammary epithelial cells is similar to that of Xwnt5a, its up-regulation at confluence may be a mechanism for inhibition of cell migration beyond confluence.			HUGUET, EL (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND, GROWTH FACTORS GRP, OXFORD OX3 9DU, ENGLAND.		Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409				Ausubel FM, 1991, CURRENT PROTOCOLS MO; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BENZEEV A, 1987, J BIOL CHEM, V262, P5366; BENZEEV A, 1991, BIOESSAYS, V13, P207, DOI 10.1002/bies.950130502; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; FAWCETT J, 1994, THESIS U OXFORD; FURLONG RA, 1992, BIOESSAYS, V14, P613, DOI 10.1002/bies.950140908; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HAEUPTLE MT, 1983, J CELL BIOL, V96, P1425, DOI 10.1083/jcb.96.5.1425; HOLLIDAY R, 1972, NATURE, V238, P26, DOI 10.1038/238026a0; HUGUET EL, 1994, CANCER RES, V54, P2615; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; Johnson R. T., 1993, CELL CYCLE PRACTICAL, P1; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; MALEK AM, 1994, J HYPERTENS, V12, P989; MCCARTHY SA, 1992, J BIOL CHEM, V267, P21617; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MOON RT, 1993, DEVELOPMENT, V119, P97; MOON RT, 1993, J CELL SCI, P183; MORIMOTO A, 1991, BIOCHEM BIOPH RES CO, V179, P1042, DOI 10.1016/0006-291X(91)91924-2; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; NUSSE R, 1992, J STEROID BIOCHEM, V43, P9, DOI 10.1016/0960-0760(92)90181-H; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OLSON DJ, 1992, DEV BIOL, V151, P204, DOI 10.1016/0012-1606(92)90227-8; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEVELY JL, 1987, CELL BIOL, V59, P121; SHANNON JM, 1987, BIOCHIM BIOPHYS ACTA, V931, P143, DOI 10.1016/0167-4889(87)90200-X; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; SPIEGELMAN BM, 1983, CELL, V35, P657, DOI 10.1016/0092-8674(83)90098-3; STREULI CH, 1990, J CELL BIOL, V110, P1405; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; UNEMORI EN, 1986, J CELL BIOL, V103, P1021, DOI 10.1083/jcb.103.3.1021; VANNLEEUVEN F, 1994, NATURE, V368, P342; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; YAMASHITA J, 1994, CANCER RES, V54, P1630; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; ZAKANY J, 1993, NATURE, V362, P546, DOI 10.1038/362546a0; ZANETTI NC, 1984, J CELL BIOL, V99, P115, DOI 10.1083/jcb.99.1.115	52	62	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12851	12856		10.1074/jbc.270.21.12851	http://dx.doi.org/10.1074/jbc.270.21.12851			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759542	hybrid			2022-12-25	WOS:A1995QZ71100079
J	WANG, M; DRUCKER, DJ				WANG, M; DRUCKER, DJ			THE LIM DOMAIN HOMEOBOX GENE ISL-1 IS A POSITIVE REGULATOR OF ISLET CELL-SPECIFIC PROGLUCAGON GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ALPHA-CELLS; GLUCAGON GENE; BINDING-PROTEINS; DNA-BINDING; SOMATOSTATIN EXPRESSION; INSULIN GENE; HOMEODOMAIN; PROMOTER; ELEMENT; INTESTINE	The LIM domain homeobox gene islet 1 (isl-1) is expressed in the embryonic nervous system and may be an early marker of motor neuron specification. isl-1 is expressed in all 4 islet cell types, but a role for isl-1 in the regulation of insulin gene expression has not been demonstrated, and the genetic targets for isl-1 in the pancreas remain unknown. We show here that the proximal rat proglucagon gene promoter binds an amino-terminally truncated Trp-E-isl-1 fusion protein that lacks the LIM domains. The proglucagon gene promoter also binds full-length in vitro translated isl-1 containing the intact LIM domains. isl-1 antisera detects binding of proglucagon gene sequences to isl-1 present in a slowly-migrating complex in nuclear extracts from InR1-G9 islet cells. The transcriptional properties of the proglucagon gene promoter sequences that bind isl-1 (designated Ga, Gb, and Gc) were assessed after transfection of reporter genes into wild type and isl-1-antisense (isl-1(AS)) InR1-G9 islet cells, The proximal proglucagon gene (Ga) promoter sequence reduced TK-CAT activity by similar to 50%, but no change in the activity of the Ga-TK-CAT plasmid was seen after transfection of isl-1(AS) InR1-G9 cells. In contrast, the Gb/Gc sites activated transcription 2-3-fold in wild type InR1-G9 cells, and the isl-1-dependent activation of gene transcription through the Gb/Gc element was eliminated following transfection of isl-1(AS) InR1-G9 cells. These data demonstrate that the LIM domain homeobox gene isl-1 1) is not constrained from DNA binding by its LIM domains and 2) functions as a positive regulator of proglucagon gene transcription in the endocrine pancreas.	UNIV TORONTO,TORONTO GEN HOSP,BANTING & BEST DIABET CTR,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,TORONTO GEN HOSP,DEPT CLIN BIOCHEM,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,TORONTO GEN HOSP,DEPT MED GENET,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,TORONTO GEN HOSP,DEPT MED,TORONTO,ON M5G 2C4,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital			Drucker, Daniel J/A-4092-2010					DONG JL, 1991, MOL ENDOCRINOL, V5, P1633, DOI 10.1210/mend-5-11-1633; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; GAJIC D, 1993, ENDOCRINOLOGY, V132, P1055, DOI 10.1210/en.132.3.1055; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; LEE YC, 1990, ENDOCRINOLOGY, V127, P2217, DOI 10.1210/endo-127-5-2217; LEE YC, 1992, J BIOL CHEM, V267, P10705; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1994, MOL CELL BIOL, V14, P3514, DOI 10.1128/MCB.14.5.3514; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; SANCHEZGARCIA I, 1993, J MOL BIOL, V231, P945, DOI 10.1006/jmbi.1993.1343; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; THORENS B, 1993, DIABETES, V42, P1219, DOI 10.2337/diabetes.42.9.1219; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8917; Varshavsky A, 1987, Methods Enzymol, V151, P551, DOI 10.1016/S0076-6879(87)51044-8; WADMAN L, 1994, EMBO J, V13, P4831; WANG M, 1994, ENDOCRINOLOGY, V134, P1416, DOI 10.1210/en.134.3.1416; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	33	90	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12646	12652		10.1074/jbc.270.21.12646	http://dx.doi.org/10.1074/jbc.270.21.12646			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759514				2022-12-25	WOS:A1995QZ71100050
J	BJORNSTEDT, M; HAMBERG, M; KUMAR, S; XUE, J; HOLMGREN, A				BJORNSTEDT, M; HAMBERG, M; KUMAR, S; XUE, J; HOLMGREN, A			HUMAN THIOREDOXIN REDUCTASE DIRECTLY REDUCES LIPID HYDROPEROXIDES BY NADPH AND SELENOCYSTINE STRONGLY STIMULATES THE REACTION VIA CATALYTICALLY GENERATED SELENOLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							T-CELL LEUKEMIA; GLUTATHIONE-PEROXIDASE; PURIFICATION; SUBSTRATE; OXYGEN; LIVER; ACID; SELENODIGLUTATHIONE; 15-LIPOXYGENASE; MECHANISM	Human placenta thioredoxin reductase (HP-TR) in the presence of NADPH-catalyzed reduction of (15S)-hydroperoxy-(5Z),(8Z),11(Z),13(E)-eicosatetraenoic acid ((15S)-HPETE) into the corresponding alcohol ((15S)-HETE). Incubation of 50 nM HP-TR and 0.5 mM NADPH with 300 mu M 18-HPETE for 5 min resulted in formation of 16.5 mu M 15-HETE. After 60 min, 74.7 mu M 15-HPETE was reduced. The rate of the reduction of 15-HPETE by the HP-TR/NADPH peroxidase system was increased 8-fold by the presence of 2.5 mu M selenocystine, a diselenide amino acid. In this case, 15-HPETE was catalytically reduced by the selenol amino acid, selenocysteine, generated from the diselenide by the HP-TR/NADPH system. To a smaller extent, selenodiglutathione or human thioredoxin also potentiated the reduction of 15-HPETE by HP-TR. Hydrogen peroxide and 15-HPETE were reduced at approximately the same rate by HP-TR, thioredoxin, and selenocystine. In contrast, t-butyl hydroperoxide was reduced at a 10-fold lower rate. Our data suggest two novel pathways for the reduction and detoxification of lipid hydroperoxides, hydrogen peroxide, and organic hydroperoxides, i.e. the human thioredoxin reductase-dependent pathway and a coupled reduction in the presence of selenols or selenide resulting from the reduction of selenocystine or selenodiglutathione.	KAROLINSKA INST, MED NOBEL INST BIOCHEM, S-17177 STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska Institutet				Hamberg, Mats/0000-0002-8910-7810				BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BRYANT R W, 1981, Progress in Lipid Research, V20, P279, DOI 10.1016/0163-7827(81)90055-2; BURK RF, 1991, FASEB J, V5, P2274, DOI 10.1096/fasebj.5.9.1830557; ESAKI N, 1982, J BIOL CHEM, V257, P4386; Flohe L., 1989, GLUTATHIONE CHEM BIO, P644; FORDHUTCHINSON AW, 1991, EICOSANOIDS, V4, P65; GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1989, LIPIDS, V24, P249, DOI 10.1007/BF02535158; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1980, P NATL ACAD SCI-BIOL, V77, P5149, DOI 10.1073/pnas.77.9.5149; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; LEE BJ, 1989, J BIOL CHEM, V264, P9724; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MAIORINO M, 1988, BIOCHEM PHARMACOL, V37, P2267, DOI 10.1016/0006-2952(88)90591-6; MITSUI A, 1992, BIOCHEM BIOPH RES CO, V186, P1220, DOI 10.1016/S0006-291X(05)81536-0; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335; TANAKA H, 1987, METHOD ENZYMOL, V143, P240; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; WENDEL A, 1980, FEBS LETT, V120, P209, DOI 10.1016/0014-5793(80)80299-7; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YASUDA K, 1980, BIOCHEM BIOPH RES CO, V96, P243, DOI 10.1016/0006-291X(80)91206-1; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YODOI J, 1991, ADV CANCER RES, V57, P381; ZHANG LY, 1994, CHEM PHYS LIPIDS, V74, P151, DOI 10.1016/0009-3084(94)90056-6	33	258	260	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11761	11764		10.1074/jbc.270.20.11761	http://dx.doi.org/10.1074/jbc.270.20.11761			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744824	hybrid			2022-12-25	WOS:A1995QY73600016
J	SELBIE, LA; DARBY, K; SCHMITZPEIFFER, C; BROWNE, CL; HERZOG, H; SHINE, J; BIDEN, TJ				SELBIE, LA; DARBY, K; SCHMITZPEIFFER, C; BROWNE, CL; HERZOG, H; SHINE, J; BIDEN, TJ			SYNERGISTIC INTERACTION OF Y1-NEUROPEPTIDE-Y AND ALPHA(1B)-ADRENERGIC RECEPTORS IN THE REGULATION OF PHOSPHOLIPASE-C, PROTEIN-KINASE-C, AND ARACHIDONIC-ACID PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INTRACELLULAR CALCIUM RELEASE; HUMAN ERYTHROLEUKEMIA-CELLS; BETA-GAMMA-SUBUNITS; NEUROPEPTIDE-Y; ADENYLATE-CYCLASE; 2ND MESSENGER; CA-2+; INHIBITION; MECHANISMS	Neuropeptide Y (NPY) and norepinephrine, found colocalized in sympathetic neurons innervating blood vessels, exert synergistic responses on vasoconstriction. To examine the signaling mechanisms involved, free of complications associated with mixed receptor populations, we have established a stable Chinese hamster ovary cell line expressing both Y1-NPY and alpha(1b)-adrenergic receptors. Occupation of either receptor species, with 100 nM peptide YY (PYY) or 10 mu M phenylephrine (PE), respectively, resulted in a rapid increase in the cytoplasmic free calcium concentration ([Ca2+](i)) as assessed with Fura-2/AM. The rise due to PYY, but not that due to PE, was abolished by pretreatment with pertussis toxin, Both responses were largely maintained in the absence of extracellular Ca2+, but abolished by prior depletion of intracellular Ca2+ pools with either thapsigargin or 2,5-di-(t-butyl)-1,4-benzohydroquinone. Using cells prelabeled with myo-[H-3]inositol, PE promoted a rapid (5 s) rise in inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) as analyzed by anion-exchange high pressure liquid chromatography, whereas the response to PYY (first significant at >15 s post-stimulation) was too slow to play a causative role in Ca2+ mobilization. Combination of PE and PYY resulted in increases in [Ca2+](i) which were at best additive, whereas they promoted a clearly synergistic rise in Ins(1,4,5)P-3 at both 15 and 60 s, Co-stimulation also resulted in a synergistic activation of both protein kinase C (PKC) and [H-3]arachidonic acid release. In either instance PYY alone was without effect. The potentiation of arachidonic acid release was abolished by depletion of cellular PKC following chronic treatment with phorbol esters. It is suggested that the ability of PYY to mobilize Ca2+ in an Ins(1,4,5)P-3-independent fashion minimizes the functional importance of the capacity to potentiate PE-stimulated Ins(1,4,5)P-3 generation. Instead the major consequences of the synergistic activation of phospholipase C are mediated via PKC, the other route of the signaling pathway.	ST VINCENTS HOSP,GARVAN INST MED RES,DARLINGHURST,NSW 2010,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			Schmitz-Peiffer, Carsten/J-6918-2012; Biden, Trevor/AAW-2829-2021; Herzog, Herbert/B-8294-2008	Schmitz-Peiffer, Carsten/0000-0001-7330-7255; Biden, Trevor/0000-0001-5211-0234				AAKERLUND L, 1990, FEBS LETT, V260, P73, DOI 10.1016/0014-5793(90)80069-U; ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; ANDRIANTSITOHAI.R, 1988, BRIT J PHARMACOL, V95, P219; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIDEN TJ, 1993, BIOCHEM J, V293, P721, DOI 10.1042/bj2930721; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DANIELS AJ, 1989, BIOCHEM BIOPH RES CO, V165, P1138, DOI 10.1016/0006-291X(89)92721-6; DANIELS AJ, 1992, MOL PHARMACOL, V41, P767; DUCKLES SP, 1994, LIFE SCI, V55, P103; EDVINSSON L, 1984, BRIT J PHARMACOL, V83, P519, DOI 10.1111/j.1476-5381.1984.tb16516.x; FALLGREN B, 1994, J AUTONOM NERV SYST, V44, P151; FELDER CC, 1991, P NATL ACAD SCI USA, V88, P6477, DOI 10.1073/pnas.88.15.6477; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; IMAGAWA T, 1992, J BIOCHEM-TOKYO, V112, P508, DOI 10.1093/oxfordjournals.jbchem.a123930; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KAMAMURA K, 1991, BIOCHEM BIOPH RES CO, V179, P309; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KASSIS S, 1987, J BIOL CHEM, V262, P3429; KOLESNICK RN, 1985, J BIOL CHEM, V260, P707; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE MW, 1994, AM J PHYSIOL, V267, pC659, DOI 10.1152/ajpcell.1994.267.3.C659; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOBAUGH LA, 1990, J BIOL CHEM, V265, P18393; LOBAUGH LA, 1990, AM J PHYSIOL, V258, pC913, DOI 10.1152/ajpcell.1990.258.5.C913; LUNDBERG JM, 1988, EUR J PHARMACOL, V145, P21, DOI 10.1016/0014-2999(88)90344-5; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MCDERMOTT BJ, 1993, CARDIOVASC RES, V27, P893, DOI 10.1093/cvr/27.6.893; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MICHEL MC, 1991, TRENDS PHARMACOL SCI, V12, P389, DOI 10.1016/0165-6147(91)90610-5; MICHEL MC, 1994, BRIT J PHARMACOL, V112, P499, DOI 10.1111/j.1476-5381.1994.tb13101.x; MIHARA S, 1989, FEBS LETT, V259, P79, DOI 10.1016/0014-5793(89)81499-1; MOTULSKY HJ, 1988, AM J PHYSIOL, V255, pE880, DOI 10.1152/ajpendo.1988.255.6.E880; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PARK DG, 1993, J BIOL CHEM, V268, P4573; PEREZ DM, 1993, MOL PHARMACOL, V44, P784; PERNOW J, 1986, ACTA PHYSIOL SCAND, V126, P239, DOI 10.1111/j.1748-1716.1986.tb07811.x; POTTER EK, 1988, PHARMACOL THERAPEUT, V37, P251, DOI 10.1016/0163-7258(88)90028-9; REYNOLDS EE, 1988, BIOCHEM BIOPH RES CO, V151, P919, DOI 10.1016/S0006-291X(88)80369-3; SHO K, 1991, J BIOL CHEM, V266, P12180; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SUZUKI E, 1990, MOL PHARMACOL, V38, P725; WAEBER B, 1988, AM J HYPERTENS, V1, P193, DOI 10.1093/ajh/1.2.193; WAHLESTEDT C, 1985, J PHARMACOL EXP THER, V234, P735; WAHLESTEDT C, 1990, AM J PHYSIOL, V258, pR736, DOI 10.1152/ajpregu.1990.258.3.R736; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309	52	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11789	11796		10.1074/jbc.270.20.11789	http://dx.doi.org/10.1074/jbc.270.20.11789			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744827	hybrid			2022-12-25	WOS:A1995QY73600021
J	KONDO, S; BARNETT, GH; HARA, H; MORIMURA, T; TAKEUCHI, J				KONDO, S; BARNETT, GH; HARA, H; MORIMURA, T; TAKEUCHI, J			MDM2 PROTEIN CONFERS THE RESISTANCE OF A HUMAN GLIOBLASTOMA CELL-LINE TO CISPLATIN-INDUCED APOPTOSIS	ONCOGENE			English	Article						MDM2; CISPLATIN; P53; GLIOMA AND APOPTOSIS	WILD-TYPE P53; MYELOID LEUKEMIC-CELLS; DNA-DAMAGING AGENTS; CANCER-CHEMOTHERAPY; ANTICANCER AGENTS; GENE; INDUCTION; EXPRESSION; ACTIVATION; GROWTH	Induction of apoptosis in tumor cells is an important mechanism of chemotherapy-induced cell death. The tumor-suppressor gene p53 is required for the efficient activation of apoptosis following chemotherapy. However,, the molecular mechanism regulating p53-associated apoptosis remains controversial. In this study, we show that the expression of both wild-type p53 and MDM2 (murine double minute 2) proteins was induced when cisdiamminedichloroplatinum (cisplatin) caused apoptosis in human glioblastoma U87-MG cells, which expressed neither wild-type p53 nor MDM2 protein prior to treatment, Overexpression of MDM2 in U87-MG cells transfected with human mdm2 expression vector conferred the resistance of tumor cell to cisplatin-induced apoptosis, In contrast, the treatment with mdm2 antisense oligonucleotide targeted against mdm2 mRNA increased the susceptibility of tumor cells to apoptosis. Changes in expression level of MDM2 protein, however, did not affect the expression of wild-type p53 protein. These findings suggest that MDM2 protein may act as a negative regulator of cisplatin-induced apoptosis, and moreover, may play an important role in the development of resistance to cisplatin in human tumors.	NATL UTANO HOSP,DEPT CLIN RES CTR,KYOTO,JAPAN; NATL UTANO HOSP,DEPT NEUROSURG,KYOTO,JAPAN		KONDO, S (corresponding author), CLEVELAND CLIN FDN,CTR CANC,CTR BRAIN TUMOR,DEPT NEUROSURG,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							AKELLA R, 1992, EUR J IMMUNOL, V22, P1069, DOI 10.1002/eji.1830220429; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CAI DW, 1993, HUM GENE THER, V4, P617, DOI 10.1089/hum.1993.4.5-617; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COTTER TG, 1992, ANTICANCER RES, V12, P773; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUJIWARA T, 1994, CANCER RES, V54, P2287; HARPER JW, 1993, CELL, V75, P805; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KONDO S, 1994, BRIT J CANCER, V69, P627, DOI 10.1038/bjc.1994.123; KONDO S, 1994, CANCER RES, V54, P2928; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARIN MC, 1994, ONCOGENE, V9, P3107; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PRICE BD, 1994, CANCER RES, V54, P896; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; YIN DL, 1994, FEBS LETT, V339, P73, DOI 10.1016/0014-5793(94)80387-0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	49	124	132	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					2001	2006						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761100				2022-12-25	WOS:A1995QZ92600014
J	SCHOBITZ, B; PEZESHKI, G; POHL, T; HEMMANN, U; HEINRICH, PC; HOLSBOER, F; REUL, JMHM				SCHOBITZ, B; PEZESHKI, G; POHL, T; HEMMANN, U; HEINRICH, PC; HOLSBOER, F; REUL, JMHM			SOLUBLE INTERLEUKIN-6 (IL-6) RECEPTOR AUGMENTS CENTRAL EFFECTS OF IL-6 IN-VIVO	FASEB JOURNAL			English	Article						BODY TEMPERATURE; CYTOKINES; RAT	SIGNAL TRANSDUCER; EXPRESSION; RAT; PURIFICATION; CLONING; TARGET; GP130	The pleiotropic cytokine interleukin-6 (IL-6) controls both the peripheral and central components of the acute-phase response. These activities are mediated via the IL-6 membrane receptor, but probably also via agonistic soluble IL-6 receptors (sIL-6Rs). In the present study we conducted dose-response experiments with rats that were intracerebroventricularly i.c.v.) injected with recombinant human IL-6 and sIL-6R and determined body temperature, locomotor activity, food intake, and water consumption using radiotelemetry and continuous recordings of feeding and drinking. IL-6 injected i.c.v. at 1, 10, and 100 ng increased body temperature and decreased locomotor activity and food intake, but it did not affect water consumption. When 10 ng sIL-6R, which lacked detectable biological activity, was injected i.c.v. 1 h before 1 ng IL-6, the central effects of IL-6 were enhanced and prolonged, and this was not due to endotoxin contamination of the recombinant proteins. Our data suggest that IL-6 plays an important role in the regulation of body temperature, general activity, and food intake in sick animals. Moreover, we have shown for the first time that it is possible to potentiate the effects of a mediator in vivo by administration of the corresponding receptor, which is a novel pharmacological tool for increasing receptor capacity.	MAX PLANCK INST PSYCHIAT,INST CLIN,DEPT NEUROENDOCRINOL,D-80804 MUNICH,GERMANY; RHEIN WESTFAL TH AACHEN,INST BIOCHEM,W-5100 AACHEN,GERMANY	Max Planck Society; RWTH Aachen University			Reul, Johannes/B-4132-2019	Reul, Johannes/0000-0002-8787-4012				AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DINARELLO CA, 1991, BLOOD, V77, P1627; GRADIENT RA, 1993, NEUROSCI LETT, V153, P13; HONDA M, 1992, J IMMUNOL, V148, P2175; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; KENT S, 1992, TRENDS PHARMACOL SCI, V13, P24, DOI 10.1016/0165-6147(92)90012-U; KLIR JJ, 1994, AM J PHYSIOL, V266, pR185; LEMAY LG, 1990, AM J PHYSIOL, V258, pR798, DOI 10.1152/ajpregu.1990.258.3.R798; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MURAMAMI N, 1993, ENDOCRINOLOGY, V133, P2574, DOI 10.1210/en.133.6.2574; NOVICK D, 1990, J CHROMATOGR, V510, P331, DOI 10.1016/S0021-9673(01)93767-7; OPP M, 1989, PHYSIOL BEHAV, V45, P1069, DOI 10.1016/0031-9384(89)90239-4; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PLATASALAMAN CR, 1988, NEUROSCI RES COMMUN, V3, P159; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; ROTHWELL NJ, 1991, CAN J PHYSIOL PHARM, V69, P1465, DOI 10.1139/y91-219; SAITO M, 1992, J IMMUNOL, V148, P4066; SCHOBITZ B, 1994, CRIT REV NEUROBIOL, V8, P263; SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; SCHOBITZ B, 1993, ENDOCRINOLOGY, V132, P1569, DOI 10.1210/en.132.4.1569; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	27	128	128	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					659	664		10.1096/fasebj.9.8.7768358	http://dx.doi.org/10.1096/fasebj.9.8.7768358			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768358				2022-12-25	WOS:A1995RC10600012
J	KASUYA, J; GOKO, H; FUJITAYAMAGUCHI, Y				KASUYA, J; GOKO, H; FUJITAYAMAGUCHI, Y			MULTIPLE TRANSCRIPTS FOR THE HUMAN CARDIAC FORM OF THE CGMP-INHIBITED CAMP-PHOSPHODIESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMP PHOSPHODIESTERASE; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; HUMAN-PLATELETS; TRANSFER-RNA; FAT-CELLS; YEAST INVERTASE; MESSENGER-RNAS; GENE ENCODES	cDNAs for two distinct Type III cGMP-inhibited (cGI) cyclic nucleotide phosphodiesterases (PDE), designated cGIP1 and cGIP2, were previously cloned from rat adipose and human cardiac cDNA libraries, respectively. In this study, another cDNA (similar to 4.0 kilobase (kb)) encoding a cGI-PDE of 74 kDa (658 amino acids) was isolated from a human placental cDNA library, The nucleotide sequence of its open reading frame was virtually identical to a corresponding region in the 3' portion of the cardiac cGIP2 cDNA (similar to 7,6 kb) which encoded a similar to 125-kDa cGI-PDE (1141 amino acid). Northern blots and RNase protection assays revealed a prominent 4.4-kb transcript and a 7.6-kb transcript in human placenta. The transcription start site of the 4.4-kb transcript was assigned to cardiac cDNA nucleotide 1292, the putative beginning of exon 3 of the human cGIP2 gene, with a potential translation initiation site 183 bases downstream, as determined by RNase protection assay. The 5'-flanking region of the 4.4-kb transcript exhibited promoter activity in HeLa cells which expressed the 4.4-kb transcript, amd contained a TATAA sequence 35 base pairs upstream from the tentative transcription start site. Recombinant cGI-PDEs, expressed in Sf9 cells from the 7.6- and 4.0-kb cDNA, exhibited differences in their subcellular localization and K-m for cGMP. Thus, in human tissues, alternative transcription may contribute to generating at least two cGIP2 isoforms, cytosolic and membrane-associated cGI-PDEs with different K-m values for cGMP.	CITY HOPE NATL MED CTR,BECKMAN RES INST,DEPT MOLEC GENET,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NCI NIH HHS [CA33572] Funding Source: Medline; NIDDK NIH HHS [DK27790] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELTZER JP, 1986, J BIOL CHEM, V261, P5160; BUTCHER RW, 1966, J BIOL CHEM, V241, P1651; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CHEUNG P, 1994, FASEB J 1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU MI, 1992, GENETICS, V132, P987; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; DEGERMAN E, 1994, BBA-PROTEIN STRUCT M, V1205, P189, DOI 10.1016/0167-4838(94)90233-X; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; DEGERMAN E, 1989, ADV SEC MESS PHOSPH, V12, P171; ELLIS SR, 1986, J BIOL CHEM, V261, P9703; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; GRANT PG, 1984, BIOCHEMISTRY-US, V23, P1801, DOI 10.1021/bi00303a034; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HARRISON SA, 1986, MOL PHARMACOL, V29, P506; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KHOO JC, 1973, J BIOL CHEM, V248, P3823; KONO T, 1975, J BIOL CHEM, V250, P7826; KONO T, 1973, J BIOL CHEM, V248, P7417; KOZAK M, 1986, CELL, V46, P481; KOZAK M, 1986, J CELL BIOL, V108, P229; KOZAK M, 1987, CELL, V44, P283; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBON TR, 1992, ENDOCRINOLOGY, V130, P3265, DOI 10.1210/en.130.6.3265; LETRONG H, 1990, BIOCHEMISTRY-US, V29, P10280; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; LOPEZAPARICIO P, 1992, BIOCHEM BIOPH RES CO, V186, P517, DOI 10.1016/S0006-291X(05)80838-1; LOPEZAPARICIO P, 1993, BIOCHEM BIOPH RES CO, V193, P1137, DOI 10.1006/bbrc.1993.1744; LOTEN EG, 1970, BIOCHEM J, V120, P193; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MANGANIELLO V, 1973, J BIOL CHEM, V248, P7164; Manganiello V.C., 1990, CYCLIC NUCLEOTIDE PH, P87; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MONACO L, 1994, J BIOL CHEM, V269, P347; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; OBERNOLTE R, 1993, GENE, V129, P239, DOI 10.1016/0378-1119(93)90274-7; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; PERLMAN D, 1981, CELL, V25, P525, DOI 10.1016/0092-8674(81)90071-4; PILLAI R, 1994, J BIOL CHEM, V269, P30676; QIU YH, 1993, GENE DEV, V7, P1447, DOI 10.1101/gad.7.7b.1447; RASCON A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P149, DOI 10.1016/0167-4889(92)90038-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAKUR Y, 1993, BIOCHEM J, V292, P6577; SHIBATA H, 1990, BIOCHEM BIOPH RES CO, V170, P533, DOI 10.1016/0006-291X(90)92124-I; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V190, P516, DOI 10.1006/bbrc.1993.1078; SONNENBURG WK, 1993, J BIOL CHEM, V268, P645; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; TAIRA M, 1993, J BIOL CHEM, V268, P18573; WEBER HW, 1982, J BIOL CHEM, V257, P5339; WU M, 1987, J BIOL CHEM, V262, P12275; XIONG LM, 1990, ENDOCRINOLOGY, V126, P2102, DOI 10.1210/endo-126-4-2102; YAN PF, 1993, J BIOL CHEM, V268, P22444; ZINMAN B, 1974, J BIOL CHEM, V249, P2182; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	65	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14305	14312		10.1074/jbc.270.24.14305	http://dx.doi.org/10.1074/jbc.270.24.14305			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782288	hybrid			2022-12-25	WOS:A1995RD45500014
J	PUMIGLIA, KM; LEVINE, H; HASKE, T; HABIB, T; JOVE, R; DECKER, SJ				PUMIGLIA, KM; LEVINE, H; HASKE, T; HABIB, T; JOVE, R; DECKER, SJ			A DIRECT INTERACTION BETWEEN G-PROTEIN BETA-GAMMA-SUBUNITS AND THE, RAF-1 PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CATALYTIC SUPPORT; ADP-RIBOSYLATION; RAS; PHOSPHORYLATION; ACTIVATION; INHIBITION; DELETION; REGION; ALPHA	Raf-1 is a serine/threonine protein kinase positioned downstream of Ras in the mitogen-activated protein kinase cascade. Using a yeast two-hybrid strategy to identify other proteins that interact with and potentially regulate Raf-1, we isolated a clone encoding the carboxyl-terminal half of the G(beta 2) subunit of heterotrimeric G-proteins. In vitro, purified G(beta gamma) subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 (Raf/330). Binding assays with truncation mutants of GST-Raf indicate that the region located. between amino acids 136 and 239 is a primary determinant for interaction with G(beta gamma). In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G(beta gamma) to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect. Scatchard analysis of in vitro binding between Raf/330 and G(beta gamma) revealed an affinity of interaction (K-d = 163 +/- 36 nM), similar to that seen between G(beta gamma) and beta ARK (K-d = 87 +/- 24 nM), The formation of native heterotrimeric G(alpha beta gamma) complexes, as measured by pertussis toxin ADP-ribosylation of G(alpha), could be disrupted by increasing amounts of Raf/330, with an EC(50) of approximately 200 nM, in close agreement with the estimated binding affinity. In vivo complexes of Raf-1 and G(beta gamma) were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G(beta 2). The identification and characterization of this novel interaction raises several possibilities for signaling cross-talk between growth factor receptors and those receptors coupled to heterotrimeric G-proteins.	UNIV MICHIGAN, SCH MED, DEPT MICROBIOL & IMMUNOL, ANN ARBOR, MI 48109 USA; PARKE DAVIS PHARMACEUT, DIV RES, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48106 USA; PARKE DAVIS PHARMACEUT, DIV RES, DEPT NEUROSCI, ANN ARBOR, MI 48106 USA	University of Michigan System; University of Michigan; Pfizer; Pfizer				Pumiglia, Kevin/0000-0003-4655-0334	NCI NIH HHS [CA55652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1991, METHOD ENZYMOL, V195, P315; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HABIB T, 1994, J BIOL CHEM, V269, P25243; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HARPER JW, 1993, CELL, V75, P805; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HONDA Z, 1994, J BIOL CHEM, V269, P2307; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RON D, 1994, J BIOL CHEM, V269, P21395; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; STOKOE D, 1994, SCIENCE, V264, P1468; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	35	77	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14251	14254		10.1074/jbc.270.24.14251	http://dx.doi.org/10.1074/jbc.270.24.14251			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782277	hybrid			2022-12-25	WOS:A1995RD45500003
J	AHN, MJ; NASONBURCHENAL, K; MOASSER, MM; DMITROVSKY, E				AHN, MJ; NASONBURCHENAL, K; MOASSER, MM; DMITROVSKY, E			GROWTH SUPPRESSION OF ACUTE PROMYELOCYTIC LEUKEMIA-CELLS HAVING INCREASED EXPRESSION OF THE NONREARRANGED ALLELES - RAR-ALPHA OR PML	ONCOGENE			English	Article						RETINOIC ACID; ACUTE PROMYELOCYTIC LEUKEMIA; RAR-ALPHA; PML	TRANS-RETINOIC ACID; DIFFERENTIATION THERAPY; T(15-17) TRANSLOCATION; RIBONUCLEIC-ACID; THYROID-HORMONE; X-RECEPTOR; LINE; SEQUENCES; SURVIVAL; CLONING	The balanced t(15;17) rearrangement found in acute promyelocytic leukemia (APL) cells fuses PML on chromosome 15 to the retinoic acid receptor alpha (RAR alpha) on chromosome 17, PML/RAR alpha is expressed in APL cells with the non-rearranged alleles, PML and RAR alpha, Clinical remissions induced by all-trans-retinoic acid (RA) treatment of APL patients are linked to expression of PML/ RAR alpha, a transcription factor with reported dominant negative functions, The roles of PML and RAR alpha in the RA response of APL have not yet been fully explored, This study examines these roles by individually transfecting RAR alpha and PML into NB4 APL cells. NB4 is the sole APL cell Line containing the t(15;17), RA treatment represses NB4 cell growth and induces a myeloid phentoype, Full length cDNAs for RAR alpha and PML were individually cloned into a CMV-driven expression vector containing the neomycin resistance gene, Surprisingly, none of the obtained stable transfectants expressed exogenous RAR alpha or PML mRNAs even when reverse transcription polymerase chain reaction (RT-PCR) detection assays were used. All clones expressed the neomycin resistance gene and were similar to parental NB4 cells in their growth and differentiation properties, An explanation explored for this lack of gene expression was that increased levels of RAR alpha or PML might suppress APL cell growth, To examine this possibility, transfection experiments were repeated using an episomal vector-based expression system containing an SV40 driven RAR alpha or PML cDNA and the hygromycin B resistance gene, A new selection strategy augmented expression of the desired cDNAs, A control episomal vector lacked a cDNA insert, Following electroporation and selection, exogenous RAR alpha expression was obtained. Compared to controls, the growth of these transfectants was markedly inhibited before and after RA-treatment and these cells more prominently induced myeloid maturation markers, In contrast, exogenous PML expression was transient since these transfectants did not appear to propagate in culture, These findings indicate: (1) a growth disadvantage for NB4 cells having increased expression of RAR alpha or PML and (2) increased RAR alpha expression augmented RA-mediated maturation of NB4 cells, This implicates a role for RAR alpha or PML in regulating the growth or differentiation of APL cells, It is hypothesized this occurs through antagonism of PML/RAR alpha actions in these leukemic cells.	MEM HOSP,DEPT MED,GENITOURINARY ONCOL SERV,MOLEC MED LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,MOLEC PHARMACOL & THERAPEUT PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [K12CA001712, F32CA061646, R01CA062275] Funding Source: NIH RePORTER; NCI NIH HHS [1F32CA61646-01A1, 1R01 CA62275-01, CA01712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DALTON WT, 1988, BLOOD, V71, P242; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DMITROVSKY E, 1990, ONCOGENE, V5, P543; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KURIE JM, 1994, BBA-MOL CELL RES, V1222, P88, DOI 10.1016/0167-4889(94)90028-0; LANOTTE M, 1991, BLOOD, V77, P1080; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MILLER WH, 1990, ONCOGENE, V5, P511; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; MOASSER MM, 1995, ONCOGENE, V10, P1537; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PACE U, 1994, CANCER RES, V54, P6365; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	31	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2307	2314						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784078				2022-12-25	WOS:A1995RE54300005
J	LIN, JY; TERESKY, AK; LEVINE, AJ				LIN, JY; TERESKY, AK; LEVINE, AJ			2 CRITICAL HYDROPHOBIC AMINO-ACIDS IN THE N-TERMINAL DOMAIN OF THE P53 PROTEIN ARE REQUIRED FOR THE GAIN OF FUNCTION PHENOTYPES OF HUMAN P53 MUTANTS	ONCOGENE			English	Note						MUTANT P53; TRANSACTIVATION; TUMORIGENICITY; GAIN OF FUNCTION PHENOTYPES	LARGE-T-ANTIGEN; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; EMBRYO FIBROBLASTS; CELLS; DNA; GENE; RAS; IMMORTALIZATION; MODULATION	Some mutant forms of the p53 protein have been shown to gain new functions that are not shared by the wildtype p53 protein; (1) mutant p53 proteins can transcriptionally transactivate the multi-drug resistance gene-1 (MDR-1) and (2) when expressed in nontumorigenic cells with no endogenous p53 protein, mutant p53 proteins can enhance the tumorigenic potential of these cells (Dittmer et at, 1993). It has recently been shown (Lin et al., 1994b) that the transcriptional activator domain of the p53 protein contains two amino acids, leu-22 and trp-23, which are required by the wild-type p53 protein for transcriptional activity. To determine whether these same amino acid residues are utilized by mutant p53 proteins for their gain of function phenotype, the triple mutant p53 protein (at residues 22 and 23 in the transactivation domain and residue 281 in the DNA binding domain-a gain of function mutant) was made. While the p53-281 mutant transcriptionally activates the MDR-1 gene and enhances the tumorigenic potential of cells it is expressed in, the 22, 23, 281 triple mutant failed to carry out either of these functions.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University			Lin, Jiayuh/E-3515-2011					BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LIN J, 1994, IN PRESS COLD SPG HB, V59; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIOU G, 1990, LANCET, V335, P1171; ROVINSKI B, 1988, ONCOGENE, V2, P445; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, ONCOGENE, V6, P2055; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	30	118	122	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2387	2390						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784087				2022-12-25	WOS:A1995RE54300014
J	COLEMAN, RA; TAGGART, AKP; BENJAMIN, LR; PUGH, BF				COLEMAN, RA; TAGGART, AKP; BENJAMIN, LR; PUGH, BF			DIMERIZATION OF THE TATA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; MINOR-GROOVE; BOX COMPLEX; TFIID BINDS; TBP; SUFFICIENT; INITIATION; ELEMENT	The TATA binding protein (TBP) is a central component of all eukaryotic transcription machineries. The recruitment of TBP to the promoter is slow and possibly rate limiting in transcription complex assembly. In an effort to understand the nature of this potential rate-limiting step, we have investigated the physical state of TBP prior to DNA binding. By chemical cross-linking, gel filtration chromatography, and protein affinity chromatography, we find that the conserved carboxyl-terminal DNA binding domain of human TBP dimerizes when not bound to DNA. The data completely support the proposed dimeric structure of plant TBP, previously determined by x-ray crystallography. TBP dimers are quite stable, having an approximate equilibrium dissociation constant (K-D) in the low nanomolar range. The dimerization interface appears to be dominated by hydrophobic forces, as predicted by the crystal structure. TBP dimers do not bind DNA, but they must dissociate into monomers before stably binding to the TATA box. Dissociation of TBP dimers appears to be relatively slow, and as such has the potential to dictate the kinetics of DNA binding.	PENN STATE UNIV,CTR GENE REGULAT,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIGMS NIH HHS [GM47855] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; ICARDLIEPKALNS C, 1993, BIOCHEM BIOPH RES CO, V193, P453, DOI 10.1006/bbrc.1993.1645; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; JUPP R, 1993, J BIOL CHEM, V268, P16105; KATO K, 1994, NUCLEIC ACIDS RES, V22, P1179, DOI 10.1093/nar/22.7.1179; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LU T, 1993, ANAL BIOCHEM, V213, P318, DOI 10.1006/abio.1993.1427; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1995, IN VITRO TRANSCRIPTI, V37, P359; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3	25	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13842	13849		10.1074/jbc.270.23.13842	http://dx.doi.org/10.1074/jbc.270.23.13842			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775442	hybrid			2022-12-25	WOS:A1995RC44800041
J	LEHNER, R; KUKSIS, A				LEHNER, R; KUKSIS, A			TRIACYLGLYCEROL SYNTHESIS BY PURIFIED TRIACYLGLYCEROL SYNTHETASE OF RAT INTESTINAL-MUCOSA - ROLE OF ACYL-COA ACYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; DIACYLGLYCEROL ACYLTRANSFERASE; COENZYME-A; RADIATION INACTIVATION; PARTIAL-PURIFICATION; POLYACRYLAMIDE GELS; LIVER MICROSOMES; FUNCTIONAL SIZE; Z-PROTEIN; HYDROLASE	The activities of the proposed triacylglycerol synthetase complex, acyl-CoA Ligase, acyl-CoA acyltransferase (AAT), monoacylglycerol acyltransferase (MGAT), and diacylglycerol acyltransferase (DGAT), coeluted upon Cibacron blue 3GA-agarose affinity chromatography of detergent-solubilized rat intestinal microsomes. The AAT activity is associated with a 54-kDa protein, that binds covalently an acyl group from acyl-CoA via a thiol ester linkage (Lehner, R. and Kuksis, A. (1993) J. Biol. Chem. 268, 24726-24733). Reagents that prevent the acyl-AAT formation inhibit triacylglycerol synthesis as does the removal of AAT from the complex by immunoprecipitation. In the absence of mono- and diacylglycerol accepters, the acyl group is transferred to water. It is proposed that triacylglycerol synthesis proceeds via a sequential transfer of acyl groups from acyl-CoA ligase to the AAT, from which they are passed to the mono- and diacylglycerol acyltransferases for incorporation into the di- and triacylglycerols depending on the availability of the acyl acceptors.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA	University of Toronto				Lehner, Richard/0000-0002-6008-1805				ANDERSSON M, 1994, J LIPID RES, V35, P535; BANIS RJ, 1974, BIOCHIM BIOPHYS ACTA, V348, P210, DOI 10.1016/0005-2760(74)90232-X; BERGE RK, 1979, BIOCHIM BIOPHYS ACTA, V574, P321, DOI 10.1016/0005-2760(79)90013-4; BHAT BG, 1993, ARCH BIOCHEM BIOPHYS, V300, P663, DOI 10.1006/abbi.1993.1092; BILLHEIMER JT, 1990, J BIOL CHEM, V265, P8632; BRINDLEY DN, 1965, BIOCHIM BIOPHYS ACTA, V106, P495, DOI 10.1016/0005-2760(65)90066-4; CIANFLONE KM, 1989, J BIOL CHEM, V264, P426; FERSHT A, 1985, ENZYME STRUCTURE MEC, P115; FOLCH J, 1957, J BIOL CHEM, V226, P497; GROSS RW, 1983, BIOCHEMISTRY-US, V22, P5641, DOI 10.1021/bi00293a028; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HOFFMAN AGD, 1979, CAN J PHYSIOL PHARM, V57, P832, DOI 10.1139/y79-127; HOFFMAN AGD, 1982, BIOCHIM BIOPHYS ACTA, V710, P53, DOI 10.1016/0005-2760(82)90189-8; KNUDSEN J, 1975, BIOCHEM BIOPH RES CO, V65, P921, DOI 10.1016/S0006-291X(75)80473-6; KUKSIS A, 1975, J CHROMATOGR SCI, V13, P423, DOI 10.1093/chromsci/13.9.423; KUKSIS A, 1986, FAT ABSORPTION, V1, P233; KWANYUEN P, 1990, BIOCHIM BIOPHYS ACTA, V1039, P67, DOI 10.1016/0167-4838(90)90227-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB RG, 1980, BIOCHIM BIOPHYS ACTA, V619, P385, DOI 10.1016/0005-2760(80)90086-7; LARSON JD, 1985, ARCH BIOCHEM BIOPHYS, V273, P27; LEHNER R, 1993, J BIOL CHEM, V268, P24726; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; LIN CY, 1978, J BIOL CHEM, V253, P1954; MANGANARO F, 1985, CAN J BIOCHEM CELL B, V63, P341, DOI 10.1139/o85-050; MANGANARO F, 1985, CAN J BIOCHEM CELL B, V63, P107, DOI 10.1139/o85-016; MANLEY ER, 1974, BIOCHEM BIOPH RES CO, V58, P229, DOI 10.1016/0006-291X(74)90916-4; MENTLEIN R, 1985, BIOCHEM J, V232, P479, DOI 10.1042/bj2320479; MISHKIN S, 1974, BIOCHEM BIOPH RES CO, V60, P376; MYHER JJ, 1979, CAN J BIOCHEM CELL B, V57, P117, DOI 10.1139/o79-015; NIMMO GA, 1984, BIOCHEM J, V224, P101, DOI 10.1042/bj2240101; ODOHERTY PJA, 1975, FEBS LETT, V60, P256, DOI 10.1016/0014-5793(75)80725-3; OZASA S, 1989, J LIPID RES, V30, P1759; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIND S, 1987, BIOCHIM BIOPHYS ACTA, V901, P78, DOI 10.1016/0005-2736(87)90258-6; POLOKOFF MA, 1980, BIOCHIM BIOPHYS ACTA, V618, P129, DOI 10.1016/0005-2760(80)90060-0; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RAO GA, 1966, BIOCHIM BIOPHYS ACTA, V125, P465, DOI 10.1016/0005-2760(66)90035-X; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; SANJANWALA M, 1987, ARCH BIOCHEM BIOPHYS, V258, P299, DOI 10.1016/0003-9861(87)90348-1; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; TANAKA T, 1979, EUR J BIOCHEM, V98, P165, DOI 10.1111/j.1432-1033.1979.tb13173.x	43	51	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13630	13636		10.1074/jbc.270.23.13630	http://dx.doi.org/10.1074/jbc.270.23.13630			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775414	hybrid			2022-12-25	WOS:A1995RC44800010
J	SERRE, L; VERBREE, EC; DAUTER, Z; STUITJE, AR; DEREWENDA, ZS				SERRE, L; VERBREE, EC; DAUTER, Z; STUITJE, AR; DEREWENDA, ZS			THE ESCHERICHIA-COLI MALONYL-COA-ACYL CARRIER PROTEIN TRANSACYLASE AT 1.5-ANGSTROM RESOLUTION - CRYSTAL-STRUCTURE OF A FATTY-ACID SYNTHASE COMPONENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; COENZYME-A; COMPLEX; GENE; BIOSYNTHESIS; SYNTHETASE; EXPRESSION; CDNA	Endogenous fatty acids are synthesized in all organisms in a pathway catalyzed by the fatty acid synthase complex. In bacteria, where the fatty acids are used primarily for incorporation into components of cell membranes, fatty acid synthase is made up of several independent cytoplasmic enzymes, each catalyzing one specific reaction. The initiation of the elongation step, which extends the length of the growing acyl chain by two carbons, requires the transfer of the malonyl moiety from malonyl-CoA onto the acyl carrier protein. We report here the crystal structure (refined at 1.5-Angstrom resolution to an R factor of 0.19) of the malonyl-CoA specific transferase from Escherichia coli. The protein has an alpha/beta type architecture, but its fold is unique. The active site inferred from the location of the catalytic Ser-92 contains a typical nucleophilic elbow as observed in alpha/beta hydrolases. Serine 92 is hydrogen bonded to His-201 in a fashion similar to various serine hydrolases. However, instead of a carboxyl acid typically found in catalytic triads, the main chain carbonyl of Gln-250 serves as a hydrogen bond acceptor in an interaction with His-201. Two other residues, Arg-117 and Glu-11, are also located in the active site, although their function is not clear.	FREE UNIV AMSTERDAM,INST MOLEC BIOL SCI,DEPT GENET,BIOCTR,1081 HV AMSTERDAM,NETHERLANDS; EMBL OUTSTN,D-22603 HAMBURG,GERMANY	Vrije Universiteit Amsterdam; European Molecular Biology Laboratory (EMBL)	SERRE, L (corresponding author), UNIV ALBERTA,DEPT BIOCHEM,MRC,PROT STRUCT & FUNCT GRP,4-74 MED SCI BLDG,EDMONTON,AB T6G 2H7,CANADA.			SERRE, laurence/0000-0002-6794-1492				AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; BAKER PJ, 1990, ACTA CRYSTALLOGR A, V46, P721, DOI 10.1107/S0108767390005153; BLANCHARD H, 1994, J MOL BIOL, V241, P574, DOI 10.1006/jmbi.1994.1532; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BOURNE Y, 1994, J MOL BIOL, V238, P709, DOI 10.1006/jmbi.1994.1331; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; Brunger A. T., 1993, X PLOR MANUAL VERSIO; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; BUCKNER JS, 1978, ARCH BIOCHEM BIOPHYS, V186, P152, DOI 10.1016/0003-9861(78)90474-5; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DEREWENDA U, 1994, NAT STRUCT BIOL, V1, P36, DOI 10.1038/nsb0194-36; DEREWENDA ZS, 1991, BIOCHEM CELL BIOL, V69, P842, DOI 10.1139/o91-125; DIXON MM, 1989, BIOCHEMISTRY-US, V28, P7034; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P6135, DOI 10.1021/bi00416a046; HOLZER KP, 1989, P NATL ACAD SCI USA, V86, P4387, DOI 10.1073/pnas.86.12.4387; JONES TA, 1991, ACTA CRYSTALLOGR A, V97, P110; JOSHI AK, 1993, BIOCHEM J, V296, P143, DOI 10.1042/bj2960143; JOSHI VC, 1971, ARCH BIOCHEM BIOPHYS, V143, P493, DOI 10.1016/0003-9861(71)90234-7; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPUSAS M, 1991, BIOCHEMISTRY-US, V30, P6029; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; LAMZIN VS, 1990, ACTA CRYSTALLOGR D, V49, P129; LASKOWSKI RA, 1992, PROCHECK VERSION 2 P; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MARSDEN AFA, 1994, SCIENCE, V263, P378, DOI 10.1126/science.8278811; MATHUR M, 1992, J BIOL CHEM, V267, P19388; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PETROVICS G, 1993, MOL MICROBIOL, V8, P1083, DOI 10.1111/j.1365-2958.1993.tb01653.x; RANGAN VS, 1991, J BIOL CHEM, V266, P19180; RUCH FE, 1973, J BIOL CHEM, V248, P8080; SERRE L, 1994, J MOL BIOL, V242, P99, DOI 10.1006/jmbi.1994.1559; SHEN B, 1994, SCIENCE, V262, P1535; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SMITH S, 1985, EUR J BIOCHEM, V152, P547, DOI 10.1111/j.1432-1033.1985.tb09230.x; VERWOERT IIGS, 1992, J BACTERIOL, V174, P2851, DOI 10.1128/JB.174.9.2851-2857.1992; WEI YY, 1995, NAT STRUCT BIOL, V2, P218, DOI 10.1038/nsb0395-218; WILLIAMS.IP, 1966, J BIOL CHEM, V241, P2326; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; 1988, CCP4 SUITE PROGRAMS	42	156	163	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					12961	12964		10.1074/jbc.270.22.12961	http://dx.doi.org/10.1074/jbc.270.22.12961			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768883	hybrid			2022-12-25	WOS:A1995RB43900004
J	TEZAPSIDIS, N; NOCTOR, S; KANNAN, R; KRIEGER, TJ; MENDEMUELLER, L; HOOK, VYH				TEZAPSIDIS, N; NOCTOR, S; KANNAN, R; KRIEGER, TJ; MENDEMUELLER, L; HOOK, VYH			STIMULATION OF PROHORMONE THIOL PROTEASE (PTP) AND [MET]ENKEPHALIN BY FORSKOLIN - BLOCKADE OF ELEVATED [MET]ENKEPHALIN BY A CYSTEINE PROTEASE INHIBITOR OF PTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-PROCESSING ENZYME; LOBE SECRETORY VESICLES; ENKEPHALIN PRECURSOR; CHROMAFFIN CELLS; CYCLIC-AMP; SUBTILISIN FAMILY; CONVERTING ENZYME; ADRENAL-MEDULLA; MESSENGER-RNA; PURIFICATION	Proenkephalin and other prohormones require proteolytic processing at paired basic and monobasic residues for the biosynthesis of active neuropeptides. The novel ''prohormone thiol protease'' (PTP) has been proposed as a candidate proenkephalin processing enzyme for the production of [Met]enkephalin in chromaffin granules (Krieger, T. J., and Hook, V. Y. H. (1991) J. Biol. Chem. 266, 88376-8383). In this study, PTP was examined during elevation of cellular [Met]enkephalin by forskolin, a direct activator of adenylate cyclase that produces cAMP. Treatment of chromaffin cells with forskolin for 72 h increased enkephalin precursor cleaving activity (measured by following the conversion of the model substrate [S-35-Met]preproenkephalin to trichloroacetic acid-soluble radioactivity) in isolated chromaffin granules by 170-180% over controls (100%). The increased activity was associated with the membrane fraction, rather than the soluble fraction, of chromaffin granules. The elevated activity was inhibited by E-64c, which is a potent inhibitor of PTP and cysteine proteases; however, the activity was not inhibited by serine or aspartic protease inhibitors. The elevated activity was identified as PTP based on immunoprecipitation by anti-PTP immunoglobulins. Stimulation of PTP synthesis was involved in the forskolin-induced increase in PTP activity, as demonstrated by a 10 fold increase in [S-35]PTP pulse labeling in forskolin-treated chromaffin cells. Forskolin elevation of PTP protein levels within chromaffin granules was also detected in Western blots. Importantly, the forskolin-mediated rise in cellular [Met]enkephalin levels was completely blocked when cells were preincubated with the cysteine protease inhibitor Ep453, which is known to be converted by intracellular esterases to the more effective inhibitor E-64c (Buttle, D. J., Saklatvala, J., Tamai, M., and Barrett, A. J. (1992) Biochem. J. 281, 175-177). Both E-64c and Ep453 inhibit PTP, with E-64c being more potent (Azaryan, A. V., and Hook, V. Y. H. (1994b) Arch. Biochem. Biophys. 314, 171-177). These results demonstrate a role for PTP in proenkephalin processing in chromaffin cells and indicate that [Met] enkephalin formation and PTP are both regulated by cAMP.	UNIV CALIF SAN DIEGO,MED CTR,DEPT MED,SAN DIEGO,CA 92103; UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814; MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	University of California System; University of California San Diego; Uniformed Services University of the Health Sciences - USA; Medical College of Wisconsin								AZARYAN AV, 1994, FEBS LETT, V341, P197, DOI 10.1016/0014-5793(94)80456-7; AZARYAN AV, 1994, ARCH BIOCHEM BIOPHYS, V314, P171, DOI 10.1006/abbi.1994.1426; AZARYAN AV, 1995, J BIOL CHEM, V270, P8201, DOI 10.1074/jbc.270.14.8201; AZARYAN AV, 1995, IN PRESS J NEUROCHEM; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BUTTLE DJ, 1992, BIOCHEM J, V281, P175, DOI 10.1042/bj2810175; CARMICHAEL SW, 1990, NEUROSCIENCE, V34, P433, DOI 10.1016/0306-4522(90)90152-T; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; EIDEN LE, 1984, P NATL ACAD SCI-BIOL, V81, P3949, DOI 10.1073/pnas.81.13.3949; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; HOOK VYH, 1993, J BIOL CHEM, V268, P20570; HOOK VYH, 1985, J BIOL CHEM, V260, P5991; HOOK VYH, 1985, P NATL ACAD SCI USA, V82, P4745, DOI 10.1073/pnas.82.14.4745; KONRADI C, 1993, P NATL ACAD SCI USA, V90, P7005, DOI 10.1073/pnas.90.15.7005; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; KRIEGER TJ, 1992, J NEUROCHEM, V59, P26, DOI 10.1111/j.1471-4159.1992.tb08871.x; LOH YP, 1985, J BIOL CHEM, V260, P7194; LUNDBERG JM, 1979, P NATL ACAD SCI USA, V76, P4079, DOI 10.1073/pnas.76.8.4079; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; PARISH DC, 1986, J BIOL CHEM, V261, P4392; POLLARD HB, 1978, J BIOL CHEM, V254, P1170; SCHILLER MR, 1995, IN PRESS BIOCHEMISTR; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; STEINER DF, 1992, J BIOL CHEM, V267, P23435; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; WAN DC, 1991, MOL BRAIN RES, V9, P135, DOI 10.1016/0169-328X(91)90138-N; YOSHIKAWA K, 1984, J BIOL CHEM, V259, P4301	29	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13285	13290		10.1074/jbc.270.22.13285	http://dx.doi.org/10.1074/jbc.270.22.13285			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768928	hybrid			2022-12-25	WOS:A1995RB43900052
J	WHITE, CB; CHEN, Q; KENYON, GL; BABBITT, PC				WHITE, CB; CHEN, Q; KENYON, GL; BABBITT, PC			A NOVEL ACTIVITY OF OMPT - PROTEOLYSIS UNDER EXTREME DENATURING CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI OUTER-MEMBRANE; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; FUSION PROTEINS; CREATINE-KINASE; CLEAVAGE SITE; PROTEASE; GENE; PURIFICATION; TRANSPORT	A novel property of the bacterial outer membrane protein T, OmpT, has been discovered. It is active under extreme denaturing conditions. This finding emerged during characterization of a protease associated with the degradation of recombinant proteins expressed as inclusion bodies in Escherichia coli. These inclusion body proteins are stable to proteolytic degradation until they are solubilized by denaturation. The protease that degrades them under denaturing conditions was identified as OmpT on the basis of substrate specificity, inhibitor profile, and confirmation that its N-terminal sequence is identical with that of OmpT. A previously unknown property of this enzyme, OmpT's preference for denatured substrates, may provide a clue to its physiological function. To facilitate further characterization of this proteolytic activity, we have optimized a system to extract and assay OmpT under denaturing conditions using a soluble substrate, rabbit muscle creatine.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF DAVIS,DEPT FOOD SCI,DAVIS,CA 95616	University of California System; University of California San Francisco; University of California System; University of California Davis					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017323, R01AR017323] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR17323] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABBITT PC, 1990, BIO-TECHNOL, V8, P945, DOI 10.1038/nbt1090-945; BABBITT PC, 1992, FASEB J, V6, pA325; BABBITT PC, 1991, PROTEIN REFOLDING, P154; BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; BELEW M, 1970, METHODS ENZYMOLOGY P, P576; CERRITELLI SM, 1993, BIOCHIMIE, V75, P107, DOI 10.1016/0300-9084(93)90031-M; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GRODBERG J, 1988, NUCLEIC ACIDS RES, V16, P1209, DOI 10.1093/nar/16.3.1209; HANKE C, 1992, MOL GEN GENET, V233, P42, DOI 10.1007/BF00587559; HARRIS JI, 1956, NATURE, V177, P471, DOI 10.1038/177471a0; HATZFELD M, 1992, FEBS LETT, V302, P239, DOI 10.1016/0014-5793(92)80450-U; INOKUCHI K, 1982, NUCLEIC ACIDS RES, V10, P6957, DOI 10.1093/nar/10.21.6957; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KLAUSER T, 1992, EMBO J, V11, P2327, DOI 10.1002/j.1460-2075.1992.tb05292.x; LASSEN SF, 1992, BIOCHEM INT, V27, P601; LEYTUS SP, 1981, P NATL ACAD SCI-BIOL, V78, P1485, DOI 10.1073/pnas.78.3.1485; LUNDRIGAN MD, 1992, FEMS MICROBIOL LETT, V97, P51; MANNING PA, 1977, FEMS MICROBIOL LETT, V1, P275, DOI 10.1111/j.1574-6968.1977.tb00631.x; MATSUBARA H, 1970, METHOD ENZYMOL, P642; MIZUNO T, 1983, J BIOL CHEM, V258, P6932; MUTOH N, 1982, FEBS LETT, V137, P171, DOI 10.1016/0014-5793(82)80341-4; OTTENSEN M, 1970, METHODS ENZYMOLOGY P, P199; PRESCOTT JM, 1970, METHODS ENZYMOLOGY P, P530; QIZHI Y, 1985, SCI SIN B, V28, P484; QIZHI Y, 1982, SCI SINICA, V25, P1296; RONCARI G, 1976, METHODS ENZYMOLOGY P, P522; SHAPIRA E, 1969, J BIOL CHEM, V244, P1026; SUGIMURA K, 1988, J BACTERIOL, V170, P5625, DOI 10.1128/jb.170.12.5625-5632.1988; SUGIMURA K, 1988, J BACTERIOL, V170, P3650, DOI 10.1128/jb.170.8.3650-3654.1988; TANZER ML, 1959, J BIOL CHEM, V234, P3201; ZHAO GP, 1993, J BIOL CHEM, V268, P14912; ZHOU HM, 1986, BIOCHIM BIOPHYS ACTA, V869, P69, DOI 10.1016/0167-4838(86)90311-0	32	44	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					12990	12994		10.1074/jbc.270.22.12990	http://dx.doi.org/10.1074/jbc.270.22.12990			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768890	hybrid			2022-12-25	WOS:A1995RB43900011
J	YADA, Y; HIGUCHI, K; IMOKAWA, G				YADA, Y; HIGUCHI, K; IMOKAWA, G			PURIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF MEMBRANE-BOUND EPIDERMAL CERAMIDASES FROM GUINEA-PIG SKIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; LEUKEMIA HL-60 CELLS; LONG-CHAIN BASES; SIGNAL TRANSDUCTION; PORCINE EPIDERMIS; BETA-GLUCOSIDASE; GAUCHER DISEASE; PHORBOL ESTERS; SPHINGOSINE	Ceramidase (CDase) catalyzes the hydrolysis of ceramides to yield sphingosine and fatty acid, In this paper, two forms of membrane bound alkaline ceramidase, have been, for the first time, purified from guinea pig epidermis by chromatography on DEAE-cellulose, phenyl-Superose, HCA-hyroxyapatite, isoelectric focusing, Mono Q, and TSK-3000SW column, One species (CDase-I) migrated upon SDS-polyacrylamide gel electrophoresis as a single band with an apparent molecular mass of 60 kDa; the other (CDase-II) was only partially purified with apparent M(r) of about 148,000 estimated by gel filtration. The specific activities of the two species increased by 1.130- (for CDase-I) and 400-fold (for CDase-II) over the original tissue extract. The activity of both enzymes for ceramide species decreased in the order of linoleoyl > oleoyl > palmitoylsphingosine. The optimal pH for enzyme activity was approximately 7.0-9.0 for CDase-I and 7.5-8.5 for CDase-II, Interestingly, both enzymes were inhibited by the reaction product sphingosine with a concentration for half-maximal inhibition (ID50) of 100-130 mu M, compared to the apparent kinetic parameters with CDase-I (K-m = 90 mu M, V-max = 0.62 unit) and CDase-II (K-m = 140 mu M, V-max = 0.50 units). Some lipids, such as phosphatidylcholine and sphingomyelin, are also inhibitory with IC50 values of 50-250 mu M, suggesting well controlled CDase activity by sphingolipid metabolites. These studies begin to elucidate a regulatory mechanism for the balance of the ratio of ceramide/sphingosine which can serve as an intracellular effector molecule in epidermis.	KAO CORP,INST FUNDAMENTAL RES,HAGO,TOCHIGI 32134,JAPAN	KAO Corporation								AL BJM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P245, DOI 10.1016/0005-2760(89)90274-9; ANDERSON DS, 1951, BRIT J DERMATOL, V63, P283, DOI 10.1111/j.1365-2133.1951.tb13728.x; BALLOU LR, 1992, IMMUNOL TODAY, V13, P339, DOI 10.1016/0167-5699(92)90167-6; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BLANK IRVIN H., 1939, JOUR INVEST DERMAL, V2, P231; BREMER EG, 1986, J BIOL CHEM, V261, P2434; DOLE VPJ, 1956, CLIN INVESTIGATOR, V35, P350; ELIAS PM, 1975, J CELL BIOL, V65, P180, DOI 10.1083/jcb.65.1.180; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; GATT S, 1966, J BIOL CHEM, V241, P3724; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; IMOKAWA G, 1986, J INVEST DERMATOL, V87, P758, DOI 10.1111/1523-1747.ep12456950; IMOKAWA G, 1985, J INVEST DERMATOL, V83, P282; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARET A, 1983, FEBS LETT, V160, P93, DOI 10.1016/0014-5793(83)80943-0; MARET A, 1984, BIOCHIM BIOPHYS ACTA, V799, P91, DOI 10.1016/0304-4165(84)90330-1; MELTON JL, 1987, BIOCHIM BIOPHYS ACTA, V921, P191, DOI 10.1016/0005-2760(87)90018-X; MERRILL AH, 1992, NUTR REV, V50, P78; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; NILSSON A, 1969, BIOCHIM BIOPHYS ACTA, V176, P339, DOI 10.1016/0005-2760(69)90192-1; NUTTER LM, 1987, CANCER RES, V47, P4407; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OISHI K, 1988, J BIOL CHEM, V263, P6865; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; ROSENWALD AG, 1993, J BIOL CHEM, V268, P4577; SHAPIRO D, 1961, J AM CHEM SOC, V83, P3327, DOI 10.1021/ja01476a033; STEVENS VL, 1989, CANCER RES, V49, P3229; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; WERTZ PW, 1990, FEBS LETT, V268, P110, DOI 10.1016/0014-5793(90)80985-R; WERTZ PW, 1987, J INVEST DERMATOL, V89, P419, DOI 10.1111/1523-1747.ep12471781; WERTZ PW, 1989, BIOCHIM BIOPHYS ACTA, V1002, P213, DOI 10.1016/0005-2760(89)90289-0; WERTZ PW, 1990, J INVEST DERMATOL, V94, P159, DOI 10.1111/1523-1747.ep12874122; WILSON E, 1986, J BIOL CHEM, V261, P2616; YADA Y, 1991, BIOCHEM J, V279, P665, DOI 10.1042/bj2790665; YAVIN E, 1969, BIOCHEMISTRY-US, V8, P1692, DOI 10.1021/bi00832a052	43	56	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12677	12684		10.1074/jbc.270.21.12677	http://dx.doi.org/10.1074/jbc.270.21.12677			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759519	hybrid			2022-12-25	WOS:A1995QZ71100055
J	DEBOER, CJ; VANKRIEKEN, JHJM; KLUINNELEMANS, HC; KLUIN, PM; SCHUURING, E				DEBOER, CJ; VANKRIEKEN, JHJM; KLUINNELEMANS, HC; KLUIN, PM; SCHUURING, E			CYCLIN D1 MESSENGER-RNA OVEREXPRESSION AS A MARKER FOR MANTLE CELL LYMPHOMA	ONCOGENE			English	Article						MANTLE CELL LYMPHOMA; 11Q13; BCL-1; PRAD1; CCND1; NHL	GENOMIC ORGANIZATION; CENTROCYTIC LYMPHOMA; GENE REARRANGEMENT; CHROMOSOME 11Q13; EXPRESSION; TRANSLOCATION; BREAKPOINTS; LEUKEMIA; CLONING; LINES	In mantle cell lymphoma (MCL) a recurrent chromosomal rearrangement, t(11;14)(q13;q32), has been described. Most breakpoints have been detected within the 120 kb BCL-1 region, upstream of the cyclin D1 gene. To evaluate the association between BCL-1 rearrangement and expression of cyclin D1 in lymphoproliferative disorders, we analysed a series of 24 MCL, 56 other B-cell non-Hodgkin's lymphomas (NHL), 28 chronic B-cell leukemias, 18 hematopoietic cell lines and 10 normal lymphoid tissues at the RNA level. Hematopoietic cell lines with a known 11q13 translocation showed high expression of the 4.5 kb cyclin D1 transcript. Three B-cell lines without known 11q13 breakpoint showed low expression. We detected high expression in all (11/11) MCL with and in 11 out of 13 cases of MCL without detectable t(11;14) rearrangement. In three cases with a rearrangement at the 3' end of cyclin D1, two showed overexpression of the 1.5 kb transcript and one expression of an aberrant (3.0 kb) transcript. In other lymphoproliferative disorders, only 5/15 hairy cell leukemias, all without detectable t(11;14), and 5/8 B-cell leukemias suspected to be MCL in leukemic phase showed expression levels comparable to MCL, whereas no or only low expression were observed in 56 cases of other NHL, seven chronic B-cell leukemias and all (10/10) normal lymphoid tissues. Cell sorting experiments on fresh tonsils showed that this low expression was present in normal B-cells and not in T-cells. In contrast to other studies, our data indicate that cyclin D1 is expressed in many lymphoproliferative disorders and normal tissues, albeit at low levels. High levels of expression of cyclin D1 however is restricted to MCL and some hairy cell leukemias. We therefore propose that overexpression of cyclin D1 is a reliable marker for the classification of MCL.	LEIDEN UNIV,ACAD HOSP LEIDEN,DEPT PATHOL,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV,ACAD HOSP LEIDEN,DEPT HEMATOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC			Kluin-Nelemans, Johanna C/F-8658-2018; van Krieken, Joannes H J M/D-4138-2009	Kluin-Nelemans, Johanna C/0000-0003-2617-9427; van Krieken, Joannes H J M/0000-0001-6544-1040				AKIYAMA N, 1994, CANCER RES, V54, P377; BANKS PM, 1992, AM J SURG PATHOL, V16, P637, DOI 10.1097/00000478-199207000-00001; BATES S, 1994, ONCOGENE, V9, P1633; BONTROP RE, 1986, TISSUE ANTIGENS, V27, P22; BOSCH F, 1994, BLOOD, V84, P2726; BOSCH ML, 1987, HUM IMMUNOL, V19, P91, DOI 10.1016/0198-8859(87)90097-8; DEBOER CJ, 1993, CANCER RES, V53, P4148; DEKROON JFE, 1992, BLOOD S1, V80, pA436; FALKENBURG JHF, 1986, EXP HEMATOL, V14, P101; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JADAYEL D, 1994, BLOOD, V83, P3664; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KLUINNELEMANS HC, 1991, LEUKEMIA, V5, P221; KLUINNELEMANS JC, 1994, LEUKEMIA, V8, P2095; KLUINNELEMANS JC, 1994, BLOOD, V84, P3134; KOEFFLER HP, 1980, BLOOD, V56, P344; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LANGE B, 1987, BLOOD, V70, P192; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MELO JV, 1986, INT J CANCER, V38, P531, DOI 10.1002/ijc.2910380413; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; NACHEVA E, 1990, BRIT J HAEMATOL, V74, P70, DOI 10.1111/j.1365-2141.1990.tb02540.x; OKA K, 1994, BRIT J HAEMATOL, V86, P786, DOI 10.1111/j.1365-2141.1994.tb04830.x; RAFFELD M, 1992, LEUKEMIA LYMPHOMA, V8, P161, DOI 10.3109/10428199209054902; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; RIMOKH R, 1994, BLOOD, V83, P3689; RIMOKH R, 1993, BLOOD, V81, P3063; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, ONCOGENE, V7, P355; SCHUURING E, 1995, IN PRESS GENE; SETO M, 1992, ONCOGENE, V7, P1401; TAM SW, 1994, ONCOGENE, V9, P2663; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WILLIAMS ME, 1994, ANN ONCOL, V5, pS71, DOI 10.1093/annonc/5.suppl_1.S71; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZUCCA E, 1994, ANN ONCOL, V5, P507, DOI 10.1093/oxfordjournals.annonc.a058904; ZUCCA E, 1994, LEUKEMIA LYMPHOMA, V13, P105, DOI 10.3109/10428199409051659	43	103	104	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1833	1840						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753558				2022-12-25	WOS:A1995QX46900016
J	JIANG, HP; LIN, J; SU, ZZ; HERLYN, M; KERBEL, RS; WEISSMAN, BE; WELCH, DR; FISHER, PB				JIANG, HP; LIN, J; SU, ZZ; HERLYN, M; KERBEL, RS; WEISSMAN, BE; WELCH, DR; FISHER, PB			THE MELANOMA DIFFERENTIATION-ASSOCIATED GENE MDA-6, WHICH ENCODES THE CYCLIN-DEPENDENT KINASE INHIBITOR P21, IS DIFFERENTIALLY EXPRESSED DURING GROWTH, DIFFERENTIATION AND PROGRESSION IN HUMAN-MELANOMA CELLS	ONCOGENE			English	Article						TERMINAL CELL DIFFERENTIATION; GROWTH CONTROL; MATRIGEL-ASSISTED PROGRESSION; METASTASIS SUPPRESSION	HUMAN-MALIGNANT MELANOMA; GLIOBLASTOMA-MULTIFORME CELLS; RECOMBINANT HUMAN FIBROBLAST; POLYMERASE CHAIN-REACTION; WILD-TYPE P53; ANTIGENIC PHENOTYPE; TRANSFORMED PHENOTYPE; IMMUNE INTERFERON; MESSENGER-RNA; SUPPRESSION	The combination of recombinant human fibroblast interferon (IFN-beta) and the antileukemic compound mezerein (MEZ) induces terminal differentiation with an irreversible loss of proliferative capacity in human melanoma cells, Using subtraction hybridization, cDNAs were identified that display enhanced expression in terminally differentiated and growth arrested human melanoma cells (Jiang and Fisher, 1993; Jiang et al., 1994a), A specific melanoma differentiation-associated (mda) cDNA, mda-6, is described whose expression inversely correlates with melanoma progression and growth, mda-6 is identical to WAF1/CIP1/SDI1 that encodes the M-r 21 000 protein (p21) that is an inhibitor of cyclin-dependent kinases, Actively growing normal melanocyte, SV40-immortalized human melanocyte and dysplastic nevus cell. lines synthesize elevated levels of mda-6 mRNA; whereas, actively proliferating radial and early vertical growth phase primary melanomas as well as metastatic human melanoma cells produce reduced levels of mda-6 mRNA, Treatment of primary and metastatic human melanoma cells with IFN-beta+MEZ results in growth inhibition and an increase in mda-6 expression, mda-6 expression also increases when human melanoma cells are grown to high saturation densities or when grown in serum-free medium, Using anti-p53 and anti-p21 antibodies, an inverse correlation is found between p53 and p21 protein levels during growth arrest and differentiation, Induction of growth arrest and terminal differentiation in H0-1 human melanoma cells by IFN-beta+MEZ results in a temporal decrease in wildtype p53 protein levels with a corresponding increase in p21 levels, In the Matrigel-assisted melanoma progression model, mda-6 expression decreases in early vertical growth phase primary human melanoma cells selected for autonomous or enhanced tumor formation in nude mice, In metastatic human melanoma cells displaying a loss of metastatic potential resulting from introduction of a normal human chromosome 6, mda-6 mRNA levels increase, Taken together, these studies indicate that mda-6 (p21) may function as a negative regulator of melanoma growth, progression and metastasis.	COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES,DEPT PATHOL, CTR COMPREHENS CANC, NEW YORK, NY 10027 USA; COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES,DEPT UROL, CTR COMPREHENS CANC, NEW YORK, NY 10027 USA; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; SUNNYBROOK HLTH SCI CTR, DIV CANC RES, TORONTO, ON M4N 3M5, CANADA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; PENN STATE UNIV, COLL MED,MILTON S HERSHEY MED CTR,DEPT PATHOL, DIV EXPTL PATHOL, HERSHEY, PA 17033 USA	Columbia University; Columbia University; The Wistar Institute; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NCI NIH HHS [CA43208, CA35675, CA25874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043208, P01CA025874, R01CA035675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1986, ANTICANCER RES, V6, P765; FISHER PB, 1991, STATUS DIFFERENTIATI, V2, P201; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUARINI L, 1992, PIGM CELL RES, P123; GUARINI L, 1989, CANCER IMMUNOL IMMUN, V30, P262, DOI 10.1007/BF01744892; HARPER JW, 1993, CELL, V75, P805; HAYES TE, 1991, NEW BIOL, V3, P259; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1992, INT J ONCOL, V1, P227; JIMENEZ JJ, 1987, SCIENCE, V238, P1278, DOI 10.1126/science.3685979; Kerbel R S, 1990, Adv Cancer Res, V55, P87, DOI 10.1016/S0065-230X(08)60469-8; KHOCHBIN S, 1988, J MOL BIOL, V200, P55, DOI 10.1016/0022-2836(88)90333-6; KOBAYASHI H, 1994, AM J PATHOL, V144, P776; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI Y, 1994, ONCOGENE, V9, P2261; LIN J, 1994, INT J ONCOL, V5, P5; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Loganzo Frank Jr., 1994, Molecular and Cellular Differentiation, V2, P23; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LOTAN R, 1993, RETINOIDS ONCOLOGY, P43; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; MANCIANTI ML, 1988, J INVEST DERMATOL, V90, P134, DOI 10.1111/1523-1747.ep12462099; MELBER K, 1989, CANCER RES, V49, P3650; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MICHIELI P, 1994, CANCER RES, V54, P3391; MILLIKIN D, 1991, CANCER RES, V51, P5449; MONTANO X, 1994, ONCOGENE, V9, P1455; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; REDDY PG, 1991, J NATL CANCER I, V83, P1307, DOI 10.1093/jnci/83.18.1307; RICHON VM, 1989, ONCOGENE, V4, P165; RON D, 1994, P NATL ACAD SCI USA, V91, P1985, DOI 10.1073/pnas.91.6.1985; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN DW, 1983, P NATL ACAD SCI-BIOL, V80, P5919, DOI 10.1073/pnas.80.19.5919; SHOBAT O, 1987, ONCOGENE, V1, P277; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SU ZZ, 1991, MOL CARCINOGEN, V4, P231, DOI 10.1002/mc.2940040310; SU ZZ, 1993, CANCER RES, V53, P1929; TOKUNAGA K, 1987, CANCER RES, V47, P5616; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAXMAN S, 1988, STATUS DIFFERENTIATI, V1; WAXMAN S, 1991, STATUS DIFFERENTIATI, V2; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WELCH DR, 1994, ONCOGENE, V9, P255; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	73	181	192	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1855	1864						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753561				2022-12-25	WOS:A1995QX46900019
J	KLUG, A; SCHWABE, JWR				KLUG, A; SCHWABE, JWR			PROTEIN MOTIFS .5. ZINC FINGERS	FASEB JOURNAL			English	Review						AUTONOMOUS FOLDING; DNA BINDING; TRANSCRIPTION FACTOR; MINIDOMAIN	DNA-BINDING DOMAIN; TRANSCRIPTION FACTOR-IIIA; CRYSTAL-STRUCTURE; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURE; NUCLEOCAPSID PROTEIN; NMR STRUCTURE; COMPLEX	The term zinc finger was first used to describe a 30-residue, repeated sequence motif found in an unusually abundant Xenopus transcription factor, It was proposed that each motif is folded around a central zinc ion to form an independent minidomain and that adjacent zinc fingers are combined as modules to make up a DNA-binding domain with the modules ''gripping'' the DNA (hence the term finger), We now know that these proposals were correct and that these DNA-binding motifs are found in many eukaryotic DNA-binding proteins. More recently, crystal structures of three different complexes between zinc finger domains and their target DNA binding sites have revealed a remarkably simple mode of interaction with DNA. The simplicity of the zinc finger structure, and of its interaction with DNA, is a very striking feature of this protein domain, After the discovery of the zinc finger motif, patterns of potential zinc ligands have been found in several other proteins, some of which also bind to DNA. Structural studies of these domains have revealed how zinc can stabilize quite diverse protein architectures, In total, 10 such small zinc-binding domains have been studied structurally. These form a diverse collection, but each in turn has been termed a zinc finger motif-although clearly what they have in common is only their zinc-binding property, which stabilizes an apparently autonomously folded unit.			KLUG, A (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Schwabe, John WR/A-9132-2008	Schwabe, John WR/0000-0003-2865-4383				BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; CHOO Y, 1994, IN PRES P NATL ACAD; CHOO Y, 1994, IN PRESS NATURE; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; FAIRALL L, 1992, NUCLEIC ACIDS RES, V20, P4727, DOI 10.1093/nar/20.18.4727; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FOURMY D, 1993, J MOL BIOL, V231, P1078, DOI 10.1006/jmbi.1993.1353; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KNEGTEL RM, 1993, J BIOMOL NMR, V1, P1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MERIC C, 1989, J VIROL, V63, P1558; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAKASEKO Y, 1992, J MOL BIOL, V228, P619, DOI 10.1016/0022-2836(92)90845-B; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; NEKLUDOVA L, 1994, P NATL ACAD SCI USA, V91, P6948, DOI 10.1073/pnas.91.15.6948; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1993, STRUCTURE, V1, P187, DOI 10.1016/0969-2126(93)90020-H; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SOUTH TL, 1993, PROTEIN SCI, V2, P3; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2	52	511	617	3	58	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					597	604		10.1096/fasebj.9.8.7768350	http://dx.doi.org/10.1096/fasebj.9.8.7768350			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768350				2022-12-25	WOS:A1995RC10600004
J	LACRONIQUE, V; LOPEZ, S; MIQUEROL, L; PORTEU, A; KAHN, A; RAYMONDJEAN, M				LACRONIQUE, V; LOPEZ, S; MIQUEROL, L; PORTEU, A; KAHN, A; RAYMONDJEAN, M			IDENTIFICATION AND FUNCTIONAL-CHARACTERIZATION OF AN ERYTHROID-SPECIFIC ENHANCER IN THE L-TYPE PYRUVATE-KINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; PORPHOBILINOGEN DEAMINASE GENE; TRANSCRIPTION FACTOR; TRANSGENIC MICE; GLOBIN GENE; BETA-GLOBIN; REGULATORY ELEMENT; DNA INTERACTIONS; INVIVO PROTEIN; CACCC ELEMENT	The rat L-type pyruvate kinase gene is transcribed either from promoter L in the liver or promoter L' in erythroid cells. We have now cloned and functionally characterized an erythroid-specific enhancer, mapped in the fetal liver as hypersensitive site B (HSSB) at 3.7 kilobases upstream from the promoter L'. Protein-DNA interactions were examined in the 200-base pair core of the site by in vivo footprinting experiments. In the fetal liver, footprints were revealed at multiple GATA and CACC/GT motifs, whose association is the hallmark of erythroid-specific regulatory sequences. Functional analysis of the HSSB element in transgenic mice revealed properties of a cell-restricted enhancer. Indeed, this element was able to activate the linked ubiquitous herpes simplex virus thymidine kinase promoter in erythroid tissues. The activation was also observed in a variety of nonerythroid tissues known to synthesize GATA-binding factors. In the context of L'-PK transgenes, HSSB was not needed for an erythroid-specific activation of the L' promoter, while it was required to stimulate the L' promoter activity to a proper level. Finally, HSSB cannot be replaced by strong ubiquitous viral or cellular enhancers, suggesting a preferential interaction of the HSSB region with the L' promoter.	UNIV PARIS 05,INST COCHIN GENET MOLEC,INSERM,U129,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Penard-Lacronique, Virginie/R-1938-2019; Penard-Lacronique, Virginie/E-5729-2016	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331				ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BOQUET D, 1992, EUR J BIOCHEM, V207, P13, DOI 10.1111/j.1432-1033.1992.tb17013.x; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CARTIER N, 1992, ONCOGENE, V7, P1413; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONCORDET JP, 1991, NUCLEIC ACIDS RES, V19, P4173, DOI 10.1093/nar/19.15.4173; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; FISHER KD, 1993, J BIOL CHEM, V268, P23915; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GALLARDA JL, 1989, GENE DEV, V3, P845; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; KAHN A, 1982, METHOD ENZYMOL, V90, P131; KELLEY C, 1993, DEVELOPMENT, V118, P817; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LACRONIQUE V, 1992, NUCLEIC ACIDS RES, V20, P5669, DOI 10.1093/nar/20.21.5669; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; ORKIN SH, 1992, BLOOD, V80, P575; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; PURUCKER M, 1990, NUCLEIC ACIDS RES, V18, P7407, DOI 10.1093/nar/18.24.7407; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; SHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90; SON HJ, 1991, MOL CELL BIOL, V11, P4244, DOI 10.1128/MCB.11.8.4244; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TALBOT D, 1989, NATURE, V338, P1384; TREMP GL, 1989, J BIOL CHEM, V264, P19904; TSAI SF, 1994, NATURE, V371, P221; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG ZY, 1994, J BIOL CHEM, V269, P10079	51	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14989	14997		10.1074/jbc.270.25.14989	http://dx.doi.org/10.1074/jbc.270.25.14989			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797480	hybrid			2022-12-25	WOS:A1995RE66600025
J	APTE, SS; OLSEN, BR; MURPHY, G				APTE, SS; OLSEN, BR; MURPHY, G			THE GENE STRUCTURE OF TISSUE INHIBITOR OF METALLOPROTEINASES (TIMP)-3 AND ITS INHIBITORY ACTIVITIES DEFINE THE DISTINCT TIMP GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN-EMBRYO FIBROBLASTS; DEVELOPMENTAL EXPRESSION; TERMINAL DOMAIN; TRANSFORMATION; PURIFICATION; FLUID	Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) play a critical role in extracellular matrix homeostasis. We have previously cloned human and mouse TIMP-3 cDNAs and mapped their chromosomal loci (Apte, S. S., Mattei, M-G., and Olsen, B. R. (1994) Genomics 19, 86-90; Apte, S. S., Hayashi, K., Seldin, M. F., Mattei, M-G;., Hayashi, M., and Olsen, B. R. (1994) Dev. Dynam. 200, 177-197); the identification of TIMP3 mutations in Sorsby's fundus dystrophy has underscored the functional importance! of TIMP-3. We now report that TIMP-3 is encoded by five exons spanning over 30 kilobase pairs of mouse genomic DNA. In the attribution of protein domains to specific exons, as well as exon structures, the Timp-3 and Timp-1 genes are similar, confirming the common evolutionary origin of the TIMPs and defining a distinct gene family. We have expressed human and mouse TIMP-3 in mouse NSO myeloma cells. In each case, an N-glycosylated. 27-kDa protein was generated, that, like TIMP-1 and TIMP-2, inhibited collagenase-1, stromelysin-1, and gelatinases A and B. TIMP-3 and TIMP-1 inhibition were quantitatively similar, implying that all TIMPs are equally efficient in MMP inhibition. Instead, differential regulation of the TIMP genes or divergent C-terminal protein sequences may underlie distinct biological functions for each TIMP.	STRANGEWAYS RES LAB,DEPT CELL & MOLEC BIOL,CAMBRIDGE CB1 4RN,ENGLAND		APTE, SS (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.			Apte, Suneel/0000-0001-8441-1226	NHLBI NIH HHS [HL33014] Funding Source: Medline; NIAMS NIH HHS [AR36819, AR36820] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036819, R37AR036820, R56AR036819, R01AR036820, R37AR036819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; APTE SS, 1994, DEV DYNAM, V200, P177, DOI 10.1002/aja.1002000302; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; BLENIS J, 1983, P NATL ACAD SCI-BIOL, V80, P770, DOI 10.1073/pnas.80.3.770; BODDEN MK, 1994, J BIOL CHEM, V269, P18943; COULOMBE B, 1988, MOL CELL BIOL, V8, P3227, DOI 10.1128/MCB.8.8.3227; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; GEWERT DR, 1987, EMBO J, V6, P651, DOI 10.1002/j.1460-2075.1987.tb04804.x; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; JONES SE, 1994, FEBS LETT, V352, P171, DOI 10.1016/0014-5793(94)00951-1; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Liotta L A, 1990, Semin Cancer Biol, V1, P99; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1981, BIOCHEM J, V195, P167, DOI 10.1042/bj1950167; MURPHY G, 1985, BIOCHIM BIOPHYS ACTA, V839, P214, DOI 10.1016/0304-4165(85)90039-X; NOMURA S, 1989, DEVELOPMENT, V105, P575; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; PELLETIER JP, 1990, ARTHRITIS RHEUM, V33, P1466, DOI 10.1002/art.1780331003; REPONEN P, 1995, DEV DYNAM, V202, P388, DOI 10.1002/aja.1002020408; SILBIGER SM, 1994, GENE, V141, P293, DOI 10.1016/0378-1119(94)90588-6; SUN Y, 1994, CANCER RES, V54, P1139; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Werb Z, 1992, Matrix Suppl, V1, P337; WICK M, 1994, J BIOL CHEM, V269, P18953; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676	35	279	289	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14313	14318		10.1074/jbc.270.24.14313	http://dx.doi.org/10.1074/jbc.270.24.14313			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782289	hybrid			2022-12-25	WOS:A1995RD45500015
J	BOUABOULA, M; BOURRIE, B; RINALDICARMONA, M; SHIRE, D; LEFUR, G; CASELLAS, P				BOUABOULA, M; BOURRIE, B; RINALDICARMONA, M; SHIRE, D; LEFUR, G; CASELLAS, P			STIMULATION OF CANNABINOID RECEPTOR CB1 INDUCES KROX-24 EXPRESSION IN HUMAN ASTROCYTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; RAT-BRAIN; MESSENGER-RNA; INHIBITION; PROTEIN; MARIJUANA; DIFFERENTIATION; LOCALIZATION; INVOLVEMENT; MEMBRANES	The recent isolation and cloning of the G protein-coupled central cannabinoid receptor (CB1) from brain tissue has provided a molecular basis to elucidate how cannabinoid compounds may mediate their psychoactive effects. Here we report the high expression of cannabinoid receptors in human astrocytoma tumors of different grades, in the astrocytoma cell lines U373 MG and GL-15, as well as in normal astrocytes. From an analysis of the coupling mechanisms of functional CB1 receptors in U373 MG, we show that, in addition to the inhibition of adenylyl cyclase, activation by the cannabinoid agonist CP-55940 induces the expression of the immediate-early gene krox-24, also known as NGFI-A, zif/268, egr-1, and TIS8. The amount of Krox-24 protein and the level of Krox-24 DNA binding activity, as measured by Western blot and electrophoretic mobility shift assay, respectively, were also increased by the addition of CP-55940. These effects were blocked by incubation with pertussis toxin but not by treatment with hydrolysis-resistant cAMP analogues, suggesting that the transduction pathway between the cannabinoid receptor and krox-24 involves a pertussis toxin-sensitive GTP-binding protein and is independent of cARIP metabolism. The specific involvement of CB1 in Krox-24 induction was demonstrated in Chinese hamster ovary cells transfected with the human CB1 receptor and also in experiments using the CB1-selective cannabinoid antagonist SR 141716A.	SANOFI RECH,F-34184 MONTPELLIER,FRANCE; SANOFI RECH,F-75008 PARIS,FRANCE; SANOFI RECH,F-31676 LABEGE,FRANCE	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France								BOUABOULA M, 1993, EUR J BIOCHEM, V214, P173, DOI 10.1111/j.1432-1033.1993.tb17910.x; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; CAO XM, 1993, J BIOL CHEM, V268, P16949; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DAUMASDUPORT C, 1988, CANCER, V15, P2152; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DORNAND J, 1992, J CELL PHYSIOL, V151, P71, DOI 10.1002/jcp.1041510112; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; FELDER CC, 1992, MOL PHARMACOL, V42, P838; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HISANAGA K, 1990, MOL BRAIN RES, V8, P69, DOI 10.1016/0169-328X(90)90011-2; HOLLISTER LE, 1986, PHARMACOL REV, V38, P1; HOWLETT AC, 1984, MOL PHARMACOL, V26, P532; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; HOWLETT AC, 1987, NEUROPHARMACOLOGY, V26, P507, DOI 10.1016/0028-3908(87)90035-9; JANSEN EM, 1992, BRAIN RES, V575, P93, DOI 10.1016/0006-8993(92)90428-C; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Legoux P, 1992, Eur Cytokine Netw, V3, P553; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MAILLEUX P, 1992, NEUROSCIENCE, V48, P355; MARX J, 1990, SCIENCE, V249, P624, DOI 10.1126/science.2166339; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MILOUX B, 1994, GENE, V149, P341, DOI 10.1016/0378-1119(94)90173-2; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; PREISSIG SH, 1979, ACTA CYTOL, V23, P412; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SHIRE G, 1995, J BIOL CHEM, V270, P3726; TAHIR SK, 1991, PHARMACOL BIOCHEM BE, V40, P617, DOI 10.1016/0091-3057(91)90372-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANBOXEL JA, 1974, NATURE, V251, P443, DOI 10.1038/251443a0; WATZL B, 1991, INT J IMMUNOPHARMACO, V13, P1091, DOI 10.1016/0192-0561(91)90160-9	46	150	161	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13973	13980		10.1074/jbc.270.23.13973	http://dx.doi.org/10.1074/jbc.270.23.13973			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775459	hybrid			2022-12-25	WOS:A1995RC44800058
J	CHE, MX; ORTIZ, DF; ARIAS, IM				CHE, MX; ORTIZ, DF; ARIAS, IM			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF A CDNA-ENCODING THE BILE CANALICULAR, PURINE-SPECIFIC NA+-NUCLEOSIDE COTRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							XENOPUS-LAEVIS OOCYTES; RAT; TRANSPORT; MEMBRANE; ADENOSINE; RABBIT; CELLS; ATP	We previously characterized a purine-specific Na+- nucleoside cotransport system in bile canalicular membrane. The function of this transport system may be related to conserving nucleosides and preventing cholestasis. We report here the isolation of a cDNA encoding a Na+-dependent nucleoside transporter from rat liver using an expression cloning strategy. The substrate specificities and kinetic characteristics of the cloned cotransporter are consistent with the properties of the Na+-dependent, purine-selective nucleoside transporter in bile canalicular membranes. The nucleotide sequence predicts a protein of 659 amino acids (72 kDa) with 14 putative membrane-spanning domains. Northern blot analysis showed that the transcripts are present in liver and several other tissues. Data base searches indicate significant sequence similarity to the pyrimidine-selective nucleoside transporter (cNT1) of rat jejunum. Although these two subtypes of Na+-nucleoside cotransporter have different substrate specificities and tissue localizations, they are members of a single gene family.			CHE, MX (corresponding author), TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035652, R01DK035652] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35652] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERHFELD G, 1989, J PHYSIOL-LONDON, V418, P88; CHAREST R, 1985, J BIOL CHEM, V260, P5789; CHE MX, 1992, J BIOL CHEM, V267, P9684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVAL JL, 1991, LIFE SCI, V49, P1435, DOI 10.1016/0024-3205(91)90043-B; DOIN R, 1985, SCIENCE, V227, P1296; FORRESTER T, 1990, J PHYSIOL-LONDON, V268, P371; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; KITAMURA T, 1991, HEPATOLOGY, V14, P640, DOI 10.1016/0270-9139(91)90051-V; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIN SH, 1989, J BIOL CHEM, V264, P14403; LINDEN J, 1994, J BIOL CHEM, V269, P27900; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PALACIN M, 1990, J BIOL CHEM, V265, P7142; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1028, P289, DOI 10.1016/0005-2736(90)90178-Q; RODEN M, 1991, GASTROENTEROLOGY, V100, P1553, DOI 10.1016/0016-5085(91)90652-2; SHIMA S, 1990, JPN J PHARMACOL, V53, P473, DOI 10.1254/jjp.53.473; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; WILLIAMS TC, 1991, BIOCHEM J, V274, P27, DOI 10.1042/bj2740027; WU XC, 1992, J BIOL CHEM, V267, P8813	22	147	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13596	13599		10.1074/jbc.270.23.13596	http://dx.doi.org/10.1074/jbc.270.23.13596			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775409	hybrid			2022-12-25	WOS:A1995RC44800005
J	CORNEL, MJ; WILLIAMS, TA; LAMANGO, NS; COATES, D; CORVOL, P; SOUBRIER, F; HOHEISEL, J; LEHRACH, H; ISAAC, RE				CORNEL, MJ; WILLIAMS, TA; LAMANGO, NS; COATES, D; CORVOL, P; SOUBRIER, F; HOHEISEL, J; LEHRACH, H; ISAAC, RE			CLONING AND EXPRESSION OF AN EVOLUTIONARY CONSERVED SINGLE-DOMAIN ANGIOTENSIN-CONVERTING ENZYME FROM DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 HOMOLOGOUS DOMAINS; MOLECULAR-BIOLOGY; MESSENGER-RNAS; GENE; SITES; TRANSCRIPTION; SPECIFICITIES; PEPTIDES; ISOZYMES; FORMS	Mammalian somatic angiotensin converting enzyme (EC 3.4.15.1, ACE) consists of two highly homologous (N- and C-) domains encoded by a duplicated gene. We have identified an apparent single-domain (67 kDa) insect angiotensin converting enzyme (AnCE) in embryos of Drosophila melanogaster which converts angiotensin I to angiotensin II (K-m, 365 mu M), removes Phe-Arg from the C terminus of bradykinin (K-m, 22 mu M), and is inhibited by ACE inhibitors, captopril (IC50 = 1.1 x 10(-9) M) and trandolaprilat (IC50 = 1.6 x 10(-8) M). We also report the cloning and expression of a Drosophila AnCE cDNA which codes for a single-domain 615-amino acid protein with a predicted 17-amino acid signal peptide and regions with high levels of homology to both the N- and C-domains of mammalian somatic ACE, especially around the active site consensus sequence. Northern analysis identified a single 2.1-kilobase mRNA in Drosophila embryos, and Southern analysis of Drosophila genomic DNA indicates that the insect gene is not duplicated. When expressed in COS-7 cells, the AnCE protein is a secreted enzyme, which converts angiotensin I to angiotensin II and is inhibited by captopril (IC50 = 5.6 x 10(-9) M) and trandolaprilat (IC50 = 2 x 10(-8) M). The evolutionary significance of these results is discussed.	UNIV LEEDS, DEPT PURE & APPL BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; IMPERIAL CANC RES FUND, GENOME ANAL LAB, LONDON WC2A 3PX, ENGLAND; COLL FRANCE, EXPTL MED LAB, INSERM, U36, F-75005 PARIS, FRANCE; DEUTSCH KREBSFORSCHUNGSZENTRUM, MOLEC GENET GENOME ANAL LAB, D-69120 HEIDELBERG, GERMANY	University of Leeds; Cancer Research UK; The Genome Analysis Centre (TGAC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Helmholtz Association; German Cancer Research Center (DKFZ)			Williams, Tracy/K-5604-2013; Lamango, Nazarius/W-8459-2019	Williams, Tracy Ann/0000-0002-2388-6444				ASHBURNER M, 1989, DROSOPHILA LABORATOR; BELDENT V, 1993, J BIOL CHEM, V268, P26428; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; DAS M, 1975, J BIOL CHEM, V250, P6762; DAYHOFF MO, 1979, ATLAS PROTEIN SEQ S3, V5; DEDDISH PA, 1994, P NATL ACAD SCI USA, V91, P7807, DOI 10.1073/pnas.91.16.7807; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; HOOPER NM, 1987, BIOCHEM J, V241, P625, DOI 10.1042/bj2410625; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUBERT C, 1991, J BIOL CHEM, V266, P15377; JASPARD E, 1993, J BIOL CHEM, V268, P9496; Jowett T., 1986, DROSOPHILA, P275; KASTURI S, 1994, BIOCHEMISTRY-US, V33, P6228, DOI 10.1021/bi00186a024; Kenny AJ, 1987, MAMMALIAN ECTOENZYME, P169; KENNY AJ, 1991, DEGRADATION BIOACTIV, P47; KOIKE G, 1994, BIOCHEM BIOPH RES CO, V198, P380, DOI 10.1006/bbrc.1994.1053; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LAMANGO NS, 1994, BIOCHEM J, V299, P651, DOI 10.1042/bj2990651; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; Sambrook J, 1989, MOL CLONING LABORATO; SHAI SY, 1992, CIRC RES, V70, P1274, DOI 10.1161/01.RES.70.6.1274; SOFFER RL, 1976, ANNU REV BIOCHEM, V45, P73, DOI 10.1146/annurev.bi.45.070176.000445; SOUBRIER F, 1993, J HYPERTENS, V11, P599, DOI 10.1097/00004872-199306000-00003; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; SOUBRIER F, 1993, J HYPERTENS, V11, P471, DOI 10.1097/00004872-199305000-00001; THEKKUMKARA TJ, 1992, NUCLEIC ACIDS RES, V20, P683, DOI 10.1093/nar/20.4.683; TURNER AJ, 1987, J NEUROCHEM, V48, P910, DOI 10.1111/j.1471-4159.1987.tb05603.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WEI L, 1991, J BIOL CHEM, V266, P9002; WEI L, 1991, J BIOL CHEM, V266, P5540; WILLIAMS TA, 1994, J BIOL CHEM, V269, P29430; WILLIAMS TA, 1992, BIOCHEM J, V288, P875, DOI 10.1042/bj2880875; 1991, PROGRAM MANUAL GCG P	43	136	141	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13613	13619		10.1074/jbc.270.23.13613	http://dx.doi.org/10.1074/jbc.270.23.13613			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775412	hybrid			2022-12-25	WOS:A1995RC44800008
J	KOZYAVKIN, SA; PUSHKIN, AV; EISERLING, FA; STETTER, KO; LAKE, JA; SLESAREV, AI				KOZYAVKIN, SA; PUSHKIN, AV; EISERLING, FA; STETTER, KO; LAKE, JA; SLESAREV, AI			DNA ENZYMOLOGY ABOVE 100-DEGREES-C - TOPOISOMERASE V UNLINKS CIRCULAR DNA AT 80-120-DEGREES-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXTREMELY THERMOPHILIC ARCHAEBACTERIA; DESULFUROCOCCUS-AMYLOLYTICUS; PYROCOCCUS-FURIOSUS; ELECTRON-MICROSCOPY; POLYMERASE; ARCHAEA; TEMPERATURE; BACTERIA; AMPLIFICATION; SEQUENCES	The widespread application of polymerase chain reaction and related techniques in biology and medicine has led to a heightened interest in thermophilic enzymes of DNA metabolism. Some of these enzymes are stable for hours at 100 degrees C, but no enzymatic activity on duplex DNA at temperatures above 100 degrees C has so far been demonstrated. Recently, we isolated topoisomerase V from the hyperthermophile Methanopyrus kandleri, which grows up to 110 degrees C. This novel enzyme is similar to eukaryotic topoisomerase I and acts on duplex DNA regions. We now show that topoisomerase V catalyzes the unlinking of double-stranded circular DNA at temperatures up to 122 degrees C. In this in vitro system, maximal DNA unlinking occurs at 108 degrees C and corresponds to complementary strands being linked at most once. These results further imply that in the presence of sufficient positive supercoiling DNA can exist as a double helix even at 122 degrees C.	NIDDK,MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV REGENSBURG,W-8400 REGENSBURG,GERMANY; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Regensburg; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				Kozyavkin, Sergei/0000-0001-5605-5113				ACHENBACHRICHTE.L, 1987, SYST APPL MICROBIOL, V9, P34; ADAMS W, 1992, BIOCATALYSIS EXTREME; COWAN DA, 1987, BIOCHEM J, V247, P121, DOI 10.1042/bj2470121; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; DANSON J, 1992, BIOCH SOC S, V58; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; GAGUA AV, 1981, NATURE, V294, P662, DOI 10.1038/294662a0; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; JOHNSON D, 1975, NUCLEIC ACIDS RES, V2, P2049, DOI 10.1093/nar/2.11.2049; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KOCH R, 1990, FEMS MICROBIOL LETT, V71, P21, DOI 10.1111/j.1574-6968.1990.tb03792.x; KONG HM, 1993, J BIOL CHEM, V268, P1965; KOZYAVKIN SA, 1994, J BIOL CHEM, V269, P11081; Kristjansson Jakob K., 1992, P1; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; Lawyer F C, 1993, PCR Methods Appl, V2, P275; LOWE SE, 1993, MICROBIOL REV, V57, P451, DOI 10.1128/MMBR.57.2.451-509.1993; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PUSHKIN AV, 1993, FEMS MICROBIOL LETT, V113, P167; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; RIVERA MC, 1992, SCIENCE, V257, P74, DOI 10.1126/science.1621096; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHEN Y, 1993, NATURE, V366, P48, DOI 10.1038/366048a0; SLESAREV AI, 1991, J BIOL CHEM, V266, P12321; SLESAREV AI, 1994, J BIOL CHEM, V269, P3295; SLESAREV AI, 1990, J BIOMOL STRUCT DYN, V7, P935, DOI 10.1080/07391102.1990.10508533; SLESAREV AI, 1988, EUR J BIOCHEM, V173, P395, DOI 10.1111/j.1432-1033.1988.tb14012.x; SLESAREV AI, 1993, NATURE, V364, P735, DOI 10.1038/364735a0; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STETTER KO, 1993, NATURE, V365, P743, DOI 10.1038/365743a0; STETTER KO, 1982, NATURE, V300, P258, DOI 10.1038/300258a0; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; VOLOGODSKII AV, 1992, TOPOLOGY PHYSICS CIR; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	41	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13593	13595		10.1074/jbc.270.23.13593	http://dx.doi.org/10.1074/jbc.270.23.13593			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775408	hybrid			2022-12-25	WOS:A1995RC44800004
J	WEISS, C; GOLOUBINOFF, P				WEISS, C; GOLOUBINOFF, P			A MUTANT AT POSITION-87 OF THE GROEL CHAPERONIN IS AFFECTED IN PROTEIN-BINDING AND ATP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-COMPLEX POLYPEPTIDE-1; HEAT-SHOCK GENES; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; COOPERATIVITY; MORPHOGENESIS; PURIFICATION; STRESS; HSP60	The highly conserved aspartic acid residue at position 87 of the Escherichia coli chaperonin GroEL was mutated to glutamic acid. When expressed in an E. coli groEL mutant strain deficient for phage morphogenesis, plasmid-encoded GroEL mutant D87E restored T-4 phage morphogenesis. It did not, however, reactivate the transcription of a recombinant luciferase operon from Vibrio fischeri. In vitro, GroEL mutant D87E was found to be impaired in the ability to bind nonnative proteins and to hydrolyze ATP, resulting in less efficient refolding of urea-denatured ribulose-1,5-bisphosphate carboxylase/oxygenase. Mutant oligomer D87E GroEL(14) was able to bind GroES(7) as efficiently as wild-type GroEL(14). The conserved aspartic acid residue at position 87 located in the equatorial domain of GroEL (Braig, K., Otwinowski, Z., Hegde, R., Boisvert, D. C., Joachimiak, A., Horwich, A. L., and Sigler, P. B. (1994) Nature 371, 578-586) is thus inferred to have a dual effect on the binding of nonnative proteins to the GroEL(14) core chaperonin and on ATP hydrolysis.	HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BOT,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem				Goloubinoff, Pierre/0000-0002-4802-0807				ADAR YY, 1992, J BACTERIOL, V174, P7138, DOI 10.1128/jb.174.22.7138-7143.1992; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BLOOM M, 1986, J BACTERIOL, V166, P380, DOI 10.1128/jb.166.2.380-384.1986; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P278; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GREENER T, 1993, EMBO J, V12, P889, DOI 10.1002/j.1460-2075.1993.tb05729.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; KUSUKAWA N, 1988, GENE DEV, V2, P874, DOI 10.1101/gad.2.7.874; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEATHERBARROW RJ, 1987, ENZFITTER PROGRAM; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; REVEL HR, 1980, J VIROL, V33, P366, DOI 10.1128/JVI.33.1.366-376.1980; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; ULITZUR S, 1988, J BIOLUM CHEMILUM, V2, P81, DOI 10.1002/bio.1170020205; VIITANEN PV, 1992, PROTEINSCI, V7, P363	45	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13956	13960		10.1074/jbc.270.23.13956	http://dx.doi.org/10.1074/jbc.270.23.13956			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775456	hybrid			2022-12-25	WOS:A1995RC44800055
J	KUZMIN, I; DUH, FM; LATIF, F; GEIL, L; ZBAR, B; LERMAN, MI				KUZMIN, I; DUH, FM; LATIF, F; GEIL, L; ZBAR, B; LERMAN, MI			IDENTIFICATION OF THE PROMOTER OF THE HUMAN VON HIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE	ONCOGENE			English	Article						VON HIPPEL-LINDAU DISEASE; PROMOTER; TUMOR SUPPRESSOR	HUMAN RETINOBLASTOMA GENE; TRANSCRIPTION FACTOR; SMALL REGION; CHROMOSOME-3; CARCINOMA; NRF-1; LOCUS; DNA	The von Hippel-Lindau (VHL) disease gene is a novel multiple tumor suppressor gene which plays a causal role in the origin of some common cancers including clear cell renal carcinomas and hemangioblastomas of the central nervous system. Here we report the identification of transcription start sites and the promoter of the human VHL gene. The promoter sequence does not contain TATA and CCAAT boxes. Transcription is initiated around a putative SP1 binding site about 60 bp upstream from the first AUG codon in the VHL mRNA. Several putative transcription factor binding sites, notably for nuclear respiratory factor 1 and PAX, were found upstream of the transcription start sites, Promoter-luciferase expression constructs demonstrate, that the promoter is functional when transfected into 293 cells (transformed primary human embryonal kidney cells) and UMRC 6 renal carcinoma cells. Activity is dependent on correct orientation of the promoter. A minimal promoter region of 106 bp was delineated, A set of VHL minigenes, containing the 5' flanking VHL genomic region, was constructed and transfected into UMRC 6 cells. In these cells the level of transcription from the minigenes driven by VHL promoter was comparable with endogenous VHL expression.	NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	KUZMIN, I (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, IMMUNOBIOL LAB, FREDERICK, MD 21702 USA.							BERGER SL, 1987, ANAL BIOCHEM, V161, P272, DOI 10.1016/0003-2697(87)90451-9; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BRAUCH H, 1995, IN PRESS HUM GENET; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHANG ACY, 1988, FOCUS, V10, P66; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GLENN GM, 1991, HUM GENET, V87, P207, DOI 10.1007/BF00204184; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GROSSMAN HB, 1985, J SURG ONCOL, V28, P237; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOFMANN W, 1993, ONCOGENE, V8, P3123; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KANNO H, 1994, CANCER RES, V54, P4845; KUZMIN I, 1994, CANCER RES, V54, P2486; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LATIF F, 1993, CANCER RES, V53, P861; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P1145; PLACHOV D, 1990, DEVELOPMENT, V110, P643; RICHARDS FM, 1994, HUM MOL GENET, V3, P595, DOI 10.1093/hmg/3.4.595; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SHUIN T, 1994, CANCER RES, V54, P2852; TANG A, 1989, ONCOGENE, V4, P401; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WADA KN, 1992, NUCLEIC ACIDS RES, V20, P2111, DOI 10.1093/nar/20.suppl.2111; YAO M, 1993, HUM GENET, V92, P605, DOI 10.1007/BF00420947	43	70	73	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2185	2194						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784063				2022-12-25	WOS:A1995RB70300014
J	MISRAPRESS, A; RIM, CS; YAO, H; ROBERSON, MS; STORK, PJS				MISRAPRESS, A; RIM, CS; YAO, H; ROBERSON, MS; STORK, PJS			A NOVEL MITOGEN-ACTIVATED PROTEIN-KINASE PHOSPHATASE - STRUCTURE, EXPRESSION, AND REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; TYROSINE-PHOSPHATASE; MAP KINASE; PC12 CELLS; PHOSPHORYLATION; DIFFERENTIATION; SPECIFICITY; RECEPTOR; RAS	Mitogen-activated protein (MAP) kinase lies at the convergence of various extracellular ligand-mediated signaling pathways. It is activated by the dual-specificity kinase, MAP kinase kinase or MEK. MAP kinase inactivation is mediated by dephosphorylation via specific MAP kinase phosphatases (MKPs). One MKP (MKP-1 (also known as 3CH134, Erp, or CL100)) has been reported to be expressed in a wide range of tissues and cells. We report the identification of a second widely expressed MKP, termed MKP-2, isolated from PC12 cells. MKP-2 showed significant homology with MKP-1 (58.8% at the amino acid level) and, like MKP-1, displayed vanadate-sensitive phosphatase activity against MAP kinase in vitro. Overexpression of MKP-2 in vive inhibited MAP kinase-dependent gene transcription in PC12 cells. MKP-2 differed from MKP-1 in its tissue distribution and in its extent of induction by growth factors sind agents that induce cellular stress, suggesting that these MKPs may have distinct physiological functions.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MICROBIOL & IMMUNOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University								ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALLESSI DR, 1993, ONCOGENE, V8, P2015; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHARLES CH, 1992, ONCOGENE, V7, P187; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DRUKER B, 1992, BLOOD, V79, P2215; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; FRIEDMAN LK, 1994, J NEUROSCI, V14, P2697; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HOWLEY PM, 1983, METHOD ENZYMOL, V101, P387; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; KWAK SP, 1994, J BIOL CHEM, V269, P3596; LLOYD ED, 1992, J NEUROCHEM, V59, P1099, DOI 10.1111/j.1471-4159.1992.tb08352.x; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LUEHRSEN KR, 1992, METHOD ENZYMOL, V216, P397; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MISRAPRESS A, 1994, J BIOL CHEM, V269, P23220; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PENNYPACKER KR, 1993, J NEUROCHEM, V60, P204, DOI 10.1111/j.1471-4159.1993.tb05839.x; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STORK P, 1995, IN PRESS METHODS NEU; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; THOMAS SM, 1991, MOL CELL BIOL, V11, P4739, DOI 10.1128/MCB.11.9.4739; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CEHM, V268	52	215	218	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14587	14596		10.1074/jbc.270.24.14587	http://dx.doi.org/10.1074/jbc.270.24.14587			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782322	hybrid			2022-12-25	WOS:A1995RD45500055
J	EMILI, A; INGLES, CJ				EMILI, A; INGLES, CJ			PROMOTER-DEPENDENT PHOTOCROSS-LINKING OF THE ACIDIC TRANSCRIPTIONAL ACTIVATOR E2F-1 TO THE TATA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; RETINOBLASTOMA PROTEIN; FACTOR-TFIIB; CLONING; YEAST; GENE; TRANSACTIVATION; INTERACTS; SEQUENCE; INVITRO	Sequence-specific transcriptional activators, such as the human factor E2F-1, increase the rate of initiation of transcription by RNA polymerase II, possibly by contacting one or more of the RNA polymerase II-associated general initiation factors. One candidate target of transactivators is the TATA-binding protein (TBP), which, when bound to a promoter, nucleates the formation of a preinitiation complex. Previous studies using affinity chromatography techniques have shown that the activation domains of certain activators, including the acidic activation domain of E2F-1, can interact with TBP in the absence of DNA Using a site directed photoaffinity cross-linking approach, we demonstrate here that the activation domain of the chimeric activator LexA-E2F-1 can be cross-linked to TBP when both factors are bound to a transcriptionally responsive RNA polymerase II promoter. Mutations within the activation domain of LexA-E2F-1 that impaired its ability to activate transcription in vitro were found to reduce cross-linking of LexA-E2F-1 to TBP. The association of initiation factor TFIIB with the TBP-promoter complex did not preclude this promoter-dependent cross-linking of LexA-E2F-1 to TBP. TFIIB itself could also be crosslinked to LexA-E2F-1; however, this cross-linking was promoter-independent. In contrast, TFIIA strongly inhibited the promoter-dependent cross-linking of LexA-E2F-1 to TBP. These results directly demonstrate that acidic activators such as E2F-1 can interact with TBP during the earliest stages in the assembly of an RNA polymerase II preinitiation complex.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5G 1L6,CANADA	University of Toronto; University of Toronto								BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; HORII T, 1981, CELL, V23, P689, DOI 10.1016/0092-8674(81)90432-3; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; RANISB JA, 1992, SCIENCE, V256, P1127; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SN X, 1994, GENE DEV, V8, P2336; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; SUNDSETH R, 1992, J BIOL CHEM, V267, P7845; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; YOUNG KC, 1994, GENE DEV, V8, P2097; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	36	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13674	13680		10.1074/jbc.270.23.13674	http://dx.doi.org/10.1074/jbc.270.23.13674			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775419	hybrid			2022-12-25	WOS:A1995RC44800016
J	HABIB, GM; CARTER, BZ; SEPULVEDA, AR; SHI, ZZ; WAN, DF; LEBOVITZ, RM; LIEBERMAN, MW				HABIB, GM; CARTER, BZ; SEPULVEDA, AR; SHI, ZZ; WAN, DF; LEBOVITZ, RM; LIEBERMAN, MW			IDENTIFICATION OF A 6TH PROMOTER THAT DIRECTS THE TRANSCRIPTION OF GAMMA-GLUTAMYL-TRANSPEPTIDASE TYPE-III RNA IN MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; MESSENGER-RNAS; TRANSFERASE TRANSPEPTIDASE; EPITHELIAL-CELLS; POLYMERASE-II; 5' ENDS; RAT; GENE; TRANSFECTION; SEQUENCES	We have previously identified five promoters in the 5'-flanking region of the mouse gamma-glutamyl transpeptidase (gamma GT) gene. We now report the localization of a sixth promoter that supports the transcription of type III RNA, the major gamma GT RNA in fetal liver. We made a fetal liver cDNA library enriched for gamma GT RNA and obtained 12 gamma GT type III-specific clones. The longest clone is consistent with a transcription start site for type III RNA at a position 5' to the type IV promoter and about 5 kilobase(s) (kb) 5' to the first coding exon. We estimated by ribonuclease protection assay that about 80% of the gamma GT mRNA in fetal liver was type III. Primer extension and nuclease protection analyses mapped the 5' end of type III mRNA in fetal liver and kidney to a single cluster of potential major and minor transcription start sites. Deletion analysis using transient expression of chloramphenicol acetyltransferase constructs of the type III promoter region revealed the greatest activity with a 1-kb 5'-flanking fragment in mouse kidney proximal tubular cells and no detectable activity in NIH-3T3 fibroblasts. These studies demonstrate that the type III 5' region of the mouse gamma GT gene is organized into two distinct exons (IIIa and IIIb) and that type III RNA is expressed under the control of its own promoter.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030	Baylor College of Medicine					NATIONAL CANCER INSTITUTE [R37CA039392, R01CA039392] Funding Source: NIH RePORTER; NCI NIH HHS [CA39392] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT Z, 1961, NATURE, V191, P767, DOI 10.1038/191767a0; BRAUN L, 1987, CANCER RES, V47, P4116; BROUILLET A, 1994, J BIOL CHEM, V269, P14878; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CARTER BZ, 1994, J BIOL CHEM, V269, P24581; CHASSANDE O, 1994, J BIOL CHEM, V269, P14484; CHOBERT MN, 1990, J BIOL CHEM, V265, P2352; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURTHOYS NP, 1983, MINER ELECTROL METAB, V9, P236; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GHUSH D, 1990, NUCLEIC ACIDS RES, V18, P1749; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GRIFFITHS SA, 1989, CANCER LETT, V46, P69, DOI 10.1016/0304-3835(89)90217-6; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JBILO O, 1994, J BIOL CHEM, V269, P20829; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; MUKAI T, 1986, J BIOL CHEM, V261, P3347; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; Ruoslahti E, 1979, Adv Cancer Res, V29, P275, DOI 10.1016/S0065-230X(08)60849-0; SCHAFFNER DL, 1993, AM J PATHOL, V142, P1051; SEPULVEDA AR, 1994, J BIOL CHEM, V269, P10699; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TATE SS, 1981, METHOD ENZYMOL, V113, P400; TATEISHI N, 1976, GANN, V67, P215; TODA K, 1994, MOL ENDOCRINOL, V8, P210, DOI 10.1210/me.8.2.210; UENO T, 1988, BIOCHIM BIOPHYS ACTA, V950, P411, DOI 10.1016/0167-4781(88)90138-8; VOCI A, 1994, HORM METAB RES, V26, P133, DOI 10.1055/s-2007-1000793; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WULHRICH RP, 1990, KIDNEY INT, V37, P783	34	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13711	13715		10.1074/jbc.270.23.13711	http://dx.doi.org/10.1074/jbc.270.23.13711			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775425	hybrid			2022-12-25	WOS:A1995RC44800022
J	LESUFFLEUR, T; ROCHE, F; HILL, AS; LACASA, M; FOX, M; SWALLOW, DM; ZWEIBAUM, A; REAL, FX				LESUFFLEUR, T; ROCHE, F; HILL, AS; LACASA, M; FOX, M; SWALLOW, DM; ZWEIBAUM, A; REAL, FX			CHARACTERIZATION OF A MUCIN CDNA CLONE ISOLATED FROM HT-29 MUCUS-SECRETING CELLS - THE 3' END OF MUC5AC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; INTESTINAL MUCIN; MONOCLONAL-ANTIBODIES; EXPRESSION; GENE; SEQUENCE; DIFFERENTIATION; HYBRIDIZATION; LOCALIZATION; ADAPTATION	HT-29 cells resistant to 10(-6) M methotrexate (HT29-MTX) secrete mucins with gastric immunoreactivity (Lesuffleur, T., Barbat, A., Dussaulx, E., and Zweibaum, A. (1990) Cancer Res. 50, 6334-6343). A 3310-base pair mucin cDNA clone (L31) was isolated from an HT29-MTX expression library using a polyclonal serum specific for normal gastric mucosa. It shows a high level of identity (98.6%) to clone NP3a isolated from a nasal polyp cDNA library (Meerzaman, D., Charles, P., Daskal, E., Polymeropoulos, M. H., Martin, B. M., and Rose, M. C. (1994) J. Biol. Chem. 269, 12932-12939). However, as a result of changes in reading frame, the 1042-amino acid deduced peptide contains four regions of a low similarity to the NP3a peptide. The amino acid sequence shows 36.3% similarity to part of the carboxyl-terminal sequence of MUC2 including the so called D4 domain and 21.3% to the pro von Willebrand factor. A short amino acid sequence is similar to cysteine-rich sequences repeated in tracheobronchial, gastric, and colonic mucin cDNAs. The gene corresponding to L31 is located in the mucin gene cluster on chromosome 11p15.5. The patterns of mRNA expression were indistinguishable from those revealed with the JER58 probe (MUC5AC). Southern blot analysis indicates that the L31 and JER 58 sequences are within 20 kilobase pairs of each other. Together, these results suggest that L31 clone is the 3' end of MUC5AC.	UNIV AUTONOMA BARCELONA, INST MUNICIPAL INVEST MED, E-08003 BARCELONA, SPAIN; UNIV LONDON UNIV COLL, GALTON LAB, MRC, HUMAN BIOCHEM GENET UNIT, LONDON NW1 2HE, ENGLAND; UNIV PARIS 06, F-75005 PARIS, FRANCE	Autonomous University of Barcelona; University of London; University College London; UDICE-French Research Universities; Sorbonne Universite	LESUFFLEUR, T (corresponding author), INSERM, U178, 16 AVE PAUL VAILLANT COUTURIER, F-94807 VILLEJUIF, FRANCE.		Arribas, Francisco X Real/H-5275-2015; lesuffleur, thecla/AAC-2980-2020	Arribas, Francisco X Real/0000-0001-9501-498X; 				AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; BARA J, 1986, CANCER RES, V46, P3983; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; CARRATO C, 1994, GASTROENTEROLOGY, V107, P160, DOI 10.1016/0016-5085(94)90073-6; CHAMBERS JA, 1994, J CELL SCI, V107, P413; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CONG NV, 1990, HUM GENET, V86, P167; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DUFOSSE J, 1993, BIOCHEM J, V293, P329, DOI 10.1042/bj2930329; GAMBUS G, 1993, GASTROENTEROLOGY, V104, P93; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; GUYONNETDUPERAT V, 1995, BIOCHEM J, V304, P211; HARVEY CB, 1993, ANN HUM GENET, V57, P179, DOI 10.1111/j.1469-1809.1993.tb01593.x; HO SB, 1993, CANCER RES, V53, P641; KITAMURA H, 1994, GASTROENTEROLOGY, V106, pA403; LAN MS, 1990, J BIOL CHEM, V265, P15294; LESUFFLEUR T, 1994, CRIT REV ONCOL HEMAT, V17, P153, DOI 10.1016/1040-8428(94)90053-1; LESUFFLEUR T, 1991, INT J CANCER, V49, P721, DOI 10.1002/ijc.2910490516; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; LESUFFLEUR T, 1993, J CELL SCI, V106, P771; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; ORIOL R, 1977, IMMUNOLOGY, V32, P131; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; ROSE MC, 1992, AM J PHYSIOL, V263, pL413, DOI 10.1152/ajplung.1992.263.4.L413; ROSE MC, 1989, J BIOL CHEM, V264, P8193; RYSAVY FR, 1992, COMPUT APPL BIOSCI, V8, P149; SHELTONINLOES BB, 1987, BIOCHEM BIOPH RES CO, V144, P657, DOI 10.1016/S0006-291X(87)80016-5; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; ZWEIBAUM A, 1984, INT J CANCER, V34, P591, DOI 10.1002/ijc.2910340502; ZWEIBAUM A, 1975, TISSUE ANTIGENS, V6, P121; ZWEIBAUM A, 1969, NATURE, V223, P84, DOI 10.1038/223084a0	41	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13665	13673		10.1074/jbc.270.23.13665	http://dx.doi.org/10.1074/jbc.270.23.13665			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775418	hybrid			2022-12-25	WOS:A1995RC44800015
J	YU, JX; CHAO, L; CHAO, J				YU, JX; CHAO, L; CHAO, J			MOLECULAR-CLONING, TISSUE-SPECIFIC EXPRESSION, AND CELLULAR-LOCALIZATION OF HUMAN PROSTASIN MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA PREKALLIKREIN; BOAR SPERM ACROSIN; 4 TANDEM REPEATS; SERINE PROTEASE; COAGULATION FACTOR; CONVERTING ENZYME; DISULFIDE BONDS; APPLE DOMAINS; FACTOR-XI; CDNA	We have purified a novel human serine proteinase, designated as prostasin, from seminal fluid (Yu ct al., 1994). In the present study, we have cloned and characterized the full-length cDNA encoding prostasin and identified its tissue-specific expression and cellular localization. A cDNA fragment was obtained by polymerase chain reaction using degenerate oligonucleotide primers derived from the NH2-terminal and internal amino acid sequences. A fall-length cDNA sequence encoding prostasin was obtained by amplification of the 5'- and 3'-ends of the cDNA. It contains a 1,032-base coding region a 572-base 3'-noncoding region and a 138-base 5'-noncoding sequence. Prostasin cDNA encodes a protein of 343 amino acids, which consists of a 32-amino acid signal peptide and a 311-amino acid proprostasin. Proprostasin is then cleaved between Arg(12) and Ile(13) to generate a 12-amino acid light chain and a 299-amino acid heavy chain, which are associated through a disulfide bond. The deduced amino acid sequence of the heavy chain has 34-42% identity to human acrosin, plasma kallikrein, and hepsin. A potential N-glycosylation site at Asn(127) and the catalytic triad of His(53), Asp(102), and Ser(206) have been identified. The deduced prostasin has a unique 19-amino acid hydrophobic portion at the COOH terminus, which makes it suitable to anchor in the cell membrane. Carboxyl-terminal sequencing of purified prostasin indicates that the hydrophobic portion is removed and that there is a cleavage between Arg(290) and pro(291) during secretion. Southern blot analysis, following a reverse transcription polymerase chain reaction, indicates that prostasin mRNA is expressed in prostate, liver, salivary gland, kidney, lung, pancreas, colon, bronchus, renal proximal tubular cells, and prostate carcinoma LNCaP cells. Cellular localization of prostasin mRNA was identified within epithelial cells of the human prostate gland by in situ hybridization histochemistry.	MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,CHARLESTON,SC 29425	Medical University of South Carolina					NHLBI NIH HHS [HL 29397] Funding Source: Medline; NIDCR NIH HHS [DE 09731] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009731] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADHAM IM, 1990, HUM GENET, V84, P125; BABA T, 1989, FEBS LETT, V244, P296, DOI 10.1016/0014-5793(89)80549-6; BELDENT V, 1993, J BIOL CHEM, V268, P26428; CHAI KX, 1993, J BIOL CHEM, V268, P24498; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DETRISAC CJ, 1984, KIDNEY INT, V25, P383, DOI 10.1038/ki.1984.28; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; JONES R, 1988, DEVELOPMENT, V102, P781; KLEMM U, 1991, HUM GENET, V87, P635; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; LILIA H, 1985, J CLIN INVEST, V76, P1899; MANIATIS T., 1982, MOL CLONING LABORATO, P382; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2050, DOI 10.1021/bi00222a007; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; Shivaji S, 1990, PROTEINS SEMINAL PLA; STONE KL, 1989, PRACTICAL GUIDE PROT, P37; TOPFERPETERSEN E, 1990, FEBS LETT, V275, P139, DOI 10.1016/0014-5793(90)81458-Z; TOPFERPETERSEN E, 1988, BIOL CHEM H-S, V369, P69, DOI 10.1515/bchm3.1988.369.1.69; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WEI L, 1991, J BIOL CHEM, V266, P5540; YOUNG CL, 1978, ATLAS PROTEIN SEQ S3, V5, P73; YU JX, 1994, J BIOL CHEM, V269, P18843	27	111	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13483	13489		10.1074/jbc.270.22.13483	http://dx.doi.org/10.1074/jbc.270.22.13483			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768952	hybrid			2022-12-25	WOS:A1995RB43900078
J	HAMAWY, MM; MINOGUCHI, K; SWAIM, WD; MERGENHAGEN, SE; SIRAGANIAN, RP				HAMAWY, MM; MINOGUCHI, K; SWAIM, WD; MERGENHAGEN, SE; SIRAGANIAN, RP			A 77-KDA PROTEIN ASSOCIATES WITH PP125(FAK) IN MAST-CELLS AND BECOMES TYROSINE-PHOSPHORYLATED BY HIGH-AFFINITY IGE RECEPTOR AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA RBL-2H3 CELLS; FOCAL ADHESION KINASE; IMMUNOGLOBULIN-E; HISTAMINE-RELEASE; FIBRONECTIN; ADHERENCE; PP125FAK; IDENTIFICATION; STIMULATION; ACTIVATION	The focal adhesion kinase, pp125(FAK), is a novel nonreceptor protein tyrosine kinase expressed in different cells including mast cells. Here we report that a 77-kDa protein associates with pp125(FAK) in the mast cell analog, rat basophilic leukemia (RBL-2H3) cells. When pp125(FAK) immunoprecipitates were subjected to an in vitro kinase assay, there was prominent phosphorylation on tyrosine of pp125(FAK) and of a 77-kDa protein. By V8 protease digestion mapping and by immunoblotting with two different anti-pp125(FAK) antibodies, the 77-kDa protein was distinct from pp125(FAK). This Fak Associated Protein or FAP was detected in RBL-2H3 cells but not in fibroblasts. The aggregation of the high affinity IgE receptor, Fc epsilon RI, induced the in vivo tyrosine phosphorylation of FAP. However, there was a marked decrease in the in vitro phosphorylation of FAP in the immunoprecipitates from Fc epsilon RI aggregated cells. Both of these Fc epsilon RI-mediated effects were enhanced by cell adhesion. There was strong association of FAP with non-tyrosine-phosphorylated pp125(FAK). Thus this interaction does not appear to be mediated by the Src homology 2 domain. Together the data indicate that FAP associates with pp125(FAK) and suggest that FAP may play a role in Fc epsilon RI signaling.			HAMAWY, MM (corresponding author), NIDR,IMMUNOL LAB,BLDG 10,RM 1N106,BETHESDA,MD 20892, USA.							BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHAN PY, 1994, J BIOL CHEM, V269, P20567; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EISEMAN E, 1992, NATURE, V355, P78; FUKAMACHI H, 1994, J IMMUNOL, V152, P642; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1994, IMMUNOL TODAY, V15, P62, DOI 10.1016/0167-5699(94)90135-X; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1994, MOLECULAR PATHOGENESIS OF PERIODONTAL DISEASE, P235; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HAMAWY MM, 1995, IN PRESS CELL SIGNAL; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HATAI M, 1994, FEBS LETT, V350, P113, DOI 10.1016/0014-5793(94)00745-4; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; MINOGUCHI K, 1994, MOL IMMUNOL, V31, P519; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RUDOLPH AK, 1981, EUR J IMMUNOL, V11, P527, DOI 10.1002/eji.1830110617; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SIRAGANIAN RP, 1988, INFLAMMATION BASIC P, P513; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SWAIM WD, 1994, J BIOL CHEM, V269, P19466; SWIETER M, 1993, J IMMUNOL, V150, P617; TANIGUCHI T, 1994, ONCOGENE, V9, P861; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1994, J CELL SCI, V107, P1583; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413	47	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12305	12309		10.1074/jbc.270.20.12305	http://dx.doi.org/10.1074/jbc.270.20.12305			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744883	hybrid			2022-12-25	WOS:A1995QY73600088
J	PENCO, S; PASTORINO, S; BIANCHISCARRA, G; GARRE, C				PENCO, S; PASTORINO, S; BIANCHISCARRA, G; GARRE, C			LACTOFERRIN DOWN-MODULATES THE ACTIVITY OF THE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR PROMOTER IN INTERLEUKIN-1-BETA-STIMULATED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CSF MESSENGER-RNA; GM-CSF; POSTTRANSCRIPTIONAL REGULATION; ENDOTHELIAL-CELLS; GENE-EXPRESSION; MAMMALIAN-CELLS; INTERLEUKIN-1; PROTEINS; DNA; PURIFICATION	The human neutrophil lactoferrin (Lf), a cationic iron-binding glycoprotein, has an inhibitor role on granulocyte macrophage colony-stimulating factor (GM-CSF) production via interleukin-1 (IL-1). The nuclear localization of Lf suggests that it may be involved in the transcriptional regulation of GM-CSF gene expression. To explore this possibility, the effect of Lf on GM-CSF gene expression was investigated in various cell lines and in primary cultures of fibroblasts. Down-regulation of GM-CSF mRNA level was observed in Lf-transfected embryonic fibroblasts induced to produce GM-CSF by IL-1 beta. In 5637 cell-line and in embryonic fibroblasts, co-transfection experiments, in which an Lf expression vector was used together with a vector carrying a reporter gene linked to the GM-CSF promoter, revealed that Lf reduces the activity of the GM-CSF promoter. This effect is marked in IL-1 beta-stimulated cells. These findings suggest that Lf plays a negative role in GM-CSF expression at the transcriptional level, perhaps through the mediation of IL-1 beta.	UNIV GENOA,INST BIOL & GENET,I-16132 GENOA,ITALY	University of Genoa			Scarrà, Giovanna Bianchi/G-8933-2014	Scarrà, Giovanna Bianchi/0000-0002-6127-1192; Penco, Silvana/0000-0003-1050-095X				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELILLO A, 1992, FEBS LETT, V298, P195, DOI 10.1016/0014-5793(92)80055-L; FALKENBURG JHF, 1991, BLOOD, V78, P658; GARRE C, 1992, J CELL PHYSIOL, V153, P477, DOI 10.1002/jcp.1041530306; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gramigni C., 1992, Acta Medica Romana, V30, P248; HE JL, 1995, NATURE, V373, P721, DOI 10.1038/373721a0; HUTCHENS TW, 1991, PEDIATR RES, V29, P243, DOI 10.1203/00006450-199103000-00005; KAUSHANSKY K, 1989, J IMMUNOL, V143, P2525; KUCZEK ES, 1991, J IMMUNOL, V146, P2426; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPREAVE F, 1990, INT J BIOL MACROMOL, V12, P2, DOI 10.1016/0141-8130(90)90073-J; LOMAX KJ, 1989, J CLIN INVEST, V83, P514, DOI 10.1172/JCI113912; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MOCHIZUKI DY, 1987, P NATL ACAD SCI USA, V84, P5267, DOI 10.1073/pnas.84.15.5267; MUEGGE K, 1993, P NATL ACAD SCI USA, V90, P7054, DOI 10.1073/pnas.90.15.7054; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NIMER SD, 1989, J IMMUNOL, V143, P2374; PALACIOS R, 1982, EUR J IMMUNOL, V12, P895, DOI 10.1002/eji.1830121018; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RAMBALDI A, 1987, BLOOD, V69, P1409; RODRIGUEZCIMADE.JC, 1990, BLOOD, V76, P1481; ROSS HJ, 1991, BLOOD, V77, P1787; SANCHEZ L, 1992, ARCH DIS CHILD, V67, P657, DOI 10.1136/adc.67.5.657; SEELENTAG WK, 1987, EMBO J, V6, P2261, DOI 10.1002/j.1460-2075.1987.tb02499.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WELTE K, 1985, P NATL ACAD SCI USA, V82, P1526, DOI 10.1073/pnas.82.5.1526; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; ZUCALI JR, 1989, BLOOD, V74, P1531	36	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12263	12268		10.1074/jbc.270.20.12263	http://dx.doi.org/10.1074/jbc.270.20.12263			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744878	hybrid			2022-12-25	WOS:A1995QY73600083
J	ANANT, S; MACGINNITIE, AJ; DAVIDSON, NO				ANANT, S; MACGINNITIE, AJ; DAVIDSON, NO			APOBEC-1, THE CATALYTIC SUBUNIT OF THE MAMMALIAN APOLIPOPROTEIN-B MESSENGER-RNA EDITING ENZYME, IS A NOVEL RNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INTESTINE; SITE	Apolipoprotein B (apoB) mRNA editing is mediated by an enzyme complex which includes the catalytic subunit, apobec-1. Recombinant GST/APOBEC-1 binds with high specificity to a rat apoB RNA template as demonstrated by UV cross-linking and electrophoretic mobility shift assay (ERISA), ApoB RNA binding was competed by poly(U), poly(A,U), and tRNA, but not by poly(A) or other homopolymeric ribonucleotides, UV cross-linking of GST/APOBEC-1 to an apoB RNA template was uninfluenced by the binding of proteins of similar to 60 and similar to 44 kDa, present in S100 extracts prepared from different sources, The binding of these proteins was similarly uninfluenced by the simultaneous binding of GST/APO-BEC-1. Moreover, the inclusion of heterologous S100 extracts in the RNA binding reactions completely abrogated the competitive displacement of GST/APOBEC-1 by tRNA. EMSA revealed the onset of RNA binding within 1-2 min, and its specificity was confirmed by a supershift with anti-GST/APOBEC-1 antisera. The structural specificity for apoB RNA binding, as inferred from EMSA, appears to be distinct from apoB RNA editing since wild-type chicken apoB RNA,which is not editable, and several mutant chicken apoB RNAs containing clustered mutations within the minimal apoB RNA editing cassette, bound with efficiency similar to the rat apoB RNA template. In conclusion, while the data suggest that apobec-1 binds AU-rich templates, the importance of this observation in the context of mammalian apoB mRNA editing remains unknown.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago			Anant, Shrikant/AAF-8020-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, P01HL018577, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38180, HL-18577] Funding Source: Medline; NIDDK NIH HHS [DK-42086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1219, P1, DOI 10.1016/0167-4781(94)90240-2; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIDSON NO, 1994, TRENDS CARDIOVAS MED, V4, P231, DOI 10.1016/1050-1738(94)90039-6; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; GARCIA ZC, 1992, ARTERIOSCLER THROMB, V12, P172, DOI 10.1161/01.ATV.12.2.172; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INUI Y, 1994, J LIPID RES, V35, P1477; LAU PP, 1991, NUCLEIC ACIDS RES, V18, P5817; LU PP, 1994, P NATL ACAD SCI USA, V91, P8522; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SHAH RR, 1991, J BIOL CHEM, V266, P16301; TENG BB, 1992, J BIOL CHEM, V267, P21265; TENG BB, 1993, SCIENCE, V264, P1816; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000	26	104	108	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14762	14767		10.1074/jbc.270.24.14762	http://dx.doi.org/10.1074/jbc.270.24.14762			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782342	hybrid			2022-12-25	WOS:A1995RD45500079
J	HRMOVA, M; GARRETT, TPJ; FINCHER, GB				HRMOVA, M; GARRETT, TPJ; FINCHER, GB			SUBSITE AFFINITIES AND DISPOSITION OF CATALYTIC AMINO-ACIDS IN THE SUBSTRATE-BINDING REGION OF BARLEY 1,3-BETA-GLUCANASES - IMPLICATIONS IN PLANT-PATHOGEN INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORDEUM-VULGARE; ALPHA-AMYLASES; ACTION PATTERN; ENZYMES; PURIFICATION; ENDO-1,4-BETA-XYLANASE; OLIGOSACCHARIDES; PARAMETERS; EVOLUTION; SITE	Oligo-1,3-beta-glucosides with degrees of polymerization of 2-9 were labeled at their reducing terminal residues by catalytic tritiation. These substrates were used in detailed kinetic and thermodynamic analyses to examine substrate binding in 1,3-beta-D-glucan glucanohydrolase (EC 3.2,1.39) isoenzymes GI, GII, and GIII from young seedlings of barley (Hordeum vulgare). Bond-cleavage frequencies, together with the kinetic parameter k(cat)/K-m, have been calculated as a function of substrate chain length to define the number of subsites that accommodate individual beta-glucosyl residues and to estimate binding energies at each subsite, Each isoenzyme has eight beta-glucosyl-binding subsites. The catalytic amino acids are located between the third and fourth subsite from the nonreducing terminus of the substrate. Negative binding energies in subsites adjacent to the hydrolyzed glycosidic linkage suggest that some substrate distortion may occur in this region during binding and that the resultant strain induced in the substrate might facilitate hydrolytic cleavage. If the 1,3-beta-glucanases exert their function as pathogenesis-related proteins by hydrolyzing the branched or substituted 1,3; 1,6-beta-glucans of fungal walls, it is clear that relatively extended regions of the cell wall polysaccharide must fit into the substrate-binding cleft of the enzyme.	UNIV ADELAIDE,DEPT PLANT SCI,GLEN OSMOND,SA 5064,AUSTRALIA; BIOMOLEC RES INST,PARKVILLE,VIC 3052,AUSTRALIA	University of Adelaide			Hrmova, Maria/AAH-3951-2020	Hrmova, Maria/0000-0002-3545-0605				AJANDOUZ EH, 1992, BIOCHIM BIOPHYS ACTA, V1159, P193, DOI 10.1016/0167-4838(92)90025-9; Allen J D, 1980, Methods Enzymol, V64, P248; ALLEN JD, 1976, BIOCHEM J, V159, P121, DOI 10.1042/bj1590121; BIELY P, 1983, BIOCHIM BIOPHYS ACTA, V743, P155, DOI 10.1016/0167-4838(83)90429-6; BIELY P, 1991, EUR J BIOCHEM, V200, P157, DOI 10.1111/j.1432-1033.1991.tb21062.x; BIELY P, 1981, EUR J BIOCHEM, V119, P559, DOI 10.1111/j.1432-1033.1981.tb05644.x; BOLLER T, 1987, PLANT MICROBE INTERA, V2, P385; BRAY MR, 1992, EUR J BIOCHEM, V204, P191, DOI 10.1111/j.1432-1033.1992.tb16623.x; BRUCKNER J, 1955, BIOCHEM J, V60, P200; CHEN L, 1993, J MOL BIOL, V234, P888, DOI 10.1006/jmbi.1993.1635; CHEN L, 1993, J BIOL CHEM, V268, P13318; CHEN L, 1995, J BIOL CHEM, V270, P8093, DOI 10.1074/jbc.270.14.8093; COLE FE, 1964, BIOCHIM BIOPHYS ACTA, V81, P122, DOI 10.1016/0926-6569(64)90342-6; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DYGERT S, 1965, ANAL BIOCHEM, V13, P367, DOI 10.1016/0003-2697(65)90327-1; EVANS EA, 1974, J LABELLED COMPD, V10, P569, DOI 10.1002/jlcr.2590100407; HAHN MG, 1992, MOL PLANT PATHOL, V2, P103; HIROMI K, 1970, BIOCHEM BIOPH RES CO, V40, P1, DOI 10.1016/0006-291X(70)91037-5; HIROMI K, 1973, BIOCHIM BIOPHYS ACTA, V302, P362, DOI 10.1016/0005-2744(73)90164-2; HOJ PB, 1995, PLANT J, V7, P367, DOI 10.1046/j.1365-313X.1995.7030367.x; HRMOVA M, 1993, BIOCHEM J, V289, P453, DOI 10.1042/bj2890453; KAUFFMANN S, 1987, EMBO J, V6, P3209, DOI 10.1002/j.1460-2075.1987.tb02637.x; MACGREGOR AW, 1992, CARBOHYD RES, V227, P301, DOI 10.1016/0008-6215(92)85080-J; MACGREGOR EA, 1994, CARBOHYD RES, V257, P249, DOI 10.1016/0008-6215(94)80039-1; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MAUCH F, 1988, PLANT PHYSIOL, V87, P325, DOI 10.1104/pp.87.2.325; MOREAU A, 1994, EUR J BIOCHEM, V219, P261, DOI 10.1111/j.1432-1033.1994.tb19937.x; NAZAROVA NI, 1982, BIOORG KHIM+, V8, P1189; Nelson N, 1944, J BIOL CHEM, V153, P375; PERELLA FW, 1988, ANAL BIOCHEM, V174, P437; PHILLIPS DC, 1966, SCI AM, V215, P78, DOI 10.1038/scientificamerican1166-78; SAMUELS ML, 1991, STATISTICS LIFE SCI; SHIBAOKA T, 1974, J BIOCHEM-TOKYO, V76, P475, DOI 10.1093/oxfordjournals.jbchem.a130591; SKRIVER K, 1991, P NATL ACAD SCI USA, V88, P7266, DOI 10.1073/pnas.88.16.7266; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; Stone BA, 1993, CHEM BIOL 1 3 BETA G; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; SUGANUMA T, 1991, CARBOHYD RES, V212, P201, DOI 10.1016/0008-6215(91)84057-L; THOMA JA, 1970, BIOCHEMISTRY-US, V9, P1768, DOI 10.1021/bi00810a016; THOMA JA, 1976, CARBOHYD RES, V48, P105, DOI 10.1016/S0008-6215(00)83518-1; THOMA JA, 1971, J BIOL CHEM, V246, P5621; VARGHESE JN, 1994, P NATL ACAD SCI USA, V91, P2785, DOI 10.1073/pnas.91.7.2785; WESSELS JGH, 1993, NEW PHYTOL, V123, P397, DOI 10.1111/j.1469-8137.1993.tb03751.x; WONG YS, 1977, J BIOL CHEM, V252, P1402; XU PL, 1992, GENE, V120, P157, DOI 10.1016/0378-1119(92)90089-8	45	31	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14556	14563		10.1074/jbc.270.24.14556	http://dx.doi.org/10.1074/jbc.270.24.14556			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782319	hybrid			2022-12-25	WOS:A1995RD45500050
J	TANAKA, S; NEFF, L; BARON, R; LEVY, JB				TANAKA, S; NEFF, L; BARON, R; LEVY, JB			TYROSINE PHOSPHORYLATION AND TRANSLOCATION OF THE C-CBL PROTEIN AFTER ACTIVATION OF TYROSINE KINASE SIGNALING PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; V-CBL; RECEPTOR; GRB2; TRANSFORMATION; ONCOGENE; TRANSDUCTION; ASSOCIATION; TRUNCATION; BINDING	The c-cbl protooncogene product (c-Cbl) is a 120-kDa protein that has been shown to bind to the Src homology 3 domains of various proteins, suggesting its involvement in signal transduction pathways. We identified one of the most prominent tyrosine-phosphorylated proteins in Fc gamma receptor (Fc gamma R)-stimulated macrophages; to be c-Cbl. Tyrosine phosphorylation of c-Cbl occurred within 20 s after stimulation and reached maximum levels within 3-5 min. c-Cbl was also tyrosine-phosphorylated in epidermal growth factor (EGF) receptor-over-expressing cells upon EGF stimulation, in macrophages in response to CSF-1 treatment, and in v-src transformed cells. Furthermore, we found that c-Cbl associated with these kinases in vivo. In vitro, c-Cbl bound to the Src homology 3 domains of Src, Fyn, and Lyn in both unstimulated and Fc gamma R-stimulated macrophages. Examination of cells by immunofluorescence revealed that c-Cbl is diffusely distributed in the cytoplasm in both unstimulated macrophages and EGF receptor-overexpressing cells and translocated to a more specific compartment of the cell, consistent with the trans-Golgi region, following Fc gamma R clustering and EGF stimulation, respectively. These results suggest that c-Cbl is involved in the signaling pathways utilized by different types of tyrosine kinases.	YALE UNIV,SCH MED,DEPT ORTHOPED,NEW HAVEN,CT 06510	Yale University	TANAKA, S (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.		Tanaka, Sakae/Y-3061-2019	Tanaka, Sakae/0000-0001-9210-9414	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042927] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42927] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EISEMAN E, 1992, NATURE, V355, P78; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509	21	166	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14347	14351		10.1074/jbc.270.24.14347	http://dx.doi.org/10.1074/jbc.270.24.14347			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782294	hybrid			2022-12-25	WOS:A1995RD45500020
J	CARRERA, AC; BORLADO, LR; GONZALEZGARCIA, A; ROBERTS, TM; MARTINEZA, C				CARRERA, AC; BORLADO, LR; GONZALEZGARCIA, A; ROBERTS, TM; MARTINEZA, C			ROLE OF THE AUTOPHOSPHORYLATION SITE ON THE BIOLOGICAL FUNCTION OF PP56(LCK)	ONCOGENE			English	Article						AUTOPHOSPHORYLATION; KINASES; FUNCTION	CELL ANTIGEN RECEPTOR; GTPASE-ACTIVATING PROTEIN; TYROSINE KINASE P56LCK; T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; THYMOCYTE DEVELOPMENT; SIGNAL TRANSDUCTION; NUCLEAR FACTOR; EXPRESSION; GENE	Src-family tyrosine kinases act as signaling molecules in a aide array of cellular activation processes. The existence of the various src-family members reflects the requirement for different cell-surface receptors to transmit cell-type specific intracellular signals. The structural basis for the functional specificity of src-kinases is being actively investigated. In the present report we have analysed the contribution of the area surrounding the autophosphorylation site (located at subdomain VII of the catalytic domain) in determining src-kinases activity and functional specificity. To this end we analysed the kinase activities of the lymphoid src-kinase pp56(lck) and a mutant of pp56(lck) in which this region has been exchanged for the corresponding area of the serine/threonine kinase c-Raf. Our studies indicate that the change at subdomain VII affected the ability of pp56(lck) to phosphorylate physiological substrates. Furthermore, when analysed in T cells, the mutant at subdomain VII failed to induce interleukin-2 production, a specific biological function of pp56(lck). Thus, the area surrounding the autophosphorylation site of pp56(lck) plays a critical role in mediating its specific biological function.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT MOLEC & CELLULAR BIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	CARRERA, AC (corresponding author), UNIV AUTONOMA MADRID, CSIC, CTR NACL BIOTECNOL, CAMPUS CANTOBLANCO, E-28049 MADRID, SPAIN.		Gonzalez-Garcia, Ana/D-9736-2014	Gonzalez-Garcia, Ana/0000-0002-6669-1735; Carrera, Ana/0000-0002-3999-5434	NCI NIH HHS [CA 43803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; ANDERSON SJ, 1993, NATURE, V365, P552, DOI 10.1038/365552a0; BALDARI CT, 1993, J BIOL CHEM, V268, P8406; BEVERLEY PCL, 1981, EUR J IMMUNOL, V11, P329, DOI 10.1002/eji.1830110412; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P2065, DOI 10.1021/bi00431a015; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CARRERA AC, 1995, J BIOL CHEM, V270, P3385, DOI 10.1074/jbc.270.7.3385; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOYASU S, 1992, J BIOL CHEM, V267, P3375; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MALEK SN, 1993, J BIOL CHEM, V268, P22557; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VEGA MA, 1990, EUR J IMMUNOL, V20, P453, DOI 10.1002/eji.1830200235; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WOODROW MA, 1993, J IMMUNOL, V150, P3853; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	7	7	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2379	2386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784086				2022-12-25	WOS:A1995RE54300013
J	LUJAN, HD; MOWATT, MR; WU, JJ; LU, Y; LEES, A; CHANCE, MR; NASH, TE				LUJAN, HD; MOWATT, MR; WU, JJ; LU, Y; LEES, A; CHANCE, MR; NASH, TE			PURIFICATION OF A VARIANT-SPECIFIC SURFACE PROTEIN OF GIARDIA-LAMBLIA AND CHARACTERIZATION OF ITS METAL-BINDING PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY ABSORPTION-SPECTROSCOPY; ANTIGENIC VARIATION; ZINC-BINDING; FINE-STRUCTURE; EXAFS; SITES; CLEAVAGE; GENE; TOOL; DNA	Giardia lamblia, an intestinal parasite of humans and other vertebrates, undergoes surface antigenic variation by modulating the expression of different variant-specific surface proteins (VSP). VSPs are cysteine-rich surface proteins that bind zinc and other heavy metals in vitro. We developed an immunoaffinity chromatographic method to purify a VSP in order to determine its biochemical properties. The sequences of two different proteolytic fragments agreed with the sequence deduced from the cloned gene, and amino-terminal sequence indicated the removal of a 14 residue signal peptide, consistent with the transport of VSP to the cell surface, The protein is not glycosylated and has an isoelectric point of 5.3. X-ray microanalyses indicated that the major metals in Giardia trophozoites, as well as purified VSP, are zinc and iron. The zinc concentration in Giardia cells was found to be 0.43 mM and the iron concentration 0.80 mM when compared with standard samples (zinc) or calculated hom a known physical constants (iron), We propose that metal coordination stabilizes VSPs, rendering them resistant to proteolytic attack in the upper small intestine. Moreover, the ability to bind ions by Giardia may play a role in nutritional deficiency and/or malabsorption in heavily infected persons.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,BRONX,NY 10461; UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20814	Yeshiva University; Albert Einstein College of Medicine; Uniformed Services University of the Health Sciences - USA	LUJAN, HD (corresponding author), NIAID,PARASIT DIS LAB,9000 ROCKVILLE PIKE,BLDG 4,RM 126,BETHESDA,MD 20892, USA.			Lees, Andrew/0000-0002-8370-4876				ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; AGGARWAL A, 1989, MOL BIOCHEM PARASIT, V32, P39, DOI 10.1016/0166-6851(89)90127-8; ALEY SB, 1993, EXP PARASITOL, V77, P295, DOI 10.1006/expr.1993.1087; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BACHMAYE.H, 1967, P NATL ACAD SCI USA, V57, P122, DOI 10.1073/pnas.57.1.122; BERTINI I, 1994, BIOINORG CHEM, V1, P37; CHANCE MR, 1992, P NATL ACAD SCI USA, V89, P10041, DOI 10.1073/pnas.89.21.10041; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; DAS S, 1991, J BIOL CHEM, V266, P21318; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; ELLIS JE, 1993, FEBS LETT, V325, P196, DOI 10.1016/0014-5793(93)81072-8; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FUJIWARA K, 1988, J IMMUNOL METHODS, V112, P77, DOI 10.1016/0022-1759(88)90036-1; GABRIEL O, 1992, GLYCOBIOLOGY, V2, P437, DOI 10.1093/glycob/2.5.437; GILLIN FD, 1990, P NATL ACAD SCI USA, V87, P4463, DOI 10.1073/pnas.87.12.4463; GOTTSTEIN B, 1990, PARASITE IMMUNOL, V12, P659, DOI 10.1111/j.1365-3024.1990.tb00995.x; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PA, 1981, REV MOD PHYS, V53, P769, DOI 10.1103/RevModPhys.53.769; LUJAN HD, 1994, J EUKARYOT MICROBIOL, V41, P169, DOI 10.1111/j.1550-7408.1994.tb01491.x; LYTLE FW, 1989, PHYSICA B, V158, P701; MANTEI N, 1992, ANALYZESIGNALASE; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MOWATT MR, 1991, MOL BIOCHEM PARASIT, V49, P215, DOI 10.1016/0166-6851(91)90065-E; NASH T, 1992, PARASITOL TODAY, V8, P229, DOI 10.1016/0169-4758(92)90119-M; NASH TE, 1992, MOL BIOCHEM PARASIT, V51, P219, DOI 10.1016/0166-6851(92)90072-R; NASH TE, 1990, J IMMUNOL, V144, P4362; NASH TE, 1990, EXP PARASITOL, V71, P415, DOI 10.1016/0014-4894(90)90067-M; NASH TE, 1993, P NATL ACAD SCI USA, V90, P5489, DOI 10.1073/pnas.90.12.5489; NASH TE, 1988, J IMMUNOL, V141, P636; PEISACH J, 1982, BIOPHYS J, V38, P277, DOI 10.1016/S0006-3495(82)84559-1; PIMENTA PFP, 1991, INFECT IMMUN, V59, P3989, DOI 10.1128/IAI.59.11.3989-3996.1991; ROWLETT RS, 1994, BIOCHEMISTRY-US, V36, P13967; SAGI I, 1990, J AM CHEM SOC, V112, P8639, DOI 10.1021/ja00180a001; SCHEURING EM, 1994, BIOCHEMISTRY-US, V33, P6310, DOI 10.1021/bi00186a034; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; THIEL EC, 1994, BIOINORG CHEM, V1, P1; THOMPSON RCA, 1993, ADV PARASIT, V32, P71, DOI 10.1016/S0065-308X(08)60207-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSON SM, 1994, EUR J BIOCHEM, V220, P439, DOI 10.1111/j.1432-1033.1994.tb18641.x; UDOMKESMALEE E, 1992, AM J CLIN NUTR, V56, P50, DOI 10.1093/ajcn/56.1.50; VAUGH D, 1986, XRAY DATA BOOKLET; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZHANG YY, 1993, INFECT IMMUN, V61, P520, DOI 10.1128/IAI.61.2.520-524.1993	45	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13807	13813		10.1074/jbc.270.23.13807	http://dx.doi.org/10.1074/jbc.270.23.13807			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775437	hybrid			2022-12-25	WOS:A1995RC44800036
J	TANG, AH; TU, CPD				TANG, AH; TU, CPD			PENTOBARBITAL-INDUCED CHANGES IN DROSOPHILA GLUTATHIONE-S-TRANSFERASE D21 MESSENGER-RNA STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; EXTRAHEPATIC TISSUES; MULTIGENE FAMILY; INTRONLESS GENE; CYTOCHROME-P-450; SEQUENCE; LIVER; EXPRESSION; INDUCTION	The Drosophila glutathione S-transferase (gstD) genes are a family of divergently transcribed, intronless genes and pseudogenes. Under control conditions, the steady-state level of gstD1 mRNA is 20-fold higher than that of the gstD21 mRNA despite a lower transcription rate of the gstD1 gene, The GST D1 protein level is four times as abundant as the GST D21 protein. The gstD1 and gstD21 genes responded rapidly to pentobarbital (PB) as changes in mRNA levels were detectable within 30 min of treatment. Maximal induction of gstD1 and gstD21 resulted in 3-fold and 20-fold elevation of their respective mRNA levels, The major mechanism for the increase in gstD1 mRNAs appears to be transcriptional activation, The 2-fold increase in the rate of gstD21 transcription, however, cannot fully account for the 20-fold increase in the steady-state level of gstD21 mRNA Therefore, post-transcriptional mechanism(s) should also be responsible for the increase of gstD21 mRNA by PB, Because the gstD21 mRNA is relatively unstable under control conditions, induction of the intronless gstD21 mRNA by PB occurs mainly at the level of enhanced mRNA stability, The GST D1 protein level in adult Drosophila was increased approximately 2-fold after PB treatment, whereas the GST D21 level remained relatively the same, Thus, an increase in gstD21 mRNA stability by PB treatment is probably coupled to a regulatory effect at the translational level.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Tang, Amy/L-3226-2016	Tang, Amy/0000-0002-5772-2878	NCRR NIH HHS [2S07 RR07082] Funding Source: Medline; NIEHS NIH HHS [ES 05661] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005661] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADESNIK M, 1986, CRIT REV BIOCHEM MOL, V19, P247, DOI 10.3109/10409238609084657; ATCHISON M, 1983, J BIOL CHEM, V258, P1285; AWASTHI YC, 1994, INT J BIOCHEM, V26, P295, DOI 10.1016/0020-711X(94)90050-7; BEALL C, 1992, BIOCHEM GENET, V30, P515, DOI 10.1007/BF01037590; Belasco J.G., 2012, CONTROL MESSENGER RN; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHEN RT, 1994, P NATL ACAD SCI USA, V91, P6069, DOI 10.1073/pnas.91.13.6069; CHRISTOU M, 1987, ARCH BIOCHEM BIOPHYS, V258, P519, DOI 10.1016/0003-9861(87)90374-2; COCHRANE BJ, 1987, INSECT BIOCHEM, V17, P731, DOI 10.1016/0020-1790(87)90043-6; COCHRANE BJ, 1992, ACS SYM SER, V505, P53; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FYRBERG EA, 1980, CELL, V19, P365, DOI 10.1016/0092-8674(80)90511-5; GOODMANGILMAN A, 1990, GOODMAN GILMANS PHAR, P358; Habig W H, 1981, Methods Enzymol, V77, P398; HARDWICK JP, 1983, J BIOL CHEM, V258, P8081; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HAYAOKA T, 1982, PESTIC BIOCHEM PHYS, V17, P113, DOI 10.1016/0048-3575(82)90015-3; HAYES JD, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P3; HE JS, 1991, J BIOL CHEM, V266, P7864; HO IK, 1981, ANNU REV PHARMACOL, V21, P83, DOI 10.1146/annurev.pa.21.040181.000503; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LIFTON RP, 1977, COLD SPRING HARB SYM, V42, P1047, DOI 10.1101/SQB.1978.042.01.105; LISTOWSKY I, 1988, DRUG METAB REV, V19, P305, DOI 10.3109/03602538808994138; LOVE JD, 1985, ANAL BIOCHEM, V150, P429, DOI 10.1016/0003-2697(85)90532-9; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MULLIN CA, 1992, MOL MECHANISMS INSEC; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OTTEA JA, 1981, PESTIC BIOCHEM PHYS, V15, P10, DOI 10.1016/0048-3575(81)90029-8; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PIKE SF, 1985, BIOCHEM PHARMACOL, V34, P2489, DOI 10.1016/0006-2952(85)90531-3; REDDY CC, 1983, ARCH BIOCHEM BIOPHYS, V224, P87, DOI 10.1016/0003-9861(83)90192-3; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; ROUSH RT, 1987, ANNU REV ENTOMOL, V32, P361, DOI 10.1146/annurev.en.32.010187.002045; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J, 1989, MOL CLONING LABORATO; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SIMON JA, 1987, NUCLEIC ACIDS RES, V15, P2971, DOI 10.1093/nar/15.7.2971; TANG AH, 1994, J BIOL CHEM, V269, P27876; TANG AH, 1994, THESIS PENNSYLVANIA; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TOUNG YPS, 1991, BIOCHEM BIOPH RES CO, V178, P1205, DOI 10.1016/0006-291X(91)91021-4; TOUNG YPS, 1993, J BIOL CHEM, V268, P9737; TOUNG YPS, 1990, P NATL ACAD SCI USA, V87, P31, DOI 10.1073/pnas.87.1.31; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; TU CPD, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P379; TU CPD, 1985, J BIOL CHEM, V260, P9961; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; YAMAZOE Y, 1987, J BIOL CHEM, V262, P7423	53	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13819	13825		10.1074/jbc.270.23.13819	http://dx.doi.org/10.1074/jbc.270.23.13819			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775439	hybrid			2022-12-25	WOS:A1995RC44800038
J	PLUMMER, TH; TARENTINO, AL; HAUER, CR				PLUMMER, TH; TARENTINO, AL; HAUER, CR			NOVEL, SPECIFIC O-GLYCOSYLATION OF SECRETED FLAVOBACTERIUM-MENINGOSEPTICUM PROTEINS - ASP-SER-ASTERISK AND ASP-THR-ASTERISK-THR CONSENSUS SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGE CHROMATOGRAPHY; MOLECULAR-CLONING; PRIMARY SEQUENCE; GLYCOPROTEIN; LINKAGE	A new type of O-linked oligosaccharide has been discovered on several proteins secreted by the Gram-negative bacterium Flavobacterium meningosepticum, including Endo F-2 (three sites), Endo F-3 (one site), and a P40 protease (one site). The oligosaccharide moiety is covalently attached via a mannose residue to a serine or threonine at consensus sites corresponding to Asp-Ser* or Asp-Thr*-Thr. Preliminary characterization by mass spectroscopy revealed an oligosaccharide of 1244 Da at each of the proposed glycosylation sites. Collision-associated dissociation analysis showed a characteristic daughter ion series of m/z 218, 394, and 556, indicative of a common Flavobacterium oligosaccharide. Compositional analysis demonstrated an unusual profile of monosaccharides, including hexoses, methylated hexoses, and uronic acid derivatives.	SUNY ALBANY,SCH PUBL HLTH,ALBANY,NY 12201	State University of New York (SUNY) System; State University of New York (SUNY) Albany	PLUMMER, TH (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,DIV MOLEC MED,ALBANY,NY 12201, USA.			Hauer, Christoph/0000-0001-8704-2198	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER; NCRR NIH HHS [1-P41-RR05351-05] Funding Source: Medline; PHS HHS [30471] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CARLSON DM, 1968, J BIOL CHEM, V243, P616; CLARKE AJ, 1991, ANAL BIOCHEM, V199, P68, DOI 10.1016/0003-2697(91)90270-4; DUBIOS M, 1956, ANAL CHEM, V28, P350, DOI DOI 10.1021/AC60111A017; ERICKSON PR, 1993, J BIOL CHEM, V268, P23780; GERWIG GJ, 1993, J BIOL CHEM, V268, P26956; GRIMWOOD BG, 1994, ARCH BIOCHEM BIOPHYS, V311, P127, DOI 10.1006/abbi.1994.1217; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; KARCHER U, 1993, J BIOL CHEM, V268, P26821; MERKLE RK, 1994, METHOD ENZYMOL, V231, P1; MESCHER MF, 1976, J BIOL CHEM, V251, P2005; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; REINHOLD BB, 1995, J BIOL CHEM, V270, P13197, DOI 10.1074/jbc.270.22.13197; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V316, P399, DOI 10.1006/abbi.1995.1053; TARENTINO AL, 1992, J BIOL CHEM, V267, P3868; TARENTINO AL, 1993, J BIOL CHEM, V268, P9702; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TARENTINO AL, 1990, J BIOL CHEM, V265, P6961; TARENTINO AL, 1995, IN PRESS ARCH BIOCH; TOWNSEND RR, 1991, CARBOHYD RES, V215, P211, DOI 10.1016/0008-6215(91)84021-6; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; YORK WS, 1986, METHOD ENZYMOL, V118, P3	21	49	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13192	13196		10.1074/jbc.270.22.13192	http://dx.doi.org/10.1074/jbc.270.22.13192			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768916	hybrid			2022-12-25	WOS:A1995RB43900039
J	POSAS, F; CAMPS, M; ARINO, JQ				POSAS, F; CAMPS, M; ARINO, JQ			THE PPZ PROTEIN PHOSPHATASES ARE IMPORTANT DETERMINANTS OF SALT TOLERANCE IN YEAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; KINASE GENE; ATPASE; DOWNSTREAM; TRANSPORT; MUTATIONS; HOMOLOGS; PATHWAY; TRK1; PAIR	Protein phosphatases PPZ1 and PPZ2 represent a novel form of Ser/Thr phosphatases structurally related to type 1 phosphatases and characterized by an unusual amino-terminal region. We have found that the deletion of PPZ1 gene results in increased tolerance to Na+ and Li+ cations. Simultaneous deletion of PPZ2 gene results in an additional increase in salt tolerance. After exposure to high concentration of Li+, the intracellular content of the cation was markedly decreased in ppz1 Delta ppz2 Delta mutants when compared to wild type cells. No significant differences were observed between both strains when the Li+ influx was measured, but ppz1 Delta ppz2 Delta mutants eliminated Li+ more efficiently than wild type cells. This can be explained by the fact that expression of the ENA1 gene, which encodes the major component of the efflux system for these cations, is strongly increased in ppz1 Delta ppz2 Delta cells. As expected, the disruption of the PPZ genes did not complement the characteristic hypersensitivity for Na+ and Li+ of a ena1 Delta strain. The lack of protein phosphatase 2B (calcineurin) has been found to decrease salt resistance by reducing the expression of the ENA1 gene. We have observed that the disruption of the PPZ genes substantially enhances the resistance of the hypersensitive calcineurin-deficient mutants. Since PPZ phosphatases have been found to be functionally related to the protein kinase C/mitogen-activated kinase pathway, we have tested bck1 or mpk1/slt2 deletion mutants and found that they do not display altered salt sensitivity. However, disruption of PPZ1 fails to increase salt resistance in a mpk1/slt2 background. In conclusion, we postulate the existence in yeast of a novel PPZ-mediated pathway involved in salt homeostasis that is opposite to and independent of the recently described calcineurin-mediated pathway.	UNIV AUTONOMA BARCELONA,FAC VET,DEPT BIOQUIM & BIOL MOLEC,E-08193 BARCELONA,SPAIN	Autonomous University of Barcelona			Arino, Joaquin/D-3756-2011; Posas, Francesc/K-1364-2013; Zhang, Ning/F-1387-2014	Arino, Joaquin/0000-0002-6774-2987; Posas, Francesc/0000-0002-4164-7076; Arino Carmona, Joaquin/0000-0002-0390-4270				COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HARO R, 1993, PHYSIOL PLANTARUM, V89, P868, DOI 10.1111/j.1399-3054.1993.tb05298.x; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HUGHERS V, 1993, EUR J BIOCHEM, V216, P2669; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; LEE KS, 1993, MOL CELL BIOL, V13, P5843, DOI 10.1128/MCB.13.9.5843; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEVIN DE, 1993, J NIH RES, V5, P49; MARTINEZ R, 1991, MOL GEN GENET, V227, P149, DOI 10.1007/BF00260720; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; MURGUIA JR, 1995, SCIENCE, V267, P232; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; POSAS F, 1993, FEBS LETT, V318, P282, DOI 10.1016/0014-5793(93)80529-4; POSAS F, 1992, J BIOL CHEM, V267, P11734; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; RODRIGUEZNAVARRO A, 1981, BIOCHIM BIOPHYS ACTA, V640, P352, DOI 10.1016/0005-2736(81)90558-7; RODRIGUEZNAVARRO A, 1994, BBA-BIOENERGETICS, V1187, P203, DOI 10.1016/0005-2728(94)90111-2; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sherman F., 1986, METHODS YEAST GENETI; SKALA J, 1991, YEAST, V7, P651, DOI 10.1002/yea.320070614; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; TRECO DA, 1989, CURRENT PROTOCOLS MO, V2; WARD MP, 1994, MOL CELL BIOL, V14, P5619, DOI 10.1128/MCB.14.9.5619; WELIHINDA AA, 1994, BBA-BIOMEMBRANES, V1193, P107, DOI 10.1016/0005-2736(94)90339-5	34	122	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13036	13041		10.1074/jbc.270.22.13036	http://dx.doi.org/10.1074/jbc.270.22.13036			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768897	hybrid			2022-12-25	WOS:A1995RB43900018
J	MARTEL, C; LALLEMAND, D; CREMISI, C				MARTEL, C; LALLEMAND, D; CREMISI, C			SPECIFIC C-MYC AND MAX REGULATION IN EPITHELIAL-CELLS	ONCOGENE			English	Article						C-MYC; MAX; C-FOS; EPITHELIAL CELLS	DENSITY-DEPENDENT REGULATION; MESSENGER-RNA; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; RAS COTRANSFORMATION; TRANSGENIC MICE; PROTO-ONCOGENE; DNA-BINDING; BSC-1 CELLS; 3T3 CELLS	We have investigated c-myc, max and c-fos mRNA and protein expression in proliferating, quiescent and stimulated immortalized, SV40 T antigen (LT) transformed and tumor-derived epithelial cells as well in human primary keratinocytes and have compared them to their expression in fibroblasts. In proliferating immortalized and tumor-derived epithelial cells, the levels of c-myc, max and c-fos expression were comparable and much higher than in transformed fibroblasts, c-myc and c-fos mRNA and protein levels remained high even during quiescence, when cells stopped dividing. In contrast, whereas max mRNA was constitutively expressed, max protein levels decreased in both fibroblasts and epithelial cells at high cell density. Changing the medium to serum-free medium of confluent epithelial cells induced a complete proliferative response which started with a transient increase in c-fos and c-myc mRNA, followed by the expression of max, Addition of serum to the medium did not induce additional effects. In fibroblasts, similar treatment induced the arrest of c-myc expression and growth, but max expression was also induced in these cells by serum. Our results therefore show that max expression is growth regulated in both immortalized and transformed epithelial as well as fibroblast cells, In contrast, in epithelial cells, c-myc displayed two contrasting behaviors.	INST PASTEUR, UNITE TECHNOL CELLULAIRE, F-75724 PARIS 15, FRANCE; INST PASTEUR, UNITE VIRUS ONCOGENES, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			lallemand, dominique/O-7445-2017	lallemand, dominique/0000-0002-0212-7342				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COOK PW, 1991, J CELL PHYSIOL, V146, P277, DOI 10.1002/jcp.1041460213; CREMISI C, 1989, MECH B CELL NEOPLASI, P314; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEAN M, 1986, J BIOL CHEM, V261, P9161; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; DULBECCO R, 1973, NATURE, V246, P197, DOI 10.1038/246197a0; DULBECCO R, 1970, NATURE, V227, P802, DOI 10.1038/227802a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HOLLEY RW, 1977, P NATL ACAD SCI USA, V74, P5046, DOI 10.1073/pnas.74.11.5046; HOLLEY RW, 1978, P NATL ACAD SCI USA, V75, P339, DOI 10.1073/pnas.75.1.339; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORELLO D, 1989, ONCOGENE, V4, P955; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ONCLERCQ R, 1989, NUCLEIC ACIDS RES, V17, P735, DOI 10.1093/nar/17.2.735; ONCLERCQ R, 1989, ONCOGENE RES, V4, P293; ONCLERCQ R, 1988, J VIROL, V62, P4533, DOI 10.1128/JVI.62.12.4533-4537.1988; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; PIENTENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SAMBROOK J, 1989, COLD SPR HARB LAB PR; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SPENCER CA, 1991, ADV CANCER RES, V56, P1; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WATERS CM, 1991, ONCOGENE, V6, P797; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	63	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2195	2205						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784064				2022-12-25	WOS:A1995RB70300015
J	CHANG, PY; GOODYEAR, LJ; BENECKE, H; MARKUNS, JS; MOLLER, DE				CHANG, PY; GOODYEAR, LJ; BENECKE, H; MARKUNS, JS; MOLLER, DE			IMPAIRED INSULIN SIGNALING IN SKELETAL-MUSCLES FROM TRANSGENIC MICE EXPRESSING KINASE-DEFICIENT INSULIN-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; TYROSINE KINASE; MONOCLONAL-ANTIBODIES; SUBSTRATE PHOSPHORYLATION; TRANSFECTED CELLS; OBESE MICE; STIMULATION; PROTEIN; RAT	Transgenic mice which overexpress kinase-deficient human insulin receptors in muscle were used to study the relationship between insulin receptor tyrosine kinase and the in vivo activation of several downstream signaling pathways. Intravenous insulin stimulated insulin receptor tyrosine kinase activity by 7-fold in control muscle versus less than or equal to 1.5-fold in muscle from transgenic mice. Similarly, insulin failed to stimulate tyrosyl phosphorylation of receptor beta-subunits or insulin receptor substrate 1 (IRS-1) in transgenic muscle, Insulin substantially stimulated IRS-1 associated phosphatidylinositol (PI) 3-kinase in control versus absent stimulation in transgenic muscles. In contrast, insulin-like growth factor 1 modestly stimulated PI 3-kinase in both control and transgenic muscle, The effects of insulin to stimulate p42 mitogen activated protein kinase and c-fos mRNA expression were also markedly impaired in transgenic muscle. Specific immunoprecipitation of human receptors followed by measurement of residual insulin receptors suggested the presence of hybrid mouse-human heterodimers, In contrast, negligible hybrid formation involving insulin-like growth factor 1 receptors was evident, We conclude that (i) transgenic expression of kinase-defective insulin receptors exerts dominant-negative effects at the level of receptor autophosphorylation and kinase activation; (ii) insulin receptor tyrosine kinase activity is required for in vivo insulin-stimulated IRS-1 phosphorylation, IRS-1-associated PI 3-kinase activation, phosphorylation of mitogen-activated protein kinase, and c-fos gene induction in skeletal muscle; (iii) hybrid receptor formation is likely to contribute to the in vivo dominant-negative effects of kinase-defective receptor expression.	BETH ISRAEL HOSP, DEPT MED, CHARLES A DANA RES INST, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT MED, HARVARD THORNDIKE LAB, BOSTON, MA 02215 USA; JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School				Markuns, Jeffrey/0000-0002-8044-2575	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR042238] Funding Source: NIH RePORTER; NIAMS NIH HHS [R29-AR42238] Funding Source: Medline; PHS HHS [R01 45874-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHANG PY, 1994, J BIOL CHEM, V269, P16034; CHIN JE, 1991, J BIOL CHEM, V266, P15587; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; GIORGINO F, 1993, J CLIN INVEST, V91, P2020, DOI 10.1172/JCI116424; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; GRAKO KA, 1994, MOL ENDOCRINOL, V8, P682, DOI 10.1210/me.8.6.682; GRIGORESCU F, 1984, J BIOL CHEM, V259, P5003; HARING H, 1989, DIABETES METAB REV, V5, P431; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HEI YJ, 1993, J BIOL CHEM, V268, P13203; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; JACOB R, 1989, J CLIN INVEST, V83, P1717, DOI 10.1172/JCI114072; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KLEIN HH, 1993, DIABETES, V42, P883, DOI 10.2337/diabetes.42.6.883; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEMARCHANDBRUST.Y, 1982, AM J PHYSIOL, V243, pE74; LEMARCHANDBRUSTEL Y, 1985, NATURE, V315, P676, DOI 10.1038/315676a0; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOUNTJOY KG, 1990, BIOCHEM BIOPH RES CO, V169, P978, DOI 10.1016/0006-291X(90)91990-A; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OLSON AL, 1994, ENDOCRINOLOGY, V134, P271, DOI 10.1210/en.134.1.271; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; PANG L, 1993, BIOCHEM BIOPH RES CO, V196, P301, DOI 10.1006/bbrc.1993.2249; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SELVA E, 1993, J BIOL CHEM, V268, P2250; SOOS MA, 1989, P NATL ACAD SCI USA, V86, P5217, DOI 10.1073/pnas.86.14.5217; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAUB R, 1987, J BIOL CHEM, V262, P10893; Taylor Simeon I., 1993, P83; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; UENO H, 1993, J BIOL CHEM, V268, P22814; UENO H, 1992, J BIOL CHEM, V267, P1470; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WHITE MF, 1994, INSULIN RESISTANCE, P9; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WILDEN PA, 1994, MOL ENDOCRINOL, V8, P558, DOI 10.1210/me.8.5.558; YAMAGUCHI Y, 1993, ENDOCRINOLOGY, V132, P1132, DOI 10.1210/en.132.3.1132; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; ZHOU GX, 1993, BIOCHEM BIOPH RES CO, V197, P578, DOI 10.1006/bbrc.1993.2518	58	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12593	12600		10.1074/jbc.270.21.12593	http://dx.doi.org/10.1074/jbc.270.21.12593			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759507	hybrid			2022-12-25	WOS:A1995QZ71100042
J	THOLANIKUNNEL, BG; GRANNEMAN, JG; MALBON, CC				THOLANIKUNNEL, BG; GRANNEMAN, JG; MALBON, CC			THE M(R)-35,000 BETA-ADRENERGIC-RECEPTOR MESSENGER-RNA-BINDING PROTEIN BINDS TRANSCRIPTS OF G-PROTEIN-LINKED RECEPTORS WHICH UNDERGO AGONIST-INDUCED DESTABILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; 3' UNTRANSLATED REGION; CELL-FREE SYSTEM; MOLECULAR-CLONING; BETA-3-ADRENERGIC RECEPTOR; GENE-EXPRESSION; DOWN-REGULATION; RICH DOMAINS; TURNOVER	The M(r) 35,000 beta-adrenergic receptor mRNA-binding protein, termed beta-ARB protein, is induced by beta-adrenergic agonists and binds to beta(2)-receptor mRNAs that display agonist-induced destabilization. Recently a cognate sequence in the mRNA was identified that provides for recognition by beta-ARE protein. In the present work we test the ability of the beta-ARB to discriminate among G-protein-linked receptor mRNAs that either do or do not display agonist-induced destabilization and test the predictive value of the presence of the cognate sequence to identify receptors displaying post-transcriptional regulation. Transcripts of beta(2)-, but not rat beta(1)-, rat beta(3)-, or human beta(3)-adrenergic receptors bind beta-ARB protein, linking agonist-induced destabilization of mRNA to transcripts with the cognate sequence. Scanning GeneBank for G-protein-linked receptor transcripts with the cognate sequence revealed several candidates, including the thrombin receptor. We demonstrate that the thrombin receptor mRNA is recognized by beta-ARB protein and like the beta(2)-receptor is regulated post-transcriptionally by agonist and cAMP. Thus, the domain of regulation by beta-ARB protein includes transcripts of G-protein-linked receptors other than beta(2)-adrenergic receptors.	SUNY STONY BROOK, UNIV MED CTR, DEPT PHARMACOL, DIABET & METAB DIS RES PROGRAM, STONY BROOK, NY 11794 USA; WAYNE STATE UNIV, DEPT PSYCHIAT, DETROIT, MI 48201 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; Wayne State University			malbon, craig/ABF-3604-2020		NIDDK NIH HHS [DK25410] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025410] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; BAHOU WF, 1991, J CLIN INVESTI, V91, P1405; BAHOUTH SW, 1992, MOL PHARMACOL, V42, P971; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; GRANNEMAN JG, 1994, ENDOCRINOLOGY, V135, P1025, DOI 10.1210/en.135.3.1025; GRANNEMAN JG, 1992, ENDOCRINOLOGY, V130, P109, DOI 10.1210/en.130.1.109; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; GRANNEMAN JG, 1995, IN PRESS J AM PHYSL; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HADCOCK JR, 1991, TRENDS NEUROSCI, V14, P242, DOI 10.1016/0166-2236(91)90124-D; HADCOCK JR, 1993, J NEUROCHEM, V60, P1, DOI 10.1111/j.1471-4159.1993.tb05816.x; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HOUGH C, 1990, BIOCHEM BIOPH RES CO, V170, P46, DOI 10.1016/0006-291X(90)91238-N; HUANG LY, 1993, J BIOL CHEM, V268, P25769; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELIAS JM, 1993, FEBS LETT, V324, P127, DOI 10.1016/0014-5793(93)81377-C; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PELTZ SW, 1991, CRIT REV EUKAR GENE, V1, P99; PORT JD, 1992, J BIOL CHEM, V267, P24103; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; ROSS J, 1988, MOL BIOL MED, V5, P1; SCARPACE PJ, 1985, MOL PHARMACOL, V28, P495; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STEITZ JA, 1982, COLD SPRING HARB SYM, V47, P893, DOI 10.1101/SQB.1983.047.01.103; STOLLE CA, 1988, GENE, V62, P65, DOI 10.1016/0378-1119(88)90580-X; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x	57	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12787	12793		10.1074/jbc.270.21.12787	http://dx.doi.org/10.1074/jbc.270.21.12787			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759533	hybrid			2022-12-25	WOS:A1995QZ71100070
J	NAKAOKA, T; KOJIMA, N; OGITA, T; TSUJI, S				NAKAOKA, T; KOJIMA, N; OGITA, T; TSUJI, S			CHARACTERIZATION OF THE PHOSPHATIDYLSERINE-BINDING REGION OF RAT MARCKS (MYRISTOYLATED, ALANINE-RICH PROTEIN-KINASE-C SUBSTRATE) - ITS REGULATION THROUGH PHOSPHORYLATION OF SERINE-152	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-V; TRANSLOCATION; ASSOCIATION; CALMODULIN; MEMBRANE; CHICKEN; DOMAIN	We reported previously that recombinant myristoylated, alanine-rich protein kinase C substrate (MARCKS) expressed in Escherichia coli as well as MARCKS purified from rat brain specifically bound to phosphatidylserine (PS) in a calcium-independent manner and that the binding was regulated through phosphorylation of MARCKS (Nakaoka, T., Kojima, N., Hamamoto, T., Kurosawa, N., Lee, Y. C,, Kawasaki, H., Suzuki, K., and Tsuji, S. (1993) J. Biochem. (Tokyo) 114, 449-452), In this study, to identify the minimum PS-binding region of MARCKS and the regulatory phosphorylation site, the binding of MARCKS to PS was examined in deletion mutants producing glutathione S-transferase (GST) fusion proteins, The mutant proteins GST-6-180 and GST-127-160 had almost the same ability to bind to immobilized PS as MARCKS purified from rat brain, whereas GST-127-152 did not bind to it, In addition, the binding of GST-6-156 to immobilized PS was 62% of that of GST-6-180, but that of GST-6-152 was only 8% and that of GST-6-135 was not detected, The effect of phosphorylation by protein kinase C was examined in several mutants of GST-6-180 whose serine residues were substituted with alanine, After phosphorylation, the mutants GST-6-180[S156A and S163A], GST-6-180[S156A], and GST-6-180[S163A] did not bind to immobilized PS like native MARCKS and GST-6-180, However, even after phosphorylation, GST-6-180[S152A] and GST-6-180[S152A and S156A] could bind to immobilized PS. These results strongly suggest that MARCKS binds to PS molecules in the inner leaflet of the plasma membrane through residues 127-156, with residues 153-156 (FKKS) being particularly important in the binding of MARCKS to PS, and that the binding is regulated through the protein kinase C-catalyzed phosphorylation of the serine at residue 152.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,MOLEC GLYCOBIOL LAB,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,BUNKYO KU,TOKYO 112,JAPAN	RIKEN; University of Tokyo								ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; COUCSSENS L, 1986, SCIENCE, V233, P859; ELUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KALAFATIS M, 1992, J BIOL CHEM, V267, P21580; KIM JY, 1994, J BIOL CHEM, V269, P28214; MANENTI S, 1994, J BIOL CHEM, V269, P8309; MAYER LD, 1983, BIOCHEMISTRY-US, V22, P6226, DOI 10.1021/bi00295a029; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; NAKAOKA T, 1993, J BIOCHEM-TOKYO, V114, P449, DOI 10.1093/oxfordjournals.jbchem.a124196; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; OKAMURAIKEDA K, 1992, J BIOL CHEM, V267, P18284; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; YU FX, 1992, J BIOL CHEM, V267, P14616	22	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12147	12151		10.1074/jbc.270.20.12147	http://dx.doi.org/10.1074/jbc.270.20.12147			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744864	hybrid			2022-12-25	WOS:A1995QY73600067
J	PAANANEN, K; SAARINEN, J; ANNILA, A; KOVANEN, PT				PAANANEN, K; SAARINEN, J; ANNILA, A; KOVANEN, PT			PROTEOLYSIS AND FUSION OF LOW-DENSITY-LIPOPROTEIN PARTICLES STRENGTHEN THEIR BINDING TO HUMAN AORTIC PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTORS; PLASMA-LIPOPROTEINS; APOLIPOPROTEIN-B; CHOLESTEROL; GLYCOSAMINOGLYCANS; ATHEROSCLEROSIS; ACCUMULATION; FIBROBLASTS; INHIBITION; RESIDUES	Lipid droplets resembling those seen in the extracellular space of the arterial intima were generated in vitro when granule proteases of rat serosal mast cells degraded the apolipoprotein B-100 (apoB-100) component of granule bound low density lipoprotein (LDL), and the particles fused on the granule surface (Paananen, K., and Kovanen, P. T. (1994) J. Biol. Chem. 269, 2023-2031). Moreover, the binding of the fused particles to the heparin proteoglycan component of the granules was found to be strengthened. We have now treated LDL particles with alpha-chymotrypsin and examined the strength with which the proteolytically modified LDL binds to human aortic proteoglycans on an affinity column. We found that chymotryptic degradation of the LDL particles triggered particle fusion. The higher the degree of proteolytic degradation, the higher were the degree of fusion and the strength of binding to the aortic proteoglycans. Separation of the proteolyzed particles by size exclusion chromatography into two fractions, unfused and fused particles, and analysis of their binding strengths revealed that not only the fused but also the unfused proteolyzed particles bound more tightly to the proteoglycans than did the native LDL particles. To investigate the mechanism underlying this increase in binding strength, we attached [C-13]dimethyl groups to the lysines and used NMR spectroscopy to quantify the active lysine residues of apoB-100, which are thought to be located in basic areas of apoB-100 and involved in binding of LDL to proteoglycans. Analysis of the C-13-labeled particles showed that, despite loss of apoB-100 fragments from the particles, the number of active lysine residues in the unfused proteolyzed particles had not decreased. In the fused proteolyzed particles, the number of active lysine residues was markedly increased. Thus, proteolytic fusion appears to increase the number of basic domains of apoB-100, which would explain the observed increase in the strength of binding of the modified LDL particles to arterial proteoglycans. Since the fused particles resemble the small lipid droplets found in the atherosclerotic arterial intima, this LDL modification offers a plausible mechanism for the focal accumulation of lipid droplets in the extracellular proteoglycan matrix during atherogenesis.	WIHURI RES INST, SF-00140 HELSINKI, FINLAND; STATE TECH RES CTR FINLAND, SF-02044 ESPOO, FINLAND	Wihuri Research Institute			Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250				BARTOLD PM, 1985, ANAL BIOCHEM, V150, P320, DOI 10.1016/0003-2697(85)90517-2; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CAMEJO G, 1993, J BIOL CHEM, V268, P14131; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHANG JY, 1983, METHOD ENZYMOL, V91, P41, DOI 10.1016/S0076-6879(83)91009-1; Forte T, 1972, Adv Lipid Res, V10, P1; FRANK JS, 1989, J LIPID RES, V30, P967; GUYTON JR, 1990, EUR HEART J, V11, P20, DOI 10.1093/eurheartj/11.suppl_E.20; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KAARTINEN M, 1994, ARTERIOSCLER THROMB, V14, P966, DOI 10.1161/01.ATV.14.6.966; KAARTINEN M, 1994, CIRCULATION, V90, P1669, DOI 10.1161/01.CIR.90.4.1669; KOVANEN PT, 1991, J BIOL CHEM, V266, P4430; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; MACEK J, 1987, J CHROMATOGR-BIOMED, V414, P156, DOI 10.1016/0378-4347(87)80034-8; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MAHLEY RW, 1977, J BIOL CHEM, V252, P7279; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; PAANANEN K, 1994, J BIOL CHEM, V269, P2023; PASQUINELLI G, 1989, SCANNING MICROSCOPY, V3, P1151; PLANE F, 1993, ATHEROSCLEROSIS, V103, P73, DOI 10.1016/0021-9150(93)90041-R; RADDING CM, 1960, J CLIN INVEST, V39, P1560, DOI 10.1172/JCI104177; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; Smith E B, 1974, Adv Lipid Res, V12, P1; VIJAYAGOPAL P, 1992, ARTERIOSCLER THROMB, V12, P237, DOI 10.1161/01.ATV.12.2.237; WAGNER WD, 1986, ARTERIOSCLEROSIS, V6, P407, DOI 10.1161/01.ATV.6.4.407; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097	33	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12257	12262		10.1074/jbc.270.20.12257	http://dx.doi.org/10.1074/jbc.270.20.12257			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744877	hybrid			2022-12-25	WOS:A1995QY73600082
J	SMARDOVA, J; WALKER, A; MORRISON, LE; KABRUN, N; ENRIETTO, PJ				SMARDOVA, J; WALKER, A; MORRISON, LE; KABRUN, N; ENRIETTO, PJ			THE ROLE OF THE CARBOXY-TERMINUS OF V-REL IN TRANSFORMATION AND ACTIVATION OF ENDOGENOUS GENE-EXPRESSION	ONCOGENE			English	Article						V-REL; ONCOGENES; GENE EXPRESSION; TRANSFORMATION	NF-KAPPA-B; CHICKEN SPLEEN-CELLS; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; ONCOGENIC TRANSFORMATION; TRANSCRIPTION FACTORS; EMBRYO FIBROBLASTS; ESTROGEN-RECEPTOR; CELLULAR PROTEINS; HOMOLOGY DOMAIN	Proteins within the Rel/NF-kappa B transcription factor family can be divided into two functional domains, a homologous amino terminal region, the Rel Homology Domain, and a divergent carboxy terminal domain. The amino terminal sequences specify DNA binding, nuclear localization, and interaction with the I kappa B family of inhibitory proteins. The carboxy terminus of each protein functions as a transcriptional activation domain, however, precise definition of sequence requirements has been difficult. To further define these sequences, small 100 bp deletions were constructed throughout the carboxy terminus of v-Rel. Each resulting mutant was assayed for DNA binding, localization, protein complex formation, activation of endogenous gene expression and ability to transform bone marrow cells and fibroblasts. Surprisingly, deletion within the carboxy terminus had marginal effects on transforming potential. However, three separate regions were required for full activation of gene expression. Taken together, these results suggest that the carboxy terminus of v-Rel contains multiple sequences that participate in the activation of gene expression.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [R01 CA 51792, CA 09176] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1987, CURRENT PROCOLS MOL; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRIPPA MP, 1993, EMBO J, V12, P3855, DOI 10.1002/j.1460-2075.1993.tb06064.x; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GARSON K, 1990, ONCOGENE, V5, P1431; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; GILMORE TD, 1991, TRENDS GENET, V7, P307; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1990, ONCOGENE, V5, P1843; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INOUE J-I, 1991, P NATL ACAD SCI USA, V88, P3175; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1992, SEM DEV BIOL, V3, P15; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN J, 1992, ONCOGENE, V7, P1903; LEHN DA, 1993, DNA CELL BIOL, V12, P753, DOI 10.1089/dna.1993.12.753; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MACCABE JA, 1990, J EXPER ZOO, V257, P208; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; RUBEN SM, 1991, SCIENCE, V254, P11, DOI 10.1126/science.1925549; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992	60	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					2017	2026						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761102				2022-12-25	WOS:A1995QZ92600016
J	MAJELLO, B; DELUCA, P; SUSKE, G; LANIA, L				MAJELLO, B; DELUCA, P; SUSKE, G; LANIA, L			DIFFERENTIAL TRANSCRIPTIONAL REGULATION OF C-MYC PROMOTER THROUGH THE SAME DNA-BINDING SITES TARGETED BY SP1-LIKE PROTEINS	ONCOGENE			English	Article						C-MYC TRANSCRIPTION; SP1; SP3	TRANS-ACTIVATION; FACTOR E2F; SP1; PRODUCT; DOMAINS; GENE; TRANSACTIVATION; ELEMENTS; COMPLEX; CLONING	Sp1 and Sp3 are closely related members of a gene family encoding proteins with very similar structural features. The zinc finger DNA binding domains of Sp1 and Sp3 are highly conserved and they bind to GC and GT box with comparable affinities. To begin to delineate the specific roles of these two members of the Sp1-like gene family, here we have analysed the DNA binding specificity and their effects on activation of human c-myc promoter. We found that both proteins bind to the same sites of c-myc promoter, upstream to both the P1 and P2 initiation sites. Cotransfection experiments, in mammalian and insect cells, indicated that Sp1 trans-activate c-myc promoter, whereas Sp3 did not. In addition, enforced expression of Sp3 repressed Spl-mediated activation of c-myc. Finally, we found that Sp1 and E2F-1/DP-1 cooperatively trans-activate c-myc promoter. In contrast enforced expression of Sp3 fails to repress EZF-1/DP-1-mediated activation.	UNIV NAPLES FEDERICO II, DIPARTIMENTO GENET BIOL GEN & MOLEC, I-80134 NAPLES, ITALY; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	University of Naples Federico II; Philipps University Marburg			De Luca, Pasquale/AAL-5673-2021	De Luca, Pasquale/0000-0003-4289-6784; Suske, Guntram/0000-0002-4807-0513; Majello, Barbara/0000-0003-2789-3585				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BROOME HE, 1987, MOL CELL BIOL, V7, P2988, DOI 10.1128/MCB.7.8.2988; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHANG Y, 1991, ONCOGENE, V6, P1979; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LAMANTIA G, 1992, NUCLEIC ACIDS RES, V20, P4129, DOI 10.1093/nar/20.16.4129; LIPP M, 1989, ONCOGENE, V4, P535; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SPENCER CA, 1991, ADV CANCER RES, V56, P1; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527	33	120	121	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1841	1848						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753559				2022-12-25	WOS:A1995QX46900017
J	AIZENBERG, J; HANSON, J; ILAN, M; LEISEROWITZ, L; KOETZLE, TF; ADDADI, L; WEINER, S				AIZENBERG, J; HANSON, J; ILAN, M; LEISEROWITZ, L; KOETZLE, TF; ADDADI, L; WEINER, S			MORPHOGENESIS OF CALCITIC SPONGE SPICULES - A ROLE FOR SPECIALIZED PROTEINS INTERACTING WITH GROWING CRYSTALS	FASEB JOURNAL			English	Article						BIOMINERALIZATION; CALCISPONGES; X-RAY DIFFRACTION; CALCITE; CRYSTAL MORPHOLOGY	MACROMOLECULES	Crystals formed in biological tissues often adopt remarkable morphologies that are thought to be determined mainly by the shapes of the confined spaces in which they grow. Another possible way of controlling crystal shape, demonstrated only in vitro, is by means of specialized proteins preferentially interacting with certain crystal faces. In so doing, they reduce the rate of growth in these directions and consequently change the overall crystal shape. In an X-ray diffraction study of the distribution of defects within the lattice of calcite crystals produced by certain sponges, we show that a remarkable correlation exists between the defect patterns or crystal texture and the macroscopic morphology of the spicules. This was observed in two cases in which proteins are present within the spicule crystal, but not in a third case where such intracrystalline proteins are absent. Furthermore, one of the spicules exhibited marked differences in texture even within families of structurally identical crystal planes, demonstrating that the organisms exert exquisite control over the microenvironment in which crystals grow. We conclude that highly controlled intercalation of specialized proteins inside the crystals is an additional means by which organisms control spicule growth.	WEIZMANN INST SCI,DEPT MAT & INTERFACES,REHOVOT,ISRAEL; TEL AVIV UNIV,DEPT ZOOL,TEL AVIV,ISRAEL; BROOKHAVEN NATL LAB,DEPT CHEM,UPTON,NY	Weizmann Institute of Science; Tel Aviv University; United States Department of Energy (DOE); Brookhaven National Laboratory	AIZENBERG, J (corresponding author), WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL.		Ilan, Micha/ABG-4106-2020; Hanson, jonathan C/E-3517-2010	Ilan, Micha/0000-0002-4188-4573; Hanson, Jonathan/0000-0003-0686-3985				ADDADI L, 1994, MOL CRYST LIQ CRYS A, V248, P185, DOI 10.1080/10587259408027179; AIZENBERG J, 1994, J CRYST GROWTH, V142, P156, DOI 10.1016/0022-0248(94)90283-6; ALBECK S, 1993, J AM CHEM SOC, V115, P11691, DOI 10.1021/ja00078a005; BERMAN A, 1993, SCIENCE, V259, P776, DOI 10.1126/science.259.5096.776; BERMAN A, 1990, SCIENCE, V250, P664, DOI 10.1126/science.250.4981.664; BERMAN A, 1988, NATURE, V331, P546, DOI 10.1038/331546a0; GOLDSMITH JR, 1961, AM MINERAL, V46, P453; Guinier A., 1963, XRAY DIFFRACTION; Haeckel E., 1872, KALKSCHWAMME; Jones W. C., 1970, Symp. zool. Soc. Lond., VNo. 25, P91; JONES WC, 1955, Q J MICROSC SCI, V96, P129; JONES WC, 1970, CALC TISS RES, V4, P314; LEDGER PW, 1975, TISSUE CELL, V7, P13, DOI 10.1016/S0040-8166(75)80004-8; Lowenstam HA, 1989, BIOMINERALIZATION; MANN S, 1989, BIOMINERALIZATION CH, P189; Minchin E.A., 1898, Q J MICROSC SCI, V40, P469; Simkiss K, 1986, BIOMINERALIZATION LO, P19; Simkiss K, 1989, BIOMINERALIZATION CE; TSURNAMAL M, 1975, ISRAEL J ZOOL, V24, P137; WEINER S, 1991, TRENDS BIOCHEM SCI, V16, P252, DOI 10.1016/0968-0004(91)90098-G	20	103	104	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					262	268		10.1096/fasebj.9.2.7781928	http://dx.doi.org/10.1096/fasebj.9.2.7781928			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781928				2022-12-25	WOS:A1995QJ24900015
J	BAJZAR, L; MANUEL, R; NESHEIM, ME				BAJZAR, L; MANUEL, R; NESHEIM, ME			PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C; PLASMINOGEN-ACTIVATOR; ENZYME COMPLEXES; FACTOR-VA; BLOOD; SYSTEM; PROTHROMBIN; MECHANISM; PLASMA; EXPRESSION	Previous studies demonstrated that tissue plasminogen activator-induced fibrinolysis in vitro is retarded in the presence of prothrombin (II) activation and that the anticoagulant-activated protein C appears profibrinolytic by preventing the formation of thrombin (IIa)-like activity during fibrinolysis. To disclose the molecular connection between the generation of IIa and the inhibition of fibrinolysis, a lysis assay that is sensitive to the antifibrinolytic effect of II activation was developed tend was used to purify a 60-kDa single-chain protein from human plasma. Because the lysis of a clot, produced from purified components, is retarded when this protein is present and when II activation occurs in situ, the protein was named TAFI (thrombin-activatable fibrinolysis inhibitor). TAFI is cleaved by IIa yielding 35-, 25-, and 14-kDa products. Amino-terminal sequence analyses identified TAFI as a precursor of a plasma carboxypeptidase B (CPB). Formation of the 35-kDa product correlates with both prolongation of lysis time and CPB-like activity. Prolongation of lysis time saturates at about 125 nM TAFI. Activated TAFI inhibits the activation of Glu-plasminogen but does not prolong the lysis of clots formed in the presence of Lys-plasminogen. 2-Guanidinoethylmercaptosuccinic acid, a competitive inhibitor of CPB, completely inhibits prolongation of lysis by activated TAFI in a purified system and the prolongation induced by II activation in barium-adsorbed plasma. This suggests that TAFI accounts for the antifibrinolytic effect that accompanies prothrombin activation and that activated protein C appears profibrinolytic by attenuating TAFI activation.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada; Queens University - Canada								BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; COMP PC, 1981, J CLIN INVEST, V68, P1221, DOI 10.1172/JCI110368; COTE HCF, 1994, J BIOL CHEM, V269, P11374; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; Damus P S, 1976, Methods Enzymol, V45, P653; DEFOUW NJ, 1990, ADV EXP MED BIOL, V281, P235; EATON DL, 1991, J BIOL CHEM, V266, P21833; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ESMON NL, 1982, J BIOL CHEM, V257, P859; FOLK JE, 1960, J BIOL CHEM, V235, P2272; FREDEMNBURGH JC, 1992, FIBRINOLYSIS S2, V6, P68; GAFFNEY PJ, 1993, FIBRINOLYSIS, V7, P2, DOI 10.1016/0268-9499(93)90039-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCKAY TJ, 1978, BIOCHEMISTRY-US, V17, P401, DOI 10.1021/bi00596a003; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1983, J BIOL CHEM, V245, P14708; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; SAKATA Y, 1986, BLOOD, V68, P1218; SMITH RAG, 1986, BIOCHEM J, V239, P477, DOI 10.1042/bj2390477; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; TAYLOR FB, 1981, FED PROC, V40, P2092; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WANG W, 1994, J BIOL CHEM, V269, P15937; WEINSTEIN RE, 1993, SEMIN THROMB HEMOST, V19, P368, DOI 10.1055/s-2007-993288; WEINSTEIN RE, 1991, THROMB RES, V63, P123, DOI 10.1016/0049-3848(91)90275-2; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x	41	595	619	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14477	14484		10.1074/jbc.270.24.14477	http://dx.doi.org/10.1074/jbc.270.24.14477			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782309	hybrid			2022-12-25	WOS:A1995RD45500039
J	HAWKINS, MG; MCGHEE, JD				HAWKINS, MG; MCGHEE, JD			ELT-2, A 2ND GATA FACTOR FROM THE NEMATODE CAENORHABDITIS-ELEGANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE ZINC FINGER; TRANSCRIPTION FACTOR GATA-1; NITROGEN REGULATORY GENE; DNA-BINDING DOMAIN; LEADER SEQUENCE; EXPRESSION; PROTEIN; FAMILY; ACTIVATION; ESTERASE	We have previously shown that a tandem pair of (A/T)GATA(A/G) sequences in the promoter region of the Caenorhabditis elegans gut esterase gene (ges-1) controls the tissue specificity of ges-1 expression in vivo. The ges-1 GATA region was used as a probe to screen a C. elegans cDNA expression library, and a gene for a new C. elegans GATA-factor (named elt-2) was isolated. The longest open reading frame in the elt-2 cDNA codes for a protein of M(r) 47,000 with a single zinc finger domain, similar (approximately 75% amino acid identity) to the C-terminal fingers of all other two-fingered GATA factors isolated to date. A similar degree of relatedness is found with the single-finger DNA binding domains of GATA factors identified in invertebrates. An upstream region in the ELT 8 protein with the sequence C-X(2)-C-X(16)-C-X(2)-C has some of the characteristics of a zinc finger domain but is highly diverged from the zinc finger domains of other GATA factors. The elt-2 gene is expressed as an SL1 trans-spliced message, which can be detected at all stages of development except oocytes; however, elt-2 message levels are 5-10-fold higher in embryos than in other stages. The genomic clone for elt-2 has been characterized and mapped near the center of the C. elegans X chromosome. ELT-2 protein, produced by in. vitro transcription-translation, binds to ges-1 GATA-containing oligonucleotides similar to a factor previously identified in C. elegans embryo extracts, both as assayed by electrophoretic migration and by competition with wild type and mutant oligonucleotides. However, there is as yet no direct evidence that elt-2 does or does not control ges-1.	UNIV CALGARY,HLTH SCI CTR,DEPT MED BIOCHEM,CALGARY,AB T2N 4N1,CANADA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba				McGhee, James/0000-0001-7266-7275				AAMODT EJ, 1991, SCIENCE, V252, P579, DOI 10.1126/science.2020855; ABEL T, 1993, DEVELOPMENT, V119, P623; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BRENNER S, 1974, GENETICS, V77, P71; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; EGAN CR, 1995, IN PRESS DEV BIOL; ENGEL JD, 1991, SEMIN HEMATOL, V28, P158; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HORVITZ HR, 1979, MOL GEN GENET, V175, P129, DOI 10.1007/BF00425528; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; KENNEDY BP, 1993, J MOL BIOL, V229, P890, DOI 10.1006/jmbi.1993.1094; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LAVERRIERE AC, 1994, J BIOL CHEM, V268, P23177; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; ORKIN SH, 1992, BLOOD, V80, P575; RAMAIN P, 1993, DEVELOPMENT, V118, P1277; SAMBROOK J, 1989, LABORATORY MANUAL; SCHWARTZBAUER G, 1992, NUCLEIC ACIDS RES, V20, P4429, DOI 10.1093/nar/20.17.4429; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; STROEHER VL, 1994, DEV BIOL, V163, P367, DOI 10.1006/dbio.1994.1155; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WINNICK J, 1993, DEVELOPMENT, V119, P1055; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	35	71	76	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14666	14671		10.1074/jbc.270.24.14666	http://dx.doi.org/10.1074/jbc.270.24.14666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782329	hybrid			2022-12-25	WOS:A1995RD45500065
J	WALKER, PK; LEONG, LEC; PORTER, AG				WALKER, PK; LEONG, LEC; PORTER, AG			SEQUENCE AND STRUCTURAL DETERMINANTS OF THE INTERACTION BETWEEN THE 5'-NONCODING REGION OF PICORNAVIRUS RNA AND RHINOVIRUS PROTEASE 3C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' NONCODING REGION; COMMON COLD VIRUS; POLIOVIRUS RNA; CYSTEINE PROTEASES; SERINE PROTEASES; VIRAL-RNA; EXPRESSION; DISTINCT; GENE	It has previously been established that human rhinovirus 14 protease 3C binds specifically to the 5'-noncoding region of the viral RNA. A series of mutants of protease 3C and deletion or point mutants of the 5'-noncoding region of the viral RNA were analyzed to elucidate the sites of interaction between the protease and the RNA. Amino acids in protease SC essential for RNA binding were found to be discontinuous in the amino acid sequence, and mutations which destroyed RNA binding did not affect the catalytic (proteolytic) activity of protease 3C. Based on the three-dimensional structure of rhinovirus 14 protease 3C, the RNA binding region is located in an extended area distinct from the catalytic triad. A single stem-loop structure of 27 nucleotides (stem-loop d) in the 5'-noncoding region was necessary and sufficient to bind protease 3C. Mutagenesis of either the base-paired stem or unpaired loop or bulge regions of stem-loop d suggested that the base-paired stem, but not the loop or bulge, carries important determinants of protease 3C binding. This conclusion is strengthened by the observation that rhinovirus 14 protease 3C bound specifically to the 5'-noncoding region of poliovirus RNA, and only the base-paired stem of stem-loop d is conserved between poliovirus and rhinovirus RNAs.			WALKER, PK (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE.							ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; ANDINO R, 1990, J VIROL, V64, P607, DOI 10.1128/JVI.64.2.607-612.1990; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; HAMMERLE T, 1992, J VIROL, V66, P6028; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; LEONG LEC, 1993, J BIOL CHEM, V268, P25735; LEONG LEC, 1992, J CRYST GROWTH, V122, P246, DOI 10.1016/0022-0248(92)90253-F; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PORTER AG, 1993, J VIROL, V67, P6917, DOI 10.1128/JVI.67.12.6917-6921.1993; RIVERA VM, 1988, VIROLOGY, V165, P42, DOI 10.1016/0042-6822(88)90656-3; ROHLL JB, 1994, J VIROL, V68, P4384, DOI 10.1128/JVI.68.7.4384-4391.1994; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAENGER W, 1990, PRINCIPLES NUCLEIC A, P116; SKINNER MA, 1989, J MOL BIOL, V207, P379, DOI 10.1016/0022-2836(89)90261-1; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; STANWAY G, 1984, NUCLEIC ACIDS RES, V12, P7859, DOI 10.1093/nar/12.20.7859; TRONO D, 1988, J VIROL, V62, P2291, DOI 10.1128/JVI.62.7.2291-2299.1988; 1991, PROGRAM MANUAL GCG P	27	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14510	14516		10.1074/jbc.270.24.14510	http://dx.doi.org/10.1074/jbc.270.24.14510			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782313	hybrid			2022-12-25	WOS:A1995RD45500044
J	ZHUANG, HM; NIU, ZT; HE, TC; PATEL, SV; WOJCHOWSKI, DM				ZHUANG, HM; NIU, ZT; HE, TC; PATEL, SV; WOJCHOWSKI, DM			ERYTHROPOIETIN-DEPENDENT INHIBITION OF APOPTOSIS IS SUPPORTED BY CARBOXYL-TRUNCATED RECEPTOR FORMS AND BLOCKED BY DOMINANT-NEGATIVE FORMS OF JAK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; C-MYC; TYROSINE KINASE(S); CYTOSOLIC DOMAINS; PROGENITOR CELLS; PROTEIN-KINASE; EXPRESSION; BCL-2; SURVIVAL; LINE	Apoptosis, or programmed cell death (PCD), recently has emerged as an important homeostatic mechanism within several hematopoietic lineages. This process is subject to both positive and negative modulation by cytokines and within the erythroid lineage is inhibited by interleukin-3, stem cell factor, and erythropoietin (Epo). Through the expression of carboxyl-truncated Epo receptor mutants in FDC-P1 cells, a receptor form possessing 80 membrane-proximal cytoplasmic residues is shown to efficiently mediate Epo-dependent inhibition of PCD. This is in contrast to previous studies that attributed this activity to a distal carboxyl-terminal receptor subdomain (and/or heterodimerization of wild type Epo receptors with a truncated non-functional receptor form). Epo-dependent inhibition of PCD also is shown to be blocked by ectopic expression of kinase-deficient dominant-negative forms of Jak2 (Jak2 Delta VIII and Jak2-829), further underlining a role of this membrane-proximal subdomain of the Epo receptor in the inhibition of PCD. To our knowledge, this comprises the first direct evidence for an essential role for a Jak tyrosine kinase (Jak2) in this apoptotic response pathway.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, DEPT VET SCI, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, CTR GENE REGULAT, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NHLBI NIH HHS [HL44491, HL03042] Funding Source: Medline; NIDDK NIH HHS [DK40242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040242, R29DK040242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BULLOCK G, 1993, EXP HEMATOL, V21, P1640; Cohen J J, 1992, Semin Immunol, V4, P363; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; HE TC, 1994, J BIOL CHEM, V269, P18291; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOFFMAN B, 1994, ONCOGENE, V9, P1807; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; IWAI K, 1994, BLOOD, V84, P1201; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; LOURY MJ, 1990, TRANSFUSION BETHESDA, V30, P673; MANABE A, 1994, BLOOD, V83, P1731, DOI 10.1182/blood.V83.7.1731.bloodjournal8371731; MAY WS, 1994, J BIOL CHEM, V269, P26865; MAY WS, 1993, EXP HEMATOL, V21, P1029; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1994, J BIOL CHEM, V269, P614; MUTA K, 1993, J CELL PHYSIOL, V156, P264, DOI 10.1002/jcp.1041560207; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; NAKAMURA Y, 1994, SCIENCE, V264, P588, DOI 10.1126/science.8160019; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; OTANI H, 1993, J BIOL CHEM, V268, P22733; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE DE, 1992, MOL CELL BIOL, V12, P4553, DOI 10.1128/MCB.12.10.4553; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SABOURIN LA, 1990, J CELL PHYSIOL, V145, P564, DOI 10.1002/jcp.1041450325; SACHS L, 1993, BLOOD, V82, P15, DOI 10.1182/blood.V82.1.15.bloodjournal82115; SCHWALL R, 1993, SCIENCE, V259, P696, DOI 10.1126/science.8430322; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SPIVAK JL, 1991, BLOOD, V77, P1228; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173; WANG L, 1994, NUCLEIC ACIDS RES, V22, P1774, DOI 10.1093/nar/22.9.1774; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411; ZHUANG HM, 1994, BIOCHEM BIOPH RES CO, V204, P278, DOI 10.1006/bbrc.1994.2456	56	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14500	14504		10.1074/jbc.270.24.14500	http://dx.doi.org/10.1074/jbc.270.24.14500			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782312	hybrid			2022-12-25	WOS:A1995RD45500042
J	DOTSON, GD; DUA, RK; CLEMENS, JC; WOOTEN, EW; WOODARD, RW				DOTSON, GD; DUA, RK; CLEMENS, JC; WOOTEN, EW; WOODARD, RW			OVERPRODUCTION AND ONE-STEP PURIFICATION OF ESCHERICHIA-COLI 3-DEOXY-D-MANNO-OCTULOSONIC ACID 8-PHOSPHATE SYNTHASE AND OXYGEN-TRANSFER STUDIES DURING CATALYSIS USING ISOTOPIC-SHIFTED HETERONUCLEAR NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE; RABBIT MUSCLE; PHOSPHOENOLPYRUVATE; SYNTHETASE; MECHANISM; ANALOGS; STEREOCHEMISTRY	The enzyme 3-deoxy-D-manno-octulosonic acid 8-phosphhate synthase catalyzes the condensation of D-arabinose 5-phosphate with phosphoenolpyruvate to give the unique 8-carbon acidic sugar 3-deoxy-D-manno-octulosonic acid 8-phosphate (KDO 8-P) found only in Gramnegative bacteria and required for lipid A maturation and cellular growth. The Escherichia coli gene kdsA that encodes KDO 8-P synthase has been amplified by polymerase chain reaction methodologies and subcloned into the expression vector, pT7-7. A simple one-step purification yields 200 mg of homogeneous KDO 8-P synthase per liter of cell culture. [2-C-13,O-18]Phosphoenolpyruvate (PEP) was prepared by first, exchange of [2-C-13]-3-bromopyruvate with H-2(2) O-18 followed by reaction of the labeled bromopyruvate with trimethylphosphite. The fate of the enolic oxygen in this multilabeled PEP, during the course of the KDO 8-P synthase-catalyzed reaction with D-arabinose 5-phosphate, was monitored by C-13 and P-31 NMR spectroscopy. The inorganic phosphate formed during the reaction was further analyzed via mass spectral analysis of its trimethyl ester derivative. The C-13 NMR spectrum of an incubation mixture of [2-C-13]PEP and D-arabinose 5-phosphate in H-2(2) O-18 in the presence of KDO 8-P synthase was also recorded, [2-C-13]KDO 8-P was utilized to determine the extent of nonenzymatic incorporation of O-18 into the C-2 position of KDO 8-P. The results indicate that the enolic oxygen of the PEP is recovered with the inorganic phosphate, and the C-2 oxygen of KDO 8-P originates from the solvent, H2O2.	UNIV MICHIGAN,COLL PHARM,INTERDEPARTMENTAL PROGRAM MED CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOCHEM,DIV BIOPHYS RES,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Woodard, Ronald/0000-0002-7472-3653	NCRR NIH HHS [2507RR0557-28] Funding Source: Medline; NIGMS NIH HHS [T32 GM07767, GM 42544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM042544, T32GM007767] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1990, CHEM REV, V90, P1131, DOI 10.1021/cr00105a004; ANTON DL, 1983, BIOCHEMISTRY-US, V22, P5903, DOI 10.1021/bi00294a033; BANERJEE RV, 1988, BIOCHEMISTRY-US, V27, P9062, DOI 10.1021/bi00425a027; BONDINELL WE, 1971, J BIOL CHEM, V246, P6191; CLARK VM, 1963, J AM CHEM SOC, V85, P3705, DOI 10.1021/ja00905a043; DELEO AB, 1973, J BIOL CHEM, V248, P2344; DOTSON GD, 1993, BIOCHEMISTRY-US, V32, P12392, DOI 10.1021/bi00097a017; HANSEN DE, 1981, J BIOL CHEM, V256, P5967; HANSEN DE, 1982, J BIOL CHEM, V257, P4795; HANSEN PE, 1983, ANN REPORTS NMR SPEC, V15, P118; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOHEN A, 1993, BIOORG MED CHEM LETT, V3, P1577, DOI 10.1016/S0960-894X(00)80021-9; KOHLBRENNER WE, 1987, J BIOL CHEM, V262, P4534; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MARQUARDT JL, 1993, J AM CHEM SOC, V115, P10393; METZLER DE, 1977, BIOCH CHEM REACTIONS, P418; RAY PH, 1983, ACS SYM SER, V231, P141; RAY PH, 1980, J BACTERIOL, V141, P635, DOI 10.1128/JB.141.2.635-644.1980; STUBBE JA, 1972, BIOCHEMISTRY-US, V11, P338, DOI 10.1021/bi00753a005; STUBBE JA, 1971, BIOCHEMISTRY-US, V10, P2669; TABOR S, 1990, CURRENT PROTOCOLS MO; WOISETSCHLAGER M, 1987, MOL GEN GENET, V207, P369, DOI 10.1007/BF00331603; WOOTEN EW, 1994, J MAGN RESON SER A, V107, P50, DOI 10.1006/jmra.1994.1046; ZEMELL RI, 1975, J BIOL CHEM, V250, P4959	25	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13698	13705		10.1074/jbc.270.23.13698	http://dx.doi.org/10.1074/jbc.270.23.13698			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775423	hybrid			2022-12-25	WOS:A1995RC44800020
J	ROUSSO, I; BRODSKY, I; LEWIS, A; SHEVES, M				ROUSSO, I; BRODSKY, I; LEWIS, A; SHEVES, M			THE ROLE OF WATER IN RETINAL COMPLEXATION TO BACTERIOOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIFF-BASE; PURPLE MEMBRANE; BACTERIORHODOPSIN; RESONANCE; CHROMOPHORE; HYDRATION; MECHANISM; RHODOPSIN; PROTEINS; EXCHANGE	A system is described that allows for the delineation of the factors that effect the complexation of retinal to the apoprotein of bacteriorhodopsin. This complexation is investigated in various states of hydration, in H2O and D2O, at a variety of pH levels, with mutant membranes and labeled retinals. The complexation reaction was also investigated using absorption spectroscopy and vibrational spectra using difference Fourier transform infrared spectroscopy. The results demonstrate the crucial role of water in controlling the protein conformations that lead to protein/ligand binding reactions and begin to shed new Light on the protein control of a reaction that normally cannot take place in an aqueous medium.	WEIZMANN INST SCI, DEPT ORGAN CHEM, IL-76100 REHOVOT, ISRAEL; HEBREW UNIV JERUSALEM, DEPT APPL PHYS, IL-91904 JERUSALEM, ISRAEL	Weizmann Institute of Science; Hebrew University of Jerusalem			Rousso, Itay/A-7662-2013	Rousso, Itay/0000-0002-4399-9171				BIRGE RR, 1990, ANNU REV PHYS CHEM, V41, P683, DOI 10.1146/annurev.pc.41.100190.003343; DEGRIP WJ, 1985, BIOCHIM BIOPHYS ACTA, V809, P97, DOI 10.1016/0005-2728(85)90172-0; DEGROOT HJM, 1989, BIOCHEMISTRY-US, V28, P3346, DOI 10.1021/bi00434a033; DOUKAS AG, 1981, BIOPHYS J, V33, P275, DOI 10.1016/S0006-3495(81)84889-8; DUPUIS P, 1980, REV CAN BIOL EXPTL, V39, P247; Ebrey T.G., 1993, THERMODYNAMICS MEMBR, P353; EHRENBERG B, 1980, P NATL ACAD SCI-BIOL, V77, P6571, DOI 10.1073/pnas.77.11.6571; FRIEDMAN N, 1994, BIOCHEMISTRY-US, V33, P1971, DOI 10.1021/bi00174a001; GARTNER W, 1983, BIOCHEMISTRY-US, V22, P2637, DOI 10.1021/bi00280a007; GAT Y, 1993, J AM CHEM SOC, V115, P3772, DOI 10.1021/ja00062a052; GAT Y, 1994, PHOTOCHEM PHOTOBIOL, V59, P371, DOI 10.1111/j.1751-1097.1994.tb05050.x; HILDEBRANDT P, 1984, BIOCHEMISTRY-US, V23, P5539, DOI 10.1021/bi00318a025; HUMPHREY W, 1994, BIOCHEMISTRY-US, V33, P3668, DOI 10.1021/bi00178a025; KORENSTEIN R, 1977, NATURE, V270, P184, DOI 10.1038/270184a0; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LEWIS A, 1974, P NATL ACAD SCI USA, V71, P4462, DOI 10.1073/pnas.71.11.4462; LUGTENBURG J, 1985, PURE APPL CHEM, V57, P759; MAEDA A, 1994, BIOCHEMISTRY-US, V33, P1713, DOI 10.1021/bi00173a013; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; Oesterhelt D, 1974, Methods Enzymol, V31, P667; PAJARES MA, 1989, J BIOL CHEM, V264, P6804; PAPADOPOULOS G, 1990, J MOL BIOL, V214, P15, DOI 10.1016/0022-2836(90)90140-H; RUDIGER A, 1993, JUL INT BIOPH SOC M, P196; RUPLEY JA, 1991, ADV PROTEIN CHEM, V41, P37; SAMPOGNA RV, 1994, BIOPHYS J, V66, P1341, DOI 10.1016/S0006-3495(94)80925-7; SCHERRER P, 1989, BIOCHEMISTRY-US, V28, P829, DOI 10.1021/bi00428a063; SCHRECKENBACH T, 1977, EUR J BIOCHEM, V76, P499, DOI 10.1111/j.1432-1033.1977.tb11620.x; SCHRECKENBACH T, 1978, BIOCHEMISTRY-US, V17, P5353, DOI 10.1021/bi00618a005; SCHWEIGER U, 1994, BIOCHEMISTRY-US, V33, P535, DOI 10.1021/bi00168a019; SMITH SO, 1987, J AM CHEM SOC, V109, P3108, DOI 10.1021/ja00244a038; VARO G, 1983, BIOPHYS J, V43, P47, DOI 10.1016/S0006-3495(83)84322-7	32	17	17	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13860	13868		10.1074/jbc.270.23.13860	http://dx.doi.org/10.1074/jbc.270.23.13860			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775444	hybrid			2022-12-25	WOS:A1995RC44800043
J	CADENE, M; BOUDIER, C; DEMARCILLAC, GD; BIETH, JG				CADENE, M; BOUDIER, C; DEMARCILLAC, GD; BIETH, JG			INFLUENCE OF LOW-MOLECULAR-MASS HEPARIN ON THE KINETICS OF NEUTROPHIL ELASTASE INHIBITION BY MUCUS PROTEINASE-INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE PANCREATIC ELASTASE; 2-STEP REACTION-MECHANISM; HUMAN-LEUKOCYTE ELASTASE; AMINO-ACID SEQUENCE; ALPHA-1-PROTEINASE INHIBITOR; ANTI-THROMBIN; PROTEASE INHIBITOR; BINDING; ANTITHROMBIN; SECRETIONS	Commercial low molecular mass heparin accelerates the inhibition of neutrophil elastase by mucus proteinase inhibitor, the predominant antielastase of lung secretions (Faller, B., Mely, Y., Gerard, D., and Bieth, J. G. (1992) Biochemistry 31, 8285-8290). To study the kinetic mechanism of this rate enhancement, we have isolated a 4.5-kDa heparin fragment from commercial heparin. This compound is fairly monodisperse as shown by analytical ultracentrifugation. It binds elastase and inhibitor with a 1:1 stoichiometry and an equilibrium dissociation constant of 3 and 210 nar, respectively. It also forms a tight complex with EI. Flow calorimetry shows that the inhibitor-heparin interaction is characterized by a large negative enthalpy change (Delta H-o = -45.2 kJ mol(-1)) and a small entropy change (Delta S = -23.7 J K-1 mol(-1)). Stopped-flow kinetics run under pseudo-first-order conditions ( I-o much greater than E(o) ) show that in the absence of heparin the inhibition conforms to a simple bimolecular reaction, GRAPHICS where, k(a) = 3.1 x 10(6) m(-1)s(-1), k(d) = 10(-4) s(-1), and K-i = 33 pm, whereas in the presence of heparin, E and I react via a two-step mechanism, GRAPHICS where K-i* = 86 nnr, k(2) = 2.2 s(-1), k(-2) = 10(-3) s(-1), and K-i = 37 pM. Thus, heparin increases both the rate of inhibition by promoting the formation of a high affinity EI* intermediate and the rate of EI dissociation. Since the dissociation is negligible in bronchial secretions where the inhibitor concentration is much higher than K-i, it may be concluded that heparin significantly potentiates the inhibitor's antielastase potential in vivo.	UNIV LOUIS PASTEUR STRASBOURG 1,FAC PHARM,INSERM,U392,ENZYMOL LAB,F-67400 ILLKIRCH GRAFFENS,FRANCE; INST BIOL MOLEC PLANTES,CNRS,F-67000 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Boudier, Christian/N-3841-2018	Boudier, Christian/0000-0002-5534-6389; Cadene, Martine/0000-0003-4936-2662				AHMED T, 1992, AM REV RESPIR DIS, V145, P566, DOI 10.1164/ajrccm/145.3.566; ALBERTY RA, 1958, J PHYS CHEM-US, V62, P154, DOI 10.1021/j150560a005; BEATTY K, 1980, J BIOL CHEM, V255, P3931; Bieth J., 1974, BAYER S, P463; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; BIETH JG, 1986, BIOL EXTRACELLULAR M, V1, P217; BIETH JG, 1974, BIOCH MED, V32, P387; BJORK I, 1982, J BIOL CHEM, V257, P9487; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BOUDIER C, 1989, BIOCHIM BIOPHYS ACTA, V995, P36, DOI 10.1016/0167-4838(89)90230-6; CAMPBELL EJ, 1986, AM REV RESPIR DIS, V134, P984; CASTILLO MJ, 1979, ANAL BIOCHEM, V99, P53, DOI 10.1016/0003-2697(79)90043-5; CASU B, 1990, HAEMOSTASIS, V20, P62; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CLARK JG, 1983, INT REV CONNECTIVE T, P249; DANIELSSON A, 1981, BIOCHEM J, V193, P427; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DELAUDER S, 1992, BIOCHIM BIOPHYS ACTA, V1159, P141, DOI 10.1016/0167-4838(92)90018-9; EISENBERG SP, 1990, J BIOL CHEM, V265, P976; FALLER B, 1992, BIOCHEMISTRY-US, V31, P8285, DOI 10.1021/bi00150a023; FALLER B, 1993, BIOCHEMISTRY-US, V32, P9230, DOI 10.1021/bi00086a031; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Jacques L. B., 1967, CAN J PHYSIOL PHARM, V45, P787; JORDAN R, 1979, J BIOL CHEM, V254, P2902; KRAMPS JA, 1984, AM REV RESPIR DIS, V129, P959; LANE DL, 1989, HEPARIN CHEM BIOL PR; LAURENT TC, 1961, ARCH BIOCHEM BIOPHYS, V92, P224, DOI 10.1016/0003-9861(61)90341-1; LI EHH, 1974, BIOCHEMISTRY-US, V13, P5012, DOI 10.1021/bi00721a023; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MCELVANEY NG, 1992, J CLIN INVEST, V90, P1296, DOI 10.1172/JCI115994; MELLET P, 1995, BIOCHEMISTRY-US, V34, P2645, DOI 10.1021/bi00008a031; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V61, P201; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; REDINI F, 1988, BIOCHEM J, V252, P515, DOI 10.1042/bj2520515; SALLENAVE JM, 1992, BIOL CHEM H-S, V373, P27, DOI 10.1515/bchm3.1992.373.1.27; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; SINHA S, 1987, P NATL ACAD SCI USA, V84, P2228, DOI 10.1073/pnas.84.8.2228; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P1301, DOI 10.1021/bi00379a015; STEPHANO C, 1988, ANN CHIM, V78, P55; Taylor JC, 1987, PULMONARY EMPHYSEMA; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TOURNIER JM, 1983, ANAL BIOCHEM, V131, P345, DOI 10.1016/0003-2697(83)90181-1; TYLERCROSS R, 1993, ARCH BIOCHEM BIOPHYS, V306, P528, DOI 10.1006/abbi.1993.1548	53	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13204	13209		10.1074/jbc.270.22.13204	http://dx.doi.org/10.1074/jbc.270.22.13204			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768918	hybrid			2022-12-25	WOS:A1995RB43900041
J	LIPKIND, G; GONG, QM; STEINER, DF				LIPKIND, G; GONG, QM; STEINER, DF			MOLECULAR MODELING OF THE SUBSTRATE-SPECIFICITY OF PROHORMONE CONVERTASES SPC2 AND SPC3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PROCESSING ENZYME; CRYSTAL-STRUCTURE; SUBTILISIN BPN'; YEAST KEX2; EGLIN-C; ENDOPROTEASE FAMILY; CONSENSUS SEQUENCE; SERINE PROTEASES; GENE-PRODUCT	In this paper we describe the results of molecular modeling of the structures of the active sites of two subtilisin-like prohormone convertases (SPCs), SPC2 (PC2) and SPC3 (PC1/PC3). These enzymes are members of a recently discovered family of cellular proteases involved in the processing of precursor proteins. Although these proteases all possess catalytic domains similar to the bacterial subtilisins no tertiary structural data from x-ray analysis are yet available. We have shown that despite the high structural homology of the subtilisins and the SPCs, the structure of the loop which lies immediately below the active sites differs due to the presence of a cis-peptide bond (Tyr(167)-pro(168)) in this loop in the subtilisins and its absence in the SPCs. Accordingly, we have proposed a new alignment for the amino acid sequences of the SPCs in this region. Both SPC2 and SPC3 participate in the processing of prohormones at dibasic cleavage sites, typically Lys-Arg or Arg-Arg. To investigate the structural basis of the substrate specificity of these SPCs, we have carried out molecular mechanic calculations of the optimal arrangement and interactions of peptide substrates containing several residues of arginine or lysine, i.e. Arg, Ala-Ala Ala-Arg, Arg-AZa-Ala-Arg, Arg-Ala-Arg-Arg, Arg-Ala-Lys-Arg, in the putative active sites. Such subtilisin-based modeling has allowed us to identify those negatively charged residues, Asp and Glu, in the S1, S2, and S4 subsites, which can directly interact with basic residues in the substrates via formation of salt bridges and thereby contribute to the substrate selectivity of the SPCs.	UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago					NIDDK NIH HHS [DK 20595, DK 13914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, R37DK013914, P30DK020595, R01DK013914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; BODE W, 1986, EMBO J, V5, P813, DOI 10.1002/j.1460-2075.1986.tb04286.x; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRYAN P, 1986, P NATL ACAD SCI USA, V83, P3743, DOI 10.1073/pnas.83.11.3743; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; Creighton T. E., 1993, PROTEINS STRUCTURES; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GROS P, 1989, J MOL BIOL, V210, P347, DOI 10.1016/0022-2836(89)90336-7; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; HIRONO S, 1984, J MOL BIOL, V178, P389, DOI 10.1016/0022-2836(84)90150-5; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; MATTHEWS DA, 1975, J BIOL CHEM, V250, P7120; MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; RHEINNECKER M, 1993, BIOCHEMISTRY-US, V32, P1199, DOI 10.1021/bi00056a001; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHERAGA HA, 1971, CHEM REV, V71, P195, DOI 10.1021/cr60270a003; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SEIDAH NG, 1991, GENOMICS, V11, P103, DOI 10.1016/0888-7543(91)90106-O; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, PROG BRAIN RES, V92, P235, DOI 10.1016/S0079-6123(08)61179-6; Steiner D F, 1969, Recent Prog Horm Res, V25, P207; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STEINER DF, 1994, ENDOCRINOLOGY, P1296; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WELLS JA, 1987, P NATL ACAD SCI USA, V84, P5167, DOI 10.1073/pnas.84.15.5167; WELLS JA, 1988, TRENDS BIOCHEM SCI, V13, P291, DOI 10.1016/0968-0004(88)90121-1; WELLS JA, 1995, J CELL BIOCH B, V19, P233; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0	46	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13277	13284		10.1074/jbc.270.22.13277	http://dx.doi.org/10.1074/jbc.270.22.13277			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768927	hybrid			2022-12-25	WOS:A1995RB43900051
J	NEYA, S; KAKU, T; FUNASAKI, N; SHIRO, Y; IIZUKA, T; IMAI, K; HORI, H				NEYA, S; KAKU, T; FUNASAKI, N; SHIRO, Y; IIZUKA, T; IMAI, K; HORI, H			NOVEL LIGAND-BINDING PROPERTIES OF THE MYOGLOBIN SUBSTITUTED WITH MONOAZAHEMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL HISTIDINE; PROSTHETIC GROUP; HEME; COMPLEXES; OXYGEN; AUTOOXIDATION; METMYOGLOBIN; FORMYLATION; HEMOGLOBIN; REDUCTION	The iron complex of alpha-azamesoporphyrin XIII was combined with apomyoglobin to investigate influence of the meso nitrogen on ligand binding properties in the reconstituted protein. Stoichiometric complex formation between the two components was confirmed, and conservation of the native coordination structures in the resultant myoglobin was established with spectroscopic criteria and apparently normal ligand binding. The visible absorption spectra of various ferric and ferrous derivatives are characteristic with less intense Soret peaks and enhanced visible bands. The electron paramagnetic resonance spectrum with g = 5.2 suggests an anomalous intermediate spin (S = 3/2) character for the aquomet protein. The oxygen affinity of reduced azaheme myoglobin, 0.010 mm Hg, is 50 times larger than that of the native myoglobin. In addition, azaheme myoglobin forms stable complexes with imidazole, pyridine, or cyanide in ferrous state. All of these new properties were consistently explained in terms of stronger equatorial Ligand field of the heme iron in a narrower coordination cavity. Similarities of azaheme to verdoheme were also pointed out.	INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN; OSAKA UNIV,SCH MED,DEPT PHYSICOCHEM PHYSIOL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN	RIKEN; Osaka University; Osaka University	NEYA, S (corresponding author), KYOTO PHARMACEUT UNIV,DEPT PHYS CHEM,KYOTO 607,JAPAN.							ADLER AD, 1970, J INORG NUCL CHEM, V32, P2443, DOI 10.1016/0022-1902(70)80535-8; ASAKURA T, 1978, METHOD ENZYMOL, V52, P445; BALCH AL, 1993, J AM CHEM SOC, V115, P1422, DOI 10.1021/ja00057a027; BALCH AL, 1993, INORG CHEM, V32, P291, DOI 10.1021/ic00055a011; BELLELLI A, 1990, J BIOL CHEM, V365, P18898; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRAULT D, 1974, BIOCHEMISTRY-US, V13, P4591, DOI 10.1021/bi00719a019; ENGEL J, 1978, J CHEM SOC PERK T 1, P871, DOI 10.1039/p19780000871; ERCOLANI C, 1991, J CHEM SOC DALTON, P1309, DOI 10.1039/dt9910001309; Fischer H, 1936, LIEBIGS ANN CHEM, V523, P154; FUHRHOP JH, 1975, PORPHYRINS METALLOPO, P757; FUJII H, 1990, THESIS KYOTO U KYOTO; GRIGG R, 1978, J CHEM SOC P2, P407; Hambright P., 1975, PORPHYRINS METALLOPO, P234; HARRIS RLN, 1966, J CHEM SOC C, P22, DOI 10.1039/j39660000022; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HOFFMAN BM, 1983, ACCOUNTS CHEM RES, V16, P15, DOI 10.1021/ar00085a003; HORI H, 1990, J BIOL CHEM, V265, P15028; Imai K, 1981, Methods Enzymol, V76, P438; Jackson A. H., 1978, PORPHYRINS, VI, P365; KEILIN D, 1955, BIOCHEM J, V61, P153, DOI 10.1042/bj0610153; KENNEDY BJ, 1986, INORG CHEM, V25, P2539, DOI 10.1021/ic00235a011; KOENIG DF, 1965, ACTA CRYSTALLOGR, V18, P663, DOI 10.1107/S0365110X65001536; LAMAR GN, 1977, BIOCHEM BIOPH RES CO, V77, P104, DOI 10.1016/S0006-291X(77)80170-8; Lever ABP, 1993, PHTHALOCYANINES PROP, V3, P1; MALTEMPO MM, 1979, BIOCHEMISTRY-US, V18, P2935, DOI 10.1021/bi00581a003; MAXWELL JC, 1976, BIOCHEMISTRY-US, V15, P388, DOI 10.1021/bi00647a023; NEYA S, 1989, BIOCHIM BIOPHYS ACTA, V996, P226, DOI 10.1016/0167-4838(89)90251-3; NEYA S, 1994, BBA-PROTEIN STRUCT M, V1208, P31, DOI 10.1016/0167-4838(94)90156-2; NEYA S, 1988, J BIOL CHEM, V263, P8810; NEYA S, 1993, J BIOL CHEM, V268, P8935; OLIVAS E, 1977, J BIOL CHEM, V252, P4038; PADLAN EA, 1975, J BIOL CHEM, V250, P7069; PALMER SM, 1985, INORG CHEM, V24, P2040, DOI 10.1021/ic00207a017; Rothgeb T M, 1978, Methods Enzymol, V52, P473; SAITO S, 1986, J CHEM SOC PERK T 1, P1, DOI 10.1039/p19860000001; SCHEIDT WR, 1989, ACTA CRYSTALLOGR C, V45, P1214, DOI 10.1107/S0108270189000715; Scheidt WR, 1983, IRON PORPHYRINS 1, P89; SCHONBAUM GR, 1976, ENZYMES, V13, P303; SEYBERT DW, 1977, J MOL BIOL, V113, P419, DOI 10.1016/0022-2836(77)90150-4; SHRIVER DF, 1994, INORG CHEM, P667; Siedel W, 1933, H-S Z PHYSIOL CHEM, V214, P145, DOI 10.1515/bchm2.1933.214.3-4.145; SONO M, 1982, J BIOL CHEM, V257, P5496; SONO M, 1976, J BIOL CHEM, V251, P2664; SONO M, 1975, J BIOL CHEM, V250, P5227; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TAMURA M, 1973, BIOCHIM BIOPHYS ACTA, V295, P467, DOI 10.1016/0005-2795(73)90042-1; TAMURA M, 1973, BIOCHIM BIOPHYS ACTA, V317, P34, DOI 10.1016/0005-2795(73)90197-9; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; THOMPSON JA, 1993, INORG CHEM, V24, P2040; WEBER PC, 1982, BIOCHEMISTRY-US, V21, P5116, DOI 10.1021/bi00264a001	54	27	27	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13118	13123		10.1074/jbc.270.22.13118	http://dx.doi.org/10.1074/jbc.270.22.13118			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768907	hybrid			2022-12-25	WOS:A1995RB43900029
J	POOLMAN, B; KNOL, J; LOLKEMA, JS				POOLMAN, B; KNOL, J; LOLKEMA, JS			KINETIC-ANALYSIS OF LACTOSE AND PROTON COUPLING IN GLU(379) MUTANTS OF THE LACTOSE TRANSPORT PROTEIN OF STREPTOCOCCUS-THERMOPHILUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTANTS; ESCHERICHIA-COLI; LAC PERMEASE; HISTIDINE-RESIDUES; CARRIER PROTEIN; SYSTEM; ARGININE-302; MECHANISM; MEMBRANE; TYROSINE	The role of Glu(379) in the lactose-H+ symport protein (LacS) of Streptococcus thermophilus was studied by analyzing the kinetic mechanism of transport of wild-type and Ala(379), Asp(379), and Gln(379) mutant proteins. Glu(379) forms part of the sequence motif Lys-X-X-His-X-X-Glu that is present in a number of sugar transport proteins, including LacY of Escherichia coli. The E379A and E379Q mutants were defective in the uptake of lactose against a concentration gradient and lactose dependent proton uptake, but catalyzed facilitated influx of lactose down a concentration gradient and equilibrium exchange with rates similar to that of the wild-type enzyme. The E879D mutant was partially defective in the coupled transport of lactose and protons. These results suggest that an acidic residue at position 379 is required for the coupled uptake of lactose and protons and are consistent with a mechanism in which lactose transport in the E379A and E379Q mutants occurs by uniport rather than proton symport. Lactose efflux down a concentration gradient in wild-type LacS and LacS-E379D increased with pH with apparent pK (pK(alpha)) values of greater than or equal to 8.5 and 8.0, respectively, whereas efflux in the E379Q mutant increased sigmoidally with a pK(alpha) of about 6.0. Imposition of an artificial membrane potential (inside negative) in membrane vesicles bearing wild-type LacS or LacS-E379Q not only inhibited the lactose efflux mediated by wild-type but also that of the mutant enzyme. To associate the role of Glu(379) with specific step(s) in the translocation cycle of LacS, the properties of wild-type LacS and the Glu(379) mutants have been evaluated by numerical analysis of simple kinetic schemes for translocation catalysis by solute H+ symport proteins. The properties of the wild-type enzyme are consistent with a mechanism in which the order of ligand binding on the inside is substrate first and proton last, whereas the order is random (or proton first, substrate last) at the outer surface of the membrane. The wild-type enzyme is asymmetric with regard to proton binding; the pK for proton binding on the outside is at least 4 units higher than the pK on the inside. The properties of the Glu(379) mutants correspond with a lowering of the pK on the outside (pK(OUT) similar to pK(IN)), and the induction of a leak pathway in which the binary enzyme-substrate complex becomes mobile.			POOLMAN, B (corresponding author), UNIV GRONINGEN,GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST,DEPT MICROBIOL,KERKLAAN 30,9751 NN HAREN,NETHERLANDS.		Knol, Jan/A-2178-2010; Knol, Jan/AAL-6487-2020	Knol, Jan/0000-0002-2103-5961; Knol, Jan/0000-0002-2103-5961				CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1989, BIOCHEMISTRY-US, V28, P2533, DOI 10.1021/bi00432a028; CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; FOUCAUD C, 1992, J BIOL CHEM, V267, P22087; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; FRANCO PJ, 1991, J BIOL CHEM, V266, P6693; HARLOW E, 1988, ANTIBODIES LABORATOR; HENDERSON PJF, 1986, METHOD ENZYMOL, V125, P387; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KING SC, 1989, J BIOL CHEM, V264, P7390; KING SC, 1990, J BIOL CHEM, V265, P3153; KING SC, 1989, BIOCHIM BIOPHYS ACTA, V982, P253, DOI 10.1016/0005-2736(89)90062-X; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE JA, 1989, BIOCHEMISTRY-US, V28, P2540, DOI 10.1021/bi00432a029; LEE JI, 1993, J BIOL CHEM, V268, P20007; LIANG WS, 1992, THESIS U CAMBRIDGE; LOLKEMA JS, 1993, J BIOL CHEM, V268, P17850; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P1284, DOI 10.1021/bi00219a018; LOLKEMA JS, 1995, J BIOL CHEM, V270, P12670, DOI 10.1074/jbc.270.21.12670; MATZKE EA, 1992, J BIOL CHEM, V267, P19095; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P6638, DOI 10.1021/bi00395a012; POOLMAN B, 1992, J BIOL CHEM, V267, P9150; POOLMAN B, 1989, J BACTERIOL, V171, P244, DOI 10.1128/jb.171.1.244-253.1989; POOLMAN B, 1995, P NATL ACAD SCI USA, V92, P778, DOI 10.1073/pnas.92.3.778; POOLMAN B, 1983, EUR J BIOCHEM, V135, P41, DOI 10.1111/j.1432-1033.1983.tb07615.x; POOLMAN B, 1990, MOL MICROBIOL, V4, P1629, DOI 10.1111/j.1365-2958.1990.tb00539.x; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; PUTTNER IB, 1986, BIOCHEMISTRY-US, V25, P4483; PUTTNER IB, 1989, BIOCHEMISTRY-US, V28, P2525, DOI 10.1021/bi00432a027; ROEPE PD, 1990, PROG CELL R, V1, P213; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VIITANEN P, 1983, BIOCHEMISTRY-US, V22, P2531, DOI 10.1021/bi00279a034; WALZ D, 1988, CELL BIOPHYS, V12, P13, DOI 10.1007/BF02918348	37	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					12995	13003		10.1074/jbc.270.22.12995	http://dx.doi.org/10.1074/jbc.270.22.12995			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768891	hybrid, Green Submitted			2022-12-25	WOS:A1995RB43900012
J	RYLE, MJ; LANZILOTTA, WN; MORTENSON, LE; WATT, GD; SEEFELDT, LC				RYLE, MJ; LANZILOTTA, WN; MORTENSON, LE; WATT, GD; SEEFELDT, LC			EVIDENCE FOR A CENTRAL ROLE OF LYSINE-15 OF AZOTOBACTER-VINELANDII NITROGENASE IRON PROTEIN IN NUCLEOTIDE BINDING AND PROTEIN CONFORMATIONAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNESIUM ADENOSINE 5'-TRIPHOSPHATE; ELECTRON-PARAMAGNETIC-RESONANCE; CLOSTRIDIUM-PASTEURIANUM; MOFE PROTEIN; FE PROTEIN; BINDING; MGATP; METALLOCLUSTERS; AZOFERREDOXIN; COMPONENT	Biological nitrogen fixation catalyzed by purified nitrogenase requires the hydrolysis of a minimum of 16 MgATP for each N-2 reduced. In the present study, we demonstrate a central function for Lys-1B of Azotobacter vinelandii nitrogenase iron protein (FeP) in the interaction of nucleotides with nitrogenase. Changing Lys-1B of the FeP to Arg resulted in an FeP with a dramatically reduced affinity for both MgATP and MgADP. From equilibrium column binding experiments at different nucleotide concentrations, apparent dissociation constants (K-d) for wild type FeP binding of MgADP (143 mu M) and MgATP (571 mu M) were determined. Over the same nucleotide concentration ranges, the K15R FeP showed no significant affinity for either nucleotide. This contrasts sharply with previous results with an FeP in which Lys-1B was changed to Gln (K15Q) where it was found that the K15Q FeP bound MgADP with the same affinity as wild type FeP and MgATP with a slightly reduced affinity. Analysis of K15R FeP by EPR, circular dichroism (CD), and microcoulometry revealed that the [4Fe-4S] cluster was unaffected by the amino acid change and that addition of either MgADP or MgATP did not result in the protein conformational changes normally detected by these techniques. These results are integrated into a model for how MgATP and MgADP bind and induce conformational changes within the FeP.	UTAH STATE UNIV,DEPT CHEM & BIOCHEM,LOGAN,UT 84322; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; BRIGHAM YOUNG UNIV,DEPT CHEM & BIOCHEM,PROVO,UT 84602	Utah System of Higher Education; Utah State University; University System of Georgia; University of Georgia; Brigham Young University				Seefeldt, Lance/0000-0002-6457-9504				ANDERSON GL, 1984, BIOCHEMISTRY-US, V23, P2118, DOI 10.1021/bi00305a002; BOLIN JT, 1993, P NATL ACAD SCI USA, V90, P1078, DOI 10.1073/pnas.90.3.1078; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; CHEN L, 1994, J BIOL CHEM, V269, P3290; CHROMY V, 1974, CLIN CHEM, V20, P1362; CORDEWENER J, 1983, EUR J BIOCHEM, V132, P47, DOI 10.1111/j.1432-1033.1983.tb07323.x; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HAGEMAN RV, 1980, BIOCHEMISTRY-US, V19, P2333, DOI 10.1021/bi00552a009; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; KIM J, 1994, BIOCHEMISTRY-US, V33, P389, DOI 10.1021/bi00168a001; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; LOWE DJ, 1993, BIOCHEM J, V292, P93, DOI 10.1042/bj2920093; MEYER J, 1988, BIOCHEMISTRY-US, V27, P6150, DOI 10.1021/bi00416a048; MORTENSON LE, 1993, ADV ENZYMOL RAMB, V67, P299; NORMAND P, 1989, J MOL EVOL, V29, P436, DOI 10.1007/BF02602914; ORMEJOHNSON WH, 1992, SCIENCE, V257, P1639, DOI 10.1126/science.1529351; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEEFELDT LC, 1994, PROTEIN SCI, V3, P2073, DOI 10.1002/pro.5560031120; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SEEFELDT LC, 1993, PROTEIN SCI, V2, P93; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; STEPHENS PJ, 1979, P NATL ACAD SCI USA, V76, P2585, DOI 10.1073/pnas.76.6.2585; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER MN, 1974, J BIOL CHEM, V249, P6356; WATT GD, 1977, BIOCHEMISTRY-US, V16, P264, DOI 10.1021/bi00621a017; WATT GD, 1986, BIOCHEMISTRY-US, V25, P8156, DOI 10.1021/bi00373a005; WATT GD, 1979, ANAL BIOCHEM, V99, P399, DOI 10.1016/S0003-2697(79)80024-X; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643; YATES MG, 1991, BIOL NITROGEN FIXATI, P685; ZUMFT WG, 1974, EUR J BIOCHEM, V46, P525, DOI 10.1111/j.1432-1033.1974.tb03646.x; ZUMFT WG, 1972, BIOCHEM BIOPH RES CO, V48, P1525, DOI 10.1016/0006-291X(72)90887-X	37	42	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13112	13117		10.1074/jbc.270.22.13112	http://dx.doi.org/10.1074/jbc.270.22.13112			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768906	hybrid			2022-12-25	WOS:A1995RB43900028
J	TORTI, M; RAMASCHI, G; MONTSARRAT, N; SINIGAGLIA, F; BALDUINI, C; PLANTAVID, M; BRETON, M; CHAP, H; MAUCO, G				TORTI, M; RAMASCHI, G; MONTSARRAT, N; SINIGAGLIA, F; BALDUINI, C; PLANTAVID, M; BRETON, M; CHAP, H; MAUCO, G			EVIDENCE FOR A GLYCOPROTEIN-IIB-IIIA-INDEPENDENT AND AGGREGATION-INDEPENDENT MECHANISM OF PHOSPHATIDYLINOSITOL 3',4'-BISPHOSPHATE SYNTHESIS IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-STIMULATED PLATELETS; CONCANAVALIN-A; PHOSPHOLIPASE-C; TYROSINE PHOSPHORYLATION; ACTIVATED PLATELETS; COMPLEX; THROMBOSPONDIN; CYTOSKELETON; PROTEINS; BINDING	The synthesis of phosphatidylinositol 3',4'-bisphosphate (PtdIns(3,4)P-2) in P-32-labeled human platelets induced by the tetrameric lectin concanavalin A and the physiological agonist thrombin were compared. Like thrombin, concanavalin A stimulated a time dependent accumulation of PtdIns(3,4)P-2, which reached maximal levels after 5 min of stimulation. However, while synthesis of PtdIns(3,4)P-2 induced by thrombin was dependent on platelet aggregation, the production of PtdIns(3,4)P-2 induced by concanavalin A was unchanged when aggregation was prevented by the omission of stirring or when fibrinogen binding to platelets was inhibited by the tetrapeptide RGDS. Accumulation of PtdIns(SP)P, was not observed in platelets stimulated with succinyl-concanavalin A, a dimeric derivative of the lectin that binds to the same receptors on the platelet surface but does not promote clustering of membrane glycoproteins. The synthesis of PtdIns(3,4)P-2 induced by concanavalin A was also independent of the membrane glycoprotein IIb-IIIa, as normal accumulation of this Lipid was observed in platelets from two patients affected by Glanzmann thrombasthenia. In contrast, thrombin showed a strongly reduced ability to stimulate PtdIns(3,4)P-2 production in thrombasthenic platelets. Although concanavalin A was able to induce association of the regulatory subunit of the phosphatidylinositol 3-kinase with tyrosine-phosphorylated proteins, the tyrosine kinase inhibitor tyrphostin AG-213 did not inhibit the lectin-induced synthesis of PtdIns(3,4)P-2. These results demonstrate the existence of a novel mechanism of PtdIns(3,4)P-2 synthesis in human platelets, which is independent of glycoprotein IIb-IIIa and aggregation, but requires clustering of membrane glycoproteins. As clustering events occur during platelet aggregation promoted by physiological agonists, this new mechanism may also be involved in the aggregation-dependent production of PtdIns(3,4)P-2 in thrombin-stimulated platelets.	UNIV GENOA,INST BIOL CHEM,I-31059 GENOA,ITALY; HOP PURPAN,INSERM,U326,F-31059 TOULOUSE,FRANCE	University of Genoa; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	TORTI, M (corresponding author), UNIV PAVIA,DEPT BIOCHEM,VIA BASSI 21,I-27100 PAVIA,ITALY.		Mauco, Gerard/A-3164-2016	Mauco, Gerard/0000-0003-2998-2397				BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BILLAH MM, 1982, J BIOL CHEM, V257, P2705; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUINEBAULT C, 1993, BIOCHEM J, V292, P851, DOI 10.1042/bj2920851; GUINEBAULT C, 1995, IN PRESS J CELL BIOL; GUNTHER GR, 1973, P NATL ACAD SCI USA, V70, P1012, DOI 10.1073/pnas.70.4.1012; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; KAKAIYA RM, 1988, THROMB HAEMOSTASIS, V59, P281; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LAWLER J, 1986, BLOOD, V67, P1197; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; MOROI M, 1984, BIOCHIM BIOPHYS ACTA, V798, P295, DOI 10.1016/0304-4165(84)90101-6; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; NOLAN RD, 1990, J BIOL CHEM, V265, P2441; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1988, BLOOD, V71, P831; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAMASCHI G, 1993, CELL BIOCHEM FUNCT, V11, P241, DOI 10.1002/cbf.290110404; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; SINIGAGLIA F, 1988, BIOCHEM BIOPH RES CO, V154, P258, DOI 10.1016/0006-291X(88)90678-X; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SULTAN C, 1991, J BIOL CHEM, V266, P23554; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TORTI M, 1992, CELL BIOCHEM FUNCT, V10, P53, DOI 10.1002/cbf.290100109; TORTI M, 1995, J CELL BIOCHEM, V57, P30, DOI 10.1002/jcb.240570105; TORTI M, 1992, J BIOL CHEM, V267, P8293; TORTI M, 1994, P NATL ACAD SCI USA, V91, P4239, DOI 10.1073/pnas.91.10.4239; WHEELER ME, 1985, J CELL BIOL, V101, P993, DOI 10.1083/jcb.101.3.993; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1994, J BIOL CHEM, V268, P2251	41	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13179	13185		10.1074/jbc.270.22.13179	http://dx.doi.org/10.1074/jbc.270.22.13179			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768914	hybrid			2022-12-25	WOS:A1995RB43900037
J	GUILLOUF, C; ROSSELLI, F; KRISHNARAJU, K; MOUSTACCHI, E; HOFFMAN, B; LIEBERMANN, DA				GUILLOUF, C; ROSSELLI, F; KRISHNARAJU, K; MOUSTACCHI, E; HOFFMAN, B; LIEBERMANN, DA			P53 INVOLVEMENT IN CONTROL OF G2 EXIT OF THE CELL-CYCLE - ROLE IN DNA DAMAGE-INDUCED APOPTOSIS	ONCOGENE			English	Article						P53; DNA DAMAGING AGENTS; APOPTOSIS; G2 CHECKPOINT	WILD-TYPE P53; ATAXIA-TELANGIECTASIA; ERYTHROLEUKEMIA-CELLS; INDUCTION; AGENTS; RADIATION; CAFFEINE; PROTEIN; GROWTH; LINE	DNA damage in proliferating mammalian cells induces a complex cellular response comprising perturbation of the cell cycle and programmed cell death. The relationship between p53-dependent and p53-independent apoptotic cell death, as well as the cell cycle checkpoints induced by DNA damaging agents were explored in hematopoietic cells, using M1 myeloblastic leukemia cells, which are null for p53 expression, genetically engineered M1 variants, expressing p53(ts) and bcl-2 transgenes, as well as myeloblast enriched bone-marrow cells obtained from wild type p53 (wt p53) and p53-deficient mice. It is shown that gamma-irradiation of M1p53(ts) cells activated a function of the temperature sensitive mutant transgene p53 (p53(ts)), promoting increased apoptosis relative to parental, null p53 M1 cells. It is also shown that the kinetics of apoptotic cell death induced by gamma-irradiation correlated with the rapidity of exit from gamma-ray-induced G2 arrest for all the different hematopoietic cell types indicated above. Finally, data has been obtained to demonstrate that, in addition to a role in apoptosis and G1 arrest, wild-type p53 positively modulated the exit from the gamma-ray-induced G2 checkpoint. Taken together, these findings indicate that this new function for p53 is a component of the physiological pathway by which p53 exerts its role in apoptosis.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; INST CURIE,CNRS,UA 1292,F-75231 PARIS 05,FRANCE	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Filippo, Rosselli/AAO-6393-2020	Filippo, Rosselli/0000-0003-1080-5745	NCI NIH HHS [1RO1CA51162, 1RO1CA43618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043618, R01CA051162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; FRITSCHE M, 1993, ONCOGENE, V8, P307; GUILLOUF C, 1995, IN PRESS BLOOD; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IMAMURA J, 1994, BLOOD, V8, P2412; IMRAY FP, 1983, MUTAT RES, V112, P369; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; NATARAJAN AT, 1980, HUM GENET, V54, P183, DOI 10.1007/BF00278969; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P203, DOI 10.1080/09553009414550241; RADFORD IR, 1994, INT J RADIAT BIOL, V66, P557, DOI 10.1080/09553009414551621; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SELVAKUMARAN M, 1994, MOL CELL BIOL, V4, P2352; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; WALDREN CA, 1978, RADIAT RES, V73, P95, DOI 10.2307/3574576; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, ONCOGENE, V9, P3743	40	168	168	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2263	2270						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784074				2022-12-25	WOS:A1995RB70300025
J	LUKAS, J; BARTKOVA, J; WELCKER, M; PETERSEN, OW; PETERS, G; STRAUSS, M; BARTEK, J				LUKAS, J; BARTKOVA, J; WELCKER, M; PETERSEN, OW; PETERS, G; STRAUSS, M; BARTEK, J			CYCLIN D2 IS A MODERATELY OSCILLATING NUCLEOPROTEIN REQUIRED FOR G1 PHASE PROGRESSION IN SPECIFIC CELL-TYPES	ONCOGENE			English	Article						CELL CYCLE; D-TYPE CYCLINS; ONCOGENE; G1 REGULATION	HUMAN BREAST-CANCER; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; NUCLEAR-PROTEIN; GROWTH-FACTOR; D1; CLONING; G(1); PHOSPHORYLATION; DIFFERENTIATION	To explore regulation and function of cyclin D2, a candidate cell cycle-regulatory proto-oncogene, we examined subcellular localisation, cell type- and cell cycle-dependent expression, and requirement of cyclin D2 protein for G1 progression, in a panel of 40 human normal and cancer cell types. Except for lymphoid cells and sarcoma cell lines, expression of cyclin D2 was considerably more restricted than that of cyclin D1, whereas both D-type cyclin proteins were low or undetectable in cells lacking functional retinoblastoma gene product. In G1 cells, the cyclin D2 protein was more resistant to extraction and localised predominantly to nuclei, whereas it became more soluble and distributed in both nuclei and cytoplasm from G1/S transition onwards. Centrifugal elutriation and multiparameter flow cytometry analyses of several cell types showed moderate cell cycle oscillation with maximum levels of the cyclin D2 protein reached in late G1. Microinjection and/or electroporation of antibodies to cyclin D2 during G1 arrested the cyclin D2-expressing lymphocytes, breast myoepithelium, and U-2-OS sarcoma cells in G1 phase, whereas cyclin D2-negative cell types were unaffected by such treatment. Consistent with the putative protooncogenic role of cyclin D2 in specific cell types, our data show that this G1 cyclin has properties closely resembling those of cyclin D1, including the essential positive role in regulation of G1.	DANISH CANC SOC, DIV CANC BIOL, DK-2100 COPENHAGEN 0, DENMARK; UNIV COPENHAGEN, PANUM INST, INST MED ANAT A, STRUCT CELL BIOL UNIT, DK-2200 COPENHAGEN N, DENMARK; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; MAX PLANCK GESELL, MAX DELBRUCK HAUS, D-13122 BERLIN, GERMANY	Danish Cancer Society; University of Copenhagen; Cancer Research UK; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; Welcker, Markus/0000-0001-6723-4790; Petersen, Ole William/0000-0003-1691-749X				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CLARKE C, 1994, EPITHELIAL CELL BIOL, V3, P38; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; HANNA Z, 1993, ONCOGENE, V8, P1661; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LEACH FS, 1993, CANCER RES, V53, P1986; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1994, ONCOGENE, V9, P2159; LUKAS J, 1994, J IMMUNOL METHODS, V170, P255, DOI 10.1016/0022-1759(94)90400-6; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORK C, 1990, DIFFERENTIATION, V43, P146; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PALMERO I, 1993, ONCOGENE, V8, P1049; PETERSEN OW, 1988, DIFFERENTIATION, V39, P197, DOI 10.1111/j.1432-0436.1988.tb00094.x; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; TAM SW, 1994, ONCOGENE, V9, P2663; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	56	129	130	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2125	2134						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784057				2022-12-25	WOS:A1995RB70300007
J	GARRETT, JE; CAPUANO, IV; HAMMERLAND, LG; HUNG, BCP; BROWN, EM; HEBERT, SC; NEMETH, EF; FULLER, F				GARRETT, JE; CAPUANO, IV; HAMMERLAND, LG; HUNG, BCP; BROWN, EM; HEBERT, SC; NEMETH, EF; FULLER, F			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF HUMAN PARATHYROID CALCIUM RECEPTOR CDNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; EXTRACELLULAR DIVALENT-CATIONS; PROTEIN-KINASE-C; INTRACELLULAR CALCIUM; CYTOSOLIC CALCIUM; CELLS; CA-2+; HYPERPARATHYROIDISM; ACCUMULATION; MESSENGERS	Parathyroid cells express a cell surface receptor, coupled to the mobilization of intracellular Ca2+, that is activated by increases in the concentration of extracellular Ca2+ and by a variety of other cations, This ''Ca2+ receptor'' (CaR) serves as the primary physiological regulator of parathyroid hormone secretion, Alterations in the CaR have been proposed to underlie the increases in Ca2+ set-point seen in primary hyperparathyroidism due to parathyroid adenoma, We have isolated human CaR cDNAs from an adenomatous parathyroid gland, The cloned receptor, expressed in Xenopus oocytes, responds to extracellular application of physiologically relevant concentrations of Ca2+ and other CaR agonists, The rank order of potency of CaR agonists displayed by the native receptor (Gd3+ > neomycin B > Ca2+ > Mg2+) is maintained by the expressed receptor, The nucleotide sequence of the human CaR cDNA predicts a protein of 1078 amino acids with high sequence similarity to a bovine CaR, and displays seven putative membrane-spanning regions common to G protein-coupled receptors. The deduced protein sequence shows potential sites for N-linked glycosylation and phosphorylation by protein kinase C and has a low level of sequence similarity to the metabotropic glutamate receptors, Comparison of the cDNA sequence to that of the normal human CaR gene showed no alteration in the coding region sequence of the CaR in this particular instance of parathyroid adenoma, Human cDNA clones with differing 5'-untranslated regions were isolated, suggesting alternative splicing of the parathyroid CaR mRNA, A rare variant cDNA clone representing a 10 amino acid insertion into the extracellular domain was also isolated. Northern blot analysis of normal and adenomatous parathyroid gland mRNA identified a predominant transcript of similar to 5.4 kilobases, and less abundant transcripts of similar to 10, 4.8 and 4.2 kilobases in RNA from the adenoma. While there is no evidence for alteration of the primary amino acid sequence of the CaR in this adenoma, modulation of CaR biosynthesis through alternative RNA processing may play a role in set-point alterations.	NPS PHARMACEUT, DEPT PHARMACOL, SALT LAKE CITY, UT 84108 USA; BRIGHAM & WOMENS HOSP, DIV ENDOCRINE HYPERTENS, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV RENAL, MOLEC PHYSIOL & BIOPHYS LAB, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	GARRETT, JE (corresponding author), NPS PHARMACEUT, DEPT BIOL MOLEC, 420 CHIPETA WAY, SALT LAKE CITY, UT 84108 USA.		Centeno, Patricia Pacios/O-8368-2016					BROWN E, 1987, FEBS LETT, V218, P113, DOI 10.1016/0014-5793(87)81029-3; BROWN EM, 1991, ENDOCRINOLOGY, V128, P3047, DOI 10.1210/endo-128-6-3047; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BROWN EM, 1986, PROGR SURGERY, V18, P13; CHEN CJ, 1989, ENDOCRINOLOGY, V124, P233, DOI 10.1210/endo-124-1-233; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EL-HAJJ FULEIHAN G, 1991, ENDOCRINOLOGY, V128, P2931, DOI 10.1210/endo-128-6-2931; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FOX J, 1993, J BONE MINER RES, V8, pS181; FRIED RM, 1986, J BIOL CHEM, V261, P7669; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; KHOSLA S, 1993, J CLIN ENDOCR METAB, V76, P715, DOI 10.1210/jc.76.3.715; KIFOR O, 1988, ENDOCRINOLOGY, V123, P2723, DOI 10.1210/endo-123-6-2723; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KURTZ A, 1989, P NATL ACAD SCI USA, V86, P3423, DOI 10.1073/pnas.86.9.3423; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEMETH EF, 1987, J BIOL CHEM, V262, P5188; NEMETH EF, 1990, CELL CALCIUM, V11, P323, DOI 10.1016/0143-4160(90)90033-Q; NEMETH EF, 1994, NEWS PHYSL, V10, P1; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; POLLAK MR, 1994, J CLIN INVEST, V93, P1108, DOI 10.1172/JCI117062; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; RACKE FK, 1993, J PHYSIOL-LONDON, V468, P141, DOI 10.1113/jphysiol.1993.sp019764; RACKE FK, 1993, J PHYSIOL-LONDON, V468, P163, DOI 10.1113/jphysiol.1993.sp019765; RACKE FK, 1993, FEBS LETT, V333, P132, DOI 10.1016/0014-5793(93)80390-G; SAMBROOK J, 1989, MOL CHANGE LABORATOR; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH VL, 1990, CELL REGUL, V1, P165, DOI 10.1091/mbc.1.2.165; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341	35	419	452	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12919	12925		10.1074/jbc.270.21.12919	http://dx.doi.org/10.1074/jbc.270.21.12919			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759551	hybrid			2022-12-25	WOS:A1995QZ71100089
J	LEZOUALCH, F; SEUGNET, I; MONNIER, AL; GHYSDAEL, J; BEHR, JP; DEMENEIX, BA				LEZOUALCH, F; SEUGNET, I; MONNIER, AL; GHYSDAEL, J; BEHR, JP; DEMENEIX, BA			INHIBITION OF NEUROGENIC PRECURSOR PROLIFERATION BY ANTISENSE ALPHA-THYROID HORMONE-RECEPTOR OLIGONUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA RESPONSE ELEMENTS; CHICK OPTIC TECTUM; RETINOIC ACID; DIFFERENTIAL EXPRESSION; CELL-PROLIFERATION; BRAIN-DEVELOPMENT; GENE; PROTEIN; BINDING; BETA	Thyroid hormone 3,5,3'-triiodo-L-thyronine (T-3) is required for normal brain development in vertebrates. T-3 acts through two classes of nuclear receptors (TR alpha and TR beta) that have distinct developmental spatial and temporal distributions suggesting different functions during neuronal development. One possibility is that TR alpha, which is expressed early in embryogenesis, is involved in neuroblast proliferation. To test this hypothesis we used the embryonic chick optic lobe, as we found that T-3 stimulates [H-3]thymidine incorporation in this tissue both in vivo and in vitro during embryonic days 6-9. We applied oligonucleotides (ODNs) against TR alpha and TR beta to primary cultures of chick optic lobes. By employing a cationic lipid vector we could use very low ODN concentrations (< 150 nM). Antisense ODNs against TR alpha significantly inhibited [H-3]thymidine incorporation, whereas antisense TR beta had no significant effect, However, both ODNs inhibited expression of TRs, as they blocked transcription from a T-3-activated reporter gene. Random ODNs used as controls had no significant effect on [H-3]thymidine incorporation or on T-3-dependent transcription. These observations suggest that TR alpha is implicated in neuroblast proliferation and add credence to the hypothesis that the multiplicity of nuclear receptors allows for specific actions of T-3 during development.	NATL MUSEUM NAT HIST, PHYSIOL GEN & COMPAREE LAB, CNRS, URA 90, F-75005 PARIS, FRANCE; INST CURIE, ONCOGENESE RETROVIRALE & MOLEC LAB, CNRS, URA 1443, F-91405 ORSAY, FRANCE; UNIV STRASBOURG 1, CHIM GENET LAB, CNRS, URA 1386, F-67401 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Lezoualc'h, Frank/E-5031-2016; GHYSDAEL, Jacques/F-3377-2013					ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; Baffoni G. M., 1960, Rendiconti Accad Lincei (8), V28, P102; BALAZS R, 1968, J NEUROCHEM, V15, P1335, DOI 10.1111/j.1471-4159.1968.tb05913.x; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BETRAM J, 1994, BIOCHEM BIOPH RES CO, V200, P661; BRADLEY DJ, 1989, P NATL ACAD SCI USA, V86, P7250, DOI 10.1073/pnas.86.18.7250; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CAPACCIOLI S, 1993, BIOCHEM BIOPH RES CO, V197, P818, DOI 10.1006/bbrc.1993.2552; DELUZE A, 1993, P NATL ACAD SCI USA, V90, P7322, DOI 10.1073/pnas.90.15.7322; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FORREST D, 1991, EMBO J, V10, P269, DOI 10.1002/j.1460-2075.1991.tb07947.x; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HIRST MA, 1992, P NATL ACAD SCI USA, V89, P5527, DOI 10.1073/pnas.89.12.5527; JACOBSON M, 1991, DEV NEUROBIOL, P282; KAWAHARA A, 1991, DEVELOPMENT, V112, P933; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAVAIL JH, 1971, BRAIN RES, V28, P421; LAVAIL JH, 1971, BRAIN RES, V28, P391, DOI 10.1016/0006-8993(71)90053-9; LEZOUALCH F, 1992, MOL ENDOCRINOL, V6, P1797, DOI 10.1210/me.6.11.1797; LOUIS JC, 1981, EXP BRAIN RES, V42, P63; NICHOLSO.JL, 1972, BRAIN RES, V44, P13, DOI 10.1016/0006-8993(72)90362-9; Oppenheimer J H, 1976, Recent Prog Horm Res, V32, P529; PRATI M, 1992, ENDOCRINOLOGY, V130, P2651, DOI 10.1210/en.130.5.2651; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STRAIT KA, 1991, P NATL ACAD SCI USA, V88, P3887, DOI 10.1073/pnas.88.9.3887; STRAIT KA, 1992, MOL ENDOCRINOL, V6, P1874, DOI 10.1210/me.6.11.1874; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; Thommes R C, 1987, J Exp Zool Suppl, V1, P273; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YEN PM, 1992, J BIOL CHEM, V267, P3565	41	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12100	12108		10.1074/jbc.270.20.12100	http://dx.doi.org/10.1074/jbc.270.20.12100			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744858	hybrid			2022-12-25	WOS:A1995QY73600061
J	STURZL, M; BRANDSTETTER, H; ZIETZ, C; EISENBURG, B; RAIVICH, G; GEARING, DP; BROCKMEYER, NH; HOFSCHNEIDER, PH				STURZL, M; BRANDSTETTER, H; ZIETZ, C; EISENBURG, B; RAIVICH, G; GEARING, DP; BROCKMEYER, NH; HOFSCHNEIDER, PH			IDENTIFICATION OF INTERLEUKIN-1 AND PLATELET-DERIVED GROWTH FACTOR-B AS MAJOR MITOGENS FOR THE SPINDLE CELLS OF KAPOSIS-SARCOMA - A COMBINED IN-VITRO AND IN-VIVO ANALYSIS	ONCOGENE			English	Article						KAPOSIS SARCOMA; PDGF; INTERLEUKIN ONCOSTATIN; IN SITU HYBRIDIZATION; GP130	IL-6 SIGNAL TRANSDUCER; YOUNG HOMOSEXUAL MEN; ONCOSTATIN-M; EXPRESSION; RECEPTOR; AUTOCRINE; CULTURE; INVITRO; GP130; HYBRIDIZATION	By means of a combined in vitro and in vivo analysis we provide evidence that IL-1 beta and PDGF-B, but not OSM (oncostatin M) or IL-6, are major mitogens for the spindle cells of Kaposi's sarcoma (KS) in vivo. PDGF-B and IL-1 beta stimulated proliferation of cultivated KS spindle cells in vitro. Analysis of gene expression in vivo revealed that both factors as well as the PDGF beta-receptor are present in KS lesions, By contrast, IL-6 had no effect and OSM inhibited proliferation of cultivated KS spindle cells. Again, the effect of these factors on cultivated KS spindle cells in vitro was reflected by the gene expression observed in KS lesions in vivo. Neither the expression of IL-6 receptor nor of OSM could be detected in KS lesions by in situ hybridization, Moreover, in situ hybridization revealed an identical pattern of gene expression in cultivated KS spindle cells and KS spindle cells in vivo with respect to the above-mentioned cytokines [PDGF-B, IL-1 beta, IL-1 alpha, IL-6, OSM] and their receptors [PDGF beta-receptor, gp130, IL-6 receptor, leukemia inhibitory factor (LII;) receptor]. This further supported the suitability of cultivated KS spindle cells as an in vitro model in order to determine which cytokines may activate proliferation of KS spindle cells in vivo.	UNIV MUNICH, INST PATHOL, D-80337 MUNICH, GERMANY; MAX PLANCK INST PSYCHIAT, NEUROMORPHOL ABT, D-82152 MARTINSRIED, GERMANY; IMMUNEX RES & DEV CORP, SEATTLE, WA 98101 USA; UNIV ESSEN GESAMTHSCH KLIN, HAUTKLIN, ESSEN, GERMANY	University of Munich; Max Planck Society; University of Duisburg Essen	STURZL, M (corresponding author), MAX PLANCK INST BIOCHEM, VIRUSFORSCH ABT, KLOPFERSPITZ 18A, D-82152 MARTINSRIED, GERMANY.		Stürzl, Michael/B-3019-2015; Raivich, Gennadij/A-6770-2011; Raivich, Gennadij/AAL-7229-2021	Stürzl, Michael/0000-0002-9276-2824; 				ALBINI A, 1988, J CELL BIOCHEM, V36, P369, DOI 10.1002/jcb.240360406; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BOVI PD, 1986, CANCER RES, V46, P6333; CAI J, 1994, AM J PATHOL, V145, P74; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORBEIL J, 1991, J IMMUNOL, V146, P2972; COZZOLINO F, 1990, P NATL ACAD SCI USA, V87, P6487, DOI 10.1073/pnas.87.17.6487; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FRIEDMANKIEN AE, 1981, J AM ACAD DERMATOL, V5, P468, DOI 10.1016/S0190-9622(81)80010-2; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GOTTLIEB GJ, 1982, HUM PATHOL, V13, P882, DOI 10.1016/S0046-8177(82)80047-6; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; HAMILTON AS, 1994, J ACQ IMMUN DEF SYND, V7, P410; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; KAAYA EE, 1992, EUR J CANCER, V28A, P1890, DOI 10.1016/0959-8049(92)90030-6; KAPOSI M, 1872, ARCH DERMATOL SYPHIL, V4, P742; LEPEZUNIGA JL, 1987, J CLIN MICROBIOL, V25, P1695, DOI 10.1128/JCM.25.9.1695-1700.1987; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; REGEZI JA, 1993, AM J PATHOL, V143, P240; ROTH WK, 1988, INT J CANCER, V42, P767, DOI 10.1002/ijc.2910420523; ROTH WK, 1989, ONCOGENE, V4, P483; SCHIRREN CG, 1990, BRIT J DERMATOL, V123, P313, DOI 10.1111/j.1365-2133.1990.tb06290.x; SCHULZEOSTHOFF K, 1990, J INVEST DERMATOL, V95, P238, DOI 10.1111/1523-1747.ep12478105; SNOVER DC, 1985, CLIN BIOCH ANAL, P181; STURZL M, 1990, ANAL BIOCHEM, V185, P164, DOI 10.1016/0003-2697(90)90274-D; STURZL M, 1992, AIDS RES HUM RETROV, V8, P1753, DOI 10.1089/aid.1992.8.1753; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; WERNER S, 1989, INT J CANCER, V43, P1137, DOI 10.1002/ijc.2910430629; XERRI L, 1991, AM J PATHOL, V138, P9; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YANG J, 1994, J IMMUNOL, V152, P943	41	65	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					2007	2016						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761101				2022-12-25	WOS:A1995QZ92600015
J	BROWN, HA; GUTOWSKI, S; KAHN, RA; STERNWEIS, PC				BROWN, HA; GUTOWSKI, S; KAHN, RA; STERNWEIS, PC			PARTIAL-PURIFICATION AND CHARACTERIZATION OF ARF-SENSITIVE PHOSPHOLIPASE-D FROM PORCINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; ADENYLATE-CYCLASE; REGULATORY COMPONENT; HYDRODYNAMIC PROPERTIES; CHOLERA-TOXIN; BINDING; HYDROLYSIS; ACTIVATION; CGMP	Phospholipase D (PLD) activity from membranes of cultured cells can be activated by guanosine 5'-O-(3-thiotriphosphate) and the small GTP-dependent protein, Arf. While this activity was readily apparent in membranes from HL60 cells, it was much lower or not observable in membranes from various mammalian tissues. However, extraction of porcine brain membranes with detergent and subsequent chromatography with SP-Sepharose revealed a large peak of Arf-sensitive PLD activity. This activity has been enriched through several steps of chromatography and characterized with respect to size, nucleotide specificity, and sensitivity to different Arf and Arf-like proteins. Hydrodynamic analysis indicated that the enriched PLD had an s(20,w) of 5.1 and a Stokes radius of 4.3 nm. These parameters indicate that the enzyme has an apparent molecular mass of 95,000 Da. Effective stimulation of the enriched enzyme was achieved with GTP as well as nonhydrolyzable analogs. All of the Arf subtypes tested were effective activators of PLD activity. Arf derived from yeast could activate mammalian PLD but with lower potency. The Arf-related Arl proteins were ineffective. PLD that has been highly enriched retained a requirement for phosphatidylinositol 4,5-bisphosphate for efficient expression of activity. Additionally, the ability of recombinant or purified porcine brain Arf to stimulate PLD activity was reduced relative to impure fractions of Arf activity. Thus, porcine PLD that has been purified about 5,000-10,000-fold is synergistically activated by Arf in combination with other cytosolic components that are described in the accompanying paper (Singer, W. D., Brown, H. A., Bokoch, G. M., and Sternweis, P. C. (1995) J. Biol. Chem. 270, 14944-14950). Taken together, these data suggest that physiological regulation of Arf-sensitive PLD may involve the coordinate assembly of several interacting regulatory subunits.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; NCI, DIV CANC TREATMENT, BIOL CHEM LAB, DEV THERAPEUT PROGRAM, BETHESDA, MD 20892 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NIGMS NIH HHS [GM15817, GM31954] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015817, R01GM031954] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTIA NJ, 1970, CAN J BIOCHEM CELL B, V48, P643, DOI 10.1139/o70-103; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CLARKE S, 1975, J BIOL CHEM, V250, P5459; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; EINSET E, 1958, J BIOL CHEM, V231, P703; EXTON JH, 1990, J BIOL CHEM, V265, P1; FALCK JR, 1991, ACS SYM SER, V463, P145; HAGA T, 1977, J BIOL CHEM, V252, P5776; Heller M, 1978, Adv Lipid Res, V16, P267; HOWLETT AC, 1980, J BIOL CHEM, V255, P2861; HUANG KS, 1991, METHOD ENZYMOL, V197, P567; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1993, HDB EXPT PHARM GTPAS, P529; KOBAYASHI M, 1991, METHOD ENZYMOL, V197, P575; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OKAMURA S, 1994, J BIOL CHEM, V269, P31207; PAGES F, 1992, J BIOL CHEM, V267, P22018; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; SAITO M, 1975, ARCH BIOCHEM BIOPHYS, V169, P318, DOI 10.1016/0003-9861(75)90346-X; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; TAKI T, 1979, J BIOL CHEM, V254, P9761; TERUI T, 1994, J BIOL CHEM, V269, P28130; WANG XM, 1994, J BIOL CHEM, V269, P20312	45	130	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14935	14943		10.1074/jbc.270.25.14935	http://dx.doi.org/10.1074/jbc.270.25.14935			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797473	hybrid			2022-12-25	WOS:A1995RE66600017
J	LENTING, PJ; TERMAAT, H; CLIJSTERS, PPFM; DONATH, MJSH; VANMOURIK, JA; MERTENS, K				LENTING, PJ; TERMAAT, H; CLIJSTERS, PPFM; DONATH, MJSH; VANMOURIK, JA; MERTENS, K			CLEAVAGE AT ARGININE-145 IN HUMAN BLOOD-COAGULATION FACTOR-IX CONVERTS THE ZYMOGEN INTO A FACTOR-VIII BINDING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; FACTOR-X ACTIVATION; PLASMA THROMBOPLASTIN ANTECEDENT; RUSSELLS VIPER VENOM; CHRISTMAS-FACTOR; PLASMINOGEN-ACTIVATOR; FACTOR-XIA; EXTRINSIC PATHWAY; INHIBITOR TYPE-1; PROTEIN-S	The transition of the factor IX zymogen into the enzyme factor IXa beta was investigated. For this purpose, the activation intermediate factors IX alpha and IXa alpha were purified after cleavage of the Arg(145)-Ala(146) and Arg(180)-Val(181) bonds, respectively. These intermediates were compared for a number of functional properties with factor IXa beta, which is cleaved at both positions. Factor IXa alpha was equal to factor IXa beta in hydrolyzing the synthetic substrate CH3SO2-Leu-Gly-Arg-p-nitroanilide (k(cat)/K-m approximate to 120 s(-1) M(-1)) but was less efficient in factor X activation. Factor IX alpha was incapable of generating factor Xa but displayed reactivity toward p-nitrophenol p-guanidino-benzoate and the peptide substrate. The catalytic efficiency, however, was 4-fold lower compared with factor IXa alpha and factor IXa beta. Factor IX alpha and factor IXa beta had similar affinity for the inhibitor benzamidine (K-i approximate to 2.5 mM), and amidolytic activity of both species was inhibited by Glu-Gly-Arg-chloromethyl ketone and antithrombin III. Unlike factor IXa beta, factor IX alpha was unable to form SDS stable complexes with antithrombin III. Moreover, inhibition of factor IXa beta and factor IX alpha by Glu-Gly-Arg-chloromethyl ketone followed distinct pathways, because factor IX alpha was inhibited in a nonirreversible manner and displayed only minor incorporation of the dansylated inhibitor into its catalytic site. These data demonstrate that the catalytic site of factor IX alpha differs from that of the fully activated factor IXa beta. Factor IX and its derivatives were also compared with regard to complex assembly with factor VIII in direct binding studies employing the immobilized factor VIII light chain. Factor IX alpha and factor IXa beta displayed a 30-fold higher affinity for the factor VIII light chain (K-d approximate to 12 nM) than the factor IX zymogen. Factor IXa alpha showed lower affinity (K-d approximate to 50 nM) than factor IX alpha and factor IXa beta, which may explain the lower efficiency of factor X activation by factor IXa alpha. Collectively, our data indicate that cleavage of the Arg(180)-Val(181) bond develops full amidolytic activity but results in suboptimal binding to the factor VIII light chain. With regard to cleavage of the Arg(145)-Ala(146) bond, we have demonstrated that this results in the transition of the factor IX zymogen into an enzyme that lacks proteolytic activity. Moreover, the same cleavage fully exposes the binding site for the factor VIII light chain, suggesting that cleavage of the Arg(145)-Ala(146) bond serves a previously unrecognized role in the assembly of the factor IX-factor VIII complex.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT BLOOD COAGULAT,1066 CX AMSTERDAM,NETHERLANDS				Lenting, Peter/F-8269-2013; Lenting, Peter/AAH-5663-2019	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429				BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1983, BIOCHEMISTRY-US, V22, P4047, DOI 10.1021/bi00286a009; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE R, 1980, J BIOL CHEM, V255, P5336; CHEUNG WF, 1992, J BIOL CHEM, V267, P20529; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; ELDERING E, 1992, J BIOL CHEM, V267, P7013; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GERATZ JD, 1979, ARCH BIOCHEM BIOPHYS, V197, P551, DOI 10.1016/0003-9861(79)90279-0; GRIFFITH MJ, 1985, J CLIN INVEST, V75, P4, DOI 10.1172/JCI111694; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KREUTTER K, 1994, BIOCHEMISTRY-US, V33, P13792, DOI 10.1021/bi00250a033; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LEYTE A, 1989, BIOCHEM J, V263, P187, DOI 10.1042/bj2630187; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; LIU LW, 1991, J BIOL CHEM, V266, P23632; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MERTENS K, 1990, THROMB HAEMOSTASIS, V64, P138; MERTENS K, 1982, THROMB HAEMOSTASIS, V47, P96; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; MERTENS K, 1994, Patent No. 5692; MERTENS K, 1995, THROMB HAEMOSTASIS, V54, P654; MORTON PA, 1989, J BIOL CHEM, V264, P7228; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; NEUENSCHWANDER P, 1990, ANAL BIOCHEM, V184, P347, DOI 10.1016/0003-2697(90)90692-3; PATTSON PA, 1990, J BIOL CHEM, V265, P17086; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; PERSSON E, 1993, J BIOL CHEM, V268, P22531; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PROROK M, 1994, BIOCHEMISTRY-US, V33, P9784, DOI 10.1021/bi00198a050; RAWALASHEIKH R, 1992, BLOOD, V79, P398; ROBERTS HR, 1993, THROMB HAEMOSTASIS, V70, P1; RUSSELL ME, 1990, J BIOL CHEM, V265, P2569; SPERLING R, 1978, J BIOL CHEM, V253, P3898; STEIN RL, 1986, BIOCHEMISTRY-US, V25, P5414, DOI 10.1021/bi00367a011; STEL HV, 1984, THESIS U AMSTERDAM, P51; STENFLO J, 1991, BLOOD, V78, P1637; TANS G, 1987, EUR J BIOCHEM, V164, P637, DOI 10.1111/j.1432-1033.1987.tb11174.x; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; WALSH PN, 1982, J CLIN INVEST, V73, P1392; WU QY, 1994, J BIOL CHEM, V269, P3725	55	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14884	14890		10.1074/jbc.270.25.14884	http://dx.doi.org/10.1074/jbc.270.25.14884			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797466	hybrid			2022-12-25	WOS:A1995RE66600010
J	MACGINNITIE, AJ; ANANT, S; DAVIDSON, NO				MACGINNITIE, AJ; ANANT, S; DAVIDSON, NO			MUTAGENESIS OF APOBEC-1, THE CATALYTIC SUBUNIT OF THE MAMMALIAN APOLIPOPROTEIN-B MESSENGER-RNA EDITING ENZYME, REVEALS DISTINCT DOMAINS THAT MEDIATE CYTOSINE NUCLEOSIDE DEAMINASE, RNA-BINDING, AND RNA EDITING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SITE	Apolipoprotein (apo) B48 is synthesized by mammalian small intestine as a result of post-transcriptional RNA editing. This process is mediated by an enzyme complex containing a catalytic subunit, apobec-1, which is homologous to other cytidine deaminases, particularly in a domain (H/C)-(A/V)-E-(X)(24-30)-P-C-(X)(2)-C which coordinates zinc. apobec-1, expressed as a glutathione S-transferase fusion protein, demonstrates both apoB RNA editing and cytidine deaminase activity. His(61) Cys(93), and Cys(96), the putative zinc-coordinating residues, were mutated to Arg, Ser, and Ser, respectively, with loss of RNA editing activity and either great reduction or abolition of cytidine deaminase activity. Mutation of the catalytically active Glu(63) residue to Gln and pro(92) to Leu abolished both cytidine deaminase and RNA editing activity. The conservative His(61) --> Cys mutation, which should coordinate zinc, retained both editing and cytidine deaminase activity. Thus, zinc binding is required for both apoB RNA editing and cytidine deaminase activity. Mutation of the first four leucines within the heptad repeat of the leucine-rich region (LRR) of apobec-1 resulted in reduced RNA editing but preservation of wild-type cytidine deaminase activity, GST/APOBEC-1 was also demonstrated to cross-link to apoB RNA. Mutation of His(61) --> Arg abolished RNA binding, while the Glu(63), Gln and Cys(96) --> Ser mutant proteins showed wild-type levels of RNA binding. The remaining mutants had reduced levels of activity. Overexpression of wild-type apobec-1 in McA 7777 cells resulted in a 5-6-fold increase in editing of endogenous apoB. Transfection of the His(61) --> Cys, LRR, and Cys(93) --> Ser mutants increased endogenous editing 23-fold, while Glu(63) --> Gln and His(61) --> Arg mutants acted as dominant negatives, reducing endogenous editing. These data suggest that apobec-1 has distinct functional domains which modulate activity in the context of the apoB mRNA editing enzyme.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago			Anant, Shrikant/AAF-8020-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018577, R01HL038180, R37HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38180, HL-18577] Funding Source: Medline; NIDDK NIH HHS [DK-42086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; ANDERSSON S, 1992, J BIOL CHEM, V264, P8222; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1219, P1, DOI 10.1016/0167-4781(94)90240-2; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BHATTACHARYA S, 1994, TRENDS BIOCHEM SCI, V19, P105, DOI 10.1016/0968-0004(94)90200-3; BHAUMIK D, 1993, J BIOL CHEM, V268, P5464; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BOYUM A, 1994, EXP HEMATOL, V22, P208; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIES MS, 1989, J BIOL CHEM, V264, P13395; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; FUNAHASHI T, 1995, J LIPID RES, V36, P414; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; MOORE JT, 1993, J BIOL CHEM, V268, P2288; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; ROTH GJ, 1991, BLOOD, V77, P5; SMITH AA, 1994, BIOCHEMISTRY-US, V33, P6468, DOI 10.1021/bi00187a012; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TENG B, 1993, SCIENCE, V260, P1819; WILSON DK, 1991, SCIENCE, V25, P1278; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	31	111	117	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14768	14775		10.1074/jbc.270.24.14768	http://dx.doi.org/10.1074/jbc.270.24.14768			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782343	hybrid			2022-12-25	WOS:A1995RD45500080
J	MOLINARI, M; MAKI, M; CARAFOLI, E				MOLINARI, M; MAKI, M; CARAFOLI, E			PURIFICATION OF MU-CALPAIN BY A NOVEL AFFINITY-CHROMATOGRAPHY APPROACH - NEW INSIGHTS INTO THE MECHANISM OF THE INTERACTION OF THE PROTEASE WITH TARGETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; ERYTHROCYTE PLASMA-MEMBRANE; CALCIUM-DEPENDENT PROTEASE; HAND STRUCTURE-DOMAIN; BINDING; CALPASTATIN; CALMODULIN; DEGRADATION; PROTEINS; PHOSPHODIESTERASE	A calmodulin-binding motif is a common structural feature of a number of calpain substrates (1). Since a calmodulin-like domain has been identified in both subunits of the calpain molecule, the proposal was made that the domain(s) would recognize the calmodulin-binding motifs of the substrates prior to the enzymatic modification by calpain. In keeping with the proposal, a succesful attempt to purify mu-calpain hom human erythrocytes was made by using an affinity chromatography approach in which the synthetic peptide C49, containing the calmodulin-binding domain of the plasma membrane Ca2+-ATPase, was coupled to a Sepharose matrix. The calmodulin-like domain of the catalytic subunit of human mu-calpain expressed in Escherichia coli was also retained by the C49-Sepharose column. Both mu-calpain and tbe calmodulin-like domain interacted with C49 in a Ca2+-dependent way and were eluted from the column by Ca2+-chelating agents. The finding confirmed the interaction between the calmodulin-binding domain of the plasma membrane Ca2+-ATPase and the calmodulinlike domain of mu-calpain. Experiments were performed to establish whether irreversibly inactivated mu-calpain or its expressed C-terminal portion containing the calmodulin-like domain could activate the hydrolysis of ATP by the plasma membrane Ca2+ pump, in keeping with the evident ATPase stimulation of the same pump by calmodulin. A stimulation was observed, but it was much weaker than that induced by calmodulin.	KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 60601, JAPAN; ETH ZURICH, INST BIOCHEM 3, CH-8092 ZURICH, SWITZERLAND	Kyoto University; ETH Zurich			Molinari, Maurizio/N-2587-2019; Carafoli, Ernesto/K-5192-2016; Maki, Masatoshi/AAM-6839-2021	Molinari, Maurizio/0000-0002-7636-5829; Carafoli, Ernesto/0000-0002-7826-0094; Maki, Masatoshi/0000-0001-9144-5491				ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; BANIK NL, 1987, NEUROCHEM PATHOL, V7, P57, DOI 10.1007/BF02834292; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; DELCERRO S, 1994, NEUROSCI LETT, V167, P149, DOI 10.1016/0304-3940(94)91049-9; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P13936; GOPINATH RM, 1977, BIOCHEM BIOPH RES CO, V77, P1203, DOI 10.1016/S0006-291X(77)80107-1; GUNDERSEN RE, 1987, J BIOL CHEM, V262, P4602; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; INOMATA M, 1989, J BIOL CHEM, V264, P18838; INOMATA M, 1990, BIOCHEM BIOPH RES CO, V171, P625, DOI 10.1016/0006-291X(90)91192-U; JAMES P, 1989, J BIOL CHEM, V264, P8289; JARRETT HW, 1977, BIOCHEM BIOPH RES CO, V77, P1210, DOI 10.1016/S0006-291X(77)80108-3; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; KAWASAKI H, 1993, ARCH BIOCHEM BIOPHYS, V305, P467, DOI 10.1006/abbi.1993.1448; KUBOKI M, 1987, BIOCHIM BIOPHYS ACTA, V929, P164, DOI 10.1016/0167-4889(87)90172-8; KUBOKI M, 1990, J BIOCHEM-TOKYO, V107, P776, DOI 10.1093/oxfordjournals.jbchem.a123124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEE WJ, 1990, BIOCHEM INT, V22, P163; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MA H, 1993, J BIOCHEM, V113, P591, DOI 10.1093/oxfordjournals.jbchem.a124088; MINAMI Y, 1987, J BIOCHEM-TOKYO, V101, P889, DOI 10.1093/oxfordjournals.jbchem.a121956; MINAMI Y, 1988, J BIOCHEM-TOKYO, V104, P927, DOI 10.1093/oxfordjournals.jbchem.a122585; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Roberts DM, 1993, CURR OPIN CELL BIOL, V5, P242, DOI 10.1016/0955-0674(93)90110-C; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SHIMOHAMA S, 1991, BRAIN RES, V558, P105, DOI 10.1016/0006-8993(91)90722-8; SIMAN R, 1990, FID RES FDN, V4, P145; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; VORRHERR T, 1990, BIOCHEMISTRY-US, V29, P355; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V267, P317, DOI 10.1016/0003-9861(88)90037-9; YANG HQ, 1994, J BIOL CHEM, V269, P18977; YOSHIZAWA T, 1995, BIOCHEM BIOPH RES CO, V208, P376, DOI 10.1006/bbrc.1995.1348	47	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14576	14581		10.1074/jbc.270.24.14576	http://dx.doi.org/10.1074/jbc.270.24.14576			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782321	hybrid			2022-12-25	WOS:A1995RD45500053
J	HALSTEAD, J; KEMP, A; IGNOTZ, RA				HALSTEAD, J; KEMP, A; IGNOTZ, RA			EVIDENCE FOR INVOLVEMENT OF PHOSPHATIDYLCHOLINE-PHOSPHOLIPASE-C AND PROTEIN-KINASE-C IN TRANSFORMING GROWTH-FACTOR-BETA SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TGF-BETA; MEDIATED HYDROLYSIS; CELLS; INHIBITION; ACTIVATION; RECEPTOR; TRANSDUCTION; STIMULATION; RAS	Transforming growth factor-beta (TGF-beta) is a multifunctional peptide that elicits a wide variety of responses in cells. TGF-beta binds to cell surface receptors that contain cytoplasmic serine/threonine kinase domains. Here we provide evidence that both phospholipase C and protein kinase C (pFC) are involved in the TGF-beta activation of transcription and luciferase expression from the p3TP-Lux plasmid. Down-regulation of PKC prevents TGF-beta 1 induction of luciferase expression. Staurosporin and Calphostin C, inhibitors of PKC, block the ability of TGF-beta 1 to initiate transcription of the luciferase gene. Further, D609, an inhibitor of phosphatidylcholine-phospholipase C (PC-PLC), and secondarily PKC also blocks TGF-1-induced transcription of the transgene in A549 cells while the phosphatidylinositol-PLC pathway inhibitor U73122 is without effect; TGF-beta elevates steady-state mRNA levels for the endogenous PAI-1 and fibronectin genes. Treatment of cells with calphostin C or D609 prevents the TGF-beta-induced increase in these mRNAs. Together, these results suggest that PC-PLC and PKC are in a TGF-beta signaling pathway that results in elevated gene expression.	UNIV MASSACHUSETTS,MED CTR,DEPT CELL BIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester								BLEASDALE JE, 1993, NEUROPROTOCOLS, V3, P125; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; DIAZMECO MT, 1992, MOL CELL BIOL, V12, P302, DOI 10.1128/MCB.12.1.302; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; HOWE PH, 1989, CANCER RES, V49, P6024; IGNOTZ R A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P75; KATAOKA R, 1993, J BIOL CHEM, V268, P19851; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRICE BD, 1989, J BIOL CHEM, V264, P16638; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; TWARDZIK DR, 1989, J NATL CANCER I, V81, P1132; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAN ZF, 1994, J BIOL CHEM, V269, P13231	33	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13600	13603		10.1074/jbc.270.23.13600	http://dx.doi.org/10.1074/jbc.270.23.13600			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775410	hybrid			2022-12-25	WOS:A1995RC44800006
J	WATANABE, K; FUKUCHI, T; HOSOYA, H; SHIRASAWA, T; MATUOKA, K; MIKI, H; TAKENAWA, T				WATANABE, K; FUKUCHI, T; HOSOYA, H; SHIRASAWA, T; MATUOKA, K; MIKI, H; TAKENAWA, T			SPLICING ISOFORMS OF RAT ASH/GRB2 - ISOLATION AND CHARACTERIZATION OF THE CDNA AND GENOMIC DNA CLONES AND IMPLICATIONS FOR THE PHYSIOLOGICAL ROLES OF THE ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; SH3 DOMAINS; PROTEIN; GRB2; BINDS; SOS; SEVENLESS; ACTIVATOR; SEQUENCE	We obtained three types of cDNA clones homologous to Ash/Grb2(Ash-l) cDNA from rats. One of these clones, Ash-psi was an unusual transcribed gene having 93% identity in the nucleotide sequence to Ash-l. The other two clones, Ash-m and -s, had nucleotide sequences identical with Ash-l cDNA in the amino-terminal region. The coding sequence of Ash-m cDNA is 42 nucleotides shorter than that of Ash-l cDNA. The defective region of Ash-m cDNA encodes 14 amino acid residues (157 to 170 of Ash-l), which comprise the most conserved region of the second SH3 domain. On the other hand, the coding sequence of Ash-s terminated at the end of the first SH3 domain due to a stop codon at the boundary of the sequence, thereby differing from Ash-l cDNA Cloning of the genomic DNA of the Ash-l-encoding gene, determination of the gene organization, and nucleotide sequencing revealed that the two isoforms, as well as Ash-l, are generated from a single gene by unusual alternative splicings. The gene spans more than 16 kilobases and contains 6 exons and 5 introns. Ash-m and Ash-s mRNAs were detected in various tissues by reverse-transcribed polymerase chain reaction. Ash-m physically associated with dynamin, but the association with Sos was less effective than that of Ash-l in rat pheochromocytoma PC12 cell lysates, irrespective of treatment with nerve growth factor. In contrast, Ash-s formed a complex with dynamin and Sos in cell lysates. Moreover, the newly formed carboxyl-terminal SH3 of Ash-m by splicing bound different proteins from those bound to the carboxyl-terminal SH3 domain of Ash-l, suggesting that Ash-m generates different signals. Microinjection of Ash-m or Ash-s into Balb/c 3T3 cells inhibited DNA synthesis induced by platelet-derived growth factor. These results show that these isoforms act as dominant negative regulators of mitogenic signals by Ash-l.	UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL,MINATO KU,TOKYO 108,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERENTOL,DEPT EXPTL BIOL,TOKYO 173,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERENTOL,DEPT MOLEC PATHOL,TOKYO 173,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERENTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO 173,JAPAN	University of Tokyo								BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUO LH, 1983, METHOD ENZYMOL, V100, P60; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maniatis T., 1982, MOL CLONING; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MESSING J, 1981, NUCLEIC ACIDS RES, V10, P1755; MIKI H, 1994, J BIOL CHEM, V269, P5489; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; WATANABE K, 1992, GENE, V114, P261, DOI 10.1016/0378-1119(92)90585-D	27	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13733	13739		10.1074/jbc.270.23.13733	http://dx.doi.org/10.1074/jbc.270.23.13733			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775428	hybrid			2022-12-25	WOS:A1995RC44800025
J	BRUNEAU, N; LOMBARDO, D				BRUNEAU, N; LOMBARDO, D			CHAPERONE FUNCTION OF A GRP 94-RELATED PROTEIN FOR FOLDING AND TRANSPORT OF THE PANCREATIC BILE SALT-DEPENDENT LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; CHOLESTEROL ESTERASE; MEMBRANE-GLYCOPROTEINS; STIMULATED LIPASE; CDNA CLONING; PURIFICATION; CELL; GLYCOSYLATION; EXPRESSION; OLIGOSACCHARIDES	In its fundamental attributes, the secretion pathway of the pancreatic bile salt-dependent lipase (BSDL) followed that described for all enzymes involved in regulated secretion. This route was inhibited by drugs that affect protein synthesis and intracellular transport. In the presence of monensin, BSDL was solely detected in microsome membrane fractions. The association of BSDL with intracellular membranes involved a protein complex, formed by at least two proteins of 94 and 56 kDa. In cells experiencing the metabolic stress due to azetidine-2-carboxylic acid, BSDL was additionally associated with a protein of 46 kDa. Affinity blotting showed that BSDL bound directly to the 94-kDa protein (p94). It was suggested that p94 could be a molecular chaperone, further identified as related to the 94-kDa glucose regulated protein (Grp 94). The membrane-associated BSDL (i.e. BSDL bound to the Grp 94-related p94) was O- and N-glycosylated and consequently appeared released from membranes in the trans-Golgi compartment. Therefore and for the first time, it is suggested that a multiprotein complex including the chaperone Grp 94-related p94 protein may play an essential role in the folding and transport of BSDL. One hypothesis is that the association of BSDL with membrane via the Grp 94-related p94 along its secretion pathway is required for its complete O-glycosylation, which occurs on the extended mucin-like structures present on the C-terminal part of the protein.	FAC MED TIMONE,INSERM,U260,F-13385 MARSEILLE 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Bruneau, Nadine/O-2100-2016	Bruneau, Nadine/0000-0002-1523-3128				ABOUAKIL N, 1993, J BIOL CHEM, V268, P25755; ABOUAKIL N, 1988, BIOCHIM BIOPHYS ACTA, V961, P299, DOI 10.1016/0005-2760(88)90077-X; ALBERS GHR, 1987, DIFFERENTIATION, V34, P210, DOI 10.1111/j.1432-0436.1987.tb00068.x; BABA T, 1991, BIOCHEMISTRY-US, V30, P500, DOI 10.1021/bi00216a028; BENNETT G, 1987, CELL TISSUE RES, V250, P355; BOSNER MS, 1988, P NATL ACAD SCI USA, V85, P7438, DOI 10.1073/pnas.85.20.7438; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DIPERSIO LP, 1994, BIOCHEMISTRY-US, V33, P3442, DOI 10.1021/bi00177a038; DOOLITTLE MH, 1991, ANAL BIOCHEM, V195, P364, DOI 10.1016/0003-2697(91)90342-Q; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ESCRIBANO MJ, 1989, J BIOL CHEM, V264, P21865; FERGUSON MAJ, 1992, BIOCHEM SOC T, V20, P243, DOI 10.1042/bst0200243; FITTING T, 1982, J BIOL CHEM, V257, P4011; FONTAINE RN, 1991, BIOCHEMISTRY-US, V30, P7008, DOI 10.1021/bi00242a028; FREEDMAN SD, 1993, BIOCHEM BIOPH RES CO, V197, P992, DOI 10.1006/bbrc.1993.2577; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GJELLESVIK DR, 1992, BIOCHIM BIOPHYS ACTA, V1124, P123, DOI 10.1016/0005-2760(92)90088-D; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HANSSON L, 1993, J BIOL CHEM, V268, P26692; HOOPER NM, 1991, BIOCHEM J, V280, P745, DOI 10.1042/bj2800745; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAMIESON JD, 1968, J CELL BIOL, V39, P589, DOI 10.1083/jcb.39.3.589; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1984, J BIOL CHEM, V259, P4616; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOMBARDO D, 1978, BIOCHIM BIOPHYS ACTA, V527, P142, DOI 10.1016/0005-2744(78)90263-2; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MAS E, 1993, BIOCHEM J, V289, P609, DOI 10.1042/bj2890609; MAS E, 1993, EUR J BIOCHEM, V216, P807, DOI 10.1111/j.1432-1033.1993.tb18201.x; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MIRALLES F, 1993, EUR J CELL BIOL, V60, P115; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; REGGIO HA, 1978, J CELL BIOL, V77, P288, DOI 10.1083/jcb.77.2.288; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; REUE K, 1991, J LIPID RES, V32, P267; ROBBI M, 1991, J BIOL CHEM, V266, P20498; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rudd E.A., 1984, P185; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SCHEELE G, 1985, J BIOL CHEM, V260, P926; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; STROUS GJA, 1980, CELL, V22, P709; SUGO T, 1993, EUR J BIOCHEM, V216, P799, DOI 10.1111/j.1432-1033.1993.tb18200.x; VELEZGRANELL CS, 1994, J CELL SCI, V107, P539	54	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13524	13533		10.1074/jbc.270.22.13524	http://dx.doi.org/10.1074/jbc.270.22.13524			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768954	hybrid			2022-12-25	WOS:A1995RB43900084
J	GIETZ, RD; GRAHAM, KC; LITCHFIELD, DW				GIETZ, RD; GRAHAM, KC; LITCHFIELD, DW			INTERACTIONS BETWEEN THE SUBUNITS OF CASEIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; BETA-SUBUNIT; MOLECULAR-CLONING; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; PROTEIN; PHOSPHORYLATION; EXPRESSION; YEAST; IDENTIFICATION	Casein kinase II (CKII) is a protein serine/threonine kinase known to control the activity of a variety of regulatory nuclear proteins. This enzyme has a tetrameric structure composed of two catalytic (alpha and/or alpha') subunits and two beta subunits. We have examined the subunit composition of tetrameric complexes of purified bovine CKII by immunoprecipitation using alpha, alpha', or beta subunit-specific antibodies. These experiments indicate that the enzyme can exist as homotetramers (i.e. alpha(2) beta(2) alpha(2)'beta(2)) as well as heterotetramers (i.e. alpha alpha'beta(2),). To further examine subunit interactions between the alpha, alpha', or beta subunits of CKII, we have utilized the yeast two hybrid system (Fields, S. and Song, O. (1989) Nature 340: 245-246). For these studies, each subunit of human CKII was expressed in yeast as a fusion with the DNA binding domain or with the transcriptional activation domain of the yeast GAL4 transcriptional activator. These studies demonstrate that the alpha or alpha' subunits of CKII can interact with the beta subunits of CKII, but not with other alpha or alpha' subunits. By comparison, the beta subunits of CRII can interact with alpha, alpha', or beta subunits. These results indicate that the CKII holoenzyme forms because of the ability of beta subunits to dimerize, bringing two heterodimers (alpha beta or alpha'beta) into a tetrameric complex.	UNIV MANITOBA, MANITOBA INST CELL BIOL, MANITOBA CANC TREATMENT & RES FDN, WINNIPEG, MB R3E 0V9, CANADA; UNIV MANITOBA, DEPT HUMAN GENET, WINNIPEG, MB R3E 0V9, CANADA	University of Manitoba; University of Manitoba			Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620				BIDWAI AP, 1993, ARCH BIOCHEM BIOPHYS, V300, P265, DOI 10.1006/abbi.1993.1037; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPER JW, 1993, CELL, V75, P805; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; HU E, 1990, J BIOL CHEM, V265, P20609; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JAKOBI R, 1989, EUR J BIOCHEM, V183, P227, DOI 10.1111/j.1432-1033.1989.tb14917.x; JEDLICKI A, 1992, FEBS LETT, V297, P280, DOI 10.1016/0014-5793(92)80556-V; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; MARIDOR G, 1991, J BIOL CHEM, V266, P2362; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; Miller JH., 1972, EXPT MOL GENETICS; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PAETKAU DW, 1994, GENE DEV, V8, P2035, DOI 10.1101/gad.8.17.2035; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WU JLC, 1988, MOL CELL BIOL, V8, P4981; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217; [No title captured]	42	117	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13017	13021		10.1074/jbc.270.22.13017	http://dx.doi.org/10.1074/jbc.270.22.13017			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768894	hybrid			2022-12-25	WOS:A1995RB43900015
J	GUZDER, SN; HABRAKEN, Y; SUNG, P; PRAKASH, L; PRAKASH, S				GUZDER, SN; HABRAKEN, Y; SUNG, P; PRAKASH, L; PRAKASH, S			RECONSTITUTION OF YEAST NUCLEOTIDE EXCISION-REPAIR WITH PURIFIED RAD PROTEINS, REPLICATION PROTEIN-A, AND TRANSCRIPTION FACTOR TFIIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STRANDED-DNA ENDONUCLEASE; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; DAMAGED DNA; GENE; ENCODES; HELICASE; ATPASE	Nucleotide excision repair (NER) functions to remove DNA damage caused by ultraviolet light and by other agents that distort the DNA helix. The NER machinery has been conserved in structure and function from yeast to humans, and in humans, defective NER is the underlying cause of the cancer-prone disease xeroderma pigmentosum. Here, we reconstitute the incision reaction of NER in Saccharomyces cerevisiae using purified protein factors. The Rad14 protein, the Rad4-Rad23 complex, the Rad2 nuclease, the Rad1-Rad10 nuclease, replication protein A, and the RNA polymerase II transcription factor TFIIH were purified to near homegeneity from yeast. We show that these protein factors are both necessary and sufficient for dual incision of DNA damaged by either ultraviolet light or N-acetoxy-2-aminoacetylfluorene. Incision in the reconstituted system requires ATP, which cannot be substituted by adenosine 5'-O-(3-thiotriphosphate), suggesting that the hydrolysis of ATP is indispensable for the incision reaction. The excision DNA fragments formed as a result of dual incision are in the 24-27-nucleotide range.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NCI NIH HHS [CA41621, CA35035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035035, R37CA035035, R01CA041621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY V, 1991, P NATL ACAD SCI USA, V88, P9712, DOI 10.1073/pnas.88.21.9712; BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CLUGSTON CK, 1992, CANCER RES, V52, P6375; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; GIETZ RD, 1988, GENE, V74, P535, DOI 10.1016/0378-1119(88)90186-2; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SUNG P, 1994, J BIOL CHEM, V269, P8303; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757	28	197	198	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					12973	12976		10.1074/jbc.270.22.12973	http://dx.doi.org/10.1074/jbc.270.22.12973			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768886	hybrid			2022-12-25	WOS:A1995RB43900007
J	NAKAMUTA, M; OKA, K; KRUSHKAL, J; KOBAYASHI, K; YAMAMOTO, M; LI, WH; CHAN, L				NAKAMUTA, M; OKA, K; KRUSHKAL, J; KOBAYASHI, K; YAMAMOTO, M; LI, WH; CHAN, L			ALTERNATIVE MESSENGER-RNA SPLICING AND DIFFERENTIAL PROMOTER UTILIZATION DETERMINE TISSUE-SPECIFIC EXPRESSION OF THE APOLIPOPROTEIN-B MESSENGER-RNA-EDITING PROTEIN (APOBEC1) GENE IN MICE - STRUCTURE AND EVOLUTION OF APOBEC1 AND RELATED NUCLEOSIDE NUCLEOTIDE DEAMINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; MESSENGER-RNA; TYROSINE PHOSPHATASE; RESPONSIVE ELEMENTS; PHYLOGENETIC TREES; ENHANCER ELEMENTS; SEQUENCE; INVITRO; COMPILATION; BINDING	Apolipoprotein (ape) B mRNA editing consists of a C-->U conversion involving the first base of the codon CAA, encoding Gin 2153, to UAA, a stop codon. Editing occurs in the intestine only in most mammals, and in both the liver and intestine in a few mammalian species including mouse. We have cloned the cDNA for the mouse apoB mRNA editing protein, apobec1. Expression of mouse apobec1 cDNA in HepG2 cells results in the editing of the intracellular apoB mRNA. The cDNA predicts a 229-amino acid protein showing 92, 66, and 70% identity to the rat; rabbit, and human proteins, respectively. Based on the estimated values of divergence of apobec1 sequences in terms of the numbers of synonymous and non-synonymous substitutions per site, we found that apobec1 is a fairly rapidly evolving protein. Sequence comparison among mammalian apobec1 sequences has permitted the identification of seven conserved regions that may be functionally important for editing activity. We present a phylogenetic tree relating apobec1 sequences to double-stranded RNA adenosine deaminase and other nucleotide/nucleoside deaminases. Northern blot analysis indicates that apobec1 mRNA exists in two different sizes, a similar to 2,2-kilobase (kb) form in small intestine and a similar to 2.4-kb form in liver, spleen, kidney, lung, muscle, and heart. To study the molecular basis for the different sized apobec1 mRNAs, we cloned the apobec1 gene and characterized its exon-intron organization together with the sequences expressed in the hepatic and intestinal mRNA. The mouse apobec1 gene contains 8 exons and spans similar to 25 kb, and is located in chromosome 6. The major hepatic mRNA intestinal mRNA misses the first 3 exons and its transcription is initiated in exon 4. The intestinal mRNA also contains at its 5' end a unique 102-nucleotide piece that is absent in the Liver mRNA. We also identified two alternatively spliced hepatic apobec1 mRNAs with different acceptor sites in exon 4. Transient expression studies using promoter-reporter gene constructs in HeLa, Hepa, and Caco-2 cells indicate that the 5'-flanking sequences of the liver mRNA (i.e. upstream of exon 1) have predominantly hepatic promoter activity and the 5'-flanking sequences of the major small intestine mRNA (i.e. upstream of exon 4) have preferential intestinal promoter activity. We conclude that alternative mRNA splicing and differential promoter utilization determine the tissue specific expression of the apobec1 gene in mice. Our observations provide information on unique aspects of the molecular basis of the tissue-specific expression of apobec1 mRNA and the evolutionary basis of RNA editing.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; UNIV TEXAS,CTR DEMOG & POPULAT GENET,HOUSTON,TX 77225; CHILDRENS NUTR RES CTR,HOUSTON,TX 77030; NATL DEF MED COLL,DEPT BIOCHEM 2,TOKOROZAWA,SAITAMA 359,JAPAN	Baylor College of Medicine; University of Texas System; National Defense Medical College - Japan	NAKAMUTA, M (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Kobayashi, Kunihisa/V-9554-2019	Kobayashi, Kunihisa/0000-0002-7741-846X; Li, Wen-Hsiung/0000-0003-1086-1456	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL027341, P50HL027341] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3093, DOI 10.1093/nar/21.13.3093; BARKER WC, 1993, NUCLEIC ACIDS RES, V21, P2967; BARNES C, 1993, BIOCHEM BIOPH RES CO, V197, P1410, DOI 10.1006/bbrc.1993.2634; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENNE R, 1993, RNA; BENSON D, 1993, NUCLEIC ACIDS RES, V21, P2963, DOI 10.1093/nar/21.13.2963; BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BHATTACHARYA S, 1994, TRENDS BIOCHEM SCI, V19, P105, DOI 10.1016/0968-0004(94)90200-3; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHAN L, 1995, SCI MED, V2, P68; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; COLEMAN RD, 1989, BIOCHIM BIOPHYS ACTA, V1037, P129; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FAISST S, 1990, CELL, V61, P497; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GREEVE J, 1993, J LIPID RES, V34, P1367; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; HIESEL R, 1994, P NATL ACAD SCI USA, V91, P629, DOI 10.1073/pnas.91.2.629; IMBERT J, 1989, MOL CELL BIOL, V9, P5315, DOI 10.1128/MCB.9.12.5315; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P9627, DOI 10.1093/nar/15.23.9627; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Kimura MA, 1985, NEUTRAL THEORY MOL E; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEVYWILSON B, 1988, MOL CELL BIOL, V8, P71, DOI 10.1128/MCB.8.1.71; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NAGALLA SR, 1994, MOL ENDOCRINOL, V8, P943, DOI 10.1210/me.8.8.943; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RICE CM, 1993, NUCLEIC ACIDS RES, V21, P2967, DOI 10.1093/nar/21.13.2967; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCANU AM, 1990, LIPOPROTEIN; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; Scott James, 1994, Current Opinion in Lipidology, V5, P87, DOI 10.1097/00041433-199404000-00004; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; Sneath P.H.A., 1973, NUMERICAL TAXONOMY P; SOMMER A, 1991, BIOCHEMISTRY-US, V30, P11245, DOI 10.1021/bi00111a008; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1994, J BIOL CHEM, V269, P29395; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; VANTHOOFT FM, 1982, P NATL ACAD SCI-BIOL, V79, P179; WU CI, 1985, P NATL ACAD SCI USA, V82, P1741, DOI 10.1073/pnas.82.6.1741; WU JH, 1990, J BIOL CHEM, V265, P12312; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YI TL, 1992, GENOMICS, V14, P793, DOI 10.1016/S0888-7543(05)80189-2; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHARKIKH AA, 1991, GENE, V101, P251, DOI 10.1016/0378-1119(91)90419-C	70	89	92	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13042	13056		10.1074/jbc.270.22.13042	http://dx.doi.org/10.1074/jbc.270.22.13042			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768898	hybrid			2022-12-25	WOS:A1995RB43900019
J	MA, Q; DONG, LQ; WHITLOCK, JP				MA, Q; DONG, LQ; WHITLOCK, JP			TRANSCRIPTIONAL ACTIVATION BY THE MOUSE AH RECEPTOR - INTERPLAY BETWEEN MULTIPLE STIMULATORY AND INHIBITORY FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXIN-RESPONSIVE ENHANCER; HEAT-SHOCK PROTEIN; DNA RECOGNITION; BINDING; CLONING; MECHANISM; LIGAND; CDNA; GENE; ARNT	The aromatic hydrocarbon receptor (AhR) is a ligand-dependent transcription factor that mediates cellular responses to the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). We cloned AhR cDNA from C57BL/6 mouse liver and verified by transfection that it encodes a functional protein. Analyses of deletion mutants indicate that the carboxyl half of AhR contains several types of transactivation domain, which function independently of domains that mediate TCDD recognition, DNA binding, and heterodimerization with the Ah receptor nuclear translocator (Arnt) protein. The transactivation domains function independently of each other, display different levels of activity, and act synergistically when Linked. In addition, AhR contains an 82-amino acid domain:that inhibits transactivation. The inhibitory domain displays specificity, in that it blocks the transactivating functions of AhR and Arnt, but not that of the herpes simplex protein VP16. The inhibitory activity depends upon the cell type in which AhR is expressed, implying that a cell-specific protein mediates the effect.			MA, Q (corresponding author), STANFORD UNIV, SCH MED, DEPT MOLEC PHARMACOL, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003719] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03719] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILAR JC, 1991, NEW ENGL J MED, V324, P261; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CARVER LA, 1994, J BIOL CHEM, V269, P30109; CHANG CY, 1993, PHARMACOGENETICS, V3, P312, DOI 10.1097/00008571-199312000-00005; CHEN HS, 1994, J BIOL CHEM, V269, P27554; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; ELFERINK CJ, 1994, RECEPTOR, V4, P157; EMA M, 1994, J BIOL CHEM, V269, P27337; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FISHER JM, 1990, J BIOL CHEM, V265, P9676; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JAIN S, 1994, J BIOL CHEM, V269, P31518; JOHNSON ES, 1992, CRIT REV TOXICOL, V21, P451, DOI 10.3109/10408449209089883; JONES PBC, 1986, P NATL ACAD SCI USA, V83, P2802, DOI 10.1073/pnas.83.9.2802; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LI H, 1994, J BIOL CHEM, V269, P28098; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MILLER AG, 1983, J BIOL CHEM, V258, P3523; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1994, MOL PHARMACOL, V46, P915; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; REICK M, 1994, MOL CELL BIOL, V14, P5653, DOI 10.1128/MCB.14.9.5653; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811	54	78	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12697	12703		10.1074/jbc.270.21.12697	http://dx.doi.org/10.1074/jbc.270.21.12697			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759522	hybrid			2022-12-25	WOS:A1995QZ71100058
J	MATSUDA, S; KAWASAKI, H; MORIGUCHI, T; GOTOH, Y; NISHIDA, E				MATSUDA, S; KAWASAKI, H; MORIGUCHI, T; GOTOH, Y; NISHIDA, E			ACTIVATION OF PROTEIN-KINASE CASCADES BY OSMOTIC SHOCK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; EPIDERMAL GROWTH-FACTOR; MAP KINASE; SIGNAL-TRANSDUCTION; XENOPUS-OOCYTES; THREONINE PHOSPHORYLATION; TYROSINE; INVITRO; RAF; IDENTIFICATION	Osmotic shock induces a variety of biochemical and physiological responses in vertebrate cells. By analyzing extracts obtained from rat 3Y1 fibroblastic cells exposed to hyper-osmolar media, we have found that mitogen-activated protein kinases (MAPKs) and stress-activated protein kinases (SAPKs, also known as JNKs) are both activated in response to osmotic shock, MAPKK1 (MEK1) was also activated markedly, Furthermore, Raf-1 and MEKK were activated strikingly by the osmotic shock, Activation of Raf-1 and MEKK. in response to osmotic shock was detected also in PC12 cells, in which MEKK activation by the osmotic shock was much stronger than that by epidermal growth factor. Activation of SAPKs in PC12 cells by the osmotic shock was also more marked than that by epidermal growth factor, The activated MEKK phosphorylated not only MAPKKs but also XMEK2, which is distantly related to MAPKK, Recombinant wild-type XMEK2, but not kinase-negative XMEK2, was able to phosphorylate and activate recombinant SAPK alpha in vitro, In addition, this activity of XMEK2 was activated by the activated MEKK. These results suggest that the MAPK cascade consisting of Raf-1, MAPKK, and MAPK and the SAPK cascade consisting of MEKK, XMEK2, and SAPK are both activated in response to osmotic shock, Finally, it was found that XMEK2 is a good substrate for SAPK.	KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University			Moriguchi, Tetsuo/D-7061-2012; Kawasaki, Hiroshi/C-4404-2015; KAWASAKI, Hiroshi/L-3736-2015	Moriguchi, Tetsuo/0000-0002-9598-4991; Kawasaki, Hiroshi/0000-0002-2514-1497				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HACCARD O, 1993, SCIENCE, V267, P1262; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MINHONG Y, 1994, NATURE, V372, P798; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1992, INT REV CYTOL, V138, P211, DOI 10.1016/S0074-7696(08)61589-2; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIDA E, 1987, J BIOL CHEM, V262, P16200; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TERADA Y, 1994, J BIOL CHEM, V49, P31296; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738	52	147	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12781	12786		10.1074/jbc.270.21.12781	http://dx.doi.org/10.1074/jbc.270.21.12781			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759532	hybrid			2022-12-25	WOS:A1995QZ71100069
J	DAVIDSON, GA; VARHOL, RJ				DAVIDSON, GA; VARHOL, RJ			KINETICS OF THAPSIGARGIN-CA2+-ATPASE (SARCOPLASMIC-RETICULUM) INTERACTION REVEALS A 2-STEP BINDING MECHANISM AND PICOMOLAR INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACTIVE-SITE; CROSS-LINKING; NUCLEOTIDE BINDING; TUMOR PROMOTER; CALCIUM-PUMP; ATPASE; CA2+-ATPASE; CA-2+-ATPASE; PROTEIN; PHOSPHORYLATION	Thapsigargin is a high affinity inhibitor of sarco- and endoplasmic reticulum (SERCA) type ATPases. We have used kinetics to determine the dissociation constant of thapsigargin-sarcoplasmic reticulum Ca2+-ATPase interaction in the absence and presence of non-ionic detergent. The observed ''off'' rate constant was measured as 0.0052 s(-1) at 26 degrees C by the kinetics of inhibition of ATPase activity following transfer from an inactivated thapsigargin-ATPase complex to native ATPase. Inactive ATPase was produced by cross-linking the active site with glutaraldehyde. The observed dissociation rate constant was increased 7-fold by 0.1% Triton X-100, indicating that perturbation of the transmembrane and stalk region by detergent altered the binding parameters of the inhibitor. In addition, thapsigargin stabilized the ATPase against inactivation caused by detergent in the absence of Ca2+. The observed ''on'' rate constant of thapsigargin was measured at 26 degrees C as 25 s(-1) irrespective of thapsigargin concentration, by the kinetics of thapsigargin-induced change in intrinsic fluorescence. An Arrhenius plot showed a temperature dependence of this rate constant, indicative of a conformational change in the protein with an activation energy of 9.5 kcal/mol for thapsigargin binding. The affinity of the Ca2+-ATPase for thapsigargin was calculated to be greater than 2 PM at pH 7.0 and 26 degrees C.			DAVIDSON, GA (corresponding author), UNIV CAPE TOWN,SCH MED,DEPT CHEM PATHOL,MED RES COUNCIL BIOMEMBRANE RES UNIT,CAPE TOWN 7925,SOUTH AFRICA.							CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; CHRISTENSEN SB, 1985, TETRAHEDRON LETT, V26, P107, DOI 10.1016/S0040-4039(00)98480-6; CHRISTENSEN SB, 1993, FEBS LETT, V335, P345, DOI 10.1016/0014-5793(93)80416-R; DEAN WL, 1978, BIOCHEMISTRY-US, V17, P1683, DOI 10.1021/bi00602a016; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; HENDERSON IMJ, 1994, BIOCHEM J, V297, P625, DOI 10.1042/bj2970625; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LACAPERE JJ, 1990, J BIOL CHEM, V265, P8583; MCINTOSH DB, 1988, J BIOL CHEM, V263, P12220; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MCINTOSH DB, 1985, BIOCHEMISTRY-US, V24, P1244, DOI 10.1021/bi00326a029; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MCINTOSH DB, 1984, BIOCHEMISTRY-US, V53, P1959; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; NORREGAARD A, 1993, FEBS LETT, V336, P248, DOI 10.1016/0014-5793(93)80813-A; ROSS DC, 1987, J BIOL CHEM, V262, P12977; ROSS DC, 1991, J BIOL CHEM, V266, P4613; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; TAKAYASU K, 1993, BIOL CHEM H-S, V374, P550; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VERJOVSKIALMEID.S, 1981, J BIOL CHEM, V256, P2940; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; WICTOME M, 1992, BIOCHEM J, V283, P525, DOI 10.1042/bj2830525	28	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11731	11734		10.1074/jbc.270.20.11731	http://dx.doi.org/10.1074/jbc.270.20.11731			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744817	hybrid			2022-12-25	WOS:A1995QY73600008
J	FOLETTI, D; GUERINI, D; CARAFOLI, E				FOLETTI, D; GUERINI, D; CARAFOLI, E			SUBCELLULAR TARGETING OF THE ENDOPLASMIC-RETICULUM AND PLASMA-MEMBRANE CA2+ PUMPS - A STUDY USING RECOMBINANT CHIMERAS	FASEB JOURNAL			English	Article						CHIMERIC PROTEINS; PUMP EXPRESSION; MEMBRANE TARGETING	SARCOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; CALCIUM-PUMP; CA-2+ PUMP; INTRACELLULAR MEMBRANES; MONOCLONAL-ANTIBODIES; TRYPSIN PROTEOLYSIS; HUMAN-ERYTHROCYTES; GOLGI RETENTION; CA-2+-ATPASE	ATP-powered Ca2+ pumps are located in the plasma membrane (PMCA) and the sarco(endo)plasmic reticulum (SERCA). The two pump types share numerous structural and functional features; nevertheless, they are strictly targeted to different cell compartments. Chimeric SERCA/PMCA pumps were constructed to investigate the structural determinants responsible for their specific cellular location. The level of expression of the chimeric constructs and of the wild-type pumps in COS-7 and Sf9 cells was the same and so was their stability. One exception was chimera D, which showed special propensity to degradation. The chimeric constructs had no Ca2+-dependent ATPase activity, although in one trace amounts of the Ca2+-dependent phosphoenzyme intermediate were detected. Thus, the exchange of the regions encompassing the (NHP2-terminal) transmembrane domains apparently is incompatible with the activity of the pump. The immunofluorescence experiments showed that the 85 NH2-terminal residues of the SERCA pump, encompassing the first transmembrane domain, contain a signal-promoting retention of chimeric constructs otherwise consisting of the PMCA pump structure in the endoplasmic reticulum. Additional structural determinants most likely also contribute to the retention of the SERCA pump in the endoplasmic reticulum: one chimeric construct (E) composed of the first two transmembrane domains of the PMCA pump, followed by the remainder of the SERCA pump structure, was still retained, even if not completely in the endoplasmic reticulum.	SWISS FED INST TECHNOL,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND	ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BENAIM G, 1984, J BIOL CHEM, V259, P8471; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; CARAFOLI E, 1992, CURR TOP CELL REGUL, V32, P209; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIESI M, 1984, BIOCHEMISTRY-US, V23, P2595, DOI 10.1021/bi00307a009; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HEIM R, 1992, J BIOL CHEM, V267, P24476; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LYTTON J, 1992, J BIOL CHEM, V267, P14483; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V20, P1; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012; ZVARITCH E, 1995, J BIOL CHEM, V270, P1280	51	37	37	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					670	680		10.1096/fasebj.9.8.7768360	http://dx.doi.org/10.1096/fasebj.9.8.7768360			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768360				2022-12-25	WOS:A1995RC10600014
J	OBRIEN, JS; CARSON, GS; SEO, HC; HIRAIWA, M; WEILER, S; TOMICH, JM; BARRANGER, JA; KAHN, M; AZUMA, N; KISHIMOTO, Y				OBRIEN, JS; CARSON, GS; SEO, HC; HIRAIWA, M; WEILER, S; TOMICH, JM; BARRANGER, JA; KAHN, M; AZUMA, N; KISHIMOTO, Y			IDENTIFICATION OF THE NEUROTROPHIC FACTOR SEQUENCE OF PROSAPOSIN	FASEB JOURNAL			English	Article						NEURITE OUTGROWTH; RECEPTOR; SAPOSIN PEPTIDE	SPHINGOLIPID ACTIVATOR PROTEINS; SAPOSIN PROTEINS; GAUCHER DISEASE; SERTOLI CELLS; GANGLIOSIDES; DEFICIENCY; PRECURSOR; PATIENT	Prosaposin, recently identified as a neurotrophic factor (1), is the precursor of saposins A, B, C, and D. The neurotrophic activity of prosaposin resides in the saposin C domain. We have pinpointed the active sequence to a linear 12-mer located in the NH2-terminal sequence of saposin C (LIDNNKTEKEIL). Nanomolar concentrations of a 22-mer peptide encompassing this region stimulated neurite outgrowth and choline acetyltransferase activity, and prevented cell death in neuroblastoma cells. In primary cerebellar granule cells, the 22-mer also stimulated neurite outgrowth. Studies of the neuroblastoma line NS20Y using a radiolabeled 18-mer from the neurotrophic region identified a high-affinity (K-d = 70 pM) binding site indicative of receptor-ligand interaction. The 22-mer stimulated protein phosphorylation of several proteins, some of which were tyrosine-phosphorylated after brief exposure similar to saposin C. Circular dichroism studies demonstrated that the 22-mer was converted from a random to a helical structure by addition of ganglioside GM(1). The results are consistent with receptor-ligand binding by the peptide initiating a signal transduction cascade and resulting in neuronal differentiation.	NHLBI,BETHESDA,MD 20892; KANSAS STATE UNIV AGR & APPL SCI,DEPT BIOCHEM,MANHATTAN,KS 66506; UNIV PITTSBURGH,DEPT HUMAN GENET,GENET MOLEC LAB,PITTSBURGH,PA 15261; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT PATHOBIOL,SEATTLE,WA 98195	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Kansas State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle	OBRIEN, JS (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT NEUROSCI,LA JOLLA,CA 92093, USA.			TOMICH, JOHN/0000-0001-7848-8307	NIDDK NIH HHS [DK43709] Funding Source: Medline; NINDS NIH HHS [NS08682, NS13559] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013559] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; FU Q, 1994, J MOL NEUROSCI, V5, P59, DOI 10.1007/BF02736694; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HO MW, 1971, P NATL ACAD SCI USA, V68, P2810, DOI 10.1073/pnas.68.11.2810; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KONDOH K, 1993, J COMP NEUROL, V334, P590, DOI 10.1002/cne.903340407; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; MORIMOTO S, 1990, ANAL BIOCHEM, V190, P154, DOI 10.1016/0003-2697(90)90173-7; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; SANO A, 1992, BIOCHIM BIOPHYS ACTA, V1120, P75, DOI 10.1016/0167-4838(92)90426-E; SANO A, 1994, BIOCHEM BIOPH RES CO, V204, P994, DOI 10.1006/bbrc.1994.2558; SANO A, 1989, BIOCHEM BIOPH RES CO, V165, P1191, DOI 10.1016/0006-291X(89)92728-9; SANO A, 1989, J BIOL CHEM, V263, P19597; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; SPRECHERLEVY H, 1993, CELL MOL BIOL, V39, P287; SYLVESTER SR, 1984, BIOL REPROD, V31, P1087, DOI 10.1095/biolreprod31.5.1087; THANGNIPON W, 1992, NEUROCHEM RES, V17, P45, DOI 10.1007/BF00966864; UEMURA K, 1991, J BIOCHEM-TOKYO, V110, P96, DOI 10.1093/oxfordjournals.jbchem.a123549; WEILER S, 1993, J MOL NEUROSCI, V4, P161, DOI 10.1007/BF02782499; WEILER S, 1994, IN PRESS PROTEIN RES	27	112	116	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1995	9	8					681	685		10.1096/fasebj.9.8.7768361	http://dx.doi.org/10.1096/fasebj.9.8.7768361			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768361				2022-12-25	WOS:A1995RC10600015
J	LAI, CF; RIPPERGER, J; MORELLA, KK; WANG, YP; GEARING, DP; FEY, GH; BAUMANN, H				LAI, CF; RIPPERGER, J; MORELLA, KK; WANG, YP; GEARING, DP; FEY, GH; BAUMANN, H			SEPARATE SIGNALING MECHANISMS ARE INVOLVED IN THE CONTROL OF STAT PROTEIN-ACTIVATION AND GENE-REGULATION VIA THE INTERLEUKIN-6 RESPONSE ELEMENT BY THE BOX-3 MOTIF OF GP130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; EXPRESSION; RECEPTOR	The cytoplasmic receptor sequences required for the transcriptional control via the IL-6 response element (IL-6RE) and the hematopoietin receptor response element (HRRE) in hepatoma cells were defined by transient expression of wild-type and mutant granulocyte-colony stimulating factor receptor-gp130 chimeric receptors. gp130 generated two separate transcriptional signals, one of which was directed to IL-6RE and required an intact box 3 motif, and another, which was directed to HRRE and was box 3-independent. The activation of DNA-binding of STAT3 required the same gp130 domains as the IL-6RE response. A box 3-independent activation of STAT proteins was achieved by overexpression of the kinases JAK2 or TYK2. The increase in the DNA-binding activity of STAT proteins, however, did not result in a corresponding increase in transcription via either IL-6RE or HRRE. The data indicate that activation of the DNA-binding potential of STAT proteins via gp130 is not sufficient to achieve transcriptional up-regulation of specific target genes.	SYSTEMIX,PALO ALTO,CA 94304; ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263; UNIV ERLANGEN NURNBERG,CHAIR GENET,D-91058 ERLANGEN,GERMANY; CHILDRENS HOSP,DIV ENDOCRINOL,BUFFALO,NY 14222	Roswell Park Cancer Institute; University of Erlangen Nuremberg; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NCI NIH HHS [CA26122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KUMAR G, 1994, J IMMUNOL, V153, P4436; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1994, BLOOD, V83, P3457; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WARD LD, 1994, J BIOL CHEM, V269, P23286; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHUANG H, 1994, J BIOL CHEM, V269, P2411	27	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14847	14850		10.1074/jbc.270.25.14847	http://dx.doi.org/10.1074/jbc.270.25.14847			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797460	hybrid			2022-12-25	WOS:A1995RE66600002
J	OTSU, M; URADE, R; KITO, M; OMURA, F; KIKUCHI, M				OTSU, M; URADE, R; KITO, M; OMURA, F; KIKUCHI, M			A POSSIBLE ROLE OF ER-60 PROTEASE IN THE DEGRADATION OF MISFOLDED PROTEINS IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; PRE-GOLGI COMPARTMENT; DISULFIDE-ISOMERASE; PHOSPHOLIPASE-C; MOLECULAR-CLONING; RAPID DEGRADATION; CYSTEINE PROTEASE; T-CELL; SEQUENCE; RETENTION	Wild-type human lysozyme (hLZM) is secreted when expressed in mouse L cells, whereas misfolded mutant hLZMs are retained and eventually degraded in a pre-Golgi compartment (Omura, F., Otsu, M., Yoshimori, T., Tashiro, Y., and Kikuchi, M. (1992) Eur. J. Biochem. 210, 591-599). These misfolded mutant hLZMs are associated with protein disulfide isomerase (Otsu, M., Omura, F., Yoshimori, T., and Kikuchi, M. (1994) J. Biol. Chem. 269, 6874-6877). From the observation that this degradation is sensitive to cysteine protease inhibitors, such as N-acetyl-leucyl-leucyl-norleucinal and N-acetyl-leucyl-leucyl-methioninal, but not to the serine protease inhibitors, 1-chloro-3-tosylamido-7-amino-2-heptanone and (p-amidinophenyl)methanesulfonyl fluoride, it was suggested that some cysteine proteases are likely responsible for the degradation of abnormal proteins in the endoplasmic reticulum (ER). ER-60 protease (ER-60), an ER resident protein with cysteine protease activity (Urade, R., Nasu, M., Moriyama, T., Wada, K., and Kito, M. (1992) J. Biol. Chem. 267, 15152-15159), was found to associate with misfolded hLZMs, but not with the wildtype protein, in mouse L cells. Furthermore, denatured hLZM is degraded by ER-60 in vitro, whereas native hLZM is not. These results suggest that ER-60 could be a component of the proteolytic machinery for the degradation of misfolded mutant hLZMs in the ER.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University								AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; CHUN KT, 1990, J BIOL CHEM, V265, P22004; DEGAN E, 1991, J CELL BIOL, V112, P1099; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; INOUE S, 1991, J BIOL CHEM, V266, P13311; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; LE A, 1992, J BIOL CHEM, V267, P172; LIPPINCOTTSCHWA.J, 1988, CELL, V54, P209; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OMURA F, 1992, EUR J BIOCHEM, V210, P591, DOI 10.1111/j.1432-1033.1992.tb17459.x; OTSU M, 1994, J BIOL CHEM, V269, P6874; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; SATO R, 1990, J BIOL CHEM, V265, P11880; SRIVASTAVA SP, 1993, BIOCHEM BIOPH RES CO, V193, P971, DOI 10.1006/bbrc.1993.1720; TANIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V152, P962, DOI 10.1016/S0006-291X(88)80377-2; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1992, FEBS LETT, V312, P83, DOI 10.1016/0014-5793(92)81415-I; WADA I, 1991, J BIOL CHEM, V266, P19599; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; YOUNG J, 1993, J BIOL CHEM, V268, P19810; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735	32	97	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14958	14961		10.1074/jbc.270.25.14958	http://dx.doi.org/10.1074/jbc.270.25.14958			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797475	hybrid			2022-12-25	WOS:A1995RE66600020
J	ARGETSINGER, LS; HSU, GW; MYERS, MG; BILLESTRUP, N; WHITE, MF; CARTERSU, C				ARGETSINGER, LS; HSU, GW; MYERS, MG; BILLESTRUP, N; WHITE, MF; CARTERSU, C			GROWTH-HORMONE, INTERFERON-GAMMA, AND LEUKEMIA INHIBITORY FACTOR PROMOTED TYROSYL PHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3'-KINASE; FACTOR-I; GLUCOSE TRANSPORTERS; BINDING-PROTEIN; MESSENGER-RNA; KINASE; EXPRESSION; CELLS	The identification of JAK2 as a growth hormone (G:H) receptor-associated, GH-activated tyrosine kinase has established tyrosyl phosphorylation as a signaling mechanism for GH. In the present study, GH is shown to stimulate tyrosyl phosphorylation of insulin receptor substrate 1 (IRS-1), the principle substrate of the insulin receptor. Tyrosyl phosphorylation if IRS-1 is a critical step in insulin signaling and provides binding sites for proteins with the appropriate Src homology 2 domains, including the 85-kDa regulatory subunit of phosphatidylinositol (PI) 3'-kinase. In 3T3-F442A fibroblasts, GH-dependent tyrosyl phosphorylation of IRS-1 was detected by I min and at GH concentrations as low as 5 ng/ml (0.23 nM). Tyrosyl phosphorylation of IRS-1 was transient, with maximal stimulation detected at 30 rain and diminished signal detected at 60 min. The ability of GH receptor (GHR) to transduce the signal for IRS-1 tyrosyl phosphorylation is mediated by the intracellular region of GHR between amino acids 295 and 380 by a mechanism not involving the two tyrosines in this region. This region of GHR is required for GH-dependent JAK2 association and activation (VanderKuur, J. A., Wang, X., Zhang,L., Campbell, G. S., Allevato, G., Billestrup, N., Norstedt, G., and Carter-Su, C. (1994:) J. Biol. Chem. 269, 21709-21717). When other cytokines that activate JAK2 were tested for the ability to stimulate the tyrosyl phosphorylation of IRS-1, stimulation was detected with interferon-gamma and leukemia inhibitory factor. The correlation between JAK2 tyrosyl phosphorylation and IRS-1 tyrosyl phosphorylation in response to GH, interferon-gamma, and leukemia inhibitory factor rind in cells expressing different GHR mutants, provides evidence that IRS-1 may interact with JAK2 or an auxiliary molecule that binds to JAK2. GH is also shown to stimulate binding of IRS-1 to the 85-kDa regulatory subunit of PI 3'-kinase. The ability of GH to stimulate tyrosyl phosphorylation of IRS-1 and its association with PI 3'-kinase provides a biochemical basis for responses shared by insulin and GH including the well characterized insulin-like metabolic effects of GH observed in a variety of cell types.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; HAGEDORN RES LAB,DK-2820 GENTOFTE,DENMARK	University of Michigan System; University of Michigan; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Novo Nordisk; Hagedorn Research Institute				Billestrup, Nils/0000-0002-4968-8067	NIDDK NIH HHS [R01-DK34171, R01 DK043808, R01 DK034171, DK36836, DK 43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, P30DK036836, R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS TE, 1990, MOL CELL ENDOCRINOL, V73, P135, DOI 10.1016/0303-7207(90)90126-S; [Anonymous], 1994, PROGRAM MANUAL WISCO; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; BURNSIDE J, 1991, ENDOCRINOLOGY, V128, P3183, DOI 10.1210/endo-128-6-3183; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CIOFFI JA, 1990, NUCLEIC ACIDS RES, V18, P6451, DOI 10.1093/nar/18.21.6451; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOULD GW, 1994, J BIOL CHEM, V269, P26622; HAUSER SD, 1990, MOL CELL ENDOCRINOL, V72, P187, DOI 10.1016/0303-7207(90)90143-V; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; JACOBS S, 1983, J BIOL CHEM, V258, P9581; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUMAR CS, 1989, J BIOL CHEM, V2264, P17939; LAM K, 1994, J BIOL CHEM, V269, P20648; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MIURA O, 1994, J BIOL CHEM, V269, P614; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V114, P3577; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUON MJ, 1994, J BIOL CHEM, V269, P27920; RUBIN JB, 1983, NATURE, V305, P438, DOI 10.1038/305438a0; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAITO M, 1992, J IMMUNOL, V148, P4066; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHWARTZ J, 1988, ENDOCRINOLOGY, V122, P2247; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAI PKK, 1990, J BIOL CHEM, V265, P21828; TANNER JW, 1992, BIOCHEM J, V282, P99, DOI 10.1042/bj2820099; TANTI JF, 1994, J BIOL CHEM, V269, P6051; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YANG XJ, 1993, J NEUROSCI, V13, P3006; YIN TG, 1994, J BIOL CHEM, V269, P26614; YIN TG, 1994, EXP HEMATOL, V22, P467; ZHANG J, 1993, J BIOL CHEM, V268, P22251	81	220	223	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14685	14692		10.1074/jbc.270.24.14685	http://dx.doi.org/10.1074/jbc.270.24.14685			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782332	hybrid			2022-12-25	WOS:A1995RD45500068
J	KIMURA, K; WHITE, BH; SIDHU, A				KIMURA, K; WHITE, BH; SIDHU, A			COUPLING OF HUMAN D-1 DOPAMINE-RECEPTORS TO DIFFERENT GUANINE-NUCLEOTIDE-BINDING PROTEINS - EVIDENCE THAT D-1 DOPAMINE-RECEPTORS CAN COUPLE TO BOTH G(S) AND G(O)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE HYDROLYSIS; RAT STRIATUM; ADENYLATE-CYCLASE; STIMULATION; ALPHA; EXPRESSION; INHIBITION; SUBUNITS; CHANNELS; AGONIST	Coupling between D-1 dopamine receptors and G proteins in cell lines expressing human D-1 receptors and different G proteins was examined. Pertussis toxin (PTX) treatment of rat pituitary GH(4)C(1) cells significantly reduced, but did not abolish, agonist high affinity binding sites of the D-1 dopamine receptor; in SK-N-MC neuroblastoma cells, PTX failed to have any effect on D-1 high affinity sites. Cholera toxin (CTX) treatment of GH(4)C(1) cells reduced but did not abolish the high affinity sites of D-1 receptors, while in SK-N-MC cells, treatment with CTX abolished all the high affinity sites. Western blot analyses with specific antisera indicated that G(s) alpha, Q(i1)alpha, G(i3)alpha and G(q) alpha were expressed in both cell lines, while G(i2)alpha and G(o) alpha were expressed in GH(4)C(1) but not SK-N-MC cells. Antisera NEI-805 (anti-G(s) alpha) and 9072 (anti-G(o) alpha) immunoprecipitated 24 +/- 4.3 and 34.4 +/- 6.9%, respectively, of G protein-associated D-1 dopamine receptors. Antisera 3646 (anti-G(i1)alpha), 1521 (anti-G(i2)alpha), 1518 (anti-G(i3)alpha), and 0941 (anti-G(q) alpha) failed to coimmunoprecipitate appreciable levels df soluble receptors. These data indicate that D-1 dopamine receptors are coupled to both G(s) alpha and G(o) alpha but not to G(q) alpha.	GEORGETOWN UNIV,MED CTR,DEPT PEDIAT,WASHINGTON,DC 20007	Georgetown University			Kimura, Kazuhiro/A-5029-2012		NINDS NIH HHS [NS-30912, NS-29685] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029685, R01NS030912] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; BERTORELLO A, 1988, ACTA PHYSIOL SCAND, V132, P441, DOI 10.1111/j.1748-1716.1988.tb08350.x; BERTORELLO A, 1989, AM J PHYSIOL, V256, pF9; BIRNBAUMER L, 1990, FASEB J, V4, P3068; CALFIELD MP, 1994, J PHYSL, V477, P415; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; FELDER CC, 1989, J PHARMACOL EXP THER, V248, P171; FELDER CC, 1990, AM J PHYSIOL, V259, pF297, DOI 10.1152/ajprenal.1990.259.2.F297; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; HUFF RM, 1985, J BIOL CHEM, V260, P864; JOUNEAUX C, 1994, J BIOL CHEM, V269, P1845; KELLY E, 1988, J NEUROCHEM, V51, P918, DOI 10.1111/j.1471-4159.1988.tb01828.x; KIMURA K, 1995, J NEUROCHEM, V64, P2118; KIMURA K, 1994, J NEUROCHEM, V63, P2093; KITAI ST, 1993, ADV NEUROL, V60, P40; LATINEN JT, 1993, J NEUROCHEM, V61, P1461; LAW SF, 1993, J BIOL CHEM, V268, P10721; LAW SF, 1991, J BIOL CHEM, V266, P17885; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MCMILLIAN MK, 1992, J NEUROCHEM, V58, P1308, DOI 10.1111/j.1471-4159.1992.tb11343.x; MOISES HC, 1994, J NEUROSCI, V14, P3842; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEER EJ, 1994, PROTEIN SCI, V3, P3; ODOWD BF, 1993, J NEUROCHEM, V60, P804, DOI 10.1111/j.1471-4159.1993.tb03224.x; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; PIOMELLI D, 1991, NATURE, V353, P164, DOI 10.1038/353164a0; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RUBINSTEIN JE, 1990, BIOCHEM PHARMACOL, V39, P1965, DOI 10.1016/0006-2952(90)90616-S; SCHNEIDER H, 1994, FEBS LETT, V351, P281, DOI 10.1016/0014-5793(94)00878-7; SCHUBERT B, 1989, SCIENCE, V245, P516, DOI 10.1126/science.2547248; SCHULTZ G, 1993, ARZNEIMITTEL-FORSCH, V43-1, P229; SIDHU A, 1990, J BIOL CHEM, V265, P10065; SIDHU A, 1991, J NEUROCHEM, V57, P1445, DOI 10.1111/j.1471-4159.1991.tb08312.x; SIDHU A, 1994, BIOCHEMISTRY-US, V33, P11246, DOI 10.1021/bi00203a021; SIDHU A, 1994, J NEUROCHEM, V63, P201; SIDHU A, 1990, BIOCHEM BIOPH RES CO, V166, P1849; SUGAMORI KS, 1994, P NATL ACAD SCI USA, V91, P10536, DOI 10.1073/pnas.91.22.10536; UNDIE AS, 1994, J NEUROCHEM, V62, P2045; VALLAR L, 1990, J BIOL CHEM, V265, P10320; WALDO GL, 1992, J BIOL CHEM, V267, P25798; WALLACE MA, 1990, NEUROSCI LETT, V110, P155, DOI 10.1016/0304-3940(90)90804-I; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; ZHOU X-M, 1991, Molecular and Cellular Neuroscience, V2, P464	48	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14672	14678		10.1074/jbc.270.24.14672	http://dx.doi.org/10.1074/jbc.270.24.14672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782330	hybrid			2022-12-25	WOS:A1995RD45500066
J	LUTHRIA, DL; BAYKOUSHEVA, SP; SPRECHER, H				LUTHRIA, DL; BAYKOUSHEVA, SP; SPRECHER, H			DOUBLE-BOND REMOVAL FROM ODD-NUMBERED CARBONS DURING PEROXISOMAL BETA-OXIDATION OF ARACHIDONIC-ACID REQUIRES BOTH 2,4-DIENOYL-COA REDUCTASE AND DELTA(3,5),DELTA(2,4)-DIENOYL-COA ISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; RAT-LIVER PEROXISOMES; METABOLISM; PATHWAY; EXISTENCE; CELLS; COA; IDENTIFICATION; MITOCHONDRIA; DEGRADATION	The pathway for the peroxisomal beta-oxidation of arachidonic acid (5,8,11,14-20:4) was elucidated by comparing its metabolism with 4,7,10-hexadecatrienoic acid (4,7,10-16:3) and 5,8-tetradecadienoic acid (5,8-14:2) which are formed, respectively, after two and three cycles of arachidonic acid degradation. When [1-C-14]4,7,10-16:3 was incubated with peroxisomes in the presence of NAD(+) and NADPH, it resulted in a time-dependent increase in the production of acid-soluble radioactivity which was accompanied by the synthesis of 2-trans-4,7,10-hexadecatetraenoic acid and two 3,5,7,10-hexadecatetraenoic acid isomers. The formation of conjugated trienoic acids suggests that peroxisomes contain Delta(3.5),Delta(2,4)-dienoyl-CoA isomerase with the ability to convert 2-trans-4,7,10-hexadecatetraenoic acid to 3,5,7,10-hexadecatetraenoic acid. When 1-C-14-labeled 6,9,12-octadecatrienoic acid or 7,10,13,16-docosatetraenoic acid was incubated without nucleotides, the 3-hydroxy metabolites accumulated, since further degradation requires NAD(+)-dependent 3-hydroxyacyl-CoA dehydrogenase. When [1-C-14]5,8,11,14-20:4 was incubated under identical conditions, no polar metabolite was detected, but 2-trans-4,8,11,14-eicosapentaenoic acid accumulated. When NADPH was added to incubations, 3-hydroxy-8,11,14-eicosatrienoic, 2-trans-4,8,11,14-eicosapentaenoic, 2-trans-8,11,14-eicosatetraenoic, and 8,11,14-eicosatrienoic acids were produced. Analogous compounds were formed from [1-C-14]5,8-14:2. Our results show that the removal of double bonds from odd-numbered carbons in arachidonic acid thus requires both NADPH-dependent 2,4-dienoyl-CoA reductase and Delta(3,5),Delta(2,4)-dienoyl-CoA isomerase. One complete cycle of 5,8-14:2 and 5,8,11,14-20:4 beta-oxidation yields, respectively, 6-dodecenoic and 6,9,12 octadecatrienoic acids.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University			Baykoucheva, Svetla P/H-1969-2011	Baykoucheva, Svetla P/0000-0001-7066-058X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020387] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20387] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bar-Tana J, 1975, Methods Enzymol, V35, P117, DOI 10.1016/0076-6879(75)35146-X; BARTLETT K, 1990, BIOCHEM J, V270, P175, DOI 10.1042/bj2700175; BAYKOUSHEVA SP, 1994, J BIOL CHEM, V269, P18390; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; CHEN LS, 1994, BIOCHEMISTRY-US, V33, P10527, DOI 10.1021/bi00200a039; CHEN LS, 1995, BIOCHEMISTRY-US, V34, P442, DOI 10.1021/bi00002a008; DAS AK, 1992, J BIOL CHEM, V267, P9724; DERRICK JP, 1989, BIOCHEM J, V262, P801, DOI 10.1042/bj2620801; DICZFALUSY U, 1990, BIOCHIM BIOPHYS ACTA, V1043, P182, DOI 10.1016/0005-2760(90)90294-8; DOMMES V, 1981, J BIOL CHEM, V256, P8259; DOMMES V, 1982, EUR J BIOCHEM, V125, P335, DOI 10.1111/j.1432-1033.1982.tb06688.x; GORDON JA, 1990, J CLIN INVEST, V85, P1173, DOI 10.1172/JCI114550; GORDON JA, 1994, J BIOL CHEM, V269, P4103; GORDON JA, 1991, BIOCHIM BIOPHYS ACTA, V1085, P21, DOI 10.1016/0005-2760(91)90227-9; HADJIAGAPIOU C, 1987, PROSTAG OTH LIPID M, V34, P579, DOI 10.1016/0090-6980(87)90100-6; HADJIAGAPIOU C, 1990, J BIOL CHEM, V265, P4369; HADJIAGAPIOU C, 1991, ARCH BIOCHEM BIOPHYS, V292, P112; HAKKOLA EH, 1993, EUR J BIOCHEM, V215, P199, DOI 10.1111/j.1432-1033.1993.tb18023.x; HILTUNEN JK, 1986, J BIOL CHEM, V261, P6484; HORIE S, 1989, ARCH BIOCHEM BIOPHYS, V274, P64, DOI 10.1016/0003-9861(89)90415-3; HOVIK R, 1987, BIOCHEM J, V247, P531, DOI 10.1042/bj2470531; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KATES M, 1972, TECHNIQUES LIPIDOLOG, P383; KUNAU WH, 1974, EUR J BIOCHEM, V48, P311, DOI 10.1111/j.1432-1033.1974.tb03770.x; LUO MJ, 1994, J BIOL CHEM, V269, P2384; MATHUR SN, 1990, J BIOL CHEM, V265, P21048; OSMUNDSEN H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P141, DOI 10.1016/0005-2760(91)90089-Z; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SPRECHER H, 1982, METHOD ENZYMOL, V86, P357; SPRECHER HW, 1965, BIOCHEMISTRY-US, V4, P1856, DOI 10.1021/bi00885a024; STOFFEL W, 1967, J LIPID RES, V8, P196; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; WIGREN J, 1993, J LIPID RES, V34, P625	36	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13771	13776		10.1074/jbc.270.23.13771	http://dx.doi.org/10.1074/jbc.270.23.13771			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775433	hybrid, Green Submitted			2022-12-25	WOS:A1995RC44800030
J	ITOH, H; KOBAYASHI, R; WAKUI, H; KOMATSUDA, A; OHTANI, H; MIURA, AB; OTAKA, M; MASAMUNE, O; ANDOH, H; KOYAMA, K; SATO, Y; TASHIMA, Y				ITOH, H; KOBAYASHI, R; WAKUI, H; KOMATSUDA, A; OHTANI, H; MIURA, AB; OTAKA, M; MASAMUNE, O; ANDOH, H; KOYAMA, K; SATO, Y; TASHIMA, Y			MAMMALIAN 60-KDA STRESS PROTEIN (CHAPERONIN HOMOLOG) - IDENTIFICATION, BIOCHEMICAL-PROPERTIES, AND LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; PURIFICATION; BACTERIAL; GROEL; HSP60; ELECTROPHORESIS; MITOCHONDRIA; FAMILY; CELL	Mammalian chaperonin homolog (HSP60) was purified from porcine livers cytosol using a tandem ATP-Sepharose column and Mono and column chromatography. A partial amino acid sequence (96 amino acid residues) of this protein was determined and coincided with those of human HSP60 with 96.9% homology, which was deduced from the nucleotide sequence of the cDNA. The sequence of the NH2 termini of the purified protein (5 amino acid residues) coincided with the signal sequence of HSP60. These facts led to the identification of the 60-kDa liver protein with the chaperonin homolog. Dihydrofolate reductase was able to form a stable complex with the liver chaperonin homolog. The liver chaperonin homolog was detected by at least five spots around pI = 5.6 on two-dimensional gel electrophoresis. Immunoblotting studies using an antibody against chaperonin homolog showed that the chaperonin homolog was localized in the cytosol, mitochondrial, and nuclear fractions of porcine Liver. The chaperonin homolog was localized both in the mitochondria and cytoplasm of rat kidneys at the electron microscopic level. The chaperonin homolog in the cytosol, but not in the other subcellular fractions, was cross-reacted with an antibody against the synthetic peptide corresponding to the signal peptide of HSP60 as well as the purified chaperonin homolog on immunoblotting. These results suggested that the functional chaperonin homolog in the cytosol may be transported into the mitochondria and the protein may be processed to mitochondrial HSP60 in the organella.	AKITA UNIV,SCH MED,DEPT INTERNAL MED 3,AKITA 010,JAPAN; AKITA UNIV,SCH MED,DEPT INTERNAL MED 1,AKITA 010,JAPAN; AKITA UNIV,SCH MED,DEPT SURG 1,AKITA 010,JAPAN; KAGAWA MED SCH,DEPT CHEM,KAGAWA 76107,JAPAN	Akita University; Akita University; Akita University; Kagawa University	ITOH, H (corresponding author), AKITA UNIV,SCH MED,DEPT BIOCHEM,1-1-1 HONDO,AKITA 010,JAPAN.							ANDERSEN KJ, 1977, ANAL BIOCHEM, V83, P703, DOI 10.1016/0003-2697(77)90075-6; BERNATH P, 1962, METHOD ENZYMOL, V5, P597, DOI 10.1016/S0076-6879(62)05283-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISH P, 1990, SCIENCE, V250, P1269; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUPTA RS, 1985, CAN J BIOCHEM CELL B, V63, P489, DOI 10.1139/o85-068; HORN T, 1979, J MOL BIOL, V129, P359; IKAWA S, 1992, P NATL ACAD SCI USA, V89, P2012, DOI 10.1073/pnas.89.6.2012; ITOH H, 1990, ARCH BIOCHEM BIOPHYS, V282, P290, DOI 10.1016/0003-9861(90)90119-J; ITOH H, 1990, EUR J BIOCHEM, V193, P429, DOI 10.1111/j.1432-1033.1990.tb19356.x; ITOH H, 1993, INT J BIOCHEM, V25, P69; ITOH H, 1991, INT J BIOCHEM, V23, P1185; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; LAD PJ, 1983, ANAL BIOCHEM, V133, P350, DOI 10.1016/0003-2697(83)90095-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MIZZEN LA, 1989, J BIOL CHEM, V264, P20664; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHTANI H, 1993, HISTOCHEMISTRY, V100, P423, DOI 10.1007/BF00267822; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; SANDERS BM, 1994, BIOCHEM J, V297, P21, DOI 10.1042/bj2970021; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SINGH B, 1990, BIOCHEM BIOPH RES CO, V169, P391, DOI 10.1016/0006-291X(90)90344-M; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WAKUI H, 1992, INT J BIOCHEM, V24, P1507; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063	34	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13429	13435		10.1074/jbc.270.22.13429	http://dx.doi.org/10.1074/jbc.270.22.13429			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768945	hybrid			2022-12-25	WOS:A1995RB43900071
J	SHACKELTON, LM; MANN, DM; MILLIS, AJT				SHACKELTON, LM; MANN, DM; MILLIS, AJT			IDENTIFICATION OF A 38-KDA HEPARIN-BINDING GLYCOPROTEIN (GP38K) IN DIFFERENTIATING VASCULAR SMOOTH-MUSCLE CELLS AS A MEMBER OF A GROUP OF PROTEINS ASSOCIATED WITH TISSUE REMODELING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; BASEMENT-MEMBRANE; CAROTID-ARTERY; MESSENGER-RNA; ALPHA-ACTIN; EXPRESSION; MODULATION; PHENOTYPE; ATHEROSCLEROSIS; PROLIFERATION	Cultured aortic smooth muscle cells (SMC) exhibit morphological and phenotypic modulation characterized by a change from a substrate attached monolayer culture to a multilayered nodular cell culture in which SMC are imbedded into the extracellular matrix. Associated with nodule formation is a change in the pattern of SMC gene expression including increased expression of a well characterized marker of smooth muscle cell differentiation, SM alpha-actin, and a 38-kDa glycoprotein (gp38k). gp38k has sequence homology with proteins reported to be correlated with tissue remodeling. To characterize the gp38k mRNA we designed degenerate oligonucleotides based on partial polypeptide sequencing to select a cDNA encoding the full-length gp38k. Southern analysis indicates that porcine gp38k is present as a single copy gene. Northern analysis indicates that the increase in gp38k is correlated with an increase in the steady state level of gp38k mRNA; and is present in cultures that have initiated the formation of multilayered foci and nodules. The correlation between SMC differentiation and gp38k expression is further established by using culture conditions that facilitate SMC differentiation. Cultures seeded onto reconstituted extracellular matrix show rapid formation of nodules and increased expression of gp38k mRNA. Comparison of the gp38k and cDNA sequences with nucleotide and protein sequences available through GenBank. and SwissProt data banks revealed that molecules homologous to gp38k were present in human, mouse, bovine, and Drosophila tissues, suggesting that the gp38k may be a member of a gene family. Although a function for gp38k has not been identified, this report represents the first report of its correlation with a specific process important in phenotypic and morphological modulation of vascular SMC.	SUNY ALBANY,DEPT BIOL SCI,CTR CELL DIFFERENTIAT,ALBANY,NY 12222; AMER RED CROSS,DEPT BIOCHEM,ROCKVILLE,MD 20855	State University of New York (SUNY) System; State University of New York (SUNY) Albany; American Red Cross					NHLBI NIH HHS [HL40417] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040417] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BIRUKOV KG, 1993, EXP CELL RES, V204, P46, DOI 10.1006/excr.1993.1007; BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; BRENNAN MJ, 1983, DEV BIOL, V97, P391, DOI 10.1016/0012-1606(83)90095-7; BRENNAN MJ, 1982, J CELL PHYSIOL, V112, P284, DOI 10.1002/jcp.1041120219; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAMLEYCAMPBELL JH, 1981, J CELL BIOL, V89, P379, DOI 10.1083/jcb.89.2.379; CHANG NCA, 1993, S27879 ACC; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1993, MANUFACTURERS PROTOC; CLOWES AW, 1983, LAB INVEST, V49, P327; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; CORJAY MH, 1989, J BIOL CHEM, V264, P10501; DAMORE PA, 1993, GROWTH FACTORS, V8, P61, DOI 10.3109/08977199309029135; DAVIDSON JM, 1993, J CELL PHYSIOL, V155, P149, DOI 10.1002/jcp.1041550119; DEMOULIERE A, 1992, EXP CELL RES, V201, P64; DIEMER V, 1992, J BIOL CHEM, V267, P5257; DILLEY RJ, 1987, ATHEROSCLEROSIS, V63, P99, DOI 10.1016/0021-9150(87)90109-2; DONNELLY KM, 1991, MOL ENDOCRINOL, V5, P356, DOI 10.1210/mend-5-3-356; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FRID MG, 1992, DEV BIOL, V158, P185; GIMBRONE MA, 1975, LAB INVEST, V33, P16; GLUKHOVA M, 1993, DEV BIOL, V157, P437, DOI 10.1006/dbio.1993.1147; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HEDIN U, 1987, DIFFERENTIATION, V33, P239, DOI 10.1111/j.1432-0436.1987.tb01563.x; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525, DOI 10.1161/01.RES.71.6.1525; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; JOHNSON DE, 1990, J AM COLL CARDIOL, V15, P419, DOI 10.1016/S0735-1097(10)80071-3; KIRKPATRICK RB, 1995, GENE, V153, P147, DOI 10.1016/0378-1119(94)00756-I; KOCHER O, 1991, LAB INVEST, V65, P459; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; KUNZELAMNN U, 1992, Cellular Physiology and Biochemistry, V2, P49, DOI 10.1159/000154625; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MATSUDAIRA P, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P1; MAY JF, 1975, VIRCHOWS ARCH B, V18, P205; MILLIS AJT, 1986, J CELL PHYSIOL, V127, P366, DOI 10.1002/jcp.1041270304; MILLIS AJT, 1985, J BIOL CHEM, V260, P3754; MOSSE PRL, 1985, LAB INVEST, V53, P556; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V17, P433, DOI 10.1016/S0735-1097(10)80111-1; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; PAULY RR, 1992, CIRCULATION, V86, P68; RAINES EW, 1993, BRIT HEART J, V69, pS30; ROSENBERG ME, 1993, J LAB CLIN MED, V121, P205; ROSS R, 1971, J CELL BIOL, V50, P159, DOI 10.1083/jcb.50.1.159; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SELL C, 1992, CELL BIOL INT REP, V16, P221, DOI 10.1016/S0309-1651(06)80124-4; SENDAI Y, 1994, BIOL REPROD, V50, P927, DOI 10.1095/biolreprod50.4.927; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; STRAUCH AR, 1992, J CELL BIOCHEM, V50, P266, DOI 10.1002/jcb.240500307; THOMASSALGAR S, 1994, J BIOL CHEM, V267, P17879; THYBERG J, 1983, DIFFERENTIATION, V25, P156; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; WADA KN, 1990, NUCLEIC ACIDS RES, V18, P2367, DOI 10.1093/nar/18.suppl.2367	60	193	210	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13076	13083		10.1074/jbc.270.22.13076	http://dx.doi.org/10.1074/jbc.270.22.13076			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768902	hybrid			2022-12-25	WOS:A1995RB43900023
J	SOLWAY, J; SELTZER, J; SAMAHA, FF; KIM, S; ALGER, LE; NIU, Q; MORRISEY, EE; IP, HS; PARMACEK, MS				SOLWAY, J; SELTZER, J; SAMAHA, FF; KIM, S; ALGER, LE; NIU, Q; MORRISEY, EE; IP, HS; PARMACEK, MS			STRUCTURE AND EXPRESSION OF A SMOOTH-MUSCLE CELL-SPECIFIC GENE, SM22-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-C GENE; ALPHA-ACTIN PROMOTER; 5'-FLANKING REGION; BINDING FACTOR; BLOOD-VESSELS; CHICK-EMBRYO; MYOD FAMILY; ENHANCER; TRANSCRIPTION; PROTEINS	SM22 alpha is expressed exclusively in smooth muscle-containing tissues of adult animals and is one of the earliest markers of differentiated smooth muscle cells (SMCs). To examine the molecular mechanisms that regulate SMC-specific gene expression, Foe have isolated and structurally characterized the murine SM22 alpha gene. SM22 alpha is a 6.2-kilobase single copy gene composed of five exons. SM22 alpha mRNA is expressed at high levels in the aorta, uterus, lung, and intestine, and in primary cultures of rat aortic SMCs, and the SMC line, A7r5. ln contrast to genes encoding SMC contractile proteins, SM22 alpha gene expression is not decreased in proliferating SMCs. Transient transfection experiments demonstrated that 441 base pairs of SM22 alpha 5'-flanking sequence was necessary and sufficient to program high level transcription of a luciferase reporter gene in both primary rat aortic SMCs and A7r5 cells. DNA sequence analyses revealed that the 441-base pair promoter contains two CArG/SRF boxes, a CACC box, and one potential MEF-2 binding site, cis-acting elements which are each important regulators of striated muscle transcription. Taken together, these studies have identified the murine SM22 alpha promoter as an excellent model system for studies of developmentally regulated, Lineage-specific gene expression in SMCs.	UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	University of Chicago			Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530; Parmacek, Michael/0000-0003-1449-4665; Ip, Hon/0000-0003-4844-7533	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051145, R01HL048257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034566] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL48257, R01HL51145] Funding Source: Medline; NIAID NIH HHS [U01 AI34566] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AYMESOUTHGATE A, 1989, J CELL BIOL, V108, P521, DOI 10.1083/jcb.108.2.521; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; BLANK RS, 1992, J BIOL CHEM, V267, P984; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARROLL SL, 1986, J BIOL CHEM, V261, P8965; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHAPONNIER C, 1990, EUR J BIOCHEM, V190, P559, DOI 10.1111/j.1432-1033.1990.tb15610.x; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DEVLIN BH, 1989, J BIOL CHEM, V264, P13896; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; FRID MG, 1993, J VASC RES, V30, P279, DOI 10.1159/000159007; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; GIMONA M, 1992, EUR J BIOCHEM, V205, P1067, DOI 10.1111/j.1432-1033.1992.tb16875.x; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; GONZALEZCRUSSI F, 1971, AM J ANAT, V130, P441, DOI 10.1002/aja.1001300406; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GREPIN C, 1994, MOL CELL BIOL, V9, P5022; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HIRAKOW R, 1981, ANAT EMBRYOL, V163, P299, DOI 10.1007/BF00315706; HOOD LC, 1992, ANAT RECORD, V234, P291, DOI 10.1002/ar.1092340215; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; Le Lievre C S, 1975, J Embryol Exp Morphol, V34, P125; LEESMILLER JP, 1987, J BIOL CHEM, V262, P2988; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MIN BH, 1990, J BIOL CHEM, V265, P16667; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOSSE PRL, 1985, LAB INVEST, V53, P556; MURPHY ME, 1978, AM J ANAT, V151, P345, DOI 10.1002/aja.1001510304; NISHIDA W, 1993, GENE, V130, P297, DOI 10.1016/0378-1119(93)90435-6; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSBOURN JK, 1995, GENE, V154, P249, DOI 10.1016/0378-1119(94)00847-L; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PARMACEK MS, 1990, J BIOL CHEM, V265, P15970; PARMACEK MS, 1989, J BIOL CHEM, V264, P13217; POOLE TJ, 1989, J EXP ZOOL, V251, P224, DOI 10.1002/jez.1402510210; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, AM J PATHOL, V143, P987; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SAWTELL NM, 1989, J CELL BIOL, V109, P2929, DOI 10.1083/jcb.109.6.2929; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; STRASSER P, 1992, GENBANK DIRECT SUBMI; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TAUBMAN MB, 1987, J CELL BIOL, V104, P1505, DOI 10.1083/jcb.104.6.1505; UEKI N, 1987, P NATL ACAD SCI USA, V84, P9049, DOI 10.1073/pnas.84.24.9049; ZANELLATO AMC, 1990, ARTERIOSCLEROSIS, V10, P996, DOI 10.1161/01.ATV.10.6.996	70	227	247	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13460	13469		10.1074/jbc.270.22.13460	http://dx.doi.org/10.1074/jbc.270.22.13460			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768949	hybrid			2022-12-25	WOS:A1995RB43900075
J	HERZINGER, T; WOLF, DA; EICK, D; KIND, P				HERZINGER, T; WOLF, DA; EICK, D; KIND, P			THE PRB-RELATED PROTEIN P130 IS A POSSIBLE EFFECTOR OF TRANSFORMING GROWTH-FACTOR-BETA-1 INDUCED CELL-CYCLE ARREST IN KERATINOCYTES	ONCOGENE			English	Article						GROWTH CONTROL; TUMOR SUPPRESSOR GENES	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; HUMAN MYC PROMOTER; TGF-BETA; C-MYC; TRANS-ACTIVATION; DEPENDENT KINASE; DIRECT BINDING; INHIBITION; P107	Transforming growth factor beta 1 (TGF-beta 1) is known to inhibit epithelial cell growth by inducing a G1 cell cycle arrest. We have studied the effect of TGF-beta 1 on protein binding to a transcription factor E2F consensus element in extracts from early passage human keratinocytes (HFKs) and a permanent human keratinocyte cell line (HaCaT). Treatment of these cells with TGF-beta 1 resulted in the formation of a DNA binding complex between the pRb-related protein p130 and E2F. Formation of the E2F-p130 complex correlated with inhibition of cell cycle progression in G1 and suppression of the E2F-regulated cdc2 gene. While p130 mRNA and protein levels were not influenced by TGF-beta 1, the activity of cyclin-dependent kinase 2 (Cdk2) towards p130 in vitro was inhibited. The results identify p130 as a downstream target of TGF-beta 1 and a possible mediator of the G1 cell cycle arrest.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,MOLEK PATHOL ABT,D-80337 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich			Wolf, Dieter/AAE-5890-2021	Wolf, Dieter/0000-0002-3761-1070				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1994, J BIOL CHEM, V269, P1306; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GIORDANO A, 1991, ONCOGENE, V6, P481; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MASSAGUE J, 1992, CANCER SURV, V12, P81; MAYOL X, 1993, ONCOGENE, V8, P2561; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; ONG G, 1991, ONCOGENE, V6, P761; PAGANO M, 1992, ONCOGENE, V7, P1681; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WOLF DA, 1995, ONCOGENE, V10, P2067; WOLF DA, 1993, MOL ENDOCRINOL, V7, P924, DOI 10.1210/me.7.7.924; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	54	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2079	2084						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784052				2022-12-25	WOS:A1995RB70300002
J	DEER, JLR; HURLEY, JB; YARFITZ, SL				DEER, JLR; HURLEY, JB; YARFITZ, SL			G-PROTEIN CONTROL OF DROSOPHILA PHOTORECEPTOR PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOLIGO-FORBESI PHOTORECEPTORS; GTP-BINDING PROTEIN; ALPHA-SUBUNITS; NORPA GENE; MOLECULAR-CLONING; PH DOMAIN; MELANOGASTER; PURIFICATION; EXPRESSION; ACTIVATION	Light stimulates phosphatidylinositol bisphosphate phospholipase C (PLC) activity in Drosophila photoreceptors. We have investigated the mechanism of this reaction by assaying PLC activity in Drosophila head membranes using exogenous phospholipid substrates. PLC activation depends on the photoconversion of rhodopsin to metarhodopsin and is reduced in norpA(EE5) PLC and ninaE(P332) rhodopsin mutants. NorpA PLC is stimulated by light at free Ca2+ concentrations between 10 nM and 1 mu M. This finding is consistent with a Ca2+ mediated positive feedback mechanism that contributes to the rapid temporal response of invertebrate photoreceptor cells. The guanyl nucleotide dependence of light-stimulated PLC activity indicates that a G protein regulates NorpA. This was confirmed by the observation that light stimulation of PLC activity is deficient in mutants that lack the eye-specific G protein beta subunit G beta e. These results indicate that G beta e functions as the beta subunit of the G protein coupling rhodopsin to NorpA PLC.	UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NEI NIH HHS [EY06641] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CHEN CK, 1994, INVEST OPHTH VIS SCI, V35, P1485; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; DOLPH PJ, 1994, NATURE, V370, P59, DOI 10.1038/370059a0; EBERHARD DA, 1988, TRENDS NEUROSCI, V11, P517, DOI 10.1016/0166-2236(88)90174-9; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; FEIN A, 1986, SCIENCE, V232, P1543, DOI 10.1126/science.3487116; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; GUILLON G, 1992, CELL SIGNAL, V4, P11, DOI 10.1016/0898-6568(92)90004-R; HOTTA Y, 1970, P NATL ACAD SCI USA, V67, P1156, DOI 10.1073/pnas.67.3.1156; JHON DY, 1993, J BIOL CHEM, V268, P6654; JIANG YW, 1994, BIOCHEM BIOPH RES CO, V203, P1195, DOI 10.1006/bbrc.1994.2309; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LEE YJ, 1994, NEURON, V13, P1143, DOI 10.1016/0896-6273(94)90052-3; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOTT JS, 1992, FEBS LETT, V312, P241, DOI 10.1016/0014-5793(92)80943-B; Maniatis T., 1982, MOL CLONING; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; MINKE B, 1992, SENSORY TRANSDUCTION, P202; MINTA A, 1989, J BIOL CHEM, V264, P8171; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NAGY K, 1991, Q REV BIOPHYS, V24, P165, DOI 10.1017/S0033583500003401; NOBES C, 1992, BIOCHEM J, V287, P545, DOI 10.1042/bj2870545; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; PAYNE R, 1986, J GEN PHYSIOL, V87, P243, DOI 10.1085/jgp.87.2.243; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; POTTINGER JDD, 1991, BIOCHEM J, V279, P323, DOI 10.1042/bj2790323; RANGANATHAN R, 1994, NEURON, V13, P837, DOI 10.1016/0896-6273(94)90250-X; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; RYBA NJ, 1993, BIOCHEM J, V292, P333, DOI 10.1042/bj2920333; SCHNEUWLY S, 1991, J BIOL CHEM, V266, P24314; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOYOSHIMA S, 1990, J BIOL CHEM, V265, P14842; WOLFGANG WJ, 1990, J NEUROSCI, V10, P1014; WU DQ, 1992, J BIOL CHEM, V267, P1811; YARFITZ S, 1991, NEURON, V7, P429, DOI 10.1016/0896-6273(91)90295-B; YARFITZ SL, 1994, J BIOL CHEM, V269, P30340; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V97, P1251, DOI 10.1093/oxfordjournals.jbchem.a135171; ZHU LQ, 1993, J BIOL CHEM, V268, P15994; ZINKL GM, 1990, VISUAL NEUROSCI, V5, P429, DOI 10.1017/S0952523800000559; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	52	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12623	12628		10.1074/jbc.270.21.12623	http://dx.doi.org/10.1074/jbc.270.21.12623			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759511	hybrid			2022-12-25	WOS:A1995QZ71100046
J	LICHTNER, RB; KAUFMANN, AM; KITTMANN, A; ROHDESCHULZ, B; WALTER, J; WILLIAMS, L; ULLRICH, A; SCHIRRMACHER, V; KHAZAIE, K				LICHTNER, RB; KAUFMANN, AM; KITTMANN, A; ROHDESCHULZ, B; WALTER, J; WILLIAMS, L; ULLRICH, A; SCHIRRMACHER, V; KHAZAIE, K			LIGAND-MEDIATED ACTIVATION OF ECTOPIC EGF RECEPTOR PROMOTES MATRIX PROTEIN ADHESION AND LUNG COLONIZATION OF RAT MAMMARY ADENOCARCINOMA CELLS	ONCOGENE			English	Article						EGF RECEPTOR; METASTASIS; MATRIX	EPIDERMAL-GROWTH-FACTOR; HUMAN-BREAST CANCER; CARCINOMA-CELLS; TRANSGENIC MICE; TGF-ALPHA; METASTATIC PROPERTIES; DUCTAL MORPHOGENESIS; EXTRACELLULAR-MATRIX; ESTROGEN-RECEPTORS; EXPRESSION	Increased expression of EGF receptor (EGFR) in metastases of human mammary carcinoma as compared to cells of the primary cancer suggests a contribution of EGFR to mammary carcinoma metastasis. To test for a positive causative link, we investigated 13762NF rat mammary adenocarcinoma cloned tumor cell lines of high (MTLn3) or low (MTC) metastatic potential, While MTC cells expressed barely detectable amounts of EGFR, MTLn3 cells expressed readily detectable levels of functional receptors. A full length cDNA of the human EGFR (HER) was introduced by infection with a retroviral vector into MTC cells, Expression of HER was stable and receptors were functional with respect to surface expression, ligand binding and EGF-stimulated phosphorylation, Independent clones of the transfectants were isolated and characterized. Ligand stimulation of MTC HER cells and derived clones led to enhanced adhesion of tells to extracellular matrix proteins. Implantation of cells intravenously into female nu/nu mice revealed ligand-dependent enhancement of lung colonizing potential of EGFR-expressing cells.	GERMAN CANC RES CTR, DIV CELLULAR IMMUNOL, D-69120 HEIDELBERG, GERMANY; ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE, VIC 3050, AUSTRALIA; MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Max Planck Society	LICHTNER, RB (corresponding author), SCHERING AG, RES LABS, MULLERSTR 170-178, D-13342 BERLIN, GERMANY.			Kaufmann, Andreas/0000-0001-7732-3009				ADELMANNGRILL BC, 1990, EUR J CELL BIOL, V51, P322; BARKER S, 1989, BRIT J CANCER, V60, P673, DOI 10.1038/bjc.1989.338; BATTAGLIA F, 1988, EUR J CANCER CLIN ON, V24, P1685, DOI 10.1016/0277-5379(88)90068-5; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BOYD D, 1989, CANCER RES, V49, P2427; CAMPOSGONZALEZ R, 1990, CELL MOTIL CYTOSKEL, V15, P34, DOI 10.1002/cm.970150106; CHAUDHRY A, 1994, CANCER RES, V54, P981; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DITTADI R, 1993, BRIT J CANCER, V67, P7, DOI 10.1038/bjc.1993.2; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; ENGSTROM W, 1986, J CELL SCI, V86, P47; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HART IR, 1991, BRIT J CANCER, V63, P9, DOI 10.1038/bjc.1991.4; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KAUFMANN AM, 1994, INT J ONCOL, V4, P1149; KERBEL RS, 1987, P NATL ACAD SCI USA, V84, P1263, DOI 10.1073/pnas.84.5.1263; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KHAZAIE K, 1991, ONCOGENE, V6, P21; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAIHO M, 1989, CANCER RES, V49, P2533; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEWIS S, 1990, J CLIN PATHOL, V43, P385, DOI 10.1136/jcp.43.5.385; LICHTNER RB, 1993, CLIN EXP METASTAS, V11, P113, DOI 10.1007/BF00880072; LICHTNER RB, 1992, J BIOL CHEM, V267, P11872; LICHTNER RB, 1988, J CELL PHYSIOL, V137, P285, DOI 10.1002/jcp.1041370211; LICHTNER RB, 1989, EXP CELL BIOL, V57, P146; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NERI A, 1982, J NATL CANCER I, V68, P507; NICHOLSON RI, 1994, BREAST CANCER RES TR, V29, P117, DOI 10.1007/BF00666187; NICHOLSON S, 1991, BRIT J CANCER, V63, P146, DOI 10.1038/bjc.1991.30; NICOLSON G L, 1986, Cancer Reviews, V3, P25; NICOLSON GL, 1992, ONCOGENE, V7, P1127; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; NICOLSON GL, 1983, INT REV EXP PATHOL, V25, P77; NICOLSON GL, 1990, ONCOGENE, V5, P747; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; ROHDESCHULZ B, 1995, IN PRESS INVASION ME; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAINSBURY JRC, 1985, LANCET, V1, P364; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SCHIRRMACHER V, 1985, ADV CANCER RES, V43, P1, DOI 10.1016/S0065-230X(08)60942-2; SCHIRRMACHER V, 1980, IMMUNOBIOLOGY, V157, P89, DOI 10.1016/S0171-2985(80)80091-X; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YU DH, 1994, CANCER RES, V54, P3260	63	53	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1823	1832						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753557				2022-12-25	WOS:A1995QX46900015
J	SATO, K; KASHIWAYA, Y; KEON, CA; TSUCHIYA, N; KING, MT; RADDA, GK; CHANCE, B; CLARKE, K; VEECH, RL				SATO, K; KASHIWAYA, Y; KEON, CA; TSUCHIYA, N; KING, MT; RADDA, GK; CHANCE, B; CLARKE, K; VEECH, RL			INSULIN, KETONE-BODIES, AND MITOCHONDRIAL ENERGY TRANSDUCTION	FASEB JOURNAL			English	Article						TRICARBOXYLIC ACID CYCLE INTERMEDIATES; MITOCHONDRIAL REDOX STATES; DELTA-PH; E(MITO/CYTO), DELTA-G(ATP)	PHOSPHATE-TRANSPORT; TISSUES; RESPIRATION; METABOLISM; MECHANISM; MEMBRANE; KINETICS; PLASMA; CELLS	Addition of insulin or a physiological ratio of ketone bodies to buffer with 10 mM glucose increased efficiency (hydraulic work/energy from O-2 consumed) of working rat heart by 25%, and the two in combination increased efficiency by 36%. These additions increased the content of acetyl CoA by 9- to 18-fold, increased the contents of metabolites of the first third of the tricarboxylic acid (TCA) cycle 2- to 5-fold, and decreased succinate, oxaloacetate, and aspartate 2- to 3-fold. Succinyl CoA, fumarate, and malate were essentially unchanged. The changes in content of TCA metabolites resulted from a reduction of the free mitochondrial NAD couple by 2- to 10-fold and oxidation of the mitochondrial coenzyme Q couple by 2- to 4-fold. Cytosolic pH, measured using P-31-NMR spectra, was invariant at about 7.0. The total intracellular bicarbonate indicated an increase in mitochondrial pH from 7.1 with glucose to 7.2, 7.5, and 7.4 with insulin, ketones, and the combination, respectively. The decrease in Eh(7) of the mitochondrial NAD couple, Eh(NAD+/NADH)(7), from -280 to -300 mV and the increase in Eh(7) of the coenzyme Q couple, Eh(Q/QH2)(7), from -4 to +12 mV was equivalent to an increase from -53 kJ to -60 kJ/2 mol e in the reaction catalyzed by the mitochondrial NADH dehydrogenase multienzyme complex (EC 1.6.5.3). The increase in the redox energy of the mitochondrial cofactor couples paralleled the increase in the free energy of cytosolic ATP hydrolysis, Delta G(ATP). The potential of the mitochondrial relative to the cytosolic phases, E(mito/cyto), calculated from Delta G(ATP) and Delta pH on the assumption of a 4 H+ transfer for each ATP synthesized, was -143 mV during perfusion with glucose or glucose plus insulin, and decreased to -120 mV on addition of ketones. Viewed in this light, the moderate ketosis characteristic of prolonged fasting or type II diabetes appears to be an elegant compensation for the defects in mitochondrial energy transduction associated with acute insulin deficiency or mitochondrial senescence.	NIAAA, METAB & MOLEC BIOL LAB, ROCKVILLE, MD 20852 USA; UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND; UNIV PENN, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of Oxford; University of Pennsylvania								ALEXANDRE A, 1978, P NATL ACAD SCI USA, V75, P5296, DOI 10.1073/pnas.75.11.5296; Altman PL, 1971, RESP CIRC, P16; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BRAND MD, 1994, BIOCHEM J, V297, P27, DOI 10.1042/bj2970027; BURTON K, 1953, BIOCHEM J, V54, P94, DOI 10.1042/bj0540094; BURTON K, 1953, BIOCHEM J, V54, P86, DOI 10.1042/bj0540086; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; CHANCE B, 1961, J BIOL CHEM, V236, P1577; CHRISTOF.C, 1969, J APPL PHYSIOL, V26, P56, DOI 10.1152/jappl.1969.26.1.56; CLARK WM, 1960, OXIDATION REDUCTION, P349; CLARKE K, 1987, AM J PHYSIOL, V253, pH412, DOI 10.1152/ajpheart.1987.253.2.H412; CORNELL NW, 1979, ANAL BIOCHEM, V95, P524, DOI 10.1016/0003-2697(79)90766-8; COTY WA, 1974, J BIOL CHEM, V249, P2593; DAVIS RJ, 1981, BIOCHEM J, V196, P133, DOI 10.1042/bj1960133; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DENTON RM, 1987, BIOCHEM SOC SYMP, P127; DOBSON GP, 1991, ANAL BIOCHEM, V195, P232, DOI 10.1016/0003-2697(91)90322-K; ENGEL PC, 1969, BIOCHEM J, V115, P621, DOI 10.1042/bj1150621; FELIG P, 1970, NEW ENGL J MED, V282, P166; FOLBERGROVA J, 1969, J NEUROCHEM, V16, P191, DOI 10.1111/j.1471-4159.1969.tb05937.x; GOLDBERG ND, 1966, J BIOL CHEM, V241, P3997; GROEN AK, 1982, J BIOL CHEM, V257, P2754; GUYNN RW, 1973, J BIOL CHEM, V248, P6957; HAGLER HK, 1986, J MICROSC-OXFORD, V141, P311, DOI 10.1111/j.1365-2818.1986.tb02725.x; HALESTRAP AP, 1975, BIOCHEM J, V148, P85, DOI 10.1042/bj1480085; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; KING MT, 1988, METHOD ENZYMOL, V166, P70; Klingenberg M, 1970, Essays Biochem, V6, P119; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MASUDA T, 1990, J BIOL CHEM, V265, P20321; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; NEELY JR, 1967, AM J PHYSIOL, V212, P804; NEELY JR, 1967, AM J PHYSIOL, V212, P815; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PETTE D, 1962, BIOCHEM BIOPH RES CO, V7, P425, DOI 10.1016/0006-291X(62)90328-5; REYNAFARJE B, 1978, P NATL ACAD SCI USA, V75, P4788, DOI 10.1073/pnas.75.10.4788; Sendroy J, 1934, J BIOL CHEM, V105, P597; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SLATER EC, 1969, ENERGY LEVEL METABOL, P1; SRERE PA, 1981, TRENDS BIOCHEM SCI, V6, P4, DOI 10.1016/0968-0004(81)90003-7; UMBREIT WW, 1972, MANOMETRIC BIOCH TEC, P6; Veech R L, 1986, Adv Exp Med Biol, V194, P617; VEECH RL, 1994, ALCOHOL CLIN EXP RES, V18, P1040, DOI 10.1111/j.1530-0277.1994.tb00081.x; VELOSO D, 1973, J BIOL CHEM, V248, P4811; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEHRLE JP, 1989, J MEMBRANE BIOL, V111, P199, DOI 10.1007/BF01871006; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514	51	306	314	3	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1995	9	8					651	658		10.1096/fasebj.9.8.7768357	http://dx.doi.org/10.1096/fasebj.9.8.7768357			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768357				2022-12-25	WOS:A1995RC10600011
J	MIHM, S; GALTER, D; DROGE, W				MIHM, S; GALTER, D; DROGE, W			MODULATION OF TRANSCRIPTION FACTOR NF-KAPPA-B ACTIVITY BY INTRACELLULAR GLUTATHIONE LEVELS AND BY VARIATIONS OF THE EXTRACELLULAR CYSTEINE SUPPLY	FASEB JOURNAL			English	Article						TNF-ALPHA; DNA-BINDING ACTIVITY; MOLT-4 CELLS; NF-KAPPA-B CONTROLS	HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-BINDING ACTIVITY; OXIDATION-REDUCTION; REDOX REGULATION; BUTHIONINE SULFOXIMINE; ENDOPLASMIC-RETICULUM; ACTIVATION; PROTEIN; INVITRO; LYMPHOCYTES	HIV-infected individuals and SIV-infected rhesus macaques have, on the average, decreased plasma cysteine and cystine concentrations and decreased intracellular glutathione levels. We now show that a depletion of intracellular glutathione in a human T cell line (Molt-4) inhibits the activation and nuclear translocation of the transcription factor NF kappa B, whereas incubation with increasing extracellular concentrations of cysteine inhibits the DNA-binding and transactivating activity of NF kappa B. Because inhibition of DNA-binding activity is associated with increasing intracellular glutathione disulfide levels and GSSG can be shown to inhibit the DNA-binding activity directly in cell-free systems, our studies suggest that GSSG is a physiologically relevant inhibitor in intact cells also, NF kappa B controls many immunologically important genes, so our studies suggest that the immune system may be sensitive not only against a cysteine and glutathione deficiency but also against an excess of cysteine.	DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT IMMUNOCHEM, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Galter, Dagmar/C-4826-2011	Galter, Dagmar/0000-0001-6485-6244				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BUHL R, 1989, LANCET, V2, P1294; CACERES J, 1990, ONCOGENE, V5, P59; DANIEL MD, 1988, J VIROL, V62, P4123, DOI 10.1128/JVI.62.11.4123-4128.1988; DROGE W, 1986, IMMUNOBIOLOGY, V172, P151; DROGE W, 1988, BIOL CHEM H-S, V369, P143, DOI 10.1515/bchm3.1988.369.1.143; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; ECK HP, 1991, LANCET, V338, P346, DOI 10.1016/0140-6736(91)90482-5; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; ECK HP, 1992, INT IMMUNOL, V4, P7, DOI 10.1093/intimm/4.1.7; FEDORCSAK I, 1977, EXP CELL RES, V108, P331, DOI 10.1016/S0014-4827(77)80040-2; FRAME MC, 1991, ONCOGENE, V6, P205; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GMUNDER H, 1991, EUR J BIOCHEM, V201, P113, DOI 10.1111/j.1432-1033.1991.tb16263.x; GMUNDER H, 1990, CELL IMMUNOL, V129, P32, DOI 10.1016/0008-8749(90)90184-S; GMUNDER H, 1991, CELL IMMUNOL, V138, P229, DOI 10.1016/0008-8749(91)90147-4; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HAMILOS DL, 1985, J IMMUNOL, V135, P2740; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; ISHII T, 1985, J CELL PHYSIOL, V125, P151, DOI 10.1002/jcp.1041250119; KINSCHERF R, 1994, FASEB J, V8, P448, DOI 10.1096/fasebj.8.6.7909525; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MESTDAGH N, 1992, BIOCHEM PHARMACOL, V43, P1529, DOI 10.1016/0006-2952(92)90211-Z; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOLITOR JA, 1991, NEW BIOL, V3, P987; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SEXTON DJ, 1992, COMP BIOCHEM PHYS B, V103, P897, DOI 10.1016/0305-0491(92)90211-9; STAAL FJT, 1992, LANCET, V339, P909, DOI 10.1016/0140-6736(92)90939-Z; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WILLIAMS TM, 1991, SCIENCE, V254, P1791, DOI 10.1126/science.1840704; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	49	147	148	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1995	9	2					246	252		10.1096/fasebj.9.2.7781927	http://dx.doi.org/10.1096/fasebj.9.2.7781927			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781927				2022-12-25	WOS:A1995QJ24900013
J	TICHER, A; ASHKENAZI, IE; REINBERG, AE				TICHER, A; ASHKENAZI, IE; REINBERG, AE			PRESERVATION OF THE FUNCTIONAL ADVANTAGE OF HUMAN TIME STRUCTURE	FASEB JOURNAL			English	Article						BIOLOGICAL RHYTHMS; HUMAN TEMPORAL ORDER; ADAPTIVE VALUE	CIRCADIAN-RHYTHMS	Upon exposure to sustained and synchronized diurnal activity, most human variables exhibit rhythms with a 24 h period. The best-fitting cosine curve to the data with a selected period (24 h) may yield parameters like acrophase (estimated peak time), amplitude, and mesor (rhythm adjusted mean). The sequential array of the rhythms' acrophases constructs the temporal order. Analyzing 168 different human rhythms revealed a time-dependent distribution with regard to the number of acrophases/h and to the clustering of variables according to function. Rhythms' amplitude/mesor ratios yielded a five modal distribution. The modes occurred at those clock times where repetitive habitual signals are anticipated. It is assumed that these specific features evolved to optimize the adaptive value of the temporal order.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,CHRONOBIOL UNIT,IL-69978 TEL AVIV,ISRAEL; FDN A ROTHSCHILD,CHRONOBIOL UNIT,F-75940 PARIS 19,FRANCE	Tel Aviv University; Sackler Faculty of Medicine								ANDLAUER P, 1979, J PHYSIOL-PARIS, V75, P507; ASCHOFF J, 1982, BIOL TIMEKEEPING, P143; ASCHOFF J, 1992, CIRCADIAN RHYTHMS DI, V7, P16; DEPRINS J, 1986, ANN REV CHRONOPHARMA, V2, P7; GOI G, 1989, CHRONOBIOLOGIA, V16, P63; GUIGNARD MM, 1980, ACTA ENDOCRINOL-COP, V94, P536, DOI 10.1530/acta.0.0940536; HALBERG F, 1967, J PHYSIOLOGY PARIS, V59, P117; HAUS E, 1990, ANN R CHRON, V7, P153; Haus E, 1988, ANN REV CHRONOPHARMA, V4, P333; KLEIN KE, 1977, VIGILANCE THEORY OPE, P111; MILLS JN, 1978, CHRONOBIOLOGIA, V5, P14; MINORS DS, 1989, CHRONOBIOL INT, V6, P29, DOI 10.3109/07420528909059140; MINORS DS, 1990, OCCUP MED, V5, P165; MINORS DS, 1989, BIOL RHYTHMS CLIN PR, P272; Monk T H, 1989, Clin Geriatr Med, V5, P331; Moore-Ede MC., 1982, CLOCKS TIME US; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; PITTENDRIGH CS, 1961, HARVEY LECT, V56, P93; REINBERG A, 1988, EUR J APPL PHYSIOL O, V57, P15, DOI 10.1007/BF00691232; Reinberg A, 1983, BIOL RHYTHMS MED; Reinberg A.E., 1992, BIOL RHYTHMS CLIN LA, P243; Sneath P.H.A., 1973, NUMERICAL TAXONOMY P; WINGET CM, 1985, MED SCI SPORT EXER, V17, P498; 1985, SAS USERS GUIDE STAT	24	25	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					269	272		10.1096/fasebj.9.2.7781929	http://dx.doi.org/10.1096/fasebj.9.2.7781929			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781929				2022-12-25	WOS:A1995QJ24900016
J	FROELICHAMMON, SJ; PATCHAN, MW; OSHEROFF, N; THOMPSON, RB				FROELICHAMMON, SJ; PATCHAN, MW; OSHEROFF, N; THOMPSON, RB			TOPOISOMERASE-II BINDS TO ELLIPTICINE IN THE ABSENCE OR PRESENCE OF DNA - CHARACTERIZATION OF ENZYME DRUG-INTERACTIONS BY FLUORESCENCE SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; INTERCALATING AGENTS; ANTITUMOR DRUGS; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; BIOLOGICAL PROPERTIES; ANTINEOPLASTIC DRUGS; NUCLEOTIDE-SEQUENCE; FISSION YEAST; CELL-NUCLEI	Although a number of drugs currently in use for the treatment of human cancers act by stimulating topoisomerase II-mediated DNA breakage, little is known regarding interactions between these agents and the enzyme. To further define the mechanism of drug action, interactions between ellipticine (an intercalative drug with clinical relevance) and yeast topoisomerase II were characterized. By utilizing a yeast genetic system, topoisomerase II was identified as the primary cellular target of the drug. Furthermore, ellipticine did not inhibit enzyme-mediated DNA religation, suggesting that it stimulates DNA breakage by enhancing the forward rate of cleavage. Finally, ellipticine binding to DNA, topoisomerase II, and the enzyme . DNA complex was assessed by steady-state and frequency domain fluorescence spectroscopy. As determined by changes in fluorescence intensity and emission maximum wavelength, and by lifetime analysis, only the protonated species of ellipticine bound to a double stranded 40-mer oligonucleotide containing a topoisomerase II cleavage site (K-D approximate to 65 nM). In contrast, predominantly deprotonated ellipticine bound to the enzyme . DNA complex (K-D approximate to 1.5 mu M) or to the enzyme in the absence of nucleic acids (K-D approximate to 160 nM). These findings suggest that ellipticine interacts directly with topoisomerase II and that the enzyme dictates the ionic state of the drug in the ternary complex. A model is presented in which the topoisomerase II . ellipticine DNA complex is formed via initial drug binding to either the enzyme or DNA.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	Vanderbilt University; University System of Maryland; University of Maryland Baltimore				Patchan, Marcia/0000-0002-0485-0403	NCI NIH HHS [5 T32 CA09582] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUCLAIR C, 1984, J MED CHEM, V27, P1161, DOI 10.1021/jm00375a013; AUCLAIR C, 1987, ARCH BIOCHEM BIOPHYS, V58, P1; BUZDAR AU, 1990, ONCOLOGY, V47, P101; CHARCOSSET JY, 1985, CANCER RES, V45, P4229; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHOW KC, 1988, MOL PHARMACOL, V34, P467; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CORBETT AH, 1993, ANTIMICROB AGENTS CH, V37, P2599, DOI 10.1128/AAC.37.12.2599; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; DAVENPORT D, 1981, FLUORESCENCE SPECTRO, P203; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; ELSEA SH, 1992, J BIOL CHEM, V267, P13150; FROELICHAMMON SJ, 1994, J BIOL CHEM, V269, P7719; GIACCONE G, 1994, ANTICANCER RES, V14, P269; GIAEVER G, 1986, J BIOL CHEM, V261, P2448; GOODWIN S, 1959, J AM CHEM SOC, V81, P1903, DOI 10.1021/ja01517a031; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; HOOPER DC, 1989, REV INFECT DIS S5, V11, P902; HOOPER DC, 1993, DRUGS, V3, P8; JURAYJ J, 1994, J MED CHEM, V37, P2190, DOI 10.1021/jm00040a011; KATTAN J, 1994, AM J CLIN ONCOL-CANC, V17, P242, DOI 10.1097/00000421-199406000-00013; KOHN KW, 1975, CANCER RES, V35, P71; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LARUE L, 1988, J MED CHEM, V31, P1951, DOI 10.1021/jm00118a014; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU LF, 1990, DNA TOPOLOGY ITS BIO, P371; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; MONNOT M, 1991, J BIOL CHEM, V266, P1820; NABIEV I, 1994, BIOCHEMISTRY-US, V33, P9013, DOI 10.1021/bi00196a020; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; NITISS JL, 1993, CANCER RES, V53, P89; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PAOLETTI C, 1981, CANCER TREAT REP, V65, P107; PEREZ RP, 1992, INVEST NEW DRUG, V10, P99, DOI 10.1007/BF00873125; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; POMMIER Y, 1985, BIOCHEMISTRY-US, V24, P6406, DOI 10.1021/bi00344a014; POMMIER Y, 1984, BIOCHEMISTRY-US, V23, P3194, DOI 10.1021/bi00309a013; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1991, J BIOL CHEM, V26, P14585; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROSS WE, 1981, BIOCHIM BIOPHYS ACTA, V654, P129, DOI 10.1016/0005-2787(81)90145-3; ROUESSE J, 1993, EUR J CANCER, V29A, P856, DOI 10.1016/S0959-8049(05)80424-1; RUCKDESCHEL JC, 1992, J MED CHEM, V35, P4854, DOI 10.1021/jm00104a011; SANDER M, 1983, J BIOL CHEM, V258, P8421; SCHNEIDER E, 1989, BIOCHEM PHARMACOL, V38, P263, DOI 10.1016/0006-2952(89)90036-1; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SHEN LL, 1989, J BIOL CHEM, V264, P2973; SORACE RA, 1978, CHEM-BIOL INTERACT, V23, P379, DOI 10.1016/0009-2797(78)90098-4; SORENSEN BS, 1990, BIOCHEMISTRY-US, V29, P9507; STEINER RF, 1982, EXCITED STATES BOPOL, P203; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; THOMPSON RB, 1988, ANAL CHEM, V60, P670, DOI 10.1021/ac00158a014; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; UEMURA T, 1986, EMBO J, V5, P2355, DOI 10.1002/j.1460-2075.1986.tb04504.x; WAHL P, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P417, DOI 10.1073/pnas.65.2.417; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WARING MJ, 1981, ANNU REV BIOCHEM, V50, P159, DOI 10.1146/annurev.bi.50.070181.001111; WATT PM, BIOCH J; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126; WOODWIN S, 1959, J AM CHEM SOC, V81, P4434; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x; ZEGAR I, 1989, CHEM-BIOL INTERACT, V72, P277, DOI 10.1016/0009-2797(89)90004-5; ZHANG H, 1990, CANCER CELL-MON REV, V2, P23; [No title captured]	74	124	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14998	15004		10.1074/jbc.270.25.14998	http://dx.doi.org/10.1074/jbc.270.25.14998			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797481	hybrid			2022-12-25	WOS:A1995RE66600026
J	KOROTCHKINA, LG; PATEL, MS				KOROTCHKINA, LG; PATEL, MS			MUTAGENESIS STUDIES OF THE PHOSPHORYLATION SITES OF RECOMBINANT HUMAN PYRUVATE-DEHYDROGENASE - SITE-SPECIFIC REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; PHOSPHATE PHOSPHATASE; COMPLEX; HEART; KINASE; COMPONENT; BINDING; PYROPHOSPHATE; MUSCLE	Mammalian pyruvate dehydrogenase (alpha(2) beta(2)) (E(1)) is regulated by phosphorylation-dephosphorylation, catalyzed by the E(1)-kinase and the phospho-E(1)-phosphatase. Using site-directed mutagenesis of the three phosphorylation sites (sites 1, 2, and 3) on E(1) alpha, several human E(1) mutants were made with single, double, and triple mutations by changing Ser to Ala, Mutation at site 1 but not at sites 2 and/or 3 decreased E(1) specific activity and also increased K-m values for thiamin pyrophosphate and pyruvate. Sites 1, 2, and 3 in the E(1) mutants were phosphorylated either individually or in the presence of the other sites by the dihydrolipoamide acetyltransferase-protein X-E(1) kinase indicating a site-independent mechanism of phosphorylation. Phosphorylation of each site resulted in complete inactivation of the E(1). However, the rates of phosphorylation and inactivation were site-specific. Sites 1, 2, and 3 were dephosphorylated either individually or in the presence of the other sites by the phospho-E(1)-phosphatase resulting in complete reactivation of the E(1). The rates of dephosphorylation and reactivation were similar for sites 1, 2, and 3, indicating a random dephosphorylation mechanism.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIDDK NIH HHS [DK20478] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020478] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI MS, 1993, J BIOL CHEM, V268, P22353; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER JR, 1977, BIOCHEM BIOPH RES CO, V74, P1667, DOI 10.1016/0006-291X(77)90636-2; CATE RL, 1978, J BIOL CHEM, V253, P496; DAHL HHM, 1987, J BIOL CHEM, V262, P7398; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; KERBEY AL, 1985, BIOCHEM J, V231, P523, DOI 10.1042/bj2310523; KERBEY AL, 1981, BIOCHEM J, V195, P51, DOI 10.1042/bj1950051; KERR DS, 1987, PEDIATR RES, V22, P312, DOI 10.1203/00006450-198709000-00015; Khailova L, 1990, BIOCH PHYSL TDP ENZY, P251; Khailova L S, 1977, Biokhimiia, V42, P113; KHAILOVA LS, 1989, ANN NY ACAD SCI, V573, P36, DOI 10.1111/j.1749-6632.1989.tb14985.x; KHAILOVA LS, 1985, BIOCHEM INT, V11, P509; KHAILOVA LS, 1982, BIOCHEM INT, V5, P525; Korochkina L G, 1993, Biokhimiia, V58, P1503; KOROTCHKINA LG, 1995, PROTEIN EXPRES PURIF, V6, P79, DOI 10.1006/prep.1995.1011; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; LINN TC, 1969, P NATL ACAD SCI USA, V64, P227, DOI 10.1073/pnas.64.1.227; OMKUMAR RV, 1994, J BIOL CHEM, V269, P16862; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; RAHMATULLAH M, 1986, J BIOL CHEM, V261, P6515; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; ROBINSON BH, 1993, FEBS LETT, V328, P99, DOI 10.1016/0014-5793(93)80973-X; ROCHE TE, 1972, BIOCHEM BIOPH RES CO, V48, P840, DOI 10.1016/0006-291X(72)90684-5; SALE GJ, 1982, BIOCHEM J, V203, P99, DOI 10.1042/bj2030099; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STANLEY CJ, 1980, BIOCHEM J, V191, P147, DOI 10.1042/bj1910147; STEPP LR, 1985, BIOCHEMISTRY-US, V24, P7187, DOI 10.1021/bi00346a026; SUGDEN PH, 1978, BIOCHEM J, V173, P659, DOI 10.1042/bj1730659; SUGDEN PH, 1978, BIOCHEM J, V169, P433, DOI 10.1042/bj1690433; SUGDEN PH, 1979, BIOCHEM J, V181, P419, DOI 10.1042/bj1810419; TEAGUE WM, 1979, BIOCHEM BIOPH RES CO, V87, P244, DOI 10.1016/0006-291X(79)91672-3; WALSH DA, 1976, BIOCHEM J, V157, P41, DOI 10.1042/bj1570041; YEAMAN SJ, 1978, BIOCHEMISTRY-US, V17, P2364, DOI 10.1021/bi00605a017; ZHAO Y, 1994, J BIOL CHEM, V269, P18583	37	91	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14297	14304		10.1074/jbc.270.24.14297	http://dx.doi.org/10.1074/jbc.270.24.14297			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782287	hybrid			2022-12-25	WOS:A1995RD45500013
J	SUDOL, M; BORK, P; EINBOND, A; KASTURY, K; DRUCK, T; NEGRINI, M; HUEBNER, K; LEHMAN, D				SUDOL, M; BORK, P; EINBOND, A; KASTURY, K; DRUCK, T; NEGRINI, M; HUEBNER, K; LEHMAN, D			CHARACTERIZATION OF THE MAMMALIAN YAP (YES-ASSOCIATED PROTEIN) GENE AND ITS ROLE IN DEFINING A NOVEL PROTEIN MODULE, THE WW DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ENDOCRINE NEOPLASIA; LIGAND-BINDING SITE; SH3 DOMAINS; C-SRC; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; SMALL REGION; KINASE-C; SEARCH; CDNA	We report cDNA cloning and characterization of the human and mouse orthologs of the chicken YAP (Yes-associated protein) gene which encodes a novel protein that binds to the SH3 (Src homology 3) domain of the Yes proto-oncogene product. Sequence comparison between mouse, human, and chicken YAP proteins showed an inserted sequence in the mouse YAP that represented an imperfect repeat of an upstream sequence. Further analysis of this sequence revealed a putative protein module that is found in various structural, regulatory, and signaling molecules in yeast, nematode, and mammals including human dystrophin. Because one of the prominent features of this sequence motif is two tryptophans (W), we named it the WW domain (Bork, P., and Sudol, M. (1994) Trends Biochem. Sci. 19, 531-533). Since its delineation, more proteins have been shown to contain this domain, and we report here on the widespread distribution of the WW module and present a discussion of its possible function. We have also shown that the human YAP gene is well conserved among higher eukaryotes, but it may not be conserved in yeast. Its expression at the RNA level in adult human tissues is nearly ubiquitous, being relatively high in placenta, prostate, ovary, and testis, but is not detectable in peripheral blood leukocytes. Using fluorescence in situ hybridization on human metaphase chromosomes and by analyzing rodent-human hybrids by Southern blot hybridization and polymerase chain reaction amplification, we mapped the human YAP gene to chromosome band 11q13, a region to which the multiple endocrine neoplasia type I gene has been mapped.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	European Molecular Biology Laboratory (EMBL); Jefferson University	SUDOL, M (corresponding author), ROCKEFELLER UNIV,MOLEC ONCOL LAB,BOX 169,1230 YORK AVE,NEW YORK,NY 10021, USA.		Bork, Peer/F-1813-2013; Negrini, Massimo/J-2377-2016	Bork, Peer/0000-0002-2627-833X; Negrini, Massimo/0000-0002-0007-1920	NCI NIH HHS [CA51083, CA45757, CA01605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045757, P01CA051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BORK P, 1991, FEBS LETT, V286, P47, DOI 10.1016/0014-5793(91)80937-X; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; BYSTROM C, 1990, P NATL ACAD SCI USA, V87, P1968, DOI 10.1073/pnas.87.5.1968; CICCHETTI P, 1992, SCIENCE, V267, P803; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; FUJIMORI M, 1992, AM J HUM GENET, V50, P399; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; Harian J. E., 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUEBNER K, 1991, AM J HUM GENET, V48, P726; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; HUIBREGTSE JM, 1995, IN PRESS COLD SPRING, V59; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOONIN EV, 1994, EMBO J, V13, P493, DOI 10.1002/j.1460-2075.1994.tb06287.x; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LEMAIRE C, 1988, EMBO J, V7, P4157, DOI 10.1002/j.1460-2075.1988.tb03311.x; LI N, 1993, NATURE, V63, P85; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOU ZW, 1993, GENE CHROMOSOME CANC, V7, P15, DOI 10.1002/gcc.2870070104; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P6568, DOI 10.1073/pnas.83.17.6568; NAKAMURA Y, 1989, AM J HUM GENET, V44, P751; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OBRIEN SJ, 1993, GENOME PR R, P758; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Potts W M, 1988, Oncogene Res, V3, P343; RHODE K, 1993, CABIOS, V9, P183; RICHARD CW, 1991, AM J HUM GENET, V49, P1189; ROBERTS RG, 1994, HUM MUTAT, V4, P1, DOI 10.1002/humu.1380040102; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHIMKE RN, 1986, NEW ENGL J MED, V314, P1315, DOI 10.1056/NEJM198605153142010; SCHINZEL A, 1993, GENOME PRIORITY REPO, V1, P658; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1993, MOL BASIS HUMAN CANC, P203; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; TINSLEY MJ, 1994, P NATL ACAD SCI USA, V91, P8307; WENG Z, 1993, J BIOL CHEM, V2686, P14956; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	66	266	280	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14733	14741		10.1074/jbc.270.24.14733	http://dx.doi.org/10.1074/jbc.270.24.14733			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782338	hybrid			2022-12-25	WOS:A1995RD45500075
J	VANHORSSEN, AM; VANDENHURK, WH; BAILYES, EM; HUTTON, JC; MARTENS, GJM; LINDBERG, I				VANHORSSEN, AM; VANDENHURK, WH; BAILYES, EM; HUTTON, JC; MARTENS, GJM; LINDBERG, I			IDENTIFICATION OF THE REGION WITHIN THE NEUROENDOCRINE POLYPEPTIDE 7B2 RESPONSIBLE FOR THE INHIBITION OF PROHORMONE CONVERTASE PC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY POLYPEPTIDE; PROCESSING ENDOPROTEASES; ENDOCRINE PROTEIN; SEQUENCE; CELLS; CLONING; RAT; PROOPIOMELANOCORTIN; PROINSULIN; VESICLES	The highly conserved polypeptide 7B2 and the subtilisin-related prohormone convertases PC1/PC3 and PC2 are broadly distributed in neurons and endocrine cells and are localized to secretory granules. We recently showed that recombinant 7B2 is in vitro a potent inhibitor of PC2 activity, but not of PC1/PC3, and that newly synthesized 7B2 is transiently associated with proPC2 in vivo. In the present study, in vitro mutagenesis was used to identify the region within the 7B2 sequence responsible for the inhibition of PC2. Mutant proteins were produced in a prokaryotic expression system and their effects on PC1/PC3 and PC2 activities were studied by two different in vitro enzyme assays. None of the 7B2 mutant proteins inhibited PC1/PC3 activity. Truncation studies revealed that a short segment within the COOH-terminal portion of 7B2 is critical for its inhibitory effect on PC2. This segment contains a pair of basic amino acid residues which may represent a recognition motif for PC2. Single amino acid substitutions within this Lys(171)-Lys(172) site strongly diminished and a double mutation abolished the inhibitory potency of 7B2. Our results indicate that, although amino acid residues directly surrounding this dibasic pair also contribute to PC2 inhibition, the Lys(171)-Lys(172) site is particularly important for the ability of 7B2 to inhibit PC2.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, NEW ORLEANS, LA 70112 USA; CATHOLIC UNIV NIJMEGEN, DEPT ANIM PHYSIOL, 6525 ED NIJMEGEN, NETHERLANDS; UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QR, ENGLAND	Louisiana State University System; Radboud University Nijmegen; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Martens, Gerard JM/D-1925-2010; Lindberg, Iris/Q-3825-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [R56 DA005084, DA05084] Funding Source: Medline; NIDDK NIH HHS [R01 DK049703] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		AYOUBI TAY, 1990, J BIOL CHEM, V265, P15644; BAILYES EM, 1992, BIOCHEM J, V286, P223, DOI 10.1042/bj2860223; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; BRAYTON KA, 1988, DNA-J MOLEC CELL BIO, V7, P713, DOI 10.1089/dna.1988.7.713; CROWTHER NJ, 1994, PROTEIN ENG, V7, P137, DOI 10.1093/protein/7.1.137; CULLINAN WE, 1991, ENZYME, V45, P285, DOI 10.1159/000468902; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; IGUCHI H, 1987, J NEUROCHEM, V49, P1810, DOI 10.1111/j.1471-4159.1987.tb02440.x; LAZURE C, 1991, INT J PEPT PROT RES, V38, P392; LINDBERG I, 1995, IN PRESS BIOCHEMISTR, V34; MARCINKIEWICZ M, 1987, CELL TISSUE RES, V250, P205, DOI 10.1007/BF00214673; MARTENS GJM, 1988, FEBS LETT, V234, P160, DOI 10.1016/0014-5793(88)81324-3; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MARTENS GJM, 1989, EUR J BIOCHEM, V181, P75, DOI 10.1111/j.1432-1033.1989.tb14695.x; MBIKAY M, 1989, INT J PEPT PROT RES, V33, P39; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; PAQUET L, 1994, J BIOL CHEM, V269, P19279; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SIGAFOOS J, 1993, CELL MOL NEUROBIOL, V13, P271, DOI 10.1007/BF00733755; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; STEEL JH, 1988, ENDOCRINOLOGY, V122, P270, DOI 10.1210/endo-122-1-270; STEINER DF, 1992, J BIOL CHEM, V267, P23435; VANDUIJNHOVEN HLP, 1991, J IMMUNOL METHODS, V142, P187, DOI 10.1016/0022-1759(91)90106-P; VIEAU D, 1991, J NEUROENDOCRINOL, V3, P229, DOI 10.1111/j.1365-2826.1991.tb00268.x; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; YI Z, 1993, J BIOL CHEM, V268, P5615	33	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14292	14296						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782286				2022-12-25	WOS:A1995RD45500012
J	AROCA, P; BOTTARO, DP; ISHIBASHI, T; AARONSON, SA; SANTOS, E				AROCA, P; BOTTARO, DP; ISHIBASHI, T; AARONSON, SA; SANTOS, E			HUMAN DUAL-SPECIFICITY PHOSPHATASE VHR ACTIVATES MATURATION PROMOTION FACTOR AND TRIGGERS MEIOTIC MATURATION IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; MAP KINASE; ONCOGENE PRODUCT; M-PHASE; CELL-DIVISION; RAS PROTEINS; INDUCTION; EXTRACTS; CDC25; MPF	Bacterially expressed, dual specificity phosphatase VHR protein induced germinal vesicle breakdown (GVBD) when microinjected into Xenopus oocytes, albeit with slower kinetics than that observed in progesterone- or insulin-induced maturation, A mutant VHR protein missing an essential cysteine residue for its in vitro phosphatase activity completely lacked activity in injected oocytes, VHR injection done in conjunction with progesterone or insulin treatment resulted in highly synergized GVBD responses showing much faster kinetics than that produced by VHR or either hormone alone, The delayed kinetics of VHR-induced GVBD and the synergistic responses obtained in the presence of hormones suggested that this protein may be promoting G(2)/M transition by weakly mimicking the action of cdc25, the dual specificity phosphatase that physiologically activates the maturation promotion factor. Various experimental observations are consistent with such a role for the injected VHR in oocytes: 1) as opposed to hormone-treated oocytes, histone H1 kinase activation is not preceded by MAPK activation in the process of GVBD in VHR-injected oocytes; 2) incubation of purified VHR with highly concentrated cell-free extracts of untreated oocytes resulted in activation of histone H1 kinase activity in the lysates; 3) coinjection of VHR with activated Ras proteins resulted in synergized responses, faster than those produced by either protein alone; 4) coinjection of VHR with the purified aminoterminal SH2 domain of the p85 subunit of phosphatidylinositol 3-kinase (which blocks insulin-induced GVBD) does not affect VHR-induced maturation. The biological actions of VHR in oocytes clearly distinguish it from other dual specificity phosphatases, which have shown inhibitory effects when tested in oocytes, We speculate that VHR may represent a dual specificity phosphatase responsible for activation of cdk-cyclin complex(es) at a still undetermined stage of the cell cycle.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Aroca, Pilar/P-2141-2017; Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Aroca, Pilar/0000-0002-7557-6931; Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				ALESSI DR, 1993, ONCOGENE, V8, P2015; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; ERIKSON E, 1990, J BIOL CHEM, V264, P13711; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GRAZIANI G, 1992, ONCOGENE, V7, P229; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; ISHIBASHI T, 1993, P NATL ACAD SCI USA, V89, P12170; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MARX J, 1994, SCIENCE, V263, P1093, DOI 10.1126/science.8108726; MARX J, 1994, SCIENCE, V263, P319, DOI 10.1126/science.8278804; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1992, METHOD CELL BIOL, V36, P581; NEBREDA AR, 1993, ONCOGENE, V8, P467; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1990, New Biologist, V2, P389; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	47	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14229	14234		10.1074/jbc.270.23.14229	http://dx.doi.org/10.1074/jbc.270.23.14229			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775484	Green Submitted, hybrid			2022-12-25	WOS:A1995RC44800092
J	BAECKSTROM, D; ZHANG, K; ASKER, N; RUETSCHI, U; EK, M; HANSSON, GC				BAECKSTROM, D; ZHANG, K; ASKER, N; RUETSCHI, U; EK, M; HANSSON, GC			EXPRESSION OF THE LEUKOCYTE-ASSOCIATED SIALOGLYCOPROTEIN CD43 BY A COLON-CARCINOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; WISKOTT-ALDRICH SYNDROME; MAJOR SIALOGLYCOPROTEIN; HUMAN-PLASMA; TUMOR-CELLS; LEUKOSIALIN; SIALOPHORIN; GLYCOPROTEINS; ADHESION; PROTEINS	The colon adenocarcinoma cell line COLO 205 secretes L-CanAg, a mucin-like glycoprotein carrying the carcinoma-associated sialyl-Lewis a carbohydrate epitope. In an attempt to identify its apoprotein, an NH2-terminal peptide sequence was obtained from purified L-CanAg. In all interpretable positions, this sequence showed 100% identity to the NH2-terminal of human CD43 (leukosialin, sialophorin), a plasma membrane bound sialoglycoprotein hitherto only identified in leukocytes and other hematopoietic cells. An antiserum against deglycosylated L-CanAg and an anti-CD43 antiserum both immunoprecipitated a 61-kDa band, interpreted as the CD43 precursor, from COLO 205 cells as well as hom the known CD43-expressing cell line HL-60. Results from immunoprecipitations following pulse-chase experiments and tunicamycin treatments were in agreement with earlier studies on the CD43 precursor. RNA blot analysis confirmed the expression of CD43 by the COLO 205 cell line, whereas three other colon carcinoma cell lines were negative. The glycosylation-dependent monoclonal antibody Leu-22, which recognizes leukocyte CD43, failed to bind L-CanAg, probably due to its much more extensive glycosylation, We conclude that L-CanAg is the secreted extracellular domain of a novel glycoform of CD43 and that CD43, if expressed in other carcinoma cells, may have escaped notice in studies relying on glycosylation-dependent monoclonal antibodies against leukocyte CD43.	GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT CLIN CHEM, S-41345 GOTHENBURG, SWEDEN	Sahlgrenska University Hospital; University of Gothenburg	BAECKSTROM, D (corresponding author), GOTHENBURG UNIV, DEPT MED BIOCHEM, MEDICINAREGATAN 9A, S-41390 GOTHENBURG, SWEDEN.		Hansson, Gunnar C./AAF-7324-2019; Hansson, Gunnar C/A-1236-2009	Hansson, Gunnar C./0000-0002-1900-1869; Hansson, Gunnar C/0000-0002-1900-1869; Johansson, Malin E. V./0000-0002-4237-6677				[Anonymous], 1994, PROGRAM MANUAL WISCO; ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; AXELSSON B, 1989, SCAND J IMMUNOL, V30, P539, DOI 10.1111/j.1365-3083.1989.tb02461.x; BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; BAECKSTROM D, 1993, CANCER RES, V53, P755; BAECKSTROM D, 1994, J BIOL CHEM, V269, P14430; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CARLSTEDT I, 1985, ESSAYS BIOCHEM, V20, P40; CARRAWAY KL, 1992, J CELL SCI, V103, P299; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; GUM JR, 1987, J BIOL CHEM, V262, P1092; HANSSON GC, 1994, BIOCHEM BIOPH RES CO, V198, P181, DOI 10.1006/bbrc.1994.1026; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; IOACHIM HL, 1994, INT J CANCER, P132; JOHANSSON C, 1991, TUMOR BIOL, V12, P159, DOI 10.1159/000217701; KRENOVA D, 1993, TRANSPL P, V25, P2797; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON LN, 1988, INT J CANCER, V42, P877, DOI 10.1002/ijc.2910420615; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MANJUNATH N, 1993, J IMMUNOL, V151, P1528; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; REMOLD-O'DONNELL E, 1990, Immunodeficiency Reviews, V2, P151; REMOLDODONNELL E, 1994, J IMMUNOL, V152, P3595; REMOLDODONNELL E, 1987, BIOCHEMISTRY-US, V26, P3908, DOI 10.1021/bi00387a025; REMOLDODONNELL E, 1986, J BIOL CHEM, V261, P7526; RIEU P, 1992, EUR J IMMUNOL, V22, P3021, DOI 10.1002/eji.1830221138; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SCHMID K, 1992, P NATL ACAD SCI USA, V89, P663, DOI 10.1073/pnas.89.2.663; SCHMID K, 1980, J BIOL CHEM, V255, P3221; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; WONG RCK, 1990, J IMMUNOL, V144, P1455; ZHANG K, 1994, INT J CANCER, V59, P823, DOI 10.1002/ijc.2910590619	39	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13688	13692		10.1074/jbc.270.23.13688	http://dx.doi.org/10.1074/jbc.270.23.13688			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775421	hybrid			2022-12-25	WOS:A1995RC44800018
J	FAULKNER, KM; BONAVENTURA, C; CRUMBLISS, AL				FAULKNER, KM; BONAVENTURA, C; CRUMBLISS, AL			A SPECTROELECTROCHEMICAL METHOD FOR DIFFERENTIATION OF STERIC AND ELECTRONIC EFFECTS IN HEMOGLOBINS AND MYOGLOBINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE BINDING; METHYLENE-BLUE; OXYGEN; AUTOXIDATION; OXIDATION; REDUCTION; STEREOCHEMISTRY; AUTOOXIDATION; MECHANISM; SITE	Spectroelectrochemical techniques are described which enable us to compare anion effects on redox curves of structurally distinct hemoglobins with oxygenation curves obtained under equivalent conditions. Nernst plots for tetrameric vertebrate Hbs show evidence of cooperativity, with the T state conformation more resistant to oxidation than the R state. Anions shift the conformation toward the T state and decrease the ease of oxidation, with variations in anion sensitivity similar to those observed in oxygen equilibria. Oxygen binding, unlike electron exchange, is known to be subject to steric constraints that vary considerably in natural and engineered hemoglobins that have differences in the distal residues of the heme pocket. Since oxidation curves are not subject to steric hindrance, anion-induced differences between the oxidation and oxygenation curves can be indicative of anion-induced alterations in the stereochemistry of the heme pocket that alters the ease of ligand entry or exit. Addition of inositol hexaphosphate to solutions of Hb A in 0.2 M nitrate generates such differences: the ease of electron abstraction from deoxy (T state) Hb A is unaffected, while, as previously reported, the oxygenation of deoxy (T state) Hb A is greatly hindered. The difference between inositol hexaphosphate effects on initial stages of oxidation and oxygenation indicates that the explanation for ''multiple T states'' in oxygen binding lies in the ability of the polyanion to greatly increase steric hindrance to ligand entry, without appreciable changes in the electronic features of the heme environment.	DUKE UNIV,DEPT CHEM,DURHAM,NC 27708; DUKE UNIV,SCH ENVIRONM,MARINE LAB,BEAUFORT,NC 28516	Duke University; Duke University								ABRAHAM EC, 1975, J BIOL CHEM, V250, P3929; ALAYASH AI, 1992, ARCH BIOCHEM BIOPHYS, V298, P114, DOI 10.1016/0003-9861(92)90101-2; ANTONINI E, 1964, J BIOL CHEM, V239, P907; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BANERJEE R, 1969, J MOL BIOL, V42, P337, DOI 10.1016/0022-2836(69)90047-3; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNORI M, 1964, J BIOL CHEM, V239, P2340; BRUNORI M, 1968, J BIOL CHEM, V243, P2950; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CHANG CK, 1975, P NATL ACAD SCI USA, V72, P1166, DOI 10.1073/pnas.72.3.1166; DESBOIS A, 1975, J MOL BIOL, V92, P479, DOI 10.1016/0022-2836(75)90293-4; DICERA E, 1987, BIOCHEMISTRY-US, V26, P6494, DOI 10.1021/bi00394a031; DONG SJ, 1989, BIOELECTROCH BIOENER, V21, P233, DOI 10.1016/0302-4598(89)85003-2; EDELSTEIN SJ, 1975, J BIOL CHEM, V250, P961; ELLIS WR, 1986, THESIS CALTECH PASAD; FULTZ ML, 1982, ANAL CHIM ACTA, V140, P1, DOI 10.1016/S0003-2670(01)95447-9; GEIBEL J, 1978, J AM CHEM SOC, V100, P3575, DOI 10.1021/ja00479a047; GREENWALD RA, 1985, CRC HDB METHODS OXYG, P137; HEINEMAN WR, 1975, ANAL CHEM, V47, P79, DOI 10.1021/ac60351a001; Imai K., 1982, ALLOSTERIC EFFECTS H; JOHNSON ME, 1974, BIOCHEMISTRY-US, V13, P3653, DOI 10.1021/bi00715a005; Kiese M., 1974, METHEMOGLOBINEMIA CO; KRISTENSEN EW, 1991, J ELECTROANAL CHEM, V309, P61, DOI 10.1016/0022-0728(91)87004-N; LINSTROM T, 1973, BIOCHEMISTRY-US, V12, P134; MATTHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MISRA HP, 1972, J BIOL CHEM, V247, P6960; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; OLSON JS, 1976, P NATL ACAD SCI USA, V73, P1140, DOI 10.1073/pnas.73.4.1140; PERRELLA M, 1990, BIOPHYS CHEM, V35, P97, DOI 10.1016/0301-4622(90)80064-E; Perrella M, 1981, Methods Enzymol, V76, P133; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PERUTZ MF, 1990, MECHANISMS COOPERATI; REISBERG PI, 1980, J BIOL CHEM, V255, P4144; RIFKIND JM, 1974, BIOCHEMISTRY-US, V13, P2475, DOI 10.1021/bi00709a003; RIGGS AF, 1956, J GEN PHYSIOL, V39, P585, DOI 10.1085/jgp.39.4.585; ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425a0; RUBIN MM, 1966, J MOL BIOL, V21, P265, DOI 10.1016/0022-2836(66)90097-0; SHIKAMA K, 1984, BIOCHEM J, V223, P279, DOI 10.1042/bj2230279; SONG SH, 1988, BIOELECTROCH BIOENER, V19, P337, DOI 10.1016/0302-4598(88)80014-X; SUSLICK KS, 1984, J AM CHEM SOC, V106, P4522, DOI 10.1021/ja00328a036; Taylor JF, 1942, J BIOL CHEM, V144, P15; TAYLOR JOHN FULLER, 1939, JOUR BIOL CHEM, V131, P649; TRAYLOR TG, 1980, J AM CHEM SOC, V102, P5939, DOI 10.1021/ja00538a055; TRAYLOR TG, 1982, ANNU REV BIOPHYS BIO, V11, P105, DOI 10.1146/annurev.bb.11.060182.000541; WINTERBOURN CC, 1985, ENVIRON HEALTH PERSP, V64, P321, DOI 10.2307/3430020; WOPSCHALL RH, 1967, ANAL CHEM, V39, P1527, DOI 10.1021/ac50156a019; YE JN, 1988, ANAL CHEM, V60, P2263, DOI 10.1021/ac00171a021	49	78	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13604	13612		10.1074/jbc.270.23.13604	http://dx.doi.org/10.1074/jbc.270.23.13604			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775411	hybrid			2022-12-25	WOS:A1995RC44800007
J	LI, QX; EVIN, G; SMALL, DH; MULTHAUP, G; BEYREUTHER, K; MASTERS, CL				LI, QX; EVIN, G; SMALL, DH; MULTHAUP, G; BEYREUTHER, K; MASTERS, CL			PROTEOLYTIC PROCESSING OF ALZHEIMERS-DISEASE BETA-A4 AMYLOID PRECURSOR PROTEIN IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; HUMAN BRAIN; CALPAIN; IDENTIFICATION; PEPTIDE; CALCIUM; CELLS; INHIBITOR; PURIFICATION; EXPRESSION	The processing of amyloid precursor protein (APP) and production of beta A4 amyloid are events likely to influence the development and progression of Alzheimer's disease, since beta A4 is the major constituent of amyloid deposited in this disorder. Our previous studies showed that human platelets contain full-length APP (APP(FL)) and are a suitable substrate to study normal APP processing, In the present study, we show that a 22-kDa beta A4-containing carboxyl-terminal fragment (22-CTF) of APP is present in unstimulated platelets. Both APP(FL) and 22-CTF are proteolytically degraded when platelets are activated with thrombin, collagen, or calcium ionophore A23187. Complete cleavage of APP(FL) and 22-CTF require the presence of extracellular calcium, Following stimulation in the presence of calcium, a new CTF of 17 kDa is generated, and the NH2-terminal epitope of beta A4 amyloid is lost. Preincubation of platelets with the cell-permeable cysteine protease inhibitors calpeptin, (2S,3S)-trans-epoxysuccinyl-L-leucyl-amido-3-methylbutane ethyl ester (E64d), Na-alpha-p-tosyl-L-lysine chloromethyl ketone, or calcium chelator EGTA before platelet stimulation inhibits the degradation of both APP(FL) and 22-CTF. Divalent metal ions including zinc, copper, and cobalt inhibit the degradation of APP(FL) and 22-CTF. This study suggests that a calcium-dependent neutral cysteine protease is involved in the proteolytic processing of an amyloidogenic species of APP in human platelets.	UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL PK HOSP,MENTAL HLTH RES INST VICTORIA,PARKVILLE,VIC 3052,AUSTRALIA; UNIV HEIDELBERG,CTR MOLEC BIOL,W-6900 HEIDELBERG,GERMANY	University of Melbourne; Ruprecht Karls University Heidelberg			Evin, Genevieve M/E-5891-2013					ARIYOSHI H, 1991, BIOCHEM INT, V23, P1019; ASHALL F, 1994, TRENDS BIOCHEM SCI, V19, P42, DOI 10.1016/0968-0004(94)90173-2; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1990, J BIOL CHEM, V265, P15977; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COLE GM, 1990, BIOCHEM BIOPH RES CO, V170, P288, DOI 10.1016/0006-291X(90)91272-T; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; FOX JEB, 1990, BLOOD, V76, P2510; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FURUKAWA K, 1994, BRAIN RES, V662, P259, DOI 10.1016/0006-8993(94)90822-2; GARDELLA JE, 1992, LAB INVEST, V67, P303; GHISO J, 1994, NEUROSCI LETT, V171, P213, DOI 10.1016/0304-3940(94)90642-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HILBICH C, 1993, J BIOL CHEM, V268, P26571; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KNOPS J, 1992, J BIOL CHEM, V267, P16022; KONIG G, 1992, J BIOL CHEM, V267, P10804; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LI QX, 1994, BLOOD, V84, P133, DOI 10.1182/blood.V84.1.133.133; MATSUMOTO A, 1993, EUR J BIOCHEM, V217, P21, DOI 10.1111/j.1432-1033.1993.tb18213.x; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MCGOWAN EB, 1983, ARCH BIOCHEM BIOPHYS, V227, P287, DOI 10.1016/0003-9861(83)90373-9; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; NILSSON E, 1990, NEUROBIOL AGING, V11, P425, DOI 10.1016/0197-4580(90)90009-O; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; ODA A, 1993, J BIOL CHEM, V268, P12603; PETERSON C, 1986, P NATL ACAD SCI USA, V83, P7999, DOI 10.1073/pnas.83.20.7999; PETERSON C, 1991, NEUROSCI LETT, V121, P239, DOI 10.1016/0304-3940(91)90694-O; PHILLIPS DR, 1977, J BIOL CHEM, V252, P5602; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SCHLOSSMACHER MG, 1992, NEUROBIOL AGING, V13, P421, DOI 10.1016/0197-4580(92)90117-G; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH RP, 1992, BLOOD, V80, P2252; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; VANNOSTRAND WE, 1991, BIOCHEM BIOPH RES CO, V175, P15, DOI 10.1016/S0006-291X(05)81193-3; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YANO Y, 1993, THROMB RES, V71, P385, DOI 10.1016/0049-3848(93)90163-I; YOSHIDA N, 1983, J BIOL CHEM, V258, P7168; ZHONG ZY, 1994, J BIOL CHEM, V269, P12179	66	104	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14140	14147		10.1074/jbc.270.23.14140	http://dx.doi.org/10.1074/jbc.270.23.14140			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775475	hybrid			2022-12-25	WOS:A1995RC44800080
J	RINDISBACHER, L; COTTET, S; WITTEK, R; KRAEHENBUHL, JP; CORTHESY, B				RINDISBACHER, L; COTTET, S; WITTEK, R; KRAEHENBUHL, JP; CORTHESY, B			PRODUCTION OF HUMAN SECRETORY COMPONENT WITH DIMERIC IGA BINDING-CAPACITY USING VIRAL EXPRESSION SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-EPITHELIAL TRANSPORT; INFECTIOUS VACCINIA VIRUS; HUMAN GASTRIC EPITHELIUM; 5' FLANKING SEQUENCE; IMMUNOGLOBULIN-A IGA; PROTEOLYTIC DEGRADATION; HELICOBACTER-PYLORI; CHOLERA-TOXIN; POLYMERIC IG; INSECT CELLS	The cDNA encoding the NH2-terminal 589 amino acids of the extracellular domain of the human polymeric immunoglobulin receptor was inserted into transfer vectors to generate recombinant baculo- and vaccinia viruses. Following infection of insect and mammalian cells, respectively, the resulting truncated protein corresponding to human secretory component (hSC) was secreted with high efficiency into serum-free culture medium. The Sf9 insect cell/baculovirus system yielded as much as 50 mg of hSC/liter of culture, while the mammalian cells/vaccinia virus system produced up to 10 mg of protein/liter. The M(r) of recombinant hSC varied depending on the cell line in which it was expressed (70,000 in Sf9 cells and 85-95,000 in CV-1, TK- 143B and HeLa). These variations in M(r) resulted from different glycosylation patterns, as evidenced by endoglycosidase digestion. Efficient single-step purification of the recombinant protein was achieved either by concanavalin A affinity chromatography or by Ni2+-chelate affinity chromatography, when a 6xHis tag was engineered to the carboxyl terminus of hSC. Recombinant hSC retained the capacity to specifically reassociate with dimeric IgA purified from hybridoma cells.	UNIV LAUSANNE, INST BIOL ANIM, CH-1015 LAUSANNE, SWITZERLAND; SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND; UNIV LAUSANNE, INST BIOCHEM, CH-1066 EPALINGES, SWITZERLAND	University of Lausanne; Swiss Institute Experimental Cancer Research; University of Lausanne								APTER FM, 1993, INFECT IMMUN, V61, P5279, DOI 10.1128/IAI.61.12.5279-5285.1993; APTER FM, 1993, INFECT IMMUN, V61, P5271, DOI 10.1128/IAI.61.12.5271-5278.1993; BAKOS MA, 1991, J IMMUNOL, V147, P3419; BAKOS MA, 1994, MOL IMMUNOL, V31, P165, DOI 10.1016/0161-5890(94)90088-4; BERTHOLET C, 1986, EMBO J, V5, P1951, DOI 10.1002/j.1460-2075.1986.tb04449.x; BERTHOLET C, 1985, P NATL ACAD SCI USA, V82, P2096, DOI 10.1073/pnas.82.7.2096; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; BRANDTZAEG P, 1989, CURR TOP MICROBIOL, V146, P13; BROWN WR, 1970, J CLIN INVEST, V49, P1374, DOI 10.1172/JCI106354; DRILLIEN R, 1983, VIROLOGY, V131, P385, DOI 10.1016/0042-6822(83)90506-8; EIFFERT H, 1984, H-S Z PHYSIOL CHEM, V365, P1489, DOI 10.1515/bchm2.1984.365.2.1489; ELBEIN AD, 1982, J BIOL CHEM, V257, P1573; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; GARCIAPARDO A, 1979, MOL IMMUNOL, V16, P477; HANGGI M, 1986, EMBO J, V5, P1071, DOI 10.1002/j.1460-2075.1986.tb04324.x; HARLOW E, 1988, ANTIBODIES LABORATOR; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853; KRAEHENBUHL JP, 1992, TRENDS CELL BIOL, V2, P134; KRAJCI P, 1989, BIOCHEM BIOPH RES CO, V158, P783, DOI 10.1016/0006-291X(89)92790-3; KUHN LC, 1982, TRENDS BIOCHEM SCI, V7, P299, DOI 10.1016/0968-0004(82)90017-2; LEE CK, 1994, INFECT IMMUN, V62, P887, DOI 10.1128/IAI.62.3.887-891.1994; LINDH E, 1977, ACTA PATH MICRO IM C, V85, P449; LINDH E, 1975, J IMMUNOL, V114, P284; MACKETT M, 1982, P NATL ACAD SCI-BIOL, V79, P7415, DOI 10.1073/pnas.79.23.7415; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; MCCUNE JM, 1981, J EXP MED, V154, P138, DOI 10.1084/jem.154.1.138; MESTECKY J, 1991, GASTROENTEROL CLIN N, V20, P441; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MILLER LK, 1993, CURR OPIN GENET DEV, V3, P97, DOI 10.1016/S0959-437X(05)80348-X; MIZOGUCHI A, 1982, J BIOL CHEM, V257, P9612; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; NEUTRA MR, 1994, AM J TROP MED HYG, V50, P10; PANICALI D, 1982, P NATL ACAD SCI-BIOL, V79, P4927, DOI 10.1073/pnas.79.16.4927; PARKHOUSE RM, 1973, BIOCHEM J, V136, P607, DOI 10.1042/bj1360607; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PIWNICAWORMS H, 1990, CURRENT PROTOCOLS S, V13; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; PUTLITZ JZ, 1990, BIO-TECHNOL, V8, P651, DOI 10.1038/nbt0790-651; Sambrook J, 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAERER E, 1991, J MEMBRANE BIOL, V123, P93, DOI 10.1007/BF01998081; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555, P1; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; UNDERDOWN BJ, 1974, J IMMUNOL, V112, P949; WELTZIN R, 1989, J CELL BIOL, V108, P1673, DOI 10.1083/jcb.108.5.1673; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	56	48	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14220	14228		10.1074/jbc.270.23.14220	http://dx.doi.org/10.1074/jbc.270.23.14220			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775483	hybrid			2022-12-25	WOS:A1995RC44800091
J	SHARMA, S; ROSE, DR				SHARMA, S; ROSE, DR			CLONING, OVEREXPRESSION, PURIFICATION, AND CHARACTERIZATION OF THE CARBOXYL-TERMINAL NUCLEOTIDE-BINDING DOMAIN OF P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; MULTIDRUG RESISTANCE; CYSTIC-FIBROSIS; MALTOSE-BINDING; PERIPLASMIC PERMEASES; STRUCTURAL MODEL; DRUG TRANSPORT; ATP HYDROLYSIS; GENE-PRODUCT; IDENTIFICATION	Multidrug-resistant tumor cells overexpress P-glycoprotein (170 kDa), a member of the ABC (ATP Binding Cassette)-transporter superfamily. P-glycoprotein has been implicated in transport of a broad range of amphiphilic, hydrophobic drugs from tumor cells. The sequence and structural organization of P-glycoprotein, which consists of 12 transmembrane helices and two cytoplasmic nucleotide binding domains, is similar to other ABC-transporters. It is believed that-the nucleotide binding domains of various ABC transporters, which have 30-50% sequence identity, play an important role in coupling ATP hydrolysis to the transport process. To allow structure-function studies of the nucleotide binding domains, the carboxyl-terminal nucleotide binding domain (NBD) of Chinese hamster P-gly-coprotein has been cloned, overexpressed, and purified both by itself and as a fusion with maltose-binding protein. It has been demonstrated that the carboxyl-terminal NBD, when overexpressed in Escherichia coli in the absence of transmembrane helices, has very low ATPase activity. This suggests that the amino-terminal nucleotide binding domain and possibly interaction with the transmembrane domains may be required for full ATPase activity. It is also consistent with the idea that the ATPase activity of P-glycoprotein is stimulated in the presence of drugs. Circular dichroism spectral analysis and the ability of carboxyl-terminal NBD, both by itself and as a fusion with maltose-binding protein, to bind ATP-agarose beads and P-glycoprotein specific monoclonal antibodies suggests that the polypeptide folds into a functional domain. Gel filtration chromatography and cross-linking studies indicate that the carboxyl-terminal NBD has a tendency to self-associate to form oligomers. It is speculated that the carboxyl-terminal NBD may play a role in self-association of P-glycoprotein molecules in the plasma membrane.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA	University of Toronto	SHARMA, S (corresponding author), UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M4X 1K9,CANADA.							ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1993, P NATL ACAD SCI USA, V89, P8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CLIFFLET S, 1988, ANAL BIOCHEM, V168, P1; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GALLAGHER MP, 1989, EUR J BIOCHEM, V180, P133, DOI 10.1111/j.1432-1033.1989.tb14623.x; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1993, ANN REV BIOCH, V92, P385; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GUAN C, 1987, GENE, V67, P21; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KESSEL D, 1968, CANCER RES, V28, P938; KO YH, 1993, J BIOL CHEM, V268, P24330; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; LELONG IH, 1992, FEBS LETT, V304, P256, DOI 10.1016/0014-5793(92)80632-Q; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MAMAN JD, 1994, BIOCHEMISTRY-US, V33, P1300, DOI 10.1021/bi00172a003; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SHUMAN HA, 1980, J BIOL CHEM, V256, P560; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; 1992, PET SYSTEM MANUAL	40	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14085	14093		10.1074/jbc.270.23.14085	http://dx.doi.org/10.1074/jbc.270.23.14085			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775470	hybrid			2022-12-25	WOS:A1995RC44800073
J	ONRUST, R; FINKELSTEIN, J; TURNER, J; NAKTINIS, V; ODONNELL, M				ONRUST, R; FINKELSTEIN, J; TURNER, J; NAKTINIS, V; ODONNELL, M			ASSEMBLY OF A CHROMOSOMAL REPLICATION MACHINE - 2 DNA-POLYMERASES, A CLAMP LOADER, AND SLIDING CLAMPS IN ONE HOLOENZYME PARTICLE .3. INTERFACE BETWEEN TWO POLYMERASES AND THE CLAMP LOADER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III ACCESSORY PROTEINS; ESCHERICHIA-COLI; SUBUNIT; GENE; IDENTIFICATION; CHI; PSI; OVEREXPRESSION; GAMMA; TAU	The nine-subunit DNA polymerase (Pol) III* coupled to its beta sliding clamp is a rapid and highly processive replicating machine. The multiple subunits are needed for the complicated task of duplicating the Escherichia coli chromosome. In this report, Pol III* was constituted from individual pure proteins, and its structure was studied. Constitution of the Pol III* particle requires an ordered addition of the subunits, and the final structure contains 14 polypeptides in the ratio alpha(2) epsilon(2) theta(2) tau(2) gamma(2) delta(1) delta(1)' chi(1) psi(1). The structure can be summarized as being composed of two core polymerases (alpha epsilon theta) held together by a dimer of tau and one gamma complex clamp loader (gamma(2) delta(1) delta(1)'chi(1) psi(1)) for loading beta onto DNA. At the center of the structure, the related tau and gamma subunits form a heterotetramer upon which the two core polymerases and clamp loader proteins assemble. The single copy nature of the delta, delta', chi, and psi subunits confers a structural asymmetry with respect to the two polymerases, presumably for the different functions of replicating the leading and lagging strands.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HEARST RES FDN,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute; Cornell University; Cornell University					NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; CARTER JR, 1993, NUCLEIC ACIDS RES, V21, P3281, DOI 10.1093/nar/21.14.3281; CARTER JR, 1993, J BACTERIOL, V175, P5604, DOI 10.1128/JB.175.17.5604-5610.1993; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; CARTER JR, 1993, MOL GEN GENET, V241, P399, DOI 10.1007/BF00284693; CARTER JR, 1993, J BACTERIOL, V174, P7013; DONG ZM, 1993, J BIOL CHEM, V268, P11758; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; Kornberg A., 1992, DNA REPLICATION, P165; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1992, BIOESSAYS, V14, P105, DOI 10.1002/bies.950140206; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; ONRUST R, 1993, THESIS CORNELL U; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; XIAO H, 1993, J BIOL CHEM, V268, P11779; XIAO H, 1993, J BIOL CHEM, V268, P11773; XIAO H, 1995, J BIOL CHEM, P13378; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	25	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13366	13377		10.1074/jbc.270.22.13366	http://dx.doi.org/10.1074/jbc.270.22.13366			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768938	hybrid			2022-12-25	WOS:A1995RB43900063
J	STUKENBERG, PT; ODONNELL, M				STUKENBERG, PT; ODONNELL, M			ASSEMBLY OF A CHROMOSOMAL REPLICATION MACHINE - 2 DNA-POLYMERASES, A CLAMP LOADER, AND SLIDING CLAMPS IN ONE HOLOENZYME PARTICLE .5. 4 DIFFERENT POLYMERASE CLAMP COMPLEXES ON DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III HOLOENZYME; ESCHERICHIA-COLI; ACCESSORY PROTEINS; SIZE CLASSES; SUBUNIT; PURIFICATION; FORK	Several different subassemblies of DNA polymerase III holoenzyme can be purified from Escherichia coli. Toward the goal of understanding the functional significance of these subassemblies, we have used the gamma complex clamp loader and the beta ring to assemble each different polymerase onto DNA. Through use of radioactive labeled proteins, the subunit structure of each resulting processive polymerase has been determined. Use of DNA polymerase III core, the gamma complex, and beta results in a core-beta complex on DNA; the gamma complex is not incorporated into the structure. The addition of tau to the assembly reaction to form either core(1)-tau(2) or core(2)-tau(2) results in a more efficient polymerase and more stabile association of core-tau beta on DNA, although the gamma complex still does not remain on DNA. The gamma complex clamp loader was retained on DNA with the other subunits only if it was first assembled into the polymerase (Pol) III* structure. The clamp loader within Pol III* appeared to be capable of loading two beta clamps onto DNA for both core polymerases within Pol III*, consistent with the hypothesis that one replicase can simultaneously replicate both strands of a duplex chromosome. These findings extend those of an earlier study showing that distinctive polymerases can be assembled depending on the presence or absence of tau (Maki, S., and Kornberg, A (1988) J. Biol. Chem. 263, 6561-6569). The significance of these distinct polymerases in separate paths of DNA metabolism is discussed.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HEARST RES FDN,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute; Cornell University; Cornell University				Stukenberg, Todd/0000-0002-6788-2111	NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI N, 1981, J BIOL CHEM, V256, P5294; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FRADKIN LG, 1992, J BIOL CHEM, V267, P10318; GREENSTEIN D, 1987, J MOL BIOL, V197, P157, DOI 10.1016/0022-2836(87)90115-X; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KELMAN Z, 1995, IN PRESS METHODS ENZ, V262; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MAKI S, 1988, J BIOL CHEM, V263, P6561; MEYER TF, 1979, J BIOL CHEM, V254, P2636; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; SINHA NK, 1980, J BIOL CHEM, V225, P4290; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1993, THESIS CORNELL U; XIAO H, 1993, J BIOL CHEM, V268, P11773; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	27	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13384	13391		10.1074/jbc.270.22.13384	http://dx.doi.org/10.1074/jbc.270.22.13384			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768940	hybrid			2022-12-25	WOS:A1995RB43900065
J	WAXMAN, DJ; RAM, PA; PARK, SH; CHOI, HK				WAXMAN, DJ; RAM, PA; PARK, SH; CHOI, HK			INTERMITTENT PLASMA GROWTH-HORMONE TRIGGERS TYROSINE PHOSPHORYLATION AND NUCLEAR TRANSLOCATION OF A LIVER-EXPRESSED, STAT 5-RELATED DNA-BINDING PROTEIN - PROPOSED ROLE AS AN INTRACELLULAR REGULATOR OF MALE-SPECIFIC LIVER GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEXUALLY DIMORPHIC EXPRESSION; C-FOS; RAT-LIVER; HYPOPHYSECTOMIZED RATS; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; PROLACTIN RECEPTOR; SECRETORY PATTERN; ULTRADIAN PATTERN; KINASE	Growth hormone (GH) exerts sexually dimorphic effects on liver gene transcription that are regulated by the temporal pattern of pituitary GH release, which is intermittent in male rats and nearly continuous in females. To investigate the influence of these GH secretory patterns on intracellular hepatocyte signaling, we compared the pattern of Liver nuclear protein tyrosine phosphorylation in male and female rats. An M(r) similar to 93,000 polypeptide, p93, was found to be tyrosine phosphorylated to a high level in male but not female rats. GH, but not prolactin, rapidly stimulated p93 tyrosine phosphorylation in hypophysectomized rats. Intermittent plasma GH pulses triggered repeated p93 phosphorylation, while continuous GH exposure led to desensitization and a dramatic decline in Liver nuclear p93. p93 was cross-reactive with two monoclonal antibodies raised to mammary Stat 5, whose tyrosine phosphorylation is stimulated by prolactin. Intermittent GH pulsation translocated Liver Stat 5/p93 protein from the cytosol to the nucleus and also activated its DNA binding activity, as demonstrated using a mammary Stat 5-binding DNA element derived from the beta-casein gene. p93 is thus a liver-expressed, Stat 5-related DNA binding protein that undergoes tyrosine phosphorylation and nuclear translocation in response to intermittent plasma GH stimulation and is proposed to be an intracellular mediator of the stimulatory effects of GH pulses on male-specific liver gene expression.			WAXMAN, DJ (corresponding author), BOSTON UNIV,DEPT BIOL,DIV CELL & MOLEC BIOL,5 CUMMINGTON ST,BOSTON,MA 02215, USA.			Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK033765, R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1992, J BIOL CHEM, V267, P22095; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASPLIN CM, 1989, J CLIN ENDOCR METAB, V69, P239, DOI 10.1210/jcem-69-2-239; BAXTER RC, 1984, ENDOCRINOLOGY, V115, P2009, DOI 10.1210/endo-115-5-2009; BICK T, 1992, ENDOCRINOLOGY, V131, P423, DOI 10.1210/en.131.1.423; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; COLOSI P, 1993, J BIOL CHEM, V268, P12617; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; JANSSON JO, 1988, J CLIN INVEST, V82, P1871, DOI 10.1172/JCI113804; JANSSON JO, 1987, ENDOCRINOLOGY, V120, P1551, DOI 10.1210/endo-120-4-1551; JANSSON JO, 1982, ACTA PHYSIOL SCAND, V114, P261, DOI 10.1111/j.1748-1716.1982.tb06980.x; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; JEFFERY S, 1990, BIOCHEM J, V266, P69, DOI 10.1042/bj2660069; JOHNSON RJ, 1988, J ENDOCRINOL, V119, P101, DOI 10.1677/joe.0.1190101; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MACLEOD JN, 1991, J ENDOCRINOL, V131, P395, DOI 10.1677/joe.0.1310395; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MODE A, 1982, ENDOCRINOLOGY, V111, P1692, DOI 10.1210/endo-111-5-1692; MOLLER C, 1992, J BIOL CHEM, V267, P23403; NAGANO M, 1994, J BIOL CHEM, V269, P13337; PAMPORI NA, 1991, BIOCHEM PHARMACOL, V41, P1299, DOI 10.1016/0006-2952(91)90101-A; PAMPORI NA, 1991, ACTA ENDOCRINOL-COP, V124, P283, DOI 10.1530/acta.0.1240283; POSTELVINAY MC, 1976, FEBS LETT, V69, P137, DOI 10.1016/0014-5793(76)80670-9; RAZ R, 1994, J BIOL CHEM, V269, P24391; ROBERTSON JA, 1990, MOL ENDOCRINOL, V4, P1235, DOI 10.1210/mend-4-8-1235; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; RUI H, 1994, J BIOL CHEM, V269, P5364; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SRIVASTAVA PK, 1993, BIOCHEM J, V294, P159, DOI 10.1042/bj2940159; STROM A, 1994, DNA CELL BIOL, V13, P805, DOI 10.1089/dna.1994.13.805; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; TIONG TS, 1991, ENDOCRINOLOGY, V129, P1628, DOI 10.1210/endo-129-3-1628; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG X, 1994, P NATL ACAD SCI USA, V91, P1361; WANG XY, 1993, J BIOL CHEM, V268, P3573; WASMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055; WAXMAN DJ, 1988, J BIOL CHEM, V263, P11396; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; WESTIN S, 1992, J STEROID BIOCHEM, V43, P1045, DOI 10.1016/0960-0760(92)90332-D; WINER LM, 1990, J CLIN ENDOCR METAB, V70, P1678, DOI 10.1210/jcem-70-6-1678; YAMADA K, 1984, BIOCHEM J, V220, P361, DOI 10.1042/bj2200361; YAMAZOE Y, 1989, MOL PHARMACOL, V35, P707; Zaphiropoulos P G, 1988, Acta Med Scand Suppl, V723, P161; ZHAO SP, 1994, FASEB J, V8, pA1250; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	69	208	210	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13262	13270		10.1074/jbc.270.22.13262	http://dx.doi.org/10.1074/jbc.270.22.13262			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768925	hybrid			2022-12-25	WOS:A1995RB43900049
J	KINOSHITA, T; YOKOTA, T; ARAI, KI; MIYAJIMA, A				KINOSHITA, T; YOKOTA, T; ARAI, KI; MIYAJIMA, A			REGULATION OF BCL-2 EXPRESSION BY ONCOGENIC RAS PROTEIN IN HEMATOPOIETIC-CELLS	ONCOGENE			English	Article						APOPTOSIS; INTERLEUKIN; COLONY-STIMULATING FACTOR; BCL-X; CELL SURVIVAL	COLONY-STIMULATING FACTOR; COMMON BETA-SUBUNIT; C-MYC; SIGNAL-TRANSDUCTION; TYROSINE KINASE; BONE-MARROW; GM-CSF; APOPTOSIS; DEATH; INTERLEUKIN-3	Interleukin 3 (IL-3) and granulocyte-macrophage colony stimulating factor (GM-CSF) induce DNA synthesis and suppress apoptosis of hematopoietic cells. IL3/GM-CSF exert pleiotropic functions by activating multiple signaling cascades through distinct domains of the common receptor subunit. As we previously reported, the Ras signaling pathway plays a pivotal role in suppressing apoptotic death rather than stimulating DNA synthesis in IL-3 dependent hematopoietic cells. In order to clarify the molecular basis of Ras-induced cell survival, we investigated the effect of Ras activation on the expression of Bcl-2 and its related molecules. Activation of the Ras pathway by using an inducible oncogenic Ras resulted in the rapid up-regulation of bcl-2 and bcl-x(L), and the level of expression was nearly equivalent to that observed in growing cells. On the other hand, expression of bar, an antagonistic bcl-2 homologue, was not affected by oncogenic Ras or IL-3-deprivation. Thus, the Ras pathway regulates the expression of Bcl-2 and its related survival protein, and this appears to underlie the mechanism by which IL3/GM-CSF inhibit apoptosis through activation of the Ras pathway.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT CELL BIOL,PALO ALTO,CA 94304; UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MOLEC & CELLULAR BISCI,BUNKYO KU,TOKYO 113,JAPAN	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Tokyo; University of Tokyo			Yokota, Takashi/J-8483-2015					ALLEN PD, 1993, BLOOD REV, V7, P63, DOI 10.1016/0268-960X(93)90025-Y; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Cormier F, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104811; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; ITOH N, 1993, J IMMUNOL, V151, P621; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NUNEZ G, 1990, J IMMUNOL, V14, P3602; OKUDA K, 1994, J BIOL CHEM, V269, P24602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REED JC, 1994, J CELL BIOL, V124, P537; SAKAMAKI, 1994, FEBS LETT, V353, P133; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIROUZU M, 1992, ONCOGENE, V7, P475; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TORIGOE T, 1992, BLOOD, V80, P617; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1057; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	47	156	158	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2207	2212						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784065				2022-12-25	WOS:A1995RB70300016
J	LOLKEMA, JS; POOLMAN, B				LOLKEMA, JS; POOLMAN, B			UNCOUPLING IN SECONDARY TRANSPORT PROTEINS - A MECHANISTIC EXPLANATION FOR MUTANTS OF LAC PERMEASE WITH AN UNCOUPLED PHENOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LACTOSE CARRIER; ESCHERICHIA-COLI; PROTONS; HISTIDINE-322; PHENYLALANINE; REPLACEMENT; TYROSINE; KINETICS; EFFLUX; PH	The kinetic behavior of a H+-substrate symporter has been studied in which in addition to the unloaded (E) and fully loaded states (E.S.H) of the carrier also one of the binary complexes (E.S or E.H) may reorient its binding sites. This results in two types of uncoupled mutants, the ES leak and the EH leak type, The effects of pH and substrate concentration (pS) on the coupling of transport have been analyzed, In the enzyme with the ES leak, the proton:substrate stoichiometry (v(H+)lv(S)) and the substrate accumulation levels decrease sigmoidally from fully coupled at low pH to completely uncoupled at high pH. Importantly, the coupling inferred from initial rate measurements is higher than from steady state accumulation levels. In the enzyme with the EH leak, the coupling inferred from the accumulation levels increases hom no coupling at low pH to full coupling at high pH and saturating substrate concentration, The v(H+)/v(S) increases sigmoidally with pH from <1 to >1 and is highly dependent on pS. At each pH value a substrate concentration can be found that results in apparent complete coupling between the two fluxes. The ES leak and the ER leak mutants provide a mechanism for substrate-induced and substrate-inhibited proton leakage, respectively, Furthermore, substrate efflux down a concentration gradient is inhibited by a membrane potential (inside negative) under uncoupled conditions in the case of an ES leak but not in the case of an EH leak. The properties of the mutants mimic those of various transport mutants that have been described, in particular mutants of the lactose transport protein of Escherichia coli. The analysis offers general means for targeted experimentation, which allows discrimination between various types of transport mutants.			LOLKEMA, JS (corresponding author), UNIV GRONINGEN,GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST,DEPT MICROBIOL,KERKLAAN 30,9751 NN HAREN,NETHERLANDS.							BROOKER RJ, 1985, J BIOL CHEM, V260, P6181; BROOKER RJ, 1990, J BIOL CHEM, V265, P4155; BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; FRANCO PJ, 1991, J BIOL CHEM, V266, P6693; GARCIA ML, 1983, BIOCHEMISTRY-US, V22, P2524, DOI 10.1021/bi00279a033; KABACK HR, 1990, BACTERIA, V12, P151; KING SC, 1989, J BIOL CHEM, V264, P7390; KING SC, 1990, J BIOL CHEM, V265, P3153; KING SC, 1990, J BIOL CHEM, V265, P9645; KRUPKA RM, 1993, BIOCHIM BIOPHYS ACTA, V1183, P105, DOI 10.1016/0005-2728(93)90009-5; LOLKEMA JS, 1993, J BIOL CHEM, V268, P17850; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; MATZKE EA, 1992, J BIOL CHEM, V267, P19095; PAGE MGP, 1987, BIOCHIM BIOPHYS ACTA, V897, P112, DOI 10.1016/0005-2736(87)90319-1; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; PUTTNER IB, 1989, BIOCHEMISTRY-US, V28, P2525, DOI 10.1021/bi00432a027; VIITANEN P, 1993, BIOCHEMISTRY-US, V22, P2524	17	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12670	12676		10.1074/jbc.270.21.12670	http://dx.doi.org/10.1074/jbc.270.21.12670			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759518	hybrid, Green Submitted			2022-12-25	WOS:A1995QZ71100054
J	SZYF, M; THEBERGE, J; BOZOVIC, V				SZYF, M; THEBERGE, J; BOZOVIC, V			RAS INDUCES A GENERAL DNA DEMETHYLATION ACTIVITY IN MOUSE EMBRYONAL P19 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLATION PATTERNS; CARCINOMA-CELLS; EXPRESSION; DIFFERENTIATION; SUBUNIT; INVIVO	We demonstrate that expression of v-Ha-ras in mouse embryonal P19 cells results in genome-wide demethylation. Analysis of the pattern of methylation of specific genes reveals that different types of genes are demethylated in the ras transfectants: skeletal muscle specific genes, a gene specifically expressed in the adrenal cortex (c21), ubiquitous genes, and exogenously introduced sequences. Transient transfection and in vitro demethylation assays reveal that the ras transfectants express high levels of a general DNA demethylation activity. This demonstrates that the general DNA demethylation activity in mouse embryonal cells is controlled by an important cellular signal transducer and that DNA demethylase is a potential downstream effector of Ras.			SZYF, M (corresponding author), MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,3655 DRUMMOND ST,MONTREAL,PQ H3G 1Y6,CANADA.							Ausubel FM., 1988, CURRENT PROTOCOLS MO; BOULTER CA, 1988, ONCOGENE, V2, P207; BRANDEIS M, 1993, BIOESSAYS, V13, P709; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DRABER P, 1989, INT J DEV BIOL, V3, P369; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEINBERG AP, 1988, CANCER RES, V48, P1159; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; GARDNER PD, 1987, MOL BRAIN RES, V3, P69, DOI 10.1016/0169-328X(87)90046-5; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; NUR I, 1985, J BACTERIOL, V164, P19, DOI 10.1128/JB.164.1.19-24.1985; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275; RAZIN A, 1985, BIOCH BIOL DNA METHY, P239; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; RUDNICKI MA, 1989, BIOCHEM CELL BIOL, V67, P590, DOI 10.1139/o89-091; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SALUZ HP, 1986, P NATL ACAD SCI USA, V83, P7167, DOI 10.1073/pnas.83.19.7167; SHEMER R, 1991, J BIOL CHEM, V266, P23676; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SZYF M, 1985, P NATL ACAD SCI USA, V82, P8090, DOI 10.1073/pnas.82.23.8090; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; SZYF M, 1991, J BIOL CHEM, V266, P10027; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; UHLER MD, 1987, J BIOL CHEM, V262, P15202; YISRAELI J, 1985, DNA METHYLATION BIOC, P353	32	52	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12690	12696		10.1074/jbc.270.21.12690	http://dx.doi.org/10.1074/jbc.270.21.12690			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759521	hybrid			2022-12-25	WOS:A1995QZ71100057
J	WELCH, RW; WANG, YH; CROSSMAN, A; PARK, JB; KIRK, KL; LEVINE, M				WELCH, RW; WANG, YH; CROSSMAN, A; PARK, JB; KIRK, KL; LEVINE, M			ACCUMULATION OF VITAMIN-C (ASCORBATE) AND ITS OXIDIZED METABOLITE DEHYDROASCORBIC ACID OCCURS BY SEPARATE MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COULOMETRIC ELECTROCHEMICAL DETECTION; ADRENOMEDULLARY CHROMAFFIN CELLS; HUMAN-NEUTROPHILS; INSITU KINETICS; TRANSPORT; FIBROBLASTS; GLUCOSE; REDUCTASE; DISULFIDE; AFFINITY	It is unknown whether ascorbate alone (vitamin C), its oxidized metabolite dehydroascorbic acid alone, or both species are transported into human cells. This problem was addressed using specific assays for each compound, freshly synthesized pure dehydroascorbic acid, the specially synthesized analog 6-chloroascorbate, and a new assay for 6-chloroascorbate. Ascorbate and dehydroascorbic acid were transported and accumulated distinctly; neither competed with the other, Ascorbate was accumulated as ascorbate by sodium-dependent carrier-mediated active transport, Dehydroascorbic acid transport and accumulation as ascorbate was at least 10-fold faster than ascorbate transport and was sodium-independent. Once transported, dehydroascorbic acid was immediately reduced intracellularly to ascorbate. The analog 6-chloroascorbate had no effect on dehydroascorbic acid transport but was a competitive inhibitor of ascorbate transport. The K-i for 6-chloroascorbate (2.9-4.4 mu M) was similar to the K-m for ascorbate transport (9.8-12.6 mu M) 6-Chloroascorbate was itself transported and accumulated in fibroblasts by a sodium-dependent transporter. These data provide new information that ascorbate and dehydroascorbic acid are transported into human neutrophils and fibroblasts by two distinct mechanisms and that the compound available for intracellular utilization is ascorbate.	NIDDKD,CELL BIOL & GENET LAB,BETHESDA,MD 20892; NIDDK,BIOORGAN CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BIGLEY R, 1983, DIABETES, V32, P545, DOI 10.2337/diabetes.32.6.545; BIGLEY RH, 1974, J EXP MED, V139, P1084, DOI 10.1084/jem.139.5.1084; Borsook H, 1937, J BIOL CHEM, V117, P237; Cleland W W, 1979, Methods Enzymol, V63, P103; COASSIN M, 1991, ARCH BIOCHEM BIOPHYS, V290, P458, DOI 10.1016/0003-9861(91)90566-2; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; DHARIWAL KR, 1989, J BIOL CHEM, V264, P15404; DILIBERTO EJ, 1983, J BIOL CHEM, V258, P2886; DYER DL, 1994, AM J PHYSIOL, V267, pC301, DOI 10.1152/ajpcell.1994.267.1.C301; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HALLIWELL B, 1987, FEBS LETT, V213, P15, DOI 10.1016/0014-5793(87)81456-4; HENDRY JM, 1964, CLIN CHIM ACTA, V9, P498, DOI 10.1016/0009-8981(64)90089-0; KISS J, 1980, HELV CHIM ACTA, V63, P1728, DOI 10.1002/hlca.19800630642; LAM KW, 1993, OPHTHALMIC RES, V25, P100, DOI 10.1159/000267272; LEVINE M, 1994, ASIAN PAC J CLIN  S1, V2, P5; MELHORN RJ, 1991, J BIOL CHEM, V266, P2724; MENNITI FS, 1987, J BIOL CHEM, V262, P7651; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NEALE KD, 1972, ELEMENTARY KINETICS; OKAMURA M, 1980, CLIN CHIM ACTA, V103, P259; PADH H, 1987, BIOCHIM BIOPHYS ACTA, V901, P283, DOI 10.1016/0005-2736(87)90125-8; ROSENBAUM JT, 1985, AM J PATHOL, V120, P244; STAHL RL, 1985, BIOCHIM BIOPHYS ACTA, V839, P119, DOI 10.1016/0304-4165(85)90189-8; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WASHKO P, 1992, J BIOL CHEM, V267, P23568; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1989, NEW ENGL J MED, V321, P329; WELCH RW, 1993, BIOCHEM J, V294, P505, DOI 10.1042/bj2940505; WELCH RW, 1993, ANAL BIOCHEM, V210, P199, DOI 10.1006/abio.1993.1173; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WILSON JX, 1989, J MEMBRANE BIOL, V111, P83, DOI 10.1007/BF01869211; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; WINKLER BS, 1992, BIOCHIM BIOPHYS ACTA, V1117, P287, DOI 10.1016/0304-4165(92)90026-Q; ZHOU A, 1991, BIOCHEM J, V274, P739, DOI 10.1042/bj2740739	37	168	173	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12584	12592		10.1074/jbc.270.21.12584	http://dx.doi.org/10.1074/jbc.270.21.12584			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759506	hybrid			2022-12-25	WOS:A1995QZ71100041
J	MARX, UC; AUSTERMANN, S; BAYER, P; ADERMANN, K; EJCHART, A; STICHT, H; WALTER, S; SCHMID, FX; JAENICKE, R; FORSSMANN, WG; ROSCH, P				MARX, UC; AUSTERMANN, S; BAYER, P; ADERMANN, K; EJCHART, A; STICHT, H; WALTER, S; SCHMID, FX; JAENICKE, R; FORSSMANN, WG; ROSCH, P			STRUCTURE OF HUMAN PARATHYROID-HORMONE-1-37 IN SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; NUCLEAR-MAGNETIC-RESONANCE; DNA-BINDING DOMAIN; LEUCINE-ZIPPER MOTIF; MOLECULAR-DYNAMICS; DISTANCE GEOMETRY; PEPTIDE-FRAGMENTS; ZINC FINGER; NMR; TRIFLUOROETHANOL	Human parathyroid hormone (hPTH), amino acids Ser(1) to Leu(37), is biologically active with respect to both receptor binding and activation of adenylate cyclase to influence the serum calcium concentration. It induces DNA synthesis via an unknown signal pathway. We investigated the structure of hPTH(1-37) in H2O/buffer solution under near physiological conditions, that is pH 6.0 and 270 mM salt, by circular dichroism, ultracentrifugation, nuclear magnetic resonance spectroscopy, and molecular dynamics calculations. Complete sequence specific assignments of all H-1 resonances were performed by using H-1 two-dimensional NMR measurements (double quantum-filtered correlated spectroscopy, nuclear Overhauser effect spectroscopy (NOESY), and total correlation spectroscopy with suppression of NOESY-type cross-peaks spectra). hPTH(1-37) obtained helical structure and showed hydrophobic interactions defining a tertiary structure. The NH2-terminal four amine acids of hPTH(1-37) did not show a stable conformation. Evidence for an alpha-helical region between IIe(5) and Asn(10) was found. This region was followed by a flexible link (Gly(12), Lys(13)) and a well defined turn region, His(14) to Ser(17). The latter was stabilized by hydrophobic interactions between Trp(23) and Leu(15). Ser(17) through at least Leu(28) formed an alpha-helix. Arg(20) and Lys(27) were involved in the core built by His(14) to Ser(17). Unrestrained molecular dynamics simulations indicated that the structure was stable on the 200 ps time scale.	UNIV BAYREUTH, LEHRSTUHL BIOCHEM, D-95440 BAYREUTH, GERMANY; NIEDERSACHS INST PEPTID FORSCH GMBH, D-30625 HANNOVER, GERMANY; UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, D-93053 REGENSBURG, GERMANY	University of Bayreuth; University of Regensburg			Bayer, Peter/B-8803-2009; Rösch, Paul/I-5445-2014	Bayer, Peter/0000-0003-0435-7202; Rösch, Paul/0000-0003-3330-2446; Sticht, Heinrich/0000-0001-5644-045X; Marx, Ute C./0000-0002-7077-9940				ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; Atherton E., 1990, SOLID PHASE PEPTIDE; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BARDEN JA, 1993, EUR J BIOCHEM, V215, P315, DOI 10.1111/j.1432-1033.1993.tb18037.x; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BRADLEY EK, 1990, J MOL BIOL, V215, P607, DOI 10.1016/S0022-2836(05)80172-X; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER A, 1993, X PLOR 3 1 MANUAL; BUCK M, 1993, BIOCHEMISTRY-US, V32, P669, DOI 10.1021/bi00053a036; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; CHOREV M, 1990, BIOCHEMISTRY-US, V29, P1580, DOI 10.1021/bi00458a032; CHOREV M, 1994, STRUCTURE FUNCTION A, P139; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Ernst R.R., 1992, ANGEW CHEM, V104, P817; FORSSMANN WG, 1993, PEPTIDE CHEMISTRY 1992, P553; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARD T, 1990, BIOCHEMISTRY-US, V29, P9015; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; JUNIUS FK, 1993, EUR J BIOCHEM, V214, P415, DOI 10.1111/j.1432-1033.1993.tb17937.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; LANCELIN JM, 1994, FEBS LETT, V343, P261, DOI 10.1016/0014-5793(94)80568-7; LLINAS M, 1975, J AM CHEM SOC, V97, P4731, DOI 10.1021/ja00849a040; LOPEZHILKER S, 1992, J LAB CLIN MED, V119, P738; MERUTKA G, 1993, BIOCHEMISTRY-US, V32, P13089, DOI 10.1021/bi00211a019; MORRISET.JD, 1973, BIOCHEMISTRY-US, V12, P1290, DOI 10.1021/bi00731a008; MORTON CJ, 1994, EUR J BIOCHEM, V219, P97, DOI 10.1111/j.1432-1033.1994.tb19919.x; MUJEEB A, 1994, P NATL ACAD SCI USA, V91, P8248, DOI 10.1073/pnas.91.17.8248; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; POTTS JT, 1982, ADV PROTEIN CHEM, V35, P323, DOI 10.1016/S0065-3233(08)60471-4; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SAUDEK V, 1991, PROTEIN ENG, V4, P519, DOI 10.1093/protein/4.5.519; SCHLUTER KD, 1989, J BIOL CHEM, V264, P11087; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SOMJEN D, 1990, BIOCHEM J, V272, P781; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; STICHT H, 1993, EUR J BIOCHEM, V218, P973, DOI 10.1111/j.1432-1033.1993.tb18455.x; STRICKLAND LA, 1993, BIOCHEMISTRY-US, V32, P6050, DOI 10.1021/bi00074a016; TORDA AE, 1990, J MOL BIOL, V214, P223, DOI 10.1016/0022-2836(90)90157-H; VANBUUREN AR, 1993, BIOPOLYMERS, V33, P1159, DOI 10.1002/bip.360330802; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WILLBOLD D, 1994, SCIENCE, V264, P1584, DOI 10.1126/science.7515512; WILLBOLD D, 1993, BIOCHEMISTRY-US, V32, P8439, DOI 10.1021/bi00084a008; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Woody R. W., 1994, CIRCULAR DICHROISM P, P473; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YANG JT, 1986, CALCULATION PROTEIN, P208; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	64	68	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15194	15202		10.1074/jbc.270.25.15194	http://dx.doi.org/10.1074/jbc.270.25.15194			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797503	hybrid			2022-12-25	WOS:A1995RE66600054
J	NEESE, RA; SCHWARZ, JM; FAIX, D; TURNER, S; LETSCHER, A; VU, D; HELLERSTEIN, MK				NEESE, RA; SCHWARZ, JM; FAIX, D; TURNER, S; LETSCHER, A; VU, D; HELLERSTEIN, MK			GLUCONEOGENESIS AND INTRAHEPATIC TRIOSE PHOSPHATE FLUX IN RESPONSE TO FASTING OR SUBSTRATE LOADS - APPLICATION OF THE MASS ISOTOPOMER DISTRIBUTION ANALYSIS TECHNIQUE WITH TESTING OF ASSUMPTIONS AND POTENTIAL PROBLEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE-INDUCED HYPERTRIGLYCERIDEMIA; COA POOL INVIVO; HEPATIC GLYCOGEN; PYRUVATE-DEHYDROGENASE; STABLE ISOTOPES; C-13 NMR; GLUCOSE; HUMANS; RAT; PATHWAYS	We measured gluconeogenesis (GNG) in rats by mass isotopomer distribution analysis, which allows enrichment of the true biosynthetic precursor pool (hepatic cytosolic triose phosphates) to be determined. Fractional GNG from infused [3-C-13]lactate, [1-C-13]lactate, and [2-C-13]glycerol was 88 +/- 2, 89 +/- 3, and 87 +/- 2%, respectively, after 48 h of fasting, [2-C-13]Glycerol was the most efficient label and allowed measurement of rate of ap appearance of intrahepatic triose phosphate (Ra triose-P), by dilution. IV fructose (10-15 mg/kg/min) increased absolute GNG by 81-147%, Ra triose-P increased proportionately, but endogenous Ra triose-P was almost completely suppressed, suggesting feedback control, Interestingly, 15-17% of fructose was directly converted to glucose without entering hepatic triose-P, IV glucose reduced GNG and Ra triose-P, 24-h fasting reduced hepatic glucose production by half, but absolute GNG was unchanged due to increased fractional GNG (51-87%). Reduced hepatic glucose production was entirely due to decreased glycogen input, from 7.3 +/- 1.8 to 1.1 +/- 0.2 mg/kg/min, Ra triose-P fell during fasting, but efficiency of triose-P disposal into GNG increased, maintaining GNG constant, Secreted glucuronyl conjugates and plasma glucose results correlated closely, In summary, GNG and intrahepatic triose-P flux can be measured by mass isotopomer distribution analysis with [2-C-13]glycerol.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, DEPT MED, DIV ENDOCRINOL & METAB, SAN FRANCISCO, CA 94101 USA	University of California System; University of California Berkeley; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040995] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-40995] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARION WJ, 1980, J BIOL CHEM, V255, P396; BIERMANN CJ, 1989, ANAL CARBOHYDRATES G, P98; CHANDRAMOULI V, 1993, METABOLISM, V42, P1420, DOI 10.1016/0026-0495(93)90192-Q; CONSOLI A, 1993, DIABETES, V42, P732, DOI 10.2337/diabetes.42.5.732; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; DAVIDSON MB, 1981, METABOLISM, V30, P279, DOI 10.1016/0026-0495(81)90152-9; Exton J H, 1970, Recent Prog Horm Res, V26, P411; FAIX D, 1993, J LIPID RES, V34, P2063; FAIX D, 1992, FASEB J, V6, pA4933; Good CA, 1933, J BIOL CHEM, V100, P485; GOPHER A, 1990, P NATL ACAD SCI USA, V87, P5449, DOI 10.1073/pnas.87.14.5449; GUO ZK, 1992, ANAL BIOCHEM, V204, P273, DOI 10.1016/0003-2697(92)90238-3; HELLERSTEIN MK, 1994, J CLIN INVEST, V93, P265, DOI 10.1172/JCI116955; HELLERSTEIN MK, 1986, P NATL ACAD SCI USA, V83, P7044, DOI 10.1073/pnas.83.18.7044; HELLERSTEIN MK, 1995, METABOLISM, V44, P172, DOI 10.1016/0026-0495(95)90261-9; HELLERSTEIN MK, 1989, J CLIN INVEST, V84, P228, DOI 10.1172/JCI114145; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206; HELLERSTEIN MK, 1991, J BIOL CHEM, V266, P10920; HELLERSTEIN MK, 1991, AM J PHYSIOL, V261, pE479, DOI 10.1152/ajpendo.1991.261.4.E479; HELLERSTEIN MK, 1994, FASEB J, V8, pA957; HELLERSTEIN MK, 1991, J BIOL CHEM, V266, P10912; HENRY RJ, 1983, J CHROMATOGR, V256, P419, DOI 10.1016/S0021-9673(01)88259-5; HETENYI G, 1982, FED PROC, V41, P104; HIRANO T, 1988, AM J PHYSIOL, V255, pE236, DOI 10.1152/ajpendo.1988.255.3.E236; HOLNESS MJ, 1986, BIOCHEM J, V235, P441, DOI 10.1042/bj2350441; JAHOOR F, 1990, AM J PHYSIOL, V258, pE288, DOI 10.1152/ajpendo.1990.258.2.E288; JENSSEN T, 1990, J CLIN INVEST, V86, P489, DOI 10.1172/JCI114735; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; Katz J., 1991, AM J PHYSIOL, V259, pE757; KELLEHER JK, 1986, AM J PHYSIOL, V250, pE296, DOI 10.1152/ajpendo.1986.250.3.E296; KELLEHER JK, 1994, AM J PHYSIOL, V266, pE384, DOI 10.1152/ajpendo.1994.266.3.E384; KELLEHER JK, 1992, AM J PHYSIOL, V262, pE118, DOI 10.1152/ajpendo.1992.262.1.E118; KREBS HA, 1966, BIOCHEM J, V101, P242, DOI 10.1042/bj1010242; LEE WNP, 1992, BIOL MASS SPECTROM, V21, P114, DOI 10.1002/bms.1200210210; LETSCHER AE, 1994, FASEB J, V8, pA954; LIN ECC, 1977, ANNU REV BIOCHEM, V46, P765, DOI 10.1146/annurev.bi.46.070177.004001; MCGARRY JD, 1987, ANNU REV NUTR, V7, P51, DOI 10.1146/annurev.nu.07.070187.000411; NEESE RA, 1994, FASEB J, V8, pA919; NEWGARD CB, 1984, DIABETES, V33, P192, DOI 10.2337/diabetes.33.2.192; PARK OJ, 1992, BIOCHEM J, V282, P753, DOI 10.1042/bj2820753; ROGNSTAD R, 1988, Medical Science Research, V16, P293; ROTHER KI, 1994, DIABETES, V43, pA133; ROTHMAN DL, 1991, SCIENCE, V254, P573, DOI 10.1126/science.1948033; SCHUMANN WC, 1991, J BIOL CHEM, V266, P6985; SEGLEN PO, 1974, BIOCHIM BIOPHYS ACTA, V338, P317, DOI 10.1016/0304-4165(74)90292-X; SENIOR B, 1968, NEW ENGL J MED, V279, P965, DOI 10.1056/NEJM196810312791803; SHIKAMA H, 1978, AM J PHYSIOL, V235, pE354, DOI 10.1152/ajpendo.1978.235.4.E354; SHULMAN GI, 1990, AM J PHYSIOL, V259, pE335, DOI 10.1152/ajpendo.1990.259.3.E335; SHULMAN GI, 1992, PHYSIOL REV, V72, P1019, DOI 10.1152/physrev.1992.72.4.1019; SISTARE FD, 1985, J BIOL CHEM, V260, P2761; Soskin S, 1937, AM J PHYSIOL, V120, P761, DOI 10.1152/ajplegacy.1937.120.4.761; STEELE R, 1971, AM J PHYSIOL, V221, P883, DOI 10.1152/ajplegacy.1971.221.3.883; Tilghman SM, 1976, GLUCONEOGENESIS ITS, P47; TSIENG KY, 1984, ANAL CHEM, V56, P517; WALSH K, 1985, J BIOL CHEM, V260, P8430; WEINMAN EO, 1957, PHYSIOL REV, V37, P252, DOI 10.1152/physrev.1957.37.2.252; YOUN JH, 1990, AM J PHYSIOL, V258, pE899, DOI 10.1152/ajpendo.1990.258.6.E899; ZAVARONI I, 1982, METABOLISM, V31, P1077, DOI 10.1016/0026-0495(82)90155-X	59	123	137	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14452	14463		10.1074/jbc.270.24.14452	http://dx.doi.org/10.1074/jbc.270.24.14452			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782307	hybrid			2022-12-25	WOS:A1995RD45500035
J	ZAUBERMAN, A; LUPO, A; OREN, M				ZAUBERMAN, A; LUPO, A; OREN, M			IDENTIFICATION OF P53 TARGET GENES THROUGH IMMUNE SELECTION OF GENOMIC DNA - THE CYCLIN-G GENE CONTAINS 2 DISTINCT P53 BINDING-SITES	ONCOGENE			English	Article						P53 TARGETS; CYCLINS; CELL CYCLE; TUMOR SUPPRESSOR; DNA BINDING	WILD-TYPE P53; PROTEIN; EXPRESSION; TRANSACTIVATION; P53-PROTEIN; INHIBITOR; KINASES; ELEMENT; MUTANT; P21	An immune-selection procedure was employed in order to isolate p53-binding sites from rat genomic DNA. One such site was found to reside within the first intron of the cyclin G gene. Cyclin G mRNA levels are strongly elevated upon induction of wild type p53 activity in cells carrying a temperature sensitive p53 mutant. The cyclin G gene also carries a second p53-binding motif upstream to its transcriptional start site. The presence of two high affinity p53-binding sites may confer upon the cyclin G gene the potential to be activated very efficiently by p53. These data raise the possibility that cyclin G may be a downstream mediator of at least some of the biological effects of p53.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science					NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GANNON JV, 1991, NATURE, V349, P802; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARPER JW, 1993, CELL, V75, P805; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; OTTO A, 1993, ONCOGENE, V8, P2591; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAMURA K, 1993, ONCOGENE, V8, P2113; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	33	152	155	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2361	2366						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784084				2022-12-25	WOS:A1995RE54300011
J	MAMALAKI, A; BOUTOU, E; HUREL, C; PATSAVOUDI, E; TZARTOS, S; MATSAS, R				MAMALAKI, A; BOUTOU, E; HUREL, C; PATSAVOUDI, E; TZARTOS, S; MATSAS, R			THE BM88 ANTIGEN, A NOVEL NEURON-SPECIFIC MOLECULE, ENHANCES THE DIFFERENTIATION OF MOUSE NEUROBLASTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; MONOCLONAL-ANTIBODIES; POSTNATAL-DEVELOPMENT; ADHESION MOLECULES; CEREBELLAR CORTEX; PROTEIN; EXPRESSION; RAT; FILOPODIA; CADHERIN	The BM88 antigen is a neuron-specific molecule widely distributed in the mammalian nervous system. It is a 22-kDa, apparently not glycosylated, integral membrane protein, which appears early during brain development and remains at high levels in the mature animal. Here, we describe the cDNA cloning of the porcine BM88 antigen and present evidence that this protein is involved in neuroblastoma cell differentiation. The deduced protein is a novel molecule consisting of 140 amino acids and bears a putative transmembrane domain at the COOH-terminal region. The mRNA of this protein is expressed only in neural tissues, where it is restricted to neurons. Stably transfected Neuro-2a cells overexpressing the BM88 antigen exhibited a significant change in morphology, reflected by enhanced process outgrowth, and a slower rate of division. Moreover, in the presence of differentiation agents, such as sucrose and retinoic acid, an accelerated differentiation of the transfected Neuro-2a cells was observed. Especially in the presence of sucrose, the consequent overexpression of the BM88 antigen in the transfected cells resulted in their enhanced morphological differentiation accompanied by the induction of neurofilament protein expression. Our results suggest that the BM88 antigen plays a role in the differentiation of neuroblastoma cells.	HELLEN INST PASTEUR,DEPT BIOCHEM,GR-11521 ATHENS,GREECE					Boutou, Effrossyni/0000-0003-0343-2434				ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; ALTMAN J, 1972, J COMP NEUROL, V145, P399, DOI 10.1002/cne.901450402; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CATTANEO E, 1991, TRENDS NEUROSCI, V14, P338, DOI 10.1016/0166-2236(91)90158-Q; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; FEANY MB, 1993, NATURE, V364, P537, DOI 10.1038/364537a0; GRAHAM F, 1973, VIROLOGY, V52, P452; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KIOUSSI C, 1992, NEUROSCIENCE, V50, P69, DOI 10.1016/0306-4522(92)90382-C; KUMAGAITOHDA C, 1993, J NEUROCHEM, V61, P526; KUMAR S, 1994, J BIOL CHEM, V269, P11318; LECLERC N, 1993, P NATL ACAD SCI USA, V90, P6223, DOI 10.1073/pnas.90.13.6223; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; MERKOURI E, 1992, NEUROSCIENCE, V50, P53, DOI 10.1016/0306-4522(92)90381-B; MORTON AJ, 1992, EUR J NEUROSCI, V4, P910, DOI 10.1111/j.1460-9568.1992.tb00117.x; PATSAVOUDI E, 1995, J NEUROSCI RES, V40, P506, DOI 10.1002/jnr.490400410; PATSAVOUDI E, 1989, NEUROSCIENCE, V30, P463, DOI 10.1016/0306-4522(89)90266-2; PATSAVOUDI E, 1991, J NEUROCHEM, V56, P782, DOI 10.1111/j.1471-4159.1991.tb01992.x; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; ROSS J, 1975, TISSUE CELL, V7, P107, DOI 10.1016/S0040-8166(75)80010-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V82, P5463; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WALSH FS, 1992, COLD SPRING HARB SYM, V57, P431, DOI 10.1101/SQB.1992.057.01.048; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WOOD JN, 1981, BIOSCIENCE REP, V1, P263, DOI 10.1007/BF01114913; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062	41	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14201	14208		10.1074/jbc.270.23.14201	http://dx.doi.org/10.1074/jbc.270.23.14201			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775480	hybrid			2022-12-25	WOS:A1995RC44800088
J	XU, XX; YANG, WN; JACKOWSKI, S; ROCK, CO				XU, XX; YANG, WN; JACKOWSKI, S; ROCK, CO			CLONING OF A NOVEL PHOSPHOPROTEIN REGULATED BY COLONY-STIMULATING FACTOR-1 SHARES A DOMAIN WITH THE DROSOPHILA DISABLED GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; FACTOR-I RECEPTOR; FMS PROTO-ONCOGENE; C-MYC EXPRESSION; PHOSPHATIDYLCHOLINE HYDROLYSIS; MITOGENIC RESPONSE; GROWTH-FACTOR; CSF-1; PURIFICATION; MACROPHAGES	A unique protein with an apparent molecular mass of 96 kilodaltons (p96) was detected in the murine macrophage cell line, BAC1.2F5. The murine cDNA encoding p96 was cloned and sequenced, along with cDNAs representing two alternatively spliced forms of the protein. All three proteins possessed identical amino-terminal domains with significant similarity to the amino-terminal domain of the Drosophila disabled gene product and carboxyl-terminal domains containing proline-rich sequences characteristic of src homology region (domain 3) binding regions. BAC1.2F5 cells predominately expressed the p96 protein, although mRNA and protein corresponding to the p67 splice variant were also detected. Electrophoretic gel retardation of p96 in response to stimulation of the cells with colony-stimulating factor 1 was noticeable within 5 min after growth factor addition and reached a maximum at 60 min. Metabolic labeling experiments showed that the gel retardation of p96 was associated with increased phosphorylation of the protein exclusively on serine residues. These data identify a novel protein that is phosphorylated in response to mitogenic growth factor stimulation.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [T32 CA09346, CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009346, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT RL, 1992, DEVELOPMENT, V116, P953; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOUDHURY GG, 1991, FEBS LETT, V282, P351, DOI 10.1016/0014-5793(91)80511-Z; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GUILBERT LJ, 1986, J CELL BIOCHEM, V31, P203, DOI 10.1002/jcb.240310303; HARLOW E, 1988, ANTIBODIES LABORATOR; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAIRO G, 1991, IMMUNOL TODAY, V12, P362, DOI 10.1016/0167-5699(91)90067-4; VEIS N, 1991, J CELL PHYSIOL, V147, P298, DOI 10.1002/jcp.1041470215; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; YEUNG YG, 1987, P NATL ACAD SCI USA, V84, P1268, DOI 10.1073/pnas.84.5.1268; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	43	129	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14184	14191		10.1074/jbc.270.23.14184	http://dx.doi.org/10.1074/jbc.270.23.14184			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775479	hybrid			2022-12-25	WOS:A1995RC44800086
J	LEHMANN, JM; MOORE, LB; SMITHOLIVER, TA; WILKISON, WO; WILLSON, TM; KLIEWER, SA				LEHMANN, JM; MOORE, LB; SMITHOLIVER, TA; WILKISON, WO; WILLSON, TM; KLIEWER, SA			AN ANTIDIABETIC THIAZOLIDINEDIONE IS A HIGH-AFFINITY LIGAND FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA(PPAR-GAMMA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENHANCES ADIPOCYTE DIFFERENTIATION; GLUCOCORTICOID RECEPTOR; FATTY-ACIDS; SUPERFAMILY; MEMBER; IDENTIFICATION; DOMAINS; FAMILY; CELLS; AGENT	Thiazolidinedione derivatives are antidiabetic agents that increase the insulin sensitivity of target tissues in animal models of non-insulin dependent diabetes mellitus. In vitro, thiazolidinediones promote adipocyte differentiation of preadipocyte and mesenchymal stem cell lines; however, the molecular basis for this adipogenic effect has remained unclear. Here, we report that thiazolidinediones are potent and selective activators of peroxisome proliferator activated receptor gamma (PPAR gamma), a member of the nuclear receptor superfamily recently shown to function in adipogenesis. The most potent of these agents, BRL49653, binds to PPAR gamma with a K-d of approximately 40 nM. Treatment of pluripotent C3H10T1/2 stem cells with BRL49653 results in efficient differentiation to adipocytes. These data are the first demonstration of a high affinity PPAR ligand and provide strong evidence that PPAR gamma is a molecular target for the adipogenic effects of thiazolidinediones. Furthermore, these data raise the intriguing possibility that PPAR gamma is a target for the therapeutic actions of this class of compounds.	GLAXO INC,RES INST,DEPT MED CHEM,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT BIOCHEM,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT CELLULAR BIOCHEM,RES TRIANGLE PK,NC 27709	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline			feinstein, doug/M-9414-2019					CANTELLO BCC, 1994, J MED CHEM, V37, P3977, DOI 10.1021/jm00049a017; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; COLCA JR, 1990, NEW ANTIDIABETIC DRU, P255; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HARRIS PKW, 1994, MOL PHARMACOL, V45, P439; HIRAGUN A, 1988, J CELL PHYSIOL, V134, P124, DOI 10.1002/jcp.1041340115; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HUSSMAN M, 1991, MOL CELL BIOL, V11, P4097; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, TRENDS ENDOCRIN MET, V4, P291, DOI 10.1016/1043-2760(93)90048-J; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MCGARRY JD, 1994, J CELL BIOCHEM, V55, P29, DOI 10.1002/jcb.240550005; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SPARKS RL, 1991, J CELL PHYSIOL, V146, P101, DOI 10.1002/jcp.1041460114; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	30	3292	3458	6	178	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					12953	12956		10.1074/jbc.270.22.12953	http://dx.doi.org/10.1074/jbc.270.22.12953			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768881	hybrid			2022-12-25	WOS:A1995RB43900002
J	LEIDICH, SD; KOSTOVA, Z; LATEK, RR; COSTELLO, LC; DRAPP, DA; GRAY, W; FASSLER, JS; ORLEAN, P				LEIDICH, SD; KOSTOVA, Z; LATEK, RR; COSTELLO, LC; DRAPP, DA; GRAY, W; FASSLER, JS; ORLEAN, P			TEMPERATURE-SENSITIVE YEAST GPI ANCHORING MUTANTS GPI2 AND GPI3 ARE DEFECTIVE IN THE SYNTHESIS OF N-ACETYLGLUCOSAMINYL PHOSPHATIDYLINOSITOL - CLONING OF THE GP12 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; CELL-SURFACE MOLECULES; SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; PIG-A; BIOSYNTHESIS; PROTEIN; LYMPHOMA; THY-1; EXPRESSION	To identify genes required for the synthesis of glycosyl phosphatidylinositol (GPI) membrane anchors in yeast, we devised a way to isolate GPI anchoring mutants in which colonies are screened for defects in [H-3]-inositoI incorporation into protein. The gpi1 mutant, identified in this way, is temperature sensitive for growth and defective in vitro in the synthesis of GlcNAc-phosphatidylinositol, the first intermediate in GPI biosynthesis (Leidich, S. D., Drapp, D. A., and Orlean, P. (1994) J. Biol. Chem. 269, 10193-10196). We report the isolation of two more conditionally lethal mutants, gpi2 and gpi3, which, like gpi1, have a temperature-sensitive defect in the incorporation of [H-3]inositol into protein and which lack in vitro GlcNAc-phosphatidylinositol synthetic activity. Haploid Saccharomyces cerevisiae strains containing any pairwise combination of the gpi1, gpi2, and gpi3 mutations are inviable. The GPI2 gene, cloned by complementation of the gpi2 mutant's temperature sensitivity, encodes a hydrophobic 269-amino acid protein that resembles no other gene product known to participate in GPI assembly. Gene disruption experiments show that GPI2 is required for vegetative growth. Overexpression of the GPI2 gene causes partial suppression of the gpi1 mutant's temperature sensitivity, a result that suggests that the Gpi1 and Gpi2 proteins interact with one another in vivo. The gpi3 mutant is defective in the SPT14 gene, which encodes a yeast protein similar to the product of the mammalian PIG-A gene, which complements a GlcNAc-phosphatidylinositol synthesis-defective human cell line. In yeast, at least three gene products are required for the first step in GPI synthesis, as is the case in mammalian cells, and utilization of several different proteins at this stage is therefore likely to be a general characteristic of the GPI synthetic pathway.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801; UNIV IOWA,DEPT BIOL,IOWA CITY,IA 52242	University of Illinois System; University of Illinois Urbana-Champaign; University of Iowa			Gray, William M/F-9402-2010	Gray, William M/0000-0002-1320-290X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040306, R01GM046220] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46220, GM40306] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; De Nobel Hans, 1994, Trends in Cell Biology, V4, P42, DOI 10.1016/0962-8924(94)90003-5; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FASSLER JS, 1988, GENETICS, V118, P203; FASSLER JS, 1991, MOL GEN GENET, V230, P310, DOI 10.1007/BF00290682; FATEMI SH, 1986, CELL, V46, P653, DOI 10.1016/0092-8674(86)90340-5; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEIDICH SD, J BIOL CHEM, V1013, P94; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PUOTI A, 1991, J BIOL CHEM, V266, P21051; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; VELOURS J, 1988, EUR J BIOCHEM, V170, P637, DOI 10.1111/j.1432-1033.1988.tb13745.x; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	39	102	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13029	13035		10.1074/jbc.270.22.13029	http://dx.doi.org/10.1074/jbc.270.22.13029			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768896	hybrid			2022-12-25	WOS:A1995RB43900017
J	SULLI, C; SCHWARTZBACH, SD				SULLI, C; SCHWARTZBACH, SD			THE POLYPROTEIN PRECURSOR TO THE EUGLENA LIGHT-HARVESTING CHLOROPHYLL A/B-BINDING PROTEIN IS TRANSPORTED TO THE GOLGI-APPARATUS PRIOR TO CHLOROPLAST IMPORT AND POLYPROTEIN PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LHCP-II APOPROTEIN; THYLAKOID MEMBRANE-PROTEIN; ENDOPLASMIC-RETICULUM; TRANSIT PEPTIDE; PHOTOSYSTEM-II; SECRETORY PROTEINS; CELLS; GRACILIS; SIGNAL; LOCALIZATION	The major Euglena thylakoid protein, the light harvesting chlorophyll alb-binding protein of photosystem II (pLHCPII) is synthesized in the cytoplasm as a polyprotein precursor composed of a 141 amino acid presequence containing a signal peptide domain followed by eight mature LHCPIIs covalently Linked by a decapeptide. To determine the transport route from cytoplasm to chloroplast and the site of polyprotein processing, EugIena was pulse labeled with [S-35]sulfate, organelles separated on sucrose gradients, and pLRCPII and LHCPII immunoprecipitated and separated on SDS gels. After a 10-min pulse, the pLHCPII polyprotein was found in the endoplasmic reticulum (ER) and Golgi apparatus. LHCPII was undetectable after a 10-min pulse consistent with the 20-min half-life for pLHCPII processing. When pulse-labeled cells were chased for 20 or 40 min with unlabeled sulfate, the fraction of pLHCPII in the ER decreased, and the fraction in the Golgi apparatus increased. LHCPII appeared only in thylakoids and chloroplasts, never in the ER or Gels apparatus. Na,CO, extraction, a treatment that releases soluble but not integral membrane proteins, did not remove pLHCPII from ER and Golgi membranes. Trypsin digestion of ER and Golgi membranes produced 4 pLHCPII membrane protected fragments. The Euglena pLRCPII polyprotein is transported as an integral membrane protein from the ER to the Golgi apparatus and from the Gels apparatus to the chloroplast. Polyprotein processing appears to occur during or soon after chloroplast import of the membrane-bound precursor.	UNIV NEBRASKA, SCH BIOL SCI, LINCOLN, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln								ARION WJ, 1989, METHOD ENZYMOL, V174, P58; AUCHINCLOSS AH, 1992, J BIOL CHEM, V267, P10439; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BOWLES DJ, 1976, BIOCHIM BIOPHYS ACTA, V443, P360, DOI 10.1016/0005-2787(76)90500-1; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHAN RL, 1990, EMBO J, V9, P333, DOI 10.1002/j.1460-2075.1990.tb08115.x; CHIDANANDA S, 1993, MOL BIOL CELL, V4, pA105; DOCKERTY A, 1979, PLANT PHYSIOL, V63, P468, DOI 10.1104/pp.63.3.468; FELDMAN RI, 1987, J BIOL CHEM, V262, P9332; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GALBRAITH DW, 1992, PLANTA, V186, P324, DOI 10.1007/BF00195312; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; GILLOTT MA, 1980, PROTOPLASMA, V105, P45, DOI 10.1007/BF01279848; GRUNOW A, 1993, EUR J CELL BIOL, V61, P10; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HORRUM MA, 1980, PLANTA, V149, P376, DOI 10.1007/BF00571173; HUANG LQ, 1992, PLANT PHYSIOL, V99, P247, DOI 10.1104/pp.99.1.247; JACKSON RC, 1977, P NATL ACAD SCI USA, V74, P5598, DOI 10.1073/pnas.74.12.5598; JONES EW, 1991, J BIOL CHEM, V266, P7963; KISHORE R, 1993, P NATL ACAD SCI USA, V90, P11845, DOI 10.1073/pnas.90.24.11845; KISHORE R, 1992, PLANT SCI, V85, P79, DOI 10.1016/0168-9452(92)90096-5; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOHORN BD, 1986, J CELL BIOL, V102, P972, DOI 10.1083/jcb.102.3.972; KOHORN BD, 1991, J BIOL CHEM, V266, P12048; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LILJESTROM P, 1991, J VIROL, V65, P147; LIN Q, 1994, J BIOL CHEM, V269, P9436; MONROY AF, 1987, PLANT SCI, V51, P61, DOI 10.1016/0168-9452(87)90221-4; MUCHHAL US, 1992, PLANT MOL BIOL, V18, P287, DOI 10.1007/BF00034956; MUCHHAL US, 1994, NUCLEIC ACIDS RES, V22, P5737, DOI 10.1093/nar/22.25.5737; OSAFUNE T, 1991, EXP CELL RES, V193, P320, DOI 10.1016/0014-4827(91)90103-2; OSAFUNE T, 1983, EXP CELL RES, V148, P530, DOI 10.1016/0014-4827(83)90176-3; OSAFUNE T, 1991, J ELECTRON MICROSC, V40, P41; OSAFUNE T, 1980, J ULTRA MOL STRUCT R, V73, P77, DOI 10.1016/0022-5320(80)90117-3; OSAFUNE T, 1990, J ELECTRON MICROSC, V39, P168; OSAFUNE T, 1980, J ULTRA MOL STRUCT R, V73, P64, DOI 10.1016/0022-5320(80)90116-1; OSAFUNE T, 1992, J STRUCT BIOL, V109, P97, DOI 10.1016/1047-8477(92)90041-8; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; RIKIN A, 1988, P NATL ACAD SCI USA, V85, P5117, DOI 10.1073/pnas.85.14.5117; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SAIDHA T, 1985, BIOCHEM J, V232, P357, DOI 10.1042/bj2320357; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIFF JA, 1991, J PHOTOCH PHOTOBIO B, V11, P219, DOI 10.1016/1011-1344(91)80262-G; SHARIF AL, 1989, EUR J BIOCHEM, V184, P353, DOI 10.1111/j.1432-1033.1989.tb15026.x; SHIGEMORI Y, 1994, PLANT MOL BIOL, V24, P209, DOI 10.1007/BF00040587; SHORE G, 1975, J CELL BIOL, V64, P557, DOI 10.1083/jcb.64.3.557; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; TOKUNAGA M, 1979, J PROTOZOOL, V26, P471, DOI 10.1111/j.1550-7408.1979.tb04655.x; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WAINWRIGHT IM, 1992, J PHYCOL, V28, P643, DOI 10.1111/j.0022-3646.1992.00643.x; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169	58	64	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13084	13090		10.1074/jbc.270.22.13084	http://dx.doi.org/10.1074/jbc.270.22.13084			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768903	hybrid			2022-12-25	WOS:A1995RB43900024
J	XIAO, H; NAKTINIS, V; ODONNELL, M				XIAO, H; NAKTINIS, V; ODONNELL, M			ASSEMBLY OF A CHROMOSOMAL REPLICATION MACHINE - 2 DNA-POLYMERASES, A CLAMP LOADER, AND SLIDING CLAMPS IN ONE HOLOENZYME PARTICLE .4. ATP-BINDING SITE MUTANTS IDENTIFY THE CLAMP LOADER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; III HOLOENZYME; GAMMA-SUBUNIT; EXCISION REPAIR; BETA-SUBUNIT; TAU-SUBUNIT; PROTEIN; GENE; PURIFICATION; MECHANISM	The gamma complex (gamma delta delta'chi psi and tau complex (tau delta delta'chi psi) clamp loaders require ATP hydrolysis to load beta sliding clamps onto DNA. The beta sliding clamp tethers the polymerase (Pol) III* replicase to DNA for processive synthesis. Pol III* contains both gamma and tau, but only one each of the delta, delta', chi, and psi subunits. Hence, there is ambiguity with respect to which clamp loader, the gamma or tau complex, exists in the Pol III* replicase structure. In this study, ATP-binding site mutants of gamma and tau have been prepared, and these mutants, when assembled into either the gamma or tau complex, are inactive in clamp loading. These mutants have been used as a tool to determine the identity of the clamp loader in Pol III*. The nine-subunit Pol III* has been assembled using either mutant gamma or tau in place of wild-type gamma or tau. The results show that mutation of gamma inactivates Pol III* activity, but mutation of tau does not, indicating that the gamma complex (and not the tau complex) is the clamp loader of Pol III*. The tau subunit carries the task of dimerizing the core polymerase, and it is this association of tau with core that appears to direct the single copy subunits away from tau and onto gamma.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HEARST RES FDN,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute; Cornell University; Cornell University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISWAS SB, 1984, J BIOL CHEM, V259, P7990; BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; DONG A, 1993, J BIOL CHEM, V268, P11758; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6547; MAKI S, 1988, J BIOL CHEM, V263, P6555; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; ODONNELL M, 1992, BIOESSAYS, V14, P105, DOI 10.1002/bies.950140206; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511	29	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13378	13383		10.1074/jbc.270.22.13378	http://dx.doi.org/10.1074/jbc.270.22.13378			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768939	hybrid			2022-12-25	WOS:A1995RB43900064
J	MADANI, A; SOULIER, J; SCHMID, M; PLICHTOVA, R; LERME, F; GATEAUROESCH, O; GARNIER, JP; PLA, M; SIGAUX, F; STERN, MH				MADANI, A; SOULIER, J; SCHMID, M; PLICHTOVA, R; LERME, F; GATEAUROESCH, O; GARNIER, JP; PLA, M; SIGAUX, F; STERN, MH			THE 8-KD PRODUCT OF THE PUTATIVE ONCOGENE MTCP-1 IS A MITOCHONDRIAL PROTEIN	ONCOGENE			English	Note						MITOCHONDRIA; T-CELL PROLYMPHOCYTIC LEUKEMIA; (X-14) TRANSLOCATION; MTCP-1	CHRONIC LYMPHOCYTIC-LEUKEMIA; ATAXIA-TELANGIECTASIA; TRANSLOCATION; CHROMOSOME; GENE; ABNORMALITIES; SEQUENCE; IMPORT	An unusually small (8 kD) protein (p8(MTCP-1)) is coded by the putative oncogene MTCP-1 (also called c6.1B), involved in the translocation t(X;14)(q28;q11) associated with some mature T-cell proliferations. Here, we show by subcellular fractionation and by confocal microscopy that this protein is located in the mitochondria. This localization orientates toward a role of p8(MTCP-1) in the mitochondrial metabolism which may be relevant for the oncogenic process.	HOP ST LOUIS,HEMATOL MOLEC LAB,F-75475 PARIS,FRANCE; HOP ST LOUIS,INSERM,U93,F-75475 PARIS,FRANCE; HOP ST LOUIS,INST HEMATOL,SERV COMMUN IMAGERIE CELLULAIRE,F-75475 PARIS,FRANCE; HOP ST LOUIS,BIOCHIM LAB,F-75475 PARIS,FRANCE; FAC MED LYON SUD,INSERM,U189,F-69921 OULLINS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)			Stern, Marc-Henri/A-2728-2011	Stern, Marc-Henri/0000-0002-8100-2272				BEATTY DW, 1986, S AFR MED J, V69, P115; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; CANKI N, 1983, ZDRAV VESTN, V52, P567; DALLAPICCOLA B, 1984, INT J CANCER, V34, P171, DOI 10.1002/ijc.2910340206; FISCH P, 1993, ONCOGENE, V8, P3271; GASNIER F, 1993, ANAL BIOCHEM, V212, P173, DOI 10.1006/abio.1993.1309; GLICK B, 1991, ANNU REV GENET, V25, P21; GOYNS MH, 1993, LEUKEMIA, V7, P848; KADENBACH B, 1990, BIOCHIM BIOPHYS ACTA, V1015, P368, DOI 10.1016/0005-2728(90)90042-3; KENWRICK S, 1992, HUM MOL GENET, V1, P179, DOI 10.1093/hmg/1.3.179; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; MACKAY IR, 1989, IMMUNOL TODAY, V10, P315, DOI 10.1016/0167-5699(89)90088-1; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHERRINGTON PD, 1994, ONCOGENE, V9, P2377; SOULIER J, 1994, ONCOGENE, V9, P3565; STERN MH, 1993, ONCOGENE, V8, P2475; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAYLOR AMR, 1981, INT J CANCER, V27, P311, DOI 10.1002/ijc.2910270309; TAYLOR AMR, 1992, LEUKEMIA, V6, P961; THICK J, 1994, LEUKEMIA, V8, P564; WITZIG TE, 1986, AM J HEMATOL, V21, P139, DOI 10.1002/ajh.2830210204	25	30	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2259	2262						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784073				2022-12-25	WOS:A1995RB70300024
J	VELASCO, JA; RAMSAMOOJ, P; THRAVES, PJ; EVA, A; DRITSCHILO, A; NOTARIO, V				VELASCO, JA; RAMSAMOOJ, P; THRAVES, PJ; EVA, A; DRITSCHILO, A; NOTARIO, V			COREGULATED EXPRESSION OF DBL AND POLY(ADP-RIBOSE) POLYMERASE IN EWINGS-SARCOMA CELLS AND DBL-TRANSFORMED NIH3T3 FIBROBLASTS	ONCOGENE			English	Note						EWINGS SARCOMA; GENE EXPRESSION; DBL ONCOGENE; POLY(ADP-RIBOSE) POLYMERASE; NIH3T3 FIBROBLASTS	PROTO-ONCOGENE; DNA; PROTOONCOGENE; CLONING; PRODUCT; ORIGIN; CDNA; GENE	Poly(ADP-ribose) polymerase (PADPRP) is a ubiquitous enzyme constitutively expressed at low levels in the majority of eukaryotic cells, including most mammalian tumors and tumor-derived cell lines. Overexpression of PADPRP following the introduction of cDNA recombinant constructs into various cell types results in cell death. An exception to this effect are Ewing's sarcoma (ES) cells, which have been shown to contain elevated steady-state levels of PADPRP mRNA and high constitutive levels of protein and polymerase activity. In fact, this excess of PADPRP has been suggested to participate in the intrinsic radiosensitivity of Ewing's sarcomas, a highly malignant childhood bone tumor frequently curable with radiotherapy. It appears that ES cells might possess a hitherto unknown mechanism(s) by which PADPRP overexpression is controlled and made compatible with cell survival and proliferation. In order to investigate the contribution of other genetic alterations to PADPRP regulation in ES cells, we analysed the expression levels of PADPRP and of other genes, such as oncogenes and tumor suppressor genes, which may enhance the proliferative potential of ES cells. We have detected a positive correlation between the expression levels of the DNA-repair enzyme poly(ADP-ribose) polymerase and the dbl proto-oncogene in Ewing's sarcoma cells. The co-regulated expression of these genes has been established in NIH3T3 cells transformed by the human dbl oncogene or by overexpression of the dbl proto-oncogene. In both instances, the increase in dbl expression resulted in elevated levels of PADPRP mRNA and polymerase activity. The dbl oncogene was more efficient than the proto-oncogene in upregulating PADPRP expression. The inability of other oncogenes to upregulate PADPRP upon transformation of NIH3T3 cells demonstrated the specificity of the dbl in the process. Transfection of dbl-transformed NIH3T3 cells with retroviral PADPRP vectors resulted in the establishment of clones with PADPRP levels higher than those detectable in untransformed NIH3T3 cells transfected with the same retroviral constructs. These results suggest that dbl plays a role in the mechanism by which mammalian cells autoregulate their endogenous levels of PADPRP. Post-translational modification of the dbl or proto-dbl proteins by cytoplasmic PADPRP does not participate in the mechanism(s) underlying the observed PADPRP/dbl co-regulation.	GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,WASHINGTON,DC 20007; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			/AFP-0764-2022; Eva, Alessandra/J-8268-2016; /AAB-6461-2022	Eva, Alessandra/0000-0003-2949-078X; 	NATIONAL CANCER INSTITUTE [R01CA058986] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; AVILA MA, 1994, YEAST, V10, P1003, DOI 10.1002/yea.320100803; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BHATIA K, 1990, J CELL PHYSIOL, V144, P345, DOI 10.1002/jcp.1041440221; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; DEFRANCISCIS V, 1991, CANCER RES, V51, P4234; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GRAZIANI G, 1989, ONCOGENE, V4, P823; HUPPI K, 1989, NUCLEIC ACIDS RES, V17, P3387, DOI 10.1093/nar/17.9.3387; IKAI K, 1980, P NATL ACAD SCI-BIOL, V77, P3682, DOI 10.1073/pnas.77.6.3682; JORGENSEN TJ, 1993, RADIAT ONCOL INVEST, V1, P189; KAISER P, 1992, MOL GEN GENET, V232, P231, DOI 10.1007/BF00280001; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; NOTARIO V, 1990, ONCOGENE, V5, P1425; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; Prasad Sarada, 1994, Applied and Theoretical Electrophoresis, V4, P3; PRASAD SC, 1990, CANCER RES, V50, P38; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; THOMASSIN H, 1985, BIOCHEM BIOPH RES CO, V133, P654, DOI 10.1016/0006-291X(85)90955-6; VECCHIO G, 1989, ONCOGENE, V4, P897; VELASCO JA, 1994, ONCOGENE, V9, P2065; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683	25	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2253	2258						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784072				2022-12-25	WOS:A1995RB70300023
J	BRAUWEILER, A; GARL, P; FRANKLIN, AA; GIEBLER, HA; NYBORG, JK				BRAUWEILER, A; GARL, P; FRANKLIN, AA; GIEBLER, HA; NYBORG, JK			A MOLECULAR MECHANISM FOR HUMAN T-CELL LEUKEMIA-VIRUS LATENCY AND TAX TRANSACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; TRANSCRIPTIONAL CONTROL REGION; MULTIPLE NUCLEAR FACTORS; CAMP-RESPONSIVE ELEMENT; DNA-BINDING PROTEINS; HTLV-I; ENHANCER ELEMENT; 21-BASE-PAIR ENHANCER; TRANS-ACTIVATOR; GENE-PRODUCT	The human T cell leukemia virus type I (HTLV-I) is the causative agent of an aggressive T-cell malignancy in humans. While the virus appears to maintain a state of latency in most infected cells, high level virion production is an essential step in the HTLV-I Life cycle, The virally-encoded Tax protein, a potent activator of gene expression, is believed to control the switch from latency to replication. Tax stimulation of HTLV-I transcription is mediated through cellular activating transcription factor/cAMP response element binding proteins, which bind the three al-base pair (bp) repeat viral enhancer elements, In this report, we show that viral latency may result from a highly unstable interaction between CREB and the HTLV-I 21-bp repeats, resulting in rapid dissociation of CREB from the viral promoter. In the presence Tax, the dissociation rate of CREB from a 21-bp repeat element is decreased. This stabilization is highly specific, requiring the amino-terminal region of CREB and appropriate 21-bp repeat sequences. me suggest that Tax stabilization of CREB binding to the viral promoter leads to an increase in gene expression, possibly providing the switch from latency to high level replication of the virus.	COLORADO STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,FT COLLINS,CO 80523	Colorado State University					NATIONAL CANCER INSTITUTE [R55CA055035, R01CA055035] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BEIMLING P, 1992, ONCOGENE, V7, P257; BEIMLING P, 1988, ONCOGENE, V4, P511; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CONNOR LM, 1993, VIROLOGY, V195, P569, DOI 10.1006/viro.1993.1408; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FUJII M, 1991, ONCOGENE, V6, P2349; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; ISHIBASHI K, 1987, J IMMUNOL, V139, P1509; KAWANO F, 1985, CANCER-AM CANCER SOC, V55, P851, DOI 10.1002/1097-0142(19850215)55:4<851::AID-CNCR2820550424>3.0.CO;2-J; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; NAKAMURA M, 1989, NUCLEIC ACIDS RES, V17, P5207, DOI 10.1093/nar/17.13.5207; NYBORG JK, 1990, J BIOL CHEM, V265, P8237; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PACAUCCARALERTK.S, 1994, MOL CELL BIOL, V14, P456; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; TSUCHIYA H, 1994, ONCOGENE, V9, P337; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	41	80	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12814	12822		10.1074/jbc.270.21.12814	http://dx.doi.org/10.1074/jbc.270.21.12814			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759537	hybrid			2022-12-25	WOS:A1995QZ71100074
J	LAW, B; ROSSIE, S				LAW, B; ROSSIE, S			THE DIMERIC AND CATALYTIC SUBUNIT FORMS OF PROTEIN PHOSPHATASE 2A FROM RAT-BRAIN ARE STIMULATED BY C-2-CERAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CERAMIDE; PURIFICATION; PHOSPHORYLATION; IDENTIFICATION; CALCINEURIN; TYPE-2A; GROWTH; KINASE	Protein phosphatase 2A (PP-2A) is a heterotrimeric enzyme consisting of a catalytic (C) subunit and A and B regulatory subunits, PP-2A is activated by ceramide in vitro suggesting that PP-2A may be a target of this putative second messenger in vivo (Dobrowsky, R. T., Kamibayashi, C., Mumby, M. C., and Hannun, Y. A. (1993) J. Biol. Chem. 268, 15523-15530). In this study, sensitivity to ceramide was only observed when the B subunit was present, suggesting that the B subunit was required for ceramide activation, Here we show that dimeric PP-2A, produced from trimeric PP-2A by heparin-agarose-induced dissociation of the B subunit and isolated by preparative native electrophoresis, is activated by ceramide, The catalytic subunit of PP-2A, produced from trimeric PP-2A by freezing and thawing in the presence of 0.2 m beta-mercaptoethanol and isolated by gel filtration, is also activated by ceramide, The trimeric and catalytic subunit forms of PP-2A exhibit a similar dose dependence of activation by ceramide, and are stimulated to a similar extent at ceramide concentrations yielding maximal activation, These findings indicate that neither the A nor the B subunit is required for ceramide stimulation of PP-2A Together, these results demonstrate that the catalytic subunit contains a ceramide binding site and suggest that efforts to understand the mechanism of activation of PP-2A by ceramide should be focused on this subunit, The discovery that the catalytic subunit contains a ceramide binding site raises the possibility that other members of this serine/threonine phosphatase gene family may contain Lipid binding sites and be regulated by ceramide or other Lipid second messengers.	PURDUE UNIV,DEPT BIOCHEM 1153,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NINDS NIH HHS [NS31221] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031221, R29NS031221] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOLLAG DM, 1991, PROTEIN METHODS, P145; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHEN SC, 1989, J BIOL CHEM, V264, P7267; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DENT P, 1990, FEBS LETT, V259, P281, DOI 10.1016/0014-5793(90)80027-G; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; FAVRE B, 1994, J BIOL CHEM, V269, P16311; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GUO H, 1993, J BIOL CHEM, V268, P11193; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KIM MY, 1991, J BIOL CHEM, V266, P484; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LEE J, 1993, J BIOL CHEM, V268, P19192; MAIZEL JV, 1971, METHOD VIROL, V51, P179; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; TAMURA S, 1980, EUR J BIOCHEM, V104, P347, DOI 10.1111/j.1432-1033.1980.tb04435.x; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; XIE HY, 1993, J BIOL CHEM, V268, P13364; XIE HY, 1994, J BIOL CHEM, V269, P1981	34	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12808	12813		10.1074/jbc.270.21.12808	http://dx.doi.org/10.1074/jbc.270.21.12808			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759536	hybrid			2022-12-25	WOS:A1995QZ71100073
J	ZHOU, GC; BAO, ZQ; DIXON, JE				ZHOU, GC; BAO, ZQ; DIXON, JE			COMPONENTS OF A NEW HUMAN PROTEIN-KINASE SIGNAL-TRANSDUCTION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN	We have identified two components of a new protein kinase signaling cascade, MAPK/ERK kinase 5 (MEK5) and extracellular signal-regulated kinase 5 (ERK5). The MEK5 cDNA was isolated by degenerate PCR and encodes a 444-amino acid protein, which has approximately 40% identity to known MEKs. ERK5 was identified by a specific interaction with the MEK5 mutants S311A/T315A and K195M in the yeast two-hybrid system, The proteins were found to interact in an in vitro binding assay as well. ERK5 did not interact with MEK1 or MEK2. ERK5 is predicted to contain 815 amino acids and is approximately twice the size of all known ERKs. The C terminus of ERK5 has sequences which suggest that it may be targeted to the cytoskeleton. Sequences located in the N terminus of MEK5 may be important in coupling GTPase signaling molecules to the MEK5 protein kinase cascade. Both MEK5 and ERK5 are expressed in many adult tissue and are abundant in heart and skeletal muscle. A recombinant GST-ERK5 kinase domain displays autophosphorylation on Ser/Thr and Tyr residues.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018024, R37DK018024] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDKD 18024] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LUNDBLAD V, 1988, CURRENT PROTOCOLS MO; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGER R, 1994, J BIOL CHEM, V269, P25699; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	29	523	546	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12665	12669		10.1074/jbc.270.21.12665	http://dx.doi.org/10.1074/jbc.270.21.12665			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759517	hybrid			2022-12-25	WOS:A1995QZ71100053
J	CHEN, YR; HARTMANN, FC				CHEN, YR; HARTMANN, FC			A SIGNATURE OF THE OXYGENASE INTERMEDIATE IN CATALYSIS BY RIBULOSE-BISPHOSPHATE CARBOXYLASE OXYGENASE AS PROVIDED BY A SITE-DIRECTED MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							1,5-BISPHOSPHATE CARBOXYLASE; ACTIVE-SITE; RIBULOSEBISPHOSPHATE CARBOXYLASE; MECHANISM; PRODUCTS; SPINACH	An uncharacterized minor transient product, observed in our earlier studies of substrate turnover by the E48Q mutant of Rhodospirillum rubrum ribulose-bisphosphate carboxylase/oxygenase (Lee, E. H., Harpel, M. R., Chen, Y. R., and Hartman, F. C. (1993) J. Biol. Chem. 268, 26583-26591), becomes a major product when it is trapped and stabilized with berate as an additive to the reaction mixture. Chemical characterization establishes this novel product as D-glycero-2,3-pentodiulose 1,5-bisphosphate, thereby demonstrating oxidation of the C-3 hydroxyl of D- ribulose 1,5-bisphosphate to a carbonyl. As the formation of the novel oxidation product is oxygen-dependent and generates hydrogen peroxide, its precursor must be a peroxy derivative of ribulose bisphosphate. Thus, discovery of the dicarbonyl bisphosphate lends direct support to the long standing, but heretofore unproven, postulate that the normal pathway for oxidative cleavage of ribulose bisphosphate by the wild-type enzyme entails a peroxy intermediate. Our results also suggest that stabilization of the peroxy intermediate by the wild-type enzyme promotes carbon-carbon scission as opposed to elimination of hydrogen peroxide.	OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN PROGRAM,OAK RIDGE,TN 37831; UNIV TENNESSEE,GRAD SCH BIOMED SCI,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville								ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; BRANDEN R, 1984, BIOCHEMISTRY-US, V23, P4378; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; EDMONDSON DL, 1990, FEBS LETT, V260, P62, DOI 10.1016/0014-5793(90)80066-R; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1376, DOI 10.1104/pp.93.4.1376; HARPEL MR, 1994, BIOCHEMISTRY-US, V33, P5553, DOI 10.1021/bi00184a026; HARPEL MR, 1993, ANAL BIOCHEM, V209, P367, DOI 10.1006/abio.1993.1136; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; JORDAN DB, 1983, ARCH BIOCHEM BIOPHYS, V227, P425, DOI 10.1016/0003-9861(83)90472-1; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LARSON EM, 1995, IN PRESS BIOCHEMISTR, V34; LEE EH, 1993, J BIOL CHEM, V268, P26583; LORIMER GH, 1973, BIOCHEMISTRY-US, V12, P18, DOI 10.1021/bi00725a004; MASSEY V, 1994, J BIOL CHEM, V269, P22459; SCHLOSS JV, 1982, METHOD ENZYMOL, V90, P522; SCHNEIDER G, 1992, ANNU REV BIOPH BIOM, V21, P119, DOI 10.1146/annurev.bb.21.060192.001003; YOKOTA A, 1991, PLANT CELL PHYSIOL, V32, P755; ZHU GH, 1991, PLANT PHYSIOL, V97, P1354, DOI 10.1104/pp.97.4.1354	21	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11741	11744		10.1074/jbc.270.20.11741	http://dx.doi.org/10.1074/jbc.270.20.11741			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744819	hybrid			2022-12-25	WOS:A1995QY73600011
J	CUENDA, A; NOGUES, M; HENAO, F; GUTIERREZMERINO, C				CUENDA, A; NOGUES, M; HENAO, F; GUTIERREZMERINO, C			INTERACTION BETWEEN GLYCOGEN-PHOSPHORYLASE AND SARCOPLASMIC-RETICULUM MEMBRANES AND ITS FUNCTIONAL IMPLICATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CA-2+ RELEASE; MECHANISM; ATPASE; CA2+; AMP; FLUORESCENCE; MODULATION; ACTIVATION; COMPLEX	Skeletal muscle glycogen phosphorylase b binds to sarcoplasmic reticulum (SR) membranes with a dissociation constant of 1.7 +/- 0.6 mg of phosphorylase/ml at 25 degrees C at physiological pH and ionic strength. Raising the temperature to 37 degrees C produced a 2-3-fold decrease in the dissociation constant. The SR membranes could bind up to 1.1 +/- 0.1 mg of glycogen phosphorylase b/mg of SR protein, whereas liposomes prepared with endogenous SR lipids and reconstituted Ca2+-ATPase were unable to bind glycogen phosphorylase, Binding of glycogen phosphorylase b to SR membranes is accompanied by inhibition of its activity in the presence of AMP. The V-max for glycogen phosphorylase b associated with SR membranes is 40 +/- 5% of that for purified glycogen phosphorylase and shows a decreased affinity for its allosteric activators, AMP and IMP. These kinetic effects are also observed with purified glycogen phosphorylase b when starch or cu-amylose is used as substrate instead of glycogen. Treatment of SR membranes with alpha-amylase produced dissociation of glycogen phosphorylase b from the SR membranes. Thus, linear polysaccharide fragments of glycogen bound to the SR membranes are likely mediating the binding of glycogen phosphorylase b to these membranes.	UNIV EXTREMADURA, FAC CIENCIAS, DEPT BIOQUIM & BIOL MOLEC, E-06080 BADAJOZ, SPAIN	Universidad de Extremadura			Gutierrez-Merino, Carlos/K-4574-2014; Henao, Fernando/F-6694-2016	Gutierrez-Merino, Carlos/0000-0003-3673-7007; Henao, Fernando/0000-0003-1117-8544				ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BUC MH, 1971, BIOCHIMIE, V53, P283, DOI 10.1016/S0300-9084(71)80094-9; Busby S J, 1976, Curr Top Cell Regul, V10, P89; CUENDA A, 1990, EUR J BIOCHEM, V194, P663, DOI 10.1111/j.1432-1033.1990.tb15666.x; CUENDA A, 1994, BBA-BIOMEMBRANES, V1194, P35, DOI 10.1016/0005-2736(94)90200-3; CUENDA A, 1993, BIOCHEM BIOPH RES CO, V196, P1127, DOI 10.1006/bbrc.1993.2368; CUENDA A, 1991, FEBS LETT, V283, P273, DOI 10.1016/0014-5793(91)80606-4; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ENTMAN ML, 1980, J BIOL CHEM, V255, P6245; ENTMAN ML, 1976, J BIOL CHEM, V251, P3140; FERNANDEZSALGUERO P, 1990, BIOCHIM BIOPHYS ACTA, V1022, P33, DOI 10.1016/0005-2736(90)90397-7; FISCHER EH, 1978, VERSATILITY PROTEINS, P133; Fiske CH, 1925, J BIOL CHEM, V66, P375; GUTIERREZMERINO C, 1989, BIOCHEMISTRY-US, V28, P3398, DOI 10.1021/bi00434a039; GUTIERREZMERINO C, 1983, TRENDS BIOCHEM SCI, V8, P8; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MADSEN NB, 1967, J BIOL CHEM, V242, P3301; MATA AM, 1985, BIOCHEM BIOPH RES CO, V133, P176, DOI 10.1016/0006-291X(85)91857-1; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MERINO CG, 1987, ARCH BIOCHEM BIOPHYS, V252, P303, DOI 10.1016/0003-9861(87)90035-X; MERINO CG, 1976, FEBS LETT, V67, P9, DOI 10.1016/0014-5793(76)80859-9; MERINO CG, 1980, J BIOCHEM-TOKYO, V87, P1483, DOI 10.1093/oxfordjournals.jbchem.a132889; MEYER F, 1970, J BIOL CHEM, V245, P6642; MORANGE M, 1976, EUR J BIOCHEM, V65, P553, DOI 10.1111/j.1432-1033.1976.tb10373.x; PICKART CM, 1982, J BIOL CHEM, V257, P5319; ROSS DC, 1987, J BIOL CHEM, V262, P2042; STRAUSBAUCH PH, 1967, METHOD ENZYMOL, V11, P671; VARSANYI M, 1981, FEBS LETT, V131, P223, DOI 10.1016/0014-5793(81)80372-9; Wang J. H, 1972, ENZYMES, V7, P435; WANSON JC, 1968, J CELL BIOL, V38, P130, DOI 10.1083/jcb.38.1.130; WANSON JC, 1972, J CELL BIOL, V54, P206, DOI 10.1083/jcb.54.2.206; WARREN GB, 1974, P NATL ACAD SCI USA, V78, P795	38	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11998	12004		10.1074/jbc.270.20.11998	http://dx.doi.org/10.1074/jbc.270.20.11998			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744850	hybrid			2022-12-25	WOS:A1995QY73600050
J	LI, JJ; OBERLEY, LW; STCLAIR, DK; RIDNOUR, LA; OBERLEY, TD				LI, JJ; OBERLEY, LW; STCLAIR, DK; RIDNOUR, LA; OBERLEY, TD			PHENOTYPIC CHANGES INDUCED IN HUMAN BREAST-CANCER CELLS BY OVEREXPRESSION OF MANGANESE-CONTAINING SUPEROXIDE-DISMUTASE	ONCOGENE			English	Article						BREAST; CANCER; MNSOD; TRANSFECTION; SOFT AGAR; NUDE MICE	SYRIAN-HAMSTER TISSUES; GLUTATHIONE-PEROXIDASE; ANTIOXIDANT ENZYMES; IMMUNOHISTOCHEMICAL LOCALIZATION; KIDNEY DEVELOPMENT; TRANSFECTED CELLS; EXPRESSION VECTOR; TRANSGENIC MICE; MAMMALIAN-CELLS; DOWNS-SYNDROME	Human manganese containing superoxide dismutase (MnSOD) cDNA was transfected into a human breast cancer cell line (MCF-7) in order to examine the effect of increased functional MnSOD on the cellular phenotype. A MnSOD-overexpressing clone was compared to control vector-transfected cells and to wild type MCF-7 cells. Southern blotting indicated incorporation of MnSOD cDNA into genomic DNA in the MnSOD overexpressing cell line. The MnSOD overexpressing cell line showed a 5.7-fold increase in MnSOD activity compared to wild type MCF-7 cells. Similar increases in MnSOD immunoreactive protein and mRNA levels were observed by Western and Northern blotting as well as using RT-PCR, The plating efficiency of cells grown in different concentrations of serum (1 to 20%) was decreased in the MnSOD overexpressing cell line. The fraction in soft agar culture was also after MnSOD cDNA transfection. When inoculated in nude mice, tumor growth was markedly inhibited in MnSOD overexpressing cells compared to wild type MCF-7 cells or plasmid control cells, These results support the hypothesis that increased MnSOD expression suppresses the malignant phenotype of human breast cancer cells and suggests that the MnSOD gene is a tumor suppressor gene in human breast cancer.	UNIV IOWA, RADIAT RES LAB, MED LABS 14, IOWA CITY, IA 52242 USA; UNIV KENTUCKY, GRAD CTR TOXICOL, LEXINGTON, KY 40506 USA; WILLIAM S MIDDLETON MEM VET ADM MED CTR, PATHOL SERV, MADISON, WI 53705 USA	University of Iowa; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital				Li, Jian Jian/0000-0003-3694-9675; Ridnour, Lisa A./0000-0001-9446-8349	NATIONAL CANCER INSTITUTE [R29CA049797, R01CA049797, R01CA041267] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41267, CA 49797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN SC, 1985, CANCER RES, V45, P1611; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; AMSTAD P, 1994, J BIOL CHEM, V269, P1606; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; CEBALLOS I, 1988, BIOCHIM BIOPHYS ACTA, V949, P58, DOI 10.1016/0167-4781(88)90054-1; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CHURCH SL, 1992, GENOMICS, V14, P823, DOI 10.1016/S0888-7543(05)80202-2; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; ELROYSTEIN O, 1988, CELL, V52, P259, DOI 10.1016/0092-8674(88)90515-6; EMANUEL JR, 1991, NUCLEIC ACIDS RES, V19, P2790, DOI 10.1093/nar/19.10.2790; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FERNANDEZPOL JA, 1982, CANCER RES, V42, P609; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V53, P205, DOI 10.1016/0165-4608(91)90097-E; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPMAN M, 1976, CANCER RES, V36, P4595; LOVEN DP, 1984, INT J CANCER, V33, P783, DOI 10.1002/ijc.2910330612; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, MOL CLONING; MINCGOLOMB D, 1991, EMBO J, V10, P2119, DOI 10.1002/j.1460-2075.1991.tb07745.x; NEGRINI M, 1994, CANCER RES, V54, P1331; NORRIS KH, 1990, MUTAT RES, V237, P95, DOI 10.1016/0921-8734(90)90015-J; Oberley L.W., 1985, HDB METHODS OXYGEN R, P217; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1989, FREE RADICAL BIO MED, V6, P379, DOI 10.1016/0891-5849(89)90083-X; OBERLEY LW, 1994, DRUGS DIET DIS, P47; OBERLEY TD, 1991, AM J PATHOL, V139, P355; OBERLEY TD, 1990, AM J PATHOL, V137, P199; OBERLEY TD, 1991, FREE RADICAL BIO MED, V10, P79, DOI 10.1016/0891-5849(91)90024-W; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI DOI 10.1074/jbc.RA117.001068; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; ROSENBERG CD, 1990, CANCER RES, V50, P1559; SAFFORD SE, 1994, CANCER RES, V54, P4261; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; SPITZ DR, 1990, ARCH BIOCHEM BIOPHYS, V279, P249, DOI 10.1016/0003-9861(90)90489-L; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0	49	245	250	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					1989	2000						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761099				2022-12-25	WOS:A1995QZ92600013
J	DENG, GE; PODACK, ER				DENG, GE; PODACK, ER			DEOXYRIBONUCLEASE INDUCTION IN APOPTOTIC CYTOTOXIC T-LYMPHOCYTES	FASEB JOURNAL			English	Article						APOPTOSIS; NUCLEASE; GROWTH FACTOR DEPRIVATION; CELL DEATH; DNA FRAGMENTATION	PROGRAMMED CELL-DEATH; ENDONUCLEASE; IDENTIFICATION; PURIFICATION; EXPRESSION; THYMOCYTES; SURVIVAL; NUCLEASE; BCL-2; LINES	IL-2-dependent CTLL2 cells, upon IL-2 deprivation, die by apoptosis, which is accompanied by the fragmentation of genomic DNA. Two major deoxyribonuclease activities were detected in the extract of IL-2-deprived CTLL2 cells in a zymographic assay. They were designated nuc-58 and nuc-40, based on their apparent molecular mass of 58 and 40 kDa. The activity of both DNases was greatly induced in CTLL2 cells deprived of IL-2 or treated with the kinase inhibitor staurosporine. Deregulated expression of bcl-2 cDNA suppressed the induction of both nuclease activities. Nuc-58 was dependent on both Ca2+ and Mg2+ ions whereas nuc-40 was also active in the presence of Mg2+ ions alone. Nuc-40 showed a preferential nuclear localization over that of nuc-58, which was found primarily in the cytoplasm, Optimal activity of both DNases required neutral pH and was inhibited by zinc ions. The physicochemical characteristics of the nucleases indicate that they are novel DNases associated with apoptosis in CTLL2 cells.	UNIV MIAMI, SCH MED, DEPT MICROBIOL & IMMUNOL, MIAMI, FL 33136 USA	University of Miami								BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FERNANDES RS, 1993, ANTICANCER RES, V13, P1253; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GILLIS S, 1977, J EXP MED, V146, P468, DOI 10.1084/jem.146.2.468; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KORSMEYER SJ, 1990, CURR TOP MICROBIOL, V166, P203; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LUCAS M, 1994, BIOCHEM PHARMACOL, V47, P667, DOI 10.1016/0006-2952(94)90129-5; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Peitsch Manuel C., 1994, Trends in Cell Biology, V4, P37, DOI 10.1016/0962-8924(94)90002-7; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RIBEIRO JM, 1993, BIOCHEMISTRY-US, V32, P9129, DOI 10.1021/bi00086a018; ROSENTHAL AL, 1977, ANAL BIOCHEM, V80, P76, DOI 10.1016/0003-2697(77)90627-3; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; Wyllie A H, 1992, Semin Immunol, V4, P389; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40	27	24	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1995	9	8					665	669		10.1096/fasebj.9.8.7768359	http://dx.doi.org/10.1096/fasebj.9.8.7768359			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RC106	7768359				2022-12-25	WOS:A1995RC10600013
J	BRIGGS, SD; BRYANT, SS; JOVE, R; SANDERSON, SD; SMITHGALL, TE				BRIGGS, SD; BRYANT, SS; JOVE, R; SANDERSON, SD; SMITHGALL, TE			THE RAS GTPASE-ACTIVATING PROTEIN (GAP) IS AN SH3 DOMAIN-BINDING PROTEIN AND SUBSTRATE FOR THE SRC-RELATED TYROSINE KINASE, HCK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE HCK; C-SRC; PHOSPHATIDYLINOSITOL 3'-KINASE; GROWTH-FACTOR; 3T3 CELLS; EXPRESSION; PHOSPHORYLATION; ASSOCIATION; REGION; IDENTIFICATION	The Ras GTPase-activating protein (GAP) is a target for protein tyrosine kinases of both the receptor and cytoplasmic classes and may serve to integrate tyrosine kinase and Pas signaling pathways. In this report, we provide evidence that GAP is an SH3 domain-binding protein and substrate for the Src-related tyrosine kinase lick which has been implicated in the regulation of myeloid cell growth, differentiation, and function. Wild-type (WT) or kinase-inactive (K269E) mutant lick proteins were co expressed with bovine GAP using the baculovirus/Sf-9 cell system. GAP was readily phosphorylated on tyrosine by WT but not K269E lick. GAP was present in WT Hck immunoprecipitates from the coinfected cells, indicative of Hck . GAP complex formation. Unexpectedly, GAP also associated with the kinase-inactive mutant of Hck, suggesting that tyrosine autophosphorylation of Hck is not required for complex formation. The WT and K269E forms of Hck also associated with GAP mutants lacking either the C-terminaI catalytic domain (Delta CAT) or the Src homology region (Delta SH), indicating that these GAP domains are dispensable for complex formation. Recombinant GST fusion proteins containing the Hck, Src, Fyn, or Lck SH3 domains associated with full-length GAP, Delta CAT, and Delta SH, all of which share an N-terminal proline-rich region resembling an SH3-binding motif (PPLPPPPPQLP). Deletion of the highly conserved YXY sequence from the Hck SH3 domain abolished binding, GAP-SH3 interaction was also inhibited by the proline-rich peptide GFPPLP-PPPPQLPTLG, which corresponds to N-terminal amino acids 129-144 of bovine GAP. An N-terminal deletion mutant of GAP lacking this proline-rich region did not bind to the lick SH3 domain. These data implicate the Hck SH3 domain in GAP interaction, and suggest a general function for the SH3 domains of Src family kinases in recognition of GAP via its proline-rich N-terminal domain.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC, OMAHA, NE 68198 USA; UNIV MICHIGAN, SCH MED, MOLEC & CELLULAR BIOL PROGRAM, ANN ARBOR, MI 48109 USA	University of Nebraska System; University of Nebraska Medical Center; University of Michigan System; University of Michigan				Briggs, Scott D/0000-0003-2852-3594	NATIONAL CANCER INSTITUTE [R01CA055652, P30CA036727, R01CA058667] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA36727, CA58667, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOULET I, 1992, ONCOGENE, V7, P703; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; ENGLISH BK, 1993, J EXP MED, V178, P1017, DOI 10.1084/jem.178.3.1017; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HJERMSTAD SJ, 1993, BIOCHEMISTRY-US, V32, P10519, DOI 10.1021/bi00090a031; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LICHTENBERG U, 1992, ONCOGENE, V7, P849; LINNEKIN D, 1994, BLOOD, V84, P94, DOI 10.1182/blood.V84.1.94.bloodjournal84194; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; OKADA M, 1993, J BIOL CHEM, V268, P18070; PARK S, 1992, J BIOL CHEM, V267, P11612; PARK S, 1992, J BIOL CHEM, V267, P17194; PARK S, 1993, J BIOL CHEM, V268, P25728; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRONK GJ, 1992, ONCOGENE, V7, P389; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SANDERSON SD, 1994, J MED CHEM, V37, P3171, DOI 10.1021/jm00045a023; SATOH T, 1992, J BIOL CHEM, V267, P2537; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	56	61	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14718	14724		10.1074/jbc.270.24.14718	http://dx.doi.org/10.1074/jbc.270.24.14718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782336	hybrid			2022-12-25	WOS:A1995RD45500073
J	HOLTMANN, MH; HADAC, EM; MILLER, LJ				HOLTMANN, MH; HADAC, EM; MILLER, LJ			CRITICAL CONTRIBUTIONS OF AMINO-TERMINAL EXTRACELLULAR DOMAINS IN AGONIST BINDING AND ACTIVATION OF SECRETIN AND VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTORS - STUDIES OF CHIMERIC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CLONING; PEPTIDE; GENE	Secretin and vasoactive intestinal polypeptide (VIP) receptors are closely related G protein-coupled receptors in a recently described family possessing a large amino-terminal ectodomain, We postulated that this domain might be critical for agonist recognition and therefore constructed a series of six chimeric receptors, exchanging the amino terminus, the first extracellular loop, or both in secretin and VIP receptors, Constructs were expressed in COS cells and characterized by cAMP generation and binding of both secretin and MP radioligands, Wild type receptors demonstrated high affinity binding of respective ligands (IC50 values (in nM): at the secretin receptor: 2.2 for secretin, > 1000 for VIP; at the MP receptor: 2.2 for VIP, >1000 for secretin) and appropriately sensitive and selective biological responses (EC(50) values (in nM): at the secretin receptor: 1.5 for secretin, 127 for VIP; at the VIP receptor: 1.0 for VIP, 273 for secretin). Replacement of the secretin receptor amino terminus with that of the VIP receptor resulted in biological responsiveness typical of the VIP receptor (EC(50) = 120 nM for secretin, 1.7 nM for VIP), The converse was not true, with this domain of the secretin receptor not able to provide the same response when incorporated into the VIP receptor (EC(50) = 50 nM for VIP, 30 nM for secretin). The addition of both the first loop and the amino terminus of the secretin receptor was effective in yielding a secretin receptor-like response (EC(50) = 2.0 nM for secretin, 47 Im for VIP). All chimeric constructs expressing selectivity for secretin-stimulated activity bound this hormone with high affinity (IC50 = 0.2-2.2 nM); however, there was divergence between VIP binding and biological activity, Thus, the amino terminus of secretin and VIP receptors plays a key role in agonist recognition and responsiveness, with the first loop playing a critical complementary role for the secretin receptor.	MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,ROCHESTER,MN 55905	Mayo Clinic					NIDDK NIH HHS [DK46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046577, R01DK046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BISSONNETTE BM, 1984, AM J PHYSIOL, V246, pG710, DOI 10.1152/ajpgi.1984.246.6.G710; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG RRC, 1994, MOL PHARMACOL, V45, P690; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MUTT V, 1980, GASTROINTESTINAL HOR, P85; ROSSELIN G, 1986, PEPTIDES, V7, P89, DOI 10.1016/0196-9781(86)90170-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6	19	166	175	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14394	14398		10.1074/jbc.270.24.14394	http://dx.doi.org/10.1074/jbc.270.24.14394			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782300	hybrid			2022-12-25	WOS:A1995RD45500027
J	OHGURO, H; VANHOOSER, JP; MILAM, AH; PALCZEWSKI, K				OHGURO, H; VANHOOSER, JP; MILAM, AH; PALCZEWSKI, K			RHODOPSIN PHOSPHORYLATION AND DEPHOSPHORYLATION IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ROD OUTER SEGMENTS; LIGHT-DEPENDENT PHOSPHORYLATION; COUPLED RECEPTOR KINASES; PHOTOEXCITED RHODOPSIN; VISUAL TRANSDUCTION; BOVINE RHODOPSIN; 48-KDA PROTEIN; ACTIVATION; SITES; IDENTIFICATION	Rhodopsin is an important member of the superfamily of G protein-coupled receptors. In vitro studies have suggested that multiphosphorylation of rhodopsin is a pivotal step in phototransduction. Because the in vitro biochemical experiments were conducted under non-physiological conditions, we investigated the phosphorylation of mouse rhodopsin in vivo and determined the sites of phosphorylation and the time course of dephosphorylation. We found that a single phosphate group is incorporated into the rhodopsin molecule in a light-dependent manner, primarily at Ser(338) after flashes and at Ser(334) after continuous illumination. Dephosphorylation of these sites had different kinetics and spatial distribution in rod outer segments. Dephosphorylation of Ser(338) was complete within 30 min, while Ser(334) was dephosphorylated much slower (requiring up to 60 min), correlating with the regeneration of rhodopsin. These results suggest that phosphorylation of Ser(338) and Ser(334) plays different roles in phototransduction.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	OHGURO, H (corresponding author), UNIV WASHINGTON,SCH MED,DEPT OPHTHALMOL,RJ-10,SEATTLE,WA 98195, USA.				NATIONAL EYE INSTITUTE [R29EY008061, R01EY001311, R01EY008061, R01EY009339] Funding Source: NIH RePORTER; NEI NIH HHS [EY01311, EY08061, EY09339] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1988, HYBRIDOMA, V7, P237, DOI 10.1089/hyb.1988.7.237; ATON BR, 1984, BIOCHEMISTRY-US, V23, P1737, DOI 10.1021/bi00303a024; BALKEMA GW, 1985, NATURE, V316, P630, DOI 10.1038/316630a0; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BINDER BM, 1990, J BIOL CHEM, V265, P15333; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; DOWLING JE, 1963, NATURE, V199, P972, DOI 10.1038/199972a0; DOWLING JE, 1963, J GEN PHYSIOL, V46, P1287, DOI 10.1085/jgp.46.6.1287; FARNSWORTH CC, 1982, METHOD ENZYMOL, V81, P124; FRANK RN, 1973, J BIOL CHEM, V248, P596; HARGRAVE PA, 1994, REGULATION CELLULAR, P25; HODGKIN AL, 1987, J PHYSIOL-LONDON, V391, P347, DOI 10.1113/jphysiol.1987.sp016742; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; KUHN H, 1974, NATURE, V250, P588, DOI 10.1038/250588a0; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIEBMAN PA, 1983, J BIOL CHEM, V258, P1205; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; MOLDAY RS, 1988, PROGR RETINAL RES, V8, P173; NEWTON AC, 1993, TRENDS BIOCHEM SCI, V18, P275, DOI 10.1016/0968-0004(93)90032-I; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1995, IN PRESS J BIOL CHEM; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PAULSEN R, 1983, NATURE, V302, P417, DOI 10.1038/302417a0; PULLEN N, 1994, BIOCHEMISTRY-US, V33, P14536, DOI 10.1021/bi00252a021; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; SCHNAPF JL, 1983, J PHYSIOL-LONDON, V343, P147, DOI 10.1113/jphysiol.1983.sp014886; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; 1993, J AM VET MED ASSOC, V202, P2	38	166	170	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14259	14262		10.1074/jbc.270.24.14259	http://dx.doi.org/10.1074/jbc.270.24.14259			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782279	hybrid			2022-12-25	WOS:A1995RD45500005
J	BENESCH, RE; KWONG, S				BENESCH, RE; KWONG, S			COUPLED REACTIONS IN HEMOGLOBIN - HEME-GLOBIN AND DIMER-DIMER ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAMERS; CHAINS	Five different human hemoglobins were used to test the postulate that dissociation of hemoglobin (Hb) tetramers into alpha beta dimers and dissociation of heme from globin are linked reactions, Spectrophotometric measurements of the initial rate of heme transfer from Hb to serum albumin were made over a 3000-fold range of Hb concentration and yielded the heme-globin dissociation rate constant for tetramers and that for dimers. The tetramer-dimer dissociation constant (K-4,K-2) could then be calculated from the rate constant at intermediate concentrations. The values obtained for the five hemoglobins, spanning a 250-fold range in K-4,K-2, were in good agreement with those found by direct methods. The relation between this new linkage reaction of hemoglobin and the classical ones, such as the reciprocal relation between the binding of oxygen and protons, is discussed briefly.			BENESCH, RE (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.				NHLBI NIH HHS [HL-05791] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL005791, R01HL005791] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENESCH RE, 1991, J PROTEIN CHEM, V10, P503, DOI 10.1007/BF01025478; BENESCH RE, 1994, METHOD ENZYMOL, V231, P496; BENESCH RE, 1990, J BIOL CHEM, V265, P14881; BUNN HF, 1968, J BIOL CHEM, V243, P465; Cassoly R, 1981, Methods Enzymol, V76, P121; CHARACHE S, 1975, JOHNS HOPKINS MED J, V136, P132; DIDONATO A, 1983, J BIOL CHEM, V258, P1890; HRKAL Z, 1974, EUR J BIOCHEM, V43, P73, DOI 10.1111/j.1432-1033.1974.tb03386.x; JONES RT, 1967, J CLIN INVEST, V46, P1840, DOI 10.1172/JCI105674; Kilmartin J V, 1981, Methods Enzymol, V76, P167; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303; WINTERHALTER KH, 1971, BIOCHEMISTRY-US, V10, P3790, DOI 10.1021/bi00796a023; WYMAN J, 1948, ADV PROTEIN CHEM, V4, P407, DOI 10.1016/S0065-3233(08)60011-X; ZWART A, 1984, CLIN CHEM, V30, P373; ZWART A, 1981, J CLIN CHEM CLIN BIO, V19, P457	16	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13785	13786		10.1074/jbc.270.23.13785	http://dx.doi.org/10.1074/jbc.270.23.13785			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775434	hybrid			2022-12-25	WOS:A1995RC44800032
J	BORKOWSKI, JA; RANSOM, RW; SEABROOK, GR; TRUMBAUER, M; CHEN, H; HILL, RG; STRADER, CD; HESS, JF				BORKOWSKI, JA; RANSOM, RW; SEABROOK, GR; TRUMBAUER, M; CHEN, H; HILL, RG; STRADER, CD; HESS, JF			TARGETED DISRUPTION OF A B-2 BRADYKININ RECEPTOR GENE IN MICE ELIMINATES BRADYKININ ACTION IN SMOOTH-MUSCLE AND NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; PHARMACOLOGICAL CHARACTERIZATION; VAS-DEFERENS; ANTAGONIST; RAT; POTENT; PHOSPHOLIPASE-A2; STIMULATION; KALLIKREIN; ACTIVATION	Mice that are homozygous for the targeted disruption of the gene encoding the B-2, bradykinin receptor have been generated. The gene disruption results in a deletion of the entire coding sequence for the B-2 receptor. The disruption of the B-2 receptor gene has been confirmed by genetic, biochemical, and pharmacological analyses. Mice that are homozygous for the disruption of the B-2 receptor gene are fertile and indistinguishable from their littermates by visual inspection. Bradykinin fails to produce responses in pharmacological preparations from ileum, uterus, and the superior cervical ganglia from these mice. Therefore, expression of a single gene appears to be responsible for conferring responsiveness to bradykinin in these tissues.	MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT MOLEC PHARMACOL & BIOCHEM, RAHWAY, NJ 07065 USA; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT ANIM BIOCHEM & MOLEC BIOL, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME RES LABS, DEPT NEW LEAD PHARMACOL, West Point, PA 19586 USA; MERCK SHARP & DOHME RES LABS, DEPT PHARMACOL, HARLOW CM20 2QR, ESSEX, ENGLAND	Merck & Company; Merck & Company; Merck & Company; Merck & Company								BORKOWSKI JA, 1995, IN PRESS CAN J PHYSL; BRAAS KM, 1988, BRIT J PHARMACOL, V94, P3, DOI 10.1111/j.1476-5381.1988.tb11492.x; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BURCH RM, 1989, AGENTS ACTIONS, V27, P258, DOI 10.1007/BF01972790; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; DEBLOIS D, 1989, IMMUNOPHARMACOLOGY, V17, P187, DOI 10.1016/0162-3109(89)90047-7; DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7; FARMER SG, 1989, MOL PHARMACOL, V36, P1; FARMER SG, 1994, BRIT J PHARMACOL, V112, P461, DOI 10.1111/j.1476-5381.1994.tb13095.x; FARMER SG, 1992, ANNU REV PHARMACOL, V32, P511; HEDER G, 1994, ANDROLOGIA, V26, P295; HESS JF, 1994, MOL PHARMACOL, V45, P1; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; KAYA H, 1989, J BIOL CHEM, V264, P4972; LIEBMANN C, 1991, EUR J PHARMACOL, V199, P363, DOI 10.1016/0014-2999(91)90501-G; LIEBMANN C, 1994, MOL PHARMACOL, V46, P949; LINZ W, 1993, J CARDIOVASC PHARM, V22, pS1, DOI 10.1097/00005344-199306229-00002; LLONA I, 1987, J PHARMACOL EXP THER, V241, P608; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MCINTYRE P, 1993, MOL PHARMACOL, V44, P346; MENKE JG, 1994, J BIOL CHEM, V269, P21583; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4412, DOI 10.1073/pnas.91.10.4412; PARRATT JR, 1994, TRENDS PHARMACOL SCI, V15, P19, DOI 10.1016/0165-6147(94)90129-5; PERKINS MN, 1993, BRIT J PHARMACOL, V110, P1441, DOI 10.1111/j.1476-5381.1993.tb13982.x; PESQUERO JB, 1994, J BIOL CHEM, V269, P26920; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; RANSOM RW, 1992, BRIT J PHARMACOL, V105, P919, DOI 10.1111/j.1476-5381.1992.tb09078.x; REGOLI D, 1986, EUR J PHARMACOL, V127, P219, DOI 10.1016/0014-2999(86)90367-5; REGOLI D, 1978, CAN J PHYSIOL PHARM, V56, P674, DOI 10.1139/y78-109; REGOLI D, 1977, CAN J PHYSIOL PHARM, V55, P855, DOI 10.1139/y77-115; REGOLI D, 1980, PHARMACOL REV, V32, P1; RHALEB NE, 1992, EUR J PHARMACOL, V210, P115, DOI 10.1016/0014-2999(92)90661-M; RIFO J, 1987, EUR J PHARMACOL, V142, P305, DOI 10.1016/0014-2999(87)90120-8; SAHA JK, 1990, J PHARMACOL EXP THER, V252, P1012; SAWUTZ DG, 1994, P NATL ACAD SCI USA, V91, P4693, DOI 10.1073/pnas.91.11.4693; SCHNECK KA, 1994, EUR J PHARM-MOLEC PH, V266, P277, DOI 10.1016/0922-4106(94)90137-6; SEABROOK GR, 1995, IN PRESS BR J PHARM; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TROPEA MM, 1993, J PHARMACOL EXP THER, V264, P930; VALDES G, 1993, BIOL REPROD, V49, P802, DOI 10.1095/biolreprod49.4.802; Vavrek RJ, 1985, PEPTIDES, P655; WIRTH K, 1991, EUR J PHARMACOL, V205, P217, DOI 10.1016/0014-2999(91)90824-A; YAMAWAKI I, 1994, AM J PHYSIOL, V266, pL156, DOI 10.1152/ajplung.1994.266.2.L156; YOKOYAMA S, 1994, BIOCHEM BIOPH RES CO, V200, P634, DOI 10.1006/bbrc.1994.1495	47	203	203	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13706	13710		10.1074/jbc.270.23.13706	http://dx.doi.org/10.1074/jbc.270.23.13706			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775424	hybrid			2022-12-25	WOS:A1995RC44800021
J	CHEN, HF; KENDALL, DA				CHEN, HF; KENDALL, DA			ARTIFICIAL TRANSMEMBRANE SEGMENTS - REQUIREMENTS FOR STOP TRANSFER AND POLYPEPTIDE ORIENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; POSITIVELY CHARGED RESIDUES; AMINO-ACID SEQUENCE; ESCHERICHIA-COLI; MEMBRANE-PROTEINS; SIGNAL PEPTIDE; ANCHOR DOMAIN; STRUCTURAL REQUIREMENTS; HYDROPHOBIC DOMAIN; DELETION ANALYSIS	Transmembrane segments of proteins generally consist of a long stretch of hydrophobic amino acids, which can function to initiate membrane insertion (start-stop sequences), initiate translocation (signal-anchor sequences), or stop further translocation of the following polypeptide chain (stop-transfer sequences). In this study, we have taken Escherichia coli alkaline phosphatase, a transported and water-soluble protein, and examined the requirements for converting it into a transmembrane protein with particular orientation. Since the wild type enzyme is transported, there is no predisposition against membrane translocation, yet it is not a membrane protein, so it does not possess any intrinsic membrane topogenic preferences. A series of potential transmembrane segments was introduced into an internal position of the enzyme to test the ability of each to initiate translocation, stop translocation, and adopt a particular orientation. For this purpose, cassette mutagenesis was used to incorporate new structural segments composed of polymers of alanines and leucines. The threshold value of hydrophobicity required to function as a stop-transfer sequence was determined. For a transmembrane segment of typical length (21 residues), this value is equivalent to the hydrophobicity of 16 alanines and 5 leucines. Interestingly, much shorter segments mill also suffice to stop translocation, but these must be composed of more highly hydrophobic residues (e.g. 11 leucines). When the wild type amino-terminal signal peptide is deleted or made dysfunctional, sufficiently hydrophobic internal segments can initiate translocation of the following polypeptide and function as a signal anchor. Furthermore, in so doing, the orientation of the protein is changed from N-out-C-in to N-in-C-out.	UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,STORRS,CT 06269	University of Connecticut					NIGMS NIH HHS [GM37639] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037639] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; ARFMANN HA, 1977, BIOPOLYMERS, V16, P1815, DOI 10.1002/bip.1977.360160815; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Boyd D, 1987, PHOSPHATE METABOLISM, P89; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DAVIS NG, 1986, P NATL ACAD SCI USA, V83, P5091, DOI 10.1073/pnas.83.14.5091; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; DAVIS NG, 1985, J MOL BIOL, V181, P111, DOI 10.1016/0022-2836(85)90329-8; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; DOUD SK, 1993, BIOCHEMISTRY-US, V32, P1251, DOI 10.1021/bi00056a008; Eisenberg D., 1982, FARADAY S CHEM SOC, V17, P109, DOI DOI 10.1039/FS9821700109; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FERRETTI JA, 1969, BIOPOLYMERS, V7, P155, DOI 10.1002/bip.1969.360070203; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HSU MC, 1983, VIROLOGY, V126, P361, DOI 10.1016/0042-6822(83)90485-3; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KHORANA HG, 1979, P NATL ACAD SCI USA, V76, P5046, DOI 10.1073/pnas.76.10.5046; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM EE, 1989, CLIN CHIM ACTA, V186, P175; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LOCKER JK, 1992, J BIOL CHEM, V267, P21911; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MICHAELIS S, 1986, J BACTERIOL, V167, P160, DOI 10.1128/jb.167.1.160-167.1986; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PARKS GD, 1989, J CELL BIOL, V109, P2023, DOI 10.1083/jcb.109.5.2023; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; ROTH M, 1989, NATURE, V340, P659, DOI 10.1038/340659a0; RUSSEL M, 1982, CELL, V28, P177, DOI 10.1016/0092-8674(82)90387-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SPIESS M, 1987, EMBO J, V6, P2683, DOI 10.1002/j.1460-2075.1987.tb02560.x; TAHARA Y, 1992, BIOCHEMISTRY-US, V31, P8747, DOI 10.1021/bi00152a010; TANFORD C, 1978, SCIENCE, V200, P1012, DOI 10.1126/science.653353; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; VLASUK GP, 1984, J BIOL CHEM, V259, P6195; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x	51	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14115	14122		10.1074/jbc.270.23.14115	http://dx.doi.org/10.1074/jbc.270.23.14115			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775472	hybrid			2022-12-25	WOS:A1995RC44800077
J	PLAWNER, LL; PHILBRICK, WM; BURTIS, WJ; BROADUS, AE; STEWART, AF				PLAWNER, LL; PHILBRICK, WM; BURTIS, WJ; BROADUS, AE; STEWART, AF			CELL-TYPE-SPECIFIC SECRETION OF PARATHYROID HORMONE-RELATED PROTEIN VIA THE REGULATED VERSUS THE CONSTITUTIVE SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE; PRECURSOR; GLUCOSE; CANCER; GENE	Parathyroid hormone-related protein (PTHrP) is endoproteolytically processed to yield a family of mature secretory forms. These include an amino-terminal, a mid-region, and a carboxyl-terminal form. Prior studies suggested that the mid-region form is secreted via the regulated secretory pathway, whereas the amino- and carboxyl-terminal forms are secreted via the constitutive pathway. Further, PTHrP is unusual in that it is produced under normal circumstances by neuroendocrine cell types as well as by prototypical constitutively secreting cell types. The potential for cell-specific secretory pathway use by PTHrP has not been explored. Using immunohistochemical and perifusion techniques, we demonstrate that all three PTHrP daughter peptides are secreted via the regulated pathway in neuroendocrine cells. In contrast, all three daughter peptides are secreted in a constitutive fashion by non-neuroendocrine cells. Thus, the secretion of PTRrP is unique in that it appears to be cell-specific. When it is expressed in neuroendocrine cells that contain the regulated pathway, it is secreted in a regulated fashion; when it is expressed in non-neuroendocrine cells, it defaults to the constitutive pathway. This phenomenon has not previously been described for a polypeptide hormone in naturally occurring cells.	W HAVEN VET AFFAIRS MED CTR,DIV ENDOCRINOL & METAB,W HAVEN,CT 06516; YALE UNIV,SCH MED,DIV ENDOCRINOL & METAB,NEW HAVEN,CT 06520	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030102, R37AR030102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047168] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 30102] Funding Source: Medline; NIDDK NIH HHS [DK47168] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRANDT DW, 1991, ENDOCRINOLOGY, V128, P2999, DOI 10.1210/endo-128-6-2999; BRANDT DW, 1991, ENDOCRINOLOGY, V129, P2466, DOI 10.1210/endo-129-5-2466; BURTIS WJ, 1994, J CLIN ENDOCR METAB, V78, P317, DOI 10.1210/jc.78.2.317; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; BUZZETTI R, 1989, J CLIN INVEST, V83, P733, DOI 10.1172/JCI113940; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; DEFTOS LJ, 1993, J CLIN INVEST, V92, P727, DOI 10.1172/JCI116643; DRUCKER DJ, 1989, MOL ENDOCRINOL, V3, P1589, DOI 10.1210/mend-3-10-1589; FENTON AJ, 1991, ENDOCRINOLOGY, V129, P1762, DOI 10.1210/endo-129-4-1762; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; GAICH G, 1993, ENDOCRINOLOGY, V132, P1402, DOI 10.1210/en.132.3.1402; KELLY RB, 1985, SCIENCE, V240, P25; LI KW, 1994, ENDOCRINOLOGY, V134, P1812, DOI 10.1210/en.134.4.1812; LOH YP, 1993, MECHANISMS INTRACELL; ORLOFF JJ, 1994, ENDOCR REV, V15, P40, DOI 10.1210/er.15.1.40; RABBANI SA, 1993, BIOCHEMISTRY-US, V32, P4931, DOI 10.1021/bi00069a030; RIZZOLI R, 1994, INT J CANCER, V56, P422, DOI 10.1002/ijc.2910560323; SCHAUER E, 1994, J CLIN INVEST, V93, P2258, DOI 10.1172/JCI117224; SOIFER NE, 1992, J BIOL CHEM, V267, P18236; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; VOLLMAR AM, 1994, J CLIN INVEST, V94, P539, DOI 10.1172/JCI117367; WU TL, 1991, J CLIN ENDOCR METAB, V73, P1002, DOI 10.1210/jcem-73-5-1002; YANG KH, 1994, BIOCHEMISTRY-US, V33, P7460, DOI 10.1021/bi00189a054; ZAWALICH WS, 1988, DIABETES, V37, P1294, DOI 10.2337/diabetes.37.9.1294	25	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14078	14084		10.1074/jbc.270.23.14078	http://dx.doi.org/10.1074/jbc.270.23.14078			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775469	hybrid			2022-12-25	WOS:A1995RC44800072
J	WU, J; MATUNIS, MJ; KRAEMER, D; BLOBEL, G; COUTAVAS, E				WU, J; MATUNIS, MJ; KRAEMER, D; BLOBEL, G; COUTAVAS, E			NUP358, A CYTOPLASMICALLY EXPOSED NUCLEOPORIN WITH PEPTIDE REPEATS, RAN-GTP BINDING-SITES, ZINC FINGERS, A CYCLOPHILIN-A HOMOLOGOUS DOMAIN, AND A LEUCINE-RICH REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE COMPLEX PROTEIN; NUCLEAR-PORE; IMPORT; RECEPTOR; RAN/TC4	The Ras-related nuclear protein, Ran, has been implicated in nuclear transport, By screening a HeLa cell lambda expression library with Ran-GTP and sequencing overlapping cDNA clones, we have obtained the derived primary structure of a protein with a calculated molecular mass of 358 kDa, Using antibodies raised against an expressed segment of this protein, we obtained punctate nuclear surface staining by immunofluorescence microscopy that is characteristic for nucleoporins, Electron microscopy of immunogold-decorated rat liver nuclear envelopes sublocalized the 358-kDa protein at (or near) the tip of the cytoplasmic fibers of the nuclear pore complex (NPC), In agreement with current convention, this protein was therefore termed Nup358 (for nucleoporin of 358 kDa), Nup358 contains a leucine-rich region, four potential Ran binding sites (i.e. Ran binding protein 1 homologous domains) flanked by nucleoporin-characteristic FXFG or FG repeats, eight zinc finger motifs, and a C-terminal cyclophilin A homologous domain, Consistent with the location of Nup358 at the cytoplasmic fibers of the NPC, we found decoration with Ran-gold at only the cytoplasmic side of the NPC, Thus, Nup358 is the first nucleoporin shown to contain binding sites for two of three soluble nuclear transport factors so far isolated, namely karyopherin and Ran-GTP.			WU, J (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA.			Coutavas, Elias/0000-0003-4904-0081; Matunis, Michael/0000-0002-9350-6611	NIGMS NIH HHS [1F32GM16758-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016758] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; CORDES VC, 1993, J CELL BIOL, V123, P1333, DOI 10.1083/jcb.123.6.1333; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CULLEN BR, 1994, NATURE, V372, P319, DOI 10.1038/372319a0; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; HARLOW E, 1988, ANTIBODIES LABORATOR; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1993, J CELL BIOL, V121, P1, DOI 10.1083/jcb.121.1.1; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Sambrook J, 1989, MOL CLONING LABORATO; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	28	405	411	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14209	14213		10.1074/jbc.270.23.14209	http://dx.doi.org/10.1074/jbc.270.23.14209			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775481	hybrid			2022-12-25	WOS:A1995RC44800089
J	FORRESTER, K; LUPOLD, SE; OTT, VL; CHAY, CH; BAND, V; WANG, XW; HARRIS, CC				FORRESTER, K; LUPOLD, SE; OTT, VL; CHAY, CH; BAND, V; WANG, XW; HARRIS, CC			EFFECTS OF P53 MUTANTS ON WILD-TYPE P53-MEDIATED TRANSACTIVATION ARE CELL-TYPE DEPENDENT	ONCOGENE			English	Article						P53; P53 MUTANTS; TRANSACTIVATION; CELL TYPE SPECIFICITY	TRANSCRIPTIONAL ACTIVITY; GENE AMPLIFICATION; PROTEIN COMPLEXES; RAS MUTATIONS; CYCLE CONTROL; BINDING-SITE; DNA-DAMAGE; LINES; CANCER; EXPRESSION	The spectrum of p53 mutations differs among human cancer types. We have hypothesized that the p53 mutational spectrum observed in particular tumor types reflects the functional ability of different p53 mutants to modulate wild-type (WT) p53-dependent gene transcription. Missense p53 mutants representing several mutational hotspot codons were cotransfected with WT p53 and analysed for their effects on p53-dependent transactivation of a reporter construct containing a specific p53 binding sequence (PG(13)-CAT) in human tumor cell lines lacking endogenous p53. Our results show that the ability of p53 mutants to inhibit WT p53-mediated transactivation is cell type dependent. In cell lines derived from a lung adenocarcinoma and mesothelioma, the transactivation function of WT p53 was strongly inhibited by all p53 mutants examined. However, in cell lines derived from a prostate carcinoma and an osteosarcoma, the mutants examined generally had only minimal dominant negative effects. In cell lines derived from a hepatocellular carcinoma and an ovarian carcinoma, two mutants (248(trp) and 273(his)) enhanced WT p53 mediated-transactivation of the reporter construct. Additional mutants retained the ability to inhibit WT p53-mediated transactivation in these cell lines. In addition, in a series of four breast tumor cell lines, the p53 mutants examined had similar effects on WT p53 transactivation ability including enhanced transactivation activity in the 273(his) cotransfectants. The p53 mutants were incapable of transactivating the PG(13)-CAT reporter in the absence of WT p53 expression. Therefore, the dominant negative effects of p53 mutants on WT p53 function may vary depending on the particular cell type. In addition, mutants with stronger inhibitory capabilities may confer a selective advantage during the tumorigenic process.	NCI,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892; TUFTS UNIV NEW ENGLAND MED CTR,DEPT RADIOL ONCOL & BIOCHEM,BOSTON,MA 02111	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tufts Medical Center			Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAND V, 1990, CANCER RES, V50, P7351; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CHEN JY, 1993, ONCOGENE, V8, P2159; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; FREBOURG T, 1994, CANCER RES, V54, P878; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBLATT MS, 1994, CANCER RES, V55, P4855; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LIU XL, 1994, CARCINOGENESIS, V15, P1969, DOI 10.1093/carcin/15.9.1969; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; METCALF RA, 1992, CANCER RES, V52, P2610; MILLER CW, 1993, ONCOGENE, V8, P1815; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1993, ONCOGENE, V8, P2001; MIYASHITA T, 1995, CELL, V80, P293; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PONCHEL F, 1994, CANCER RES, V54, P2064; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TIBBETTS LM, 1984, P AM ASSOC CANC RES, V25, P45; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; YAGINUMA Y, 1992, CANCER RES, V52, P4196; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG W, 1993, CANCER RES, V53, P4772	69	105	105	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2103	2111						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784055				2022-12-25	WOS:A1995RB70300005
J	LIEVENS, PMJ; DONADY, JJ; TUFARELLI, C; NEUFELD, EJ				LIEVENS, PMJ; DONADY, JJ; TUFARELLI, C; NEUFELD, EJ			REPRESSOR ACTIVITY OF CCAAT DISPLACEMENT PROTEIN IN HL-60 MYELOID-LEUKEMIA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSORY ORGAN IDENTITY; GAMMA-GLOBIN GENE; DNA-BINDING; CUT LOCUS; DROSOPHILA; EXPRESSION; PROMOTER; REGION; ACTIVATION; ACID	CCAAT displacement protein (CDP)/cut is implicated in several systems as a transcriptional repressor of developmentally regulated genes. In myeloid leukemia cells, CDP/cut binding activity as assayed on the promoter of the phagocyte-specific cytochrome heavy chain gene gp91-phox varies inversely with expression of gp91-phox mRNA. We used two approaches to ascertain whether CDP/cut serves as a repressor of gp91-phox gene expression, First, we used transient transfection assays in 3T3 cells to demonstrate that the CDP/cut binding site from the gp91-phox promoter acts as a negative regulatory element in artificial promoter constructs, Second, we isolated a stable transformant of HL-60 myeloid cells constitutively expressing transfected CDP/cut cDNA, Stable transformants carrying expression vector alone or expressing CDP/cut mRNA were induced to differentiate along the macrophage lineage with phorbol ester or along the neutrophil lineage with dimethyl sulfoxide or retinoic acid/dimethylformamide, Northern blot analysis was used to assess induction of mRNAs encoding gp91-phox, and the myeloid oxidase cytosolic components, p47 and p67, In the stable transformant expressing transfected CDP/cut cDNA, gp91-phox induction was selectively reduced, whereas morphologic differentiation and induction of mRNA for myeloid oxidase components p47 and p67 were unaffected, These data provide persuasive evidence that CDP/cut acts to repress the gp91-phox gene.	CHILDRENS HOSP, DANA FARBER CANC INST, DIV PEDIAT HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Tufarelli, Cristina/AAD-3265-2019; Neufeld, Ellis J./F-9331-2011	Tufarelli, Cristina/0000-0002-1053-4618; Neufeld, Ellis J./0000-0001-8092-6281	NHLBI NIH HHS [HL49196] Funding Source: Medline; NIDDK NIH HHS [DK01977] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K12DK001977] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; HARADA R, 1994, J BIOL CHEM, V269, P2062; JACK JW, 1985, CELL, V42, P869, DOI 10.1016/0092-8674(85)90283-1; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIU S, 1991, GENETICS, V127, P151; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; McDonagh K, 1991, BLOOD, V78, p255a; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; Sambrook J, 1989, MOL CLONING LABORATO; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; VALARCHE I, 1993, DEVELOPMENT, V119, P881; YOON SO, 1994, J BIOL CHEM, V269, P18453; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	29	100	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12745	12750		10.1074/jbc.270.21.12745	http://dx.doi.org/10.1074/jbc.270.21.12745			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759529	hybrid			2022-12-25	WOS:A1995QZ71100065
J	ROSS, DC; EGAN, TJ; PURVES, LR				ROSS, DC; EGAN, TJ; PURVES, LR			PERIODATE MODIFICATION OF HUMAN SERUM TRANSFERRIN FE(III)-BINDING SITES - INHIBITION OF CARBONATE INSERTION INTO FE(III)-CHELATOR-TRANSFERRIN AND CU(II)-CHELATOR-TRANSFERRIN TERNARY COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-BINDING SITE; N-TERMINAL HALF; HUMAN LACTOFERRIN; X-RAY; MOLECULAR-STRUCTURE; INORGANIC ANIONS; FERRIC IONS; OVOTRANSFERRIN; IRON(III); RELEASE	Periodate modification of human serum transferrin produces a species that binds Fe(III) weakly at pH 7.4 contrary to previous reports that Fe(III)-binding activity is completely lost, Ternary complexes of periodate-modified transferrin and either Fe(III) with nitrilotriacetate (NTA), oxalate, citrate, or EDTA, or of Cu(II) with oxalate could be formed. Peak wavelength maxima of these spectral bands are identical to those reported for native transferrin in the absence of bicarbonate. No carbonate ternary complexes of periodate-modified transferrin with Fe(III), Al(III), Cu(II), or Zn(II) could be formed. Conditional (Fe(NTA)) binding constants (log K) for C- and N-terminal modified sites are 7.33 and 7.54, respectively, The respective extinction coefficients at 470 nm are decreased 45% compared with the native protein. The electron paramagnetic resonance spectrum of the complex closely resembles that of the Fe(III) NTA ternary complex formed with native transferrin in the absence of bicarbonate. Anions, including bicarbonate, at high concentrations destabilize formation of this Fe(III)NTA ternary complex, while Fe(III) chelators readily remove the bound Fe(III), Bicarbonate, sulfate, and pyrophosphate still bind to the modified binding sites in the absence of metal although with slightly lower affinity and with lower molar difference absorptivities, Results are interpreted as an inhibition of a crucial protein conformational change by an intramolecular cross-link, preventing formation of the particularly stable metal carbonate ternary complex hom the less stable metal-chelate ternary complex, The method can be used to produce monosited transferrins.			ROSS, DC (corresponding author), UNIV CAPE TOWN,RED CROSS WAR MEM CHILDRENS HOSP,DEPT CHEM PATHOL,RONDEBOSCH 7700,SOUTH AFRICA.							AESCHBACH R, 1976, BIOCHIM BIOPHYS ACTA, V439, P292, DOI 10.1016/0005-2795(76)90064-7; AINSCOUGH EW, 1980, INORG CHEM, V19, P3655, DOI 10.1021/ic50214a018; AISEN P, 1973, ANN NY ACAD SCI, V222, P337, DOI 10.1111/j.1749-6632.1973.tb15272.x; AISEN P, 1973, BIOCHEMISTRY-US, V12, P3679, DOI 10.1021/bi00743a017; AISEN P, 1978, J BIOL CHEM, V253, P1930; AISEN P, 1967, J BIOL CHEM, V242, P2484; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ANDERSON BF, 1987, P NATL ACAD SCI USA, V84, P1768; ANDRSEN SO, 1966, ACTA PHYSL SCAN S263, V66, P31; AZARI P, 1970, ARCH BIOCHEM BIOPHYS, V138, P32, DOI 10.1016/0003-9861(70)90280-8; Baes C.F., 1976, HYDROLYSIS CATIONS, DOI 10.1002/bbpc.19770810252; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; BAKER EN, 1992, J INORG BIOCHEM, V47, P147, DOI 10.1016/0162-0134(92)84061-Q; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BALDWIN DA, 1981, BIOCHEM BIOPH RES CO, V99, P1101, DOI 10.1016/0006-291X(81)90732-4; BALDWIN DA, 1987, S AFR J SCI, V83, P22; BALI PK, 1989, J AM CHEM SOC, V111, P4457, DOI 10.1021/ja00194a047; BATES GW, 1971, J BIOL CHEM, V246, P3679; BERTINI I, 1988, INORG CHEM, V27, P1081, DOI 10.1021/ic00279a029; BINFORD JS, 1974, J BIOL CHEM, V249, P407; CHITAMBAR CR, 1986, J CLIN INVEST, V78, P1538, DOI 10.1172/JCI112746; DAY CL, 1992, J BIOL CHEM, V267, P13857; DUBACH J, 1991, BIOPHYS J, V59, P1091, DOI 10.1016/S0006-3495(91)82324-4; EATON SS, 1990, J BIOL CHEM, V265, P7138; EATON SS, 1989, J BIOL CHEM, V264, P4776; EGAN TJ, 1992, INORG CHEM, V31, P1994, DOI 10.1021/ic00037a005; EGAN TJ, 1993, S AFR J SCI, V89, P446; EVANS RW, 1980, BIOCHEM J, V189, P541, DOI 10.1042/bj1890541; FOLEY AA, 1988, BIOCHIM BIOPHYS ACTA, V965, P154, DOI 10.1016/0304-4165(88)90051-7; FORDHUTCHINSON AW, 1971, EUR J BIOCHEM, V21, P55, DOI 10.1111/j.1432-1033.1971.tb01439.x; FRIEDEN E, 1980, TRENDS BIOCHEM SCI, V5, pR11; GABER BP, 1974, J AM CHEM SOC, V96, P6868, DOI 10.1021/ja00829a010; GEOGHEGAN KF, 1980, J BIOL CHEM, V255, P1429; GERSTEIN M, 1993, J MOL BIOL, V234, P357, DOI 10.1006/jmbi.1993.1592; GROSSMANN JG, 1992, J MOL BIOL, V225, P811, DOI 10.1016/0022-2836(92)90402-6; HARRIS WR, 1990, INORG CHEM, V29, P119, DOI 10.1021/ic00326a024; HARRIS WR, 1985, BIOCHEMISTRY-US, V24, P7412, DOI 10.1021/bi00346a057; HARRIS WR, 1990, J INORG BIOCHEM, V38, P175, DOI 10.1016/0162-0134(90)84011-D; HARRIS WR, 1991, BIOCHEMISTRY-US, V30, P6930, DOI 10.1021/bi00242a017; HARRIS WR, 1988, J INORG BIOCHEM, V33, P211, DOI 10.1016/0162-0134(88)80050-3; HSUAN JJ, 1986, BIOCHEM J, V238, P931, DOI 10.1042/bj2380931; HSUAN JJ, 1987, BIOCHEM J, V247, P467, DOI 10.1042/bj2470467; KOJIMA N, 1981, J BIOL CHEM, V256, P2034; KYSTEVA MA, 1976, BIOCHIM BIOPHYS ACTA, V453, P484; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON SM, 1980, JNCI-J NATL CANCER I, V64, P41; LEGRAND D, 1990, BIOCHEM J, V266, P575; LESTAS AN, 1976, BRIT J HAEMATOL, V32, P341, DOI 10.1111/j.1365-2141.1976.tb00937.x; LIN LN, 1993, BIOCHEMISTRY-US, V32, P9398, DOI 10.1021/bi00087a019; LIN LN, 1991, BIOCHEMISTRY-US, V30, P11660, DOI 10.1021/bi00114a008; LINDLEY PF, 1993, ACTA CRYSTALLOGR D, V49, P292, DOI 10.1107/S0907444992012101; LONNERDAL B, 1977, FEBS LETT, V75, P89, DOI 10.1016/0014-5793(77)80059-8; MAKEY DG, 1976, BIOCHIM BIOPHYS ACTA, V453, P250, DOI 10.1016/0005-2795(76)90270-1; MARQUES HM, 1991, J INORG BIOCHEM, V41, P187, DOI 10.1016/0162-0134(91)80011-6; MARTEL AE, 1974, CRITICAL STABILITY C, V3, P161; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P139; MARTIN RB, 1986, J INORG BIOCHEM, V28, P181, DOI 10.1016/0162-0134(86)80081-2; MAY PM, 1988, TALANTA, V35, P933, DOI 10.1016/0039-9140(88)80224-8; MCDEVITT MR, 1990, INORG CHEM, V29, P3425, DOI 10.1021/ic00343a029; NAJARIAN RC, 1978, J BIOL CHEM, V253, P38; PATCH MG, 1981, INORG CHIM ACTA, V56, P71; PECORARO VL, 1981, BIOCHEMISTRY-US, V20, P7033, DOI 10.1021/bi00527a040; PENNER MH, 1987, ARCH BIOCHEM BIOPHYS, V252, P7, DOI 10.1016/0003-9861(87)90002-6; PENNER MH, 1983, ARCH BIOCHEM BIOPHYS, V255, P740; PRICE EM, 1972, BIOCHEM BIOPH RES CO, V46, P646; PRINCIOTTO JV, 1975, NATURE, V255, P87, DOI 10.1038/255087a0; ROGERS TB, 1977, J BIOL CHEM, V252, P8108; ROSKAMS AJ, 1990, P NATL ACAD SCI USA, V87, P9024, DOI 10.1073/pnas.87.22.9024; ROSSENEUMOTREFF MY, 1971, BIOPOLYMERS, V10, P1039, DOI 10.1002/bip.360100610; SARRA R, 1990, ACTA CRYSTALLOGR B, V46, P763, DOI 10.1107/S0108768190006450; SCHLABACH MR, 1975, J BIOL CHEM, V250, P2182; SHONGWE MS, 1992, BIOCHEMISTRY-US, V31, P4451, DOI 10.1021/bi00133a010; SMIT S, 1981, J INORG BIOCHEM, V15, P329, DOI 10.1016/S0162-0134(00)80236-6; SOLA M, 1990, INORG CHEM, V29, P1113, DOI 10.1021/ic00331a002; TAN AT, 1969, BIOCHEMISTRY-US, V8, P3711, DOI 10.1021/bi00837a033; TEUWISSEN B, 1972, EUR J BIOCHEM, V31, P239, DOI 10.1111/j.1432-1033.1972.tb02526.x; TSANG CP, 1975, BIOCHIM BIOPHYS ACTA, V386, P32, DOI 10.1016/0005-2795(75)90243-3; VERWEIJ H, 1982, BIOCHIM BIOPHYS ACTA, V701, P180, DOI 10.1016/0167-4838(82)90111-X; YOUNG JW, 1968, EUR J BIOCHEM, V4, P385, DOI 10.1111/j.1432-1033.1968.tb00223.x; ZWEIER JL, 1977, J BIOL CHEM, V252, P6090	80	9	9	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12404	12410		10.1074/jbc.270.21.12404	http://dx.doi.org/10.1074/jbc.270.21.12404			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759481	hybrid			2022-12-25	WOS:A1995QZ71100014
J	SMITH, TK; MEISTER, A				SMITH, TK; MEISTER, A			CHEMICAL MODIFICATION OF ACTIVE-SITE RESIDUES IN GAMMA-GLUTAMYL-TRANSPEPTIDASE ASPARTATE-422 AND CYSTEINE-453	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERASE TRANSPEPTIDASE; BINDING; IDENTIFICATION; GLUTATHIONE; SEQUENCE; SUBUNIT	gamma-Glutamyl transpeptidase, an enzyme of central significance in glutathione metabolism, is inactivated by iodoacetamide, which esterifies an active site carboxyl group identified here as that of Asp-422. Treatment of the inactivated enzyme with hydroxylamine leads to de-esterification and to restoration of enzymatic activity. N-Acetylimidazole, which also inactivates the enzyme, acetylates several amino acid residues. Acetylation exposes Cys-453, which is buried in the native enzyme, to reaction with iodoacetamide. Incubation of the acetylated enzyme with glutamine produces a stabilized gamma-glutamyl-enzyme form which is (a) located exclusively on the light subunit, (b) more labile to base than to acid, (c) destabilized by denaturation of the enzyme with guanidinium ions, and (d) reactive with hydroxylamine to form gamma-glutamylhydroxamate. Stabilization of the gamma-glutamyl-enzyme appears to be associated with acetylation of lysine residues (including Lys-99). These and other findings suggest that the alpha-amino group of the gamma-glutamyl substrate is linked electrostatically to Asp-422 so as to facilitate reaction of the gamma-carbonyl of the substrate with an enzyme hydroxyl group to form a gamma-glutamyl-enzyme.			SMITH, TK (corresponding author), CORNELL UNIV, COLL MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012034] Funding Source: NIH RePORTER; NIDDK NIH HHS [2 R37 DK12034] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLOMA J, 1986, NUCLEIC ACIDS RES, V14, P1393, DOI 10.1093/nar/14.3.1393; ELCE JS, 1980, BIOCHEM J, V185, P473, DOI 10.1042/bj1850473; GARDELL SJ, 1980, FEBS LETT, V122, P171, DOI 10.1016/0014-5793(80)80430-3; IKEDA Y, 1993, J BIOL CHEM, V268, P3980; IKEDA Y, 1995, J BIOL CHEM, V270, P12471, DOI 10.1074/jbc.270.21.12471; LAPERCHE Y, 1989, P NATL ACAD SCI USA, V86, P3159; Means G.E., 1971, CHEM MODIFICATION PR; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meister A, 1976, ENZYMES BIOL MEMBR, Vv3, P315; Meister A, 1989, GLUTATHIONE CHEM BIO, P367; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P679; PAPANDRIKOPOULOU A, 1989, EUR J BIOCHEM, V183, P693, DOI 10.1111/j.1432-1033.1989.tb21100.x; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; REDDY GS, 1963, J CHEM SOC, P1414, DOI 10.1039/jr9630001414; REVEL JP, 1959, J BIOL CHEM, V234, P577; SAKAMURO D, 1988, GENE, V73, P1; STOLE E, 1994, J BIOL CHEM, V269, P21435; STOLE E, 1990, P NATL ACAD SCI USA, V87, P1706, DOI 10.1073/pnas.87.5.1706; STOLE E, 1991, J BIOL CHEM, V266, P17850; SUZUKI H, 1989, J BACTERIOL, V171, P5169, DOI 10.1128/jb.171.9.5169-5172.1989; SZEWCZUK A, 1965, BIOCHIM BIOPHYS ACTA, V105, P352, DOI 10.1016/S0926-6593(65)80159-X; Tate S.S., 1980, ENZYMATIC BASIS DETO, VII, P95; TATE SS, 1978, P NATL ACAD SCI USA, V75, P4806, DOI 10.1073/pnas.75.10.4806; TATE SS, 1977, P NATL ACAD SCI USA, V74, P931, DOI 10.1073/pnas.74.3.931; TATE SS, 1985, METHOD ENZYMOL, V113, P400; THOMPSON GA, 1980, J BIOL CHEM, V255, P2109; WEBER K, 1969, J BIOL CHEM, V244, P4406	29	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12476	12480		10.1074/jbc.270.21.12476	http://dx.doi.org/10.1074/jbc.270.21.12476			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759491				2022-12-25	WOS:A1995QZ71100024
J	RUBIO, S; LACAZEMASMONTEIL, T; CHAILLEYHEU, B; KAHN, A; BOURBON, JR; DUCROC, R				RUBIO, S; LACAZEMASMONTEIL, T; CHAILLEYHEU, B; KAHN, A; BOURBON, JR; DUCROC, R			PULMONARY SURFACTANT PROTEIN-A (SP-A) IS EXPRESSED BY EPITHELIAL-CELLS OF SMALL AND LARGE-INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATITIS-ASSOCIATED PROTEIN; II CELLS; ALKALINE-PHOSPHATASE; RAT LUNG; SECRETION; SEQUENCE; GENE; DIFFERENTIATION; PHAGOCYTOSIS; ORGANIZATION	Surfactant protein A (SP-A) is the most abundant protein associated with phospholipids in pulmonary surfactant, There are several lines of evidence that pulmonary and gastrointestinal epithelium produce closely related surface-active materials, although the presence of SP-A in gastrointestinal tract has so far not been reported, Indirect immunofluorescence experiments using different antibodies raised against rat pulmonary SP-A showed that some jejunal and colonic but not gastric epithelial cells positively stained for SP-A. Analysis of the proteins in cell lysates from rat small intestine and colon studied by Western blot revealed several immunoreactive bands, including the characteristic triplet of 26-, 32-, and 38-kDa monomeric proteins, less strongly labeled than in lung cells, and higher molecular mass forms of 66 and 120 kDa also present in lung cells, The 66- and 120-kDa bands displayed the expected isoelectric pH of SP-A after two-dimensional electrophoresis. Alkylation induced conversion of the 120-kDa form (almost completely) and the 66-kDa form (partly) into the 26-38-kDa monomeric species, The presence of SP-A mRNA in rat stomach, small intestine, and colon was then searched for by conventional cDNA/reverse transcriptase-polymerase chain reaction, Products of appropriate size (372 base pairs) identical to that of pulmonary tissue were amplified in small intestine and colon but not in stomach or in other tissues used as controls. Cloning and sequencing of rat colon SP-A cDNA revealed the same sequence as the one reported for rat lung SP-A Furthermore, analysis of the transcriptional initiation site of SP-A gene in colon by anchored-polymerase chain reaction showed that transcription was initiated at the same site in both colon and lung. These data, which demonstrate that small intestine and colon express SP-A constitutively and that this protein is present in some epithelial cells, extend the concept of intestinal surfactant and underline its close relationships to pulmonary surfactant.	UNIV PARIS, INSERM, U319, F-75251 PARIS 05, FRANCE; HOP ANTOINE BECLERE, SERV PEDIAT & REANIMAT NEONATALE, CLAMART, FRANCE; INST COCHIN GENET MOLEC, INSERM, U129, F-75014 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)								AMIGO L, 1992, GASTROENTEROLOGY, V102, P774; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER BD, 1983, AM J PHYSIOL, V244, pG645, DOI 10.1152/ajpgi.1983.244.6.G645; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD SW, 1986, BIOCHEM J, V240, P107, DOI 10.1042/bj2400107; DESCHRYVERKECSKEMETI K, 1989, J CLIN INVEST, V84, P1355, DOI 10.1172/JCI114306; DOYLE IR, 1994, AM J RESP CELL MOL, V11, P405, DOI 10.1165/ajrcmb.11.4.7917309; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DUCROC R, 1992, J PEDIATR GASTR NUTR, V15, P20, DOI 10.1097/00005176-199207000-00004; DUSETTI NJ, 1993, J BIOL CHEM, V268, P14470; ELIAKIM R, 1989, J BIOL CHEM, V264, P20614; ELIAKIM R, 1991, AM J PHYSIOL, V261, pG269, DOI 10.1152/ajpgi.1991.261.2.G269; FISHER JH, 1988, BIOCHIM BIOPHYS ACTA, V950, P338, DOI 10.1016/0167-4781(88)90130-3; FISHER JH, 1995, AM J RESP CELL MOL, V12, P13, DOI 10.1165/ajrcmb.12.1.7811466; FRASLON C, 1993, AM J PHYSIOL, V264, pL504, DOI 10.1152/ajplung.1993.264.5.L504; FROH D, 1990, BIOCHIM BIOPHYS ACTA, V1052, P78, DOI 10.1016/0167-4889(90)90060-Q; HAAS C, 1991, EUR J BIOCHEM, V197, P799; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HAWGOOD S, 1991, ANNU REV PHYSIOL, V53, P375, DOI 10.1146/annurev.ph.53.030191.002111; HENNING SJ, 1981, AM J PHYSIOL, V241, pG199, DOI 10.1152/ajpgi.1981.241.3.G199; HILLS BA, 1984, ARCH OTOLARYNGOL, V110, P3; HILLS BA, 1983, AM J PHYSIOL, V244, pG561, DOI 10.1152/ajpgi.1983.244.5.G561; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; ITOH K, 1989, SCAND J GASTROENTERO, V24, P23, DOI 10.3109/00365528909091116; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; KWUN SY, 1992, GASTROENTEROLOGY, V102, P104; LACAZEMASMONTEIL T, 1992, EUR J BIOCHEM, V206, P613, DOI 10.1111/j.1432-1033.1992.tb16966.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENBERGER LM, 1983, SCIENCE, V219, P1327, DOI 10.1126/science.6828859; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RICHARDS RJ, 1987, LUNG, V165, P143, DOI 10.1007/BF02714430; SANDERS RL, 1975, BIOCHEMISTRY-US, V14, P835, DOI 10.1021/bi00675a030; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SENEGASBALAS E, 1993, GASTROENTEROLOGY, V104, pA448; SENEGASBALAS FO, 1991, J HISTOCHEM CYTOCHEM, V39, P915, DOI 10.1177/39.7.1865108; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; TIETZE CC, 1992, AM J PHYSIOL, V263, pG756, DOI 10.1152/ajpgi.1992.263.5.G756; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; VANIWAARDEN JF, 1991, AM J PHYSIOL, V261, pL204, DOI 10.1152/ajplung.1991.261.2.L204; WATANABE T, 1990, J BIOL CHEM, V265, P7432; WEAVER TE, 1985, BIOCHIM BIOPHYS ACTA, V827, P260, DOI 10.1016/0167-4838(85)90210-9; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WEISER MM, 1973, J BIOL CHEM, V248, P2536; WHITSETT JA, 1985, J BIOL CHEM, V260, P5273; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395	53	106	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12162	12169		10.1074/jbc.270.20.12162	http://dx.doi.org/10.1074/jbc.270.20.12162			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744866	hybrid			2022-12-25	WOS:A1995QY73600069
J	SAGAMI, H; KIKUCHI, A; OGURA, K				SAGAMI, H; KIKUCHI, A; OGURA, K			A NOVEL TYPE OF PROTEIN MODIFICATION BY ISOPRENOID-DERIVED MATERIALS - DIPHYTANYLGLYCERYLATED PROTEINS IN HALOBACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CLEAVAGE REACTION; MEMBRANE; FARNESYLCYSTEINE; BIOSYNTHESIS; BINDING	Previous work from this laboratory has shown that a derivative of [H-3]mevalonic acid is incorporated into a number of specific proteins in Halobacterium halobium and Halobacterium cutirubrum and that the major radioactive material released by treatment with methyl iodide was neither farnesyl nor geranylgeranyl compound, which have been generally accepted to be prenyl groups of a number of prenylated proteins found in eukaryotic cells, but an unknown compound (Sagami, H., Kikuchi, A., and Ogura, K. (1994) Biochem. Biophys. Res. Commun, 203, 972-978). In the current study, the unknown compound was prepared in a large amount from H. halobium cells and analyzed by reverse and normal phase high performance liquid chromatographies followed by mass spectrometry. The mass spectrum of this compound exhibited a parent ion peak (M(+)) at m/z 682, suggesting that it is a 1-methylthio-2,3-di-O-(3',7',11',15'-tetramethylhexadecyl)glycerol (diphytanylglyceryl methylthioether). Diphytanylglyceryl methyl thioether was chemically synthesized, and its mass fragmentation pattern was completely coincident with that of the mevalonic acid-derived material from H. halobium. These results indicate that Halobacteria contains specific proteins with a novel type of modification of a cysteine residue of the proteins with a diphytanylglyceryl group in thioether linkage.			SAGAMI, H (corresponding author), TOHOKU UNIV,INST CHEM REACT SCI,AOBA KU,2-1-1 KATAHIRA,SENDAI,MIYAGI 980,JAPAN.							Blaurock A. E., 1971, NATURE-NEW BIOL, V233, P149; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHEN AJ, 1993, J BIOL CHEM, V268, P21701; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P1049, DOI 10.1080/00021369.1979.10863559; KATES M, 1965, BIOCHEMISTRY-US, V4, P1595, DOI 10.1021/bi00884a020; KUSHWAHA SC, 1975, BIOCHIM BIOPHYS ACTA, V398, P33; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MATTAR S, 1994, J BIOL CHEM, V269, P14939; MINNIKIN DE, 1975, J GEN MICROBIOL, V88, P200, DOI 10.1099/00221287-88-1-200; MOLDOVEANU N, 1988, BIOCHIM BIOPHYS ACTA, V960, P164, DOI 10.1016/0005-2760(88)90062-8; PUGH EL, 1971, CAN J BIOCHEM CELL B, V49, P953, DOI 10.1139/o71-138; RINE J, 1990, New Biologist, V2, P219; SAGAMI H, 1994, BIOCHEM BIOPH RES CO, V203, P972, DOI 10.1006/bbrc.1994.2277; SLARKE S, 1992, ANN REV BIOHC, V61, P355; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ZHANG DL, 1990, J AM CHEM SOC, V112, P1264, DOI 10.1021/ja00159a067; ZHU JK, 1993, P NATL ACAD SCI USA, V90, P8557, DOI 10.1073/pnas.90.18.8557	21	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14851	14854		10.1074/jbc.270.25.14851	http://dx.doi.org/10.1074/jbc.270.25.14851			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797461	hybrid			2022-12-25	WOS:A1995RE66600003
J	PIETRAS, RJ; ARBOLEDA, J; REESE, DM; WONGVIPAT, N; PEGRAM, MD; RAMOS, L; GORMAN, CM; PARKER, MG; SLIWKOWSKI, MX; SLAMON, DJ				PIETRAS, RJ; ARBOLEDA, J; REESE, DM; WONGVIPAT, N; PEGRAM, MD; RAMOS, L; GORMAN, CM; PARKER, MG; SLIWKOWSKI, MX; SLAMON, DJ			HER-3 TYROSINE KINASE PATHWAY TARGETS ESTROGEN-RECEPTOR AND PROMOTES HORMONE-INDEPENDENT GROWTH IN HUMAN BREAST-CANCER CELLS	ONCOGENE			English	Article						HER-2/NEU; ESTROGEN RECEPTOR; HEREGULIN; TYROSINE PHOSPHORYLATION; BREAST CANCER	MESSENGER-RIBONUCLEIC-ACID; DOWN-REGULATION; PROTO-ONCOGENE; MCF-7 CELLS; PHOSPHORYLATION; NEU; AMPLIFICATION; TRANSCRIPTION; PROTOONCOGENE; ACTIVATION	Growth of human breast cells is closely regulated by steroid hormone as well as peptide hormone receptors. Members of both receptor classes are important prognostic factors in human breast cancer. Clinical data indicate that overexpression of the HER-2 gene is associated with an estrogen receptor-negative phenotype. In this study, we demonstrate that introduction of a HER-2 cDNA, converting non-overexpressing breast cancer cells to those which overexpress this receptor, results in development of estrogen-independent growth which is insensitive to both estrogen and the antiestrogen, tamoxifen. Moreover, activation of the HER-2 receptor in breast cancer cells by the peptide growth factor, heregulin, leads to direct and rapid phosphorylation of ER on tyrosine residues, This is followed by interaction between ER and the estrogen-response elements in the nucleus and production of an estrogen-induced protein, progesterone receptor. In addition, overexpression of HER-2 receptor in estrogen-dependent tumor cells promotes ligand-independent down-regulation of ER and a delayed autoregulatory suppression of ER transcripts. These data demonstrate a direct link between these two receptor pathways and suggest one mechanism for development of endocrine resistance in human breast cancers.	GENENTECH INC,SAN FRANCISCO,CA 94080; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; MEGABIOS CORP,BURLINGAME,CA 94010	Roche Holding; Genentech; Cancer Research UK	PIETRAS, RJ (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095, USA.		Jansen, Heiko T./A-5770-2008; McKenzie, Katherine/AAY-4144-2020	Jansen, Heiko T./0000-0003-0178-396X; Pietras, Richard/0000-0002-2846-3192	NCI NIH HHS [R01 CA36827, R29 CA60835, P01 CA32737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060835, P01CA032737, R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1989, ONCOGENE, V4, P1389; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BELLINGHAM DL, 1992, MOL ENDOCRINOL, V6, P2090, DOI 10.1210/me.6.12.2090; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BORRAS M, 1994, J STEROID BIOCHEM, V48, P325, DOI 10.1016/0960-0760(94)90072-8; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; CHAZIN VR, 1992, ONCOGENE, V7, P1859; DEMAIO A, 1990, BIOCHIM BIOPHYS ACTA, V1087, P303, DOI 10.1016/0167-4781(90)90003-K; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DOUGALL WC, 1994, ONCOGENE, V9, P2109; ELLEDGE RM, 1994, J NATL CANCER I, V86, P705, DOI 10.1093/jnci/86.9.705; ERNST M, 1991, MOL ENDOCRINOL, V5, P1597, DOI 10.1210/mend-5-11-1597; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HORIGOME T, 1987, ENDOCRINOLOGY, V121, P2099; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; KOFFMAN B, 1991, J STEROID BIOCHEM, V38, P135, DOI 10.1016/0960-0760(91)90118-O; KUIPER GGJM, 1994, MOL CELL ENDOCRINOL, V100, P103, DOI 10.1016/0303-7207(94)90287-9; KUNG W, 1994, BIOCHEM BIOPH RES CO, V202, P1357, DOI 10.1006/bbrc.1994.2080; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MIGLIACCIO A, 1991, J STEROID BIOCHEM, V38, P407, DOI 10.1016/0960-0760(91)90328-3; NELSON KG, 1991, P NATL ACAD SCI USA, V88, P21, DOI 10.1073/pnas.88.1.21; NICHOLSON S, 1990, J STEROID BIOCHEM, V37, P811, DOI 10.1016/0960-0760(90)90424-J; OSBORNE CK, 1994, BREAST CANCER RES TR, V32, P49, DOI 10.1007/BF00666205; PARKER MG, 1993, BREAST CANCER RES TR, V26, P131, DOI 10.1007/BF00689686; PIETRAS RJ, 1979, J STEROID BIOCHEM, V11, P1471, DOI 10.1016/0022-4731(79)90124-9; PIETRAS RJ, 1984, BIOCHEM BIOPH RES CO, V123, P84, DOI 10.1016/0006-291X(84)90383-8; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POWER RF, 1991, SCIENCE, V213, P1636; PRESS MF, 1993, CANCER RES, V53, P4960; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; READ LD, 1990, CANCER RES, V50, P3947; REDDY KD, 1992, CANCER RES, V3, P401; REE AH, 1989, ENDOCRINOLOGY, V124, P2577, DOI 10.1210/endo-124-5-2577; RUSSELL KS, 1992, CANCER RES, V52, P6624; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; STEBLER A, 1994, BREAST CANCER RES TR, V31, P175; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; WAKELING AE, 1993, J STEROID BIOCHEM, V47, P107, DOI 10.1016/0960-0760(93)90063-3; WANG BC, 1992, CANCER RES, V52, P4102; WELSHONS WV, 1993, MOL CELL ENDOCRINOL, V94, P183, DOI 10.1016/0303-7207(93)90167-I; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; ZEILLINGER R, 1989, ONCOGENE, V4, P109	59	529	544	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2435	2446						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784095				2022-12-25	WOS:A1995RE54300022
J	OGRAM, SA; REEVES, R				OGRAM, SA; REEVES, R			DIFFERENTIAL REGULATION OF A MULTIPROMOTER GENE - SELECTIVE 12-O-TETRADECANOYLPHORBOL-13-ACETATE INDUCTION OF A SINGLE TRANSCRIPTION START SITE IN THE HMG-I/Y GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP PROTEIN HMG-I(Y); DNA-BINDING DOMAIN; GROUP-I PROTEIN; CHROMOSOMAL-PROTEINS; MESSENGER-RNAS; SATELLITE DNA; CDC2 KINASE; BETA GENE; EXPRESSION; CELLS	The human HMG-I/Y gene, encoding the non-histone ''high mobility group'' proteins HMG-I and HMG-Y, is transcriptionally activated in human K562 erythroleukemia cells by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA), TPA treatment induces differentiation of K562 cells within 2-4 days after treatment. In this report, we show that transcriptional activation of the HMG-I/Y gene is dependent on protein synthesis and is an early event (2 h after induction) in the TPA-mediated differentiation process. Of the four functional transcription start sites present in the gene, only one (start site 2) is preferentially induced upon TPA treatment. This is the first report, to our knowledge, of the preferential utilization of a specific transcription start site in response to a particular stimulus in a gene that contains multiple promoters. This indicates that each start site in the gene has the potential to be independently regulated instead of being coordinately controlled as shown in a number of other genes. In addition, sequences upstream of the inducible start site, which contains a TPA-responsive element, mediates TPA inducibility through AP1 (or an AP1-like) transcription factor. The HMG-I/Y proteins function as key regulators of gene expression and play a significant role in chromatin structural changes as well. The cloning and sequence analyses previously reported indicated the structure of the HMG-I/Y gene to be highly complex and predicted its expression to be tightly regulated. The results presented here confirm and extend these earlier findings.	WASHINGTON STATE UNIV,DEPT BIOCHEM BIOPHYS,PULLMAN,WA 99164; WASHINGTON STATE UNIV,DEPT GENET & CELL BIOL,PULLMAN,WA 99164	Washington State University; Washington State University					NIAID NIH HHS [5-R01-AI26356] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026356] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASMAN DC, 1994, J BIOL CHEM, V268, P12530; Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BONHAM K, 1993, ONCOGENE, V8, P1973; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GIANCOTTI V, 1991, EUR J BIOCHEM, V198, P211, DOI 10.1111/j.1432-1033.1991.tb16003.x; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1990, EXP CELL RES, V187, P69, DOI 10.1016/0014-4827(90)90118-T; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; JORCYK CL, 1990, ONCOGENE, V6, P323; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAZAR J, 1994, J BIOL CHEM, V269, P20352; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MAVROTHALASSITI.GJ, 1990, ONCOGENE, V5, P1337; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PATEL M, 1990, ONCOGENE, V5, P201; RADIC MZ, 1992, CHROMOSOMA, V101, P602, DOI 10.1007/BF00360537; RAM T, 1992, GENETICS MOL BIOL BR, P65; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1993, J BIOL CHEM, V268, P21137; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; REEVES R, 1992, Current Opinion in Cell Biology, V4, P413, DOI 10.1016/0955-0674(92)90006-X; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; SOLOMON WB, 1993, J BIOL CHEM, V268, P5089; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TAMIMI Y, 1993, CANCER RES, V53, P5512; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VARTIAINEN E, 1988, FEBS LETT, V228, P45, DOI 10.1016/0014-5793(88)80581-7; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WINGETT D, 1991, J IMMUNOL, V147, P3653	51	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14235	14242		10.1074/jbc.270.23.14235	http://dx.doi.org/10.1074/jbc.270.23.14235			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775485	hybrid			2022-12-25	WOS:A1995RC44800093
J	SPIRO, DJ; TAYLOR, TC; MELANCON, P; WESSLINGRESNICK, M				SPIRO, DJ; TAYLOR, TC; MELANCON, P; WESSLINGRESNICK, M			CYTOSOLIC ADP-RIBOSYLATION FACTORS ARE NOT REQUIRED FOR ENDOSOME-ENDOSOME FUSION BUT ARE NECESSARY FOR GTP-GAMMA-S INHIBITION OF FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; BREFELDIN-A; GOLGI MEMBRANES; PROTEIN ACTIVATORS; ENDOCYTIC VESICLES; GUANINE-NUCLEOTIDE; BINDING PROTEINS; CHOLERA-TOXIN; ARF PROTEIN; MDCK CELLS	A specific role for ADP-ribosylation factors (ARFs) in in vitro endosome-endosome fusion has been proposed (Lenhard, J. M., Kahn, R. A., and Stahl, P. D. (1992) J. Biol. Chem. 267, 13047-13052). However, in vivo studies have failed to support a function for ARFs in the endocytic pathway, since an antagonist of ARF activities, brefeldin A, does not interfere with receptor internalization (Schonhorn, J. E., and Wessling-Resnick, M. (1994) Mol. Cell. Biochem. 135, 159-164). This controversy surrounding the exact function of ARF in endocytic vesicle traffic prompted us to critically re-examine the involvement of ARFs in cell-free endosome fusion. Cytosol depleted of ARF activity was capable of supporting in. vitro endocytic vesicle fusion but failed to support inhibition of this reaction in the presence of guanosine 5'-3-O-(thio)triphosphate (GTP gamma S). Addition of purified ARF1 restored the ability of the ARF-depleted cytosol to inhibit endosome fusion when incubated with GTP gamma S. Both endocytic vesicle fusion and the GTP gamma S-mediated inhibition of vesicle fusion were unaffected by brefeldin A. Moreover, the ATP requirement and kinetics of cell-free fusion are not altered by brefeldin A or depletion of cytosolic ARFs. These results suggest that cytosolic ARFs are not necessary for endosomal vesicle fusion in vitro but are responsible for inhibition of fusion in the presence of GTP gamma S and cytosolic factors in a brefeldin A-resistant manner.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02115; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; University of Colorado System; University of Colorado Boulder			Melancon, Paul/P-1304-2018	Melancon, Paul/0000-0002-8085-3032	NIGMS NIH HHS [GM43378] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; FENSOME A, 1994, FEBS LETT, V349, P34, DOI 10.1016/0014-5793(94)00634-2; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; LENHARD JM, 1994, ARCH BIOCHEM BIOPHYS, V312, P474, DOI 10.1006/abbi.1994.1334; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MORGAN A, 1993, FEBS LETT, V329, P121, DOI 10.1016/0014-5793(93)80206-A; MURAYAMA T, 1993, BIOCHEMISTRY-US, V32, P561, DOI 10.1021/bi00053a022; ORCI L, 1991, CELL, V64, P1183; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SCHONHORN JE, 1994, MOL CELL BIOCHEM, V135, P159, DOI 10.1007/BF00926519; TABAS I, 1979, J BIOL CHEM, V254, P1655; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WEIDMAN PJ, 1994, J CELL BIOL, V127, P1815, DOI 10.1083/jcb.127.6.1815; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P16751; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P690; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	38	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13693	13697		10.1074/jbc.270.23.13693	http://dx.doi.org/10.1074/jbc.270.23.13693			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775422	hybrid			2022-12-25	WOS:A1995RC44800019
J	SVINARCHUK, F; PAOLETTI, J; MALVY, C				SVINARCHUK, F; PAOLETTI, J; MALVY, C			AN UNUSUALLY STABLE PURINE(PURINE-PYRIMIDINE) SHORT TRIPLEX - THE 3RD STRAND STABILIZES DOUBLE-STRANDED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX FORMATION; GENE; INHIBITION; SEQUENCE; BINDING; TRANSCRIPTION; EXPRESSION; SITES; RNA	Classical models for DNA triple helix formation assume the stabilization of these structures through the formation of Hoogsteen hydrogen bonds. This assumes that G-rich duplex DNA is more stable than tripler DNA. We report the results of co-migration assay, dimethyl sulfate footprint, and UV spectroscopic melting studies that reveal that at least in some cases of short (13-mer) purine(purine-pyrimidine) tripler the stability of double-stranded DNA is increased by the binding of the third strand. Under conditions which are usually considered as physiological (10 mM MgCl2, 150 mM Na+ or K+) and with a rate of heating/cooling of 1 degrees C/min, there is a good reversibility of the melting profiles which is consistent with a high rate of tripler formation. Other factors than Hoogsteen hydrogen bonds should therefore be involved in tripler stabilization. We suggest that oligonucleotides with similar properties could be efficient agents for artificial gene regulation.	NOVOSIBIRSK BIOORGAN CHEM INST,DEPT BIOCHEM,NOVOSIBIRSK 630090,RUSSIA	Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS	SVINARCHUK, F (corresponding author), INST GUSTAVE ROUSSY,BIOCHIM ENZYMOL LAB,CNRS,URA 147,RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.							BADER BL, 1986, EMBO J, V8, P1868; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BEASTY AM, 1988, NUCLEIC ACIDS RES, V16, P1517, DOI 10.1093/nar/16.4.1517; CHENG AJ, 1993, NUCLEIC ACIDS RES, V21, P5630, DOI 10.1093/nar/21.24.5630; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; MALKOV VA, 1993, NUCLEIC ACIDS RES, V21, P585, DOI 10.1093/nar/21.3.585; ONEILL D, 1991, P NATL ACAD SCI USA, V88, P8953, DOI 10.1073/pnas.88.20.8953; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; PORUMB H, 1994, GENE, V149, P101, DOI 10.1016/0378-1119(94)90417-0; RADHAKRISHNAN I, 1991, J MOL BIOL, V221, P1403, DOI 10.1016/0022-2836(91)90941-X; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; ROUGEE M, 1992, BIOCHEMISTRY-US, V31, P9269, DOI 10.1021/bi00153a021; SAMADASHWILY GM, 1993, EMBO J, V12, P4975, DOI 10.1002/j.1460-2075.1993.tb06191.x; SINGLETON SF, 1992, BIOCHEMISTRY-US, V31, P10995, DOI 10.1021/bi00160a008; SVINARCHUK F, 1994, NUCLEIC ACIDS RES, V22, P3742, DOI 10.1093/nar/22.18.3742; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; WU LC, 1987, CELL, V48, P331, DOI 10.1016/0092-8674(87)90436-3	22	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14068	14071		10.1074/jbc.270.23.14068	http://dx.doi.org/10.1074/jbc.270.23.14068			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775467	hybrid			2022-12-25	WOS:A1995RC44800070
J	CLEVENGER, CV; NGO, W; SOKOL, DL; LUGER, SM; GEWIRTZ, AM				CLEVENGER, CV; NGO, W; SOKOL, DL; LUGER, SM; GEWIRTZ, AM			VAV IS NECESSARY FOR PROLACTIN-STIMULATED PROLIFERATION AND IS TRANSLOCATED INTO THE NUCLEUS OF A T-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NB2 LYMPHOMA-CELLS; NUCLEOTIDE EXCHANGE FACTOR; GROWTH-HORMONE RECEPTOR; HUMAN-BREAST CANCER; PROTEIN-KINASE-C; TYROSINE KINASE; PROTOONCOGENE PRODUCT; MAP KINASE; GENE-EXPRESSION; LYMPHOCYTES-T	Stimulation of the prolactin receptor (PRLr) with ligand activates multiple kinase cascades. The proximal mediators involved in the activation of the PRL-activated Raf-1 cascade in T-cells, however, remain poorly characterized. The role of one proximal signaling protein, namely p95(vav), during PRLr signal transduction was examined in the Nb2 T-cell line. The novel results obtained here indicate that Vav is transiently associated with the PRLr and is necessary for PRL-stimulated proliferation. During PRL stimulation, a rapid and dramatic increase in guanine nucleotide exchange factor (GEF) activity was found to be associated with Vav immunoprecipitates. Concomitantly, an increase in Vav phosphorylation on serine-threonine residues was observed. The Vav-associated GEF activation could be inhibited by staurosporine and calphostin, but not herbimycin, suggesting a modulatory role for phosphorylation at serine-threonine residues. Treatment of Nb-2 cells with antisense Vav oligonucleotide ablated Vav expression and blocked PRL-driven proliferation, but failed to inhibit PRL-induced GEF activation within Nb2 lysates. These data indicate that GEF activity may not be intrinsic to Vav as has been previously suggested, but either resides in or is complemented by an associated GEF. Subsequent to the transient activation of associated GEF activity, Vav was found to translocate into the Nb2 cell nucleus. Thus, Vav may utilize two independent mechanisms in T-cells, namely the activation of an associated GEF and direct nuclear internalization, to mediate PRLr signaling.	UNIV PENN,MED CTR,DEPT INTERNAL MED,PHILADELPHIA,PA 19104	University of Pennsylvania	CLEVENGER, CV (corresponding author), UNIV PENN,MED CTR,DEPT LAB MED & PATHOL,509 BRB1,422 CURIE BLVD,PHILADELPHIA,PA 19104, USA.				NCI NIH HHS [CA-36896, CA-54384] Funding Source: Medline; NIAID NIH HHS [AI-33510] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054384, R23CA036896, R01CA036896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033510] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABAMYR SM, 1994, CURRENT PROTOCOLS MO, P1; ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNTON EW, 1988, SCIENCE, V239, P401, DOI 10.1126/science.3122324; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLEVENGER CV, 1991, SCIENCE, V253, P77, DOI 10.1126/science.2063207; CLEVENGER CV, 1990, P NATL ACAD SCI USA, V87, P6460, DOI 10.1073/pnas.87.16.6460; CLEVENGER CV, 1992, ENDOCRINOLOGY, V130, P3216, DOI 10.1210/en.130.6.3216; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; CLEVENGER CV, 1985, CYTOMETRY, V6, P208, DOI 10.1002/cyto.990060306; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; CROWE PD, 1991, MOL CELL ENDOCRINOL, V79, P29, DOI 10.1016/0303-7207(91)90092-7; CROZE F, 1988, MOL CELL ENDOCRINOL, V55, P253, DOI 10.1016/0303-7207(88)90140-2; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GOUT PW, 1980, CANCER RES, V40, P2433; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; GUYETTE WA, 1979, CELL, V17, P1013, DOI 10.1016/0092-8674(79)90340-4; HARTMANN DP, 1989, FASEB J, V3, P2194, DOI 10.1096/fasebj.3.10.2787766; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HU P, 1993, BIOESSAYS, V15, P179, DOI 10.1002/bies.950150306; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LUGER SM, 1993, BLOOD, V82, P107; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MUKHERJEE P, 1990, ENDOCRINOLOGY, V126, P88, DOI 10.1210/endo-126-1-88; NOBLE RL, 1980, CANCER RES, V40, P2437; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; RATAJCZAK MZ, 1992, BLOOD, V79, P1956; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUI H, 1994, J BIOL CHEM, V269, P5364; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SETH A, 1992, J BIOL CHEM, V267, P24769; SHIU RPC, 1985, J BIOL CHEM, V260, P1307; SHIU RPC, 1987, RECENT PROG HORM RES, V43, P277; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SKORSKI T, 1992, J EXP MED, V175, P743, DOI 10.1084/jem.175.3.743; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TOO CKL, 1989, ENDOCRINOLOGY, V124, P2185, DOI 10.1210/endo-124-5-2185; TOO CKL, 1990, BIOCHEM BIOPH RES CO, V173, P48, DOI 10.1016/S0006-291X(05)81019-8; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WULF GM, 1993, EMBO J, V12, P5065, DOI 10.1002/j.1460-2075.1993.tb06200.x; XU YH, 1992, MOL ENDOCRINOL, V6, P375, DOI 10.1210/me.6.3.375; YULEE LY, 1990, MOL CELL ENDOCRINOL, V68, P21; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087; ZHANG R, 1995, P NATL ACAD SCI USA, V91, P12755; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZMUIDZINAS A, 1985, EMBO J, V14, P1	81	102	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13246	13253		10.1074/jbc.270.22.13246	http://dx.doi.org/10.1074/jbc.270.22.13246			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768923	hybrid			2022-12-25	WOS:A1995RB43900047
J	WU, WI; MCDONOUGH, VM; NICKELS, JT; KO, JS; FISCHL, AS; VALES, TR; MERRILL, AH; CARMAN, GM				WU, WI; MCDONOUGH, VM; NICKELS, JT; KO, JS; FISCHL, AS; VALES, TR; MERRILL, AH; CARMAN, GM			REGULATION OF LIPID BIOSYNTHESIS IN SACCHAROMYCES-CEREVISIAE BY FUMONISIN B-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDATE PHOSPHATASE-ACTIVITY; YEAST PHOSPHATIDYLSERINE SYNTHASE; MIXED MICELLAR ANALYSIS; PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDYLINOSITOL SYNTHASE; FUSARIUM-MONILIFORME; SPHINGOLIPID BIOSYNTHESIS; SPHINGOSINE INHIBITION; ESCHERICHIA-COLI	The regulation of lipid biosynthesis in the yeast Saccharomyces cerevisiae by fumonisin B-1 was examined. Fumonisin B-1 inhibited the growth of yeast cells. Cells supplemented with fumonisin B, accumulated free sphinganine and phytosphingosine in a dose-dependent manner. The cellular concentration of ceramide was reduced in fumonisin B-1 supplemented cells. Ceramide synthase activity was found in yeast cell membranes and was inhibited by fumonisin B-1. Fumonisin B-1 inhibited the synthesis of the inositol containing sphingolipids inositol phosphorylceramide, mannosylinositol phosphorylceramide, and mannosyldiinositol phosphorylceramide. Fumonisin B-1 also caused a decrease in the synthesis of the major phospholipids synthesized via the CDP-diacylglycerol-dependent pathway and the synthesis of neutral lipids. The effects of fumonisin B-1 and sphingoid bases on the activities of enzymes in the pathways leading to the synthesis of sphingolipids, phospholipids, and neutral lipids were also examined. Other than ceramide synthase, fumonisin B-1 did not affect the activities of any of the enzymes examined. However, sphinganine and phytosphingosine inhibited the activities of inositol phosphorylceramide synthase, phosphatidylserine synthase, and phosphatidate phosphatase. These are key enzymes responsible for the synthesis of lipids in yeast. The data reported here indicated that the biosynthesis of sphingolipids, phospholipids and neutral lipids was coordinately regulated by fumonisin B-1 through the regulation of lipid biosynthetic enzymes by sphingoid bases.	RUTGERS STATE UNIV, COOK COLL, DEPT FOOD SCI, NEW JERSEY AGR EXPT STN, NEW BRUNSWICK, NJ 08903 USA; UNIV RHODE ISL, DEPT FOOD SCI & NUTR, KINGSTON, RI 02892 USA; EMORY UNIV, SCH MED, ROLLINS RES CTR, DEPT BIOCHEM, ATLANTA, GA 30322 USA	Rutgers State University New Brunswick; University of Rhode Island; Emory University				Merrill, Alfred/0000-0002-6673-968X	NIGMS NIH HHS [GM-46368, GM-28140, GM-49214] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM046368, R01GM028140, R29GM049214] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBAS HK, 1991, WEED SCI, V39, P673, DOI 10.1017/S004317450008855X; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BAELEE M, 1990, J BIOL CHEM, V265, P7221; BAELEE MS, 1984, J BIOL CHEM, V259, P857; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BANGHAM AD, 1972, ANNU REV BIOCHEM, V41, P753, DOI 10.1146/annurev.bi.41.070172.003541; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BEZUIDENHOUT SC, 1988, J CHEM SOC CHEM COMM, P743, DOI 10.1039/c39880000743; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; CARMAN GM, 1992, METHOD ENZYMOL, V209, P242; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CARMAN GM, 1989, PHOSPHATIDYLCHOLINE, P165; CULBERTSON MR, 1976, J BACTERIOL, V126, P232, DOI 10.1128/JB.126.1.232-242.1976; CULBERTSON MR, 1975, GENETICS, V80, P23; CULLIS PR, 1991, BIOCH LIPIDS LIPOPRO, P1; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; GREENBERG ML, 1982, MOL GEN GENET, V186, P157, DOI 10.1007/BF00331845; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, J BIOL CHEM, V262, P13620; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANSON BA, 1980, J LIPID RES, V21, P309; Henderson RJ, 1992, LIPID ANAL PRACTICAL, P65; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; HOLLAND KM, 1988, J BACTERIOL, V170, P828, DOI 10.1128/jb.170.2.828-833.1988; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1980, J BACTERIOL, V143, P176, DOI 10.1128/JB.143.1.176-181.1980; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KISS Z, 1990, J BIOL CHEM, V265, P7345; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KO JS, 1994, J BACTERIOL, V176, P5181, DOI 10.1128/jb.176.16.5181-5183.1994; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LESTER RL, 1993, ADV LIPID RES, V26, P253; LIN YP, 1989, J BIOL CHEM, V264, P8641; MARASAS WFO, 1988, ONDERSTEPOORT J VET, V55, P197; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MORASH SC, 1994, J BIOL CHEM, V269, P28769; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; PREISS J, 1986, J BIOL CHEM, V261, P8597; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; RAMGOPAL M, 1990, J LIPID RES, V31, P653; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; TAYLOR FR, 1978, J BACTERIOL, V136, P531, DOI 10.1128/JB.136.2.531-537.1978; TAYLOR FR, 1979, BIOCHIM BIOPHYS ACTA, V575, P204, DOI 10.1016/0005-2760(79)90022-5; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WANG E, 1991, J BIOL CHEM, V266, P14486; WELLS GB, 1983, J BIOL CHEM, V258, P200; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; WU WI, 1994, J BIOL CHEM, V269, P29495; WU WI, 1993, J BIOL CHEM, V268, P13830; ZHAO C, 1994, J BIOL CHEM, V269, P21480	81	98	99	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13171	13178		10.1074/jbc.270.22.13171	http://dx.doi.org/10.1074/jbc.270.22.13171			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768913	hybrid, Green Published			2022-12-25	WOS:A1995RB43900036
J	DEWAARD, M; WITCHER, DR; PRAGNELL, M; LIU, HY; CAMPBELL, KP				DEWAARD, M; WITCHER, DR; PRAGNELL, M; LIU, HY; CAMPBELL, KP			PROPERTIES OF THE ALPHA(1)-BETA ANCHORING SITE IN VOLTAGE-DEPENDENT CA2+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; BRAIN CALCIUM-CHANNEL; BETA-SUBUNIT; 1,4-DIHYDROPYRIDINE RECEPTOR; FUNCTIONAL EXPRESSION; BLOCKERS; BINDING; CLONING	In voltage-dependent Ca2+ channels, the beta subunit interacts with the alpha(1) subunit via a cytoplasmic site, A biochemical assay has been developed to quantitatively describe the interaction between both subunits, In vitro synthesized S-35-labeled beta subunits specifically bind to a glutathione S-transferase (GST) fusion protein containing the alpha(1a) interaction domain (AID(A), located between the amino-acids 383 and 400 of the cytoplasmic loop between the hydrophobic domains I and II), Kinetic analysis demonstrates that the association of S-35-labeled beta(1b) subunit to the AID(A) GST fusion protein occurs with a fast rate constant at 4 degrees C, The binding is almost irreversible as demonstrated by the absence of dissociation observed after an 8-h incubation with an 18-amino acid synthetic AID(A) peptide, The alpha(1)-beta binding site does not seem to be a target for cytoplasmic regulation, The interaction is mostly unaffected by changes in ionic strength, pH, and Ca2+ concentration or by protein kinase C phosphorylation. The specificity of subunit interaction in voltage-dependent Ca2+ channels was also followed by saturation analyses, The data obtained show that the AID(A) GST fusion protein binds to a single site on the beta(1b) with an apparent K-d of 5 nM, The affinities of AID(A) GST fusion protein for various beta subunits was measured and demonstrate that beta subunits associate with different affinities to each alpha(1) interaction domain, The rank order of AID(A) affinity for each beta subunit is as follows: beta(4) > beta(2a) > beta(1b) much greater than beta(3). The binding of the beta subunit to alpha(1) subunit can be inhibited in vitro by the AID(A) synthetic peptide with an apparent K-i of 285 nM. This interaction can also be prevented in heterologous Ca2+ channels by the injection of the AID(A) GST fusion protein into Xenopus oocytes, Our results demonstrate that the site of interaction between AID and beta subunit is responsible for anchoring the beta subunit to the alpha(1) subunit and thus allowing the beta subunit to modify Ca2+ channel activity.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,PROGRAM NEUROSCI,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa			De Waard, Michel/G-7406-2014	De Waard, Michel/0000-0002-2782-9615; Campbell, Kevin/0000-0003-2066-5889	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007343] Funding Source: NIH RePORTER; NIAID NIH HHS [T32-AI07343] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRNBAUMER L, 1994, NEURON, V13, P503; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, IN PRESS J PHYSL; EPPIG JJ, 1976, IN VITRO CELL DEV B, V12, P418; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; GRABNER M, 1994, J BIOL CHEM, V269, P23668; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LEUNG AT, 1988, J BIOL CHEM, V263, P994; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PIETROBON D, 1990, EUR J BIOCHEM, V193, P599, DOI 10.1111/j.1432-1033.1990.tb19378.x; POWERS PA, 1992, J BIOL CHEM, V267, P22967; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOONG TW, 1993, SCIENCE, V260, P1193; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1993, NEUROPHARMACOLOGY, V32, P1127, DOI 10.1016/0028-3908(93)90007-P	33	124	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12056	12064		10.1074/jbc.270.20.12056	http://dx.doi.org/10.1074/jbc.270.20.12056			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744854	hybrid			2022-12-25	WOS:A1995QY73600056
J	SOFER, A; FUTERMAN, AH				SOFER, A; FUTERMAN, AH			CATIONIC AMPHIPHILIC DRUGS INHIBIT THE INTERNALIZATION OF CHOLERA-TOXIN TO THE GOLGI-APPARATUS AND THE SUBSEQUENT ELEVATION OF CYCLIC-AMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; ENDOCYTOSIS; ENDOSOMES; BINDING; INVAGINATIONS; TRANSFERRIN	Cholera toxin (CT) consists of a pentameric B subunit which binds with high affinity to ganglioside GM(1), and an A subunit which stimulates adenylate cyclase, resulting in the elevation of cAMP. We now examine the effect of cationic amphiphilic drugs (CADs) on the internalization of rhodamine (Rh)-CT in cultured hippocampal neurons. CADs have recently been shown to inhibit receptor recycling by disrupting the assembly-disassembly of clathrin at the plasma membrane and on endosomes (Wang, L.-H., Rothberg, K. G., and Anderson, R. G. W. (1993) J. Cell Biol. 123, 1107-1117), Rh-CT was internalized by an energy- and temperature-dependent (presumably vesicular) mechanism to the Golgi apparatus. Internalization to the Golgi apparatus was completely but reversibly blocked by CADs, and the ability of CT to stimulate the elevation of cAMP was significantly reduced. In control cells, cAMP levels were elevated 2.3-fold after 20 min of incubation with CT, but in CAD-treated cells cAMP levels were only elevated 1.3-fold. The effect of CADs on CT internalization was not due to a direct effect of CADs on the Golgi apparatus. Our data demonstrate that CADs inhibit vesicular transport of CT to the Golgi apparatus and imply that the sorting of CT to the Golgi apparatus occurs in the same endosomal compartment involved in sorting recycling receptors to the plasma membrane, since both pathways are inhibited by CADs.	WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Futerman, Anthony/0000-0003-0013-0115				ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; DIPAOLA M, 1984, J CELL PHYSIOL, V118, P193, DOI 10.1002/jcp.1041180212; FISHMAN PH, 1982, J MEMBRANE BIOL, V69, P85, DOI 10.1007/BF01872268; FISHMAN PH, 1993, ADV LIPID RES, V25, P165; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Goslin K., 1991, CULTURING NERVE CELL, P251; HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89; HAREL R, 1993, J BIOL CHEM, V268, P14476; HARPER JF, 1975, J CYCLIC NUCLEOTIDE, V1, P201; HUNT RC, 1986, J BIOL CHEM, V261, P3681; JANICOT M, 1991, J BIOL CHEM, V266, P12858; JOSEPH KC, 1979, J CELL BIOL, V81, P543, DOI 10.1083/jcb.81.3.543; LEDEEN RW, 1992, TRENDS GLYCOSCI GLYC, V4, P174; LENCER WI, 1993, J CLIN INVEST, V92, P2941, DOI 10.1172/JCI116917; LENCER WI, 1992, J CELL BIOL, V117, P1197, DOI 10.1083/jcb.117.6.1197; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; NAMBIAR MP, 1993, J CELL PHYSIOL, V154, P222, DOI 10.1002/jcp.1041540203; ORLANDI PA, 1993, J BIOL CHEM, V268, P12010; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SCHWARZMANN G, 1987, GANGLIOSIDES MODULAT, P217; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; WANG E, 1991, J BIOL CHEM, V266, P14486; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	31	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12117	12122		10.1074/jbc.270.20.12117	http://dx.doi.org/10.1074/jbc.270.20.12117			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744860	hybrid			2022-12-25	WOS:A1995QY73600063
J	CARBONI, JM; YAN, N; COX, AD; BUSTELO, X; GRAHAM, SM; LYNCH, MJ; WEINMANN, R; SEIZINGER, BR; DER, CJ; BARBACID, M; MANNE, V				CARBONI, JM; YAN, N; COX, AD; BUSTELO, X; GRAHAM, SM; LYNCH, MJ; WEINMANN, R; SEIZINGER, BR; DER, CJ; BARBACID, M; MANNE, V			FARNESYLTRANSFERASE INHIBITORS ARE INHIBITORS OF RAS BUT NOT R-RAS2/TC21, TRANSFORMATION	ONCOGENE			English	Article						R-RAS2/TC21; P21 RAS; FARNESYLTRANSFERASE INHIBITORS; GERANYLGERANYLTRANSFERASE I; BISUBSTRATE ANALOGS; FARNESYLATION	GTP-BINDING PROTEINS; GERANYLGERANYL TRANSFERASE; PRENYLATION; ISOPRENYLATION; GROWTH; CELLS; FARNESYLATION; REQUIREMENT; SPECIFICITY; SEQUENCE	Recent results from several laboratories including ours strongly suggest that farnesyltransferase (FT) inhibitors belonging to distinct chemical classes block growth of oncogenic Ras transformed cells at concentrations that do not affect the growth and viability of normal cells, This is despite blocking the farnesylation and thus the membrane association of Ras in both cell types. This is a paradox given the requirement for Ras function in normal cell growth. Recent evidence that R-Ras2/TC21 utilizes components of Ras signal transduction pathways to trigger cellular transformation (Graham et al., MCB 14, 4108-4115, 1994) prompted us to consider the possibility that R-Ras2/TC21 is involved in some aspects of the growth regulation of normal cells. If so, R-Ras2/TC21 may be compensating for Ras function in untransformed cells treated with FT inhibitors. In this study, we demonstrated that a cell active bisubstrate analog FT inhibitor, BMS-186511, completely blocked the function of oncogenic Ras, but did not affect the function of oncogenic R-Ras2/TC21, as determined by several criteria including inhibition of anchorage dependent and independent growth, reversal of transformed morphology and restoration of actin cytoskeleton. While it is known that TC21 protein becomes prenylated, it is not known whether it is farnesylated or geranylgeranylated. Our in vitro prenylation experiments indicate that R-Ras2/TC21 protein serves as a good substrate for FT as well as geranylgeranyltransferase I (GGTI) and thus provide the apparent molecular basis for these differences. Overall, these results, coupled with the ubiquitous expression of R-Ras2/TC21 in many cells including untransformed NIH3T3 cells, are consistent with the possibility that R-Ras2/TC21 may be one of the factors that render normal cells insensitive to the growth inhibitory action of FT inhibitors.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT ONCOL DRUG DISCOVERY,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599	Bristol-Myers Squibb; Bristol-Myers Squibb; University of North Carolina; University of North Carolina Chapel Hill			Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010; manne, veeraswamy/B-1954-2010	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Der, Channing/0000-0002-7751-2747; Cox, Adrienne D./0000-0002-4901-2454				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; COX AD, 1993, J BIOL CHEM, V268, P11548; COX AD, 1994, ONCOGENE, V9, P3281; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JOBERTY G, 1993, FEBS LETT, V330, P323, DOI 10.1016/0014-5793(93)80897-4; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LACAL JC, 1986, MOL CELL BIOL, V6, P1002, DOI 10.1128/MCB.6.4.1002; LOWY DR, 1989, NATURE, V341, P384, DOI 10.1038/341384a0; MANNE V, 1995, DRUG DEVELOP RES, V34, P121, DOI 10.1002/ddr.430340205; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MANNE V, 1995, IN PRESS ONCOGENE; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OHYA Y, 1993, MOL BIOL CELL, V4, P1017, DOI 10.1091/mbc.4.10.1017; PATEL DV, 1995, J MED CHEM, V38, P435, DOI 10.1021/jm00003a006; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RILLING HC, 1993, ARCH BIOCHEM BIOPHYS, V301, P210, DOI 10.1006/abbi.1993.1135; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SELF AJ, 1993, ONCOGENE, V8, P655; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	54	59	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1905	1913						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761092				2022-12-25	WOS:A1995QZ92600004
J	STEINGRIMSDOTTIR, H; BEARE, D; CARR, AM; COLE, J; LEHMANN, AR				STEINGRIMSDOTTIR, H; BEARE, D; CARR, AM; COLE, J; LEHMANN, AR			UV-HYPERMUTABILITY OF XERODERMA-PIGMENTOSUM CELLS DEMONSTRATED WITH A DNA-BASED MUTATION SYSTEM	ONCOGENE			English	Article						MUTATIONS; POLYMERASE CHAIN REACTION; RESTRICTION SITE; ULTRAVIOLET; XERODERMA PIGMENTOSUM	POLYMERASE CHAIN-REACTION; NITROSOUREA-INDUCED MUTATIONS; LYMPHOCYTES-T; COMPLEMENTATION GROUP; MAMMALIAN-CELLS; CIRCULATING LYMPHOCYTES; STRAND SPECIFICITY; GENOTYPIC ANALYSIS; MOLECULAR ANALYSIS; REPAIR-PROFICIENT	We have developed a DNA-based system, to detect mutations at restriction sites without any selection in culture. DNA is exhaustively digested with a restriction enzyme. Primers Ranking a chosen site for this enzyme are used in the polymerase chain reaction (PCR). Only DNA molecules mutated at the chosen site are resistant to digestion and can serve as templates for the PCR. We have initially used this system to demonstrate the generation of mutations by ethyl methanesulphonate (EMS) at a TaqI site in the aprt gene of Chinese hamster cells, and by u.v.-C irradiation at a TaqI site in the hprt gene of human fibroblasts, In repair-deficient xeroderma pigmentosum (XP) cells the u.v.-induced mutant frequency was greatly enhanced. We have been able to detect and analyse mutations in XP cells at TaqI sites in three different genes, hprt, p53 and c-Ha-ras1. Both u.v.-C and u.v.-B irradiation have been used as mutagenic agents with both lymphoblastoid and fibroblast cells from XP patients from complementation group G. The mutant DNA molecules have been sequenced. Following u.v.-C-irradiation, the majority of mutations analysed were GC-->AT transitions, but several double and tandem mutations were also found.	UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND	University of Sussex				Carr, Antony Michael/0000-0002-2028-2389				AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; ALBERTINI RJ, 1985, MUTAT RES, V150, P411, DOI 10.1016/0027-5107(85)90138-1; ARLETT CF, 1980, CARCINOGENESIS, V1, P745, DOI 10.1093/carcin/1.9.745; ARLETT CF, 1993, CANCER RES, V53, P609; ARLETT CF, 1983, INDUCED MUTAGENESIS, P249; BIGBEE WL, 1990, MUTAT RES, V240, P165, DOI 10.1016/0165-1218(90)90056-8; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; BRIDGES BA, 1990, MUTAGENESIS, V5, P523, DOI 10.1093/mutage/5.6.523; CHIOCCA SM, 1992, P NATL ACAD SCI USA, V89, P5331, DOI 10.1073/pnas.89.12.5331; COLE J, 1994, MUTAT RES, V304, P33, DOI 10.1016/0027-5107(94)90320-4; COLE J, 1988, MUTAT RES, V204, P493, DOI 10.1016/0165-1218(88)90044-4; DORADO G, 1991, J MOL BIOL, V217, P217, DOI 10.1016/0022-2836(91)90533-C; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; FELLEYBOSCO E, 1991, NUCLEIC ACIDS RES, V19, P2913, DOI 10.1093/nar/19.11.2913; HENDERSON L, 1986, MUTAGENESIS, V1, P195, DOI 10.1093/mutage/1.3.195; HOU SM, 1993, MUTAGENESIS, V8, P43, DOI 10.1093/mutage/8.1.43; HSIA HC, 1989, J MOL BIOL, V205, P103, DOI 10.1016/0022-2836(89)90368-9; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; HUSSAIN SP, 1994, ONCOGENE, V9, P2277; HUSSAIN SP, 1994, ONCOGENE, V9, P13; KEIJZER W, 1979, MUTAT RES, V62, P183, DOI 10.1016/0027-5107(79)90231-8; KOVALIC D, 1991, NUCLEIC ACIDS RES, V19, P4560, DOI 10.1093/nar/19.16.4560; MADZAK C, 1991, J MOL BIOL, V218, P667, DOI 10.1016/0022-2836(91)90252-2; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MENICHINI P, 1991, MUTAT RES, V251, P143, DOI 10.1016/0027-5107(91)90224-C; MEUTH M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P1, DOI 10.1016/0304-419X(90)90009-P; MYERS B, 1994, MUTAGENESIS, V9, P175, DOI 10.1093/mutage/9.3.175; NALBANTOGLU J, 1983, J MOL BIOL, V167, P575, DOI 10.1016/S0022-2836(83)80099-0; NALBANTOGLU J, 1987, MOL CELL BIOL, V7, P1445, DOI 10.1128/MCB.7.4.1445; PALOMBO F, 1992, NUCLEIC ACIDS RES, V20, P1349, DOI 10.1093/nar/20.6.1349; PARRY JM, 1990, MUTAGENESIS, V5, P209, DOI 10.1093/mutage/5.3.209; POURZAND C, 1993, MUTAT RES, V288, P113, DOI 10.1016/0027-5107(93)90213-Y; ROSSI AM, 1990, MUTAT RES, V244, P353, DOI 10.1016/0165-7992(90)90084-W; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDY MS, 1992, P NATL ACAD SCI USA, V89, P890, DOI 10.1073/pnas.89.3.890; STEINGRIMSDOTTIR H, 1993, MUTAT RES, V294, P29, DOI 10.1016/0921-8777(93)90055-L; STRAUSS GH, 1979, MUTAT RES, V61, P353, DOI 10.1016/0027-5107(79)90140-4; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; YAGI T, 1991, CANCER RES, V51, P3177; ZIJLSTRA J, 1990, MUTAGENS CARCINOGENS, P187	43	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					2057	2066						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761106				2022-12-25	WOS:A1995QZ92600020
J	GALLINGER, S; VIVONA, AA; ODZE, RD; MITRI, A; OBEIRNE, CP; BERK, TC; BAPAT, BV				GALLINGER, S; VIVONA, AA; ODZE, RD; MITRI, A; OBEIRNE, CP; BERK, TC; BAPAT, BV			SOMATIC APC AND K-RAS CODON-12 MUTATIONS IN PERIAMPULLARY ADENOMAS AND CARCINOMAS FROM FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS	ONCOGENE			English	Note						AMPULLARY CANCER; FAP; APC; K-RAS; DUODENAL CANCER	DUODENAL ADENOMAS; GENE-MUTATIONS; COLI GENE; IDENTIFICATION; CANCER; TUMORS; VATER; FAP	Periampullary adenomas in the duodenum of Familial Adenomatous Polyposis (FAP) patients are among the most frequent and clinically important extracolonic neoplasms in FAP. The purpose of this study was to characterize the frequency and nature of somatic adenomatous polyposis coli (APC) gene and K-ras codon 12 mutations in periampullary adenomas and carcinomas in FAP. These molecular changes have been shown to be important during the early stages of colorectal carcinogenesis. DNA was prepared from endoscopic periampullary biopsies and paraffin blocks from 49 FAP patients. Of 143 samples, 77 were histologically normal, 29 were biopsies from small periampullary adenomas, 29 biopsies were from 19 large adenomas and eight samples were from periampullary cancers. APC mutations in the mutation cluster region and K-ras codon 12 mutations were detected by polymerase chain reaction based techniques. Somatic APC mutations consisting of deletions at codons 1464 and 1465 were detected in one small and two large periampullary adenomas. Loss of heterozygosity was seen in one periampullary carcinoma, K-ras codon 12 mutations were detected in seven of 19 large periampullary adenomas and in one of eight periampullary carcinomas. These data suggest that K-ras codon 12 mutations may be important during periampullary tumorigenesis in FAP but somatic APC mutations in the mutation cluster region are infrequent. Local environmental factors in the duodenum may contribute to differences in the molecular changes which occur during the adenoma-to-carcinoma sequence in periampullary compared to colonic tumorigenesis.	UNIV TORONTO,MT SINAI HOSP,STEVE ATANAS STAVRO FAP REGISTRY,DEPT PATHOL,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	GALLINGER, S (corresponding author), UNIV TORONTO,MT SINAI HOSP,STEVE ATANAS STAVRO FAP REGISTRY,DEPT SURG,TORONTO,ON M5G 1X5,CANADA.		Gallinger, Steven/E-4575-2013; Bapat, Bharati/B-5839-2014					BACZAKO K, 1985, HUM PATHOL, V16, P305, DOI 10.1016/S0046-8177(85)80018-6; BAPAT B, 1993, HUM MOL GENET, V2, P1957, DOI 10.1093/hmg/2.11.1957; BECKWITH PS, 1991, ARCH SURG-CHICAGO, V126, P825; BOS JL, 1989, CANCER RES, V49, P4682; CHURCH JM, 1992, DIS COLON RECTUM, V35, P1170, DOI 10.1007/BF02251971; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAYES DH, 1987, ANN SURG, V206, P572; HORII A, 1992, CANCER RES, V52, P3231; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAGELMAN DG, 1988, LANCET, V1, P1149; JOHAN G, 1992, GASTROENTEROLOGY, V102, P1980; KURTZ RC, 1987, DIGEST DIS SCI, V32, P459, DOI 10.1007/BF01296027; LEVI S, 1991, CANCER RES, V51, P3497; MIYAKI M, 1993, CANCER RES, V53, P5079; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; ODZE RD, 1993, HUM PATHOL, V24, P442, DOI 10.1016/0046-8177(93)90095-X; PENNA C, 1993, BRIT J SURG, V80, P1027, DOI 10.1002/bjs.1800800833; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RHODES M, 1992, GUT, V33, P125, DOI 10.1136/gut.33.1.125; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	25	37	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1875	1878						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753564				2022-12-25	WOS:A1995QX46900022
J	SIMONEAU, JA; COLBERG, SR; THAETE, FL; KELLEY, DE				SIMONEAU, JA; COLBERG, SR; THAETE, FL; KELLEY, DE			SKELETAL-MUSCLE GLYCOLYTIC AND OXIDATIVE ENZYME CAPACITIES ARE DETERMINANTS OF INSULIN SENSITIVITY AND MUSCLE COMPOSITION IN OBESE WOMEN	FASEB JOURNAL			English	Article						COMPUTED TOMOGRAPHY; LIMB BALANCE METHODS; MUSCLE METABOLISM	COMPUTED-TOMOGRAPHY; FAT; RESISTANCE; WEIGHT; FIBERS; MEN	Regional fat distribution is an important determinant of insulin resistance in obesity. In the current study, the relationship between skeletal muscle insulin sensitivity, mid-thigh muscle composition, and the metabolic profile of muscle was investigated. Muscle composition was assessed by computed tomography of the mid-thigh, and by activities of marker enzymes of aerobic-oxidative and glycolytic pathways and muscle fiber typing using biopsies of the vastus lateralis muscle. Muscle with reduced Hounsfield attenuation on computed tomography scans was increased in proportion to obesity, and was strongly related to insulin resistance, reduced muscle oxidative capacity, and increased anaerobic and glycolytic capacities by muscle. These findings suggest that as part of its expression of insulin resistance, skeletal muscle of obese individuals is also poorly equipped for substrate oxidation and manifests increased storage of fat.	UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA 15261 USA; VET AFFAIRS MED CTR, PITTSBURGH, PA USA; UNIV PITTSBURGH, SCH MED, DEPT RADIOL, PITTSBURGH, PA 15261 USA; UNIV LAVAL, PHYS ACT SCI LAB, Ste Foy, PQ, CANADA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Laval University			Colberg, Sheri R/A-9793-2017	Colberg, Sheri R/0000-0001-7574-2533	NCRR NIH HHS [5MO1RR00056] Funding Source: Medline; NIDDK NIH HHS [1P30DK46204] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046204] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASS A, 1969, EUR J BIOCHEM, V10, P198, DOI 10.1111/j.1432-1033.1969.tb00674.x; BORKAN GA, 1982, AM J CLIN NUTR, V36, P172, DOI 10.1093/ajcn/36.1.172; BULCKE D, 1987, J AM DIET ASSOC, V87, P196; BULCKE JA, 1981, MUSCLE NERVE, V4, P67, DOI 10.1002/mus.880040112; COLBERG SR, 1995, IN PRESS J CLIN INVE; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DESPRES JP, 1993, NUTRITION, V9, P452; DOUGLAS AR, 1988, J APPL PHYSIOL, V65, P473; EVANS DJ, 1984, METABOLISM, V33, P68, DOI 10.1016/0026-0495(84)90164-1; FERRARO RT, 1993, J CLIN INVEST, V92, P441, DOI 10.1172/JCI116586; GAUTHIER JM, 1992, MED SCI SPORT EXER, V24, P1252; HOPPELER H, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P567; HOWALD H, 1990, INT J SPORTS MED, V11, pS10, DOI 10.1055/s-2007-1024847; KELLEY DE, 1991, AM J CLIN NUTR, V54, P509, DOI 10.1093/ajcn/54.3.509; KELLEY DE, 1990, AM J PHYSIOL, V258, pE923, DOI 10.1152/ajpendo.1990.258.6.E923; LINDGARDE F, 1982, ACTA MED SCAND, V212, P99; LOWRY CV, 1978, J BIOL CHEM, V253, P8269; Newsholme E.A., 1983, BIOCH MED SCI; OLEFSKY JM, 1976, J CLIN INVEST, V57, P1165, DOI 10.1172/JCI108384; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; REICHMANN H, 1982, HISTOCHEMISTRY, V74, P27, DOI 10.1007/BF00495049; SIMONEAU JA, 1985, CAN J PHYSIOL PHARM, V63, P30, DOI 10.1139/y85-005; SIMONEAU JA, 1989, AM J PHYSIOL, V257, pE567, DOI 10.1152/ajpendo.1989.257.4.E567; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; ZURLO F, 1990, AM J PHYSIOL, V259, pE650	25	282	285	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1995	9	2					273	278		10.1096/fasebj.9.2.7781930	http://dx.doi.org/10.1096/fasebj.9.2.7781930			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781930				2022-12-25	WOS:A1995QJ24900017
J	KEANE, MM; RIVEROLEZCANO, OM; MITCHELL, JA; ROBBINS, KC; LIPKOWITZ, S				KEANE, MM; RIVEROLEZCANO, OM; MITCHELL, JA; ROBBINS, KC; LIPKOWITZ, S			CLONING AND CHARACTERIZATION OF CBL-B - A SH3 BINDING-PROTEIN WITH HOMOLOGY TO THE C-CBL PROTOONCOGENE	ONCOGENE			English	Article						CBL-B; SK3 PROTEIN INTERACTIONS; MAMMARY CELLS; DIFFERENTIATION	ACUTE PROMYELOCYTIC LEUKEMIA; MESSENGER-RNA; DNA-BINDING; ZINC FINGER; V-CBL; SACCHAROMYCES-CEREVISIAE; POINT MUTATIONS; RAR-ALPHA; GENE; SEQUENCE	We have cloned a new gene, cbl-b, with homology to the c-cbl proto-oncogene. A large protein is predicted (approx, MW 108 000) that has a proline rich domain, a nuclear localization signal, a C3HC4 zinc finger and a putative leucine zipper. There is striking nucleotide and amino acid homology to the c-cbl proto-oncogene most notably in the structural motifs described above. Cbl-b is expressed in normal and malignant mammary epithelial cells, in a variety of normal tissues, and in hematopoietic tissue and cell lines. Cbl-b expressions is up-regulated with macrophage/monocyte differentiation of the HL60 and U937 cell lines, There is direct association of the cbl-b protein with the Src Homology 3 domains of several proteins including signaling, cytoskeletal and adaptor proteins. Our data suggest that cbl-b encodes a protein which can interact with signal transduction proteins to regulate their function or to be regulated by them, Together, cbl-b and c-cbl are members of a novel family of proto-oncogenes involved in signal transduction.	USN HOSP,NCI,MED ONCOL BRANCH,BETHESDA,MD 20889; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Rivero-Lezcano, Octavio Miguel/J-9089-2015	Rivero-Lezcano, Octavio Miguel/0000-0002-8793-0731				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Battey, 1986, BASIC METHODS MOL BI; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHANET R, 1988, GENE, V74, P543, DOI 10.1016/0378-1119(88)90187-4; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KLINKEN SP, 1988, ONCOGENE RES, V3, P187; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Langdon W Y, 1992, Curr Top Microbiol Immunol, V182, P467; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LAWRENCE JB, 1988, CELL, V52, P51; LIPKOWITZ S, 1992, J BIOL CHEM, V267, P21065; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	43	182	189	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2367	2377						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784085				2022-12-25	WOS:A1995RE54300012
J	ZHAO, YM; WAGNER, F; FRANK, SJ; KRAFT, AS				ZHAO, YM; WAGNER, F; FRANK, SJ; KRAFT, AS			THE AMINO-TERMINAL PORTION OF THE JAK2 PROTEIN-KINASE IS NECESSARY FOR BINDING AND PHOSPHORYLATION OF THE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR BETA(C) CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASE; HIGH-AFFINITY; GM-CSF; CYTOPLASMIC DOMAINS; EXPRESSION CLONING; SUBUNIT; INTERLEUKIN-3; FAMILY	The binding of granulocyte-macrophage colony-stimulating factor (GM-CSF) to its receptor stimulates JAK2 protein kinase activation, protein phosphorylation, and JAK2 association with the beta(c) chain of the GM-CSF receptor. To better understand how different domains of the JAK2 function to regulate association and phosphorylation of the beta(c) receptor, the minimal portion of the beta(c) receptor necessary for JAK2 binding has been determined. Using glutathione S-transferase (GST) fusion proteins expressing different portions of the membrane-proximal domain of the beta(c) chain, we demonstrate that JAK2 binds to amino acids 458-495, but showed little binding to fusion proteins containing amino acids 483-559, 483-530, or 458-484. The GST-beta(c) 458-495 bound equally well to the wild type (WT) JAK2, a carboxyl-terminal deletion of JAK2 removing the protein kinase domain (amino acids 1000-1129), and a deletion of the kinase-like domain (amino acids 523-746). However, an amino-terminal JAK2 deletion (amino acids 2-239) markedly reduced binding to this GST-beta(c). Far Western blotting demonstrated that a GST fusion protein containing amino acids 1-294 of JAK2, but not fusion proteins containing amino acids 295-522, 523-746, or 747-1127, bound GST-beta(c) 458-559. When the JAK2 WT and deletions were transiently expressed along with the alpha and beta(c) subunits of the GM-CSF receptor and the cells were treated with GM-CSF, the following results were obtained: 1) WT JAK2 phosphorylated the beta(c) subunit in a GM-CSF-dependent manner, 2) the kinase-like domain deletion phosphorylated the beta(c) subunit, and 3) both the kinase domain deletion and the amino-terminal deletion failed to stimulate phosphorylation of the beta(c) subunit. Therefore, phosphorylation of the beta(c) subunit requires the binding of JAK2 through its amino terminus.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294; DIV ENDOCRINOL,BIRMINGHAM,AL 35294; VET ADM MED CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741, R29DK046395] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29-DK-46395, DK44741] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; COLOSI P, 1993, J BIOL CHEM, V268, P12617; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DURONIO V, 1992, J BIOL CHEM, V267, P21856; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; POLATSKAYA A, 1994, J BIOL CHEM, V269, P4607; POLATSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WEISS M, 1993, BLOOD, V82, P3298; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	32	133	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13814	13818		10.1074/jbc.270.23.13814	http://dx.doi.org/10.1074/jbc.270.23.13814			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775438	hybrid			2022-12-25	WOS:A1995RC44800037
J	PACKMAN, LC; MEWIES, M; SCRUTTON, NS				PACKMAN, LC; MEWIES, M; SCRUTTON, NS			THE FLAVINYLATION REACTION OF TRIMETHYLAMINE DEHYDROGENASE - ANALYSIS BY DIRECTED MUTAGENESIS AND ELECTROSPRAY MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE DETERMINATION; BACTERIUM; COENZYME; CLONING; FLAVIN; ASSAY; AID	The flavinylation reaction products of wild-type and mutant forms of trimethylamine dehydrogenases purified from Methylophilus methylotrophus (bacterium W(3)A(1)) and Escherichia coli were studied by electrospray mass spectrometry (ESMS). The ESMS analyses demonstrated for the first time that wild-type enzyme expressed in M. methylotrophus is predominantly in the holoenzyme form, although a small proportion is present as the deflavo enzyme. ESMS demonstrated that the deflavo forms of the recombinant wild-type and mutant enzymes are not post-translationally modified and therefore prevented from assembling with flavin mononucleotide (FMN) because of previously unrecognized modifications. The data suggest that the higher proportion of deflavo enzyme observed for the recombinant wild-type enzyme is a consequence of the higher expression levels in E. coli. Mutagenesis of the putative flavinylation base (His-29 to Gln-29) did not prevent flavinylation, but the relative proportion of flavinylated product was substantially less than that seen for the recombinant mild-type enzyme. No flavinylation products were observed for a double mutant (His-29 to Cys-29; Cys-30 to His-30), in which the positions of the putative flavinylation base and cysteine nucleophile were exchanged. Taken together, the data indicate that the assembly of trimethylamine dehydrogenase with FMN occurs during the folding of the enzyme, and in the fully folded form, deflavo enzyme is unable to recognize FMN. Results of site-directed mutagenesis experiments in the FMN-binding site suggest that following mutation the affinity for FMN during the folding process is reduced. Consequently, in the folded mutant enzymes, less flavin is trapped in the active site, and reduced levels of flavinylated product are obtained.	UNIV CAMBRIDGE,DEPT BIOCHEM,CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge								BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOYD G, 1992, FEBS LETT, V308, P271, DOI 10.1016/0014-5793(92)81291-S; KASPRZAK AA, 1983, J BACTERIOL, V156, P348, DOI 10.1128/JB.156.1.348-353.1983; KENNEY WC, 1978, FEBS LETT, V85, P137, DOI 10.1016/0014-5793(78)81265-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; LIM LW, 1988, J BIOL CHEM, V263, P3075; LIM LW, 1986, J BIOL CHEM, V261, P5140; MASSEY V, 1966, J BIOL CHEM, V241, P3417; MOORE SA, 1993, EMBO J, V12, P1767, DOI 10.1002/j.1460-2075.1993.tb05824.x; PACKMAN LC, 1995, EUR J BIOCHEM, V277, P510; RAINE ARC, 1994, PROTEIN SCI, V3, P1889, DOI 10.1002/pro.5560031028; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; ROHLFS RJ, 1995, J BIOL CHEM, V269, P30869; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCRUTTON NS, 1994, BIOESSAYS, V16, P115, DOI 10.1002/bies.950160208; SCRUTTON NS, 1994, J BIOL CHEM, V269, P13942; SINGER TP, 1984, METHOD ENZYMOL, V106, P369; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEENKAMP DJ, 1978, BIOCHEM J, V169, P263; WILSON EK, 1995, BIOCHEMISTRY-US, V34, P2584, DOI 10.1021/bi00008a024	23	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13186	13191		10.1074/jbc.270.22.13186	http://dx.doi.org/10.1074/jbc.270.22.13186			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768915	hybrid			2022-12-25	WOS:A1995RB43900038
J	SILVER, GM; FALL, R				SILVER, GM; FALL, R			CHARACTERIZATION OF ASPEN ISOPRENE SYNTHASE, AN ENZYME RESPONSIBLE FOR LEAF ISOPRENE EMISSION TO THE ATMOSPHERE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPEARMINT MENTHA-SPICATA; MONOTERPENE CYCLASE; 4S-LIMONENE SYNTHASE; GLANDULAR TRICHOMES; X-PIPERITA; DIPHOSPHATE; BIOSYNTHESIS; EXPRESSION; GENE; PHOTOSYNTHESIS	Isoprene (2-methyl-1,3-butadiene) is a volatile hydrocarbon emitted from many plant species to the atmosphere, where it plays an important role in atmospheric chemistry. An enzyme extracted from aspen (Populus tremuloides) leaves was previously found to catalyze the Mg2+-dependent elimination of pyrophosphate from dimethylallyl diphosphate (DMAPP) to form isoprene (Silver, G. M., and Fall, R. (1991) Plant Physiol. 97, 1588-1591). This enzyme, isoprene synthase, has now been purified 4000-fold to near homogeneity. The enzyme had a native molecular mass of 98-137 kDa and isoelectric point of 4.7 and contained 58- and 62-kDa subunits, implying that it is a heterodimer. Partial amino acid sequences of the two subunits indicated they are closely related to each other and that they do not share a strong homology with any other reported proteins. The isoprene synthase reaction was dependent on Mg2+ or Mn2+, and the reaction products were shown to be isoprene and pyrophosphate with a stoichiometry close to 1:1. The K-m for DMAPP was high at 8 mM, and the K-cat of 1.7 s(-1) was low, but similar to those of other allylic diphosphate-utilizing enzymes. It is argued that the isoprene synthase reaction may be much more efficient in vivo, where it is under light-dependent control. It seems probable that this unique enzyme, rather than non-enzymatic reactions, can account for the emission of hundreds of millions of metric tons of isoprene from plants to the global atmosphere each year.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; UNIV COLORADO, COOPERAT INST RES ENVIRONM SCI, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder								ALONSO WR, 1992, J BIOL CHEM, V267, P7582; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; AVRON M, 1981, BIOCH PLANTS COMPREH, P179; BAIER D, 1975, BIOCHIM BIOPHYS ACTA, V396, P141, DOI 10.1016/0005-2728(75)90197-8; BEATY JS, 1986, MOL GEN GENET, V203, P274, DOI 10.1007/BF00333966; BLACKWELL JR, 1993, PHYTOCHEMISTRY, V34, P1477, DOI 10.1016/S0031-9422(00)90831-8; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CARTIER PH, 1974, ANAL BIOCHEM, V61, P416, DOI 10.1016/0003-2697(74)90407-2; CHEN A, 1983, J BIOL CHEM, V268, P11002; COLBY SM, 1993, J BIOL CHEM, V268, P23016; CROTEAU R, 1989, J BIOL CHEM, V264, P15309; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; DENERIS ES, 1985, J BIOL CHEM, V260, P1382; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; Fehsenfeld F, 1992, GLOBAL BIOGEOCHEM CY, V6, P389, DOI 10.1029/92GB02125; GEBLER JC, 1992, J AM CHEM SOC, V114, P7354, DOI 10.1021/ja00045a004; GEGENHEIMER P, 1990, METHOD ENZYMOL, V182, P174; GOTOH T, 1988, BIOCHEM BIOPH RES CO, V156, P396, DOI 10.1016/S0006-291X(88)80854-4; GREENBERG JP, 1993, ATMOS ENVIRON A-GEN, V27, P2689, DOI 10.1016/0960-1686(93)90037-Y; HIRANO H, 1993, ELECTROPHORESIS, V14, P839, DOI 10.1002/elps.11501401134; JUSTESEN J, 1992, ANAL BIOCHEM, V207, P90, DOI 10.1016/0003-2697(92)90506-3; KUZMA J, 1993, PLANT PHYSIOL, V101, P435, DOI 10.1104/pp.101.2.435; MCCURRY SD, 1982, METHOD ENZYMOL, V90, P515; MONSON RK, 1992, PLANT PHYSIOL, V98, P1175, DOI 10.1104/pp.98.3.1175; MONSON RK, 1989, PLANT PHYSIOL, V90, P267, DOI 10.1104/pp.90.1.267; MUEHLBACHER M, 1988, BIOCHEMISTRY-US, V27, P7315, DOI 10.1021/bi00419a021; POSCH A, 1994, ELECTROPHORESIS, V15, P297, DOI 10.1002/elps.1150150150; POULTER CD, 1990, BIOCH CELL WALLS MEM, P169; POWELL GK, 1986, NUCLEIC ACIDS RES, V14, P2555, DOI 10.1093/nar/14.6.2555; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V296, P49, DOI 10.1016/0003-9861(92)90543-6; SANADZE G. A., 1966, FIZIOL RAST, V13, P458; Sanadze G. A., 1991, TRACE GAS EMISSIONS, P135; SILVER GM, 1991, PLANT PHYSIOL, V97, P1588, DOI 10.1104/pp.97.4.1588; VANKLEY H, 1977, ANAL BIOCHEM, V81, P485, DOI 10.1016/0003-2697(77)90725-4; 1993, NOVEX CATALOG, P69; [No title captured]; 1993, LIT EP008; 1992, PUBLICATION HP PEAK, P6; 1993, I350A AM INC PUBL; [No title captured]	42	114	156	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13010	13016		10.1074/jbc.270.22.13010	http://dx.doi.org/10.1074/jbc.270.22.13010			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768893	hybrid			2022-12-25	WOS:A1995RB43900014
J	HOUHOU, L; LAMOUROUX, A; BIGUET, NF; MALLET, J				HOUHOU, L; LAMOUROUX, A; BIGUET, NF; MALLET, J			EXPRESSION OF HUMAN DOPAMINE-BETA-HYDROXYLASE IN MAMMALIAN-CELLS INFECTED BY RECOMBINANT VACCINIA VIRUS - MECHANISMS FOR MEMBRANE ATTACHMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN GRANULES; PC12 PHEOCHROMOCYTOMA CELLS; UNCLEAVED SIGNAL PEPTIDE; MESSENGER-RNA; BOUND FORMS; MOLECULAR-CLONING; BOVINE; CDNA; SEQUENCE; BINDING	Dopamine beta-hydroxylase (DBH) is found in neurosecretory vesicles in both membrane-bound and soluble forms, We expressed various human DBH cDNAs in two mammalian cell lines, using the vaccinia virus expression system. The expression of a full-length DBH cDNA (DBH-f) reproduced the native DBH electrophoretic pattern and led to the synthesis of an active enzyme composed of two subunits of 77 and 73 kDa. In contrast, a truncated cDNA lacking the first ATG (DBH-t) generated a single band of 73 kDa. Analysis of mutated recombinant clones demonstrates that the two polypeptides do not result from the use of an alternative translation initiator codon. These results, combined with deglycosylation experiments, allow us to attribute the double band pattern to an optional cleavage of the signal peptide. When the NH2-terminal extremity is shortened, cleavage becomes obligatory, underlining the role of the first 14 amino acids in the regulation of the cleavage of the signal peptide, Subcellular analysis of recombinant DBH-t and DBH-f proteins indicates that DBH is anchored to the membrane by two distinct mechanisms; one of them is due to the non-removal of the signal peptide, whereas the second one is independent of the presence of the signal sequence. Moreover, quantification of the fractionation experiments suggests that the two modes of membrane attachment are additive.	CNRS,GENET MOLEC NEUROTRANSMISS & PROC NEURODEGENERATI,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								ANTREASSIAN J, 1986, NEUROCHEM INT, V8, P98; BELPAIRE F, 1968, BIOCHEM PHARMACOL, V17, P411, DOI 10.1016/0006-2952(68)90251-7; BON S, 1991, J NEUROCHEM, V57, P1100, DOI 10.1111/j.1471-4159.1991.tb08267.x; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FENG ZH, 1992, J BIOL CHEM, V267, P21808; FICHERCOLBRIE R, 1982, J NEUROCHEM, V38, P725; FOUCHIER F, 1988, BIOCHEM J, V256, P103, DOI 10.1042/bj2560103; FRIEDMAN S, 1965, J BIOL CHEM, V240, P4763; GIBSON KR, 1993, J BIOL CHEM, V268, P9490; HARTMAN BK, 1972, PHARMACOL REV, V24, P311; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JOH TH, 1986, ANN NY ACAD SCI, V493, P343; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUHN LJ, 1986, J BIOL CHEM, V261, P3816; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LEWIS EJ, 1990, J BIOL CHEM, V265, P1021; LEWIS EJ, 1992, J BIOL CHEM, V267, P494; MARGOLIS RK, 1984, ARCH BIOCHEM BIOPHYS, V228, P443, DOI 10.1016/0003-9861(84)90009-2; MCHUGH EM, 1985, J BIOL CHEM, V260, P4409; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; OYARCE AM, 1989, J MOL NEUROSCI, V1, P171, DOI 10.1007/BF02918903; POTTER LT, 1963, J PHARMACOL EXP THER, V142, P291; ROBERTSON JG, 1990, J BIOL CHEM, V265, P1029; ROISIN MP, 1984, BIOCHEM PHARMACOL, V33, P2245, DOI 10.1016/0006-2952(84)90662-2; SABBAN EL, 1987, J NEUROSCI, V7, P192; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SABBAN EL, 1987, ANN NY ACAD SCI, V493, P339; SAXENA A, 1983, J BIOL CHEM, V258, P4147; SAXENA A, 1985, J BIOL CHEM, V260, P3386; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SKOTLAND T, 1977, BIOCHEM BIOPH RES CO, V74, P1483, DOI 10.1016/0006-291X(77)90609-X; SPEEDIE MK, 1985, J CHROMATOGR, V327, P351, DOI 10.1016/S0021-9673(01)81664-2; STEWART LC, 1988, J BIOL CHEM, V263, P12183; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; STUNNENBERG HG, 1990, EXPRESSION RECOMBINA; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; TAYLOR CS, 1989, J BIOL CHEM, V264, P14; TAYLOR CS, 1989, J BIOL CHEM, V264, P15242; TAYLOR CS, 1990, THESISS GEORGETOWN U; VAYER P, 1990, NEUROSCI RES COMMUN, V6, P77; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WANG NY, 1990, BIOCHEMISTRY-US, V29, P6466, DOI 10.1021/bi00479a019; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WU HJ, 1990, J NEUROCHEM, V55, P97, DOI 10.1111/j.1471-4159.1990.tb08826.x	47	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12601	12606		10.1074/jbc.270.21.12601	http://dx.doi.org/10.1074/jbc.270.21.12601			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759508	hybrid			2022-12-25	WOS:A1995QZ71100043
J	NILLER, HH; GLASER, G; KNUCHEL, R; WOLF, H				NILLER, HH; GLASER, G; KNUCHEL, R; WOLF, H			NUCLEOPROTEIN COMPLEXES AND DNA 5'-ENDS AT ORIP OF EPSTEIN-BARR-VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; RAJI CELLS; REPLICATION ORIGIN; STABLE REPLICATION; NUCLEAR ANTIGEN-1; HUMAN TELOMERES; PLASMID ORIGIN; BINDING; EBNA-1; SITES	Understanding protein-DNA interactions in vivo at origins of DNA replication throughout the cell cycle may shed further insight on the mechanisms of initiation and replication control. The Burkitt's lymphoma cell line Raji harbors multiple copies of latent Epstein-Barr virus. Once per cell cycle the origin of plasmid replication of Epstein-Barr virus provides replication function in cis for the viral DNA. Here we examined in vivo nucleoprotein complexes on the initiator element of the origin before and after DNA synthesis. For this purpose Raji cells were synchronously growth arrested in G(1) phase by mimosine and in mitosis by colchicine, respectively. The association of the initiator element with proteins was visualized by footprinting with dimethyl sulfate and Ligation mediated polymerase chain reaction. Methylation patterns indicated a novel binding activity within each element of a nonamer repeated three times at the initiator element. This activity was strongly diminished in mitotic cells. Furthermore, 5'-ends of Epstein-Barr virus DNA were mapped to the nonamers by ligation mediated polymerase chain reaction, suggesting potential initiation sites for replication from DS.	UNIV REGENSBURG,INST PATHOL,D-93053 REGENSBURG,GERMANY	University of Regensburg	NILLER, HH (corresponding author), UNIV REGENSBURG,INST MED MICROBIOL & HYG,FRANZ JOSEF STR ALLEE 11,D-93053 REGENSBURG,GERMANY.							ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; ADAMS A, 1975, P NATL ACAD SCI USA, V72, P1477, DOI 10.1073/pnas.72.4.1477; AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BROWN WRA, 1989, NATURE, V338, P774, DOI 10.1038/338774a0; CHITTENDEN T, 1989, J VIROL, V63, P3016, DOI 10.1128/JVI.63.7.3016-3025.1989; CROSS SH, 1989, NATURE, V338, P771, DOI 10.1038/338771a0; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DHAR V, 1991, MOL CELL BIOL, V11, P6268, DOI 10.1128/MCB.11.12.6268; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; FRAPPIER L, 1992, J VIROL, V66, P1786, DOI 10.1128/JVI.66.3.1786-1790.1992; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GUSSANDER E, 1984, J VIROL, V52, P549, DOI 10.1128/JVI.52.2.549-556.1984; HAMPAR B, 1974, P NATL ACAD SCI USA, V71, P631, DOI 10.1073/pnas.71.3.631; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; INOUE S, 1981, J CELL BIOL, V91, pS131, DOI 10.1083/jcb.91.3.131s; KIMBALL AS, 1989, MOL CELL BIOL, V9, P2738, DOI 10.1128/MCB.9.6.2738; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LAMBROOK J, 1989, MOL CLONING LABORATO; LINDAHL T, 1976, J MOL BIOL, V102, P511, DOI 10.1016/0022-2836(76)90331-4; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MAXAM AM, 1980, METHOD ENZYMOL, V65, P497; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NONOYAMA M, 1972, NATURE-NEW BIOL, V238, P169, DOI 10.1038/newbio238169a0; OH SJ, 1991, J VIROL, V65, P514, DOI 10.1128/JVI.65.1.514-519.1991; PLATT THK, 1993, J VIROL, V67, P1739, DOI 10.1128/JVI.67.3.1739-1745.1993; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; SALUZ HP, 1990, LABORATORY GUIDE IN; WEN LT, 1990, VIROLOGY, V178, P293, DOI 10.1016/0042-6822(90)90407-I; WYSOKENSKI DA, 1989, J VIROL, V63, P2657, DOI 10.1128/JVI.63.6.2657-2666.1989; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	41	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12864	12868		10.1074/jbc.270.21.12864	http://dx.doi.org/10.1074/jbc.270.21.12864			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759544	hybrid			2022-12-25	WOS:A1995QZ71100081
J	SAHLIN, M; LASSMANN, G; POTSCH, S; SJOBERG, BM; GRASLUND, A				SAHLIN, M; LASSMANN, G; POTSCH, S; SJOBERG, BM; GRASLUND, A			TRANSIENT FREE-RADICALS IN IRON OXYGEN RECONSTITUTION OF MUTANT PROTEIN R2 Y122F - POSSIBLE PARTICIPANTS IN ELECTRON-TRANSFER CHAINS IN RIBONUCLEOTIDE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; HYDROGEN-PEROXIDE; SMALL SUBUNIT; ACTIVATION; RESONANCE; MECHANISM; COFACTOR; EPR	Ferrous iron/oxygen reconstitution of the mutant R2 apoprotein Y122F leads to formation of a diferric center similar to that of the wild-type R2 protein of Escherichia coli ribonucleotide reductase. This reconstitution reac tion requires two extra electrons, supplied or transferred by the protein matrix of R2. We observed several transient free radical species using stopped flow and freeze quench EPR and stopped now UV-visible spectroscopy. Three of the radicals occur in the time window 0.1-2 s, i.e. concomitant with formation of the diferric site. They include a strongly iron-coupled radical (singlet EPR signal) observed only at less than or equal to 77 K, a singlet EPR signal observed only at room temperature, and a radical at Tyr-356 (light absorption at 410 nm), an invariant residue proposed to be part of an electron transfer chain in catalysis. Three additional transient radicals species are observed in the time window 6 s to 20 min. Two of these are conclusively identified, by specific deuteration, as tryptophan radicals. Comparing side chain geometry and distance to the iron center with EPR characteristics of the radicals, we propose certain Trp residues in R2 as likely to harbor these transient radicals.	STOCKHOLM UNIV, ARRHENIUS LABS, DEPT BIOPHYS, S-10691 STOCKHOLM, SWEDEN; MAX DELBRUCK CTR MOLEC MED, D-13125 BERLIN, GERMANY; TECH UNIV BERLIN, MAX VOLMER INST BIOPHYS & PHYS CHEM, D-10623 BERLIN, GERMANY	Stockholm University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Technical University of Berlin	SAHLIN, M (corresponding author), STOCKHOLM UNIV, ARRHENIUS LABS, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN.			Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1993, BIOCHEMISTRY-US, V26, P5541; ACHENBAC.H, 1972, CHEM BER-RECL, V105, P784, DOI 10.1002/cber.19721050307; ANDERSSON B., 1991, CURR TOP BIOENERG, V16, P1; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BACKES G, 1989, BIOCHEMISTRY-US, V28, P1923, DOI 10.1021/bi00430a074; BAUGHER JF, 1977, J PHYS CHEM-US, V81, P1349, DOI 10.1021/j100529a002; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; BOLLINGER JM, 1991, J AM CHEM SOC, V113, P6289, DOI 10.1021/ja00016a066; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; DAVYDOV R, 1994, J AM CHEM SOC, V116, P11120, DOI 10.1021/ja00103a029; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FLOSSMANN W, 1978, RADIAT RES, V73, P75, DOI 10.2307/3574574; FONTECAVE M, 1990, BIOCHEM BIOPH RES CO, V168, P659, DOI 10.1016/0006-291X(90)92371-6; FRANZEN S, 1993, J PHYS CHEM-US, V97, P3040, DOI 10.1021/j100114a035; GALLI C, 1995, J AM CHEM SOC, V117, P740, DOI 10.1021/ja00107a017; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; GRASLUND A, 1985, ENVIRON HEALTH PERSP, V64, P139, DOI 10.2307/3430005; HENRIKSEN MA, 1994, J AM CHEM SOC, V116, P9773, DOI 10.1021/ja00100a062; HOFFMAN BM, 1981, J BIOL CHEM, V256, P6556; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4330; KIM ST, 1993, P NATL ACAD SCI USA, V90, P8023, DOI 10.1073/pnas.90.17.8023; LAM KY, 1993, J CHEM SOC DALTON, P2797, DOI 10.1039/dt9930002797; LAND EJ, 1961, T FARADAY SOC, V57, P1885, DOI 10.1039/tf9615701885; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LASSMANN G, 1992, BIOCHEM BIOPH RES CO, V188, P879, DOI 10.1016/0006-291X(92)91138-G; LINDSTROM B, 1974, J LABELLED COMPD, V10, P187, DOI 10.1002/jlcr.2590100202; LING JS, 1994, J BIOL CHEM, V269, P5595; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MORTON JR, 1964, CHEM REV, V64, P453, DOI 10.1021/cr60230a005; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; PRUTZ WA, 1979, INT J RADIAT BIOL, V36, P513, DOI 10.1080/09553007914551301; RAVI N, 1994, J AM CHEM SOC, V116, P8007, DOI 10.1021/ja00097a007; REGNSTROM K, 1994, J BIOL CHEM, V269, P6355; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1986, J MAGN RESON, V67, P135, DOI 10.1016/0022-2364(86)90417-8; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SAHLIN M, 1982, J BIOL CHEM, V257, P366; SAHLIN M, 1994, J BIOL CHEM, V269, P11699; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; STONE EW, 1962, J CHEM PHYS, V37, P1326, DOI 10.1063/1.1733281; STUBBE JA, 1980, J BIOL CHEM, V255, P8027; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003	58	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12361	12372		10.1074/jbc.270.21.12361	http://dx.doi.org/10.1074/jbc.270.21.12361			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759477	hybrid			2022-12-25	WOS:A1995QZ71100009
J	WISEMAN, RW; KUSHMERICK, MJ				WISEMAN, RW; KUSHMERICK, MJ			CREATINE-KINASE EQUILIBRATION FOLLOWS SOLUTION THERMODYNAMICS IN SKELETAL-MUSCLE - P-31 NMR-STUDIES USING CREATINE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATED BETA-GUANIDINOPROPIONATE; RAT MUSCLE; CYCLOCREATINE PHOSPHATE; ADENINE-NUCLEOTIDES; SUSTAIN ATP; PHOSPHOCREATINE; FIBERS; ISCHEMIA; COMPARTMENTATION; CONTRACTION	The hypothesis tested was whether creatine kinase (CK) equilibrates with its substrates and products in the cytosol as if in solution. We used the creatine analogs cyclocreatine (cCr) or beta-guanidopropionate (beta GPA) to test if mass action ratios (Gamma) for CK in muscle could be predicted from combined equilibrium constants (K-comb) measured in solutions mimicking the intracellular environment. Mice were fed cCr or beta GPA and their muscles assayed for substrates and products of the CK reaction by P-31 NMR spectroscopy and high performance liquid chromatography. After three weeks of feeding, Gamma was indistinguishable from K-comb in cCr-treated muscles demonstrating both PCr/Cr and phospho-analog/analog must have equilibrated with a constant and uniform cellular ATP/ADP ratio. In beta GPA-treated muscles, Gamma was smaller than K-comb due to a higher content of muscle beta GPA. Feeding beta GPA for 9-12 weeks resulted in a closer agreement between K-comb and Gamma, suggesting ATP/ADP ratios are not uniform within the muscle perhaps due to transient metabolic stress in some cells. From this analysis it follows that calculation of free ADP from the CII: equilibrium for a heterogeneous population of cells with respect to total Cr and ATP content is correct only if chemical potentials of these cells are uniform.	UNIV WASHINGTON,MED CTR,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,CTR BIOENGN,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	WISEMAN, RW (corresponding author), UNIV WASHINGTON,MED CTR,DEPT RADIOL,SB-05,SEATTLE,WA 98195, USA.				NIAMS NIH HHS [AR36281, R29 AR41793, F32 AR08105] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036281, R29AR041793, F32AR008105] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHTEN E, 1990, J APPL PHYSIOL, V68, P644, DOI 10.1152/jappl.1990.68.2.644; ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; ANNESLEY TM, 1977, BIOCHEM BIOPH RES CO, V74, P185, DOI 10.1016/0006-291X(77)91392-4; ANNESLEY TM, 1978, J BIOL CHEM, V253, P8120; ANNESLEY TM, 1980, J BIOL CHEM, V255, P3924; BURKE RE, 1971, SCIENCE, V174, P709, DOI 10.1126/science.174.4010.709; CHASE PB, 1988, BIOPHYS J, V53, P935, DOI 10.1016/S0006-3495(88)83174-6; CHASE PB, 1995, AM J PHYSIOL-CELL PH, V268, pC480, DOI 10.1152/ajpcell.1995.268.2.C480; CHEVLI R, 1979, BIOCHEM MED METAB B, V21, P162, DOI 10.1016/0006-2944(79)90068-1; CONNETT RJ, 1988, AM J PHYSIOL, V254, pR949, DOI 10.1152/ajpregu.1988.254.6.R949; DEBEER R, 1992, NMR BASIC PRINCIPLES, V26, P202; FITCH CD, 1968, J BIOL CHEM, V243, P2024; FITCH CD, 1974, J BIOL CHEM, V249, P1060; FITCH CD, 1975, AM J PHYSIOL, V228, P1123, DOI 10.1152/ajplegacy.1975.228.4.1123; FRIEDMAN DL, 1991, J BIOL CHEM, V266, P22404; GARLICK PB, 1992, AM J PHYSIOL, V263, pH497, DOI 10.1152/ajpheart.1992.263.2.H497; GELLERICH FN, 1992, FEBS LETT, V297, P55, DOI 10.1016/0014-5793(92)80326-C; GEORGE P, 1960, PROG BIOPHYS MOL BIO, V10, P1; GRIFFITHS GR, 1976, J BIOL CHEM, V251, P2049; HINTZ CS, 1982, AM J PHYSIOL, V242, pC218, DOI 10.1152/ajpcell.1982.242.3.C218; HUMPHREY SM, 1991, AM J PHYSIOL, V260, pH6, DOI 10.1152/ajpheart.1991.260.1.H6; HUTSON SM, 1989, BIOCHEMISTRY-US, V28, P4325, DOI 10.1021/bi00436a030; KUBY SA, 1954, J BIOL CHEM, V210, P65; KUSHMERICK MJ, 1985, J EXP BIOL, V115, P165; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LOPRESTI P, 1989, BIOCHIM BIOPHYS ACTA, V998, P317, DOI 10.1016/0167-4838(89)90291-4; MAINWOOD GW, 1982, CAN J PHYSIOL PHARM, V60, P120, DOI 10.1139/y82-020; MCFARLAND EW, 1994, BIOPHYS J, V67, P1; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; MEYER RA, 1989, AM J PHYSIOL, V257, pC1149, DOI 10.1152/ajpcell.1989.257.6.C1149; MEYER RA, 1988, AM J PHYSIOL, V254, pC548, DOI 10.1152/ajpcell.1988.254.4.C548; MEYER RA, 1986, AM J PHYSIOL, V250, pC264, DOI 10.1152/ajpcell.1986.250.2.C264; MEYER RA, 1984, AM J PHYSIOL, V248, pC279; MOERLAND TS, 1989, AM J PHYSIOL, V257, pC810, DOI 10.1152/ajpcell.1989.257.4.C810; MURPHY E, 1988, BIOCHEMISTRY-US, V27, P526, DOI 10.1021/bi00402a003; NEMETH PA, 1993, AM J PHYSIOL, V264, pC411, DOI 10.1152/ajpcell.1993.264.2.C411; NODA L, 1954, J BIOL CHEM, V210, P83; PHILLIPS SK, 1993, J PHYSIOL-LONDON, V463, P157, DOI 10.1113/jphysiol.1993.sp019589; PHILLIPS SK, 1993, J PHYSIOL-LONDON, V462, P135, DOI 10.1113/jphysiol.1993.sp019547; ROBERTS JJ, 1982, AM J PHYSIOL, V248, pH911; ROWLEY GL, 1971, J AM CHEM SOC, V93, P5542, DOI 10.1021/ja00750a038; SAKS VA, 1985, J BIOL CHEM, V260, P7757; SHOUBRIDGE EA, 1985, BIOCHEM J, V232, P125, DOI 10.1042/bj2320125; SHOUBRIDGE EA, 1987, AM J PHYSIOL, V252, pC532, DOI 10.1152/ajpcell.1987.252.5.C532; SHOUBRIDGE EA, 1984, BIOCHIM BIOPHYS ACTA, V805, P79, DOI 10.1016/0167-4889(84)90039-9; TURNER DM, 1985, ARCH BIOCHEM BIOPHYS, V238, P642, DOI 10.1016/0003-9861(85)90210-3; TURNER DM, 1987, J BIOL CHEM, V262, P6605; UGURBIL K, 1985, J MAGN RESON, V64, P207, DOI 10.1016/0022-2364(85)90345-2; VEECH RL, 1979, J BIOL CHEM, V254, P6538; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WATTS DC, 1973, ENZYMES, P383; WISEMAN R, 1994, FASEB J, V8, pA10; WISEMAN RW, 1993, NMR BIOMED, V6, P153, DOI 10.1002/nbm.1940060208; WISEMAN RW, 1992, ANAL BIOCHEM, V204, P383, DOI 10.1016/0003-2697(92)90255-6; WOZNICKI DT, 1980, J NEUROCHEM, V34, P1247, DOI 10.1111/j.1471-4159.1980.tb09966.x; YAMASHITA K, 1991, J MUSCLE RES CELL M, V12, P37, DOI 10.1007/BF01781172	57	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12428	12438		10.1074/jbc.270.21.12428	http://dx.doi.org/10.1074/jbc.270.21.12428			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759484	hybrid			2022-12-25	WOS:A1995QZ71100017
J	JAMES, SR; PATERSON, A; HARDEN, TK; DOWNES, CP				JAMES, SR; PATERSON, A; HARDEN, TK; DOWNES, CP			KINETIC-ANALYSIS OF PHOSPHOLIPASE C-BETA ISOFORMS USING PHOSPHOLIPID-DETERGENT MIXED MICELLES - EVIDENCE FOR INTERFACIAL CATALYSIS INVOLVING DISTINCT MICELLE BINDING AND CATALYTIC STEPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ACTIVATION; C-DELTA-1; STIMULATION; HYDROLYSIS; VESICLES; ENZYMES; ASSOCIATION; BRAIN	Phosphatidylinositol 4,5-bisphosphate (PtdIns (4,5)P-2) hydrolysis by three different beta-isoforms of phospholipase C (PLC) was examined to investigate the catalytic action of these extracellular signal-regulated enzymes. Depletion of phospholipase C from solution by incubation with sucrose-loaded vesicles of differing compositions followed by ultracentrifugation demonstrated stable attachment of PLC to the vesicles from which an equilibrium association constant of PLC with PtdIns (4,5)P-2 could be determined. A mixed micellar system was established to assay PLC activity using dodecyl maltoside, which behaved as an essentially inert diluent of PtdIns (4,5)P-2 with respect to PLC beta activity. Kinetic analyses were performed to test whether PLC beta activity was dependent on both bulk PtdIns (4,5)P-2 concentration and surface concentration in the micelles as has been shown for other lipid metabolising enzymes. Each of the PLC beta isoforms behaved similarly in these analyses, which indicated the involvement of at least two binding events. Interfacial Michaelis constants were calculated to be between 0.1-0.2 mol fraction for all three enzymes, and K-s (the equilibrium dissociation constant of PLC for lipid) ranged between 100-200 mu M. The apparent multiple interfacial binding events did not appear to result from lipid-induced PLC beta oligomerization implying that PLC beta monomers possess more than one lipid-binding site, Surface dilution of PLC catalyzed PtdIns (4,5)P-2 hydrolysis was assessed in the presence of increasing concentrations of various nonsubstrate phospholipids, which profoundly reduced PLC activity, suggesting that these lipids may inhibit enzyme action. The data indicate that G protein-regulated isoforms of PLC operate with separate lipid binding and catalytic steps and imply that under physiological conditions, PLC beta isoforms operate under first-order conditions. These findings may have implications for the mechanisms of regulation of PLC beta s by G protein subunits.	UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	JAMES, SR (corresponding author), UNIV DUNDEE, INST MED SCI, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029536, R01GM029536] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29536] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CARPENTER G, 1993, ADV SEC MESS PHOSPH, V28, P179; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; CREBA JA, 1983, BIOCHEM J, V212, P733, DOI 10.1042/bj2120733; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Dennis EA, 1983, ENZYMES, P307; EATON BR, 1976, ARCH BIOCHEM BIOPHYS, V176, P604, DOI 10.1016/0003-9861(76)90204-6; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FREMONT DH, 1993, P NATL ACAD SCI USA, V90, P342, DOI 10.1073/pnas.90.1.342; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HIRASAWA K, 1981, BIOCHEM J, V193, P607, DOI 10.1042/bj1930607; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; JAMES SR, 1994, BIOCHEM J, V298, P499, DOI 10.1042/bj2980499; JONES GA, 1993, J BIOL CHEM, V268, P20845; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; LEE SB, 1993, J BIOL CHEM, V268, P25952; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; PARK DG, 1993, J BIOL CHEM, V268, P3710; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; PATERSON A, 1994, IN PRESS METHODS NEU, V6; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12748, DOI 10.1021/bi00166a006; REBECCHI MJ, 1993, J BIOL CHEM, V268, P1735; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; SCHNABEL P, 1993, EUR J BIOCHEM, V217, P1109, DOI 10.1111/j.1432-1033.1993.tb18343.x; Segel IH, 1975, ENZYME KINETICS, P346; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANCE DE, 1985, BIOCH LIPIDS MEMBRAN, P242; VOLWERK JJ, 1994, BIOCHEMISTRY-US, V33, P3464, DOI 10.1021/bi00178a002; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WALDO GL, 1994, METHOD ENZYMOL, V238, P195; WU DQ, 1993, J BIOL CHEM, V268, P3704	44	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11872	11881		10.1074/jbc.270.20.11872	http://dx.doi.org/10.1074/jbc.270.20.11872			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744837	hybrid			2022-12-25	WOS:A1995QY73600033
J	XIE, YH; MORIMOTO, T				XIE, YH; MORIMOTO, T			4 HYDROPHOBIC SEGMENTS IN THE NH2-TERMINAL 1/3 (H1-H4) OF NA,K-ATPASE ALPHA-SUBUNIT ALTERNATELY INITIATE AND HALT MEMBRANE TRANSLOCATION OF THE NEWLY SYNTHESIZED POLYPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; CDNA SEQUENCE; MONOCLONAL-ANTIBODY; MAMMALIAN KIDNEY; BETA-SUBUNIT; K+-ATPASE; NA+,K+-ATPASE; PROTEINS; DOMAINS; SIGNAL	Transmembrane disposition of the NH2-terminal third of the Na,K-ATPase a subunit was studied using an experimental approach that involved in vitro endoplasmic reticulum membrane insertion of chimeras, These chimeras consisted of four truncated amino-terminal segments of the a subunit linked at amino acid residues 126, 179, 313, and 439 to chloramphenicol acetyltransferase (CAT), a reporter protein, that contains a consensus sequence for N-linked glycosylation. The fusion sites were located after one of the four hydrophobic segments (H1-H4), The results showed that the chimeras in which the a subunit was truncated at positions 126 and 313 were glycosylated, and the glycosylated peptides were protected by membranes from proteolysis. However, the other two chimeras were not glycosylated and the inserted peptides were digested by protease into fragments which did not immunoprecipitate with anti-CAT. These results clearly demonstrate that hydrophobic segments H1 and H3 function as signal/anchor type II, and H2 and H4 function as halt transfer signals, Furthermore, membrane insertion of the NH2-terminal third of Na,K-ATPase alpha subunit is achieved by a series of alternate signal/anchor type II and halt transfer sequences.	NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University	XIE, YH (corresponding author), NYU,SCH MED,DEPT CELL BIOL,550 1ST AVE,NEW YORK,NY 10016, USA.				NIDDK NIH HHS [DK20277] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; FARLEY RA, 1986, AM J PHYSIOL, V250, pC896, DOI 10.1152/ajpcell.1986.250.6.C896; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; GLYNN IM, 1985, ENZYMES BIOL MEMBR, P35; HARA Y, 1987, J BIOCHEM-TOKYO, V102, P43, DOI 10.1093/oxfordjournals.jbchem.a122039; HOMAREDA H, 1989, MOL CELL BIOL, V9, P5742, DOI 10.1128/MCB.9.12.5742; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KANO I, 1990, BIOCHEM CELL BIOL, V68, P1262, DOI 10.1139/o90-187; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPP J, 1988, J CELL BIOL, V106, P1813, DOI 10.1083/jcb.106.6.1813; Mercer Robert W., 1993, V137C, P139; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; NICHOLAS RA, 1984, BIOCHEMISTRY-US, V23, P888, DOI 10.1021/bi00300a015; NOGUCHI S, 1986, FEBS LETT, V196, P315, DOI 10.1016/0014-5793(86)80270-8; OVCHINNIKOV YA, 1987, TRENDS BIOCHEM SCI, V12, P434, DOI 10.1016/0968-0004(87)90210-6; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; SKOU JC, 1992, BIOCHIM BIOPHYS ACTA, V988, P185; VASILETS LA, 1993, BIOCHIM BIOPHYS ACTA, V154, P201; WALTER P, 1983, METHOD ENZYMOL, V96, P84	31	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11985	11991		10.1074/jbc.270.20.11985	http://dx.doi.org/10.1074/jbc.270.20.11985			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744848	hybrid			2022-12-25	WOS:A1995QY73600048
J	YAMAGUCHI, N; FUKUDA, MN				YAMAGUCHI, N; FUKUDA, MN			GOLGI RETENTION MECHANISM OF BETA-1,4-GALACTOSYLTRANSFERASE - MEMBRANE-SPANNING DOMAIN-DEPENDENT HOMODIMERIZATION AND ASSOCIATION WITH ALPHA-TUBULINS AND BETA-TUBULINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULL-LENGTH CDNA; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; BOVINE BETA-1,4-GALACTOSYLTRANSFERASE; HUMAN GALACTOSYLTRANSFERASE; N-ACETYLGLUCOSAMINIDE; SECRETORY PATHWAY; PROTEIN; SIGNAL	Recent studies on proteins residing in the Golgi complex revealed that the membrane-spanning domain of these proteins are largely responsible for their retention in the Golgi complex. We show here that beta-1,4-galactosyltransferase (GT) forms homodimers and large oligomers in vivo, and the formation of the homodimers is dependent on cysteine and histidine residues within the transmembrane domain. Double mutations of these residues, Cys(29) --> Ser and His(32) --> Leu, abolish homodimerization and simultaneously reduce the Golgi retention. Co-immunoprecipitation of GT and various GT chimeras with anti-GT and anti-reporter molecule antibodies revealed that large aggregates of GT are associated with alpha- and beta-tubulins and also with other cellular proteins. This association between tubulins and GT suggests a supportive role of the cytoskeleton in the Golgi retention mechanism.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037016] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK37016] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RD, 1982, SCIENCE, V218, P1127, DOI 10.1126/science.6183744; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; BARKER R, 1972, J BIOL CHEM, V247, P7135; BAYNA EM, 1988, CELL, V53, P145, DOI 10.1016/0092-8674(88)90496-5; BENG JM, 1990, J BIOL CHEM, V265, P6513; BEYER TA, 1982, GLYCOCONJUGATES, V3, P25; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BURKE J, 1992, J BIOL CHEM, V267, P24433; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; ECKSTEIN DJ, 1992, EXP CELL RES, V201, P83, DOI 10.1016/0014-4827(92)90350-H; FIDDES JC, 1979, NATURE, V281, P351, DOI 10.1038/281351a0; HO WC, 1989, EUR J CELL BIOL, V48, P250; IIDA H, 1991, J HISTOCHEM CYTOCHEM, V39, P1349, DOI 10.1177/39.10.1719068; KREIS TE, 1990, CELL MOTIL CYTOSKEL, V15, P67, DOI 10.1002/cm.970150202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWA.J, 1990, CELL, V60, P821; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTH J, 1985, J CELL BIOL, V100, P118, DOI 10.1083/jcb.100.1.118; ROTH J, 1982, J CELL BIOL, V92, P223; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SCHACHTER H, 1980, BIOCH GLYCOPROTEINS, P85; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; STROUS GJ, 1991, BIOL CELL, V71, P25, DOI 10.1016/0248-4900(91)90048-R; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; SUGANUMA T, 1991, J HISTOCHEM CYTOCHEM, V39, P299, DOI 10.1177/39.3.1899684; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TANG BL, 1992, J BIOL CHEM, V267, P10122; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; UEMURA M, 1992, CANCER RES, V52, P6153; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; ZAGOURAS P, 1991, J VIROL, V65, P1976, DOI 10.1128/JVI.65.4.1976-1984.1991	57	126	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12170	12176		10.1074/jbc.270.20.12170	http://dx.doi.org/10.1074/jbc.270.20.12170			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744867	hybrid			2022-12-25	WOS:A1995QY73600070
J	BRONDELLO, JM; MCKENZIE, FR; SUN, H; TONKS, NK; POUYSSEGUR, J				BRONDELLO, JM; MCKENZIE, FR; SUN, H; TONKS, NK; POUYSSEGUR, J			CONSTITUTIVE MAP KINASE PHOSPHATASE (MKP-1) EXPRESSION BLOCKS G1 SPECIFIC GENE-TRANSCRIPTION AND S-PHASE ENTRY IN FIBROBLASTS	ONCOGENE			English	Article						CELL CYCLE ENTRY; GENE TRANSCRIPTION; GROWTH CONTROL; MAP KINASE CASCADE; PHOSPHATASES	PROTEIN-TYROSINE-PHOSPHATASE; IMMEDIATE-EARLY GENE; EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; C-FOS; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; COMPLEX-FORMATION; ENCODED PROTEIN; 3T3 CELLS	MAP kinase (mitogen activated protein kinase) represents a ubiquitously expressed family of kinases whose long term activation via phosphorylation is essential for the mitogenic response in fibroblasts. Two family members, p42 and p44 MAP kinase are cytosolic proteins in quiescent cells, but become nuclear following mitogenic stimulation, Inactivation of MAP kinases occurs via a specific phosphatase, MKP-1. Hence, we examined the localisation of this phosphatase, to determine the cellular site of MAP kinase inactivation, Transient transfection of CCL39 fibroblasts with epitope-tagged MKP-1 showed the protein to be entirely nuclear in both quiescent and mitogen stimulated cells, whereas a catalytically inactive mutant in which the essential cysteine was mutated to serine (MKP-1CS) was predominately cytoplasmic and again serum stimulation failed to alter the protein's localisation. Expression of either wild type or inactive MKP-1 did not alter the cytosolic localisation of p44 MAP kinase in quiescent cells nor the ability of MAP kinase to translocate to the nucleus following mitogen stimulation, Expression of wild type MKP-1 inhibited serum stimulated early (c-fos promoter) and late (dhfr promoter) transcriptional events as web as entry into S-phase. This inhibition was reversed by the co-expression of an active MAP kinase. We conclude that in the continual expression of MKP-1, the cellular localisation of MAP kinase is unaffected and that inactivation of MAP kinase by MKP-1 is a nuclear process leading to the inhibition of cell division.	CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE,FRANCE; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Cold Spring Harbor Laboratory			Brondello, Jean-Marc/U-8232-2017	Brondello, Jean-Marc/0000-0001-5991-3945				AHN NG, 1990, J BIOL CHEM, V265, P11487; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUNET A, 1994, ONCOGENE, V9, P3379; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; EGAN SE, 1993, NATURE, V363, P35; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KWAK SP, 1993, J BIOL CHEM, V269, P3596; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCKENZIE FR, 1992, J BIOL CHEM, V267, P22759; MELOCHE S, 1992, MOL ENDOCRINOL, V63, P845; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SARCEVIC B, 1993, J BIOL CHEM, V268, P25075; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WARNE PH, 1993, NATURE, V364, P1031; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	58	154	159	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1895	1904						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761091				2022-12-25	WOS:A1995QZ92600003
J	ZHANG, YJ; YU, DH; XIA, WY; HUNG, MC				ZHANG, YJ; YU, DH; XIA, WY; HUNG, MC			HER-2/NEU-TARGETING CANCER-THERAPY VIA ADENOVIRUS-MEDIATED E1A DELIVERY IN AN ANIMAL-MODEL	ONCOGENE			English	Article						HER-2/NEU; GENE THERAPY; E1A; ADENOVIRAL VECTOR	NEGATIVE BREAST-CANCER; GROWTH-FACTOR RECEPTOR; NECROSIS-FACTOR-ALPHA; HUMAN TUMOR-CELLS; OVARIAN-CANCER; NEU ONCOGENE; GENE-PRODUCTS; RECURRENT DISEASE; INCREASED RISK; POOR SURVIVAL	Overexpression of HER-2/neu has been demonstrated in human ovarian cancer and correlated with poor prognosis. We previously found that the adenovirus type 5 early region 1A (EIA) gene product can repress overexpression and suppress the tumorigenic potential of the HER-2/neu-overexpressing cancer cells. To develop an efficient HER-2/neu-targeting gene therapy with EIA, a replication-deficient adenovirus containing the E1A gene, Ad.E1A(+), was used to transduce the HER-2/neu-overexpressing human ovarian cancer cell line SK-OV3.ip1. Tumor cell growth in vitro and colony formation in soft agarose were greatly inhibited by Ad.E1A(+) transduction. To test therapeutic efficacy in vivo, tumor-bearing mice were established by i.p. injection with ovarian cancer cells and treated by i.p. injection of 10(8) PFU viral solution containing either replication-deficient Ad.E1A(+); control virus Ad.E1A(-) which is the same adenovirus as Ad.E1A(+) except for E1A deletion, or just PBS. Ad.E1A(+) significantly prolonged survival in treated mice for 1 year (80%) whereas in control groups, ah mice died of cancer within 4.5 months. Immunohistochemistry analysis indicated that Ad.E1A protein was expressed in tumor tissue and expression of HER-2/neu p185 protein was suppressed in vivo. As a control, another ovarian cancer cell Une 2774, in which HER-2/neu is expressed at a basal level, was also inoculated i.p. following the same therapeutic procedure. Ad.E1A(+) could not prolong survival of 2774 cells, indicating that Ad.E1A(+) specifically targeted HER-2/neu-overexpressing tumor cells and functioned as an antitumor agent.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58880, R01-CA60856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES RS, 1990, J VIROL, V64, P4115, DOI 10.1128/JVI.64.9.4115-4122.1990; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERCHUCK A, 1990, CANCER RES, V50, P4087; BORG A, 1990, CANCER RES, V50, P4332; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1990, ONCOGENE, V5, P75; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Graham FL, 1991, METHOD MOL BIOL, P109; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KENYON DJ, 1991, VIROLOGY, V180, P818, DOI 10.1016/0042-6822(91)90099-W; KERN JA, 1990, CANCER RES, V50, P5284; LI QT, 1993, HUM GENE THER, V4, P403, DOI 10.1089/hum.1993.4.4-403; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MITRA AB, 1994, CANCER RES, V54, P637; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; MYMRYK JS, 1994, ONCOGENE, V9, P1187; PARK JB, 1989, CANCER RES, V49, P6605; PATERSON MC, 1991, CANCER RES, V51, P556; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; PRESS MF, 1994, CANCER RES, V54, P5675; PRESS MF, 1993, CANCER RES, V53, P4960; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAWADA Y, 1986, J EXP MED, V163, P563, DOI 10.1084/jem.163.3.563; SAWADA Y, 1994, INT J CANCER, V57, P598, DOI 10.1002/ijc.2910570426; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V23, P177; YAGINUMA Y, 1992, CANCER RES, V52, P4196; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1991, ONCOGENE, V6, P343; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YONEMURA Y, 1991, CANCER RES, V51, P1034; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; ZHANG X, 1989, ONCOGENE, V4, P985	55	77	81	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1947	1954						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761095				2022-12-25	WOS:A1995QZ92600008
J	MANNE, V; YAN, N; CARBONI, JM; TUOMARI, AV; RICCA, CS; BROWN, JG; ANDAHAZY, ML; SCHMIDT, RJ; PATEL, D; ZAHLER, R; WEINMANN, R; DER, CJ; COX, AD; HUNT, JT; GORDON, EM; BARBACID, M; SEIZINGER, BR				MANNE, V; YAN, N; CARBONI, JM; TUOMARI, AV; RICCA, CS; BROWN, JG; ANDAHAZY, ML; SCHMIDT, RJ; PATEL, D; ZAHLER, R; WEINMANN, R; DER, CJ; COX, AD; HUNT, JT; GORDON, EM; BARBACID, M; SEIZINGER, BR			BISUBSTRATE INHIBITORS OF FARNESYLTRANSFERASE - A NOVEL CLASS OF SPECIFIC INHIBITORS OF RAS TRANSFORMED-CELLS	ONCOGENE			English	Article						P21 RAS PROTEINS; TRANSFORMATION; POSTTRANSLATIONAL MODIFICATIONS; MEVALONATE; FARNESYLTRANSFERASE INHIBITORS; GERANYLGERANYLTRANSFERASE	FARNESYL-PROTEIN TRANSFERASE; GERANYLGERANYL TRANSFERASE; SELECTIVE-INHIBITION; CDNA CLONING; POSTTRANSLATIONAL MODIFICATION; PRENYLATED PROTEINS; ALPHA-SUBUNIT; BETA-SUBUNIT; GTP-BINDING; P21RAS	We describe the biological properties of a new class of potent farnesyltransferase (FT) inhibitors designed as bisubstrate analog inhibitors. These inhibitors incorporate the structural motifs of both farnesyl pyrophosphate and the CAAX tetrapeptide, the two substrates of the reaction catalyzed by FT. Both the phosphinate inhibitor, EMS-185878, and the phosphonate inhibitor, BMS-184467, exhibited higher in vitro FT selectivity than some of the previously reported CVFM peptidomimentics and benzodiazepine analogs. Xenopus oocyte maturation induced by microinjected oncogenic Ras proteins was blocked by coinjected EMS-184467 and EMS-185878. However, both inhibitors showed poor cell activity presumably because of the doubly charged nature of the compounds. Thus, masking the charge on the carboxylate ion markedly improved the cell permeability of EMS-185878, leading to EMS-186511, the methyl carboxyl ester prodrug. EMS-186511 inhibited FT activity in whole cells as determined by inhibition of p21 Ras protein processing, inhibition of farnesylation of proteins including Ras and the accumulation of unfarnesylated Ras proteins in the cytosolic fraction. While the cellular effects of these bisubstrate analog inhibitors had no significant effect on growth of untransformed NIH3T3 cells, they produced pronounced inhibition of Ras transformed cell growth. Both the anchorage dependent and independent growth of ras transformed cells were severely curtailed by micromolar concentrations of EMS-186511, We also found that both H-ras and K-pas transformed cells are affected by this bisubstrate inhibitor. However, K-ras transformed cells appear to be less sensitive. The inhibition of FT activity in cells and the ensuing inhibition of ras transformed cell growth is further manifested in distinct morphological changes in cells. Cells flattened, became less refractile and grew in contact inhibited monolayer. Moreover, the highly diffused character of the actin cytoskeleton in the ras transformed cells was dramatically reverted to an organized network of stress cables crisscrossing the entire cells upon treatment with EMS-186511. All of these effects of EMS-186511 are limited to ras transformed cells that utilize farnesylated Ras, but are not seen in transformed cells that use geranylgeranyl Ras or myristoyl Ras. Significantly, these FT inhibitors did not produce any signs of gross cytotoxicity in untransformed, ras transformed cells or other oncogene transformed cells.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DIV DISCOVERY CHEM,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT BIOL MOLEC,PRINCETON,NJ 08543; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599	Bristol-Myers Squibb; Bristol-Myers Squibb; University of North Carolina; University of North Carolina Chapel Hill	MANNE, V (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,ONCOL DRUG DISCOVERY,PRINCETON,NJ 08543, USA.		manne, veeraswamy/B-1954-2010	Der, Channing/0000-0002-7751-2747; Cox, Adrienne D./0000-0002-4901-2454; Hunt, John/0000-0001-6389-1021; manne, veeraswamy/0000-0002-1179-5529				AARONSON SA, 1971, J GEN VIROL, V13, P245, DOI 10.1099/0022-1317-13-2-245; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUENGER E, 1986, BIOCHEM BIOPH RES CO, V139, P209, DOI 10.1016/S0006-291X(86)80100-0; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CASEY PJ, 1992, J LIPID RES, V33, P1731; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; CROWELL PL, 1991, J BIOL CHEM, V266, P17679; CROWELL PL, 1994, BIOCHEM PHARMACOL, V47, P1405, DOI 10.1016/0006-2952(94)90341-7; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GEORGES RN, 1993, CANCER RES, V53, P1743; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GRAHAM SL, 1994, J MED CHEM, V37, P725, DOI 10.1021/jm00032a004; GRAY GD, 1993, CANCER RES, V53, P577; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P14182; KASHANISABET M, 1994, CANCER RES, V54, P900; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOIZUMI M, 1993, BIOL PHARM BULL, V16, P879; KOTHAPALLI R, 1993, LIPIDS, V28, P969, DOI 10.1007/BF02537116; LEFTHERIS K, 1994, BIOORG MED CHEM LETT, V4, P887, DOI 10.1016/S0960-894X(01)80257-2; LIU WC, 1992, J ANTIBIOT, V45, P454, DOI 10.7164/antibiotics.45.454; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANNE V, 1995, DRUG DEVELOP RES, V34, P121, DOI 10.1002/ddr.430340205; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MANNE V, 1991, MOL BASIS CANCER, P27; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; NEWMAN CMH, 1993, BIOCHIM BIOPHYS ACTA, V1155, P79, DOI 10.1016/0304-419X(93)90023-6; NIGAM M, 1993, J BIOL CHEM, V268, P20695; OHYA Y, 1993, MOL BIOL CELL, V4, P1017, DOI 10.1091/mbc.4.10.1017; OMURA S, 1993, J ANTIBIOT, V46, P222, DOI 10.7164/antibiotics.46.222; PATEL DV, 1995, J MED CHEM, V38, P435, DOI 10.1021/jm00003a006; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; QIAN YM, 1994, J BIOL CHEM, V269, P12410; REESE JH, 1991, MOL CELL BIOCHEM, V104, P109; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1993, ARCH BIOCHEM BIOPHYS, V301, P210, DOI 10.1006/abbi.1993.1135; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANDERPYL D, 1992, J ANTIBIOT, V45, P1802; WALLACE RA, 1973, J EXP ZOOL, V18, P321; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	82	137	141	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1763	1779						17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753553				2022-12-25	WOS:A1995QX46900010
J	RATTAN, SIS				RATTAN, SIS			GERONTOGENES - REAL OR VIRTUAL	FASEB JOURNAL			English	Article						AGING; LIFE SPAN; HOMEOSTASIS; VIRTUAL GENES	DIETARY RESTRICTION; CAENORHABDITIS-ELEGANS; PROTEIN-SYNTHESIS; LIFE-SPAN; OXIDATIVE DAMAGE; DNA-POLYMERASES; REPAIR; AGE; DROSOPHILA; LIVER	The view that the life span of an organism is intrinsically limited and is largely species-specific necessarily involves certain notions of genetic elements of regulation. The term gerontogenes refers to any such genetic elements that are involved in the regulation of aging and life span. The existence of genes for programmed aging is generally discounted on the basis of evolutionary arguments against the notion of the adaptive nature of aging. It is suggested here that the concept of gerontogenes be linked with the idea of genes involved in homeostasis and longevity assurance, which is not contradictory to the nonadaptive nature of aging. Because these genes were not originally selected as real genes for aging, their involvement in aging is an emergent property making them virtual gerontogenes. Some experimental evidence is available that suggests that sets of genes involved in the maintenance and repair of various cellular functions are the primary candidates qualifying as virtual gerontogenes.			RATTAN, SIS (corresponding author), AARHUS UNIV, DEPT CHEM, CELLULAR AGING LAB, DK-8000 AARHUS C, DENMARK.			Rattan, Suresh I.S./0000-0002-3478-1381				ARKING R, 1988, EXP GERONTOL, V23, P59, DOI 10.1016/0531-5565(88)90020-4; ARKING R, 1988, EXP AGING RES, V14, P125, DOI 10.1080/03610738808259737; CHATTERJEE B, 1989, FASEB J, V3, P169, DOI 10.1096/fasebj.3.2.2464518; CUTLER RG, 1985, MOL BIOL AGING GENE, P307; FRIEDMAN DB, 1988, GENETICS, V118, P75; FRIEDMAN DB, 1988, J GERONTOL, V43, pB102, DOI 10.1093/geronj/43.4.B102; GRUBE K, 1992, P NATL ACAD SCI USA, V89, P11759, DOI 10.1073/pnas.89.24.11759; HART RW, 1981, NATURWISSENSCHAFTEN, V68, P552, DOI 10.1007/BF00401663; HAYFLICK L, 1991, MUTAT RES, V256, P69, DOI 10.1016/0921-8734(91)90002-S; Holland Barbara, 1985, SOVIET SISTERHOOD BR, P15, DOI DOI 10.2307/2499207; HOLLIDAY R, 1988, PERSPECT BIOL MED, V32, P109; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; HOLLIDAY R, 1992, NEWS PHYSIOL SCI, V7, P38; ISHIGAMI A, 1990, ARCH BIOCHEM BIOPHYS, V283, P362, DOI 10.1016/0003-9861(90)90655-I; JOHNSON TE, 1988, J GERONTOL, V43, pB87, DOI 10.1093/geronj/43.4.B87; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KIRKWOOD TBL, 1979, PROC R SOC SER B-BIO, V205, P531, DOI 10.1098/rspb.1979.0083; Kirkwood Thomas B. L., 1992, P35; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LUCKINBILL LS, 1993, ARCH GERONTOL GERIAT, V16, P17, DOI 10.1016/0167-4943(93)90023-B; MACIEIRACOELHO A, 1993, EXP GERONTOL, V28, P1, DOI 10.1016/0531-5565(93)90016-7; Martin George M., 1992, P41; MCFARLAND GA, 1994, EXP CELL RES, V212, P167, DOI 10.1006/excr.1994.1132; MEDVEDEV ZA, 1990, BIOL REV, V65, P375, DOI 10.1111/j.1469-185X.1990.tb01428.x; MERRY BJ, 1991, MECH AGEING DEV, V58, P139, DOI 10.1016/0047-6374(91)90088-H; MERRY BJ, 1992, EXP GERONTOL, V27, P191, DOI 10.1016/0531-5565(92)90043-Y; MERRY BJ, 1991, COMP BIOCHEM PHYS A, V98, P559, DOI 10.1016/0300-9629(91)90446-J; NUELL MJ, 1989, EXP GERONTOL, V24, P469, DOI 10.1016/0531-5565(89)90053-3; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; RATTAN SIS, 1988, TRENDS BIOTECHNOL, V6, P58, DOI 10.1016/0167-7799(88)90092-3; RATTAN SIS, 1994, BIOCHEM BIOPH RES CO, V201, P665, DOI 10.1006/bbrc.1994.1752; RATTAN SIS, 1989, INT REV CYTOL, V116, P47; RATTAN SIS, 1991, PERSPECT BIOL MED, V34, P526; RATTAN SIS, 1985, BIOESSAYS, V2, P226, DOI 10.1002/bies.950020511; ROOSE MR, 1991, EVOLUTIONARY BIOL AG; SACHER GA, 1982, PERSPECT BIOL MED, V25, P339; SMITH JR, 1992, EXP GERONTOL, V27, P409, DOI 10.1016/0531-5565(92)90073-9; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; SRIVASTAVA V, 1992, EXP GERONTOL, V27, P593, DOI 10.1016/0531-5565(92)90014-Q; SRIVASTAVA VK, 1991, EXP GERONTOL, V26, P453, DOI 10.1016/0531-5565(91)90034-J; THWEATT R, 1992, BIOCHEM BIOPH RES CO, V187, P1, DOI 10.1016/S0006-291X(05)81449-4; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; WERAARCHAKUL N, 1989, EXP CELL RES, V181, P197, DOI 10.1016/0014-4827(89)90193-6; WHITEHEAD I, 1993, J GERONTOL, V48, pB124, DOI 10.1093/geronj/48.4.B124; YOUNGMAN LD, 1992, P NATL ACAD SCI USA, V89, P9112, DOI 10.1073/pnas.89.19.9112; YOUNGMAN LD, 1993, MUTAT RES, V295, P165, DOI 10.1016/0921-8734(93)90018-X; YU BP, 1990, REV BIOL RES AGING, V4, P349; [No title captured]	50	33	35	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1995	9	2					284	286		10.1096/fasebj.9.2.7781932	http://dx.doi.org/10.1096/fasebj.9.2.7781932			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7781932				2022-12-25	WOS:A1995QJ24900019
J	GENGRINOVITCH, S; GREENBERG, SM; COHEN, T; GITAYGOREN, H; ROCKWELL, P; MAIONE, TE; LEVI, BZ; NEUFELD, G				GENGRINOVITCH, S; GREENBERG, SM; COHEN, T; GITAYGOREN, H; ROCKWELL, P; MAIONE, TE; LEVI, BZ; NEUFELD, G			PLATELET FACTOR-IV INHIBITS THE MITOGENIC ACTIVITY OF VEGF(121) AND VEGF(165) USING SEVERAL CONCURRENT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; HEPARIN-LIKE MOLECULES; FIBROBLAST GROWTH; FACTOR-IV; CELL-SURFACE; TUMOR-GROWTH; FACTOR RECEPTOR; FACTOR GENE; ANGIOGENESIS	The 121-amino acid form of vascular endothelial growth factor (VEGF(121)) and the 165-amino acid form (VEGF(165)) are mitogenic for vascular endothelial cells and induce angiogenesis in vivo. VEGF(165) possesses a heparin binding ability and in the absence of heparin-like molecules does not bind efficiently to the VEGF receptors of vascular endothelial cells, The binding of I-125-VEGF(165) to the VEGF receptors of endothelial cells, and the heparin dependent binding of I-125-VEGF(165) to a soluble extracellular domain of the VEGF receptor KDR/flk-1, were inhibited by the angiogenesis inhibitor platelet factor-4 (PF4). In contrast, PF4 was not able to inhibit the binding of VEGF(121), a VEGF isoform which lacks a heparin binding capacity, to the VEGF receptors of the cells or to KDR/flk-1. These results indicate that PF4 may inhibit VEGF(165) binding to VEGF receptors by disrupting the interaction of VEGF(165) with cell surface heparan sulfates, Since PF4 mutants lacking a heparin binding ability retain their anti-angiogenic activity, alternative inhibitory mechanisms were also examined. I-125-PF4 bound with high affinity (K-d 5 x 10(-9) M) to VEGF(165)-coated wells, The binding of I-125-PF4 to the VEGF(165)-coated wells was inhibited by several types of heparin binding proteins, including unlabeled PF4 and unlabeled VEGF(165). The binding was not inhibited by proteins which lack a heparin binding capacity, nor was it inhibited by VEGF(121). Heparinase did not inhibit the binding of I-125-PF4 to VEGF(165), indicating that heparin-like molecules are not required. These experiments suggest that PF4 can bind to heparin binding proteins such as VEGF(165) leading to an inhibition of their receptor binding ability, In agreement with these results, we have observed that PF4 inhibits efficiently the VEGF(165) induced proliferation of vascular endothelial cells. Unexpectedly, PF4 also inhibited efficiently the VEGF(121)-induced proliferation of the cells, indicating that PF4 can disrupt VEGF receptor mediated signal transduction using an unknown mechanism which does not interfere with VEGF(121) binding.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL; REPLIGEN CORP,CAMBRIDGE,MA 02139; TECHNION ISRAEL INST TECHNOL,DEPT FOOD ENGN & BIOTECHNOL,IL-32000 HAIFA,ISRAEL; IMCLONE SYST INC,NEW YORK,NY 10014	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Eli Lilly			Neufeld, Gera/F-1524-2019					BARZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196, DOI 10.1016/0167-4889(85)90177-6; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; CAVARI S, 1993, FEBS LETT, V323, P155, DOI 10.1016/0014-5793(93)81469-G; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DANESI R, 1993, BRIT J CANCER, V68, P932, DOI 10.1038/bjc.1993.457; DIPIETRO LA, 1993, AM J PATHOL, V143, P678; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; GAGLIARDI A, 1993, CANCER RES, V53, P533; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; HAHNENBERGER R, 1993, GLYCOBIOLOGY, V3, P567, DOI 10.1093/glycob/3.6.567; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KUSAKA M, 1994, BRIT J CANCER, V69, P212, DOI 10.1038/bjc.1994.41; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVINE SP, 1990, BLOOD, V75, P902; MAIONE TE, 1991, CANCER RES, V51, P2077; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; NGUYEN NM, 1993, ANTICANCER RES, V13, P2143; NORRBY K, 1993, HAEMOSTASIS, V23, P141; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; PERETZ D, 1992, BIOCHEM BIOPH RES CO, V182, P1340, DOI 10.1016/0006-291X(92)91880-Y; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; POLAKOWSKI IJ, 1993, AM J PATHOL, V143, P507; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; SATO Y, 1993, JPN J CANCER RES, V84, P485, DOI 10.1111/j.1349-7006.1993.tb00163.x; SATO Y, 1990, BIOCHEM BIOPH RES CO, V172, P595, DOI 10.1016/0006-291X(90)90715-Y; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SENGER DR, 1986, CANCER RES, V46, P5629; SHARPE RJ, 1990, JNCI-J NATL CANCER I, V82, P848, DOI 10.1093/jnci/82.10.848; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; TESSLER S, 1994, J BIOL CHEM, V269, P12456; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WATSON JB, 1994, J CLIN INVEST, V94, P261, DOI 10.1172/JCI117316; WILKS JW, 1991, INT J RADIAT BIOL, V60, P73, DOI 10.1080/09553009114551581; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025	56	170	194	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15059	15065		10.1074/jbc.270.25.15059	http://dx.doi.org/10.1074/jbc.270.25.15059			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797488	hybrid			2022-12-25	WOS:A1995RE66600034
J	CAI, TQ; WRIGHT, SD				CAI, TQ; WRIGHT, SD			ENERGETICS OF LEUKOCYTE INTEGRIN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; MONOCLONAL-ANTIBODIES; POLYMORPHONUCLEAR LEUKOCYTES; TRANSIENT ADHESION; HUMAN-MONOCYTES; BINDING-SITE; CD11B CD18; RECEPTOR; MACROPHAGES; PROTEIN	Cell adhesion mediated by leukocyte integrin CR3 (CD11b/CD18, alpha(m) beta(2)) may be rapidly modulated without changes in receptor number, and transient changes in adhesivity are thought to be driven by reversible alteration of the affinity of CR3 for ligand. Here we measure the binding affinity of CR3 using purified active and inactive receptor and the ligand, C3bi, coupled to alkaline phosphatase. Immobilized, active CR3 bound saturably and with high affinity (12.5 +/- 4.7 nM). In contrast, inactive CR3 exhibited no measurable binding. High affinity binding could be restored by the addition of the activating anti-CR3 monoclonal antibody KIM-127 to inactive CR3. Since the affinity of KIM-127 for active and inactive receptor was identical, it cannot contribute the energy to convert a low affinity receptor into a high affinity receptor. Rather, KIM-127 appears to facilitate binding of C3bi by lowering the activation energy for the shift from an inactive to an active state. These results suggest that CR3-mediated binding and detachment of cells is not driven by a reversible change in affinity but by two mechanistically distinct processes, an energetically neutral activation step for binding and an energy-dependent step that reverses binding of ligand.	ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Rockefeller University								ABBAS AK, 1991, CELLULAR MOL IMMUNOL, P265; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CRAMER EB, 1986, J CELL BIOL, V102, P1868, DOI 10.1083/jcb.102.5.1868; DANA N, 1986, J IMMUNOL, V137, P3259; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DUSTIN ML, 1989, NATURE, V34, P619; ELEMER GS, 1994, J IMMUNOL, V152, P5836; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HERMANOWSKIVOSA.A, 1992, CELL, V68, P341; HORWITZ A, 1986, J CELL BIOL, V101, P2134; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KHAN SA, 1982, J BIOL CHEM, V257, P1864; KILMARTIN IV, 1976, BR MED B, V32, P209; LAUFFENBURGER DA, 1993, RECEPTOR MODELS BIND, P32; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; LAW SK, 1979, J IMMUNOL, V123, P1388; LO SK, 1989, J IMMUNOL, V143, P3325; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; NAHAS GG, 1971, P SOC EXP BIOL MED, V138, P350; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; Pangburn MK, 1986, IMMUNOBIOLOGY COMPLE, P45; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; ROSS GD, 1987, COMPLEMENT INFLAMMAT, V4, P61, DOI 10.1159/000463010; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SMYTH SS, 1993, BLOOD, V81, P2827; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; VANVOORHIS WC, 1983, J EXP MED, V158, P126, DOI 10.1084/jem.158.1.126; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876	38	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14358	14365		10.1074/jbc.270.24.14358	http://dx.doi.org/10.1074/jbc.270.24.14358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782296	hybrid			2022-12-25	WOS:A1995RD45500022
J	DELAFONTAINE, P; MENG, XP; KU, L; DU, J				DELAFONTAINE, P; MENG, XP; KU, L; DU, J			REGULATION OF VASCULAR SMOOTH-MUSCLE CELL INSULIN-LIKE GROWTH-FACTOR-I RECEPTORS BY PHOSPHOROTHIOATE OLIGONUCLEOTIDES - EFFECTS ON CELL-GROWTH AND EVIDENCE THAT SENSE TARGETING AT THE ATG SITE INCREASES RECEPTOR EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ANTISENSE; FIBROBLASTS; RNA	We have recently shown that insulin-like growth factor I (IGF I) is a mediator of angiotensin II-induced mitogenesis in vascular smooth muscle cells (Delafontaine, P., and Lou H. (1993) J. Biol. Chem. 268, 16866-16870). To study the role of the IGF I receptor: in vascular smooth muscle cell growth, phosphorothioate oligonucleotides were used to modulate IGF I receptors. An antisense oligonucleotide targeting the ATG site inhibited basal and serum-induced DNA synthesis in vascular smooth muscle cells. Mismatch oligonucleotide had no effect, while surprisingly sense oligonucleotide increased IGF I receptor number and basal and serum-induced DNA synthesis. A 51% reduction in IGF I receptor number following exposure to 5 mu M antisense oligonucleotide markedly inhibited angiotensin II-induced mitogenesis. A 70% increase in IGF I receptor number following exposure to 5 mu M sense oligonucleotide resulted in a 4-fold increase in basal [H-3]thymidine incorporation, and angiotensin II (1-1000 nM) had no additive stimulatory effect. An antisense oligonucleotide targeting a sequence starting at +109 base pairs (relative to ATG) also reduced IGF I receptor number, however, the corresponding sense oligonucleotide was without effect. These findings demonstrate that alterations in vascular smooth muscle cell IGF I receptor density play a critical role in the proliferative response of vascular smooth muscle cells to serum and to angiotensin II. In addition, the surprising observation that an ATG-directed sense oligonucleotide up-regulates IGF I receptors identifies a novel effect of oligonucleotides on gene expression.	BETHUNE UNIV MED SCI,CLIN HOSP 2,CHANGCHUN 130021,PEOPLES R CHINA	Jilin University	DELAFONTAINE, P (corresponding author), EMORY UNIV,DEPT MED,DIV CARDIOL,PO DRAWER LL,ATLANTA,GA 30322, USA.			Delafontaine, Patrice/0000-0003-3744-3617	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047035, R29HL045317, R01HL045317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045215] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45317, HL47035] Funding Source: Medline; NIDDK NIH HHS [DK 45215] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1991, INSULIN LIKE GROWTH; CLEMMONS DR, 1985, CIRC RES, V56, P418, DOI 10.1161/01.RES.56.3.418; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; CLEMMONS DR, 1985, ENDOCRINOLOGY, V117, P77, DOI 10.1210/endo-117-1-77; COLMAN A, 1990, J CELL SCI, V97, P399; DELAFONTAINE P, 1991, HYPERTENSION, V17, P693, DOI 10.1161/01.HYP.17.5.693; DELAFONTAINE P, 1993, J BIOL CHEM, V268, P16866; DU J, 1995, IN PRESS CIRC RES; FRENSTER JH, 1994, CLIN RES, V42, P124; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; INOUYE M, 1988, GENE, V72, P25, DOI 10.1016/0378-1119(88)90124-2; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KNEE RS, 1994, ENDOCR SOC, V1140, P485; PFEIFLE B, 1987, ENDOCRINOLOGY, V120, P2251, DOI 10.1210/endo-120-6-2251; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; REISS K, 1991, CANCER RES, V51, P5997; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SHI Y, 1993, CIRCULATION, V88, P190; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; ULLRICH A, 1986, EMBO J, V10, P2503; VERVERIS JJ, 1993, CIRC RES, V72, P1285, DOI 10.1161/01.RES.72.6.1285; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451	29	46	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14383	14388		10.1074/jbc.270.24.14383	http://dx.doi.org/10.1074/jbc.270.24.14383			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782298	hybrid			2022-12-25	WOS:A1995RD45500025
J	LIN, YZ; YAO, SY; VEACH, RA; TORGERSON, TR; HAWIGER, J				LIN, YZ; YAO, SY; VEACH, RA; TORGERSON, TR; HAWIGER, J			INHIBITION OF NUCLEAR TRANSLOCATION OF TRANSCRIPTION FACTOR NF-KAPPA-B BY A SYNTHETIC PEPTIDE-CONTAINING A CELL MEMBRANE-PERMEABLE MOTIF AND NUCLEAR-LOCALIZATION SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOPLASMIC-RETICULUM; SIGNAL PEPTIDE; GROWTH-FACTOR; PROTEINS; ACTIVATION; PRECURSOR	To control agonist-induced nuclear translocation of transcription factor kappa B (NF-kappa B) in intact cells, cell-permeable synthetic peptides were devised. Their import into intact cells was dependent on a hydrophobic region selected from the signal peptide sequences and was verified by their inaccessibility to extracellular proteases and by confocal laser scanning microscopy. When a cell-permeable peptide carried a functional cargo representing the nuclear localization sequence of NF-kappa B p50, it inhibited in a concentration-dependent manner nuclear translocation of NF-kappa B in cultured endothelial and monocytic cells stimulated with lipopolysaccharide or tumor necrosis factor-alpha. Synthetic peptide analogues with deleted hydrophobic cell membrane-permeable motif or with a mutated nuclear localization sequence were inactive. Cell membrane-permeable peptides were not cytotoxic within the concentration range used in these experiments. These results suggest that cell permeable synthetic peptides carrying a functional cargo can be applied to control signal transduction-dependent subcellular traffic of transcription factors mediating the cellular responses to different agonists. Moreover, this approach can be used to study other intracellular processes involving proteins with functionally distinct domains.			LIN, YZ (corresponding author), VANDERBILT UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, 221 KIRKLAND HALL, NASHVILLE, TN 37232 USA.			Veach, Ruth Ann/0000-0003-0038-8802				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HOLMSEN H, 1974, BIOCHEM J, V144, P385, DOI 10.1042/bj1440385; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; KAJSTURA J, 1989, FOLIA HISTOCHEM CYTO, V27, P39; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIN YZ, 1988, BIOCHEMISTRY-US, V27, P5640, DOI 10.1021/bi00415a037; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WANG K, 1982, METHOD ENZYMOL, V85, P514; YAMANE K, 1988, J BIOL CHEM, V263, P5368	23	827	935	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14255	14258		10.1074/jbc.270.24.14255	http://dx.doi.org/10.1074/jbc.270.24.14255			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782278	hybrid			2022-12-25	WOS:A1995RD45500004
J	NAKADA, N; GMUNDER, H; HIRATA, T; ARISAWA, M				NAKADA, N; GMUNDER, H; HIRATA, T; ARISAWA, M			CHARACTERIZATION OF THE BINDING-SITE FOR CYCLOTHIALIDINE ON THE B-SUBUNIT OF DNA GYRASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOLONE ANTIBACTERIALS; CATALYTIC PROPERTIES; NALIDIXIC-ACID; A-PROTEIN; MECHANISM; INHIBITION; TOPOISOMERASES; PURIFICATION; NOVOBIOCIN; ATP	The mechanism of inhibition of DNA gyrase by cyclothialidine, a novel gyrase inhibitor isolated from Streptomyces filipinensis NR0484, has been studied further by using [C-14]benzoylcyclothialidine and a reconstituted Escherichia coli gyrase system consisting of the A subunit, the B subunit and relaxed ColE1 DNA The mechanism of inhibition was also studied with the 43-kDa N-terminal fragment of the B subunit. The [C-14]benzoylcyclothialidine could bind to the B subunit alone but not to the A subunit nor to the plasmid DNA alone. Furthermore, the compound also bound to the 43-kDa N-terminal fragment of the B subunit. Scatchard analysis of [C-14]benzoylcyclothialidine binding to DNA gyrase shelved that the binding affinity of the compound increased, depending on the assembly of the gyrase (A(2)B(2)). DNA complex. This suggests that the binding site of cyclothialidine on the B subunit or its vicinity causes a conformational change during the assembly of the gyrase . DNA complex (increase in affinity: B --> A(2)B(2) --> A(2)B(2) . DNA). Furthermore, displacement curves of [C-14]benzoylcyclothialidine binding by nonlabeled cyclothialidine, ATP analogues, and coumarin antibiotics indicated that cyclothialidine, coumarins, and ATP share a common (or overlapping) site of action on the E subunit of DNA gyrase; however, the microenvironment of the binding sites may differ.	F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND	Roche Holding	NAKADA, N (corresponding author), NIPPON ROCHE RES CTR, 200 KAJIWARA, KAMAKURA, KANAGAWA 247, JAPAN.							ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; BATES AD, 1989, EMBO J, V8, P1861, DOI 10.1002/j.1460-2075.1989.tb03582.x; CONTRERAS A, 1992, MOL MICROBIOL, V6, P1617; DELCASTILLO I, 1991, P NATL ACAD SCI USA, V88, P8860, DOI 10.1073/pnas.88.19.8860; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; GILBERT EJ, 1994, MOL MICROBIOL, V12, P365, DOI 10.1111/j.1365-2958.1994.tb01026.x; HALLETT P, 1990, GENE, V93, P139, DOI 10.1016/0378-1119(90)90148-K; JACKSON AP, 1991, J MOL BIOL, V217, P15, DOI 10.1016/0022-2836(91)90606-7; KAMIYAMA T, 1994, J ANTIBIOT, V47, P37, DOI 10.7164/antibiotics.47.37; LEWIS RJ, 1994, J MOL BIOL, V241, P128, DOI 10.1006/jmbi.1994.1480; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; NAKADA N, 1994, ANTIMICROB AGENTS CH, V38, P1966, DOI 10.1128/AAC.38.9.1966; NAKADA N, 1993, ANTIMICROB AGENTS CH, V37, P2656, DOI 10.1128/AAC.37.12.2656; OTTER R, 1983, METHOD ENZYMOL, V100, P171; RAU DC, 1987, J MOL BIOL, V193, P555, DOI 10.1016/0022-2836(87)90266-X; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; SHEN LL, 1989, J BIOL CHEM, V264, P2973; SHEN LL, 1985, P NATL ACAD SCI USA, V82, P307, DOI 10.1073/pnas.82.2.307; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3886, DOI 10.1021/bi00435a039; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; SUTCLIFFE JA, 1989, ANTIMICROB AGENTS CH, V33, P2027, DOI 10.1128/AAC.33.12.2027; WATANABE J, 1994, J ANTIBIOT, V47, P32, DOI 10.7164/antibiotics.47.32; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	31	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14286	14291		10.1074/jbc.270.24.14286	http://dx.doi.org/10.1074/jbc.270.24.14286			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782285	hybrid			2022-12-25	WOS:A1995RD45500011
J	VILLACRES, EC; WU, ZL; HUA, TH; NIELSEN, MD; WATTERS, JJ; YAN, C; BEAVO, J; STORM, DR				VILLACRES, EC; WU, ZL; HUA, TH; NIELSEN, MD; WATTERS, JJ; YAN, C; BEAVO, J; STORM, DR			DEVELOPMENTALLY EXPRESSED CA2+-SENSITIVE ADENYLYL-CYCLASE ACTIVITY IS DISRUPTED IN THE BRAINS OF TYPE-I ADENYLYL-CYCLASE MUTANT MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; CA1; STIMULATION; CALMODULIN; ONTOGENESIS; RECEPTORS; CALCIUM; NEURONS; AREA	The type I Ca2+-sensitive adenylyl cyclase has been implicated in several forms of synaptic plasticity in vertebrates. Mutant mice in which this enzyme was inactivated by targeted mutagenesis show deficient spatial memory and altered long term potentiation (Wu, Z. L., Thomas, S. A., Villacres, E., C., Xia, Z., Simmons, M. L., Chavkin, C., Palmiter, R. D., and Storm, D. R. (1995) Proc. Natl Acad Sci. U.S.A. 92, 220-224). Long term potentiation in the CA1 region of the rat hippocampus develops during the first 2 weeks after birth and reaches maximal expression at postnatal day 15 with a gradual decline at later stages of development. Here we report that Ca2+-stimulated adenylyl cyclase activity in rat hip pocampus, cerebellum, and cortex increases significantly between postnatal days 1-16. This increase appears to be due to enhanced expression of type I adenylyl cyclase rather than type VIII adenylyl cyclase, the other adenylyl cyclase that is directly stimulated by Ca2+ and calmodulin. Type I adenylyl cyclase mRNA in the hippocampus increased 7-fold during this developmental period. The developmental expression of Ca2+-stimulated adenylyl cyclase activity in mouse brain was attenuated in mutant mice lacking type I adenylyl cyclase. Changes in expression of the type I adenylyl cyclase during the period of long term potentiation development are consistent with the hypothesis that this enzyme is important for neuroplasticity and spatial memory in vertebrates.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Yan, Chen/0000-0002-1397-6358	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020498, K08NS001653] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21723] Funding Source: Medline; NINDS NIH HHS [NS 20498, NS 01653] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BROADDUS WC, 1990, DEV BRAIN RES, V52, P265, DOI 10.1016/0165-3806(90)90244-S; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310; CHAVEZNORIEGA LE, 1992, BRAIN RES, V574, P85, DOI 10.1016/0006-8993(92)90803-H; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FRANK DA, 1994, CELL, V79, P45; FREY U, 1991, NEUROSCI LETT, V129, P111, DOI 10.1016/0304-3940(91)90732-9; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HARRIS KM, 1984, J PHYSIOL-LONDON, V346, P27, DOI 10.1113/jphysiol.1984.sp015005; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; KESHLES O, 1984, BIOCHEM PHARMACOL, V33, P3231, DOI 10.1016/0006-2952(84)90082-0; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; POKORNY J, 1981, BRAIN RES BULL, V7, P113, DOI 10.1016/0361-9230(81)90075-7; RIUS RA, 1994, BRAIN RES, V643, P50, DOI 10.1016/0006-8993(94)90007-8; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHWARTZKROIN PA, 1982, DEV BRAIN RES, V2, P453; STANTON PK, 1985, BRAIN RES, V358, P343, DOI 10.1016/0006-8993(85)90981-3; TEYLER TJ, 1989, NEUROPSYCHOLOGIA, V27, P31, DOI 10.1016/0028-3932(89)90088-2; WAYMAN GA, 1994, J BIOL CHEM, V2695, P25400; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; YAN C, 1994, J NEUROSCI, V14, P973	31	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14352	14357		10.1074/jbc.270.24.14352	http://dx.doi.org/10.1074/jbc.270.24.14352			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782295	hybrid			2022-12-25	WOS:A1995RD45500021
J	HALL, PA; KEARSEY, JM; COATES, PJ; NORMAN, DG; WARBRICK, E; COX, LS				HALL, PA; KEARSEY, JM; COATES, PJ; NORMAN, DG; WARBRICK, E; COX, LS			CHARACTERIZATION OF THE INTERACTION BETWEEN PCNA AND GADD45	ONCOGENE			English	Article						GADD45; PCNA; 2-YBRID; CYCLINS; P21(CIP1)	CELL NUCLEAR ANTIGEN; DNA POLYMERASE-DELTA; AUXILIARY PROTEIN; ESCHERICHIA-COLI; CYCLIN PCNA; REPAIR; P53; INHIBITOR; SUBUNIT; KINASES	We have examined the interaction between the DNA replication and repair protein PCNA, and the growth arrest and DNA damage induced protein Gadd45. An anti-Gadd45 polyclonal antibody co-immunoprecipitates PCNA but in reciprocal experiments, an anti-C terminal anti-PCNA antibody failed to co-immunoprecipitate Gadd45, We used a yeast two hybrid assay to demonstrate that human Gadd45 interacts with both human and S. pombe PCNA, We have determined that the N-terminal 94 amino acids of Gadd45 bind to PCNA, and using a series of N-terminal and C-terminal deletions of human PCNA we have mapped two potential Gadd45 binding sites, Deletion of the last 6 amino acids of PCNA ablated interaction, suggesting a role in Gadd45 binding, This explains the inability of an anti-C terminal PCNA antibody to co-immunoprecipitate Gadd45, Using a peptide ELISA approach, we showed that Gadd45 protein binds strongly to three regions of PCNA (residues 1-20, 61-80, and 196-215) and weakly to residues 121-170, The crystal structure of PCNA provides insight into our genetic and immunochemical data, Our results confirm an interaction between PCNA and Gadd45, define regions of both molecules involved in this interaction, and are consistent with a potential stoichiometry of 2 Gadd45 molecules to each PCNA monomer. These data provide support for the notion that PCNA-Gadd45 interactions co-ordinate cell cycle and DNA repair.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,DEPT ANAT & PHYSIOL,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee	HALL, PA (corresponding author), UNIV DUNDEE,DEPT PATHOL,DUNDEE DD1 9SY,SCOTLAND.		Coates, Philip J/H-6854-2019; Warbrick, Emma/C-6424-2008; Cox, Lynne/AAT-2047-2021	Coates, Philip J/0000-0003-1518-6306; Cox, Lynne/0000-0002-5306-285X				ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CANMAN CE, 1994, CANCER RES, V54, P5054; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; COX LS, 1995, UNPUB; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLORES RH, 1994, P NATL ACAD SCI USA, V91, P8655; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HALL PA, 1993, ONCOGENE, V8, P203; HALL PA, 1994, EUR J CANCER, V12, P2001; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRICE BD, 1992, CANCER RES, V52, P3814; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH M, 1994, SCIENCE, V226, P1376; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; VANLAAR T, 1994, ONCOGENE, V9, P981; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WASEEM NH, 1990, J CELL SCI, V96, P121; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1992, CELL, V71, P504; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	42	122	125	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2427	2433						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784094				2022-12-25	WOS:A1995RE54300021
J	ANTONSSON, C; ARULAMPALAM, V; WHITELAW, ML; PETTERSSON, S; POELLINGER, L				ANTONSSON, C; ARULAMPALAM, V; WHITELAW, ML; PETTERSSON, S; POELLINGER, L			CONSTITUTIVE FUNCTION OF THE BASIC HELIX-LOOP-HELIX PAS FACTOR ARNT - REGULATION OF TARGET PROMOTERS VIA THE E-BOX MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOBIOTIC-RESPONSIVE ELEMENT; PROTEIN-DNA INTERACTIONS; AH-RECEPTOR; DIOXIN RECEPTOR; TRANSCRIPTION FACTOR; BINDING; ENHANCER; GENE; RECOGNITION; CLONING	Arnt is a nuclear basic helix-loop-helix (bHLH) transcription factor that, contiguous with the bHLH motif, contains a region of homology (PAS) with the Drosophila factors Per and Sim. Arnt dimerizes in a ligand-dependent manner with the bHLH dioxin receptor, a process that enables the dioxin-(2,3,7,8-tetrachlorodibenzo-p-dioxin)-activated Arnt-dioxin receptor complex to recognize dioxin response elements of target promoters. In the absence of dioxin, Arnt does not bind to this target sequence motif. The constitutive function of Arnt is presently not understood. Here we demonstrate that Arnt constitutively bound the E box motif CACGTG that is also recognized by a number of distinct bHLH factors, including USF and Max. Importantly, amino acids that have been identified to be critical for E box recognition by Max and USF are conserved in Arnt. Consistent with these observations, full-length Arnt, but not an Arnt deletion mutant lacking its potent C-terminal transactivation domain, constitutively activated CACGTG E box-driven reporter genes in vivo. These results indicate a role of Arnt in regulation of a network of target genes that is distinct from that regulated by the Arnt-dioxin receptor complex in dioxin-stimulated cells.	NOVUM,KAROLINSKA INST,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN; NOVUM,KAROLINSKA INST,DEPT BIOSCI,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska Institutet			Pettersson, Sven/F-9511-2015					ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DORSHKIND K, 1994, CELL, V79, P751, DOI 10.1016/0092-8674(94)90065-5; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; EMA M, 1994, J BIOCHEM-TOKYO, V116, P845, DOI 10.1093/oxfordjournals.jbchem.a124605; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GRANT PA, 1992, NUCLEIC ACIDS RES, V20, P4401, DOI 10.1093/nar/20.17.4401; GREGOR PD, 1992, GENE DEV, V4, P1730; HANKINSON O, 1994, TRENDS ENDOCRIN MET, V5, P240, DOI 10.1016/1043-2760(94)P3082-I; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORRD ND, 1994, MOL PHARMACOL, V46, P618; JAIN S, 1994, J BIOL CHEM, V269, P31518; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; LI H, 1994, J BIOL CHEM, V269, P28098; LI H, 1994, J BIOL CHEM, V1, P639; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; LUSSKA A, 1994, J BIOL CHEM, V77, P451; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAMBROOKJ, 1989, MOL CLONING LABORATO; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TAKAHASHI JS, 1992, SCIENCE, V258, P238, DOI 10.1126/science.1384127; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WESTON K, 1988, VIROLOGY, V162, P406, DOI 10.1016/0042-6822(88)90481-3; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITLOCK JP, 1994, TRENDS ENDOCRIN MET, V5, P183, DOI 10.1016/1043-2760(94)90075-2; WOLBERGER C, 1994, STRUCT BIOL, V1, P413	48	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13968	13972		10.1074/jbc.270.23.13968	http://dx.doi.org/10.1074/jbc.270.23.13968			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775458	hybrid			2022-12-25	WOS:A1995RC44800057
J	GARDNER, PR; RAINERI, I; EPSTEIN, LB; WHITE, CW				GARDNER, PR; RAINERI, I; EPSTEIN, LB; WHITE, CW			SUPEROXIDE RADICAL AND IRON MODULATE ACONITASE ACTIVITY IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; DIHYDROXY-ACID DEHYDRATASE; TUMOR-NECROSIS-FACTOR; FE-S CLUSTER; ESCHERICHIA-COLI; RNA-BINDING; HYPERBARIC-OXYGEN; HYDROGEN-PEROXIDE; RESPIRATORY-CHAIN; ELECTRON-TRANSFER	Aconitase is a member of a family of iron-sulfur-containing (de)hydratases whose activities are modulated in bacteria by superoxide radical (O-2(radical anion))-mediated inactivation and iron-dependent reactivation. The inactivation-reactivation of aconitase(s) in cultured mammalian cells was explored since these reactions may impact important and diverse aconitase functions in the cytoplasm and mitochondria. Conditions which increase O-2(radical anion) production including exposure to the redox-cycling agent phenazine methosulfate (PMS), inhibitors of mitochondrial ubiquinol-cytochrome c oxidoreductase, or hyperoxia inactivated aconitase in mammalian cells. Overproduction of mitochondrial Mn-superoxide dismutase protected aconitase from inactivation by PMS or inhibitors of ubiquinol-cytochrome c oxidoreductase, but not from normobaric hyperoxia. Aconitase activity was reactivated t(1/2), of 12 +/- 3 min) upon removal of PMS. The iron chelator deferoxamine impaired reactivation and increased net inactivation of aconitase by O-2(radical anion). The ability of ubiquinol-cytochrome c oxidoreductase-generated O-2(radical anion) to inactivate aconitase in several cell types correlated with the fraction of the aconitase activity localized in mitochondria. Extracellular O-2(radical anion) generated with xanthine oxidase did not affect aconitase activity nor did exogenous superoxide dismutase decrease aconitase inactivation by PMS. The results demonstrate a dynamic and cyclical O-2(radical anion)-mediated inactivation and iron-dependent reactivation of the mammalian [4Fe-4S] aconitases under normal and stress conditions and provide further evidence for the membrane compartmentalization of O-2(radical anion).	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV PULM MED, DENVER, CO 80206 USA; UNIV CALIF SAN FRANCISCO, SCH MED, CANC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA	National Jewish Health; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Gardner, Paul/0000-0001-8189-0903	NCI NIH HHS [CA27903, CA44446] Funding Source: Medline; NHLBI NIH HHS [HL46481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027903, R01CA044446, R37CA027903] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL046481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BEERS RF, 1952, J BIOL CHEM, V195, P133; BOEHME DE, 1976, NATURE, V262, P418, DOI 10.1038/262418a0; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Boveris A., 1982, SUPEROXIDE DISMUTASE, VII, P15, DOI DOI 10.1007/978-1-4615-9035-4_5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN OR, 1978, BIOCHEM BIOPH RES CO, V85, P1219, DOI 10.1016/0006-291X(78)90672-1; BROWN OR, 1980, BIOCH INT, V1, P304; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; Crapo J D, 1978, Methods Enzymol, V53, P382; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; FLINT DH, 1993, J BIOL CHEM, V268, P25547; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1993, ARCH BIOCHEM BIOPHYS, V301, P98, DOI 10.1006/abbi.1993.1120; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GARDNER PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P106, DOI 10.1016/0003-9861(91)90270-S; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; IQBAL J, 1991, FREE RADICAL BIO MED, V10, P69, DOI 10.1016/0891-5849(91)90023-V; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KSENZENKO M, 1983, FEBS LETT, V155, P19, DOI 10.1016/0014-5793(83)80200-2; KUO CF, 1987, J BIOL CHEM, V262, P4724; LIOCHEV SI, 1993, ARCH BIOCHEM BIOPHYS, V301, P379, DOI 10.1006/abbi.1993.1159; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LOSCHEN G, 1971, FEBS LETT, V18, P261, DOI 10.1016/0014-5793(71)80459-3; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MINAKAMI S, 1958, J BIOCHEM-TOKYO, V45, P341, DOI 10.1093/oxfordjournals.jbchem.a126874; MULLNER EW, 1992, EUR J BIOCHEM, V208, P597, DOI 10.1111/j.1432-1033.1992.tb17224.x; PRODROMOU C, 1992, EUR J BIOCHEM, V204, P599, DOI 10.1111/j.1432-1033.1992.tb16673.x; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; SATO H, 1994, BIOCHEM BIOPH RES CO, V201, P38, DOI 10.1006/bbrc.1994.1666; SIWECKI G, 1990, BIOCHEM INT, V20, P191; SMYKRANDALL E, 1993, FREE RADICAL BIO MED, V14, P609, DOI 10.1016/0891-5849(93)90142-H; SUZUKI YJ, 1994, FREE RADICAL BIO MED, V16, P63, DOI 10.1016/0891-5849(94)90244-5; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; TANG CK, 1992, J BIOL CHEM, V267, P24466; TONG JJ, 1994, J BIOL CHEM, V269, P24920; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; TYLER DD, 1975, BIOCHEM J, V147, P493, DOI 10.1042/bj1470493; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6	58	413	424	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13399	13405		10.1074/jbc.270.22.13399	http://dx.doi.org/10.1074/jbc.270.22.13399			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768942	hybrid			2022-12-25	WOS:A1995RB43900067
J	HATA, Y; SUDHOF, TC				HATA, Y; SUDHOF, TC			A NOVEL UBIQUITOUS FORM OF MUNC-18 INTERACTS WITH MULTIPLE SYNTAXINS - USE OF THE YEAST 2-HYBRID SYSTEM TO STUDY INTERACTIONS BETWEEN PROTEINS INVOLVED IN MEMBRANE TRAFFIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSION; IDENTIFICATION; SYNAPTOTAGMIN; RECEPTORS; NEUREXINS; ALPHA; GENE	Mune-18-1 is a 67-kDa neuronal protein that binds tightly 60 syntaxin 1 and functions in synaptic vesicle exocytosis (Hata, Y., Slaughter, C. A., and Sudhof, T. C. (1993a) Nature 366, 347-351). We have now characterized a new Munc-18 isoform, Munc-18-2, that exhibits 63% amino acid sequence identity with Munc-18-1. Munc-18-2 is expressed in most tissues, whereas Munc-18-1 is primarily expressed in brain. Using recombinant Munc-18-1 and Munc-18-2 produced in COS cells, we show that both forms of Munc-18 bind tightly to syntaxins 1A, 2, and 3 but not to syntaxin 4. In an independent approach 60 study the binding specificities of Munc-18-1 and Munc-18-2, we used the yeast two-hybrid system. This assay system depends on protein-protein interactions in the cell nucleus. We validated its utility for studying membrane trafficking proteins by testing well characterized interactions between cytosolic proteins that are known to be physiologically important in exocytosis. Strong interactions, such as the binding of syntaxins 1-4 with SNAP-25, were effectively detected by the yeast two-hybrid assay, but weak binding, such as the binding of syntaxins to synaptotagmin or of synaptotagmin to neurexins, was not. Studies on full-length and truncated forms of Munc-18s by the yeast two-hybrid system confirmed their interactions with syntaxins. Both the N and the C terminus of Munc-18 were essential for binding. Munc-18-1 and Munc-18-2 bind only to syntaxins 1A, 2, and 3 but not 4 and 5 by yeast-two hybrid system assays. Our studies demonstrate that neural and non-neural tissues have distinct forms of Munc-18, which may function in different types of exocytosis. The lack of specificity of the interactions between syntaxins and Munc-18s indicates that specificity of membrane trafficking reactions is not dependent on this interaction.	UNIV TEXAS,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED SCH,DEPT MOLEC GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PELHAM HRB, 1993, NATURE, V364, P582, DOI 10.1038/364582a0; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Rose MD., 1990, METHODS YEAST GENETI; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; SUDHOF TC, 1993, CELL, V75, P1; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	36	160	166	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13022	13028		10.1074/jbc.270.22.13022	http://dx.doi.org/10.1074/jbc.270.22.13022			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768895	hybrid			2022-12-25	WOS:A1995RB43900016
J	SWIERCZYNSKI, SL; BLACKSHEAR, PJ				SWIERCZYNSKI, SL; BLACKSHEAR, PJ			MEMBRANE ASSOCIATION OF THE MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE (MARCKS) PROTEIN - MUTATIONAL ANALYSIS PROVIDES EVIDENCE FOR COMPLEX INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMINENT CELLULAR SUBSTRATE; ROUS-SARCOMA VIRUS; PLASMA-MEMBRANE; MOLECULAR-CLONING; SUBCELLULAR-LOCALIZATION; DEPENDENT BINDING; GENE-PRODUCT; RAT-BRAIN; PHOSPHORYLATION; CELLS	The myristoylated alanine-rich C kinase substrate (MARCKS) protein, a prominent cellular substrate for protein kinase C, is associated with membranes in various cell types. MARCKS is myristoylated at its amino terminus; this modification is thought to play the major role in anchoring MARCKS to cellular membranes. Recent studies have suggested that the protein's basic phosphorylation site/calmodulin binding domain may also be involved in the membrane association of MARCKS through electrostatic interactions, The present studies used mutations in the primary structure of the protein to investigate the nature of the association between MARCKS and cell membranes. In chick embryo fibroblasts, activation of protein kinase C led to a decrease in MARCKS membrane association as determined by cell fractionation techniques. Cell-free assays revealed that nonmyristoylated MARCKS exhibited almost no affinity for fibroblast membranes, despite readily demonstrable binding of the mild-type protein. Similar experiments in which the four serines in the phosphorylation site domain were mutated to aspartic acids, mimicking phosphorylation, decreased, but did not eliminate, membrane binding when compared to either the wild-type protein or a comparable tetra-asparagine mutant. Addition of calmodulin in the presence of Ca2+ also inhibited binding of the wild-type protein to membranes, presumably by neutralizing the phosphorylation site domain, or by physically interfering with its membrane association. Surprisingly, expression of a nonmyristoylatable mutant form of MARCKS in intact cells led to only a 46% decrease in its plasma membrane association, as determined by cell fractionation and immunoelectron microscopy. These results are consistent with a complex model of the interaction of MARCKS with cellular membranes, in which the myristoyl moiety, the positively charged phosphorylation site domain, and possibly other domains make independent contributions to membrane binding in intact cells.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; Howard Hughes Medical Institute			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AMESS B, 1992, FEBS LETT, V297, P285; BIEMANS R, 1992, AIDS, V6, P541, DOI 10.1097/00002030-199206000-00003; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1992, GENOMICS, V14, P168, DOI 10.1016/S0888-7543(05)80300-3; BLACKSHEAR PJ, 1986, MECHANISMS INSULIN A, V7, P211; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CLARKE PR, 1993, FEBS LETT, V336, P37, DOI 10.1016/0014-5793(93)81604-X; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FEDER D, 1991, J BIOL CHEM, V266, P19040; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HINRICHSEN RD, 1993, P NATL ACAD SCI USA, V90, P1585, DOI 10.1073/pnas.90.4.1585; INUI K, 1980, BIOCHIM BIOPHYS ACTA, V598, P616, DOI 10.1016/0005-2736(80)90041-3; JAMES G, 1989, J BIOL CHEM, V264, P20998; KAMINCHIK J, 1991, J VIROL, V65, P583, DOI 10.1128/JVI.65.2.583-588.1991; KIM J, 1994, J BIOL CHEM, V268, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; KRUEGER JG, 1982, CELL, V28, P889, DOI 10.1016/0092-8674(82)90068-X; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; MANENTI S, 1993, J BIOL CHEM, V268, P6878; MCILHINNEY RAJ, 1990, BIOCHEM J, V271, P681, DOI 10.1042/bj2710681; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SIGAL CT, 1993, MOL CELL BIOL, V13, P3084, DOI 10.1128/MCB.13.5.3084; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SPACH DH, 1986, J BIOL CHEM, V261, P2750; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; STUMPO DJ, 1994, P NATL ACAD SCI USA, V92, P944; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253	62	99	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13436	13445		10.1074/jbc.270.22.13436	http://dx.doi.org/10.1074/jbc.270.22.13436			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768946	hybrid			2022-12-25	WOS:A1995RB43900072
J	XUE, JC; CHEN, CG; ZHU, JM; KUNAPULI, SP; DERIEL, JK; YU, L; LIUCHEN, LY				XUE, JC; CHEN, CG; ZHU, JM; KUNAPULI, SP; DERIEL, JK; YU, L; LIUCHEN, LY			THE 3RD EXTRACELLULAR LOOP OF THE MU-OPIOID RECEPTOR IS IMPORTANT FOR AGONIST SELECTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-2-ADRENERGIC RECEPTORS; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; RAT-BRAIN; BINDING; LIGAND; SPECIFICITY; MOUSE; SITE; CDNA	To investigate the interaction between the mu opioid receptor and its ligands, we compared the binding of mu-selective ligands to two mu/kappa chimeric opioid receptors and to mu and kappa receptors. The two chimeras were constructed from cloned rat mu and kappa receptors in which a segment from the middle of the third intracellular loop to the C terminus was exchanged. When this portion of the kappa receptor was replaced by that of the mu receptor, affinities of mu selective agonists, DAMGO (Tyr-D-Ala-Gly-NMePhe-Gly-ol), PL017 (Tyr-Pro-NMePhe-D-Pro-NH2), sufentanil, and morphine, were greatly increased as compared to those for the kappa receptor. Conversely, when this region of the gamma receptor was substituted by that of the kappa receptor, affinities for these agonists were substantially decreased as compared with those of the mu receptor. Unlike selective agonists, the mu-selective antagonist, CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-penicillamine-Thr-NH2), displayed a low affinity for both chimeric receptors, similar to that of the kappa receptor. Thus, the region from the middle of the third intracellular loop to the C terminus of the mu receptor is important for the binding of selective agonists. Conversely, the determinants for selective binding of the antagonist CTAP reside in a more extended region of the receptor.	TEMPLE UNIV,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; TEMPLE UNIV,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19104; TEMPLE UNIV,SCH MED,FELS INST MOLEC BIOL & CANC RES,PHILADELPHIA,PA 19104; INDIANA UNIV,SCH MED,DEPT MED & MOLEC GENET,INDIANAPOLIS,IN 46202	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL INSTITUTE ON DRUG ABUSE [R29DA004745, R01DA004745] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 04745] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; CHANG KJ, 1983, J PHARMACOL EXP THER, V227, P403; CHEN Y, 1993, MOL PHARMACOL, V44, P8; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; KOSTERLITZ HW, 1981, BRIT J PHARMACOL, V73, pP299; KRAMER TH, 1989, J PHARMACOL EXP THER, V249, P544; LEYSEN JE, 1983, EUR J PHARMACOL, V87, P209, DOI 10.1016/0014-2999(83)90331-X; LI SX, 1993, BIOCHEM J, V295, P629, DOI 10.1042/bj2950629; LIUCHEN LY, 1991, EUR J PHARMACOL, V203, P195, DOI 10.1016/0014-2999(91)90715-3; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; ONOGI T, 1995, FEBS LETT, V357, P93, DOI 10.1016/0014-5793(94)01341-W; PASTERNAK GW, 1988, OPIATE RECEPTORS; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, J BIOL CHEM, V269, P25966; WUSTER M, 1980, LIFE SCI, V27, P163, DOI 10.1016/0024-3205(80)90459-2; XUE JC, 1994, J BIOL CHEM, V269, P30195; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; ZHU J, 1995, LIFE SCI, V56, P201	25	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					12977	12979						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768887				2022-12-25	WOS:A1995RB43900008
J	BAKKER, AHF; WEENINGVERHOEFF, EJD; VERHEIJEN, JH				BAKKER, AHF; WEENINGVERHOEFF, EJD; VERHEIJEN, JH			THE ROLE OF THE LYSYL BINDING-SITE OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN THE INTERACTION WITH A FORMING FIBRIN CLOT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRINGLE-2 DOMAIN; STRUCTURAL DOMAINS; LYSINE; ACID; RESOLUTION; KINETICS; PROTEINS; FINGER; GLU	To describe the role of the lysyl binding site in the interaction of tissue-type plasminogen activator (t-PA, FGK1K2P) with a forming fibrin clot, we performed binding experiments with domain deletion mutants GR1K2P, K2P, and the corresponding point mutants lacking the lysyl binding site in the absence and the presence of epsilon-amino caproic acid (EACA). Occupation of the lysyl binding site in the K2 domain with EACA has a pronounced effect on the binding of FGK1K2P to a fibrin clot (C-50 = 77 +/- 11 nM versus 376 +/- 45 nM with EACA). Deleting the lysyl binding site in the K2 domain (substitution D236N) also impairs fibrin binding but to a lesser extent (C-50 = 169 +/- 20 nM). Although the binding of K2P to a fibrin clot is weak (C-50 = 1163 +/- 490 nM), it still is 2 orders of magnitude stronger than the binding of EACA to K2P. Therefore it was surprising to find that deletion of the lysyl binding site in K2P completely abolishes fibrin binding. Even when both the F domain and the lysyl binding site were deleted, considerable fibrin binding is still observed (C-50 = 557 +/- 126 nM), suggesting other than F and K2-mediated interactions. The binding of FGK1K2P, FGK1K2P (D236N), GK1K2P, and GK1K2P (D236N) to fibrin could be competitively inhibited by FGK1K2P and K2P, indicating that all molecules recognize the same interaction sites on a fibrin clot. Based on these results, a new model for the interaction of t-PA with a forming fibrin clot is proposed. The fibrin binding sites in t-PA are not confined to the F and K2 domain. The main role of the lysyl binding site in the K2 domain of t-PA appears indirect rather than direct, most likely stabilizing a conformation favorable for fibrin binding.	TNO,PREVENT & HLTH,GAUBIUS LAB,2301 CE LEIDEN,NETHERLANDS	Netherlands Organization Applied Science Research								ALLEN RA, 1981, THROMB HAEMOSTASIS, V45, P43; BAKKER AHF, 1993, J BIOL CHEM, V268, P18496; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BYEON IJL, 1991, J MOL BIOL, V222, P1035, DOI 10.1016/0022-2836(91)90592-T; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHRISTENSEN U, 1992, BIOCHEM J, V285, P419, DOI 10.1042/bj2850419; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DEMUNK GAW, 1989, BIOCHEMISTRY-US, V28, P7318, DOI 10.1021/bi00444a026; DESERRANO VS, 1993, BIOCHEMISTRY-US, V32, P3540, DOI 10.1021/bi00065a004; DEVOS AM, 1992, BIOCHEMISTRY-US, V31, P270, DOI 10.1021/bi00116a037; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; DEVRIES C, 1990, THESIS U AMSTERDAM; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANELLIPIPERNO A, 1978, J EXP MED, V148, P223, DOI 10.1084/jem.148.1.223; HASEGAWA A, 1985, Patent No. 156169; HORREVOETS AJG, 1994, J BIOL CHEM, V269, P12639; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; ICHIMURA M, 1987, Patent No. 217379; KACZMAREK E, 1993, J BIOL CHEM, V268, P2474; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGOSSIAN SS, 1993, BIOCHIM BIOPHYS ACTA, V1163, P250, DOI 10.1016/0167-4838(93)90159-O; MARKUS G, 1978, J BIOL CHEM, V253, P733; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NIEUWENHUIZEN W, 1985, FIBRINOGEN STRUCTURA, P331; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; PANNEKOEK H, 1990, THROMB HAEMOSTASIS, V64, P600; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; RADCLIFFE R, 1978, ARCH BIOCHEM BIOPHYS, V189, P185, DOI 10.1016/0003-9861(78)90131-5; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; RAUBER P, 1988, ANAL BIOCHEM, V168, P259, DOI 10.1016/0003-2697(88)90316-8; RIJKEN DC, 1986, J BIOL CHEM, V261, P3098; Sambrook J, 1989, MOL CLONING LABORATO; THORSEN S, 1972, THROMB DIATH HAEMOST, V28, P65; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VERHEIJEN JH, 1985, THROMB RES, V39, P281, DOI 10.1016/0049-3848(85)90223-3; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; VERHEIJEN JH, 1982, THROMB RES, V27, P175; Wallen P., 1981, PROGR FIBRINOLYSIS, V5, P16; WEENINGVERHOEFF EJD, 1990, PROTEIN ENG, V4, P191, DOI 10.1093/protein/4.2.191	42	18	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12355	12360		10.1074/jbc.270.21.12355	http://dx.doi.org/10.1074/jbc.270.21.12355			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759476	hybrid, Green Submitted			2022-12-25	WOS:A1995QZ71100008
J	HUSSAIN, A; GARNETT, C; KLEIN, MG; TSAIWU, JJ; SCHNEIDER, MF; INESI, G				HUSSAIN, A; GARNETT, C; KLEIN, MG; TSAIWU, JJ; SCHNEIDER, MF; INESI, G			DIRECT INVOLVEMENT OF INTRACELLULAR CA2+ TRANSPORT ATPASE IN THE DEVELOPMENT OF THAPSIGARGIN RESISTANCE BY CHINESE-HAMSTER LUNG FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; INHIBITION; CELLS; CA-2+-ATPASE; CA2+-ATPASE; EXPRESSION; PUMP	Thapsigargin (TG), a specific inhibitor of intracellular Ca2+ transport ATPases (SERCA), inhibits cell proliferation when added to culture media in the nanomolar concentration range, However, long term exposure to gradually increasing concentrations of TG induces resistance to TG inhibition in both the parental Chinese hamster lung fibroblast DC-3F and a subline derived from it via transfection and stable expression of a full-length cDNA encoding avian SERCA1 ATPase (DC-3F/Ca cells), TG resistance develops in parallel with selection of cells expressing higher levels of the endogenous SERCA2 as well as of the exogenous transfected SERCA1 ATPase, whose Ca2+ transport function can be studied in situ by imaging techniques and following isolation in microsomal fractions, Microsomes isolated from resistant cells contain two functionally distinct populations of ATPases: a population that is inhibited by stoichiometric titration with TG, and a population displaying resistance to inhibition even when TG exceeds the enzyme stoichiometry, It is apparent that resistance to TG develops in parallel with (a) selection of cells expressing high levels of SERCA ATPases, and (b) selection of an ATPase that is resistant to TG.	UNIV MARYLAND,CTR CANC,SCH MED,DEPT MED,DIV ONCOL,BALTIMORE,MD; VET ADM MED CTR,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA)	HUSSAIN, A (corresponding author), UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201, USA.			Garnett, Christine/0000-0002-4108-2511	NHLBI NIH HHS [HL27867] Funding Source: Medline; NINDS NIH HHS [NS33578] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033578] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIAN JH, 1991, J BIOL CHEM, V266, P8801; BIEDLER JL, 1970, CANCER RES, V30, P1174; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; GUTHEIL JC, 1994, J BIOL CHEM, V269, P7976; HUSSAIN A, 1992, ARCH BIOCHEM BIOPHYS, V296, P539, DOI 10.1016/0003-9861(92)90608-Y; INESI G, 1994, J MEMBRANE BIOL, V141, P1; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYTTON J, 1991, J BIOL CHEM, V266, P17067; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; TAO JG, 1992, J BIOL CHEM, V267, P24972; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WALDRON RT, 1994, FASEB J, V8, pA1416	20	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12140	12146		10.1074/jbc.270.20.12140	http://dx.doi.org/10.1074/jbc.270.20.12140			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744863	hybrid			2022-12-25	WOS:A1995QY73600066
J	KANNO, T; BROWN, K; SIEBENLIST, U				KANNO, T; BROWN, K; SIEBENLIST, U			EVIDENCE IN SUPPORT OF A ROLE FOR HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I TAX IN ACTIVATING NF-KAPPA-B VIA STIMULATION OF SIGNALING PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HTLV-I; P50	The human T-cell leukemia virus type I Tax protein activates NF-kappa B transcription factors from preformed cytoplasmic pools, including those pools that are retained by the I kappa B-alpha inhibitory protein. Degradation of I kappa B-alpha is enhanced by Tax, resulting in the liberation of some NF-kappa B, which then translocates into the nucleus. Here we have investigated the mechanism by which Tax causes degradation of I kappa B-alpha. Two I kappa B-alpha mutants defective in extracellular signal induced degradation of I kappa B-alpha also blocked Tax-mediated kappa B-dependent transactivation when cotransfected into Jurkat T cells. Cotransfected wild-type I kappa B-alpha or an irrelevant mutant did not significantly effect transactivation induced by Tax. The signal-defective I kappa B-alpha proteins are mutated at either of two closely spaced serines in the N terminus of the protein (Ser(32) and Ser(36)). In wild-type I kappa B-alpha one or both of these serines are inducibly phosphorylated with extracellular stimuli, and such phosphorylation appears necessary for subsequent degradation and thus activation of NF-kappa B. These results suggest that Tax triggers I kappa B-alpha degradation and thus NF-kappa B activation by a mechanism that converges with that induced by extracellular stimulation such as phorbol 12-myristate 13-acetate/ionomycin or tumor necrosis factor alpha. A role for Tax in activating signal transduction pathways upstream of I kappa B-alpha is implied.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; HIRAI H, 1994, P NATL ACAD SCI USA, V1, P3584; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MUNOZ E, 1994, J VIROL, V68, P8035; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; WATANABE M, 1993, ONCOGENE, V8, P2949	15	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11745	11748		10.1074/jbc.270.20.11745	http://dx.doi.org/10.1074/jbc.270.20.11745			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744820	hybrid			2022-12-25	WOS:A1995QY73600012
J	SVENSSON, LT; ALEXSON, SEH; HILTUNEN, JK				SVENSSON, LT; ALEXSON, SEH; HILTUNEN, JK			VERY LONG-CHAIN AND LONG-CHAIN ACYL-COA THIOESTERASES IN RAT-LIVER MITOCHONDRIA - IDENTIFICATION, PURIFICATION, CHARACTERIZATION, AND INDUCTION BY PEROXISOME PROLIFERATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE MITOCHONDRIA; BETA-OXIDATION ENZYMES; FATTY-ACID OXIDATION; PALMITOYL-COENZYME; HYDROLASE ACTIVITY; CLOFIBRATE; PROTEIN; CARBOXYLESTERASE; FRACTIONS; CARNITINE	We have previously reported that long chain acyl-CoA thioesterase activity was induced about 10-fold in rat liver mitochondria, when treating rats with the peroxisome proliferator di(2-ehtylhexyl)phtalate (Wilcke M., and Alexson S. E. H (1994) Eur. J. Biochem. 222, 803-811). Here we have characterized two enzymes which are responsible for the majority of long chain acyl-CoA thioesterase activity in mitochondria from animals treated with peroxisome proliferators. A 40-kDa enzyme was purified and characterized as a very long chain acyl-CoA thioesterase (MTE-I). The second enzyme was partially purified and characterized as a long chain acyl-CoA thioesterase (MTE-II). MTE-I was inhibited by p-chloromercuribenzoic acid, which implicates the importance of a cysteine residue in, or close, to the active site. Antibodies against MTE-I demonstrated the presence of immunologically related acyl-CoA thioesterases in peroxisomes and cytosol, High expression of MTE-I was found in liver from peroxisome proliferator treated rats and in heart and brown fat from control and induced rats. Comparison of physical and catalytical characteristics of the enzymes studied here and previously purified acyl-CoA thioesterases suggest that MTE-I and MTE-II are novel enzymes.	KAROLINSKA INST, HUDDINGE UNIV HOSP, DEPT MED LAB SCI & TECHNOL, S-14186 HUDDINGE, SWEDEN; UNIV STOCKHOLM, WENNER GREN INST, DEPT METAB RES, ARRHENIUS LABS F3, S-10691 STOCKHOLM, SWEDEN; UNIV OULU, BIOCTR, DEPT MED BIOCHEM, SF-90220 OULU, FINLAND; KUOPIO UNIV, DEPT BIOCHEM & BIOTECHNOL, SF-70211 KUOPIO, FINLAND	Karolinska Institutet; Stockholm University; University of Oulu; University of Eastern Finland				Svensson, Thomas/0000-0002-9190-2979				ALEXSON SEH, 1988, J BIOL CHEM, V263, P13564; ALEXSON SEH, 1989, BIOCHIM BIOPHYS ACTA, V1005, P13, DOI 10.1016/0005-2760(89)90025-8; ALEXSON SEH, 1985, BIOCHIM BIOPHYS ACTA, V834, P149, DOI 10.1016/0005-2760(85)90150-X; ALEXSON SEH, 1993, EUR J BIOCHEM, V214, P719, DOI 10.1111/j.1432-1033.1993.tb17973.x; ALEXSON SEH, 1989, BIOCHEM J, V262, P41, DOI 10.1042/bj2620041; BAKKE OM, 1982, BIOCHEM PHARMACOL, V31, P3930, DOI 10.1016/0006-2952(82)90313-6; BERGE RK, 1983, INT J BIOCHEM, V15, P191, DOI 10.1016/0020-711X(83)90065-4; BERGE RK, 1979, EUR J BIOCHEM, V96, P393, DOI 10.1111/j.1432-1033.1979.tb13051.x; BERGE RK, 1979, BIOCHIM BIOPHYS ACTA, V574, P321, DOI 10.1016/0005-2760(79)90013-4; BERGE RK, 1984, EUR J BIOCHEM, V141, P637, DOI 10.1111/j.1432-1033.1984.tb08239.x; BERGE RK, 1981, FEBS LETT, V124, P43, DOI 10.1016/0014-5793(81)80050-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; COOPER HM, 1989, CURRENT PROTOCOLS MO, V2; GROSS RW, 1983, BIOCHEMISTRY-US, V22, P5641, DOI 10.1021/bi00293a028; HAKKOLA EH, 1989, J HISTOCHEM CYTOCHEM, V37, P1863, DOI 10.1177/37.12.2584694; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HESS R, 1965, NATURE, V208, P856, DOI 10.1038/208856a0; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; IZAI K, 1992, J BIOL CHEM, V267, P1027; KAWASHIMA Y, 1981, J PHARMACOBIO-DYNAM, V4, P711, DOI 10.1248/bpb1978.4.711; KELLER H, 1993, ANN NY ACAD SCI, V684, P157, DOI 10.1111/j.1749-6632.1993.tb32279.x; KNAUER TE, 1979, BIOCHEM J, V179, P515, DOI 10.1042/bj1790515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1977, SCIENCE, V197, P580, DOI 10.1126/science.195342; LEE KY, 1979, J BIOL CHEM, V254, P4516; LIN AY, 1984, NEUROCHEM RES, V9, P1571, DOI 10.1007/BF00964592; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MANNAERTS GP, 1978, BIOCHIM BIOPHYS ACTA, V529, P201, DOI 10.1016/0005-2760(78)90063-2; MENTLEIN R, 1986, BIOCHEM PHARMACOL, V35, P2727, DOI 10.1016/0006-2952(86)90181-4; MENTLEIN R, 1985, BIOCHEM J, V232, P479, DOI 10.1042/bj2320479; MIYAZAWA S, 1981, EUR J BIOCHEM, V117, P425, DOI 10.1111/j.1432-1033.1981.tb06356.x; MOHAN PF, 1989, J NUTR, V119, P496, DOI 10.1093/jn/119.3.496; NEAT CE, 1980, BIOCHEM J, V186, P369, DOI 10.1042/bj1860369; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; VOLTTI H, 1979, BIOCHEM J, V182, P95, DOI 10.1042/bj1820095; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x; YAMADA J, 1994, ARCH BIOCHEM BIOPHYS, V308, P118, DOI 10.1006/abbi.1994.1017	43	66	67	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12177	12183		10.1074/jbc.270.20.12177	http://dx.doi.org/10.1074/jbc.270.20.12177			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744868	hybrid			2022-12-25	WOS:A1995QY73600071
J	MOLINARI, M; MILNER, J				MOLINARI, M; MILNER, J			P53 IN COMPLEX WITH DNA IS RESISTANT TO UBIQUITIN-DEPENDENT PROTEOLYSIS IN THE PRESENCE OF HPV-16 E6	ONCOGENE			English	Article						P53-DNA; UBIQUITIN-DEPENDENT PROTEOLYSIS; HPV-16 E6	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; CELL-CYCLE; GENE AMPLIFICATION; PROTEIN; CONFORMATION; BINDING; DEGRADATION; ONCOPROTEIN; PHOSPHORYLATION	The tumour suppressor p53 is a transcription factor with high affinity for specific DNA target sequences. Wild type p53 has a very short half life in normal cells but the protein shows transient accumulation in response to DNA damage, accompanied by up-regulation of target genes such as p21 and induction of growth arrest in G1 of the cell cycle. The rapid turnover of p53 may involve the ubiquitin-dependent proteolytic pathway. In order to investigate p53 turnover we have employed an in vitro system with rabbit reticulocyte lysate, in which ubiquitin-dependent degradation of p53 is mediated by the oncoprotein E6 of human papilloma virus type 16 (HPV-16). Using this system we have previously shown that E6-mediated degradation is preferential for p53 in the 1620(+) conformation (reactive with the monoclonal antibody PAb1620). p53-1620(+) is a pre-requisite for specific DNA binding and we have now asked if p53 in complex with DNA remains susceptible to ubiquitin-dependent proteolysis in the presence of E6. Our results indicate that p53-DNA complexes are resistant to degradation, whereas the 'free' protein is completely degraded within 20 min. Moreover, E6 did not complex with p53-DNA, possibly due to masking of sites recognised either by E6 or by the E6-associated protein (E6-AP) which facilitates E6-p53 interaction. Preincubation with E6 inhibited the DNA binding capacity of p53 and this effect could be explained, at least in part, by ubiquitination of the p53 protein.	UNIV YORK,DEPT BIOL,YORKSHIRE CANC RES CAMPAIGAN P53 GRP,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK								ANDERSON C, 1994, IN PRESS SEMINARS CA; BLUMENFELD N, 1994, J BIOL CHEM, V13, P9574; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CIECHANOVER A, 1994, J BIOL CHEM, V13, P9582; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, ONCOGENE, V9, P1225; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; GU ZM, 1994, ONCOGENE, V9, P629; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL AR, 1995, ONCOGENE, V10, P561; HARPER JW, 1993, CELL, V75, P805; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1990, ONCOGENE, V5, P1683; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIM D, 1994, ONCOGENE, V9, P1869; PINES J, 1994, NATURE, V371, P742, DOI 10.1038/371742a0; RIVAS CI, 1992, BLOOD, V79, P1982; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SRINIVASAN R, 1993, CANCER RES, V53, P5361; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG W, 1992, ONCOGENE, V7, P1646	53	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1849	1854						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753560				2022-12-25	WOS:A1995QX46900018
J	WANG, XC; VERTINO, A; EDDY, RL; BYERS, MG; JANISAIT, SN; SHOWS, TB; LAU, JTY				WANG, XC; VERTINO, A; EDDY, RL; BYERS, MG; JANISAIT, SN; SHOWS, TB; LAU, JTY			CHROMOSOME MAPPING AND ORGANIZATION OF THE HUMAN BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE GENE - DIFFERENTIAL AND CELL-TYPE SPECIFIC USAGE OF UPSTREAM EXON SEQUENCES IN B-LYMPHOBLASTOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; HUMAN LYMPHOCYTES-B; TRANSCRIPTIONAL REGULATION; INSITU HYBRIDIZATION; MARKER PROFILES; HUMAN-LEUKEMIA; HUMAN GENOME; T-CELLS; SIALYLTRANSFERASE; GLYCOSYLTRANSFERASES	The human beta-galactoside alpha2,6-sialyltransferase (EC 2.4.99.1) (SiaT-1) gene is localized to human chromosome 3 (q21-q28) by Southern analysis of somatic cell hybrids and by in situ hybridization of metaphase chromosomes. Comparative analysis between the human and the previously reported rat SiaT-1 genomic sequences demonstrates precise conservation of the intron/exon boundaries throughout the coding domains. Furthermore, there is extensive inter-species sequence similarity in some of the exons that contain information only for the 5'-leader regions. Human genomic sequences were also analyzed to reconcile reported differences in the 5'-untranslated region in SiaT-1 mRNAs. In cultured cell lines of the B-lineage, Reh, Nalm-6, Jok-1, Ball-1, Daudi, and Louckes, the study demonstrates that three upstream exons, Exons(Y+Z) and Exon(X), are mutually exclusively utilized, resulting in at least two distinct populations of SiaT-1 mRNA being synthesized. None of these exons is present in the SiaT-1 mRNA isotype expressed in HepG2 human hepatoma cells. In all B-lymphoblastoid cell lines examined, the basal level SiaT-1 mRNA is maintained by the expression of an isotype containing the Exons(Y+Z) sequence. The slightly smaller SiaT-1 mRNA, which contains the Exon(X) sequence but not Exons(Y+Z) sequence, is synthesized at a high level and found only in Jok-1, Daudi, and Louckes, the cell lines with mature B-cell phenotype. The study also provides further evidence that induced SiaT-1 expression accompanies the appearance of CDw75, a putatively sialylated cell surface epitope and a marker of human mature B-lymphocytes. The SiaT-1 induction is the result of the appearance of a novel form of SiaT-1 mRNA isotype.	ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263; ROSWELL PK CANC INST,DEPT HUMAN GENET,BUFFALO,NY 14263	Roswell Park Cancer Institute; Roswell Park Cancer Institute					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005196] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038193] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00333] Funding Source: Medline; NICHD NIH HHS [HD05196] Funding Source: Medline; NIGMS NIH HHS [GM38193] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; CHERIF D, 1989, HUM GENET, V81, P358, DOI 10.1007/BF00283691; CHERIF D, 1988, CANCER RES, V48, P1489; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P109; DUNCAN AMV, 1986, BIOCHEM BIOPH RES CO, V141, P1185, DOI 10.1016/S0006-291X(86)80169-3; EPSTEIN AL, 1984, J IMMUNOL, V133, P1028; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; GUY K, 1991, IMMUNOLOGY, V74, P206; HULL E, 1991, BIOCHEM BIOPH RES CO, V176, P608, DOI 10.1016/S0006-291X(05)80227-X; KOYANAGI Y, 1984, MED MICROBIOL IMMUN, V173, P127, DOI 10.1007/BF02123761; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LANCE P, 1989, BIOCHEM BIOPH RES CO, V164, P225, DOI 10.1016/0006-291X(89)91706-3; MINOWADA J, 1981, J CANCER RES CLIN, V101, P91, DOI 10.1007/BF00405069; MITTLER RS, 1983, J IMMUNOL, V131, P1754; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MUNRO S, 1992, CELL, V68, P1003, DOI 10.1016/0092-8674(92)90070-S; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; OHANLON TP, 1992, GLYCOBIOLOGY, V2, P257, DOI 10.1093/glycob/2.3.257; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PETERSON RC, 1984, P NATL ACAD SCI-BIOL, V81, P4363, DOI 10.1073/pnas.81.14.4363; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; ROSSOWSKI W, 1983, BRIT J CANCER, V47, P158, DOI 10.1038/bjc.1983.19; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; SASAKI R, 1982, LEUKEMIA RES, V6, P197, DOI 10.1016/0145-2126(82)90025-X; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1982, ADV HUM GENET, V12, P341; SMELAND E, 1985, SCAND J IMMUNOL, V21, P205, DOI 10.1111/j.1365-3083.1985.tb01422.x; STAMENKOVIC I, 1990, J EXP MED, V172, P641, DOI 10.1084/jem.172.2.641; STAMENKOVIC I, 1992, CELL, V68, P1003, DOI 10.1016/0092-8674(92)90071-J; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WANG XC, 1990, J BIOL CHEM, V265, P17849; WANG XC, 1989, J BIOL CHEM, V264, P1854; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P2512; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	45	111	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4355	4361						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7786324				2022-12-25	WOS:A1993KN53300079
J	KOSSYKH, VG; SCHLAGMAN, SL; HATTMAN, S				KOSSYKH, VG; SCHLAGMAN, SL; HATTMAN, S			PHAGE-T4 DNA [N-6-ADENINE]METHLYLTRANSFERASE - OVEREXPRESSION, PURIFICATION, AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ADENINE METHYLASE; CATALYTIC PROPERTIES; HOMOGENEOUS ENZYME; METHYLTRANSFERASE; BACTERIOPHAGE-T4; RESTRICTION; GENE; DAM; RECOGNITION	The bacteriophage T4 dam gene, encoding the Dam DNA [N-6-adenine]methyltransferase (MTase), has been subcloned into the plasmid expression vector, pJW2, In this construct, designated pINT4dam, transcription is from the regulatable phage lambda p(R) and p(L) promoters, arranged in tandem, A two-step purification scheme using DEAE-cellulose and phosphocellulose columns in series, followed by hydroxyapatite chromatography, was developed to purify the enzyme to near homogeneity, The yield of purified protein was 2 mg/g of cell paste. The MTase has an s(20,w) of 3.0 S and a Stokes radius of 23 Angstrom and exists in solution as a monomer. The K-m for the methyl donor, S-adenosylmethionine, is 0.1 x 10(-6) M, and the K-m for substrate nonglucosylated, unmethylated T4 gt(-)dam(-) DNA is 1.1 x 10(-12) M. The products of DNA methylation, S-adenosyl-L-homocysteine and methylated DNA, are competitive inhibitors of the reaction; K-i values of 2.4 x 10(-6) M and 4.6 x 10(-12) M, respectively, were observed. T4 Dam methylates the palindromic tetranucleotide, GATC, designated the canonical sequence, However, at high MTase:DNA ratios, T4 Dam can methylate some noncanonical sequences belonging to GAY (where Y represents cytosine or thymine).			KOSSYKH, VG (corresponding author), UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029227] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29227] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS JE, 1978, J MOL BIOL, V126, P381, DOI 10.1016/0022-2836(78)90047-5; CHANDRASEGARAN S, 1988, GENE, V74, P15, DOI 10.1016/0378-1119(88)90240-5; Chandrasegaran S, 1988, STRUCTURE EXPRESSION, V1, P149; CHENG SC, 1984, J BIOL CHEM, V259, P1571; DELACAMPA AG, 1987, J MOL BIOL, V196, P457, DOI 10.1016/0022-2836(87)90024-6; DUBEY AK, 1992, NUCLEIC ACIDS RES, V20, P1579, DOI 10.1093/nar/20.7.1579; EVERETT EA, 1990, J BIOL CHEM, V265, P17713; Hattman S, 1983, BACTERIOPHAGE T4, P152; HERMAN GE, 1982, J BIOL CHEM, V257, P2605; KASZUBSKA W, 1992, GENE, V118, P5, DOI 10.1016/0378-1119(92)90242-H; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD PM, 1984, EMBO J, V3, P2863, DOI 10.1002/j.1460-2075.1984.tb02221.x; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Miller J. H., 1972, EXPT MOL GENETICS, P433; Modrich P., 1982, NUCLEASES, P109; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NWOSU VU, 1988, NUCLEIC ACIDS RES, V16, P3705, DOI 10.1093/nar/16.9.3705; NWOSU VU, 1992, BIOCHEM J, V283, P745, DOI 10.1042/bj2830745; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; Sambrook J, 1989, MOL CLONING LABORATO; SCHLAGMAN SL, 1983, GENE, V22, P139, DOI 10.1016/0378-1119(83)90098-7; SCHLAGMAN SL, 1989, NUCLEIC ACIDS RES, V17, P9101, DOI 10.1093/nar/17.22.9101; SCHLAGMAN SL, 1988, GENE, V73, P517, DOI 10.1016/0378-1119(88)90516-1; SHAPIRO SK, 1966, ANAL BIOCHEM, V15, P323, DOI 10.1016/0003-2697(66)90038-8; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TAYLOR JD, 1990, BIOCHEMISTRY-US, V29, P10727, DOI 10.1021/bi00500a003; WANG HY, 1990, NUCLEIC ACIDS RES, V18, P1070, DOI 10.1093/nar/18.4.1070; WILSON GG, 1991, NUCLEIC ACIDS RES, V19, P2539, DOI 10.1093/nar/19.10.2539; WOODBURY CP, 1980, J BIOL CHEM, V255, P1526; WU JC, 1988, NUCLEIC ACIDS RES, V16, P703, DOI 10.1093/nar/16.2.703	32	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14389	14393		10.1074/jbc.270.24.14389	http://dx.doi.org/10.1074/jbc.270.24.14389			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782299	hybrid			2022-12-25	WOS:A1995RD45500026
J	REDDY, R; SMITH, D; WAYMAN, G; WU, ZL; VILLACRES, EC; STORM, DR				REDDY, R; SMITH, D; WAYMAN, G; WU, ZL; VILLACRES, EC; STORM, DR			VOLTAGE-SENSITIVE ADENYLYL-CYCLASE ACTIVITY IN CULTURED NEURONS - A CALCIUM-INDEPENDENT PHENOMENON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; RAT-BRAIN; AREA CA1; CALMODULIN; PROTEIN; ACTIVATION; CLONING; STIMULATION; EXPRESSION; HIPPOCAMPUS	Catalytic subunits of mammalian adenylyl cyclases have been proposed to contain 12 transmembrane domains, a property shared with some voltage-sensitive ion channels. Here we report that adenylyl cyclase activity in cerebellar neurons is synergistically stimulated by depolarizing agents and beta-adrenergic receptor activation. This phenomenon is Ca2+-independent and not attributable to Ca2+-stimulated adenylyl cyclase activity. Cholera toxin and forskolin also synergistically stimulate adenylyl cyclase activity in combination with depolarizing agents. We hypothesize that conformational changes in the catalytic subunit of the enzymes caused by changes in the membrane potential may enhance stimulation of adenylyl cyclases by the guanylyl nucleotide stimulatory protein. This novel mechanism for regulation of adenylyl cyclases generates robust cAMP signals that may contribute to various neuromodulatory events including some forms of neuroplasticity.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NINDS NIH HHS [NS20498] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020498] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BARRETT EF, 1988, J PHYSIOL-LONDON, V402, P65, DOI 10.1113/jphysiol.1988.sp017194; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CATTERALL WA, 1975, J BIOL CHEM, V250, P4053; CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310; CHAVEZNORIEGA LE, 1992, BRAIN RES, V574, P85, DOI 10.1016/0006-8993(92)90803-H; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; CHEUNG WY, 1982, HDB EXP PHARM, V58, P301; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P9189; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1985, P NATL ACAD SCI USA, V82, P5992, DOI 10.1073/pnas.82.17.5992; MAY DC, 1985, J BIOL CHEM, V260, P5829; MOSS J, 1977, J BIOL CHEM, V252, P2455; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NARAHASHI T, 1964, J GEN PHYSIOL, V47, P965, DOI 10.1085/jgp.47.5.965; NESTLER EJ, 1983, NATURE, V305, P583, DOI 10.1038/305583a0; Pieroni J P, 1993, Curr Opin Neurobiol, V3, P345, DOI 10.1016/0959-4388(93)90127-K; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SHIMIZU H, 1970, MOL PHARMACOL, V6, P184; STEVENS CF, 1994, NEURON, V13, P769, DOI 10.1016/0896-6273(94)90244-5; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WATSON PA, 1990, J BIOL CHEM, V265, P6569; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	55	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14340	14346		10.1074/jbc.270.24.14340	http://dx.doi.org/10.1074/jbc.270.24.14340			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782293	hybrid			2022-12-25	WOS:A1995RD45500019
J	RICCI, B; SHARP, D; OROURKE, E; KIENZLE, B; BLINDERMAN, L; GORDON, D; SMITHMONROY, C; ROBINSON, G; GREGG, RE; RADER, DJ; WETTERAU, JR				RICCI, B; SHARP, D; OROURKE, E; KIENZLE, B; BLINDERMAN, L; GORDON, D; SMITHMONROY, C; ROBINSON, G; GREGG, RE; RADER, DJ; WETTERAU, JR			A 30-AMINO ACID TRUNCATION OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN LARGE SUBUNIT DISRUPTS ITS INTERACTION WITH PROTEIN DISULFIDE-ISOMERASE AND CAUSES ABETALIPOPROTEINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROLYL 4-HYDROXYLASE; ENDOPLASMIC-RETICULUM; GENE; MUTAGENESIS; COMPLEX; CLONING	The microsomal triglyceride transfer protein (MTP) is a heterodimer composed of the multifunctional enzgme, protein disulfide-isomerase, and a unique large, 97 kDa, subunit. It is found as a soluble protein within the lumen of the endoplasmic reticulum of liver and intestine and is required for the assembly of very low density lipoproteins and chylomicrons. Mutations in MTP which result in an absence of MTP function have been shown to cause abetalipoproteinemia. Here, the gene encoding the MTP 97-kDa subunit of an abetalipoproteinemic subject, which we have previously demonstrated lacks MTP activity and protein (Wetterau, J. R., Aggerbeck, L. P., Bouma, M.-E., Eisenberg, C., Munck, A., Hermier, M., Schmitz, J., Gay, G., Rader, D. J., and Gregg, R. E. (1992) Science 258, 999-1001), was isolated and sequenced. A nonsense mutation, which predicts the truncation of the protein by 30 amino acids, was identified. To investigate if this apparently subtle change in MTP could explain the observed absence of MTP, protein disulfide-isomerase was co-expressed with either the normal or mutant MTP 97-kDa subunit in Sf9 insect cells using a baculovirus expression system. Although there were high levels of expression of both the normal and mutant forms of the MTP 97-kDA subunit, only the normal subunit was able to form a stable, soluble complex with protein disulfide-isomerase. These results indicate that the carboxyl-terminal 30 amino acids of the MTP 97-kDa subunit plays an important role in its interaction with protein disulfide-isomerase.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT METAB DIS,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; UNIV PENN,DEPT MED,DIV MED GENET,PHILADELPHIA,PA 19104	Bristol-Myers Squibb; Bristol-Myers Squibb; University of Pennsylvania								ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LACKNER KJ, 1986, J CLIN INVEST, V78, P1707, DOI 10.1172/JCI112766; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; PATEL SB, 1994, CIRCULATION, V90, P186; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHARP D, 1994, BIOCHEMISTRY-US, V33, P9057, DOI 10.1021/bi00197a005; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SHOULDERS CC, 1994, CIRCULATION, V90, P186; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006	20	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14281	14285		10.1074/jbc.270.24.14281	http://dx.doi.org/10.1074/jbc.270.24.14281			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782284	hybrid			2022-12-25	WOS:A1995RD45500010
J	LALLE, P; MOYRETLALLE, C; WANG, Q; VIALLE, JM; NAVARRO, C; BRESSACDEPAILLERETS, B; MAGAUD, JP; OZTURK, M				LALLE, P; MOYRETLALLE, C; WANG, Q; VIALLE, JM; NAVARRO, C; BRESSACDEPAILLERETS, B; MAGAUD, JP; OZTURK, M			GENOMIC STABILITY AND WILD-TYPE P53 FUNCTION OF LYMPHOBLASTOID-CELLS WITH GERM-LINE P53 MUTATION	ONCOGENE			English	Article						P53; LI-FRAUMENI SYNDROME; EPSTEIN-BARR VIRUS; LYMPHOBLASTOID CELLS; GENOMIC STABILITY	DINUCLEOTIDE REPEAT POLYMORPHISM; TUMOR-SUPPRESSOR GENE; CANCER-PRONE FAMILY; FRAUMENI SYNDROME; BREAST-CANCER; CHROMOSOMAL-ABNORMALITIES; CYCLE ARREST; FIBROBLASTS; APOPTOSIS; PROTEIN	Increased cancer risk associated with germ-line p53 mutation was linked to a deficit in the ability to maintain genomic stability. Accordingly, normal fibroblasts from cancer-prone individuals accumulate genomic aberrations with concomitant loss of mild-type p53 allele during in vitro culture. We tested whether such changes also occur in EBV-immortalized lymphoblastoid cells. Both normal and p53 germ-line mutant lymphoblastoid cells maintained functional p53 and genomic stability during long term in vitro culture. These unexpected differences between fibroblastic and lymphoblastic cells suggest that phenotypic expression of p53 deficiency is cell type specific. This could contribute to selective tissular localization of tumours observed in patients with Li-Fraumeni syndrome despite the presence of a mutant p53 allele in all cells.	CTR LEON BERARD, INSERM, CJF 9302, ONCOL MOLEC LAB, F-69373 LYON 08, FRANCE; HOP EDOUARD HERRIOT, INSERM, CJF 9307, CENT HEMATOL & CYTOGENET LAB, F-69437 LYON, FRANCE; INST GUSTAVE ROUSSY, DIAGNOST MOLEC LAB, F-94805 VILLEJUIF, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy			OZTURK, MEHMET/AAS-7241-2021; Moyret-Lalle, Caroline/G-2742-2013; LALLE, Philippe/G-7734-2018; ozturk, mehmet/G-3330-2014; Paillerets, Brigitte Bressac-de/D-8954-2018	OZTURK, MEHMET/0000-0002-6092-9706; Moyret-Lalle, Caroline/0000-0002-8359-2018; Paillerets, Brigitte Bressac-de/0000-0003-0245-8608				ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BIRCH JM, 1994, CANCER RES, V54, P1298; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BOND JA, 1994, ONCOGENE, V9, P1885; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DEINARD AS, 1992, NUCLEIC ACIDS RES, V20, P1171, DOI 10.1093/nar/20.5.1171-a; DELDEIRY WS, 1994, CANCER RES, V54, P1169; DUTHU A, 1992, ONCOGENE, V7, P2161; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HARDNEN DG, 1985, ISCN INT SYSTEM HUMA; HARVEY M, 1993, ONCOGENE, V8, P2457; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; Jones Michael H., 1992, Human Molecular Genetics, V1, P131, DOI 10.1093/hmg/1.2.131; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KLINEDINST DK, 1991, MUTAT RES, V250, P365, DOI 10.1016/0027-5107(91)90193-R; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAW JC, 1991, CANCER RES, V51, P6385; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1969, J NATL CANCER I, V43, P1365; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LYNCH HT, 1978, CANCER, V41, P2055, DOI 10.1002/1097-0142(197805)41:5<2055::AID-CNCR2820410554>3.0.CO;2-X; MAGAUD JP, 1985, HUM GENET, V69, P238, DOI 10.1007/BF00293032; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MAZOYER S, 1994, ONCOGENE, V9, P1237; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OCONNOR PM, 1993, CANCER RES, V53, P4776; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Sambrook J, 1989, MOL CLONING LABORATO; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEEL CM, 1977, NATURE, V270, P349, DOI 10.1038/270349a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WILLIAMS WR, 1985, FAM CANCER, P151; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	66	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2447	2454						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784096				2022-12-25	WOS:A1995RE54300023
J	ZURAWSKI, SM; CHOMARAT, P; DJOSSOU, O; BIDAUD, C; MCKENZIE, ANJ; MIOSSEC, P; BANCHEREAU, J; ZURAWSKI, G				ZURAWSKI, SM; CHOMARAT, P; DJOSSOU, O; BIDAUD, C; MCKENZIE, ANJ; MIOSSEC, P; BANCHEREAU, J; ZURAWSKI, G			THE PRIMARY BINDING SUBUNIT OF THE HUMAN INTERLEUKIN-4 RECEPTOR IS ALSO A COMPONENT OF THE INTERLEUKIN-13 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-4; HIGH-AFFINITY; SIGNAL-TRANSDUCTION; MOUSE INTERLEUKIN-2; EXPRESSION CLONING; LIGAND-BINDING; GAMMA-CHAIN; IL-13; PROTEINS; CELLS	Interleukin (IL)-13 elicits a subset of the biological activities of the related IL-4. The basis of this functional similarity is that their specific cell-surface receptors (called IL-13R and IL-4R) are distinct, yet are complex and share a common subunit(s). The IL-4R primary binding subunit (called IL-4R alpha) does not by itself bind IL-13. We show that the ability of IL-13 to partially compete for IL-4 binding to some human cell types depended on co-expression of IL-4R and IL-13R. However, IL-13 binding was always associated with IL-4 binding. Hyperexpression of IL-4R alpha on cells expressing both IL-4R and IL-13R decreased their binding affinity for IL-4, abrogated the ability of IL-13 to compete for IL-4 binding, and yet had no effect on IL-13R properties. Anti-human IL-4R alpha monoclonal antibodies which blocked the biological function and binding of IL-4 also blocked the function and binding of IL-13. These data show that IL-4R alpha is a secondary component of IL-13R.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,PALO ALTO,CA 94304; SCHERING PLOUGH CORP,IMMUNOL RES LAB,F-69571 DARDILLY,FRANCE	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; Schering Plough Corporation								ABRAMS JS, 1992, IMMUNOL REV, V127, P5, DOI 10.1111/j.1600-065X.1992.tb01406.x; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; CABRILLAT H, 1987, BIOCHEM BIOPH RES CO, V149, P995, DOI 10.1016/0006-291X(87)90507-9; DEFRANCE T, 1987, J IMMUNOL, V139, P1135; DOHERTY TM, 1993, J IMMUNOL, V151, P7151; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FERNANDEZBOTRAN R, 1991, J EXP MED, V174, P673, DOI 10.1084/jem.174.3.673; FERNANDEZBOTRAN R, 1990, P NATL ACAD SCI USA, V87, P4202, DOI 10.1073/pnas.87.11.4202; FOXWELL BMJ, 1989, EUR J IMMUNOL, V19, P1637, DOI 10.1002/eji.1830190918; GALIZZI JP, 1990, J BIOL CHEM, V265, P439; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; GARONNE P, 1991, EUR J IMMUNOL, V21, P1365; HARADA N, 1992, J BIOL CHEM, V267, P22752; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; HARADA N, 1992, IL 4 STRUCTURE FUNCT, P33; HERBERT JM, 1993, FEBS LETT, V328, P268, DOI 10.1016/0014-5793(93)80941-M; HURWITZ R, 1979, INT J CANCER, V23, P174, DOI 10.1002/ijc.2910230206; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE HV, 1988, J BIOL CHEM, V263, P10817; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MATTHEWS DJ, 1995, BLOOD, V85, P38, DOI 10.1182/blood.V85.1.38.bloodjournal85138; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; RENARD N, 1994, BLOOD, V84, P2253; RIGLEY KP, 1991, INT IMMUNOL, V3, P197, DOI 10.1093/intimm/3.2.197; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; VANKIMMENADE A, 1988, EUR J BIOCHEM, V173, P109; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1992, EMBO J, V11, P3905, DOI 10.1002/j.1460-2075.1992.tb05483.x; ZURAWSKI SM, 1993, EMBO J, V12, P5113, DOI 10.1002/j.1460-2075.1993.tb06206.x	38	216	243	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13869	13878		10.1074/jbc.270.23.13869	http://dx.doi.org/10.1074/jbc.270.23.13869			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775445	hybrid			2022-12-25	WOS:A1995RC44800044
J	CASASNOVAS, JM; SPRINGER, TA				CASASNOVAS, JM; SPRINGER, TA			KINETICS AND THERMODYNAMICS OF VIRUS BINDING TO RECEPTOR - STUDIES WITH RHINOVIRUS, INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1), AND SURFACE-PLASMON RESONANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE FORMS; NEUTRALIZATION; ANTIBODY; CELLS; IMMUNOGLOBULIN; EXPRESSION; VARIANTS; CANYON; LFA-1	We have studied the kinetics and thermodynamics of a virus interacting with its receptor using human rhinovirus serotype 3 (HRV3), soluble intercellular adhesion molecule-1 (ICAM-1, CD54) containing Ig superfamily domains 1-5 (sICAM-1), and surface plasmon resonance. There were two classes of binding sites for sICAM-1 on HRV3, each comprising about 50% of the total sites, with association rate constants of 2450 +/- 300 and 134 +/- 11 M(-1) s(-1). These rates are low, consistent with binding to a relatively inaccessible site in the rhinovirus canyon. By contrast, three monoclonal antibodies bound to sICAM-1 with a single rate constant of 17,000-48,000 M(-1) s(-1). The dissociation rate constant for RRV3 was 1.7 +/- 0.1 x 10(-3) s(-1), giving calculated dissociation constants of 0.7 +/- 0.1 and 12.5 +/- 1.2 mu M. Agreement was good with saturation binding in solution, which showed two sites of similar abundance with K-D of 0.55 +/- 0.2 and 5.7 +/- 2.0 mu M. A bivalent chimera of ICAM-1 with the IgA1 Fc region bound with K-D = 50 and 410 nar, showing 17-fold enhanced affinity. Lowering pH from 8.0 to 6.0 reduced affinity by approximately 50-fold, primarily by reducing the on rate. Thermodynamic measurements showed that binding of ICAM-1 to HRV3 is endothermic, by contrast to binding to monoclonal antibody. The heat that is absorbed of 3.5 and 6.3 kcal/mol for the two classes of ICAM-1 binding sites may contribute to receptor-mediated disruption of virions, which has an activation energy of about 42 kcal/mol.	HARVARD UNIV,SCH MED,CTR BLOOD RES,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School			Casasnovas, Jose M/L-6299-2014	Casasnovas, Jose M/0000-0002-2873-6410				Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; CASASNOVAS JM, 1994, J VIROL, V68, P5882, DOI 10.1128/JVI.68.9.5882-5889.1994; Casasnovas Jose M., 1994, Methods (Orlando), V6, P157, DOI 10.1006/meth.1994.1018; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GREVE JM, 1991, J VIROL, V65, P6015, DOI 10.1128/JVI.65.11.6015-6023.1991; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HOOVERLITTY H, 1993, J VIROL, V67, P390, DOI 10.1128/JVI.67.1.390-397.1993; KAPLAN G, 1990, J VIROL, V64, P4697, DOI 10.1128/JVI.64.10.4697-4702.1990; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KIM S, 1989, J MOL BIOL, V210, P91, DOI 10.1016/0022-2836(89)90293-3; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; MASON DW, 1986, HDB EXPT IMMUNOLOGY, V1; MCCLELLAND A, 1991, P NATL ACAD SCI USA, V88, P7993, DOI 10.1073/pnas.88.18.7993; OLIVEIRA MA, 1993, STRUCTURE, V1, P51, DOI 10.1016/0969-2126(93)90008-5; OLSON NH, 1993, P NATL ACAD SCI USA, V90, P507, DOI 10.1073/pnas.90.2.507; ROSSMANN MG, 1989, J BIOL CHEM, V264, P14587; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; RUECKERT RR, 1990, VIROLOGY, P507; SAUTER NK, 1989, BIOCHEMISTRY-US, V28, P8388, DOI 10.1021/bi00447a018; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH TJ, 1993, J VIROL, V67, P1148, DOI 10.1128/JVI.67.3.1148-1158.1993; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; YAFAL AG, 1993, VIROLOGY, V197, P507	35	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13216	13224		10.1074/jbc.270.22.13216	http://dx.doi.org/10.1074/jbc.270.22.13216			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768920	hybrid			2022-12-25	WOS:A1995RB43900043
J	HAUSDORFF, SF; BENNETT, AM; NEEL, BG; BIRNBAUM, MJ				HAUSDORFF, SF; BENNETT, AM; NEEL, BG; BIRNBAUM, MJ			DIFFERENT SIGNALING ROLES OF SHPTP2 IN INSULIN-INDUCED GLUT1 EXPRESSION AND GLUT4 TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; 3T3-L1 ADIPOCYTES; TRANSPORTER GENE; CELL-SURFACE; PHOSPHORYLATION; ACTIVATION; SH-PTP2	Insulin activates hexose transport via at least two mechanisms: a p21(ras)-dependent pathway, leading to an increase in the amount of cell surface GLUT1; and a metabolic, p21(ras)-independent pathway, leading to translocation of the insulin-responsive transporter GLUT4 to the cell surface. Following insulin stimulation, SHPTP2, a non-transmembrane protein-tyrosine phosphatase, associates with insulin receptor substrate 1 via its Src homology 2 (SH2) domains. Microinjection of a glutathione S-transferase fusion protein encoding the N- and C-terminal SH2 domains of SHPTP2 (GST-NC-SH2) or anti-SHPTP2 antibodies into NIH-3T3 fibroblasts overexpressing the insulin receptor blocks insulin-induced DNA synthesis. Microinjection of either GST-NC-SH2 or anti-SHPTP2 antibodies into 3T3-L1 adipocytes inhibited the insulin-stimulated increase in expression of GLUT1. In contrast, translocation of GLUT4 to the cell surface was unaffected by either GST-NC-SH2 or anti-SHPTP2 antibodies. These data confirm a role for SHPTP2 in insulin-stimulated mitogenesis and indicate that whereas SHPTP2 is necessary for insulin-stimulated expression of GLUT1, it is not required for activation of the metabolic pathway leading to GLUT4 translocation.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02215; BETH ISRAEL HOSP,MOLEC MED UNIT,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center				Birnbaum, Morris/0000-0001-9972-8680; Bennett, Anton/0000-0001-5187-7599	NCI NIH HHS [CA49152] Funding Source: Medline; NIDDK NIH HHS [DK39519] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049152, R37CA049152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13801; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FINGAR DC, 1994, J BIOL CHEM, V269, P10127; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21931; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PLUSKEY S, 1995, J BIOL CHEM, V270, P2879; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1994, J BIOL CHEM, V269, P1; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	27	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					12965	12968		10.1074/jbc.270.22.12965	http://dx.doi.org/10.1074/jbc.270.22.12965			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768884	hybrid			2022-12-25	WOS:A1995RB43900005
J	KUDO, S; FUKUDA, M				KUDO, S; FUKUDA, M			TISSUE-SPECIFIC TRANSCRIPTIONAL REGULATION OF HUMAN LEUKOSIALIN (CD43) GENE IS ACHIEVED BY DNA METHYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; MONOCLONAL-ANTIBODY; CPG METHYLATION; SURFACE SIALOGLYCOPROTEIN; MAJOR SIALOGLYCOPROTEIN; CELL-DIFFERENTIATION; BINDING PROTEIN; IDENTIFICATION; ACTIVATION; SEQUENCE	The expression of human leukosialin (CD43), a major sialoglycoprotein on the surface of hematopoietic cells, is regulated in cell lineage-specific as well as differentiation stage-specific manners. me have shown previously that transcription from the TATA-less promoter is mediated by the transcription factor Spl, which binds to repeats of a GGGTGG motif in the 3'-flanking sequence. This regulatory region is ubiquitously functional in mammalian cells, providing a high transcriptional potential. No cis-acting element responsible for the specificity of this gene expression was revealed by extensive studies using transient as well as stable expression systems. Here, we demonstrate that DNA methylation plays a key role in leukosialin gene expression. Southern blot analysis of genomic DNAs from various human cell lines with methylation-sensitive and -insensitive restriction enzymes showed a tight correlation between gene activity and demethylation state of the 5'-region of the leukosialin gene. Consistent results were obtained from the same analysis of genomic DNAs from various human tissues. In addition, in vitro DNA methylation of the 3'-region drastically reduced transcriptional activity in a transient expression system. These results indicate that DNA methylation around the 5'-region of the leukosialin gene is required to shut off a high level of transcription. Thus, the tissue-specific expression of the leukosialin gene is constitutively achieved by alteration of DNA methylation.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA33895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON LC, 1978, BLOOD, V52, P57; BEDNARIK DP, 1991, NEW BIOL, V3, P969; BETTAIEB A, 1988, BLOOD, V71, P1226; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; DRAGONE LL, 1995, P NATL ACAD SCI USA, V92, P626, DOI 10.1073/pnas.92.2.626; DYER MJS, 1981, J EXP MED, V154, P1164, DOI 10.1084/jem.154.4.1164; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FELGNER P, 1987, P NATL ACAD SCI USA, V87, P7413; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GULLEY ML, 1988, J IMMUNOL, V140, P3751; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KLEMPNAUER KH, 1993, ONCOGENE, V8, P111; KUDO S, 1991, J BIOL CHEM, V266, P8483; KUDO S, 1994, EUR J BIOCHEM, V223, P319, DOI 10.1111/j.1432-1033.1994.tb18997.x; KUDO S, 1990, J BIOL CHEM, V265, P1102; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MEEHAN RR, 1989, GENE DEV, V2, P921; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; Sambrook J, 1989, MOL CLONING LABORATO; SHELLEY CS, 1990, BIOCHEM J, V270, P569, DOI 10.1042/bj2700569; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; VARGASCORTES M, 1988, SCAND J IMMUNOL, V27, P661, DOI 10.1111/j.1365-3083.1988.tb02399.x; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	38	56	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13298	13302		10.1074/jbc.270.22.13298	http://dx.doi.org/10.1074/jbc.270.22.13298			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768930	hybrid			2022-12-25	WOS:A1995RB43900054
J	SANKAR, S; MAHOOTIBROOKS, N; CENTRELLA, M; MCCARTHY, TL; MADRI, JA				SANKAR, S; MAHOOTIBROOKS, N; CENTRELLA, M; MCCARTHY, TL; MADRI, JA			EXPRESSION OF TRANSFORMING GROWTH-FACTOR TYPE-III RECEPTOR IN VASCULAR ENDOTHELIAL-CELLS INCREASES THEIR RESPONSIVENESS TO TRANSFORMING GROWTH-FACTOR-BETA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR CELLS; EXTRACELLULAR-MATRIX; CRYSTAL-STRUCTURE; SURFACE PROTEINS; BINDING; CLONING; RESISTANT; GROWTH-FACTOR-BETA-2; INHIBITION; BETAGLYCAN	Bovine aortic endothelial cells (BAECs) express both type I and type II receptors for transforming growth factor beta (TGF beta). These cells respond to TGF beta 1 but are relatively refractory to another isoform of TGF beta, termed TGF beta 2. TGF beta s are thought to signal through receptor complexes composed of type I and/or type II receptors, both of which appear to be functional serine-threonine kinases. The TGF beta type III receptor, on the other hand, does not seem to have any direct signaling capacity. We have now stably transfected BAECs with the type III receptor cDNA. These cells displayed surface expression of the type III receptor protein, as determined by crosslinking with iodinated TGF beta 1 and immunoprecipitation with antibodies to the type III receptor protein. Transfected BAECs exhibit increased responsiveness to TGF beta 2 by several different criteria including an increase in plasminogen activator inhibitor-1 protein and inhibition of migration and proliferation. Thus, the type III receptor protein may play a role in presenting TGF beta 2 to the type II receptor and increase responsiveness to TGF beta 2 to a level comparable to that of TGF beta 1.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PLAST SURG,NEW HAVEN,CT 06510	Yale University; Yale University					NHLBI NIH HHS [R01HL28373] Funding Source: Medline; NIAMS NIH HHS [R01AR39201] Funding Source: Medline; NIDDK NIH HHS [P01 DK38979] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038979] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYD FT, 1989, J BIOL CHEM, V264, P1172; CENTRELLA M, 1988, P NATL ACAD SCI USA, V85, P5889, DOI 10.1073/pnas.85.16.5889; CENTRELLA M, 1995, IN PRESS MOL CELL BI; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHINKERS M, 1987, J CELL PHYSIOL, V130, P1, DOI 10.1002/jcp.1041300102; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRANZEN P, 1993, EXP CELL RES, V207, P681; GEISER AG, 1992, J BIOL CHEM, V267, P2588; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MADRI JA, 1980, HUM PATHOL, V11, P353, DOI 10.1016/S0046-8177(80)80031-1; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MADRI JA, 1987, AM J PATHOL, V94, P179; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MERWIN JR, 1991, AM J PATHOL, V138, P37; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; PRATT BM, 1984, AM J PATHOL, V117, P349; QIAN SW, 1992, P NATL ACAD SCI USA, V89, P6290, DOI 10.1073/pnas.89.14.6290; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROLL FJ, 1980, J CELL BIOL, V859, P597; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEGARINI PR, 1992, J BIOL CHEM, V267, P1048; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TENDIJKE P, 1990, MOL CELL BIOL, V10, P4473, DOI 10.1128/MCB.10.9.4473; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; TSUCHIDA K, 1993, BIOCHEM BIOPH RES CO, V191, P790, DOI 10.1006/bbrc.1993.1286; WANG XF, 1991, CELL, V51, P797; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	47	108	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13567	13572		10.1074/jbc.270.22.13567	http://dx.doi.org/10.1074/jbc.270.22.13567			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768960	hybrid			2022-12-25	WOS:A1995RB43900090
J	SMID, A; RIVA, M; BOUET, F; SENTENAC, A; CARLES, C				SMID, A; RIVA, M; BOUET, F; SENTENAC, A; CARLES, C			THE ASSOCIATION OF 3 SUBUNITS WITH YEAST RNA-POLYMERASE IS STABILIZED BY A14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIVE-SITE; GENE DISRUPTION; H ACTIVITY; DNA; PROTEIN; TRANSFORMATION; MUTAGENESIS; CYCLOPHILIN; PLASMIDS	RNA polymerase I of Saccharomyces cerevisiae is composed of 14 subunits. Ah of the corresponding genes have been cloned with the exception of the RPB14 gene encoding A14, a specific polypeptide of this enzyme. We report the cloning and the characterization of RPA14. The A14 polypeptide was separated from the other RNA polymerase I subunits by reverse-phase high pressure Liquid chromatography and digested with proteinase It. Based on the amino acid sequence of one of the resulting peptides, a degenerate oligonucleotide was synthesized and used to isolate the RPA14 gene from a yeast subgenomic DNA Library. RPA14 is a single copy gene that maps to chromosome IV and is flanked by CYP1 and HOM2. Disruption of RPA14 is not lethal, but growth of the rpal4=URA3 mutant strain is impaired at 37 and 38 degrees C. RNA polymerase I was purified from the rpa14=URA3 strain. After two purification steps, the enzyme did not contain the subunits A14, ABC23, and A43. This form of the enzyme was not active in a nonspecific in vitro transcription assay. These results demonstrate that A14 is a genuine subunit of RNA polymerase I and suggest that A14 plays a role in the stability of a subgroup of subunits.	CEA SACLAY,SERV BIOCHIM & GENET MOLEC,F-91191 GIF SUR YVETTE,FRANCE; CEA SACLAY,INGN PROT LAB,F-91191 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BUHLER JM, 1974, J BIOL CHEM, V249, P5963; BUHLER JM, 1980, J BIOL CHEM, V255, P9949; BUHLER JM, 1979, STRUCTURAL STUDIES Y; CARLES C, 1991, J BIOL CHEM, V266, P24092; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HAGER GL, 1977, BIOCHEMISTRY-US, V16, P1, DOI 10.1021/bi00620a001; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HUET J, 1976, BIOCHIMIE, V58, P71, DOI 10.1016/S0300-9084(76)80357-4; HUET J, 1976, NATURE, V261, P431, DOI 10.1038/261431a0; HUET J, 1975, P NATL ACAD SCI USA, V72, P3034, DOI 10.1073/pnas.72.8.3034; HUET J, 1977, J BIOL CHEM, V252, P8848; IBORRA F, 1979, J BIOL CHEM, V254, P920; LEFEBVRE O, 1992, P NATL ACAD SCI USA, V89, P10512, DOI 10.1073/pnas.89.21.10512; LILJELUND P, 1992, P NATL ACAD SCI USA, V89, P9302, DOI 10.1073/pnas.89.19.9302; LINK AJ, 1991, GENETICS, V127, P681; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MCLAUGHLIN MM, 1992, GENE, V111, P85, DOI 10.1016/0378-1119(92)90606-P; MORTIMER RK, 1991, MOL CELLULAR BIOL YE, P737; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; RIVA M, 1990, J BIOL CHEM, V265, P16498; RIVA M, 1987, J BIOL CHEM, V262, P14377; RIVA M, 1982, J BIOL CHEM, V257, P4570; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENTENAC A, 1992, TRANSCRIPTIONAL REGU, P27; SIKORSKI RS, 1989, GENETICS, V122, P19; STETTLER S, 1992, J BIOL CHEM, V267, P21390; STETTLER S, 1993, MOL GEN GENET, V239, P169, DOI 10.1007/BF00281615; SYKES K, 1993, P NATL ACAD SCI USA, V90, P5853, DOI 10.1073/pnas.90.12.5853; THOMAS D, 1989, MOL GEN GENET, V217, P149, DOI 10.1007/BF00330954; THUILLIER V, 1995, EMBO J, V14, P351, DOI 10.1002/j.1460-2075.1995.tb07009.x; THURIAUX P, 1992, MOL CELLULAR BIOL YE, P1; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; VALENZUELA P, 1976, BIOCHEM BIOPH RES CO, V71, P26, DOI 10.1016/0006-291X(76)90244-8; WERNER M, 1993, J BIOL CHEM, V268, P20721; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	44	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13534	13540		10.1074/jbc.270.22.13534	http://dx.doi.org/10.1074/jbc.270.22.13534			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768955	hybrid			2022-12-25	WOS:A1995RB43900085
J	BABITZKE, P; YANOFSKY, C				BABITZKE, P; YANOFSKY, C			STRUCTURAL FEATURES OF L-TRYPTOPHAN REQUIRED FOR ACTIVATION OF TRAP, THE TRP RNA-BINDING ATTENUATION PROTEIN OF BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ATTENUATION; OPERON; APOREPRESSOR; EXPRESSION; ACID; MTRB	A filter binding assay was used to determine the structural features of L-tryptophan required for activation of TRAP, the trp RNA-binding attenuation protein of Bacillus subtilis. We examined the ability of L-tryptophan and 26 of its analogs to activate TRAP. Our findings show that TRAP activation by L-tryptophan is highly cooperative. We also observed that TRAP activation is stereospecific; D-tryptophan did not activate. Our results further indicate that the alpha-amino group and the carbonyl moiety of the alpha-carboxyl group of the ligand are required for TRAP activation and that the heterocyclic amino nitrogen of L-tryptophan greatly enhances TRAP activation. We also found that changes at several positions of the indole ring of L-tryptophan resulted in reduced TRAP activation. In addition, indole and 5-methylindole were shown to be effective competitors of L-tryptophan activation of TRAP.	PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	BABITZKE, P (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.		Babitzke, Paul/AAL-3048-2020	Babitzke, Paul/0000-0003-2481-1062	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM009738, R01GM009738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM09738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTSON AA, 1994, J MOL BIOL, V244, P1, DOI 10.1006/jmbi.1994.1698; ARVIDSON DN, 1986, J BIOL CHEM, V261, P238; BABITZKE P, 1992, J BACTERIOL, V174, P2059, DOI 10.1128/JB.174.7.2059-2064.1992; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; HOCH SO, 1971, J BACTERIOL, V105, P38, DOI 10.1128/JB.105.1.38-45.1971; JOACHIMIAK A, 1983, P NATL ACAD SCI-BIOL, V80, P668, DOI 10.1073/pnas.80.3.668; KANE JF, 1977, J BACTERIOL, V132, P419, DOI 10.1128/JB.132.2.419-425.1977; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; LANE AN, 1985, EUR J BIOCHEM, V157, P405; MARMORSTEIN RQ, 1987, J BIOL CHEM, V262, P4922; MARMORSTEIN RQ, 1989, J BIOL CHEM, V264, P9149; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990	17	35	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12452	12456		10.1074/jbc.270.21.12452	http://dx.doi.org/10.1074/jbc.270.21.12452			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759487	hybrid			2022-12-25	WOS:A1995QZ71100020
J	COLEMAN, T; SEIP, RL; GIMBLE, JM; LEE, D; MAEDA, N; SEMENKOVICH, CF				COLEMAN, T; SEIP, RL; GIMBLE, JM; LEE, D; MAEDA, N; SEMENKOVICH, CF			COOH-TERMINAL DISRUPTION OF LIPOPROTEIN-LIPASE IN MICE IS LETHAL IN HOMOZYGOTES, BUT HETEROZYGOTES HAVE ELEVATED TRIGLYCERIDES AND IMPAIRED ENZYME-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; SMOOTH-MUSCLE CELLS; TRANSGENIC MICE; MESSENGER-RNA; DEFICIENCY; EXPRESSION; GENE; MACROPHAGES; SECRETION	The role of the enzyme lipoprotein Lipase (LPL) in atherosclerosis is uncertain. To generate an animal model of LPL deficiency, we targeted the LPL gene in embryonic stem cells with a vector designed to disrupt the COOH terminus of the protein and used these cells to generate LPL-deficient mice, Germ line transmission of the disrupted LPL allele was achieved with two chimeric males, and offspring from each of these animals were phenotypically identical. Pups homozygous (-/-) for LPL deficiency died within 48 h of birth with extreme elevations of serum triglycerides (13,327 mg/dl) associated with essentially absent LPL enzyme activity in heart and carcass. Newborn heterozygous (+/-) LPL-deficient pups had lower LPL enzyme activity and higher triglycerides (370 versus 121 mg/dl) than wild type (+/+) littermates. Adult heterozygotes had higher triglycerides than mild type mice with ad libitum feeding (236 mg/dl for +/- versus 88 mg/dl for +/+) and after fasting for 4 h (98 mg/dl for +/- versus 51 for +/+) or 12 h (109 mg/dl for +/- versus 56 mg/dl for +/+), Triglycerides mere present as very low density Lipoprotein particles and chylomicrons, but high density lipoprotein cholesterol levels were not decreased in +/- animals. Plasma heparin-releasable LPL activity was 43% lower in +/- versus +/+ adult animals. LPL activity, mRNA, and protein were lower in the tissues of +/- versus +/+ mice. Homozygous LPL deficiency caused by disruption of the COOH terminus of the enzyme is lethal in mice, Heterozygous LPL deficiency caused by this mutation is associated with mild to moderate hypertriglyceridemia without affecting static HDL cholesterol levels. Heterozygous LPL-deficient mice could be useful for determining if hypertriglyceridemia, independently or in combination with other discrete defects, influences atherosclerosis.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV ATHEROSCLEROSIS NUTR & LIPID RES,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; OKLAHOMA MED RES FDN,OKLAHOMA CITY,OK 73104; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	Washington University (WUSTL); Washington University (WUSTL); Oklahoma Medical Research Foundation; University of North Carolina; University of North Carolina Chapel Hill				Semenkovich, Clay/0000-0003-1163-1871	NATIONAL CANCER INSTITUTE [R29CA050898, R01CA050898] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047436, R37HL042630, R01HL042630] Funding Source: NIH RePORTER; NCI NIH HHS [CA50898] Funding Source: Medline; NHLBI NIH HHS [HL47436, HL42630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSTIN MA, 1992, ARTERIOSCLER THROMB, V11, P2; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BLANCHETTEMACKI.EJ, 1986, LAB INVEST, V55, P347; BRUIN T, 1994, EUR J BIOCHEM, V221, P1019, DOI 10.1111/j.1432-1033.1994.tb18819.x; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; CONNELLY PW, 1994, J BIOL CHEM, V269, P20554; DAVIS RC, 1990, J BIOL CHEM, V265, P17960; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; HATANAKA K, 1986, BIOCHIM BIOPHYS ACTA, V878, P440, DOI 10.1016/0005-2760(86)90254-7; HUA XX, 1991, GENE, V107, P247, DOI 10.1016/0378-1119(91)90325-6; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; IZZO C, 1981, CLIN CHEM, V27, P371; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOZAKI K, 1993, J LIPID RES, V34, P1765; LALOUEL JM, 1992, CURR OPIN LIPIDOL, V3, P86; LEBOEUF RC, 1994, J LIPID RES, V35, P121; LIU MS, 1994, J BIOL CHEM, V269, P11417; MATTSSON L, 1993, J CLIN INVEST, V92, P1759, DOI 10.1172/JCI116764; MIESENBOCK G, 1990, J CLIN INVEST, V91, P448; MULDER M, 1993, J BIOL CHEM, V268, P9369; NISHINA PM, 1993, J LIPID RES, V34, P1413; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; OLIVECRONA T, 1986, BIOCHIM BIOPHYS ACTA, V876, P243, DOI 10.1016/0005-2760(86)90280-8; PATERNITI JR, 1983, SCIENCE, V221, P167, DOI 10.1126/science.6857276; PERITZ LN, 1990, CLIN INVEST MED, V13, P259; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; RENIER G, 1993, ARTERIOSCLER THROMB, V13, P190, DOI 10.1161/01.ATV.13.2.190; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; RUTLEDGE JC, 1994, J LIPID RES, V35, P1152; SEIP RL, 1995, AM J PHYSIOL-ENDOC M, V268, pE229, DOI 10.1152/ajpendo.1995.268.2.E229; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; SHACHTER NS, 1994, J CLIN INVEST, V93, P1683, DOI 10.1172/JCI117151; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SLYPER AH, 1992, LANCET, V340, P289, DOI 10.1016/0140-6736(92)92368-P; TABAS I, 1993, J BIOL CHEM, V268, P20419; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS KJ, 1991, J CLIN INVEST, V88, P1300, DOI 10.1172/JCI115434; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILSON DE, 1990, J CLIN INVEST, V86, P735, DOI 10.1172/JCI114770; WONG H, 1994, J BIOL CHEM, V269, P10319; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; ZECHNER R, 1991, GENOMICS, V11, P62, DOI 10.1016/0888-7543(91)90102-K; ZSIGMOND E, 1994, J BIOL CHEM, V269, P18757	49	108	112	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12518	12525		10.1074/jbc.270.21.12518	http://dx.doi.org/10.1074/jbc.270.21.12518			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7759497	Green Published, hybrid			2022-12-25	WOS:A1995QZ71100031
J	NILSSON, M; TOFTGARD, R; BOHM, S				NILSSON, M; TOFTGARD, R; BOHM, S			ACTIVATED HA-RAS BUT NOT TPA INDUCES TRANSCRIPTION THROUGH BINDING-SITES FOR ACTIVATING TRANSCRIPTION FACTOR 3/JUN AND A NOVEL NUCLEAR FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS PROMOTER; VL30 TRANSCRIPTION; TUMOR-PROMOTER; ONCOGENE; ELEMENT; PROTEINS; ENHANCER; GENE; JUN; SEQUENCES	We report the identification of a 20-base pair sequence mediating induced transcription in response to an activated Ha-ras gene and epidermal growth factor (EGF) but not 12-O-tetradecanoylphorbol-13-acetate stimulation. This signal-specific nuclear target is present in the long terminal repeat of a mouse VL30 retrotransposon expressed in epidermis. Functional studies and in vitro binding analyses using cultured keratinocytes (Balb/MK) reveal that the response element is composed of two cooperating sequence motifs in juxtaposed position, both of which are targets for induced binding activity 1-2 h after EGF stimulation. Of many different activating transcription factor/cAMP-responsive element binding protein/activating protein 1 factors tested, one part of the sequence selectively binds endogenous proteins immunologically related to activating transcription factor 3 (ATF3) and Jun isotypes. The other sequence is a target for a nuclear factor showing binding specificity unrelated to factors known to mediate EGF- or ras-induced transcription as determined by its sequence specificity and by antibody experiments. This component has been characterized and partially purified by gel filtration chromatography and velocity centrifugation revealing a Stokes radius of 43.6 Angstrom and a sedimentation coefficient of 9.7 S in solution. Based on these parameters, a molecular mass of 178,000 Da was calculated. The results indicate that the specific binding of ATF3/Jun and a previously uncharacterized factor account for signal-specific transcription in response to EGF or an activated Ha-ras gene in a cell type in which the cooperative action of an activated Ha-ras gene and 12-O-tetradecanoylphorbol-13-acetate cause tumor growth.	KAROLINSKA INST,NOVUM,DEPT BIOSCI,S-14157 HUDDINGE,SWEDEN	Karolinska Institutet	NILSSON, M (corresponding author), KAROLINSKA INST,NOVUM,CTR NUTR & TOXICOL,S-14157 HUDDINGE,SWEDEN.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOHM S, 1993, J BIOL CHEM, V268, P3952; BOHM S, 1991, J BIOL CHEM, V266, P24834; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHATTON B, 1994, ONCOGENE, V9, P375; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; GALIEN R, 1991, ONCOGENE, V6, P849; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; KOIKE M, 1993, MOL CARCINOGEN, V8, P105, DOI 10.1002/mc.2940080207; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NILSSON M, 1994, J VIROL, V68, P276, DOI 10.1128/JVI.68.1.276-288.1994; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OWEN RD, 1990, MOL CELL BIOL, V10, P1; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; RYSECK RP, 1991, ONCOGENE, V6, P533; Sherman M R, 1975, Methods Enzymol, V36, P211; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STRUHL K, 1990, CURRENT PROTOCOLS MO; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; TANFORD L, 1961, PHYSICAL CHEM MACROM, P34; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; VANDUUREN BL, 1969, PROG EXP TUMOR RES, V11, P31; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; YAMAGUCHI Y, 1989, J VIROL, V63, P1040, DOI 10.1128/JVI.63.3.1040-1048.1989; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	41	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12210	12218		10.1074/jbc.270.20.12210	http://dx.doi.org/10.1074/jbc.270.20.12210			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744871	hybrid			2022-12-25	WOS:A1995QY73600076
